/*
SQLyog Ultimate v12.09 (64 bit)
MySQL - 5.5.58 : Database - paindatabase
*********************************************************************
*/

/*!40101 SET NAMES utf8 */;

/*!40101 SET SQL_MODE=''*/;

/*!40014 SET @OLD_UNIQUE_CHECKS=@@UNIQUE_CHECKS, UNIQUE_CHECKS=0 */;
/*!40014 SET @OLD_FOREIGN_KEY_CHECKS=@@FOREIGN_KEY_CHECKS, FOREIGN_KEY_CHECKS=0 */;
/*!40101 SET @OLD_SQL_MODE=@@SQL_MODE, SQL_MODE='NO_AUTO_VALUE_ON_ZERO' */;
/*!40111 SET @OLD_SQL_NOTES=@@SQL_NOTES, SQL_NOTES=0 */;
CREATE DATABASE /*!32312 IF NOT EXISTS*/`paindatabase` /*!40100 DEFAULT CHARACTER SET utf8 */;

USE `paindatabase`;

/*Table structure for table `atc_codes` */

DROP TABLE IF EXISTS `atc_codes`;

CREATE TABLE `atc_codes` (
  `ATC` varchar(30) DEFAULT NULL,
  `ATC_link` varchar(60) DEFAULT NULL,
  `Name` varchar(30) DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

/*Data for the table `atc_codes` */

/*Table structure for table `atc_li` */

DROP TABLE IF EXISTS `atc_li`;

CREATE TABLE `atc_li` (
  `ATC_li` varchar(30) DEFAULT NULL,
  `ATC` varchar(30) DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

/*Data for the table `atc_li` */

/*Table structure for table `drugbank` */

DROP TABLE IF EXISTS `drugbank`;

CREATE TABLE `drugbank` (
  `drugbank_Name` varchar(200) DEFAULT NULL,
  `drugbank_id` varchar(200) NOT NULL,
  `drugbank_Type` varchar(200) DEFAULT NULL,
  `Groups` varchar(200) DEFAULT NULL,
  `Description` text,
  `Structure` varchar(200) DEFAULT NULL,
  `CAS_number` varchar(200) DEFAULT NULL,
  `Weight` varchar(200) DEFAULT NULL,
  `has_Pathway_table` varchar(200) DEFAULT NULL,
  `has_target_table` varchar(200) DEFAULT NULL,
  `KEGG_Drug` varchar(200) DEFAULT NULL,
  `KEGG_Drug_link` varchar(200) DEFAULT NULL,
  `drugbank_url` varchar(200) DEFAULT NULL,
  PRIMARY KEY (`drugbank_id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

/*Data for the table `drugbank` */

insert  into `drugbank`(`drugbank_Name`,`drugbank_id`,`drugbank_Type`,`Groups`,`Description`,`Structure`,`CAS_number`,`Weight`,`has_Pathway_table`,`has_target_table`,`KEGG_Drug`,`KEGG_Drug_link`,`drugbank_url`) values ('Choline','DB00122','Small Molecule','Approved, Nutraceutical','A basic constituent of lecithin that is found in many plants and animal organs. It is important as a precursor of acetylcholine, as a methyl donor in various metabolic processes, and in lipid metabolism.','DB00122.svg','62-49-7','Average: 104.1708','true','true','D07690','http://www.genome.jp/dbget-bin/www_bget?drug:D07690','https://www.drugbank.ca/drugs/DB00122'),('Masoprocol','DB00179','Small Molecule','Approved, Investigational','A potent lipoxygenase inhibitor that interferes with arachidonic acid metabolism. The compound also inhibits formyltetrahydrofolate synthetase, carboxylesterase, and cyclooxygenase to a lesser extent. It also serves as an antioxidant in fats and oils. [PubChem]','DB00179.svg','27686-84-6','Average: 302.3649','None','true','None','None','https://www.drugbank.ca/drugs/DB00179'),('Tramadol','DB00193','Small Molecule','Approved, Investigational','A narcotic analgesic proposed for moderate to severe pain. It may be habituating. Tramadol is also prepared as a variable release capsules, marketed under the brand name ConZip. For example, a 150 mg capsule will contain 37.5 mg of the immediate release form and 112.5 mg of the extended release form.','DB00193.svg','27203-92-5','Average: 263.3752','true','true','D08623','http://www.genome.jp/dbget-bin/www_bget?drug:D08623','https://www.drugbank.ca/drugs/DB00193'),('Mesalazine','DB00244','Small Molecule','Approved','An anti-inflammatory agent, structurally related to the salicylates, which is active in inflammatory bowel disease. It is considered to be the active moiety of sulphasalazine. (From Martindale, The Extra Pharmacopoeia, 30th ed)','DB00244.svg','89-57-6','Average: 153.1354','None','true','D00377','http://www.genome.jp/dbget-bin/www_bget?drug:D00377','https://www.drugbank.ca/drugs/DB00244'),('Methysergide','DB00247','Small Molecule','Approved','An ergot derivative that is a congener of lysergic acid diethylamide. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize serotonin in the carcinoid syndrome.','DB00247.svg','361-37-5','Average: 353.458','None','true','None','None','https://www.drugbank.ca/drugs/DB00247'),('Morphine','DB00295','Small Molecule','Approved, Investigational','The principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central nervous system and on smooth muscle. In January, 2017, morphine was approved for the treatment of chronic pain.','DB00295.svg','57-27-2','Average: 285.3377','true','true','D08233','http://www.genome.jp/dbget-bin/www_bget?drug:D08233','https://www.drugbank.ca/drugs/DB00295'),('Acetaminophen','DB00316','Small Molecule','Approved','Acetaminophen, also known as paracetamol, is commonly used for its analgesic and antipyretic effects. Its therapeutic effects are similar to salicylates, but it lacks anti-inflammatory, antiplatelet, and gastric ulcerative effects.','DB00316.svg','103-90-2','Average: 151.1626','true','true','D00217','http://www.genome.jp/dbget-bin/www_bget?drug:D00217','https://www.drugbank.ca/drugs/DB00316'),('Codeine','DB00318','Small Molecule','Approved, Illicit','An opioid analgesic related to morphine but with less potent analgesic properties and mild sedative effects. It also acts centrally to suppress cough.','DB00318.svg','76-57-3','Average: 299.3642','true','true','D03580','http://www.genome.jp/dbget-bin/www_bget?drug:D03580','https://www.drugbank.ca/drugs/DB00318'),('Hydromorphone','DB00327','Small Molecule','Approved, Illicit','An opioid analgesic derived from morphine and used mainly as an analgesic. It has a shorter duration of action and is more potent than morphine. [PubChem]','DB00327.svg','466-99-9','Average: 285.3377','true','true','C07042','http://www.genome.jp/dbget-bin/www_bget?cpd:C07042','https://www.drugbank.ca/drugs/DB00327'),('Indomethacin','DB00328','Small Molecule','Approved, Investigational','Indomethacin is a non-steroidal antiinflammatory agent (NSAIA) with antiinflammatory, analgesic and antipyretic activity. Its pharmacological effect is thought to be mediated through inhibition of the enzyme cyclooxygenase (COX), the enzyme responsible for catalyzes the rate-limiting step in prostaglandin synthesis via the arachidonic acid pathway.','DB00328.svg','53-86-1','Average: 357.788','true','true','D00141','http://www.genome.jp/dbget-bin/www_bget?drug:D00141','https://www.drugbank.ca/drugs/DB00328'),('Methadone','DB00333','Small Molecule','Approved','A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of morphine. It also has a depressant action on the cough center and may be given to control intractable cough associated with terminal lung cancer. Methadone is also used as part of the treatment of dependence on opioid drugs, although prolonged use of methadone itself may result in dependence. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3).','DB00333.svg','76-99-3','Average: 309.4452','true','true','C07163','http://www.genome.jp/dbget-bin/www_bget?cpd:C07163','https://www.drugbank.ca/drugs/DB00333'),('Nabumetone','DB00461','Small Molecule','Approved','Nabumetone is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid family (which includes diclofenac). Marketed under the brand name Relafen, it has been shown to have a slightly lower risk of gastrointestinal side effects than most other non-selective NSAIDs.','DB00461.svg','42924-53-8','Average: 228.2863','true','true','D00425','http://www.genome.jp/dbget-bin/www_bget?drug:D00425','https://www.drugbank.ca/drugs/DB00461'),('Ketorolac','DB00465','Small Molecule','Approved','A pyrrolizine carboxylic acid derivative structurally related to indomethacin. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed)','DB00465.svg','74103-06-3','None','true','true','C07062','http://www.genome.jp/dbget-bin/www_bget?cpd:C07062','https://www.drugbank.ca/drugs/DB00465'),('Celecoxib','DB00482','Small Molecule','Approved, Investigational','is a non-steroidal anti-inflammatory drug (NSAID) used in the treatment of osteoarthritis, rheumatoid arthritis, acute pain, painful menstruation and menstrual symptoms, and is also used to reduce numbers of colon and rectum polyps in patients with familial adenomatous polyposis. It is marketed by Pfizer under the brand name','DB00482.svg','169590-42-5','Average: 381.372','true','true','D00567','http://www.genome.jp/dbget-bin/www_bget?drug:D00567','https://www.drugbank.ca/drugs/DB00482'),('Oxycodone','DB00497','Small Molecule','Approved, Illicit, Investigational','Oxycodone is a semisynthetic derivative of codeine that acts as a narcotic analgesic more potent and addicting than codeine. An extended-release (ER) form of oxycodone (Xtampza ER) was approved for the management of daily, around-the-clock pain management in April, 2016.','DB00497.svg','76-42-6','Average: 315.3636','true','true','D05312','http://www.genome.jp/dbget-bin/www_bget?drug:D05312','https://www.drugbank.ca/drugs/DB00497'),('Tolmetin','DB00500','Small Molecule','Approved','A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. [PubChem]','DB00500.svg','26171-23-3','Average: 257.2845','true','true','None','None','https://www.drugbank.ca/drugs/DB00500'),('Piroxicam','DB00554','Small Molecule','Approved, Investigational','A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. [PubChem]','DB00554.svg','36322-90-4','Average: 331.346','true','true','D00127','http://www.genome.jp/dbget-bin/www_bget?drug:D00127','https://www.drugbank.ca/drugs/DB00554'),('Carbamazepine','DB00564','Small Molecule','Approved, Investigational','An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. [PubChem]','DB00564.svg','298-46-4','Average: 236.2686','true','true','D00252','http://www.genome.jp/dbget-bin/www_bget?drug:D00252','https://www.drugbank.ca/drugs/DB00564'),('Fenoprofen','DB00573','Small Molecule','Approved','An anti-inflammatory analgesic and antipyretic highly bound to plasma proteins. It is pharmacologically similar to aspirin, but causes less gastrointestinal bleeding. [PubChem]','DB00573.svg','29679-58-1','Average: 242.2699','true','true','D00968','http://www.genome.jp/dbget-bin/www_bget?drug:D00968','https://www.drugbank.ca/drugs/DB00573'),('Valdecoxib','DB00580','Small Molecule','Approved, Investigational, Withdrawn','Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about possible increased risk of heart attack and stroke.','DB00580.svg','181695-72-7','Average: 314.359','true','true','119607','http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=119607','https://www.drugbank.ca/drugs/DB00580'),('Diclofenac','DB00586','Small Molecule','Approved, Vet approved','A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt. [PubChem]','DB00586.svg','15307-86-5','None','true','true','D07816','http://www.genome.jp/dbget-bin/www_bget?drug:D07816','https://www.drugbank.ca/drugs/DB00586'),('Sulindac','DB00605','Small Molecule','Approved, Investigational','Sulindac is a nonsteroidal anti-inflammatory agent (NSAIA) of the arylalkanoic acid class that is marketed in the U.S. by Merck as Clinoril. Like other NSAIAs, it may be used in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted in vivo to an active sulfide compound by liver enzymes. The sulfide metabolite then undergoes enterohepatic circulation; it is excreted in the bile and then reabsorbed from the intestine. This is thought to help maintain constant blood levels with reduced gastrointestinal side effects. Some studies have shown sulindac to be relatively less irritating to the stomach than other NSAIA\'s except for drugs of the cyclooxygenase-2 (COX-2) inhibitor class. The exact mechanism of its NSAIA properties is unknown, but it is thought to act on enzymes COX-1 and COX-2, inhibiting prostaglandin synthesis.','DB00605.svg','38194-50-2','Average: 356.411','true','true','D00120','http://www.genome.jp/dbget-bin/www_bget?drug:D00120','https://www.drugbank.ca/drugs/DB00605'),('Chloroquine','DB00608','Small Molecule','Approved, Investigational, Vet approved','The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.','DB00608.svg','54-05-7','Average: 319.872','None','true','D02366','http://www.genome.jp/dbget-bin/www_bget?drug:D02366','https://www.drugbank.ca/drugs/DB00608'),('Adenosine','DB00640','Small Molecule','Approved, Investigational','A nucleoside that is composed of adenine and d-ribose. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter.','DB00640.svg','58-61-7','Average: 267.2413','true','true','D00045','http://www.genome.jp/dbget-bin/www_bget?drug:D00045','https://www.drugbank.ca/drugs/DB00640'),('Dextropropoxyphene','DB00647','Small Molecule','Approved, Illicit, Investigational, Withdrawn','Dextropropoxyphene is an analgesic in the opioid category, patented (1955) and manufactured by Eli Lilly and Company. It is intended to treat mild pain and also has antitussive and local anaesthetic effects. The drug has been taken off the market in Europe and the US due to concerns of fatal overdoses and heart arrhythmias. An estimated 10 million patients have used these products.','DB00647.svg','469-62-5','Average: 339.4712','true','true','C07406','http://www.genome.jp/dbget-bin/www_bget?cpd:C07406','https://www.drugbank.ca/drugs/DB00647'),('Magnesium sulfate','DB00653','Small Molecule','Approved, Investigational, Vet approved','A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. (From AMA Drug Evaluations Annual, 1992, p1083)','DB00653.svg','7487-88-9','Average: 120.368','None','true','D01108','http://www.genome.jp/dbget-bin/www_bget?drug:D01108','https://www.drugbank.ca/drugs/DB00653'),('Sumatriptan','DB00669','Small Molecule','Approved, Investigational','A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of migraine disorders. A transdermal patch version of sumatriptan is currently in phase I trials in the U.S. under the code name NP101 (NuPathe).','DB00669.svg','103628-46-2','Average: 295.4','None','true','D00451','http://www.genome.jp/dbget-bin/www_bget?drug:D00451','https://www.drugbank.ca/drugs/DB00669'),('Sufentanil','DB00708','Small Molecule','Approved, Investigational','An opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. [PubChem]','DB00708.svg','56030-54-7','Average: 386.551','true','true','D05938','http://www.genome.jp/dbget-bin/www_bget?drug:D05938','https://www.drugbank.ca/drugs/DB00708'),('Flurbiprofen','DB00712','Small Molecule','Approved, Investigational','Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically prior to ocular surgery to prevent or reduce intraoperative miosis. Flurbiprofen is structurally and pharmacologically related to fenoprofen, ibuprofen, and ketoprofen.','DB00712.svg','5104-49-4','Average: 244.2609','true','true','D00330','http://www.genome.jp/dbget-bin/www_bget?drug:D00330','https://www.drugbank.ca/drugs/DB00712'),('Etodolac','DB00749','Small Molecule','Approved, Investigational, Vet approved','Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis.','DB00749.svg','41340-25-4','Average: 287.3535','true','true','D00315','http://www.genome.jp/dbget-bin/www_bget?drug:D00315','https://www.drugbank.ca/drugs/DB00749'),('Olopatadine','DB00768','Small Molecule','Approved','Used to treat allergic conjunctivitis (itching eyes), olopatadine inhibits the release of histamine from mast cells. It is a relatively selective histamine H1 antagonist that inhibits the in vivo and in vitro type 1 immediate hypersensitivity reaction including inhibition of histamine induced effects on human conjunctival epithelial cells.','DB00768.svg','113806-05-6','Average: 337.4122','true','true','C07789','http://www.genome.jp/dbget-bin/www_bget?cpd:C07789','https://www.drugbank.ca/drugs/DB00768'),('Naproxen','DB00788','Small Molecule','Approved, Vet approved','An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout.','DB00788.svg','22204-53-1','None','true','true','D00118','http://www.genome.jp/dbget-bin/www_bget?drug:D00118','https://www.drugbank.ca/drugs/DB00788'),('Alfentanil','DB00802','Small Molecule','Approved, Illicit','A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. [PubChem]','DB00802.svg','71195-58-9','Average: 416.5172','true','true','C08005','http://www.genome.jp/dbget-bin/www_bget?cpd:C08005','https://www.drugbank.ca/drugs/DB00802'),('Phenylbutazone','DB00812','Small Molecule','Approved, Vet approved','A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter\'s syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit considerations indicate that this drug should not be employed for this disease. (From AMA Drug Evaluations Annual, 1994, p1822)','DB00812.svg','50-33-9','Average: 308.3743','true','true','D00510','http://www.genome.jp/dbget-bin/www_bget?drug:D00510','https://www.drugbank.ca/drugs/DB00812'),('Fentanyl','DB00813','Small Molecule','Approved, Illicit, Investigational, Vet approved','A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078)','DB00813.svg','437-38-7','Average: 336.4705','true','true','D00320','http://www.genome.jp/dbget-bin/www_bget?drug:D00320','https://www.drugbank.ca/drugs/DB00813'),('Meloxicam','DB00814','Small Molecule','Approved, Vet approved','Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve the symptoms of arthritis, primary dysmenorrhea, fever; and as an analgesic, especially where there is an inflammatory component. It is closely related to piroxicam. In Europe it is marketed under the brand names Movalis, Melox, and Recoxa. In North America it is generally marketed under the brand name Mobic. In Latin America, the drug is marketed as Tenaron. [Wikipedia]','DB00814.svg','71125-38-7','Average: 351.401','true','true','D00969','http://www.genome.jp/dbget-bin/www_bget?drug:D00969','https://www.drugbank.ca/drugs/DB00814'),('Carprofen','DB00821','Small Molecule','Approved, Vet approved, Withdrawn','Carprofen is a non-steroidal anti-inflammatory drug (NSAID) that is used by veterinarians as a supportive treatment for the relief of arthritic symptoms in geriatric dogs. Carprofen was previously used in human medicine for over 10 years (1985-1995). It was generally well tolerated, with the majority of adverse effects being mild, such as gastro-intestinal pain and nausea, similar to those recorded with aspirin and other non-steroidal anti-inflammatory drugs. It is no longer marketed for human usage, after being withdrawn on commercial grounds. [Wikipedia]','DB00821.svg','53716-49-7','Average: 273.714','true','true','C18364','http://www.genome.jp/dbget-bin/www_bget?cpd:C18364','https://www.drugbank.ca/drugs/DB00821'),('Nalbuphine','DB00844','Small Molecule','Approved','A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States.','DB00844.svg','20594-83-6','Average: 357.4434','true','true','D08246','http://www.genome.jp/dbget-bin/www_bget?drug:D08246','https://www.drugbank.ca/drugs/DB00844'),('Levorphanol','DB00854','Small Molecule','Approved','A narcotic analgesic that may be habit-forming. It is nearly as effective orally as by injection.','DB00854.svg','77-07-6','Average: 257.3706','true','true','D08123','http://www.genome.jp/dbget-bin/www_bget?drug:D08123','https://www.drugbank.ca/drugs/DB00854'),('Diflunisal','DB00861','Small Molecule','Approved, Investigational','Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear to be associated with inhibition of prostaglandin synthesis via the arachidonic acid pathway. Diflunisal is used to relieve pain accompanied with inflammation and in the symptomatic treatment of rheumatoid arthritis and osteoarthritis.','DB00861.svg','22494-42-4','Average: 250.1976','true','true','D00130','http://www.genome.jp/dbget-bin/www_bget?drug:D00130','https://www.drugbank.ca/drugs/DB00861'),('Remifentanil','DB00899','Small Molecule','Approved','Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anaesthetic. Remifentanil is a specific mu-type-opioid receptor agonist. Hence, it causes a reduction in sympathetic nervous system tone, respiratory depression and analgesia.','DB00899.svg','132875-61-7','Average: 376.4467','true','true','C08021','http://www.genome.jp/dbget-bin/www_bget?cpd:C08021','https://www.drugbank.ca/drugs/DB00899'),('Amantadine','DB00915','Small Molecule','Approved','An antiviral that is used in the prophylactic or symptomatic treatment of influenza A. It is also used as an antiparkinsonian agent, to treat extrapyramidal reactions, and for postherpetic neuralgia. The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake. [PubChem]','DB00915.svg','768-94-5','Average: 151.2487','None','true','C06818','http://www.genome.jp/dbget-bin/www_bget?cpd:C06818','https://www.drugbank.ca/drugs/DB00915'),('Buprenorphine','DB00921','Small Molecule','Approved, Illicit, Investigational, Vet approved','Buprenorphine is a derivative of the opioid alkaloid thebaine that is a more potent (25 - 40 times) and longer lasting analgesic than morphine. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use.','DB00921.svg','52485-79-7','Average: 467.6401','true','true','D07132','http://www.genome.jp/dbget-bin/www_bget?drug:D07132','https://www.drugbank.ca/drugs/DB00921'),('Salicylic acid','DB00936','Small Molecule','Approved, Investigational, Vet approved','A compound obtained from the bark of the white willow and wintergreen leaves, and also prepared synthetically. It has bacteriostatic, fungicidal, and keratolytic actions. Its salts, the salicylates, are used as analgesics.','DB00936.svg','69-72-7','Average: 138.1207','true','true','D00097','http://www.genome.jp/dbget-bin/www_bget?drug:D00097','https://www.drugbank.ca/drugs/DB00936'),('Meclofenamic acid','DB00939','Small Molecule','Approved, Vet approved','A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. [PubChem]','DB00939.svg','644-62-2','Average: 296.149','None','true','D02341','http://www.genome.jp/dbget-bin/www_bget?drug:D02341','https://www.drugbank.ca/drugs/DB00939'),('Acetylsalicylic acid','DB00945','Small Molecule','Approved, Vet approved','The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Acetylsalicylic acid also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)','DB00945.svg','50-78-2','Average: 180.1574','true','true','D00109','http://www.genome.jp/dbget-bin/www_bget?drug:D00109','https://www.drugbank.ca/drugs/DB00945'),('Hydrocodone','DB00956','Small Molecule','Approved, Illicit','Narcotic analgesic related to codeine, but more potent and more addicting by weight. It is used also as cough suppressant.','DB00956.svg','125-29-1','Average: 299.3642','true','true','D08045','http://www.genome.jp/dbget-bin/www_bget?drug:D08045','https://www.drugbank.ca/drugs/DB00956'),('Bromfenac','DB00963','Small Molecule','Approved','Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool to optimize surgical outcomes.','DB00963.svg','91714-94-2','Average: 334.165','true','true','60726','http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=60726','https://www.drugbank.ca/drugs/DB00963'),('Oxaprozin','DB00991','Small Molecule','Approved','Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis.','DB00991.svg','21256-18-8','Average: 293.3166','true','true','D00463','http://www.genome.jp/dbget-bin/www_bget?drug:D00463','https://www.drugbank.ca/drugs/DB00991'),('Ketoprofen','DB01009','Small Molecule','Approved, Vet approved','Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.','DB01009.svg','22071-15-4','Average: 254.2806','true','true','D00132','http://www.genome.jp/dbget-bin/www_bget?drug:D00132','https://www.drugbank.ca/drugs/DB01009'),('Ibuprofen','DB01050','Small Molecule','Approved','Ibuprofen, a propionic acid derivative, is a prototypical nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.','DB01050.svg','15687-27-1','Average: 206.2808','true','true','D00126','http://www.genome.jp/dbget-bin/www_bget?drug:D00126','https://www.drugbank.ca/drugs/DB01050'),('Diphenoxylate','DB01081','Small Molecule','Approved, Illicit','A meperidine congener used as an antidiarrheal, usually in combination with atropine. At high doses, it acts like morphine. Its unesterified metabolite difenoxin has similar properties and is used similarly. It has little or no analgesic activity. This medication is classified as a Schedule V under the Controlled Substances Act by the Food and Drug Administration (FDA) and the DEA in the United States when used in preparations. When diphenoxylate is used alone, it is classified as a Schedule II.','DB01081.svg','915-30-0','Average: 452.5873','true','true','D00301','http://www.genome.jp/dbget-bin/www_bget?drug:D00301','https://www.drugbank.ca/drugs/DB01081'),('Oxymorphone','DB01192','Small Molecule','Approved, Investigational, Vet approved','An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092). On June 8, 2017, FDA requested Endo Pharmaceuticals to remove the medication from the market due to opioid misuse and abuse risks associated with the product\'s injectable reformulation.','DB01192.svg','76-41-5','Average: 301.3371','true','true','C08019','http://www.genome.jp/dbget-bin/www_bget?cpd:C08019','https://www.drugbank.ca/drugs/DB01192'),('Mitoxantrone','DB01204','Small Molecule','Approved, Investigational','An anthracenedione-derived antineoplastic agent. [PubChem]','DB01204.svg','65271-80-9','Average: 444.4809','None','true','C11195','http://www.genome.jp/dbget-bin/www_bget?cpd:C11195','https://www.drugbank.ca/drugs/DB01204'),('Magnesium salicylate','DB01397','Small Molecule','Approved','Magnesium salicylate is a common analgesic and non-steroidal anti-inflammatory drug (NSAID) used to treat mild to moderate muscular pain. It is also used to treat headaches, general back pain, and certain joint pains like arthritis.','DB01397.svg','18917-89-0','Average: 298.531','true','true','C07995','http://www.genome.jp/dbget-bin/www_bget?cpd:C07995','https://www.drugbank.ca/drugs/DB01397'),('Antipyrine','DB01435','Small Molecule','Approved, Investigational','An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29)','DB01435.svg','60-80-0','Average: 188.2258','true','true','D01776','http://www.genome.jp/dbget-bin/www_bget?drug:D01776','https://www.drugbank.ca/drugs/DB01435'),('Bezitramide','DB01459','Small Molecule','Experimental, Illicit, Withdrawn','Bezitramide is a narcotic analgesic which was discovered in 1961, clinically tested around the 1970\'s [1], and marketed under the name Burgodin(R). After cases of fatal overdose in the Netherlands in 2004 the drug was withdrawn from the market.','DB01459.svg','15301-48-1','Average: 492.6114','None','None','None','None','https://www.drugbank.ca/drugs/DB01459'),('Ecgonine','DB01525','Small Molecule','Experimental, Illicit','None','DB01525.svg','481-37-8','Average: 185.2203','None','None','91460','http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=91460','https://www.drugbank.ca/drugs/DB01525'),('Carfentanil','DB01535','Small Molecule','Illicit, Investigational, Vet approved','Carfentanil or carfentanyl (Wildnil) is an analogue of the popular synthetic opioid analgesic fentanyl, and is one of the most potent opioids known (also the most potent opioid used commercially). Carfentanil was first synthesized in 1974 by a team of chemists at Janssen Pharmaceutica which included Paul Janssen. It has a quantitative potency approximately 10,000 times that of morphine and 100 times that of fentanyl, with activity in humans starting at about 1 microgram. It is marketed under the trade name Wildnil as a general anaesthetic agent for large animals. Carfentanil is intended for large-animal use only as its extreme potency makes it inappropriate for use in humans. Currently sufentanil, approximately 10â€“20 times less potent (500 to 1000 times the efficacy of morphine per weight) than carfentanil, is the maximum strength fentanyl analog for use in humans.','DB01535.svg','59708-52-0','Average: 394.5066','true','true','46505501','http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46505501','https://www.drugbank.ca/drugs/DB01535'),('Dihydromorphine','DB01565','Small Molecule','Experimental, Illicit','A semisynthetic analgesic used in the study of narcotic receptors. It has abuse potential. [PubChem]','DB01565.svg','509-60-4','Average: 287.3535','true','true','C11782','http://www.genome.jp/dbget-bin/www_bget?cpd:C11782','https://www.drugbank.ca/drugs/DB01565'),('Etoricoxib','DB01628','Small Molecule','Approved, Investigational','Etoricoxib is a new COX-2 selective inhibitor. Current therapeutic indications are: treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. Like any other COX-2 selective inhibitor, Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2). This reduces the generation of prostaglandins (PGs) from arachidonic acid.','DB01628.svg','202409-33-4','Average: 358.842','true','true','D03710','http://www.genome.jp/dbget-bin/www_bget?drug:D03710','https://www.drugbank.ca/drugs/DB01628'),('Castanospermine','DB01816','Small Molecule','Experimental','None','DB01816.svg','79831-76-8','Average: 189.209','None','true','None','None','https://www.drugbank.ca/drugs/DB01816'),('7-Nitroindazole','DB02207','Small Molecule','Experimental','None','DB02207.svg','2942-42-9','Average: 163.1335','None','true','None','None','https://www.drugbank.ca/drugs/DB02207'),('Nimesulide','DB04743','Small Molecule','Approved, Investigational, Withdrawn','Nimesulide is a relatively COX-2 selective, non-steroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. Its approved indications are the treatment of acute pain, the symptomatic treatment of osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years old. Due to concerns about the risk of hepatotoxicity, nimesulide has been withdrawn from market in many countries.','DB04743.svg','51803-78-2','Average: 308.31','None','true','4495','http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=4495','https://www.drugbank.ca/drugs/DB04743'),('PTC299','DB05173','Small Molecule','Investigational','PTC299 is a novel, orally administered small-molecule designed to inhibit the production of vascular endothelial growth factor (VEGF) in tumors. Overexpression of VEGF plays a key role in multiple diseases including cancer and macular degeneration. PTC299 was discovered through PTC\'s GEMS technology by targeting the post-transcriptional processes that regulate VEGF formation, and is currently being developed for the treatment of cancer.','DB05173.svg','None','None','None','None','None','None','https://www.drugbank.ca/drugs/DB05173'),('Samarium (153Sm) lexidronam','DB05273','Small Molecule','Approved, Investigational','Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body\'s organs or to treat certain diseases.Samarium Sm 153 lexidronam is used to help relieve the bone pain that may occur with certain kinds of cancer. The radioactive samarium is taken up in the bone cancer area and gives off radiation that helps provide relief of pain.','DB05273.svg','122575-21-7','Average: 586.021','None','None','None','None','https://www.drugbank.ca/drugs/DB05273'),('Icatibant','DB06196','Small Molecule','Approved, Investigational','Icatibant (Firazyr) is a synthetic peptidomimetic drug consisting of ten amino acids, and acts as an effective and specific antagonist of bradykinin B2 receptors. It has been approved in the EU for use in hereditary angioedema, and is under investigation for a number of other conditions in which bradykinin is thought to play a significant role. Icatibant currently has orphan drug status in the United States and FDA approved on August 25, 2011.','DB06196.svg','130308-48-4','Average: 1304.522','None','true','None','None','https://www.drugbank.ca/drugs/DB06196'),('Nitrous oxide','DB06690','Small Molecule','Approved, Vet approved','Nitrous oxide, commonly known as \"laughing gas\", is a chemical compound with the chemical formula N2O. At room temperature, it is a colorless non-flammable gas, with a pleasant, slightly sweet odor and taste. It is used in surgery and dentistry for its anesthetic and analgesic effects. It is known as \"laughing gas\" due to the euphoric effects of inhaling it, a property that has led to its recreational use as an inhalant drug [Wikipedia].','DB06690.svg','10024-97-2','Average: 44.0128','None','None','None','None','https://www.drugbank.ca/drugs/DB06690'),('Ketobemidone','DB06738','Small Molecule','Approved, Investigational','Ketobemidone is a powerful opioid analgesic. Its effectiveness against pain is in the same range as morphine, and it also has some NMDA-antagonist properties. This makes it useful for some types of pain that don\'t respond well to other opioids. The most commonly cited equalisation ratio for analgesic doses is 25 mg of ketobemidone hydrobromide to 60 mg of morphine hydrochloride or sulfate and circa 8 mg of ketobemidone by injection.','DB06738.svg','469-79-4','Average: 247.3327','true','true','None','None','https://www.drugbank.ca/drugs/DB06738'),('Seratrodast','DB06739','Small Molecule','Approved','Seratrodast (INN) is a thromboxane receptor antagonist used primarily in the treatment of asthma.','DB06739.svg','112665-43-7','Average: 354.446','None','true','None','None','https://www.drugbank.ca/drugs/DB06739'),('Drotaverine','DB06751','Small Molecule','Approved, Investigational','Drotaverine (INN, also known as drotaverin) is an antispasmodic drug, structurally related to papaverine. Drotaverine is a selective inhibitor of phosphodiesterase 4, and has no anticholinergic effects. Drotaverine has been shown to possess dose-dependant analgesic effects in animal models. One small study has shown drotaverine to be eliminated mainly non-renally.','DB06751.svg','14009-24-6','Average: 397.5072','None','true','None','None','https://www.drugbank.ca/drugs/DB06751'),('Nepafenac','DB06802','Small Molecule','Approved, Investigational','Nepafenac is a non-steroidal anti-inflammatory prodrug (NSAID) usually sold as a prescription eye drop. It is used to treat pain and inflammation associated with cataract surgery.','DB06802.svg','78281-72-8','Average: 254.2839','true','true','None','None','https://www.drugbank.ca/drugs/DB06802'),('Ferulic acid','DB07767','Small Molecule','Experimental','None','DB07767.svg','1135-24-6','Average: 194.184','None','true','None','None','https://www.drugbank.ca/drugs/DB07767'),('Kebuzone','DB08940','Small Molecule','Experimental','Kebuzone (also known as ketophenylbutazone ) is a non-steroidal anti-inflammatory drug.','DB08940.svg','853-34-9','Average: 322.3578','None','None','None','None','https://www.drugbank.ca/drugs/DB08940'),('Dimetotiazine','DB08967','Small Molecule','Approved','Dimetotiazine has considerable antiemetic & serotonin antagonistic action used mainly in allergic skin conditions.','DB08967.svg','7456-24-8','Average: 391.55','None','None','310264930','http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=310264930','https://www.drugbank.ca/drugs/DB08967'),('Pholcodine','DB09209','Small Molecule','Approved, Illicit','Pholcodine formula is 3-o-morpholinoethylmorphine and it is classified as an antitussive which is defined as an opioid cough suppressant. It belongs to the opioid family of compounds and it is widely used.','DB09209.svg','509-67-1','Average: 398.4953','None','true','None','None','https://www.drugbank.ca/drugs/DB09209'),('Loxoprofen','DB09212','Small Molecule','Approved, Investigational','Loxoprofen (INN) is a non-steroidal anti-inflammatory drug in the propionic acid derivatives group, which also includes ibuprofen and naproxen, among others. It is marketed in Brazil, Mexico and Japan by Sankyo as its sodium salt, loxoprofen sodium, under the trade name Loxonin, Argentina as Oxeno and in India as Loxomac. It is available in these countries for oral administration, and a transdermal preparation was approved for sale in Japan in January 2006.','DB09212.svg','68767-14-6','Average: 246.3016','None','true','None','None','https://www.drugbank.ca/drugs/DB09212'),('Curcumin','DB11672','Small Molecule','Approved, Investigational','Curcumin, also known as diferuloylmethane, is an active component in the golden spice turmeric (Curcuma longa) and in','DB11672.svg','458-37-7','Average: 368.3799','None','true','None','None','https://www.drugbank.ca/drugs/DB11672'),('Mizoribine','DB12617','Small Molecule','Investigational','Mizoribine has been investigated for the treatment of Rheumatoid Arthritis.','DB12617.svg','50924-49-7','Average: 259.216','None','None','None','None','https://www.drugbank.ca/drugs/DB12617'),('Apocynin','DB12618','Small Molecule','Investigational','Acetovanillone has been used in trials studying the treatment of Bronchial Asthma and Chronic Obstructive Pulmonary Disease.','DB12618.svg','498-02-2','Average: 166.1739','None','None','None','None','https://www.drugbank.ca/drugs/DB12618'),('Higenamine','DB12779','Small Molecule','Investigational','Higenamine is under investigation in clinical trial NCT01451229 (Pharmacokinetics and Pharmacodynamics of Higenamine in Chinese Healthy Subjects).','DB12779.svg','5843-65-2','Average: 271.3111','None','None','None','None','https://www.drugbank.ca/drugs/DB12779'),('Fentiazac','DB13217','Small Molecule','Experimental','None','DB13217.svg','18046-21-4','Average: 329.8','None','None','None','None','https://www.drugbank.ca/drugs/DB13217'),('Bufexamac','DB13346','Small Molecule','Approved, Experimental','Bufexamac is a non-steroidal anti-inflammatory drug (NSAID) under the market name Droxaryl, Malipuran, Paraderm and Parfenac. It is typically administered topically for the treatment of subacute and chronic eczema of the skin, including atopic eczema and other inflammatory dermatoses, as well as sunburn and other minor burns, and itching. It has also been used in suppositories in combination with local anaesthetics indicated for haemorrhoids. The use of bufexamac has been discontinued in Canada and the United States, which may be due to undetermined clinical efficacy and a high prevalence of contact sensitization','DB13346.svg','2438-72-4','Average: 223.272','None','true','None','None','https://www.drugbank.ca/drugs/DB13346'),('Aloxiprin','DB13509','Small Molecule','Experimental','None','DB13509.svg','9014-67-9','Average: 282.119','None','None','None','None','https://www.drugbank.ca/drugs/DB13509'),('Pranoprofen','DB13514','Small Molecule','Experimental, Investigational','None','DB13514.svg','52549-17-4','Average: 255.2686','None','None','None','None','https://www.drugbank.ca/drugs/DB13514');

/*Table structure for table `drugbank_keggdrug` */

DROP TABLE IF EXISTS `drugbank_keggdrug`;

CREATE TABLE `drugbank_keggdrug` (
  `kegg_id` varchar(200) DEFAULT NULL,
  `KEGG_Drug_link` varchar(200) DEFAULT NULL,
  `drugbank_id` varchar(200) DEFAULT NULL,
  `drugbank_url` varchar(200) DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

/*Data for the table `drugbank_keggdrug` */

insert  into `drugbank_keggdrug`(`kegg_id`,`KEGG_Drug_link`,`drugbank_id`,`drugbank_url`) values ('D00567','http://www.genome.jp/dbget-bin/www_bget?drug:D00567','DB00482','https://www.drugbank.ca/drugs/DB00482\n'),('D00097','http://www.genome.jp/dbget-bin/www_bget?drug:D00097','DB00936','https://www.drugbank.ca/drugs/DB00936\n'),('D00045','http://www.genome.jp/dbget-bin/www_bget?drug:D00045','DB00640','https://www.drugbank.ca/drugs/DB00640\n'),('C08019','http://www.genome.jp/dbget-bin/www_bget?cpd:C08019','DB01192','https://www.drugbank.ca/drugs/DB01192\n'),('D00969','http://www.genome.jp/dbget-bin/www_bget?drug:D00969','DB00814','https://www.drugbank.ca/drugs/DB00814\n'),('C08021','http://www.genome.jp/dbget-bin/www_bget?cpd:C08021','DB00899','https://www.drugbank.ca/drugs/DB00899\n'),('C07789','http://www.genome.jp/dbget-bin/www_bget?cpd:C07789','DB00768','https://www.drugbank.ca/drugs/DB00768\n'),('D00463','http://www.genome.jp/dbget-bin/www_bget?drug:D00463','DB00991','https://www.drugbank.ca/drugs/DB00991\n'),('D07816','http://www.genome.jp/dbget-bin/www_bget?drug:D07816','DB00586','https://www.drugbank.ca/drugs/DB00586\n'),('60726','http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=60726','DB00963','https://www.drugbank.ca/drugs/DB00963\n'),('D00510','http://www.genome.jp/dbget-bin/www_bget?drug:D00510','DB00812','https://www.drugbank.ca/drugs/DB00812\n'),('D05938','http://www.genome.jp/dbget-bin/www_bget?drug:D05938','DB00708','https://www.drugbank.ca/drugs/DB00708\n'),('C07995','http://www.genome.jp/dbget-bin/www_bget?cpd:C07995','DB01397','https://www.drugbank.ca/drugs/DB01397\n'),('C08005','http://www.genome.jp/dbget-bin/www_bget?cpd:C08005','DB00802','https://www.drugbank.ca/drugs/DB00802\n'),('D00252','http://www.genome.jp/dbget-bin/www_bget?drug:D00252','DB00564','https://www.drugbank.ca/drugs/DB00564\n'),('D08233','http://www.genome.jp/dbget-bin/www_bget?drug:D08233','DB00295','https://www.drugbank.ca/drugs/DB00295\n'),('D08623','http://www.genome.jp/dbget-bin/www_bget?drug:D08623','DB00193','https://www.drugbank.ca/drugs/DB00193\n'),('D00118','http://www.genome.jp/dbget-bin/www_bget?drug:D00118','DB00788','https://www.drugbank.ca/drugs/DB00788\n'),('D00968','http://www.genome.jp/dbget-bin/www_bget?drug:D00968','DB00573','https://www.drugbank.ca/drugs/DB00573\n'),('D01776','http://www.genome.jp/dbget-bin/www_bget?drug:D01776','DB01435','https://www.drugbank.ca/drugs/DB01435\n'),('D00315','http://www.genome.jp/dbget-bin/www_bget?drug:D00315','DB00749','https://www.drugbank.ca/drugs/DB00749\n'),('C07042','http://www.genome.jp/dbget-bin/www_bget?cpd:C07042','DB00327','https://www.drugbank.ca/drugs/DB00327\n'),('46505501','http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46505501','DB01535','https://www.drugbank.ca/drugs/DB01535\n'),('D05312','http://www.genome.jp/dbget-bin/www_bget?drug:D05312','DB00497','https://www.drugbank.ca/drugs/DB00497\n'),('D00126','http://www.genome.jp/dbget-bin/www_bget?drug:D00126','DB01050','https://www.drugbank.ca/drugs/DB01050\n'),('D03580','http://www.genome.jp/dbget-bin/www_bget?drug:D03580','DB00318','https://www.drugbank.ca/drugs/DB00318\n'),('C07163','http://www.genome.jp/dbget-bin/www_bget?cpd:C07163','DB00333','https://www.drugbank.ca/drugs/DB00333\n'),('D00217','http://www.genome.jp/dbget-bin/www_bget?drug:D00217','DB00316','https://www.drugbank.ca/drugs/DB00316\n'),('D00130','http://www.genome.jp/dbget-bin/www_bget?drug:D00130','DB00861','https://www.drugbank.ca/drugs/DB00861\n'),('D07132','http://www.genome.jp/dbget-bin/www_bget?drug:D07132','DB00921','https://www.drugbank.ca/drugs/DB00921\n'),('C18364','http://www.genome.jp/dbget-bin/www_bget?cpd:C18364','DB00821','https://www.drugbank.ca/drugs/DB00821\n'),('D00330','http://www.genome.jp/dbget-bin/www_bget?drug:D00330','DB00712','https://www.drugbank.ca/drugs/DB00712\n'),('D00141','http://www.genome.jp/dbget-bin/www_bget?drug:D00141','DB00328','https://www.drugbank.ca/drugs/DB00328\n'),('D03710','http://www.genome.jp/dbget-bin/www_bget?drug:D03710','DB01628','https://www.drugbank.ca/drugs/DB01628\n'),('D00320','http://www.genome.jp/dbget-bin/www_bget?drug:D00320','DB00813','https://www.drugbank.ca/drugs/DB00813\n'),('119607','http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=119607','DB00580','https://www.drugbank.ca/drugs/DB00580\n'),('D00132','http://www.genome.jp/dbget-bin/www_bget?drug:D00132','DB01009','https://www.drugbank.ca/drugs/DB01009\n'),('D00127','http://www.genome.jp/dbget-bin/www_bget?drug:D00127','DB00554','https://www.drugbank.ca/drugs/DB00554\n'),('D08246','http://www.genome.jp/dbget-bin/www_bget?drug:D08246','DB00844','https://www.drugbank.ca/drugs/DB00844\n'),('D00425','http://www.genome.jp/dbget-bin/www_bget?drug:D00425','DB00461','https://www.drugbank.ca/drugs/DB00461\n'),('D00120','http://www.genome.jp/dbget-bin/www_bget?drug:D00120','DB00605','https://www.drugbank.ca/drugs/DB00605\n'),('C07406','http://www.genome.jp/dbget-bin/www_bget?cpd:C07406','DB00647','https://www.drugbank.ca/drugs/DB00647\n'),('D08123','http://www.genome.jp/dbget-bin/www_bget?drug:D08123','DB00854','https://www.drugbank.ca/drugs/DB00854\n'),('C11782','http://www.genome.jp/dbget-bin/www_bget?cpd:C11782','DB01565','https://www.drugbank.ca/drugs/DB01565\n'),('C07062','http://www.genome.jp/dbget-bin/www_bget?cpd:C07062','DB00465','https://www.drugbank.ca/drugs/DB00465\n'),('D07690','http://www.genome.jp/dbget-bin/www_bget?drug:D07690','DB00122','https://www.drugbank.ca/drugs/DB00122\n'),('D00301','http://www.genome.jp/dbget-bin/www_bget?drug:D00301','DB01081','https://www.drugbank.ca/drugs/DB01081\n'),('D00109','http://www.genome.jp/dbget-bin/www_bget?drug:D00109','DB00945','https://www.drugbank.ca/drugs/DB00945\n'),('D08045','http://www.genome.jp/dbget-bin/www_bget?drug:D08045','DB00956','https://www.drugbank.ca/drugs/DB00956\n');

/*Table structure for table `drugbank_target` */

DROP TABLE IF EXISTS `drugbank_target`;

CREATE TABLE `drugbank_target` (
  `target_name` varchar(200) NOT NULL,
  `Kind` varchar(200) DEFAULT NULL,
  `Organism` varchar(200) DEFAULT NULL,
  `General_Function` text,
  `Specific_Function` text,
  `Gene_Name` varchar(200) DEFAULT NULL,
  `Molecular_Weight` varchar(200) DEFAULT NULL,
  `drugbank_id` varchar(200) DEFAULT NULL,
  `Gene_sequence` text,
  PRIMARY KEY (`target_name`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

/*Data for the table `drugbank_target` */

insert  into `drugbank_target`(`target_name`,`Kind`,`Organism`,`General_Function`,`Specific_Function`,`Gene_Name`,`Molecular_Weight`,`drugbank_id`,`Gene_sequence`) values ('3-phosphoinositide-dependent protein kinase 1','None','Human','Protein serine/threonine kinase activity','Serine/threonine kinase which acts as a master kinase, phosphorylating and activating a subgroup of the AGC family of protein kinases. Its targets include: protein kinase B (PKB/AKT1, PKB/AKT2, PKB/AKT3), p70 ribosomal protein S6 kinase (RPS6KB1), p90 ribosomal protein S6 kinase (RPS6KA1, RPS6KA2 and RPS6KA3), cyclic AMP-dependent protein kinase (PRKACA), protein kinase C (PRKCD and PRKCZ), serum and glucocorticoid-inducible kinase (SGK1, SGK2 and SGK3), p21-activated kinase-1 (PAK1), protein kinase PKN (PKN1 and PKN2). Plays a central role in the transduction of signals from insulin by providing the activating phosphorylation to PKB/AKT1, thus propagating the signal to downstream targets controlling cell proliferation and survival, as well as glucose and amino acid uptake and storage. Negatively regulates the TGF-beta-induced signaling by: modulating the association of SMAD3 and SMAD7 with TGF-beta receptor, phosphorylating SMAD2, SMAD3, SMAD4 and SMAD7, preventing the nuclear translocation of SMAD3 and SMAD4 and the translocation of SMAD7 from the nucleus to the cytoplasm in response to TGF-beta. Activates PPARG transcriptional activity and promotes adipocyte differentiation. Activates the NF-kappa-B pathway via phosphorylation of IKKB. The tyrosine phosphorylated form is crucial for the regulation of focal adhesions by angiotensin II. Controls proliferation, survival, and growth of developing pancreatic cells. Participates in the regulation of Ca(2+) entry and Ca(2+)-activated K(+) channels of mast cells. Essential for the motility of vascular endothelial cells (ECs) and is involved in the regulation of their chemotaxis. Plays a critical role in cardiac homeostasis by serving as a dual effector for cell survival and beta-adrenergic response. Plays an important role during thymocyte development by regulating the expression of key nutrient receptors on the surface of pre-T cells and mediating Notch-induced cell growth and proliferative responses. Provides negative feedback inhibition to toll-like receptor-mediated NF-kappa-B activation in macrophages. Isoform 3 is catalytically inactive.','PDPK1','63151.305','DB00482','>lcl|BSEQ0021289|3-phosphoinositide-dependent protein kinase 1 (PDPK1)\nATGGCCAGGACCACCAGCCAGCTGTATGACGCCGTGCCCATCCAGTCCAGCGTGGTGTTA\nTGTTCCTGCCCATCCCCATCAATGGTGAGGACCCAGACTGAGTCCAGCACGCCCCCTGGC\nATTCCTGGTGGCAGCAGGCAGGGCCCCGCCATGGACGGCACTGCAGCCGAGCCTCGGCCC\nGGCGCCGGCTCCCTGCAGCATGCCCAGCCTCCGCCGCAGCCTCGGAAGAAGCGGCCTGAG\nGACTTCAAGTTTGGGAAAATCCTTGGGGAAGGCTCTTTTTCCACGGTTGTCCTGGCTCGA\nGAACTGGCAACCTCCAGAGAATATGCGATTAAAATTCTGGAGAAGCGACATATCATAAAA\nGAGAACAAGGTCCCCTATGTAACCAGAGAGCGGGATGTCATGTCGCGCCTGGATCACCCC\nTTCTTTGTTAAGCTTTACTTCACATTTCAGGACGACGAGAAGCTGTATTTCGGCCTTAGT\nTATGCCAAAAATGGAGAACTACTTAAATATATTCGCAAAATCGGTTCATTCGATGAGACC\nTGTACCCGATTTTACACGGCTGAGATTGTGTCTGCTTTAGAGTACTTGCACGGCAAGGGC\nATCATTCACAGGGACCTTAAACCGGAAAACATTTTGTTAAATGAAGATATGCACATCCAG\nATCACAGATTTTGGAACAGCAAAAGTCTTATCCCCAGAGAGCAAACAAGCCAGGGCCAAC\nTCATTCGTGGGAACAGCGCAGTACGTTTCTCCAGAGCTGCTCACGGAGAAGTCCGCCTGT\nAAGAGTTCAGACCTTTGGGCTCTTGGATGCATAATATACCAGCTTGTGGCAGGACTCCCA\nCCATTCCGAGCTGGAAACGAGTATCTTATATTTCAGAAGATCATTAAGTTGGAATATGAC\nTTTCCAGAAAAATTCTTCCCTAAGGCAAGAGACCTCGTGGAGAAACTTTTGGTTTTAGAT\nGCCACAAAGCGGTTAGGCTGTGAGGAAATGGAAGGATACGGACCTCTTAAAGCACACCCG\nTTCTTCGAGTCCGTCACGTGGGAGAACCTGCACCAGCAGACGCCTCCGAAGCTCACCGCT\nTACCTGCCGGCTATGTCGGAAGACGACGAGGACTGCTATGGCAATTATGACAATCTCCTG\nAGCCAGTTTGGCTGCATGCAGGTGTCTTCGTCCTCCTCCTCACACTCCCTGTCAGCCTCC\nGACACGGGCCTGCCCCAGAGGTCAGGCAGCAACATAGAGCAGTACATTCACGATCTGGAC\nTCGAACTCCTTTGAACTGGACTTACAGTTTTCCGAAGATGAGAAGAGGTTGTTGTTGGAG\nAAGCAGGCTGGCGGAAACCCTTGCCTAACAGGACGTATTATCTGA'),('5\'-AMP-activated protein kinase catalytic subunit alpha-1','None','Human','Tau-protein kinase activity','Catalytic subunit of AMP-activated protein kinase (AMPK), an energy sensor protein kinase that plays a key role in regulating cellular energy metabolism. In response to reduction of intracellular ATP levels, AMPK activates energy-producing pathways and inhibits energy-consuming processes: inhibits protein, carbohydrate and lipid biosynthesis, as well as cell growth and proliferation. AMPK acts via direct phosphorylation of metabolic enzymes, and by longer-term effects via phosphorylation of transcription regulators. Also acts as a regulator of cellular polarity by remodeling the actin cytoskeleton; probably by indirectly activating myosin. Regulates lipid synthesis by phosphorylating and inactivating lipid metabolic enzymes such as ACACA, ACACB, GYS1, HMGCR and LIPE; regulates fatty acid and cholesterol synthesis by phosphorylating acetyl-CoA carboxylase (ACACA and ACACB) and hormone-sensitive lipase (LIPE) enzymes, respectively. Regulates insulin-signaling and glycolysis by phosphorylating IRS1, PFKFB2 and PFKFB3. AMPK stimulates glucose uptake in muscle by increasing the translocation of the glucose transporter SLC2A4/GLUT4 to the plasma membrane, possibly by mediating phosphorylation of TBC1D4/AS160. Regulates transcription and chromatin structure by phosphorylating transcription regulators involved in energy metabolism such as CRTC2/TORC2, FOXO3, histone H2B, HDAC5, MEF2C, MLXIPL/ChREBP, EP300, HNF4A, p53/TP53, SREBF1, SREBF2 and PPARGC1A. Acts as a key regulator of glucose homeostasis in liver by phosphorylating CRTC2/TORC2, leading to CRTC2/TORC2 sequestration in the cytoplasm. In response to stress, phosphorylates \'Ser-36\' of histone H2B (H2BS36ph), leading to promote transcription. Acts as a key regulator of cell growth and proliferation by phosphorylating TSC2, RPTOR and ATG1/ULK1: in response to nutrient limitation, negatively regulates the mTORC1 complex by phosphorylating RPTOR component of the mTORC1 complex and by phosphorylating and activating TSC2. In response to nutrient limitation, promotes autophagy by phosphorylating and activating ATG1/ULK1. AMPK also acts as a regulator of circadian rhythm by mediating phosphorylation of CRY1, leading to destabilize it. May regulate the Wnt signaling pathway by phosphorylating CTNNB1, leading to stabilize it. Also has tau-protein kinase activity: in response to amyloid beta A4 protein (APP) exposure, activated by CAMKK2, leading to phosphorylation of MAPT/TAU; however the relevance of such data remains unclear in vivo. Also phosphorylates CFTR, EEF2K, KLC1, NOS3 and SLC12A1.','PRKAA1','64008.64','DB00945','>lcl|BSEQ0010471|5\'-AMP-activated protein kinase catalytic subunit alpha-1 (PRKAA1)\nATGCGCAGACTCAGTTCCTGGAGAAAGATGGCGACAGCCGAGAAGCAGAAACACGACGGG\nCGGGTGAAGATCGGCCACTACATTCTGGGTGACACGCTGGGGGTCGGCACCTTCGGCAAA\nGTGAAGGTTGGCAAACATGAATTGACTGGGCATAAAGTAGCTGTGAAGATACTCAATCGA\nCAGAAGATTCGGAGCCTTGATGTGGTAGGAAAAATCCGCAGAGAAATTCAGAACCTCAAG\nCTTTTCAGGCATCCTCATATAATTAAACTGTACCAGGTCATCAGTACACCATCTGATATT\nTTCATGGTGATGGAATATGTCTCAGGAGGAGAGCTATTTGATTATATCTGTAAGAATGGA\nAGGCTGGATGAAAAAGAAAGTCGGCGTCTGTTCCAACAGATCCTTTCTGGTGTGGATTAT\nTGTCACAGGCATATGGTGGTCCATAGAGATTTGAAACCTGAAAATGTCCTGCTTGATGCA\nCACATGAATGCAAAGATAGCTGATTTTGGTCTTTCAAACATGATGTCAGATGGTGAATTT\nTTAAGAACAAGTTGTGGCTCACCCAACTATGCTGCACCAGAAGTAATTTCAGGAAGATTG\nTATGCAGGCCCAGAGGTAGATATATGGAGCAGTGGGGTTATTCTCTATGCTTTATTATGT\nGGAACCCTTCCATTTGATGATGACCATGTGCCAACTCTTTTTAAGAAGATATGTGATGGG\nATCTTCTATACCCCTCAATATTTAAATCCTTCTGTGATTAGCCTTTTGAAACATATGCTG\nCAGGTGGATCCCATGAAGAGGGCCACAATCAAAGATATCAGGGAACATGAATGGTTTAAA\nCAGGACCTTCCAAAATATCTCTTTCCTGAGGATCCATCATATAGTTCAACCATGATTGAT\nGATGAAGCCTTAAAAGAAGTATGTGAAAAGTTTGAGTGCTCAGAAGAGGAAGTTCTCAGC\nTGTCTTTACAACAGAAATCACCAGGATCCTTTGGCAGTTGCCTACCATCTCATAATAGAT\nAACAGGAGAATAATGAATGAAGCCAAAGATTTCTATTTGGCGACAAGCCCACCTGATTCT\nTTTCTTGATGATCATCACCTGACTCGGCCCCATCCTGAAAGAGTACCATTCTTGGTTGCT\nGAAACACCAAGGGCACGCCATACCCTTGATGAATTAAATCCACAGAAATCCAAACACCAA\nGGTGTAAGGAAAGCAAAATGGCATTTAGGAATTAGAAGTCAAAGTCGACCAAATGATATT\nATGGCAGAAGTATGTAGAGCAATCAAACAATTGGATTATGAATGGAAGGTTGTAAACCCA\nTATTATTTGCGTGTACGAAGGAAGAATCCTGTGACAAGCACTTACTCCAAAATGAGTCTA\nCAGTTATACCAAGTGGATAGTAGAACTTATCTACTGGATTTCCGTAGTATTGATGATGAA\nATTACAGAAGCCAAATCAGGGACTGCTACTCCACAGAGATCGGGATCAGTTAGCAACTAT\nCGATCTTGCCAAAGGAGTGATTCAGATGCTGAGGCTCAAGGAAAATCCTCAGAAGTTTCT\nCTTACCTCATCTGTGACCTCACTTGACTCTTCTCCTGTTGACCTAACTCCAAGACCTGGA\nAGTCACACAATAGAATTTTTTGAGATGTGTGCAAATCTAATTAAAATTCTTGCACAATAA'),('5-hydroxytryptamine receptor 1','protein group','Human','None','None','None','None','DB01221','None'),('5-hydroxytryptamine receptor 1A','None','Human','Serotonin receptor activity','G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling inhibits adenylate cyclase activity and activates a phosphatidylinositol-calcium second messenger system that regulates the release of Ca(2+) ions from intracellular stores. Plays a role in the regulation of 5-hydroxytryptamine release and in the regulation of dopamine and 5-hydroxytryptamine metabolism. Plays a role in the regulation of dopamine and 5-hydroxytryptamine levels in the brain, and thereby affects neural activity, mood and behavior. Plays a role in the response to anxiogenic stimuli.','HTR1A','46106.335','DB01149','>lcl|BSEQ0018935|5-hydroxytryptamine receptor 1A (HTR1A)\nATGGATGTGCTCAGCCCTGGTCAGGGCAACAACACCACATCACCACCGGCTCCCTTTGAG\nACCGGCGGCAACACTACTGGTATCTCCGACGTGACCGTCAGCTACCAAGTGATCACCTCT\nCTGCTGCTGGGCACGCTCATCTTCTGCGCGGTGCTGGGCAATGCGTGCGTGGTGGCTGCC\nATCGCCTTGGAGCGCTCCCTGCAGAACGTGGCCAATTATCTTATTGGCTCTTTGGCGGTC\nACCGACCTCATGGTGTCGGTGTTGGTGCTGCCCATGGCCGCGCTGTATCAGGTGCTCAAC\nAAGTGGACACTGGGCCAGGTAACCTGCGACCTGTTCATCGCCCTCGACGTGCTGTGCTGC\nACCTCATCCATCTTGCACCTGTGCGCCATCGCGCTGGACAGGTACTGGGCCATCACGGAC\nCCCATCGACTACGTGAACAAGAGGACGCCCCGGCGCGCCGCTGCGCTCATCTCGCTCACT\nTGGCTTATTGGCTTCCTCATCTCTATCCCGCCCATGCTGGGCTGGCGCACCCCGGAAGAC\nCGCTCGGACCCCGACGCATGCACCATTAGCAAGGATCATGGCTACACTATCTATTCCACC\nTTTGGAGCTTTCTACATCCCGCTGCTGCTCATGCTGGTTCTCTATGGGCGCATATTCCGA\nGCTGCGCGCTTCCGCATCCGCAAGACGGTCAAAAAGGTGGAGAAGACCGGAGCGGACACC\nCGCCATGGAGCATCTCCCGCCCCGCAGCCCAAGAAGAGTGTGAATGGAGAGTCGGGGAGC\nAGGAACTGGAGGCTGGGCGTGGAGAGCAAGGCTGGGGGTGCTCTGTGCGCCAATGGCGCG\nGTGAGGCAAGGTGACGATGGCGCCGCCCTGGAGGTGATCGAGGTGCACCGAGTGGGCAAC\nTCCAAAGAGCACTTGCCTCTGCCCAGCGAGGCTGGTCCTACCCCTTGTGCCCCCGCCTCT\nTTCGAGAGGAAAAATGAGCGCAACGCCGAGGCGAAGCGCAAGATGGCCCTGGCCCGAGAG\nAGGAAGACAGTGAAGACGCTGGGCATCATCATGGGCACCTTCATCCTCTGCTGGCTGCCC\nTTCTTCATCGTGGCTCTTGTTCTGCCCTTCTGCGAGAGCAGCTGCCACATGCCCACCCTG\nTTGGGCGCCATAATCAATTGGCTGGGCTACTCCAACTCTCTGCTTAACCCCGTCATTTAC\nGCATACTTCAACAAGGACTTTCAAAACGCGTTTAAGAAGATCATTAAGTGTAAGTTCTGC\nCGCCAGTGA'),('5-hydroxytryptamine receptor 1B','None','Human','Serotonin receptor activity','G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. Arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Regulates the release of 5-hydroxytryptamine, dopamine and acetylcholine in the brain, and thereby affects neural activity, nociceptive processing, pain perception, mood and behavior. Besides, plays a role in vasoconstriction of cerebral arteries.','HTR1B','43567.535','DB00320','>lcl|BSEQ0019015|5-hydroxytryptamine receptor 1B (HTR1B)\nATGGAGGAACCGGGTGCTCAGTGCGCTCCACCGCCGCCCGCGGGCTCCGAGACCTGGGTT\nCCTCAAGCCAACTTATCCTCTGCTCCCTCCCAAAACTGCAGCGCCAAGGACTACATTTAC\nCAGGACTCCATCTCCCTACCCTGGAAAGTACTGCTGGTTATGCTATTGGCGCTCATCACC\nTTGGCCACCACGCTCTCCAATGCCTTTGTGATTGCCACAGTGTACCGGACCCGGAAACTG\nCACACCCCGGCTAACTACCTGATCGCCTCTCTGGCGGTCACCGACCTGCTTGTGTCCATC\nCTGGTGATGCCCATCAGCACCATGTACACTGTCACCGGCCGCTGGACACTGGGCCAGGTG\nGTCTGTGACTTCTGGCTGTCGTCGGACATCACTTGTTGCACTGCCTCCATCCTGCACCTC\nTGTGTCATCGCCCTGGACCGCTACTGGGCCATCACGGACGCCGTGGAGTACTCAGCTAAA\nAGGACTCCCAAGAGGGCGGCGGTCATGATCGCGCTGGTGTGGGTCTTCTCCATCTCTATC\nTCGCTGCCGCCCTTCTTCTGGCGTCAGGCTAAGGCCGAAGAGGAGGTGTCGGAATGCGTG\nGTGAACACCGACCACATCCTCTACACGGTCTACTCCACGGTGGGTGCTTTCTACTTCCCC\nACCCTGCTCCTCATCGCCCTCTATGGCCGCATCTACGTAGAAGCCCGCTCCCGGATTTTG\nAAACAGACGCCCAACAGGACCGGCAAGCGCTTGACCCGAGCCCAGCTGATAACCGACTCC\nCCCGGGTCCACGTCCTCGGTCACCTCTATTAACTCGCGGGTTCCCGACGTGCCCAGCGAA\nTCCGGATCTCCTGTGTATGTGAACCAAGTCAAAGTGCGAGTCTCCGACGCCCTGCTGGAA\nAAGAAGAAACTCATGGCCGCTAGGGAGCGCAAAGCCACCAAGACCCTAGGGATCATTTTG\nGGAGCCTTTATTGTGTGTTGGCTACCCTTCTTCATCATCTCCCTAGTGATGCCTATCTGC\nAAAGATGCCTGCTGGTTCCACCTAGCCATCTTTGACTTCTTCACATGGCTGGGCTATCTC\nAACTCCCTCATCAACCCCATAATCTATACCATGTCCAATGAGGACTTTAAACAAGCATTC\nCATAAACTGATACGTTTTAAGTGCACAAGTTGA'),('5-hydroxytryptamine receptor 1D','None','Human','Serotonin receptor activity','G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. Regulates the release of 5-hydroxytryptamine in the brain, and thereby affects neural activity. May also play a role in regulating the release of other neurotransmitters. May play a role in vasoconstriction.','HTR1D','41906.38','DB00320','>lcl|BSEQ0010459|5-hydroxytryptamine receptor 1D (HTR1D)\nATGTCCCCACTGAACCAGTCAGCAGAAGGCCTTCCCCAGGAGGCCTCCAACAGATCCCTG\nAATGCCACAGAAACCTCAGAGGCTTGGGATCCCAGGACCCTCCAGGCGCTCAAGATCTCC\nCTTGCCGTGGTCCTTTCCGTCATCACACTGGCCACAGTCCTCTCCAATGCCTTTGTACTC\nACCACCATCTTACTCACCAGGAAGCTCCACACCCCTGCCAACTACCTGATTGGCTCCCTG\nGCCACCACCGACCTCTTGGTTTCCATCTTGGTAATGCCCATCAGCATCGCCTATACCATC\nACCCACACCTGGAACTTTGGCCAAATCTTGTGTGACATCTGGCTGTCCTCTGACATCACG\nTGCTGCACAGCCTCCATCCTGCATCTCTGTGTCATTGCTCTGGACAGGTACTGGGCAATC\nACAGATGCCCTGGAATACAGTAAACGCAGGACGGCTGGCCACGCGGCCACCATGATCGCC\nATTGTCTGGGCCATCTCCATCTGCATCTCCATCCCCCCGCTCTTCTGGCGGCAGGCCAAG\nGCCCAGGAGGAGATGTCGGACTGTCTGGTGAACACCTCTCAGATCTCCTACACCATCTAC\nTCCACCTGTGGGGCCTTCTACATTCCCTCGGTGTTGCTCATCATCCTATATGGCCGGATC\nTACCGGGCTGCCCGGAACCGCATCCTGAATCCACCCTCACTCTATGGGAAGCGCTTCACC\nACGGCCCACCTCATCACAGGCTCTGCCGGGTCCTCGCTCTGCTCGCTCAACTCCAGCCTC\nCATGAGGGGCACTCGCACTCGGCTGGCTCCCCTCTCTTTTTCAACCACGTGAAAATCAAG\nCTTGCTGACAGTGCCCTGGAACGCAAGAGGATTTCTGCTGCTCGAGAAAGGAAAGCCACT\nAAAATCCTGGGCATCATTCTGGGGGCCTTTATCATCTGCTGGCTGCCCTTCTTCGTGGTG\nTCTCTGGTCCTCCCCATCTGCCGGGACTCCTGCTGGATCCACCCGGCGCTCTTTGACTTC\nTTCACCTGGCTAGGCTATTTAAACTCCCTCATCAATCCAATAATCTACACTGTGTTTAAT\nGAAGAGTTTCGGCAAGCTTTTCAGAAAATTGTCCCTTTCCGGAAGGCCTCCTAG'),('5-hydroxytryptamine receptor 1E','None','Human','Serotonin receptor activity','G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity.','HTR1E','41681.57','DB00216','>lcl|BSEQ0010336|5-hydroxytryptamine receptor 1E (HTR1E)\nATGAACATCACAAACTGTACCACAGAGGCCAGCATGGCTATAAGACCCAAGACCATCACT\nGAGAAGATGCTCATTTGCATGACTCTGGTGGTCATCACCACCCTCACCACGTTGCTGAAC\nTTGGCTGTGATCATGGCTATTGGCACCACCAAGAAGCTCCACCAGCCTGCCAACTACCTA\nATCTGTTCTCTGGCCGTGACGGACCTCCTGGTGGCAGTGCTCGTCATGCCCCTGAGCATC\nATCTACATTGTCATGGATCGCTGGAAGCTTGGGTACTTCCTCTGTGAGGTGTGGCTGAGT\nGTGGACATGACCTGCTGCACCTGCTCCATCCTCCACCTCTGTGTCATTGCCCTGGACAGG\nTACTGGGCCATCACCAATGCTATTGAATACGCCAGGAAGAGGACGGCCAAGAGGGCCGCG\nCTGATGATCCTTACCGTCTGGACCATCTCCATTTTCATCTCCATGCCCCCTCTGTTCTGG\nAGAAGCCACCGCCGCCTAAGCCCTCCCCCTAGTCAGTGCACCATCCAGCACGACCATGTT\nATCTACACCATTTACTCCACGCTGGGTGCGTTTTATATCCCCTTGACTTTGATACTGATT\nCTCTATTACCGGATTTACCACGCGGCCAAGAGCCTTTACCAGAAAAGGGGATCAAGTCGG\nCACTTAAGCAACAGAAGCACAGATAGCCAGAATTCTTTTGCAAGTTGTAAACTTACACAG\nACTTTCTGTGTGTCTGACTTCTCCACCTCAGACCCTACCACAGAGTTTGAAAAGTTCCAT\nGCCTCCATCAGGATCCCCCCCTTCGACAATGATCTAGATCACCCAGGAGAACGTCAGCAG\nATCTCTAGCACCAGGGAACGGAAGGCAGCACGCATCCTGGGGCTGATTCTGGGTGCATTC\nATTTTATCCTGGCTGCCATTTTTCATCAAAGAGTTGATTGTGGGTCTGAGCATCTACACC\nGTGTCCTCGGAAGTGGCCGACTTTCTGACGTGGCTCGGTTATGTGAATTCTCTGATCAAC\nCCTCTGCTCTATACGAGTTTTAATGAAGACTTTAAGCTGGCTTTTAAAAAGCTCATTAGA\nTGCCGAGAGCATACTTAG'),('5-hydroxytryptamine receptor 1F','None','Human','Serotonin receptor activity','G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity.','HTR1F','41708.505','DB00953','>lcl|BSEQ0010324|5-hydroxytryptamine receptor 1F (HTR1F)\nATGGATTTCTTAAATTCATCTGATCAAAACTTGACCTCAGAGGAACTGTTAAACAGAATG\nCCATCCAAAATTCTGGTGTCCCTCACTCTGTCTGGGCTGGCACTGATGACAACAACTATC\nAACTCCCTTGTGATCGCTGCAATTATTGTGACCCGGAAGCTGCACCATCCAGCCAATTAT\nTTAATTTGTTCCCTTGCAGTCACAGATTTTCTTGTGGCTGTCCTGGTGATGCCCTTCAGC\nATTGTGTATATTGTGAGAGAGAGCTGGATTATGGGGCAAGTGGTCTGTGACATTTGGCTG\nAGTGTTGACATTACCTGCTGCACGTGCTCCATCTTGCATCTCTCAGCTATAGCTTTGGAT\nCGGTATCGAGCAATCACAGATGCTGTTGAGTATGCCAGGAAAAGGACTCCAAAGCATGCT\nGGCATTATGATTACAATAGTTTGGATTATATCTGTTTTTATCTCTATGCCTCCTCTATTC\nTGGAGGCACCAAGGAACTAGCAGAGATGATGAATGCATCATCAAGCACGACCACATTGTT\nTCCACCATTTACTCAACATTTGGAGCTTTCTACATCCCACTGGCATTGATTTTGATCCTT\nTACTACAAAATATATAGAGCAGCAAAGACATTATACCACAAGAGACAAGCAAGTAGGATT\nGCAAAGGAGGAGGTGAATGGCCAAGTCCTTTTGGAGAGTGGTGAGAAAAGCACTAAATCA\nGTTTCCACATCCTATGTACTAGAAAAGTCTTTATCTGACCCATCAACAGACTTTGATAAA\nATTCATAGCACAGTGAGAAGTCTCAGGTCTGAATTCAAGCATGAGAAATCTTGGAGAAGG\nCAAAAGATCTCAGGTACAAGAGAACGGAAAGCAGCCACTACCCTGGGATTAATCTTGGGT\nGCATTTGTAATATGTTGGCTTCCTTTTTTTGTAAAAGAATTAGTTGTTAATGTCTGTGAC\nAAATGTAAAATTTCTGAAGAAATGTCCAATTTTTTGGCATGGCTTGGGTATCTCAATTCC\nCTTATAAATCCACTGATTTACACAATCTTTAATGAAGACTTCAAGAAAGCATTCCAAAAG\nCTTGTGCGATGTCGATGTTAG'),('5-hydroxytryptamine receptor 2','protein group','Human','None','None','None','None','DB01221','None'),('5-hydroxytryptamine receptor 2A','None','Human','Virus receptor activity','G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling activates phospholipase C and a phosphatidylinositol-calcium second messenger system that modulates the activity of phosphatidylinositol 3-kinase and promotes the release of Ca(2+) ions from intracellular stores. Affects neural activity, perception, cognition and mood. Plays a role in the regulation of behavior, including responses to anxiogenic situations and psychoactive substances. Plays a role in intestinal smooth muscle contraction, and may play a role in arterial vasoconstriction.(Microbial infection) Acts as a receptor for human JC polyomavirus/JCPyV.','HTR2A','52602.58','DB01149','>lcl|BSEQ0020465|5-hydroxytryptamine receptor 2A (HTR2A)\nATGGATATTCTTTGTGAAGAAAATACTTCTTTGAGCTCAACTACGAACTCCCTAATGCAA\nTTAAATGATGACACCAGGCTCTACAGTAATGACTTTAACTCCGGAGAAGCTAACACTTCT\nGATGCATTTAACTGGACAGTCGACTCTGAAAATCGAACCAACCTTTCCTGTGAAGGGTGC\nCTCTCACCGTCGTGTCTCTCCTTACTTCATCTCCAGGAAAAAAACTGGTCTGCTTTACTG\nACAGCCGTAGTGATTATTCTAACTATTGCTGGAAACATACTCGTCATCATGGCAGTGTCC\nCTAGAGAAAAAGCTGCAGAATGCCACCAACTATTTCCTGATGTCACTTGCCATAGCTGAT\nATGCTGCTGGGTTTCCTTGTCATGCCCGTGTCCATGTTAACCATCCTGTATGGGTACCGG\nTGGCCTCTGCCGAGCAAGCTTTGTGCAGTCTGGATTTACCTGGACGTGCTCTTCTCCACG\nGCCTCCATCATGCACCTCTGCGCCATCTCGCTGGACCGCTACGTCGCCATCCAGAATCCC\nATCCACCACAGCCGCTTCAACTCCAGAACTAAGGCATTTCTGAAAATCATTGCTGTTTGG\nACCATATCAGTAGGTATATCCATGCCAATACCAGTCTTTGGGCTACAGGACGATTCGAAG\nGTCTTTAAGGAGGGGAGTTGCTTACTCGCCGATGATAACTTTGTCCTGATCGGCTCTTTT\nGTGTCATTTTTCATTCCCTTAACCATCATGGTGATCACCTACTTTCTAACTATCAAGTCA\nCTCCAGAAAGAAGCTACTTTGTGTGTAAGTGATCTTGGCACACGGGCCAAATTAGCTTCT\nTTCAGCTTCCTCCCTCAGAGTTCTTTGTCTTCAGAAAAGCTCTTCCAGCGGTCGATCCAT\nAGGGAGCCAGGGTCCTACACAGGCAGGAGGACTATGCAGTCCATCAGCAATGAGCAAAAG\nGCATGCAAGGTGCTGGGCATCGTCTTCTTCCTGTTTGTGGTGATGTGGTGCCCTTTCTTC\nATCACAAACATCATGGCCGTCATCTGCAAAGAGTCCTGCAATGAGGATGTCATTGGGGCC\nCTGCTCAATGTGTTTGTTTGGATCGGTTATCTCTCTTCAGCAGTCAACCCACTAGTCTAC\nACACTGTTCAACAAGACCTATAGGTCAGCCTTTTCACGGTATATTCAGTGTCAGTACAAG\nGAAAACAAAAAACCATTGCAGTTAATTTTAGTGAACACAATACCGGCTTTGGCCTACAAG\nTCTAGCCAACTTCAAATGGGACAAAAAAAGAATTCAAAGCAAGATGCCAAGACAACAGAT\nAATGACTGCTCAATGGTTGCTCTAGGAAAGCAGCATTCTGAAGAGGCTTCTAAAGACAAT\nAGCGACGGAGTGAATGAAAAGGTGAGCTGTGTGTGA'),('5-hydroxytryptamine receptor 2B','None','Human','Serotonin receptor activity','G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling activates a phosphatidylinositol-calcium second messenger system that modulates the activity of phosphatidylinositol 3-kinase and down-stream signaling cascades and promotes the release of Ca(2+) ions from intracellular stores. Plays a role in the regulation of dopamine and 5-hydroxytryptamine release, 5-hydroxytryptamine uptake and in the regulation of extracellular dopamine and 5-hydroxytryptamine levels, and thereby affects neural activity. May play a role in the perception of pain. Plays a role in the regulation of behavior, including impulsive behavior. Required for normal proliferation of embryonic cardiac myocytes and normal heart development. Protects cardiomyocytes against apoptosis. Plays a role in the adaptation of pulmonary arteries to chronic hypoxia. Plays a role in vasoconstriction. Required for normal osteoblast function and proliferation, and for maintaining normal bone density. Required for normal proliferation of the interstitial cells of Cajal in the intestine.','HTR2B','54297.41','DB00320','>lcl|BSEQ0016079|5-hydroxytryptamine receptor 2B (HTR2B)\nATGGCTCTCTCTTACAGAGTGTCTGAACTTCAAAGCACAATTCCTGAGCACATTTTGCAG\nAGCACCTTTGTTCACGTTATCTCTTCTAACTGGTCTGGATTACAGACAGAATCAATACCA\nGAGGAAATGAAACAGATTGTTGAGGAACAGGGAAATAAACTGCACTGGGCAGCTCTTCTG\nATACTCATGGTGATAATACCCACAATTGGTGGAAATACCCTTGTTATTCTGGCTGTTTCA\nCTGGAGAAGAAGCTGCAGTATGCTACTAATTACTTTCTAATGTCCTTGGCGGTGGCTGAT\nTTGCTGGTTGGATTGTTTGTGATGCCAATTGCCCTCTTGACAATAATGTTTGAGGCTATG\nTGGCCCCTCCCACTTGTTCTATGTCCTGCCTGGTTATTTCTTGACGTTCTCTTTTCAACC\nGCATCCATCATGCATCTCTGTGCCATTTCAGTGGATCGTTACATAGCCATCAAAAAGCCA\nATCCAGGCCAATCAATATAACTCACGGGCTACAGCATTCATCAAGATTACAGTGGTGTGG\nTTAATTTCAATAGGCATTGCCATTCCAGTCCCTATTAAAGGGATAGAGACTGATGTGGAC\nAACCCAAACAATATCACTTGTGTGCTGACAAAGGAACGTTTTGGCGATTTCATGCTCTTT\nGGCTCACTGGCTGCCTTCTTCACACCTCTTGCAATTATGATTGTCACCTACTTTCTCACT\nATCCATGCTTTACAGAAGAAGGCTTACTTAGTCAAAAACAAGCCACCTCAACGCCTAACA\nTGGTTGACTGTGTCTACAGTTTTCCAAAGGGATGAAACACCTTGCTCGTCACCGGAAAAG\nGTGGCAATGCTGGATGGTTCTCGAAAGGACAAGGCTCTGCCCAACTCAGGTGATGAAACA\nCTTATGCGAAGAACATCCACAATTGGGAAAAAGTCAGTGCAGACCATTTCCAACGAACAG\nAGAGCCTCAAAGGTCCTAGGGATTGTGTTTTTCCTCTTTTTGCTTATGTGGTGTCCCTTC\nTTTATTACAAATATAACTTTAGTTTTATGTGATTCCTGTAACCAAACTACTCTCCAAATG\nCTCCTGGAGATATTTGTGTGGATAGGCTATGTTTCCTCAGGAGTGAATCCTTTGGTCTAC\nACCCTCTTCAATAAGACATTTCGGGATGCATTTGGCCGATATATCACCTGCAATTACCGG\nGCCACAAAGTCAGTAAAAACTCTCAGAAAACGCTCCAGTAAGATCTACTTCCGGAATCCA\nATGGCAGAGAACTCTAAGTTTTTCAAGAAACATGGAATTCGAAATGGGATTAACCCTGCC\nATGTACCAGAGTCCAATGAGGCTCCGAAGTTCAACCATTCAGTCTTCATCAATCATTCTA\nCTAGATACGCTTCTCCTCACTGAAAATGAAGGTGACAAAACTGAAGAGCAAGTTAGTTAT\nGTATAG'),('5-hydroxytryptamine receptor 2C','None','Human','Serotonin receptor activity','G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling activates a phosphatidylinositol-calcium second messenger system that modulates the activity of phosphatidylinositol 3-kinase and down-stream signaling cascades and promotes the release of Ca(2+) ions from intracellular stores. Regulates neuronal activity via the activation of short transient receptor potential calcium channels in the brain, and thereby modulates the activation of pro-opiomelacortin neurons and the release of CRH that then regulates the release of corticosterone. Plays a role in the regulation of appetite and eating behavior, responses to anxiogenic stimuli and stress. Plays a role in insulin sensitivity and glucose homeostasis.','HTR2C','51820.705','DB01149','>lcl|BSEQ0010373|5-hydroxytryptamine receptor 2C (HTR2C)\nATGGTGAACCTGAGGAATGCGGTGCATTCATTCCTTGTGCACCTAATTGGCCTATTGGTT\nTGGCAATGTGATATTTCTGTGAGCCCAGTAGCAGCTATAGTAACTGACATTTTCAATACC\nTCCGATGGTGGACGCTTCAAATTCCCAGACGGGGTACAAAACTGGCCAGCACTTTCAATC\nGTCATCATAATAATCATGACAATAGGTGGCAACATCCTTGTGATCATGGCAGTAAGCATG\nGAAAAGAAACTGCACAATGCCACCAATTACTTCTTAATGTCCCTAGCCATTGCTGATATG\nCTAGTGGGACTACTTGTCATGCCCCTGTCTCTCCTGGCAATCCTTTATGATTATGTCTGG\nCCACTACCTAGATATTTGTGCCCCGTCTGGATTTCTTTAGATGTTTTATTTTCAACAGCG\nTCCATCATGCACCTCTGCGCTATATCGCTGGATCGGTATGTAGCAATACGTAATCCTATT\nGAGCATAGCCGTTTCAATTCGCGGACTAAGGCCATCATGAAGATTGCTATTGTTTGGGCA\nATTTCTATAGGTGTATCAGTTCCTATCCCTGTGATTGGACTGAGGGACGAAGAAAAGGTG\nTTCGTGAACAACACGACGTGCGTGCTCAACGACCCAAATTTCGTTCTTATTGGGTCCTTC\nGTAGCTTTCTTCATACCGCTGACGATTATGGTGATTACGTATTGCCTGACCATCTACGTT\nCTGCGCCGACAAGCTTTGATGTTACTGCACGGCCACACCGAGGAACCGCCTGGACTAAGT\nCTGGATTTCCTGAAGTGCTGCAAGAGGAATACGGCCGAGGAAGAGAACTCTGCAAACCCT\nAACCAAGACCAGAACGCACGCCGAAGAAAGAAGAAGGAGAGACGTCCTAGGGGCACCATG\nCAGGCTATCAACAATGAAAGAAAAGCTTCGAAAGTCCTTGGGATTGTTTTCTTTGTGTTT\nCTGATCATGTGGTGCCCATTTTTCATTACCAATATTCTGTCTGTTCTTTGTGAGAAGTCC\nTGTAACCAAAAGCTCATGGAAAAGCTTCTGAATGTGTTTGTTTGGATTGGCTATGTTTGT\nTCAGGAATCAATCCTCTGGTGTATACTCTGTTCAACAAAATTTACCGAAGGGCATTCTCC\nAACTATTTGCGTTGCAATTATAAGGTAGAGAAAAAGCCTCCTGTCAGGCAGATTCCAAGA\nGTTGCCGCCACTGCTTTGTCTGGGAGGGAGCTTAATGTTAACATTTATCGGCATACCAAT\nGAACCGGTGATCGAGAAAGCCAGTGACAATGAGCCCGGTATAGAGATGCAAGTTGAGAAT\nTTAGAGTTACCAGTAAATCCCTCCAGTGTGGTTAGCGAAAGGATTAGCAGTGTGTGA'),('5-hydroxytryptamine receptor 3A','None','Human','Voltage-gated potassium channel activity','This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses in neurons. It is a cation-specific, but otherwise relatively nonselective, ion channel.','HTR3A','55279.835','DB01221','>lcl|BSEQ0010242|5-hydroxytryptamine receptor 3A (HTR3A)\nATGCTTGGAAAGCTCGCTATGCTGCTGTGGGTCCAGCAGGCGCTGCTCGCCTTGCTCCTC\nCCCACACTCCTGGCACAGGGAGAAGCCAGGAGGAGCCGAAACACCACCAGGCCCGCTCTG\nCTGAGGCTGTCGGATTACCTTTTGACCAACTACAGGAAGGGTGTGCGCCCCGTGAGGGAC\nTGGAGGAAGCCAACCACCGTATCCATTGACGTCATTGTCTATGCCATCCTCAACGTGGAT\nGAGAAGAATCAGGTGCTGACCACCTACATCTGGTACCGGCAGTACTGGACTGATGAGTTT\nCTCCAGTGGAACCCTGAGGACTTTGACAACATCACCAAGTTGTCCATCCCCACGGACAGC\nATCTGGGTCCCGGACATTCTCATCAATGAGTTCGTGGATGTGGGGAAGTCTCCAAATATC\nCCGTACGTGTATATTCGGCATCAAGGCGAAGTTCAGAACTACAAGCCCCTTCAGGTGGTG\nACTGCCTGTAGCCTCGACATCTACAACTTCCCCTTCGATGTCCAGAACTGCTCGCTGACC\nTTCACCAGTTGGCTGCACACCATCCAGGACATCAACATCTCTTTGTGGCGCTTGCCAGAA\nAAGGTGAAATCCGACAGGAGTGTCTTCATGAACCAGGGAGAGTGGGAGTTGCTGGGGGTG\nCTGCCCTACTTTCGGGAGTTCAGCATGGAAAGCAGTAACTACTATGCAGAAATGAAGTTC\nTATGTGGTCATCCGCCGGCGGCCCCTCTTCTATGTGGTCAGCCTGCTACTGCCCAGCATC\nTTCCTCATGGTCATGGACATCGTGGGCTTCTACCTGCCCCCCAACAGTGGCGAGAGGGTC\nTCTTTCAAGATTACACTCCTCCTGGGCTACTCGGTCTTCCTGATCATCGTTTCTGACACG\nCTGCCGGCCACTGCCATCGGCACTCCTCTCATTGGTGTCTACTTTGTGGTGTGCATGGCT\nCTGCTGGTGATAAGTTTGGCCGAGACCATCTTCATTGTGCGGCTGGTGCACAAGCAAGAC\nCTGCAGCAGCCCGTGCCTGCTTGGCTGCGTCACCTGGTTCTGGAGAGAATCGCCTGGCTA\nCTTTGCCTGAGGGAGCAGTCAACTTCCCAGAGGCCCCCAGCCACCTCCCAAGCCACCAAG\nACTGATGACTGCTCAGCCATGGGAAACCACTGCAGCCACATGGGAGGACCCCAGGACTTC\nGAGAAGAGCCCGAGGGACAGATGTAGCCCTCCCCCACCACCTCGGGAGGCCTCGCTGGCG\nGTGTGTGGGCTGCTGCAGGAGCTGTCCTCCATCCGGCAATTCCTGGAAAAGCGGGATGAG\nATCCGAGAGGTGGCCCGAGACTGGCTGCGCGTGGGCTCCGTGCTGGACAAGCTGCTATTC\nCACATTTACCTGCTAGCGGTGCTGGCCTACAGCATCACCCTGGTTATGCTCTGGTCCATC\nTGGCAGTACGCTTGA'),('5-hydroxytryptamine receptor 6','None','Human','Serotonin receptor activity','This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It has a high affinity for tricyclic psychotropic drugs (By similarity). Controls pyramidal neurons migration during corticogenesis, through the regulation of CDK5 activity (By similarity). Is an activator of TOR signaling (PubMed:23027611).','HTR6','46953.625','DB00321','>lcl|BSEQ0010666|5-hydroxytryptamine receptor 6 (HTR6)\nATGGTCCCAGAGCCGGGCCCAACCGCCAATAGCACCCCGGCCTGGGGGGCAGGGCCGCCG\nTCGGCCCCGGGGGGCAGCGGCTGGGTGGCGGCCGCGCTGTGCGTGGTCATCGCGCTGACG\nGCGGCGGCCAACTCGCTGCTGATCGCGCTCATCTGCACTCAGCCCGCGCTGCGCAACACG\nTCCAACTTCTTCCTGGTGTCGCTCTTCACGTCTGACCTGATGGTGGGGCTGGTGGTGATG\nCCGCCGGCCATGCTGAACGCGCTGTACGGGCGCTGGGTGCTGGCGCGCGGCCTCTGCCTG\nCTCTGGACCGCCTTCGACGTGATGTGCTGCAGCGCCTCCATCCTCAACCTCTGCCTCATC\nAGCCTGGACCGCTACCTGCTCATCCTCTCGCCGCTGCGCTACAAGCTGCGCATGACGCCC\nCTGCGTGCCCTGGCCCTAGTCCTGGGCGCCTGGAGCCTCGCCGCTCTCGCCTCCTTCCTG\nCCCCTGCTGCTGGGCTGGCACGAGCTGGGCCACGCACGGCCACCCGTCCCTGGCCAGTGC\nCGCCTGCTGGCCAGCCTGCCTTTTGTCCTTGTGGCGTCGGGCCTCACCTTCTTCCTGCCC\nTCGGGTGCCATATGCTTCACCTACTGCAGGATCCTGCTAGCTGCCCGCAAGCAGGCCGTG\nCAGGTGGCCTCCCTCACCACCGGCATGGCCAGTCAGGCCTCGGAGACGCTGCAGGTGCCC\nAGGACCCCACGCCCAGGGGTGGAGTCTGCTGACAGCAGGCGTCTAGCCACGAAGCACAGC\nAGGAAGGCCCTGAAGGCCAGCCTGACGCTGGGCATCCTGCTGGGCATGTTCTTTGTGACC\nTGGTTGCCCTTCTTTGTGGCCAACATAGTCCAGGCCGTGTGCGACTGCATCTCCCCAGGC\nCTCTTCGATGTCCTCACATGGCTGGGTTACTGTAACAGCACCATGAACCCCATCATCTAC\nCCACTCTTCATGCGGGACTTCAAGCGGGCGCTGGGCAGGTTCCTGCCATGTCCACGCTGT\nCCCCGGGAGCGCCAGGCCAGCCTGGCCTCGCCATCACTGCGCACCTCTCACAGCGGCCCC\nCGGCCCGGCCTTAGCCTACAGCAGGTGCTGCCGCTGCCCCTGCCGCCGGACTCAGATTCG\nGACTCAGACGCAGGCTCAGGCGGCTCCTCGGGCCTGCGGCTCACGGCCCAGCTGCTGCTT\nCCTGGCGAGGCCACCCAGGACCCCCCGCTGCCCACCAGGGCCGCTGCCGCCGTCAATTTC\nTTCAACATCGACCCCGCGGAGCCCGAGCTGCGGCCGCATCCACTTGGCATCCCCACGAAC\nTGA'),('5-hydroxytryptamine receptor 7','None','Human','Serotonin receptor activity','This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.','HTR7','53554.43','DB00589','>lcl|BSEQ0010453|5-hydroxytryptamine receptor 7 (HTR7)\nATGATGGACGTTAACAGCAGCGGCCGCCCGGACCTCTACGGGCACCTCCGCTCTTTCCTT\nCTGCCAGAAGTGGGGCGCGGGCTGCCCGACTTGAGCCCCGACGGTGGCGCCGACCCGGTC\nGCGGGCTCCTGGGCGCCGCACCTGCTGAGCGAGGTGACAGCCAGCCCGGCGCCCACCTGG\nGACGCGCCCCCGGACAATGCCTCCGGCTGTGGGGAACAGATCAACTACGGCAGAGTCGAG\nAAAGTTGTGATCGGCTCCATCCTGACGCTCATCACGCTGCTGACGATCGCGGGCAACTGC\nCTGGTGGTGATCTCCGTGTGCTTCGTCAAGAAGCTCCGCCAGCCCTCCAACTACCTGATC\nGTGTCCCTGGCGCTGGCCGACCTCTCGGTGGCTGTGGCGGTCATGCCCTTCGTCAGCGTC\nACCGACCTCATCGGGGGCAAGTGGATCTTTGGACACTTTTTCTGTAATGTCTTCATCGCC\nATGGACGTCATGTGCTGCACGGCCTCGATCATGACCCTGTGCGTGATCAGCATTGACAGG\nTACCTTGGGATCACAAGGCCCCTCACATACCCTGTGAGGCAGAATGGGAAATGCATGGCG\nAAGATGATTCTCTCCGTCTGGCTTCTCTCCGCCTCCATCACCTTACCTCCACTCTTTGGA\nTGGGCTCAGAATGTAAATGATGATAAGGTGTGCTTGATCAGCCAGGACTTTGGCTATACG\nATTTACTCTACCGCAGTGGCATTTTATATCCCCATGTCCGTCATGCTTTTCATGTACTAC\nCAGATTTACAAGGCTGCCAGGAAGAGTGCTGCCAAACACAAGTTTCCTGGCTTCCCTCGA\nGTGGAGCCAGACAGCGTCATCGCCCTGAATGGCATAGTGAAGCTCCAGAAGGAGGTGGAA\nGAGTGTGCAAACCTTTCGAGACTCCTCAAGCATGAAAGGAAAAACATCTCCATCTTTAAG\nCGAGAACAGAAAGCAGCCACCACCCTGGGGATCATCGTCGGGGCCTTTACCGTGTGCTGG\nCTGCCATTTTTCCTCCTCTCGACAGCCAGACCCTTCATCTGTGGCACTTCCTGCAGCTGC\nATCCCACTGTGGGTGGAGAGGACATTTCTGTGGCTAGGCTATGCAAACTCTCTCATTAAC\nCCTTTTATATATGCCTTCTTCAACCGGGACCTGAGGACCACCTATCGCAGCCTGCTCCAG\nTGCCAGTACCGGAATATCAACCGGAAGCTCTCAGCTGCAGGCATGCATGAAGCCCTGAAG\nCTTGCTGAGAGGCCAGAGAGACCTGAGTTTGTGCTACAAAATGCTGACTACTGTAGAAAA\nAAAGGTCATGATTCATGA'),('78 kDa glucose-regulated protein','None','Human','Unfolded protein binding','Probably plays a role in facilitating the assembly of multimeric protein complexes inside the endoplasmic reticulum. Involved in the correct folding of proteins and degradation of misfolded proteins via its interaction with DNAJC10, probably to facilitate the release of DNAJC10 from its substrate.','HSPA5','72332.425','DB00945','>lcl|BSEQ0019063|78 kDa glucose-regulated protein (HSPA5)\nATGAAGCTCTCCCTGGTGGCCGCGATGCTGCTGCTGCTCAGCGCGGCGCGGGCCGAGGAG\nGAGGACAAGAAGGAGGACGTGGGCACGGTGGTCGGCATCGACCTGGGGACCACCTACTCC\nTGCGTCGGCGTGTTCAAGAACGGCCGCGTGGAGATCATCGCCAACGATCAGGGCAACCGC\nATCACGCCGTCCTATGTCGCCTTCACTCCTGAAGGGGAACGTCTGATTGGCGATGCCGCC\nAAGAACCAGCTCACCTCCAACCCCGAGAACACGGTCTTTGACGCCAAGCGGCTCATCGGC\nCGCACGTGGAATGACCCGTCTGTGCAGCAGGACATCAAGTTCTTGCCGTTCAAGGTGGTT\nGAAAAGAAAACTAAACCATACATTCAAGTTGATATTGGAGGTGGGCAAACAAAGACATTT\nGCTCCTGAAGAAATTTCTGCCATGGTTCTCACTAAAATGAAAGAAACCGCTGAGGCTTAT\nTTGGGAAAGAAGGTTACCCATGCAGTTGTTACTGTACCAGCCTATTTTAATGATGCCCAA\nCGCCAAGCAACCAAAGACGCTGGAACTATTGCTGGCCTAAATGTTATGAGGATCATCAAC\nGAGCCTACGGCAGCTGCTATTGCTTATGGCCTGGATAAGAGGGAGGGGGAGAAGAACATC\nCTGGTGTTTGACCTGGGTGGCGGAACCTTCGATGTGTCTCTTCTCACCATTGACAATGGT\nGTCTTCGAAGTTGTGGCCACTAATGGAGATACTCATCTGGGTGGAGAAGACTTTGACCAG\nCGTGTCATGGAACACTTCATCAAACTGTACAAAAAGAAGACGGGCAAAGATGTCAGGAAA\nGACAATAGAGCTGTGCAGAAACTCCGGCGCGAGGTAGAAAAGGCCAAACGGGCCCTGTCT\nTCTCAGCATCAAGCAAGAATTGAAATTGAGTCCTTCTATGAAGGAGAAGACTTTTCTGAG\nACCCTGACTCGGGCCAAATTTGAAGAGCTCAACATGGATCTGTTCCGGTCTACTATGAAG\nCCCGTCCAGAAAGTGTTGGAAGATTCTGATTTGAAGAAGTCTGATATTGATGAAATTGTT\nCTTGTTGGTGGCTCGACTCGAATTCCAAAGATTCAGCAACTGGTTAAAGAGTTCTTCAAT\nGGCAAGGAACCATCCCGTGGCATAAACCCAGATGAAGCTGTAGCGTATGGTGCTGCTGTC\nCAGGCTGGTGTGCTCTCTGGTGATCAAGATACAGGTGACCTGGTACTGCTTGATGTATGT\nCCCCTTACACTTGGTATTGAAACTGTGGGAGGTGTCATGACCAAACTGATTCCAAGGAAC\nACAGTGGTGCCTACCAAGAAGTCTCAGATCTTTTCTACAGCTTCTGATAATCAACCAACT\nGTTACAATCAAGGTCTATGAAGGTGAAAGACCCCTGACAAAAGACAATCATCTTCTGGGT\nACATTTGATCTGACTGGAATTCCTCCTGCTCCTCGTGGGGTCCCACAGATTGAAGTCACC\nTTTGAGATAGATGTGAATGGTATTCTTCGAGTGACAGCTGAAGACAAGGGTACAGGGAAC\nAAAAATAAGATCACAATCACCAATGACCAGAATCGCCTGACACCTGAAGAAATCGAAAGG\nATGGTTAATGATGCTGAGAAGTTTGCTGAGGAAGACAAAAAGCTCAAGGAGCGCATTGAT\nACTAGAAATGAGTTGGAAAGCTATGCCTATTCTCTAAAGAATCAGATTGGAGATAAAGAA\nAAGCTGGGAGGTAAACTTTCCTCTGAAGATAAGGAGACCATGGAAAAAGCTGTAGAAGAA\nAAGATTGAATGGCTGGAAAGCCACCAAGATGCTGACATTGAAGACTTCAAAGCTAAGAAG\nAAGGAACTGGAAGAAATTGTTCAACCAATTATCAGCAAACTCTATGGAAGTGCAGGCCCT\nCCCCCAACTGGTGAAGAGGATACAGCAGAAAAAGATGAGTTGTAG'),('Acetyl-CoA acetyltransferase, mitochondrial','None','Human','Metal ion binding','Plays a major role in ketone body metabolism.','ACAT1','45199.2','DB00795','>lcl|BSEQ0018914|Acetyl-CoA acetyltransferase, mitochondrial (ACAT1)\nATGGCTGTGCTGGCGGCACTTCTGCGCAGCGGCGCCCGCAGCCGCAGCCCCCTGCTCCGG\nAGGCTGGTGCAGGAAATAAGATATGTGGAACGGAGTTATGTATCAAAACCCACTTTGAAG\nGAAGTGGTCATAGTAAGTGCTACAAGAACACCCATTGGATCTTTTTTAGGCAGCCTTTCC\nTTGCTGCCAGCCACTAAGCTTGGTTCCATTGCAATTCAGGGAGCCATTGAAAAGGCAGGG\nATTCCAAAAGAAGAAGTGAAAGAAGCATACATGGGTAATGTTCTACAAGGAGGTGAAGGA\nCAAGCTCCTACAAGGCAGGCAGTATTGGGTGCAGGCTTACCTATTTCTACTCCATGTACC\nACCATAAACAAAGTTTGTGCTTCAGGAATGAAAGCCATCATGATGGCCTCTCAAAGTCTT\nATGTGTGGACATCAGGATGTGATGGTGGCAGGTGGGATGGAGAGCATGTCCAATGTTCCA\nTATGTAATGAACAGAGGATCAACACCATATGGTGGGGTAAAGCTTGAAGATTTGATTGTA\nAAAGACGGGCTAACTGATGTCTACAATAAAATTCATATGGGCAGCTGTGCTGAGAATACA\nGCAAAGAAGCTGAATATTGCACGAAATGAACAGGACGCTTATGCTATTAATTCTTATACC\nAGAAGTAAAGCAGCATGGGAAGCTGGGAAATTTGGAAATGAAGTTATTCCTGTCACAGTT\nACAGTAAAAGGTCAACCAGATGTAGTGGTGAAAGAAGATGAAGAATATAAACGTGTTGAT\nTTTAGCAAAGTTCCAAAGCTGAAGACAGTTTTCCAGAAAGAAAATGGCACAGTAACAGCT\nGCCAATGCCAGTACACTGAATGATGGAGCAGCTGCTCTGGTTCTCATGACGGCAGATGCA\nGCGAAGAGGCTCAATGTTACACCACTGGCAAGAATAGTAGCATTTGCTGACGCTGCTGTA\nGAACCTATTGATTTTCCAATTGCTCCTGTATATGCTGCATCTATGGTTCTTAAAGATGTG\nGGATTGAAAAAAGAAGATATTGCAATGTGGGAAGTAAATGAAGCCTTTAGTCTGGTTGTA\nCTAGCAAACATTAAAATGTTGGAGATTGATCCCCAAAAAGTGAATATCAATGGAGGAGCT\nGTTTCTCTGGGACATCCAATTGGGATGTCTGGAGCCAGGATTGTTGGTCATTTGACTCAT\nGCCTTGAAGCAAGGAGAATACGGTCTTGCCAGTATTTGCAATGGAGGAGGAGGTGCTTCT\nGCCATGCTAATTCAGAAGCTGTAG'),('Acetylcholinesterase','None','Human','Serine hydrolase activity','Terminates signal transduction at the neuromuscular junction by rapid hydrolysis of the acetylcholine released into the synaptic cleft. Role in neuronal apoptosis.','ACHE','67795.525','DB00122','>lcl|BSEQ0010296|Acetylcholinesterase (ACHE)\nATGAGGCCCCCGCAGTGTCTGCTGCACACGCCTTCCCTGGCTTCCCCACTCCTTCTCCTC\nCTCCTCTGGCTCCTGGGTGGAGGAGTGGGGGCTGAGGGCCGGGAGGATGCAGAGCTGCTG\nGTGACGGTGCGTGGGGGCCGGCTGCGGGGCATTCGCCTGAAGACCCCCGGGGGCCCTGTC\nTCTGCTTTCCTGGGCATCCCCTTTGCGGAGCCACCCATGGGACCCCGTCGCTTTCTGCCA\nCCGGAGCCCAAGCAGCCTTGGTCAGGGGTGGTAGACGCTACAACCTTCCAGAGTGTCTGC\nTACCAATATGTGGACACCCTATACCCAGGTTTTGAGGGCACCGAGATGTGGAACCCCAAC\nCGTGAGCTGAGCGAGGACTGCCTGTACCTCAACGTGTGGACACCATACCCCCGGCCTACA\nTCCCCCACCCCTGTCCTCGTCTGGATCTATGGGGGTGGCTTCTACAGTGGGGCCTCCTCC\nTTGGACGTGTACGATGGCCGCTTCTTGGTACAGGCCGAGAGGACTGTGCTGGTGTCCATG\nAACTACCGGGTGGGAGCCTTTGGCTTCCTGGCCCTGCCGGGGAGCCGAGAGGCCCCGGGC\nAATGTGGGTCTCCTGGATCAGAGGCTGGCCCTGCAGTGGGTGCAGGAGAACGTGGCAGCC\nTTCGGGGGTGACCCGACATCAGTGACGCTGTTTGGGGAGAGCGCGGGAGCCGCCTCGGTG\nGGCATGCACCTGCTGTCCCCGCCCAGCCGGGGCCTGTTCCACAGGGCCGTGCTGCAGAGC\nGGTGCCCCCAATGGACCCTGGGCCACGGTGGGCATGGGAGAGGCCCGTCGCAGGGCCACG\nCAGCTGGCCCACCTTGTGGGCTGTCCTCCAGGCGGCACTGGTGGGAATGACACAGAGCTG\nGTAGCCTGCCTTCGGACACGACCAGCGCAGGTCCTGGTGAACCACGAATGGCACGTGCTG\nCCTCAAGAAAGCGTCTTCCGGTTCTCCTTCGTGCCTGTGGTAGATGGAGACTTCCTCAGT\nGACACCCCAGAGGCCCTCATCAACGCGGGAGACTTCCACGGCCTGCAGGTGCTGGTGGGT\nGTGGTGAAGGATGAGGGCTCGTATTTTCTGGTTTACGGGGCCCCAGGCTTCAGCAAAGAC\nAACGAGTCTCTCATCAGCCGGGCCGAGTTCCTGGCCGGGGTGCGGGTCGGGGTTCCCCAG\nGTAAGTGACCTGGCAGCCGAGGCTGTGGTCCTGCATTACACAGACTGGCTGCATCCCGAG\nGACCCGGCACGCCTGAGGGAGGCCCTGAGCGATGTGGTGGGCGACCACAATGTCGTGTGC\nCCCGTGGCCCAGCTGGCTGGGCGACTGGCTGCCCAGGGTGCCCGGGTCTACGCCTACGTC\nTTTGAACACCGTGCTTCCACGCTCTCCTGGCCCCTGTGGATGGGGGTGCCCCACGGCTAC\nGAGATCGAGTTCATCTTTGGGATCCCCCTGGACCCCTCTCGAAACTACACGGCAGAGGAG\nAAAATCTTCGCCCAGCGACTGATGCGATACTGGGCCAACTTTGCCCGCACAGGGGATCCC\nAATGAGCCCCGAGACCCCAAGGCCCCACAATGGCCCCCGTACACGGCGGGGGCTCAGCAG\nTACGTTAGTCTGGACCTGCGGCCGCTGGAGGTGCGGCGGGGGCTGCGCGCCCAGGCCTGC\nGCCTTCTGGAACCGCTTCCTCCCCAAATTGCTCAGCGCCACCGACACGCTCGACGAGGCG\nGAGCGCCAGTGGAAGGCCGAGTTCCACCGCTGGAGCTCCTACATGGTGCACTGGAAGAAC\nCAGTTCGACCACTACAGCAAGCAGGATCGCTGCTCAGACCTGTGA'),('Acid-sensing ion channel 1','None','Human','Ligand-gated sodium channel activity','Isoform 2 and isoform 3 function as proton-gated sodium channels; they are activated by a drop of the extracellular pH and then become rapidly desensitized. The channel generates a biphasic current with a fast inactivating and a slow sustained phase. Has high selectivity for sodium ions and can also transport lithium ions with high efficiency. Isoform 2 can also transport potassium, but with lower efficiency. It is nearly impermeable to the larger rubidium and cesium ions. Isoform 3 can also transport calcium ions. Mediates glutamate-independent Ca(2+) entry into neurons upon acidosis. This Ca(2+) overloading is toxic for cortical neurons and may be in part responsible for ischemic brain injury. Heteromeric channel assembly seems to modulate channel properties. Functions as a postsynaptic proton receptor that influences intracellular Ca(2+) concentration and calmodulin-dependent protein kinase II phosphorylation and thereby the density of dendritic spines. Modulates activity in the circuits underlying innate fear.Isoform 1 does not display proton-gated cation channel activity.','ASIC1','59908.915','DB00586','>lcl|BSEQ0010105|Acid-sensing ion channel 1 (ASIC1)\nATGGAACTGAAGGCCGAGGAGGAGGAGGTGGGTGGCGTCCAGCCGGTGAGCATCCAGGCC\nTTCGCCAGCAGCTCCACACTGCACGGCCTGGCCCACATCTTCTCCTACGAGCGGCTGTCT\nCTGAAGCGGGCACTGTGGGCCCTGTGCTTCCTGGGCTCGCTGGCTGTGCTGCTGTGTGTG\nTGCACGGAGCGTGTGCAGTACTACTTCCACTACCACCATGTCACCAAGCTCGACGAGGTG\nGCTGCCTCTCAGCTTACCTTCCCTGCTGTCACGCTGTGCAACCTCAACGAGTTCCGCTTT\nAGCCAAGTCTCCAAGAATGACCTGTATCATGCTGGGGAGCTGCTGGCCCTGCTCAACAAC\nAGGTATGAGATACCAGACACACAGATGGCAGATGAAAAGCAGCTGGAGATACTGCAGGAC\nAAAGCCAACTTCCGCAGCTTCAAACCCAAACCCTTCAACATGCGTGAGTTCTACGACCGA\nGCTGGGCACGACATTCGAGACATGCTGCTCTCCTGCCACTTCCGGGGGGAGGTCTGCAGC\nGCTGAAGACTTCAAGGTGGTCTTCACACGCTATGGAAAGTGCTACACGTTCAACTCGGGC\nCGAGATGGGCGGCCGCGGCTGAAGACCATGAAGGGTGGGACGGGCAATGGGCTGGAAATC\nATGCTGGACATCCAGCAGGACGAGTACCTGCCTGTGTGGGGGGAGACTGACGAGACGTCC\nTTCGAAGCAGGCATCAAAGTGCAGATCCATAGTCAGGATGAACCTCCTTTCATCGACCAG\nCTGGGCTTTGGCGTGGCCCCAGGCTTCCAGACCTTTGTGGCCTGCCAGGAGCAGCGGCTC\nATCTACCTGCCCCCACCCTGGGGCACCTGCAAAGCTGTTACCATGGACTCGGATTTGGAT\nTTCTTCGACTCCTACAGCATCACTGCCTGCCGCATCGACTGTGAGACGCGCTACCTGGTG\nGAGAACTGCAACTGCCGCATGGTGCACATGCCAGGGGATGCCCCATACTGTACTCCAGAG\nCAGTACAAGGAGTGTGCAGATCCTGCTCTGGACTTCCTGGTGGAGAAGGACCAGGAGTAC\nTGCGTGTGTGAAATGCCTTGCAACCTGACCCGCTATGGCAAAGAGCTGTCCATGGTCAAG\nATCCCCAGCAAAGCCTCAGCCAAGTACCTGGCCAAGAAGTTCAACAAATCTGAGCAATAC\nATAGGGGAGAACATCCTGGTGCTGGACATTTTCTTTGAAGTCCTCAACTATGAGACCATT\nGAACAGAAGAAGGCCTATGAGATTGCAGGGCTCCTGGGTGACATCGGGGGCCAGATGGGG\nCTGTTCATCGGGGCCAGCATCCTCACGGTGCTGGAGCTCTTTGACTACGCCTACGAGGTC\nATTAAGCACAAGCTGTGCCGACGAGGAAAATGCCAGAAGGAGGCCAAAAGGAGCAGTGCG\nGACAAGGGCGTGGCCCTCAGCCTGGACGACGTCAAAAGACACAACCCGTGCGAGAGCCTT\nCGGGGCCACCCTGCCGGGATGACATACGCTGCCAACATCCTACCTCACCATCCGGCCCGA\nGGCACGTTCGAGGACTTTACCTGCTGA'),('Adenosine receptor A1','None','Human','Purine nucleoside binding','Receptor for adenosine. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase.','ADORA1','36511.325','DB00640','>lcl|BSEQ0010133|Adenosine receptor A1 (ADORA1)\nATGCCGCCCTCCATCTCAGCTTTCCAGGCCGCCTACATCGGCATCGAGGTGCTCATCGCC\nCTGGTCTCTGTGCCCGGGAACGTGCTGGTGATCTGGGCGGTGAAGGTGAACCAGGCGCTG\nCGGGATGCCACCTTCTGCTTCATCGTGTCGCTGGCGGTGGCTGATGTGGCCGTGGGTGCC\nCTGGTCATCCCCCTCGCCATCCTCATCAACATTGGGCCACAGACCTACTTCCACACCTGC\nCTCATGGTTGCCTGTCCGGTCCTCATCCTCACCCAGAGCTCCATCCTGGCCCTGCTGGCA\nATTGCTGTGGACCGCTACCTCCGGGTCAAGATCCCTCTCCGGTACAAGATGGTGGTGACC\nCCCCGGAGGGCGGCGGTGGCCATAGCCGGCTGCTGGATCCTCTCCTTCGTGGTGGGACTG\nACCCCTATGTTTGGCTGGAACAATCTGAGTGCGGTGGAGCGGGCCTGGGCAGCCAACGGC\nAGCATGGGGGAGCCCGTGATCAAGTGCGAGTTCGAGAAGGTCATCAGCATGGAGTACATG\nGTCTACTTCAACTTCTTTGTGTGGGTGCTGCCCCCGCTTCTCCTCATGGTCCTCATCTAC\nCTGGAGGTCTTCTACCTAATCCGCAAGCAGCTCAACAAGAAGGTGTCGGCCTCCTCCGGC\nGACCCGCAGAAGTACTATGGGAAGGAGCTGAAGATCGCCAAGTCGCTGGCCCTCATCCTC\nTTCCTCTTTGCCCTCAGCTGGCTGCCTTTGCACATCCTCAACTGCATCACCCTCTTCTGC\nCCGTCCTGCCACAAGCCCAGCATCCTTACCTACATTGCCATCTTCCTCACGCACGGCAAC\nTCGGCCATGAACCCCATTGTCTATGCCTTCCGCATCCAGAAGTTCCGCGTCACCTTCCTT\nAAGATTTGGAATGACCATTTCCGCTGCCAGCCTGCACCTCCCATTGACGAGGATCTCCCA\nGAAGAGAGGCCTGATGACTAG'),('Adenosine receptor A2a','None','Human','Identical protein binding','Receptor for adenosine. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase.','ADORA2A','44706.925','DB00640','>lcl|BSEQ0016254|Adenosine receptor A2a (ADORA2A)\nATGCCCATCATGGGCTCCTCGGTGTACATCACGGTGGAGCTGGCCATTGCTGTGCTGGCC\nATCCTGGGCAATGTGCTGGTGTGCTGGGCCGTGTGGCTCAACAGCAACCTGCAGAACGTC\nACCAACTACTTTGTGGTGTCACTGGCGGCGGCCGACATCGCAGTGGGTGTGCTCGCCATC\nCCCTTTGCCATCACCATCAGCACCGGGTTCTGCGCTGCCTGCCACGGCTGCCTCTTCATT\nGCCTGCTTCGTCCTGGTCCTCACGCAGAGCTCCATCTTCAGTCTCCTGGCCATCGCCATT\nGACCGCTACATTGCCATCCGCATCCCGCTCCGGTACAATGGCTTGGTGACCGGCACGAGG\nGCTAAGGGCATCATTGCCATCTGCTGGGTGCTGTCGTTTGCCATCGGCCTGACTCCCATG\nCTAGGTTGGAACAACTGCGGTCAGCCAAAGGAGGGCAAGAACCACTCCCAGGGCTGCGGG\nGAGGGCCAAGTGGCCTGTCTCTTTGAGGATGTGGTCCCCATGAACTACATGGTGTACTTC\nAACTTCTTTGCCTGTGTGCTGGTGCCCCTGCTGCTCATGCTGGGTGTCTATTTGCGGATC\nTTCCTGGCGGCGCGACGACAGCTGAAGCAGATGGAGAGCCAGCCTCTGCCGGGGGAGCGG\nGCACGGTCCACACTGCAGAAGGAGGTCCATGCTGCCAAGTCACTGGCCATCATTGTGGGG\nCTCTTTGCCCTCTGCTGGCTGCCCCTACACATCATCAACTGCTTCACTTTCTTCTGCCCC\nGACTGCAGCCACGCCCCTCTCTGGCTCATGTACCTGGCCATCGTCCTCTCCCACACCAAT\nTCGGTTGTGAATCCCTTCATCTACGCCTACCGTATCCGCGAGTTCCGCCAGACCTTCCGC\nAAGATCATTCGCAGCCACGTCCTGAGGCAGCAAGAACCTTTCAAGGCAGCTGGCACCAGT\nGCCCGGGTCTTGGCAGCTCATGGCAGTGACGGAGAGCAGGTCAGCCTCCGTCTCAACGGC\nCACCCGCCAGGAGTGTGGGCCAACGGCAGTGCTCCCCACCCTGAGCGGAGGCCCAATGGC\nTATGCCCTGGGGCTGGTGAGTGGAGGGAGTGCCCAAGAGTCCCAGGGGAACACGGGCCTC\nCCAGACGTGGAGCTCCTTAGCCATGAGCTCAAGGGAGTGTGCCCAGAGCCCCCTGGCCTA\nGATGACCCCCTGGCCCAGGATGGAGCAGGAGTGTCCTGA'),('Adenosine receptor A2b','None','Human','G-protein coupled adenosine receptor activity','Receptor for adenosine. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase.','ADORA2B','36332.655','DB00640','>lcl|BSEQ0010029|Adenosine receptor A2b (ADORA2B)\nATGCTGCTGGAGACACAGGACGCGCTGTACGTGGCGCTGGAGCTGGTCATCGCCGCGCTT\nTCGGTGGCGGGCAACGTGCTGGTGTGCGCCGCGGTGGGCACGGCGAACACTCTGCAGACG\nCCCACCAACTACTTCCTGGTGTCCCTGGCTGCGGCCGACGTGGCCGTGGGGCTCTTCGCC\nATCCCCTTTGCCATCACCATCAGCCTGGGCTTCTGCACTGACTTCTACGGCTGCCTCTTC\nCTCGCCTGCTTCGTGCTGGTGCTCACGCAGAGCTCCATCTTCAGCCTTCTGGCCGTGGCA\nGTCGACAGATACCTGGCCATCTGTGTCCCGCTCAGGTATAAAAGTTTGGTCACGGGGACC\nCGAGCAAGAGGGGTCATTGCTGTCCTCTGGGTCCTTGCCTTTGGCATCGGATTGACTCCA\nTTCCTGGGGTGGAACAGTAAAGACAGTGCCACCAACAACTGCACAGAACCCTGGGATGGA\nACCACGAATGAAAGCTGCTGCCTTGTGAAGTGTCTCTTTGAGAATGTGGTCCCCATGAGC\nTACATGGTATATTTCAATTTCTTTGGGTGTGTTCTGCCCCCACTGCTTATAATGCTGGTG\nATCTACATTAAGATCTTCCTGGTGGCCTGCAGGCAGCTTCAGCGCACTGAGCTGATGGAC\nCACTCGAGGACCACCCTCCAGCGGGAGATCCATGCAGCCAAGTCACTGGCCATGATTGTG\nGGGATTTTTGCCCTGTGCTGGTTACCTGTGCATGCTGTTAACTGTGTCACTCTTTTCCAG\nCCAGCTCAGGGTAAAAATAAGCCCAAGTGGGCAATGAATATGGCCATTCTTCTGTCACAT\nGCCAATTCAGTTGTCAATCCCATTGTCTATGCTTACCGGAACCGAGACTTCCGCTACACT\nTTTCACAAAATTATCTCCAGGTATCTTCTCTGCCAAGCAGATGTCAAGAGTGGGAATGGT\nCAGGCTGGGGTACAGCCTGCTCTCGGTGTGGGCCTATGA'),('Adenosine receptor A3','None','Human','G-protein coupled adenosine receptor activity','Receptor for adenosine. The activity of this receptor is mediated by G proteins which inhibits adenylyl cyclase. Possible role in reproduction.','ADORA3','36184.175','DB00640','>lcl|BSEQ0010106|Adenosine receptor A3 (ADORA3)\nATGCCCAACAACAGCACTGCTCTGTCATTGGCCAATGTTACCTACATCACCATGGAAATT\nTTCATTGGACTCTGCGCCATAGTGGGCAACGTGCTGGTCATCTGCGTGGTCAAGCTGAAC\nCCCAGCCTGCAGACCACCACCTTCTATTTCATTGTCTCTCTAGCCCTGGCTGACATTGCT\nGTTGGGGTGCTGGTCATGCCTTTGGCCATTGTTGTCAGCCTGGGCATCACAATCCACTTC\nTACAGCTGCCTTTTTATGACTTGCCTACTGCTTATCTTTACCCACGCCTCCATCATGTCC\nTTGCTGGCCATCGCTGTGGACCGATACTTGCGGGTCAAGCTTACCGTCAGATACAAGAGG\nGTCACCACTCACAGAAGAATATGGCTGGCCCTGGGCCTTTGCTGGCTGGTGTCATTCCTG\nGTGGGATTGACCCCCATGTTTGGCTGGAACATGAAACTGACCTCAGAGTACCACAGAAAT\nGTCACCTTCCTTTCATGCCAATTTGTTTCCGTCATGAGAATGGACTACATGGTATACTTC\nAGCTTCCTCACCTGGATTTTCATCCCCCTGGTTGTCATGTGCGCCATCTATCTTGACATC\nTTTTACATCATTCGGAACAAACTCAGTCTGAACTTATCTAACTCCAAAGAGACAGGTGCA\nTTTTATGGACGGGAGTTCAAGACGGCTAAGTCCTTGTTTCTGGTTCTTTTCTTGTTTGCT\nCTGTCATGGCTGCCTTTATCTATCATCAACTGCATCATCTACTTTAATGGTGAGGTACCA\nCAGCTTGTGCTGTACATGGGCATCCTGCTGTCCCATGCCAACTCCATGATGAACCCTATC\nGTCTATGCCTATAAAATAAAGAAGTTCAAGGAAACCTACCTTTTGATCCTCAAAGCTTGT\nGTGGTCTGCCATCCCTCTGATTCTTTGGACACAAGCATTGAGAAGAATTCTGAGTAG'),('Aldo-keto reductase family 1 member B10','None','Human','Retinal dehydrogenase activity','Acts as all-trans-retinaldehyde reductase. Can efficiently reduce aliphatic and aromatic aldehydes, and is less active on hexoses (in vitro). May be responsible for detoxification of reactive aldehydes in the digested food before the nutrients are passed on to other organs.','AKR1B10','36019.295','DB06246','>lcl|BSEQ0017419|Aldo-keto reductase family 1 member B10 (AKR1B10)\nATGGCCACGTTTGTGGAGCTCAGTACCAAAGCCAAGATGCCCATTGTGGGCCTGGGCACT\nTGGAAGTCTCCTCTTGGCAAAGTGAAAGAAGCAGTGAAGGTGGCCATTGATGCAGGATAT\nCGGCACATTGACTGTGCCTATGTCTATCAGAATGAACATGAAGTGGGGGAAGCCATCCAA\nGAGAAGATCCAAGAGAAGGCTGTGAAGCGGGAGGACCTGTTCATCGTCAGCAAGTTGTGG\nCCCACTTTCTTTGAGAGACCCCTTGTGAGGAAAGCCTTTGAGAAGACCCTCAAGGACCTG\nAAGCTGAGCTATCTGGACGTCTATCTTATTCACTGGCCACAGGGATTCAAGTCTGGGGAT\nGACCTTTTCCCCAAAGATGATAAAGGTAATGCCATCGGTGGAAAAGCAACGTTCTTGGAT\nGCCTGGGAGGCCATGGAGGAGCTGGTGGATGAGGGGCTGGTGAAAGCCCTTGGGGTCTCC\nAATTTCAGCCACTTCCAGATCGAGAAGCTCTTGAACAAACCTGGACTGAAATATAAACCA\nGTGACTAACCAGGTTGAGTGTCACCCATACCTCACACAGGAGAAACTGATCCAGTACTGC\nCACTCCAAGGGCATCACCGTTACGGCCTACAGCCCCCTGGGCTCTCCGGATAGACCTTGG\nGCCAAGCCAGAAGACCCTTCCCTGCTGGAGGATCCCAAGATTAAGGAGATTGCTGCAAAG\nCACAAAAAAACCGCAGCCCAGGTTCTGATCCGTTTCCATATCCAGAGGAATGTGATTGTC\nATCCCCAAGTCTGTGACACCAGCACGCATTGTTGAGAACATTCAGGTCTTTGACTTTAAA\nTTGAGTGATGAGGAGATGGCAACCATACTCAGCTTCAACAGAAACTGGAGGGCCTGTAAC\nGTGTTGCAATCCTCTCATTTGGAAGACTATCCCTTCAATGCAGAATATTGA'),('Aldo-keto reductase family 1 member C1','None','Human','Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity','Converts progesterone to its inactive form, 20-alpha-dihydroxyprogesterone (20-alpha-OHP). In the liver and intestine, may have a role in the transport of bile. May have a role in monitoring the intrahepatic bile acid concentration. Has a low bile-binding ability. May play a role in myelin formation.','AKR1C1','36788.02','DB00936','>lcl|BSEQ0016018|Aldo-keto reductase family 1 member C1 (AKR1C1)\nATGGATTCGAAATATCAGTGTGTGAAGCTGAATGATGGTCACTTCATGCCTGTCCTGGGA\nTTTGGCACCTATGCGCCTGCAGAGGTTCCTAAAAGTAAAGCTTTAGAGGCCACCAAATTG\nGCAATTGAAGCTGGCTTCCGCCATATTGATTCTGCTCATTTATACAATAATGAGGAGCAG\nGTTGGACTGGCCATCCGAAGCAAGATTGCAGATGGCAGTGTGAAGAGAGAAGACATATTC\nTACACTTCAAAGCTTTGGTGCAATTCCCATCGACCAGAGTTGGTCCGACCAGCCTTGGAA\nAGGTCACTGAAAAATCTTCAATTGGATTATGTTGACCTCTACCTTATTCATTTTCCAGTG\nTCTGTAAAGCCAGGTGAGGAAGTGATCCCAAAAGATGAAAATGGAAAAATACTATTTGAC\nACAGTGGATCTCTGTGCCACATGGGAGGCCGTGGAGAAGTGTAAAGATGCAGGATTGGCC\nAAGTCCATCGGGGTGTCCAACTTCAACCGCAGGCAGCTGGAGATGATCCTCAACAAGCCA\nGGGCTCAAGTACAAGCCTGTCTGCAACCAGGTGGAATGTCATCCTTACTTCAACCAGAGA\nAAACTGCTGGATTTCTGCAAGTCAAAAGACATTGTTCTGGTTGCCTATAGTGCTCTGGGA\nTCCCACCGAGAAGAACCATGGGTGGACCCGAACTCCCCGGTGCTCTTGGAGGACCCAGTC\nCTTTGTGCCTTGGCAAAAAAGCACAAGCGAACCCCAGCCCTGATTGCCCTGCGCTACCAG\nCTACAGCGTGGGGTTGTGGTCCTGGCCAAGAGCTACAATGAGCAGCGCATCAGACAGAAC\nGTGCAGGTGTTTGAATTCCAGTTGACTTCAGAGGAGATGAAAGCCATAGATGGCCTAAAC\nAGAAATGTGCGATATTTGACCCTTGATATTTTTGCTGGCCCCCCTAATTATCCATTTTCT\nGATGAATATTAA'),('Aldo-keto reductase family 1 member C3','None','Human','Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity','Catalyzes the conversion of aldehydes and ketones to alcohols. Catalyzes the reduction of prostaglandin (PG) D2, PGH2 and phenanthrenequinone (PQ) and the oxidation of 9-alpha,11-beta-PGF2 to PGD2. Functions as a bi-directional 3-alpha-, 17-beta- and 20-alpha HSD. Can interconvert active androgens, estrogens and progestins with their cognate inactive metabolites. Preferentially transforms androstenedione (4-dione) to testosterone.','AKR1C3','36852.89','DB00328','>lcl|BSEQ0018982|Aldo-keto reductase family 1 member C3 (AKR1C3)\nATGGATTCAAAACATCAGTGTTTGAAGCTAAATGATGGTCACTTCATGCCTGTCCTGGGA\nTTTGGCACCTATGCACCTCCAGAGGTTCCGAGAAGTAAAGCTTTGGAGGTCACAAAATTA\nGCAATAGAAGCTGGGTTCCGCCATATAGATTCTGCTCATTTATACAATAATGAGGAGCAG\nGTTGGACTGGCCATCCGAAGCAAGATTGCAGATGGCAGTGTGAAGAGAGAAGACATATTC\nTACACTTCAAAGCTTTGGTCCACTTTTCATCGACCAGAGTTGGTCCGACCAGCCTTGGAA\nAACTCACTGAAGAAAGCTCAATTGGACTATGTTGACCTCTATCTTATTCATTCTCCAATG\nTCTCTAAAGCCAGGTGAGGAACTTTCACCAACAGATGAAAATGGAAAAGTAATATTTGAC\nATAGTGGATCTCTGTACCACCTGGGAGGCCATGGAGAAGTGTAAGGATGCAGGATTGGCC\nAAGTCCATTGGGGTGTCAAACTTCAACCGCAGGCAGCTGGAGATGATCCTCAACAAGCCA\nGGACTCAAGTACAAGCCTGTCTGCAACCAGGTAGAATGTCATCCGTATTTCAACCGGAGT\nAAATTGCTAGATTTCTGCAAGTCGAAAGATATTGTTCTGGTTGCCTATAGTGCTCTGGGA\nTCTCAACGAGACAAACGATGGGTGGACCCGAACTCCCCGGTGCTCTTGGAGGACCCAGTC\nCTTTGTGCCTTGGCAAAAAAGCACAAGCGAACCCCAGCCCTGATTGCCCTGCGCTACCAG\nCTGCAGCGTGGGGTTGTGGTCCTGGCCAAGAGCTACAATGAGCAGCGCATCAGACAGAAC\nGTGCAGGTTTTTGAGTTCCAGTTGACTGCAGAGGACATGAAAGCCATAGATGGCCTAGAC\nAGAAATCTCCACTATTTTAACAGTGATAGTTTTGCTAGCCACCCTAATTATCCATATTCA\nGATGAATATTAA'),('Aldose reductase','None','Human','Glyceraldehyde oxidoreductase activity','Catalyzes the NADPH-dependent reduction of a wide variety of carbonyl-containing compounds to their corresponding alcohols with a broad range of catalytic efficiencies.','AKR1B1','35853.125','DB06246','>lcl|BSEQ0016195|Aldose reductase (AKR1B1)\nATGGCAAGCCGTCTCCTGCTCAACAACGGCGCCAAGATGCCCATCCTGGGGTTGGGTACC\nTGGAAGTCCCCTCCAGGGCAGGTGACTGAGGCCGTGAAGGTGGCCATTGACGTCGGGTAC\nCGCCACATCGACTGTGCCCATGTGTACCAGAATGAGAATGAGGTGGGGGTGGCCATTCAG\nGAGAAGCTCAGGGAGCAGGTGGTGAAGCGTGAGGAGCTCTTCATCGTCAGCAAGCTGTGG\nTGCACGTACCATGAGAAGGGCCTGGTGAAAGGAGCCTGCCAGAAGACACTCAGCGACCTG\nAAGCTGGACTACCTGGACCTCTACCTTATTCACTGGCCGACTGGCTTTAAGCCTGGGAAG\nGAATTTTTCCCATTGGATGAGTCGGGCAATGTGGTTCCCAGTGACACCAACATTCTGGAC\nACGTGGGCGGCCATGGAAGAGCTGGTGGATGAAGGGCTGGTGAAAGCTATTGGCATCTCC\nAACTTCAACCATCTCCAGGTGGAGATGATCTTAAACAAACCTGGCTTGAAGTATAAGCCT\nGCAGTTAACCAGATTGAGTGCCACCCATATCTCACTCAGGAGAAGTTAATCCAGTACTGC\nCAGTCCAAAGGCATCGTGGTGACCGCCTACAGCCCCCTCGGCTCTCCTGACAGGCCCTGG\nGCCAAGCCCGAGGACCCTTCTCTCCTGGAGGATCCCAGGATCAAGGCGATCGCAGCCAAG\nCACAATAAAACTACAGCCCAGGTCCTGATCCGGTTCCCCATGCAGAGGAACTTGGTGGTG\nATCCCCAAGTCTGTGACACCAGAACGCATTGCTGAGAACTTTAAGGTCTTTGACTTTGAA\nCTGAGCAGCCAGGATATGACCACCTTACTCAGCTACAACAGGAACTGGAGGGTCTGTGCC\nTTGTTGAGCTGTACCTCCCACAAGGATTACCCCTTCCATGAAGAGTTTTGA'),('Alpha-1-acid glycoprotein 2','None','Human','None','Functions as transport protein in the blood stream. Binds various hydrophobic ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability. Appears to function in modulating the activity of the immune system during the acute-phase reaction.','ORM2','23602.43','DB00333','>lcl|BSEQ0012546|Alpha-1-acid glycoprotein 2 (ORM2)\nATGGCGCTGTCCTGGGTTCTTACAGTCCTGAGCCTCCTACCTCTGCTGGAAGCCCAGATC\nCCATTGTGTGCCAACCTAGTACCGGTGCCCATCACCAACGCCACCCTGGACCGGATCACT\nGGCAAGTGGTTTTATATCGCATCGGCCTTTCGAAACGAGGAGTACAATAAGTCGGTTCAG\nGAGATCCAAGCAACCTTCTTTTACTTTACCCCCAACAAGACAGAGGACACGATCTTTCTC\nAGAGAGTACCAGACCCGCCAGAACCAGTGCTTCTATAACTCCAGTTACCTGAATGTCCAG\nCGGGAGAATGGGACCGTCTCCAGATACGAGGGAGGCCGAGAACATGTTGCTCACCTGCTG\nTTCCTTAGGGACACCAAGACCTTGATGTTTGGTTCCTACCTGGACGATGAGAAGAACTGG\nGGGCTGTCTTTCTATGCTGACAAGCCAGAGACGACCAAGGAGCAACTGGGAGAGTTCTAC\nGAAGCTCTCGACTGCTTGTGCATTCCCAGGTCAGATGTCATGTACACCGACTGGAAAAAG\nGATAAGTGTGAGCCACTGGAGAAGCAGCACGAGAAGGAGAGGAAACAGGAGGAGGGGGAA\nTCCTAG'),('Alpha-1A adrenergic receptor','None','Human','Protein heterodimerization activity','This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.','ADRA1A','51486.005','DB01149','>lcl|BSEQ0010352|Alpha-1A adrenergic receptor (ADRA1A)\nATGGTGTTTCTCTCGGGAAATGCTTCCGACAGCTCCAACTGCACCCAACCGCCGGCACCG\nGTGAACATTTCCAAGGCCATTCTGCTCGGGGTGATCTTGGGGGGCCTCATTCTTTTCGGG\nGTGCTGGGTAACATCCTAGTGATCCTCTCCGTAGCCTGTCACCGACACCTGCACTCAGTC\nACGCACTACTACATCGTCAACCTGGCGGTGGCCGACCTCCTGCTCACCTCCACGGTGCTG\nCCCTTCTCCGCCATCTTCGAGGTCCTAGGCTACTGGGCCTTCGGCAGGGTCTTCTGCAAC\nATCTGGGCGGCAGTGGATGTGCTGTGCTGCACCGCGTCCATCATGGGCCTCTGCATCATC\nTCCATCGACCGCTACATCGGCGTGAGCTACCCGCTGCGCTACCCAACCATCGTCACCCAG\nAGGAGGGGTCTCATGGCTCTGCTCTGCGTCTGGGCACTCTCCCTGGTCATATCCATTGGA\nCCCCTGTTCGGCTGGAGGCAGCCGGCCCCCGAGGACGAGACCATCTGCCAGATCAACGAG\nGAGCCGGGCTACGTGCTCTTCTCAGCGCTGGGCTCCTTCTACCTGCCTCTGGCCATCATC\nCTGGTCATGTACTGCCGCGTCTACGTGGTGGCCAAGAGGGAGAGCCGGGGCCTCAAGTCT\nGGCCTCAAGACCGACAAGTCGGACTCGGAGCAAGTGACGCTCCGCATCCATCGGAAAAAC\nGCCCCGGCAGGAGGCAGCGGGATGGCCAGCGCCAAGACCAAGACGCACTTCTCAGTGAGG\nCTCCTCAAGTTCTCCCGGGAGAAGAAAGCGGCCAAAACGCTGGGCATCGTGGTCGGCTGC\nTTCGTCCTCTGCTGGCTGCCTTTTTTCTTAGTCATGCCCATTGGGTCTTTCTTCCCTGAT\nTTCAAGCCCTCTGAAACAGTTTTTAAAATAGTATTTTGGCTCGGATATCTAAACAGCTGC\nATCAACCCCATCATATACCCATGCTCCAGCCAAGAGTTCAAAAAGGCCTTTCAGAATGTC\nTTGAGAATCCAGTGTCTCTGCAGAAAGCAGTCTTCCAAACATGCCCTGGGCTACACCCTG\nCACCCGCCCAGCCAGGCCGTGGAAGGGCAACACAAGGACATGGTGCGCATCCCCGTGGGA\nTCAAGAGAGACCTTCTACAGGATCTCCAAGACGGATGGCGTTTGTGAATGGAAATTTTTC\nTCTTCCATGCCCCGTGGATCTGCCAGGATTACAGTGTCCAAAGACCAATCCTCCTGTACC\nACAGCCCGGGTGAGAAGTAAAAGCTTTTTGCAGGTCTGCTGCTGTGTAGGGCCCTCAACC\nCCCAGCCTTGACAAGAACCATCAAGTTCCAACCATTAAGGTCCACACCATCTCCCTCAGT\nGAGAACGGGGAGGAAGTCTAG'),('Alpha-1B adrenergic receptor','None','Human','Protein heterodimerization activity','This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.','ADRA1B','56835.375','DB01149','>lcl|BSEQ0010400|Alpha-1B adrenergic receptor (ADRA1B)\nATGAATCCCGACCTGGACACCGGCCACAACACATCAGCACCTGCCCACTGGGGAGAGTTG\nAAAAATGCCAACTTCACTGGCCCCAACCAGACCTCGAGCAACTCCACACTGCCCCAGCTG\nGACATCACCAGGGCCATCTCTGTGGGCCTGGTGCTGGGCGCCTTCATCCTCTTTGCCATC\nGTGGGCAACATCCTAGTCATCTTGTCTGTGGCCTGCAACCGGCACCTGCGGACGCCCACC\nAACTACTTCATTGTCAACCTGGCCATGGCCGACCTGCTGTTGAGCTTCACCGTCCTGCCC\nTTCTCAGCGGCCCTAGAGGTGCTCGGCTACTGGGTGCTGGGGCGGATCTTCTGTGACATC\nTGGGCAGCCGTGGATGTCCTGTGCTGCACAGCGTCCATTCTGAGCCTGTGCGCCATCTCC\nATCGATCGCTACATCGGGGTGCGCTACTCTCTGCAGTATCCCACGCTGGTCACCCGGAGG\nAAGGCCATCTTGGCGCTGCTCAGTGTCTGGGTCTTGTCCACCGTCATCTCCATCGGGCCT\nCTCCTTGGGTGGAAGGAGCCGGCACCCAACGATGACAAGGAGTGCGGGGTCACCGAAGAA\nCCCTTCTATGCCCTCTTCTCCTCTCTGGGCTCCTTCTACATCCCTCTGGCGGTCATTCTA\nGTCATGTACTGCCGTGTCTATATAGTGGCCAAGAGAACCACCAAGAACCTAGAGGCAGGA\nGTCATGAAGGAGATGTCCAACTCCAAGGAGCTGACCCTGAGGATCCATTCCAAGAACTTT\nCACGAGGACACCCTTAGCAGTACCAAGGCCAAGGGCCACAACCCCAGGAGTTCCATAGCT\nGTCAAACTTTTTAAGTTCTCCAGGGAAAAGAAAGCAGCTAAGACGTTGGGCATTGTGGTC\nGGTATGTTCATCTTGTGCTGGCTACCCTTCTTCATCGCTCTACCGCTTGGCTCCTTGTTC\nTCCACCCTGAAGCCCCCCGACGCCGTGTTCAAGGTGGTGTTCTGGCTGGGCTACTTCAAC\nAGCTGCCTCAACCCCATCATCTACCCATGCTCCAGCAAGGAGTTCAAGCGCGCTTTCGTG\nCGCATCCTCGGGTGCCAGTGCCGCGGCCGCGGCCGCCGCCGACGCCGCCGCCGCCGTCGC\nCTGGGCGGCTGCGCCTACACCTACCGGCCGTGGACGCGCGGCGGCTCGCTGGAGCGCTCG\nCAGTCGCGCAAGGACTCGCTGGACGACAGCGGCAGCTGCCTGAGCGGCAGCCAGCGGACC\nCTGCCCTCGGCCTCGCCGAGCCCGGGCTACCTGGGCCGCGGCGCGCCACCGCCAGTCGAG\nCTGTGCGCCTTCCCCGAGTGGAAGGCGCCCGGCGCCCTCCTGAGCCTGCCCGCGCCTGAG\nCCCCCCGGCCGCCGCGGCCGCCACGACTCGGGCCCGCTCTTCACCTTCAAGCTCCTGACC\nGAGCCCGAGAGCCCCGGGACCGACGGCGGCGCCAGCAACGGAGGCTGCGAGGCCGCGGCC\nGACGTGGCCAACGGGCAGCCGGGCTTCAAAAGCAACATGCCCCTGGCGCCCGGGCAGTTT\nTAG'),('Alpha-1D adrenergic receptor','None','Human','Alpha1-adrenergic receptor activity','This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.','ADRA1D','60462.205','DB00696','>lcl|BSEQ0019002|Alpha-1D adrenergic receptor (ADRA1D)\nATGACTTTCCGCGATCTCCTGAGCGTCAGTTTCGAGGGACCCCGCCCGGACAGCAGCGCA\nGGGGGCTCCAGCGCGGGCGGCGGCGGGGGCAGCGCGGGCGGCGCGGCCCCCTCGGAGGGC\nCCGGCGGTGGGCGGCGTGCCGGGGGGCGCGGGCGGCGGCGGCGGCGTGGTGGGCGCAGGC\nAGCGGCGAGGACAACCGGAGCTCCGCGGGGGAGCCGGGGAGCGCGGGCGCGGGCGGCGAC\nGTGAATGGCACGGCGGCCGTCGGGGGACTGGTGGTGAGCGCGCAGGGCGTGGGCGTGGGC\nGTCTTCCTGGCAGCCTTCATCCTTATGGCCGTGGCAGGTAACCTGCTTGTCATCCTCTCA\nGTGGCCTGCAACCGCCACCTGCAGACCGTCACCAACTATTTCATCGTGAACCTGGCCGTG\nGCCGACCTGCTGCTGAGCGCCACCGTACTGCCCTTCTCGGCCACCATGGAGGTTCTGGGC\nTTCTGGGCCTTTGGCCGCGCCTTCTGCGACGTATGGGCCGCCGTGGACGTGCTGTGCTGC\nACGGCCTCCATCCTCAGCCTCTGCACCATCTCCGTGGACCGGTACGTGGGCGTGCGCCAC\nTCACTCAAGTACCCAGCCATCATGACCGAGCGCAAGGCGGCCGCCATCCTGGCCCTGCTC\nTGGGTCGTAGCCCTGGTGGTGTCCGTAGGGCCCCTGCTGGGCTGGAAGGAGCCCGTGCCC\nCCTGACGAGCGCTTCTGCGGTATCACCGAGGAGGCGGGCTACGCTGTCTTCTCCTCCGTG\nTGCTCCTTCTACCTGCCCATGGCGGTCATCGTGGTCATGTACTGCCGCGTGTACGTGGTC\nGCGCGCAGCACCACGCGCAGCCTCGAGGCGGGCGTCAAGCGCGAGCGAGGCAAGGCCTCC\nGAGGTGGTGCTGCGCATCCACTGTCGCGGCGCGGCCACGGGCGCCGACGGGGCGCACGGC\nATGCGCAGCGCCAAGGGCCACACCTTCCGCAGCTCGCTCTCCGTGCGCCTGCTCAAGTTC\nTCCCGTGAGAAGAAAGCGGCCAAGACTCTGGCCATCGTCGTGGGTGTCTTCGTGCTCTGC\nTGGTTCCCTTTCTTCTTTGTCCTGCCGCTCGGCTCCTTGTTCCCGCAGCTGAAGCCATCG\nGAGGGCGTCTTCAAGGTCATCTTCTGGCTCGGCTACTTCAACAGCTGCGTGAACCCGCTC\nATCTACCCCTGTTCCAGCCGCGAGTTCAAGCGCGCCTTCCTCCGTCTCCTGCGCTGCCAG\nTGCCGTCGTCGCCGGCGCCGCCGCCCTCTCTGGCGTGTCTACGGCCACCACTGGCGGGCC\nTCCACCAGCGGCCTGCGCCAGGACTGCGCCCCGAGTTCGGGCGACGCGCCCCCCGGAGCG\nCCGCTGGCCCTCACCGCGCTCCCCGACCCCGACCCCGAACCCCCAGGCACGCCCGAGATG\nCAGGCTCCGGTCGCCAGCCGTCGAAAGCCACCCAGCGCCTTCCGCGAGTGGAGGCTGCTG\nGGGCCGTTCCGGAGACCCACGACCCAGCTGCGCGCCAAAGTCTCCAGCCTGTCGCACAAG\nATCCGCGCCGGGGGCGCGCAGCGCGCAGAGGCAGCGTGCGCCCAGCGCTCAGAGGTGGAG\nGCTGTGTCCCTAGGCGTCCCACACGAGGTGGCCGAGGGCGCCACCTGCCAGGCCTACGAA\nTTGGCCGACTACAGCAACCTACGGGAGACCGATATTTAA'),('Alpha-2 adrenergic receptors','protein group','Human','None','None','None','None','DB11477','None'),('Alpha-2A adrenergic receptor','None','Human','Thioesterase binding','Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol.','ADRA2A','48956.275','DB00320','>lcl|BSEQ0021256|Alpha-2A adrenergic receptor (ADRA2A)\nATGTTCCGCCAGGAGCAGCCGTTGGCCGAGGGCAGCTTTGCGCCCATGGGCTCCCTGCAG\nCCGGACGCGGGCAACGCGAGCTGGAACGGGACCGAGGCGCCGGGGGGCGGCGCCCGGGCC\nACCCCTTACTCCCTGCAGGTGACGCTGACGCTGGTGTGCCTGGCCGGCCTGCTCATGCTG\nCTCACCGTGTTCGGCAACGTGCTCGTCATCATCGCCGTGTTCACGAGCCGCGCGCTCAAG\nGCGCCCCAAAACCTCTTCCTGGTGTCTCTGGCCTCGGCCGACATCCTGGTGGCCACGCTC\nGTCATCCCTTTCTCGCTGGCCAACGAGGTCATGGGCTACTGGTACTTCGGCAAGGCTTGG\nTGCGAGATCTACCTGGCGCTCGACGTGCTCTTCTGCACGTCGTCCATCGTGCACCTGTGC\nGCCATCAGCCTGGACCGCTACTGGTCCATCACACAGGCCATCGAGTACAACCTGAAGCGC\nACGCCGCGCCGCATCAAGGCCATCATCATCACCGTGTGGGTCATCTCGGCCGTCATCTCC\nTTCCCGCCGCTCATCTCCATCGAGAAGAAGGGCGGCGGCGGCGGCCCGCAGCCGGCCGAG\nCCGCGCTGCGAGATCAACGACCAGAAGTGGTACGTCATCTCGTCGTGCATCGGCTCCTTC\nTTCGCTCCCTGCCTCATCATGATCCTGGTCTACGTGCGCATCTACCAGATCGCCAAGCGT\nCGCACCCGCGTGCCACCCAGCCGCCGGGGTCCGGACGCCGTCGCCGCGCCGCCGGGGGGC\nACCGAGCGCAGGCCCAACGGTCTGGGCCCCGAGCGCAGCGCGGGCCCGGGGGGCGCAGAG\nGCCGAACCGCTGCCCACCCAGCTCAACGGCGCCCCTGGCGAGCCCGCGCCGGCCGGGCCG\nCGCGACACCGACGCGCTGGACCTGGAGGAGAGCTCGTCTTCCGACCACGCCGAGCGGCCT\nCCAGGGCCCCGCAGACCCGAGCGCGGTCCCCGGGGCAAAGGCAAGGCCCGAGCGAGCCAG\nGTGAAGCCGGGCGACAGCCTGCCGCGGCGCGGGCCGGGGGCGACGGGGATCGGGACGCCG\nGCTGCAGGGCCGGGGGAGGAGCGCGTCGGGGCTGCCAAGGCGTCGCGCTGGCGCGGGCGG\nCAGAACCGCGAGAAGCGCTTCACGTTCGTGCTGGCCGTGGTCATCGGAGTGTTCGTGGTG\nTGCTGGTTCCCCTTCTTCTTCACCTACACGCTCACGGCCGTCGGGTGCTCCGTGCCACGC\nACGCTCTTCAAATTCTTCTTCTGGTTCGGCTACTGCAACAGCTCGTTGAACCCGGTCATC\nTACACCATCTTCAACCACGATTTCCGCCGCGCCTTCAAGAAGATCCTCTGTCGGGGGGAC\nAGGAAGCGGATCGTGTGA'),('Alpha-2B adrenergic receptor','None','Human','Epinephrine binding','Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phentolamine > mianserine > spiperone > prazosin > alprenolol > propanolol > pindolol.','ADRA2B','49565.8','DB00589','>lcl|BSEQ0010397|Alpha-2B adrenergic receptor (ADRA2B)\nATGGACCACCAGGACCCCTACTCCGTGCAGGCCACAGCGGCCATAGCGGCGGCCATCACC\nTTCCTCATTCTCTTTACCATCTTCGGCAACGCTCTGGTCATCCTGGCTGTGTTGACCAGC\nCGCTCGCTGCGCGCCCCTCAGAACCTGTTCCTGGTGTCGCTGGCCGCCGCCGACATCCTG\nGTGGCCACGCTCATCATCCCTTTCTCGCTGGCCAACGAGCTGCTGGGCTACTGGTACTTC\nCGGCGCACGTGGTGCGAGGTGTACCTGGCGCTCGACGTGCTCTTCTGCACCTCGTCCATC\nGTGCACCTGTGCGCCATCAGCCTGGACCGCTACTGGGCCGTGAGCCGCGCGCTGGAGTAC\nAACTCCAAGCGCACCCCGCGCCGCATCAAGTGCATCATCCTCACTGTGTGGCTCATCGCC\nGCCGTCATCTCGCTGCCGCCCCTCATCTACAAGGGCGACCAGGGCCCCCAGCCGCGCGGG\nCGCCCCCAGTGCAAGCTCAACCAGGAGGCCTGGTACATCCTGGCCTCCAGCATCGGATCT\nTTCTTTGCTCCTTGCCTCATCATGATCCTTGTCTACCTGCGCATCTACCTGATCGCCAAA\nCGCAGCAACCGCAGAGGTCCCAGGGCCAAGGGGGGGCCTGGGCAGGGTGAGTCCAAGCAG\nCCCCGACCCGACCATGGTGGGGCTTTGGCCTCAGCCAAACTGCCAGCCCTGGCCTCTGTG\nGCTTCTGCCAGAGAGGTCAACGGACACTCGAAGTCCACTGGGGAGAAGGAGGAGGGGGAG\nACCCCTGAAGATACTGGGACCCGGGCCTTGCCACCCAGTTGGGCTGCCCTTCCCAACTCA\nGGCCAGGGCCAGAAGGAGGGTGTTTGTGGGGCATCTCCAGAGGATGAAGCTGAAGAGGAG\nGAAGAGGAGGAGGAGGAGGAGGAAGAGTGTGAACCCCAGGCAGTGCCAGTGTCTCCGGCC\nTCAGCTTGCAGCCCCCCGCTGCAGCAGCCACAGGGCTCCCGGGTGCTGGCCACCCTACGT\nGGCCAGGTGCTCCTGGGCAGGGGCGTGGGTGCTATAGGTGGGCAGTGGTGGCGTCGACGG\nGCGCAGCTGACCCGGGAGAAGCGCTTCACCTTCGTGCTGGCTGTGGTCATTGGCGTTTTT\nGTGCTCTGCTGGTTCCCCTTCTTCTTCAGCTACAGCCTGGGAGCCATCTGCCCGAAGCAC\nTGCAAGGTGCCCCATGGCCTCTTCCAGTTCTTCTTCTGGATCGGCTACTGCAACAGCTCA\nCTGAACCCTGTTATCTACACCATCTTCAACCAGGACTTCCGCCGTGCCTTCCGGAGGATC\nCTGTGCCGCCCGTGGACCCAGACGGCCTGGTGA'),('Alpha-2C adrenergic receptor','None','Human','Protein homodimerization activity','Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.','ADRA2C','49521.585','DB00589','>lcl|BSEQ0010255|Alpha-2C adrenergic receptor (ADRA2C)\nATGGCGTCCCCGGCGCTGGCGGCGGCGCTGGCGGTGGCGGCAGCGGCGGGCCCCAATGCG\nAGCGGCGCGGGCGAGAGGGGCAGCGGCGGGGTTGCCAATGCCTCGGGGGCTTCCTGGGGG\nCCGCCGCGCGGCCAGTACTCGGCGGGCGCGGTGGCAGGGCTGGCTGCCGTGGTGGGCTTC\nCTCATCGTCTTCACCGTGGTGGGCAACGTGCTGGTGGTGATCGCCGTGCTGACCAGCCGG\nGCGCTGCGCGCGCCACAGAACCTCTTCCTGGTGTCGCTGGCCTCGGCCGACATCCTGGTG\nGCCACGCTGGTCATGCCCTTCTCGTTGGCCAACGAGCTCATGGCCTACTGGTACTTCGGG\nCAGGTGTGGTGCGGCGTGTACCTGGCGCTCGATGTGCTGTTTTGCACCTCGTCGATCGTG\nCATCTGTGTGCCATCAGCCTGGACCGCTACTGGTCGGTGACGCAGGCCGTCGAGTACAAC\nCTGAAGCGCACACCACGCCGCGTCAAGGCCACCATCGTGGCCGTGTGGCTCATCTCGGCC\nGTCATCTCCTTCCCGCCGCTGGTCTCGCTCTACCGCCAGCCCGACGGCGCCGCCTACCCG\nCAGTGCGGCCTCAACGACGAGACCTGGTACATCCTGTCCTCCTGCATCGGCTCCTTCTTC\nGCGCCCTGCCTCATCATGGGCCTGGTCTACGCGCGCATCTACCGAGTGGCCAAGCTGCGC\nACGCGCACGCTCAGCGAGAAGCGCGCCCCCGTGGGCCCCGACGGTGCGTCCCCGACTACC\nGAAAACGGGCTGGGCGCGGCGGCAGGCGCAGGCGAGAACGGGCACTGCGCGCCCCCGCCC\nGCCGACGTGGAGCCGGACGAGAGCAGCGCAGCGGCCGAGAGGCGGCGGCGCCGGGGCGCG\nTTGCGGCGGGGCGGGCGGCGGCGAGCGGGCGCGGAGGGGGGCGCGGGCGGTGCGGACGGG\nCAGGGGGCGGGGCCGGGGGCGGCTGAGTCGGGGGCGCTGACCGCCTCCAGGTCCCCGGGG\nCCCGGTGGCCGCCTGTCGCGCGCCAGCTCGCGCTCCGTCGAGTTCTTCCTGTCGCGCCGG\nCGCCGGGCGCGCAGCAGCGTGTGCCGCCGCAAGGTGGCCCAGGCGCGCGAGAAGCGCTTC\nACCTTTGTGCTGGCTGTGGTCATGGGCGTGTTCGTGCTCTGCTGGTTCCCCTTCTTCTTC\nAGCTACAGCCTGTACGGCATCTGCCGCGAGGCCTGCCAGGTGCCCGGCCCGCTCTTCAAG\nTTCTTCTTCTGGATCGGCTACTGCAACAGCTCGCTCAACCCGGTCATCTACACGGTCTTC\nAACCAGGATTTCCGGCGATCCTTTAAGCACATCCTCTTCCGACGGAGGAGAAGGGGCTTC\nAGGCAGTGA'),('Alpha-7 nicotinic cholinergic receptor subunit','None','Human','None','None','CHRNA7','2987.635','DB01221','>lcl|BSEQ0006706|87 bp\nGGATAACAGTCTTACTCTCTCTTACCGTCTTCATGCTGCTCGTGGCTGAGATCATGCCCG\nCAACATCCGATTCGGTACCATTGATAG'),('Alpha-synuclein','None','Human','None','None','SNCA','14460.155','DB02709','>lcl|BSEQ0021281|Alpha-synuclein (SNCA)\nATGGATGTATTCATGAAAGGACTTTCAAAGGCCAAGGAGGGAGTTGTGGCTGCTGCTGAG\nAAAACCAAACAGGGTGTGGCAGAAGCAGCAGGAAAGACAAAAGAGGGTGTTCTCTATGTA\nGGCTCCAAAACCAAGGAGGGAGTGGTGCATGGTGTGGCAACAGTGGCTGAGAAGACCAAA\nGAGCAAGTGACAAATGTTGGAGGAGCAGTGGTGACGGGTGTGACAGCAGTAGCCCAGAAG\nACAGTGGAGGGAGCAGGGAGCATTGCAGCAGCCACTGGCTTTGTCAAAAAGGACCAGTTG\nGGCAAGAATGAAGAAGGAGCCCCACAGGAAGGAATTCTGGAAGATATGCCTGTGGATCCT\nGACAATGAGGCTTATGAAATGCCTTCTGAGGAAGGGTATCAAGACTACGAACCTGAAGCC\nTAA'),('alpha1-acid glycoprotein','protein group','Human','None','None','None','None','DB00497','None'),('alpha1-acid glycoprotein (Protein Group)','Protein group','Human','None','Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...','None','None','DB00497',NULL),('Aminopeptidase N','None','Human','Zinc ion binding','Broad specificity aminopeptidase. Plays a role in the final digestion of peptides generated from hydrolysis of proteins by gastric and pancreatic proteases. May play a critical role in the pathogenesis of cholesterol gallstone disease. May be involved in the metabolism of regulatory peptides of diverse cell types, responsible for the processing of peptide hormones, such as angiotensin III and IV, neuropeptides, and chemokines. Found to cleave antigen peptides bound to major histocompatibility complex class II molecules of presenting cells and to degrade neurotransmitters at synaptic junctions. Is also implicated as a regulator of IL-8 bioavailability in the endometrium, and therefore may contribute to the regulation of angiogenesis. Is used as a marker for acute myeloid leukemia and plays a role in tumor invasion. In case of human coronavirus 229E (HCoV-229E) infection, serves as receptor for HCoV-229E spike glycoprotein. Mediates as well human cytomegalovirus (HCMV) infection.(Microbial infection) Acts as a receptor for human coronavirus 229E/HCoV-229E.','ANPEP','109538.68','DB06196','>lcl|BSEQ0010757|Aminopeptidase N (ANPEP)\nATGGCCAAGGGCTTCTATATTTCCAAGTCCCTGGGCATCCTGGGGATCCTCCTGGGCGTG\nGCAGCCGTGTGCACAATCATCGCACTGTCAGTGGTGTACTCCCAGGAGAAGAACAAGAAC\nGCCAACAGCTCCCCCGTGGCCTCCACCACCCCGTCCGCCTCAGCCACCACCAACCCCGCC\nTCGGCCACCACCTTGGACCAAAGTAAAGCGTGGAATCGTTACCGCCTCCCCAACACGCTG\nAAACCCGATTCCTACCGGGTGACGCTGAGACCGTACCTCACCCCCAATGACAGGGGCCTG\nTACGTTTTTAAGGGCTCCAGCACCGTCCGTTTCACCTGCAAGGAGGCCACTGACGTCATC\nATCATCCACAGCAAGAAGCTCAACTACACCCTCAGCCAGGGGCACAGGGTGGTCCTGCGT\nGGTGTGGGAGGCTCCCAGCCCCCCGACATTGACAAGACTGAGCTGGTGGAGCCCACCGAG\nTACCTGGTGGTGCACCTCAAGGGCTCCCTGGTGAAGGACAGCCAGTATGAGATGGACAGC\nGAGTTCGAGGGGGAGTTGGCAGATGACCTGGCGGGCTTCTACCGCAGCGAGTACATGGAG\nGGCAATGTCAGAAAGGTGGTGGCCACTACACAGATGCAGGCTGCAGATGCCCGGAAGTCC\nTTCCCATGCTTCGATGAGCCGGCCATGAAGGCCGAGTTCAACATCACGCTTATCCACCCC\nAAGGACCTGACAGCCCTGTCCAACATGCTTCCCAAAGGTCCCAGCACCCCACTTCCAGAA\nGACCCCAACTGGAATGTCACTGAGTTCCACACCACGCCCAAGATGTCCACGTACTTGCTG\nGCCTTCATTGTCAGTGAGTTCGACTACGTGGAGAAGCAGGCATCCAATGGTGTCTTGATC\nCGGATCTGGGCCCGGCCCAGTGCCATTGCGGCGGGCCACGGCGATTATGCCCTGAACGTG\nACGGGCCCCATCCTTAACTTCTTTGCTGGTCATTATGACACACCCTACCCACTCCCAAAA\nTCAGACCAGATTGGCCTGCCAGACTTCAACGCCGGCGCCATGGAGAACTGGGGACTGGTG\nACCTACCGGGAGAACTCCCTGCTGTTCGACCCCCTGTCCTCCTCCAGCAGCAACAAGGAG\nCGGGTGGTCACTGTGATTGCTCATGAGCTGGCCCACCAGTGGTTCGGGAACCTGGTGACC\nATAGAGTGGTGGAATGACCTGTGGCTGAACGAGGGCTTCGCCTCCTACGTGGAGTACCTG\nGGTGCTGACTATGCGGAGCCCACCTGGAACTTGAAAGACCTCATGGTGCTGAATGATGTG\nTACCGCGTGATGGCAGTGGATGCACTGGCCTCCTCCCACCCGCTGTCCACACCCGCCTCG\nGAGATCAACACGCCGGCCCAGATCAGTGAGCTGTTTGACGCCATCTCCTACAGCAAGGGC\nGCCTCAGTCCTCAGGATGCTCTCCAGCTTCCTGTCCGAGGACGTATTCAAGCAGGGCCTG\nGCGTCCTACCTCCACACCTTTGCCTACCAGAACACCATCTACCTGAACCTGTGGGACCAC\nCTGCAGGAGGCTGTGAACAACCGGTCCATCCAACTCCCCACCACCGTGCGGGACATCATG\nAACCGCTGGACCCTGCAGATGGGCTTCCCGGTCATCACGGTGGATACCAGCACGGGGACC\nCTTTCCCAGGAGCACTTCCTCCTTGACCCCGATTCCAATGTTACCCGCCCCTCAGAATTC\nAACTACGTGTGGATTGTGCCCATCACATCCATCAGAGATGGCAGACAGCAGCAGGACTAC\nTGGCTGATAGATGTAAGAGCCCAGAACGATCTCTTCAGCACATCAGGCAATGAGTGGGTC\nCTGCTGAACCTCAATGTGACGGGCTATTACCGGGTGAACTACGACGAAGAGAACTGGAGG\nAAGATTCAGACTCAGCTGCAGAGAGACCACTCGGCCATCCCTGTCATCAATCGGGCACAG\nATCATTAATGACGCCTTCAACCTGGCCAGTGCCCATAAGGTCCCTGTCACTCTGGCGCTG\nAACAACACCCTCTTCCTGATTGAAGAGAGACAGTACATGCCCTGGGAGGCCGCCCTGAGC\nAGCCTGAGCTACTTCAAGCTCATGTTTGACCGCTCCGAGGTCTATGGCCCCATGAAGAAC\nTACCTGAAGAAGCAGGTCACACCCCTCTTCATTCACTTCAGAAATAATACCAACAACTGG\nAGGGAGATCCCAGAAAACCTGATGGACCAGTACAGCGAGGTTAATGCCATCAGCACCGCC\nTGCTCCAACGGAGTTCCAGAGTGTGAGGAGATGGTCTCTGGCCTTTTCAAGCAGTGGATG\nGAGAACCCCAATAATAACCCGATCCACCCCAACCTGCGGTCCACCGTCTACTGCAACGCT\nATCGCCCAGGGCGGGGAGGAGGAGTGGGACTTCGCCTGGGAGCAGTTCCGAAATGCCACA\nCTGGTCAATGAGGCTGACAAGCTCCGGGCAGCCCTGGCCTGCAGCAAAGAGTTGTGGATC\nCTGAACAGGTACCTGAGCTACACCCTGAACCCGGACTTAATCCGGAAGCAGGACGCCACC\nTCTACCATCATCAGCATTACCAACAACGTCATTGGGCAAGGTCTGGTCTGGGACTTTGTC\nCAGAGCAACTGGAAGAAGCTTTTTAACGATTATGGTGGTGGCTCGTTCTCCTTCTCCAAC\nCTCATCCAGGCAGTGACACGACGATTCTCCACCGAGTATGAGCTGCAGCAGCTGGAGCAG\nTTCAAGAAGGACAACGAGGAAACAGGCTTCGGCTCAGGCACCCGGGCCCTGGAGCAAGCC\nCTGGAGAAGACGAAAGCCAACATCAAGTGGGTGAAGGAGAACAAGGAGGTGGTGCTCCAG\nTGGTTCACAGAAAACAGCAAATAG'),('Amyloid beta A4 protein','None','Human','Transition metal ion binding','Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Couples to apoptosis-inducing pathways such as those mediated by G(O) and JIP. Inhibits G(o) alpha ATPase activity (By similarity). Acts as a kinesin I membrane receptor, mediating the axonal transport of beta-secretase and presenilin 1. Involved in copper homeostasis/oxidative stress through copper ion reduction. In vitro, copper-metallated APP induces neuronal death directly or is potentiated through Cu(2+)-mediated low-density lipoprotein oxidation. Can regulate neurite outgrowth through binding to components of the extracellular matrix such as heparin and collagen I and IV. The splice isoforms that contain the BPTI domain possess protease inhibitor activity. Induces a AGER-dependent pathway that involves activation of p38 MAPK, resulting in internalization of amyloid-beta peptide and leading to mitochondrial dysfunction in cultured cortical neurons. Provides Cu(2+) ions for GPC1 which are required for release of nitric oxide (NO) and subsequent degradation of the heparan sulfate chains on GPC1.Beta-amyloid peptides are lipophilic metal chelators with metal-reducing activity. Bind transient metals such as copper, zinc and iron. In vitro, can reduce Cu(2+) and Fe(3+) to Cu(+) and Fe(2+), respectively. Beta-amyloid 42 is a more effective reductant than beta-amyloid 40. Beta-amyloid peptides bind to lipoproteins and apolipoproteins E and J in the CSF and to HDL particles in plasma, inhibiting metal-catalyzed oxidation of lipoproteins. Beta-APP42 may activate mononuclear phagocytes in the brain and elicit inflammatory responses. Promotes both tau aggregation and TPK II-mediated phosphorylation. Interaction with overexpressed HADH2 leads to oxidative stress and neurotoxicity. Also binds GPC1 in lipid rafts.Appicans elicit adhesion of neural cells to the extracellular matrix and may regulate neurite outgrowth in the brain.The gamma-CTF peptides as well as the caspase-cleaved peptides, including C31, are potent enhancers of neuronal apoptosis.N-APP binds TNFRSF21 triggering caspase activation and degeneration of both neuronal cell bodies (via caspase-3) and axons (via caspase-6).','APP','86942.715','DB02709','>lcl|BSEQ0019416|Amyloid beta A4 protein (APP)\nATGCTGCCCGGTTTGGCACTGCTCCTGCTGGCCGCCTGGACGGCTCGGGCGCTGGAGGTA\nCCCACTGATGGTAATGCTGGCCTGCTGGCTGAACCCCAGATTGCCATGTTCTGTGGCAGA\nCTGAACATGCACATGAATGTCCAGAATGGGAAGTGGGATTCAGATCCATCAGGGACCAAA\nACCTGCATTGATACCAAGGAAGGCATCCTGCAGTATTGCCAAGAAGTCTACCCTGAACTG\nCAGATCACCAATGTGGTAGAAGCCAACCAACCAGTGACCATCCAGAACTGGTGCAAGCGG\nGGCCGCAAGCAGTGCAAGACCCATCCCCACTTTGTGATTCCCTACCGCTGCTTAGTTGGT\nGAGTTTGTAAGTGATGCCCTTCTCGTTCCTGACAAGTGCAAATTCTTACACCAGGAGAGG\nATGGATGTTTGCGAAACTCATCTTCACTGGCACACCGTCGCCAAAGAGACATGCAGTGAG\nAAGAGTACCAACTTGCATGACTACGGCATGTTGCTGCCCTGCGGAATTGACAAGTTCCGA\nGGGGTAGAGTTTGTGTGTTGCCCACTGGCTGAAGAAAGTGACAATGTGGATTCTGCTGAT\nGCGGAGGAGGATGACTCGGATGTCTGGTGGGGCGGAGCAGACACAGACTATGCAGATGGG\nAGTGAAGACAAAGTAGTAGAAGTAGCAGAGGAGGAAGAAGTGGCTGAGGTGGAAGAAGAA\nGAAGCCGATGATGACGAGGACGATGAGGATGGTGATGAGGTAGAGGAAGAGGCTGAGGAA\nCCCTACGAAGAAGCCACAGAGAGAACCACCAGCATTGCCACCACCACCACCACCACCACA\nGAGTCTGTGGAAGAGGTGGTTCGAGAGGTGTGCTCTGAACAAGCCGAGACGGGGCCGTGC\nCGAGCAATGATCTCCCGCTGGTACTTTGATGTGACTGAAGGGAAGTGTGCCCCATTCTTT\nTACGGCGGATGTGGCGGCAACCGGAACAACTTTGACACAGAAGAGTACTGCATGGCCGTG\nTGTGGCAGCGCCATGTCCCAAAGTTTACTCAAGACTACCCAGGAACCTCTTGCCCGAGAT\nCCTGTTAAACTTCCTACAACAGCAGCCAGTACCCCTGATGCCGTTGACAAGTATCTCGAG\nACACCTGGGGATGAGAATGAACATGCCCATTTCCAGAAAGCCAAAGAGAGGCTTGAGGCC\nAAGCACCGAGAGAGAATGTCCCAGGTCATGAGAGAATGGGAAGAGGCAGAACGTCAAGCA\nAAGAACTTGCCTAAAGCTGATAAGAAGGCAGTTATCCAGCATTTCCAGGAGAAAGTGGAA\nTCTTTGGAACAGGAAGCAGCCAACGAGAGACAGCAGCTGGTGGAGACACACATGGCCAGA\nGTGGAAGCCATGCTCAATGACCGCCGCCGCCTGGCCCTGGAGAACTACATCACCGCTCTG\nCAGGCTGTTCCTCCTCGGCCTCGTCACGTGTTCAATATGCTAAAGAAGTATGTCCGCGCA\nGAACAGAAGGACAGACAGCACACCCTAAAGCATTTCGAGCATGTGCGCATGGTGGATCCC\nAAGAAAGCCGCTCAGATCCGGTCCCAGGTTATGACACACCTCCGTGTGATTTATGAGCGC\nATGAATCAGTCTCTCTCCCTGCTCTACAACGTGCCTGCAGTGGCCGAGGAGATTCAGGAT\nGAAGTTGATGAGCTGCTTCAGAAAGAGCAAAACTATTCAGATGACGTCTTGGCCAACATG\nATTAGTGAACCAAGGATCAGTTACGGAAACGATGCTCTCATGCCATCTTTGACCGAAACG\nAAAACCACCGTGGAGCTCCTTCCCGTGAATGGAGAGTTCAGCCTGGACGATCTCCAGCCG\nTGGCATTCTTTTGGGGCTGACTCTGTGCCAGCCAACACAGAAAACGAAGTTGAGCCTGTT\nGATGCCCGCCCTGCTGCCGACCGAGGACTGACCACTCGACCAGGTTCTGGGTTGACAAAT\nATCAAGACGGAGGAGATCTCTGAAGTGAAGATGGATGCAGAATTCCGACATGACTCAGGA\nTATGAAGTTCATCATCAAAAATTGGTGTTCTTTGCAGAAGATGTGGGTTCAAACAAAGGT\nGCAATCATTGGACTCATGGTGGGCGGTGTTGTCATAGCGACAGTGATCGTCATCACCTTG\nGTGATGCTGAAGAAGAAACAGTACACATCCATTCATCATGGTGTGGTGGAGGTTGACGCC\nGCTGTCACCCCAGAGGAGCGCCACCTGTCCAAGATGCAGCAGAACGGCTACGAAAATCCA\nACCTACAAGTTCTTTGAGCAGATGCAGAACTAG'),('Apoptosis regulator Bcl-2','None','Human','Ubiquitin protein ligase binding','Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1). May attenuate inflammation by impairing NLRP1-inflammasome activation, hence CASP1 activation and IL1B release (PubMed:17418785).','BCL2','26265.66','DB01050','>lcl|BSEQ0021924|Apoptosis regulator Bcl-2 (BCL2)\nATGGCGCACGCTGGGAGAACAGGGTACGATAACCGGGAGATAGTGATGAAGTACATCCAT\nTATAAGCTGTCGCAGAGGGGCTACGAGTGGGATGCGGGAGATGTGGGCGCCGCGCCCCCG\nGGGGCCGCCCCCGCACCGGGCATCTTCTCCTCCCAGCCCGGGCACACGCCCCATCCAGCC\nGCATCCCGGGACCCGGTCGCCAGGACCTCGCCGCTGCAGACCCCGGCTGCCCCCGGCGCC\nGCCGCGGGGCCTGCGCTCAGCCCGGTGCCACCTGTGGTCCACCTGACCCTCCGCCAGGCC\nGGCGACGACTTCTCCCGCCGCTACCGCCGCGACTTCGCCGAGATGTCCAGCCAGCTGCAC\nCTGACGCCCTTCACCGCGCGGGGACGCTTTGCCACGGTGGTGGAGGAGCTCTTCAGGGAC\nGGGGTGAACTGGGGGAGGATTGTGGCCTTCTTTGAGTTCGGTGGGGTCATGTGTGTGGAG\nAGCGTCAACCGGGAGATGTCGCCCCTGGTGGACAACATCGCCCTGTGGATGACTGAGTAC\nCTGAACCGGCACCTGCACACCTGGATCCAGGATAACGGAGGCTGGGATGCCTTTGTGGAA\nCTGTACGGCCCCAGCATGCGGCCTCTGTTTGATTTCTCCTGGCTGTCTCTGAAGACTCTG\nCTCAGTTTGGCCCTGGTGGGAGCTTGCATCACCCTGGGTGCCTATCTGGGCCACAAGTGA'),('Arachidonate 15-lipoxygenase','None','Human','Phosphatidylinositol-4,5-bisphosphate binding','Non-heme iron-containing dioxygenase that catalyzes the stereo-specific peroxidation of free and esterified polyunsaturated fatty acids generating a spectrum of bioactive lipid mediators. Converts arachidonic acid into 12-hydroperoxyeicosatetraenoic acid/12-HPETE and 15-hydroperoxyeicosatetraenoic acid/15-HPETE. Also converts linoleic acid to 13-hydroperoxyoctadecadienoic acid. May also act on (12S)-hydroperoxyeicosatetraenoic acid/(12S)-HPETE to produce hepoxilin A3. Probably plays an important role in the immune and inflammatory responses. Through the oxygenation of membrane-bound phosphatidylethanolamine in macrophages may favor clearance of apoptotic cells during inflammation by resident macrophages and prevent an autoimmune response associated with the clearance of apoptotic cells by inflammatory monocytes. In parallel, may regulate actin polymerization which is crucial for several biological processes, including macrophage function. May also regulate macrophage function through regulation of the peroxisome proliferator activated receptor signaling pathway. Finally, it is also involved in the cellular response to IL13/interleukin-13. In addition to its role in the immune and inflammatory responses, may play a role in epithelial wound healing in the cornea maybe through production of lipoxin A4. May also play a role in endoplasmic reticulum stress response and the regulation of bone mass.','ALOX15','74803.795','DB02709','>lcl|BSEQ0010075|Arachidonate 15-lipoxygenase (ALOX15)\nATGGGTCTCTACCGCATCCGCGTGTCCACTGGGGCCTCGCTCTATGCCGGTTCCAACAAC\nCAGGTGCAGCTGTGGCTGGTCGGCCAGCACGGGGAGGCGGCGCTCGGGAAGCGACTGTGG\nCCCGCACGGGGCAAGGAGACAGAACTCAAGGTGGAAGTACCGGAGTATCTGGGGCCGCTG\nCTGTTTGTGAAACTGCGCAAACGGCACCTCCTTAAGGACGACGCCTGGTTCTGCAACTGG\nATCTCTGTGCAGGGCCCCGGAGCCGGGGACGAGGTCAGGTTCCCTTGTTACCGCTGGGTG\nGAGGGCAACGGCGTCCTGAGCCTGCCTGAAGGCACCGGCCGCACTGTGGGCGAGGACCCT\nCAGGGCCTGTTCCAGAAACACCGGGAAGAAGAGCTGGAAGAGAGAAGGAAGTTGTACCGG\nTGGGGAAACTGGAAGGACGGGTTAATTCTGAATATGGCTGGGGCCAAACTATATGACCTC\nCCTGTGGATGAGCGATTTCTGGAAGACAAGAGAGTTGACTTTGAGGTTTCGCTGGCCAAG\nGGGCTGGCCGACCTCGCTATCAAAGACTCTCTAAATGTTCTGACTTGCTGGAAGGATCTA\nGATGACTTCAACCGGATTTTCTGGTGTGGTCAGAGCAAGCTGGCTGAGCGCGTGCGGGAC\nTCCTGGAAGGAAGATGCCTTATTTGGGTACCAGTTTCTTAATGGCGCCAACCCCGTGGTG\nCTGAGGCGCTCTGCTCACCTTCCTGCTCGCCTAGTGTTCCCTCCAGGCATGGAGGAACTG\nCAGGCCCAGCTGGAGAAGGAGCTGGAGGGAGGCACACTGTTCGAAGCTGACTTCTCCCTG\nCTGGATGGGATCAAGGCCAACGTCATTCTCTGTAGCCAGCAGCACCTGGCTGCCCCTCTA\nGTCATGCTGAAATTGCAGCCTGATGGGAAACTCTTGCCCATGGTCATCCAGCTCCAGCTG\nCCCCGCACAGGATCCCCACCACCTCCCCTTTTCTTGCCTACGGATCCCCCAATGGCCTGG\nCTTCTGGCCAAATGCTGGGTGCGCAGCTCTGACTTCCAGCTCCATGAGCTGCAGTCTCAT\nCTTCTGAGGGGACACTTGATGGCTGAGGTCATTGTTGTGGCCACCATGAGGTGCCTGCCG\nTCGATACATCCTATCTTCAAGCTTATAATTCCCCACCTGCGATACACCCTGGAAATTAAC\nGTCCGGGCCAGGACTGGGCTGGTCTCTGACATGGGAATTTTCGACCAGATAATGAGCACT\nGGTGGGGGAGGCCACGTGCAGCTGCTCAAGCAAGCTGGAGCCTTCCTAACCTACAGCTCC\nTTCTGTCCCCCTGATGACTTGGCCGACCGGGGGCTCCTGGGAGTGAAGTCTTCCTTCTAT\nGCCCAAGATGCGCTGCGGCTCTGGGAAATCATCTATCGGTATGTGGAAGGAATCGTGAGT\nCTCCACTATAAGACAGACGTGGCTGTGAAAGACGACCCAGAGCTGCAGACCTGGTGTCGA\nGAGATCACTGAAATCGGGCTGCAAGGGGCCCAGGACCGAGGGTTTCCTGTCTCTTTACAG\nGCTCGGGACCAGGTTTGCCACTTTGTCACCATGTGTATCTTCACCTGCACCGGCCAACAC\nGCCTCTGTGCACCTGGGCCAGCTGGACTGGTACTCTTGGGTGCCTAATGCACCCTGCACG\nATGCGGCTGCCCCCGCCAACCACCAAGGATGCAACGCTGGAGACAGTGATGGCGACACTG\nCCCAACTTCCACCAGGCTTCTCTCCAGATGTCCATCACTTGGCAGCTGGGCAGACGCCAG\nCCCGTTATGGTGGCTGTGGGCCAGCATGAGGAGGAGTATTTTTCGGGCCCTGAGCCTAAG\nGCTGTGCTGAAGAAGTTCAGGGAGGAGCTGGCTGCCCTGGATAAGGAAATTGAGATCCGG\nAATGCAAAGCTGGACATGCCCTACGAGTACCTGCGGCCCAGCGTGGTGGAAAACAGTGTG\nGCCATCTAA'),('Arachidonate 5-lipoxygenase','None','Human','Iron ion binding','Catalyzes the first step in leukotriene biosynthesis, and thereby plays a role in inflammatory processes.','ALOX5','77982.595','DB02709','>lcl|BSEQ0010032|Arachidonate 5-lipoxygenase (ALOX5)\nATGCCCTCCTACACGGTCACCGTGGCCACTGGCAGCCAGTGGTTCGCCGGCACTGACGAC\nTACATCTACCTCAGCCTCGTGGGCTCGGCGGGCTGCAGCGAGAAGCACCTGCTGGACAAG\nCCCTTCTACAACGACTTCGAGCGTGGCGCGGTGGATTCATACGACGTGACTGTGGACGAG\nGAACTGGGCGAGATCCAGCTGGTCAGAATCGAGAAGCGCAAGTACTGGCTGAATGACGAC\nTGGTACCTGAAGTACATCACGCTGAAGACGCCCCACGGGGACTACATCGAGTTCCCCTGC\nTACCGCTGGATCACCGGCGATGTCGAGGTTGTCCTGAGGGATGGACGCGCAAAGTTGGCC\nCGAGATGACCAAATTCACATTCTCAAGCAACACCGACGTAAAGAACTGGAAACACGGCAA\nAAACAATATCGATGGATGGAGTGGAACCCTGGCTTCCCCTTGAGCATCGATGCCAAATGC\nCACAAGGATTTACCCCGTGATATCCAGTTTGATAGTGAAAAAGGAGTGGACTTTGTTCTG\nAATTACTCCAAAGCGATGGAGAACCTGTTCATCAACCGCTTCATGCACATGTTCCAGTCT\nTCTTGGAATGACTTCGCCGACTTTGAGAAAATCTTTGTCAAGATCAGCAACACTATTTCT\nGAGCGGGTCATGAATCACTGGCAGGAAGACCTGATGTTTGGCTACCAGTTCCTGAATGGC\nTGCAACCCTGTGTTGATCCGGCGCTGCACAGAGCTGCCCGAGAAGCTCCCGGTGACCACG\nGAGATGGTAGAGTGCAGCCTGGAGCGGCAGCTCAGCTTGGAGCAGGAGGTCCAGCAAGGG\nAACATTTTCATCGTGGACTTTGAGCTGCTGGATGGCATCGATGCCAACAAAACAGACCCC\nTGCACACTCCAGTTCCTGGCCGCTCCCATCTGCTTGCTGTATAAGAACCTGGCCAACAAG\nATTGTCCCCATTGCCATCCAGCTCAACCAAATCCCGGGAGATGAGAACCCTATTTTCCTC\nCCTTCGGATGCAAAATACGACTGGCTTTTGGCCAAAATCTGGGTGCGTTCCAGTGACTTC\nCACGTCCACCAGACCATCACCCACCTTCTGCGAACACATCTGGTGTCTGAGGTTTTTGGC\nATTGCAATGTACCGCCAGCTGCCTGCTGTGCACCCCATTTTCAAGCTGCTGGTGGCACAC\nGTGAGATTCACCATTGCAATCAACACCAAGGCCCGTGAGCAGCTCATCTGCGAGTGTGGC\nCTCTTTGACAAGGCCAACGCCACAGGGGGCGGTGGGCACGTGCAGATGGTGCAGAGGGCC\nATGAAGGACCTGACCTATGCCTCCCTGTGCTTTCCCGAGGCCATCAAGGCCCGGGGCATG\nGAGAGCAAAGAAGACATCCCCTACTACTTCTACCGGGACGACGGGCTCCTGGTGTGGGAA\nGCCATCAGGACGTTCACGGCCGAGGTGGTAGACATCTACTACGAGGGCGACCAGGTGGTG\nGAGGAGGACCCGGAGCTGCAGGACTTCGTGAACGATGTCTACGTGTACGGCATGCGGGGC\nCGCAAGTCCTCAGGCTTCCCCAAGTCGGTCAAGAGCCGGGAGCAGCTGTCGGAGTACCTG\nACCGTGGTGATCTTCACCGCCTCCGCCCAGCACGCCGCGGTCAACTTCGGCCAGTACGAC\nTGGTGCTCCTGGATCCCCAATGCGCCCCCAACCATGCGAGCCCCGCCACCGACTGCCAAG\nGGCGTGGTGACCATTGAGCAGATCGTGGACACGCTGCCCGACCGCGGCCGCTCCTGCTGG\nCATCTGGGTGCAGTGTGGGCGCTGAGCCAGTTCCAGGAAAACGAGCTGTTCCTGGGCATG\nTACCCAGAAGAGCATTTTATCGAGAAGCCTGTGAAGGAAGCCATGGCCCGATTCCGCAAG\nAACCTCGAGGCCATTGTCAGCGTGATTGCTGAGCGCAACAAGAAGAAGCAGCTGCCATAT\nTACTACTTGTCCCCAGACCGGATTCCGAACAGTGTGGCCATCTGA'),('Aryl hydrocarbon receptor','None','Human','Transcription regulatory region dna binding','Ligand-activated transcriptional activator. Binds to the XRE promoter region of genes it activates. Activates the expression of multiple phase I and II xenobiotic chemical metabolizing enzyme genes (such as the CYP1A1 gene). Mediates biochemical and toxic effects of halogenated aromatic hydrocarbons. Involved in cell-cycle regulation. Likely to play an important role in the development and maturation of many tissues. Regulates the circadian clock by inhibiting the basal and circadian expression of the core circadian component PER1. Inhibits PER1 by repressing the CLOCK-ARNTL/BMAL1 heterodimer mediated transcriptional activation of PER1.','AHR','96146.705','DB02709','>lcl|BSEQ0017203|Aryl hydrocarbon receptor (AHR)\nATGAACAGCAGCAGCGCCAACATCACCTACGCCAGTCGCAAGCGGCGGAAGCCGGTGCAG\nAAAACAGTAAAGCCAATCCCAGCTGAAGGAATCAAGTCAAATCCTTCCAAGCGGCATAGA\nGACCGACTTAATACAGAGTTGGACCGTTTGGCTAGCCTGCTGCCTTTCCCACAAGATGTT\nATTAATAAGTTGGACAAACTTTCAGTTCTTAGGCTCAGCGTCAGTTACCTGAGAGCCAAG\nAGCTTCTTTGATGTTGCATTAAAATCCTCCCCTACTGAAAGAAACGGAGGCCAGGATAAC\nTGTAGAGCAGCAAATTTCAGAGAAGGCCTGAACTTACAAGAAGGAGAATTCTTATTACAG\nGCTCTGAATGGCTTTGTATTAGTTGTCACTACAGATGCTTTGGTCTTTTATGCTTCTTCT\nACTATACAAGATTATCTAGGGTTTCAGCAGTCTGATGTCATACATCAGAGTGTATATGAA\nCTTATCCATACCGAAGACCGAGCTGAATTTCAGCGTCAGCTACACTGGGCATTAAATCCT\nTCTCAGTGTACAGAGTCTGGACAAGGAATTGAAGAAGCCACTGGTCTCCCCCAGACAGTA\nGTCTGTTATAACCCAGACCAGATTCCTCCAGAAAACTCTCCTTTAATGGAGAGGTGCTTC\nATATGTCGTCTAAGGTGTCTGCTGGATAATTCATCTGGTTTTCTGGCAATGAATTTCCAA\nGGGAAGTTAAAGTATCTTCATGGACAGAAAAAGAAAGGGAAAGATGGATCAATACTTCCA\nCCTCAGTTGGCTTTGTTTGCGATAGCTACTCCACTTCAGCCACCATCCATACTTGAAATC\nCGGACCAAAAATTTTATCTTTAGAACCAAACACAAACTAGACTTCACACCTATTGGTTGT\nGATGCCAAAGGAAGAATTGTTTTAGGATATACTGAAGCAGAGCTGTGCACGAGAGGCTCA\nGGTTATCAGTTTATTCATGCAGCTGATATGCTTTATTGTGCCGAGTCCCATATCCGAATG\nATTAAGACTGGAGAAAGTGGCATGATAGTTTTCCGGCTTCTTACAAAAAACAACCGATGG\nACTTGGGTCCAGTCTAATGCACGCCTGCTTTATAAAAATGGAAGACCAGATTATATCATT\nGTAACTCAGAGACCACTAACAGATGAGGAAGGAACAGAGCATTTACGAAAACGAAATACG\nAAGTTGCCTTTTATGTTTACCACTGGAGAAGCTGTGTTGTATGAGGCAACCAACCCTTTT\nCCTGCCATAATGGATCCCTTACCACTAAGGACTAAAAATGGCACTAGTGGAAAAGACTCT\nGCTACCACATCCACTCTAAGCAAGGACTCTCTCAATCCTAGTTCCCTCCTGGCTGCCATG\nATGCAACAAGATGAGTCTATTTATCTCTATCCTGCTTCAAGTACTTCAAGTACTGCACCT\nTTTGAAAACAACTTTTTCAACGAATCTATGAATGAATGCAGAAATTGGCAAGATAATACT\nGCACCGATGGGAAATGATACTATCCTGAAACATGAGCAAATTGACCAGCCTCAGGATGTG\nAACTCATTTGCTGGAGGTCACCCAGGGCTCTTTCAAGATAGTAAAAACAGTGACTTGTAC\nAGCATAATGAAAAACCTAGGCATTGATTTTGAAGACATCAGACACATGCAGAATGAAAAA\nTTTTTCAGAAATGATTTTTCTGGTGAGGTTGACTTCAGAGACATTGACTTAACGGATGAA\nATCCTGACGTATGTCCAAGATTCTTTAAGTAAGTCTCCCTTCATACCTTCAGATTATCAA\nCAGCAACAGTCCTTGGCTCTGAACTCAAGCTGTATGGTACAGGAACACCTACATCTAGAA\nCAGCAACAGCAACATCACCAAAAGCAAGTAGTAGTGGAGCCACAGCAACAGCTGTGTCAG\nAAGATGAAGCACATGCAAGTTAATGGCATGTTTGAAAATTGGAACTCTAACCAATTCGTG\nCCTTTCAATTGTCCACAGCAAGACCCACAACAATATAATGTCTTTACAGACTTACATGGG\nATCAGTCAAGAGTTCCCCTACAAATCTGAAATGGATTCTATGCCTTATACACAGAACTTT\nATTTCCTGTAATCAGCCTGTATTACCACAACATTCCAAATGTACAGAGCTGGACTACCCT\nATGGGGAGTTTTGAACCATCCCCATACCCCACTACTTCTAGTTTAGAAGATTTTGTCACT\nTGTTTACAACTTCCTGAAAACCAAAAGCATGGATTAAATCCACAGTCAGCCATAATAACT\nCCTCAGACATGTTATGCTGGGGCCGTGTCGATGTATCAGTGCCAGCCAGAACCTCAGCAC\nACCCACGTGGGTCAGATGCAGTACAATCCAGTACTGCCAGGCCAACAGGCATTTTTAAAC\nAAGTTTCAGAATGGAGTTTTAAATGAAACATATCCAGCTGAATTAAATAACATAAATAAC\nACTCAGACTACCACACATCTTCAGCCACTTCATCATCCGTCAGAAGCCAGACCTTTTCCT\nGATTTGACATCCAGTGGATTCCTGTAA'),('Arylamine N-acetyltransferase','None','Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)','Catalyzes the transfer of the acetyl group from acetyl coenzyme A to the free amino group of arylamines and hydrazines (PubMed:18795795). Is able to utilize not only acetyl-CoA, but also n-propionyl-CoA and acetoacetyl-CoA as acyl donors, although at a lower rate (PubMed:19014350). As acetyl-CoA and propionyl-CoA are products of cholesterol catabolism and the nat gene is likely present in the same operon than genes involved in cholesterol degradation, this enzyme could have a role in the utilization and regulation of these CoA species (PubMed:19014350).','Arylamine n-acetyltransferase activity','nat','31028.88','DB00244','>lcl|BSEQ0051281|Arylamine N-acetyltransferase (nat)\nATGGCACTGGATCTGACCGCGTACTTCGATCGCATCAACTATCGCGGCGCTACCGATCCA\nACCCTGGATGTTCTGCAGGATCTGGTGACCGTGCACAGTCGAACGATTCCGTTCGAGAAC\nCTCGACCCGCTGCTGGGGGTGCCGGTCGACGACCTCAGTCCACAGGCGCTGGCCGACAAG\nCTGGTACTTCGGCGCCGAGGCGGGTACTGCTTTGAGCACAACGGGCTGATGGGTTATGTG\nCTGGCCGAACTCGGCTATCGGGTGCGCCGATTCGCCGCCCGCGTCGTCTGGAAGCTCGCG\nCCGGACGCGCCCCTGCCGCCGCAGACGCACACCCTGCTGGGGGTCACGTTCCCCGGCTCG\nGGCGGATGCTATCTCGTCGACGTCGGATTCGGCGGCCAAACACCGACCTCACCGCTTCGC\nCTCGAAACCGGCGCCGTCCAGCCGACAACGCACGAACCTTATCGGCTCGAGGACCGCGTC\nGACGGCTTTGTCTTGCAGGCGATGGTCCGGGACACATGGCAGACACTGTACGAATTCACC\nACCCAGACCCGCCCGCAGATCGATCTGAAAGTGGCCAGCTGGTACGCCTCAACACACCCG\nGCATCGAAGTTCGTCACGGGACTGACCGCCGCGGTGATCACCGACGACGCCCGGTGGAAC\nCTATCTGGCCGCGACCTTGCCGTTCACCGTGCCGGTGGTACCGAGAAGATCCGCCTTGCC\nGATGCGGCAGCGGTTGTCGACACCCTGAGCGAACGGTTCGGGATCAACGTGGCAGATATC\nGGCGAGCGCGGCGCGCTCGAGACGCGCATCGACGAGCTATTGGCTCGGCAGCCAGGAGCC\nGATGCGCCGTAA'),('ATP synthase subunit delta, mitochondrial','None','Human','Transporter activity','Mitochondrial membrane ATP synthase (F(1)F(0) ATP synthase or Complex V) produces ATP from ADP in the presence of a proton gradient across the membrane which is generated by electron transport complexes of the respiratory chain. F-type ATPases consist of two structural domains, F(1) - containing the extramembraneous catalytic core, and F(0) - containing the membrane proton channel, linked together by a central stalk and a peripheral stalk. During catalysis, ATP turnover in the catalytic domain of F(1) is coupled via a rotary mechanism of the central stalk subunits to proton translocation. Part of the complex F(1) domain and of the central stalk which is part of the complex rotary element. Rotation of the central stalk against the surrounding alpha(3)beta(3) subunits leads to hydrolysis of ATP in three separate catalytic sites on the beta subunits.','ATP5D','17489.755','DB01028','>lcl|BSEQ0018958|ATP synthase subunit delta, mitochondrial (ATP5D)\nATGCTGCCCGCCGCGCTGCTCCGCCGCCCGGGACTTGGCCGCCTCGTCCGCCACGCCCGT\nGCCTATGCCGAGGCCGCCGCCGCCCCGGCTGCCGCCTCTGGCCCCAACCAGATGTCCTTC\nACCTTCGCCTCTCCCACGCAGGTGTTCTTCAACGGTGCCAACGTCCGGCAGGTGGACGTG\nCCCACGCTGACCGGAGCCTTCGGCATCCTGGCGGCCCACGTGCCCACGCTGCAGGTCCTG\nCGGCCGGGGCTGGTCGTGGTGCATGCAGAGGACGGCACCACCTCCAAATACTTTGTGAGC\nAGCGGTTCCATCGCAGTGAACGCCGACTCTTCGGTGCAGTTGTTGGCCGAAGAGGCCGTG\nACGCTGGACATGTTGGACCTGGGGGCAGCCAAGGCAAACTTGGAGAAGGCCCAGGCGGAG\nCTGGTGGGGACAGCTGACGAGGCCACGCGGGCAGAGATCCAGATCCGAATCGAGGCCAAC\nGAGGCCCTGGTGAAGGCCCTGGAGTAG'),('ATP-binding cassette sub-family B member 5','None','Human','Efflux transmembrane transporter activity','Drug efflux transporter present in a number of stem cells that acts as a regulator of cellular differentiation. Able to mediate efflux from cells of the rhodamine dye and of the therapeutic drug doxorubicin. Specifically present in limbal stem cells, where it plays a key role in corneal development and repair.','ABCB5','138639.48','DB00482','>lcl|BSEQ0011699|ATP-binding cassette sub-family B member 5 (ABCB5)\nATGGAAAATTCAGAAAGAGCTGAAGAAATGCAAGAAAATTATCAGAGAAATGGAACTGCA\nGAAGAACAGCCAAAACTGAGAAAGGAAGCAGTTGGATCTATTGAGATATTCCGCTTTGCT\nGATGGACTGGACATCACACTCATGATCCTGGGTATACTGGCATCACTGGTCAATGGAGCC\nTGCCTTCCTTTAATGCCACTGGTTTTAGGAGAAATGAGTGATAACCTTATTAGTGGATGT\nCTAGTCCAAACTAACACAACAAATTATCAGAACTGTACTCAGTCTCAAGAGAAGCTGAAT\nGAAGATATGACTCTGTTGACCCTGTATTATGTTGGAATAGGTGTTGCTGCCTTGATTTTT\nGGTTACATACAGATTTCCTTGTGGATTATAACTGCAGCACGACAGACCAAGAGGATTCGA\nAAACAGTTTTTTCATTCAGTTTTGGCACAGGACATCGGCTGGTTTGATAGCTGTGACATC\nGGTGAACTTAACACTCGCATGACAGATGACATTGACAAAATCAGTGATGGTATTGGAGAT\nAAGATTGCTCTGTTGTTTCAAAACATGTCTACTTTTTCGATTGGCCTGGCAGTTGGTTTG\nGTGAAGGGCTGGAAACTCACCCTAGTGACTCTATCCACGTCTCCTCTTATAATGGCTTCA\nGCGGCAGCATGTTCTAGGATGGTCATCTCATTGACCAGTAAGGAATTAAGTGCCTATTCC\nAAAGCTGGGGCTGTGGCAGAAGAAGTCTTGTCATCAATCCGAACAGTCATAGCCTTTAGG\nGCCCAGGAGAAAGAACTTCAAAGGTATACACAGAATCTCAAAGATGCAAAGGATTTTGGC\nATAAAAAGGACTATAGCTTCAAAAGTGTCTCTTGGTGCTGTGTACTTCTTTATGAATGGA\nACCTATGGACTTGCTTTTTGGTATGGAACCTCCTTGATTCTTAATGGAGAACCTGGATAT\nACCATCGGGACTGTTCTTGCTGTTTTCTTTAGTGTAATCCATAGCAGTTATTGCATTGGA\nGCAGCAGTCCCTCACTTTGAAACCTTCGCAATAGCCCGAGGAGCTGCCTTTCATATTTTC\nCAGGTTATTGATAAGAAACCCAGTATAGATAACTTTTCCACAGCTGGATATAAACCTGAA\nTCCATAGAAGGAACTGTGGAATTTAAAAATGTTTCTTTCAATTATCCATCAAGACCATCT\nATCAAGATTCTGAAAGGTCTGAATCTCAGAATTAAGTCTGGAGAGACAGTCGCCTTGGTC\nGGTCTCAATGGCAGTGGGAAGAGTACGGTAGTCCAGCTTCTGCAGAGGTTATATGATCCG\nGATGATGGCTTTATCATGGTGGATGAGAATGACATCAGAGCTTTAAATGTGCGGCATTAT\nCGAGACCATATTGGAGTGGTTAGTCAAGAGCCTGTTTTGTTCGGGACCACCATCAGTAAC\nAATATCAAGTATGGACGAGATGATGTGACTGATGAAGAGATGGAGAGAGCAGCAAGGGAA\nGCAAATGCGTATGATTTTATCATGGAGTTTCCTAATAAATTTAATACATTGGTAGGGGAA\nAAAGGAGCTCAAATGAGTGGAGGGCAGAAACAGAGGATCGCAATTGCTCGTGCCTTAGTT\nCGAAACCCCAAGATTCTGATTTTAGATGAGGCTACGTCTGCCCTGGATTCAGAAAGCAAG\nTCAGCTGTTCAAGCTGCACTGGAGAAGGCGAGCAAAGGTCGGACTACAATCGTGGTAGCA\nCACCGACTTTCTACTATTCGAAGTGCAGATTTGATTGTGACCCTAAAGGATGGAATGCTG\nGCGGAGAAAGGAGCACATGCTGAACTAATGGCAAAACGAGGTCTATATTATTCACTTGTG\nATGTCACAGGATATTAAAAAAGCTGATGAACAGATGGAGTCAATGACATATTCTACTGAA\nAGAAAGACCAACTCACTTCCTCTGCACTCTGTGAAGAGCATCAAGTCAGACTTCATTGAC\nAAGGCTGAGGAATCCACCCAATCTAAAGAGATAAGTCTTCCTGAAGTCTCTCTATTAAAA\nATTTTAAAGTTAAACAAGCCTGAATGGCCTTTTGTGGTTCTGGGGACATTGGCTTCTGTT\nCTAAATGGAACTGTTCATCCAGTATTTTCCATCATCTTTGCAAAAATTATAACCATGTTT\nGGAAATAATGATAAAACCACATTAAAGCATGATGCAGAAATTTATTCCATGATATTCGTC\nATTTTGGGTGTTATTTGCTTTGTCAGTTATTTCATGCAGGGATTATTTTACGGCAGAGCA\nGGGGAAATTTTAACGATGAGATTAAGACACTTGGCCTTCAAAGCCATGTTATATCAGGAT\nATTGCCTGGTTTGATGAAAAGGAAAACAGCACAGGAGGCTTGACAACAATATTAGCCATA\nGATATAGCACAAATTCAAGGAGCAACAGGTTCCAGGATTGGCGTCTTAACACAAAATGCA\nACTAACATGGGACTTTCAGTTATCATTTCCTTTATATATGGATGGGAGATGACATTCCTG\nATTCTGAGTATTGCTCCAGTACTTGCCGTGACAGGAATGATTGAAACCGCAGCAATGACT\nGGATTTGCCAACAAAGATAAGCAAGAACTTAAGCATGCTGGAAAGATAGCAACTGAAGCT\nTTGGAGAATATACGTACTATAGTGTCATTAACAAGGGAAAAAGCCTTCGAGCAAATGTAT\nGAAGAGATGCTTCAGACTCAACACAGAAATACCTCGAAGAAAGCACAGATTATTGGAAGC\nTGTTATGCATTCAGCCATGCCTTTATATATTTTGCCTATGCGGCAGGGTTTCGATTTGGA\nGCCTATTTAATTCAAGCTGGACGAATGACCCCAGAGGGCATGTTCATAGTTTTTACTGCA\nATTGCATATGGAGCTATGGCCATCGGAGAAACGCTCGTTTTGGCTCCTGAATATTCCAAA\nGCCAAATCGGGGGCTGCGCATCTGTTTGCCTTGTTGGAAAAGAAACCAAATATAGACAGC\nCGCAGTCAAGAAGGGAAAAAGCCAGACACATGTGAAGGGAATTTAGAGTTTCGAGAAGTC\nTCTTTCTTCTATCCATGTCGCCCAGATGTTTTCATCCTCCGTGGCTTATCCCTCAGTATT\nGAGCGAGGAAAGACAGTAGCATTTGTGGGGAGCAGCGGCTGTGGGAAAAGCACTTCTGTT\nCAACTTCTGCAGAGACTTTATGACCCCGTGCAAGGACAAGTGCTGTTTGATGGTGTGGAT\nGCAAAAGAATTGAATGTACAGTGGCTCCGTTCCCAAATAGCAATCGTTCCTCAAGAGCCT\nGTGCTCTTCAACTGCAGCATTGCTGAGAACATCGCCTATGGTGACAACAGCCGTGTGGTG\nCCATTAGATGAGATCAAAGAAGCCGCAAATGCAGCAAATATCCATTCTTTTATTGAAGGT\nCTCCCTGAGAAATACAACACACAAGTTGGACTGAAAGGAGCACAGCTTTCTGGCGGCCAG\nAAACAAAGACTAGCTATTGCAAGGGCTCTTCTCCAAAAACCCAAAATTTTATTGTTGGAT\nGAGGCCACTTCAGCCCTCGATAATGACAGTGAGAAGGTGGTTCAGCATGCCCTTGATAAA\nGCCAGGACGGGAAGGACATGCCTAGTGGTCACTCACAGGCTCTCTGCAATTCAGAACGCA\nGATTTGATAGTGGTTCTGCACAATGGAAAGATAAAGGAACAAGGAACTCATCAAGAGCTC\nCTGAGAAATCGAGACATATATTTTAAGTTAGTGAATGCACAGTCAGTGCAGTGA'),('ATP-binding cassette sub-family G member 2','None','Human','Xenobiotic-transporting atpase activity','High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from the brain. Appears to play a major role in the multidrug resistance phenotype of several cancer cell lines. Implicated in the efflux of numerous drugs and xenobiotics: mitoxantrone, the photosensitizer pheophorbide, camptothecin, methotrexate, azidothymidine (AZT), and the anthracyclines daunorubicin and doxorubicin.','ABCG2','72313.47','DB00482','>lcl|BSEQ0016303|ATP-binding cassette sub-family G member 2 (ABCG2)\nATGTCTTCCAGTAATGTCGAAGTTTTTATCCCAGTGTCACAAGGAAACACCAATGGCTTC\nCCCGCGACAGCTTCCAATGACCTGAAGGCATTTACTGAAGGAGCTGTGTTAAGTTTTCAT\nAACATCTGCTATCGAGTAAAACTGAAGAGTGGCTTTCTACCTTGTCGAAAACCAGTTGAG\nAAAGAAATATTATCGAATATCAATGGGATCATGAAACCTGGTCTCAACGCCATCCTGGGA\nCCCACAGGTGGAGGCAAATCTTCGTTATTAGATGTCTTAGCTGCAAGGAAAGATCCAAGT\nGGATTATCTGGAGATGTTCTGATAAATGGAGCACCGCGACCTGCCAATTTCAAATGTAAT\nTCAGGTTACGTGGTACAAGATGATGTTGTGATGGGCACTCTGACGGTGAGAGAAAACTTA\nCAGTTCTCAGCAGCTCTTCGGCTTGCAACAACTATGACGAATCATGAAAAAAACGAACGG\nATTAACAGGGTCATTCAAGAGTTAGGTCTGGATAAAGTGGCAGACTCCAAGGTTGGAACT\nCAGTTTATCCGTGGTGTGTCTGGAGGAGAAAGAAAAAGGACTAGTATAGGAATGGAGCTT\nATCACTGATCCTTCCATCTTGTTCTTGGATGAGCCTACAACTGGCTTAGACTCAAGCACA\nGCAAATGCTGTCCTTTTGCTCCTGAAAAGGATGTCTAAGCAGGGACGAACAATCATCTTC\nTCCATTCATCAGCCTCGATATTCCATCTTCAAGTTGTTTGATAGCCTCACCTTATTGGCC\nTCAGGAAGACTTATGTTCCACGGGCCTGCTCAGGAGGCCTTGGGATACTTTGAATCAGCT\nGGTTATCACTGTGAGGCCTATAATAACCCTGCAGACTTCTTCTTGGACATCATTAATGGA\nGATTCCACTGCTGTGGCATTAAACAGAGAAGAAGACTTTAAAGCCACAGAGATCATAGAG\nCCTTCCAAGCAGGATAAGCCACTCATAGAAAAATTAGCGGAGATTTATGTCAACTCCTCC\nTTCTACAAAGAGACAAAAGCTGAATTACATCAACTTTCCGGGGGTGAGAAGAAGAAGAAG\nATCACAGTCTTCAAGGAGATCAGCTACACCACCTCCTTCTGTCATCAACTCAGATGGGTT\nTCCAAGCGTTCATTCAAAAACTTGCTGGGTAATCCCCAGGCCTCTATAGCTCAGATCATT\nGTCACAGTCGTACTGGGACTGGTTATAGGTGCCATTTACTTTGGGCTAAAAAATGATTCT\nACTGGAATCCAGAACAGAGCTGGGGTTCTCTTCTTCCTGACGACCAACCAGTGTTTCAGC\nAGTGTTTCAGCCGTGGAACTCTTTGTGGTAGAGAAGAAGCTCTTCATACATGAATACATC\nAGCGGATACTACAGAGTGTCATCTTATTTCCTTGGAAAACTGTTATCTGATTTATTACCC\nATGAGGATGTTACCAAGTATTATATTTACCTGTATAGTGTACTTCATGTTAGGATTGAAG\nCCAAAGGCAGATGCCTTCTTCGTTATGATGTTTACCCTTATGATGGTGGCTTATTCAGCC\nAGTTCCATGGCACTGGCCATAGCAGCAGGTCAGAGTGTGGTTTCTGTAGCAACACTTCTC\nATGACCATCTGTTTTGTGTTTATGATGGTCTGTTGGTCAATCTCACAACCATTGCATCTT\nGGCTGTCATGGCTTCAGTACTTCAGCATTCCACGATATGGATTTACGGCTTTGCAGCATA\nATGAATTTTTGGGACAAAACTTCTGCCCAGGACTCAATGCAACAGGAAACAATCCTTGTA\nACTATGCAACATGTACTGGCGAAGAATATTTGGTAA'),('B2 bradykinin receptor','None','Human','Type 1 angiotensin receptor binding','Receptor for bradykinin. It is associated with G proteins that activate a phosphatidylinositol-calcium second messenger system.','BDKRB2','44460.15','DB06196','>lcl|BSEQ0017128|B2 bradykinin receptor (BDKRB2)\nATGTTCTCTCCCTGGAAGATATCAATGTTTCTGTCTGTTCGTGAGGACTCCGTGCCCACC\nACGGCCTCTTTCAGCGCCGACATGCTCAATGTCACCTTGCAAGGGCCCACTCTTAACGGG\nACCTTTGCCCAGAGCAAATGCCCCCAAGTGGAGTGGCTGGGCTGGCTCAACACCATCCAG\nCCCCCCTTCCTCTGGGTGCTGTTCGTGCTGGCCACCCTAGAGAACATCTTTGTCCTCAGC\nGTCTTCTGCCTGCACAAGAGCAGCTGCACGGTGGCAGAGATCTACCTGGGGAACCTGGCC\nGCAGCAGACCTGATCCTGGCCTGCGGGCTGCCCTTCTGGGCCATCACCATCTCCAACAAC\nTTCGACTGGCTCTTTGGGGAGACGCTCTGCCGCGTGGTGAATGCCATTATCTCCATGAAC\nCTGTACAGCAGCATCTGTTTCCTGATGCTGGTGAGCATCGACCGCTACCTGGCCCTGGTG\nAAAACCATGTCCATGGGCCGGATGCGCGGCGTGCGCTGGGCCAAGCTCTACAGCTTGGTG\nATCTGGGGGTGTACGCTGCTCCTGAGCTCACCCATGCTGGTGTTCCGGACCATGAAGGAG\nTACAGCGATGAGGGCCACAACGTCACCGCTTGTGTCATCAGCTACCCATCCCTCATCTGG\nGAAGTGTTCACCAACATGCTCCTGAATGTCGTGGGCTTCCTGCTGCCCCTGAGTGTCATC\nACCTTCTGCACGATGCAGATCATGCAGGTGCTGCGGAACAACGAGATGCAGAAGTTCAAG\nGAGATCCAGACAGAGAGGAGGGCCACGGTGCTAGTCCTGGTTGTGCTGCTGCTATTCATC\nATCTGCTGGCTGCCCTTCCAGATCAGCACCTTCCTGGATACGCTGCATCGCCTCGGCATC\nCTCTCCAGCTGCCAGGACGAGCGCATCATCGATGTAATCACACAGATCGCCTCCTTCATG\nGCCTACAGCAACAGCTGCCTCAACCCACTGGTGTACGTGATCGTGGGCAAGCGCTTCCGA\nAAGAAGTCTTGGGAGGTGTACCAGGGAGTGTGCCAGAAAGGGGGCTGCAGGTCAGAACCC\nATTCAGATGGAGAACTCCATGGGCACACTGCGGACCTCCATCTCCGTGGAACGCCAGATT\nCACAAACTGCAGGACTGGGCAGGGAGCAGACAGTGA'),('BDNF/NT-3 growth factors receptor','None','Human','Protein homodimerization activity','Receptor tyrosine kinase involved in the development and the maturation of the central and the peripheral nervous systems through regulation of neuron survival, proliferation, migration, differentiation, and synapse formation and plasticity. Receptor for BDNF/brain-derived neurotrophic factor and NTF4/neurotrophin-4. Alternatively can also bind NTF3/neurotrophin-3 which is less efficient in activating the receptor but regulates neuron survival through NTRK2. Upon ligand-binding, undergoes homodimerization, autophosphorylation and activation. Recruits, phosphorylates and/or activates several downstream effectors including SHC1, FRS2, SH2B1, SH2B2 and PLCG1 that regulate distinct overlapping signaling cascades. Through SHC1, FRS2, SH2B1, SH2B2 activates the GRB2-Ras-MAPK cascade that regulates for instance neuronal differentiation including neurite outgrowth. Through the same effectors controls the Ras-PI3 kinase-AKT1 signaling cascade that mainly regulates growth and survival. Through PLCG1 and the downstream protein kinase C-regulated pathways controls synaptic plasticity. Thereby, plays a role in learning and memory by regulating both short term synaptic function and long-term potentiation. PLCG1 also leads to NF-Kappa-B activation and the transcription of genes involved in cell survival. Hence, it is able to suppress anoikis, the apoptosis resulting from loss of cell-matrix interactions. May also play a role in neutrophin-dependent calcium signaling in glial cells and mediate communication between neurons and glia.','NTRK2','91998.175','DB00321','>lcl|BSEQ0021932|BDNF/NT-3 growth factors receptor (NTRK2)\nATGTCGTCCTGGATAAGGTGGCATGGACCCGCCATGGCGCGGCTCTGGGGCTTCTGCTGG\nCTGGTTGTGGGCTTCTGGAGGGCCGCTTTCGCCTGTCCCACGTCCTGCAAATGCAGTGCC\nTCTCGGATCTGGTGCAGCGACCCTTCTCCTGGCATCGTGGCATTTCCGAGATTGGAGCCT\nAACAGTGTAGATCCTGAGAACATCACCGAAATTTTCATCGCAAACCAGAAAAGGTTAGAA\nATCATCAACGAAGATGATGTTGAAGCTTATGTGGGACTGAGAAATCTGACAATTGTGGAT\nTCTGGATTAAAATTTGTGGCTCATAAAGCATTTCTGAAAAACAGCAACCTGCAGCACATC\nAATTTTACCCGAAACAAACTGACGAGTTTGTCTAGGAAACATTTCCGTCACCTTGACTTG\nTCTGAACTGATCCTGGTGGGCAATCCATTTACATGCTCCTGTGACATTATGTGGATCAAG\nACTCTCCAAGAGGCTAAATCCAGTCCAGACACTCAGGATTTGTACTGCCTGAATGAAAGC\nAGCAAGAATATTCCCCTGGCAAACCTGCAGATACCCAATTGTGGTTTGCCATCTGCAAAT\nCTGGCCGCACCTAACCTCACTGTGGAGGAAGGAAAGTCTATCACATTATCCTGTAGTGTG\nGCAGGTGATCCGGTTCCTAATATGTATTGGGATGTTGGTAACCTGGTTTCCAAACATATG\nAATGAAACAAGCCACACACAGGGCTCCTTAAGGATAACTAACATTTCATCCGATGACAGT\nGGGAAGCAGATCTCTTGTGTGGCGGAAAATCTTGTAGGAGAAGATCAAGATTCTGTCAAC\nCTCACTGTGCATTTTGCACCAACTATCACATTTCTCGAATCTCCAACCTCAGACCACCAC\nTGGTGCATTCCATTCACTGTGAAAGGCAACCCCAAACCAGCGCTTCAGTGGTTCTATAAC\nGGGGCAATATTGAATGAGTCCAAATACATCTGTACTAAAATACATGTTACCAATCACACG\nGAGTACCACGGCTGCCTCCAGCTGGATAATCCCACTCACATGAACAATGGGGACTACACT\nCTAATAGCCAAGAATGAGTATGGGAAGGATGAGAAACAGATTTCTGCTCACTTCATGGGC\nTGGCCTGGAATTGACGATGGTGCAAACCCAAATTATCCTGATGTAATTTATGAAGATTAT\nGGAACTGCAGCGAATGACATCGGGGACACCACGAACAGAAGTAATGAAATCCCTTCCACA\nGACGTCACTGATAAAACCGGTCGGGAACATCTCTCGGTCTATGCTGTGGTGGTGATTGCG\nTCTGTGGTGGGATTTTGCCTTTTGGTAATGCTGTTTCTGCTTAAGTTGGCAAGACACTCC\nAAGTTTGGCATGAAAGGTTTTGTTTTGTTTCATAAGATCCCACTGGATGGGTAG'),('Beta adrenergic receptor','protein group','Human','None','None','None','None','DB00321','None'),('C-type lectin domain family 14 member A','None','Human','Carbohydrate binding','None','CLEC14A','51635.005','DB02709','>lcl|BSEQ0013678|C-type lectin domain family 14 member A (CLEC14A)\nATGAGGCCGGCGTTCGCCCTGTGCCTCCTCTGGCAGGCGCTCTGGCCCGGGCCGGGCGGC\nGGCGAACACCCCACTGCCGACCGTGCTGGCTGCTCGGCCTCGGGGGCCTGCTACAGCCTG\nCACCACGCTACCATGAAGCGGCAGGCGGCCGAGGAGGCCTGCATCCTGCGAGGTGGGGCG\nCTCAGCACCGTGCGTGCGGGCGCCGAGCTGCGCGCTGTGCTCGCGCTCCTGCGGGCAGGC\nCCAGGGCCCGGAGGGGGCTCCAAAGACCTGCTGTTCTGGGTCGCACTGGAGCGCAGGCGT\nTCCCACTGCACCCTGGAGAACGAGCCTTTGCGGGGTTTCTCCTGGCTGTCCTCCGACCCC\nGGCGGTCTCGAAAGCGACACGCTGCAGTGGGTGGAGGAGCCCCAACGCTCCTGCACCGCG\nCGGAGATGCGCGGTACTCCAGGCCACCGGTGGGGTCGAGCCCGCAGGCTGGAAGGAGATG\nCGATGCCACCTGCGCGCCAACGGCTACCTGTGCAAGTACCAGTTTGAGGTCTTGTGTCCT\nGCGCCGCGCCCCGGGGCCGCCTCTAACTTGAGCTATCGCGCGCCCTTCCAGCTGCACAGC\nGCCGCTCTGGACTTCAGTCCACCTGGGACCGAGGTGAGTGCGCTCTGCCGGGGACAGCTC\nCCGATCTCAGTTACTTGCATCGCGGACGAAATCGGCGCTCGCTGGGACAAACTCTCGGGC\nGATGTGTTGTGTCCCTGCCCCGGGAGGTACCTCCGTGCTGGCAAATGCGCAGAGCTCCCT\nAACTGCCTAGACGACTTGGGAGGCTTTGCCTGCGAATGTGCTACGGGCTTCGAGCTGGGG\nAAGGACGGCCGCTCTTGTGTGACCAGTGGGGAAGGACAGCCGACCCTTGGGGGGACCGGG\nGTGCCCACCAGGCGCCCGCCGGCCACTGCAACCAGCCCCGTGCCGCAGAGAACATGGCCA\nATCAGGGTCGACGAGAAGCTGGGAGAGACACCACTTGTCCCTGAACAAGACAATTCAGTA\nACATCTATTCCTGAGATTCCTCGATGGGGATCACAGAGCACGATGTCTACCCTTCAAATG\nTCCCTTCAAGCCGAGTCAAAGGCCACTATCACCCCATCAGGGAGCGTGATTTCCAAGTTT\nAATTCTACGACTTCCTCTGCCACTCCTCAGGCTTTCGACTCCTCCTCTGCCGTGGTCTTC\nATATTTGTGAGCACAGCAGTAGTAGTGTTGGTGATCTTGACCATGACAGTACTGGGGCTT\nGTCAAGCTCTGCTTTCACGAAAGCCCCTCTTCCCAGCCAAGGAAGGAGTCTATGGGCCCG\nCCGGGCCTGGAGAGTGATCCTGAGCCCGCTGCTTTGGGCTCCAGTTCTGCACATTGCACA\nAACAATGGGGTGAAAGTCGGGGACTGTGATCTGCGGGACAGAGCAGAGGGTGCCTTGCTG\nGCGGAGTCCCCTCTTGGCTCTAGTGATGCATAG'),('C-X-C chemokine receptor type 1','None','Human','Interleukin-8 receptor activity','Receptor to interleukin-8, which is a powerful neutrophils chemotactic factor. Binding of IL-8 to the receptor causes activation of neutrophils. This response is mediated via a G-protein that activate a phosphatidylinositol-calcium second messenger system. This receptor binds to IL-8 with a high affinity and to MGSA (GRO) with a low affinity.','CXCR1','39790.735','DB01009','>lcl|BSEQ0012471|C-X-C chemokine receptor type 1 (CXCR1)\nATGTCAAATATTACAGATCCACAGATGTGGGATTTTGATGATCTAAATTTCACTGGCATG\nCCACCTGCAGATGAAGATTACAGCCCCTGTATGCTAGAAACTGAGACACTCAACAAGTAT\nGTTGTGATCATCGCCTATGCCCTAGTGTTCCTGCTGAGCCTGCTGGGAAACTCCCTGGTG\nATGCTGGTCATCTTATACAGCAGGGTCGGCCGCTCCGTCACTGATGTCTACCTGCTGAAC\nCTGGCCTTGGCCGACCTACTCTTTGCCCTGACCTTGCCCATCTGGGCCGCCTCCAAGGTG\nAATGGCTGGATTTTTGGCACATTCCTGTGCAAGGTGGTCTCACTCCTGAAGGAAGTCAAC\nTTCTACAGTGGCATCCTGCTGTTGGCCTGCATCAGTGTGGACCGTTACCTGGCCATTGTC\nCATGCCACACGCACACTGACCCAGAAGCGTCACTTGGTCAAGTTTGTTTGTCTTGGCTGC\nTGGGGACTGTCTATGAATCTGTCCCTGCCCTTCTTCCTTTTCCGCCAGGCTTACCATCCA\nAACAATTCCAGTCCAGTTTGCTATGAGGTCCTGGGAAATGACACAGCAAAATGGCGGATG\nGTGTTGCGGATCCTGCCTCACACCTTTGGCTTCATCGTGCCGCTGTTTGTCATGCTGTTC\nTGCTATGGATTCACCCTGCGTACACTGTTTAAGGCCCACATGGGGCAGAAGCACCGAGCC\nATGAGGGTCATCTTTGCTGTCGTCCTCATCTTCCTGCTTTGCTGGCTGCCCTACAACCTG\nGTCCTGCTGGCAGACACCCTCATGAGGACCCAGGTGATCCAGGAGAGCTGTGAGCGCCGC\nAACAACATCGGCCGGGCCCTGGATGCCACTGAGATTCTGGGATTTCTCCATAGCTGCCTC\nAACCCCATCATCTACGCCTTCATCGGCCAAAATTTTCGCCATGGATTCCTCAAGATCCTG\nGCTATGCATGGCCTGGTCAGCAAGGAGTTCTTGGCACGTCATCGTGTTACCTCCTACACT\nTCTTCGTCTGTCAATGTCTCTTCCAACCTCTGA'),('Calcium-transporting ATPase type 2C member 1','None','Human','Signal transducer activity','This magnesium-dependent enzyme catalyzes the hydrolysis of ATP coupled with the transport of the calcium.','ATP2C1','100576.42','DB01028','>lcl|BSEQ0018927|Calcium-transporting ATPase type 2C member 1 (ATP2C1)\nATGAAGGTTGCACGTTTTCAAAAAATACCTAATGGTGAAAATGAGACAATGATTCCTGTA\nTTGACATCAAAAAAAGCAAGTGAATTACCAGTCAGTGAAGTTGCAAGCATTCTCCAAGCT\nGATCTTCAGAATGGTCTAAACAAATGTGAAGTTAGTCATAGGCGAGCCTTTCATGGCTGG\nAATGAGTTTGATATTAGTGAAGATGAGCCACTGTGGAAGAAGTATATTTCTCAGTTTAAA\nAATCCCCTTATTATGCTGCTTCTGGCTTCTGCAGTCATCAGTGTTTTAATGCATCAGTTT\nGATGATGCCGTCAGTATCACTGTGGCAATACTTATCGTTGTTACAGTTGCCTTTGTTCAG\nGAATATCGTTCAGAAAAATCTCTTGAAGAATTGAGTAAACTTGTGCCACCAGAATGCCAT\nTGTGTGCGTGAAGGAAAATTGGAGCATACACTTGCCCGAGACTTGGTTCCAGGTGATACA\nGTTTGCCTTTCTGTTGGGGATAGAGTTCCTGCTGACTTACGCTTGTTTGAGGCTGTGGAT\nCTTTCCATTGATGAGTCCAGCTTGACAGGTGAGACAACGCCTTGTTCTAAGGTGACAGCT\nCCTCAGCCAGCTGCAACTAATGGAGATCTTGCATCGAGAAGTAACATTGCCTTTATGGGA\nACACTGGTCAGATGTGGCAAAGCAAAGGGTGTTGTCATTGGAACAGGAGAAAATTCTGAA\nTTTGGGGAGGTTTTTAAAATGATGCAAGCAGAAGAGGCACCAAAAACCCCTCTGCAGAAG\nAGCATGGACCTCTTAGGAAAACAACTTTCCTTTTACTCCTTTGGTATAATAGGAATCATC\nATGTTGGTTGGCTGGTTACTGGGAAAAGATATCCTGGAAATGTTTACTATTAGTGTAAGT\nTTGGCTGTAGCAGCAATTCCTGAAGGTCTCCCCATTGTGGTCACAGTGACGCTAGCTCTT\nGGTGTTATGAGAATGGTGAAGAAAAGGGCCATTGTGAAAAAGCTGCCTATTGTTGAAACT\nCTGGGCTGCTGTAATGTGATTTGTTCAGATAAAACTGGAACACTGACGAAGAATGAAATG\nACTGTTACTCACATATTTACTTCAGATGGTCTGCATGCTGAGGTTACTGGAGTTGGCTAT\nAATCAATTTGGGGAAGTGATTGTTGATGGTGATGTTGTTCATGGATTCTATAACCCAGCT\nGTTAGCAGAATTGTTGAGGCGGGCTGTGTGTGCAATGATGCTGTAATTAGAAACAATACT\nCTAATGGGGAAGCCAACAGAAGGGGCCTTAATTGCTCTTGCAATGAAGATGGGTCTTGAT\nGGACTTCAACAAGACTACATCAGAAAAGCTGAATACCCTTTTAGCTCTGAGCAAAAGTGG\nATGGCTGTTAAGTGTGTACACCGAACACAGCAGGACAGACCAGAGATTTGTTTTATGAAA\nGGTGCTTACGAACAAGTAATTAAGTACTGTACTACATACCAGAGCAAAGGGCAGACCTTG\nACACTTACTCAGCAGCAGAGAGATGTGTACCAACAAGAGAAGGCACGCATGGGCTCAGCG\nGGACTCAGAGTTCTTGCTTTGGCTTCTGGTCCTGAACTGGGACAGCTGACATTTCTTGGC\nTTGGTGGGAATCATTGATCCACCTAGAACTGGTGTGAAAGAAGCTGTTACAACACTCATT\nGCCTCAGGAGTATCAATAAAAATGATTACTGGAGATTCACAGGAGACTGCAGTTGCAATC\nGCCAGTCGTCTGGGATTGTATTCCAAAACTTCCCAGTCAGTCTCAGGAGAAGAAATAGAT\nGCAATGGATGTTCAGCAGCTTTCACAAATAGTACCAAAGGTTGCAGTATTTTACAGAGCT\nAGCCCAAGGCACAAGATGAAAATTATTAAGTCGCTACAGAAGAACGGTTCAGTTGTAGCC\nATGACAGGAGATGGAGTAAATGATGCAGTTGCTCTGAAGGCTGCAGACATTGGAGTTGCG\nATGGGCCAGACTGGTACAGATGTTTGCAAAGAGGCAGCAGACATGATCCTAGTGGATGAT\nGATTTTCAAACCATAATGTCTGCAATCGAAGAGGGTAAAGGGATTTATAATAACATTAAA\nAATTTCGTTAGATTCCAGCTGAGCACGAGTATAGCAGCATTAACTTTAATCTCATTGGCT\nACATTAATGAACTTTCCTAATCCTCTCAATGCCATGCAGATTTTGTGGATCAATATTATT\nATGGATGGACCCCCAGCTCAGAGCCTTGGAGTAGAACCAGTGGATAAAGATGTCATTCGT\nAAACCTCCTCGCAACTGGAAAGACAGCATTTTGACTAAAAACTTGATACTTAAAATACTT\nGTTTCATCAATAATCATTGTTTGTGGGACTTTGTTTGTCTTCTGGCGTGAGCTACGAGAC\nAATGTGATTACACCTCGAGACACAACAATGACCTTCACATGCTTTGTGTTTTTTGACATG\nTTCAATGCACTAAGTTCCAGATCCCAGACCAAGTCTGTGTTTGAGATTGGACTCTGCAGT\nAATAGAATGTTTTGCTATGCAGTTCTTGGATCCATCATGGGACAATTACTAGTTATTTAC\nTTTCCTCCGCTTCAGAAGGTTTTTCAGACTGAGAGCCTAAGCATACTGGGTCTGGCTCTG\nGGAGAGGAGTGGACAGCAGCTGGTTGA'),('cAMP-specific 3\',5\'-cyclic phosphodiesterase 4A','None','Human','Metal ion binding','Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.','PDE4A','98142.155','DB05676','>lcl|BSEQ0016323|cAMP-specific 3\',5\'-cyclic phosphodiesterase 4A (PDE4A)\nATGGAACCCCCGACCGTCCCCTCGGAAAGGAGCCTGTCTCTGTCACTGCCCGGGCCCCGG\nGAGGGCCAGGCCACCCTGAAGCCTCCCCCGCAGCACCTGTGGCGGCAGCCTCGGACCCCC\nATCCGTATCCAGCAGCGCGGCTACTCCGACAGCGCGGAGCGCGCCGAGCGGGAGCGGCAG\nCCGCACCGGCCCATAGAGCGCGCCGATGCCATGGACACCAGCGACCGGCCCGGCCTGCGC\nACGACCCGCATGTCCTGGCCCTCGTCCTTCCATGGCACTGGCACCGGCAGCGGCGGCGCG\nGGCGGAGGCAGCAGCAGGCGCTTCGAGGCAGAGAATGGGCCGACACCATCTCCTGGCCGC\nAGCCCCCTGGACTCGCAGGCGAGCCCAGGACTCGTGCTGCACGCCGGGGCGGCCACCAGC\nCAGCGCCGGGAGTCCTTCCTGTACCGCTCAGACAGCGACTATGACATGTCACCCAAGACC\nATGTCCCGGAACTCATCGGTCACCAGCGAGGCGCACGCTGAAGACCTCATCGTAACACCA\nTTTGCTCAGGTGCTGGCCAGCCTCCGGAGCGTCCGTAGCAACTTCTCACTCCTGACCAAT\nGTGCCCGTTCCCAGTAACAAGCGGTCCCCGCTGGGCGGCCCCACCCCTGTCTGCAAGGCC\nACGCTGTCAGAAGAAACGTGTCAGCAGTTGGCCCGGGAGACTCTGGAGGAGCTGGACTGG\nTGTCTGGAGCAGCTGGAGACCATGCAGACCTATCGCTCTGTCAGCGAGATGGCCTCGCAC\nAAGTTCAAAAGGATGTTGAACCGTGAGCTCACACACCTGTCAGAAATGAGCAGGTCCGGA\nAACCAGGTCTCAGAGTACATTTCCACAACATTCCTGGACAAACAGAATGAAGTGGAGATC\nCCATCACCCACGATGAAGGAACGAGAAAAACAGCAAGCGCCGCGACCAAGACCCTCCCAG\nCCGCCCCCGCCCCCTGTACCACACTTACAGCCCATGTCCCAAATCACAGGGTTGAAAAAG\nTTGATGCATAGTAACAGCCTGAACAACTCTAACATTCCCCGATTTGGGGTGAAGACCGAT\nCAAGAAGAGCTCCTGGCCCAAGAACTGGAGAACCTGAACAAGTGGGGCCTGAACATCTTT\nTGCGTGTCGGATTACGCTGGAGGCCGCTCACTCACCTGCATCATGTACATGATATTCCAG\nGAGCGGGACCTGCTGAAGAAATTCCGCATCCCTGTGGACACGATGGTGACATACATGCTG\nACGCTGGAGGATCACTACCACGCTGACGTGGCCTACCATAACAGCCTGCACGCAGCTGAC\nGTGCTGCAGTCCACCCACGTACTGCTGGCCACGCCTGCACTAGATGCAGTGTTCACGGAC\nCTGGAGATTCTCGCCGCCCTCTTCGCGGCTGCCATCCACGATGTGGATCACCCTGGGGTC\nTCCAACCAGTTCCTCATCAACACCAATTCGGAGCTGGCGCTCATGTACAACGATGAGTCG\nGTGCTCGAGAATCACCACCTGGCCGTGGGCTTCAAGCTGCTGCAGGAGGACAACTGCGAC\nATCTTCCAGAACCTCAGCAAGCGCCAGCGGCAGAGCCTACGCAAGATGGTCATCGACATG\nGTGCTGGCCACGGACATGTCCAAGCACATGACCCTCCTGGCTGACCTGAAGACCATGGTG\nGAGACCAAGAAAGTGACCAGCTCAGGGGTCCTCCTGCTAGATAACTACTCCGACCGCATC\nCAGGTCCTCCGGAACATGGTGCACTGTGCCGACCTCAGCAACCCCACCAAGCCGCTGGAG\nCTGTACCGCCAGTGGACAGACCGCATCATGGCCGAGTTCTTCCAGCAGGGTGACCGAGAG\nCGCGAGCGTGGCATGGAAATCAGCCCCATGTGTGACAAGCACACTGCCTCCGTGGAGAAG\nTCTCAGGTGGGTTTTATTGACTACATTGTGCACCCATTGTGGGAGACCTGGGCGGACCTT\nGTCCACCCAGATGCCCAGGAGATCTTGGACACTTTGGAGGACAACCGGGACTGGTACTAC\nAGCGCCATCCGGCAGAGCCCATCTCCGCCACCCGAGGAGGAGTCAAGGGGGCCAGGCCAC\nCCACCCCTGCCTGACAAGTTCCAGTTTGAGCTGACGCTGGAGGAGGAAGAGGAGGAAGAA\nATATCAATGGCCCAGATACCGTGCACAGCCCAAGAGGCATTGACTGCGCAGGGATTGTCA\nGGAGTCGAGGAAGCTCTGGATGCAACCATAGCCTGGGAGGCATCCCCGGCCCAGGAGTCG\nTTGGAAGTTATGGCACAGGAAGCATCCCTGGAGGCCGAGCTGGAGGCAGTGTATTTGACA\nCAGCAGGCACAGTCCACAGGCAGTGCACCTGTGGCTCCGGATGAGTTCTCGTCCCGGGAG\nGAATTCGTGGTTGCTGTAAGCCACAGCAGCCCCTCTGCCCTGGCTCTTCAAAGCCCCCTT\nCTCCCTGCTTGGAGGACCCTGTCTGTTTCAGAGCATGCCCCGGGCCTCCCGGGCCTCCCC\nTCCACGGCGGCCGAGGTGGAGGCCCAACGAGAGCACCAGGCTGCCAAGAGGGCTTGCAGT\nGCCTGCGCAGGGACATTTGGGGAGGACACATCCGCACTCCCAGCTCCTGGTGGCGGGGGG\nTCAGGTGGAGACCCTACCTGA'),('cAMP-specific 3\',5\'-cyclic phosphodiesterase 4B','None','Human','Metal ion binding','Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. May be involved in mediating central nervous system effects of therapeutic agents ranging from antidepressants to antiasthmatic and anti-inflammatory agents.','PDE4B','83342.695','DB05676','>lcl|BSEQ0016107|cAMP-specific 3\',5\'-cyclic phosphodiesterase 4B (PDE4B)\nATGAAGGAGCACGGGGGCACCTTCAGTAGCACCGGAATCAGCGGTGGTAGCGGTGACTCT\nGCTATGGACAGCCTGCAGCCGCTCCAGCCTAACTACATGCCTGTGTGTTTGTTTGCAGAA\nGAATCTTATCAAAAATTAGCAATGGAAACGCTGGAGGAATTAGACTGGTGTTTAGACCAG\nCTAGAGACCATACAGACCTACCGGTCTGTCAGTGAGATGGCTTCTAACAAGTTCAAAAGA\nATGCTGAACCGGGAGCTGACACACCTCTCAGAGATGAGCCGATCAGGGAACCAGGTGTCT\nGAATACATTTCAAATACTTTCTTAGACAAGCAGAATGATGTGGAGATCCCATCTCCTACC\nCAGAAAGACAGGGAGAAAAAGAAAAAGCAGCAGCTCATGACCCAGATAAGTGGAGTGAAG\nAAATTAATGCATAGTTCAAGCCTAAACAATACAAGCATCTCACGCTTTGGAGTCAACACT\nGAAAATGAAGATCACCTGGCCAAGGAGCTGGAAGACCTGAACAAATGGGGTCTTAACATC\nTTTAATGTGGCTGGATATTCTCACAATAGACCCCTAACATGCATCATGTATGCTATATTC\nCAGGAAAGAGACCTCCTAAAGACATTCAGAATCTCATCTGACACATTTATAACCTACATG\nATGACTTTAGAAGACCATTACCATTCTGACGTGGCATATCACAACAGCCTGCACGCTGCT\nGATGTAGCCCAGTCGACCCATGTTCTCCTTTCTACACCAGCATTAGACGCTGTCTTCACA\nGATTTGGAGATCCTGGCTGCCATTTTTGCAGCTGCCATCCATGACGTTGATCATCCTGGA\nGTCTCCAATCAGTTTCTCATCAACACAAATTCAGAACTTGCTTTGATGTATAATGATGAA\nTCTGTGTTGGAAAATCATCACCTTGCTGTGGGTTTCAAACTGCTGCAAGAAGAACACTGT\nGACATCTTCATGAATCTCACCAAGAAGCAGCGTCAGACACTCAGGAAGATGGTTATTGAC\nATGGTGTTAGCAACTGATATGTCTAAACATATGAGCCTGCTGGCAGACCTGAAGACAATG\nGTAGAAACGAAGAAAGTTACAAGTTCAGGCGTTCTTCTCCTAGACAACTATACCGATCGC\nATTCAGGTCCTTCGCAACATGGTACACTGTGCAGACCTGAGCAACCCCACCAAGTCCTTG\nGAATTGTATCGGCAATGGACAGACCGCATCATGGAGGAATTTTTCCAGCAGGGAGACAAA\nGAGCGGGAGAGGGGAATGGAAATTAGCCCAATGTGTGATAAACACACAGCTTCTGTGGAA\nAAATCCCAGGTTGGTTTCATCGACTACATTGTCCATCCATTGTGGGAGACATGGGCAGAT\nTTGGTACAGCCTGATGCTCAGGACATTCTCGATACCTTAGAAGATAACAGGAACTGGTAT\nCAGAGCATGATACCTCAAAGTCCCTCACCACCACTGGACGAGCAGAACAGGGACTGCCAG\nGGTCTGATGGAGAAGTTTCAGTTTGAACTGACTCTCGATGAGGAAGATTCTGAAGGACCT\nGAGAAGGAGGGAGAGGGACACAGCTATTTCAGCAGCACAAAGACGCTTTGTGTGATTGAT\nCCAGAAAACAGAGATTCCCTGGGAGAGACTGACATAGACATTGCAACAGAAGACAAGTCC\nCCCGTGGATACATAA'),('cAMP-specific 3\',5\'-cyclic phosphodiesterase 4C','None','Human','Metal ion binding','Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.','PDE4C','79900.795','DB06246','>lcl|BSEQ0011691|cAMP-specific 3\',5\'-cyclic phosphodiesterase 4C (PDE4C)\nATGGAGAACCTGGGGGTCGGCGAAGGGGCAGAGGCTTGCAGCAGGTTGAGTCGCTCTCGC\nGGCCGCCACAGCATGACCAGAGCCCCGAAGCACCTGTGGCGGCAACCCCGGCGCCCCATC\nCGCATCCAACAGCGCTTCTATTCGGATCCGGACAAGTCCGCGGGCTGCCGCGAGAGGGAC\nCTGAGCCCGCGGCCGGAGCTCAGGAAGTCGCGGCTCTCCTGGCCCGTTTCCTCCTGCAGG\nCGCTTTGACCTGGAAAATGGGCTCTCGTGTGGGAGGAGGGCCCTGGACCCTCAGTCCAGC\nCCTGGCCTGGGCCGGATTATGCAGGCTCCAGTCCCGCACAGCCAGCGGCGCGAGTCCTTC\nCTGTACCGCTCAGATAGCGACTATGAACTCTCGCCCAAGGCCATGTCTCGGAACTCCTCT\nGTGGCCAGCGACCTACATGGAGAGGACATGATTGTGACGCCCTTTGCCCAGGTCCTGGCC\nAGTCTGCGGACCGTTCGGAGCAACGTGGCGGCCCTTGCCCGCCAGCAATGCCTAGGAGCA\nGCCAAGCAGGGACCCGTCGGAAACCCTTCATCCAGCAATCAGCTCCCTCCTGCAGAGGAC\nACGGGGCAGAAGCTGGCATTGGAGACGCTAGACGAGCTGGACTGGTGCCTGGATCAGTTG\nGAGACGCTGCAGACCCGGCACTCGGTGGGGGAGATGGCCTCCAACAAGTTCAAGCGGATC\nCTGAACCGGGAGTTGACCCACCTGTCCGAAACCAGCCGCTCCGGGAACCAGGTGTCCGAG\nTACATCTCCCGGACCTTCCTGGACCAGCAGACCGAGGTGGAGCTGCCCAAGGTGACCGCT\nGAGGAGGCCCCACAGCCCATGTCCCGGATCAGTGGCCTACATGGGCTCTGCCACAGTGCC\nAGCCTCTCCTCAGCCACTGTCCCACGCTTTGGGGTCCAGACTGACCAGGAGGAGCAACTG\nGCCAAGGAGCTAGAAGACACCAACAAGTGGGGACTTGATGTGTTCAAGGTGGCGGAGCTA\nAGTGGGAACCGGCCCCTCACAGCTATCATATTCAGCATTTTTCAGGAGCGGGACCTGCTG\nAAGACATTCCAGATCCCAGCAGACACACTGGCCACCTACCTGCTGATGCTGGAAGGTCAC\nTACCACGCCAATGTGGCCTACCACAACAGCCTACATGCCGCCGACGTGGCCCAGTCCACG\nCATGTGCTGCTGGCTACGCCCGCCCTCGAGGCTGTGTTCACAGACTTGGAAATCCTGGCT\nGCCCTCTTTGCAAGCGCCATCCACGACGTGGACCATCCTGGGGTCTCCAACCAGTTTCTG\nATTAACACCAACTCAGAGCTGGCGCTTATGTACAACGACGCCTCGGTGCTGGAGAACCAT\nCACCTGGCTGTGGGCTTCAAGCTGCTGCAGGCAGAGAACTGCGATATCTTCCAGAACCTC\nAGCGCCAAGCAGCGACTGAGTCTGCGCAGGATGGTCATTGACATGGTGCTGGCCACAGAC\nATGTCCAAACACATGAACCTCCTGGCCGACCTCAAGACCATGGTGGAGACCAAGAAGGTG\nACAAGCCTCGGTGTCCTCCTCCTGGACAACTATTCCGACCGAATCCAGGTCTTGCAGAAC\nCTGGTGCACTGTGCTGATCTGAGCAACCCCACCAAGCCGCTGCCCCTGTACCGCCAGTGG\nACGGACCGCATCATGGCCGAGTTCTTCCAGCAGGGAGACCGCGAGCGTGAGTCGGGCCTG\nGACATCAGTCCCATGTGTGACAAGCATACGGCCTCAGTGGAGAAGTCCCAGGTGGGTTTC\nATTGACTACATTGCTCACCCACTGTGGGAGACTTGGGCTGACCTGGTCCACCCAGATGCA\nCAGGACCTGCTGGACACGCTGGAGGACAATCGAGAGTGGTACCAGAGCAAGATCCCCCGA\nAGTCCCTCAGACCTCACCAACCCCGAGCGGGACGGGCCTGACAGATTCCAGTTTGAACTG\nACTCTGGAGGAGGCAGAGGAAGAGGATGAGGAGGAAGAAGAGGAGGGGGAAGAGACAGCT\nTTAGCCAAAGAGGCCTTGGAGTTGCCTGACACTGAACTCCTGTCCCCTGAAGCCGGCCCA\nGACCCTGGGGACTTACCCCTCGACAACCAGAGGACTTAG'),('cAMP-specific 3\',5\'-cyclic phosphodiesterase 4D','None','Human','Ubiquitin protein ligase binding','Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.','PDE4D','91114.1','DB06246','>lcl|BSEQ0020514|cAMP-specific 3\',5\'-cyclic phosphodiesterase 4D (PDE4D)\nATGGAGGCAGAGGGCAGCAGCGCGCCGGCCCGGGCGGGCAGCGGAGAGGGCAGCGACAGC\nGCCGGCGGGGCCACGCTCAAAGCCCCCAAGCATCTCTGGAGGCACGAGCAGCACCACCAG\nTACCCGCTCCGGCAGCCCCAGTTCCGCCTCCTGCATCCCCATCACCACCTGCCCCCGCCG\nCCGCCACCCTCGCCCCAGCCCCAGCCCCAGTGTCCGCTACAGCCGCCGCCGCCGCCCCCC\nCTGCCGCCGCCCCCGCCGCCGCCCGGGGCTGCCCGCGGCCGCTACGCCTCGAGCGGGGCC\nACCGGCCGCGTCCGGCATCGCGGCTACTCGGACACCGAGCGCTACCTGTACTGTCGCGCC\nATGGACCGCACCTCCTACGCGGTGGAGACCGGCCACCGGCCCGGCCTGAAGAAATCCAGG\nATGTCCTGGCCCTCCTCGTTCCAGGGACTCAGGCGTTTTGATGTGGACAATGGCACATCT\nGCGGGACGGAGTCCCTTGGATCCCATGACCAGCCCAGGATCCGGGCTAATTCTCCAAGCA\nAATTTTGTCCACAGTCAACGACGGGAGTCCTTCCTGTATCGATCCGACAGCGATTATGAC\nCTCTCTCCAAAGTCTATGTCCCGGAACTCCTCCATTGCCAGTGATATACACGGAGATGAC\nTTGATTGTGACTCCATTTGCTCAGGTCTTGGCCAGTCTGCGAACTGTACGAAACAACTTT\nGCTGCATTAACTAATTTGCAAGATCGAGCACCTAGCAAAAGATCACCCATGTGCAACCAA\nCCATCCATCAACAAAGCCACCATAACAGAGGAGGCCTACCAGAAACTGGCCAGCGAGACC\nCTGGAGGAGCTGGACTGGTGTCTGGACCAGCTAGAGACCCTACAGACCAGGCACTCCGTC\nAGTGAGATGGCCTCCAACAAGTTTAAAAGGATGCTTAATCGGGAGCTCACCCATCTCTCT\nGAAATGAGTCGGTCTGGAAATCAAGTGTCAGAGTTTATATCAAACACATTCTTAGATAAG\nCAACATGAAGTGGAAATTCCTTCTCCAACTCAGAAGGAAAAGGAGAAAAAGAAAAGACCA\nATGTCTCAGATCAGTGGAGTCAAGAAATTGATGCACAGCTCTAGTCTGACTAATTCAAGT\nATCCCAAGGTTTGGAGTTAAAACTGAACAAGAAGATGTCCTTGCCAAGGAACTAGAAGAT\nGTGAACAAATGGGGTCTTCATGTTTTCAGAATAGCAGAGTTGTCTGGTAACCGGCCCTTG\nACTGTTATCATGCACACCATTTTTCAGGAACGGGATTTATTAAAAACATTTAAAATTCCA\nGTAGATACTTTAATTACATATCTTATGACTCTCGAAGACCATTACCATGCTGATGTGGCC\nTATCACAACAATATCCATGCTGCAGATGTTGTCCAGTCTACTCATGTGCTATTATCTACA\nCCTGCTTTGGAGGCTGTGTTTACAGATTTGGAGATTCTTGCAGCAATTTTTGCCAGTGCA\nATACATGATGTAGATCATCCTGGTGTGTCCAATCAATTTCTGATCAATACAAACTCTGAA\nCTTGCCTTGATGTACAATGATTCCTCAGTCTTAGAGAACCATCATTTGGCTGTGGGCTTT\nAAATTGCTTCAGGAAGAAAACTGTGACATTTTCCAGAATTTGACCAAAAAACAAAGACAA\nTCTTTAAGGAAAATGGTCATTGACATCGTACTTGCAACAGATATGTCAAAACACATGAAT\nCTACTGGCTGATTTGAAGACTATGGTTGAAACTAAGAAAGTGACAAGCTCTGGAGTTCTT\nCTTCTTGATAATTATTCCGATAGGATTCAGGTTCTTCAGAATATGGTGCACTGTGCAGAT\nCTGAGCAACCCAACAAAGCCTCTCCAGCTGTACCGCCAGTGGACGGACCGGATAATGGAG\nGAGTTCTTCCGCCAAGGAGACCGAGAGAGGGAACGTGGCATGGAGATAAGCCCCATGTGT\nGACAAGCACAATGCTTCCGTGGAAAAATCACAGGTGGGCTTCATAGACTATATTGTTCAT\nCCCCTCTGGGAGACATGGGCAGACCTCGTCCACCCTGACGCCCAGGATATTTTGGACACT\nTTGGAGGACAATCGTGAATGGTACCAGAGCACAATCCCTCAGAGCCCCTCTCCTGCACCT\nGATGACCCAGAGGAGGGCCGGCAGGGTCAAACTGAGAAATTCCAGTTTGAACTAACTTTA\nGAGGAAGATGGTGAGTCAGACACGGAAAAGGACAGTGGCAGTCAAGTGGAAGAAGACACT\nAGCTGCAGTGACTCCAAGACTCTTTGTACTCAAGACTCAGAGTCTACTGAAATTCCCCTT\nGATGAACAGGTTGAAGAGGAGGCAGTAGGGGAAGAAGAGGAAAGCCAGCCTGAAGCCTGT\nGTCATAGATGATCGTTCTCCTGACACGTAA'),('Cannabinoid receptor 1','None','Human','Drug binding','Involved in cannabinoid-induced CNS effects. Acts by inhibiting adenylate cyclase. Could be a receptor for anandamide. Inhibits L-type Ca(2+) channel current. Isoform 2 and isoform 3 have altered ligand binding.','CNR1','52857.365','DB09288','>lcl|BSEQ0010146|Cannabinoid receptor 1 (CNR1)\nATGAAGTCGATCCTAGATGGCCTTGCAGATACCACCTTCCGCACCATCACCACTGACCTC\nCTGTACGTGGGCTCAAATGACATTCAGTACGAAGACATCAAAGGTGACATGGCATCCAAA\nTTAGGGTACTTCCCACAGAAATTCCCTTTAACTTCCTTTAGGGGAAGTCCCTTCCAAGAG\nAAGATGACTGCGGGAGACAACCCCCAGCTAGTCCCAGCAGACCAGGTGAACATTACAGAA\nTTTTACAACAAGTCTCTCTCGTCCTTCAAGGAGAATGAGGAGAACATCCAGTGTGGGGAG\nAACTTCATGGACATAGAGTGTTTCATGGTCCTGAACCCCAGCCAGCAGCTGGCCATTGCA\nGTCCTGTCCCTCACGCTGGGCACCTTCACGGTCCTGGAGAACCTCCTGGTGCTGTGCGTC\nATCCTCCACTCCCGCAGCCTCCGCTGCAGGCCTTCCTACCACTTCATCGGCAGCCTGGCG\nGTGGCAGACCTCCTGGGGAGTGTCATTTTTGTCTACAGCTTCATTGACTTCCACGTGTTC\nCACCGCAAAGATAGCCGCAACGTGTTTCTGTTCAAACTGGGTGGGGTCACGGCCTCCTTC\nACTGCCTCCGTGGGCAGCCTGTTCCTCACAGCCATCGACAGGTACATATCCATTCACAGG\nCCCCTGGCCTATAAGAGGATTGTCACCAGGCCCAAGGCCGTGGTGGCGTTTTGCCTGATG\nTGGACCATAGCCATTGTGATCGCCGTGCTGCCTCTCCTGGGCTGGAACTGCGAGAAACTG\nCAATCTGTTTGCTCAGACATTTTCCCACACATTGATGAAACCTACCTGATGTTCTGGATC\nGGGGTCACCAGCGTACTGCTTCTGTTCATCGTGTATGCGTACATGTATATTCTCTGGAAG\nGCTCACAGCCACGCCGTCCGCATGATTCAGCGTGGCACCCAGAAGAGCATCATCATCCAC\nACGTCTGAGGATGGGAAGGTACAGGTGACCCGGCCAGACCAAGCCCGCATGGACATTAGG\nTTAGCCAAGACCCTGGTCCTGATCCTGGTGGTGTTGATCATCTGCTGGGGCCCTCTGCTT\nGCAATCATGGTGTATGATGTCTTTGGGAAGATGAACAAGCTCATTAAGACGGTGTTTGCA\nTTCTGCAGTATGCTCTGCCTGCTGAACTCCACCGTGAACCCCATCATCTATGCTCTGAGG\nAGTAAGGACCTGCGACACGCTTTCCGGAGCATGTTTCCCTCTTGTGAAGGCACTGCGCAG\nCCTCTGGATAACAGCATGGGGGACTCGGACTGCCTGCACAAACACGCAAACAATGCAGCC\nAGTGTTCACAGGGCCGCAGAAAGCTGCATCAAGAGCACGGTCAAGATTGCCAAGGTAACC\nATGTCTGTGTCCACAGACACGTCTGCCGAGGCTCTGTGA'),('Cannabinoid receptor 2','None','Human','Cannabinoid receptor activity','Heterotrimeric G protein-coupled receptor for endocannabinoid 2-arachidonoylglycerol mediating inhibition of adenylate cyclase. May function in inflammatory response, nociceptive transmission and bone homeostasis.','CNR2','39680.275','DB14011','>lcl|BSEQ0009931|Cannabinoid receptor 2 (CNR2)\nATGGAGGAATGCTGGGTGACAGAGATAGCCAATGGCTCCAAGGATGGCTTGGATTCCAAC\nCCTATGAAGGATTACATGATCCTGAGTGGTCCCCAGAAGACAGCTGTTGCTGTGTTGTGC\nACTCTTCTGGGCCTGCTAAGTGCCCTGGAGAACGTGGCTGTGCTCTATCTGATCCTGTCC\nTCCCACCAACTCCGCCGGAAGCCCTCATACCTGTTCATTGGCAGCTTGGCTGGGGCTGAC\nTTCCTGGCCAGTGTGGTCTTTGCATGCAGCTTTGTGAATTTCCATGTTTTCCATGGTGTG\nGATTCCAAGGCTGTCTTCCTGCTGAAGATTGGCAGCGTGACTATGACCTTCACAGCCTCT\nGTGGGTAGCCTCCTGCTGACCGCCATTGACCGATACCTCTGCCTGCGCTATCCACCTTCC\nTACAAAGCTCTGCTCACCCGTGGAAGGGCACTGGTGACCCTGGGCATCATGTGGGTCCTC\nTCAGCACTAGTCTCCTACCTGCCCCTCATGGGATGGACTTGCTGTCCCAGGCCCTGCTCT\nGAGCTTTTCCCACTGATCCCCAATGACTACCTGCTGAGCTGGCTCCTGTTCATCGCCTTC\nCTCTTTTCCGGAATCATCTACACCTATGGGCATGTTCTCTGGAAGGCCCATCAGCATGTG\nGCCAGCTTGTCTGGCCACCAGGACAGGCAGGTGCCAGGAATGGCCCGAATGAGGCTGGAT\nGTGAGGTTGGCCAAGACCCTAGGGCTAGTGTTGGCTGTGCTCCTCATCTGTTGGTTCCCA\nGTGCTGGCCCTCATGGCCCACAGCCTGGCCACTACGCTCAGTGACCAGGTCAAGAAGGCC\nTTTGCTTTCTGCTCCATGCTGTGCCTCATCAACTCCATGGTCAACCCTGTCATCTATGCT\nCTACGGAGTGGAGAGATCCGCTCCTCTGCCCATCACTGCCTGGCTCACTGGAAGAAGTGT\nGTGAGGGGCCTTGGGTCAGAGGCAAAAGAAGAAGCCCCGAGATCCTCAGTCACCGAGACA\nGAGGCTGATGGGAAAATCACTCCGTGGCCAGATTCCAGAGATCTAGACCTCTCTGATTGC\nTGA'),('Carbonic anhydrase 2','None','Human','Zinc ion binding','Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion into the anterior chamber of the eye. Contributes to intracellular pH regulation in the duodenal upper villous epithelium during proton-coupled peptide absorption. Stimulates the chloride-bicarbonate exchange activity of SLC26A6.','CA2','29245.895','DB00580','>lcl|BSEQ0018938|Carbonic anhydrase 2 (CA2)\nATGTCCCATCACTGGGGGTACGGCAAACACAACGGACCTGAGCACTGGCATAAGGACTTC\nCCCATTGCCAAGGGAGAGCGCCAGTCCCCTGTTGACATCGACACTCATACAGCCAAGTAT\nGACCCTTCCCTGAAGCCCCTGTCTGTTTCCTATGATCAAGCAACTTCCCTGAGGATCCTC\nAACAATGGTCATGCTTTCAACGTGGAGTTTGATGACTCTCAGGACAAAGCAGTGCTCAAG\nGGAGGACCCCTGGATGGCACTTACAGATTGATTCAGTTTCACTTTCACTGGGGTTCACTT\nGATGGACAAGGTTCAGAGCATACTGTGGATAAAAAGAAATATGCTGCAGAACTTCACTTG\nGTTCACTGGAACACCAAATATGGGGATTTTGGGAAAGCTGTGCAGCAACCTGATGGACTG\nGCCGTTCTAGGTATTTTTTTGAAGGTTGGCAGCGCTAAACCGGGCCTTCAGAAAGTTGTT\nGATGTGCTGGATTCCATTAAAACAAAGGGCAAGAGTGCTGACTTCACTAACTTCGATCCT\nCGTGGCCTCCTTCCTGAATCCTTGGATTACTGGACCTACCCAGGCTCACTGACCACCCCT\nCCTCTTCTGGAATGTGTGACCTGGATTGTGCTCAAGGAACCCATCAGCGTCAGCAGCGAG\nCAGGTGTTGAAATTCCGTAAACTTAACTTCAATGGGGAGGGTGAACCCGAAGAACTGATG\nGTGGACAACTGGCGCCCAGCTCAGCCACTGAAGAACAGGCAAATCAAAGCTTCCTTCAAA\nTAA'),('Carbonic anhydrase 3','None','Human','Zinc ion binding','Reversible hydration of carbon dioxide.','CA3','29557.215','DB00580','>lcl|BSEQ0012520|Carbonic anhydrase 3 (CA3)\nATGGCCAAGGAGTGGGGCTACGCCAGTCACAACGGTCCTGACCACTGGCATGAACTTTTC\nCCAAATGCCAAGGGGGAAAACCAGTCGCCCGTTGAGCTGCATACTAAAGACATCAGGCAT\nGACCCTTCTCTGCAGCCATGGTCTGTGTCTTATGATGGTGGCTCTGCCAAGACCATCCTG\nAATAATGGGAAGACCTGCCGAGTTGTATTTGATGATACTTATGATAGGTCAATGCTGAGA\nGGGGGTCCTCTCCCTGGACCCTACCGACTTCGCCAGTTTCATCTTCACTGGGGCTCTTCG\nGATGATCATGGCTCTGAGCACACCGTGGATGGAGTCAAGTATGCAGCGGAGCTTCATTTG\nGTTCACTGGAACCCGAAGTATAACACTTTTAAAGAAGCCCTGAAGCAGCGCGATGGGATC\nGCTGTGATTGGCATTTTTCTGAAGATAGGACATGAGAATGGCGAGTTCCAGATTTTCCTT\nGATGCATTGGACAAGATTAAGACAAAGGGCAAGGAGGCGCCCTTCACAAAGTTTGACCCA\nTCCTGCCTGTTCCCGGCATGCCGGGACTACTGGACCTACCAGGGCTCATTCACCACGCCG\nCCCTGCGAGGAATGCATTGTGTGGCTGCTGCTGAAGGAGCCCATGACCGTGAGCTCTGAC\nCAGATGGCCAAGCTGCGGAGCCTCCTCTCCAGTGCTGAGAACGAGCCCCCAGTGCCTCTT\nGTGAGCAACTGGCGACCTCCACAGCCTATCAATAACAGGGTGGTGAGAGCTTCCTTCAAA\nTGA'),('Carbonyl reductase [NADPH] 1','None','Human','Prostaglandin-e2 9-reductase activity','NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol. Can convert prostaglandin E2 to prostaglandin F2-alpha. Can bind glutathione, which explains its higher affinity for glutathione-conjugated substrates. Catalyzes the reduction of S-nitrosoglutathione.','CBR1','30374.73','DB02709','>lcl|BSEQ0012150|Carbonyl reductase [NADPH] 1 (CBR1)\nATGTCGTCCGGCATCCATGTAGCGCTGGTGACTGGAGGCAACAAGGGCATCGGCTTGGCC\nATCGTGCGCGACCTGTGCCGGCTGTTCTCGGGGGACGTGGTGCTCACGGCGCGGGACGTG\nACGCGGGGCCAGGCGGCCGTACAGCAGCTGCAGGCGGAGGGCCTGAGCCCGCGCTTCCAC\nCAGCTGGACATCGACGATCTGCAGAGCATCCGCGCCCTGCGCGACTTCCTGCGCAAGGAG\nTACGGGGGCCTGGACGTGCTGGTCAACAACGCGGGCATCGCCTTCAAGGTTGCTGATCCC\nACACCCTTTCATATTCAAGCTGAAGTGACGATGAAAACAAATTTCTTTGGTACCCGAGAT\nGTGTGCACAGAATTACTCCCTCTAATAAAACCCCAAGCATCCTGCGTACTGTCTGCATGG\nTCATGCCTCTCCCAAAATCCTTCAGGAGGAAAGTCCAAGCCCTTAGCATGGTTCACAGAG\nATGTCCATAATCTGCCGCTGCTTAACTCTGGGCCCATTTTAA'),('Casein kinase II subunit alpha','None','Human','Protein serine/threonine kinase activity','Catalytic subunit of a constitutively active serine/threonine-protein kinase complex that phosphorylates a large number of substrates containing acidic residues C-terminal to the phosphorylated serine or threonine. Regulates numerous cellular processes, such as cell cycle progression, apoptosis and transcription, as well as viral infection. May act as a regulatory node which integrates and coordinates numerous signals leading to an appropriate cellular response. During mitosis, functions as a component of the p53/TP53-dependent spindle assembly checkpoint (SAC) that maintains cyclin-B-CDK1 activity and G2 arrest in response to spindle damage. Also required for p53/TP53-mediated apoptosis, phosphorylating \'Ser-392\' of p53/TP53 following UV irradiation. Can also negatively regulate apoptosis. Phosphorylates the caspases CASP9 and CASP2 and the apoptotic regulator NOL3. Phosphorylation protects CASP9 from cleavage and activation by CASP8, and inhibits the dimerization of CASP2 and activation of CASP8. Regulates transcription by direct phosphorylation of RNA polymerases I, II, III and IV. Also phosphorylates and regulates numerous transcription factors including NF-kappa-B, STAT1, CREB1, IRF1, IRF2, ATF1, SRF, MAX, JUN, FOS, MYC and MYB. Phosphorylates Hsp90 and its co-chaperones FKBP4 and CDC37, which is essential for chaperone function. Regulates Wnt signaling by phosphorylating CTNNB1 and the transcription factor LEF1. Acts as an ectokinase that phosphorylates several extracellular proteins. During viral infection, phosphorylates various proteins involved in the viral life cycles of EBV, HSV, HBV, HCV, HIV, CMV and HPV. Phosphorylates PML at \'Ser-565\' and primes it for ubiquitin-mediated degradation. Plays an important role in the circadian clock function by phosphorylating ARNTL/BMAL1 at \'Ser-90\' which is pivotal for its interaction with CLOCK and which controls CLOCK nuclear entry (PubMed:11239457, PubMed:11704824, PubMed:16193064, PubMed:19188443, PubMed:20625391, PubMed:22406621). Phosphorylates CCAR2 at \'Thr-454\' in gastric carcinoma tissue (PubMed:24962073).','CSNK2A1','45143.25','DB02709','>lcl|BSEQ0010842|Casein kinase II subunit alpha (CSNK2A1)\nATGTCGGGACCCGTGCCAAGCAGGGCCAGAGTTTACACAGATGTTAATACACACAGACCT\nCGAGAATACTGGGATTACGAGTCACATGTGGTGGAATGGGGAAATCAAGATGACTACCAG\nCTGGTTCGAAAATTAGGCCGAGGTAAATACAGTGAAGTATTTGAAGCCATCAACATCACA\nAATAATGAAAAAGTTGTTGTTAAAATTCTCAAGCCAGTAAAAAAGAAGAAAATTAAGCGT\nGAAATAAAGATTTTGGAGAATTTGAGAGGAGGTCCCAACATCATCACACTGGCAGACATT\nGTAAAAGACCCTGTGTCACGAACCCCCGCCTTGGTTTTTGAACACGTAAACAACACAGAC\nTTCAAGCAATTGTACCAGACGTTAACAGACTATGATATTCGATTTTACATGTATGAGATT\nCTGAAGGCCCTGGATTATTGTCACAGCATGGGAATTATGCACAGAGATGTCAAGCCCCAT\nAATGTCATGATTGATCATGAGCACAGAAAGCTACGACTAATAGACTGGGGTTTGGCTGAG\nTTTTATCATCCTGGCCAAGAATATAATGTCCGAGTTGCTTCCCGATACTTCAAAGGTCCT\nGAGCTACTTGTAGACTATCAGATGTACGATTATAGTTTGGATATGTGGAGTTTGGGTTGT\nATGCTGGCAAGTATGATCTTTCGGAAGGAGCCATTTTTCCATGGACATGACAATTATGAT\nCAGTTGGTGAGGATAGCCAAGGTTCTGGGGACAGAAGATTTATATGACTATATTGACAAA\nTACAACATTGAATTAGATCCACGTTTCAATGATATCTTGGGCAGACACTCTCGAAAGCGA\nTGGGAACGCTTTGTCCACAGTGAAAATCAGCACCTTGTCAGCCCTGAGGCCTTGGATTTC\nCTGGACAAACTGCTGCGATATGACCACCAGTCACGGCTTACTGCAAGAGAGGCAATGGAG\nCACCCCTATTTCTACACTGTTGTGAAGGACCAGGCTCGAATGGGTTCATCTAGCATGCCA\nGGGGGCAGTACGCCCGTCAGCAGCGCCAATATGATGTCAGGGATTTCTTCAGTGCCAACC\nCCTTCACCCCTTGGACCTCTGGCAGGCTCACCAGTGATTGCTGCTGCCAACCCCCTTGGG\nATGCCTGTTCCAGCTGCCGCTGGCGCTCAGCAGTAA'),('Cathepsin L1','None','Human','Serpin family protein binding','Important for the overall degradation of proteins in lysosomes.','CTSL','37563.97','DB07477','>lcl|BSEQ0011548|Cathepsin L1 (CTSL)\nATGAATCCTACACTCATCCTTGCTGCCTTTTGCCTGGGAATTGCCTCAGCTACTCTAACA\nTTTGATCACAGTTTAGAGGCACAGTGGACCAAGTGGAAGGCGATGCACAACAGATTATAC\nGGCATGAATGAAGAAGGATGGAGGAGAGCAGTGTGGGAGAAGAACATGAAGATGATTGAA\nCTGCACAATCAGGAATACAGGGAAGGGAAACACAGCTTCACAATGGCCATGAACGCCTTT\nGGAGACATGACCAGTGAAGAATTCAGGCAGGTGATGAATGGCTTTCAAAACCGTAAGCCC\nAGGAAGGGGAAAGTGTTCCAGGAACCTCTGTTTTATGAGGCCCCCAGATCTGTGGATTGG\nAGAGAGAAAGGCTACGTGACTCCTGTGAAGAATCAGGGTCAGTGTGGTTCTTGTTGGGCT\nTTTAGTGCTACTGGTGCTCTTGAAGGACAGATGTTCCGGAAAACTGGGAGGCTTATCTCA\nCTGAGTGAGCAGAATCTGGTAGACTGCTCTGGGCCTCAAGGCAATGAAGGCTGCAATGGT\nGGCCTAATGGATTATGCTTTCCAGTATGTTCAGGATAATGGAGGCCTGGACTCTGAGGAA\nTCCTATCCATATGAGGCAACAGAAGAATCCTGTAAGTACAATCCCAAGTATTCTGTTGCT\nAATGACACCGGCTTTGTGGACATCCCTAAGCAGGAGAAGGCCCTGATGAAGGCAGTTGCA\nACTGTGGGGCCCATTTCTGTTGCTATTGATGCAGGTCATGAGTCCTTCCTGTTCTATAAA\nGAAGGCATTTATTTTGAGCCAGACTGTAGCAGTGAAGACATGGATCATGGTGTGCTGGTG\nGTTGGCTACGGATTTGAAAGCACAGAATCAGATAACAATAAATATTGGCTGGTGAAGAAC\nAGCTGGGGTGAAGAATGGGGCATGGGTGGCTACGTAAAGATGGCCAAAGACCGGAGAAAC\nCATTGTGGAATTGCCTCAGCAGCCAGCTACCCCACTGTGTGA'),('Cellular tumor antigen p53','None','Human','None','None','TP53','43652.79','DB00945','>lcl|BSEQ0021858|Cellular tumor antigen p53 (TP53)\nATGGAGGAGCCGCAGTCAGATCCTAGCGTCGAGCCCCCTCTGAGTCAGGAAACATTTTCA\nGACCTATGGAAACTACTTCCTGAAAACAACGTTCTGTCCCCCTTGCCGTCCCAAGCAATG\nGATGATTTGATGCTGTCCCCGGACGATATTGAACAATGGTTCACTGAAGACCCAGGTCCA\nGATGAAGCTCCCAGAATGCCAGAGGCTGCTCCCCCCGTGGCCCCTGCACCAGCAGCTCCT\nACACCGGCGGCCCCTGCACCAGCCCCCTCCTGGCCCCTGTCATCTTCTGTCCCTTCCCAG\nAAAACCTACCAGGGCAGCTACGGTTTCCGTCTGGGCTTCTTGCATTCTGGGACAGCCAAG\nTCTGTGACTTGCACGTACTCCCCTGCCCTCAACAAGATGTTTTGCCAACTGGCCAAGACC\nTGCCCTGTGCAGCTGTGGGTTGATTCCACACCCCCGCCCGGCACCCGCGTCCGCGCCATG\nGCCATCTACAAGCAGTCACAGCACATGACGGAGGTTGTGAGGCGCTGCCCCCACCATGAG\nCGCTGCTCAGATAGCGATGGTCTGGCCCCTCCTCAGCATCTTATCCGAGTGGAAGGAAAT\nTTGCGTGTGGAGTATTTGGATGACAGAAACACTTTTCGACATAGTGTGGTGGTGCCCTAT\nGAGCCGCCTGAGGTTGGCTCTGACTGTACCACCATCCACTACAACTACATGTGTAACAGT\nTCCTGCATGGGCGGCATGAACCGGAGGCCCATCCTCACCATCATCACACTGGAAGACTCC\nAGTGGTAATCTACTGGGACGGAACAGCTTTGAGGTGCGTGTTTGTGCCTGTCCTGGGAGA\nGACCGGCGCACAGAGGAAGAGAATCTCCGCAAGAAAGGGGAGCCTCACCACGAGCTGCCC\nCCAGGGAGCACTAAGCGAGCACTGCCCAACAACACCAGCTCCTCTCCCCAGCCAAAGAAG\nAAACCACTGGATGGAGAATATTTCACCCTTCAGATCCGTGGGCGTGAGCGCTTCGAGATG\nTTCCGAGAGCTGAATGAGGCCTTGGAACTCAAGGATGCCCAGGCTGGGAAGGAGCCAGGG\nGGGAGCAGGGCTCACTCCAGCCACCTGAAGTCCAAAAAGGGTCAGTCTACCTCCCGCCAT\nAAAAAACTCATGTTCAAGACAGAAGGGCCTGACTCAGACTGA'),('cGMP-dependent 3\',5\'-cyclic phosphodiesterase','None','Human','Tpr domain binding','Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes.Isoform PDE2A2: Regulates Mitochondrial cAMP Levels and Respiration.','PDE2A','105715.85','DB06246','>lcl|BSEQ0021934|cGMP-dependent 3\',5\'-cyclic phosphodiesterase (PDE2A)\nATGGTCCTGGTGCTGCACCACATCCTCATCGCTGTTGTCCAATTCCTCAGGCGGGGCCAG\nCAGGTCTTCCTCAAGCCGGACGAGCCGCCGCCGCCGCCGCAGCCATGCGCCGACAGCCTG\nCAGGACGCCTTGCTGAGTCTGGGCTCTGTCATCGACATTTCAGGCCTGCAACGTGCTGTC\nAAGGAGGCCCTGTCAGCTGTGCTCCCCCGAGTGGAAACTGTCTACACCTACCTACTGGAT\nGGTGAGTCCCAGCTGGTGTGTGAGGACCCCCCACATGAGCTGCCCCAGGAGGGGAAAGTC\nCGGGAGGCTATCATCTCCCAGAAGCGGCTGGGCTGCAATGGGCTGGGCTTCTCAGACCTG\nCCAGGGAAGCCCTTGGCCAGGCTGGTGGCTCCACTGGCTCCTGATACCCAAGTGCTGGTC\nATGCCGCTAGCGGACAAGGAGGCTGGGGCCGTGGCAGCTGTCATCTTGGTGCACTGTGGC\nCAGCTGAGTGATAATGAGGAATGGAGCCTGCAGGCGGTGGAGAAGCATACCCTGGTCGCC\nCTGCGGAGGGTGCAGGTCCTGCAGCAGCGCGGGCCCAGGGAGGCTCCCCGAGCCGTCCAG\nAACCCCCCGGAGGGGACGGCGGAAGACCAGAAGGGCGGGGCGGCGTACACCGACCGCGAC\nCGCAAGATCCTCCAACTGTGCGGGGAACTCTACGACCTGGATGCCTCTTCCCTGCAGCTC\nAAAGTGCTCCAATACCTGCAGCAGGAGACCCGGGCATCCCGCTGCTGCCTCCTGCTGGTG\nTCGGAGGACAATCTCCAGCTTTCTTGCAAGGTCATCGGAGACAAAGTGCTCGGGGAAGAG\nGTCAGCTTTCCCTTGACAGGATGCCTGGGCCAGGTGGTGGAAGACAAGAAGTCCATCCAG\nCTGAAGGACCTCACCTCCGAGGATGTACAACAGCTGCAGAGCATGTTGGGCTGTGAGCTG\nCAGGCCATGCTCTGTGTCCCTGTCATCAGCCGGGCCACTGACCAGGTGGTGGCCTTGGCC\nTGCGCCTTCAACAAGCTAGAAGGAGACTTGTTCACCGACGAGGACGAGCATGTGATCCAG\nCACTGCTTCCACTACACCAGCACCGTGCTCACCAGCACCCTGGCCTTCCAGAAGGAACAG\nAAACTCAAGTGTGAGTGCCAGGCTCTTCTCCAAGTGGCAAAGAACCTCTTCACCCACCTG\nGATGACGTCTCTGTCCTGCTCCAGGAGATCATCACGGAGGCCAGAAACCTCAGCAACGCA\nGAGATCTGCTCTGTGTTCCTGCTGGATCAGAATGAGCTGGTGGCCAAGGTGTTCGACGGG\nGGCGTGGTGGATGATGAGAGCTATGAGATCCGCATCCCGGCCGATCAGGGCATCGCGGGA\nCACGTGGCGACCACGGGCCAGATCCTGAACATCCCTGACGCATATGCCCATCCGCTTTTC\nTACCGCGGCGTGGACGACAGCACCGGCTTCCGCACGCGCAACATCCTCTGCTTCCCCATC\nAAGAACGAGAACCAGGAGGTCATCGGTGTGGCCGAGCTGGTGAACAAGATCAATGGGCCA\nTGGTTCAGCAAGTTCGACGAGGACCTGGCGACGGCCTTCTCCATCTACTGCGGCATCAGC\nATCGCCCATTCTCTCCTATACAAAAAAGTGAATGAGGCTCAGTATCGCAGCCACCTGGCC\nAATGAGATGATGATGTACCACATGAAGGTCTCCGATGATGAGTATACCAAACTTCTCCAT\nGATGGGATCCAGCCTGTGGCTGCCATTGACTCCAATTTTGCAAGTTTCACCTATACCCCT\nCGTTCCCTGCCCGAGGATGACACGTCCATGGCCATCCTGAGCATGCTGCAGGACATGAAT\nTTCATCAACAACTACAAAATTGACTGCCCGACCCTGGCCCGGTTCTGTTTGATGGTGAAG\nAAGGGCTACCGGGATCCCCCCTACCACAACTGGATGCACGCCTTTTCTGTCTCCCACTTC\nTGCTACCTGCTCTACAAGAACCTGGAGCTCACCAACTACCTCGAGGACATCGAGATCTTT\nGCCTTGTTTATTTCCTGCATGTGTCATGACCTGGACCACAGAGGCACAAACAACTCTTTC\nCAGGTGGCCTCGAAATCTGTGCTGGCTGCGCTCTACAGCTCTGAGGGCTCCGTCATGGAG\nAGGCACCACTTTGCTCAGGCCATCGCCATCCTCAACACCCACGGCTGCAACATCTTTGAT\nCATTTCTCCCGGAAGGACTATCAGCGCATGCTGGATCTGATGCGGGACATCATCTTGGCC\nACAGACCTGGCCCACCATCTCCGCATCTTCAAGGACCTCCAGAAGATGGCTGAGGTGGGC\nTACGACCGAAACAACAAGCAGCACCACAGACTTCTCCTCTGCCTCCTCATGACCTCCTGT\nGACCTCTCTGACCAGACCAAGGGCTGGAAGACTACGAGAAAGATCGCGGAGCTGATCTAC\nAAAGAATTCTTCTCCCAGGGAGACCTGGAGAAGGCCATGGGCAACAGGCCGATGGAGATG\nATGGACCGGGAGAAGGCCTATATCCCTGAGCTGCAAATCAGCTTCATGGAGCACATTGCA\nATGCCCATCTACAAGCTGTTGCAGGACCTGTTCCCCAAAGCGGCAGAGCTGTACGAGCGC\nGTGGCCTCCAACCGTGAGCACTGGACCAAGGTGTCCCACAAGTTCACCATCCGCGGCCTC\nCCAAGTAACAACTCGCTGGACTTCCTGGATGAGGAGTACGAGGTGCCTGATCTGGATGGC\nACTAGGGCCCCCATCAATGGCTGCTGCAGCCTTGATGCTGAGTGA'),('cGMP-specific 3\',5\'-cyclic phosphodiesterase','None','Human','Metal ion binding','Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. This phosphodiesterase catalyzes the specific hydrolysis of cGMP to 5\'-GMP (PubMed:9714779, PubMed:15489334). Specifically regulates nitric-oxide-generated cGMP (PubMed:15489334).','PDE5A','99984.14','DB06246','>lcl|BSEQ0009989|cGMP-specific 3\',5\'-cyclic phosphodiesterase (PDE5A)\nATGGAGCGGGCCGGCCCCAGCTTCGGGCAGCAGCGACAGCAGCAGCAGCCCCAGCAGCAG\nAAGCAGCAGCAGAGGGATCAGGACTCGGTCGAAGCATGGCTGGACGATCACTGGGACTTT\nACCTTCTCATACTTTGTTAGAAAAGCCACCAGAGAAATGGTCAATGCATGGTTTGCTGAG\nAGAGTTCACACCATCCCTGTGTGCAAGGAAGGTATCAGAGGCCACACCGAATCTTGCTCT\nTGTCCCTTGCAGCAGAGTCCTCGTGCAGATAACAGTGCCCCTGGAACACCAACCAGGAAA\nATCTCTGCCTCTGAATTTGACCGGCCTCTTAGACCCATTGTTGTCAAGGATTCTGAGGGA\nACTGTGAGCTTCCTCTCTGACTCAGAAAAGAAGGAACAGATGCCTCTAACCCCTCCAAGG\nTTTGATCATGATGAAGGGGACCAGTGCTCAAGACTCTTGGAATTAGTGAAGGATATTTCT\nAGTCATTTGGATGTCACAGCCTTATGTCACAAAATTTTCTTGCATATCCATGGACTGATA\nTCTGCTGACCGCTATTCCCTGTTCCTTGTCTGTGAAGACAGCTCCAATGACAAGTTTCTT\nATCAGCCGCCTCTTTGATGTTGCTGAAGGTTCAACACTGGAAGAAGTTTCAAATAACTGT\nATCCGCTTAGAATGGAACAAAGGCATTGTGGGACATGTGGCAGCGCTTGGTGAGCCCTTG\nAACATCAAAGATGCATATGAGGATCCTCGGTTCAATGCAGAAGTTGACCAAATTACAGGC\nTACAAGACACAAAGCATTCTTTGTATGCCAATTAAGAATCATAGGGAAGAGGTTGTTGGT\nGTAGCCCAGGCCATCAACAAGAAATCAGGAAACGGTGGGACATTTACTGAAAAAGATGAA\nAAGGACTTTGCTGCTTATTTGGCATTTTGTGGTATTGTTCTTCATAATGCTCAGCTCTAT\nGAGACTTCACTGCTGGAGAACAAGAGAAATCAGGTGCTGCTTGACCTTGCTAGTTTAATT\nTTTGAAGAACAACAATCATTAGAAGTAATTTTGAAGAAAATAGCTGCCACTATTATCTCT\nTTCATGCAAGTGCAGAAATGCACCATTTTCATAGTGGATGAAGATTGCTCCGATTCTTTT\nTCTAGTGTGTTTCACATGGAGTGTGAGGAATTAGAAAAATCATCTGATACATTAACAAGG\nGAACATGATGCAAACAAAATCAATTACATGTATGCTCAGTATGTCAAAAATACTATGGAA\nCCACTTAATATCCCAGATGTCAGTAAGGATAAAAGATTTCCCTGGACAACTGAAAATACA\nGGAAATGTAAACCAGCAGTGCATTAGAAGTTTGCTTTGTACACCTATAAAAAATGGAAAG\nAAGAATAAAGTTATAGGGGTTTGCCAACTTGTTAATAAGATGGAGGAGAATACTGGCAAG\nGTTAAGCCTTTCAACCGAAATGACGAACAGTTTCTGGAAGCTTTTGTCATCTTTTGTGGC\nTTGGGGATCCAGAACACGCAGATGTATGAAGCAGTGGAGAGAGCCATGGCCAAGCAAATG\nGTCACATTGGAGGTTCTGTCGTATCATGCTTCAGCAGCAGAGGAAGAAACAAGAGAGCTA\nCAGTCGTTAGCGGCTGCTGTGGTGCCATCTGCCCAGACCCTTAAAATTACTGACTTTAGC\nTTCAGTGACTTTGAGCTGTCTGATCTGGAAACAGCACTGTGTACAATTCGGATGTTTACT\nGACCTCAACCTTGTGCAGAACTTCCAGATGAAACATGAGGTTCTTTGCAGATGGATTTTA\nAGTGTTAAGAAGAATTATCGGAAGAATGTTGCCTATCATAATTGGAGACATGCCTTTAAT\nACAGCTCAGTGCATGTTTGCTGCTCTAAAAGCAGGCAAAATTCAGAACAAGCTGACTGAC\nCTGGAGATACTTGCATTGCTGATTGCTGCACTAAGCCACGATTTGGATCACCGTGGTGTG\nAATAACTCTTACATACAGCGAAGTGAACATCCACTTGCCCAGCTTTACTGCCATTCAATC\nATGGAACACCATCATTTTGACCAGTGCCTGATGATTCTTAATAGTCCAGGCAATCAGATT\nCTCAGTGGCCTCTCCATTGAAGAATATAAGACCACGTTGAAAATAATCAAGCAAGCTATT\nTTAGCTACAGACCTAGCACTGTACATTAAGAGGCGAGGAGAATTTTTTGAACTTATAAGA\nAAAAATCAATTCAATTTGGAAGATCCTCATCAAAAGGAGTTGTTTTTGGCAATGCTGATG\nACAGCTTGTGATCTTTCTGCAATTACAAAACCCTGGCCTATTCAACAACGGATAGCAGAA\nCTTGTAGCAACTGAATTTTTTGATCAAGGAGACAGAGAGAGAAAAGAACTCAACATAGAA\nCCCACTGATCTAATGAACAGGGAGAAGAAAAACAAAATCCCAAGTATGCAAGTTGGGTTC\nATAGATGCCATCTGCTTGCAACTGTATGAGGCCCTGACCCACGTGTCAGAGGACTGTTTC\nCCTTTGCTAGATGGCTGCAGAAAGAACAGGCAGAAATGGCAGGCCCTTGCAGAACAGCAG\nGAGAAGATGCTGATTAATGGGGAAAGCGGCCAGGCCAAGCGGAACTGA'),('Chloride channel protein ClC-Ka','None','Human','Voltage-gated chloride channel activity','Voltage-gated chloride channel. Chloride channels have several functions including the regulation of cell volume; membrane potential stabilization, signal transduction and transepithelial transport. May be important in urinary concentrating mechanisms.','CLCNKA','75284.08','DB04552','>lcl|BSEQ0011704|Chloride channel protein ClC-Ka (CLCNKA)\nATGGAGGAGTTGGTGGGGCTGCGTGAGGGCTTCTCAGGGGACCCTGTGACTCTGCAGGAG\nCTGTGGGGCCCCTGTCCCCACATCCGCCGAGCCATCCAAGGTGGCCTGGAGTGGCTAAAG\nCAGAAGGTGTTCCGCCTGGGAGAAGACTGGTACTTCCTGATGACCCTCGGGGTGCTCATG\nGCCCTGGTCAGCTATGCCATGAACTTTGCCATCGGGTGTGTGGTCCGAGCACACCAGTGG\nCTGTACAGGGAGATTGGGGACAGCCACCTGCTCCGGTATCTTTCCTGGACTGTGTACCCT\nGTGGCCCTCGTCTCTTTCTCCTCAGGCTTCTCCCAGAGCATCACGCCCTCCTCTGGAGGT\nTCTGGAATCCCGGAGCTGAAGACCATGTTGGCGGGTGTGATCTTGGAGGACTACCTGGAT\nATCAAGAACTTTGGGGCCAAGGTGGTGGGCCTCTCCTGCACCCTGGCCACCGGCAGCACC\nCTGTTCCTGGGCAAAGTGGGCCCTTTCGTGCACCTGTCTGTAATGATCGCTGCCTACCTG\nGGCCGTGTGCGCACCACGACCATCGGGGAGCCTGAGAACAAGAGCAAGCAAAACGAAATG\nCTGGTGGCAGCGGCGGCAGTGGGCGTGGCCACAGTCTTTGCAGCTCCCTTCAGCGGCGTC\nCTGTTCAGCATCGAGGTCATGTCTTCCCACTTCTCTGTCCGGGATTACTGGAGGGGCTTC\nTTTGCGGCCACCTGCGGGGCCTTCATATTCCGGCTCCTGGCAGTCTTCAACAGCGAGCAG\nGAGACCATCACCTCCCTCTACAAGACCAGTTTCCGGGTGGACGTTCCCTTCGACCTGCCT\nGAGATCTTCTTTTTTGTGGCGCTGGGTGGCATCTGCGGCGTCCTGAGCTGTGCTTACCTC\nTTCTGTCAGCGAACCTTCCTCAGCTTCATCAAGACCAATCGGTACAGCTCCAAACTGCTG\nGCTACTAGCAAGCCTGTGTACTCCGCTCTGGCCACCTTGCTTCTCGCCTCCATCACCTAC\nCCGCCTGGTGTGGGCCACTTCCTAGCTTCTCGGCTGTCCATGAAGCAGCATCTGGACTCG\nCTGTTCGACAACCACTCCTGGGCGCTGATGACCCAGAACTCCAGCCCACCCTGGCCCGAG\nGAGCTCGACCCCCAGCACCTTTGGTGGGAATGGTACCACCCGCGGTTCACCATCTTTGGG\nACCCTTGCCTTCTTCCTGGTTATGAAGTTCTGGATGCTGATTCTGGCCACCACCATCCCC\nATGCCTGCCGGGTACTTCATGCCCATCTTTATCCTTGGAGCTGCCATCGGGCGCCTCTTG\nGGAGAGGCTCTTGCCGTCGCCTTCCCTGAGGGCATTGTGACTGGAGGGGTTACCAATCCC\nATCATGCCCGGGGGGTATGCTCTGGCAGGGGCTGCAGCCTTCTCAGGGGCTGTGACCCAC\nACCATCTCCACGGCGCTGCTGGCCTTTGAGCTGACCGGCCAGATAGTGCATGCACTGCCC\nGTGCTGATGGCGGTGCTGGCAGCCAACGCCATTGCACAGAGCTGCCAGCCCTCCTTCTAT\nGATGGCACCATCATTGTCAAGAAGCTGCCATACCTGCCACGGATTCTGGGCCGCAACATC\nGGCTCCCACCATGTGAGGGTGGAGCACTTCATGAACCACAGCATCACCACACTGGCCAAG\nGACACGCCGCTGGAGGAGGTGGTCAAGGTTGTGACCTCCACAGACGTGACCGAGTATCCC\nCTGGTGGAGAGCACAGAGTCCCAGATCCTGGTAGGCATCGTGCAGAGGGCCCAGCTGGTG\nCAGGCCCTCCAGGCTGAGCCTCCTTCCAGGGCTCCAGGACACCAGTGTCTCCAGGACATC\nTTGGCCAGGGGCTGCCCCACGGAACCAGTGACCCTGACGCTATTCTCAGAGACCACCTTG\nCACCAGGCACAAAACCTCTTTAAGCTGTTGAACCTTCAGTCCCTCTTCGTGACATCGCGG\nGGCAGAGCTGTGGGCTGCGTGTCCTGGGTGGAGATGAAGAAAGCAATTTCCAACCTGACA\nAATCCGCCAGCTCCAAAGTGA'),('Choline-phosphate cytidylyltransferase A','None','Human','Lipid binding','Controls phosphatidylcholine synthesis.','PCYT1A','41730.67','DB00122','>lcl|BSEQ0010428|Choline-phosphate cytidylyltransferase A (PCYT1A)\nATGGATGCACAGTGTTCAGCCAAGGTCAATGCAAGGAAGAGGAGAAAAGAGGCGCCCGGA\nCCCAACGGGGCAACAGAAGAAGATGGGGTTCCTTCCAAAGTGCAGCGCTGTGCAGTGGGC\nTTACGGCAACCAGCTCCTTTTTCTGATGAAATTGAAGTTGACTTTAGTAAGCCCTATGTC\nAGGGTAACTATGGAAGAAGCCAGCAGAGGAACTCCTTGTGAGCGACCTGTGAGAGTTTAT\nGCCGATGGAATATTTGACTTATTTCACTCTGGTCACGCCCGAGCTCTGATGCAAGCGAAG\nAACCTTTTCCCTAATACGTACCTCATTGTGGGAGTTTGCAGTGATGAGCTCACACACAAC\nTTCAAAGGCTTCACGGTGATGAACGAGAATGAGCGCTATGACGCAGTCCAGCACTGCCGC\nTACGTGGATGAGGTGGTGAGGAATGCGCCCTGGACGCTGACACCCGAGTTCCTGGCCGAA\nCACCGGATTGATTTTGTAGCCCATGATGATATTCCTTATTCATCTGCTGGCAGTGATGAT\nGTTTATAAGCACATCAAGGAGGCAGGCATGTTTGCTCCAACACAGAGGACAGAAGGTATC\nTCCACATCAGACATCATCACCCGAATTGTGCGGGATTATGATGTGTATGCGAGGCGGAAC\nCTGCAGAGGGGCTACACAGCAAAGGAGCTCAATGTCAGCTTTATCAACGAGAAGAAATAC\nCACTTGCAGGAGAGGGTTGACAAAGTAAAGAAGAAAGTGAAAGATGTGGAGGAAAAGTCA\nAAAGAATTTGTTCAGAAGGTGGAGGAAAAAAGCATTGACCTCATTCAGAAGTGGGAGGAG\nAAGTCCCGAGAATTCATTGGAAGTTTTCTGGAAATGTTTGGTCCGGAAGGAGCACTGAAA\nCATATGCTGAAAGAGGGGAAGGGCCGGATGCTGCAGGCCATCAGCCCGAAGCAGAGCCCC\nAGCAGCAGCCCTACTCGCGAGCGCTCCCCCTCCCCCTCTTTCCGATGGCCCTTCTCCGGC\nAAGACTTCCCCACCTTGCTCCCCAGCAAATCTCTCCAGGCACAAGGCTGCAGCCTATGAT\nATCAGTGAGGATGAAGAAGACTAA'),('Choline-phosphate cytidylyltransferase B','None','Human','Choline-phosphate cytidylyltransferase activity','Controls phosphatidylcholine synthesis.','PCYT1B','41939.76','DB00122','>lcl|BSEQ0010347|Choline-phosphate cytidylyltransferase B (PCYT1B)\nATGGTAGGCCATCAGGAGTGCATCATGGAAGAGGACAATCGCGCTCCCCAATTGTGGCGC\nAAGACCCTGACTGCACCTGCCCCATTTGCTGATGAAACCAACTGCCAGTGTCAAGCACCC\nCATGAAAAACTGACCATTGCTCAGGCCCGCTTAGGAACACCAGCTGACAGGCCTGTCAGA\nGTATACGCCGATGGAATATTTGACCTCTTCCACTCAGGTCATGCAAGAGCCCTTATGCAA\nGCAAAAACACTGTTTCCCAACAGCTACTTGTTGGTAGGAGTTTGCAGTGATGATCTCACC\nCACAAATTCAAAGGTTTCACCGTGATGAATGAAGCCGAGAGATACGAAGCTCTCAGACAC\nTGTCGCTACGTAGACGAAGTTATCAGAGATGCTCCCTGGACACTCACGCCAGAGTTTCTG\nGAAAAACACAAGATTGACTTTGTGGCTCATGATGACATTCCGTATTCCTCTGCTGGCTCT\nGATGATGTTTACAAGCACATAAAGGAAGCAGGGATGTTCGTTCCAACGCAGAGAACAGAA\nGGCATCTCAACATCGGACATCATTACCAGAATTGTTCGTGACTATGATGTTTATGCCCGA\nCGTAACCTCCAGAGAGGGTATACAGCCAAGGAACTGAATGTCAGCTTTATAAATGAGAAG\nAGGTACCGTTTCCAGAACCAAGTGGACAAAATGAAGGAAAAAGTCAAGAATGTGGAGGAA\nAGATCAAAGGAATTTGTGAACAGAGTGGAAGAAAAGAGCCATGATCTAATTCAAAAGTGG\nGAAGAGAAGTCAAGGGAATTCATTGGCAACTTCCTAGAACTGTTTGGACCTGATGGAGCA\nTGGAAGCAGATGTTCCAGGAGAGGAGCAGCCGGATGCTGCAGGCCTTATCCCCGAAGCAG\nAGCCCTGTGAGCAGCCCAACCCGGAGCCGGTCCCCTTCCCGCTCCCCATCGCCCACCTTC\nTCATGGCTTCCACTCAAAACCTCACCCCCTTCCTCACCCAAAGCAGCCTCAGCCTCTATC\nAGCAGCATGAGCGAGGGGGATGAGGATGAAAAGTAG'),('Cholinesterase','None','Human','Identical protein binding','Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.','BCHE','68417.575','DB01221','>lcl|BSEQ0016707|Cholinesterase (BCHE)\nATGCATAGCAAAGTCACAATCATATGCATCAGATTTCTCTTTTGGTTTCTTTTGCTCTGC\nATGCTTATTGGGAAGTCACATACTGAAGATGACATCATAATTGCAACAAAGAATGGAAAA\nGTCAGAGGGATGAACTTGACAGTTTTTGGTGGCACGGTAACAGCCTTTCTTGGAATTCCC\nTATGCACAGCCACCTCTTGGTAGACTTCGATTCAAAAAGCCACAGTCTCTGACCAAGTGG\nTCTGATATTTGGAATGCCACAAAATATGCAAATTCTTGCTGTCAGAACATAGATCAAAGT\nTTTCCAGGCTTCCATGGATCAGAGATGTGGAACCCAAACACTGACCTCAGTGAAGACTGT\nTTATATCTAAATGTATGGATTCCAGCACCTAAACCAAAAAATGCCACTGTATTGATATGG\nATTTATGGTGGTGGTTTTCAAACTGGAACATCATCTTTACATGTTTATGATGGCAAGTTT\nCTGGCTCGGGTTGAAAGAGTTATTGTAGTGTCAATGAACTATAGGGTGGGTGCCCTAGGA\nTTCTTAGCTTTGCCAGGAAATCCTGAGGCTCCAGGGAACATGGGTTTATTTGATCAACAG\nTTGGCTCTTCAGTGGGTTCAAAAAAATATAGCAGCCTTTGGTGGAAATCCTAAAAGTGTA\nACTCTCTTTGGAGAAAGTGCAGGAGCAGCTTCAGTTAGCCTGCATTTGCTTTCTCCTGGA\nAGCCATTCATTGTTCACCAGAGCCATTCTGCAAAGTGGATCCTTTAATGCTCCTTGGGCG\nGTAACATCTCTTTATGAAGCTAGGAACAGAACGTTGAACTTAGCTAAATTGACTGGTTGC\nTCTAGAGAGAATGAGACTGAAATAATCAAGTGTCTTAGAAATAAAGATCCCCAAGAAATT\nCTTCTGAATGAAGCATTTGTTGTCCCCTATGGGACTCCTTTGTCAGTAAACTTTGGTCCG\nACCGTGGATGGTGATTTTCTCACTGACATGCCAGACATATTACTTGAACTTGGACAATTT\nAAAAAAACCCAGATTTTGGTGGGTGTTAATAAAGATGAAGGGACAGCTTTTTTAGTCTAT\nGGTGCTCCTGGCTTCAGCAAAGATAACAATAGTATCATAACTAGAAAAGAATTTCAGGAA\nGGTTTAAAAATATTTTTTCCAGGAGTGAGTGAGTTTGGAAAGGAATCCATCCTTTTTCAT\nTACACAGACTGGGTAGATGATCAGAGACCTGAAAACTACCGTGAGGCCTTGGGTGATGTT\nGTTGGGGATTATAATTTCATATGCCCTGCCTTGGAGTTCACCAAGAAGTTCTCAGAATGG\nGGAAATAATGCCTTTTTCTACTATTTTGAACACCGATCCTCCAAACTTCCGTGGCCAGAA\nTGGATGGGAGTGATGCATGGCTATGAAATTGAATTTGTCTTTGGTTTACCTCTGGAAAGA\nAGAGATAATTACACAAAAGCCGAGGAAATTTTGAGTAGATCCATAGTGAAACGGTGGGCA\nAATTTTGCAAAATATGGGAATCCAAATGAGACTCAGAACAATAGCACAAGCTGGCCTGTC\nTTCAAAAGCACTGAACAAAAATATCTAACCTTGAATACAGAGTCAACAAGAATAATGACG\nAAACTACGTGCTCAACAATGTCGATTCTGGACATCATTTTTTCCAAAAGTCTTGGAAATG\nACAGGAAATATTGATGAAGCAGAATGGGAGTGGAAAGCAGGATTCCATCGCTGGAACAAT\nTACATGATGGACTGGAAAAATCAATTTAACGATTACACTAGCAAGAAAGAAAGTTGTGTG\nGGTCTCTAA'),('CHRNA7-FAM7A fusion protein','None','Human','Extracellular ligand-gated ion channel activity','None','CHRFAM7A','46217.335','DB07720','>lcl|BSEQ0017280|CHRNA7-FAM7A fusion protein (CHRFAM7A)\nATGCAAAAATATTGCATCTACCAGCATTTTCAGTTCCAATTGCTAATCCAGCATTTGTGG\nATAGCTGCAAACTGCGATATTGCTGATGAGCGCTTTGACGCCACATTCCACACTAACGTG\nTTGGTGAATTCTTCTGGGCATTGCCAGTACCTGCCTCCAGGCATATTCAAGAGTTCCTGC\nTACATCGATGTACGCTGGTTTCCCTTTGATGTGCAGCACTGCAAACTGAAGTTTGGGTCC\nTGGTCTTACGGAGGCTGGTCCTTGGATCTGCAGATGCAGGAGGCAGATATCAGTGGCTAT\nATCCCCAATGGAGAATGGGACCTAGTGGGAATCCCCGGCAAGAGGAGTGAAAGGTTCTAT\nGAGTGCTGCAAAGAGCCCTACCCTGATGTCACCTTCACAGTGACCATGCGCCGCAGGACG\nCTCTACTATGGCCTCAACCTGCTGATCCCCTGTGTGCTCATCTCCGCCCTCGCCCTGCTG\nGTGTTCCTGCTTCCTGCAGATTCCGGGGAGAAGATTTCCCTGGGGATAACAGTCTTACTC\nTCTCTTACCGTCTTCATGCTGCTCGTGGCTGAGATCATGCCCGCAACATCCGATTCGGTA\nCCATTGATAGCCCAGTACTTCGCCAGCACCATGATCATCGTGGGCCTCTCGGTGGTGGTG\nACGGTGATCGTGCTGCAGTACCACCACCACGACCCCGACGGGGGCAAGATGCCCAAGTGG\nACCAGAGTCATCCTTCTGAACTGGTGCGCGTGGTTCCTGCGAATGAAGAGGCCCGGGGAG\nGACAAGGTGCGCCCGGCCTGCCAGCACAAGCAGCGGCGCTGCAGCCTGGCCAGTGTGGAG\nATGAGTGCCGTGGCGCCGCCGCCCGCCAGCAACGGGAACCTGCTGTACATCGGCTTCCGC\nGGCCTGGACGGCGTGCACTGTGTCCCGACCCCCGACTCTGGGGTAGTGTGTGGCCGCATG\nGCCTGCTCCCCCACGCACGATGAGCACCTCCTGCACGGCGGGCAACCCCCCGAGGGGGAC\nCCGGACTTGGCCAAGATCCTGGAGGAGGTCCGCTACATTGCCAACCGCTTCCGCTGCCAG\nGACGAAAGCGAGGCGGTCTGCAGCGAGTGGAAGTTCGCCGCCTGTGTGGTGGACCGCCTG\nTGCCTCATGGCCTTCTCGGTCTTCACCATCATCTGCACCATCGGCATCCTGATGTCGGCT\nCCCAACTTCGTGGAGGCCGTGTCCAAAGACTTTGCGTAA'),('Coagulation factor X','None','Human','Serine-type endopeptidase activity','Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting.','F10','54731.255','DB12598','>lcl|BSEQ0010205|Coagulation factor X (F10)\nATGGGGCGCCCACTGCACCTCGTCCTGCTCAGTGCCTCCCTGGCTGGCCTCCTGCTGCTC\nGGGGAAAGTCTGTTCATCCGCAGGGAGCAGGCCAACAACATCCTGGCGAGGGTCACGAGG\nGCCAATTCCTTTCTTGAAGAGATGAAGAAAGGACACCTCGAAAGAGAGTGCATGGAAGAG\nACCTGCTCATACGAAGAGGCCCGCGAGGTCTTTGAGGACAGCGACAAGACGAATGAATTC\nTGGAATAAATACAAAGATGGCGACCAGTGTGAGACCAGTCCTTGCCAGAACCAGGGCAAA\nTGTAAAGACGGCCTCGGGGAATACACCTGCACCTGTTTAGAAGGATTCGAAGGCAAAAAC\nTGTGAATTATTCACACGGAAGCTCTGCAGCCTGGACAACGGGGACTGTGACCAGTTCTGC\nCACGAGGAACAGAACTCTGTGGTGTGCTCCTGCGCCCGCGGGTACACCCTGGCTGACAAC\nGGCAAGGCCTGCATTCCCACAGGGCCCTACCCCTGTGGGAAACAGACCCTGGAACGCAGG\nAAGAGGTCAGTGGCCCAGGCCACCAGCAGCAGCGGGGAGGCCCCTGACAGCATCACATGG\nAAGCCATATGATGCAGCCGACCTGGACCCCACCGAGAACCCCTTCGACCTGCTTGACTTC\nAACCAGACGCAGCCTGAGAGGGGCGACAACAACCTCACCAGGATCGTGGGAGGCCAGGAA\nTGCAAGGACGGGGAGTGTCCCTGGCAGGCCCTGCTCATCAATGAGGAAAACGAGGGTTTC\nTGTGGTGGAACCATTCTGAGCGAGTTCTACATCCTAACGGCAGCCCACTGTCTCTACCAA\nGCCAAGAGATTCAAGGTGAGGGTAGGGGACCGGAACACGGAGCAGGAGGAGGGCGGTGAG\nGCGGTGCACGAGGTGGAGGTGGTCATCAAGCACAACCGGTTCACAAAGGAGACCTATGAC\nTTCGACATCGCCGTGCTCCGGCTCAAGACCCCCATCACCTTCCGCATGAACGTGGCGCCT\nGCCTGCCTCCCCGAGCGTGACTGGGCCGAGTCCACGCTGATGACGCAGAAGACGGGGATT\nGTGAGCGGCTTCGGGCGCACCCACGAGAAGGGCCGGCAGTCCACCAGGCTCAAGATGCTG\nGAGGTGCCCTACGTGGACCGCAACAGCTGCAAGCTGTCCAGCAGCTTCATCATCACCCAG\nAACATGTTCTGTGCCGGCTACGACACCAAGCAGGAGGATGCCTGCCAGGGGGACAGCGGG\nGGCCCGCACGTCACCCGCTTCAAGGACACCTACTTCGTGACAGGCATCGTCAGCTGGGGA\nGAGGGCTGTGCCCGTAAGGGGAAGTACGGGATCTACACCAAGGTCACCGCCTTCCTCAAG\nTGGATCGACAGGTCCATGAAAACCAGGGGCTTGCCCAAGGCCAAGAGCCATGCCCCGGAG\nGTCATAACGTCCTCTCCATTAAAGTGA'),('Coagulation factor XII','None','Human','Serine-type endopeptidase activity','Factor XII is a serum glycoprotein that participates in the initiation of blood coagulation, fibrinolysis, and the generation of bradykinin and angiotensin. Prekallikrein is cleaved by factor XII to form kallikrein, which then cleaves factor XII first to alpha-factor XIIa and then trypsin cleaves it to beta-factor XIIa. Alpha-factor XIIa activates factor XI to factor XIa.','F12','67791.53','DB12598','>lcl|BSEQ0017508|Coagulation factor XII (F12)\nATGAGGGCTCTGCTGCTCCTGGGGTTCCTGCTGGTGAGCTTGGAGTCAACACTTTCGATT\nCCACCTTGGGAAGCCCCCAAGGAGCATAAGTACAAAGCTGAAGAGCACACAGTCGTTCTC\nACTGTCACCGGGGAGCCCTGCCACTTCCCCTTCCAGTACCACCGGCAGCTGTACCACAAA\nTGTACCCACAAGGGCCGGCCAGGCCCTCAGCCCTGGTGTGCTACCACCCCCAACTTTGAT\nCAGGACCAGCGATGGGGATACTGTTTGGAGCCCAAGAAAGTGAAAGACCACTGCAGCAAA\nCACAGCCCCTGCCAGAAAGGAGGGACCTGTGTGAACATGCCAAGCGGCCCCCACTGTCTC\nTGTCCACAACACCTCACTGGAAACCACTGCCAGAAAGAGAAGTGCTTTGAGCCTCAGCTT\nCTCCGGTTTTTCCACAAGAATGAGATATGGTATAGAACTGAGCAAGCAGCTGTGGCCAGA\nTGCCAGTGCAAGGGTCCTGATGCCCACTGCCAGCGGCTGGCCAGCCAGGCCTGCCGCACC\nAACCCGTGCCTCCATGGGGGTCGCTGCCTAGAGGTGGAGGGCCACCGCCTGTGCCACTGC\nCCGGTGGGCTACACCGGAGCCTTCTGCGACGTGGACACCAAGGCAAGCTGCTATGATGGC\nCGCGGGCTCAGCTACCGCGGCCTGGCCAGGACCACGCTCTCGGGTGCGCCCTGTCAGCCG\nTGGGCCTCGGAGGCCACCTACCGGAACGTGACTGCCGAGCAAGCGCGGAACTGGGGACTG\nGGCGGCCACGCCTTCTGCCGGAACCCGGACAACGACATCCGCCCGTGGTGCTTCGTGCTG\nAACCGCGACCGGCTGAGCTGGGAGTACTGCGACCTGGCACAGTGCCAGACCCCAACCCAG\nGCGGCGCCTCCGACCCCGGTGTCCCCTAGGCTTCATGTCCCACTCATGCCCGCGCAGCCG\nGCACCGCCGAAGCCTCAGCCCACGACCCGGACCCCGCCTCAGTCCCAGACCCCGGGAGCC\nTTGCCGGCGAAGCGGGAGCAGCCGCCTTCCCTGACCAGGAACGGCCCACTGAGCTGCGGG\nCAGCGGCTCCGCAAGAGTCTGTCTTCGATGACCCGCGTCGTTGGCGGGCTGGTGGCGCTA\nCGCGGGGCGCACCCCTACATCGCCGCGCTGTACTGGGGCCACAGTTTCTGCGCCGGCAGC\nCTCATCGCCCCCTGCTGGGTGCTGACGGCCGCTCACTGCCTGCAGGACCGGCCCGCACCC\nGAGGATCTGACGGTGGTGCTCGGCCAGGAACGCCGTAACCACAGCTGTGAGCCGTGCCAG\nACGTTGGCCGTGCGCTCCTACCGCTTGCACGAGGCCTTCTCGCCCGTCAGCTACCAGCAC\nGACCTGGCTCTGTTGCGCCTTCAGGAGGATGCGGACGGCAGCTGCGCGCTCCTGTCGCCT\nTACGTTCAGCCGGTGTGCCTGCCAAGCGGCGCCGCGCGACCCTCCGAGACCACGCTCTGC\nCAGGTGGCCGGCTGGGGCCACCAGTTCGAGGGGGCGGAGGAATATGCCAGCTTCCTGCAG\nGAGGCGCAGGTACCGTTCCTCTCCCTGGAGCGCTGCTCAGCCCCGGACGTGCACGGATCC\nTCCATCCTCCCCGGCATGCTCTGCGCAGGGTTCCTCGAGGGCGGCACCGATGCGTGCCAG\nGGTGATTCCGGAGGCCCGCTGGTGTGTGAGGACCAAGCTGCAGAGCGCCGGCTCACCCTG\nCAAGGCATCATCAGCTGGGGATCGGGCTGTGGTGACCGCAACAAGCCAGGCGTCTACACC\nGATGTGGCCTACTACCTGGCCTGGATCCGGGAGCACACCGTTTCCTGA'),('Cyclooxygenase 2','None','Canis lupus familiaris','None','Enzyme binding','PTGS2','68974.625','DB14060','>lcl|BSEQ0051974|Cyclooxygenase 2 (PTGS2)\nATGCTGGCCCGCGCCCTGGTGCTCTGCGCCGCCCTGGCGGTCGTCCGCGCAGCAAATCCT\nTGCTGTTCCCACCCATGTCAAAACCAAGGTATTTGTATGAGCACAGGATTTGACCAGTAT\nAAGTGTGACTGTACCCGAACAGGATTCTACGGCGAAAACTGCTCAACACCGGAATTTCTG\nACAAGAATAAAATTATACCTGAAACCCACTCCAAATACAGTACACTACATACTTACCCAC\nTTCAAGGGAGTCTGGAACATTGTCAATAACATCCCCTTCCTGCGAAATACAATTATGAAA\nTATGTGTTGACATCCCGGTCACATTTGATTGAGAGTCCACCAACTTATAATGTGAACTAC\nGGCTATAAAAGCTGGGAAGCCTTTTCTAACCTCTCCTATTATACCAGAGCTCTTCCCCCT\nGTACCTGATGACTGTCCAACACCCATGGGTGTGAAAGGCAAGAAAGAGCTTCCTGATTCA\nAAAGAGATTGTGGAAAAGTTTCTTCTGCGAAGAAAGTTCATTCCTGATCCCCAAGGCACC\nAATATGATGTTTGCATTCTTTGCCCAGCACTTTACCCATCAATTTTTCAAGACAGATCAT\nAAGCGAGGACCAGCTTTCACCAAAGGATTGGGCCATGGGGTGGACTTAAATCATGTTTAT\nGGGGAAACTTTGGATAGACAACATAAACTGCGCCTTTTCAAGGATGGAAAAATGAAATAT\nCAGGTAATTGATGGAGAGGTGTATCCTCCTACCGTCAAAGATACTCAGGTCGAGATGATC\nTACCCACCTCATGTTCCTGAACACCTGCAGTTTGCTGTGGGCCAGGAGGTCTTTGGTCTG\nGTGCCTGGTCTGATGATGTATGCCACCATTTGGCTGCGGGAGCATAACAGAGTGTGTGAT\nGTGCTTAAACAGGAGCACCCAGAATGGGATGATGAGCGGTTATTCCAGACGAGCAGGCTA\nATACTTATAGGAGAAACCATTAAGATTGTGATTGAAGACTATGTACAACACTTGAGTGGC\nTATCACTTCAAGCTGAAGTTTGACCCAGAGCTGCTTTTCAACCAACAATTCCAGTACCAA\nAACCGCATTGCTGCTGAGTTTAACACACTCTACCACTGGCATCCCCTCCTGCCTGACACC\nTTGCAAATAGATGACCAGGAGTACAATTTCCAACAGTTTATCTACAACAACTCTATATTA\nTTGGAACATGGCCTTACCCAGTTTGTGGAATCATTCAGCAGGCAAATTGCTGGCAGGGTT\nGCCGGTGGCAGGAATGTTCCAGCTGCAGTACAACAAGTAGCAAAAGCTTCGATTGACCAG\nAGCAGACAGATGAAATACCAGTCTCTTAATGAGTATCGCAAACGCTTTAGGCTGAAGCCC\nTATACATCATTCGAAGAACTTACAGGAGAGAAGGAAATGGCTGCGGGGTTGGAGGCCCTT\nTATGGTGATATTGATGCCATGGAGCTGTATCCTGCCCTCTTGGTAGAAAAGCCTCGTCCA\nGATGCCATCTTTGGTGAGACCATGGTAGAAATGGGAGCACCATTCTCCTTGAAAGGACTT\nATGGGTAATCCCATCTGTTCACCTGACTACTGGAAGCCTAGCACCTTTGGTGGAGAAGTA\nGGCTTTAAAATCATCAACACTGCCTCAATCCAGTCTCTCATCTGCAATAACGTGAAGGGC\nTGTCCATTCACTGCATTCTCTGTTCAAGACGGACAACTCACCAAAACAGTCACCATTAAT\nGCAAGCTCTTCGCACTCCGGTCTAGATGACATCAATCCCACAGTCCTACTGAAAGAACGG\nTCAACTGAACTATAG'),('Cystic fibrosis transmembrane conductance regulator','None','Human','Pdz domain binding','Involved in the transport of chloride ions. May regulate bicarbonate secretion and salvage in epithelial cells by regulating the SLC4A7 transporter. Can inhibit the chloride channel activity of ANO1. Plays a role in the chloride and bicarbonate homeostasis during sperm epididymal maturation and capacitation.','CFTR','168139.895','DB01050','>lcl|BSEQ0010831|Cystic fibrosis transmembrane conductance regulator (CFTR)\nATGCAGAGGTCGCCTCTGGAAAAGGCCAGCGTTGTCTCCAAACTTTTTTTCAGCTGGACC\nAGACCAATTTTGAGGAAAGGATACAGACAGCGCCTGGAATTGTCAGACATATACCAAATC\nCCTTCTGTTGATTCTGCTGACAATCTATCTGAAAAATTGGAAAGAGAATGGGATAGAGAG\nCTGGCTTCAAAGAAAAATCCTAAACTCATTAATGCCCTTCGGCGATGTTTTTTCTGGAGA\nTTTATGTTCTATGGAATCTTTTTATATTTAGGGGAAGTCACCAAAGCAGTACAGCCTCTC\nTTACTGGGAAGAATCATAGCTTCCTATGACCCGGATAACAAGGAGGAACGCTCTATCGCG\nATTTATCTAGGCATAGGCTTATGCCTTCTCTTTATTGTGAGGACACTGCTCCTACACCCA\nGCCATTTTTGGCCTTCATCACATTGGAATGCAGATGAGAATAGCTATGTTTAGTTTGATT\nTATAAGAAGACTTTAAAGCTGTCAAGCCGTGTTCTAGATAAAATAAGTATTGGACAACTT\nGTTAGTCTCCTTTCCAACAACCTGAACAAATTTGATGAAGGACTTGCATTGGCACATTTC\nGTGTGGATCGCTCCTTTGCAAGTGGCACTCCTCATGGGGCTAATCTGGGAGTTGTTACAG\nGCGTCTGCCTTCTGTGGACTTGGTTTCCTGATAGTCCTTGCCCTTTTTCAGGCTGGGCTA\nGGGAGAATGATGATGAAGTACAGAGATCAGAGAGCTGGGAAGATCAGTGAAAGACTTGTG\nATTACCTCAGAAATGATTGAAAATATCCAATCTGTTAAGGCATACTGCTGGGAAGAAGCA\nATGGAAAAAATGATTGAAAACTTAAGACAAACAGAACTGAAACTGACTCGGAAGGCAGCC\nTATGTGAGATACTTCAATAGCTCAGCCTTCTTCTTCTCAGGGTTCTTTGTGGTGTTTTTA\nTCTGTGCTTCCCTATGCACTAATCAAAGGAATCATCCTCCGGAAAATATTCACCACCATC\nTCATTCTGCATTGTTCTGCGCATGGCGGTCACTCGGCAATTTCCCTGGGCTGTACAAACA\nTGGTATGACTCTCTTGGAGCAATAAACAAAATACAGGATTTCTTACAAAAGCAAGAATAT\nAAGACATTGGAATATAACTTAACGACTACAGAAGTAGTGATGGAGAATGTAACAGCCTTC\nTGGGAGGAGGGATTTGGGGAATTATTTGAGAAAGCAAAACAAAACAATAACAATAGAAAA\nACTTCTAATGGTGATGACAGCCTCTTCTTCAGTAATTTCTCACTTCTTGGTACTCCTGTC\nCTGAAAGATATTAATTTCAAGATAGAAAGAGGACAGTTGTTGGCGGTTGCTGGATCCACT\nGGAGCAGGCAAGACTTCACTTCTAATGGTGATTATGGGAGAACTGGAGCCTTCAGAGGGT\nAAAATTAAGCACAGTGGAAGAATTTCATTCTGTTCTCAGTTTTCCTGGATTATGCCTGGC\nACCATTAAAGAAAATATCATCTTTGGTGTTTCCTATGATGAATATAGATACAGAAGCGTC\nATCAAAGCATGCCAACTAGAAGAGGACATCTCCAAGTTTGCAGAGAAAGACAATATAGTT\nCTTGGAGAAGGTGGAATCACACTGAGTGGAGGTCAACGAGCAAGAATTTCTTTAGCAAGA\nGCAGTATACAAAGATGCTGATTTGTATTTATTAGACTCTCCTTTTGGATACCTAGATGTT\nTTAACAGAAAAAGAAATATTTGAAAGCTGTGTCTGTAAACTGATGGCTAACAAAACTAGG\nATTTTGGTCACTTCTAAAATGGAACATTTAAAGAAAGCTGACAAAATATTAATTTTGCAT\nGAAGGTAGCAGCTATTTTTATGGGACATTTTCAGAACTCCAAAATCTACAGCCAGACTTT\nAGCTCAAAACTCATGGGATGTGATTCTTTCGACCAATTTAGTGCAGAAAGAAGAAATTCA\nATCCTAACTGAGACCTTACACCGTTTCTCATTAGAAGGAGATGCTCCTGTCTCCTGGACA\nGAAACAAAAAAACAATCTTTTAAACAGACTGGAGAGTTTGGGGAAAAAAGGAAGAATTCT\nATTCTCAATCCAATCAACTCTATACGAAAATTTTCCATTGTGCAAAAGACTCCCTTACAA\nATGAATGGCATCGAAGAGGATTCTGATGAGCCTTTAGAGAGAAGGCTGTCCTTAGTACCA\nGATTCTGAGCAGGGAGAGGCGATACTGCCTCGCATCAGCGTGATCAGCACTGGCCCCACG\nCTTCAGGCACGAAGGAGGCAGTCTGTCCTGAACCTGATGACACACTCAGTTAACCAAGGT\nCAGAACATTCACCGAAAGACAACAGCATCCACACGAAAAGTGTCACTGGCCCCTCAGGCA\nAACTTGACTGAACTGGATATATATTCAAGAAGGTTATCTCAAGAAACTGGCTTGGAAATA\nAGTGAAGAAATTAACGAAGAAGACTTAAAGGAGTGCTTTTTTGATGATATGGAGAGCATA\nCCAGCAGTGACTACATGGAACACATACCTTCGATATATTACTGTCCACAAGAGCTTAATT\nTTTGTGCTAATTTGGTGCTTAGTAATTTTTCTGGCAGAGGTGGCTGCTTCTTTGGTTGTG\nCTGTGGCTCCTTGGAAACACTCCTCTTCAAGACAAAGGGAATAGTACTCATAGTAGAAAT\nAACAGCTATGCAGTGATTATCACCAGCACCAGTTCGTATTATGTGTTTTACATTTACGTG\nGGAGTAGCCGACACTTTGCTTGCTATGGGATTCTTCAGAGGTCTACCACTGGTGCATACT\nCTAATCACAGTGTCGAAAATTTTACACCACAAAATGTTACATTCTGTTCTTCAAGCACCT\nATGTCAACCCTCAACACGTTGAAAGCAGGTGGGATTCTTAATAGATTCTCCAAAGATATA\nGCAATTTTGGATGACCTTCTGCCTCTTACCATATTTGACTTCATCCAGTTGTTATTAATT\nGTGATTGGAGCTATAGCAGTTGTCGCAGTTTTACAACCCTACATCTTTGTTGCAACAGTG\nCCAGTGATAGTGGCTTTTATTATGTTGAGAGCATATTTCCTCCAAACCTCACAGCAACTC\nAAACAACTGGAATCTGAAGGCAGGAGTCCAATTTTCACTCATCTTGTTACAAGCTTAAAA\nGGACTATGGACACTTCGTGCCTTCGGACGGCAGCCTTACTTTGAAACTCTGTTCCACAAA\nGCTCTGAATTTACATACTGCCAACTGGTTCTTGTACCTGTCAACACTGCGCTGGTTCCAA\nATGAGAATAGAAATGATTTTTGTCATCTTCTTCATTGCTGTTACCTTCATTTCCATTTTA\nACAACAGGAGAAGGAGAAGGAAGAGTTGGTATTATCCTGACTTTAGCCATGAATATCATG\nAGTACATTGCAGTGGGCTGTAAACTCCAGCATAGATGTGGATAGCTTGATGCGATCTGTG\nAGCCGAGTCTTTAAGTTCATTGACATGCCAACAGAAGGTAAACCTACCAAGTCAACCAAA\nCCATACAAGAATGGCCAACTCTCGAAAGTTATGATTATTGAGAATTCACACGTGAAGAAA\nGATGACATCTGGCCCTCAGGGGGCCAAATGACTGTCAAAGATCTCACAGCAAAATACACA\nGAAGGTGGAAATGCCATATTAGAGAACATTTCCTTCTCAATAAGTCCTGGCCAGAGGGTG\nGGCCTCTTGGGAAGAACTGGATCAGGGAAGAGTACTTTGTTATCAGCTTTTTTGAGACTA\nCTGAACACTGAAGGAGAAATCCAGATCGATGGTGTGTCTTGGGATTCAATAACTTTGCAA\nCAGTGGAGGAAAGCCTTTGGAGTGATACCACAGAAAGTATTTATTTTTTCTGGAACATTT\nAGAAAAAACTTGGATCCCTATGAACAGTGGAGTGATCAAGAAATATGGAAAGTTGCAGAT\nGAGGTTGGGCTCAGATCTGTGATAGAACAGTTTCCTGGGAAGCTTGACTTTGTCCTTGTG\nGATGGGGGCTGTGTCCTAAGCCATGGCCACAAGCAGTTGATGTGCTTGGCTAGATCTGTT\nCTCAGTAAGGCGAAGATCTTGCTGCTTGATGAACCCAGTGCTCATTTGGATCCAGTAACA\nTACCAAATAATTAGAAGAACTCTAAAACAAGCATTTGCTGATTGCACAGTAATTCTCTGT\nGAACACAGGATAGAAGCAATGCTGGAATGCCAACAATTTTTGGTCATAGAAGAGAACAAA\nGTGCGGCAGTACGATTCCATCCAGAAACTGCTGAACGAGAGGAGCCTCTTCCGGCAAGCC\nATCAGCCCCTCCGACAGGGTGAAGCTCTTTCCCCACCGGAACTCAAGCAAGTGCAAGTCT\nAAGCCCCAGATTGCTGCTCTGAAAGAGGAGACAGAAGAAGAGGTGCAAGATACAAGGCTT\nTAG'),('Cystine/glutamate transporter','None','Human','Cystine:glutamate antiporter activity','Sodium-independent, high-affinity exchange of anionic amino acids with high specificity for anionic form of cystine and glutamate.','SLC7A11','55422.44','DB00795','>lcl|BSEQ0016000|Cystine/glutamate transporter (SLC7A11)\nATGGTCAGAAAGCCTGTTGTGTCCACCATCTCCAAAGGAGGTTACCTGCAGGGAAATGTT\nAACGGGAGGCTGCCTTCCCTGGGCAACAAGGAGCCACCTGGGCAGGAGAAAGTGCAGCTG\nAAGAGGAAAGTCACTTTACTGAGGGGAGTCTCCATTATCATTGGCACCATCATTGGAGCA\nGGAATCTTCATCTCTCCTAAGGGCGTGCTCCAGAACACGGGCAGCGTGGGCATGTCTCTG\nACCATCTGGACGGTGTGTGGGGTCCTGTCACTATTTGGAGCTTTGTCTTATGCTGAATTG\nGGAACAACTATAAAGAAATCTGGAGGTCATTACACATATATTTTGGAAGTCTTTGGTCCA\nTTACCAGCTTTTGTACGAGTCTGGGTGGAACTCCTCATAATACGCCCTGCAGCTACTGCT\nGTGATATCCCTGGCATTTGGACGCTACATTCTGGAACCATTTTTTATTCAATGTGAAATC\nCCTGAACTTGCGATCAAGCTCATTACAGCTGTGGGCATAACTGTAGTGATGGTCCTAAAT\nAGCATGAGTGTCAGCTGGAGCGCCCGGATCCAGATTTTCTTAACCTTTTGCAAGCTCACA\nGCAATTCTGATAATTATAGTCCCTGGAGTTATGCAGCTAATTAAAGGTCAAACGCAGAAC\nTTTAAAGACGCCTTTTCAGGAAGAGATTCAAGTATTACGCGGTTGCCACTGGCTTTTTAT\nTATGGAATGTATGCATATGCTGGCTGGTTTTACCTCAACTTTGTTACTGAAGAAGTAGAA\nAACCCTGAAAAAACCATTCCCCTTGCAATATGTATATCCATGGCCATTGTCACCATTGGC\nTATGTGCTGACAAATGTGGCCTACTTTACGACCATTAATGCTGAGGAGCTGCTGCTTTCA\nAATGCAGTGGCAGTGACCTTTTCTGAGCGGCTACTGGGAAATTTCTCATTAGCAGTTCCG\nATCTTTGTTGCCCTCTCCTGCTTTGGCTCCATGAACGGTGGTGTGTTTGCTGTCTCCAGG\nTTATTCTATGTTGCGTCTCGAGAGGGTCACCTTCCAGAAATCCTCTCCATGATTCATGTC\nCGCAAGCACACTCCTCTACCAGCTGTTATTGTTTTGCACCCTTTGACAATGATAATGCTC\nTTCTCTGGAGACCTCGACAGTCTTTTGAATTTCCTCAGTTTTGCCAGGTGGCTTTTTATT\nGGGCTGGCAGTTGCTGGGCTGATTTATCTTCGATACAAATGCCCAGATATGCATCGTCCT\nTTCAAGGTGCCACTGTTCATCCCAGCTTTGTTTTCCTTCACATGCCTCTTCATGGTTGCC\nCTTTCCCTCTATTCGGACCCATTTAGTACAGGGATTGGCTTCGTCATCACTCTGACTGGA\nGTCCCTGCGTATTATCTCTTTATTATATGGGACAAGAAACCCAGGTGGTTTAGAATAATG\nTCAGAGAAAATAACCAGAACATTACAAATAATACTGGAAGTTGTACCAGAAGAAGATAAG\nTTATGA'),('Cytosolic phospholipase A2','None','Human','Phospholipase a2 activity','Selectively hydrolyzes arachidonyl phospholipids in the sn-2 position releasing arachidonic acid. Together with its lysophospholipid activity, it is implicated in the initiation of the inflammatory response.','PLA2G4A','85238.2','DB04552','>lcl|BSEQ0010457|Cytosolic phospholipase A2 (PLA2G4A)\nATGTCATTTATAGATCCTTACCAGCACATTATAGTGGAGCACCAGTATTCCCACAAGTTT\nACGGTAGTGGTGTTACGTGCCACCAAAGTGACAAAGGGGGCCTTTGGTGACATGCTTGAT\nACTCCAGATCCCTATGTGGAACTTTTTATCTCTACAACCCCTGACAGCAGGAAGAGAACA\nAGACATTTCAATAATGACATAAACCCTGTGTGGAATGAGACCTTTGAATTTATTTTGGAT\nCCTAATCAGGAAAATGTTTTGGAGATTACGTTAATGGATGCCAATTATGTCATGGATGAA\nACTCTAGGGACAGCAACATTTACTGTATCTTCTATGAAGGTGGGAGAAAAGAAAGAAGTT\nCCTTTTATTTTCAACCAAGTCACTGAAATGGTTCTAGAAATGTCTCTTGAAGTTTGCTCA\nTGCCCAGACCTACGATTTAGTATGGCTCTGTGTGATCAGGAGAAGACTTTCAGACAACAG\nAGAAAAGAACACATAAGGGAGAGCATGAAGAAACTCTTGGGTCCAAAGAATAGTGAAGGA\nTTGCATTCTGCACGTGATGTGCCTGTGGTAGCCATATTGGGTTCAGGTGGGGGTTTCCGA\nGCCATGGTGGGATTCTCTGGTGTGATGAAGGCATTATACGAATCAGGAATTCTGGATTGT\nGCTACCTACGTTGCTGGTCTTTCTGGCTCCACCTGGTATATGTCAACCTTGTATTCTCAC\nCCTGATTTTCCAGAGAAAGGGCCAGAGGAGATTAATGAAGAACTAATGAAAAATGTTAGC\nCACAATCCCCTTTTACTTCTCACACCACAGAAAGTTAAAAGATATGTTGAGTCTTTATGG\nAAGAAGAAAAGCTCTGGACAACCTGTCACCTTTACTGATATCTTTGGGATGTTAATAGGA\nGAAACACTAATTCATAATAGAATGAATACTACTCTGAGCAGTTTGAAGGAAAAAGTTAAT\nACTGCACAATGCCCTTTACCTCTTTTCACCTGTCTTCATGTCAAACCTGACGTTTCAGAG\nCTGATGTTTGCAGATTGGGTTGAATTTAGTCCATACGAAATTGGCATGGCTAAATATGGT\nACTTTTATGGCTCCCGACTTATTTGGAAGCAAATTTTTTATGGGAACAGTCGTTAAGAAG\nTATGAAGAAAACCCCTTGCATTTCTTAATGGGTGTCTGGGGCAGTGCCTTTTCCATATTG\nTTCAACAGAGTTTTGGGCGTTTCTGGTTCACAAAGCAGAGGCTCCACAATGGAGGAAGAA\nTTAGAAAATATTACCACAAAGCATATTGTGAGTAATGATAGCTCGGACAGTGATGATGAA\nTCACACGAACCCAAAGGCACTGAAAATGAAGATGCTGGAAGTGACTATCAAAGTGATAAT\nCAAGCAAGTTGGATTCATCGTATGATAATGGCCTTGGTGAGTGATTCAGCTTTATTCAAT\nACCAGAGAAGGACGTGCTGGGAAGGTACACAACTTCATGCTGGGCTTGAATCTCAATACA\nTCTTATCCACTGTCTCCTTTGAGTGACTTTGCCACACAGGACTCCTTTGATGATGATGAA\nCTGGATGCAGCTGTAGCAGATCCTGATGAATTTGAGCGAATATATGAGCCTCTGGATGTC\nAAAAGTAAAAAGATTCATGTAGTGGACAGTGGGCTCACATTTAACCTGCCGTATCCCTTG\nATACTGAGACCTCAGAGAGGGGTTGATCTCATAATCTCCTTTGACTTTTCTGCAAGGCCA\nAGTGACTCTAGTCCTCCGTTCAAGGAACTTCTACTTGCAGAAAAGTGGGCTAAAATGAAC\nAAGCTCCCCTTTCCAAAGATTGATCCTTATGTGTTTGATCGGGAAGGGCTGAAGGAGTGC\nTATGTCTTTAAACCCAAGAATCCTGATATGGAGAAAGATTGCCCAACCATCATCCACTTT\nGTTCTGGCCAACATCAACTTCAGAAAGTACAAGGCTCCAGGTGTTCCAAGGGAAACTGAG\nGAAGAGAAAGAAATCGCTGACTTTGATATTTTTGATGACCCAGAATCACCATTTTCAACC\nTTCAATTTTCAATATCCAAATCAAGCATTCAAAAGACTACATGATCTTATGCACTTCAAT\nACTCTGAACAACATTGATGTGATAAAAGAAGCCATGGTTGAAAGCATTGAATATAGAAGA\nCAGAATCCATCTCGTTGCTCTGTTTCCCTTAGTAATGTTGAGGCAAGAAGATTTTTCAAC\nAAGGAGTTTCTAAGTAAACCCAAAGCATAG'),('D(1) dopamine receptor','protein group','Human','None','None','None','None','DB00696','None'),('D(1A) dopamine receptor','None','Human','G-protein coupled amine receptor activity','Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.','DRD1','49292.765','DB00589','>lcl|BSEQ0021253|D(1A) dopamine receptor (DRD1)\nATGAGGACTCTGAACACCTCTGCCATGGACGGGACTGGGCTGGTGGTGGAGAGGGACTTC\nTCTGTTCGTATCCTCACTGCCTGTTTCCTGTCGCTGCTCATCCTGTCCACGCTCCTGGGG\nAACACGCTGGTCTGTGCTGCCGTTATCAGGTTCCGACACCTGCGGTCCAAGGTGACCAAC\nTTCTTTGTCATCTCCTTGGCTGTGTCAGATCTCTTGGTGGCCGTCCTGGTCATGCCCTGG\nAAGGCAGTGGCTGAGATTGCTGGCTTCTGGCCCTTTGGGTCCTTCTGTAACATCTGGGTG\nGCCTTTGACATCATGTGCTCCACTGCATCCATCCTCAACCTCTGTGTGATCAGCGTGGAC\nAGGTATTGGGCTATCTCCAGCCCTTTCCGGTATGAGAGAAAGATGACCCCCAAGGCAGCC\nTTCATCCTGATCAGTGTGGCATGGACCTTGTCTGTACTCATCTCCTTCATCCCAGTGCAG\nCTCAGCTGGCACAAGGCAAAACCCACAAGCCCCTCTGATGGAAATGCCACTTCCCTGGCT\nGAGACCATAGACAACTGTGACTCCAGCCTCAGCAGGACATATGCCATCTCATCCTCTGTA\nATAAGCTTTTACATCCCTGTGGCCATCATGATTGTCACCTACACCAGGATCTACAGGATT\nGCTCAGAAACAAATACGGCGCATTGCGGCCTTGGAGAGGGCAGCAGTCCACGCCAAGAAT\nTGCCAGACCACCACAGGTAATGGAAAGCCTGTCGAATGTTCTCAACCGGAAAGTTCTTTT\nAAGATGTCCTTCAAAAGAGAAACTAAAGTCCTGAAGACTCTGTCGGTGATCATGGGTGTG\nTTTGTGTGCTGTTGGCTACCTTTCTTCATCTTGAACTGCATTTTGCCCTTCTGTGGGTCT\nGGGGAGACGCAGCCCTTCTGCATTGATTCCAACACCTTTGACGTGTTTGTGTGGTTTGGG\nTGGGCTAATTCATCCTTGAACCCCATCATTTATGCCTTTAATGCTGATTTTCGGAAGGCA\nTTTTCAACCCTCTTAGGATGCTACAGACTTTGCCCTGCGACGAATAATGCCATAGAGACG\nGTGAGTATCAATAACAATGGGGCCGCGATGTTTTCCAGCCATCATGAGCCACGAGGCTCC\nATCTCCAAGGAGTGCAATCTGGTTTACCTGATCCCACATGCTGTGGGCTCCTCTGAGGAC\nCTGAAAAAGGAGGAGGCAGCTGGCATCGCCAGACCCTTGGAGAAGCTGTCCCCAGCCCTA\nTCAGTCATATTGGACTATGACACTGACGTCTCTCTGGAGAAGATCCAACCCATCACACAA\nAACGGTCAGCACCCAACCTGA'),('D(1B) dopamine receptor','None','Human','G-protein coupled amine receptor activity','Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.','DRD5','52950.5','DB00589','>lcl|BSEQ0009966|D(1B) dopamine receptor (DRD5)\nATGCTGCCGCCAGGCAGCAACGGCACCGCGTACCCGGGGCAGTTCGCTCTATACCAGCAG\nCTGGCGCAGGGGAACGCCGTGGGGGGCTCGGCGGGGGCACCGCCACTGGGGCCCTCACAG\nGTGGTCACCGCCTGCCTGCTGACCCTACTCATCATCTGGACCCTGCTGGGCAACGTGCTG\nGTGTGCGCAGCCATCGTGCGGAGCCGCCACCTGCGCGCCAACATGACCAACGTCTTCATC\nGTGTCTCTGGCCGTGTCAGACCTTTTCGTGGCGCTGCTGGTCATGCCCTGGAAGGCAGTC\nGCCGAGGTGGCCGGTTACTGGCCCTTTGGAGCGTTCTGCGACGTCTGGGTGGCCTTCGAC\nATCATGTGCTCCACTGCCTCCATCCTGAACCTGTGCGTCATCAGCGTGGACCGCTACTGG\nGCCATCTCCAGGCCCTTCCGCTACAAGCGCAAGATGACTCAGCGCATGGCCTTGGTCATG\nGTCGGCCTGGCATGGACCTTGTCCATCCTCATCTCCTTCATTCCGGTCCAGCTCAACTGG\nCACAGGGACCAGGCGGCCTCTTGGGGCGGGCTGGACCTGCCAAACAACCTGGCCAACTGG\nACGCCCTGGGAGGAGGACTTTTGGGAGCCCGACGTGAATGCAGAGAACTGTGACTCCAGC\nCTGAATCGAACCTACGCCATCTCTTCCTCGCTCATCAGCTTCTACATCCCCGTTGCCATC\nATGATCGTGACCTACACGCGCATCTACCGCATCGCCCAGGTGCAGATCCGCAGGATTTCC\nTCCCTGGAGAGGGCCGCAGAGCACGCGCAGAGCTGCCGGAGCAGCGCAGCCTGCGCGCCC\nGACACCAGCCTGCGCGCTTCCATCAAGAAGGAGACCAAGGTTCTCAAGACCCTGTCGGTG\nATCATGGGGGTCTTCGTGTGTTGCTGGCTGCCCTTCTTCATCCTTAACTGCATGGTCCCT\nTTCTGCAGTGGACACCCCGAAGGCCCTCCGGCCGGCTTCCCCTGCGTCAGTGAGACCACC\nTTCGACGTCTTCGTCTGGTTCGGCTGGGCTAACTCCTCACTCAACCCCGTCATCTATGCC\nTTCAACGCCGACTTTCAGAAGGTGTTTGCCCAGCTGCTGGGGTGCAGCCACTTCTGCTCC\nCGCACGCCGGTGGAGACGGTGAACATCAGCAATGAGCTCATCTCCTACAACCAAGACATC\nGTCTTCCACAAGGAAATCGCAGCTGCCTACATCCACATGATGCCCAACGCCGTTACCCCC\nGGCAACCGGGAGGTGGACAACGACGAGGAGGAGGGTCCTTTCGATCGCATGTTCCAGATC\nTATCAGACGTCCCCAGATGGTGACCCTGTTGCTGAGTCTGTCTGGGAGCTGGACTGCGAG\nGGGGAGATTTCTTTAGACAAAATAACACCTTTCACCCCGAATGGATTCCATTAA'),('D(2) dopamine receptor','None','Human','Potassium channel regulator activity','Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.','DRD2','50618.91','DB01221','>lcl|BSEQ0021274|D(2) dopamine receptor (DRD2)\nATGGATCCACTGAATCTGTCCTGGTATGATGATGATCTGGAGAGGCAGAACTGGAGCCGG\nCCCTTCAACGGGTCAGACGGGAAGGCGGACAGACCCCACTACAACTACTATGCCACACTG\nCTCACCCTGCTCATCGCTGTCATCGTCTTCGGCAACGTGCTGGTGTGCATGGCTGTGTCC\nCGCGAGAAGGCGCTGCAGACCACCACCAACTACCTGATCGTCAGCCTCGCAGTGGCCGAC\nCTCCTCGTCGCCACACTGGTCATGCCCTGGGTTGTCTACCTGGAGGTGGTAGGTGAGTGG\nAAATTCAGCAGGATTCACTGTGACATCTTCGTCACTCTGGACGTCATGATGTGCACGGCG\nAGCATCCTGAACTTGTGTGCCATCAGCATCGACAGGTACACAGCTGTGGCCATGCCCATG\nCTGTACAATACGCGCTACAGCTCCAAGCGCCGGGTCACCGTCATGATCTCCATCGTCTGG\nGTCCTGTCCTTCACCATCTCCTGCCCACTCCTCTTCGGACTCAATAACGCAGACCAGAAC\nGAGTGCATCATTGCCAACCCGGCCTTCGTGGTCTACTCCTCCATCGTCTCCTTCTACGTG\nCCCTTCATTGTCACCCTGCTGGTCTACATCAAGATCTACATTGTCCTCCGCAGACGCCGC\nAAGCGAGTCAACACCAAACGCAGCAGCCGAGCTTTCAGGGCCCACCTGAGGGCTCCACTA\nAAGGGCAACTGTACTCACCCCGAGGACATGAAACTCTGCACCGTTATCATGAAGTCTAAT\nGGGAGTTTCCCAGTGAACAGGCGGAGAGTGGAGGCTGCCCGGCGAGCCCAGGAGCTGGAG\nATGGAGATGCTCTCCAGCACCAGCCCACCCGAGAGGACCCGGTACAGCCCCATCCCACCC\nAGCCACCACCAGCTGACTCTCCCCGACCCGTCCCACCATGGTCTCCACAGCACTCCCGAC\nAGCCCCGCCAAACCAGAGAAGAATGGGCATGCCAAAGACCACCCCAAGATTGCCAAGATC\nTTTGAGATCCAGACCATGCCCAATGGCAAAACCCGGACCTCCCTCAAGACCATGAGCCGT\nAGGAAGCTCTCCCAGCAGAAGGAGAAGAAAGCCACTCAGATGCTCGCCATTGTTCTCGGC\nGTGTTCATCATCTGCTGGCTGCCCTTCTTCATCACACACATCCTGAACATACACTGTGAC\nTGCAACATCCCGCCTGTCCTGTACAGCGCCTTCACGTGGCTGGGCTATGTCAACAGCGCC\nGTGAACCCCATCATCTACACCACCTTCAACATTGAGTTCCGCAAGGCCTTCCTGAAGATC\nCTCCACTGCTGA'),('D(3) dopamine receptor','None','Human','G-protein coupled amine receptor activity','Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.','DRD3','44224.335','DB00589','>lcl|BSEQ0021269|D(3) dopamine receptor (DRD3)\nATGGCATCTCTGAGCCAGCTGAGTGGCCACCTGAACTACACCTGTGGGGCAGAGAACTCC\nACAGGTGCCAGCCAGGCCCGCCCACATGCCTACTATGCCCTCTCCTACTGCGCGCTCATC\nCTGGCCATCGTCTTCGGCAATGGCCTGGTGTGCATGGCTGTGCTGAAGGAGCGGGCCCTG\nCAGACTACCACCAACTACTTAGTAGTGAGCCTGGCTGTGGCAGACTTGCTGGTGGCCACC\nTTGGTGATGCCCTGGGTGGTATACCTGGAGGTGACAGGTGGAGTCTGGAATTTCAGCCGC\nATTTGCTGTGATGTTTTTGTCACCCTGGATGTCATGATGTGTACAGCCAGCATCCTTAAT\nCTCTGTGCCATCAGCATAGACAGGTACACTGCAGTGGTCATGCCCGTTCACTACCAGCAT\nGGCACGGGACAGAGCTCCTGTCGGCGCGTGGCCCTCATGATCACGGCCGTCTGGGTACTG\nGCCTTTGCTGTGTCCTGCCCTCTTCTGTTTGGCTTTAATACCACAGGGGACCCCACTGTC\nTGCTCCATCTCCAACCCTGATTTTGTCATCTACTCTTCAGTGGTGTCCTTCTACCTGCCC\nTTTGGAGTGACTGTCCTTGTCTATGCCAGAATCTATGTGGTGCTGAAACAAAGGAGACGG\nAAAAGGATCCTCACTCGACAGAACAGTCAGTGCAACAGTGTCAGGCCTGGCTTCCCCCAA\nCAAACCCTCTCTCCTGACCCGGCACATCTGGAGCTGAAGCGTTACTACAGCATCTGCCAG\nGACACTGCCTTGGGTGGACCAGGCTTCCAAGAAAGAGGAGGAGAGTTGAAAAGAGAGGAG\nAAGACTCGGAATTCCCTGAGTCCCACCATAGCGCCCAAGCTCAGCTTAGAAGTTCGAAAA\nCTCAGCAATGGCAGATTATCGACATCTTTGAAGCTGGGGCCCCTGCAACCTCGGGGAGTG\nCCACTTCGGGAGAAGAAGGCAACCCAAATGGTGGCCATTGTGCTTGGGGCCTTCATTGTC\nTGCTGGCTGCCCTTCTTCTTGACCCATGTTCTCAATACCCACTGCCAGACATGCCACGTG\nTCCCCAGAGCTTTACAGTGCCACGACATGGCTGGGCTACGTGAATAGCGCCCTCAACCCT\nGTGATCTATACCACCTTCAATATCGAGTTCCGGAAAGCCTTCCTCAAGATCCTGTCTTGC\nTGA'),('D(4) dopamine receptor','None','Human','Sh3 domain binding','Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity).','DRD4','48359.86','DB00589','>lcl|BSEQ0010271|D(4) dopamine receptor (DRD4)\nATGGGGAACCGCAGCACCGCGGACGCGGACGGGCTGCTGGCTGGGCGCGGGCCGGCCGCG\nGGGGCATCTGCGGGGGCATCTGCGGGGCTGGCTGGGCAGGGCGCGGCGGCGCTGGTGGGG\nGGCGTGCTGCTCATCGGCGCGGTGCTCGCGGGGAACTCGCTCGTGTGCGTGAGCGTGGCC\nACCGAGCGCGCCCTGCAGACGCCCACCAACTCCTTCATCGTGAGCCTGGCGGCCGCCGAC\nCTCCTCCTCGCTCTCCTGGTGCTGCCGCTCTTCGTCTACTCCGAGGTCCAGGGTGGCGCG\nTGGCTGCTGAGCCCCCGCCTGTGCGACGCCCTCATGGCCATGGACGTCATGCTGTGCACC\nGCCTCCATCTTCAACCTGTGCGCCATCAGCGTGGACAGGTTCGTGGCCGTGGCCGTGCCG\nCTGCGCTACAACCGGCAGGGTGGGAGCCGCCGGCAGCTGCTGCTCATCGGCGCCACGTGG\nCTGCTGTCCGCGGCGGTGGCGGCGCCCGTACTGTGCGGCCTCAACGACGTGCGCGGCCGC\nGACCCCGCCGTGTGCCGCCTGGAGGACCGCGACTACGTGGTCTACTCGTCCGTGTGCTCC\nTTCTTCCTACCCTGCCCGCTCATGCTGCTGCTCTACTGGGCCACGTTCCGCGGCCTGCAG\nCGCTGGGAGGTGGCACGTCGCGCCAAGCTGCACGGCCGCGCGCCCCGCCGACCCAGCGGC\nCCTGGCCCGCCTTCCCCCACGCCACCCGCGCCCCGCCTCCCCCAGGACCCCTGCGGCCCC\nGACTGTGCGCCCCCCGCGCCCGGCCTTCCCCGGGGTCCCTGCGGCCCCGACTGTGCGCCC\nGCCGCGCCCAGCCTCCCCCAGGACCCCTGCGGCCCCGACTGTGCGCCCCCCGCGCCCGGC\nCTCCCCCCGGACCCCTGCGGCTCCAACTGTGCTCCCCCCGACGCCGTCAGAGCCGCCGCG\nCTCCCACCCCAGACTCCACCGCAGACCCGCAGGAGGCGGCGTGCCAAGATCACCGGCCGG\nGAGCGCAAGGCCATGAGGGTCCTGCCGGTGGTGGTCGGGGCCTTCCTGCTGTGCTGGACG\nCCCTTCTTCGTGGTGCACATCACGCAGGCGCTGTGTCCTGCCTGCTCCGTGCCCCCGCGG\nCTGGTCAGCGCCGTCACCTGGCTGGGCTACGTCAACAGCGCCCTCAACCCCGTCATCTAC\nACTGTCTTCAACGCCGAGTTCCGCAACGTCTTCCGCAAGGCCCTGCGTGCCTGCTGCTGA'),('Delta-type opioid receptor','None','Human','Opioid receptor activity','G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain and in opiate-mediated analgesia. Plays a role in developing analgesic tolerance to morphine.','OPRD1','40368.235','DB01452','>lcl|BSEQ0010291|Delta-type opioid receptor (OPRD1)\nATGGAACCGGCCCCCTCCGCCGGCGCCGAGCTGCAGCCCCCGCTCTTCGCCAACGCCTCG\nGACGCCTACCCTAGCGCCTGCCCCAGCGCTGGCGCCAATGCGTCGGGGCCGCCAGGCGCG\nCGGAGCGCCTCGTCCCTCGCCCTGGCAATCGCCATCACCGCGCTCTACTCGGCCGTGTGC\nGCCGTGGGGCTGCTGGGCAACGTGCTTGTCATGTTCGGCATCGTCCGGTACACTAAGATG\nAAGACGGCCACCAACATCTACATCTTCAACCTGGCCTTAGCCGATGCGCTGGCCACCAGC\nACGCTGCCTTTCCAGAGTGCCAAGTACCTGATGGAGACGTGGCCCTTCGGCGAGCTGCTC\nTGCAAGGCTGTGCTCTCCATCGACTACTACAATATGTTCACCAGCATCTTCACGCTCACC\nATGATGAGTGTTGACCGCTACATCGCTGTCTGCCACCCTGTCAAGGCCCTGGACTTCCGC\nACGCCTGCCAAGGCCAAGCTGATCAACATCTGTATCTGGGTCCTGGCCTCAGGCGTTGGC\nGTGCCCATCATGGTCATGGCTGTGACCCGTCCCCGGGACGGGGCAGTGGTGTGCATGCTC\nCAGTTCCCCAGCCCCAGCTGGTACTGGGACACGGTGACCAAGATCTGCGTGTTCCTCTTC\nGCCTTCGTGGTGCCCATCCTCATCATCACCGTGTGCTATGGCCTCATGCTGCTGCGCCTG\nCGCAGTGTGCGCCTGCTGTCGGGCTCCAAGGAGAAGGACCGCAGCCTGCGGCGCATCACG\nCGCATGGTGCTGGTGGTTGTGGGCGCCTTCGTGGTGTGTTGGGCGCCCATCCACATCTTC\nGTCATCGTCTGGACGCTGGTGGACATCGACCGGCGCGACCCGCTGGTGGTGGCTGCGCTG\nCACCTGTGCATCGCGCTGGGCTACGCCAATAGCAGCCTCAACCCCGTGCTCTACGCTTTC\nCTCGACGAGAACTTCAAGCGCTGCTTCCGCCAGCTCTGCCGCAAGCCCTGCGGCCGCCCA\nGACCCCAGCAGCTTCAGCCGCGCCCGCGAAGCCACGGCCCGCGAGCGTGTCACCGCCTGC\nACCCCGTCCGATGGTCCCGGCGGTGGCGCTGCCGCCTGA'),('Dihydroorotate dehydrogenase (quinone), mitochondrial','None','Human','Ubiquinone binding','Catalyzes the conversion of dihydroorotate to orotate with quinone as electron acceptor.','DHODH','42866.93','DB08880','>lcl|BSEQ0010125|Dihydroorotate dehydrogenase (quinone), mitochondrial (DHODH)\nATGGCGTGGAGACACCTGAAAAAGCGGGCCCAGGATGCTGTGATCATCCTGGGGGGAGGA\nGGACTTCTCTTCGCCTCCTACCTGATGGCCACGGGAGATGAGCGTTTCTATGCTGAACAC\nCTGATGCCGACTCTGCAGGGGCTGCTGGACCCGGAGTCAGCCCACAGACTGGCTGTTCGC\nTTCACCTCCCTGGGGCTCCTTCCACGGGCCAGATTTCAAGACTCTGACATGCTGGAAGTG\nAGAGTTCTGGGCCATAAATTCCGAAATCCAGTAGGAATTGCTGCAGGATTTGACAAGCAT\nGGGGAAGCCGTGGACGGACTTTATAAGATGGGCTTTGGTTTTGTTGAGATAGGAAGTGTG\nACTCCAAAACCTCAGGAAGGAAACCCTAGACCCAGAGTCTTCCGCCTCCCTGAGGACCAA\nGCTGTCATTAACAGGTATGGATTTAACAGTCACGGGCTTTCAGTGGTGGAACACAGGTTA\nCGGGCCAGACAGCAGAAGCAGGCCAAGCTCACAGAAGATGGACTGCCTCTGGGGGTCAAC\nTTGGGGAAGAACAAGACCTCAGTGGACGCCGCGGAGGACTACGCAGAAGGGGTGCGCGTA\nCTGGGCCCCCTGGCCGACTACCTGGTGGTGAATGTGTCCAGCCCCAACACTGCCGGGCTG\nCGGAGCCTTCAGGGAAAGGCCGAGCTGCGCCGCCTGCTGACCAAGGTGCTGCAGGAGAGG\nGATGGCTTGCGGAGAGTGCACAGGCCGGCAGTCCTGGTGAAGATCGCTCCTGACCTCACC\nAGCCAGGATAAGGAGGACATTGCCAGTGTGGTCAAAGAGTTGGGCATCGATGGGCTGATT\nGTTACGAACACCACCGTGAGTCGCCCTGCGGGCCTCCAGGGTGCCCTGCGCTCTGAAACA\nGGAGGGCTGAGTGGGAAGCCCCTCCGGGATTTATCAACTCAAACCATTCGGGAGATGTAT\nGCACTCACCCAAGGCCGAGTTCCCATAATTGGGGTTGGTGGTGTGAGCAGCGGGCAGGAC\nGCGCTGGAGAAGATCCGGGCAGGGGCCTCCCTGGTGCAGCTGTACACGGCCCTCACCTTC\nTGGGGGCCACCCGTTGTGGGCAAAGTCAAGCGGGAACTGGAGGCCCTTCTGAAAGAGCAG\nGGCTTTGGCGGAGTCACAGATGCCATTGGAGCAGATCATCGGAGGTGA'),('DNA topoisomerase 2-alpha','None','Human','Ubiquitin binding','Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segregation of daughter chromosomes. May play a role in regulating the period length of ARNTL/BMAL1 transcriptional oscillation (By similarity).','TOP2A','174383.88','DB01204','>lcl|BSEQ0019005|DNA topoisomerase 2-alpha (TOP2A)\nATGGAAGTGTCACCATTGCAGCCTGTAAATGAAAATATGCAAGTCAACAAAATAAAGAAA\nAATGAAGATGCTAAGAAAAGACTGTCTGTTGAAAGAATCTATCAAAAGAAAACACAATTG\nGAACATATTTTGCTCCGCCCAGACACCTACATTGGTTCTGTGGAATTAGTGACCCAGCAA\nATGTGGGTTTACGATGAAGATGTTGGCATTAACTATAGGGAAGTCACTTTTGTTCCTGGT\nTTGTACAAAATCTTTGATGAGATTCTAGTTAATGCTGCGGACAACAAACAAAGGGACCCA\nAAAATGTCTTGTATTAGAGTCACAATTGATCCGGAAAACAATTTAATTAGTATATGGAAT\nAATGGAAAAGGTATTCCTGTTGTTGAACACAAAGTTGAAAAGATGTATGTCCCAGCTCTC\nATATTTGGACAGCTCCTAACTTCTAGTAACTATGATGATGATGAAAAGAAAGTGACAGGT\nGGTCGAAATGGCTATGGAGCCAAATTGTGTAACATATTCAGTACCAAATTTACTGTGGAA\nACAGCCAGTAGAGAATACAAGAAAATGTTCAAACAGACATGGATGGATAATATGGGAAGA\nGCTGGTGAGATGGAACTCAAGCCCTTCAATGGAGAAGATTATACATGTATCACCTTTCAG\nCCTGATTTGTCTAAGTTTAAAATGCAAAGCCTGGACAAAGATATTGTTGCACTAATGGTC\nAGAAGAGCATATGATATTGCTGGATCCACCAAAGATGTCAAAGTCTTTCTTAATGGAAAT\nAAACTGCCAGTAAAAGGATTTCGTAGTTATGTGGACATGTATTTGAAGGACAAGTTGGAT\nGAAACTGGTAACTCCTTGAAAGTAATACATGAACAAGTAAACCACAGGTGGGAAGTGTGT\nTTAACTATGAGTGAAAAAGGCTTTCAGCAAATTAGCTTTGTCAACAGCATTGCTACATCC\nAAGGGTGGCAGACATGTTGATTATGTAGCTGATCAGATTGTGACTAAACTTGTTGATGTT\nGTGAAGAAGAAGAACAAGGGTGGTGTTGCAGTAAAAGCACATCAGGTGAAAAATCACATG\nTGGATTTTTGTAAATGCCTTAATTGAAAACCCAACCTTTGACTCTCAGACAAAAGAAAAC\nATGACTTTACAACCCAAGAGCTTTGGATCAACATGCCAATTGAGTGAAAAATTTATCAAA\nGCTGCCATTGGCTGTGGTATTGTAGAAAGCATACTAAACTGGGTGAAGTTTAAGGCCCAA\nGTCCAGTTAAACAAGAAGTGTTCAGCTGTAAAACATAATAGAATCAAGGGAATTCCCAAA\nCTCGATGATGCCAATGATGCAGGGGGCCGAAACTCCACTGAGTGTACGCTTATCCTGACT\nGAGGGAGATTCAGCCAAAACTTTGGCTGTTTCAGGCCTTGGTGTGGTTGGGAGAGACAAA\nTATGGGGTTTTCCCTCTTAGAGGAAAAATACTCAATGTTCGAGAAGCTTCTCATAAGCAG\nATCATGGAAAATGCTGAGATTAACAATATCATCAAGATTGTGGGTCTTCAGTACAAGAAA\nAACTATGAAGATGAAGATTCATTGAAGACGCTTCGTTATGGGAAGATAATGATTATGACA\nGATCAGGACCAAGATGGTTCCCACATCAAAGGCTTGCTGATTAATTTTATCCATCACAAC\nTGGCCCTCTCTTCTGCGACATCGTTTTCTGGAGGAATTTATCACTCCCATTGTAAAGGTA\nTCTAAAAACAAGCAAGAAATGGCATTTTACAGCCTTCCTGAATTTGAAGAGTGGAAGAGT\nTCTACTCCAAATCATAAAAAATGGAAAGTCAAATATTACAAAGGTTTGGGCACCAGCACA\nTCAAAGGAAGCTAAAGAATACTTTGCAGATATGAAAAGACATCGTATCCAGTTCAAATAT\nTCTGGTCCTGAAGATGATGCTGCTATCAGCCTGGCCTTTAGCAAAAAACAGATAGATGAT\nCGAAAGGAATGGTTAACTAATTTCATGGAGGATAGAAGACAACGAAAGTTACTTGGGCTT\nCCTGAGGATTACTTGTATGGACAAACTACCACATATCTGACATATAATGACTTCATCAAC\nAAGGAACTTATCTTGTTCTCAAATTCTGATAACGAGAGATCTATCCCTTCTATGGTGGAT\nGGTTTGAAACCAGGTCAGAGAAAGGTTTTGTTTACTTGCTTCAAACGGAATGACAAGCGA\nGAAGTAAAGGTTGCCCAATTAGCTGGATCAGTGGCTGAAATGTCTTCTTATCATCATGGT\nGAGATGTCACTAATGATGACCATTATCAATTTGGCTCAGAATTTTGTGGGTAGCAATAAT\nCTAAACCTCTTGCAGCCCATTGGTCAGTTTGGTACCAGGCTACATGGTGGCAAGGATTCT\nGCTAGTCCACGATACATCTTTACAATGCTCAGCTCTTTGGCTCGATTGTTATTTCCACCA\nAAAGATGATCACACGTTGAAGTTTTTATATGATGACAACCAGCGTGTTGAGCCTGAATGG\nTACATTCCTATTATTCCCATGGTGCTGATAAATGGTGCTGAAGGAATCGGTACTGGGTGG\nTCCTGCAAAATCCCCAACTTTGATGTGCGTGAAATTGTAAATAACATCAGGCGTTTGATG\nGATGGAGAAGAACCTTTGCCAATGCTTCCAAGTTACAAGAACTTCAAGGGTACTATTGAA\nGAACTGGCTCCAAATCAATATGTGATTAGTGGTGAAGTAGCTATTCTTAATTCTACAACC\nATTGAAATCTCAGAGCTTCCCGTCAGAACATGGACCCAGACATACAAAGAACAAGTTCTA\nGAACCCATGTTGAATGGCACCGAGAAGACACCTCCTCTCATAACAGACTATAGGGAATAC\nCATACAGATACCACTGTGAAATTTGTTGTGAAGATGACTGAAGAAAAACTGGCAGAGGCA\nGAGAGAGTTGGACTACACAAAGTCTTCAAACTCCAAACTAGTCTCACATGCAACTCTATG\nGTGCTTTTTGACCACGTAGGCTGTTTAAAGAAATATGACACGGTGTTGGATATTCTAAGA\nGACTTTTTTGAACTCAGACTTAAATATTATGGATTAAGAAAAGAATGGCTCCTAGGAATG\nCTTGGTGCTGAATCTGCTAAACTGAATAATCAGGCTCGCTTTATCTTAGAGAAAATAGAT\nGGCAAAATAATCATTGAAAATAAGCCTAAGAAAGAATTAATTAAAGTTCTGATTCAGAGG\nGGATATGATTCGGATCCTGTGAAGGCCTGGAAAGAAGCCCAGCAAAAGGTTCCAGATGAA\nGAAGAAAATGAAGAGAGTGACAACGAAAAGGAAACTGAAAAGAGTGACTCCGTAACAGAT\nTCTGGACCAACCTTCAACTATCTTCTTGATATGCCCCTTTGGTATTTAACCAAGGAAAAG\nAAAGATGAACTCTGCAGGCTAAGAAATGAAAAAGAACAAGAGCTGGACACATTAAAAAGA\nAAGAGTCCATCAGATTTGTGGAAAGAAGACTTGGCTACATTTATTGAAGAATTGGAGGCT\nGTTGAAGCCAAGGAAAAACAAGATGAACAAGTCGGACTTCCTGGGAAAGGGGGGAAGGCC\nAAGGGGAAAAAAACACAAATGGCTGAAGTTTTGCCTTCTCCGCGTGGTCAAAGAGTCATT\nCCACGAATAACCATAGAAATGAAAGCAGAGGCAGAAAAGAAAAATAAAAAGAAAATTAAG\nAATGAAAATACTGAAGGAAGCCCTCAAGAAGATGGTGTGGAACTAGAAGGCCTAAAACAA\nAGATTAGAAAAGAAACAGAAAAGAGAACCAGGTACAAAGACAAAGAAACAAACTACATTG\nGCATTTAAGCCAATCAAAAAAGGAAAGAAGAGAAATCCCTGGTCTGATTCAGAATCAGAT\nAGGAGCAGTGACGAAAGTAATTTTGATGTCCCTCCACGAGAAACAGAGCCACGGAGAGCA\nGCAACAAAAACAAAATTCACAATGGATTTGGATTCAGATGAAGATTTCTCAGATTTTGAT\nGAAAAAACTGATGATGAAGATTTTGTCCCATCAGATGCTAGTCCACCTAAGACCAAAACT\nTCCCCAAAACTTAGTAACAAAGAACTGAAACCACAGAAAAGTGTCGTGTCAGACCTTGAA\nGCTGATGATGTTAAGGGCAGTGTACCACTGTCTTCAAGCCCTCCTGCTACACATTTCCCA\nGATGAAACTGAAATTACAAACCCAGTTCCTAAAAAGAATGTGACAGTGAAGAAGACAGCA\nGCAAAAAGTCAGTCTTCCACCTCCACTACCGGTGCCAAAAAAAGGGCTGCCCCAAAAGGA\nACTAAAAGGGATCCAGCTTTGAATTCTGGTGTCTCTCAAAAGCCTGATCCTGCCAAAACC\nAAGAATCGCCGCAAAAGGAAGCCATCCACTTCTGATGATTCTGACTCTAATTTTGAGAAA\nATTGTTTCGAAAGCAGTCACAAGCAAGAAATCCAAGGGGGAGAGTGATGACTTCCATATG\nGACTTTGACTCAGCTGTGGCTCCTCGGGCAAAATCTGTACGGGCAAAGAAACCTATAAAG\nTACCTGGAAGAGTCAGATGAAGATGATCTGTTTTAA'),('E3 ubiquitin-protein ligase TRIM13','None','Human','Zinc ion binding','E3 ubiquitin ligase involved in the retrotranslocation and turnover of membrane and secretory proteins from the ER through a set of processes named ER-associated degradation (ERAD). This process acts on misfolded proteins as well as in the regulated degradation of correctly folded proteins. Enhances ionizing radiation-induced p53/TP53 stability and apoptosis via ubiquitinating MDM2 and AKT1 and decreasing AKT1 kinase activity through MDM2 and AKT1 proteasomal degradation. Regulates ER stress-induced autophagy, and may act as a tumor suppressor.','TRIM13','46987.08','DB01497','>lcl|BSEQ0010745|E3 ubiquitin-protein ligase TRIM13 (TRIM13)\nATGGATGTGATGGAGCTGCTTGAAGAAGATCTCACATGCCCTATTTGTTGTAGTCTGTTT\nGATGATCCACGGGTTTTGCCTTGCTCCCACAACTTCTGCAAAAAATGCTTAGAAGGTATC\nTTAGAAGGGAGTGTGCGGAATTCCTTGTGGAGACCAGCTCCATTCAAGTGTCCTACATGC\nCGTAAGGAAACTTCAGCTACTGGAATTAATAGCCTGCAGGTTAATTACTCCCTGAAGGGT\nATTGTGGAAAAGTATAACAAGATCAAGATCTCTCCCAAAATGCCAGTATGCAAAGGACAC\nTTGGGGCAGCCTCTCAACATTTTCTGCCTGACTGATATGCAGCTGATTTGTGGGATCTGT\nGCTACTCGTGGGGAGCACACCAAACATGTCTTCTGTTCTATTGAAGATGCCTATGCTCAG\nGAAAGGGATGCCTTTGAGTCCCTCTTCCAGAGCTTTGAGACCTGGCGTCGGGGAGATGCT\nCTTTCTCGCTTGGATACCTTGGAAACTAGTAAGAGGAAATCCCTACAGTTACTGACTAAA\nGATTCAGATAAAGTGAAGGAATTTTTTGAGAAGTTACAACACACACTGGATCAAAAGAAG\nAATGAAATTCTGTCTGACTTTGAGACCATGAAACTTGCTGTTATGCAAGCATATGACCCA\nGAGATCAACAAACTCAACACCATCTTGCAGGAGCAACGGATGGCCTTTAACATTGCTGAG\nGCTTTCAAAGATGTGTCAGAACCCATTGTATTTCTGCAACAGATGCAGGAGTTTAGAGAG\nAAAATCAAAGTAATCAAGGAAACTCCTTTACCTCCCTCTAATTTGCCTGCAAGCCCTTTA\nATGAAGAACTTTGATACCAGTCAGTGGGAAGACATAAAACTAGTCGATGTGGATAAACTT\nTCTTTGCCTCAAGACACTGGCACATTCATTAGCAAGATTCCCTGGAGCTTTTATAAGTTA\nTTTTTGCTAATCCTTCTGCTTGGCCTTGTCATTGTCTTTGGTCCTACCATGTTCCTAGAA\nTGGTCATTATTTGATGACCTGGCAACTTGGAAAGGCTGTCTTTCAAACTTCAGTTCCTAT\nCTGACTAAAACAGCCGATTTCATAGAACAATCAGTTTTTTACTGGGAACAGGTGACAGAT\nGGGTTTTTCATTTTCAATGAAAGATTCAAGAATTTTACTTTGGTGGTACTGAACAATGTG\nGCAGAATTTGTGTGCAAATATAAACTATTATAA'),('Elastin','None','Human','Extracellular matrix structural constituent','Major structural protein of tissues such as aorta and nuchal ligament, which must expand rapidly and recover completely. Molecular determinant of the late arterial morphogenesis, stabilizing arterial structure by regulating proliferation and organization of vascular smooth muscle (By similarity).','ELN','68468.375','DB00533','>lcl|BSEQ0010731|Elastin (ELN)\nATGGCGGGTCTGACGGCGGCGGCCCCGCGGCCCGGAGTCCTCCTGCTCCTGCTGTCCATC\nCTCCACCCCTCTCGGCCTGGAGGGGTCCCTGGGGCCATTCCTGGTGGAGTTCCTGGAGGA\nGTCTTTTATCCAGGGGCTGGTCTCGGAGCCCTTGGAGGAGGAGCGCTGGGGCCTGGAGGC\nAAACCTCTTAAGCCAGTTCCCGGAGGGCTTGCGGGTGCTGGCCTTGGGGCAGGGCTCGGC\nGCCTTCCCCGCAGTTACCTTTCCGGGGGCTCTGGTGCCTGGTGGAGTGGCTGACGCTGCT\nGCAGCCTATAAAGCTGCTAAGGCTGGCGCTGGGCTTGGTGGTGTCCCAGGAGTTGGTGGC\nTTAGGAGTGTCTGCAGGTGCGGTGGTTCCTCAGCCTGGAGCCGGAGTGAAGCCTGGGAAA\nGTGCCGGGTGTGGGGCTGCCAGGTGTATACCCAGGTGGCGTGCTCCCAGGAGCTCGGTTC\nCCCGGTGTGGGGGTGCTCCCTGGAGTTCCCACTGGAGCAGGAGTTAAGCCCAAGGCTCCA\nGGTGTAGGTGGAGCTTTTGCTGGAATCCCAGGAGTTGGACCCTTTGGGGGACCGCAACCT\nGGAGTCCCACTGGGGTATCCCATCAAGGCCCCCAAGCTGCCTGGTGGCTATGGACTGCCC\nTACACCACAGGGAAACTGCCCTATGGCTATGGGCCCGGAGGAGTGGCTGGTGCAGCGGGC\nAAGGCTGGTTACCCAACAGGGACAGGGGTTGGCCCCCAGGCAGCAGCAGCAGCGGCAGCT\nAAAGCAGCAGCAAAGTTCGGTGCTGGAGCAGCCGGAGTCCTCCCTGGTGTTGGAGGGGCT\nGGTGTTCCTGGCGTGCCTGGGGCAATTCCTGGAATTGGAGGCATCGCAGGCGTTGGGACT\nCCAGCTGCAGCTGCAGCTGCAGCAGCAGCCGCTAAGGCAGCCAAGTATGGAGCTGCTGCA\nGGCTTAGTGCCTGGTGGGCCAGGCTTTGGCCCGGGAGTAGTTGGTGTCCCAGGAGCTGGC\nGTTCCAGGTGTTGGTGTCCCAGGAGCTGGGATTCCAGTTGTCCCAGGTGCTGGGATCCCA\nGGTGCTGCGGTTCCAGGGGTTGTGTCACCAGAAGCAGCTGCTAAGGCAGCTGCAAAGGCA\nGCCAAATACGGGGCCAGGCCCGGAGTCGGAGTTGGAGGCATTCCTACTTACGGGGTTGGA\nGCTGGGGGCTTTCCCGGCTTTGGTGTCGGAGTCGGAGGTATCCCTGGAGTCGCAGGTGTC\nCCTGGTGTCGGAGGTGTTCCCGGAGTCGGAGGTGTCCCGGGAGTTGGCATTTCCCCCGAA\nGCTCAGGCAGCAGCTGCCGCCAAGGCTGCCAAGTACGGAGTGGGGACCCCAGCAGCTGCA\nGCTGCTAAAGCAGCCGCCAAAGCCGCCCAGTTTGGGTTAGTTCCTGGTGTCGGCGTGGCT\nCCTGGAGTTGGCGTGGCTCCTGGTGTCGGTGTGGCTCCTGGAGTTGGCTTGGCTCCTGGA\nGTTGGCGTGGCTCCTGGAGTTGGTGTGGCTCCTGGCGTTGGCGTGGCTCCCGGCATTGGC\nCCTGGTGGAGTTGCAGCTGCAGCAAAATCCGCTGCCAAGGTGGCTGCCAAAGCCCAGCTC\nCGAGCTGCAGCTGGGCTTGGTGCTGGCATCCCTGGACTTGGAGTTGGTGTCGGCGTCCCT\nGGACTTGGAGTTGGTGCTGGTGTTCCTGGACTTGGAGTTGGTGCTGGTGTTCCTGGCTTC\nGGGGCAGTACCTGGAGCCCTGGCTGCCGCTAAAGCAGCCAAATATGGAGCAGCAGTGCCT\nGGGGTCCTTGGAGGGCTCGGGGCTCTCGGTGGAGTAGGCATCCCAGGCGGTGTGGTGGGA\nGCCGGACCCGCCGCCGCCGCTGCCGCAGCCAAAGCTGCTGCCAAAGCCGCCCAGTTTGGC\nCTAGTGGGAGCCGCTGGGCTCGGAGGACTCGGAGTCGGAGGGCTTGGAGTTCCAGGTGTT\nGGGGGCCTTGGAGGTATACCTCCAGCTGCAGCCGCTAAAGCAGCTAAATACGGTGCTGCT\nGGCCTTGGAGGTGTCCTAGGGGGTGCCGGGCAGTTCCCACTTGGAGGAGTGGCAGCAAGA\nCCTGGCTTCGGATTGTCTCCCATTTTCCCAGGTGGGGCCTGCCTGGGGAAAGCTTGTGGC\nCGGAAGAGAAAATGA'),('Endo-1,4-beta-xylanase Y','None','Clostridium thermocellum','Endo-1,4-beta-xylanase activity','None','xynY','119671.86','DB07767','>lcl|BSEQ0005873|3234 bp\nATGAAAAACAAGAGAGTTTTGGCAAAAATAACGGCTCTTGTGGTATTGCTGGGAGTGTTT\nTTTGTATTACCGTCAAACATAAGTCAGCTATATGCTGATTATGAAGTGGTTCATGACACT\nTTTGAAGTTAACTTTGACGGATGGTGTAACTTGGGAGTCGACACATATTTAACGGCAGTT\nGAAAATGAAGGAAACAACGGTACAAGAGGTATGATGGTAATAAATCGCTCCAGTGCGAGT\nGACGGTGCGTATTCGGAAAAAGGTTTCTATCTCGACGGTGGTGTAGAATACAAGTACAGT\nGTTTTTGTAAAACACAACGGGACCGGCACCGAAACTTTCAAACTTTCTGTGTCCTATTTG\nGATTCGGAAACAGAAGAAGAAAATAAGGAAGTAATTGCAACAAAGGATGTTGTGGCCGGA\nGAATGGACTGAGATTTCGGCAAAATACAAAGCACCCAAAACTGCAGTGAATATTACTTTG\nTCAATTACAACCGACAGCACTGTAGATTTCATTTTTGACGATGTAACCATAACCCGTAAA\nGGAATGGCTGAGGCAAACACAGTATATGCAGCAAACGCTGTGCTGAAAGATATGTATGCA\nAACTATTTCAGAGTTGGTTCGGTACTTAACTCCGGAACGGTAAACAATTCATCAATAAAG\nGCCTTGATTTTAAGAGAGTTTAACAGTATTACCTGTGAAAATGAAATGAAGCCTGATGCC\nACACTGGTTCAATCAGGATCAACCAATACAAATATCAGGGTTTCTCTTAATCGTGCAGCA\nAGTATTTTAAACTTCTGTGCACAAAATAATATAGCCGTCAGAGGTCATACACTGGTTTGG\nCACAGCCAGACACCTCAATGGTTTTTCAAAGACAATTTCCAGGACAACGGAAACTGGGTT\nTCCCAATCAGTTATGGACCAGCGTTTGGAAAGCTACATAAAAAATATGTTTGCTGAAATC\nCAAAGACAGTATCCGTCTTTGAATCTTTATGCCTATGACGTTGTAAATGAGGCAGTAAGT\nGATGATGCAAACAGGACCAGATATTATGGCGGGGCGAGGGAACCTGGATACGGAAATGGT\nAGATCTCCATGGGTTCAGATCTACGGAGACAACAAATTTATTGAGAAAGCATTTACATAT\nGCAAGAAAATATGCTCCGGCAAATTGTAAGCTTTACTACAACGATTACAACGAATATTGG\nGATCATAAGAGAGACTGTATTGCCTCAATTTGTGCAAACTTGTACAACAAGGGCTTGCTT\nGACGGTGTGGGAATGCAGTCCCATATTAATGCGGATATGAATGGATTCTCAGGTATACAA\nAATTATAAAGCAGCTTTGCAGAAATATATAAATATCGGTTGTGATGTCCAAATTACCGAG\nCTTGATATTAGTACAGAAAACGGCAAATTTAGCTTACAGCAGCAGGCTGATAAATATAAA\nGCTGTTTTCCAGGCAGCTGTTGATATAAACAGAACCTCCAGCAAAGGAAAGGTTACGGCT\nGTCTGTGTATGGGGACCTAATGACGCCAATACTTGGCTCGGTTCACAAAATGCACCTCTT\nTTGTTTAACGCAAACAATCAACCGAAACCGGCATACAATGCGGTTGCATCCATTATTCCT\nCAGTCCGAATGGGGCGACGGTAACAATCCGGCCGGCGGCGGAGGAGGAGGCAAACCGGAA\nGAGCCGGATGCAAACGGATATTATTATCATGACACTTTTGAAGGAAGCGTAGGACAGTGG\nACAGCCAGAGGACCTGCGGAAGTTCTGCTTAGCGGAAGAACGGCTTACAAAGGTTCAGAA\nTCACTCTTGGTAAGGAACCGTACGGCAGCATGGAACGGAGCACAACGGGCGCTGAATCCC\nAGAACGTTTGTTCCCGGAAACACATATTGTTTCAGCGTAGTGGCATCGTTTATTGAAGGT\nGCGTCTTCCACAACATTCTGCATGAAGCTGCAATACGTAGACGGAAGCGGCACTCAACGG\nTATGATACCATAGATATGAAAACTGTGGGTCCAAATCAGTGGGTTCACCTGTACAATCCG\nCAATACAGAATTCCTTCCGATGCAACAGATATGTATGTTTATGTGGAAACAGCGGATGAC\nACCATTAACTTCTACATAGATGAGGCAATCGGAGCGGTTGCCGGAACTGTAATCGAAGGA\nCCTGCTCCACAGCCTACACAGCCTCCGGTACTGCTTGGCGATGTAAACGGTGATGGAACC\nATTAACTCAACTGACTTGACAATGTTAAAGAGAAGCGTGTTGAGGGCAATCACCCTTACC\nGACGATGCAAAGGCTAGAGCAGACGTTGACAAGAATGGATCGATAAACAGCACTGATGTT\nTTACTTCTTTCACGCTACCTTTTAAGAGTAATCGACAAATTTCCTGTAGCAGAAAATCCT\nTCTTCTTCTTTTAAATATGAGTCGGCCGTGCAATATCGGCCGGCTCCTGATTCTTATTTA\nAACCCTTGTCCGCAGGCGGGAAGAATTGTCAAGGAAACATATACAGGAATAAACGGAACT\nAAGAGTCTTAATGTATATCTTCCATACGGTTATGATCCGAACAAAAAATATAACATTTTC\nTACCTTATGCATGGCGGCGGTGAAAATGAGAATACGATTTTCAGCAACGATGTTAAATTG\nCAAAATATCCTTGACCACGCGATTATGAACGGTGAACTTGAGCCTTTGATTGTAGTAACA\nCCCACTTTCAACGGCGGAAACTGCACGGCCCAAAACTTTTATCAGGAATTCAGGCAAAAT\nGTCATTCCTTTTGTGGAAAGCAAGTACTCTACTTATGCAGAATCAACAACCCCACAGGGA\nATAGCCGCTTCAAGAATGCACAGAGGTTTCGGCGGATTCTCAATGGGAGGATTGACAACA\nTGGTATGTAATGGTTAACTGCCTTGATTACGTTGCATATTTTATGCCTTTAAGCGGTGAC\nTACTGGTATGGAAACAGTCCGCAGGATAAGGCTAATTCAATTGCTGAAGCAATTAACAGA\nTCCGGACTTTCAAAGAGGGAGTATTTCGTATTTGCGGCCACCGGTTCCGACCATATTGCA\nTATGCTAATATGAATCCTCAAATTGAAGCTATGAAGGCTTTGCCGCATTTTGATTATACT\nTCGGATTTTTCCAAAGGTAATTTTTACTTTCTTGTAGCTCCGGGCGCCACTCACTGGTGG\nGGATACGTAAGACATTATATTTATGATGCACTTCCATATTTCTTCCATGAATGA'),('Endo-1,4-beta-xylanase Z','None','Clostridium thermocellum (strain ATCC 27405 / DSM 1237 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372)','Xylan endo-1,3-beta-xylosidase activity','None','xynZ','92262.3','DB07767','>lcl|BSEQ0012841|Endo-1,4-beta-xylanase Z (xynZ)\nATGTCAAGAAAACTTTTCAGTGTATTACTTGTTGGCTTGATGCTTATGACATCGTTGCTT\nGTCACAATAAGCAGTACATCAGCGGCATCCTTGCCAACCATGCCGCCTTCGGGATATGAC\nCAGGTAAGGAACGGCGTTCCGAGAGGGCAGGTCGTAAATATTTCTTATTTCTCCACGGCC\nACCAACAGTACCAGGCCGGCAAGAGTTTATTTGCCGCCGGGATATTCAAAGGACAAAAAA\nTACAGTGTTTTGTATCTCTTACACGGCATAGGCGGTAGTGAAAACGACTGGTTCGAAGGG\nGGAGGCAGAGCCAATGTTATTGCCGACAATCTGATTGCCGAGGGAAAAATCAAGCCCCTG\nATAATTGTAACACCGAATACTAACGCCGCCGGTCCGGGAATAGCGGACGGTTATGAAAAT\nTTCACAAAAGATTTGCTCAACAGTCTTATTCCCTATATCGAATCTAACTATTCAGTCTAC\nACCGACCGCGAACATCGGGCGATTGCAGGACTTTCAATGGGTGGAGGACAATCGTTTAAT\nATTGGATTGACCAATCTCGATAAATTTGCCTATATTGGCCCGATTTCAGCGGCTCCAAAC\nACTTATCCAAATGAGAGGCTTTTTCCTGACGGAGGAAAAGCTGCAAGGGAGAAATTGAAA\nCTGCTCTTTATTGCCTGCGGAACCAATGACAGTCTGATAGGTTTTGGACAGAGAGTACAT\nGAATATTGCGTTGCCAACAACATTAACCATGTCTATTGGCTTATTCAGGGCGGAGGACAC\nGATTTTAATGTGTGGAAGCCCGGATTGTGGAATTTCCTTCAAATGGCAGATGAAGCCGGA\nTTGACGAGGGATGGAAACACTCCGGTTCCGACACCCAGTCCAAAGCCGGCTAACACACGT\nATTGAAGCGGAAGATTATGACGGTATTAATTCTTCAAGTATTGAGATAATAGGTGTTCCA\nCCTGAAGGAGGCAGAGGAATAGGTTATATTACCAGTGGTGATTATCTGGTATACAAGAGT\nATAGACTTTGGAAACGGAGCAACGTCGTTTAAGGCCAAGGTTGCAAATGCAAATACTTCC\nAATATTGAACTTAGATTAAACGGTCCGAATGGTACTCTCATAGGCACACTCTCGGTAAAA\nTCCACAGGAGATTGGAATACATATGAGGAGCAAACTTGCAGCATTAGCAAAGTCACCGGA\nATAAATGATTTGTACTTGGTATTCAAAGGCCCTGTAAACATAGACTGGTTCACTTTTGGC\nGTTGAAAGCAGTTCCACAGGTCTGGGGGATTTAAATGGTGACGGAAATATTAACTCGTCG\nGACCTTCAGGCGTTAAAGAGGCATTTGCTCGGTATATCACCGCTTACGGGAGAGGCTCTT\nTTAAGAGCGGATGTAAATAGGAGCGGCAAAGTGGATTCTACTGACTATTCAGTGCTGAAA\nAGATATATACTCCGCATTATTACAGAGTTCCCCGGACAAGGTGATGTACAGACACCCAAT\nCCGTCTGTTACTCCGACACAAACTCCTATCCCCACGATTTCGGGAAATGCTCTTAGGGAT\nTATGCGGAGGCAAGGGGAATAAAAATCGGAACATGTGTCAACTATCCGTTTTACAACAAT\nTCAGATCCAACCTACAACAGCATTTTGCAAAGAGAATTTTCAATGGTTGTATGTGAAAAT\nGAAATGAAGTTTGATGCTTTGCAGCCGAGACAAAACGTTTTTGATTTTTCGAAAGGAGAC\nCAGTTGCTTGCTTTTGCAGAAAGAAACGGTATGCAGATGAGGGGACATACGTTGATTTGG\nCACAATCAAAACCCGTCATGGCTTACAAACGGTAACTGGAACCGGGATTCGCTGCTTGCG\nGTAATGAAAAATCACATTACCACTGTTATGACCCATTACAAAGGTAAAATTGTTGAGTGG\nGATGTGGCAAACGAATGTATGGATGATTCCGGCAACGGCTTAAGAAGCAGCATATGGAGA\nAATGTAATCGGTCAGGACTACCTTGACTATGCTTTCAGGTATGCAAGAGAAGCAGATCCC\nGATGCACTTCTTTTCTACAATGATTATAATATTGAAGACTTGGGTCCAAAGTCCAATGCG\nGTATTTAACATGATTAAAAGTATGAAGGAAAGAGGTGTGCCGATTGACGGAGTAGGATTC\nCAATGCCACTTTATCAATGGAATGAGCCCCGAGTACCTTGCCAGCATTGATCAAAATATT\nAAGAGATATGCGGAAATAGGCGTTATAGTATCCTTTACCGAAATAGATATACGCATACCT\nCAGTCGGAAAACCCGGCAACTGCATTCCAGGTACAGGCAAACAACTATAAGGAACTTATG\nAAAATTTGTCTGGCAAACCCCAATTGCAATACCTTTGTAATGTGGGGATTCACAGATAAA\nTACACATGGATTCCGGGAACTTTCCCAGGATATGGCAATCCATTGATTTATGACAGCAAT\nTACAATCCGAAACCGGCATACAATGCAATAAAGGAAGCTCTTATGGGCTATTGA'),('Endothelin-1 receptor','None','Human','Phosphatidylinositol phospholipase c activity','Receptor for endothelin-1. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order of binding affinities for ET-A is: ET1 > ET2 >> ET3.','EDNRA','48721.76','DB00945','>lcl|BSEQ0010366|Endothelin-1 receptor (EDNRA)\nATGGAAACCCTTTGCCTCAGGGCATCCTTTTGGCTGGCACTGGTTGGATGTGTAATCAGT\nGATAATCCTGAGAGATACAGCACAAATCTAAGCAATCATGTGGATGATTTCACCACTTTT\nCGTGGCACAGAGCTCAGCTTCCTGGTTACCACTCATCAACCCACTAATTTGGTCCTACCC\nAGCAATGGCTCAATGCACAACTATTGCCCACAGCAGACTAAAATTACTTCAGCTTTCAAA\nTACATTAACACTGTGATATCTTGTACTATTTTCATCGTGGGAATGGTGGGGAATGCAACT\nCTGCTCAGGATCATTTACCAGAACAAATGTATGAGGAATGGCCCCAACGCGCTGATAGCC\nAGTCTTGCCCTTGGAGACCTTATCTATGTGGTCATTGATCTCCCTATCAATGTATTTAAG\nTTCTACCAAGATGTAAAGGACTGGTGGCTCTTCGGGTTCTATTTCTGTATGCCCTTGGTG\nTGCACTGCGATCTTCTACACCCTCATGACTTGTGAGATGTTGAACAGAAGGAATGGCAGC\nTTGAGAATTGCCCTCAGTGAACATCTTAAGCAGCGTCGAGAAGTGGCAAAAACAGTTTTC\nTGCTTGGTTGTAATTTTTGCTCTTTGCTGGTTCCCTCTTCATTTAAGCCGTATATTGAAG\nAAAACTGTGTATAACGAGATGGACAAGAACCGATGTGAATTACTTAGTTTCTTACTGCTC\nATGGATTACATCGGTATTAACTTGGCAACCATGAATTCATGTATAAACCCCATAGCTCTG\nTATTTTGTGAGCAAGAAATTTAAAAATTGTTTCCAGTCATGCCTCTGCTGCTGCTGTTAC\nCAGTCCAAAAGTCTGATGACCTCGGTCCCCATGAACGGAACAAGCATCCAGTGGAAGAAC\nCACGATCAAAACAACCACAACACAGACCGGAGCAGCCATAAGGACAGCATGAACTGA'),('Est1e','None','Butyrivibrio proteoclasticus','None','None','None','28020.97','DB07767','None'),('Estrogen receptor','None','Human','Zinc ion binding','Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2, Sp1 and Sp3, to mediate ERE-independent signaling. Ligand binding induces a conformational change allowing subsequent or combinatorial association with multiprotein coactivator complexes through LXXLL motifs of their respective components. Mutual transrepression occurs between the estrogen receptor (ER) and NF-kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displace RELA/p65 and associated coregulators from the promoter. Recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50 on ERE sequences. Can also act synergistically with NF-kappa-B to activate transcription involving respective recruitment adjacent response elements; the function involves CREBBP. Can activate the transcriptional activity of TFF1. Also mediates membrane-initiated estrogen signaling involving various kinase cascades. Isoform 3 is involved in activation of NOS3 and endothelial nitric oxide production. Isoforms lacking one or several functional domains are thought to modulate transcriptional activity by competitive ligand or DNA binding and/or heterodimerization with the full length receptor. Essential for MTA1-mediated transcriptional regulation of BRCA1 and BCAS3. Isoform 3 can bind to ERE and inhibit isoform 1.','ESR1','66215.45','DB02709','>lcl|BSEQ0021831|Estrogen receptor (ESR1)\nATGACCATGACCCTCCACACCAAAGCATCTGGGATGGCCCTACTGCATCAGATCCAAGGG\nAACGAGCTGGAGCCCCTGAACCGTCCGCAGCTCAAGATCCCCCTGGAGCGGCCCCTGGGC\nGAGGTGTACCTGGACAGCAGCAAGCCCGCCGTGTACAACTACCCCGAGGGCGCCGCCTAC\nGAGTTCAACGCCGCGGCCGCCGCCAACGCGCAGGTCTACGGTCAGACCGGCCTCCCCTAC\nGGCCCCGGGTCTGAGGCTGCGGCGTTCGGCTCCAACGGCCTGGGGGGTTTCCCCCCACTC\nAACAGCGTGTCTCCGAGCCCGCTGATGCTACTGCACCCGCCGCCGCAGCTGTCGCCTTTC\nCTGCAGCCCCACGGCCAGCAGGTGCCCTACTACCTGGAGAACGAGCCCAGCGGCTACACG\nGTGCGCGAGGCCGGCCCGCCGGCATTCTACAGGCCAAATTCAGATAATCGACGCCAGGGT\nGGCAGAGAAAGATTGGCCAGTACCAATGACAAGGGAAGTATGGCTATGGAATCTGCCAAG\nGAGACTCGCTACTGTGCAGTGTGCAATGACTATGCTTCAGGCTACCATTATGGAGTCTGG\nTCCTGTGAGGGCTGCAAGGCCTTCTTCAAGAGAAGTATTCAAGGACATAACGACTATATG\nTGTCCAGCCACCAACCAGTGCACCATTGATAAAAACAGGAGGAAGAGCTGCCAGGCCTGC\nCGGCTCCGCAAATGCTACGAAGTGGGAATGATGAAAGGTGGGATACGAAAAGACCGAAGA\nGGAGGGAGAATGTTGAAACACAAGCGCCAGAGAGATGATGGGGAGGGCAGGGGTGAAGTG\nGGGTCTGCTGGAGACATGAGAGCTGCCAACCTTTGGCCAAGCCCGCTCATGATCAAACGC\nTCTAAGAAGAACAGCCTGGCCTTGTCCCTGACGGCCGACCAGATGGTCAGTGCCTTGTTG\nGATGCTGAGCCCCCCATACTCTATTCCGAGTATGATCCTACCAGACCCTTCAGTGAAGCT\nTCGATGATGGGCTTACTGACCAACCTGGCAGACAGGGAGCTGGTTCACATGATCAACTGG\nGCGAAGAGGGTGCCAGGCTTTGTGGATTTGACCCTCCATGATCAGGTCCACCTTCTAGAA\nTGTGCCTGGCTAGAGATCCTGATGATTGGTCTCGTCTGGCGCTCCATGGAGCACCCAGGG\nAAGCTACTGTTTGCTCCTAACTTGCTCTTGGACAGGAACCAGGGAAAATGTGTAGAGGGC\nATGGTGGAGATCTTCGACATGCTGCTGGCTACATCATCTCGGTTCCGCATGATGAATCTG\nCAGGGAGAGGAGTTTGTGTGCCTCAAATCTATTATTTTGCTTAATTCTGGAGTGTACACA\nTTTCTGTCCAGCACCCTGAAGTCTCTGGAAGAGAAGGACCATATCCACCGAGTCCTGGAC\nAAGATCACAGACACTTTGATCCACCTGATGGCCAAGGCAGGCCTGACCCTGCAGCAGCAG\nCACCAGCGGCTGGCCCAGCTCCTCCTCATCCTCTCCCACATCAGGCACATGAGTAACAAA\nGGCATGGAGCATCTGTACAGCATGAAGTGCAAGAACGTGGTGCCCCTCTATGACCTGCTG\nCTGGAGATGCTGGACGCCCACCGCCTACATGCGCCCACTAGCCGTGGAGGGGCATCCGTG\nGAGGAGACGGACCAAAGCCACTTGGCCACTGCGGGCTCTACTTCATCGCATTCCTTGCAA\nAAGTATTACATCACGGGGGAGGCAGAGGGTTTCCCTGCCACGGTCTGA'),('Far upstream element-binding protein 2','None','Human','Binds to the dendritic targeting element and may play a role in mRNA trafficking (By similarity). Part of a ternary complex that binds to the downstream control sequence (DCS) of the pre-mRNA. Mediates exon inclusion in transcripts that are subject to tissue-specific alternative splicing. May interact with single-stranded DNA from the far-upstream element (FUSE). May activate gene expression. Also involved in degradation of inherently unstable mRNAs that contain AU-rich elements (AREs) in their 3\'-UTR, possibly by recruiting degradation machinery to ARE-containing mRNAs.','Dna binding','KHSRP','73115.16','DB02709','>lcl|BSEQ0049900|Far upstream element-binding protein 2 (KHSRP)\nATGTCGGACTACAGCACGGGAGGACCCCCGCCCGGGCCGCCGCCGCCCGCCGGCGGGGGC\nGGGGGAGCCGGAGGCGCCGGGGGAGGCCCTCCGCCGGGCCCGCCAGGCGCGGGGGACCGG\nGGCGGCGGCGGTCCCGGCGGCGGCGGCCCGGGCGGGGGGTCGGCCGGGGGCCCCTCTCAG\nCCACCCGGCGGAGGCGGCCCGGGAATCCGCAAGGACGCTTTCGCCGACGCCGTGCAGCGG\nGCCCGCCAGATTGCAGCCAAAATTGGAGGCGATGCTGCCACGACAGTGAATAACAGCACT\nCCTGATTTTGGTTTTGGGGGCCAAAAGAGACAGTTGGAAGATGGAGATCAACCGGAGAGC\nAAGAAGCTGGCTTCCCAGGGAGACTCAATCAGTTCTCAACTTGGACCCATCCATCCTCCC\nCCAAGGACTTCAATGACAGAAGAGTACAGGGTCCCAGACGGCATGGTGGGCCTGATCATT\nGGCAGAGGAGGTGAACAAATTAACAAAATCCAACAGGATTCAGGCTGCAAAGTACAGATT\nTCTCCAGACAGCGGTGGCCTACCCGAGCGCAGTGTGTCCTTGACAGGAGCCCCAGAATCT\nGTCCAGAAAGCCAAGATGATGCTGGATGACATTGTGTCTCGGGGTCGTGGGGGCCCCCCA\nGGACAGTTCCACGACAACGCCAACGGGGGCCAGAACGGCACCGTGCAGGAGATCATGATC\nCCCGCGGGCAAGGCCGGCCTGGTCATTGGCAAGGGCGGGGAGACCATTAAGCAGCTGCAG\nGAACGCGCTGGAGTGAAGATGATCTTAATTCAGGACGGATCTCAGAATACGAATGTGGAC\nAAACCTCTCCGCATCATTGGGGATCCTTACAAAGTGCAGCAAGCCTGTGAGATGGTGATG\nGACATCCTCCGGGAACGTGACCAAGGCGGCTTTGGGGACCGGAATGAGTACGGATCTCGG\nATTGGCGGAGGCATCGATGTGCCAGTGCCCAGGCATTCTGTTGGCGTGGTCATTGGCCGG\nAGTGGAGAGATGATCAAGAAGATCCAGAATGATGCTGGCGTGCGGATACAGTTCAAGCAA\nGATGACGGGACAGGGCCCGAGAAGATTGCTCATATAATGGGGCCCCCAGACAGGTGCGAG\nCACGCAGCCCGGATCATCAACGACCTCCTCCAGAGCCTCAGGAGTGGTCCCCCAGGTCCT\nCCAGGGGGTCCAGGCATGCCCCCGGGGGGCCGAGGCCGAGGAAGAGGCCAAGGCAATTGG\nGGTCCCCCTGGCGGGGAGATGACCTTCTCCATCCCCACTCACAAGTGTGGGCTGGTCATC\nGGCCGAGGTGGCGAGAATGTGAAAGCCATAAACCAGCAGACGGGAGCCTTCGTAGAGATC\nTCCCGGCAGCTGCCACCCAACGGGGACCCCAACTTCAAGTTGTTCATCATCCGGGGTTCA\nCCCCAGCAGATTGACCACGCCAAGCAGCTTATCGAGGAAAAGATCGAGGGTCCTCTCTGC\nCCAGTTGGACCAGGCCCAGGTGGCCCAGGCCCTGCTGGCCCAATGGGGCCCTTCAATCCT\nGGGCCCTTCAACCAGGGGCCACCCGGGGCTCCCCCACATGCCGGGGGGCCCCCTCCTCAC\nCAGTACCCACCCCAGGGCTGGGGCAATACCTACCCCCAGTGGCAGCCGCCTGCTCCTCAT\nGACCCAAGCAAAGCAGCTGCAGCGGCCGCGGACCCCAACGCCGCGTGGGCCGCCTACTAC\nTCACACTACTACCAGCAGCCCCCGGGCCCCGTCCCCGGCCCCGCACCGGCCCCTGCGGCC\nCCACCGGCTCAGGGTGAGCCCCCTCAGCCCCCACCCACCGGCCAGTCGGACTACACTAAG\nGCCTGGGAAGAGTATTACAAAAAGATCGGCCAGCAGCCCCAGCAGCCCGGAGCACCCCCA\nCAGCAGGACTACACGAAGGCTTGGGAGGAGTACTACAAGAAGCAAGCGCAAGTGGCCACC\nGGAGGGGGTCCAGGAGCTCCCCCAGGCTCCCAGCCAGACTACAGTGCCGCCTGGGCGGAA\nTATTACAGACAGCAGGCCGCTTACTACGGACAGACCCCAGGTCCTGGCGGCCCCCAGCCG\nCCGCCCACGCAGCAGGGACAGCAGCAGGCTCAATGA'),('Fatty acid-binding protein, intestinal','None','Human','Transporter activity','FABP are thought to play a role in the intracellular transport of long-chain fatty acids and their acyl-CoA esters. FABP2 is probably involved in triglyceride-rich lipoprotein synthesis. Binds saturated long-chain fatty acids with a high affinity, but binds with a lower affinity to unsaturated long-chain fatty acids. FABP2 may also help maintain energy homeostasis by functioning as a lipid sensor.','FABP2','15207.165','DB01050','>lcl|BSEQ0012495|Fatty acid-binding protein, intestinal (FABP2)\nATGGCGTTTGACAGCACTTGGAAGGTAGACCGGAGTGAAAACTATGACAAGTTCATGGAA\nAAAATGGGTGTTAATATAGTGAAAAGGAAGCTTGCAGCTCATGACAATTTGAAGCTGACA\nATTACACAAGAAGGAAATAAATTCACAGTCAAAGAATCAAGCACTTTTCGAAACATTGAA\nGTTGTTTTTGAACTTGGTGTCACCTTTAATTACAATCTAGCAGACGGAACTGAACTCAGG\nGGGACCTGGAGCCTTGAGGGAAATAAACTTATTGGAAAATTCAAACGGACAGACAATGGA\nAACGAACTGAATACTGTCCGAGAAATTATAGGTGATGAACTAGTCCAGACTTATGTATAT\nGAAGGAGTAGAAGCCAAAAGGATCTTTAAAAAGGATTGA'),('Fatty-acid amide hydrolase 1','None','Human','Fatty acid amide hydrolase activity','Degrades bioactive fatty acid amides like oleamide, the endogenous cannabinoid, anandamide and myristic amide to their corresponding acids, thereby serving to terminate the signaling functions of these molecules. Hydrolyzes polyunsaturated substrate anandamide preferentially as compared to monounsaturated substrates.','FAAH','63065.28','DB00316','>lcl|BSEQ0011586|Fatty-acid amide hydrolase 1 (FAAH)\nATGGTGCAGTACGAGCTGTGGGCCGCGCTGCCTGGCGCCTCCGGGGTCGCCCTGGCCTGC\nTGCTTCGTGGCGGCGGCCGTGGCCCTGCGCTGGTCCGGGCGCCGGACGGCGCGGGGCGCG\nGTGGTCCGGGCGCGACAGAGGCAGCGAGCGGGCCTGGAGAACATGGACAGGGCGGCGCAG\nCGCTTCCGGCTCCAGAACCCAGACCTGGACTCAGAGGCGCTGCTAGCCCTGCCCCTGCCT\nCAGCTGGTGCAGAAGTTACACAGTAGAGAGCTGGCCCCTGAGGCCGTGCTCTTCACCTAT\nGTGGGAAAGGCCTGGGAAGTGAACAAAGGGACCAACTGTGTGACCTCCTATCTGGCTGAC\nTGTGAGACTCAGCTGTCTCAGGCCCCAAGGCAGGGCCTGCTCTATGGCGTCCCTGTGAGC\nCTCAAGGAGTGCTTCACCTACAAGGGCCAGGACTCCACGCTGGGCTTGAGCCTGAATGAA\nGGGGTGCCGGCGGAGTGCGACAGCGTAGTGGTGCATGTGCTGAAGCTGCAGGGTGCCGTG\nCCCTTCGTGCACACCAATGTTCCACAGTCCATGTTCAGCTATGACTGCAGTAACCCCCTC\nTTTGGCCAGACCGTGAACCCATGGAAGTCCTCCAAAAGCCCAGGGGGCTCCTCAGGGGGT\nGAAGGGGCCCTCATCGGGTCTGGAGGCTCCCCCCTGGGCTTAGGCACTGATATCGGAGGC\nAGCATCCGCTTCCCCTCCTCCTTCTGCGGCATCTGCGGCCTCAAGCCCACAGGGAACCGC\nCTCAGCAAGAGTGGCCTGAAGGGCTGTGTCTATGGACAGGAGGCAGTGCGTCTCTCCGTG\nGGCCCCATGGCCCGGGACGTGGAGAGCCTGGCACTGTGCCTGCGAGCCCTGCTGTGCGAG\nGACATGTTCCGCTTGGACCCCACTGTGCCTCCCTTGCCCTTCAGAGAAGAGGTCTACACC\nAGCTCTCAGCCCCTGCGTGTGGGGTACTATGAGACTGACAACTATACCATGCCCTCCCCG\nGCCATGAGGCGGGCCGTGCTGGAGACCAAACAGAGCCTTGAGGCTGCGGGGCACACGCTG\nGTTCCCTTCTTGCCAAGCAACATACCCCATGCTCTGGAGACCCTGTCAACAGGTGGGCTC\nTTCAGTGATGGTGGCCACACCTTCCTACAGAACTTCAAAGGTGATTTCGTGGACCCCTGC\nCTGGGGGACCTGGTCTCAATTCTGAAGCTTCCCCAATGGCTTAAAGGACTGCTGGCCTTC\nCTGGTGAAGCCTCTGCTGCCAAGGCTGTCAGCTTTCCTCAGCAACATGAAGTCTCGTTCG\nGCTGGAAAACTCTGGGAACTGCAGCACGAGATCGAGGTGTACCGCAAAACCGTGATTGCC\nCAGTGGAGGGCGCTGGACCTGGATGTGGTGCTGACCCCCATGCTGGCCCCTGCTCTGGAC\nTTGAATGCCCCAGGCAGGGCCACAGGGGCCGTCAGCTACACTATGCTGTACAACTGCCTG\nGACTTCCCTGCAGGGGTGGTGCCTGTCACCACGGTGACTGCTGAGGACGAGGCCCAGATG\nGAACATTACAGGGGCTACTTTGGGGATATCTGGGACAAGATGCTGCAGAAGGGCATGAAG\nAAGAGTGTGGGGCTGCCGGTGGCCGTGCAGTGTGTGGCTCTGCCCTGGCAAGAAGAGTTG\nTGTCTGCGGTTCATGCGGGAGGTGGAGCGACTGATGACCCCTGAAAAGCAGTCATCCTGA'),('Furin','None','Human','Serine-type endopeptidase inhibitor activity','Furin is likely to represent the ubiquitous endoprotease activity within constitutive secretory pathways and capable of cleavage at the RX(K/R)R consensus motif.','FURIN','86677.375','DB04951','>lcl|BSEQ0016777|Furin (FURIN)\nATGGAGCTGAGGCCCTGGTTGCTATGGGTGGTAGCAGCAACAGGAACCTTGGTCCTGCTA\nGCAGCTGATGCTCAGGGCCAGAAGGTCTTCACCAACACGTGGGCTGTGCGCATCCCTGGA\nGGCCCAGCGGTGGCCAACAGTGTGGCACGGAAGCATGGGTTCCTCAACCTGGGCCAGATC\nTTCGGGGACTATTACCACTTCTGGCATCGAGGAGTGACGAAGCGGTCCCTGTCGCCTCAC\nCGCCCGCGGCACAGCCGGCTGCAGAGGGAGCCTCAAGTACAGTGGCTGGAACAGCAGGTG\nGCAAAGCGACGGACTAAACGGGACGTGTACCAGGAGCCCACAGACCCCAAGTTTCCTCAG\nCAGTGGTACCTGTCTGGTGTCACTCAGCGGGACCTGAATGTGAAGGCGGCCTGGGCGCAG\nGGCTACACAGGGCACGGCATTGTGGTCTCCATTCTGGACGATGGCATCGAGAAGAACCAC\nCCGGACTTGGCAGGCAATTATGATCCTGGGGCCAGTTTTGATGTCAATGACCAGGACCCT\nGACCCCCAGCCTCGGTACACACAGATGAATGACAACAGGCACGGCACACGGTGTGCGGGG\nGAAGTGGCTGCGGTGGCCAACAACGGTGTCTGTGGTGTAGGTGTGGCCTACAACGCCCGC\nATTGGAGGGGTGCGCATGCTGGATGGCGAGGTGACAGATGCAGTGGAGGCACGCTCGCTG\nGGCCTGAACCCCAACCACATCCACATCTACAGTGCCAGCTGGGGCCCCGAGGATGACGGC\nAAGACAGTGGATGGGCCAGCCCGCCTCGCCGAGGAGGCCTTCTTCCGTGGGGTTAGCCAG\nGGCCGAGGGGGGCTGGGCTCCATCTTTGTCTGGGCCTCGGGGAACGGGGGCCGGGAACAT\nGACAGCTGCAACTGCGACGGCTACACCAACAGTATCTACACGCTGTCCATCAGCAGCGCC\nACGCAGTTTGGCAACGTGCCGTGGTACAGCGAGGCCTGCTCGTCCACACTGGCCACGACC\nTACAGCAGTGGCAACCAGAATGAGAAGCAGATCGTGACGACTGACTTGCGGCAGAAGTGC\nACGGAGTCTCACACGGGCACCTCAGCCTCTGCCCCCTTAGCAGCCGGCATCATTGCTCTC\nACCCTGGAGGCCAATAAGAACCTCACATGGCGGGACATGCAACACCTGGTGGTACAGACC\nTCGAAGCCAGCCCACCTCAATGCCAACGACTGGGCCACCAATGGTGTGGGCCGGAAAGTG\nAGCCACTCATATGGCTACGGGCTTTTGGACGCAGGCGCCATGGTGGCCCTGGCCCAGAAT\nTGGACCACAGTGGCCCCCCAGCGGAAGTGCATCATCGACATCCTCACCGAGCCCAAAGAC\nATCGGGAAACGGCTCGAGGTGCGGAAGACCGTGACCGCGTGCCTGGGCGAGCCCAACCAC\nATCACTCGGCTGGAGCACGCTCAGGCGCGGCTCACCCTGTCCTATAATCGCCGTGGCGAC\nCTGGCCATCCACCTGGTCAGCCCCATGGGCACCCGCTCCACCCTGCTGGCAGCCAGGCCA\nCATGACTACTCCGCAGATGGGTTTAATGACTGGGCCTTCATGACAACTCATTCCTGGGAT\nGAGGATCCCTCTGGCGAGTGGGTCCTAGAGATTGAAAACACCAGCGAAGCCAACAACTAT\nGGGACGCTGACCAAGTTCACCCTCGTACTCTATGGCACCGCCCCTGAGGGGCTGCCCGTA\nCCTCCAGAAAGCAGTGGCTGCAAGACCCTCACGTCCAGTCAGGCCTGTGTGGTGTGCGAG\nGAAGGCTTCTCCCTGCACCAGAAGAGCTGTGTCCAGCACTGCCCTCCAGGGTTCGCCCCC\nCAAGTCCTCGATACGCACTATAGCACCGAGAATGACGTGGAGACCATCCGGGCCAGCGTC\nTGCGCCCCCTGCCACGCCTCATGTGCCACATGCCAGGGGCCGGCCCTGACAGACTGCCTC\nAGCTGCCCCAGCCACGCCTCCTTGGACCCTGTGGAGCAGACTTGCTCCCGGCAAAGCCAG\nAGCAGCCGAGAGTCCCCGCCACAGCAGCAGCCACCTCGGCTGCCCCCGGAGGTGGAGGCG\nGGGCAACGGCTGCGGGCAGGGCTGCTGCCCTCACACCTGCCTGAGGTGGTGGCCGGCCTC\nAGCTGCGCCTTCATCGTGCTGGTCTTCGTCACTGTCTTCCTGGTCCTGCAGCTGCGCTCT\nGGCTTTAGTTTTCGGGGGGTGAAGGTGTACACCATGGACCGTGGCCTCATCTCCTACAAG\nGGGCTGCCCCCTGAAGCCTGGCAGGAGGAGTGCCCGTCTGACTCAGAAGAGGACGAGGGC\nCGGGGCGAGAGGACCGCCTTTATCAAAGACCAGAGCGCCCTCTGA'),('G-protein coupled receptor 12','None','Human','Promotes neurite outgrowth and blocks myelin inhibition in neurons (By similarity). Receptor with constitutive G(s) signaling activity that stimulates cyclic AMP production.','G-protein coupled receptor activity','GPR12','36729.785','DB14011','>lcl|BSEQ0051331|G-protein coupled receptor 12 (GPR12)\nATGAATGAAGACCTGAAGGTCAATTTAAGCGGGCTGCCTCGGGATTATTTAGATGCCGCT\nGCTGCGGAGAACATCTCGGCTGCTGTCTCCTCCCGGGTTCCTGCCGTAGAGCCAGAGCCT\nGAGCTCGTAGTCAACCCCTGGGACATTGTCTTGTGTACCTCGGGAACCCTCATCTCCTGT\nGAAAATGCCATTGTGGTCCTTATCATCTTCCACAACCCCAGCCTGCGAGCACCCATGTTC\nCTGCTAATAGGCAGCCTGGCTCTTGCAGACCTGCTGGCCGGCATTGGACTCATCACCAAT\nTTTGTTTTTGCCTACCTGCTTCAGTCAGAAGCCACCAAGCTGGTCACGATCGGCCTCATT\nGTCGCCTCTTTCTCTGCCTCTGTCTGCAGCTTGCTGGCTATCACTGTTGACCGCTACCTC\nTCACTGTACTACGCTCTGACGTACCATTCGGAGAGGACGGTCACGTTTACCTATGTCATG\nCTCGTCATGCTCTGGGGGACCTCCATCTGCCTGGGGCTGCTGCCCGTCATGGGCTGGAAC\nTGCCTCCGAGACGAGTCCACCTGCAGCGTGGTCAGACCGCTCACCAAGAACAACGCGGCC\nATCCTCTCGGTGTCCTTCCTCTTCATGTTTGCGCTCATGCTTCAGCTCTACATCCAGATC\nTGTAAGATTGTGATGAGGCACGCCCATCAGATAGCCCTGCAGCACCACTTCCTGGCCACG\nTCGCACTATGTGACCACCCGGAAAGGGGTCTCCACCCTGGCTATCATCCTGGGGACGTTT\nGCTGCTTGCTGGATGCCTTTCACCCTCTATTCCTTGATAGCGGATTACACCTACCCCTCC\nATCTATACCTACGCCACCCTCCTGCCCGCCACCTACAATTCCATCATCAACCCTGTCATA\nTATGCTTTCAGAAACCAAGAGATCCAGAAAGCGCTCTGTCTCATTTGCTGCGGCTGCATC\nCCGTCCAGTCTCGCCCAGAGAGCGCGCTCGCCCAGTGATGTGTAG'),('G-protein coupled receptor 55','None','Human','G-protein coupled receptor activity','May be involved in hyperalgesia associated with inflammatory and neuropathic pain (By similarity). Receptor for L-alpha-lysophosphatidylinositol (LPI). LPI induces Ca(2+) release from intracellular stores via the heterotrimeric G protein GNA13 and RHOA. Putative cannabinoid receptor. May play a role in bone physiology by regulating osteoclast number and function.','GPR55','36637.12','DB14011','>lcl|BSEQ0013938|G-protein coupled receptor 55 (GPR55)\nATGAGTCAGCAAAACACCAGTGGGGACTGCCTGTTTGACGGTGTCAACGAGCTGATGAAA\nACCCTACAGTTTGCAGTCCACATCCCCACCTTCGTCCTGGGCCTGCTCCTCAACCTGCTG\nGCCATCCATGGCTTCAGCACCTTCCTTAAGAACAGGTGGCCCGATTATGCTGCCACCTCC\nATCTACATGATCAACCTGGCAGTCTTTGACCTGCTGCTGGTGCTCTCCCTCCCATTCAAG\nATGGTCCTGTCCCAGGTACAGTCCCCCTTCCCGTCCCTGTGCACCCTGGTGGAGTGCCTT\nTACTTCGTCAGCATGTACGGAAGCGTCTTCACCATCTGCTTCATCAGCATGGACCGGTTC\nTTGGCCATCCGTTACCCGCTACTGGTGAGCCACCTCCGGTCCCCCAGGAAGATCTTTGGG\nATCTGCTGCACCATCTGGGTCCTGGTGTGGACCGGAAGCATCCCTATCTACAGTTTCCAT\nGGGAAAGTGGAAAAATACATGTGCTTCCACAACATGTCTGATGATACCTGGAGCGCCAAG\nGTCTTCTTCCCGCTGGAGGTGTTTGGCTTCCTCCTTCCCATGGGCATCATGGGCTTCTGC\nTGCTCCAGGAGCATCCACATCCTGCTGGGCCGCCGAGACCACACCCAGGACTGGGTGCAG\nCAGAAAGCCTGCATCTACAGCATCGCAGCCAGCCTGGCTGTCTTCGTGGTCTCCTTCCTC\nCCAGTCCACCTGGGGTTCTTCCTGCAGTTCCTGGTGAGAAACAGCTTTATCGTAGAGTGC\nAGAGCCAAGCAGAGCATCAGCTTCTTCTTGCAATTGTCCATGTGTTTCTCCAACGTCAAC\nTGCTGCCTGGATGTTTTCTGCTACTACTTTGTCATCAAAGAATTCCGCATGAACATCAGG\nGCCCACCGGCCTTCCAGGGTCCAGCTGGTCCTGCAGGACACCACGATCTCCCGGGGCTAA'),('GABA-A receptor (anion channel)','protein group','Human','None','None','None','None','DB01028','None'),('Gamma-aminobutyric acid receptor subunit alpha-1','None','Human','Inhibitory extracellular ligand-gated ion channel activity','Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).','GABRA1','51801.395','DB01028','>lcl|BSEQ0010562|Gamma-aminobutyric acid receptor subunit alpha-1 (GABRA1)\nATGAGGAAAAGTCCAGGTCTGTCTGACTGTCTTTGGGCCTGGATCCTCCTTCTGAGCACA\nCTGACTGGAAGAAGCTATGGACAGCCGTCATTACAAGATGAACTTAAAGACAATACCACT\nGTCTTCACCAGGATTTTGGACAGACTCCTAGATGGTTATGACAATCGCCTGAGACCAGGA\nTTGGGAGAGCGTGTAACCGAAGTGAAGACTGATATCTTCGTCACCAGTTTCGGACCCGTT\nTCAGACCATGATATGGAATATACAATAGATGTATTTTTCCGTCAAAGCTGGAAGGATGAA\nAGGTTAAAATTTAAAGGACCTATGACAGTCCTCCGGTTAAATAACCTAATGGCAAGTAAA\nATCTGGACTCCGGACACATTTTTCCACAATGGAAAGAAGTCAGTGGCCCACAACATGACC\nATGCCCAACAAACTCCTGCGGATCACAGAGGATGGCACCTTGCTGTACACCATGAGGCTG\nACAGTGAGAGCTGAATGTCCGATGCATTTGGAGGACTTCCCTATGGATGCCCATGCTTGC\nCCACTAAAATTTGGAAGTTATGCTTATACAAGAGCAGAAGTTGTTTATGAATGGACCAGA\nGAGCCAGCACGCTCAGTGGTTGTAGCAGAAGATGGATCACGTCTAAACCAGTATGACCTT\nCTTGGACAAACAGTAGACTCTGGAATTGTCCAGTCAAGTACAGGAGAATATGTTGTTATG\nACCACTCATTTCCACTTGAAGAGAAAGATTGGCTACTTTGTTATTCAAACATACCTGCCA\nTGCATAATGACAGTGATTCTCTCACAAGTCTCCTTCTGGCTCAACAGAGAGTCTGTACCA\nGCAAGAACTGTCTTTGGAGTAACAACTGTGCTCACCATGACAACATTGAGCATCAGTGCC\nAGAAACTCCCTCCCTAAGGTGGCTTATGCAACAGCTATGGATTGGTTTATTGCCGTGTGC\nTATGCCTTTGTGTTCTCAGCTCTGATTGAGTTTGCCACAGTAAACTATTTCACTAAGAGA\nGGTTATGCATGGGATGGCAAAAGTGTGGTTCCAGAAAAGCCAAAGAAAGTAAAGGATCCT\nCTTATTAAGAAAAACAACACTTACGCTCCAACAGCAACCAGCTACACCCCTAATTTGGCC\nAGGGGCGACCCGGGCTTAGCCACCATTGCTAAAAGTGCAACCATAGAACCTAAAGAGGTC\nAAGCCCGAAACAAAACCACCAGAACCCAAGAAAACCTTTAACAGTGTCAGCAAAATTGAC\nCGACTGTCAAGAATAGCCTTCCCGCTGCTATTTGGAATCTTTAACTTAGTCTACTGGGCT\nACGTATTTAAACAGAGAGCCTCAGCTAAAAGCCCCCACACCACATCAATAG'),('Gamma-aminobutyric acid type B receptor subunit 1','None','Human','G-protein coupled gaba receptor activity','Component of a heterodimeric G-protein coupled receptor for GABA, formed by GABBR1 and GABBR2. Within the heterodimeric GABA receptor, only GABBR1 seems to bind agonists, while GABBR2 mediates coupling to G proteins. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase, stimulates phospholipase A2, activates potassium channels, inactivates voltage-dependent calcium-channels and modulates inositol phospholipid hydrolysis. Calcium is required for high affinity binding to GABA. Plays a critical role in the fine-tuning of inhibitory synaptic transmission. Pre-synaptic GABA receptor inhibits neurotransmitter release by down-regulating high-voltage activated calcium channels, whereas postsynaptic GABA receptor decreases neuronal excitability by activating a prominent inwardly rectifying potassium (Kir) conductance that underlies the late inhibitory postsynaptic potentials. Not only implicated in synaptic inhibition but also in hippocampal long-term potentiation, slow wave sleep, muscle relaxation and antinociception. Activated by (-)-baclofen, cgp27492 and blocked by phaclofen.Isoform 1E may regulate the formation of functional GABBR1/GABBR2 heterodimers by competing for GABBR2 binding. This could explain the observation that certain small molecule ligands exhibit differential affinity for central versus peripheral sites.','GABBR1','108319.4','DB00996','>lcl|BSEQ0010206|Gamma-aminobutyric acid type B receptor subunit 1 (GABBR1)\nATGTTGCTGCTGCTGCTACTGGCGCCACTCTTCCTCCGCCCCCCGGGCGCGGGCGGGGCG\nCAGACCCCCAACGCCACCTCAGAAGGTTGCCAGATCATACACCCGCCCTGGGAAGGGGGC\nATCAGGTACCGGGGCCTGACTCGGGACCAGGTGAAGGCTATCAACTTCCTGCCAGTGGAC\nTATGAGATTGAGTATGTGTGCCGGGGGGAGCGCGAGGTGGTGGGGCCCAAGGTCCGCAAG\nTGCCTGGCCAACGGCTCCTGGACAGATATGGACACACCCAGCCGCTGTGTCCGAATCTGC\nTCCAAGTCTTATTTGACCCTGGAAAATGGGAAGGTTTTCCTGACGGGTGGGGACCTCCCA\nGCTCTGGACGGAGCCCGGGTGGATTTCCGGTGTGACCCCGACTTCCATCTGGTGGGCAGC\nTCCCGGAGCATCTGTAGTCAGGGCCAGTGGAGCACCCCCAAGCCCCACTGCCAGGTGAAT\nCGAACGCCACACTCAGAACGGCGCGCAGTGTACATCGGGGCACTGTTTCCCATGAGCGGG\nGGCTGGCCAGGGGGCCAGGCCTGCCAGCCCGCGGTGGAGATGGCGCTGGAGGACGTGAAT\nAGCCGCAGGGACATCCTGCCGGACTATGAGCTCAAGCTCATCCACCACGACAGCAAGTGT\nGATCCAGGCCAAGCCACCAAGTACCTATATGAGCTGCTCTACAACGACCCTATCAAGATC\nATCCTTATGCCTGGCTGCAGCTCTGTCTCCACGCTGGTGGCTGAGGCTGCTAGGATGTGG\nAACCTCATTGTGCTTTCCTATGGCTCCAGCTCACCAGCCCTGTCAAACCGGCAGCGTTTC\nCCCACTTTCTTCCGAACGCACCCATCAGCCACACTCCACAACCCTACCCGCGTGAAACTC\nTTTGAAAAGTGGGGCTGGAAGAAGATTGCTACCATCCAGCAGACCACTGAGGTCTTCACT\nTCGACTCTGGACGACCTGGAGGAACGAGTGAAGGAGGCTGGAATTGAGATTACTTTCCGC\nCAGAGTTTCTTCTCAGATCCAGCTGTGCCCGTCAAAAACCTGAAGCGCCAGGATGCCCGA\nATCATCGTGGGACTTTTCTATGAGACTGAAGCCCGGAAAGTTTTTTGTGAGGTGTACAAG\nGAGCGTCTCTTTGGGAAGAAGTACGTCTGGTTCCTCATTGGGTGGTATGCTGACAATTGG\nTTCAAGATCTACGACCCTTCTATCAACTGCACAGTGGATGAGATGACTGAGGCGGTGGAG\nGGCCACATCACAACTGAGATTGTCATGCTGAATCCTGCCAATACCCGCAGCATTTCCAAC\nATGACATCCCAGGAATTTGTGGAGAAACTAACCAAGCGACTGAAAAGACACCCTGAGGAG\nACAGGAGGCTTCCAGGAGGCACCGCTGGCCTATGATGCCATCTGGGCCTTGGCACTGGCC\nCTGAACAAGACATCTGGAGGAGGCGGCCGTTCTGGTGTGCGCCTGGAGGACTTCAACTAC\nAACAACCAGACCATTACCGACCAAATCTACCGGGCAATGAACTCTTCGTCCTTTGAGGGT\nGTCTCTGGCCATGTGGTGTTTGATGCCAGCGGCTCTCGGATGGCATGGACGCTTATCGAG\nCAGCTTCAGGGTGGCAGCTACAAGAAGATTGGCTACTATGACAGCACCAAGGATGATCTT\nTCCTGGTCCAAAACAGATAAATGGATTGGAGGGTCCCCCCCAGCTGACCAGACCCTGGTC\nATCAAGACATTCCGCTTCCTGTCACAGAAACTCTTTATCTCCGTCTCAGTTCTCTCCAGC\nCTGGGCATTGTCCTAGCTGTTGTCTGTCTGTCCTTTAACATCTACAACTCACATGTCCGT\nTATATCCAGAACTCACAGCCCAACCTGAACAACCTGACTGCTGTGGGCTGCTCACTGGCT\nTTAGCTGCTGTCTTCCCCCTGGGGCTCGATGGTTACCACATTGGGAGGAACCAGTTTCCT\nTTCGTCTGCCAGGCCCGCCTCTGGCTCCTGGGCCTGGGCTTTAGTCTGGGCTACGGTTCC\nATGTTCACCAAGATTTGGTGGGTCCACACGGTCTTCACAAAGAAGGAAGAAAAGAAGGAG\nTGGAGGAAGACTCTGGAACCCTGGAAGCTGTATGCCACAGTGGGCCTGCTGGTGGGCATG\nGATGTCCTCACTCTCGCCATCTGGCAGATCGTGGACCCTCTGCACCGGACCATTGAGACA\nTTTGCCAAGGAGGAACCTAAGGAAGATATTGACGTCTCTATTCTGCCCCAGCTGGAGCAT\nTGCAGCTCCAGGAAGATGAATACATGGCTTGGCATTTTCTATGGTTACAAGGGGCTGCTG\nCTGCTGCTGGGAATCTTCCTTGCTTATGAGACCAAGAGTGTGTCCACTGAGAAGATCAAT\nGATCACCGGGCTGTGGGCATGGCTATCTACAATGTGGCAGTCCTGTGCCTCATCACTGCT\nCCTGTCACCATGATTCTGTCCAGCCAGCAGGATGCAGCCTTTGCCTTTGCCTCTCTTGCC\nATAGTTTTCTCCTCCTATATCACTCTTGTTGTGCTCTTTGTGCCCAAGATGCGCAGGCTG\nATCACCCGAGGGGAATGGCAGTCGGAGGCGCAGGACACCATGAAGACAGGGTCATCGACC\nAACAACAACGAGGAGGAGAAGTCCCGGCTGTTGGAGAAGGAGAACCGTGAACTGGAAAAG\nATCATTGCTGAGAAAGAGGAGCGTGTCTCTGAACTGCGCCATCAACTCCAGTCTCGGCAG\nCAGCTCCGCTCCCGGCGCCACCCACCGACACCCCCAGAACCCTCTGGGGGCCTGCCCAGG\nGGACCCCCTGAGCCCCCCGACCGGCTTAGCTGTGATGGGAGTCGAGTGCATTTGCTTTAT\nAAGTGA'),('Gamma-aminobutyric acid type B receptor subunit 2','None','Human','G-protein coupled gaba receptor activity','Component of a heterodimeric G-protein coupled receptor for GABA, formed by GABBR1 and GABBR2. Within the heterodimeric GABA receptor, only GABBR1 seems to bind agonists, while GABBR2 mediates coupling to G proteins. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase, stimulates phospholipase A2, activates potassium channels, inactivates voltage-dependent calcium-channels and modulates inositol phospholipid hydrolysis. Plays a critical role in the fine-tuning of inhibitory synaptic transmission. Pre-synaptic GABA receptor inhibits neurotransmitter release by down-regulating high-voltage activated calcium channels, whereas postsynaptic GABA receptor decreases neuronal excitability by activating a prominent inwardly rectifying potassium (Kir) conductance that underlies the late inhibitory postsynaptic potentials. Not only implicated in synaptic inhibition but also in hippocampal long-term potentiation, slow wave sleep, muscle relaxation and antinociception.','GABBR2','105820.52','DB00996','>lcl|BSEQ0016760|Gamma-aminobutyric acid type B receptor subunit 2 (GABBR2)\nATGGCTTCCCCGCGGAGCTCCGGGCAGCCCGGGCCGCCGCCGCCGCCGCCACCGCCGCCC\nGCGCGCCTGCTACTGCTACTGCTGCTGCCGCTGCTGCTGCCTCTGGCGCCCGGGGCCTGG\nGGCTGGGCGCGGGGCGCCCCCCGGCCGCCGCCCAGCAGCCCGCCGCTCTCCATCATGGGC\nCTCATGCCGCTCACCAAGGAGGTGGCCAAGGGCAGCATCGGGCGCGGTGTGCTCCCCGCC\nGTGGAACTGGCCATCGAGCAGATCCGCAACGAGTCACTCCTGCGCCCCTACTTCCTCGAC\nCTGCGGCTCTATGACACGGAGTGCGACAACGCAAAAGGGTTGAAAGCCTTCTACGATGCA\nATAAAATACGGGCCTAACCACTTGATGGTGTTTGGAGGCGTCTGTCCATCCGTCACATCC\nATCATTGCAGAGTCCCTCCAAGGCTGGAATCTGGTGCAGCTTTCTTTTGCTGCAACCACG\nCCTGTTCTAGCCGATAAGAAAAAATACCCTTATTTCTTTCGGACCGTCCCATCAGACAAT\nGCGGTGAATCCAGCCATTCTGAAGTTGCTCAAGCACTACCAGTGGAAGCGCGTGGGCACG\nCTGACGCAAGACGTTCAGAGGTTCTCTGAGGTGCGGAATGACCTGACTGGAGTTCTGTAT\nGGCGAGGACATTGAGATTTCAGACACCGAGAGCTTCTCCAACGATCCCTGTACCAGTGTC\nAAAAAGCTGAAGGGGAATGATGTGCGGATCATCCTTGGCCAGTTTGACCAGAATATGGCA\nGCAAAAGTGTTCTGTTGTGCATACGAGGAGAACATGTATGGTAGTAAATATCAGTGGATC\nATTCCGGGCTGGTACGAGCCTTCTTGGTGGGAGCAGGTGCACACGGAAGCCAACTCATCC\nCGCTGCCTCCGGAAGAATCTGCTTGCTGCCATGGAGGGCTACATTGGCGTGGATTTCGAG\nCCCCTGAGCTCCAAGCAGATCAAGACCATCTCAGGAAAGACTCCACAGCAGTATGAGAGA\nGAGTACAACAACAAGCGGTCAGGCGTGGGGCCCAGCAAGTTCCACGGGTACGCCTACGAT\nGGCATCTGGGTCATCGCCAAGACACTGCAGAGGGCCATGGAGACACTGCATGCCAGCAGC\nCGGCACCAGCGGATCCAGGACTTCAACTACACGGACCACACGCTGGGCAGGATCATCCTC\nAATGCCATGAACGAGACCAACTTCTTCGGGGTCACGGGTCAAGTTGTATTCCGGAATGGG\nGAGAGAATGGGGACCATTAAATTTACTCAATTTCAAGACAGCAGGGAGGTGAAGGTGGGA\nGAGTACAACGCTGTGGCCGACACACTGGAGATCATCAATGACACCATCAGGTTCCAAGGA\nTCCGAACCACCAAAAGACAAGACCATCATCCTGGAGCAGCTGCGGAAGATCTCCCTACCT\nCTCTACAGCATCCTCTCTGCCCTCACCATCCTCGGGATGATCATGGCCAGTGCTTTTCTC\nTTCTTCAACATCAAGAACCGGAATCAGAAGCTCATAAAGATGTCGAGTCCATACATGAAC\nAACCTTATCATCCTTGGAGGGATGCTCTCCTATGCTTCCATATTTCTCTTTGGCCTTGAT\nGGATCCTTTGTCTCTGAAAAGACCTTTGAAACACTTTGCACCGTCAGGACCTGGATTCTC\nACCGTGGGCTACACGACCGCTTTTGGGGCCATGTTTGCAAAGACCTGGAGAGTCCACGCC\nATCTTCAAAAATGTGAAAATGAAGAAGAAGATCATCAAGGACCAGAAACTGCTTGTGATC\nGTGGGGGGCATGCTGCTGATCGACCTGTGTATCCTGATCTGCTGGCAGGCTGTGGACCCC\nCTGCGAAGGACAGTGGAGAAGTACAGCATGGAGCCGGACCCAGCAGGACGGGATATCTCC\nATCCGCCCTCTCCTGGAGCACTGTGAGAACACCCATATGACCATCTGGCTTGGCATCGTC\nTATGCCTACAAGGGACTTCTCATGTTGTTCGGTTGTTTCTTAGCTTGGGAGACCCGCAAC\nGTCAGCATCCCCGCACTCAACGACAGCAAGTACATCGGGATGAGTGTCTACAACGTGGGG\nATCATGTGCATCATCGGGGCCGCTGTCTCCTTCCTGACCCGGGACCAGCCCAATGTGCAG\nTTCTGCATCGTGGCTCTGGTCATCATCTTCTGCAGCACCATCACCCTCTGCCTGGTATTC\nGTGCCGAAGCTCATCACCCTGAGAACAAACCCAGATGCAGCAACGCAGAACAGGCGATTC\nCAGTTCACTCAGAATCAGAAGAAAGAAGATTCTAAAACGTCCACCTCGGTCACCAGTGTG\nAACCAAGCCAGCACATCCCGCCTGGAGGGCCTACAGTCAGAAAACCATCGCCTGCGAATG\nAAGATCACAGAGCTGGATAAAGACTTGGAAGAGGTCACCATGCAGCTGCAGGACACACCA\nGAAAAGACCACCTACATTAAACAGAACCACTACCAAGAGCTCAATGACATCCTCAACCTG\nGGAAACTTCACTGAGAGCACAGATGGAGGAAAGGCCATTTTAAAAAATCACCTCGATCAA\nAATCCCCAGCTACAGTGGAACACAACAGAGCCCTCTCGAACATGCAAAGATCCTATAGAA\nGATATAAACTCTCCAGAACACATCCAGCGTCGGCTGTCCCTCCAGCTCCCCATCCTCCAC\nCACGCCTACCTCCCATCCATCGGAGGCGTGGACGCCAGCTGTGTCAGCCCCTGCGTCAGC\nCCCACCGCCAGCCCCCGCCACAGACATGTGCCACCCTCCTTCCGAGTCATGGTCTCGGGC\nCTGTAA'),('Glucan 1,3-beta-glucosidase','None','Yeast','Transferase activity','Major glucan 1,3-beta-glucosidase required for cell wall integrity. Beta-glucanases participate in the metabolism of beta-glucan, the main structural component of the cell wall. Can also function biosynthetically as a transglycosylase. Functions to deliver glucan from the cell to the extracellular matrix. Does not appear to impact cell wall glucan content of biofilm cells, nor is it necessary for filamentation or biofilm formation. Involved in cell-substrate and cell-cell adhesion. Adhesion to host-cell surfaces is the first critical step during mucosal infection. XOG1 is target of human antimicrobial peptide LL-37 for inhibition of cell adhesion.','XOG1','50037.635','DB01816','>lcl|BSEQ0016397|Glucan 1,3-beta-glucosidase (XOG1)\nATGCAGTTATCATTTATCTTAACATCATCGGTATTTATATTATTGCTTGAATTTGTTAAA\nGCCCTGGTTATTTCTAATCCATTTAAACCAAATGGAAACTTGAAATTCAAGAGAGGAGGC\nGGACATAATGTTGCTTGGGATTATGATAATAATGTTATCAGAGGTGTCAATTTGGGTGGT\nTGGTTTGTCCTTGAACCATATATGACACCATCACTTTTTGAACCATTCCAAAATGGAAAT\nGATCAGTCTGGAGTTCCAGTTGACGAATATCACTGGACACAAACTTTGGGTAAGGAAGCT\nGCTCTGAGAATTTTGCAAAAACATTGGAGTACTTGGATCACTGAACAAGACTTTAAACAA\nATTAGTAATTTGGGATTGAACTTTGTTCGTATTCCTATTGGTTATTGGGCTTTCCAATTG\nTTGGATAATGATCCATACGTCCAAGGTCAAGTTCAGTATTTGGAAAAGGCTTTGGGCTGG\nGCCAGAAAGAATAATATCAGAGTTTGGATTGATTTGCACGGTGCACCAGGCTCTCAAAAT\nGGGTTTGACAACTCCGGTTTAAGAGATAGCTACAATTTCCAAAACGGTGATAACACCCAA\nGTTACTTTGAATGTATTGAATACTATTTTCAAAAAGTATGGTGGCAACGAATACTCTGAC\nGTTGTTATTGGTATTGAATTGCTTAATGAACCATTGGGTCCAGTTTTGAATATGGATAAA\nTTGAAACAATTTTTCTTGGATGGTTACAACTCTCTTAGACAAACTGGATCAGTCACCCCA\nGTTATCATTCACGATGCTTTCCAAGTCTTTGGCTATTGGAATAACTTTTTGACTGTTGCT\nGAAGGTCAATGGAATGTTGTTGTTGACCATCATCATTACCAAGTGTTTTCCGGTGGTGAA\nTTATCTCGTAACATTAACGACCACATTTCAGTTGCTTGTAACTGGGGTTGGGATGCTAAA\nAAGGAATCCCATTGGAACGTCGCTGGTGAATGGTCTGCTGCTTTGACAGATTGTGCTAAA\nTGGTTGAATGGTGTCAACAGAGGAGCACGTTATGAGGGTGCTTACGATAATGCTCCATAC\nATTGGATCCTGTCAACCAATGTTGGATATTTCCCAATGGTCTGATGAACACAAAACCGAC\nACAAGAAGATACATTGAGGCTCAATTGGATGCTTTTGAATACACTGGAGGCTGGGTCTTC\nTGGAGTTGGAAGACTGAAAATGCCCCTGAATGGAGTTTCCAAACCTTGACTTACAATGGT\nCTTTTCCCACAACCAGTTACTGATAGACAATTCCCAAACCAATGTGGCTTTCACTGA'),('Glutamate receptor 1','None','Human','Pdz domain binding','Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inactive state, characterized by the presence of bound agonist. In the presence of CACNG4 or CACNG7 or CACNG8, shows resensitization which is characterized by a delayed accumulation of current flux upon continued application of glutamate.','GRIA1','101505.245','DB01028','>lcl|BSEQ0010446|Glutamate receptor 1 (GRIA1)\nATGCAGCACATTTTTGCCTTCTTCTGCACCGGTTTCCTAGGCGCGGTAGTAGGTGCCAAT\nTTCCCCAACAATATCCAGATCGGGGGATTATTTCCAAACCAGCAGTCACAGGAACATGCT\nGCTTTTAGATTTGCTTTGTCGCAACTCACAGAGCCCCCGAAGCTGCTCCCCCAGATTGAT\nATTGTGAACATCAGCGACAGCTTTGAGATGACCTATAGATTCTGTTCCCAGTTCTCCAAA\nGGAGTCTATGCCATCTTTGGGTTTTATGAACGTAGGACTGTCAACATGCTGACCTCCTTT\nTGTGGGGCCCTCCACGTCTGCTTCATTACGCCGAGCTTTCCCGTTGATACATCCAATCAG\nTTTGTCCTTCAGCTGCGCCCTGAACTGCAGGATGCCCTCATCAGCATCATTGACCATTAC\nAAGTGGCAGAAATTTGTCTACATTTATGATGCCGACCGGGGCTTATCCGTCCTGCAGAAA\nGTCCTGGATACAGCTGCTGAGAAGAACTGGCAGGTGACAGCAGTCAACATTTTGACAACC\nACAGAGGAGGGATACCGGATGCTCTTTCAGGACCTGGAGAAGAAAAAGGAGCGGCTGGTG\nGTGGTGGACTGTGAATCAGAACGCCTCAATGCTATCTTGGGCCAGATTATAAAGCTAGAG\nAAGAATGGCATCGGCTACCACTACATTCTTGCAAATCTGGGCTTCATGGACATTGACTTA\nAACAAATTCAAGGAGAGTGGCGCCAATGTGACAGGTTTCCAGCTGGTGAACTACACAGAC\nACTATTCCGGCCAAGATCATGCAGCAGTGGAAGAATAGTGATGCTCGAGACCACACACGG\nGTGGACTGGAAGAGACCCAAGTACACCTCTGCGCTCACCTACGATGGGGTGAAGGTGATG\nGCTGAGGCTTTCCAGAGCCTGCGGAGGCAGAGAATTGATATATCTCGCCGGGGGAATGCT\nGGGGATTGTCTGGCTAACCCAGCTGTTCCCTGGGGCCAAGGGATCGACATCCAGAGAGCT\nCTGCAGCAGGTGCGATTTGAAGGTTTAACAGGAAACGTGCAGTTTAATGAGAAAGGACGC\nCGGACCAACTACACGCTCCACGTGATTGAAATGAAACATGACGGCATCCGAAAGATTGGT\nTACTGGAATGAAGATGATAAGTTTGTCCCTGCAGCCACCGATGCCCAAGCTGGGGGCGAT\nAATTCAAGTGTTCAGAACAGAACATACATCGTCACAACAATCCTAGAAGATCCTTATGTG\nATGCTCAAGAAGAACGCCAATCAGTTTGAGGGCAATGACCGTTACGAGGGCTACTGTGTA\nGAGCTGGCGGCAGAGATTGCCAAGCACGTGGGCTACTCCTACCGTCTGGAGATTGTCAGT\nGATGGAAAATACGGAGCCCGAGACCCTGACACGAAGGCCTGGAATGGCATGGTGGGAGAG\nCTGGTCTATGGAAGAGCAGATGTGGCTGTGGCTCCCTTAACTATCACTTTGGTCCGGGAA\nGAAGTTATAGATTTCTCCAAACCATTTATGAGTTTGGGGATCTCCATCATGATTAAAAAA\nCCACAGAAATCCAAGCCGGGTGTCTTCTCCTTCCTTGATCCTTTGGCTTATGAGATTTGG\nATGTGCATTGTTTTTGCCTACATTGGAGTGAGTGTTGTCCTCTTCCTGGTCAGCCGCTTC\nAGTCCCTATGAATGGCACAGTGAAGAGTTTGAGGAAGGACGGGACCAGACAACCAGTGAC\nCAGTCCAATGAGTTTGGGATATTCAACAGTTTGTGGTTCTCCCTGGGAGCCTTCATGCAG\nCAAGGATGTGACATTTCTCCCAGGTCCCTGTCTGGTCGCATCGTTGGTGGCGTCTGGTGG\nTTCTTCACCTTAATCATCATCTCCTCATATACAGCCAATCTGGCCGCCTTCCTGACCGTG\nGAGAGGATGGTGTCTCCCATTGAGAGTGCAGAGGACCTAGCGAAGCAGACAGAAATTGCC\nTACGGGACGCTGGAAGCAGGATCTACTAAGGAGTTCTTCAGGAGGTCTAAAATTGCTGTG\nTTTGAGAAGATGTGGACATACATGAAGTCAGCAGAGCCATCAGTTTTTGTGCGGACCACA\nGAGGAGGGGATGATTCGAGTGAGGAAATCCAAAGGCAAATATGCCTACCTCCTGGAGTCC\nACCATGAATGAGTACATTGAGCAGCGGAAACCCTGTGACACCATGAAGGTGGGAGGTAAC\nTTGGATTCCAAAGGCTATGGCATTGCAACACCCAAGGGGTCTGCCCTGAGAAATCCAGTA\nAACCTGGCAGTGTTAAAACTGAACGAGCAGGGGCTTTTGGACAAATTGAAAAACAAATGG\nTGGTACGACAAGGGCGAGTGCGGCAGCGGGGGAGGTGATTCCAAGGACAAGACAAGCGCT\nCTGAGCCTCAGCAATGTGGCAGGCGTGTTCTACATCCTGATCGGAGGACTTGGACTAGCC\nATGCTGGTTGCCTTAATCGAGTTCTGCTACAAATCCCGTAGTGAATCCAAGCGGATGAAG\nGGTTTTTGTTTGATCCCACAGCAATCCATCAACGAAGCCATACGGACATCGACCCTCCCC\nCGCAACAGCGGGGCAGGAGCCAGCAGCGGCGGCAGTGGAGAGAATGGTCGGGTGGTCAGC\nCATGACTTCCCCAAGTCCATGCAATCGATTCCTTGCATGAGCCACAGTTCAGGGATGCCC\nTTGGGAGCCACGGGATTGTAA'),('Glutamate receptor ionotropic, NMDA 1','None','Human','Voltage-gated cation channel activity','NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. This protein plays a key role in synaptic plasticity, synaptogenesis, excitotoxicity, memory acquisition and learning. It mediates neuronal functions in glutamate neurotransmission. Is involved in the cell surface targeting of NMDA receptors (By similarity).','GRIN1','105371.945','DB00454','>lcl|BSEQ0016071|Glutamate receptor ionotropic, NMDA 1 (GRIN1)\nATGAGCACCATGCGCCTGCTGACGCTCGCCCTGCTGTTCTCCTGCTCCGTCGCCCGTGCC\nGCGTGCGACCCCAAGATCGTCAACATTGGCGCGGTGCTGAGCACGCGGAAGCACGAGCAG\nATGTTCCGCGAGGCCGTGAACCAGGCCAACAAGCGGCACGGCTCCTGGAAGATTCAGCTC\nAATGCCACCTCCGTCACGCACAAGCCCAACGCCATCCAGATGGCTCTGTCGGTGTGCGAG\nGACCTCATCTCCAGCCAGGTCTACGCCATCCTAGTTAGCCATCCACCTACCCCCAACGAC\nCACTTCACTCCCACCCCTGTCTCCTACACAGCCGGCTTCTACCGCATACCCGTGCTGGGG\nCTGACCACCCGCATGTCCATCTACTCGGACAAGAGCATCCACCTGAGCTTCCTGCGCACC\nGTGCCGCCCTACTCCCACCAGTCCAGCGTGTGGTTTGAGATGATGCGTGTCTACAGCTGG\nAACCACATCATCCTGCTGGTCAGCGACGACCACGAGGGCCGGGCGGCTCAGAAACGCCTG\nGAGACGCTGCTGGAGGAGCGTGAGTCCAAGGCAGAGAAGGTGCTGCAGTTTGACCCAGGG\nACCAAGAACGTGACGGCCCTGCTGATGGAGGCGAAAGAGCTGGAGGCCCGGGTCATCATC\nCTTTCTGCCAGCGAGGACGATGCTGCCACTGTATACCGCGCAGCCGCGATGCTGAACATG\nACGGGCTCCGGGTACGTGTGGCTGGTCGGCGAGCGCGAGATCTCGGGGAACGCCCTGCGC\nTACGCCCCAGACGGCATCCTCGGGCTGCAGCTCATCAACGGCAAGAACGAGTCGGCCCAC\nATCAGCGACGCCGTGGGCGTGGTGGCCCAGGCCGTGCACGAGCTCCTCGAGAAGGAGAAC\nATCACCGACCCGCCGCGGGGCTGCGTGGGCAACACCAACATCTGGAAGACCGGGCCGCTC\nTTCAAGAGAGTGCTGATGTCTTCCAAGTATGCGGATGGGGTGACTGGTCGCGTGGAGTTC\nAATGAGGATGGGGACCGGAAGTTCGCCAACTACAGCATCATGAACCTGCAGAACCGCAAG\nCTGGTGCAAGTGGGCATCTACAATGGCACCCACGTCATCCCTAATGACAGGAAGATCATC\nTGGCCAGGCGGAGAGACAGAGAAGCCTCGAGGGTACCAGATGTCCACCAGACTGAAGATT\nGTGACGATCCACCAGGAGCCCTTCGTGTACGTCAAGCCCACGCTGAGTGATGGGACATGC\nAAGGAGGAGTTCACAGTCAACGGCGACCCAGTCAAGAAGGTGATCTGCACCGGGCCCAAC\nGACACGTCGCCGGGCAGCCCCCGCCACACGGTGCCTCAGTGTTGCTACGGCTTTTGCATC\nGACCTGCTCATCAAGCTGGCACGGACCATGAACTTCACCTACGAGGTGCACCTGGTGGCA\nGATGGCAAGTTCGGCACACAGGAGCGGGTGAACAACAGCAACAAGAAGGAGTGGAATGGG\nATGATGGGCGAGCTGCTCAGCGGGCAGGCAGACATGATCGTGGCGCCGCTAACCATAAAC\nAACGAGCGCGCGCAGTACATCGAGTTTTCCAAGCCCTTCAAGTACCAGGGCCTGACTATT\nCTGGTCAAGAAGGAGATTCCCCGGAGCACGCTGGACTCGTTCATGCAGCCGTTCCAGAGC\nACACTGTGGCTGCTGGTGGGGCTGTCGGTGCACGTGGTGGCCGTGATGCTGTACCTGCTG\nGACCGCTTCAGCCCCTTCGGCCGGTTCAAGGTGAACAGCGAGGAGGAGGAGGAGGACGCA\nCTGACCCTGTCCTCGGCCATGTGGTTCTCCTGGGGCGTCCTGCTCAACTCCGGCATCGGG\nGAAGGCGCCCCCAGAAGCTTCTCAGCGCGCATCCTGGGCATGGTGTGGGCCGGCTTTGCC\nATGATCATCGTGGCCTCCTACACCGCCAACCTGGCGGCCTTCCTGGTGCTGGACCGGCCG\nGAGGAGCGCATCACGGGCATCAACGACCCTCGGCTGAGGAACCCCTCGGACAAGTTTATC\nTACGCCACGGTGAAGCAGAGCTCCGTGGATATCTACTTCCGGCGCCAGGTGGAGCTGAGC\nACCATGTACCGGCATATGGAGAAGCACAACTACGAGAGTGCGGCGGAGGCCATCCAGGCC\nGTGAGAGACAACAAGCTGCATGCCTTCATCTGGGACTCGGCGGTGCTGGAGTTCGAGGCC\nTCGCAGAAGTGCGACCTGGTGACGACTGGAGAGCTGTTTTTCCGCTCGGGCTTCGGCATA\nGGCATGCGCAAAGACAGCCCCTGGAAGCAGAACGTCTCCCTGTCCATCCTCAAGTCCCAC\nGAGAATGGCTTCATGGAAGACCTGGACAAGACGTGGGTTCGGTATCAGGAATGTGACTCG\nCGCAGCAACGCCCCTGCGACCCTTACTTTTGAGAACATGGCCGGGGTCTTCATGCTGGTA\nGCTGGGGGCATCGTGGCCGGGATCTTCCTGATTTTCATCGAGATTGCCTACAAGCGGCAC\nAAGGATGCTCGCCGGAAGCAGATGCAGCTGGCCTTTGCCGCCGTTAACGTGTGGCGGAAG\nAACCTGCAGCAGTACCATCCCACTGATATCACGGGCCCGCTCAACCTCTCAGATCCCTCG\nGTCAGCACCGTGGTGTGA'),('Glutamate receptor ionotropic, NMDA 2A','None','Human','Zinc ion binding','NMDA receptor subtype of glutamate-gated ion channels possesses high calcium permeability and voltage-dependent sensitivity to magnesium. Activation requires binding of agonist to both types of subunits.','GRIN2A','165281.215','DB00454','>lcl|BSEQ0016199|Glutamate receptor ionotropic, NMDA 2A (GRIN2A)\nATGGGCAGAGTGGGCTATTGGACCCTGCTGGTGCTGCCGGCCCTTCTGGTCTGGCGCGGT\nCCGGCGCCGAGCGCGGCGGCGGAGAAGGGTCCCCCCGCGCTAAATATTGCGGTGATGCTG\nGGTCACAGCCACGACGTGACAGAGCGCGAACTTCGAACACTGTGGGGCCCCGAGCAGGCG\nGCGGGGCTGCCCCTGGACGTGAACGTGGTAGCTCTGCTGATGAACCGCACCGACCCCAAG\nAGCCTCATCACGCACGTGTGCGACCTCATGTCCGGGGCACGCATCCACGGCCTCGTGTTT\nGGGGACGACACGGACCAGGAGGCCGTAGCCCAGATGCTGGATTTTATCTCCTCCCACACC\nTTCGTCCCCATCTTGGGCATTCATGGGGGCGCATCTATGATCATGGCTGACAAGGATCCG\nACGTCTACCTTCTTCCAGTTTGGAGCGTCCATCCAGCAGCAAGCCACGGTCATGCTGAAG\nATCATGCAGGATTATGACTGGCATGTCTTCTCCCTGGTGACCACTATCTTCCCTGGCTAC\nAGGGAATTCATCAGCTTCGTCAAGACCACAGTGGACAACAGCTTTGTGGGCTGGGACATG\nCAGAATGTGATCACACTGGACACTTCCTTTGAGGATGCAAAGACACAAGTCCAGCTGAAG\nAAGATCCACTCTTCTGTCATCTTGCTCTACTGTTCCAAAGACGAGGCTGTTCTCATTCTG\nAGTGAGGCCCGCTCCCTTGGCCTCACCGGGTATGATTTCTTCTGGATTGTCCCCAGCTTG\nGTCTCTGGGAACACGGAGCTCATCCCAAAAGAGTTTCCATCGGGACTCATTTCTGTCTCC\nTACGATGACTGGGACTACAGCCTGGAGGCGAGAGTGAGGGACGGCATTGGCATCCTAACC\nACCGCTGCATCTTCTATGCTGGAGAAGTTCTCCTACATCCCCGAGGCCAAGGCCAGCTGC\nTACGGGCAGATGGAGAGGCCAGAGGTCCCGATGCACACCTTGCACCCATTTATGGTCAAT\nGTTACATGGGATGGCAAAGACTTATCCTTCACTGAGGAAGGCTACCAGGTGCACCCCAGG\nCTGGTGGTGATTGTGCTGAACAAAGACCGGGAATGGGAAAAGGTGGGCAAGTGGGAGAAC\nCATACGCTGAGCCTGAGGCACGCCGTGTGGCCCAGGTACAAGTCCTTCTCCGACTGTGAG\nCCGGATGACAACCATCTCAGCATCGTCACCCTGGAGGAGGCCCCATTCGTCATCGTGGAA\nGACATAGACCCCCTGACCGAGACGTGTGTGAGGAACACCGTGCCATGTCGGAAGTTCGTC\nAAAATCAACAATTCAACCAATGAGGGGATGAATGTGAAGAAATGCTGCAAGGGGTTCTGC\nATTGATATTCTGAAGAAGCTTTCCAGAACTGTGAAGTTTACTTACGACCTCTATCTGGTG\nACCAATGGGAAGCATGGCAAGAAAGTTAACAATGTGTGGAATGGAATGATCGGTGAAGTG\nGTCTATCAACGGGCAGTCATGGCAGTTGGCTCGCTCACCATCAATGAGGAACGTTCTGAA\nGTGGTGGACTTCTCTGTGCCCTTTGTGGAAACGGGAATCAGTGTCATGGTTTCAAGAAGT\nAATGGCACCGTCTCACCTTCTGCTTTTCTAGAACCATTCAGCGCCTCTGTCTGGGTGATG\nATGTTTGTGATGCTGCTCATTGTTTCTGCCATAGCTGTTTTTGTCTTTGAATACTTCAGC\nCCTGTTGGATACAACAGAAACTTAGCCAAAGGGAAAGCACCCCATGGGCCTTCTTTTACA\nATTGGAAAAGCTATATGGCTTCTTTGGGGCCTGGTGTTCAATAACTCCGTGCCTGTCCAG\nAATCCTAAAGGGACCACCAGCAAGATCATGGTATCTGTATGGGCCTTCTTCGCTGTCATA\nTTCCTGGCTAGCTACACAGCCAATCTGGCTGCCTTCATGATCCAAGAGGAATTTGTGGAC\nCAAGTGACCGGCCTCAGTGACAAAAAGTTTCAGAGACCTCATGACTATTCCCCACCTTTT\nCGATTTGGGACAGTGCCTAATGGAAGCACGGAGAGAAACATTCGGAATAACTATCCCTAC\nATGCATCAGTACATGACCAAATTTAATCAGAAAGGAGTAGAGGACGCCTTGGTCAGCCTG\nAAAACGGGGAAGCTGGACGCTTTCATCTACGATGCCGCAGTCTTGAATTACAAGGCTGGG\nAGGGATGAAGGCTGCAAGCTGGTGACCATCGGGAGTGGGTACATCTTTGCCACCACCGGT\nTATGGAATTGCCCTTCAGAAAGGCTCTCCTTGGAAGAGGCAGATCGACCTGGCCTTGCTT\nCAGTTTGTGGGTGATGGTGAGATGGAGGAGCTGGAGACCCTGTGGCTCACTGGGATCTGC\nCACAACGAGAAGAACGAGGTGATGAGCAGCCAGCTGGACATTGACAACATGGCGGGCGTA\nTTCTACATGCTGGCTGCCGCCATGGCCCTTAGCCTCATCACCTTCATCTGGGAGCACCTC\nTTCTACTGGAAGCTGCGCTTCTGTTTCACGGGCGTGTGCTCCGACCGGCCTGGGTTGCTC\nTTCTCCATCAGCAGGGGCATCTACAGCTGCATTCATGGAGTGCACATTGAAGAAAAGAAG\nAAGTCTCCAGACTTCAATCTGACGGGATCCCAGAGCAACATGTTAAAACTCCTCCGGTCA\nGCCAAAAACATTTCCAGCATGTCCAACATGAACTCCTCAAGAATGGACTCACCCAAAAGA\nGCTGCTGACTTCATCCAAAGAGGTTCCCTCATCATGGACATGGTTTCAGATAAGGGGAAT\nTTGATGTACTCAGACAACAGGTCCTTTCAGGGGAAAGAGAGCATTTTTGGAGACAACATG\nAACGAACTCCAAACATTTGTGGCCAACCGGCAGAAGGATAACCTCAATAACTATGTATTC\nCAGGGACAACATCCTCTTACTCTCAATGAGTCCAACCCTAACACGGTGGAGGTGGCCGTG\nAGCACAGAATCCAAAGCGAACTCTAGACCCCGGCAGCTGTGGAAGAAATCCGTGGATTCC\nATACGCCAGGATTCACTATCCCAGAATCCAGTCTCCCAGAGGGATGAGGCAACAGCAGAG\nAATAGGACCCACTCCCTAAAGAGCCCTAGGTATCTTCCAGAAGAGATGGCCCACTCTGAC\nATTTCAGAAACGTCAAATCGGGCCACGTGCCACAGGGAACCTGACAACAGTAAGAACCAC\nAAAACCAAGGACAACTTTAAAAGGTCAGTGGCCTCCAAATACCCCAAGGACTGTAGTGAG\nGTCGAGCGCACCTACCTGAAAACCAAATCAAGCTCCCCTAGAGACAAGATCTACACTATA\nGATGGTGAGAAGGAGCCTGGTTTCCACTTAGATCCACCCCAGTTTGTTGAAAATGTGACC\nCTGCCCGAGAACGTGGACTTCCCGGACCCCTACCAGGATCCCAGTGAAAACTTCCGCAAG\nGGGGACTCCACGCTGCCAATGAACCGGAACCCCTTGCATAATGAAGAGGGGCTTTCCAAC\nAACGACCAGTATAAACTCTACTCCAAGCACTTCACCTTGAAAGACAAGGGTTCCCCGCAC\nAGTGAGACCAGCGAGCGATACCGGCAGAACTCCACGCACTGCAGAAGCTGCCTTTCCAAC\nATGCCCACCTATTCAGGCCACTTCACCATGAGGTCCCCCTTCAAGTGCGATGCCTGCCTG\nCGGATGGGGAACCTCTATGACATCGATGAAGACCAGATGCTTCAGGAGACAGGTAACCCA\nGCCACCGGGGAGCAGGTCTACCAGCAGGACTGGGCACAGAACAATGCCCTTCAATTACAA\nAAGAACAAGCTAAGGATTAGCCGTCAGCATTCCTACGATAACATTGTCGACAAACCTAGG\nGAGCTAGACCTTAGCAGGCCCTCCCGGAGCATAAGCCTCAAGGACAGGGAACGGCTTCTG\nGAGGGAAATTTTTACGGCAGCCTGTTTAGTGTCCCCTCAAGCAAACTCTCGGGGAAAAAA\nAGCTCCCTTTTCCCCCAAGGTCTGGAGGACAGCAAGAGGAGCAAGTCTCTCTTGCCAGAC\nCACACCTCCGATAACCCTTTCCTCCACTCCCACAGGGATGACCAACGCTTGGTTATTGGG\nAGATGCCCCTCGGACCCTTACAAACACTCGTTGCCATCCCAGGCGGTGAATGACAGCTAT\nCTTCGGTCGTCCTTGAGGTCAACGGCATCGTACTGTTCCAGGGACAGTCGGGGCCACAAT\nGATGTGTATATTTCGGAGCATGTTATGCCTTATGCTGCAAATAAGAATAATATGTACTCT\nACCCCCAGGGTTTTAAATTCCTGCAGCAATAGACGCGTGTACAAGAAAATGCCTAGTATC\nGAATCTGATGTTTAA'),('Glutamate receptor ionotropic, NMDA 2B','None','Human','Zinc ion binding','NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. In concert with DAPK1 at extrasynaptic sites, acts as a central mediator for stroke damage. Its phosphorylation at Ser-1303 by DAPK1 enhances synaptic NMDA receptor channel activity inducing injurious Ca2+ influx through them, resulting in an irreversible neuronal death (By similarity).','GRIN2B','166365.885','DB00454','>lcl|BSEQ0010289|Glutamate receptor ionotropic, NMDA 2B (GRIN2B)\nATGAAGCCCAGAGCGGAGTGCTGTTCTCCCAAGTTCTGGTTGGTGTTGGCCGTCCTGGCC\nGTGTCAGGCAGCAGAGCTCGTTCTCAGAAGAGCCCCCCCAGCATTGGCATTGCTGTCATC\nCTCGTGGGCACTTCCGACGAGGTGGCCATCAAGGATGCCCACGAGAAAGATGATTTCCAC\nCATCTCTCCGTGGTACCCCGGGTGGAACTGGTAGCCATGAATGAGACCGACCCAAAGAGC\nATCATCACCCGCATCTGTGATCTCATGTCTGACCGGAAGATCCAGGGGGTGGTGTTTGCT\nGATGACACAGACCAGGAAGCCATCGCCCAGATCCTCGATTTCATTTCAGCACAGACTCTC\nACCCCCATCCTGGGCATCCACGGGGGCTCCTCTATGATAATGGCAGATAAGGATGAATCC\nTCCATGTTCTTCCAGTTTGGCCCATCAATTGAACAGCAAGCTTCCGTAATGCTCAACATC\nATGGAAGAATATGACTGGTACATCTTTTCTATCGTCACCACCTATTTCCCTGGCTACCAG\nGACTTTGTAAACAAGATCCGCAGCACCATTGAGAATAGCTTTGTGGGCTGGGAGCTAGAG\nGAGGTCCTCCTACTGGACATGTCCCTGGACGATGGAGATTCTAAGATCCAGAATCAGCTC\nAAGAAACTTCAAAGCCCCATCATTCTTCTTTACTGTACCAAGGAAGAAGCCACCTACATC\nTTTGAAGTGGCCAACTCAGTAGGGCTGACTGGCTATGGCTACACGTGGATCGTGCCCAGT\nCTGGTGGCAGGGGATACAGACACAGTGCCTGCGGAGTTCCCCACTGGGCTCATCTCTGTA\nTCATATGATGAATGGGACTATGGCCTCCCCGCCAGAGTGAGAGATGGAATTGCCATAATC\nACCACTGCTGCTTCTGACATGCTGTCTGAGCACAGCTTCATCCCTGAGCCCAAAAGCAGT\nTGTTACAACACCCACGAGAAGAGAATCTACCAGTCCAATATGCTAAATAGGTATCTGATC\nAATGTCACTTTTGAGGGGAGGAATTTGTCCTTCAGTGAAGATGGCTACCAGATGCACCCG\nAAACTGGTGATAATTCTTCTGAACAAGGAGAGGAAGTGGGAAAGGGTGGGGAAGTGGAAA\nGACAAGTCCCTGCAGATGAAGTACTATGTGTGGCCCCGAATGTGTCCAGAGACTGAAGAG\nCAGGAGGATGACCATCTGAGCATTGTGACCCTGGAGGAGGCACCATTTGTCATTGTGGAA\nAGTGTGGACCCTCTGAGTGGAACCTGCATGAGGAACACAGTCCCCTGCCAAAAACGCATA\nGTCACTGAGAATAAAACAGACGAGGAGCCGGGTTACATCAAAAAATGCTGCAAGGGGTTC\nTGTATTGACATCCTTAAGAAAATTTCTAAATCTGTGAAGTTCACCTATGACCTTTACCTG\nGTTACCAATGGCAAGCATGGGAAGAAAATCAATGGAACCTGGAATGGTATGATTGGAGAG\nGTGGTCATGAAGAGGGCCTACATGGCAGTGGGCTCACTCACCATCAATGAGGAACGATCG\nGAGGTGGTCGACTTCTCTGTGCCCTTCATAGAGACAGGCATCAGTGTCATGGTGTCACGC\nAGCAATGGGACTGTCTCACCTTCTGCCTTCTTAGAGCCATTCAGCGCTGACGTATGGGTG\nATGATGTTTGTGATGCTGCTCATCGTCTCAGCCGTGGCTGTCTTTGTCTTTGAGTACTTC\nAGCCCTGTGGGTTATAACAGGTGCCTCGCTGATGGCAGAGAGCCTGGTGGACCCTCTTTC\nACCATCGGCAAAGCTATTTGGTTGCTCTGGGGTCTGGTGTTTAACAACTCCGTACCTGTG\nCAGAACCCAAAGGGGACCACCTCCAAGATCATGGTGTCAGTGTGGGCCTTCTTTGCTGTC\nATCTTCCTGGCCAGCTACACTGCCAACTTAGCTGCCTTCATGATCCAAGAGGAATATGTG\nGACCAGGTTTCTGGCCTGAGCGACAAAAAGTTCCAGAGACCTAATGACTTCTCACCCCCT\nTTCCGCTTTGGGACCGTGCCCAACGGCAGCACAGAGAGAAATATTCGCAATAACTATGCA\nGAAATGCATGCCTACATGGGAAAGTTCAACCAGAGGGGTGTAGATGATGCATTGCTCTCC\nCTGAAAACAGGGAAACTGGATGCCTTCATCTATGATGCAGCAGTGCTGAACTATATGGCA\nGGCAGAGATGAAGGCTGCAAGCTGGTGACCATTGGCAGTGGGAAGGTCTTTGCTTCCACT\nGGCTATGGCATTGCCATCCAAAAAGATTCTGGGTGGAAGCGCCAGGTGGACCTTGCTATC\nCTGCAGCTCTTTGGAGATGGGGAGATGGAAGAACTGGAAGCTCTCTGGCTCACTGGCATT\nTGTCACAATGAGAAGAATGAGGTCATGAGCAGCCAGCTGGACATTGACAACATGGCAGGG\nGTCTTCTACATGTTGGGGGCGGCCATGGCTCTCAGCCTCATCACCTTCATCTGCGAACAC\nCTTTTCTATTGGCAGTTCCGACATTGCTTTATGGGTGTCTGTTCTGGCAAGCCTGGCATG\nGTCTTCTCCATCAGCAGAGGTATCTACAGCTGCATCCATGGGGTGGCGATCGAGGAGCGC\nCAGTCTGTAATGAACTCCCCCACCGCAACCATGAACAACACACACTCCAACATCCTGCGC\nCTGCTGCGCACGGCCAAGAACATGGCTAACCTGTCTGGTGTGAATGGCTCACCGCAGAGC\nGCCCTGGACTTCATCCGACGGGAGTCATCCGTCTATGACATCTCAGAGCACCGCCGCAGC\nTTCACGCATTCTGACTGCAAATCCTACAACAACCCGCCCTGTGAGGAGAACCTCTTCAGT\nGACTACATCAGTGAGGTAGAGAGAACGTTCGGGAACCTGCAGCTGAAGGACAGCAACGTG\nTACCAAGATCACTACCACCATCACCACCGGCCCCATAGTATTGGCAGTGCCAGCTCCATC\nGATGGGCTCTACGACTGTGACAACCCACCCTTCACCACCCAGTCCAGGTCCATCAGCAAG\nAAGCCCCTGGACATCGGCCTCCCCTCCTCCAAGCACAGCCAGCTCAGTGACCTGTACGGC\nAAATTCTCCTTCAAGAGCGACCGCTACAGTGGCCACGACGACTTGATCCGCTCCGATGTC\nTCTGACATCTCAACCCACACCGTCACCTATGGGAACATCGAGGGCAATGCCGCCAAGAGG\nCGTAAGCAGCAATATAAGGACAGCCTGAAGAAGCGGCCTGCCTCGGCCAAGTCCCGCAGG\nGAGTTTGACGAGATCGAGCTGGCCTACCGTCGCCGACCGCCCCGCTCCCCTGACCACAAG\nCGCTACTTCAGGGACAAGGAAGGGCTACGGGACTTCTACCTGGACCAGTTCCGAACAAAG\nGAGAACTCACCCCACTGGGAGCACGTAGACCTGACCGACATCTACAAGGAGCGGAGTGAT\nGACTTTAAGCGCGACTCCGTCAGCGGAGGAGGGCCCTGTACCAACAGGTCTCACATCAAG\nCACGGGACGGGCGACAAACACGGCGTGGTCAGCGGGGTACCTGCACCTTGGGAGAAGAAC\nCTGACCAACGTGGAGTGGGAGGACCGGTCCGGGGGCAACTTCTGCCGCAGCTGTCCCTCC\nAAGCTGCACAACTACTCCACGACGGTGACGGGTCAGAACTCGGGCAGGCAGGCGTGCATC\nCGGTGTGAGGCTTGCAAGAAAGCAGGCAACCTGTATGACATCAGTGAGGACAACTCCCTG\nCAGGAACTGGACCAGCCGGCTGCCCCAGTGGCGGTGACGTCAAACGCCTCCACCACTAAG\nTACCCTCAGAGCCCGACTAATTCCAAGGCCCAGAAGAAGAACCGGAACAAACTGCGCCGG\nCAGCACTCCTACGACACCTTCGTGGACCTGCAGAAGGAAGAAGCCGCCCTGGCCCCGCGC\nAGCGTAAGCCTGAAAGACAAGGGCCGATTCATGGATGGGAGCCCCTACGCCCACATGTTT\nGAGATGTCAGCTGGCGAGAGCACCTTTGCCAACAACAAGTCCTCAGTGCCCACTGCCGGA\nCATCACCACCACAACAACCCCGGCGGCGGGTACATGCTCAGCAAGTCGCTCTACCCTGAC\nCGGGTCACGCAAAACCCTTTCATCCCCACTTTTGGGGACGACCAGTGCTTGCTCCATGGC\nAGCAAATCCTACTTCTTCAGGCAGCCCACGGTGGCGGGGGCGTCGAAAGCCAGGCCGGAC\nTTCCGGGCCCTTGTCACCAACAAGCCGGTGGTCTCGGCCCTTCATGGGGCCGTGCCAGCC\nCGTTTCCAGAAGGACATCTGTATAGGGAACCAGTCCAACCCCTGTGTGCCTAACAACAAA\nAACCCCAGGGCTTTCAATGGCTCCAGCAATGGGCATGTTTATGAGAAACTTTCTAGTATT\nGAGTCTGATGTCTGA'),('Glutamate receptor ionotropic, NMDA 2C','None','Human','Nmda glutamate receptor activity','NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine.','GRIN2C','134207.77','DB00454','>lcl|BSEQ0010318|Glutamate receptor ionotropic, NMDA 2C (GRIN2C)\nATGGGTGGGGCCCTGGGGCCGGCCCTGTTGCTCACCTCGCTCTTCGGTGCCTGGGCAGGG\nCTGGGTCCGGGGCAGGGCGAGCAGGGCATGACGGTGGCCGTGGTGTTTAGCAGCTCAGGG\nCCGCCCCAGGCCCAGTTCCGTGCCCGCCTCACCCCCCAGAGCTTCCTGGACCTACCCCTG\nGAGATCCAGCCGCTCACAGTTGGGGTCAACACCACCAACCCCAGCAGCCTCCTCACCCAG\nATCTGCGGCCTCCTGGGTGCTGCCCACGTCCACGGCATTGTCTTTGAGGACAACGTGGAC\nACCGAGGCGGTGGCCCAGATCCTTGACTTCATCTCCTCCCAGACCCATGTGCCCATCCTC\nAGCATCAGCGGAGGCTCTGCTGTGGTCCTCACCCCCAAGGAGCCGGGCTCCGCCTTCCTG\nCAGCTGGGCGTGTCCCTGGAGCAGCAGCTGCAGGTGCTGTTCAAGGTGCTGGAAGAGTAC\nGACTGGAGCGCCTTCGCCGTCATCACCAGCCTGCACCCGGGCCACGCGCTCTTCCTGGAG\nGGCGTGCGCGCCGTCGCCGACGCCAGCCACGTGAGTTGGCGGCTGCTGGACGTGGTCACG\nCTGGAGCTGGGCCCGGGAGGGCCGCGCGCGCGCACGCAGCGCCTGCTGCGCCAGCTCGAC\nGCGCCCGTGTTTGTGGCCTACTGCTCGCGCGAGGAGGCCGAGGTGCTCTTCGCCGAGGCG\nGCGCAGGCCGGTCTGGTGGGGCCCGGCCACGTGTGGCTGGTGCCCAACCTGGCGCTGGGC\nAGCACCGATGCGCCCCCCGCCACCTTCCCCGTGGGCCTCATCAGCGTCGTCACCGAGAGC\nTGGCGCCTCAGCCTGCGCCAGAAGGTGCGCGACGGCGTGGCCATTCTGGCCCTGGGCGCC\nCACAGCTACTGGCGCCAGCATGGAACCCTGCCAGCCCCGGCCGGGGACTGCCGTGTTCAC\nCCTGGGCCCGTCAGCCCTGCCCGGGAGGCCTTCTACAGGCACCTACTGAATGTCACCTGG\nGAGGGCCGAGACTTCTCCTTCAGCCCTGGTGGGTACCTGGTCCAGCCCACCATGGTGGTG\nATCGCCCTCAACCGGCACCGCCTCTGGGAGATGGTGGGGCGCTGGGAGCATGGCGTCCTA\nTACATGAAGTACCCCGTGTGGCCTCGCTACAGTGCCTCTCTGCAGCCTGTGGTGGACAGT\nCGGCACCTGACGGTGGCCACGCTGGAAGAGCGGCCCTTTGTCATCGTGGAGAGCCCTGAC\nCCTGGCACAGGAGGCTGTGTCCCCAACACCGTGCCCTGCCGCAGGCAGAGCAACCACACC\nTTCAGCAGCGGGGACGTGGCCCCCTACACCAAGCTCTGCTGTAAGGGATTCTGCATCGAC\nATCCTCAAGAAGCTGGCCAGAGTGGTCAAATTCTCCTACGACCTGTACCTGGTGACCAAC\nGGCAAGCATGGCAAGCGGGTGCGCGGCGTATGGAACGGCATGATTGGGGAGGTGTACTAC\nAAGCGGGCAGACATGGCCATCGGCTCCCTCACCATCAATGAGGAACGCTCCGAGATCGTA\nGACTTCTCTGTACCCTTTGTGGAGACGGGCATCAGTGTGATGGTGGCTCGCAGCAATGGC\nACCGTCTCCCCCTCGGCCTTCTTGGAGCCATATAGCCCTGCAGTGTGGGTGATGATGTTT\nGTCATGTGCCTCACTGTGGTGGCCATCACCGTCTTCATGTTCGAGTACTTCAGCCCTGTC\nAGCTACAACCAGAACCTCACCAGAGGCAAGAAGTCCGGGGGCCCAGCTTTCACTATCGGC\nAAGTCCGTGTGGCTGCTGTGGGCGCTGGTCTTCAACAACTCAGTGCCCATCGAGAACCCG\nCGGGGCACCACCAGCAAGATCATGGTTCTGGTCTGGGCCTTCTTTGCTGTCATCTTCCTC\nGCCAGCTACACGGCCAACCTGGCCGCCTTCATGATCCAAGAGCAATACATCGACACTGTG\nTCGGGCCTCAGTGACAAGAAGTTTCAGCGGCCTCAAGATCAGTACCCACCTTTCCGCTTC\nGGCACGGTGCCCAACGGCAGCACGGAGCGGAACATCCGCAGTAACTACCGTGACATGCAC\nACCCACATGGTCAAGTTCAACCAGCGCTCGGTGGAGGACGCGCTCACCAGCCTCAAGATG\nGGGAAGCTGGATGCCTTCATCTATGATGCTGCTGTCCTCAACTACATGGCAGGCAAGGAC\nGAGGGCTGCAAGCTGGTCACCATTGGGTCTGGCAAGGTCTTTGCTACCACTGGCTACGGC\nATCGCCATGCAGAAGGACTCCCACTGGAAGCGGGCCATAGACCTGGCGCTCTTGCAGTTC\nCTGGGGGACGGAGAGACACAGAAACTGGAGACAGTGTGGCTCTCAGGGATCTGCCAGAAT\nGAGAAGAACGAGGTGATGAGCAGCAAGCTGGACATCGACAACATGGCAGGCGTCTTCTAC\nATGCTGCTGGTGGCCATGGGGCTGGCCCTGCTGGTCTTCGCCTGGGAGCACCTGGTCTAC\nTGGAAGCTGCGCCACTCGGTGCCCAACTCATCCCAGCTGGACTTCCTGCTGGCTTTCAGC\nAGGGGCATCTACAGCTGCTTCAGCGGGGTGCAGAGCCTCGCCAGCCCACCGCGGCAGGCC\nAGCCCGGACCTCACGGCCAGCTCGGCCCAGGCCAGCGTGCTCAAGATGCTGCAGGCAGCC\nCGCGACATGGTGACCACGGCGGGCGTAAGCAGCTCCCTGGACCGCGCCACTCGCACCATC\nGAGAATTGGGGTGGCGGCCGCCGTGCGCCCCCACCGTCCCCCTGCCCGACCCCGCGGTCT\nGGCCCCAGCCCATGCCTGCCCACCCCCGACCCGCCCCCAGAGCCGAGCCCCACGGGCTGG\nGGACCGCCAGACGGGGGTCGCGCGGCGCTTGTGCGCAGGGCTCCGCAGCCCCCGGGCCGC\nCCCCCGACGCCGGGGCCGCCCCTGTCCGACGTCTCCCGAGTGTCGCGCCGCCCAGCCTGG\nGAGGCGCGGTGGCCGGTGCGGACCGGGCACTGCGGGAGGCACCTCTCGGCCTCCGAGCGG\nCCCCTGTCGCCCGCGCGCTGTCACTACAGCTCCTTTCCTCGAGCCGACCGATCCGGCCGC\nCCCTTCCTCCCGCTCTTCCCGGAGCTGGAGGACCTGCCGCTGCTCGGTCCGGAGCAGCTG\nGCCCGGCGGGAGGCCCTGCTGCACGCGGCCTGGGCCCGGGGCTCGCGCCCGCGTCACGCT\nTCCCTGCCCAGCTCCGTGGCCGAGGCCTTCGCTCGGCCCAGCTCGCTGCCCGCTGGGTGC\nACCGGCCCCGCCTGCGCCCGCCCCGACGGCCACTCGGCCTGCAGGCGCTTGGCGCAGGCG\nCAGTCGATGTGCTTGCCGATCTACCGGGAGGCCTGCCAGGAGGGCGAGCAGGCAGGGGCC\nCCCGCCTGGCAGCACAGACAGCACGTCTGCCTGCACGCCCACGCCCACCTGCCATTTTGC\nTGGGGGGCTGTCTGTCCTCACCTTCCACCCTGTGCCAGCCACGGCTCCTGGCTCTCCGGG\nGCCTGGGGGCCTCTGGGGCACAGGGGCAGGACTCTGGGGCTGGGCACAGGCTACAGAGAC\nAGTGGGGGACTGGACGAGATCAGCAGGGTAGCCCGTGGGACGCAAGGCTTCCCGGGACCC\nTGCACCTGGAGACGGATCTCCAGTCTGGAGTCAGAAGTGTGA'),('Glutamate receptor ionotropic, NMDA 2D','None','Human','Nmda glutamate receptor activity','NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine.','GRIN2D','143750.685','DB00454','>lcl|BSEQ0016081|Glutamate receptor ionotropic, NMDA 2D (GRIN2D)\nATGCGCGGCGCCGGTGGCCCCCGCGGCCCTCGGGGCCCCGCTAAGATGCTGCTGCTGCTG\nGCGCTGGCCTGCGCCAGCCCGTTCCCGGAGGAGGCGCCGGGGCCGGGCGGGGCCGGTGGG\nCCCGGCGGCGGCCTCGGCGGGGCGCGGCCGCTCAACGTGGCGCTCGTGTTCTCGGGGCCC\nGCGTACGCGGCCGAGGCGGCACGCCTGGGCCCGGCCGTGGCGGCGGCGGTGCGCAGCCCG\nGGCCTAGACGTGCGGCCCGTGGCGCTGGTGCTCAACGGCTCGGACCCGCGCAGCCTCGTG\nCTGCAGCTCTGCGACCTGCTGTCGGGGTTGCGCGTGCACGGCGTGGTCTTCGAAGACGAC\nTCGCGCGCGCCCGCCGTCGCGCCCATCCTCGACTTCCTGTCGGCGCAGACCTCGCTGCCC\nATCGTGGCCGTGCACGGCGGCGCCGCGCTCGTGCTCACGCCCAAGGAGAAGGGCTCCACC\nTTCCTGCAGCTGGGCTCTTCCACCGAGCAACAGCTTCAGGTCATCTTTGAGGTGCTGGAG\nGAGTATGACTGGACGTCCTTTGTAGCCGTGACCACTCGTGCCCCTGGCCACCGGGCCTTC\nCTGTCCTACATTGAGGTGCTGACTGACGGTAGTCTGGTGGGCTGGGAGCACCGCGGAGCG\nCTGACGCTGGACCCTGGGGCGGGCGAGGCCGTGCTCAGTGCCCAGCTCCGCAGTGTCAGC\nGCGCAGATCCGCCTGCTCTTCTGCGCCCGAGAGGAGGCCGAGCCCGTGTTCCGCGCAGCT\nGAGGAGGCTGGCCTCACTGGATCTGGCTACGTCTGGTTCATGGTGGGGCCCCAGCTGGCT\nGGAGGCGGGGGCTCTGGGGCCCCTGGTGAGCCCCCTCTTCTGCCAGGAGGCGCCCCCCTG\nCCTGCCGGGCTGTTTGCAGTGCGCTCGGCTGGCTGGCGGGATGACCTGGCTCGGCGAGTG\nGCAGCTGGCGTGGCCGTAGTGGCCAGAGGTGCCCAGGCCCTGCTGCGTGATTATGGTTTC\nCTTCCTGAGCTCGGCCACGACTGTCGCGCCCAGAACCGCACCCACCGCGGCGAGAGTCTG\nCATAGGTACTTCATGAACATCACGTGGGATAACCGGGATTACTCCTTCAATGAGGACGGC\nTTCCTAGTGAACCCCTCCCTGGTGGTCATCTCCCTCACCAGAGACAGGACGTGGGAGGTG\nGTGGGCAGCTGGGAGCAGCAGACGCTCCGCCTCAAGTACCCGCTGTGGTCCCGCTATGGT\nCGCTTCCTGCAGCCAGTGGACGACACGCAGCACCTCACGGTGGCCACGCTGGAGGAAAGG\nCCGTTTGTCATCGTGGAGCCTGCAGACCCTATCAGCGGCACCTGCATCCGAGACTCCGTC\nCCCTGCCGGAGCCAGCTCAACCGAACCCACAGCCCTCCACCGGATGCCCCCCGCCCGGAA\nAAGCGCTGCTGCAAGGGTTTCTGCATCGACATTCTGAAGCGGCTGGCGCATACCATCGGC\nTTCAGCTACGACCTCTACCTGGTCACCAATGGCAAGCACGGAAAGAAGATCGATGGCGTC\nTGGAACGGCATGATCGGGGAGGTGTTCTACCAGCGCGCAGACATGGCCATCGGCTCCCTC\nACCATCAACGAGGAGCGCTCCGAGATCGTGGACTTCTCCGTCCCCTTCGTGGAGACCGGC\nATCAGCGTCATGGTGGCGCGCAGCAATGGCACGGTGTCCCCCTCGGCCTTCCTCGAGCCC\nTACAGCCCCGCCGTGTGGGTGATGATGTTCGTCATGTGCCTCACTGTGGTCGCCGTCACT\nGTTTTCATCTTCGAGTACCTCAGTCCTGTTGGTTACAACCGCAGCCTGGCCACGGGCAAG\nCGCCCTGGCGGTTCAACCTTCACCATTGGGAAATCCATCTGGCTGCTCTGGGCCCTGGTG\nTTCAATAATTCGGTGCCCGTGGAGAACCCCCGGGGAACCACCAGCAAAATCATGGTGCTG\nGTGTGGGCCTTCTTCGCCGTCATCTTCCTCGCCAGCTACACAGCCAACCTGGCCGCCTTC\nATGATCCAGGAGGAGTACGTGGATACTGTGTCTGGGCTCAGTGACCGCAAGTTCCAGAGG\nCCCCAGGAGCAGTACCCGCCCCTGAAGTTTGGGACCGTGCCCAACGGCTCCACGGAGAAG\nAACATCCGCAGCAACTATCCCGACATGCACAGCTACATGGTGCGCTACAACCAGCCCCGC\nGTAGAGGAAGCGCTCACTCAGCTCAAGGCAGGGAAGCTGGACGCCTTCATCTACGATGCT\nGCAGTGCTCAATTACATGGCCCGCAAGGACGAGGGCTGCAAGCTTGTCACCATCGGCTCC\nGGCAAGGTCTTCGCCACGACAGGCTATGGCATCGCCCTGCACAAGGGCTCCCGCTGGAAG\nCGGCCCATCGACCTGGCGTTGCTGCAGTTCCTGGGGGATGATGAGATCGAGATGCTGGAG\nCGGCTGTGGCTCTCTGGGATCTGCCACAATGACAAAATCGAGGTGATGAGCAGCAAGCTG\nGACATCGACAACATGGCGGGCGTCTTCTACATGCTCCTGGTGGCCATGGGCCTGTCCCTG\nCTGGTCTTCGCCTGGGAGCACCTGGTGTACTGGCGCCTGCGGCACTGCCTGGGGCCCACC\nCACCGCATGGACTTCCTGCTGGCCTTCTCCAGGGGCATGTACAGCTGCTGCAGCGCTGAG\nGCCGCCCCACCGCCCGCCAAGCCCCCGCCGCCGCCACAGCCCCTGCCCAGCCCCGCGTAC\nCCCGCGCCGCGGCCGGCTCCCGGGCCCGCACCTTTCGTGCCCCGCGAGCGCGCCTCAGTG\nGACCGCTGGCGCCGGACCAAGGGCGCGGGGCCGCCGGGGGGCGCGGGCCTGGCCGACGGC\nTTCCACCGCTACTACGGCCCCATCGAGCCGCAGGGCCTAGGCCTCGGCCTGGGCGAAGCG\nCGCGCGGCACCGCGGGGCGCAGCCGGGCGCCCGCTGTCCCCGCCGGCCGCTCAGCCCCCG\nCAGAAGCCGCCGCCCTCCTATTTCGCCATCGTACGCGACAAGGAGCCAGCCGAGCCCCCC\nGCCGGCGCCTTCCCCGGCTTCCCGTCGCCGCCCGCGCCCCCCGCCGCCGCGGCCACCGCC\nGTCGGGCCGCCACTCTGCCGCTTGGCCTTCGAGGACGAGAGCCCGCCGGCGCCCGCGCGG\nTGGCCGCGCTCGGACCCCGAGAGCCAACCCCTGCTGGGGCCAGGCGCGGGCGGCGCGGGG\nGGCACGGGGGGCGCAGGCGGAGGAGCCCCGGCCGCTCCGCCCCCGTGCCGCGCCGCGCCG\nCCCCCGTGCCCTTACCTCGATCTCGAGCCGTCGCCGTCGGACTCGGAGGACTCGGAGAGC\nCTGGGCGGCGCGTCGCTGGGCGGCCTGGAGCCCTGGTGGTTCGCCGACTTCCCTTACCCG\nTATGCCGAGCGCCTCGGGCCGCCGCCCGGCCGCTACTGGTCGGTCGACAAGCTCGGGGGC\nTGGCGCGCCGGGAGCTGGGACTACCTGCCCCCGCGCAGCGGTCCGGCCGCCTGGCACTGT\nCGGCACTGCGCCAGCCTGGAGCTGCTGCCGCCGCCGCGCCATCTCAGCTGCTCGCACGAT\nGGCCTGGACGGCGGCTGGTGGGCGCCACCGCCTCCACCCTGGGCCGCCGGGCCCCTGCCC\nCGACGCCGGGCCCGCTGCGGGTGCCCGCGGTCGCACCCGCACCGCCCGCGGGCCTCGCAC\nCGCACGCCCGCCGCCGCCGCGCCCCACCACCACAGGCACCGGCGCGCCGCTGGGGGCTGG\nGACCTCCCGCCGCCCGCGCCCACCTCGCGCTCGCTCGAGGACCTCAGCTCGTGCCCTCGC\nGCCGCCCCTGCGCGCAGGCTTACCGGGCCCTCCCGCCACGCTCGCAGGTGTCCGCACGCC\nGCGCACTGGGGGCCGCCGCTGCCCACAGCTTCCCACCGGAGACACCGGGGCGGGGACCTG\nGGCACCCGCAGGGGCTCGGCGCACTTCTCTAGCCTCGAGTCCGAGGTATGA'),('Glutamate receptor ionotropic, NMDA 3A','None','Human','Protein phosphatase 2a binding','NMDA receptor subtype of glutamate-gated ion channels with reduced single-channel conductance, low calcium permeability and low voltage-dependent sensitivity to magnesium. Mediated by glycine. May play a role in the development of dendritic spines. May play a role in PPP2CB-NMDAR mediated signaling mechanism (By similarity).','GRIN3A','125464.07','DB01221','>lcl|BSEQ0016161|Glutamate receptor ionotropic, NMDA 3A (GRIN3A)\nATGAGGAGACTGAGTTTGTGGTGGCTGCTGAGCAGGGTCTGTCTGCTGTTGCCGCCGCCC\nTGCGCACTGGTGCTGGCCGGGGTGCCCAGCTCCTCCTCGCACCCGCAGCCCTGCCAGATC\nCTCAAGCGCATCGGGCACGCGGTGAGGGTGGGCGCGGTGCACTTGCAGCCCTGGACCACC\nGCCCCCCGCGCGGCCAGCCGCGCTCCGGACGACAGCCGAGCAGGAGCCCAGAGGGATGAG\nCCGGAGCCAGGGACTAGGCGGTCCCCGGCGCCCTCGCCGGGCGCACGCTGGTTGGGGAGC\nACCCTGCATGGCCGGGGGCCGCCGGGCTCCCGTAAGCCCGGGGAGGGCGCCAGGGCGGAG\nGCCCTGTGGCCACGGGACGCCCTCCTATTTGCCGTGGACAACCTGAACCGCGTGGAAGGG\nCTGCTACCCTACAACCTGTCTTTGGAAGTAGTGATGGCCATCGAGGCAGGCCTGGGCGAT\nCTGCCACTTTTGCCCTTCTCCTCCCCTAGTTCGCCATGGAGCAGTGACCCTTTCTCCTTC\nCTGCAAAGTGTGTGCCATACCGTGGTGGTGCAAGGGGTGTCGGCGCTGCTCGCCTTCCCC\nCAGAGCCAGGGCGAAATGATGGAGCTCGACTTGGTCAGCTTAGTCCTGCACATTCCAGTG\nATCAGCATCGTGCGCCACGAGTTTCCACGGGAGAGTCAGAATCCCCTTCACCTACAACTG\nAGTTTAGAAAATTCATTAAGTTCTGATGCTGATGTCACTGTCTCAATCCTGACCATGAAC\nAACTGGTACAATTTTAGCTTGTTGCTGTGCCAGGAAGACTGGAACATCACCGACTTCCTC\nCTCCTTACCCAGAATAATTCCAAGTTCCACCTTGGTTCTATCATCAACATCACCGCTAAC\nCTCCCCTCCACCCAGGACCTCTTGAGCTTCCTACAGATCCAGCTTGAGAGTATTAAGAAC\nAGCACACCCACAGTGGTGATGTTTGGCTGCGACATGGAAAGTATCCGGCGGATTTTCGAA\nATTACAACCCAGTTTGGGGTCATGCCCCCTGAACTTCGTTGGGTGCTGGGAGATTCCCAG\nAATGTGGAGGAACTGAGGACAGAGGGTCTGCCCTTAGGGCTCATTGCTCATGGAAAAACA\nACACAGTCTGTCTTTGAGCACTACGTACAAGATGCTATGGAGCTGGTCGCAAGAGCTGTA\nGCCACAGCCACCATGATCCAACCAGAACTTGCTCTCATTCCCAGCACGATGAACTGCATG\nGAGGTGGAAACTACAAATCTCACTTCAGGACAATATTTATCAAGGTTTCTAGCCAATACC\nACTTTCAGAGGCCTCAGTGGTTCCATCAGAGTAAAAGGTTCCACCATCGTCAGCTCAGAA\nAACAACTTTTTCATCTGGAATCTTCAACATGACCCCATGGGAAAGCCAATGTGGACCCGC\nTTGGGCAGCTGGCAGGGGGGAAAGATTGTCATGGACTATGGAATATGGCCAGAGCAGGCC\nCAGAGACACAAAACCCACTTCCAACATCCAAGTAAGCTACACTTGAGAGTGGTTACCCTG\nATTGAGCATCCTTTTGTCTTCACAAGGGAGGTAGATGATGAAGGCTTGTGCCCTGCTGGC\nCAACTCTGTCTAGACCCCATGACTAATGACTCTTCCACATTGGACAGCCTTTTTAGCAGC\nCTCCATAGCAGTAATGATACAGTGCCCATTAAATTCAAGAAGTGCTGCTATGGATATTGC\nATTGATCTGCTGGAAAAGATAGCAGAAGACATGAACTTTGACTTCGACCTCTATATTGTA\nGGGGATGGAAAGTATGGAGCATGGAAAAATGGGCACTGGACTGGGCTAGTGGGTGATCTC\nCTGAGAGGGACTGCCCACATGGCAGTCACTTCCTTTAGCATCAATACTGCACGGAGCCAG\nGTGATAGATTTCACCAGCCCTTTCTTCTCCACCAGCTTGGGCATCTTAGTGAGGACCCGA\nGATACAGCAGCTCCCATTGGAGCCTTCATGTGGCCACTCCACTGGACAATGTGGCTGGGG\nATTTTTGTGGCTCTGCACATCACTGCCGTCTTCCTCACTCTGTATGAATGGAAGAGTCCA\nTTTGGTTTGACTCCCAAGGGGCGAAATAGAAGTAAAGTCTTCTCCTTTTCTTCAGCCTTG\nAACATCTGTTATGCCCTCTTGTTTGGCAGAACAGTGGCCATCAAACCTCCAAAATGTTGG\nACTGGAAGGTTTCTAATGAACCTTTGGGCCATTTTCTGTATGTTTTGCCTTTCCACATAC\nACGGCAAACTTGGCTGCTGTCATGGTAGGTGAGAAGATCTATGAAGAGCTTTCTGGAATA\nCATGACCCCAAGTTACATCATCCTTCCCAAGGATTCCGCTTTGGAACTGTCCGAGAAAGC\nAGTGCTGAAGATTATGTGAGACAAAGTTTCCCAGAGATGCATGAATATATGAGAAGGTAC\nAATGTTCCAGCCACCCCTGATGGAGTGGAGTATCTGAAGAATGATCCAGAGAAACTAGAC\nGCCTTCATCATGGACAAAGCCCTTCTGGATTATGAAGTGTCAATAGATGCTGACTGCAAA\nCTTCTCACTGTGGGGAAGCCATTTGCCATAGAAGGATACGGCATTGGCCTCCCACCCAAC\nTCTCCATTGACCGCCAACATATCCGAGCTAATCAGTCAATACAAGTCACATGGGTTTATG\nGATATGCTCCATGACAAGTGGTACAGGGTGGTTCCCTGTGGCAAGAGAAGTTTTGCTGTC\nACGGAGACTTTGCAAATGGGCATCAAACACTTCTCTGGGCTCTTTGTGCTGCTGTGCATT\nGGATTTGGTCTGTCCATTTTGACCACCATTGGTGAGCACATAGTATACAGGCTGCTGCTA\nCCACGAATCAAAAACAAATCCAAGCTGCAATACTGGCTCCACACCAGCCAGAGATTACAC\nAGAGCAATAAATACATCATTTATAGAGGAAAAGCAGCAGCATTTCAAGACCAAACGTGTG\nGAAAAGAGGTCTAATGTGGGACCCCGTCAGCTTACCGTATGGAATACTTCCAATCTGAGT\nCATGACAACCGACGGAAATACATCTTTAGTGATGAGGAAGGACAAAACCAGCTGGGCATC\nCGGATCCACCAGGACATCCCCCTCCCTCCAAGGAGAAGAGAGCTCCCTGCCTTGCGGACC\nACCAATGGGAAAGCAGACTCCCTAAATGTATCTCGGAACTCAGTGATGCAGGAACTCTCA\nGAGCTCGAGAAGCAGATTCAGGTGATCCGTCAGGAGCTGCAGCTGGCTGTGAGCAGGAAA\nACGGAGCTGGAGGAGTATCAAAGGACAAGTCGGACTTGTGAGTCCTAG'),('Glutathione S-transferase','None','Plasmodium falciparum','Glutathione transferase activity','Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. May also function as a storage protein or ligandin for parasitotoxic ferriprotoporphyrin IX (hemin).','GST','24788.9','DB00608','>lcl|BSEQ0005215|642 bp\nATGAAGCTTGGAGATAATATAGTGTTATATTATTTTGATGCAAGGGGTAAAGCTGAATTG\nATAAGATTAATTTTTGCCTACCTTGGAATAGAATATACAGATAAAAGATTTGGAGTAAAC\nGGTGATGCTTTTGTTGAATTTAAAAATTTTAAAAAAGAAAAGGATACTCCTTTTGAGCAA\nGTACCCATATTACAAATTGGAGATTTGATATTAGCTCAAAGCCAAGCTATAGTTCGTTAT\nTTATCAAAAAAATATAATATATGTGGTGAAAGTGAATTGAATGAATTTTATGCAGATATG\nATATTTTGTGGTGTTCAGGATATTCATTATAAATTTAATAATACCAATTTATTTAAACAA\nAATGAAACAACTTTTTTAAATGAGGATTTACCAAAATGGTCAGGTTATTTTGAGAAACTT\nTTAAAAAAAAATCATACAAATAATAATAATGATAAATATTATTTTGTAGGTAATAATTTA\nACATATGCTGACCTAGCTGTTTTTAATTTATATGATGATATTGAAACAAAATATCCAAGT\nAGCTTGAAAAATTTCCCTTTATTAAAAGCTCATAATGAATTTATAAGTAACTTGCCTAAT\nATCAAAAATTATATAACTAATAGAAAAGAAAGTGTATACTAA'),('Glutathione S-transferase A2','None','Human','Glutathione transferase activity','Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles.','GSTA2','25663.675','DB00608','>lcl|BSEQ0011581|Glutathione S-transferase A2 (GSTA2)\nATGGCAGAGAAGCCCAAGCTCCACTACTCCAATATACGGGGCAGAATGGAGTCCATCCGG\nTGGCTCCTGGCTGCAGCTGGAGTAGAGTTTGAAGAGAAATTTATAAAATCTGCAGAAGAT\nTTGGACAAGTTAAGAAATGATGGATATTTGATGTTCCAGCAAGTGCCAATGGTTGAGATT\nGATGGGATGAAGCTGGTGCAGACCAGAGCCATTCTCAACTACATTGCCAGCAAATACAAC\nCTCTATGGGAAAGACATAAAGGAGAAAGCCCTGATTGATATGTATATAGAAGGTATAGCA\nGATTTGGGTGAAATGATCCTTCTTCTGCCCTTTAGTCAACCTGAGGAACAAGATGCCAAG\nCTTGCCTTGATCCAAGAGAAAACAAAAAATCGCTACTTCCCTGCCTTTGAAAAAGTCTTA\nAAGAGCCACGGACAAGACTACCTTGTTGGCAACAAGCTGAGCCGGGCTGACATTCACCTG\nGTGGAACTTCTCTACTACGTGGAAGAGCTTGACTCTAGCCTTATTTCCAGCTTCCCTCTG\nCTGAAGGCCCTGAAAACCAGAATCAGTAACCTGCCCACAGTGAAGAAGTTTCTACAGCCT\nGGCAGCCCAAGGAAGCCTCCCATGGATGAGAAATCTTTAGAAGAATCAAGGAAGATTTTC\nAGGTTTTAA'),('Glutathione S-transferase P','None','Human','S-nitrosoglutathione binding','Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. Regulates negatively CDK5 activity via p25/p35 translocation to prevent neurodegeneration.','GSTP1','23355.625','DB06246','>lcl|BSEQ0010575|Glutathione S-transferase P (GSTP1)\nATGCCGCCCTACACCGTGGTCTATTTCCCAGTTCGAGGCCGCTGCGCGGCCCTGCGCATG\nCTGCTGGCAGATCAGGGCCAGAGCTGGAAGGAGGAGGTGGTGACCGTGGAGACGTGGCAG\nGAGGGCTCACTCAAAGCCTCCTGCCTATACGGGCAGCTCCCCAAGTTCCAGGACGGAGAC\nCTCACCCTGTACCAGTCCAATACCATCCTGCGTCACCTGGGCCGCACCCTTGGGCTCTAT\nGGGAAGGACCAGCAGGAGGCAGCCCTGGTGGACATGGTGAATGACGGCGTGGAGGACCTC\nCGCTGCAAATACATCTCCCTCATCTACACCAACTATGAGGCGGGCAAGGATGACTATGTG\nAAGGCACTGCCCGGGCAACTGAAGCCTTTTGAGACCCTGCTGTCCCAGAACCAGGGAGGC\nAAGACCTTCATTGTGGGAGACCAGATCTCCTTCGCTGACTACAACCTGCTGGACTTGCTG\nCTGATCCATGAGGTCCTAGCCCCTGGCTGCCTGGATGCGTTCCCCCTGCTCTCAGCATAT\nGTGGGGCGCCTCAGTGCCCGGCCCAAGCTCAAGGCCTTCCTGGCCTCCCCTGAGTACGTG\nAACCTCCCCATCAATGGCAACGGGAAACAGTGA'),('Glycine receptor (alpha-1/beta)','protein group','Human','None','None','None','None','DB14011','None'),('Glycine receptor subunit alpha-1','None','Human','Transmitter-gated ion channel activity','The glycine receptor is a neurotransmitter-gated ion channel. Binding of glycine to its receptor increases the chloride conductance and thus produces hyperpolarization (inhibition of neuronal firing).','GLRA1','52623.35','DB01028','>lcl|BSEQ0016090|Glycine receptor subunit alpha-1 (GLRA1)\nATGTACAGCTTCAATACTCTTCGACTCTACCTTTGGGAGACCATTGTATTCTTCAGCCTT\nGCTGCTTCTAAGGAGGCTGAAGCTGCTCGCTCCGCACCCAAGCCTATGTCACCCTCGGAT\nTTCCTGGATAAGCTAATGGGGAGAACCTCCGGATATGATGCCAGGATCAGGCCCAATTTT\nAAAGGTCCCCCAGTGAACGTGAGCTGCAACATTTTCATCAACAGCTTTGGTTCCATTGCT\nGAGACAACCATGGACTATAGGGTCAACATCTTCCTGCGGCAGCAATGGAACGACCCCCGC\nCTGGCCTATAATGAATACCCTGACGACTCTCTGGACCTGGACCCATCCATGCTGGACTCC\nATCTGGAAACCTGACCTGTTCTTTGCCAACGAGAAGGGGGCCCACTTCCATGAGATCACC\nACAGACAACAAATTGCTAAGGATCTCCCGGAATGGGAATGTCCTCTACAGCATCAGAATC\nACCCTGACACTGGCCTGCCCCATGGACTTGAAGAATTTCCCCATGGATGTCCAGACATGT\nATCATGCAACTGGAAAGCTTTGGATATACGATGAATGACCTCATCTTTGAGTGGCAGGAA\nCAGGGAGCCGTGCAGGTAGCAGATGGACTAACTCTGCCCCAGTTTATCTTGAAGGAAGAG\nAAGGACTTGAGATACTGCACCAAGCACTACAACACAGGTAAATTCACCTGCATTGAGGCC\nCGGTTCCACCTGGAGCGGCAGATGGGTTACTACCTGATTCAGATGTATATTCCCAGCCTG\nCTCATTGTCATCCTCTCATGGATCTCCTTCTGGATCAACATGGATGCTGCACCTGCTCGT\nGTGGGCCTAGGCATCACCACTGTGCTCACCATGACCACCCAGAGCTCCGGCTCTCGAGCA\nTCTCTGCCCAAGGTGTCCTATGTGAAAGCCATTGACATTTGGATGGCAGTTTGCCTGCTC\nTTTGTGTTCTCAGCCCTATTAGAATATGCTGCCGTTAACTTTGTGTCTCGGCAACATAAG\nGAGCTGCTCCGATTCAGGAGGAAGCGGAGACATCACAAGGAGGATGAAGCTGGAGAAGGC\nCGCTTTAACTTCTCTGCCTATGGGATGGGCCCAGCCTGTCTACAGGCCAAGGATGGCATC\nTCAGTCAAGGGCGCCAACAACAGTAACACCACCAACCCCCCTCCTGCACCATCTAAGTCC\nCCAGAGGAGATGCGAAAACTCTTCATCCAGAGGGCCAAGAAGATCGACAAAATATCCCGC\nATTGGCTTCCCCATGGCCTTCCTCATTTTCAACATGTTCTACTGGATCATCTACAAGATT\nGTCCGTAGAGAGGACGTCCACAACCAGTGA'),('Glycine receptor subunit alpha-3','None','Human','Transmitter-gated ion channel activity','The glycine receptor is a neurotransmitter-gated ion channel. Binding of glycine to its receptor increases the chloride conductance and thus produces hyperpolarization (inhibition of neuronal firing).','GLRA3','53799.775','DB14011','>lcl|BSEQ0010287|Glycine receptor subunit alpha-3 (GLRA3)\nATGGCCCACGTGAGACACTTTCGGACATTAGTTTCGGGATTTTACTTCTGGGAAGCAGCA\nCTGTTACTCAGTTTGGTTGCCACAAAGGAAACAGACAGTGCAAGATCTCGAAGTGCTCCA\nATGTCACCTTCTGATTTTCTGGATAAATTAATGGGCAGGACATCAGGATATGATGCAAGA\nATCAGACCCAATTTTAAAGGCCCTCCAGTTAATGTCACATGCAACATATTCATCAACAGC\nTTTGGCTCTATCGCAGAGACGACCATGGATTACAGAGTGAATATCTTTCTTCGTCAGAAA\nTGGAATGATCCCCGCCTCGCGTACAGTGAATATCCTGACGACTCTTTAGACCTCGACCCC\nTCCATGTTGGACTCCATTTGGAAACCTGATTTGTTCTTTGCCAATGAAAAGGGTGCCAAC\nTTTCATGAAGTCACTACAGACAACAAATTGCTAAGAATTTTCAAAAATGGAAATGTTCTT\nTATTCAATAAGATTAACATTAACACTTTCCTGTCCAATGGATCTCAAGAATTTTCCCATG\nGATGTACAAACATGTATAATGCAACTGGAAAGCTTTGGGTACACAATGAATGATCTCATT\nTTTGAATGGCAAGATGAGGCACCCGTACAAGTGGCAGAAGGACTCACTTTGCCCCAGTTT\nCTGTTGAAAGAAGAAAAAGATTTACGATACTGCACTAAACATTACAATACAGGAAAGTTT\nACGTGTATAGAAGTGCGATTCCATCTGGAGCGACAAATGGGATACTATCTGATCCAGATG\nTACATTCCCAGTCTCCTGATTGTTATTCTATCCTGGGTTTCATTCTGGATCAACATGGAT\nGCAGCACCGGCCAGGGTAGCTCTGGGGATAACCACTGTGCTAACGATGACTACACAGAGT\nTCAGGATCACGAGCTTCCTTGCCAAAAGTTTCATATGTCAAAGCTATTGATATTTGGATG\nGCAGTATGCCTCCTTTTTGTGTTTTCAGCACTTCTGGAGTATGCAGCTGTAAATTTTGTA\nTCAAGACAACACAAAGAACTTCTGAGATTTCGACGAAAGAGAAAGAATAAGGATGATGAG\nGTAAGGGAAAGCCGATTCAGCTTCACAGCCTATGGAATGGGACCATGTCTACAAGCAAAG\nGATGGCATGACTCCAAAGGGCCCCAACCACCCTGTCCAGGTAATGCCAAAAAGTCCTGAT\nGAAATGAGGAAGGTCTTTATCGACCGGGCCAAGAAGATTGATACCATCTCCCGAGCCTGC\nTTCCCATTAGCTTTTTTGATTTTTAATATTTTCTACTGGGTTATCTATAAAATTCTTAGG\nCATGAGGATATTCATCAGCAGCAAGATTAA'),('Group IIE secretory phospholipase A2','None','Human','Phospholipase a2 activity','PA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides. Has a preference for arachidonic-containing phospholipids.','PLA2G2E','15988.525','DB03585','>lcl|BSEQ0012633|Group IIE secretory phospholipase A2 (PLA2G2E)\nATGAAATCTCCCCACGTGCTGGTGTTCCTTTGCCTCCTGGTGGCTCTGGTCACCGGGAAC\nCTGGTTCAGTTTGGGGTGATGATCGAGAAGATGACAGGCAAGTCCGCCCTGCAGTACAAC\nGACTATGGCTGTTACTGCGGCATCGGTGGCTCCCACTGGCCGGTGGACCAGACTGACTGG\nTGCTGCCACGCCCACGACTGCTGCTACGGGCGTCTGGAGAAGCTGGGCTGTGAGCCCAAA\nCTGGAAAAGTATCTTTTCTCTGTCAGCGAACGTGGCATTTTCTGCGCCGGCAGGACCACC\nTGCCAGCGGCTGACCTGCGAGTGTGACAAGAGGGCTGCCCTCTGCTTTCGCCGCAACCTG\nGGCACCTACAACCGCAAATATGCCCATTATCCCAACAAGCTGTGCACCGGGCCCACCCCG\nCCCTGCTGA'),('Hematopoietic prostaglandin D synthase','None','Human','Protein homodimerization activity','Bifunctional enzyme which catalyzes both the conversion of PGH2 to PGD2, a prostaglandin involved in smooth muscle contraction/relaxation and a potent inhibitor of platelet aggregation, and the conjugation of glutathione with a wide range of aryl halides and organic isothiocyanates. Also exhibits low glutathione-peroxidase activity towards cumene hydroperoxide.','HPGDS','23343.65','DB07615','>lcl|BSEQ0016336|Hematopoietic prostaglandin D synthase (HPGDS)\nATGCCAAACTACAAACTCACTTATTTTAATATGAGGGGGAGAGCAGAAATTATTCGTTAC\nATATTTGCTTATTTGGACATACAGTATGAAGACCACAGAATAGAACAAGCTGACTGGCCT\nGAAATCAAATCAACTCTCCCATTTGGAAAAATCCCCATTTTGGAAGTTGATGGACTTACT\nCTTCACCAGAGCCTAGCAATAGCAAGATATTTGACCAAAAACACAGATTTGGCTGGAAAC\nACAGAAATGGAACAATGTCATGTTGATGCTATTGTGGACACTCTGGATGATTTCATGTCA\nTGTTTTCCTTGGGCAGAGAAAAAGCAAGATGTGAAAGAGCAGATGTTCAATGAGCTGCTC\nACGTATAATGCGCCTCATCTTATGCAAGACTTGGACACATATTTAGGGGGGAGAGAATGG\nCTTATTGGTAACTCTGTAACTTGGGCAGACTTCTACTGGGAGATTTGCAGTACCACACTT\nTTGGTCTTTAAGCCTGACCTGTTAGACAACCATCCAAGGCTGGTGACTTTACGGAAGAAA\nGTCCAAGCCATTCCTGCCGTCGCTAACTGGATAAAACGAAGGCCCCAAACCAAACTCTAG'),('High affinity nerve growth factor receptor','None','Human','Transmembrane receptor protein tyrosine kinase activity','Receptor tyrosine kinase involved in the development and the maturation of the central and peripheral nervous systems through regulation of proliferation, differentiation and survival of sympathetic and nervous neurons. High affinity receptor for NGF which is its primary ligand, it can also bind and be activated by NTF3/neurotrophin-3. However, NTF3 only supports axonal extension through NTRK1 but has no effect on neuron survival. Upon dimeric NGF ligand-binding, undergoes homodimerization, autophosphorylation and activation. Recruits, phosphorylates and/or activates several downstream effectors including SHC1, FRS2, SH2B1, SH2B2 and PLCG1 that regulate distinct overlapping signaling cascades driving cell survival and differentiation. Through SHC1 and FRS2 activates a GRB2-Ras-MAPK cascade that regulates cell differentiation and survival. Through PLCG1 controls NF-Kappa-B activation and the transcription of genes involved in cell survival. Through SHC1 and SH2B1 controls a Ras-PI3 kinase-AKT1 signaling cascade that is also regulating survival. In absence of ligand and activation, may promote cell death, making the survival of neurons dependent on trophic factors.Isoform TrkA-III is resistant to NGF, constitutively activates AKT1 and NF-kappa-B and is unable to activate the Ras-MAPK signaling cascade. Antagonizes the anti-proliferative NGF-NTRK1 signaling that promotes neuronal precursors differentiation. Isoform TrkA-III promotes angiogenesis and has oncogenic activity when overexpressed.','NTRK1','87496.465','DB00321','>lcl|BSEQ0010727|High affinity nerve growth factor receptor (NTRK1)\nATGAAGGAGGCCGCCCTCATCTGCCTGGCACCCTCTGTACCCCCGATCTTGACGGTGAAG\nTCCTGGGACACCATGCAGTTGCGGGCTGCTAGATCTCGGTGCACAAACTTGTTGGCAGCA\nAGCTACATCGAGAACCAGCAGCATCTGCAGCATCTGGAGCTCCGTGATCTGAGGGGCCTG\nGGGGAGCTGAGAAACCTCACCATCGTGAAGAGTGGTCTCCGTTTCGTGGCGCCAGATGCC\nTTCCATTTCACTCCTCGGCTCAGTCGCCTGAATCTCTCCTTCAACGCTCTGGAGTCTCTC\nTCCTGGAAAACTGTGCAGGGCCTCTCCTTACAGGAACTGGTCCTGTCGGGGAACCCTCTG\nCACTGTTCTTGTGCCCTGCGCTGGCTACAGCGCTGGGAGGAGGAGGGACTGGGCGGAGTG\nCCTGAACAGAAGCTGCAGTGTCATGGGCAAGGGCCCCTGGCCCACATGCCCAATGCCAGC\nTGTGGTGTGCCCACGCTGAAGGTCCAGGTGCCCAATGCCTCGGTGGATGTGGGGGACGAC\nGTGCTGCTGCGGTGCCAGGTGGAGGGGCGGGGCCTGGAGCAGGCCGGCTGGATCCTCACA\nGAGCTGGAGCAGTCAGCCACGGTGATGAAATCTGGGGGTCTGCCATCCCTGGGGCTGACC\nCTGGCCAATGTCACCAGTGACCTCAACAGGAAGAACGTGACGTGCTGGGCAGAGAACGAT\nGTGGGCCGGGCAGAGGTCTCTGTTCAGGTCAACGTCTCCTTCCCGGCCAGTGTGCAGCTG\nCACACGGCGGTGGAGATGCACCACTGGTGCATCCCCTTCTCTGTGGATGGGCAGCCGGCA\nCCGTCTCTGCGCTGGCTCTTCAATGGCTCCGTGCTCAATGAGACCAGCTTCATCTTCACT\nGAGTTCCTGGAGCCGGCAGCCAATGAGACCGTGCGGCACGGGTGTCTGCGCCTCAACCAG\nCCCACCCACGTCAACAACGGCAACTACACGCTGCTGGCTGCCAACCCCTTCGGCCAGGCC\nTCCGCCTCCATCATGGCTGCCTTCATGGACAACCCTTTCGAGTTCAACCCCGAGGACCCC\nATCCCTGACACTAACAGCACATCTGGAGACCCGGTGGAGAAGAAGGACGAAACACCTTTT\nGGGGTCTCGGTGGCTGTGGGCCTGGCCGTCTTTGCCTGCCTCTTCCTTTCTACGCTGCTC\nCTTGTGCTCAACAAATGTGGACGGAGAAACAAGTTTGGGATCAACCGCCCGGCTGTGCTG\nGCTCCAGAGGATGGGCTGGCCATGTCCCTGCATTTCATGACATTGGGTGGCAGCTCCCTG\nTCCCCCACCGAGGGCAAAGGCTCTGGGCTCCAAGGCCACATCATCGAGAACCCACAATAC\nTTCAGTGATGCCTGTGTTCACCACATCAAGCGCCGGGACATCGTGCTCAAGTGGGAGCTG\nGGGGAGGGCGCCTTTGGGAAGGTCTTCCTTGCTGAGTGCCACAACCTCCTGCCTGAGCAG\nGACAAGATGCTGGTGGCTGTCAAGGCACTGAAGGAGGCGTCCGAGAGTGCTCGGCAGGAC\nTTCCAGCGTGAGGCTGAGCTGCTCACCATGCTGCAGCACCAGCACATCGTGCGCTTCTTC\nGGCGTCTGCACCGAGGGCCGCCCCCTGCTCATGGTCTTTGAGTATATGCGGCACGGGGAC\nCTCAACCGCTTCCTCCGATCCCATGGACCTGATGCCAAGCTGCTGGCTGGTGGGGAGGAT\nGTGGCTCCAGGCCCCCTGGGTCTGGGGCAGCTGCTGGCCGTGGCTAGCCAGGTCGCTGCG\nGGGATGGTGTACCTGGCGGGTCTGCATTTTGTGCACCGGGACCTGGCCACACGCAACTGT\nCTAGTGGGCCAGGGACTGGTGGTCAAGATTGGTGATTTTGGCATGAGCAGGGATATCTAC\nAGCACCGACTATTACCGTGTGGGAGGCCGCACCATGCTGCCCATTCGCTGGATGCCGCCC\nGAGAGCATCCTGTACCGTAAGTTCACCACCGAGAGCGACGTGTGGAGCTTCGGCGTGGTG\nCTCTGGGAGATCTTCACCTACGGCAAGCAGCCCTGGTACCAGCTCTCCAACACGGAGGCA\nATCGACTGCATCACGCAGGGACGTGAGTTGGAGCGGCCACGTGCCTGCCCACCAGAGGTC\nTACGCCATCATGCGGGGCTGCTGGCAGCGGGAGCCCCAGCAACGCCACAGCATCAAGGAT\nGTGCACGCCCGGCTGCAAGCCCTGGCCCAGGCACCTCCTGTCTACCTGGATGTCCTGGGC\nTAG'),('Histamine H1 receptor','None','Human','Histamine receptor activity','In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.','HRH1','55783.61','DB01403','>lcl|BSEQ0016093|Histamine H1 receptor (HRH1)\nATGAGCCTCCCCAATTCCTCCTGCCTCTTAGAAGACAAGATGTGTGAGGGCAACAAGACC\nACTATGGCCAGCCCCCAGCTGATGCCCCTGGTGGTGGTCCTGAGCACTATCTGCTTGGTC\nACAGTAGGGCTCAACCTGCTGGTGCTGTATGCCGTACGGAGTGAGCGGAAGCTCCACACT\nGTGGGGAACCTGTACATCGTCAGCCTCTCGGTGGCGGACTTGATCGTGGGTGCCGTCGTC\nATGCCTATGAACATCCTCTACCTGCTCATGTCCAAGTGGTCACTGGGCCGTCCTCTCTGC\nCTCTTTTGGCTTTCCATGGACTATGTGGCCAGCACAGCGTCCATTTTCAGTGTCTTCATC\nCTGTGCATTGATCGCTACCGCTCTGTCCAGCAGCCCCTCAGGTACCTTAAGTATCGTACC\nAAGACCCGAGCCTCGGCCACCATTCTGGGGGCCTGGTTTCTCTCTTTTCTGTGGGTTATT\nCCCATTCTAGGCTGGAATCACTTCATGCAGCAGACCTCGGTGCGCCGAGAGGACAAGTGT\nGAGACAGACTTCTATGATGTCACCTGGTTCAAGGTCATGACTGCCATCATCAACTTCTAC\nCTGCCCACCTTGCTCATGCTCTGGTTCTATGCCAAGATCTACAAGGCCGTACGACAACAC\nTGCCAGCACCGGGAGCTCATCAATAGGTCCCTCCCTTCCTTCTCAGAAATTAAGCTGAGG\nCCAGAGAACCCCAAGGGGGATGCCAAGAAACCAGGGAAGGAGTCTCCCTGGGAGGTTCTG\nAAAAGGAAGCCAAAAGATGCTGGTGGTGGATCTGTCTTGAAGTCACCATCCCAAACCCCC\nAAGGAGATGAAATCCCCAGTTGTCTTCAGCCAAGAGGATGATAGAGAAGTAGACAAACTC\nTACTGCTTTCCACTTGATATTGTGCACATGCAGGCTGCGGCAGAGGGGAGTAGCAGGGAC\nTATGTAGCCGTCAACCGGAGCCATGGCCAGCTCAAGACAGATGAGCAGGGCCTGAACACA\nCATGGGGCCAGCGAGATATCAGAGGATCAGATGTTAGGTGATAGCCAATCCTTCTCTCGA\nACGGACTCAGATACCACCACAGAGACAGCACCAGGCAAAGGCAAATTGAGGAGTGGGTCT\nAACACAGGCCTGGATTACATCAAGTTTACTTGGAAGAGGCTCCGCTCGCATTCAAGACAG\nTATGTATCTGGGTTGCACATGAACCGCGAAAGGAAGGCCGCCAAACAGTTGGGTTTTATC\nATGGCAGCCTTCATCCTCTGCTGGATCCCTTATTTCATCTTCTTCATGGTCATTGCCTTC\nTGCAAGAACTGTTGCAATGAACATTTGCACATGTTCACCATCTGGCTGGGCTACATCAAC\nTCCACACTGAACCCCCTCATCTACCCCTTGTGCAATGAGAACTTCAAGAAGACATTCAAG\nAGAATTCTGCATATTCGCTCCTAA'),('Histamine H2 receptor','None','Human','Histamine receptor activity','The H2 subclass of histamine receptors mediates gastric acid secretion. Also appears to regulate gastrointestinal motility and intestinal secretion. Possible role in regulating cell growth and differentiation. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase and, through a separate G protein-dependent mechanism, the phosphoinositide/protein kinase (PKC) signaling pathway (By similarity).','HRH2','40097.65','DB00321','>lcl|BSEQ0018919|Histamine H2 receptor (HRH2)\nATGGCACCCAATGGCACAGCCTCTTCCTTTTGCCTGGACTCTACCGCATGCAAGATCACC\nATCACCGTGGTCCTTGCGGTCCTCATCCTCATCACCGTTGCTGGCAATGTGGTCGTCTGT\nCTGGCCGTGGGCTTGAACCGCCGGCTCCGCAACCTGACCAATTGTTTCATCGTGTCCTTG\nGCTATCACTGACCTGCTCCTCGGCCTCCTGGTGCTGCCCTTCTCTGCCATCTACCAGCTG\nTCCTGCAAGTGGAGCTTTGGCAAGGTCTTCTGCAATATCTACACCAGCCTGGATGTGATG\nCTCTGCACAGCCTCCATTCTTAACCTCTTCATGATCAGCCTCGACCGGTACTGCGCTGTC\nATGGACCCACTGCGGTACCCTGTGCTGGTCACCCCAGTTCGGGTCGCCATCTCTCTGGTC\nTTAATTTGGGTCATCTCCATTACCCTGTCCTTTCTGTCTATCCACCTGGGGTGGAACAGC\nAGGAACGAGACCAGCAAGGGCAATCATACCACCTCTAAGTGCAAAGTCCAGGTCAATGAA\nGTGTACGGGCTGGTGGATGGGCTGGTCACCTTCTACCTCCCGCTACTGATCATGTGCATC\nACCTACTACCGCATCTTCAAGGTCGCCCGGGATCAGGCCAAGAGGATCAATCACATTAGC\nTCCTGGAAGGCAGCCACCATCAGGGAGCACAAAGCCACAGTGACACTGGCCGCCGTCATG\nGGGGCCTTCATCATCTGCTGGTTTCCCTACTTCACCGCGTTTGTGTACCGTGGGCTGAGA\nGGGGATGATGCCATCAATGAGGTGTTAGAAGCCATCGTTCTGTGGCTGGGCTATGCCAAC\nTCAGCCCTGAACCCCATCCTGTATGCTGCGCTGAACAGAGACTTCCGCACCGGGTACCAA\nCAGCTCTTCTGCTGCAGGCTGGCCAACCGCAACTCCCACAAAACTTCTCTGAGGTCCAAC\nGCCTCTCAGCTGTCCAGGACCCAAAGCCGAGAACCCAGGCAACAGGAAGAGAAACCCCTG\nAAGCTCCAGGTGTGGAGTGGGACAGAAGTCACGGCCCCCCAGGGAGCCACAGACAGACCA\nTGGCTTTGCCTTCCAGAATGCTGGTCTGTGGAACTGACCCATTCATTCATTCATTTGTTC\nATTCATTCATTTGCAAACATTCATCCAATTCCCACCACATGCCAGGAATTATGA'),('Histamine H4 receptor','None','Human','Histamine receptor activity','The H4 subclass of histamine receptors could mediate the histamine signals in peripheral tissues. Displays a significant level of constitutive activity (spontaneous activity in the absence of agonist).','HRH4','44495.375','DB00321','>lcl|BSEQ0009967|Histamine H4 receptor (HRH4)\nATGCCAGATACTAATAGCACAATCAATTTATCACTAAGCACTCGTGTTACTTTAGCATTT\nTTTATGTCCTTAGTAGCTTTTGCTATAATGCTAGGAAATGCTTTGGTCATTTTAGCTTTT\nGTGGTGGACAAAAACCTTAGACATCGAAGTAGTTATTTTTTTCTTAACTTGGCCATCTCT\nGACTTCTTTGTGGTTTCAGAGTCTTGGAAGGATGAAGGTAGTGAATGTGAACCTGGATTT\nTTTTCGGAATGGTACATCCTTGCCATCACATCATTCTTGGAATTCGTGATCCCAGTCATC\nTTAGTCGCTTATTTCAACATGAATATTTATTGGAGCCTGTGGAAGCGTGATCATCTCAGT\nAGGTGCCAAAGCCATCCTGGACTGACTGCTGTCTCTTCCAACATCTGTGGACACTCATTC\nAGAGGTAGACTATCTTCAAGGAGATCTCTTTCTGCATCGACAGAAGTTCCTGCATCCTTT\nCATTCAGAGAGACAGAGGAGAAAGAGTAGTCTCATGTTTTCCTCAAGAACCAAGATGAAT\nAGCAATACAATTGCTTCCAAAATGGGTTCCTTCTCCCAATCAGATTCTGTAGCTCTTCAC\nCAAAGGGAACATGTTGAACTGCTTAGAGCCAGGAGATTAGCCAAGTCACTGGCCATTCTC\nTTAGGGGTTTTTGCTGTTTGCTGGGCTCCATATTCTCTGTTCACAATTGTCCTTTCATTT\nTATTCCTCAGCAACAGGTCCTAAATCAGTTTGGTATAGAATTGCATTTTGGCTTCAGTGG\nTTCAATTCCTTTGTCAATCCTCTTTTGTATCCATTGTGTCACAAGCGCTTTCAAAAGGCT\nTTCTTGAAAATATTTTGTATAAAAAAGCAACCTCTACCATCACAACACAGTCGGTCAGTA\nTCTTCTTAA'),('Histone deacetylase 10','None','Human','Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes.','Enzyme binding','HDAC10','71444.08','DB13346','>lcl|BSEQ0051551|Histone deacetylase 10 (HDAC10)\nATGGGGACCGCGCTTGTGTACCATGAGGACATGACGGCCACCCGGCTGCTCTGGGACGAC\nCCCGAGTGCGAGATCGAGCGTCCTGAGCGCCTGACCGCAGCCCTGGATCGCCTGCGGCAG\nCGCGGCCTGGAACAGAGGTGTCTGCGGTTGTCAGCCCGCGAGGCCTCGGAAGAGGAGCTG\nGGCCTGGTGCACAGCCCAGAGTATGTATCCCTGGTCAGGGAGACCCAGGTCCTAGGCAAG\nGAGGAGCTGCAGGCGCTGTCCGGACAGTTCGACGCCATCTACTTCCACCCGAGTACCTTT\nCACTGCGCGCGGCTGGCCGCAGGGGCTGGACTGCAGCTGGTGGACGCTGTGCTCACTGGA\nGCTGTGCAAAATGGGCTTGCCCTGGTGAGGCCTCCCGGGCACCATGGCCAGAGGGCGGCT\nGCCAACGGGTTCTGTGTGTTCAACAACGTGGCCATAGCAGCTGCACATGCCAAGCAGAAA\nCACGGGCTACACAGGATCCTCGTCGTGGACTGGGATGTGCACCATGGCCAGGGGATCCAG\nTATCTCTTTGAGGATGACCCCAGCGTCCTTTACTTCTCCTGGCACCGCTATGAGCATGGG\nCGCTTCTGGCCTTTCCTGCGAGAGTCAGATGCAGACGCAGTGGGGCGGGGACAGGGCCTC\nGGCTTCACTGTCAACCTGCCCTGGAACCAGGTTGGGATGGGAAACGCTGACTACGTGGCT\nGCCTTCCTGCACCTGCTGCTCCCACTGGCCTTTGAGTTTGACCCTGAGCTGGTGCTGGTC\nTCGGCAGGATTTGACTCAGCCATCGGGGACCCTGAGGGGCAAATGCAGGCCACGCCAGAG\nTGCTTCGCCCACCTCACACAGCTGCTGCAGGTGCTGGCCGGCGGCCGGGTCTGTGCCGTG\nCTGGAGGGCGGCTACCACCTGGAGTCACTGGCGGAGTCAGTGTGCATGACAGTACAGACG\nCTGCTGGGTGACCCGGCCCCACCCCTGTCAGGGCCAATGGCGCCATGTCAGAGTGCCCTA\nGAGTCCATCCAGAGTGCCCGTGCTGCCCAGGCCCCGCACTGGAAGAGCCTCCAGCAGCAA\nGATGTGACCGCTGTGCCGATGAGCCCCAGCAGCCACTCCCCAGAGGGGAGGCCTCCACCT\nCTGCTGCCTGGGGGTCCAGTGTGTAAGGCAGCTGCATCTGCACCGAGCTCCCTCCTGGAC\nCAGCCGTGCCTCTGCCCCGCACCCTCTGTCCGCACCGCTGTTGCCCTGACAACGCCGGAT\nATCACATTGGTTCTGCCCCCTGACGTCATCCAACAGGAAGCGTCAGCCCTGAGGGAGGAG\nACAGAAGCCTGGGCCAGGCCACACGAGTCCCTGGCCCGGGAGGAGGCCCTCACTGCACTT\nGGGAAGCTCCTGTACCTCTTAGATGGGATGCTGGATGGGCAGGTGAACAGTGGTATAGCA\nGCCACTCCAGCCTCTGCTGCAGCAGCCACCCTGGATGTGGCTGTTCGGAGAGGCCTGTCC\nCACGGAGCCCAGAGGCTGCTGTGCGTGGCCCTGGGACAGCTGGACCGGCCTCCAGACCTC\nGCCCATGACGGGAGGAGTCTGTGGCTGAACATCAGGGGCAAGGAGGCGGCTGCCCTATCC\nATGTTCCATGTCTCCACGCCACTGCCAGTGATGACCGGTGGTTTCCTGAGCTGCATCTTG\nGGCTTGGTGCTGCCCCTGGCCTATGGCTTCCAGCCTGACCTGGTGCTGGTGGCGCTGGGG\nCCTGGCCATGGCCTGCAGGGCCCCCACGCTGCACTCCTGGCTGCAATGCTTCGGGGGCTG\nGCAGGGGGCCGAGTCCTGGCCCTCCTGGAGGAGAACTCCACACCCCAGCTAGCAGGGATC\nCTGGCCCGGGTGCTGAATGGAGAGGCACCTCCTAGCCTAGGCCCTTCCTCTGTGGCCTCC\nCCAGAGGACGTCCAGGCCCTGATGTACCTGAGAGGGCAGCTGGAGCCTCAGTGGAAGATG\nTTGCAGTGCCATCCTCACCTGGTGGCTTGA'),('Histone deacetylase 6','None','Human','Zinc ion binding','Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes (By similarity). Plays a central role in microtubule-dependent cell motility via deacetylation of tubulin. Involved in the MTA1-mediated epigenetic regulation of ESR1 expression in breast cancer.In addition to its protein deacetylase activity, plays a key role in the degradation of misfolded proteins: when misfolded proteins are too abundant to be degraded by the chaperone refolding system and the ubiquitin-proteasome, mediates the transport of misfolded proteins to a cytoplasmic juxtanuclear structure called aggresome. Probably acts as an adapter that recognizes polyubiquitinated misfolded proteins and target them to the aggresome, facilitating their clearance by autophagy.','HDAC6','131418.19','DB13346','>lcl|BSEQ0021857|Histone deacetylase 6 (HDAC6)\nATGACCTCAACCGGCCAGGATTCCACCACAACCAGGCAGCGAAGAAGTAGGCAGAACCCC\nCAGTCGCCCCCTCAGGACTCCAGTGTCACTTCGAAGCGAAATATTAAAAAGGGAGCCGTT\nCCCCGCTCTATCCCCAATCTAGCGGAGGTAAAGAAGAAAGGCAAAATGAAGAAGCTCGGC\nCAAGCAATGGAAGAAGACCTAATCGTGGGACTGCAAGGGATGGATCTGAACCTTGAGGCT\nGAAGCACTGGCTGGCACTGGCTTGGTGTTGGATGAGCAGTTAAATGAATTCCATTGCCTC\nTGGGATGACAGCTTCCCGGAAGGCCCTGAGCGGCTCCATGCCATCAAGGAGCAACTGATC\nCAGGAGGGCCTCCTAGATCGCTGCGTGTCCTTTCAGGCCCGGTTTGCTGAAAAGGAAGAG\nCTGATGTTGGTTCACAGCCTAGAATATATTGATCTGATGGAAACAACCCAGTACATGAAT\nGAGGGAGAACTCCGTGTCCTAGCAGACACCTACGACTCAGTTTATCTGCATCCGAACTCA\nTACTCCTGTGCCTGCCTGGCCTCAGGCTCTGTCCTCAGGCTGGTGGATGCGGTCCTGGGG\nGCTGAGATCCGGAATGGCATGGCCATCATTAGGCCTCCTGGACATCACGCCCAGCACAGT\nCTTATGGATGGCTATTGCATGTTCAACCACGTGGCTGTGGCAGCCCGCTATGCTCAACAG\nAAACACCGCATCCGGAGGGTCCTTATCGTAGATTGGGATGTGCACCACGGTCAAGGAACA\nCAGTTCACCTTCGACCAGGACCCCAGTGTCCTCTATTTCTCCATCCACCGCTACGAGCAG\nGGTAGGTTCTGGCCCCACCTGAAGGCCTCTAACTGGTCCACCACAGGTTTCGGCCAAGGC\nCAAGGATATACCATCAATGTGCCTTGGAACCAGGTGGGGATGCGGGATGCTGACTACATT\nGCTGCTTTCCTGCACGTCCTGCTGCCAGTCGCCCTCGAGTTCCAGCCTCAGCTGGTCCTG\nGTGGCTGCTGGATTTGATGCCCTGCAAGGGGACCCCAAGGGTGAGATGGCCGCCACTCCG\nGCAGGGTTCGCCCAGCTAACCCACCTGCTCATGGGTCTGGCAGGAGGCAAGCTGATCCTG\nTCTCTGGAGGGTGGCTACAACCTCCGCGCCCTGGCTGAAGGCGTCAGTGCTTCGCTCCAC\nACCCTTCTGGGAGACCCTTGCCCCATGCTGGAGTCACCTGGTGCCCCCTGCCGGAGTGCC\nCAGGCTTCAGTTTCCTGTGCTCTGGAAGCCCTTGAGCCCTTCTGGGAGGTTCTTGTGAGA\nTCAACTGAGACCGTGGAGAGGGACAACATGGAGGAGGACAATGTAGAGGAGAGCGAGGAG\nGAAGGACCCTGGGAGCCCCCTGTGCTCCCAATCCTGACATGGCCAGTGCTACAGTCTCGC\nACAGGGCTGGTCTATGACCAAAATATGATGAATCACTGCAACTTGTGGGACAGCCACCAC\nCCTGAGGTACCCCAGCGCATCTTGCGGATCATGTGCCGTCTGGAGGAGCTGGGCCTTGCC\nGGGCGCTGCCTCACCCTGACACCGCGCCCTGCCACAGAGGCTGAGCTGCTCACCTGTCAC\nAGTGCTGAGTACGTGGGTCATCTCCGGGCCACAGAGAAAATGAAAACCCGGGAGCTGCAC\nCGTGAGAGTTCCAACTTTGACTCCATCTATATCTGCCCCAGTACCTTCGCCTGTGCACAG\nCTTGCCACTGGCGCTGCCTGCCGCCTGGTGGAGGCTGTGCTCTCAGGAGAGGTTCTGAAT\nGGTGCTGCTGTGGTGCGTCCCCCAGGACACCACGCAGAGCAGGATGCAGCTTGCGGTTTT\nTGCTTTTTCAACTCTGTGGCTGTGGCTGCTCGCCATGCCCAGACTATCAGTGGGCATGCC\nCTACGGATCCTGATTGTGGATTGGGATGTCCACCACGGTAATGGAACTCAGCACATGTTT\nGAGGATGACCCCAGTGTGCTATATGTGTCCCTGCACCGCTATGATCATGGCACCTTCTTC\nCCCATGGGGGATGAGGGTGCCAGCAGCCAGATCGGCCGGGCTGCGGGCACAGGCTTCACC\nGTCAACGTGGCATGGAACGGGCCCCGCATGGGTGATGCTGACTACCTAGCTGCCTGGCAT\nCGCCTGGTGCTTCCCATTGCCTACGAGTTTAACCCAGAACTGGTGCTGGTCTCAGCTGGC\nTTTGATGCTGCACGGGGGGATCCGCTGGGGGGCTGCCAGGTGTCACCTGAGGGTTATGCC\nCACCTCACCCACCTGCTGATGGGCCTTGCCAGTGGCCGCATTATCCTTATCCTAGAGGGT\nGGCTATAACCTGACATCCATCTCAGAGTCCATGGCTGCCTGCACTCGCTCCCTCCTTGGA\nGACCCACCACCCCTGCTGACCCTGCCACGGCCCCCACTATCAGGGGCCCTGGCCTCAATC\nACTGAGACCATCCAAGTCCATCGCAGATACTGGCGCAGCTTACGGGTCATGAAGGTAGAA\nGACAGAGAAGGACCCTCCAGTTCTAAGTTGGTCACCAAGAAGGCACCCCAACCAGCCAAA\nCCTAGGTTAGCTGAGCGGATGACCACACGAGAAAAGAAGGTTCTGGAAGCAGGCATGGGG\nAAAGTCACCTCGGCATCATTTGGGGAAGAGTCCACTCCAGGCCAGACTAACTCAGAGACA\nGCTGTGGTGGCCCTCACTCAGGACCAGCCCTCAGAGGCAGCCACAGGGGGAGCCACTCTG\nGCCCAGACCATTTCTGAGGCAGCCATTGGGGGAGCCATGCTGGGCCAGACCACCTCAGAG\nGAGGCTGTCGGGGGAGCCACTCCGGACCAGACCACCTCAGAGGAGACTGTGGGAGGAGCC\nATTCTGGACCAGACCACCTCAGAGGATGCTGTTGGGGGAGCCACGCTGGGCCAGACTACC\nTCAGAGGAGGCTGTAGGAGGAGCTACACTGGCCCAGACCACCTCGGAGGCAGCCATGGAG\nGGAGCCACACTGGACCAGACTACGTCAGAGGAGGCTCCAGGGGGCACCGAGCTGATCCAA\nACTCCTCTAGCCTCGAGCACAGACCACCAGACCCCCCCAACCTCACCTGTGCAGGGAACT\nACACCCCAGATATCTCCCAGTACACTGATTGGGAGTCTCAGGACCTTGGAGCTAGGCAGC\nGAATCTCAGGGGGCCTCAGAATCTCAGGCCCCAGGAGAGGAGAACCTACTAGGAGAGGCA\nGCTGGAGGTCAGGACATGGCTGATTCGATGCTGATGCAGGGATCTAGGGGCCTCACTGAT\nCAGGCCATATTTTATGCTGTGACACCACTGCCCTGGTGTCCCCATTTGGTGGCAGTATGC\nCCCATACCTGCAGCAGGCCTAGACGTGACCCAACCTTGTGGGGACTGTGGAACAATCCAA\nGAGAATTGGGTGTGTCTCTCTTGCTATCAGGTCTACTGTGGTCGTTACATCAATGGCCAC\nATGCTCCAACACCATGGAAATTCTGGACACCCGCTGGTCCTCAGCTACATCGACCTGTCA\nGCCTGGTGTTACTACTGTCAGGCCTATGTCCACCACCAGGCTCTCCTAGATGTGAAGAAC\nATCGCCCACCAGAACAAGTTTGGGGAGGATATGCCCCACCCACACTAA'),('Ig gamma-2 chain C region','None','Human','Immunoglobulin receptor binding','None','IGHG2','35900.445','DB04688','None'),('Ig kappa chain C region','None','Human','Immunoglobulin receptor binding','None','IGKC','11608.765','DB04688','None'),('Inhibitor of nuclear factor kappa-B kinase subunit alpha','None','Human','Scaffold protein binding','Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. Acts as part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B on serine residues. These modifications allow polyubiquitination of the inhibitors and subsequent degradation by the proteasome. In turn, free NF-kappa-B is translocated into the nucleus and activates the transcription of hundreds of genes involved in immune response, growth control, or protection against apoptosis. Negatively regulates the pathway by phosphorylating the scaffold protein TAXBP1 and thus promoting the assembly of the A20/TNFAIP3 ubiquitin-editing complex (composed of A20/TNFAIP3, TAX1BP1, and the E3 ligases ITCH and RNF11). Therefore, CHUK plays a key role in the negative feedback of NF-kappa-B canonical signaling to limit inflammatory gene activation. As part of the non-canonical pathway of NF-kappa-B activation, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. In turn, these complexes regulate genes encoding molecules involved in B-cell survival and lymphoid organogenesis. Participates also in the negative feedback of the non-canonical NF-kappa-B signaling pathway by phosphorylating and destabilizing MAP3K14/NIK. Within the nucleus, phosphorylates CREBBP and consequently increases both its transcriptional and histone acetyltransferase activities. Modulates chromatin accessibility at NF-kappa-B-responsive promoters by phosphorylating histones H3 at \'Ser-10\' that are subsequently acetylated at \'Lys-14\' by CREBBP. Additionally, phosphorylates the CREBBP-interacting protein NCOA3. Also phosphorylates FOXO3 and may regulate this pro-apoptotic transcription factor (PubMed:15084260).','CHUK','84638.88','DB00795','>lcl|BSEQ0013243|Inhibitor of nuclear factor kappa-B kinase subunit alpha (CHUK)\nATGGAGCGGCCCCCGGGGCTGCGGCCGGGCGCGGGCGGGCCCTGGGAGATGCGGGAGCGG\nCTGGGCACCGGCGGCTTCGGGAACGTCTGTCTGTACCAGCATCGGGAACTTGATCTCAAA\nATAGCAATTAAGTCTTGTCGCCTAGAGCTAAGTACCAAAAACAGAGAACGATGGTGCCAT\nGAAATCCAGATTATGAAGAAGTTGAACCATGCCAATGTTGTAAAGGCCTGTGATGTTCCT\nGAAGAATTGAATATTTTGATTCATGATGTGCCTCTTCTAGCAATGGAATACTGTTCTGGA\nGGAGATCTCCGAAAGCTGCTCAACAAACCAGAAAATTGTTGTGGACTTAAAGAAAGCCAG\nATACTTTCTTTACTAAGTGATATAGGGTCTGGGATTCGATATTTGCATGAAAACAAAATT\nATACATCGAGATCTAAAACCTGAAAACATAGTTCTTCAGGATGTTGGTGGAAAGATAATA\nCATAAAATAATTGATCTGGGATATGCCAAAGATGTTGATCAAGGAAGTCTGTGTACATCT\nTTTGTGGGAACACTGCAGTATCTGGCCCCAGAGCTCTTTGAGAATAAGCCTTACACAGCC\nACTGTTGATTATTGGAGCTTTGGGACCATGGTATTTGAATGTATTGCTGGATATAGGCCT\nTTTTTGCATCATCTGCAGCCATTTACCTGGCATGAGAAGATTAAGAAGAAGGATCCAAAG\nTGTATATTTGCATGTGAAGAGATGTCAGGAGAAGTTCGGTTTAGTAGCCATTTACCTCAA\nCCAAATAGCCTTTGTAGTTTAGTAGTAGAACCCATGGAAAACTGGCTACAGTTGATGTTG\nAATTGGGACCCTCAGCAGAGAGGAGGACCTGTTGACCTTACTTTGAAGCAGCCAAGATGT\nTTTGTATTAATGGATCACATTTTGAATTTGAAGATAGTACACATCCTAAATATGACTTCT\nGCAAAGATAATTTCTTTTCTGTTACCACCTGATGAAAGTCTTCATTCACTACAGTCTCGT\nATTGAGCGTGAAACTGGAATAAATACTGGTTCTCAAGAACTTCTTTCAGAGACAGGAATT\nTCTCTGGATCCTCGGAAACCAGCCTCTCAATGTGTTCTAGATGGAGTTAGAGGCTGTGAT\nAGCTATATGGTTTATTTGTTTGATAAAAGTAAAACTGTATATGAAGGGCCATTTGCTTCC\nAGAAGTTTATCTGATTGTGTAAATTATATTGTACAGGACAGCAAAATACAGCTTCCAATT\nATACAGCTGCGTAAAGTGTGGGCTGAAGCAGTGCACTATGTGTCTGGACTAAAAGAAGAC\nTATAGCAGGCTCTTTCAGGGACAAAGGGCAGCAATGTTAAGTCTTCTTAGATATAATGCT\nAACTTAACAAAAATGAAGAACACTTTGATCTCAGCATCACAACAACTGAAAGCTAAATTG\nGAGTTTTTTCACAAAAGCATTCAGCTTGACTTGGAGAGATACAGCGAGCAGATGACGTAT\nGGGATATCTTCAGAAAAAATGCTAAAAGCATGGAAAGAAATGGAAGAAAAGGCCATCCAC\nTATGCTGAGGTTGGTGTCATTGGATACCTGGAGGATCAGATTATGTCTTTGCATGCTGAA\nATCATGGAGCTACAGAAGAGCCCCTATGGAAGACGTCAGGGAGACTTGATGGAATCTCTG\nGAACAGCGTGCCATTGATCTATATAAGCAGTTAAAACACAGACCTTCAGATCACTCCTAC\nAGTGACAGCACAGAGATGGTGAAAATCATTGTGCACACTGTGCAGAGTCAGGACCGTGTG\nCTCAAGGAGCTGTTTGGTCATTTGAGCAAGTTGTTGGGCTGTAAGCAGAAGATTATTGAT\nCTACTCCCTAAGGTGGAAGTGGCCCTCAGTAATATCAAAGAAGCTGACAATACTGTCATG\nTTCATGCAGGGAAAAAGGCAGAAAGAAATATGGCATCTCCTTAAAATTGCCTGTACACAG\nAGTTCTGCCCGGTCCCTTGTAGGATCCAGTCTAGAAGGTGCAGTAACCCCTCAGACATCA\nGCATGGCTGCCCCCGACTTCAGCAGAACATGATCATTCTCTGTCATGTGTGGTAACTCCT\nCAAGATGGGGAGACTTCAGCACAAATGATAGAAGAAAATTTGAACTGCCTTGGCCATTTA\nAGCACTATTATTCATGAGGCAAATGAGGAACAGGGCAATAGTATGATGAATCTTGATTGG\nAGTTGGTTAACAGAATGA'),('Inhibitor of nuclear factor kappa-B kinase subunit beta','None','Human','Scaffold protein binding','Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. Acts as part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B on 2 critical serine residues. These modifications allow polyubiquitination of the inhibitors and subsequent degradation by the proteasome. In turn, free NF-kappa-B is translocated into the nucleus and activates the transcription of hundreds of genes involved in immune response, growth control, or protection against apoptosis. In addition to the NF-kappa-B inhibitors, phosphorylates several other components of the signaling pathway including NEMO/IKBKG, NF-kappa-B subunits RELA and NFKB1, as well as IKK-related kinases TBK1 and IKBKE. IKK-related kinase phosphorylations may prevent the overproduction of inflammatory mediators since they exert a negative regulation on canonical IKKs. Phosphorylates FOXO3, mediating the TNF-dependent inactivation of this pro-apoptotic transcription factor. Also phosphorylates other substrates including NCOA3, BCL10 and IRS1. Within the nucleus, acts as an adapter protein for NFKBIA degradation in UV-induced NF-kappa-B activation.','IKBKB','86563.245','DB00795','>lcl|BSEQ0010805|Inhibitor of nuclear factor kappa-B kinase subunit beta (IKBKB)\nATGTTTTCAGGGGGGTGTCATAGCCCCGGGTTTGGCCGCCCCAGCCCCGCCTTCCCCGCC\nCCGGGGAGCCCGCCCCCTGCCCCGCGTCCCTGCCGACAGGAAACAGGTGAGCAGATTGCC\nATCAAGCAGTGCCGGCAGGAGCTCAGCCCCCGGAACCGAGAGCGGTGGTGCCTGGAGATC\nCAGATCATGAGAAGGCTGACCCACCCCAATGTGGTGGCTGCCCGAGATGTCCCTGAGGGG\nATGCAGAACTTGGCGCCCAATGACCTGCCCCTGCTGGCCATGGAGTACTGCCAAGGAGGA\nGATCTCCGGAAGTACCTGAACCAGTTTGAGAACTGCTGTGGTCTGCGGGAAGGTGCCATC\nCTCACCTTGCTGAGTGACATTGCCTCTGCGCTTAGATACCTTCATGAAAACAGAATCATC\nCATCGGGATCTAAAGCCAGAAAACATCGTCCTGCAGCAAGGAGAACAGAGGTTAATACAC\nAAAATTATTGACCTAGGATATGCCAAGGAGCTGGATCAGGGCAGTCTTTGCACATCATTC\nGTGGGGACCCTGCAGTACCTGGCCCCAGAGCTACTGGAGCAGCAGAAGTACACAGTGACC\nGTCGACTACTGGAGCTTCGGCACCCTGGCCTTTGAGTGCATCACGGGCTTCCGGCCCTTC\nCTCCCCAACTGGCAGCCCGTGCAGTGGCATTCAAAAGTGCGGCAGAAGAGTGAGGTGGAC\nATTGTTGTTAGCGAAGACTTGAATGGAACGGTGAAGTTTTCAAGCTCTTTACCCTACCCC\nAATAATCTTAACAGTGTCCTGGCTGAGCGACTGGAGAAGTGGCTGCAACTGATGCTGATG\nTGGCACCCCCGACAGAGGGGCACGGATCCCACGTATGGGCCCAATGGCTGCTTCAAGGCC\nCTGGATGACATCTTAAACTTAAAGCTGGTTCATATCTTGAACATGGTCACGGGCACCATC\nCACACCTACCCTGTGACAGAGGATGAGAGTCTGCAGAGCTTGAAGGCCAGAATCCAACAG\nGACACGGGCATCCCAGAGGAGGACCAGGAGCTGCTGCAGGAAGCGGGCCTGGCGTTGATC\nCCCGATAAGCCTGCCACTCAGTGTATTTCAGACGGCAAGTTAAATGAGGGCCACACATTG\nGACATGGATCTTGTTTTTCTCTTTGACAACAGTAAAATCACCTATGAGACTCAGATCTCC\nCCACGGCCCCAACCTGAAAGTGTCAGCTGTATCCTTCAAGAGCCCAAGAGGAATCTCGCC\nTTCTTCCAGCTGAGGAAGGTGTGGGGCCAGGTCTGGCACAGCATCCAGACCCTGAAGGAA\nGATTGCAACCGGCTGCAGCAGGGACAGCGAGCCGCCATGATGAATCTCCTCCGAAACAAC\nAGCTGCCTCTCCAAAATGAAGAATTCCATGGCTTCCATGTCTCAGCAGCTCAAGGCCAAG\nTTGGATTTCTTCAAAACCAGCATCCAGATTGACCTGGAGAAGTACAGCGAGCAAACCGAG\nTTTGGGATCACATCAGATAAACTGCTGCTGGCCTGGAGGGAAATGGAGCAGGCTGTGGAG\nCTCTGTGGGCGGGAGAACGAAGTGAAACTCCTGGTAGAACGGATGATGGCTCTGCAGACC\nGACATTGTGGACTTACAGAGGAGCCCCATGGGCCGGAAGCAGGGGGGAACGCTGGACGAC\nCTAGAGGAGCAAGCAAGGGAGCTGTACAGGAGACTAAGGGAAAAACCTCGAGACCAGCGA\nACTGAGGGTGACAGTCAGGAAATGGTACGGCTGCTGCTTCAGGCAATTCAGAGCTTCGAG\nAAGAAAGTGCGAGTGATCTATACGCAGCTCAGTAAAACTGTGGTTTGCAAGCAGAAGGCG\nCTGGAACTGTTGCCCAAGGTGGAAGAGGTGGTGAGCTTAATGAATGAGGATGAGAAGACT\nGTTGTCCGGCTGCAGGAGAAGCGGCAGAAGGAGCTCTGGAATCTCCTGAAGATTGCTTGT\nAGCAAGGTCCGTGGTCCTGTCAGTGGAAGCCCGGATAGCATGAATGCCTCTCGACTTAGC\nCAGCCTGGGCAGCTGATGTCTCAGCCCTCCACGGCCTCCAACAGCTTACCTGAGCCAGCC\nAAGAAGAGTGAAGAACTGGTGGCTGAAGCACATAACCTCTGCACCCTGCTAGAAAATGCC\nATACAGGACACTGTGAGGGAACAAGACCAGAGTTTCACGGCCCTAGACTGGAGCTGGTTA\nCAGACGGAAGAAGAAGAGCACAGCTGCCTGGAGCAGGCCTCATGA'),('Integrin alpha-5','None','Human','Integrin alpha-5/beta-1 is a receptor for fibronectin and fibrinogen. It recognizes the sequence R-G-D in its ligands. ITGA5:ITGB1 binds to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1 (PubMed:18635536, PubMed:25398877). ITGA5:ITGB1 acts as a receptor for fibrillin-1 (FBN1) and mediates R-G-D-dependent cell adhesion to FBN1 (PubMed:12807887, PubMed:17158881).','Epidermal growth factor receptor binding','ITGA5','114535.52','DB02709','>lcl|BSEQ0049692|Integrin alpha-5 (ITGA5)\nATGGGGAGCCGGACGCCAGAGTCCCCTCTCCACGCCGTGCAGCTGCGCTGGGGCCCCCGG\nCGCCGACCCCCGCTGCTGCCGCTGCTGTTGCTGCTGCTGCCGCCGCCACCCAGGGTCGGG\nGGCTTCAACTTAGACGCGGAGGCCCCAGCAGTACTCTCGGGGCCCCCGGGCTCCTTCTTC\nGGATTCTCAGTGGAGTTTTACCGGCCGGGAACAGACGGGGTCAGTGTGCTGGTGGGAGCA\nCCCAAGGCTAATACCAGCCAGCCAGGAGTGCTGCAGGGTGGTGCTGTCTACCTCTGTCCT\nTGGGGTGCCAGCCCCACACAGTGCACCCCCATTGAATTTGACAGCAAAGGCTCTCGGCTC\nCTGGAGTCCTCACTGTCCAGCTCAGAGGGAGAGGAGCCTGTGGAGTACAAGTCCTTGCAG\nTGGTTCGGGGCAACAGTTCGAGCCCATGGCTCCTCCATCTTGGCATGCGCTCCACTGTAC\nAGCTGGCGCACAGAGAAGGAGCCACTGAGCGACCCCGTGGGCACCTGCTACCTCTCCACA\nGATAACTTCACCCGAATTCTGGAGTATGCACCCTGCCGCTCAGATTTCAGCTGGGCAGCA\nGGACAGGGTTACTGCCAAGGAGGCTTCAGTGCCGAGTTCACCAAGACTGGCCGTGTGGTT\nTTAGGTGGACCAGGAAGCTATTTCTGGCAAGGCCAGATCCTGTCTGCCACTCAGGAGCAG\nATTGCAGAATCTTATTACCCCGAGTACCTGATCAACCTGGTTCAGGGGCAGCTGCAGACT\nCGCCAGGCCAGTTCCATCTATGATGACAGCTACCTAGGATACTCTGTGGCTGTTGGTGAA\nTTCAGTGGTGATGACACAGAAGACTTTGTTGCTGGTGTGCCCAAAGGGAACCTCACTTAC\nGGCTATGTCACCATCCTTAATGGCTCAGACATTCGATCCCTCTACAACTTCTCAGGGGAA\nCAGATGGCCTCCTACTTTGGCTATGCAGTGGCCGCCACAGACGTCAATGGGGACGGGCTG\nGATGACTTGCTGGTGGGGGCACCCCTGCTCATGGATCGGACCCCTGACGGGCGGCCTCAG\nGAGGTGGGCAGGGTCTACGTCTACCTGCAGCACCCAGCCGGCATAGAGCCCACGCCCACC\nCTTACCCTCACTGGCCATGATGAGTTTGGCCGATTTGGCAGCTCCTTGACCCCCCTGGGG\nGACCTGGACCAGGATGGCTACAATGATGTGGCCATCGGGGCTCCCTTTGGTGGGGAGACC\nCAGCAGGGAGTAGTGTTTGTATTTCCTGGGGGCCCAGGAGGGCTGGGCTCTAAGCCTTCC\nCAGGTTCTGCAGCCCCTGTGGGCAGCCAGCCACACCCCAGACTTCTTTGGCTCTGCCCTT\nCGAGGAGGCCGAGACCTGGATGGCAATGGATATCCTGATCTGATTGTGGGGTCCTTTGGT\nGTGGACAAGGCTGTGGTATACAGGGGCCGCCCCATCGTGTCCGCTAGTGCCTCCCTCACC\nATCTTCCCCGCCATGTTCAACCCAGAGGAGCGGAGCTGCAGCTTAGAGGGGAACCCTGTG\nGCCTGCATCAACCTTAGCTTCTGCCTCAATGCTTCTGGAAAACACGTTGCTGACTCCATT\nGGTTTCACAGTGGAACTTCAGCTGGACTGGCAGAAGCAGAAGGGAGGGGTACGGCGGGCA\nCTGTTCCTGGCCTCCAGGCAGGCAACCCTGACCCAGACCCTGCTCATCCAGAATGGGGCT\nCGAGAGGATTGCAGAGAGATGAAGATCTACCTCAGGAACGAGTCAGAATTTCGAGACAAA\nCTCTCGCCGATTCACATCGCTCTCAACTTCTCCTTGGACCCCCAAGCCCCAGTGGACAGC\nCACGGCCTCAGGCCAGCCCTACATTATCAGAGCAAGAGCCGGATAGAGGACAAGGCTCAG\nATCTTGCTGGACTGTGGAGAAGACAACATCTGTGTGCCTGACCTGCAGCTGGAAGTGTTT\nGGGGAGCAGAACCATGTGTACCTGGGTGACAAGAATGCCCTGAACCTCACTTTCCATGCC\nCAGAATGTGGGTGAGGGTGGCGCCTATGAGGCTGAGCTTCGGGTCACCGCCCCTCCAGAG\nGCTGAGTACTCAGGACTCGTCAGACACCCAGGGAACTTCTCCAGCCTGAGCTGTGACTAC\nTTTGCCGTGAACCAGAGCCGCCTGCTGGTGTGTGACCTGGGCAACCCCATGAAGGCAGGA\nGCCAGTCTGTGGGGTGGCCTTCGGTTTACAGTCCCTCATCTCCGGGACACTAAGAAAACC\nATCCAGTTTGACTTCCAGATCCTCAGCAAGAATCTCAACAACTCGCAAAGCGACGTGGTT\nTCCTTTCGGCTCTCCGTGGAGGCTCAGGCCCAGGTCACCCTGAACGGTGTCTCCAAGCCT\nGAGGCAGTGCTATTCCCAGTAAGCGACTGGCATCCCCGAGACCAGCCTCAGAAGGAGGAG\nGACCTGGGACCTGCTGTCCACCATGTCTATGAGCTCATCAACCAAGGCCCCAGCTCCATT\nAGCCAGGGTGTGCTGGAACTCAGCTGTCCCCAGGCTCTGGAAGGTCAGCAGCTCCTATAT\nGTGACCAGAGTTACGGGACTCAACTGCACCACCAATCACCCCATTAACCCAAAGGGCCTG\nGAGTTGGATCCCGAGGGTTCCCTGCACCACCAGCAAAAACGGGAAGCTCCAAGCCGCAGC\nTCTGCTTCCTCGGGACCTCAGATCCTGAAATGCCCGGAGGCTGAGTGTTTCAGGCTGCGC\nTGTGAGCTCGGGCCCCTGCACCAACAAGAGAGCCAAAGTCTGCAGTTGCATTTCCGAGTC\nTGGGCCAAGACTTTCTTGCAGCGGGAGCACCAGCCATTTAGCCTGCAGTGTGAGGCTGTG\nTACAAAGCCCTGAAGATGCCCTACCGAATCCTGCCTCGGCAGCTGCCCCAAAAAGAGCGT\nCAGGTGGCCACAGCTGTGCAATGGACCAAGGCAGAAGGCAGCTATGGCGTCCCACTGTGG\nATCATCATCCTAGCCATCCTGTTTGGCCTCCTGCTCCTAGGTCTACTCATCTACATCCTC\nTACAAGCTTGGATTCTTCAAACGCTCCCTCCCATATGGCACCGCCATGGAAAAAGCTCAG\nCTCAAGCCTCCAGCCACCTCTGATGCCTGA'),('Integrin beta-3','None','Human','Virus receptor activity','Integrin alpha-V/beta-3 (ITGAV:ITGB3) is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Integrin alpha-IIb/beta-3 (ITGA2B:ITGB3) is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. Integrins alpha-IIb/beta-3 and alpha-V/beta-3 recognize the sequence R-G-D in a wide array of ligands. Integrin alpha-IIb/beta-3 recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain. Following activation integrin alpha-IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen. This step leads to rapid platelet aggregation which physically plugs ruptured endothelial surface. Fibrinogen binding enhances SELP expression in activated platelets (By similarity).(Microbial infection) Integrin ITGAV:ITGB3 acts as a receptor for herpes virus 8/HHV-8 (PubMed:18045938). Integrin ITGAV:ITGB3 acts as a receptor for coxsackievirus A9 (PubMed:7519807). Acts as a receptor for Hantaan virus (PubMed:9618541). Integrin ITGAV:ITGB3 acts as a receptor for cytomegalovirus/HHV-5 (PubMed:15834425). Integrin ITGA5:ITGB3 acts as a receptor for human metapneumovirus (PubMed:24478423). Integrin ITGAV:ITGB3 acts aP05556s a receptor for human parechovirus 1 (PubMed:11160695). Integrin ITGAV:ITGB3 acts as a receptor for west nile virus (PubMed:23658209). In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi\'s sarcoma lesions (PubMed:10397733).','ITGB3','87056.975','DB02709','>lcl|BSEQ0021847|Integrin beta-3 (ITGB3)\nATGCGAGCGCGGCCGCGGCCCCGGCCGCTCTGGGCGACTGTGCTGGCGCTGGGGGCGCTG\nGCGGGCGTTGGCGTAGGAGGGCCCAACATCTGTACCACGCGAGGTGTGAGCTCCTGCCAG\nCAGTGCCTGGCTGTGAGCCCCATGTGTGCCTGGTGCTCTGATGAGGCCCTGCCTCTGGGC\nTCACCTCGCTGTGACCTGAAGGAGAATCTGCTGAAGGATAACTGTGCCCCAGAATCCATC\nGAGTTCCCAGTGAGTGAGGCCCGAGTACTAGAGGACAGGCCCCTCAGCGACAAGGGCTCT\nGGAGACAGCTCCCAGGTCACTCAAGTCAGTCCCCAGAGGATTGCACTCCGGCTCCGGCCA\nGATGATTCGAAGAATTTCTCCATCCAAGTGCGGCAGGTGGAGGATTACCCTGTGGACATC\nTACTACTTGATGGACCTGTCTTACTCCATGAAGGATGATCTGTGGAGCATCCAGAACCTG\nGGTACCAAGCTGGCCACCCAGATGCGAAAGCTCACCAGTAACCTGCGGATTGGCTTCGGG\nGCATTTGTGGACAAGCCTGTGTCACCATACATGTATATCTCCCCACCAGAGGCCCTCGAA\nAACCCCTGCTATGATATGAAGACCACCTGCTTGCCCATGTTTGGCTACAAACACGTGCTG\nACGCTAACTGACCAGGTGACCCGCTTCAATGAGGAAGTGAAGAAGCAGAGTGTGTCACGG\nAACCGAGATGCCCCAGAGGGTGGCTTTGATGCCATCATGCAGGCTACAGTCTGTGATGAA\nAAGATTGGCTGGAGGAATGATGCATCCCACTTGCTGGTGTTTACCACTGATGCCAAGACT\nCATATAGCATTGGACGGAAGGCTGGCAGGCATTGTCCAGCCTAATGACGGGCAGTGTCAT\nGTTGGTAGTGACAATCATTACTCTGCCTCCACTACCATGGATTATCCCTCTTTGGGGCTG\nATGACTGAGAAGCTATCCCAGAAAAACATCAATTTGATCTTTGCAGTGACTGAAAATGTA\nGTCAATCTCTATCAGAACTATAGTGAGCTCATCCCAGGGACCACAGTTGGGGTTCTGTCC\nATGGATTCCAGCAATGTCCTCCAGCTCATTGTTGATGCTTATGGGAAAATCCGTTCTAAA\nGTAGAGCTGGAAGTGCGTGACCTCCCTGAAGAGTTGTCTCTATCCTTCAATGCCACCTGC\nCTCAACAATGAGGTCATCCCTGGCCTCAAGTCTTGTATGGGACTCAAGATTGGAGACACG\nGTGAGCTTCAGCATTGAGGCCAAGGTGCGAGGCTGTCCCCAGGAGAAGGAGAAGTCCTTT\nACCATAAAGCCCGTGGGCTTCAAGGACAGCCTGATCGTCCAGGTCACCTTTGATTGTGAC\nTGTGCCTGCCAGGCCCAAGCTGAACCTAATAGCCATCGCTGCAACAATGGCAATGGGACC\nTTTGAGTGTGGGGTATGCCGTTGTGGGCCTGGCTGGCTGGGATCCCAGTGTGAGTGCTCA\nGAGGAGGACTATCGCCCTTCCCAGCAGGACGAATGCAGCCCCCGGGAGGGTCAGCCCGTC\nTGCAGCCAGCGGGGCGAGTGCCTCTGTGGTCAATGTGTCTGCCACAGCAGTGACTTTGGC\nAAGATCACGGGCAAGTACTGCGAGTGTGACGACTTCTCCTGTGTCCGCTACAAGGGGGAG\nATGTGCTCAGGCCATGGCCAGTGCAGCTGTGGGGACTGCCTGTGTGACTCCGACTGGACC\nGGCTACTACTGCAACTGTACCACGCGTACTGACACCTGCATGTCCAGCAATGGGCTGCTG\nTGCAGCGGCCGCGGCAAGTGTGAATGTGGCAGCTGTGTCTGTATCCAGCCGGGCTCCTAT\nGGGGACACCTGTGAGAAGTGCCCCACCTGCCCAGATGCCTGCACCTTTAAGAAAGAATGT\nGTGGAGTGTAAGAAGTTTGACCGGGGAGCCCTACATGACGAAAATACCTGCAACCGTTAC\nTGCCGTGACGAGATTGAGTCAGTGAAAGAGCTTAAGGACACTGGCAAGGATGCAGTGAAT\nTGTACCTATAAGAATGAGGATGACTGTGTCGTCAGATTCCAGTACTATGAAGATTCTAGT\nGGAAAGTCCATCCTGTATGTGGTAGAAGAGCCAGAGTGTCCCAAGGGCCCTGACATCCTG\nGTGGTCCTGCTCTCAGTGATGGGGGCCATTCTGCTCATTGGCCTTGCCGCCCTGCTCATC\nTGGAAACTCCTCATCACCATCCACGACCGAAAAGAATTCGCTAAATTTGAGGAAGAACGC\nGCCAGAGCAAAATGGGACACAGCCAACAACCCACTGTATAAAGAGGCCACGTCTACCTTC\nACCAATATCACGTACCGGGGCACTTAA'),('Intercellular adhesion molecule 1','None','Human','Virus receptor activity','ICAM proteins are ligands for the leukocyte adhesion protein LFA-1 (integrin alpha-L/beta-2). During leukocyte trans-endothelial migration, ICAM1 engagement promotes the assembly of endothelial apical cups through ARHGEF26/SGEF and RHOG activation.(Microbial infection) Acts as a receptor for major receptor group rhinovirus A-B capsid proteins (PubMed:1968231, PubMed:2538243). Acts as a receptor for Coxsackievirus A21 capsid proteins (PubMed:11160747, PubMed:16004874, PubMed:9539703). Upon Kaposi\'s sarcoma-associated herpesvirus/HHV-8 infection, is degraded by viral E3 ubiquitin ligase MIR2, presumably to prevent lysis of infected cells by cytotoxic T-lymphocytes and NK cell (PubMed:11413168).','ICAM1','57824.785','DB12598','>lcl|BSEQ0020505|Intercellular adhesion molecule 1 (ICAM1)\nATGGCTCCCAGCAGCCCCCGGCCCGCGCTGCCCGCACTCCTGGTCCTGCTCGGGGCTCTG\nTTCCCAGGACCTGGCAATGCCCAGACATCTGTGTCCCCCTCAAAAGTCATCCTGCCCCGG\nGGAGGCTCCGTGCTGGTGACATGCAGCACCTCCTGTGACCAGCCCAAGTTGTTGGGCATA\nGAGACCCCGTTGCCTAAAAAGGAGTTGCTCCTGCCTGGGAACAACCGGAAGGTGTATGAA\nCTGAGCAATGTGCAAGAAGATAGCCAACCAATGTGCTATTCAAACTGCCCTGATGGGCAG\nTCAACAGCTAAAACCTTCCTCACCGTGTACTGGACTCCAGAACGGGTGGAACTGGCACCC\nCTCCCCTCTTGGCAGCCAGTGGGCAAGAACCTTACCCTACGCTGCCAGGTGGAGGGTGGG\nGCACCCCGGGCCAACCTCACCGTGGTGCTGCTCCGTGGGGAGAAGGAGCTGAAACGGGAG\nCCAGCTGTGGGGGAGCCCGCTGAGGTCACGACCACGGTGCTGGTGAGGAGAGATCACCAT\nGGAGCCAATTTCTCGTGCCGCACTGAACTGGACCTGCGGCCCCAAGGGCTGGAGCTGTTT\nGAGAACACCTCGGCCCCCTACCAGCTCCAGACCTTTGTCCTGCCAGCGACTCCCCCACAA\nCTTGTCAGCCCCCGGGTCCTAGAGGTGGACACGCAGGGGACCGTGGTCTGTTCCCTGGAC\nGGGCTGTTCCCAGTCTCGGAGGCCCAGGTCCACCTGGCACTGGGGGACCAGAGGTTGAAC\nCCCACAGTCACCTATGGCAACGACTCCTTCTCGGCCAAGGCCTCAGTCAGTGTGACCGCA\nGAGGACGAGGGCACCCAGCGGCTGACGTGTGCAGTAATACTGGGGAACCAGAGCCAGGAG\nACACTGCAGACAGTGACCATCTACAGCTTTCCGGCGCCCAACGTGATTCTGACGAAGCCA\nGAGGTCTCAGAAGGGACCGAGGTGACAGTGAAGTGTGAGGCCCACCCTAGAGCCAAGGTG\nACGCTGAATGGGGTTCCAGCCCAGCCACTGGGCCCGAGGGCCCAGCTCCTGCTGAAGGCC\nACCCCAGAGGACAACGGGCGCAGCTTCTCCTGCTCTGCAACCCTGGAGGTGGCCGGCCAG\nCTTATACACAAGAACCAGACCCGGGAGCTTCGTGTCCTGTATGGCCCCCGACTGGACGAG\nAGGGATTGTCCGGGAAACTGGACGTGGCCAGAAAATTCCCAGCAGACTCCAATGTGCCAG\nGCTTGGGGGAACCCATTGCCCGAGCTCAAGTGTCTAAAGGATGGCACTTTCCCACTGCCC\nATCGGGGAATCAGTGACTGTCACTCGAGATCTTGAGGGCACCTACCTCTGTCGGGCCAGG\nAGCACTCAAGGGGAGGTCACCCGCAAGGTGACCGTGAATGTGCTCTCCCCCCGGTATGAG\nATTGTCATCATCACTGTGGTAGCAGCCGCAGTCATAATGGGCACTGCAGGCCTCAGCACG\nTACCTCTATAACCGCCAGCGGAAGATCAAGAAATACAGACTACAACAGGCCCAAAAAGGG\nACCCCCATGAAACCGAACACACAAGCCACGCCTCCCTGA'),('Interferon gamma','None','Human','Interferon-gamma receptor binding','Produced by lymphocytes activated by specific antigens or mitogens. IFN-gamma, in addition to having antiviral activity, has important immunoregulatory functions. It is a potent activator of macrophages, it has antiproliferative effects on transformed cells and it can potentiate the antiviral and antitumor effects of the type I interferons.','IFNG','19348.165','DB05676','>lcl|BSEQ0010664|Interferon gamma (IFNG)\nATGAAATATACAAGTTATATCTTGGCTTTTCAGCTCTGCATCGTTTTGGGTTCTCTTGGC\nTGTTACTGCCAGGACCCATATGTAAAAGAAGCAGAAAACCTTAAGAAATATTTTAATGCA\nGGTCATTCAGATGTAGCGGATAATGGAACTCTTTTCTTAGGCATTTTGAAGAATTGGAAA\nGAGGAGAGTGACAGAAAAATAATGCAGAGCCAAATTGTCTCCTTTTACTTCAAACTTTTT\nAAAAACTTTAAAGATGACCAGAGCATCCAAAAGAGTGTGGAGACCATCAAGGAAGACATG\nAATGTCAAGTTTTTCAATAGCAACAAAAAGAAACGAGATGACTTCGAAAAGCTGACTAAT\nTATTCGGTAACTGACTTGAATGTCCAACGCAAAGCAATACATGAACTCATCCAAGTGATG\nGCTGAACTGTCGCCAGCAGCTAAAACAGGGAAGCGAAAAAGGAGTCAGATGCTGTTTCGA\nGGTCGAAGAGCATCCCAGTAA'),('Interleukin-1 beta','None','Human','Protein domain specific binding','Potent proinflammatory cytokine. Initially discovered as the major endogenous pyrogen, induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation and cytokine production, B-cell activation and antibody production, and fibroblast proliferation and collagen production. Promotes Th17 differentiation of T-cells.','IL1B','30747.7','DB05767','>lcl|BSEQ0010737|Interleukin-1 beta (IL1B)\nATGGCAGAAGTACCTGAGCTCGCCAGTGAAATGATGGCTTATTACAGTGGCAATGAGGAT\nGACTTGTTCTTTGAAGCTGATGGCCCTAAACAGATGAAGTGCTCCTTCCAGGACCTGGAC\nCTCTGCCCTCTGGATGGCGGCATCCAGCTACGAATCTCCGACCACCACTACAGCAAGGGC\nTTCAGGCAGGCCGCGTCAGTTGTTGTGGCCATGGACAAGCTGAGGAAGATGCTGGTTCCC\nTGCCCACAGACCTTCCAGGAGAATGACCTGAGCACCTTCTTTCCCTTCATCTTTGAAGAA\nGAACCTATCTTCTTCGACACATGGGATAACGAGGCTTATGTGCACGATGCACCTGTACGA\nTCACTGAACTGCACGCTCCGGGACTCACAGCAAAAAAGCTTGGTGATGTCTGGTCCATAT\nGAACTGAAAGCTCTCCACCTCCAGGGACAGGATATGGAGCAACAAGTGGTGTTCTCCATG\nTCCTTTGTACAAGGAGAAGAAAGTAATGACAAAATACCTGTGGCCTTGGGCCTCAAGGAA\nAAGAATCTGTACCTGTCCTGCGTGTTGAAAGATGATAAGCCCACTCTACAGCTGGAGAGT\nGTAGATCCCAAAAATTACCCAAAGAAGAAGATGGAAAAGCGATTTGTCTTCAACAAGATA\nGAAATCAATAACAAGCTGGAATTTGAGTCTGCCCAGTTCCCCAACTGGTACATCAGCACC\nTCTCAAGCAGAAAACATGCCCGTCTTCCTGGGAGGGACCAAAGGCGGCCAGGATATAACT\nGACTTCACCATGCAATTTGTGTCTTCCTAA'),('Interleukin-2','None','Human','Kinase activator activity','Produced by T-cells in response to antigenic or mitogenic stimulation, this protein is required for T-cell proliferation and other activities crucial to regulation of the immune response. Can stimulate B-cells, monocytes, lymphokine-activated killer cells, natural killer cells, and glioma cells.','IL2','17627.52','DB05676','>lcl|BSEQ0016290|Interleukin-2 (IL2)\nATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACAAACAGT\nGCACCTACTTCAAGTTCTACAAAGAAAACACAGCTACAACTGGAGCATTTACTGCTGGAT\nTTACAGATGATTTTGAATGGAATTAATAATTACAAGAATCCCAAACTCACCAGGATGCTC\nACATTTAAGTTTTACATGCCCAAGAAGGCCACAGAACTGAAACATCTTCAGTGTCTAGAA\nGAAGAACTCAAACCTCTGGAGGAAGTGCTAAATTTAGCTCAAAGCAAAAACTTTCACTTA\nAGACCCAGGGACTTAATCAGCAATATCAACGTAATAGTTCTGGAACTAAAGGGATCTGAA\nACAACATTCATGTGTGAATATGCTGATGAGACAGCAACCATTGTAGAATTTCTGAACAGA\nTGGATTACCTTTTGTCAAAGCATCATCTCAACACTGACTTGA'),('Interleukin-6','None','Human','Interleukin-6 receptor binding','Cytokine with a wide variety of biological functions. It is a potent inducer of the acute phase response. Plays an essential role in the final differentiation of B-cells into Ig-secreting cells Involved in lymphocyte and monocyte differentiation. Acts on B-cells, T-cells, hepatocytes, hematopoietic progenitor cells and cells of the CNS. Required for the generation of T(H)17 cells. Also acts as a myokine. It is discharged into the bloodstream after muscle contraction and acts to increase the breakdown of fats and to improve insulin resistance. It induces myeloma and plasmacytoma growth and induces nerve cells differentiation.','IL6','23717.965','DB05767','>lcl|BSEQ0021839|Interleukin-6 (IL6)\nATGAACTCCTTCTCCACAAGCGCCTTCGGTCCAGTTGCCTTCTCCCTGGGGCTGCTCCTG\nGTGTTGCCTGCTGCCTTCCCTGCCCCAGTACCCCCAGGAGAAGATTCCAAAGATGTAGCC\nGCCCCACACAGACAGCCACTCACCTCTTCAGAACGAATTGACAAACAAATTCGGTACATC\nCTCGACGGCATCTCAGCCCTGAGAAAGGAGACATGTAACAAGAGTAACATGTGTGAAAGC\nAGCAAAGAGGCACTGGCAGAAAACAACCTGAACCTTCCAAAGATGGCTGAAAAAGATGGA\nTGCTTCCAATCTGGATTCAATGAGGAGACTTGCCTGGTGAAAATCATCACTGGTCTTTTG\nGAGTTTGAGGTATACCTAGAGTACCTCCAGAACAGATTTGAGAGTAGTGAGGAACAAGCC\nAGAGCTGTGCAGATGAGTACAAAAGTCCTGATCCAGTTCCTGCAGAAAAAGGCAAAGAAT\nCTAGATGCAATAACCACCCCTGACCCAACCACAAATGCCAGCCTGCTGACGAAGCTGCAG\nGCACAGAACCAGTGGCTGCAGGACATGACAACTCATCTCATTCTGCGCAGCTTTAAGGAG\nTTCCTGCAGTCCAGCCTGAGGGCTCTTCGGCAAATGTAG'),('Intermediate conductance calcium-activated potassium channel protein 4','None','Human','Protein phosphatase binding','Forms a voltage-independent potassium channel that is activated by intracellular calcium (PubMed:26148990). Activation is followed by membrane hyperpolarization which promotes calcium influx. Required for maximal calcium influx and proliferation during the reactivation of naive T-cells. The channel is blocked by clotrimazole and charybdotoxin but is insensitive to apamin (PubMed:17157250, PubMed:18796614).','KCNN4','47695.12','DB00468','>lcl|BSEQ0016087|Intermediate conductance calcium-activated potassium channel protein 4 (KCNN4)\nATGGGCGGGGATCTGGTGCTTGGCCTGGGGGCCTTGAGACGCCGAAAGCGCTTGCTGGAG\nCAGGAGAAGTCTCTGGCCGGCTGGGCACTGGTGCTGGCAGGAACTGGCATTGGACTCATG\nGTGCTGCATGCAGAGATGCTGTGGTTCGGGGGGTGCTCGTGGGCGCTCTACCTGTTCCTG\nGTTAAATGCACGATCAGCATTTCCACCTTCTTACTCCTCTGCCTCATCGTGGCCTTTCAT\nGCCAAAGAGGTCCAGCTGTTCATGACCGACAACGGGCTGCGGGACTGGCGCGTGGCGCTG\nACCGGGCGGCAGGCGGCGCAGATCGTGCTGGAGCTGGTGGTGTGTGGGCTGCACCCGGCG\nCCCGTGCGGGGCCCGCCGTGCGTGCAGGATTTAGGGGCGCCGCTGACCTCCCCGCAGCCC\nTGGCCGGGATTCCTGGGCCAAGGGGAAGCGCTGCTGTCCCTGGCCATGCTGCTGCGTCTC\nTACCTGGTGCCCCGCGCCGTGCTCCTGCGCAGCGGCGTCCTGCTCAACGCTTCCTACCGC\nAGCATCGGCGCTCTCAATCAAGTCCGCTTCCGCCACTGGTTCGTGGCCAAGCTTTACATG\nAACACGCACCCTGGCCGCCTGCTGCTCGGCCTCACGCTTGGCCTCTGGCTGACCACCGCC\nTGGGTGCTGTCCGTGGCCGAGAGGCAGGCTGTTAATGCCACTGGGCACCTTTCAGACACA\nCTTTGGCTGATCCCCATCACATTCCTGACCATCGGCTATGGTGACGTGGTGCCGGGCACC\nATGTGGGGCAAGATCGTCTGCCTGTGCACTGGAGTCATGGGTGTCTGCTGCACAGCCCTG\nCTGGTGGCCGTGGTGGCCCGGAAGCTGGAGTTTAACAAGGCAGAGAAGCACGTGCACAAC\nTTCATGATGGATATCCAGTATACCAAAGAGATGAAGGAGTCCGCTGCCCGAGTGCTACAA\nGAAGCCTGGATGTTCTACAAACATACTCGCAGGAAGGAGTCTCATGCTGCCCGCAGGCAT\nCAGCGCAAGCTGCTGGCCGCCATCAACGCGTTCCGCCAGGTGCGGCTGAAACACCGGAAG\nCTCCGGGAACAAGTGAACTCCATGGTGGACATCTCCAAGATGCACATGATCCTGTATGAC\nCTGCAGCAGAATCTGAGCAGCTCACACCGGGCCCTGGAGAAACAGATTGACACGCTGGCG\nGGGAAGCTGGATGCCCTGACTGAGCTGCTTAGCACTGCCCTGGGGCCGAGGCAGCTTCCA\nGAACCCAGCCAGCAGTCCAAGTAG'),('Kallikrein-1','None','Human','Serine-type endopeptidase activity','Glandular kallikreins cleave Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin.','KLK1','28889.425','DB12598','>lcl|BSEQ0010764|Kallikrein-1 (KLK1)\nATGTGGTTCCTGGTTCTGTGCCTCGCCCTGTCCCTGGGGGGGACTGGTGCTGCGCCCCCG\nATTCAGTCCCGGATTGTGGGAGGCTGGGAGTGTGAGCAGCATTCCCAGCCCTGGCAGGCG\nGCTCTGTACCATTTCAGCACTTTCCAGTGTGGGGGCATCCTGGTGCACCGCCAGTGGGTG\nCTCACAGCTGCTCATTGCATCAGCGACAATTACCAGCTCTGGCTGGGTCGCCACAACTTG\nTTTGACGACGAAAACACAGCCCAGTTTGTTCATGTCAGTGAGAGCTTCCCACACCCTGGC\nTTCAACATGAGCCTCCTGGAGAACCACACCCGCCAAGCAGACGAGGACTACAGCCACGAC\nCTCATGCTGCTCCGCCTGACAGAGCCTGCTGATACCATCACAGATGCTGTGAAGGTCGTG\nGAGTTGCCCACCGAGGAACCCGAAGTGGGGAGCACCTGTTTGGCTTCCGGCTGGGGCAGC\nATCGAACCAGAGAATTTCTCATTTCCAGATGATCTCCAGTGTGTGGACCTCAAAATCCTG\nCCTAATGATGAGTGCAAAAAAGCCCACGTCCAGAAGGTGACAGACTTCATGCTGTGTGTC\nGGACACCTGGAAGGTGGCAAAGACACCTGTGTGGGTGATTCAGGGGGCCCGCTGATGTGT\nGATGGTGTGCTCCAAGGTGTCACATCATGGGGCTACGTCCCTTGTGGCACCCCCAATAAG\nCCTTCTGTCGCCGTCAGAGTGCTGTCTTATGTGAAGTGGATCGAGGACACCATAGCGGAG\nAACTCCTGA'),('Kappa-type opioid receptor','None','Human','Opioid receptor activity','G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain. Plays a role in mediating reduced physical activity upon treatment with synthetic opioids. Plays a role in the regulation of salivation in response to synthetic opioids. May play a role in arousal and regulation of autonomic and neuroendocrine functions.','OPRK1','42644.665','DB01452','>lcl|BSEQ0021645|Kappa-type opioid receptor (OPRK1)\nATGGACTCCCCGATCCAGATCTTCCGCGGGGAGCCGGGCCCTACCTGCGCCCCGAGCGCC\nTGCCTGCCCCCCAACAGCAGCGCCTGGTTTCCCGGCTGGGCCGAGCCCGACAGCAACGGC\nAGCGCCGGCTCGGAGGACGCGCAGCTGGAGCCCGCGCACATCTCCCCGGCCATCCCGGTC\nATCATCACGGCGGTCTACTCCGTAGTGTTCGTCGTGGGCTTGGTGGGCAACTCGCTGGTC\nATGTTCGTGATCATCCGATACACAAAGATGAAGACAGCAACCAACATTTACATATTTAAC\nCTGGCTTTGGCAGATGCTTTAGTTACTACAACCATGCCCTTTCAGAGTACGGTCTACTTG\nATGAATTCCTGGCCTTTTGGGGATGTGCTGTGCAAGATAGTAATTTCCATTGATTACTAC\nAACATGTTCACCAGCATCTTCACCTTGACCATGATGAGCGTGGACCGCTACATTGCCGTG\nTGCCACCCCGTGAAGGCTTTGGACTTCCGCACACCCTTGAAGGCAAAGATCATCAATATC\nTGCATCTGGCTGCTGTCGTCATCTGTTGGCATCTCTGCAATAGTCCTTGGAGGCACCAAA\nGTCAGGGAAGACGTCGATGTCATTGAGTGCTCCTTGCAGTTCCCAGATGATGACTACTCC\nTGGTGGGACCTCTTCATGAAGATCTGCGTCTTCATCTTTGCCTTCGTGATCCCTGTCCTC\nATCATCATCGTCTGCTACACCCTGATGATCCTGCGTCTCAAGAGCGTCCGGCTCCTTTCT\nGGCTCCCGAGAGAAAGATCGCAACCTGCGTAGGATCACCAGACTGGTCCTGGTGGTGGTG\nGCAGTCTTCGTCGTCTGCTGGACTCCCATTCACATATTCATCCTGGTGGAGGCTCTGGGG\nAGCACCTCCCACAGCACAGCTGCTCTCTCCAGCTATTACTTCTGCATCGCCTTAGGCTAT\nACCAACAGTAGCCTGAATCCCATTCTCTACGCCTTTCTTGATGAAAACTTCAAGCGGTGT\nTTCCGGGACTTCTGCTTTCCACTGAAGATGAGGATGGAGCGGCAGAGCACTAGCAGAGTC\nCGAAATACAGTTCAGGATCCTGCTTACCTGAGGGACATCGATGGGATGAATAAACCAGTA\nTGA'),('Lactotransferrin','None','Human','Serine-type endopeptidase activity','Transferrins are iron binding transport proteins which can bind two Fe(3+) ions in association with the binding of an anion, usually bicarbonate.Lactotransferrin is a major iron-binding and multifunctional protein found in exocrine fluids such as breast milk and mucosal secretions. Has antimicrobial activity, which depends on the extracellular cation concentration. Antimicrobial properties include bacteriostasis, which is related to its ability to sequester free iron and thus inhibit microbial growth, as well as direct bactericidal properties leading to the release of lipopolysaccharides from the bacterial outer membrane. Can also prevent bacterial biofilm development in P.aeruginosa infection. Has weak antifungal activity against C.albicans. Has anabolic, differentiating and anti-apoptotic effects on osteoblasts and can also inhibit osteoclastogenesis, possibly playing a role in the regulation of bone growth. Promotes binding of species C adenoviruses to epithelial cells, promoting adenovirus infection. Can inhibit papillomavirus infections. Stimulates the TLR4 signaling pathway leading to NF-kappa-B activation and subsequent pro-inflammatory cytokine production while also interfering with the lipopolysaccharide (LPS)-stimulated TLR4 signaling. Inhibits neutrophil granulocyte migration to sites of apoptosis, when secreted by apoptotic cells. Stimulates VEGFA-mediated endothelial cell migration and proliferation. Binds heparin, chondroitin sulfate and possibly other glycosaminoglycans (GAGs). Also binds specifically to pneumococcal surface protein A (pspA), the lipid A portion of bacterial lipopolysaccharide (LPS), lysozyme and DNA.Lactoferricin binds to the bacterial surface and is crucial for the bactericidal functions. Has some antiviral activity against papillomavirus infection. N-terminal region shows strong antifungal activity against C.albicans. Contains two BBXB heparin-binding consensus sequences that appear to form the predominate functional GAG-binding site.Kaliocin-1 has antimicrobial activity and is able to permeabilize different ions through liposomal membranes.Lactoferroxins A, B and C have opioid antagonist activity. Lactoferroxin A shows preference for mu-receptors, while lactoferroxin B and C have somewhat higher degrees of preference for kappa-receptors than for mu-receptors.The lactotransferrin transferrin-like domain 1 functions as a serine protease of the peptidase S60 family that cuts arginine rich regions. This function contributes to the antimicrobial activity.Isoform DeltaLf: transcription factor with antiproliferative properties and ability to induce cell cycle arrest. Binds to the DeltaLf response element found in the SKP1, BAX, DCPS, and SELH promoters.','LTF','78181.225','DB08439','>lcl|BSEQ0020499|Lactotransferrin (LTF)\nATGAGAAAAGTGCGTGGCCCTCCTGTCAGCTGCATAAAGAGAGACTCCCCCATCCAGTGT\nATCCAGGCCATTGCGGAAAACAGGGCCGATGCTGTGACCCTTGATGGTGGTTTCATATAC\nGAGGCAGGCCTGGCCCCCTACAAACTGCGACCTGTAGCGGCGGAAGTCTACGGGACCGAA\nAGACAGCCACGAACTCACTATTATGCCGTGGCTGTGGTGAAGAAGGGCGGCAGCTTTCAG\nCTGAACGAACTGCAAGGTCTGAAGTCCTGCCACACAGGCCTTCGCAGGACCGCTGGATGG\nAATGTCCCTATAGGGACACTTCGTCCATTCTTGAATTGGACGGGTCCACCTGAGCCCATT\nGAGGCAGCTGTGGCCAGGTTCTTCTCAGCCAGCTGTGTTCCCGGTGCAGATAAAGGACAG\nTTCCCCAACCTGTGTCGCCTGTGTGCGGGGACAGGGGAAAACAAATGTGCCTTCTCCTCC\nCAGGAACCGTACTTCAGCTACTCTGGTGCCTTCAAGTGTCTGAGAGACGGGGCTGGAGAC\nGTGGCTTTTATCAGAGAGAGCACAGTGTTTGAGGACCTGTCAGACGAGGCTGAAAGGGAC\nGAGTATGAGTTACTCTGCCCAGACAACACTCGGAAGCCAGTGGACAAGTTCAAAGACTGC\nCATCTGGCCCGGGTCCCTTCTCATGCCGTTGTGGCACGAAGTGTGAATGGCAAGGAGGAT\nGCCATCTGGAATCTTCTCCGCCAGGCACAGGAAAAGTTTGGAAAGGACAAGTCACCGAAA\nTTCCAGCTCTTTGGCTCCCCTAGTGGGCAGAAAGATCTGCTGTTCAAGGACTCTGCCATT\nGGGTTTTCGAGGGTGCCCCCGAGGATAGATTCTGGGCTGTACCTTGGCTCCGGCTACTTC\nACTGCCATCCAGAACTTGAGGAAAAGTGAGGAGGAAGTGGCTGCCCGGCGTGCGCGGGTC\nGTGTGGTGTGCGGTGGGCGAGCAGGAGCTGCGCAAGTGTAACCAGTGGAGTGGCTTGAGC\nGAAGGCAGCGTGACCTGCTCCTCGGCCTCCACCACAGAGGACTGCATCGCCCTGGTGCTG\nAAAGGAGAAGCTGATGCCATGAGTTTGGATGGAGGATATGTGTACACTGCAGGCAAATGT\nGGTTTGGTGCCTGTCCTGGCAGAGAACTACAAATCCCAACAAAGCAGTGACCCTGATCCT\nAACTGTGTGGATAGACCTGTGGAAGGATATCTTGCTGTGGCGGTGGTTAGGAGATCAGAC\nACTAGCCTTACCTGGAACTCTGTGAAAGGCAAGAAGTCCTGCCACACCGCCGTGGACAGG\nACTGCAGGCTGGAATATCCCCATGGGCCTGCTCTTCAACCAGACGGGCTCCTGCAAATTT\nGATGAATATTTCAGTCAAAGCTGTGCCCCTGGGTCTGACCCGAGATCTAATCTCTGTGCT\nCTGTGTATTGGCGACGAGCAGGGTGAGAATAAGTGCGTGCCCAACAGCAACGAGAGATAC\nTACGGCTACACTGGGGCTTTCCGGTGCCTGGCTGAGAATGCTGGAGACGTTGCATTTGTG\nAAAGATGTCACTGTCTTGCAGAACACTGATGGAAATAACAATGAGGCATGGGCTAAGGAT\nTTGAAGCTGGCAGACTTTGCGCTGCTGTGCCTCGATGGCAAACGGAAGCCTGTGACTGAG\nGCTAGAAGCTGCCATCTTGCCATGGCCCCGAATCATGCCGTGGTGTCTCGGATGGATAAG\nGTGGAACGCCTGAAACAGGTGTTGCTCCACCAACAGGCTAAATTTGGGAGAAATGGATCT\nGACTGCCCGGACAAGTTTTGCTTATTCCAGTCTGAAACCAAAAACCTTCTGTTCAATGAC\nAACACTGAGTGTCTGGCCAGACTCCATGGCAAAACAACATATGAAAAATATTTGGGACCA\nCAGTATGTCGCAGGCATTACTAATCTGAAAAAGTGCTCAACCTCCCCCCTCCTGGAAGCC\nTGTGAATTCCTCAGGAAGTAA'),('Lactoylglutathione lyase','None','Human','Zinc ion binding','Catalyzes the conversion of hemimercaptal, formed from methylglyoxal and glutathione, to S-lactoylglutathione. Involved in the regulation of TNF-induced transcriptional activity of NF-kappa-B. Required for normal osteoclastogenesis.','GLO1','20777.515','DB00328','>lcl|BSEQ0016267|Lactoylglutathione lyase (GLO1)\nATGGCAGAACCGCAGCCCCCGTCCGGCGGCCTCACGGACGAGGCCGCCCTCAGTTGCTGC\nTCCGACGCGGACCCCAGTACCAAGGATTTTCTATTGCAGCAGACCATGCTACGAGTGAAG\nGATCCTAAGAAGTCACTGGATTTTTATACTAGAGTTCTTGGAATGACGCTAATCCAAAAA\nTGTGATTTTCCCATTATGAAGTTTTCACTCTACTTCTTGGCTTATGAGGATAAAAATGAC\nATCCCTAAAGAAAAAGATGAAAAAATAGCCTGGGCGCTCTCCAGAAAAGCTACACTTGAG\nCTGACACACAATTGGGGCACTGAAGATGATGAGACCCAGAGTTACCACAATGGCAATTCA\nGACCCTCGAGGATTCGGTCATATTGGAATTGCTGTTCCTGATGTATACAGTGCTTGTAAA\nAGGTTTGAAGAACTGGGAGTCAAATTTGTGAAGAAACCTGATGATGGTAAAATGAAAGGC\nCTGGCATTTATTCAAGATCCTGATGGCTACTGGATTGAAATTTTGAATCCTAACAAAATG\nGCAACCTTAATGTAG'),('Liver carboxylesterase 1','None','Human','Triglyceride lipase activity','Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Hydrolyzes aromatic and aliphatic esters, but has no catalytic activity toward amides or a fatty acyl-CoA ester. Hydrolyzes the methyl ester group of cocaine to form benzoylecgonine. Catalyzes the transesterification of cocaine to form cocaethylene. Displays fatty acid ethyl ester synthase activity, catalyzing the ethyl esterification of oleic acid to ethyloleate.','CES1','62520.62','DB01452','>lcl|BSEQ0021334|Liver carboxylesterase 1 (CES1)\nATGTGGCTCCGTGCCTTTATCCTGGCCACTCTCTCTGCTTCCGCGGCTTGGGGGCATCCG\nTCCTCGCCACCTGTGGTGGACACCGTGCATGGCAAAGTGCTGGGGAAGTTCGTCAGCTTA\nGAAGGATTTGCACAGCCTGTGGCCATTTTCCTGGGAATCCCTTTTGCCAAGCCGCCTCTT\nGGACCCCTGAGGTTTACTCCACCGCAGCCTGCAGAACCATGGAGCTTTGTGAAGAATGCC\nACCTCGTACCCTCCTATGTGCACCCAAGATCCCAAGGCGGGGCAGTTACTCTCAGAGCTA\nTTTACAAACCGAAAGGAGAACATTCCTCTCAAGCTTTCTGAAGACTGTCTTTACCTCAAT\nATTTACACTCCTGCTGACTTGACCAAGAAAAACAGGCTGCCGGTGATGGTGTGGATCCAC\nGGAGGGGGGCTGATGGTGGGTGCGGCATCAACCTATGATGGGCTGGCCCTTGCTGCCCAT\nGAAAACGTGGTGGTGGTGACCATTCAATATCGCCTGGGCATCTGGGGATTCTTCAGCACA\nGGGGATGAACACAGCCGGGGGAACTGGGGTCACCTGGACCAGGTGGCTGCCCTGCGCTGG\nGTCCAGGACAACATTGCCAGCTTTGGAGGGAACCCAGGCTCTGTGACCATCTTTGGAGAG\nTCAGCGGGAGGAGAAAGTGTCTCTGTTCTTGTTTTGTCTCCATTGGCCAAGAACCTCTTC\nCACCGGGCCATTTCTGAGAGTGGCGTGGCCCTCACTTCTGTTCTGGTGAAGAAAGGTGAT\nGTCAAGCCCTTGGCTGAGCAAATTGCTATCACTGCTGGGTGCAAAACCACCACCTCTGCT\nGTCATGGTTCACTGCCTGCGACAGAAGACGGAAGAGGAGCTCTTGGAGACGACATTGAAA\nATGAAATTCTTATCTCTGGACTTACAGGGAGACCCCAGAGAGAGTCAACCCCTTCTGGGC\nACTGTGATTGATGGGATGCTGCTGCTGAAAACACCTGAAGAGCTTCAAGCTGAAAGGAAT\nTTCCACACTGTCCCCTACATGGTCGGAATTAACAAGCAGGAGTTTGGCTGGTTGATTCCA\nATGCAGTTGATGAGCTATCCACTCTCCGAAGGGCAACTGGACCAGAAGACAGCCATGTCA\nCTCCTGTGGAAGTCCTATCCCCTTGTTTGCATTGCTAAGGAACTGATTCCAGAAGCCACT\nGAGAAATACTTAGGAGGAACAGACGACACTGTCAAAAAGAAAGACCTGTTCCTGGACTTG\nATAGCAGATGTGATGTTTGGTGTCCCATCTGTGATTGTGGCCCGGAACCACAGAGATGCT\nGGAGCACCCACCTACATGTATGAGTTTCAGTACCGTCCAAGCTTCTCATCAGACATGAAA\nCCCAAGACGGTGATAGGAGACCACGGGGATGAGCTCTTCTCCGTCTTTGGGGCCCCATTT\nTTAAAAGAGGGTGCCTCAGAAGAGGAGATCAGACTTAGCAAGATGGTGATGAAATTCTGG\nGCCAACTTTGCTCGCAATGGAAACCCCAATGGGGAAGGGCTGCCCCACTGGCCAGAGTAC\nAACCAGAAGGAAGGGTATCTGCAGATTGGTGCCAACACCCAGGCGGCCCAGAAGCTGAAG\nGACAAAGAAGTAGCTTTCTGGACCAACCTCTTTGCCAAGAAGGCAGTGGAGAAGCCACCC\nCAGACAGAACACATAGAGCTGTGA'),('Lymphocyte antigen 96','None','Human','Lipopolysaccharide receptor activity','Binds bacterial lipopolysaccharide (LPS) (PubMed:17803912, PubMed:17569869). Cooperates with TLR4 in the innate immune response to bacterial lipopolysaccharide (LPS), and with TLR2 in the response to cell wall components from Gram-positive and Gram-negative bacteria (PubMed:11160242, PubMed:11593030). Enhances TLR4-dependent activation of NF-kappa-B (PubMed:10359581). Cells expressing both LY96 and TLR4, but not TLR4 alone, respond to LPS (PubMed:10359581).','LY96','18545.345','DB00295','>lcl|BSEQ0021698|Lymphocyte antigen 96 (LY96)\nATGTTACCATTTCTGTTTTTTTCCACCCTGTTTTCTTCCATATTTACTGAAGCTCAGAAG\nCAGTATTGGGTCTGCAACTCATCCGATGCAAGTATTTCATACACCTACTGTGGGAGAGAT\nTTAAAGCAATTATATTTCAATCTCTATATAACTGTCAACACCATGAATCTTCCAAAGCGC\nAAAGAAGTTATTTGCCGAGGATCTGATGACGATTACTCTTTTTGCAGAGCTCTGAAGGGA\nGAGACTGTGAATACAACAATATCATTCTCCTTCAAGGGAATAAAATTTTCTAAGGGAAAA\nTACAAATGTGTTGTTGAAGCTATTTCTGGGAGCCCAGAAGAAATGCTCTTTTGCTTGGAG\nTTTGTCATCCTACACCAACCTAATTCAAATTAG'),('Matrix protein 2','None','Influenza A virus (strain A/Ann Arbor/6/1960 H2N2)','Ion channel activity','Forms a proton-selective ion channel that is necessary for the efficient release of the viral genome during virus entry. After attaching to the cell surface, the virion enters the cell by endocytosis. Acidification of the endosome triggers M2 ion channel activity. The influx of protons into virion interior is believed to disrupt interactions between the viral ribonucleoprotein (RNP), matrix protein 1 (M1), and lipid bilayers, thereby freeing the viral genome from interaction with viral proteins and enabling RNA segments to migrate to the host cell nucleus, where influenza virus RNA transcription and replication occur. Also plays a role in viral proteins secretory pathway. Elevates the intravesicular pH of normally acidic compartments, such as trans-Golgi network, preventing newly formed hemagglutinin from premature switching to the fusion-active conformation (By similarity).','M','11165.62','DB00915','>lcl|BSEQ0001255|294 bp\nATGAGTCTTCTAACCGAGGTCGAAACGCCTATCAGAAACGAATGGGGGTGCAGATGCAAC\nGATTCAAGTGACCCTCTTGTTGTTGCCGCGAGTATCATTGGGATCTTGCACTTGATATTG\nTGGATTCTTGATCATCTTTTTTTCAAATGCATTTATCGCTTCTTTAAACACGGTCTGAAA\nAGAGGGCCTTCTACGGAAGGAGTACCAGAGTCTATGAGGGAAGAATATCGAAAGGAACAG\nCAGAGTGCTGTGGATGCTGACGATAGTCATTTTGTCAGCATAGAGCTGGAGTAA'),('Melatonin receptor type 1A','None','Human','Organic cyclic compound binding','High affinity receptor for melatonin. Likely to mediates the reproductive and circadian actions of melatonin. The activity of this receptor is mediated by pertussis toxin sensitive G proteins that inhibit adenylate cyclase activity.','MTNR1A','39374.315','DB02709','>lcl|BSEQ0010363|Melatonin receptor type 1A (MTNR1A)\nATGCAGGGCAACGGCAGCGCGCTGCCCAACGCCTCCCAGCCCGTGCTCCGCGGGGACGGC\nGCGCGGCCCTCGTGGCTGGCGTCCGCCCTGGCCTGCGTCCTCATCTTCACCATCGTGGTG\nGACATCCTGGGCAACCTCCTGGTCATCCTGTCGGTGTATCGGAACAAGAAGCTCAGGAAC\nGCAGGAAACATCTTTGTGGTGAGCTTAGCGGTGGCAGACCTGGTGGTGGCCATTTATCCG\nTACCCGTTGGTGCTGATGTCGATATTTAACAACGGGTGGAACCTGGGCTATCTGCACTGC\nCAAGTCAGTGGGTTCCTGATGGGCCTGAGCGTCATCGGCTCCATATTCAACATCACCGGC\nATCGCCATCAACCGCTACTGCTACATCTGCCACAGTCTCAAGTACGACAAACTGTACAGC\nAGCAAGAACTCCCTCTGCTACGTGCTCCTCATATGGCTCCTGACGCTGGCGGCCGTCCTG\nCCCAACCTCCGTGCAGGGACTCTCCAGTACGACCCGAGGATCTACTCGTGCACCTTCGCC\nCAGTCCGTCAGCTCCGCCTACACCATCGCCGTGGTGGTTTTCCACTTCCTCGTCCCCATG\nATCATAGTCATCTTCTGTTACCTGAGAATATGGATCCTGGTTCTCCAGGTCAGACAGAGG\nGTGAAACCTGACCGCAAACCCAAACTGAAACCACAGGACTTCAGGAATTTTGTCACCATG\nTTTGTGGTTTTTGTCCTTTTTGCCATTTGCTGGGCTCCTCTGAACTTCATTGGCCTGGCC\nGTGGCCTCTGACCCCGCCAGCATGGTGCCTAGGATCCCAGAGTGGCTGTTTGTGGCCAGT\nTACTACATGGCGTATTTCAACAGCTGCCTCAATGCCATTATATACGGGCTACTGAACCAA\nAATTTCAGGAAGGAATACAGGAGAATTATAGTCTCGCTCTGTACAGCCAGGGTGTTCTTT\nGTGGACAGCTCTAACGACGTGGCCGATAGGGTTAAATGGAAACCGTCTCCACTGATGACC\nAACAATAATGTAGTAAAGGTGGACTCCGTTTAA'),('Melatonin receptor type 1B','None','Human','Melatonin receptor activity','High affinity receptor for melatonin. Likely to mediates the reproductive and circadian actions of melatonin. The activity of this receptor is mediated by pertussis toxin sensitive G proteins that inhibit adenylate cyclase activity.','MTNR1B','40187.895','DB02709','>lcl|BSEQ0010249|Melatonin receptor type 1B (MTNR1B)\nATGTCAGAGAACGGCTCCTTCGCCAACTGCTGCGAGGCGGGCGGGTGGGCAGTGCGCCCG\nGGCTGGTCGGGGGCTGGCAGCGCGCGGCCCTCCAGGACCCCTCGACCTCCCTGGGTGGCT\nCCAGCGCTGTCCGCGGTGCTCATCGTCACCACCGCCGTGGACGTCGTGGGCAACCTCCTG\nGTGATCCTCTCCGTGCTCAGGAACCGCAAGCTCCGGAACGCAGGTAATTTGTTCTTGGTG\nAGTCTGGCATTGGCTGACCTGGTGGTGGCCTTCTACCCCTACCCGCTAATCCTCGTGGCC\nATCTTCTATGACGGCTGGGCCCTGGGGGAGGAGCACTGCAAGGCCAGCGCCTTTGTGATG\nGGCCTGAGCGTCATCGGCTCTGTCTTCAATATCACTGCCATCGCCATTAACCGCTACTGC\nTACATCTGCCACAGCATGGCCTACCACCGAATCTACCGGCGCTGGCACACCCCTCTGCAC\nATCTGCCTCATCTGGCTCCTCACCGTGGTGGCCTTGCTGCCCAACTTCTTTGTGGGGTCC\nCTGGAGTACGACCCACGCATCTATTCCTGCACCTTCATCCAGACCGCCAGCACCCAGTAC\nACGGCGGCAGTGGTGGTCATCCACTTCCTCCTCCCTATCGCTGTCGTGTCCTTCTGCTAC\nCTGCGCATCTGGGTGCTGGTGCTTCAGGCCCGCAGGAAAGCCAAGCCAGAGAGCAGGCTG\nTGCCTGAAGCCCAGCGACTTGCGGAGCTTTCTAACCATGTTTGTGGTGTTTGTGATCTTT\nGCCATCTGCTGGGCTCCACTTAACTGCATCGGCCTCGCTGTGGCCATCAACCCCCAAGAA\nATGGCTCCCCAGATCCCTGAGGGGCTATTTGTCACTAGCTACTTACTGGCTTATTTCAAC\nAGCTGCCTGAATGCCATTGTCTATGGGCTCTTGAACCAAAACTTCCGCAGGGAATACAAG\nAGGATCCTCTTGGCCCTTTGGAACCCACGGCACTGCATTCAAGATGCTTCCAAGGGCAGC\nCACGCGGAGGGGCTGCAGAGCCCAGCTCCACCCATCATTGGTGTGCAGCACCAGGCAGAT\nGCTCTCTAG'),('Mitogen-activated protein kinase 3','None','Human','Phosphatase binding','Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK cascade. They participate also in a signaling cascade initiated by activated KIT and KITLG/SCF. Depending on the cellular context, the MAPK/ERK cascade mediates diverse biological functions such as cell growth, adhesion, survival and differentiation through the regulation of transcription, translation, cytoskeletal rearrangements. The MAPK/ERK cascade plays also a role in initiation and regulation of meiosis, mitosis, and postmitotic functions in differentiated cells by phosphorylating a number of transcription factors. About 160 substrates have already been discovered for ERKs. Many of these substrates are localized in the nucleus, and seem to participate in the regulation of transcription upon stimulation. However, other substrates are found in the cytosol as well as in other cellular organelles, and those are responsible for processes such as translation, mitosis and apoptosis. Moreover, the MAPK/ERK cascade is also involved in the regulation of the endosomal dynamics, including lysosome processing and endosome cycling through the perinuclear recycling compartment (PNRC); as well as in the fragmentation of the Golgi apparatus during mitosis. The substrates include transcription factors (such as ATF2, BCL6, ELK1, ERF, FOS, HSF4 or SPZ1), cytoskeletal elements (such as CANX, CTTN, GJA1, MAP2, MAPT, PXN, SORBS3 or STMN1), regulators of apoptosis (such as BAD, BTG2, CASP9, DAPK1, IER3, MCL1 or PPARG), regulators of translation (such as EIF4EBP1) and a variety of other signaling-related molecules (like ARHGEF2, FRS2 or GRB10). Protein kinases (such as RAF1, RPS6KA1/RSK1, RPS6KA3/RSK2, RPS6KA2/RSK3, RPS6KA6/RSK4, SYK, MKNK1/MNK1, MKNK2/MNK2, RPS6KA5/MSK1, RPS6KA4/MSK2, MAPKAPK3 or MAPKAPK5) and phosphatases (such as DUSP1, DUSP4, DUSP6 or DUSP16) are other substrates which enable the propagation the MAPK/ERK signal to additional cytosolic and nuclear targets, thereby extending the specificity of the cascade.','MAPK3','43135.16','DB00605','>lcl|BSEQ0021655|Mitogen-activated protein kinase 3 (MAPK3)\nATGGCGGCGGCGGCGGCTCAGGGGGGCGGGGGCGGGGAGCCCCGTAGAACCGAGGGGGTC\nGGCCCGGGGGTCCCGGGGGAGGTGGAGATGGTGAAGGGGCAGCCGTTCGACGTGGGCCCG\nCGCTACACGCAGTTGCAGTACATCGGCGAGGGCGCGTACGGCATGGTCAGCTCGGCCTAT\nGACCACGTGCGCAAGACTCGCGTGGCCATCAAGAAGATCAGCCCCTTCGAACATCAGACC\nTACTGCCAGCGCACGCTCCGGGAGATCCAGATCCTGCTGCGCTTCCGCCATGAGAATGTC\nATCGGCATCCGAGACATTCTGCGGGCGTCCACCCTGGAAGCCATGAGAGATGTCTACATT\nGTGCAGGACCTGATGGAGACTGACCTGTACAAGTTGCTGAAAAGCCAGCAGCTGAGCAAT\nGACCATATCTGCTACTTCCTCTACCAGATCCTGCGGGGCCTCAAGTACATCCACTCCGCC\nAACGTGCTCCACCGAGATCTAAAGCCCTCCAACCTGCTCATCAACACCACCTGCGACCTT\nAAGATTTGTGATTTCGGCCTGGCCCGGATTGCCGATCCTGAGCATGACCACACCGGCTTC\nCTGACGGAGTATGTGGCTACGCGCTGGTACCGGGCCCCAGAGATCATGCTGAACTCCAAG\nGGCTATACCAAGTCCATCGACATCTGGTCTGTGGGCTGCATTCTGGCTGAGATGCTCTCT\nAACCGGCCCATCTTCCCTGGCAAGCACTACCTGGATCAGCTCAACCACATTCTGGGCATC\nCTGGGCTCCCCATCCCAGGAGGACCTGAATTGTATCATCAACATGAAGGCCCGAAACTAC\nCTACAGTCTCTGCCCTCCAAGACCAAGGTGGCTTGGGCCAAGCTTTTCCCCAAGTCAGAC\nTCCAAAGCCCTTGACCTGCTGGACCGGATGTTAACCTTTAACCCCAATAAACGGATCACA\nGTGGAGGAAGCGCTGGCTCACCCCTACCTGGAGCAGTACTATGACCCGACGGATGAGGTG\nGGCCAGTCCCCAGCAGCAGTGGGGCTGGGGGCAGGGGAGCAGGGGGGCACGTAG'),('Mu-type opioid receptor','None','Human','Voltage-gated calcium channel activity','Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociation of the G-protein complex with the free GTP-bound G-protein alpha and the G-protein beta-gamma dimer activating downstream cellular effectors. The agonist- and cell type-specific activity is predominantly coupled to pertussis toxin-sensitive G(i) and G(o) G alpha proteins, GNAI1, GNAI2, GNAI3 and GNAO1 isoforms Alpha-1 and Alpha-2, and to a lesser extend to pertussis toxin-insensitive G alpha proteins GNAZ and GNA15. They mediate an array of downstream cellular responses, including inhibition of adenylate cyclase activity and both N-type and L-type calcium channels, activation of inward rectifying potassium channels, mitogen-activated protein kinase (MAPK), phospholipase C (PLC), phosphoinositide/protein kinase (PKC), phosphoinositide 3-kinase (PI3K) and regulation of NF-kappa-B. Also couples to adenylate cyclase stimulatory G alpha proteins. The selective temporal coupling to G-proteins and subsequent signaling can be regulated by RGSZ proteins, such as RGS9, RGS17 and RGS4. Phosphorylation by members of the GPRK subfamily of Ser/Thr protein kinases and association with beta-arrestins is involved in short-term receptor desensitization. Beta-arrestins associate with the GPRK-phosphorylated receptor and uncouple it from the G-protein thus terminating signal transduction. The phosphorylated receptor is internalized through endocytosis via clathrin-coated pits which involves beta-arrestins. The activation of the ERK pathway occurs either in a G-protein-dependent or a beta-arrestin-dependent manner and is regulated by agonist-specific receptor phosphorylation. Acts as a class A G-protein coupled receptor (GPCR) which dissociates from beta-arrestin at or near the plasma membrane and undergoes rapid recycling. Receptor down-regulation pathways are varying with the agonist and occur dependent or independent of G-protein coupling. Endogenous ligands induce rapid desensitization, endocytosis and recycling whereas morphine induces only low desensitization and endocytosis. Heterooligomerization with other GPCRs can modulate agonist binding, signaling and trafficking properties. Involved in neurogenesis. Isoform 12 couples to GNAS and is proposed to be involved in excitatory effects. Isoform 16 and isoform 17 do not bind agonists but may act through oligomerization with binding-competent OPRM1 isoforms and reduce their ligand binding activity.','OPRM1','44778.855','DB01452','>lcl|BSEQ0021649|Mu-type opioid receptor (OPRM1)\nATGGACAGCAGCGCTGCCCCCACGAACGCCAGCAATTGCACTGATGCCTTGGCGTACTCA\nAGTTGCTCCCCAGCACCCAGCCCCGGTTCCTGGGTCAACTTGTCCCACTTAGATGGCAAC\nCTGTCCGACCCATGCGGTCCGAACCGCACCGACCTGGGCGGGAGAGACAGCCTGTGCCCT\nCCGACCGGCAGTCCCTCCATGATCACGGCCATCACGATCATGGCCCTCTACTCCATCGTG\nTGCGTGGTGGGGCTCTTCGGAAACTTCCTGGTCATGTATGTGATTGTCAGATACACCAAG\nATGAAGACTGCCACCAACATCTACATTTTCAACCTTGCTCTGGCAGATGCCTTAGCCACC\nAGTACCCTGCCCTTCCAGAGTGTGAATTACCTAATGGGAACATGGCCATTTGGAACCATC\nCTTTGCAAGATAGTGATCTCCATAGATTACTATAACATGTTCACCAGCATATTCACCCTC\nTGCACCATGAGTGTTGATCGATACATTGCAGTCTGCCACCCTGTCAAGGCCTTAGATTTC\nCGTACTCCCCGAAATGCCAAAATTATCAATGTCTGCAACTGGATCCTCTCTTCAGCCATT\nGGTCTTCCTGTAATGTTCATGGCTACAACAAAATACAGGCAAGGTTCCATAGATTGTACA\nCTAACATTCTCTCATCCAACCTGGTACTGGGAAAACCTGCTGAAGATCTGTGTTTTCATC\nTTCGCCTTCATTATGCCAGTGCTCATCATTACCGTGTGCTATGGACTGATGATCTTGCGC\nCTCAAGAGTGTCCGCATGCTCTCTGGCTCCAAAGAAAAGGACAGGAATCTTCGAAGGATC\nACCAGGATGGTGCTGGTGGTGGTGGCTGTGTTCATCGTCTGCTGGACTCCCATTCACATT\nTACGTCATCATTAAAGCCTTGGTTACAATCCCAGAAACTACGTTCCAGACTGTTTCTTGG\nCACTTCTGCATTGCTCTAGGTTACACAAACAGCTGCCTCAACCCAGTCCTTTATGCATTT\nCTGGATGAAAACTTCAAACGATGCTTCAGAGAGTTCTGTATCCCAACCTCTTCCAACATT\nGAGCAACAAAACTCCACTCGAATTCGTCAGAACACTAGAGACCACCCCTCCACGGCCAAT\nACAGTGGATAGAACTAATCATCAGCTAGAAAATCTGGAAGCAGAAACTGCTCCGTTGCCC\nTAA'),('Multidrug resistance protein 1','None','Human','Xenobiotic-transporting atpase activity','Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.','ABCB1','141477.255','DB00482','>lcl|BSEQ0016291|Multidrug resistance protein 1 (ABCB1)\nATGGATCTTGAAGGGGACCGCAATGGAGGAGCAAAGAAGAAGAACTTTTTTAAACTGAAC\nAATAAAAGTGAAAAAGATAAGAAGGAAAAGAAACCAACTGTCAGTGTATTTTCAATGTTT\nCGCTATTCAAATTGGCTTGACAAGTTGTATATGGTGGTGGGAACTTTGGCTGCCATCATC\nCATGGGGCTGGACTTCCTCTCATGATGCTGGTGTTTGGAGAAATGACAGATATCTTTGCA\nAATGCAGGAAATTTAGAAGATCTGATGTCAAACATCACTAATAGAAGTGATATCAATGAT\nACAGGGTTCTTCATGAATCTGGAGGAAGACATGACCAGGTATGCCTATTATTACAGTGGA\nATTGGTGCTGGGGTGCTGGTTGCTGCTTACATTCAGGTTTCATTTTGGTGCCTGGCAGCT\nGGAAGACAAATACACAAAATTAGAAAACAGTTTTTTCATGCTATAATGCGACAGGAGATA\nGGCTGGTTTGATGTGCACGATGTTGGGGAGCTTAACACCCGACTTACAGATGATGTCTCC\nAAGATTAATGAAGGAATTGGTGACAAAATTGGAATGTTCTTTCAGTCAATGGCAACATTT\nTTCACTGGGTTTATAGTAGGATTTACACGTGGTTGGAAGCTAACCCTTGTGATTTTGGCC\nATCAGTCCTGTTCTTGGACTGTCAGCTGCTGTCTGGGCAAAGATACTATCTTCATTTACT\nGATAAAGAACTCTTAGCGTATGCAAAAGCTGGAGCAGTAGCTGAAGAGGTCTTGGCAGCA\nATTAGAACTGTGATTGCATTTGGAGGACAAAAGAAAGAACTTGAAAGGTACAACAAAAAT\nTTAGAAGAAGCTAAAAGAATTGGGATAAAGAAAGCTATTACAGCCAATATTTCTATAGGT\nGCTGCTTTCCTGCTGATCTATGCATCTTATGCTCTGGCCTTCTGGTATGGGACCACCTTG\nGTCCTCTCAGGGGAATATTCTATTGGACAAGTACTCACTGTATTCTTTTCTGTATTAATT\nGGGGCTTTTAGTGTTGGACAGGCATCTCCAAGCATTGAAGCATTTGCAAATGCAAGAGGA\nGCAGCTTATGAAATCTTCAAGATAATTGATAATAAGCCAAGTATTGACAGCTATTCGAAG\nAGTGGGCACAAACCAGATAATATTAAGGGAAATTTGGAATTCAGAAATGTTCACTTCAGT\nTACCCATCTCGAAAAGAAGTTAAGATCTTGAAGGGTCTGAACCTGAAGGTGCAGAGTGGG\nCAGACGGTGGCCCTGGTTGGAAACAGTGGCTGTGGGAAGAGCACAACAGTCCAGCTGATG\nCAGAGGCTCTATGACCCCACAGAGGGGATGGTCAGTGTTGATGGACAGGATATTAGGACC\nATAAATGTAAGGTTTCTACGGGAAATCATTGGTGTGGTGAGTCAGGAACCTGTATTGTTT\nGCCACCACGATAGCTGAAAACATTCGCTATGGCCGTGAAAATGTCACCATGGATGAGATT\nGAGAAAGCTGTCAAGGAAGCCAATGCCTATGACTTTATCATGAAACTGCCTCATAAATTT\nGACACCCTGGTTGGAGAGAGAGGGGCCCAGTTGAGTGGTGGGCAGAAGCAGAGGATCGCC\nATTGCACGTGCCCTGGTTCGCAACCCCAAGATCCTCCTGCTGGATGAGGCCACGTCAGCC\nTTGGACACAGAAAGCGAAGCAGTGGTTCAGGTGGCTCTGGATAAGGCCAGAAAAGGTCGG\nACCACCATTGTGATAGCTCATCGTTTGTCTACAGTTCGTAATGCTGACGTCATCGCTGGT\nTTCGATGATGGAGTCATTGTGGAGAAAGGAAATCATGATGAACTCATGAAAGAGAAAGGC\nATTTACTTCAAACTTGTCACAATGCAGACAGCAGGAAATGAAGTTGAATTAGAAAATGCA\nGCTGATGAATCCAAAAGTGAAATTGATGCCTTGGAAATGTCTTCAAATGATTCAAGATCC\nAGTCTAATAAGAAAAAGATCAACTCGTAGGAGTGTCCGTGGATCACAAGCCCAAGACAGA\nAAGCTTAGTACCAAAGAGGCTCTGGATGAAAGTATACCTCCAGTTTCCTTTTGGAGGATT\nATGAAGCTAAATTTAACTGAATGGCCTTATTTTGTTGTTGGTGTATTTTGTGCCATTATA\nAATGGAGGCCTGCAACCAGCATTTGCAATAATATTTTCAAAGATTATAGGGGTTTTTACA\nAGAATTGATGATCCTGAAACAAAACGACAGAATAGTAACTTGTTTTCACTATTGTTTCTA\nGCCCTTGGAATTATTTCTTTTATTACATTTTTCCTTCAGGGTTTCACATTTGGCAAAGCT\nGGAGAGATCCTCACCAAGCGGCTCCGATACATGGTTTTCCGATCCATGCTCAGACAGGAT\nGTGAGTTGGTTTGATGACCCTAAAAACACCACTGGAGCATTGACTACCAGGCTCGCCAAT\nGATGCTGCTCAAGTTAAAGGGGCTATAGGTTCCAGGCTTGCTGTAATTACCCAGAATATA\nGCAAATCTTGGGACAGGAATAATTATATCCTTCATCTATGGTTGGCAACTAACACTGTTA\nCTCTTAGCAATTGTACCCATCATTGCAATAGCAGGAGTTGTTGAAATGAAAATGTTGTCT\nGGACAAGCACTGAAAGATAAGAAAGAACTAGAAGGTTCTGGGAAGATCGCTACTGAAGCA\nATAGAAAACTTCCGAACCGTTGTTTCTTTGACTCAGGAGCAGAAGTTTGAACATATGTAT\nGCTCAGAGTTTGCAGGTACCATACAGAAACTCTTTGAGGAAAGCACACATCTTTGGAATT\nACATTTTCCTTCACCCAGGCAATGATGTATTTTTCCTATGCTGGATGTTTCCGGTTTGGA\nGCCTACTTGGTGGCACATAAACTCATGAGCTTTGAGGATGTTCTGTTAGTATTTTCAGCT\nGTTGTCTTTGGTGCCATGGCCGTGGGGCAAGTCAGTTCATTTGCTCCTGACTATGCCAAA\nGCCAAAATATCAGCAGCCCACATCATCATGATCATTGAAAAAACCCCTTTGATTGACAGC\nTACAGCACGGAAGGCCTAATGCCGAACACATTGGAAGGAAATGTCACATTTGGTGAAGTT\nGTATTCAACTATCCCACCCGACCGGACATCCCAGTGCTTCAGGGACTGAGCCTGGAGGTG\nAAGAAGGGCCAGACGCTGGCTCTGGTGGGCAGCAGTGGCTGTGGGAAGAGCACAGTGGTC\nCAGCTCCTGGAGCGGTTCTACGACCCCTTGGCAGGGAAAGTGCTGCTTGATGGCAAAGAA\nATAAAGCGACTGAATGTTCAGTGGCTCCGAGCACACCTGGGCATCGTGTCCCAGGAGCCC\nATCCTGTTTGACTGCAGCATTGCTGAGAACATTGCCTATGGAGACAACAGCCGGGTGGTG\nTCACAGGAAGAGATTGTGAGGGCAGCAAAGGAGGCCAACATACATGCCTTCATCGAGTCA\nCTGCCTAATAAATATAGCACTAAAGTAGGAGACAAAGGAACTCAGCTCTCTGGTGGCCAG\nAAACAACGCATTGCCATAGCTCGTGCCCTTGTTAGACAGCCTCATATTTTGCTTTTGGAT\nGAAGCCACGTCAGCTCTGGATACAGAAAGTGAAAAGGTTGTCCAAGAAGCCCTGGACAAA\nGCCAGAGAAGGCCGCACCTGCATTGTGATTGCTCACCGCCTGTCCACCATCCAGAATGCA\nGACTTAATAGTGGTGTTTCAGAATGGCAGAGTCAAGGAGCATGGCACGCATCAGCAGCTG\nCTGGCACAGAAAGGCATCTATTTTTCAATGGTCAGTGTCCAGGCTGGAACAAAGCGCCAG\nTGA'),('Multidrug resistance-associated protein 5','None','Human','Organic anion transmembrane transporter activity','Acts as a multispecific organic anion pump which can transport nucleotide analogs.','ABCC5','160658.8','DB11672','>lcl|BSEQ0012531|Multidrug resistance-associated protein 5 (ABCC5)\nATGAAGGATATCGACATAGGAAAAGAGTATATCATCCCCAGTCCTGGGTATAGAAGTGTG\nAGGGAGAGAACCAGCACTTCTGGGACGCACAGAGACCGTGAAGATTCCAAGTTCAGGAGA\nACTCGACCGTTGGAATGCCAAGATGCCTTGGAAACAGCAGCCCGAGCCGAGGGCCTCTCT\nCTTGATGCCTCCATGCATTCTCAGCTCAGAATCCTGGATGAGGAGCATCCCAAGGGAAAG\nTACCATCATGGCTTGAGTGCTCTGAAGCCCATCCGGACTACTTCCAAACACCAGCACCCA\nGTGGACAATGCTGGGCTTTTTTCCTGTATGACTTTTTCGTGGCTTTCTTCTCTGGCCCGT\nGTGGCCCACAAGAAGGGGGAGCTCTCAATGGAAGACGTGTGGTCTCTGTCCAAGCACGAG\nTCTTCTGACGTGAACTGCAGAAGACTAGAGAGACTGTGGCAAGAAGAGCTGAATGAAGTT\nGGGCCAGACGCTGCTTCCCTGCGAAGGGTTGTGTGGATCTTCTGCCGCACCAGGCTCATC\nCTGTCCATCGTGTGCCTGATGATCACGCAGCTGGCTGGCTTCAGTGGACCAAATTTTCAG\nGATGGCTGTATTCTGCGGTCAGAATGA'),('Muscarinic acetylcholine receptor','protein group','Human','None','None','None','None','DB01221','None'),('Muscarinic acetylcholine receptor M1','None','Human','Phosphatidylinositol phospholipase c activity','The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.','CHRM1','51420.375','DB01403','>lcl|BSEQ0009929|Muscarinic acetylcholine receptor M1 (CHRM1)\nATGAACACTTCAGCCCCACCTGCTGTCAGCCCCAACATCACCGTCCTGGCACCAGGAAAG\nGGTCCCTGGCAAGTGGCCTTCATTGGGATCACCACGGGCCTCCTGTCGCTAGCCACAGTG\nACAGGCAACCTGCTGGTACTCATCTCTTTCAAGGTCAACACGGAGCTCAAGACAGTCAAT\nAACTACTTCCTGCTGAGCCTGGCCTGTGCTGACCTCATCATCGGTACCTTCTCCATGAAC\nCTCTATACCACGTACCTGCTCATGGGCCACTGGGCTCTGGGCACGCTGGCTTGTGACCTC\nTGGCTGGCCCTGGACTATGTGGCCAGCAATGCCTCCGTCATGAATCTGCTGCTCATCAGC\nTTTGACCGCTACTTCTCCGTGACTCGGCCCCTGAGCTACCGTGCCAAGCGCACACCCCGC\nCGGGCAGCTCTGATGATCGGCCTGGCCTGGCTGGTTTCCTTTGTGCTCTGGGCCCCAGCC\nATCCTCTTCTGGCAGTACCTGGTAGGGGAGCGGACAGTGCTAGCTGGGCAGTGCTACATC\nCAGTTCCTCTCCCAGCCCATCATCACCTTTGGCACAGCCATGGCTGCCTTCTACCTCCCT\nGTCACAGTCATGTGCACGCTCTACTGGCGCATCTACCGGGAGACAGAGAACCGAGCACGG\nGAGCTGGCAGCCCTTCAGGGCTCCGAGACGCCAGGCAAAGGGGGTGGCAGCAGCAGCAGC\nTCAGAGAGGTCTCAGCCAGGGGCTGAGGGCTCACCAGAGACTCCTCCAGGCCGCTGCTGT\nCGCTGCTGCCGGGCCCCCAGGCTGCTGCAGGCCTACAGCTGGAAGGAAGAAGAGGAAGAG\nGACGAAGGCTCCATGGAGTCCCTCACATCCTCAGAGGGAGAGGAGCCTGGCTCCGAAGTG\nGTGATCAAGATGCCAATGGTGGACCCCGAGGCACAGGCCCCCACCAAGCAGCCCCCACGG\nAGCTCCCCAAATACAGTCAAGAGGCCGACTAAGAAAGGGCGTGATCGAGCTGGCAAGGGC\nCAGAAGCCCCGTGGAAAGGAGCAGCTGGCCAAGCGGAAGACCTTCTCGCTGGTCAAGGAG\nAAGAAGGCGGCTCGGACCCTGAGTGCCATCCTCCTGGCCTTCATCCTCACCTGGACACCG\nTACAACATCATGGTGCTGGTGTCCACCTTCTGCAAGGACTGTGTTCCCGAGACCCTGTGG\nGAGCTGGGCTACTGGCTGTGCTACGTCAACAGCACCATCAACCCCATGTGCTACGCACTC\nTGCAACAAAGCCTTCCGGGACACCTTTCGCCTGCTGCTGCTTTGCCGCTGGGACAAGAGA\nCGCTGGCGCAAGATCCCCAAGCGCCCTGGCTCCGTGCACCGCACTCCCTCCCGCCAATGC\nTGA'),('Muscarinic acetylcholine receptor M2','None','Human','G-protein coupled acetylcholine receptor activity','The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then triggers calcium ion release into the cytosol.','CHRM2','51714.605','DB01403','>lcl|BSEQ0016134|Muscarinic acetylcholine receptor M2 (CHRM2)\nATGAATAACTCAACAAACTCCTCTAACAATAGCCTGGCTCTTACAAGTCCTTATAAGACA\nTTTGAAGTGGTGTTTATTGTCCTGGTGGCTGGATCCCTCAGTTTGGTGACCATTATCGGG\nAACATCCTAGTCATGGTTTCCATTAAAGTCAACCGCCACCTCCAGACCGTCAACAATTAC\nTTTTTATTCAGCTTGGCCTGTGCTGACCTTATCATAGGTGTTTTCTCCATGAACTTGTAC\nACCCTCTACACTGTGATTGGTTACTGGCCTTTGGGACCTGTGGTGTGTGACCTTTGGCTA\nGCCCTGGACTATGTGGTCAGCAATGCCTCAGTTATGAATCTGCTCATCATCAGCTTTGAC\nAGGTACTTCTGTGTCACAAAACCTCTGACCTACCCAGTCAAGCGGACCACAAAAATGGCA\nGGTATGATGATTGCAGCTGCCTGGGTCCTCTCTTTCATCCTCTGGGCTCCAGCCATTCTC\nTTCTGGCAGTTCATTGTAGGGGTGAGAACTGTGGAGGATGGGGAGTGCTACATTCAGTTT\nTTTTCCAATGCTGCTGTCACCTTTGGTACGGCTATTGCAGCCTTCTATTTGCCAGTGATC\nATCATGACTGTGCTATATTGGCACATATCCCGAGCCAGCAAGAGCAGGATAAAGAAGGAC\nAAGAAGGAGCCTGTTGCCAACCAAGACCCCGTTTCTCCAAGTCTGGTACAAGGAAGGATA\nGTGAAGCCAAACAATAACAACATGCCCAGCAGTGACGATGGCCTGGAGCACAACAAAATC\nCAGAATGGCAAAGCCCCCAGGGATCCTGTGACTGAAAACTGTGTTCAGGGAGAGGAGAAG\nGAGAGCTCCAATGACTCCACCTCAGTCAGTGCTGTTGCCTCTAATATGAGAGATGATGAA\nATAACCCAGGATGAAAACACAGTTTCCACTTCCCTGGGCCATTCCAAAGATGAGAACTCT\nAAGCAAACATGCATCAGAATTGGCACCAAGACCCCAAAAAGTGACTCATGTACCCCAACT\nAATACCACCGTGGAGGTAGTGGGGTCTTCAGGTCAGAATGGAGATGAAAAGCAGAATATT\nGTAGCCCGCAAGATTGTGAAGATGACTAAGCAGCCTGCAAAAAAGAAGCCTCCTCCTTCC\nCGGGAAAAGAAAGTCACCAGGACAATCTTGGCTATTCTGTTGGCTTTCATCATCACTTGG\nGCCCCATACAATGTCATGGTGCTCATTAACACCTTTTGTGCACCTTGCATCCCCAACACT\nGTGTGGACAATTGGTTACTGGCTTTGTTACATCAACAGCACTATCAACCCTGCCTGCTAT\nGCACTTTGCAATGCCACCTTCAAGAAGACCTTTAAACACCTTCTCATGTGTCATTATAAG\nAACATAGGCGCTACAAGGTAA'),('Muscarinic acetylcholine receptor M3','None','Human','Receptor activity','The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.','CHRM3','66127.445','DB01403','>lcl|BSEQ0009899|Muscarinic acetylcholine receptor M3 (CHRM3)\nATGACCTTGCACAATAACAGTACAACCTCGCCTTTGTTTCCAAACATCAGCTCCTCCTGG\nATACACAGCCCCTCCGATGCAGGGCTGCCCCCGGGAACCGTCACTCATTTCGGCAGCTAC\nAATGTTTCTCGAGCAGCTGGCAATTTCTCCTCTCCAGACGGTACCACCGATGACCCTCTG\nGGAGGTCATACCGTCTGGCAAGTGGTCTTCATCGCTTTCTTAACGGGCATCCTGGCCTTG\nGTGACCATCATCGGCAACATCCTGGTAATTGTGTCATTTAAGGTCAACAAGCAGCTGAAG\nACGGTCAACAACTACTTCCTCTTAAGCCTGGCCTGTGCCGATCTGATTATCGGGGTCATT\nTCAATGAATCTGTTTACGACCTACATCATCATGAATCGATGGGCCTTAGGGAACTTGGCC\nTGTGACCTCTGGCTTGCCATTGACTACGTAGCCAGCAATGCCTCTGTTATGAATCTTCTG\nGTCATCAGCTTTGACAGATACTTTTCCATCACGAGGCCGCTCACGTACCGAGCCAAACGA\nACAACAAAGAGAGCCGGTGTGATGATCGGTCTGGCTTGGGTCATCTCCTTTGTCCTTTGG\nGCTCCTGCCATCTTGTTCTGGCAATACTTTGTTGGAAAGAGAACTGTGCCTCCGGGAGAG\nTGCTTCATTCAGTTCCTCAGTGAGCCCACCATTACTTTTGGCACAGCCATCGCTGCTTTT\nTATATGCCTGTCACCATTATGACTATTTTATACTGGAGGATCTATAAGGAAACTGAAAAG\nCGTACCAAAGAGCTTGCTGGCCTGCAAGCCTCTGGGACAGAGGCAGAGACAGAAAACTTT\nGTCCACCCCACGGGCAGTTCTCGAAGCTGCAGCAGTTACGAACTTCAACAGCAAAGCATG\nAAACGCTCCAACAGGAGGAAGTATGGCCGCTGCCACTTCTGGTTCACAACCAAGAGCTGG\nAAACCCAGCTCCGAGCAGATGGACCAAGACCACAGCAGCAGTGACAGTTGGAACAACAAT\nGATGCTGCTGCCTCCCTGGAGAACTCCGCCTCCTCCGACGAGGAGGACATTGGCTCCGAG\nACGAGAGCCATCTACTCCATCGTGCTCAAGCTTCCGGGTCACAGCACCATCCTCAACTCC\nACCAAGTTACCCTCATCGGACAACCTGCAGGTGCCTGAGGAGGAGCTGGGGATGGTGGAC\nTTGGAGAGGAAAGCCGACAAGCTGCAGGCCCAGAAGAGCGTGGACGATGGAGGCAGTTTT\nCCAAAAAGCTTCTCCAAGCTTCCCATCCAGCTAGAGTCAGCCGTGGACACAGCTAAGACT\nTCTGACGTCAACTCCTCAGTGGGTAAGAGCACGGCCACTCTACCTCTGTCCTTCAAGGAA\nGCCACTCTGGCCAAGAGGTTTGCTCTGAAGACCAGAAGTCAGATCACTAAGCGGAAAAGG\nATGTCCCTGGTCAAGGAGAAGAAAGCGGCCCAGACCCTCAGTGCGATCTTGCTTGCCTTC\nATCATCACTTGGACCCCATACAACATCATGGTTCTGGTGAACACCTTTTGTGACAGCTGC\nATACCCAAAACCTTTTGGAATCTGGGCTACTGGCTGTGCTACATCAACAGCACCGTGAAC\nCCCGTGTGCTATGCTCTGTGCAACAAAACATTCAGAACCACTTTCAAGATGCTGCTGCTG\nTGCCAGTGTGACAAAAAAAAGAGGCGCAAGCAGCAGTACCAGCAGAGACAGTCGGTCATT\nTTTCACAAGCGCGCACCCGAGCAGGCCTTGTAG'),('Muscarinic acetylcholine receptor M4','None','Human','Guanyl-nucleotide exchange factor activity','The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.','CHRM4','53048.65','DB01403','>lcl|BSEQ0010281|Muscarinic acetylcholine receptor M4 (CHRM4)\nATGGCCAACTTCACACCTGTCAATGGCAGCTCGGGCAATCAGTCCGTGCGCCTGGTCACG\nTCATCATCCCACAATCGCTATGAGACGGTGGAAATGGTCTTCATTGCCACAGTGACAGGC\nTCCCTGAGCCTGGTGACTGTCGTGGGCAACATCCTGGTGATGCTGTCCATCAAGGTCAAC\nAGGCAGCTGCAGACAGTCAACAACTACTTCCTCTTCAGCCTGGCGTGTGCTGATCTCATC\nATAGGCGCCTTCTCCATGAACCTCTACACCGTGTACATCATCAAGGGCTACTGGCCCCTG\nGGCGCCGTGGTCTGCGACCTGTGGCTGGCCCTGGACTACGTGGTGAGCAACGCCTCCGTC\nATGAACCTTCTCATCATCAGCTTTGACCGCTACTTCTGCGTCACCAAGCCTCTCACCTAC\nCCTGCCCGGCGCACCACCAAGATGGCAGGCCTCATGATTGCTGCTGCCTGGGTACTGTCC\nTTCGTGCTCTGGGCGCCTGCCATCTTGTTCTGGCAGTTTGTGGTGGGTAAGCGGACGGTG\nCCCGACAACCAGTGCTTCATCCAGTTCCTGTCCAACCCAGCAGTGACCTTTGGCACAGCC\nATTGCTGCCTTCTACCTGCCTGTGGTCATCATGACGGTGCTGTACATCCACATCTCCCTG\nGCCAGTCGCAGCCGAGTCCACAAGCACCGGCCCGAGGGCCCGAAGGAGAAGAAAGCCAAG\nACGCTGGCCTTCCTCAAGAGCCCACTAATGAAGCAGAGCGTCAAGAAGCCCCCGCCCGGG\nGAGGCCGCCCGGGAGGAGCTGCGCAATGGCAAGCTGGAGGAGGCCCCCCCGCCAGCGCTG\nCCACCGCCACCGCGCCCCGTGGCTGATAAGGACACTTCCAATGAGTCCAGCTCAGGCAGT\nGCCACCCAGAACACCAAGGAACGCCCAGCCACAGAGCTGTCCACCACAGAGGCCACCACG\nCCCGCCATGCCCGCCCCTCCCCTGCAGCCGCGGGCCCTCAACCCAGCCTCCAGATGGTCC\nAAGATCCAGATTGTGACGAAGCAGACAGGCAATGAGTGTGTGACAGCCATTGAGATTGTG\nCCTGCCACGCCGGCTGGCATGCGCCCTGCGGCCAACGTGGCCCGCAAGTTCGCCAGCATC\nGCTCGCAACCAGGTGCGCAAGAAGCGGCAGATGGCGGCCCGGGAGCGCAAAGTGACACGA\nACGATCTTTGCCATTCTGCTAGCCTTCATCCTCACCTGGACGCCCTACAACGTCATGGTC\nCTGGTGAACACCTTCTGCCAGAGCTGCATCCCTGACACGGTGTGGTCCATTGGCTACTGG\nCTCTGCTACGTCAACAGCACCATCAACCCTGCCTGCTATGCTCTGTGCAACGCCACCTTT\nAAAAAGACCTTCCGGCACCTGCTGCTGTGCCAGTATCGGAACATCGGCACTGCCAGGTAG'),('Muscarinic acetylcholine receptor M5','None','Human','Phosphatidylinositol phospholipase c activity','The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.','CHRM5','60073.205','DB01403','>lcl|BSEQ0010218|Muscarinic acetylcholine receptor M5 (CHRM5)\nATGGAAGGGGATTCTTACCACAATGCAACCACCGTCAATGGCACCCCAGTAAATCACCAG\nCCTTTGGAACGCCACAGGTTGTGGGAAGTCATCACCATTGCAGCTGTGACTGCTGTGGTA\nAGCCTGATCACCATTGTGGGCAATGTCTTGGTCATGATCTCCTTCAAAGTCAACAGCCAG\nCTCAAGACAGTTAACAACTATTACCTGCTCAGCTTAGCCTGTGCAGATCTCATCATTGGA\nATCTTCTCCATGAACCTCTACACCACCTACATCCTCATGGGACGCTGGGCTCTCGGGAGT\nCTGGCTTGTGACCTTTGGCTTGCACTGGACTACGTGGCCAGCAACGCTTCTGTCATGAAC\nCTTCTGGTGATCAGTTTTGACCGTTACTTTTCCATCACAAGACCCTTGACATATCGGGCC\nAAGCGTACTCCGAAAAGGGCTGGCATCATGATTGGCTTGGCCTGGCTGATCTCCTTCATC\nCTCTGGGCCCCAGCAATCCTCTGCTGGCAGTACTTGGTTGGGAAGCGGACAGTTCCACTG\nGATGAGTGCCAGATCCAGTTTCTCTCTGAGCCCACCATCACTTTTGGCACTGCCATTGCT\nGCCTTCTACATCCCTGTTTCTGTCATGACCATCCTCTACTGTCGAATCTACCGGGAAACA\nGAGAAGCGAACCAAGGACCTGGCTGACCTCCAGGGTTCTGACTCTGTGACCAAAGCTGAG\nAAGAGAAAGCCAGCTCATAGGGCTCTGTTCAGATCCTGCTTGCGCTGTCCTCGACCCACC\nCTGGCCCAGCGGGAAAGGAACCAGGCCTCCTGGTCATCCTCCCGCAGGAGCACCTCCACC\nACTGGGAAGCCATCCCAAGCCACTGGCCCAAGCGCCAATTGGGCCAAAGCTGAGCAGCTC\nACCACCTGTAGCAGCTACCCTTCCTCAGAGGATGAGGACAAGCCCGCCACTGACCCTGTC\nCTCCAAGTGGTCTACAAGAGTCAGGGTAAGGAAAGCCCAGGGGAAGAATTCAGTGCTGAA\nGAGACTGAGGAAACTTTTGTGAAAGCTGAAACTGAAAAAAGTGACTATGACACCCCAAAC\nTACCTTCTGTCTCCAGCAGCTGCTCATAGACCCAAGAGTCAGAAATGTGTGGCCTATAAG\nTTCCGATTGGTGGTAAAAGCTGACGGGAACCAGGAGACCAACAATGGCTGTCACAAGGTG\nAAAATCATGCCCTGCCCCTTCCCAGTGGCCAAGGAACCTTCAACGAAAGGCCTCAATCCC\nAACCCCAGCCATCAAATGACCAAACGAAAGAGAGTGGTCCTAGTCAAAGAGAGGAAAGCA\nGCCCAGACACTGAGTGCCATTCTCCTGGCCTTCATCATCACATGGACCCCGTATAACATC\nATGGTCCTGGTTTCTACCTTCTGTGACAAGTGTGTCCCAGTCACCCTGTGGCACTTGGGC\nTATTGGTTGTGCTATGTCAATAGCACTGTCAACCCCATCTGCTATGCCCTCTGCAACAGA\nACCTTCAGGAAGACCTTTAAGATGCTGCTTCTCTGCCGATGGAAAAAGAAAAAAGTGGAA\nGAGAAGTTGTACTGGCAGGGGAACAGCAAGCTACCCTGA'),('Myeloperoxidase','None','Human','Peroxidase activity','Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production of hypohalous acids, primarily hypochlorous acid in physiologic situations, and other toxic intermediates that greatly enhance PMN microbicidal activity.','MPO','83867.71','DB00244','>lcl|BSEQ0016304|Myeloperoxidase (MPO)\nATGGGGGTTCCCTTCTTCTCTTCTCTCAGATGCATGGTGGACTTAGGACCTTGCTGGGCT\nGGGGGTCTCACTGCAGAGATGAAGCTGCTTCTGGCCCTAGCAGGGCTCCTGGCCATTCTG\nGCCACGCCCCAGCCCTCTGAAGGTGCTGCTCCAGCTGTCCTGGGGGAGGTGGACACCTCG\nTTGGTGCTGAGCTCCATGGAGGAGGCCAAGCAGCTGGTGGACAAGGCCTACAAGGAGCGG\nCGGGAAAGCATCAAGCAGCGGCTTCGCAGCGGCTCAGCCAGCCCCATGGAACTCCTATCC\nTACTTCAAGCAGCCGGTGGCAGCCACCAGGACGGCGGTGAGGGCCGCTGACTACCTGCAC\nGTGGCTCTAGACCTGCTGGAGAGGAAGCTGCGGTCCCTGTGGCGAAGGCCATTCAATGTC\nACTGATGTGCTGACGCCCGCCCAGCTGAATGTGTTGTCCAAGTCAAGCGGCTGCGCCTAC\nCAGGACGTGGGGGTGACTTGCCCGGAGCAGGACAAATACCGCACCATCACCGGGATGTGC\nAACAACAGACGCAGCCCCACGCTGGGGGCCTCCAACCGTGCCTTTGTGCGCTGGCTGCCG\nGCGGAGTATGAGGACGGCTTCTCTCTTCCCTACGGCTGGACGCCCGGGGTCAAGCGCAAC\nGGCTTCCCGGTGGCTCTGGCTCGCGCGGTCTCCAACGAGATCGTGCGCTTCCCCACTGAT\nCAGCTGACTCCGGACCAGGAGCGCTCACTCATGTTCATGCAATGGGGCCAGCTGTTGGAC\nCACGACCTCGACTTCACCCCTGAGCCGGCCGCCCGGGCCTCCTTCGTCACTGGCGTCAAC\nTGCGAGACCAGCTGCGTTCAGCAGCCGCCCTGCTTCCCGCTCAAGATCCCGCCCAATGAC\nCCCCGCATCAAGAACCAAGCCGACTGCATCCCGTTCTTCCGCTCCTGCCCGGCTTGCCCC\nGGGAGCAACATCACCATCCGCAACCAGATCAACGCGCTCACTTCCTTCGTGGACGCCAGC\nATGGTGTACGGCAGCGAGGAGCCCCTGGCCAGGAACCTGCGCAACATGTCCAACCAGCTG\nGGGCTGCTGGCCGTCAACCAGCGCTTCCAAGACAACGGCCGGGCCCTGCTGCCCTTTGAC\nAACCTGCACGATGACCCCTGTCTCCTCACCAACCGCTCAGCGCGCATCCCCTGCTTCCTG\nGCAGGGGACACCCGTTCCAGTGAGATGCCCGAGCTCACCTCCATGCACACCCTCTTACTT\nCGGGAGCACAACCGGCTGGCCACAGAGCTCAAGAGCCTGAACCCTAGGTGGGATGGGGAG\nAGGCTCTACCAGGAAGCCCGGAAGATCGTGGGGGCCATGGTCCAGATCATCACTTACCGG\nGACTACCTGCCCCTGGTGCTGGGGCCAACGGCCATGAGGAAGTACCTGCCCACGTACCGT\nTCCTACAATGACTCAGTGGACCCACGCATCGCCAACGTCTTCACCAATGCCTTCCGCTAC\nGGCCACACCCTCATCCAACCCTTCATGTTCCGCCTGGACAATCGGTACCAGCCCATGGAA\nCCCAACCCCCGTGTCCCCCTCAGCAGGGTCTTTTTTGCCTCCTGGAGGGTCGTGCTGGAA\nGGTGGCATTGACCCCATCCTCCGGGGCCTCATGGCCACCCCTGCCAAGCTGAATCGTCAG\nAACCAAATTGCAGTGGATGAGATCCGGGAGCGATTGTTTGAGCAGGTCATGAGGATTGGG\nCTGGACCTGCCTGCTCTGAACATGCAGCGCAGCAGGGACCACGGCCTCCCAGGATACAAT\nGCCTGGAGGCGCTTCTGTGGGCTCCCGCAGCCTGAAACTGTGGGCCAGCTGGGCACGGTG\nCTGAGGAACCTGAAATTGGCGAGGAAACTGATGGAGCAGTATGGCACGCCCAACAACATC\nGACATCTGGATGGGCGGCGTGTCCGAGCCTCTGAAGCGCAAAGGCCGCGTGGGCCCACTC\nCTCGCCTGCATCATCGGTACCCAGTTCAGGAAGCTCCGGGATGGTGATCGGTTTTGGTGG\nGAGAACGAGGGTGTGTTCAGCATGCAGCAGCGACAGGCCCTGGCCCAGATCTCATTGCCC\nCGGATCATCTGCGACAACACAGGCATCACCACCGTGTCTAAGAACAACATCTTCATGTCC\nAACTCATATCCCCGGGACTTTGTCAACTGCAGTACACTTCCTGCATTGAACCTGGCTTCC\nTGGAGGGAAGCCTCCTAG'),('N-arachidonyl glycine receptor','None','Human','G-protein coupled receptor activity','Receptor for N-arachidonyl glycine. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase. May contribute to regulation of the immune system.','GPR18','38133.27','DB14011','>lcl|BSEQ0011660|N-arachidonyl glycine receptor (GPR18)\nATGATCACCCTGAACAATCAAGATCAACCTGTCCCTTTTAACAGCTCACATCCAGATGAA\nTACAAAATTGCAGCCCTTGTCTTCTATAGCTGTATCTTCATAATTGGATTATTTGTTAAC\nATCACTGCATTATGGGTTTTCAGTTGTACCACCAAGAAGAGAACCACGGTAACCATCTAT\nATGATGAATGTGGCATTAGTGGACTTGATATTTATAATGACTTTACCCTTTCGAATGTTT\nTATTATGCAAAAGATGAATGGCCATTTGGAGAGTACTTCTGCCAGATTCTTGGAGCTCTC\nACAGTGTTTTACCCAAGCATTGCTTTATGGCTTCTTGCCTTTATTAGTGCTGACAGATAC\nATGGCCATTGTACAGCCGAAGTACGCCAAAGAACTTAAAAACACGTGCAAAGCCGTGCTG\nGCGTGTGTGGGAGTCTGGATAATGACCCTGACCACGACCACCCCTCTGCTACTGCTCTAT\nAAAGACCCAGATAAAGACTCCACTCCCGCCACCTGCCTCAAGATTTCTGACATCATCTAT\nCTAAAAGCTGTGAACGTGCTGAACCTCACTCGACTGACATTTTTTTTCTTGATTCCTTTG\nTTCATCATGATTGGGTGCTACTTGGTCATTATTCATAATCTCCTTCACGGCAGGACGTCT\nAAGCTGAAACCCAAAGTCAAGGAGAAGTCCATAAGGATCATCATCACGCTGCTGGTGCAG\nGTGCTCGTCTGCTTTATGCCCTTCCACATCTGTTTCGCTTTCCTGATGCTGGGAACGGGG\nGAGAACAGTTACAATCCCTGGGGAGCCTTTACCACCTTCCTCATGAACCTCAGCACGTGT\nCTGGATGTGATTCTCTACTACATCGTTTCAAAACAATTTCAGGCTCGAGTCATTAGTGTC\nATGCTATACCGTAATTACCTTCGAAGCATGCGCAGAAAAAGTTTCCGATCTGGTAGTCTA\nCGGTCACTAAGCAATATAAACAGTGAAATGTTATGA'),('NAD-dependent protein deacetylase sirtuin-1','None','Human','Transcription factor binding','NAD-dependent protein deacetylase that links transcriptional regulation directly to intracellular energetics and participates in the coordination of several separated cellular functions such as cell cycle, response to DNA damage, metobolism, apoptosis and autophagy. Can modulate chromatin function through deacetylation of histones and can promote alterations in the methylation of histones and DNA, leading to transcriptional repression. Deacetylates a broad range of transcription factors and coregulators, thereby regulating target gene expression positively and negatively. Serves as a sensor of the cytosolic ratio of NAD(+)/NADH which is altered by glucose deprivation and metabolic changes associated with caloric restriction. Is essential in skeletal muscle cell differentiation and in response to low nutrients mediates the inhibitory effect on skeletal myoblast differentiation which also involves 5\'-AMP-activated protein kinase (AMPK) and nicotinamide phosphoribosyltransferase (NAMPT). Component of the eNoSC (energy-dependent nucleolar silencing) complex, a complex that mediates silencing of rDNA in response to intracellular energy status and acts by recruiting histone-modifying enzymes. The eNoSC complex is able to sense the energy status of cell: upon glucose starvation, elevation of NAD(+)/NADP(+) ratio activates SIRT1, leading to histone H3 deacetylation followed by dimethylation of H3 at \'Lys-9\' (H3K9me2) by SUV39H1 and the formation of silent chromatin in the rDNA locus. Deacetylates \'Lys-266\' of SUV39H1, leading to its activation. Inhibits skeletal muscle differentiation by deacetylating PCAF and MYOD1. Deacetylates H2A and \'Lys-26\' of HIST1H1E. Deacetylates \'Lys-16\' of histone H4 (in vitro). Involved in NR0B2/SHP corepression function through chromatin remodeling: Recruited to LRH1 target gene promoters by NR0B2/SHP thereby stimulating histone H3 and H4 deacetylation leading to transcriptional repression. Proposed to contribute to genomic integrity via positive regulation of telomere length; however, reports on localization to pericentromeric heterochromatin are conflicting. Proposed to play a role in constitutive heterochromatin (CH) formation and/or maintenance through regulation of the available pool of nuclear SUV39H1. Upon oxidative/metabolic stress decreases SUV39H1 degradation by inhibiting SUV39H1 polyubiquitination by MDM2. This increase in SUV39H1 levels enhances SUV39H1 turnover in CH, which in turn seems to accelerate renewal of the heterochromatin which correlates with greater genomic integrity during stress response. Deacetylates \'Lys-382\' of p53/TP53 and impairs its ability to induce transcription-dependent proapoptotic program and modulate cell senescence. Deacetylates TAF1B and thereby represses rDNA transcription by the RNA polymerase I. Deacetylates MYC, promotes the association of MYC with MAX and decreases MYC stability leading to compromised transformational capability. Deacetylates FOXO3 in response to oxidative stress thereby increasing its ability to induce cell cycle arrest and resistance to oxidative stress but inhibiting FOXO3-mediated induction of apoptosis transcriptional activity; also leading to FOXO3 ubiquitination and protesomal degradation. Appears to have a similar effect on MLLT7/FOXO4 in regulation of transcriptional activity and apoptosis. Deacetylates DNMT1; thereby impairs DNMT1 methyltransferase-independent transcription repressor activity, modulates DNMT1 cell cycle regulatory function and DNMT1-mediated gene silencing. Deacetylates RELA/NF-kappa-B p65 thereby inhibiting its transactivating potential and augments apoptosis in response to TNF-alpha. Deacetylates HIF1A, KAT5/TIP60, RB1 and HIC1. Deacetylates FOXO1 resulting in its nuclear retention and enhancement of its transcriptional activity leading to increased gluconeogenesis in liver. Inhibits E2F1 transcriptional activity and apoptotic function, possibly by deacetylation. Involved in HES1- and HEY2-mediated transcriptional repression. In cooperation with MYCN seems to be involved in transcriptional repression of DUSP6/MAPK3 leading to MYCN stabilization by phosphorylation at \'Ser-62\'. Deacetylates MEF2D. Required for antagonist-mediated transcription suppression of AR-dependent genes which may be linked to local deacetylation of histone H3. Represses HNF1A-mediated transcription. Required for the repression of ESRRG by CREBZF. Modulates AP-1 transcription factor activity. Deacetylates NR1H3 AND NR1H2 and deacetylation of NR1H3 at \'Lys-434\' positively regulates transcription of NR1H3:RXR target genes, promotes NR1H3 proteosomal degradation and results in cholesterol efflux; a promoter clearing mechanism after reach round of transcription is proposed. Involved in lipid metabolism. Implicated in regulation of adipogenesis and fat mobilization in white adipocytes by repression of PPARG which probably involves association with NCOR1 and SMRT/NCOR2. Deacetylates ACSS2 leading to its activation, and HMGCS1. Involved in liver and muscle metabolism. Through deacteylation and activation of PPARGC1A is required to activate fatty acid oxidation in skeletel muscle under low-glucose conditions and is involved in glucose homeostasis. Involved in regulation of PPARA and fatty acid beta-oxidation in liver. Involved in positive regulation of insulin secretion in pancreatic beta cells in response to glucose; the function seems to imply transcriptional repression of UCP2. Proposed to deacetylate IRS2 thereby facilitating its insulin-induced tyrosine phosphorylation. Deacetylates SREBF1 isoform SREBP-1C thereby decreasing its stability and transactivation in lipogenic gene expression. Involved in DNA damage response by repressing genes which are involved in DNA repair, such as XPC and TP73, deacetylating XRCC6/Ku70, and faciliting recruitment of additional factors to sites of damaged DNA, such as SIRT1-deacetylated NBN can recruit ATM to initiate DNA repair and SIRT1-deacetylated XPA interacts with RPA2. Also involved in DNA repair of DNA double-strand breaks by homologous recombination and specifically single-strand annealing independently of XRCC6/Ku70 and NBN. Transcriptional suppression of XPC probably involves an E2F4:RBL2 suppressor complex and protein kinase B (AKT) signaling. Transcriptional suppression of TP73 probably involves E2F4 and PCAF. Deacetylates WRN thereby regulating its helicase and exonuclease activities and regulates WRN nuclear translocation in response to DNA damage. Deacetylates APEX1 at \'Lys-6\' and \'Lys-7\' and stimulates cellular AP endonuclease activity by promoting the association of APEX1 to XRCC1. Increases p53/TP53-mediated transcription-independent apoptosis by blocking nuclear translocation of cytoplasmic p53/TP53 and probably redirecting it to mitochondria. Deacetylates XRCC6/Ku70 at \'Lys-539\' and \'Lys-542\' causing it to sequester BAX away from mitochondria thereby inhibiting stress-induced apoptosis. Is involved in autophagy, presumably by deacetylating ATG5, ATG7 and MAP1LC3B/ATG8. Deacetylates AKT1 which leads to enhanced binding of AKT1 and PDK1 to PIP3 and promotes their activation. Proposed to play role in regulation of STK11/LBK1-dependent AMPK signaling pathways implicated in cellular senescence which seems to involve the regulation of the acetylation status of STK11/LBK1. Can deacetylate STK11/LBK1 and thereby increase its activity, cytoplasmic localization and association with STRAD; however, the relevance of such activity in normal cells is unclear. In endothelial cells is shown to inhibit STK11/LBK1 activity and to promote its degradation. Deacetylates SMAD7 at \'Lys-64\' and \'Lys-70\' thereby promoting its degradation. Deacetylates CIITA and augments its MHC class II transactivation and contributes to its stability. Deacteylates MECOM/EVI1. Isoform 2 is shown to deacetylate \'Lys-382\' of p53/TP53, however with lower activity than isoform 1. In combination, the two isoforms exert an additive effect. Isoform 2 regulates p53/TP53 expression and cellular stress response and is in turn repressed by p53/TP53 presenting a SIRT1 isoform-dependent auto-regulatory loop. In case of HIV-1 infection, interacts with and deacetylates the viral Tat protein. The viral Tat protein inhibits SIRT1 deacetylation activity toward RELA/NF-kappa-B p65, thereby potentiates its transcriptional activity and SIRT1 is proposed to contribute to T-cell hyperactivation during infection. Deacetylates PML at \'Lys-487\' and this deacetylation promotes PML control of PER2 nuclear localization. During the neurogenic transition, repress selective NOTCH1-target genes through histone deacetylation in a BCL6-dependent manner and leading to neuronal differentiation. Regulates the circadian expression of several core clock genes, including ARNTL/BMAL1, RORC, PER2 and CRY1 and plays a critical role in maintaining a controlled rhythmicity in histone acetylation, thereby contributing to circadian chromatin remodeling. Deacetylates ARNTL/BMAL1 and histones at the circadian gene promoters in order to facilitate repression by inhibitory components of the circadian oscillator. Deacetylates PER2, facilitating its ubiquitination and degradation by the proteosome. Protects cardiomyocytes against palmitate-induced apoptosis (PubMed:11672523, PubMed:12006491, PubMed:14976264, PubMed:14980222, PubMed:15126506, PubMed:15152190, PubMed:15205477, PubMed:15469825, PubMed:15692560, PubMed:16079181, PubMed:16166628, PubMed:16892051, PubMed:16998810, PubMed:17283066, PubMed:17334224, PubMed:17505061, PubMed:17612497, PubMed:17620057, PubMed:17936707, PubMed:18203716, PubMed:18296641, PubMed:18662546, PubMed:18687677, PubMed:19188449, PubMed:19220062, PubMed:19364925, PubMed:19690166, PubMed:19934257, PubMed:20097625, PubMed:20100829, PubMed:20203304, PubMed:20375098, PubMed:20620956, PubMed:20670893, PubMed:20817729, PubMed:20975832, PubMed:21149730, PubMed:21245319, PubMed:21471201, PubMed:21504832, PubMed:21555002, PubMed:21698133, PubMed:21701047, PubMed:21775285, PubMed:21807113, PubMed:21841822, PubMed:21890893, PubMed:21909281, PubMed:21947282, PubMed:22274616). Deacetylates XBP1 isoform 2; deacetylation decreases protein stability of XBP1 isoform 2 and inhibits its transcriptional activity (PubMed:20955178). Involved in the CCAR2-mediated regulation of PCK1 and NR1D1 (PubMed:24415752). Deacetylates CTNB1 at \'Lys-49\' (PubMed:24824780).SirtT1 75 kDa fragment: catalytically inactive 75SirT1 may be involved in regulation of apoptosis. May be involved in protecting chondrocytes from apoptotic death by associating with cytochrome C and interfering with apoptosome assembly.','SIRT1','81680.06','DB05073','>lcl|BSEQ0021930|NAD-dependent protein deacetylase sirtuin-1 (SIRT1)\nATGTTTGATATTGAATATTTCAGAAAAGATCCAAGACCATTCTTCAAGTTTGCAAAGGAA\nATATATCCTGGACAATTCCAGCCATCTCTCTGTCACAAATTCATAGCCTTGTCAGATAAG\nGAAGGAAAACTACTTCGCAACTATACCCAGAACATAGACACGCTGGAACAGGTTGCGGGA\nATCCAAAGGATAATTCAGTGTCATGGTTCCTTTGCAACAGCATCTTGCCTGATTTGTAAA\nTACAAAGTTGACTGTGAAGCTGTACGAGGAGATATTTTTAATCAGGTAGTTCCTCGATGT\nCCTAGGTGCCCAGCTGATGAACCGCTTGCTATCATGAAACCAGAGATTGTGTTTTTTGGT\nGAAAATTTACCAGAACAGTTTCATAGAGCCATGAAGTATGACAAAGATGAAGTTGACCTC\nCTCATTGTTATTGGGTCTTCCCTCAAAGTAAGACCAGTAGCACTAATTCCAAGTTCCATA\nCCCCATGAAGTGCCTCAGATATTAATTAATAGAGAACCTTTGCCTCATCTGCATTTTGAT\nGTAGAGCTTCTTGGAGACTGTGATGTCATAATTAATGAATTGTGTCATAGGTTAGGTGGT\nGAATATGCCAAACTTTGCTGTAACCCTGTAAAGCTTTCAGAAATTACTGAAAAACCTCCA\nCGAACACAAAAAGAATTGGCTTATTTGTCAGAGTTGCCACCCACACCTCTTCATGTTTCA\nGAAGACTCAAGTTCACCAGAAAGAACTTCACCACCAGATTCTTCAGTGATTGTCACACTT\nTTAGACCAAGCAGCTAAGAGTAATGATGATTTAGATGTGTCTGAATCAAAAGGTTGTATG\nGAAGAAAAACCACAGGAAGTACAAACTTCTAGGAATGTTGAAAGTATTGCTGAACAGATG\nGAAAATCCGGATTTGAAGAATGTTGGTTCTAGTACTGGGGAGAAAAATGAAAGAACTTCA\nGTGGCTGGAACAGTGAGAAAATGCTGGCCTAATAGAGTGGCAAAGGAGCAGATTAGTAGG\nCGGCTTGATGGTAATCAGTATCTGTTTTTGCCACCAAATCGTTACATTTTCCATGGCGCT\nGAGGTATATTCAGACTCTGAAGATGACGTCTTATCCTCTAGTTCTTGTGGCAGTAACAGT\nGATAGTGGGACATGCCAGAGTCCAAGTTTAGAAGAACCCATGGAGGATGAAAGTGAAATT\nGAAGAATTCTACAATGGCTTAGAAGATGAGCCTGATGTTCCAGAGAGAGCTGGAGGAGCT\nGGATTTGGGACTGATGGAGATGATCAAGAGGCAATTAATGAAGCTATATCTGTGAAACAG\nGAAGTAACAGACATGAACTATCCATCAAACAAATCATAG'),('NADH-ubiquinone oxidoreductase chain 1','None','Human','Nadh dehydrogenase (ubiquinone) activity','Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) that is believed to belong to the minimal assembly required for catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone (By similarity).','MT-ND1','35660.055','DB01028','>lcl|BSEQ0010354|NADH-ubiquinone oxidoreductase chain 1 (MT-ND1)\nATACCCATGGCCAACCTCCTACTCCTCATTGTACCCATTCTAATCGCAATGGCATTCCTA\nATGCTTACCGAACGAAAAATTCTAGGCTATATACAACTACGCAAAGGCCCCAACGTTGTA\nGGCCCCTACGGGCTACTACAACCCTTCGCTGACGCCATAAAACTCTTCACCAAAGAGCCC\nCTAAAACCCGCCACATCTACCATCACCCTCTACATCACCGCCCCGACCTTAGCTCTCACC\nATCGCTCTTCTACTATGAACCCCCCTCCCCATACCCAACCCCCTGGTCAACCTCAACCTA\nGGCCTCCTATTTATTCTAGCCACCTCTAGCCTAGCCGTTTACTCAATCCTCTGATCAGGG\nTGAGCATCAAACTCAAACTACGCCCTGATCGGCGCACTGCGAGCAGTAGCCCAAACAATC\nTCATATGAAGTCACCCTAGCCATCATTCTACTATCAACATTACTAATAAGTGGCTCCTTT\nAACCTCTCCACCCTTATCACAACACAAGAACACCTCTGATTACTCCTGCCATCATGACCC\nTTGGCCATAATATGATTTATCTCCACACTAGCAGAGACCAACCGAACCCCCTTCGACCTT\nGCCGAAGGGGAGTCCGAACTAGTCTCAGGCTTCAACATCGAATACGCCGCAGGCCCCTTC\nGCCCTATTCTTCATAGCCGAATACACAAACATTATTATAATAAACACCCTCACCACTACA\nATCTTCCTAGGAACAACATATGACGCACTCTCCCCTGAACTCTACACAACATATTTTGTC\nACCAAGACCCTACTTCTAACCTCCCTGTTCTTATGAATTCGAACAGCATACCCCCGATTC\nCGCTACGACCAACTCATACACCTCCTATGAAAAAACTTCCTACCACTCACCCTAGCATTA\nCTTATATGATATGTCTCCATACCCATTACAATCTCCAGCATTCCCCCTCAAACCTA'),('Neuronal acetylcholine receptor subunit alpha-10','None','Human','Receptor binding','Ionotropic receptor with a probable role in the modulation of auditory stimuli. Agonist binding may induce an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is permeable to a range of divalent cations including calcium, the influx of which may activate a potassium current which hyperpolarizes the cell membrane. In the ear, this may lead to a reduction in basilar membrane motion, altering the activity of auditory nerve fibers and reducing the range of dynamic hearing. This may protect against acoustic trauma.','CHRNA10','49704.295','DB00333','>lcl|BSEQ0010286|Neuronal acetylcholine receptor subunit alpha-10 (CHRNA10)\nATGCCGGCGCGGCGGCGCGTGCTCACCTACGGCTGCTGCTCCGAGCCCTACCCCGACGTC\nACCTTCACGCTGCTGCTGCGCCGCCGCGCCGCCGCCTACGTGTGCAACCTGCTGCTGCCC\nTGCGTGCTCATCTCGCTGCTTGCGCCGCTCGCCTTCCACCTGCCTGCCGACTCAGGCGAG\nAAGGTGTCGCTGGGCGTCACCGTGCTGCTGGCGCTCACCGTCTTCCAGTTGCTGCTGGCC\nGAGAGCATGCCACCGGCCGAGAGCGTGCCGCTCATCGGGAAGTACTACATGGCCACTATG\nACCATGGTCACATTCTCAACAGCACTCACCATCCTTATCATGAACCTGCATTACTGTGGT\nCCCAGTGTCCGCCCAGTGCCAGCCTGGGCTAGGGCCCTCCTGCTGGGACACCTGGCACGG\nGGCCTGTGCGTGCGGGAAAGAGGGGAGCCCTGTGGGCAGTCCAGGCCACCTGAGTTATCT\nCCTAGCCCCCAGTCGCCTGAAGGAGGGGCTGGCCCCCCAGCGGGCCCTTGCCACGAGCCA\nCGATGTCTGTGCCGCCAGGAAGCCCTACTGCACCACGTAGCCACCATTGCCAATACCTTC\nCGCAGCCACCGAGCTGCCCAGCGCTGCCATGAGGACTGGAAGCGCCTGGCCCGTGTGATG\nGACCGCTTCTTCCTGGCCATCTTCTTCTCCATGGCCCTGGTCATGAGCCTCCTGGTGCTG\nGTGCAGGCCCTGTGA'),('Neuronal acetylcholine receptor subunit alpha-2','None','Human','Drug binding','After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.','CHRNA2','59764.82','DB07720','>lcl|BSEQ0010520|Neuronal acetylcholine receptor subunit alpha-2 (CHRNA2)\nATGGGCCCCTCCTGTCCTGTGTTCCTGTCCTTCACAAAGCTCAGCCTGTGGTGGCTCCTT\nCTGACCCCAGCAGGTGGAGAGGAAGCTAAGCGCCCACCTCCCAGGGCTCCTGGAGACCCA\nCTCTCCTCTCCCAGTCCCACGGCATTGCCGCAGGGAGGCTCGCATACCGAGACTGAGGAC\nCGGCTCTTCAAACACCTCTTCCGGGGCTACAACCGCTGGGCGCGCCCGGTGCCCAACACT\nTCAGACGTGGTGATTGTGCGCTTTGGACTGTCCATCGCTCAGCTCATCGATGTGGATGAG\nAAGAACCAAATGATGACCACCAACGTCTGGCTAAAACAGGAGTGGAGCGACTACAAACTG\nCGCTGGAACCCCACTGATTTTGGCAACATCACATCTCTCAGGGTCCCTTCTGAGATGATC\nTGGATCCCCGACATTGTTCTCTACAACAATGCAGATGGGGAGTTTGCAGTGACCCACATG\nACCAAGGCCCACCTCTTCTCCACGGGCACTGTGCACTGGGTGCCCCCGGCCATCTACAAG\nAGCTCCTGCAGCATCGACGTCACCTTCTTCCCCTTCGACCAGCAGAACTGCAAGATGAAG\nTTTGGCTCCTGGACTTATGACAAGGCCAAGATCGACCTGGAGCAGATGGAGCAGACTGTG\nGACCTGAAGGACTACTGGGAGAGCGGCGAGTGGGCCATCGTCAATGCCACGGGCACCTAC\nAACAGCAAGAAGTACGACTGCTGCGCCGAGATCTACCCCGACGTCACCTACGCCTTCGTC\nATCCGGCGGCTGCCGCTCTTCTACACCATCAACCTCATCATCCCCTGCCTGCTCATCTCC\nTGCCTCACTGTGCTGGTCTTCTACCTGCCCTCCGACTGCGGCGAGAAGATCACGCTGTGC\nATTTCGGTGCTGCTGTCACTCACCGTCTTCCTGCTGCTCATCACTGAGATCATCCCGTCC\nACCTCGCTGGTCATCCCGCTCATCGGCGAGTACCTGCTGTTCACCATGATCTTCGTCACC\nCTGTCCATCGTCATCACCGTCTTCGTGCTCAATGTGCACCACCGCTCCCCCAGCACCCAC\nACCATGCCCCACTGGGTGCGGGGGGCCCTTCTGGGCTGTGTGCCCCGGTGGCTTCTGATG\nAACCGGCCCCCACCACCCGTGGAGCTCTGCCACCCCCTACGCCTGAAGCTCAGCCCCTCT\nTATCACTGGCTGGAGAGCAACGTGGATGCCGAGGAGAGGGAGGTGGTGGTGGAGGAGGAG\nGACAGATGGGCATGTGCAGGTCATGTGGCCCCCTCTGTGGGCACCCTCTGCAGCCACGGC\nCACCTGCACTCTGGGGCCTCAGGTCCCAAGGCTGAGGCTCTGCTGCAGGAGGGTGAGCTG\nCTGCTATCACCCCACATGCAGAAGGCACTGGAAGGTGTGCACTACATTGCCGACCACCTG\nCGGTCTGAGGATGCTGACTCTTCGGTGAAGGAGGACTGGAAGTATGTTGCCATGGTCATC\nGACAGGATCTTCCTCTGGCTGTTTATCATCGTCTGCTTCCTGGGGACCATCGGCCTCTTT\nCTGCCTCCGTTCCTAGCTGGAATGATCTGA'),('Neuronal acetylcholine receptor subunit alpha-3','None','Human','Ligand-gated ion channel activity','After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.','CHRNA3','57479.54','DB01227','>lcl|BSEQ0012491|Neuronal acetylcholine receptor subunit alpha-3 (CHRNA3)\nATGGGCTCTGGCCCGCTCTCGCTGCCCCTGGCGCTGTCGCCGCCGCGGCTGCTGCTGCTG\nCTGCTGCTGTCTCTGCTGCCAGTGGCCAGGGCCTCAGAGGCTGAGCACCGTCTATTTGAG\nCGGCTGTTTGAAGATTACAATGAGATCATCCGGCCTGTAGCCAACGTGTCTGACCCAGTC\nATCATCCATTTCGAGGTGTCCATGTCTCAGCTGGTGAAGGTGGATGAAGTAAACCAGATC\nATGGAGACCAACCTGTGGCTCAAGCAAATCTGGAATGACTACAAGCTGAAATGGAACCCC\nTCTGACTATGGTGGGGCAGAGTTCATGCGTGTCCCTGCACAGAAGATCTGGAAGCCAGAC\nATTGTGCTGTATAACAATGCTGTTGGGGATTTCCAGGTGGACGACAAGACCAAAGCCTTA\nCTCAAGTACACTGGGGAGGTGACTTGGATACCTCCGGCCATCTTTAAGAGCTCCTGTAAA\nATCGACGTGACCTACTTCCCGTTTGATTACCAAAACTGTACCATGAAGTTCGGTTCCTGG\nTCCTACGATAAGGCGAAAATCGATCTGGTCCTGATCGGCTCTTCCATGAACCTCAAGGAC\nTATTGGGAGAGCGGCGAGTGGGCCATCATCAAAGCCCCAGGCTACAAACACGACATCAAG\nTACAACTGCTGCGAGGAGATCTACCCCGACATCACATACTCGCTGTACATCCGGCGCCTG\nCCCTTGTTCTACACCATCAACCTCATCATCCCCTGCCTGCTCATCTCCTTCCTCACTGTG\nCTCGTCTTCTACCTGCCCTCCGACTGCGGTGAGAAGGTGACCCTGTGCATTTCTGTCCTC\nCTCTCCCTGACGGTGTTTCTCCTGGTGATCACTGAGACCATCCCTTCCACCTCGCTGGTC\nATCCCCCTGATTGGAGAGTACCTCCTGTTCACCATGATTTTTGTAACCTTGTCCATCGTC\nATCACCGTCTTCGTGCTCAACGTGCACTACAGAACCCCGACGACACACACAATGCCCTCA\nTGGGTGAAGACTGTATTCTTGAACCTGCTCCCCAGGGTCATGTTCATGACCAGGCCAACA\nAGCAACGAGGGCAACGCTCAGAAGCCGAGGCCCCTCTACGGTGCCGAGCTCTCAAATCTG\nAATTGCTTCAGCCGCGCAGAGTCCAAAGGCTGCAAGGAGGGCTACCCCTGCCAGGACGGG\nATGTGTGGTTACTGCCACCACCGCAGGATAAAAATCTCCAATTTCAGTGCTAACCTCACG\nAGAAGCTCTAGTTCTGAATCTGTTGATGCTGTGCTGTCCCTCTCTGCTTTGTCACCAGAA\nATCAAAGAAGCCATCCAAAGTGTCAAGTATATTGCTGAAAATATGAAAGCACAAAATGAA\nGCCAAAGAGATTCAAGATGATTGGAAGTATGTTGCCATGGTGATTGATCGTATTTTTCTG\nTGGGTTTTCACCCTGGTGTGCATTCTAGGGACAGCAGGATTGTTTCTGCAACCCCTGATG\nGCCAGGGAAGATGCATAA'),('Neuronal acetylcholine receptor subunit alpha-4','None','Human','Ligand-gated ion channel activity','After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions.','CHRNA4','69956.47','DB00564','>lcl|BSEQ0016224|Neuronal acetylcholine receptor subunit alpha-4 (CHRNA4)\nATGGAGCTAGGGGGCCCCGGAGCGCCGCGGCTGCTGCCGCCGCTGCTGCTGCTTCTGGGG\nACCGGCCTCCTGCGCGCCAGCAGCCATGTGGAGACCCGGGCCCACGCCGAGGAGCGGCTC\nCTGAAGAAACTCTTCTCCGGTTACAACAAGTGGTCCCGACCCGTGGCCAACATCTCGGAC\nGTGGTCCTCGTCCGCTTCGGCCTGTCCATCGCTCAGCTCATTGACGTGGATGAGAAGAAC\nCAGATGATGACCACGAACGTATGGGTGAAGCAGGAGTGGCACGACTACAAGCTGCGCTGG\nGACCCAGCTGACTATGAGAATGTCACCTCCATCCGCATCCCCTCCGAGCTCATCTGGCGG\nCCGGACATCGTCCTCTACAACAATGCTGACGGGGACTTCGCGGTCACCCACCTGACCAAG\nGCCCACCTGTTCCATGACGGGCGGGTGCAGTGGACTCCCCCGGCCATTTACAAGAGCTCC\nTGCAGCATCGACGTCACCTTCTTCCCCTTCGACCAGCAGAACTGCACCATGAAATTCGGC\nTCCTGGACCTACGACAAGGCCAAGATCGACCTGGTGAACATGCACAGCCGCGTGGACCAG\nCTGGACTTCTGGGAGAGTGGCGAGTGGGTCATCGTGGATGCCGTGGGCACCTACAACACC\nAGGAAGTACGAGTGCTGTGCCGAGATCTACCCGGACATCACCTATGCCTTCGTCATCCGG\nCGGCTGCCGCTCTTCTACACCATCAACCTCATCATCCCCTGCCTGCTCATCTCCTGCCTC\nACCGTGCTGGTCTTCTACCTGCCCTCCGAGTGTGGCGAGAAGATCACGCTGTGCATCTCC\nGTGCTGCTGTCGCTCACCGTCTTCCTGCTGCTCATCACCGAGATCATCCCGTCCACCTCA\nCTGGTCATCCCACTCATCGGCGAGTACCTGCTGTTCACCATGATCTTCGTCACCCTGTCC\nATCGTCATCACGGTCTTCGTGCTCAACGTGCACCACCGCTCGCCACGCACGCACACCATG\nCCCACCTGGGTACGCAGGGTCTTCCTGGACATCGTGCCACGCCTGCTCCTCATGAAGCGG\nCCGTCCGTGGTCAAGGACAATTGCCGGCGGCTCATCGAGTCCATGCATAAGATGGCCAGT\nGCCCCGCGCTTCTGGCCCGAGCCAGAAGGGGAGCCCCCTGCCACGAGCGGCACCCAGAGC\nCTGCACCCGCCCTCACCGTCCTTCTGTGTCCCCCTGGATGTGCCGGCTGAGCCTGGGCCT\nTCCTGCAAGTCACCCTCCGACCAGCTCCCTCCTCAGCAGCCCCTGGAAGCTGAGAAAGCC\nAGCCCCCACCCCTCGCCTGGACCCTGCCGCCCGCCCCACGGCACCCAGGCACCAGGGCTG\nGCCAAAGCCAGGTCCCTCAGCGTCCAGCACATGTCCAGCCCTGGCGAAGCGGTGGAAGGC\nGGCGTCCGGTGCCGGTCTCGGAGCATCCAGTACTGTGTTCCCCGAGACGATGCCGCCCCC\nGAGGCAGATGGCCAGGCTGCCGGCGCCCTGGCCTCTCGCAACACCCACTCGGCTGAGCTC\nCCACCCCCAGACCAGCCCTCTCCGTGCAAATGCACATGCAAGAAGGAGCCCTCTTCGGTG\nTCCCCGAGCGCCACGGTCAAGACCCGCAGCACCAAAGCGCCGCCCCCGCACCTGCCCCTG\nTCGCCGGCCCTGACCCGGGCGGTGGAGGGCGTCCAGTACATTGCAGACCACCTGAAGGCC\nGAAGACACAGACTTCTCGGTGAAGGAGGACTGGAAGTACGTGGCCATGGTCATCGACCGC\nATCTTCCTCTGGATGTTCATCATCGTCTGCCTGCTGGGGACGGTGGGCCTCTTCCTGCCG\nCCCTGGCTGGCTGGCATGATCTAG'),('Neuronal acetylcholine receptor subunit alpha-7','None','Human','Toxic substance binding','After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is blocked by alpha-bungarotoxin.','CHRNA7','56448.925','DB14011','>lcl|BSEQ0020606|Neuronal acetylcholine receptor subunit alpha-7 (CHRNA7)\nATGCGCTGCTCGCCGGGAGGCGTCTGGCTGGCGCTGGCCGCGTCGCTCCTGCACGTGTCC\nCTGCAAGGCGAGTTCCAGAGGAAGCTTTACAAGGAGCTGGTCAAGAACTACAATCCCTTG\nGAGAGGCCCGTGGCCAATGACTCGCAACCACTCACCGTCTACTTCTCCCTGAGCCTCCTG\nCAGATCATGGACGTGGATGAGAAGAACCAAGTTTTAACCACCAACATTTGGCTGCAAATG\nTCTTGGACAGATCACTATTTACAGTGGAATGTGTCAGAATATCCAGGGGTGAAGACTGTT\nCGTTTCCCAGATGGCCAGATTTGGAAACCAGACATTCTTCTCTATAACAGTGCTGATGAG\nCGCTTTGACGCCACATTCCACACTAACGTGTTGGTGAATTCTTCTGGGCATTGCCAGTAC\nCTGCCTCCAGGCATATTCAAGAGTTCCTGCTACATCGATGTACGCTGGTTTCCCTTTGAT\nGTGCAGCACTGCAAACTGAAGTTTGGGTCCTGGTCTTACGGAGGCTGGTCCTTGGATCTG\nCAGATGCAGGAGGCAGATATCAGTGGCTATATCCCCAATGGAGAATGGGACCTAGTGGGA\nATCCCCGGCAAGAGGAGTGAAAGGTTCTATGAGTGCTGCAAAGAGCCCTACCCCGATGTC\nACCTTCACAGTGACCATGCGCCGCAGGACGCTCTACTATGGCCTCAACCTGCTGATCCCC\nTGTGTGCTCATCTCCGCCCTCGCCCTGCTGGTGTTCCTGCTTCCTGCAGATTCCGGGGAG\nAAGATTTCCCTGGGGATAACAGTCTTACTCTCTCTTACCGTCTTCATGCTGCTCGTGGCT\nGAGATCATGCCCGCAACATCCGATTCGGTACCATTGATAGCCCAGTACTTCGCCAGCACC\nATGATCATCGTGGGCCTCTCGGTGGTGGTGACAGTGATCGTGCTGCAGTACCACCACCAC\nGACCCCGACGGGGGCAAGATGCCCAAGTGGACCAGAGTCATCCTTCTGAACTGGTGCGCG\nTGGTTCCTGCGAATGAAGAGGCCCGGGGAGGACAAGGTGCGCCCGGCCTGCCAGCACAAG\nCAGCGGCGCTGCAGCCTGGCCAGTGTGGAGATGAGCGCCGTGGCGCCGCCGCCCGCCAGC\nAACGGGAACCTGCTGTACATCGGCTTCCGCGGCCTGGACGGCGTGCACTGTGTCCCGACC\nCCCGACTCTGGGGTAGTGTGTGGCCGCATGGCCTGCTCCCCCACGCACGATGAGCACCTC\nCTGCACGGCGGGCAACCCCCCGAGGGGGACCCGGACTTGGCCAAGATCCTGGAGGAGGTC\nCGCTACATTGCCAACCGCTTCCGCTGCCAGGACGAAAGCGAGGCGGTCTGCAGCGAGTGG\nAAGTTCGCCGCCTGTGTGGTGGACCGCCTGTGCCTCATGGCCTTCTCGGTCTTCACCATC\nATCTGCACCATCGGCATCCTGATGTCGGCTCCCAACTTCGTGGAGGCCGTGTCCAAAGAC\nTTTGCGTAA'),('Neuronal acetylcholine receptor subunit beta-2','None','Human','Ligand-gated ion channel activity','After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodiun ions.','CHRNB2','57018.575','DB00564','>lcl|BSEQ0010601|Neuronal acetylcholine receptor subunit beta-2 (CHRNB2)\nATGGCCCGGCGCTGCGGCCCCGTGGCGCTGCTCCTTGGCTTCGGCCTCCTCCGGCTGTGC\nTCAGGGGTGTGGGGTACGGATACAGAGGAGCGGCTGGTGGAGCATCTCCTGGATCCTTCC\nCGCTACAACAAGCTTATCCGCCCAGCCACCAATGGCTCTGAGCTGGTGACAGTACAGCTT\nATGGTGTCACTGGCCCAGCTCATCAGTGTGCATGAGCGGGAGCAGATCATGACCACCAAT\nGTCTGGCTGACCCAGGAGTGGGAAGATTATCGCCTCACCTGGAAGCCTGAAGAGTTTGAC\nAACATGAAGAAAGTTCGGCTCCCTTCCAAACACATCTGGCTCCCAGATGTGGTCCTGTAC\nAACAATGCTGACGGCATGTACGAGGTGTCCTTCTATTCCAATGCCGTGGTCTCCTATGAT\nGGCAGCATCTTCTGGCTGCCGCCTGCCATCTACAAGAGCGCATGCAAGATTGAAGTAAAG\nCACTTCCCATTTGACCAGCAGAACTGCACCATGAAGTTCCGTTCGTGGACCTACGACCGC\nACAGAGATCGACTTGGTGCTGAAGAGTGAGGTGGCCAGCCTGGACGACTTCACACCTAGT\nGGTGAGTGGGACATCGTGGCGCTGCCGGGCCGGCGCAACGAGAACCCCGACGACTCTACG\nTACGTGGACATCACGTATGACTTCATCATTCGCCGCAAGCCGCTCTTCTACACCATCAAC\nCTCATCATCCCCTGTGTGCTCATCACCTCGCTAGCCATCCTTGTCTTCTACCTGCCATCC\nGACTGTGGCGAGAAGATGACGTTGTGCATCTCAGTGCTGCTGGCGCTCACGGTCTTCCTG\nCTGCTCATCTCCAAGATCGTGCCTCCCACCTCCCTCGACGTGCCGCTCGTCGGCAAGTAC\nCTCATGTTCACCATGGTGCTTGTCACCTTCTCCATCGTCACCAGCGTGTGCGTGCTCAAC\nGTGCACCACCGCTCGCCCACCACGCACACCATGGCGCCCTGGGTGAAGGTCGTCTTCCTG\nGAGAAGCTGCCCGCGCTGCTCTTCATGCAGCAGCCACGCCATCATTGCGCCCGTCAGCGC\nCTGCGCCTGCGGCGACGCCAGCGTGAGCGCGAGGGCGCTGGAGCCCTCTTCTTCCGCGAA\nGCCCCAGGGGCCGACTCCTGCACGTGCTTCGTCAACCGCGCGTCGGTGCAGGGGTTGGCC\nGGGGCCTTCGGGGCTGAGCCTGCACCAGTGGCGGGCCCCGGGCGCTCAGGGGAGCCGTGT\nGGCTGTGGCCTCCGGGAGGCGGTGGACGGCGTGCGCTTCATCGCAGACCACATGCGGAGC\nGAGGACGATGACCAGAGCGTGAGTGAGGACTGGAAGTACGTCGCCATGGTGATCGACCGC\nCTCTTCCTCTGGATCTTTGTCTTTGTCTGTGTCTTTGGCACCATCGGCATGTTCCTGCAG\nCCTCTCTTCCAGAACTACACCACCACCACCTTCCTCCACTCAGACCACTCAGCCCCCAGC\nTCCAAGTGA'),('Neuronal acetylcholine receptor subunit beta-4','None','Human','Ligand-gated ion channel activity','After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.','CHRNB4','56378.985','DB01227','>lcl|BSEQ0020698|Neuronal acetylcholine receptor subunit beta-4 (CHRNB4)\nATGAGGCGCGCGCCTTCCCTGGTCCTTTTCTTCCTGGTCGCCCTTTGCGGGCGCGGGAAC\nTGCCGCGTGGCCAATGCGGAGGAAAAGCTGATGGACGACCTTCTGAACAAAACCCGTTAC\nAATAACCTGATCCGCCCAGCCACCAGCTCCTCACAGCTCATCTCCATCAAGCTGCAGCTC\nTCCCTGGCCCAGCTTATCAGCGTGAATGAGCGAGAGCAGATCATGACCACCAATGTCTGG\nCTGAAACAGGAATGGACTGATTACCGCCTGACCTGGAACAGCTCCCGCTACGAGGGTGTG\nAACATCCTGAGGATCCCTGCAAAGCGCATCTGGTTGCCTGACATCGTGCTTTACAACAAC\nGCCGACGGGACCTATGAGGTGTCTGTCTACACCAACTTGATAGTCCGGTCCAACGGCAGC\nGTCCTGTGGCTGCCCCCTGCCATCTACAAGAGCGCCTGCAAGATTGAGGTGAAGTACTTT\nCCCTTCGACCAGCAGAACTGCACCCTCAAGTTCCGCTCCTGGACCTATGACCACACGGAG\nATAGACATGGTCCTCATGACGCCCACAGCCAGCATGGATGACTTTACTCCCAGTGGTGAG\nTGGGACATAGTGGCCCTCCCAGGGAGAAGGACAGTGAACCCACAAGACCCCAGCTACGTG\nGACGTGACTTACGACTTCATCATCAAGCGCAAGCCTCTGTTCTACACCATCAACCTCATC\nATCCCCTGCGTGCTCACCACCTTGCTGGCCATCCTCGTCTTCTACCTGCCATCCGACTGC\nGGCGAGAAGATGACACTGTGCATCTCAGTGCTGCTGGCACTGACATTCTTCCTGCTGCTC\nATCTCCAAGATCGTGCCACCCACCTCCCTCGATGTGCCTCTCATCGGCAAGTACCTCATG\nTTCACCATGGTGCTGGTCACCTTCTCCATCGTCACCAGCGTCTGTGTGCTCAATGTGCAC\nCACCGCTCGCCCAGCACCCACACCATGGCACCCTGGGTCAAGCGCTGCTTCCTGCACAAG\nCTGCCTACCTTCCTCTTCATGAAGCGCCCTGGCCCCGACAGCAGCCCGGCCAGAGCCTTC\nCCGCCCAGCAAGTCATGCGTGACCAAGCCCGAGGCCACCGCCACCTCCACCAGCCCCTCC\nAACTTCTATGGGAACTCCATGTACTTTGTGAACCCCGCCTCTGCAGCTTCCAAGTCTCCA\nGCCGGCTCTACCCCGGTGGCTATCCCCAGGGATTTCTGGCTGCGGTCCTCTGGGAGGTTC\nCGACAGGATGTGCAGGAGGCATTAGAAGGTGTCAGCTTCATCGCCCAGCACATGAAGAAT\nGACGATGAAGACCAGAGTGTCGTTGAGGACTGGAAGTACGTGGCTATGGTGGTGGACCGG\nCTGTTCCTGTGGGTGTTCATGTTTGTGTGCGTCCTGGGCACTGTGGGGCTCTTCCTACCG\nCCCCTCTTCCAGACCCATGCAGCTTCTGAGGGGCCCTACGCTGCCCAGCGTGACTGA'),('NF-kappa-B essential modulator','None','Human','Ubiquitin protein ligase binding','Regulatory subunit of the IKK core complex which phosphorylates inhibitors of NF-kappa-B thus leading to the dissociation of the inhibitor/NF-kappa-B complex and ultimately the degradation of the inhibitor. Its binding to scaffolding polyubiquitin seems to play a role in IKK activation by multiple signaling receptor pathways. However, the specific type of polyubiquitin recognized upon cell stimulation (either \'Lys-63\'-linked or linear polyubiquitin) and its functional importance is reported conflictingly. Also considered to be a mediator for TAX activation of NF-kappa-B. Could be implicated in NF-kappa-B-mediated protection from cytokine toxicity. Essential for viral activation of IRF3. Involved in TLR3- and IFIH1-mediated antiviral innate response; this function requires \'Lys-27\'-linked polyubiquitination.','IKBKG','48197.35','DB05289','>lcl|BSEQ0019280|NF-kappa-B essential modulator (IKBKG)\nATGGCCCTTGTGATCCAGGTGGGGAAACTAAGGCCCAGAGAAGTGAGGACCCCGCAGACT\nATCAATCCCAGTCTCTTCCCCTCACTCCCTGTGAAGCTCTCCAGCATCATCGAGGTCCCA\nTCAGGTGGGGAAAGATGCTGTTCCAGGCGCACACTAGTCTACAAGGCCAGAGCTTTCTGG\nAAGGGGGCACCCTTGCCCTGTTGGATGAATAGGCACCTCTGGAAGAGCCAACTGTGTGAG\nATGGTGCAGCCCAGTGGTGGCCCGGCAGCAGATCAGGACGTACTGGGCGAAGAGTCTCCT\nCTGGGGAAGCCAGCCATGCTGCACCTGCCTTCAGAACAGGGCGCTCCTGAGACCCTCCAG\nCGCTGCCTGGAGGAGAATCAAGAGCTCCGAGATGCCATCCGGCAGAGCAACCAGATTCTG\nCGGGAGCGCTGCGAGGAGCTTCTGCATTTCCAAGCCAGCCAGAGGGAGGAGAAGGAGTTC\nCTCATGTGCAAGTTCCAGGAGGCCAGGAAACTGGTGGAGAGACTCGGCCTGGAGAAGCTC\nGATCTGAAGAGGCAGAAGGAGCAGGCTCTGCGGGAGGTGGAGCACCTGAAGAGATGCCAG\nCAGCAGATGGCTGAGGACAAGGCCTCTGTGAAAGCCCAGGTGACGTCCTTGCTCGGGGAG\nCTGCAGGAGAGCCAGAGTCGCTTGGAGGCTGCCACTAAGGAATGCCAGGCTCTGGAGGGT\nCGGGCCCGGGCGGCCAGCGAGCAGGCGCGGCAGCTGGAGAGTGAGCGCGAGGCGCTGCAG\nCAGCAGCACAGCGTGCAGGTGGACCAGCTGCGCATGCAGGGCCAGAGCGTGGAGGCCGCG\nCTCCGCATGGAGCGCCAGGCCGCCTCGGAGGAGAAGAGGAAGCTGGCCCAGTTGCAGGTG\nGCCTATCACCAGCTCTTCCAAGAATACGACAACCACATCAAGAGCAGCGTGGTGGGCAGT\nGAGCGGAAGCGAGGAATGCAGCTGGAAGATCTCAAACAGCAGCTCCAGCAGGCCGAGGAG\nGCCCTGGTGGCCAAACAGGAGGTGATCGATAAGCTGAAGGAGGAGGCCGAGCAGCACAAG\nATTGTGATGGAGACCGTTCCGGTGCTGAAGGCCCAGGCGGATATCTACAAGGCGGACTTC\nCAGGCTGAGAGGCAGGCCCGGGAGAAGCTGGCCGAGAAGAAGGAGCTCCTGCAGGAGCAG\nCTGGAGCAGCTGCAGAGGGAGTACAGCAAACTGAAGGCCAGCTGTCAGGAGTCGGCCAGG\nATCGAGGACATGAGGAAGCGGCATGTCGAGGTCTCCCAGGCCCCCTTGCCCCCCGCCCCT\nGCCTACCTCTCCTCTCCCCTGGCCCTGCCCAGCCAGAGGAGGAGCCCCCCCGAGGAGCCA\nCCTGACTTCTGCTGTCCCAAGTGCCAGTATCAGGCCCCTGATATGGACACCCTGCAGATA\nCATGTCATGGAGTGCATTGAGTAG'),('NF-kappa-B inhibitor alpha','None','Human','Ubiquitin protein ligase binding','Inhibits the activity of dimeric NF-kappa-B/REL complexes by trapping REL dimers in the cytoplasm through masking of their nuclear localization signals. On cellular stimulation by immune and proinflammatory responses, becomes phosphorylated promoting ubiquitination and degradation, enabling the dimeric RELA to translocate to the nucleus and activate transcription.','NFKBIA','35608.65','DB00945','>lcl|BSEQ0021364|NF-kappa-B inhibitor alpha (NFKBIA)\nATGTTCCAGGCGGCCGAGCGCCCCCAGGAGTGGGCCATGGAGGGCCCCCGCGACGGGCTG\nAAGAAGGAGCGGCTACTGGACGACCGCCACGACAGCGGCCTGGACTCCATGAAAGACGAG\nGAGTACGAGCAGATGGTCAAGGAGCTGCAGGAGATCCGCCTCGAGCCGCAGGAGGTGCCG\nCGCGGCTCGGAGCCCTGGAAGCAGCAGCTCACCGAGGACGGGGACTCGTTCCTGCACTTG\nGCCATCATCCATGAAGAAAAGGCACTGACCATGGAAGTGATCCGCCAGGTGAAGGGAGAC\nCTGGCCTTCCTCAACTTCCAGAACAACCTGCAGCAGACTCCACTCCACTTGGCTGTGATC\nACCAACCAGCCAGAAATTGCTGAGGCACTTCTGGGAGCTGGCTGTGATCCTGAGCTCCGA\nGACTTTCGAGGAAATACCCCCCTACACCTTGCCTGTGAGCAGGGCTGCCTGGCCAGCGTG\nGGAGTCCTGACTCAGTCCTGCACCACCCCGCACCTCCACTCCATCCTGAAGGCTACCAAC\nTACAATGGCCACACGTGTCTACACTTAGCCTCTATCCATGGCTACCTGGGCATCGTGGAG\nCTTTTGGTGTCCTTGGGTGCTGATGTCAATGCTCAGGAGCCCTGTAATGGCCGGACTGCC\nCTTCACCTCGCAGTGGACCTGCAAAATCCTGACCTGGTGTCACTCCTGTTGAAGTGTGGG\nGCTGATGTCAACAGAGTTACCTACCAGGGCTATTCTCCCTACCAGCTCACCTGGGGCCGC\nCCAAGCACCCGGATACAGCAGCAGCTGGGCCAGCTGACACTAGAAAACCTTCAGATGCTG\nCCAGAGAGTGAGGATGAGGAGAGCTATGACACAGAGTCAGAGTTCACGGAGTTCACAGAG\nGACGAGCTGCCCTATGATGACTGTGTGTTTGGAGGCCAGCGTCTGACGTTATGA'),('Nischarin','None','Human','Phosphatidylinositol binding','Acts either as the functional imidazoline-1 receptor (I1R) candidate or as a membrane-associated mediator of the I1R signaling. Binds numerous imidazoline ligands that induces initiation of cell-signaling cascades triggering to cell survival, growth and migration. Its activation by the agonist rilmenidine induces an increase in phosphorylation of mitogen-activated protein kinases MAPK1 and MAPK3 in rostral ventrolateral medulla (RVLM) neurons that exhibited rilmenidine-evoked hypotension (By similarity). Blocking its activation with efaroxan abolished rilmenidine-induced mitogen-activated protein kinase phosphorylation in RVLM neurons (By similarity). Acts as a modulator of Rac-regulated signal transduction pathways (By similarity). Suppresses Rac1-stimulated cell migration by interacting with PAK1 and inhibiting its kinase activity (By similarity). Also blocks Pak-independent Rac signaling by interacting with RAC1 and inhibiting Rac1-stimulated NF-kB response element and cyclin D1 promoter activation (By similarity). Inhibits also LIMK1 kinase activity by reducing LIMK1 \'Tyr-508\' phosphorylation (By similarity). Inhibits Rac-induced cell migration and invasion in breast and colon epithelial cells (By similarity). Inhibits lamellipodia formation, when overexpressed (By similarity). Plays a role in protection against apoptosis. Involved in association with IRS4 in the enhancement of insulin activation of MAPK1 and MAPK3. When overexpressed, induces a redistribution of cell surface ITGA5 integrin to intracellular endosomal structures.','NISCH','166627.105','DB00697','>lcl|BSEQ0021702|Nischarin (NISCH)\nATGGCGACCGCGCGCACCTTCGGGCCCGAGCGGGAAGCCGAGCCGGCCAAGGAAGCGCGC\nGTCGTGGGCTCGGAGCTTGTGGACACTTATACGGTTTACATCATCCAGGTCACTGATGGC\nAGCCATGAGTGGACAGTAAAGCACCGCTACAGCGACTTCCATGACCTGCATGAAAAGCTC\nGTTGCAGAGAGAAAGATTGATAAAAATCTGCTTCCGCCCAAAAAGATAATTGGGAAAAAC\nTCAAGAAGCTTGGTGGAGAAGAGGGAGAAGGATCTGGAGGTCTACCTCCAGAAGCTCCTG\nGCTGCCTTCCCTGGCGTGACCCCCAGAGTACTGGCCCACTTCTTGCATTTTCACTTCTAT\nGAGATAAATGGCATCACCGCGGCACTGGCTGAAGAGCTCTTTGAGAAAGGAGAACAGCTC\nCTGGGGGCCGGCGAGGTCTTTGCCATTGGACCCCTGCAGCTGTATGCCGTCACGGAGCAG\nCTGCAGCAGGGAAAGCCCACGTGCGCCAGTGGGGATGCCAAGACCGACCTCGGGCACATC\nCTGGACTTCACCTGTCGCCTTAAGTACCTTAAGGTTTCTGGCACAGAAGGACCTTTTGGG\nACCAGCAACATTCAGGAGCAGCTCCTGCCGTTCGACCTATCAATATTCAAGTCCCTGCAT\nCAGGTGGAGATAAGTCACTGTGATGCTAAGCACATCAGAGGGCTGGTCGCATCGAAGCCC\nACCTTAGCCACGCTGAGTGTCCGCTTCTCAGCAACCTCGATGAAGGAAGTCCTTGTTCCT\nGAAGCCTCAGAATTTGATGAGTGGGAGCCTGAAGGCACAACCCTAGAAGGCCCTGTGACT\nGCCGTCATCCCCACTTGGCAGGCATTGACCACGCTTGACCTGAGCCACAACAGCATCTCC\nGAGATCGACGAGTCTGTGAAACTGATCCCAAAGATTGAGTTCCTGGACCTGAGTCACAAT\nGGATTGCTGGTTGTGGACAATCTGCAGCACCTGTATAACCTTGTGCATCTGGACCTGTCC\nTACAACAAGCTCTCCTCCTTGGAAGGGCTTCACACCAAGCTGGGGAACATCAAGACCTTA\nAACCTGGCAGGCAACCTCCTAGAGAGTCTGAGTGGCCTGCACAAGCTCTACTCACTGGTC\nAACCTGGATCTCCGGGACAACAGGATCGAACAGATGGAGGAGGTCCGGAGCATAGGCAGC\nCTCCCGTGTCTGGAGCACGTGTCTCTGCTGAACAACCCTCTGAGCATCATCCCCGACTAC\nCGGACCAAGGTGCTGGCTCAGTTCGGAGAGAGGGCCTCAGAGGTCTGTCTGGATGACACA\nGTGACCACAGAGAAGGAGCTGGACACTGTGGAAGTGCTGAAAGCAATTCAGAAAGCCAAG\nGAGGTCAAGTCCAAACTGAGCAACCCAGAGAAGAAGGGTGGTGAAGACTCCCGGCTCTCA\nGCTGCCCCCTGCATCAGACCCAGCAGCTCCCCTCCCACTGTGGCTCCCGCATCTGCCTCC\nCTGCCCCAGCCCATCCTCTCTAACCAAGGTAATCGTGTATGTATCTTGCTTCTAGTGGAG\nCCACACAGCCCTGCCTGGGCCCCCTGGCTGGGCTGGGGTTGGGGGAGAGGTGCCAGCACC\nTGCTTCCAACAGGGTCAGACACAGGGAGGGCAGTGCCTTCTGCAGGCTGGTCCTCGCGGG\nGGGACACATGGCAGGGGTGCCTGGCCTGATGCCAGCTGTTGCTTGCTTGGTGAGGACTCC\nCAATTGCTCTGA'),('Nitric oxide synthase, brain','None','Human','Tetrahydrobiopterin binding','Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In the brain and peripheral nervous system, NO displays many properties of a neurotransmitter. Probably has nitrosylase activity and mediates cysteine S-nitrosylation of cytoplasmic target proteins such SRR.','NOS1','160969.095','DB01221','>lcl|BSEQ0020449|Nitric oxide synthase, brain (NOS1)\nATGGAGGATCACATGTTCGGTGTTCAGCAAATCCAGCCCAATGTCATTTCTGTTCGTCTC\nTTCAAGCGCAAAGTTGGGGGCCTGGGATTTCTGGTGAAGGAGCGGGTCAGTAAGCCGCCC\nGTGATCATCTCTGACCTGATTCGTGGGGGCGCCGCAGAGCAGAGTGGCCTCATCCAGGCC\nGGAGACATCATTCTTGCGGTCAACGGCCGGCCCTTGGTGGACCTGAGCTATGACAGCGCC\nCTGGAGGTACTCAGAGGCATTGCCTCTGAGACCCACGTGGTCCTCATTCTGAGGGGCCCT\nGAAGGTTTCACCACGCACCTGGAGACCACCTTTACAGGTGATGGGACCCCCAAGACCATC\nCGGGTGACACAGCCCCTGGGTCCCCCCACCAAAGCCGTGGATCTGTCCCACCAGCCACCG\nGCCGGCAAAGAACAGCCCCTGGCAGTGGATGGGGCCTCGGGTCCCGGGAATGGGCCTCAG\nCATGCCTACGATGATGGGCAGGAGGCTGGCTCACTCCCCCATGCCAACGGCCTGGCCCCC\nAGGCCCCCAGGCCAGGACCCCGCGAAGAAAGCAACCAGAGTCAGCCTCCAAGGCAGAGGG\nGAGAACAATGAACTGCTCAAGGAGATAGAGCCTGTGCTGAGCCTTCTCACCAGTGGGAGC\nAGAGGGGTCAAGGGAGGGGCACCTGCCAAGGCAGAGATGAAAGATATGGGAATCCAGGTG\nGACAGAGATTTGGACGGCAAGTCACACAAACCTCTGCCCCTCGGCGTGGAGAACGACCGA\nGTCTTCAATGACCTATGGGGGAAGGGCAATGTGCCTGTCGTCCTCAACAACCCATATTCA\nGAGAAGGAGCAGCCCCCCACCTCAGGAAAACAGTCCCCCACAAAGAATGGCAGCCCCTCC\nAAGTGTCCACGCTTCCTCAAGGTCAAGAACTGGGAGACTGAGGTGGTTCTCACTGACACC\nCTCCACCTTAAGAGCACATTGGAAACGGGATGCACTGAGTACATCTGCATGGGCTCCATC\nATGCATCCTTCTCAGCATGCAAGGAGGCCTGAAGACGTCCGCACAAAAGGACAGCTCTTC\nCCTCTCGCCAAAGAGTTTATTGATCAATACTATTCATCAATTAAAAGATTTGGCTCCAAA\nGCCCACATGGAAAGGCTGGAAGAGGTGAACAAAGAGATCGACACCACTAGCACTTACCAG\nCTCAAGGACACAGAGCTCATCTATGGGGCCAAGCACGCCTGGCGGAATGCCTCGCGCTGT\nGTGGGCAGGATCCAGTGGTCCAAGCTGCAGGTATTCGATGCCCGTGACTGCACCACGGCC\nCACGGGATGTTCAACTACATCTGTAACCATGTCAAGTATGCCACCAACAAAGGGAACCTC\nAGGTCTGCCATCACCATATTCCCCCAGAGGACAGACGGCAAGCACGACTTCCGAGTCTGG\nAACTCCCAGCTCATCCGCTACGCTGGCTACAAGCAGCCTGACGGCTCCACCCTGGGGGAC\nCCAGCCAATGTGCAGTTCACAGAGATATGCATACAGCAGGGCTGGAAACCGCCTAGAGGC\nCGCTTCGATGTCCTGCCGCTCCTGCTTCAGGCCAACGGCAATGACCCTGAGCTCTTCCAG\nATTCCTCCAGAGCTGGTGTTGGAAGTTCCCATCAGGCACCCCAAGTTTGAGTGGTTCAAG\nGACCTGGGGCTGAAGTGGTACGGCCTCCCCGCCGTGTCCAACATGCTCCTAGAGATTGGC\nGGCCTGGAGTTCAGCGCCTGTCCCTTCAGTGGCTGGTACATGGGCACAGAGATTGGTGTC\nCGCGACTACTGTGACAACTCCCGCTACAATATCCTGGAGGAAGTGGCCAAGAAGATGAAC\nTTAGACATGAGGAAGACGTCCTCCCTGTGGAAGGACCAGGCGCTGGTGGAGATCAATATC\nGCGGTTCTCTATAGCTTCCAGAGTGACAAAGTGACCATTGTTGACCATCACTCCGCCACC\nGAGTCCTTCATTAAGCACATGGAGAATGAGTACCGCTGCCGGGGGGGCTGCCCTGCCGAC\nTGGGTGTGGATCGTGCCCCCCATGTCCGGAAGCATCACCCCTGTGTTCCACCAGGAGATG\nCTCAACTACCGGCTCACCCCCTCCTTCGAATACCAGCCTGATCCCTGGAACACGCATGTC\nTGGAAAGGCACCAACGGGACCCCCACAAAGCGGCGAGCCATTGGCTTCAAGAAGCTAGCA\nGAAGCTGTCAAGTTCTCGGCCAAGCTGATGGGGCAGGCTATGGCCAAGAGGGTGAAAGCG\nACCATCCTCTATGCCACAGAGACAGGCAAATCGCAAGCTTATGCCAAGACCTTGTGTGAG\nATCTTCAAACACGCCTTTGATGCCAAGGTGATGTCCATGGAAGAATATGACATTGTGCAC\nCTGGAACATGAAACTCTGGTCCTTGTGGTCACCAGCACCTTTGGCAATGGAGATCCCCCT\nGAGAATGGGGAGAAATTCGGCTGTGCTTTGATGGAAATGAGGCACCCCAACTCTGTGCAG\nGAAGAAAGGAAGAGCTACAAGGTCCGATTCAACAGCGTCTCCTCCTACTCTGACTCCCAA\nAAATCATCAGGCGATGGGCCCGACCTCAGAGACAACTTTGAGAGTGCTGGACCCCTGGCC\nAATGTGAGGTTCTCAGTTTTTGGCCTCGGCTCACGAGCATACCCTCACTTTTGCGCCTTC\nGGACACGCTGTGGACACCCTCCTGGAAGAACTGGGAGGGGAGAGGATCCTGAAGATGAGG\nGAAGGGGATGAGCTCTGTGGGCAGGAAGAGGCTTTCAGGACCTGGGCCAAGAAGGTCTTC\nAAGGCAGCCTGTGATGTCTTCTGTGTGGGAGATGATGTCAACATTGAAAAGGCCAACAAT\nTCCCTCATCAGCAATGATCGCAGCTGGAAGAGAAACAAGTTCCGCCTCACCTTTGTGGCC\nGAAGCTCCAGAACTCACACAAGGTCTATCCAATGTCCACAAAAAGCGAGTCTCAGCTGCC\nCGGCTCCTTAGCCGTCAAAACCTCCAGAGCCCTAAATCCAGTCGGTCAACTATCTTCGTG\nCGTCTCCACACCAACGGGAGCCAGGAGCTGCAGTACCAGCCTGGGGACCACCTGGGTGTC\nTTCCCTGGCAACCACGAGGACCTCGTGAATGCCCTGATCGAGCGGCTGGAGGACGCGCCG\nCCTGTCAACCAGATGGTGAAAGTGGAACTGCTGGAGGAGCGGAACACGGCTTTAGGTGTC\nATCAGTAACTGGACAGACGAGCTCCGCCTCCCGCCCTGCACCATCTTCCAGGCCTTCAAG\nTACTACCTGGACATCACCACGCCACCAACGCCTCTGCAGCTGCAGCAGTTTGCCTCCCTA\nGCTACCAGCGAGAAGGAGAAGCAGCGTCTGCTGGTCCTCAGCAAGGGTTTGCAGGAGTAC\nGAGGAATGGAAATGGGGCAAGAACCCCACCATCGTGGAGGTGCTGGAGGAGTTCCCATCT\nATCCAGATGCCGGCCACCCTGCTCCTGACCCAGCTGTCCCTGCTGCAGCCCCGCTACTAT\nTCCATCAGCTCCTCCCCAGACATGTACCCTGATGAAGTGCACCTCACTGTGGCCATCGTT\nTCCTACCGCACTCGAGATGGAGAAGGACCAATTCACCACGGCGTATGCTCCTCCTGGCTC\nAACCGGATACAGGCTGACGAACTGGTCCCCTGTTTCGTGAGAGGAGCACCCAGCTTCCAC\nCTGCCCCGGAACCCCCAAGTCCCCTGCATCCTCGTTGGACCAGGCACCGGCATTGCCCCT\nTTCCGAAGCTTCTGGCAACAGCGGCAATTTGATATCCAACACAAAGGAATGAACCCCTGC\nCCCATGGTCCTGGTCTTCGGGTGCCGGCAATCCAAGATAGATCATATCTACAGGGAAGAG\nACCCTGCAGGCCAAGAACAAGGGGGTCTTCAGAGAGCTGTACACGGCTTACTCCCGGGAG\nCCAGACAAACCAAAGAAGTACGTGCAGGACATCCTGCAGGAGCAGCTGGCGGAGTCTGTG\nTACCGAGCCCTGAAGGAGCAAGGGGGCCACATATACGTCTGTGGGGACGTCACCATGGCT\nGCTGATGTCCTCAAAGCCATCCAGCGCATCATGACCCAGCAGGGGAAGCTCTCGGCAGAG\nGACGCCGGCGTATTCATCAGCCGGATGAGGGATGACAACCGATACCATGAGGATATTTTT\nGGAGTCACCCTGCGAACGTACGAAGTGACCAACCGCCTTAGATCTGAGTCCATTGCCTTC\nATTGAAGAGAGCAAAAAAGACACCGATGAGGTTTTCAGCTCCTAA'),('Nitric oxide synthase, endothelial','None','Human','Tetrahydrobiopterin binding','Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the activation of platelets.Isoform eNOS13C: Lacks eNOS activity, dominant-negative form that may down-regulate eNOS activity by forming heterodimers with isoform 1.','NOS3','133287.62','DB05676','>lcl|BSEQ0010225|Nitric oxide synthase, endothelial (NOS3)\nATGGGCAACTTGAAGAGCGTGGCCCAGGAGCCTGGGCCACCCTGCGGCCTGGGGCTGGGG\nCTGGGCCTTGGGCTGTGCGGCAAGCAGGGCCCAGCCACCCCGGCCCCTGAGCCCAGCCGG\nGCCCCAGCATCCCTACTCCCACCAGCGCCAGAACACAGCCCCCCGAGCTCCCCGCTAACC\nCAGCCCCCAGAGGGGCCCAAGTTCCCTCGTGTGAAGAACTGGGAGGTGGGGAGCATCACC\nTATGACACCCTCAGCGCCCAGGCGCAGCAGGATGGGCCCTGCACCCCAAGACGCTGCCTG\nGGCTCCCTGGTATTTCCACGGAAACTACAGGGCCGGCCCTCCCCCGGCCCCCCGGCCCCT\nGAGCAGCTGCTGAGTCAGGCCCGGGACTTCATCAACCAGTACTACAGCTCCATTAAGAGG\nAGCGGCTCCCAGGCCCACGAACAGCGGCTTCAAGAGGTGGAAGCCGAGGTGGCAGCCACA\nGGCACCTACCAGCTTAGGGAGAGCGAGCTGGTGTTCGGGGCTAAGCAGGCCTGGCGCAAC\nGCTCCCCGCTGCGTGGGCCGGATCCAGTGGGGGAAGCTGCAGGTGTTCGATGCCCGGGAC\nTGCAGGTCTGCACAGGAAATGTTCACCTACATCTGCAACCACATCAAGTATGCCACCAAC\nCGGGGCAACCTTCGCTCGGCCATCACAGTGTTCCCGCAGCGCTGCCCTGGCCGAGGAGAC\nTTCCGAATCTGGAACAGCCAGCTGGTGCGCTACGCGGGCTACCGGCAGCAGGATGGCTCT\nGTGCGGGGGGACCCAGCCAACGTGGAGATCACCGAGCTCTGCATTCAGCACGGCTGGACC\nCCAGGAAACGGTCGCTTCGACGTGCTGCCCCTGCTGCTGCAGGCCCCAGATGATCCCCCA\nGAACTCTTCCTTCTGCCCCCCGAGCTGGTCCTTGAGGTGCCCCTGGAGCACCCCACGCTG\nGAGTGGTTTGCAGCCCTGGGCCTGCGCTGGTACGCCCTCCCGGCAGTGTCCAACATGCTG\nCTGGAAATTGGGGGCCTGGAGTTCCCCGCAGCCCCCTTCAGTGGCTGGTACATGAGCACT\nGAGATCGGCACGAGGAACCTGTGTGACCCTCACCGCTACAACATCCTGGAGGATGTGGCT\nGTCTGCATGGACCTGGATACCCGGACCACCTCGTCCCTGTGGAAAGACAAGGCAGCAGTG\nGAAATCAACGTGGCCGTGCTGCACAGTTACCAGCTAGCCAAAGTCACCATCGTGGACCAC\nCACGCCGCCACGGCCTCTTTCATGAAGCACCTGGAGAATGAGCAGAAGGCCAGGGGGGGC\nTGCCCTGCAGACTGGGCCTGGATCGTGCCCCCCATCTCGGGCAGCCTCACTCCTGTTTTC\nCATCAGGAGATGGTCAACTATTTCCTGTCCCCGGCCTTCCGCTACCAGCCAGACCCCTGG\nAAGGGGAGTGCCGCCAAGGGCACCGGCATCACCAGGAAGAAGACCTTTAAAGAAGTGGCC\nAACGCCGTGAAGATCTCCGCCTCGCTCATGGGCACGGTGATGGCGAAGCGAGTGAAGGCG\nACAATCCTGTATGGCTCCGAGACCGGCCGGGCCCAGAGCTACGCACAGCAGCTGGGGAGA\nCTCTTCCGGAAGGCTTTTGATCCCCGGGTCCTGTGTATGGATGAGTATGACGTGGTGTCC\nCTCGAACACGAGACGCTGGTGCTGGTGGTAACCAGCACATTTGGGAATGGGGATCCCCCG\nGAGAATGGAGAGAGCTTTGCAGCTGCCCTGATGGAGATGTCCGGCCCCTACAACAGCTCC\nCCTCGGCCGGAACAGCACAAGAGTTATAAGATCCGCTTCAACAGCATCTCCTGCTCAGAC\nCCACTGGTGTCCTCTTGGCGGCGGAAGAGGAAGGAGTCCAGTAACACAGACAGTGCAGGG\nGCCCTGGGCACCCTCAGGTTCTGTGTGTTCGGGCTCGGCTCCCGGGCATACCCCCACTTC\nTGCGCCTTTGCTCGTGCCGTGGACACACGGCTGGAGGAACTGGGCGGGGAGCGGCTGCTG\nCAGCTGGGCCAGGGCGACGAGCTGTGCGGCCAGGAGGAGGCCTTCCGAGGCTGGGCCCAG\nGCTGCCTTCCAGGCCGCCTGTGAGACCTTCTGTGTGGGAGAGGATGCCAAGGCCGCCGCC\nCGAGACATCTTCAGCCCCAAACGGAGCTGGAAGCGCCAGAGGTACCGGCTGAGCGCCCAG\nGCCGAGGGCCTGCAGTTGCTGCCAGGTCTGATCCACGTGCACAGGCGGAAGATGTTCCAG\nGCTACAATCCGCTCAGTGGAAAACCTGCAAAGCAGCAAGTCCACGAGGGCCACCATCCTG\nGTGCGCCTGGACACCGGAGGCCAGGAGGGGCTGCAGTACCAGCCGGGGGACCACATAGGT\nGTCTGCCCGCCCAACCGGCCCGGCCTTGTGGAGGCGCTGCTGAGCCGCGTGGAGGACCCG\nCCGGCGCCCACTGAGCCCGTGGCAGTAGAGCAGCTGGAGAAGGGCAGCCCTGGTGGCCCT\nCCCCCCGGCTGGGTGCGGGACCCCCGGCTGCCCCCGTGCACGCTGCGCCAGGCTCTCACC\nTTCTTCCTGGACATCACCTCCCCACCCAGCCCTCAGCTCTTGCGGCTGCTCAGCACCTTG\nGCAGAAGAGCCCAGGGAACAGCAGGAGCTGGAGGCCCTCAGCCAGGATCCCCGACGCTAC\nGAGGAGTGGAAGTGGTTCCGCTGCCCCACGCTGCTGGAGGTGCTGGAGCAGTTCCCGTCG\nGTGGCGCTGCCTGCCCCACTGCTCCTCACCCAGCTGCCTCTGCTCCAGCCCCGGTACTAC\nTCAGTCAGCTCGGCACCCAGCACCCACCCAGGAGAGATCCACCTCACTGTAGCTGTGCTG\nGCATACAGGACTCAGGATGGGCTGGGCCCCCTGCACTATGGAGTCTGCTCCACGTGGCTA\nAGCCAGCTCAAGCCCGGAGACCCTGTGCCCTGCTTCATCCGGGGGGCTCCCTCCTTCCGG\nCTGCCACCCGATCCCAGCTTGCCCTGCATCCTGGTGGGTCCAGGCACTGGCATTGCCCCC\nTTCCGGGGATTCTGGCAGGAGCGGCTGCATGACATTGAGAGCAAAGGGCTGCAGCCCACT\nCCCATGACTTTGGTGTTCGGCTGCCGATGCTCCCAACTTGACCATCTCTACCGCGACGAG\nGTGCAGAACGCCCAGCAGCGCGGGGTGTTTGGCCGAGTCCTCACCGCCTTCTCCCGGGAA\nCCTGACAACCCCAAGACCTACGTGCAGGACATCCTGAGGACGGAGCTGGCTGCGGAGGTG\nCACCGCGTGCTGTGCCTCGAGCGGGGCCACATGTTTGTCTGCGGCGATGTTACCATGGCA\nACCAACGTCCTGCAGACCGTGCAGCGCATCCTGGCGACGGAGGGCGACATGGAGCTGGAC\nGAGGCCGGCGACGTCATCGGCGTGCTGCGGGATCAGCAACGCTACCACGAAGACATTTTC\nGGGCTCACGCTGCGCACCCAGGAGGTGACAAGCCGCATACGCACCCAGAGCTTTTCCTTG\nCAGGAGCGTCAGTTGCGGGGCGCAGTGCCCTGGGCGTTCGACCCTCCCGGCTCAGACACC\nAACAGCCCCTGA'),('Nitric oxide synthase, inducible','None','Human','Tetrahydrobiopterin binding','Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In macrophages, NO mediates tumoricidal and bactericidal actions. Also has nitrosylase activity and mediates cysteine S-nitrosylation of cytoplasmic target proteins such COX2. As component of the iNOS-S100A8/9 transnitrosylase complex involved in the selective inflammatory stimulus-dependent S-nitrosylation of GAPDH on \'Cys-247\' implicated in regulation of the GAIT complex activity and probably multiple targets including ANXA5, EZR, MSN and VIM.','NOS2','131116.3','DB02207','>lcl|BSEQ0020444|Nitric oxide synthase, inducible (NOS2)\nATGGCCTGTCCTTGGAAATTTCTGTTCAAGACCAAATTCCACCAGTATGCAATGAATGGG\nGAAAAAGACATCAACAACAATGTGGAGAAAGCCCCCTGTGCCACCTCCAGTCCAGTGACA\nCAGGATGACCTTCAGTATCACAACCTCAGCAAGCAGCAGAATGAGTCCCCGCAGCCCCTC\nGTGGAGACGGGAAAGAAGTCTCCAGAATCTCTGGTCAAGCTGGATGCAACCCCATTGTCC\nTCCCCACGGCATGTGAGGATCAAAAACTGGGGCAGCGGGATGACTTTCCAAGACACACTT\nCACCATAAGGCCAAAGGGATTTTAACTTGCAGGTCCAAATCTTGCCTGGGGTCCATTATG\nACTCCCAAAAGTTTGACCAGAGGACCCAGGGACAAGCCTACCCCTCCAGATGAGCTTCTA\nCCTCAAGCTATCGAATTTGTCAACCAATATTACGGCTCCTTCAAAGAGGCAAAAATAGAG\nGAACATCTGGCCAGGGTGGAAGCGGTAACAAAGGAGATAGAAACAACAGGAACCTACCAA\nCTGACGGGAGATGAGCTCATCTTCGCCACCAAGCAGGCCTGGCGCAATGCCCCACGCTGC\nATTGGGAGGATCCAGTGGTCCAACCTGCAGGTCTTCGATGCCCGCAGCTGTTCCACTGCC\nCGGGAAATGTTTGAACACATCTGCAGACACGTGCGTTACTCCACCAACAATGGCAACATC\nAGGTCGGCCATCACCGTGTTCCCCCAGCGGAGTGATGGCAAGCACGACTTCCGGGTGTGG\nAATGCTCAGCTCATCCGCTATGCTGGCTACCAGATGCCAGATGGCAGCATCAGAGGGGAC\nCCTGCCAACGTGGAATTCACTCAGCTGTGCATCGACCTGGGCTGGAAGCCCAAGTACGGC\nCGCTTCGATGTGGTCCCCCTGGTCCTGCAGGCCAATGGCCGTGACCCTGAGCTCTTCGAA\nATCCCACCTGACCTTGTGCTTGAGGTGGCCATGGAACATCCCAAATACGAGTGGTTTCGG\nGAACTGGAGCTAAAGTGGTACGCCCTGCCTGCAGTGGCCAACATGCTGCTTGAGGTGGGC\nGGCCTGGAGTTCCCAGGGTGCCCCTTCAATGGCTGGTACATGGGCACAGAGATCGGAGTC\nCGGGACTTCTGTGACGTCCAGCGCTACAACATCCTGGAGGAAGTGGGCAGGAGAATGGGC\nCTGGAAACGCACAAGCTGGCCTCGCTCTGGAAAGACCAGGCTGTCGTTGAGATCAACATT\nGCTGTGCTCCATAGTTTCCAGAAGCAGAATGTGACCATCATGGACCACCACTCGGCTGCA\nGAATCCTTCATGAAGTACATGCAGAATGAATACCGGTCCCGTGGGGGCTGCCCGGCAGAC\nTGGATTTGGCTGGTCCCTCCCATGTCTGGGAGCATCACCCCCGTGTTTCACCAGGAGATG\nCTGAACTACGTCCTGTCCCCTTTCTACTACTATCAGGTAGAGGCCTGGAAAACCCATGTC\nTGGCAGGACGAGAAGCGGAGACCCAAGAGAAGAGAGATTCCATTGAAAGTCTTGGTCAAA\nGCTGTGCTCTTTGCCTGTATGCTGATGCGCAAGACAATGGCGTCCCGAGTCAGAGTCACC\nATCCTCTTTGCGACAGAGACAGGAAAATCAGAGGCGCTGGCCTGGGACCTGGGGGCCTTA\nTTCAGCTGTGCCTTCAACCCCAAGGTTGTCTGCATGGATAAGTACAGGCTGAGCTGCCTG\nGAGGAGGAACGGCTGCTGTTGGTGGTGACCAGTACGTTTGGCAATGGAGACTGCCCTGGC\nAATGGAGAGAAACTGAAGAAATCGCTCTTCATGCTGAAAGAGCTCAACAACAAATTCAGG\nTACGCTGTGTTTGGCCTCGGCTCCAGCATGTACCCTCGGTTCTGCGCCTTTGCTCATGAC\nATTGATCAGAAGCTGTCCCACCTGGGGGCCTCTCAGCTCACCCCGATGGGAGAAGGGGAT\nGAGCTCAGTGGGCAGGAGGACGCCTTCCGCAGCTGGGCCGTGCAAACCTTCAAGGCAGCC\nTGTGAGACGTTTGATGTCCGAGGCAAACAGCACATTCAGATCCCCAAGCTCTACACCTCC\nAATGTGACCTGGGACCCGCACCACTACAGGCTCGTGCAGGACTCACAGCCTTTGGACCTC\nAGCAAAGCCCTCAGCAGCATGCATGCCAAGAACGTGTTCACCATGAGGCTCAAATCTCGG\nCAGAATCTACAAAGTCCGACATCCAGCCGTGCCACCATCCTGGTGGAACTCTCCTGTGAG\nGATGGCCAAGGCCTGAACTACCTGCCGGGGGAGCACCTTGGGGTTTGCCCAGGCAACCAG\nCCGGCCCTGGTCCAAGGTATCCTGGAGCGAGTGGTGGATGGCCCCACACCCCACCAGACA\nGTGCGCCTGGAGGCCCTGGATGAGAGTGGCAGCTACTGGGTCAGTGACAAGAGGCTGCCC\nCCCTGCTCACTCAGCCAGGCCCTCACCTACTTCCTGGACATCACCACACCCCCAACCCAG\nCTGCTGCTCCAAAAGCTGGCCCAGGTGGCCACAGAAGAGCCTGAGAGACAGAGGCTGGAG\nGCCCTGTGCCAGCCCTCAGAGTACAGCAAGTGGAAGTTCACCAACAGCCCCACATTCCTG\nGAGGTGCTAGAGGAGTTCCCGTCCCTGCGGGTGTCTGCTGGCTTCCTGCTTTCCCAGCTC\nCCCATTCTGAAGCCCAGGTTCTACTCCATCAGCTCCTCCCGGGATCACACGCCCACAGAG\nATCCACCTGACTGTGGCCGTGGTCACCTACCACACCCGAGATGGCCAGGGTCCCCTGCAC\nCACGGCGTCTGCAGCACATGGCTCAACAGCCTGAAGCCCCAAGACCCAGTGCCCTGCTTT\nGTGCGGAATGCCAGCGGCTTCCACCTCCCCGAGGATCCCTCCCATCCTTGCATCCTCATC\nGGGCCTGGCACAGGCATCGCGCCCTTCCGCAGTTTCTGGCAGCAACGGCTCCATGACTCC\nCAGCACAAGGGAGTGCGGGGAGGCCGCATGACCTTGGTGTTTGGGTGCCGCCGCCCAGAT\nGAGGACCACATCTACCAGGAGGAGATGCTGGAGATGGCCCAGAAGGGGGTGCTGCATGCG\nGTGCACACAGCCTATTCCCGCCTGCCTGGCAAGCCCAAGGTCTATGTTCAGGACATCCTG\nCGGCAGCAGCTGGCCAGCGAGGTGCTCCGTGTGCTCCACAAGGAGCCAGGCCACCTCTAT\nGTTTGCGGGGATGTGCGCATGGCCCGGGACGTGGCCCACACCCTGAAGCAGCTGGTGGCT\nGCCAAGCTGAAATTGAATGAGGAGCAGGTCGAGGACTATTTCTTTCAGCTCAAGAGCCAG\nAAGCGCTATCACGAAGATATCTTTGGTGCTGTATTTCCTTACGAGGCGAAGAAGGACAGG\nGTGGCGGTGCAGCCCAGCAGCCTGGAGATGTCAGCGCTCTGA'),('NMDA receptor','protein group','Human','None','None','None','None','DB00996','None'),('NMDA receptor (Protein Group)','Protein group','Human','Voltage-gated cation channel activity','NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. This protein plays a key role in synaptic p...','None','None','DB06738',NULL),('Nociceptin receptor','None','Human','Nociceptin receptor activity','G-protein coupled opioid receptor that functions as receptor for the endogenous neuropeptide nociceptin. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling via G proteins mediates inhibition of adenylate cyclase activity and calcium channel activity. Arrestins modulate signaling via G proteins and mediate the activation of alternative signaling pathways that lead to the activation of MAP kinases. Plays a role in modulating nociception and the perception of pain. Plays a role in the regulation of locomotor activity by the neuropeptide nociceptin.','OPRL1','40692.775','DB00921','>lcl|BSEQ0016773|Nociceptin receptor (OPRL1)\nATGGAGCCCCTCTTCCCCGCGCCGTTCTGGGAGGTTATCTACGGCAGCCACCTTCAGGGC\nAACCTGTCCCTCCTGAGCCCCAACCACAGTCTGCTGCCCCCGCATCTGCTGCTCAATGCC\nAGCCACGGCGCCTTCCTGCCCCTCGGGCTCAAGGTCACCATCGTGGGGCTCTACCTGGCC\nGTGTGTGTCGGAGGGCTCCTGGGGAACTGCCTTGTCATGTACGTCATCCTCAGGCACACC\nAAAATGAAGACAGCCACCAATATTTACATCTTTAACCTGGCCCTGGCCGACACTCTGGTC\nCTGCTGACGCTGCCCTTCCAGGGCACGGACATCCTCCTGGGCTTCTGGCCGTTTGGGAAT\nGCGCTGTGCAAGACAGTCATTGCCATTGACTACTACAACATGTTCACCAGCACCTTCACC\nCTAACTGCCATGAGTGTGGATCGCTATGTAGCCATCTGCCACCCCATCCGTGCCCTCGAC\nGTCCGCACGTCCAGCAAAGCCCAGGCTGTCAATGTGGCCATCTGGGCCCTGGCCTCTGTT\nGTCGGTGTTCCCGTTGCCATCATGGGCTCGGCACAGGTCGAGGATGAAGAGATCGAGTGC\nCTGGTGGAGATCCCTACCCCTCAGGATTACTGGGGCCCGGTGTTTGCCATCTGCATCTTC\nCTCTTCTCCTTCATCGTCCCCGTGCTCGTCATCTCTGTCTGCTACAGCCTCATGATCCGG\nCGGCTCCGTGGAGTCCGCCTGCTCTCGGGCTCCCGAGAGAAGGACCGGAACCTGCGGCGC\nATCACTCGGCTGGTGCTGGTGGTAGTGGCTGTGTTCGTGGGCTGCTGGACGCCTGTCCAG\nGTCTTCGTGCTGGCCCAAGGGCTGGGGGTTCAGCCGAGCAGCGAGACTGCCGTGGCCATT\nCTGCGCTTCTGCACGGCCCTGGGCTACGTCAACAGCTGCCTCAACCCCATCCTCTACGCC\nTTCCTGGATGAGAACTTCAAGGCCTGCTTCCGCAAGTTCTGCTGTGCATCTGCCCTGCGC\nCGGGACGTGCAGGTGTCTGACCGCGTGCGCAGCATTGCCAAGGACGTGGCCCTGGCCTGC\nAAGACCTCTGAGACGGTACCGCGGCCCGCATGA'),('None','None','None','None','None','None','None','DB06738','None'),('Nuclear factor NF-kappa-B','Protein','Human','Transcriptional activator activity, rna polymerase ii core promoter proximal region sequence-specific binding','NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related...','NFKB2','96748.355 Da','DB00945',NULL),('Nuclear factor NF-kappa-B complex','protein group','Human','None','None','None','None','DB14059','None'),('Nuclear factor NF-kappa-B p100 subunit','None','Human','Transcriptional activator activity, rna polymerase ii core promoter proximal region sequence-specific binding','NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. In a non-canonical activation pathway, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. The NF-kappa-B heterodimeric RelB-p52 complex is a transcriptional activator. The NF-kappa-B p52-p52 homodimer is a transcriptional repressor. NFKB2 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p100 and generation of p52 by a cotranslational processing. The proteasome-mediated process ensures the production of both p52 and p100 and preserves their independent function. p52 binds to the kappa-B consensus sequence 5\'-GGRNNYYCC-3\', located in the enhancer region of genes involved in immune response and acute phase reactions. p52 and p100 are respectively the minor and major form; the processing of p100 being relatively poor. Isoform p49 is a subunit of the NF-kappa-B protein complex, which stimulates the HIV enhancer in synergy with p65. In concert with RELB, regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-ARNTL/BMAL1 heterodimer.','NFKB2','96748.355','DB05767','>lcl|BSEQ0016775|Nuclear factor NF-kappa-B p100 subunit (NFKB2)\nATGGAGAGTTGCTACAACCCAGGTCTGGATGGTATTATTGAATATGATGATTTCAAATTG\nAACTCCTCCATTGTGGAACCCAAGGAGCCAGCCCCAGAAACAGCTGATGGCCCCTACCTG\nGTGATCGTGGAACAGCCTAAGCAGAGAGGCTTCCGATTTCGATATGGCTGTGAAGGCCCC\nTCCCATGGAGGACTGCCCGGTGCCTCCAGTGAGAAGGGCCGAAAGACCTATCCCACTGTC\nAAGATCTGTAACTACGAGGGACCAGCCAAGATCGAGGTGGACCTGGTAACACACAGTGAC\nCCACCTCGTGCTCATGCCCACAGTCTGGTGGGCAAGCAATGCTCGGAGCTGGGGATCTGC\nGCCGTTTCTGTGGGGCCCAAGGACATGACTGCCCAATTTAACAACCTGGGTGTCCTGCAT\nGTGACTAAGAAGAACATGATGGGGACTATGATACAAAAACTTCAGAGGCAGCGGCTCCGC\nTCTAGGCCCCAGGGCCTTACGGAGGCCGAGCAGCGGGAGCTGGAGCAAGAGGCCAAAGAA\nCTGAAGAAGGTGATGGATCTGAGTATAGTGCGGCTGCGCTTCTCTGCCTTCCTTAGAGCC\nAGTGATGGCTCCTTCTCCCTGCCCCTGAAGCCAGTCATCTCCCAGCCCATCCATGACAGC\nAAATCTCCGGGGGCATCAAACCTGAAGATTTCTCGAATGGACAAGACAGCAGGCTCTGTG\nCGGGGTGGAGATGAAGTTTATCTGCTTTGTGACAAGGTGCAGAAAGATGACATTGAGGTT\nCGGTTCTATGAGGATGATGAGAATGGATGGCAGGCCTTTGGGGACTTCTCTCCCACAGAT\nGTGCATAAACAGTATGCCATTGTGTTCCGGACACCCCCCTATCACAAGATGAAGATTGAG\nCGGCCTGTAACAGTGTTTCTGCAACTGAAACGCAAGCGAGGAGGGGACGTGTCTGATTCC\nAAACAGTTCACCTATTACCCTCTGGTGGAAGACAAGGAAGAGGTGCAGCGGAAGCGGAGG\nAAGGCCTTGCCCACCTTCTCCCAGCCCTTCGGGGGTGGCTCCCACATGGGTGGAGGCTCT\nGGGGGTGCAGCCGGGGGCTACGGAGGAGCTGGAGGAGGTGGCAGCCTCGGTTTCTTCCCC\nTCCTCCCTGGCCTACAGCCCCTACCAGTCCGGCGCGGGCCCCATGGGCTGCTACCCGGGA\nGGCGGGGGCGGGGCGCAGATGGCCGCCACGGTGCCCAGCAGGGACTCCGGGGAGGAAGCC\nGCGGAGCCGAGCGCCCCCTCCAGGACCCCCCAGTGCGAGCCGCAGGCCCCGGAGATGCTG\nCAGCGAGCTCGAGAGTACAACGCGCGCCTGTTCGGCCTGGCGCAGCGCAGCGCCCGAGCC\nCTACTCGACTACGGCGTCACCGCGGACGCGCGCGCGCTGCTGGCGGGACAGCGCCACCTG\nCTGACGGCGCAGGACGAGAACGGAGACACACCACTGCACCTAGCCATCATCCACGGGCAG\nACCAGTGTCATTGAGCAGATAGTCTATGTCATCCACCACGCCCAGGACCTCGGCGTTGTC\nAACCTCACCAACCACCTGCACCAGACGCCCCTGCACCTGGCGGTGATCACGGGGCAGACG\nAGTGTGGTGAGCTTTCTGCTGCGGGTAGGTGCAGACCCAGCTCTGCTGGATCGGCATGGA\nGACTCAGCCATGCATCTGGCGCTGCGGGCAGGCGCTGGTGCTCCTGAGCTGCTGCGTGCA\nCTGCTTCAGAGTGGAGCTCCTGCTGTGCCCCAGCTGTTGCATATGCCTGACTTTGAGGGA\nCTGTATCCAGTACACCTGGCGGTCCGAGCCCGAAGCCCTGAGTGCCTGGATCTGCTGGTG\nGACAGTGGGGCTGAAGTGGAGGCCACAGAGCGGCAGGGGGGACGAACAGCCTTGCATCTA\nGCCACAGAGATGGAGGAGCTGGGGTTGGTCACCCATCTGGTCACCAAGCTCCGGGCCAAC\nGTGAACGCTCGCACCTTTGCGGGAAACACACCCCTGCACCTGGCAGCTGGACTGGGGTAC\nCCGACCCTCACCCGCCTCCTTCTGAAGGCTGGTGCTGACATCCATGCTGAAAACGAGGAG\nCCCCTGTGCCCACTGCCTTCACCCCCTACCTCTGATAGCGACTCGGACTCTGAAGGGCCT\nGAGAAGGACACCCGAAGCAGCTTCCGGGGCCACACGCCTCTTGACCTCACTTGCAGCACC\nAAGGTGAAGACCTTGCTGCTAAATGCTGCTCAGAACACCATGGAGCCACCCCTGACCCCG\nCCCAGCCCAGCAGGGCCGGGACTGTCACTTGGTGATACAGCTCTGCAGAACCTGGAGCAG\nCTGCTAGACGGGCCAGAAGCCCAGGGCAGCTGGGCAGAGCTGGCAGAGCGTCTGGGGCTG\nCGCAGCCTGGTAGACACGTACCGACAGACAACCTCACCCAGTGGCAGCCTCCTGCGCAGC\nTACGAGCTGGCTGGCGGGGACCTGGCAGGTCTACTGGAGGCCCTGTCTGACATGGGCCTA\nGAGGAGGGAGTGAGGCTGCTGAGGGGTCCAGAAACCCGAGACAAGCTGCCCAGCACAGCA\nGAGGTGAAGGAAGACAGTGCGTACGGGAGCCAGTCAGTGGAGCAGGAGGCAGAGAAGCTG\nGGCCCACCCCCTGAGCCACCAGGAGGGCTCTGCCACGGGCACCCCCAGCCTCAGGTGCAC\nTGA'),('Nuclear factor NF-kappa-B p105 subunit','None','Human','Transcriptional repressor activity, rna polymerase ii transcription regulatory region sequence-specific binding','NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor, but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function, although processing of NFKB1/p105 also appears to occur post-translationally. p50 binds to the kappa-B consensus sequence 5\'-GGRNNYYCC-3\', located in the enhancer region of genes involved in immune response and acute phase reactions. In a complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPK signaling; active MAP3K8 is released by proteasome-dependent degradation of NFKB1/p105.','NFKB1','105355.175','DB05767','>lcl|BSEQ0019061|Nuclear factor NF-kappa-B p105 subunit (NFKB1)\nATGGCAGAAGATGATCCATATTTGGGAAGGCCTGAACAAATGTTTCATTTGGATCCTTCT\nTTGACTCATACAATATTTAATCCAGAAGTATTTCAACCACAGATGGCACTGCCAACAGAT\nGGCCCATACCTTCAAATATTAGAGCAACCTAAACAGAGAGGATTTCGTTTCCGTTATGTA\nTGTGAAGGCCCATCCCATGGTGGACTACCTGGTGCCTCTAGTGAAAAGAACAAGAAGTCT\nTACCCTCAGGTCAAAATCTGCAACTATGTGGGACCAGCAAAGGTTATTGTTCAGTTGGTC\nACAAATGGAAAAAATATCCACCTGCATGCCCACAGCCTGGTGGGAAAACACTGTGAGGAT\nGGGATCTGCACTGTAACTGCTGGACCCAAGGACATGGTGGTCGGCTTCGCAAACCTGGGT\nATACTTCATGTGACAAAGAAAAAAGTATTTGAAACACTGGAAGCACGAATGACAGAGGCG\nTGTATAAGGGGCTATAATCCTGGACTCTTGGTGCACCCTGACCTTGCCTATTTGCAAGCA\nGAAGGTGGAGGGGACCGGCAGCTGGGAGATCGGGAAAAAGAGCTAATCCGCCAAGCAGCT\nCTGCAGCAGACCAAGGAGATGGACCTCAGCGTGGTGCGGCTCATGTTTACAGCTTTTCTT\nCCGGATAGCACTGGCAGCTTCACAAGGCGCCTGGAACCCGTGGTATCAGACGCCATCTAT\nGACAGTAAAGCCCCCAATGCATCCAACTTGAAAATTGTAAGAATGGACAGGACAGCTGGA\nTGTGTGACTGGAGGGGAGGAAATTTATCTTCTTTGTGACAAAGTTCAGAAAGATGACATC\nCAGATTCGATTTTATGAAGAGGAAGAAAATGGTGGAGTCTGGGAAGGATTTGGAGATTTT\nTCCCCCACAGATGTTCATAGACAATTTGCCATTGTCTTCAAAACTCCAAAGTATAAAGAT\nATTAATATTACAAAACCAGCCTCTGTGTTTGTCCAGCTTCGGAGGAAATCTGACTTGGAA\nACTAGTGAACCAAAACCTTTCCTCTACTATCCTGAAATCAAAGATAAAGAAGAAGTGCAG\nAGGAAACGTCAGAAGCTCATGCCCAATTTTTCGGATAGTTTCGGCGGTGGTAGTGGTGCT\nGGAGCTGGAGGCGGAGGCATGTTTGGTAGTGGCGGTGGAGGAGGGGGCACTGGAAGTACA\nGGTCCAGGGTATAGCTTCCCACACTATGGATTTCCTACTTATGGTGGGATTACTTTCCAT\nCCTGGAACTACTAAATCTAATGCTGGGATGAAGCATGGAACCATGGACACTGAATCTAAA\nAAGGACCCTGAAGGTTGTGACAAAAGTGATGACAAAAACACTGTAAACCTCTTTGGGAAA\nGTTATTGAAACCACAGAGCAAGATCAGGAGCCCAGCGAGGCCACCGTTGGGAATGGTGAG\nGTCACTCTAACGTATGCAACAGGAACAAAAGAAGAGAGTGCTGGAGTTCAGGATAACCTC\nTTTCTAGAGAAGGCTATGCAGCTTGCAAAGAGGCATGCCAATGCCCTTTTCGACTACGCG\nGTGACAGGAGACGTGAAGATGCTGCTGGCCGTCCAGCGCCATCTCACTGCTGTGCAGGAT\nGAGAATGGGGACAGTGTCTTACACTTAGCAATCATCCACCTTCATTCTCAACTTGTGAGG\nGATCTACTAGAAGTCACATCTGGTTTGATTTCTGATGACATTATCAACATGAGAAATGAT\nCTGTACCAGACGCCCTTGCACTTGGCAGTGATCACTAAGCAGGAAGATGTGGTGGAGGAT\nTTGCTGAGGGCTGGGGCCGACCTGAGCCTTCTGGACCGCTTGGGTAACTCTGTTTTGCAC\nCTAGCTGCCAAAGAAGGACATGATAAAGTTCTCAGTATCTTACTCAAGCACAAAAAGGCA\nGCACTACTTCTTGACCACCCCAACGGGGACGGTCTGAATGCCATTCATCTAGCCATGATG\nAGCAATAGCCTGCCATGTTTGCTGCTGCTGGTGGCCGCTGGGGCTGACGTCAATGCTCAG\nGAGCAGAAGTCCGGGCGCACAGCACTGCACCTGGCTGTGGAGCACGACAACATCTCATTG\nGCAGGCTGCCTGCTCCTGGAGGGTGATGCCCATGTGGACAGTACTACCTACGATGGAACC\nACACCCCTGCATATAGCAGCTGGGAGAGGGTCCACCAGGCTGGCAGCTCTTCTCAAAGCA\nGCAGGAGCAGATCCCCTGGTGGAGAACTTTGAGCCTCTCTATGACCTGGATGACTCTTGG\nGAAAATGCAGGAGAGGATGAAGGAGTTGTGCCTGGAACCACGCCTCTAGATATGGCCACC\nAGCTGGCAGGTATTTGACATATTAAATGGGAAACCATATGAGCCAGAGTTTACATCTGAT\nGATTTACTAGCACAAGGAGACATGAAACAGCTGGCTGAAGATGTGAAGCTGCAGCTGTAT\nAAGTTACTAGAAATTCCTGATCCAGACAAAAACTGGGCTACTCTGGCGCAGAAATTAGGT\nCTGGGGATACTTAATAATGCCTTCCGGCTGAGTCCTGCTCCTTCCAAAACACTTATGGAC\nAACTATGAGGTCTCTGGGGGTACAGTCAGAGAGCTGGTGGAGGCCCTGAGACAAATGGGC\nTACACCGAAGCAATTGAAGTGATCCAGGCAGCCTCCAGCCCAGTGAAGACCACCTCTCAG\nGCCCACTCGCTGCCTCTCTCGCCTGCCTCCACAAGGCAGCAAATAGACGAGCTCCGAGAC\nAGTGACAGTGTCTGCGACAGCGGCGTGGAGACATCCTTCCGCAAACTCAGCTTTACCGAG\nTCTCTGACCAGTGGTGCCTCACTGCTAACTCTCAACAAAATGCCCCATGATTATGGGCAG\nGAAGGACCTCTAGAAGGCAAAATTTAG'),('Nuclear receptor subfamily 1 group I member 2','None','Human','Zinc ion binding','Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism and secretion of potentially harmful xenobiotics, drugs and endogenous compounds. Activated by the antibiotic rifampicin and various plant metabolites, such as hyperforin, guggulipid, colupulone, and isoflavones. Response to specific ligands is species-specific. Activated by naturally occurring steroids, such as pregnenolone and progesterone. Binds to a response element in the promoters of the CYP3A4 and ABCB1/MDR1 genes.','NR1I2','49761.245','DB02709','>lcl|BSEQ0010672|Nuclear receptor subfamily 1 group I member 2 (NR1I2)\nCTGGAGGTGAGACCCAAAGAAAGCTGGAACCATGCTGACTTTGTACACTGTGAGGACACA\nGAGTCTGTTCCTGGAAAGCCCAGTGTCAACGCAGATGAGGAAGTCGGAGGTCCCCAAATC\nTGCCGTGTATGTGGGGACAAGGCCACTGGCTATCACTTCAATGTCATGACATGTGAAGGA\nTGCAAGGGCTTTTTCAGGAGGGCCATGAAACGCAACGCCCGGCTGAGGTGCCCCTTCCGG\nAAGGGCGCCTGCGAGATCACCCGGAAGACCCGGCGACAGTGCCAGGCCTGCCGCCTGCGC\nAAGTGCCTGGAGAGCGGCATGAAGAAGGAGATGATCATGTCCGACGAGGCCGTGGAGGAG\nAGGCGGGCCTTGATCAAGCGGAAGAAAAGTGAACGGACAGGGACTCAGCCACTGGGAGTG\nCAGGGGCTGACAGAGGAGCAGCGGATGATGATCAGGGAGCTGATGGACGCTCAGATGAAA\nACCTTTGACACTACCTTCTCCCATTTCAAGAATTTCCGGCTGCCAGGGGTGCTTAGCAGT\nGGCTGCGAGTTGCCAGAGTCTCTGCAGGCCCCATCGAGGGAAGAAGCTGCCAAGTGGAGC\nCAGGTCCGGAAAGATCTGTGCTCTTTGAAGGTCTCTCTGCAGCTGCGGGGGGAGGATGGC\nAGTGTCTGGAACTACAAACCCCCAGCCGACAGTGGCGGGAAAGAGATCTTCTCCCTGCTG\nCCCCACATGGCTGACATGTCAACCTACATGTTCAAAGGCATCATCAGCTTTGCCAAAGTC\nATCTCCTACTTCAGGGACTTGCCCATCGAGGACCAGATCTCCCTGCTGAAGGGGGCCGCT\nTTCGAGCTGTGTCAACTGAGATTCAACACAGTGTTCAACGCGGAGACTGGAACCTGGGAG\nTGTGGCCGGCTGTCCTACTGCTTGGAAGACACTGCAGGTGGCTTCCAGCAACTTCTACTG\nGAGCCCATGCTGAAATTCCACTACATGCTGAAGAAGCTGCAGCTGCATGAGGAGGAGTAT\nGTGCTGATGCAGGCCATCTCCCTCTTCTCCCCAGACCGCCCAGGTGTGCTGCAGCACCGC\nGTGGTGGACCAGCTGCAGGAGCAATTCGCCATTACTCTGAAGTCCTACATTGAATGCAAT\nCGGCCCCAGCCTGCTCATAGGTTCTTGTTCCTGAAGATCATGGCTATGCTCACCGAGCTC\nCGCAGCATCAATGCTCAGCACACCCAGCGGCTGCTGCGCATCCAGGACATACACCCCTTT\nGCTACGCCCCTCATGCAGGAGTTGTTCGGCATCACAGGTAGCTGA'),('Nuclear receptor subfamily 1 group I member 3','None','Human','Zinc ion binding','Binds and transactivates the retinoic acid response elements that control expression of the retinoic acid receptor beta 2 and alcohol dehydrogenase 3 genes. Transactivates both the phenobarbital responsive element module of the human CYP2B6 gene and the CYP3A4 xenobiotic response element.','NR1I3','39942.145','DB02709','>lcl|BSEQ0019481|Nuclear receptor subfamily 1 group I member 3 (NR1I3)\nATGGCCAGTAGGGAAGATGAGCTGAGGAACTGTGTGGTATGTGGGGACCAAGCCACAGGC\nTACCACTTTAATGCGCTGACTTGTGAGGGCTGCAAGGGTTTCTTCAGGAGAACAGTCAGC\nAAAAGCATTGGTCCCACCTGCCCCTTTGCTGGAAGCTGTGAAGTCAGCAAGACTCAGAGG\nCGCCACTGCCCAGCCTGCAGGTTGCAGAAGTGCTTAGATGCTGGCATGAGGAAAGACATG\nATACTGTCGGCAGAAGCCCTGGCATTGCGGCGAGCAAAGCAGGCCCAGCGGCGGGCACAG\nCAAACACCTGTGCAACTGAGTAAGGAGCAAGAAGAGCTGATCCGGACACTCCTGGGGGCC\nCACACCCGCCACATGGGCACCATGTTTGAACAGTTTGTGCAGTTTAGGCCTCCAGCTCAT\nCTGTTCATCCATCACCAGCCCTTGCCCACCCTGGCCCCTGTGCTGCCTCTGGTCACACAC\nTTCGCAGACATCAACACTTTCATGGTACTGCAAGTCATCAAGTTTACTAAGGACCTGCCC\nGTCTTCCGTTCCCTGCCCATTGAAGACCAGATCTCCCTTCTCAAGGGAGCAGCTGTGGAA\nATCTGTCACATCGTACTCAATACCACTTTCTGTCTCCAAACACAAAACTTCCTCTGCGGG\nCCTCTTCGCTACACAATTGAAGATGGAGCCCGTGTGGGGTTCCAGGTAGAGTTTTTGGAG\nTTGCTCTTTCACTTCCATGGAACACTACGAAAACTGCAGCTCCAAGAGCCTGAGTATGTG\nCTCTTGGCTGCCATGGCCCTCTTCTCTCCTGCTCCCTATCTTACAGACCGACCTGGAGTT\nACCCAGAGAGATGAGATTGATCAGCTGCAAGAGGAGATGGCACTGACTCTGCAAAGCTAC\nATCAAGGGCCAGCAGCGAAGGCCCCGGGATCGCTCACCTGGAACACCCTGGATACACTGG\nAGTGGGAAAATGCTGGGACCAAAGATTGGGCCGGGTTCAAAGGGAGCCCAGTGGTTGCAA\nTGA'),('O-methyltransferase','None','Synechocystis sp. (strain PCC 6803 / Kazusa)','O-methyltransferase activity','None','None','24312.805','DB07767','>lcl|BSEQ0007258|558 bp\nGTGGGGCGTTTGGATCAAGATAGCGAAGGACTATTGCTGCTCACCAGCAACGGTAAACTT\nCAGCATCGTTTGGCCCACCGGGAGTTTGCCCACCAACGTACTTATTTTGCCCAAGTAGAA\nGGCTCTCCAACGGACGAAGACCTAGAACCCCTGCGGCGGGGCATAACTTTCGCGGATTAC\nCCTACCAGACCGGCGATCGCCAAAATTATCACTGAACCAGATTTTCCCCCCAGAAATCCT\nCCCATTCGTTATCGAGCCTCCATTCCCACCAGTTGGTTAAGCATTACCCTAACGGAGGGG\nCGCAATCGTCAGGTACGTCGAATGACAGCGGCAGTGGGCTTCCCTACCCTACGATTGGTG\nCGGGTGCAAATACAGGTTACTGGTCGCTCTCCCCAACAGGGCAAAGGTAAGTCAGCAGCA\nACTTGGTGCTTAACCCTAGAAGGTTTGAGTCCGGGGCAATGGCGACCCCTGACCCCTTGG\nGAAGAAAATTTTTGCCAGCAACTCTTAACGGGAAATCCCAATGGTCCCTGGCAGAAAAAA\nTTTGGCGATCGCCGTTGA'),('Peptidyl-prolyl cis-trans isomerase FKBP1A','None','Human','Type i transforming growth factor beta receptor binding','Keeps in an inactive conformation TGFBR1, the TGF-beta type I serine/threonine kinase receptor, preventing TGF-beta receptor activation in absence of ligand. Recruites SMAD7 to ACVR1B which prevents the association of SMAD2 and SMAD3 with the activin receptor complex, thereby blocking the activin signal. May modulate the RYR1 calcium channel activity. PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides.','FKBP1A','11950.665','DB00337','>lcl|BSEQ0010487|Peptidyl-prolyl cis-trans isomerase FKBP1A (FKBP1A)\nATGGGAGTGCAGGTGGAAACCATCTCCCCAGGAGACGGGCGCACCTTCCCCAAGCGCGGC\nCAGACCTGCGTGGTGCACTACACCGGGATGCTTGAAGATGGAAAGAAATTTGATTCCTCC\nCGGGACAGAAACAAGCCCTTTAAGTTTATGCTAGGCAAGCAGGAGGTGATCCGAGGCTGG\nGAAGAAGGGGTTGCCCAGATGAGTGTGGGTCAGAGAGCCAAACTGACTATATCTCCAGAT\nTATGCCTATGGTGCCACTGGGCACCCAGGCATCATCCCACCACATGCCACTCTCGTCTTC\nGATGTGGAGCTTCTAAAACTGGAATGA'),('Peptostreptococcal albumin-binding protein','None','Finegoldia magna','None','Binds serum albumin.','pab','43057.45','DB00788','>lcl|BSEQ0007718|1164 bp\nATGAAACTTAATAAGAAATTATTAATGGCTGCACTAGCAGGTGCAATTGTAGTAGGTGGC\nGGAGTTAATACATTCGCAGCTGATGAACCTGGCGCAATAAAAGTAGACAAAGCTCCAGAA\nGCTCCTAGTCAAGAACTTAAACTAACTAAAGAAGAAGCTGAAAAGGCTCTTAAAAAAGAA\nAAGCCAATAGCAAAAGAAAGATTAAGAAGACTTGGAATTACAAGCGAATTTATTCTTAAT\nCAAATAGACAAAGCTACATCTAGAGAAGGATTAGAAAGTTTAGTTCAAACTATAAAACAA\nTCATACCTTAAAGACCATCCTATCAAAGAAGAAAAAACAGAAGAAACACCAAAATATAAT\nAACCTATTCGATAAACATGAATTAGGAGGATTAGGAAAAGACAAAGGCCCTGGAAGATTC\nGATGAGAACGGATGGGAAAACAACGAACATGGATATGAAACTAGAGAAAACGCTGAAAAA\nGCTGCAGTAAAAGCACTAGGCGATAAAGAAATTAATAAATCATATACTATTTCACAAGGT\nGTAGATGGAAGATACTACTATGTATTATCTAGAGAAGAAGCTGAAACTCCTAAAAAACCT\nGAAGAAAAGAAACCTGAAGATAAAAGACCAAAAATGACAATTGATCAATGGTTATTAAAG\nAACGCTAAAGAAGATGCAATCGCAGAATTAAAAAAAGCTGGAATCACATCTGATTTCTAC\nTTCAATGCAATTAACAAAGCAAAAACAGTTGAAGAAGTTAATGCTTTAAAGAACGAAATT\nTTAAAAGCACACGCTGGTAAGGAAGTAAACCCATCAACTCCTGAAGTAACTCCATCAGTT\nCCACAAAACCACTACCATGAAAACGACTATGCTAACATAGGCGCAGGTGAAGGTACTAAA\nGAAGACGGTAAGAAGGAAAATTCCAAAGAAGGAATCAAAAGGAAAACGGCAAGGGAAGAA\nAAACCTGGTAAAGAAGAAAAACCAGCAAAAGAAGACAAGAAAGAAAACAAAAAGAAAGAA\nAACACTGATTCTCCAAACAAGAAGAAAAAAGAAAAAGCTGCATTACCAGAAGCTGGTAGG\nCGGAAGGCTGAAATCTTAACATTAGCAGCAGCTTCATTATCAAGCGTTGCAGGTGCTTTC\nATTTCACTTAAAAAACGTAAATAA'),('Peroxisome proliferator-activated receptor alpha','None','Human','Zinc ion binding','Ligand-activated transcription factor. Key regulator of lipid metabolism. Activated by the endogenous ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Activated by oleylethanolamide, a naturally occurring lipid that regulates satiety. Receptor for peroxisome proliferators such as hypolipidemic drugs and fatty acids. Regulates the peroxisomal beta-oxidation pathway of fatty acids. Functions as transcription activator for the ACOX1 and P450 genes. Transactivation activity requires heterodimerization with RXRA and is antagonized by NR2C2. May be required for the propagation of clock information to metabolic pathways regulated by PER2.','PPARA','52224.595','DB02709','>lcl|BSEQ0021925|Peroxisome proliferator-activated receptor alpha (PPARA)\nATGGTGGACACGGAAAGCCCACTCTGCCCCCTCTCCCCACTCGAGGCCGGCGATCTAGAG\nAGCCCGTTATCTGAAGAGTTCCTGCAAGAAATGGGAAACATCCAAGAGATTTCGCAATCC\nATCGGCGAGGATAGTTCTGGAAGCTTTGGCTTTACGGAATACCAGTATTTAGGAAGCTGT\nCCTGGCTCAGATGGCTCGGTCATCACGGACACGCTTTCACCAGCTTCGAGCCCCTCCTCG\nGTGACTTATCCTGTGGTCCCCGGCAGCGTGGACGAGTCTCCCAGTGGAGCATTGAACATC\nGAATGTAGAATCTGCGGGGACAAGGCCTCAGGCTATCATTACGGAGTCCACGCGTGTGAA\nGGCTGCAAGGGCTTCTTTCGGCGAACGATTCGACTCAAGCTGGTGTATGACAAGTGCGAC\nCGCAGCTGCAAGATCCAGAAAAAGAACAGAAACAAATGCCAGTATTGTCGATTTCACAAG\nTGCCTTTCTGTCGGGATGTCACACAACGCGATTCGTTTTGGACGAATGCCAAGATCTGAG\nAAAGCAAAACTGAAAGCAGAAATTCTTACCTGTGAACATGACATAGAAGATTCTGAAACT\nGCAGATCTCAAATCTCTGGCCAAGAGAATCTACGAGGCCTACTTGAAGAACTTCAACATG\nAACAAGGTCAAAGCCCGGGTCATCCTCTCAGGAAAGGCCAGTAACAATCCACCTTTTGTC\nATACATGATATGGAGACACTGTGTATGGCTGAGAAGACGCTGGTGGCCAAGCTGGTGGCC\nAATGGCATCCAGAACAAGGAGGCGGAGGTCCGCATCTTTCACTGCTGCCAGTGCACGTCA\nGTGGAGACCGTCACGGAGCTCACGGAATTCGCCAAGGCCATCCCAGGCTTCGCAAACTTG\nGACCTGAACGATCAAGTGACATTGCTAAAATACGGAGTTTATGAGGCCATATTCGCCATG\nCTGTCTTCTGTGATGAACAAAGACGGGATGCTGGTAGCGTATGGAAATGGGTTTATAACT\nCGTGAATTCCTAAAAAGCCTAAGGAAACCGTTCTGTGATATCATGGAACCCAAGTTTGAT\nTTTGCCATGAAGTTCAATGCACTGGAACTGGATGACAGTGATATCTCCCTTTTTGTGGCT\nGCTATCATTTGCTGTGGAGATCGTCCTGGCCTTCTAAACGTAGGACACATTGAAAAAATG\nCAGGAGGGTATTGTACATGTGCTCAGACTCCACCTGCAGAGCAACCACCCGGACGATATC\nTTTCTCTTCCCAAAACTTCTTCAAAAAATGGCAGACCTCCGGCAGCTGGTGACGGAGCAT\nGCGCAGCTGGTGCAGATCATCAAGAAGACGGAGTCGGATGCTGCGCTGCACCCGCTACTG\nCAGGAGATCTACAGGGACATGTACTGA'),('Peroxisome proliferator-activated receptor delta','None','Human','Zinc ion binding','Ligand-activated transcription factor. Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Has a preference for poly-unsaturated fatty acids, such as gamma-linoleic acid and eicosapentanoic acid. Once activated by a ligand, the receptor binds to promoter elements of target genes. Regulates the peroxisomal beta-oxidation pathway of fatty acids. Functions as transcription activator for the acyl-CoA oxidase gene. Decreases expression of NPC1L1 once activated by a ligand.','PPARD','49902.99','DB00605','>lcl|BSEQ0019047|Peroxisome proliferator-activated receptor delta (PPARD)\nATGGAGCAGCCACAGGAGGAAGCCCCTGAGGTCCGGGAAGAGGAGGAGAAAGAGGAAGTG\nGCAGAGGCAGAAGGAGCCCCAGAGCTCAATGGGGGACCACAGCATGCACTTCCTTCCAGC\nAGCTACACAGACCTCTCCCGGAGCTCCTCGCCACCCTCACTGCTGGACCAACTGCAGATG\nGGCTGTGACGGGGCCTCATGCGGCAGCCTCAACATGGAGTGCCGGGTGTGCGGGGACAAG\nGCATCGGGCTTCCACTACGGTGTTCATGCATGTGAGGGGTGCAAGGGCTTCTTCCGTCGT\nACGATCCGCATGAAGCTGGAGTACGAGAAGTGTGAGCGCAGCTGCAAGATTCAGAAGAAG\nAACCGCAACAAGTGCCAGTACTGCCGCTTCCAGAAGTGCCTGGCACTGGGCATGTCACAC\nAACGCTATCCGTTTTGGTCGGATGCCGGAGGCTGAGAAGAGGAAGCTGGTGGCAGGGCTG\nACTGCAAACGAGGGGAGCCAGTACAACCCACAGGTGGCCGACCTGAAGGCCTTCTCCAAG\nCACATCTACAATGCCTACCTGAAAAACTTCAACATGACCAAAAAGAAGGCCCGCAGCATC\nCTCACCGGCAAAGCCAGCCACACGGCGCCCTTTGTGATCCACGACATCGAGACATTGTGG\nCAGGCAGAGAAGGGGCTGGTGTGGAAGCAGTTGGTGAATGGCCTGCCTCCCTACAAGGAG\nATCAGCGTGCACGTCTTCTACCGCTGCCAGTGCACCACAGTGGAGACCGTGCGGGAGCTC\nACTGAGTTCGCCAAGAGCATCCCCAGCTTCAGCAGCCTCTTCCTCAACGACCAGGTTACC\nCTTCTCAAGTATGGCGTGCACGAGGCCATCTTCGCCATGCTGGCCTCTATCGTCAACAAG\nGACGGGCTGCTGGTAGCCAACGGCAGTGGCTTTGTCACCCGTGAGTTCCTGCGCAGCCTC\nCGCAAACCCTTCAGTGATATCATTGAGCCTAAGTTTGAATTTGCTGTCAAGTTCAACGCC\nCTGGAACTTGATGACAGTGACCTGGCCCTATTCATTGCGGCCATCATTCTGTGTGGAGAC\nCGGCCAGGCCTCATGAACGTTCCACGGGTGGAGGCTATCCAGGACACCATCCTGCGTGCC\nCTCGAATTCCACCTGCAGGCCAACCACCCTGATGCCCAGTACCTCTTCCCCAAGCTGCTG\nCAGAAGATGGCTGACCTGCGGCAACTGGTCACCGAGCACGCCCAGATGATGCAGCGGATC\nAAGAAGACCGAAACCGAGACCTCGCTGCACCCTCTGCTCCAGGAGATCTACAAGGACATG\nTACTAA'),('Peroxisome proliferator-activated receptor gamma','None','Human','Zinc ion binding','Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. ARF6 acts as a key regulator of the tissue-specific adipocyte P2 (aP2) enhancer. Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated proinflammatory responses. Plays a role in the regulation of cardiovascular circadian rhythms by regulating the transcription of ARNTL/BMAL1 in the blood vessels (By similarity).','PPARG','57619.58','DB02709','>lcl|BSEQ0021642|Peroxisome proliferator-activated receptor gamma (PPARG)\nATGACCATGGTTGACACAGAGATGCCATTCTGGCCCACCAACTTTGGGATCAGCTCCGTG\nGATCTCTCCGTAATGGAAGACCACTCCCACTCCTTTGATATCAAGCCCTTCACTACTGTT\nGACTTCTCCAGCATTTCTACTCCACATTACGAAGACATTCCATTCACAAGAACAGATCCA\nGTGGTTGCAGATTACAAGTATGACCTGAAACTTCAAGAGTACCAAAGTGCAATCAAAGTG\nGAGCCTGCATCTCCACCTTATTATTCTGAGAAGACTCAGCTCTACAATAAGCCTCATGAA\nGAGCCTTCCAACTCCCTCATGGCAATTGAATGTCGTGTCTGTGGAGATAAAGCTTCTGGA\nTTTCACTATGGAGTTCATGCTTGTGAAGGATGCAAGGGTTTCTTCCGGAGAACAATCAGA\nTTGAAGCTTATCTATGACAGATGTGATCTTAACTGTCGGATCCACAAAAAAAGTAGAAAT\nAAATGTCAGTACTGTCGGTTTCAGAAATGCCTTGCAGTGGGGATGTCTCATAATGCCATC\nAGGTTTGGGCGGATGCCACAGGCCGAGAAGGAGAAGCTGTTGGCGGAGATCTCCAGTGAT\nATCGACCAGCTGAATCCAGAGTCCGCTGACCTCCGGGCCCTGGCAAAACATTTGTATGAC\nTCATACATAAAGTCCTTCCCGCTGACCAAAGCAAAGGCGAGGGCGATCTTGACAGGAAAG\nACAACAGACAAATCACCATTCGTTATCTATGACATGAATTCCTTAATGATGGGAGAAGAT\nAAAATCAAGTTCAAACACATCACCCCCCTGCAGGAGCAGAGCAAAGAGGTGGCCATCCGC\nATCTTTCAGGGCTGCCAGTTTCGCTCCGTGGAGGCTGTGCAGGAGATCACAGAGTATGCC\nAAAAGCATTCCTGGTTTTGTAAATCTTGACTTGAACGACCAAGTAACTCTCCTCAAATAT\nGGAGTCCACGAGATCATTTACACAATGCTGGCCTCCTTGATGAATAAAGATGGGGTTCTC\nATATCCGAGGGCCAAGGCTTCATGACAAGGGAGTTTCTAAAGAGCCTGCGAAAGCCTTTT\nGGTGACTTTATGGAGCCCAAGTTTGAGTTTGCTGTGAAGTTCAATGCACTGGAATTAGAT\nGACAGCGACTTGGCAATATTTATTGCTGTCATTATTCTCAGTGGAGACCGCCCAGGTTTG\nCTGAATGTGAAGCCCATTGAAGACATTCAAGACAACCTGCTACAAGCCCTGGAGCTCCAG\nCTGAAGCTGAACCACCCTGAGTCCTCACAGCTGTTTGCCAAGCTGCTCCAGAAAATGACA\nGACCTCAGACAGATTGTCACGGAACACGTGCAGCTACTGCAGGTGATCAAGAAGACGGAG\nACAGACATGAGTCTTCACCCGCTCCTGCAGGAGATCTACAAGGACTTGTACTAG'),('Phosphatidylinositol 4-kinase type 2-beta','None','Human','Together with PI4K2A and the type III PI4Ks (PIK4CA and PIK4CB) it contributes to the overall PI4-kinase activity of the cell. This contribution may be especially significant in plasma membrane, endosomal and Golgi compartments. The phosphorylation of phosphatidylinositol (PI) to PI4P is the first committed step in the generation of phosphatidylinositol 4,5-bisphosphate (PIP2), a precursor of the second messenger inositol 1,4,5-trisphosphate (InsP3). Contributes to the production of InsP3 in stimulated cells and is likely to be involved in the regulation of vesicular trafficking.','1-phosphatidylinositol 4-kinase activity','PI4K2B','54743.71','DB02709','>lcl|BSEQ0049686|Phosphatidylinositol 4-kinase type 2-beta (PI4K2B)\nATGGAGGATCCCTCCGAGCCCGACCGGTTGGCGTCCGCGGACGGCGGGAGCCCGGAGGAG\nGAGGAGGATGGGGAGCGGGAGCCGCTGCTACCGCGGATCGCCTGGGCCCACCCGCGGAGA\nGGCGCCCCAGGCAGCGCCGTGAGGCTGCTGGACGCTGCCGGGGAGGAGGGCGAGGCCGGC\nGACGAGGAGCTGCCCCTCCCGCCCGGGGACGTGGGGGTCTCCCGGAGTTCGTCCGCCGAG\nCTGGACCGGAGCCGCCCCGCGGTTTCAGTAACTATTGGTACTTCAGAGATGAATGCATTC\nTTGGATGACCCAGAATTTGCCGATATTATGCTGAGAGCAGAGCAAGCAATAGAAGTTGGA\nATTTTTCCAGAAAGAATCTCTCAAGGTTCAAGTGGAAGTTACTTTGTGAAGGATCCTAAG\nAGGAAAATTATTGGTGTGTTTAAACCCAAATCAGAAGAGCCTTATGGTCAACTCAATCCA\nAAATGGACCAAATATGTCCATAAGGTCTGCTGCCCTTGCTGCTTTGGCCGAGGCTGCCTG\nATTCCTAATCAGGGGTACCTTTCCGAAGCGGGTGCCTATCTTGTGGACAACAAGCTTCAT\nCTGAGCATTGTACCTAAAACAAAGGTGGTTTGGCTTGTCAGTGAGACATTTAACTATAAT\nGCGATTGACCGTGCAAAATCAAGAGGCAAAAAGTATGCTTTAGAAAAAGTGCCAAAAGTG\nGGTAGAAAGTTTCATAGGATAGGACTCCCTCCTAAGATTGGTTCCTTTCAGTTATTTGTT\nGAAGGTTACAAGGAGGCTGAATATTGGCTTAGGAAATTTGAAGCTGACCCTTTGCCTGAG\nAATATTAGAAAACAATTTCAGTCACAATTTGAAAGATTAGTTATTTTGGATTACATCATC\nAGAAATACAGACAGGGGCAATGATAATTGGTTAGTCAGATACGAAAAGCAGAAATGTGAA\nAAGGAAATTGACCATAAGGAATCAAAATGGATTGATGATGAAGAATTCCTTATTAAAATA\nGCTGCAATTGATAATGGTCTAGCATTTCCTTTTAAACATCCTGATGAATGGAGAGCATAT\nCCATTTCACTGGGCTTGGCTTCCTCAAGCAAAAGTTCCCTTTTCTGAAGAAATAAGAAAT\nTTGATTCTACCATATATTTCTGACATGAACTTTGTGCAAGATTTATGTGAAGATCTCTAT\nGAACTTTTTAAGACTGACAAAGGATTTGACAAAGCCACTTTTGAAAGTCAGATGTCTGTG\nATGAGGGGTCAGATCTTAAACCTTACTCAGGCATTGAGAGACGGGAAGAGTCCTTTCCAG\nCTAGTACAGATACCTTGTGTGATTGTGGAACGCAGTCAAGGTGGAAGTCAGGGTCGGATT\nGTCCACCTGAGCAATTCCTTTACCCAGACTGTCAATTGCAGGAAGCCATTTTTTTCCTCC\nTGGTAG'),('Phosphoethanolamine/phosphocholine phosphatase','None','Human','Pyrophosphatase activity','Phosphatase that has a high activity toward phosphoethanolamine (PEA) and phosphocholine (PCho). Involved in the generation of inorganic phosphate for bone mineralization.','PHOSPHO1','29712.54','DB00122','>lcl|BSEQ0020598|Phosphoethanolamine/phosphocholine phosphatase (PHOSPHO1)\nATGTGCCAGCGCCTCTGGCCGTGGCCCGCTAACCAGCCTCTCCCGGGCGGGCTCCTGCCG\nCGCCCCCTCTCGCTTGCCCCCTCCTCCTCCTCCTCCTGCTGCTCTCCCCCCTGCTCCCAG\nGACGGCAGGATGGCCGCGCAGGGCGCGCCGCGCTTCCTCCTGACCTTCGACTTCGACGAG\nACTATCGTGGACGAAAACAGCGACGATTCGATCGTGCGCGCCGCGCCGGGCCAGCGGCTC\nCCGGAGAGCCTGCGAGCCACCTACCGCGAGGGCTTCTACAACGAGTACATGCAGCGCGTC\nTTCAAGTACCTGGGCGAGCAGGGCGTGCGGCCGCGGGACCTGAGCGCCATCTACGAAGCC\nATCCCTTTGTCGCCAGGCATGAGCGACCTGCTGCAGTTTGTGGCAAAACAGGGCGCCTGC\nTTCGAGGTGATTCTCATCTCCGATGCCAACACCTTTGGCGTGGAGAGCTCGCTGCGCGCC\nGCCGGCCACCACAGCCTGTTCCGCCGCATCCTCAGCAACCCGTCGGGGCCGGATGCGCGG\nGGACTGCTGGCTCTGCGGCCGTTCCACACACACAGCTGCGCGCGCTGCCCCGCCAACATG\nTGCAAGCACAAGGTGCTCAGCGACTACCTGCGCGAGCGGGCCCACGACGGCGTGCACTTC\nGAGCGCCTCTTCTACGTGGGCGACGGCGCCAACGACTTCTGCCCCATGGGGCTGCTGGCG\nGGCGGCGACGTGGCCTTCCCGCGCCGCGGCTACCCCATGCACCGCCTCATTCAGGAGGCC\nCAGAAGGCCGAGCCCAGCTCGTTCCGCGCCAGCGTGGTGCCCTGGGAAACGGCTGCAGAT\nGTGCGCCTCCACCTGCAACAGGTGCTGAAGTCGTGCTGA'),('Phospholipase A2','None','Human','Receptor binding','PA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides, this releases glycerophospholipids and arachidonic acid that serve as the precursors of signal molecules.','PLA2G1B','16359.535','DB00795','>lcl|BSEQ0019512|Phospholipase A2 (PLA2G1B)\nATGAAACTCCTTGTGCTAGCTGTGCTGCTCACAGTGGCCGCCGCCGACAGCGGCATCAGC\nCCTCGGGCCGTGTGGCAGTTCCGCAAAATGATCAAGTGCGTGATCCCGGGGAGTGACCCC\nTTCTTGGAATACAACAACTACGGCTGCTACTGTGGCTTGGGGGGCTCAGGCACCCCCGTG\nGATGAACTGGACAAGTGCTGCCAGACACATGACAACTGCTATGACCAGGCCAAGAAGCTG\nGACAGCTGTAAATTTCTGCTGGACAACCCGTACACCCACACCTATTCATACTCGTGCTCT\nGGCTCGGCAATCACCTGTAGCAGCAAAAACAAAGAGTGTGAGGCCTTCATTTGCAACTGC\nGACCGCAACGCTGCCATCTGCTTTTCAAAAGCTCCATATAACAAGGCACACAAGAACCTG\nGACACCAAGAAGTATTGTCAGAGTTGA'),('Phospholipase A2, membrane associated','None','Human','Phospholipid binding','Thought to participate in the regulation of the phospholipid metabolism in biomembranes including eicosanoid biosynthesis. Catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides.','PLA2G2A','16082.525','DB00586','>lcl|BSEQ0016510|Phospholipase A2, membrane associated (PLA2G2A)\nATGAAGACCCTCCTACTGTTGGCAGTGATCATGATCTTTGGCCTACTGCAGGCCCATGGG\nAATTTGGTGAATTTCCACAGAATGATCAAGTTGACGACAGGAAAGGAAGCCGCACTCAGT\nTATGGCTTCTACGGCTGCCACTGTGGCGTGGGTGGCAGAGGATCCCCCAAGGATGCAACG\nGATCGCTGCTGTGTCACTCATGACTGTTGCTACAAACGTCTGGAGAAACGTGGATGTGGC\nACCAAATTTCTGAGCTACAAGTTTAGCAACTCGGGGAGCAGAATCACCTGTGCAAAACAG\nGACTCCTGCAGAAGTCAACTGTGTGAGTGTGATAAGGCTGCTGCCACCTGTTTTGCTAGA\nAACAAGACGACCTACAATAAAAAGTACCAGTACTATTCCAATAAACACTGCAGAGGGAGC\nACCCCTCGTTGCTGA'),('Phospholipase D1','None','Human','Phospholipase d activity','Implicated as a critical step in numerous cellular pathways, including signal transduction, membrane trafficking, and the regulation of mitosis. May be involved in the regulation of perinuclear intravesicular membrane traffic (By similarity).','PLD1','124183.135','DB00122','>lcl|BSEQ0004279|3225 bp\nATGTCACTGAAAAACGAGCCACGGGTAAATACCTCTGCACTGCAGAAAATTGCTGCTGAC\nATGAGTAATATCATAGAAAATCTGGACACGCGGGAACTCCACTTTGAGGGAGAGGAGGTA\nGACTACGACGTGTCTCCCAGCGATCCCAAGATACAAGAAGTGTATATCCCTTTCTCTGCT\nATTTATAACACTCAAGGATTTAAGGAGCCTAATATACAGACGTATCTCTCCGGCTGTCCA\nATAAAAGCACAAGTTCTGGAAGTGGAACGCTTCACATCTACAACAAGGGTACCAAGTATT\nAATCTTTACACTATTGAATTAACACATGGGGAATTTAAATGGCAAGTTAAGAGGAAATTC\nAAGCATTTTCAAGAATTTCACAGAGAGCTGCTCAAGTACAAAGCCTTTATCCGCATCCCC\nATTCCCACTAGAAGACACACGTTTAGGAGGCAAAACGTCAGAGAGGAGCCTCGAGAGATG\nCCCAGTTTGCCCCGTTCATCTGAAAACATGATAAGAGAAGAACAATTCCTTGGTAGAAGA\nAAACAACTGGAAGATTACTTGACAAAGATACTAAAAATGCCCATGTATAGAAACTATCAT\nGCCACAACAGAGTTTCTTGATATAAGCCAGCTGTCTTTCATCCATGATTTGGGACCAAAG\nGGCATAGAAGGTATGATAATGAAAAGATCTGGAGGACACAGAATACCAGGCTTGAATTGC\nTGTGGTCAGGGAAGAGCCTGCTACAGATGGTCAAAAAGATGGTTAATAGTGAAAGATTCC\nTTTTTATTGTATATGAAACCAGACAGCGGTGCCATTGCCTTCGTCCTGCTGGTAGACAAA\nGAATTCAAAATTAAGGTGGGGAAGAAGGAGACAGAAACGAAATATGGAATCCGAATTGAT\nAATCTTTCAAGGACACTTATTTTAAAATGCAACAGCTATAGACATGCTCGGTGGTGGGGA\nGGGGCTATAGAAGAATTCATCCAGAAACATGGCACCAACTTTCTCAAAGATCATCGATTT\nGGGTCATATGCTGCTATCCAAGAGAATGCTTTAGCTAAATGGTATGTTAATGCCAAAGGA\nTATTTTGAAGATGTGGCAAATGCAATGGAAGAGGCAAATGAAGAGATTTTTATCACAGAC\nTGGTGGCTGAGTCCAGAAATCTTCCTGAAACGCCCAGTGGTTGAGGGAAATCGTTGGAGG\nTTGGACTGCATTCTTAAACGAAAAGCACAACAAGGAGTGAGGATCTTCATAATGCTCTAC\nAAAGAGGTGGAACTCGCTCTTGGCATCAATAGTGAATACACCAAGAGGACTTTGATGCGT\nCTACATCCCAACATAAAGGTGATGAGACACCCGGATCATGTGTCATCCACCGTCTATTTG\nTGGGCTCACCATGAGAAGCTTGTCATCATTGACCAATCGGTGGCCTTTGTGGGAGGGATT\nGACCTGGCCTATGGAAGGTGGGACGACAATGAGCACAGACTCACAGACGTGGGCAGTGTG\nAAGCGGGTCACTTCAGGACCGTCTCTGGGTTCCCTCCCACCTGCCGCAATGGAGTCTATG\nGAATCCTTAAGACTCAAAGATAAAAATGAGCCTGTTCAAAACCTACCCATCCAGAAGAGT\nATTGATGATGTGGATTCAAAACTGAAAGGAATAGGAAAGCCAAGAAAGTTCTCCAAATTT\nAGTCTCTACAAGCAGCTCCACAGGCACCACCTGCACGACGCAGATAGCATCAGCAGCATT\nGACAGCACCTCCAGTTATTTTAATCACTATAGAAGTCATCACAATTTAATCCATGGTTTA\nAAACCCCACTTCAAACTCTTTCACCCGTCCAGTGAGTCTGAGCAAGGACTCACTAGACCT\nCATGCTGATACCGGGTCCATCCGTAGTTTACAGACAGGTGTGGGAGAGCTGCATGGGGAA\nACCAGATTCTGGCATGGAAAGGACTACTGCAATTTCGTCTTCAAAGACTGGGTTCAACTT\nGATAAACCTTTTGCTGATTTCATTGACAGGTACTCCACGCCCCGGATGCCCTGGCATGAC\nATTGCCTCTGCAGTCCACGGGAAGGCGGCTCGTGATGTGGCACGTCACTTCATCCAGCGC\nTGGAACTTCACAAAAATTATGAAATCAAAATATCGGTCCCTTTCTTATCCTTTTCTGCTT\nCCAAAGTCTCAAACAACAGCCCATGAGTTGAGATATCAAGTGCCTGGGTCTGTCCATGCT\nAACGTACAGTTGCTCCGCTCTGCTGCTGATTGGTCTGCTGGTATAAAGTACCATGAAGAG\nTCCATCCACGCCGCTTACGTCCATGTGATAGAGAACAGCAGGCACTATATCTATATCGAA\nAACCAGTTTTTCATAAGCTGTGCTGATGACAAAGTTGTGTTCAACAAGATAGGCGATGCC\nATTGCCCAGAGGATCCTGAAAGCTCACAGGGAAAACCAGAAATACCGGGTATATGTCGTG\nATACCACTTCTGCCAGGGTTCGAAGGAGACATTTCAACCGGCGGAGGAAATGCTCTACAG\nGCAATCATGCACTTCAACTACAGAACCATGTGCAGAGGAGAAAATTCCATCCTTGGACAG\nTTAAAAGCAGAGCTTGGTAATCAGTGGATAAATTACATATCATTCTGTGGTCTTAGAACA\nCATGCAGAGCTCGAAGGAAACCTAGTAACTGAGCTTATCTATGTCCACAGCAAGTTGTTA\nATTGCTGATGATAACACTGTTATTATTGGCTCTGCCAACATAAATGACCGCAGCATGCTG\nGGAAAGCGTGACAGTGAAATGGCTGTCATTGTGCAAGATACAGAGACTGTTCCTTCAGTA\nATGGATGGAAAAGAGTACCAAGCTGGCCGGTTTGCCCGAGGACTTCGGCTACAGTGCTTT\nAGGGTTGTCCTTGGCTATCTTGATGACCCAAGTGAGGACATTCAGGATCCAGTGAGTGAC\nAAATTCTTCAAGGAGGTGTGGGTTTCAACAGCAGCTCGAAATGCTACAATTTATGACAAG\nGTTTTCCGGTGCCTTCCCAATGATGAAGTACACAATTTAATTCAGCTGAGAGACTTTATA\nAACAAGCCCGTATTAGCTAAGGAAGATCCCATTCGAGCTGAGGAGGAACTGAAGAAGATC\nCGTGGATTTTTGGTGCAATTCCCCTTTTATTTCTTGTCTGAAGAAAGCCTACTGCCTTCT\nGTTGGGACCAAAGAGGCCATAGTGCCCATGGAGGTTTGGACTTAA'),('Phospholipase D2','None','Human','Phospholipase d activity','May have a role in signal-induced cytoskeletal regulation and/or endocytosis.','PLD2','105986.1','DB00122','>lcl|BSEQ0011575|Phospholipase D2 (PLD2)\nATGACGGCGACCCCTGAGAGCCTCTTCCCCACTGGGGACGAACTGGACTCCAGCCAGCTC\nCAGATGGAGTCCGATGAGGTGGACACCCTGAAGGAGGGAGAGGACCCAGCCGACCGGATG\nCACCCGTTTCTGGCCATCTATGAGCTTCAGTCTCTGAAAGTGCACCCCTTGGTGTTCGCA\nCCTGGGGTCCCTGTCACAGCCCAGGTGGTGGGCACCGAAAGATATACCAGCGGATCCAAG\nGTGGGAACCTGCACTCTGTATTCTGTCCGCTTGACTCACGGCGACTTTTCCTGGACAACC\nAAGAAGAAATACCGTCATTTTCAGGAGCTGCATCGGGACCTCCTGAGACACAAAGTCTTG\nATGAGTCTGCTCCCTCTGGCTCGATTTGCCGTTGCCTATTCTCCAGCCCGAGATGCAGGC\nAACAGAGAGATGCCCTCTCTACCCCGGGCAGGTCCTGAGGGCTCCACCAGACATGCAGCC\nAGCAAACAGAAATACCTGGAGAATTACCTCAACCGTCTCTTGACCATGTCTTTCTATCGC\nAACTACCATGCCATGACAGAGTTCCTGGAAGTCAGTCAGCTGTCCTTTATCCCGGACTTG\nGGCCGCAAAGGACTGGAGGGGATGATCCGGAAGCGCTCAGGTGGCCACCGTGTTCCTGGC\nCTCACCTGCTGTGGCCGAGACCAAGTTTGTTATCGCTGGTCCAAGAGGTGGCTGGTGGTG\nAAGGACTCCTTCCTGCTGTACATGTGCCTCGAGACAGGTGCCATCTCATTTGTTCAGCTC\nTTTGACCCTGGCTTTGAGGTGCAAGTGGGGAAAAGGAGCACGGAGGCACGGCACGGCGTG\nCGGATCGATACCTCCCACAGGTCCTTGATTCTCAAGTGCAGCAGCTACCGGCAGGCACGG\nTGGTGGGCCCAAGAGATCACTGAGCTGGCACAGGGCCCAGGCAGAGACTTCCTACAGCTG\nCACCGGCATGACAGCTACGCCCCACCCCGGCCTGGGACCTTGGCCCGGTGGTTTGTGAAT\nGGGGCAGGTTACTTTGCTGCTGTGGCAGATGCCATCCTTCGAGCTCAAGAGGAGATTTTC\nATCACAGACTGGTGGTTGAGTCCTGAGGTTTACCTGAAGCGTCCGGCCCATTCAGATGAC\nTGGAGACTGGACATTATGCTCAAGAGGAAGGCGGAGGAGGGTGTCCGTGTGTCTATTCTG\nCTGTTTAAAGAAGTGGAATTGGCCTTGGGCATCAACAGTGGCTATAGCAAGAGGGCGCTG\nATGCTGCTGCACCCCAACATAAAGGTGATGCGTCACCCAGACCAAGTGACGTTGTGGGCC\nCATCATGAGAAGCTCCTGGTGGTGGACCAAGTGGTAGCATTCCTGGGGGGACTGGACCTT\nGCCTATGGCCGCTGGGATGACCTGCACTACCGACTGACTGACCTTGGAGACTCCTCTGAA\nTCAGCTGCCTCCCAGCCTCCCACCCCGCGCCCAGACTCACCAGCCACCCCAGACCTCTCT\nCACAACCAATTCTTCTGGCTGGGCAAGGACTACAGCAATCTTATCACCAAGGACTGGGTG\nCAGCTGGACCGGCCTTTCGAAGATTTCATTGACAGGGAGACGACCCCTCGGATGCCATGG\nCGGGACGTTGGGGTGGTCGTCCATGGCCTACCGGCCCGGGACCTTGCCCGGCACTTCATC\nCAGCGCTGGAACTTCACCAAGACCACCAAGGCCAAGTACAAGACTCCCACATACCCCTAC\nCTGCTTCCCAAGTCTACCAGCACGGCCAATCAGCTCCCCTTCACACTTCCAGGAGGGCAG\nTGCACCACCGTACAGGTCTTGCGATCAGTGGACCGCTGGTCAGCAGGGACTCTGGAGAAC\nTCCATCCTCAATGCCTACCTGCACACCATCAGGGAGAGCCAGCACTTCCTCTACATTGAG\nAATCAGTTCTTCATTAGCTGCTCAGATGGGCGGACGGTTCTGAACAAGGTGGGCGATGAG\nATTGTGGACAGAATCCTGAAGGCCCACAAACAGGGGTGGTGTTACCGAGTCTACGTGCTT\nTTGCCCTTACTCCCTGGCTTCGAGGGTGACATCTCCACGGGCGGTGGCAACTCCATCCAG\nGCCATTCTGCACTTTACTTACAGGACCCTGTGTCGTGGGGAGTATTCAATCCTGCATCGC\nCTTAAAGCAGCCATGGGGACAGCATGGCGGGACTATATTTCCATCTGCGGGCTTCGTACA\nCACGGAGAGCTGGGCGGGCACCCCGTCTCGGAGCTCATCTACATCCACAGCAAGGTGCTC\nATCGCAGATGACCGGACAGTCATCATTGGTTCTGCAAACATCAATGACCGGAGCTTGCTG\nGGGAAGCGGGACAGTGAGCTGGCCGTGCTGATCGAGGACACAGAGACGGAACCATCCCTC\nATGAATGGGGCAGAGTATCAGGCGGGCAGTGTGATTCTTGGAGCAAATACCCGGCCAGAC\nTTGGATCTCCGAGACCCCATCTGTGATGACTTCTTCCAGTTGTGGCAAGACATGGCTGAG\nAGCAACGCCAATATCTATGAGCAGATCTTCCGCTGCCTGCCATCCAATGCCACGCGTTCC\nCTGCGGACTCTCCGGGAGTACGTGGCCGTGGAGCCCTTGGCCACGGTCAGTCCCCCCTTG\nGCTCGGTCTGAGCTCACCCAGGTCCAGGGCCACCTGGTCCACTTCCCCCTCAAGTTCCTA\nGAGGATGAGTCTTTGCTGCCCCCGCTGGGTAGCAAGGAGGGCATGATCCCCCTAGAAGTG\nTGGACATAG'),('Platelet glycoprotein IX','None','Human','None','The GPIb-V-IX complex functions as the vWF receptor and mediates vWF-dependent platelet adhesion to blood vessels. The adhesion of platelets to injured vascular surfaces in the arterial circulation is a critical initiating event in hemostasis. GP-IX may provide for membrane insertion and orientation of GP-Ib.','GP9','19045.87','DB00468','>lcl|BSEQ0016234|Platelet glycoprotein IX (GP9)\nATGCCTGCCTGGGGAGCCCTGTTCCTGCTCTGGGCCACAGCAGAGGCCACCAAGGACTGC\nCCCAGCCCATGTACCTGCCGCGCCCTGGAAACCATGGGGCTGTGGGTGGACTGCAGGGGC\nCACGGACTCACGGCCCTGCCTGCCCTGCCGGCCCGCACCCGCCACCTTCTGCTGGCCAAC\nAACAGCCTTCAGTCCGTGCCCCCGGGAGCCTTTGACCACCTGCCCCAGCTGCAGACCCTC\nGATGTGACGCAGAACCCCTGGCACTGTGACTGCAGCCTCACCTATCTGCGCCTCTGGCTG\nGAGGACCGCACGCCCGAGGCCCTGCTGCAGGTCCGCTGTGCCAGCCCCAGCCTCGCTGCC\nCATGGCCCGCTGGGCCGGCTGACAGGCTACCAGCTGGGCAGCTGTGGCTGGCAGCTGCAG\nGCGTCCTGGGTGCGCCCGGGGGTCTTGTGGGACGTGGCGCTGGTCGCCGTGGCCGCGCTG\nGGCCTGGCTCTTCTGGCTGGCCTGCTGTGTGCCACCACAGAGGCCCTGGATTGA'),('Potassium voltage-gated channel subfamily A member 1','None','Human','Voltage-gated potassium channel activity','Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain and the central nervous system, but also in the kidney (PubMed:19903818). Contributes to the regulation of the membrane potential and nerve signaling, and prevents neuronal hyperexcitability (PubMed:17156368). Forms tetrameric potassium-selective channels through which potassium ions pass in accordance with their electrochemical gradient. The channel alternates between opened and closed conformations in response to the voltage difference across the membrane (PubMed:19912772). Can form functional homotetrameric channels and heterotetrameric channels that contain variable proportions of KCNA1, KCNA2, KCNA4, KCNA5, KCNA6, KCNA7, and possibly other family members as well; channel properties depend on the type of alpha subunits that are part of the channel (PubMed:12077175, PubMed:17156368). Channel properties are modulated by cytoplasmic beta subunits that regulate the subcellular location of the alpha subunits and promote rapid inactivation of delayed rectifier potassium channels (PubMed:12077175, PubMed:17156368). In vivo, membranes probably contain a mixture of heteromeric potassium channel complexes, making it difficult to assign currents observed in intact tissues to any particular potassium channel family member. Homotetrameric KCNA1 forms a delayed-rectifier potassium channel that opens in response to membrane depolarization, followed by slow spontaneous channel closure (PubMed:19912772, PubMed:19968958, PubMed:19307729, PubMed:19903818). In contrast, a heterotetrameric channel formed by KCNA1 and KCNA4 shows rapid inactivation (PubMed:17156368). Regulates neuronal excitability in hippocampus, especially in mossy fibers and medial perforant path axons, preventing neuronal hyperexcitability. Response to toxins that are selective for KCNA1, respectively for KCNA2, suggests that heteromeric potassium channels composed of both KCNA1 and KCNA2 play a role in pacemaking and regulate the output of deep cerebellar nuclear neurons (By similarity). May function as down-stream effector for G protein-coupled receptors and inhibit GABAergic inputs to basolateral amygdala neurons (By similarity). May contribute to the regulation of neurotransmitter release, such as gamma-aminobutyric acid (GABA) release (By similarity). Plays a role in regulating the generation of action potentials and preventing hyperexcitability in myelinated axons of the vagus nerve, and thereby contributes to the regulation of heart contraction (By similarity). Required for normal neuromuscular responses (PubMed:11026449, PubMed:17136396). Regulates the frequency of neuronal action potential firing in response to mechanical stimuli, and plays a role in the perception of pain caused by mechanical stimuli, but does not play a role in the perception of pain due to heat stimuli (By similarity). Required for normal responses to auditory stimuli and precise location of sound sources, but not for sound perception (By similarity). The use of toxins that block specific channels suggest that it contributes to the regulation of the axonal release of the neurotransmitter dopamine (By similarity). Required for normal postnatal brain development and normal proliferation of neuronal precursor cells in the brain (By similarity). Plays a role in the reabsorption of Mg(2+) in the distal convoluted tubules in the kidney and in magnesium ion homeostasis, probably via its effect on the membrane potential (PubMed:23903368, PubMed:19307729).','KCNA1','56465.01','DB01028','>lcl|BSEQ0019012|Potassium voltage-gated channel subfamily A member 1 (KCNA1)\nATGACGGTGATGTCTGGGGAGAACGTGGACGAGGCTTCGGCCGCCCCGGGCCACCCCCAG\nGATGGCAGCTACCCCCGGCAGGCCGACCACGACGACCACGAGTGCTGCGAGCGCGTGGTG\nATCAACATCTCCGGGCTGCGCTTCGAGACGCAGCTCAAGACCCTGGCGCAGTTCCCCAAC\nACGCTGCTGGGCAACCCTAAGAAACGCATGCGCTACTTCGACCCCCTGAGGAACGAGTAC\nTTCTTCGACCGCAACCGGCCCAGCTTCGACGCCATCCTCTACTACTACCAGTCCGGCGGC\nCGCCTGCGGAGGCCGGTCAACGTGCCCCTGGACATGTTCTCCGAGGAGATCAAGTTTTAC\nGAGTTGGGCGAGGAGGCCATGGAGAAGTTCCGGGAGGACGAGGGCTTCATCAAGGAGGAG\nGAGCGCCCTCTGCCCGAGAAGGAGTACCAGCGCCAGGTGTGGCTGCTCTTCGAGTACCCC\nGAGAGCTCGGGGCCCGCCAGGGTCATCGCCATCGTCTCCGTCATGGTCATCCTCATCTCC\nATCGTCATCTTTTGCCTGGAGACGCTCCCCGAGCTGAAGGATGACAAGGACTTCACGGGC\nACCGTCCACCGCATCGACAACACCACGGTCATCTACAATTCCAACATCTTCACAGACCCC\nTTCTTCATCGTGGAAACGCTGTGTATCATCTGGTTCTCCTTCGAGCTGGTGGTGCGCTTC\nTTCGCCTGCCCCAGCAAGACGGACTTCTTCAAAAACATCATGAACTTCATAGACATTGTG\nGCCATCATTCCTTATTTCATCACGCTGGGCACCGAGATAGCTGAGCAGGAAGGAAACCAG\nAAGGGCGAGCAGGCCACCTCCCTGGCCATCCTCAGGGTCATCCGCTTGGTAAGGGTTTTT\nAGAATCTTCAAGCTCTCCCGCCACTCTAAGGGCCTCCAGATCCTGGGCCAGACCCTCAAA\nGCTAGTATGAGAGAGCTAGGGCTGCTCATCTTTTTCCTCTTCATCGGGGTCATCCTGTTT\nTCTAGTGCAGTGTACTTTGCCGAGGCGGAAGAAGCTGAGTCGCACTTCTCCAGTATCCCC\nGATGCTTTCTGGTGGGCGGTGGTGTCCATGACCACTGTAGGATACGGTGACATGTACCCT\nGTGACAATTGGAGGCAAGATCGTGGGCTCCTTGTGTGCCATCGCTGGTGTGCTAACAATT\nGCCCTGCCCGTACCTGTCATTGTGTCCAATTTCAACTATTTCTACCACCGAGAAACTGAG\nGGGGAAGAGCAGGCTCAGTTGCTCCACGTCAGTTCCCCTAACTTAGCCTCTGACAGTGAC\nCTCAGTCGCCGCAGTTCCTCTACTATGAGCAAGTCTGAGTACATGGAGATCGAAGAGGAT\nATGAATAATAGCATAGCCCATTATAGACAGGTCAATATCAGAACTGCCAATTGCACCACT\nGCTAACCAAAACTGCGTTAATAAGAGCAAGCTACTGACCGATGTTTAA'),('Potassium voltage-gated channel subfamily D member 2','None','Human','Voltage-gated potassium channel activity','Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain. Mediates the major part of the dendritic A-type current I(SA) in brain neurons (By similarity). This current is activated at membrane potentials that are below the threshold for action potentials. It regulates neuronal excitability, prolongs the latency before the first spike in a series of action potentials, regulates the frequency of repetitive action potential firing, shortens the duration of action potentials and regulates the back-propagation of action potentials from the neuronal cell body to the dendrites. Contributes to the regulation of the circadian rhytm of action potential firing in suprachiasmatic nucleus neurons, which regulates the circadian rhythm of locomotor activity (By similarity). Functions downstream of the metabotropic glutamate receptor GRM5 and plays a role in neuronal excitability and in nociception mediated by activation of GRM5 (By similarity). Mediates the transient outward current I(to) in rodent heart left ventricle apex cells, but not in human heart, where this current is mediated by another family member. Forms tetrameric potassium-selective channels through which potassium ions pass in accordance with their electrochemical gradient (PubMed:10551270, PubMed:15454437, PubMed:14695263, PubMed:14623880, PubMed:14980201, PubMed:16934482, PubMed:24811166, PubMed:24501278). The channel alternates between opened and closed conformations in response to the voltage difference across the membrane (PubMed:11507158). Can form functional homotetrameric channels and heterotetrameric channels that contain variable proportions of KCND2 and KCND3; channel properties depend on the type of pore-forming alpha subunits that are part of the channel. In vivo, membranes probably contain a mixture of heteromeric potassium channel complexes. Interaction with specific isoforms of the regulatory subunits KCNIP1, KCNIP2, KCNIP3 or KCNIP4 strongly increases expression at the cell surface and thereby increases channel activity; it modulates the kinetics of channel activation and inactivation, shifts the threshold for channel activation to more negative voltage values, shifts the threshold for inactivation to less negative voltages and accelerates recovery after inactivation (PubMed:15454437, PubMed:14623880, PubMed:14980201, PubMed:19171772, PubMed:24501278, PubMed:24811166). Likewise, interaction with DPP6 or DPP10 promotes expression at the cell membrane and regulates both channel characteristics and activity (By similarity).','KCND2','70535.825','DB00321','>lcl|BSEQ0019444|Potassium voltage-gated channel subfamily D member 2 (KCND2)\nATGGCGGCGGGGGTGGCAGCGTGGCTGCCTTTTGCAAGGGCAGCGGCTATCGGGTGGATG\nCCTGTGGCCTCGGGGCCTATGCCGGCTCCCCCGAGGCAGGAGAGGAAAAGGACCCAAGAT\nGCTCTCATTGTGCTGAATGTGAGTGGCACCCGCTTCCAGACGTGGCAGGACACCCTGGAA\nCGTTACCCAGACACTCTACTGGGCAGTTCTGAGAGGGACTTTTTCTACCACCCAGAAACT\nCAGCAGTATTTCTTTGACCGTGACCCAGACATCTTCCGCCACATCCTGAATTTCTACCGC\nACTGGGAAGCTCCACTATCCTCGCCACGAGTGCATCTCTGCTTACGATGAAGAACTGGCC\nTTCTTTGGCCTCATCCCGGAAATCATCGGCGACTGCTGTTATGAGGAGTACAAGGATCGC\nAGGCGAGAGAACGCCGAGCGCCTGCAGGACGACGCGGATACCGACACCGCTGGGGAGAGC\nGCCTTGCCCACCATGACTGCAAGGCAGAGGGTCTGGAGGGCCTTCGAGAACCCCCACACC\nAGCACGATGGCCCTGGTGTTCTACTATGTCACGGGGTTTTTCATTGCCGTCTCTGTCATC\nGCGAATGTGGTGGAAACAGTGCCGTGCGGATCAAGCCCAGGTCACATTAAAGAACTGCCC\nTGTGGAGAGCGGTATGCTGTGGCCTTCTTCTGCTTGGACACGGCCTGCGTCATGATCTTC\nACAGTTGAGTATTTGCTTCGCCTGGCTGCAGCGCCTAGTCGTTACCGTTTTGTGCGTAGT\nGTCATGAGTATCATCGACGTGGTGGCCATCCTGCCTTATTACATTGGGCTGGTGATGACA\nGACAATGAGGACGTCAGCGGAGCCTTTGTCACACTCCGAGTCTTCCGGGTCTTCAGGATC\nTTTAAGTTTTCCCGCCACTCTCAAGGCCTGCGCATCCTGGGGTACACACTGAAGAGTTGT\nGCCTCAGAATTGGGCTTCTTGCTTTTCTCGCTCACCATGGCTATCATCATCTTCGCTACA\nGTTATGTTCTACGCAGAGAAGGGGTCTTCGGCTAGCAAGTTCACCAGCATCCCTGCAGCC\nTTCTGGTATACCATCGTCACCATGACAACACTAGGGTATGGTGACATGGTGCCAAAAACC\nATAGCAGGGAAGATTTTTGGTTCTATCTGTTCGCTGAGTGGGGTCTTGGTCATTGCTCTA\nCCTGTTCCGGTGATTGTATCCAACTTCAGTCGCATCTACCACCAGAATCAACGAGCAGAC\nAAACGAAGGGCACAAAAGAAAGCTAGACTGGCCAGGATCCGGGCAGCCAAAAGCGGAAGC\nGCAAATGCTTACATGCAGAGCAAACGGAATGGTTTACTCAGTAATCAGCTGCAGTCCTCA\nGAGGATGAGCAGGCTTTTGTTAGCAAATCCGGCTCCAGCTTTGAAACCCAGCACCACCAC\nCTGCTTCACTGCCTGGAAAAAACCACGAATCACGAGTTTGTGGACGAACAAGTCTTTGAA\nGAAAGCTGCATGGAAGTTGCAACTGTTAATCGTCCTTCAAGTCACAGTCCTTCACTGTCT\nTCACAACAAGGAGTCACCAGCACCTGCTGTTCACGACGACACAAAAAAACTTTTCGCATC\nCCAAATGCCAATGTATCAGGAAGCCATCAAGGTAGTATACAAGAACTCAGCACGATTCAG\nATCAGATGTGTGGAGAGAACACCTCTGTCTAACAGCCGATCCAGTTTAAATGCCAAAATG\nGAAGAGTGTGTTAAACTAAACTGTGAACAACCTTATGTGACTACAGCAATAATAAGCATC\nCCAACACCTCCAGTAACCACACCAGAAGGAGACGATAGGCCAGAATCCCCTGAGTACTCA\nGGAGGAAATATTGTCAGAGTTTCTGCTTTGTAA'),('Potassium voltage-gated channel subfamily D member 3','None','Human','Metal ion binding','Pore-forming (alpha) subunit of voltage-gated rapidly inactivating A-type potassium channels. May contribute to I(To) current in heart and I(Sa) current in neurons. Channel properties are modulated by interactions with other alpha subunits and with regulatory subunits.','KCND3','73450.53','DB00321','>lcl|BSEQ0012506|Potassium voltage-gated channel subfamily D member 3 (KCND3)\nATGGCGGCCGGAGTTGCGGCCTGGCTGCCTTTTGCCCGGGCTGCGGCCATCGGGTGGATG\nCCGGTGGCCAACTGCCCCATGCCCCTGGCCCCGGCCGACAAGAACAAGCGGCAGGATGAG\nCTGATTGTCCTCAACGTGAGTGGGCGGAGGTTCCAGACCTGGAGGACCACGCTGGAGCGC\nTACCCGGACACCCTGCTGGGCAGCACGGAGAAGGAGTTCTTCTTCAACGAGGACACCAAG\nGAGTACTTCTTCGACCGGGACCCCGAGGTGTTCCGCTGCGTGCTCAACTTCTACCGCACG\nGGGAAGCTGCACTACCCGCGCTACGAGTGCATCTCTGCCTACGACGACGAGCTGGCCTTC\nTACGGCATCCTCCCGGAGATCATCGGGGACTGCTGCTACGAGGAGTACAAGGACCGCAAG\nAGGGAGAACGCCGAGCGGCTCATGGACGACAACGACTCGGAGAACAACCAGGAGTCCATG\nCCCTCGCTCAGCTTCCGCCAGACCATGTGGCGGGCCTTCGAGAACCCCCACACCAGCACG\nCTGGCCCTGGTCTTCTACTACGTGACTGGCTTCTTCATCGCTGTCTCGGTCATCACCAAC\nGTGGTGGAGACGGTGCCGTGCGGCACGGTCCCGGGCAGCAAGGAGCTGCCGTGCGGGGAG\nCGCTACTCGGTGGCCTTCTTCTGCCTGGACACGGCGTGCGTCATGATCTTCACCGTGGAG\nTACCTCCTGCGGCTCTTCGCGGCTCCCAGCCGCTACCGCTTCATCCGCAGCGTCATGAGC\nATCATCGACGTGGTGGCCATCATGCCCTACTACATCGGTCTGGTCATGACCAACAACGAG\nGACGTGTCCGGCGCCTTCGTCACGCTCCGGGTCTTCCGCGTCTTCAGGATCTTCAAGTTT\nTCCCGCCACTCCCAGGGCCTGCGGATCCTGGGCTACACACTGAAGAGCTGTGCCTCCGAA\nCTGGGCTTTCTTCTCTTCTCCCTCACCATGGCCATCATCATCTTTGCCACTGTGATGTTT\nTATGCCGAGAAGGGCTCCTCGGCCAGCAAGTTCACAAGCATCCCTGCCTCGTTTTGGTAC\nACCATTGTCACCATGACCACACTGGGATACGGAGACATGGTGCCTAAGACGATTGCAGGG\nAAGATCTTCGGCTCCATCTGCTCCTTGAGTGGCGTCCTGGTCATTGCCCTGCCAGTCCCT\nGTGATTGTTTCCAACTTTAGCCGGATTTACCACCAGAATCAGAGAGCTGATAAACGCAGG\nGCACAAAAGAAGGCCCGCCTTGCCAGGATCCGTGTGGCCAAAACAGGCAGTTCGAATGCA\nTACCTGCACAGCAAGCGCAACGGGCTCCTCAACGAGGCGCTGGAGCTGACGGGCACCCCA\nGAAGAGGAGCACATGGGCAAGACCACCTCACTCATCGAGAGCCAGCATCATCACCTGCTG\nCACTGCCTGGAAAAAACCACTGGGTTGTCCTATCTTGTGGATGATCCCCTGTTATCTGTA\nCGAACCTCCACCATCAAGAACCACGAGTTTATTGATGAGCAGATGTTTGAGCAGAACTGC\nATGGAGAGTTCAATGCAGAACTACCCATCCACAAGAAGTCCCTCACTGTCCAGCCACCCA\nGGCCTCACTACCACCTGCTGCTCCCGTCGTAGTAAGAAGACCACACACCTGCCCAATTCT\nAACCTGCCAGCTACTCGCCTGCGCAGCATGCAAGAGCTCAGCACGATCCACATCCAGGGC\nAGTGAGCAGCCCTCCCTCACAACCAGTCGCTCCAGCCTTAATTTGAAAGCAGACGACGGA\nCTGAGACCAAACTGCAAAACATCCCAGATCACCACAGCCATCATCAGCATCCCCACTCCC\nCCAGCGCTAACCCCAGAGGGGGAAAGTCGGCCACCCCCTGCCAGCCCAGGCCCCAACACG\nAACATTCCTTCCATAGCCAGCAATGTTGTCAAGGTCTCCGCCTTGTAA'),('Potassium voltage-gated channel subfamily H member 2','None','Human','Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization','Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Isoforms USO have no channel activity by themself, but modulates channel characteristics by forming heterotetramers with other isoforms which are retained intracellularly and undergo ubiquitin-dependent degradation.','KCNH2','126653.52','DB01149','>lcl|BSEQ0021259|Potassium voltage-gated channel subfamily H member 2 (KCNH2)\nATGCCGGTGCGGAGGGGCCACGTCGCGCCGCAGAACACCTTCCTGGACACCATCATCCGC\nAAGTTTGAGGGCCAGAGCCGTAAGTTCATCATCGCCAACGCTCGGGTGGAGAACTGCGCC\nGTCATCTACTGCAACGACGGCTTCTGCGAGCTGTGCGGCTACTCGCGGGCCGAGGTGATG\nCAGCGACCCTGCACCTGCGACTTCCTGCACGGGCCGCGCACGCAGCGCCGCGCTGCCGCG\nCAGATCGCGCAGGCACTGCTGGGCGCCGAGGAGCGCAAAGTGGAAATCGCCTTCTACCGG\nAAAGATGGGAGCTGCTTCCTATGTCTGGTGGATGTGGTGCCCGTGAAGAACGAGGATGGG\nGCTGTCATCATGTTCATCCTCAATTTCGAGGTGGTGATGGAGAAGGACATGGTGGGGTCC\nCCGGCTCATGACACCAACCACCGGGGCCCCCCCACCAGCTGGCTGGCCCCAGGCCGCGCC\nAAGACCTTCCGCCTGAAGCTGCCCGCGCTGCTGGCGCTGACGGCCCGGGAGTCGTCGGTG\nCGGTCGGGCGGCGCGGGCGGCGCGGGCGCCCCGGGGGCCGTGGTGGTGGACGTGGACCTG\nACGCCCGCGGCACCCAGCAGCGAGTCGCTGGCCCTGGACGAAGTGACAGCCATGGACAAC\nCACGTGGCAGGGCTCGGGCCCGCGGAGGAGCGGCGTGCGCTGGTGGGTCCCGGCTCTCCG\nCCCCGCAGCGCGCCCGGCCAGCTCCCATCGCCCCGGGCGCACAGCCTCAACCCCGACGCC\nTCGGGCTCCAGCTGCAGCCTGGCCCGGACGCGCTCCCGAGAAAGCTGCGCCAGCGTGCGC\nCGCGCCTCGTCGGCCGACGACATCGAGGCCATGCGCGCCGGGGTGCTGCCCCCGCCACCG\nCGCCACGCCAGCACCGGGGCCATGCACCCACTGCGCAGCGGCTTGCTCAACTCCACCTCG\nGACTCCGACCTCGTGCGCTACCGCACCATTAGCAAGATTCCCCAAATCACCCTCAACTTT\nGTGGACCTCAAGGGCGACCCCTTCTTGGCTTCGCCCACCAGTGACCGTGAGATCATAGCA\nCCTAAGATAAAGGAGCGAACCCACAATGTCACTGAGAAGGTCACCCAGGTCCTGTCCCTG\nGGCGCCGACGTGCTGCCTGAGTACAAGCTGCAGGCACCGCGCATCCACCGCTGGACCATC\nCTGCATTACAGCCCCTTCAAGGCCGTGTGGGACTGGCTCATCCTGCTGCTGGTCATCTAC\nACGGCTGTCTTCACACCCTACTCGGCTGCCTTCCTGCTGAAGGAGACGGAAGAAGGCCCG\nCCTGCTACCGAGTGTGGCTACGCCTGCCAGCCGCTGGCTGTGGTGGACCTCATCGTGGAC\nATCATGTTCATTGTGGACATCCTCATCAACTTCCGCACCACCTACGTCAATGCCAACGAG\nGAGGTGGTCAGCCACCCCGGCCGCATCGCCGTCCACTACTTCAAGGGCTGGTTCCTCATC\nGACATGGTGGCCGCCATCCCCTTCGACCTGCTCATCTTCGGCTCTGGCTCTGAGGAGCTG\nATCGGGCTGCTGAAGACTGCGCGGCTGCTGCGGCTGGTGCGCGTGGCGCGGAAGCTGGAT\nCGCTACTCAGAGTACGGCGCGGCCGTGCTGTTCTTGCTCATGTGCACCTTTGCGCTCATC\nGCGCACTGGCTAGCCTGCATCTGGTACGCCATCGGCAACATGGAGCAGCCACACATGGAC\nTCACGCATCGGCTGGCTGCACAACCTGGGCGACCAGATAGGCAAACCCTACAACAGCAGC\nGGCCTGGGCGGCCCCTCCATCAAGGACAAGTATGTGACGGCGCTCTACTTCACCTTCAGC\nAGCCTCACCAGTGTGGGCTTCGGCAACGTCTCTCCCAACACCAACTCAGAGAAGATCTTC\nTCCATCTGCGTCATGCTCATTGGCTCCCTCATGTATGCTAGCATCTTCGGCAACGTGTCG\nGCCATCATCCAGCGGCTGTACTCGGGCACAGCCCGCTACCACACACAGATGCTGCGGGTG\nCGGGAGTTCATCCGCTTCCACCAGATCCCCAATCCCCTGCGCCAGCGCCTCGAGGAGTAC\nTTCCAGCACGCCTGGTCCTACACCAACGGCATCGACATGAACGCGGTGCTGAAGGGCTTC\nCCTGAGTGCCTGCAGGCTGACATCTGCCTGCACCTGAACCGCTCACTGCTGCAGCACTGC\nAAACCCTTCCGAGGGGCCACCAAGGGCTGCCTTCGGGCCCTGGCCATGAAGTTCAAGACC\nACACATGCACCGCCAGGGGACACACTGGTGCATGCTGGGGACCTGCTCACCGCCCTGTAC\nTTCATCTCCCGGGGCTCCATCGAGATCCTGCGGGGCGACGTCGTCGTGGCCATCCTGGGG\nAAGAATGACATCTTTGGGGAGCCTCTGAACCTGTATGCAAGGCCTGGCAAGTCGAACGGG\nGATGTGCGGGCCCTCACCTACTGTGACCTACACAAGATCCATCGGGACGACCTGCTGGAG\nGTGCTGGACATGTACCCTGAGTTCTCCGACCACTTCTGGTCCAGCCTGGAGATCACCTTC\nAACCTGCGAGATACCAACATGATCCCGGGCTCCCCCGGCAGTACGGAGTTAGAGGGTGGC\nTTCAGTCGGCAACGCAAGCGCAAGTTGTCCTTCCGCAGGCGCACGGACAAGGACACGGAG\nCAGCCAGGGGAGGTGTCGGCCTTGGGGCCGGGCCGGGCGGGGGCAGGGCCGAGTAGCCGG\nGGCCGGCCGGGGGGGCCGTGGGGGGAGAGCCCGTCCAGTGGCCCCTCCAGCCCTGAGAGC\nAGTGAGGATGAGGGCCCAGGCCGCAGCTCCAGCCCCCTCCGCCTGGTGCCCTTCTCCAGC\nCCCAGGCCCCCCGGAGAGCCGCCGGGTGGGGAGCCCCTGATGGAGGACTGCGAGAAGAGC\nAGCGACACTTGCAACCCCCTGTCAGGCGCCTTCTCAGGAGTGTCCAACATTTTCAGCTTC\nTGGGGGGACAGTCGGGGCCGCCAGTACCAGGAGCTCCCTCGATGCCCCGCCCCCACCCCC\nAGCCTCCTCAACATCCCCCTCTCCAGCCCGGGTCGGCGGCCCCGGGGCGACGTGGAGAGC\nAGGCTGGATGCCCTCCAGCGCCAGCTCAACAGGCTGGAGACCCGGCTGAGTGCAGACATG\nGCCACTGTCCTGCAGCTGCTACAGAGGCAGATGACGCTGGTCCCGCCCGCCTACAGTGCT\nGTGACCACCCCGGGGCCTGGCCCCACTTCCACATCCCCGCTGTTGCCCGTCAGCCCCCTC\nCCCACCCTCACCTTGGACTCGCTTTCTCAGGTTTCCCAGTTCATGGCGTGTGAGGAGCTG\nCCCCCGGGGGCCCCAGAGCTTCCCCAAGAAGGCCCCACACGACGCCTCTCCCTACCGGGC\nCAGCTGGGGGCCCTCACCTCCCAGCCCCTGCACAGACACGGCTCGGACCCGGGCAGTTAG'),('Potassium voltage-gated channel subfamily KQT member 2','None','Human','Voltage-gated potassium channel activity','Probably important in the regulation of neuronal excitability. Associates with KCNQ3 to form a potassium channel with essentially identical properties to the channel underlying the native M-current, a slowly activating and deactivating potassium conductance which plays a critical role in determining the subthreshold electrical excitability of neurons as well as the responsiveness to synaptic inputs. KCNQ2/KCNQ3 current is blocked by linopirdine and XE991, and activated by the anticonvulsant retigabine. Muscarinic agonist oxotremorine-M strongly suppress KCNQ2/KCNQ3 current in cells in which cloned KCNQ2/KCNQ3 channels were coexpressed with M1 muscarinic receptors.','KCNQ2','95846.575','DB00321','>lcl|BSEQ0010632|Potassium voltage-gated channel subfamily KQT member 2 (KCNQ2)\nATGGTGCAGAAGTCGCGCAACGGCGGCGTATACCCCGGCCCGAGCGGGGAGAAGAAGCTG\nAAGGTGGGCTTCGTGGGGCTGGACCCCGGCGCGCCCGACTCCACCCGGGACGGGGCGCTG\nCTGATCGCCGGCTCCGAGGCCCCCAAGCGCGGCAGCATCCTCAGCAAACCTCGCGCGGGC\nGGCGCGGGCGCCGGGAAGCCCCCCAAGCGCAACGCCTTCTACCGCAAGCTGCAGAATTTC\nCTCTACAACGTGCTGGAGCGGCCGCGCGGCTGGGCGTTCATCTACCACGCCTACGTGTTC\nCTCCTGGTTTTCTCCTGCCTCGTGCTGTCTGTGTTTTCCACCATCAAGGAGTATGAGAAG\nAGCTCGGAGGGGGCCCTCTACATCCTGGAAATCGTGACTATCGTGGTGTTTGGCGTGGAG\nTACTTCGTGCGGATCTGGGCCGCAGGCTGCTGCTGCCGGTACCGTGGCTGGAGGGGGCGG\nCTCAAGTTTGCCCGGAAACCGTTCTGTGTGATTGACATCATGGTGCTCATCGCCTCCATT\nGCGGTGCTGGCCGCCGGCTCCCAGGGCAACGTCTTTGCCACATCTGCGCTCCGGAGCCTG\nCGCTTCCTGCAGATTCTGCGGATGATCCGCATGGACCGGCGGGGAGGCACCTGGAAGCTG\nCTGGGCTCTGTGGTCTATGCCCACAGCAAGGAGCTGGTCACTGCCTGGTACATCGGCTTC\nCTTTGTCTCATCCTGGCCTCGTTCCTGGTGTACTTGGCAGAGAAGGGGGAGAACGACCAC\nTTTGACACCTACGCGGATGCACTCTGGTGGGGCCTGATCACGCTGACCACCATTGGCTAC\nGGGGACAAGTACCCCCAGACCTGGAACGGCAGGCTCCTTGCGGCAACCTTCACCCTCATC\nGGTGTCTCCTTCTTCGCGCTGCCTGCAGGCATCTTGGGGTCTGGGTTTGCCCTGAAGGTT\nCAGGAGCAGCACAGGCAGAAGCACTTTGAGAAGAGGCGGAACCCGGCAGCAGGCCTGATC\nCAGTCGGCCTGGAGATTCTACGCCACCAACCTCTCGCGCACAGACCTGCACTCCACGTGG\nCAGTACTACGAGCGAACGGTCACCGTGCCCATGTACAGACTTATCCCCCCGCTGAACCAG\nCTGGAGCTGCTGAGGAACCTCAAGAGTAAATCTGGACTCGCTTTCAGGAAGGACCCCCCG\nCCGGAGCCGTCTCCAAGCCAGAAGGTCAGTTTGAAAGATCGTGTCTTCTCCAGCCCCCGA\nGGCGTGGCTGCCAAGGGGAAGGGGTCCCCGCAGGCCCAGACTGTGAGGCGGTCACCCAGC\nGCCGACCAGAGCCTCGAGGACAGCCCCAGCAAGGTGCCCAAGAGCTGGAGCTTCGGGGAC\nCGCAGCCGGGCACGCCAGGCTTTCCGCATCAAGGGTGCCGCGTCACGGCAGAACTCAGAA\nGAAGCAAGCCTCCCCGGAGAGGACATTGTGGATGACAAGAGCTGCCCCTGCGAGTTTGTG\nACCGAGGACCTGACCCCGGGCCTCAAAGTCAGCATCAGAGCCGTGTGTGTCATGCGGTTC\nCTGGTGTCCAAGCGGAAGTTCAAGGAGAGCCTGCGGCCCTACGACGTGATGGACGTCATC\nGAGCAGTACTCAGCCGGCCACCTGGACATGCTGTCCCGAATTAAGAGCCTGCAGTCCAGA\nGTGGACCAGATCGTGGGGCGGGGCCCAGCGATCACGGACAAGGACCGCACCAAGGGCCCG\nGCCGAGGCGGAGCTGCCCGAGGACCCCAGCATGATGGGACGGCTCGGGAAGGTGGAGAAG\nCAGGTCTTGTCCATGGAGAAGAAGCTGGACTTCCTGGTGAATATCTACATGCAGCGGATG\nGGCATCCCCCCGACAGAGACCGAGGCCTACTTTGGGGCCAAAGAGCCGGAGCCGGCGCCG\nCCGTACCACAGCCCGGAAGACAGCCGGGAGCATGTCGACAGGCACGGCTGCATTGTCAAG\nATCGTGCGCTCCAGCAGCTCCACGGGCCAGAAGAACTTCTCGGCGCCCCCGGCCGCGCCC\nCCTGTCCAGTGTCCGCCCTCCACCTCCTGGCAGCCACAGAGCCACCCGCGCCAGGGCCAC\nGGCACCTCCCCCGTGGGGGACCACGGCTCCCTGGTGCGCATCCCGCCGCCGCCTGCCCAC\nGAGCGGTCGCTGTCCGCCTACGGCGGGGGCAACCGCGCCAGCATGGAGTTCCTGCGGCAG\nGAGGACACCCCGGGCTGCAGGCCCCCCGAGGGGAACCTGCGGGACAGCGACACGTCCATC\nTCCATCCCGTCCGTGGACCACGAGGAGCTGGAGCGTTCCTTCAGCGGCTTCAGCATCTCC\nCAGTCCAAGGAGAACCTGGATGCTCTCAACAGCTGCTACGCGGCCGTGGCGCCTTGTGCC\nAAAGTCAGGCCCTACATTGCGGAGGGAGAGTCAGACACCGACTCCGACCTCTGTACCCCG\nTGCGGGCCCCCGCCACGCTCGGCCACCGGCGAGGGTCCCTTTGGTGACGTGGGCTGGGCC\nGGGCCCAGGAAGTGA'),('Potassium voltage-gated channel subfamily KQT member 3','None','Human','Voltage-gated potassium channel activity','Probably important in the regulation of neuronal excitability. Associates with KCNQ2 or KCNQ5 to form a potassium channel with essentially identical properties to the channel underlying the native M-current, a slowly activating and deactivating potassium conductance which plays a critical role in determining the subthreshold electrical excitability of neurons as well as the responsiveness to synaptic inputs.','KCNQ3','96741.515','DB00321','>lcl|BSEQ0016778|Potassium voltage-gated channel subfamily KQT member 3 (KCNQ3)\nATGAAGCCTGCAGAACACGCCACGATGTTCCTGATTGTCCTGGGGTGCTTGATTCTGGCT\nGTCCTGACCACATTCAAGGAGTATGAGACTGTCTCGGGAGACTGGCTTCTGTTACTGGAG\nACATTTGCTATTTTCATCTTTGGAGCCGAGTTTGCTTTGAGGATCTGGGCTGCTGGATGT\nTGCTGCCGATACAAAGGCTGGCGGGGCCGACTGAAGTTTGCCAGGAAGCCCCTGTGCATG\nTTGGACATCTTTGTGCTGATTGCCTCTGTGCCAGTGGTTGCTGTGGGAAACCAAGGCAAT\nGTTCTGGCCACCTCCCTGCGAAGCCTGCGCTTCCTGCAGATCCTGCGCATGCTGCGGATG\nGACCGGAGAGGTGGCACCTGGAAGCTTCTGGGCTCAGCCATCTGTGCCCACAGCAAAGAA\nCTCATCACGGCCTGGTACATCGGTTTCCTGACACTCATCCTTTCTTCATTTCTTGTCTAC\nCTGGTTGAGAAAGACGTCCCAGAGGTGGATGCACAAGGAGAGGAGATGAAAGAGGAGTTT\nGAGACCTATGCAGATGCCCTGTGGTGGGGCCTGATCACACTGGCCACCATTGGCTATGGA\nGACAAGACACCCAAAACGTGGGAAGGCCGTCTGATTGCCGCCACCTTTTCCTTAATTGGC\nGTCTCCTTTTTTGCCCTTCCAGCGGGCATCCTGGGGTCCGGGCTGGCCCTCAAGGTGCAG\nGAGCAACACCGTCAGAAGCACTTTGAGAAAAGGAGGAAGCCAGCTGCTGAGCTCATTCAG\nGCTGCCTGGAGGTATTATGCTACCAACCCCAACAGGATTGACCTGGTGGCGACATGGAGA\nTTTTATGAATCAGTCGTCTCTTTTCCTTTCTTCAGGAAAGAACAGCTGGAGGCAGCATCC\nAGCCAAAAGCTGGGTCTCTTGGATCGGGTTCGCCTTTCTAATCCTCGTGGTAGCAATACT\nAAAGGAAAGCTATTTACCCCTCTGAATGTAGATGCCATAGAAGAAAGTCCTTCTAAAGAA\nCCAAAGCCTGTTGGCTTAAACAATAAAGAGCGTTTCCGCACGGCCTTCCGCATGAAAGCC\nTACGCTTTCTGGCAGAGTTCTGAAGATGCCGGGACAGGTGACCCCATGGCGGAAGACAGG\nGGCTATGGGAATGACTTCCCCATCGAAGACATGATCCCCACCCTGAAGGCCGCCATCCGA\nGCCGTCAGAATTCTACAATTCCGTCTCTATAAAAAAAAATTCAAGGAGACTTTGAGGCCT\nTACGATGTGAAGGATGTGATTGAGCAGTATTCTGCCGGGCATCTCGACATGCTTTCCAGG\nATAAAGTACCTTCAGACGAGAATAGATATGATTTTCACCCCTGGACCTCCCTCCACGCCA\nAAACACAAGAAGTCTCAGAAAGGGTCAGCATTCACCTTCCCATCCCAGCAATCTCCCAGG\nAATGAACCATATGTAGCCAGACCATCCACATCAGAAATCGAAGACCAAAGCATGATGGGG\nAAGTTTGTAAAAGTTGAAAGACAGGTTCAGGACATGGGGAAGAAGCTGGACTTCCTCGTG\nGATATGCACATGCAACACATGGAACGGTTGCAGGTGCAGGTCACGGAGTATTACCCAACC\nAAGGGCACCTCCTCGCCAGCTGAAGCAGAGAAGAAGGAGGACAACAGGTATTCCGATTTG\nAAAACCATCATCTGCAACTATTCTGAGACAGGCCCCCCGGAACCACCCTACAGCTTCCAC\nCAGGTGACCATTGACAAAGTCAGCCCCTATGGGTTTTTTGCACATGACCCTGTGAACCTG\nCCCCGAGGGGGACCCAGTTCTGGAAAGGTTCAGGCAACTCCTCCTTCCTCAGCAACAACG\nTATGTGGAGAGGCCCACGGTCCTGCCTATCTTGACTCTTCTCGACTCCCGAGTGAGCTGC\nCACTCCCAGGCTGACCTGCAGGGCCCCTACTCGGACCGAATCTCCCCCCGGCAGAGACGT\nAGCATCACGCGAGACAGTGACACACCTCTGTCCCTGATGTCGGTCAACCACGAGGAGCTG\nGAGAGGTCTCCAAGTGGCTTCAGCATCTCCCAGGACAGAGATGATTATGTGTTCGGCCCC\nAATGGGGGGTCGAGCTGGATGAGGGAGAAGCGGTACCTCGCCGAGGGTGAGACGGACACA\nGACACGGACCCCTTCACGCCCAGCGGCTCCATGCCTCTGTCGTCCACAGGGGATGGGATT\nTCTGATTCAGTATGGACCCCTTCCAATAAGCCCATTTAA'),('Pro-opiomelanocortin','None','Human','Type 4 melanocortin receptor binding','ACTH stimulates the adrenal glands to release cortisol.MSH (melanocyte-stimulating hormone) increases the pigmentation of skin by increasing melanin production in melanocytes.Beta-endorphin and Met-enkephalin are endogenous opiates.','POMC','29423.72','DB01497','>lcl|BSEQ0016263|Pro-opiomelanocortin (POMC)\nATGCCGAGATCGTGCTGCAGCCGCTCGGGGGCCCTGTTGCTGGCCTTGCTGCTTCAGGCC\nTCCATGGAAGTGCGTGGCTGGTGCCTGGAGAGCAGCCAGTGTCAGGACCTCACCACGGAA\nAGCAACCTGCTGGAGTGCATCCGGGCCTGCAAGCCCGACCTCTCGGCCGAGACTCCCATG\nTTCCCGGGAAATGGCGACGAGCAGCCTCTGACCGAGAACCCCCGGAAGTACGTCATGGGC\nCACTTCCGCTGGGACCGATTCGGCCGCCGCAACAGCAGCAGCAGCGGCAGCAGCGGCGCA\nGGGCAGAAGCGCGAGGACGTCTCAGCGGGCGAAGACTGCGGCCCGCTGCCTGAGGGCGGC\nCCCGAGCCCCGCAGCGATGGTGCCAAGCCGGGCCCGCGCGAGGGCAAGCGCTCCTACTCC\nATGGAGCACTTCCGCTGGGGCAAGCCGGTGGGCAAGAAGCGGCGCCCAGTGAAGGTGTAC\nCCTAACGGCGCCGAGGACGAGTCGGCCGAGGCCTTCCCCCTGGAGTTCAAGAGGGAGCTG\nACTGGCCAGCGACTCCGGGAGGGAGATGGCCCCGACGGCCCTGCCGATGACGGCGCAGGG\nGCCCAGGCCGACCTGGAGCACAGCCTGCTGGTGGCGGCCGAGAAGAAGGACGAGGGCCCC\nTACAGGATGGAGCACTTCCGCTGGGGCAGCCCGCCCAAGGACAAGCGCTACGGCGGTTTC\nATGACCTCCGAGAAGAGCCAGACGCCCCTGGTGACGCTGTTCAAAAACGCCATCATCAAG\nAACGCCTACAAGAAGGGCGAGTGA'),('Prostacyclin synthase','None','Human','Prostaglandin-i synthase activity','Catalyzes the isomerization of prostaglandin H2 to prostacyclin (= prostaglandin I2).','PTGIS','57103.385','DB00812','>lcl|BSEQ0018918|Prostacyclin synthase (PTGIS)\nATGGCTTGGGCCGCGCTCCTCGGCCTCCTGGCCGCACTGTTGCTGCTGCTGCTACTGAGC\nCGCCGCCGCACGCGGCGACCTGGTGAGCCTCCCCTGGACCTGGGCAGCATCCCCTGGTTG\nGGGTATGCCTTGGACTTTGGAAAAGATGCTGCCAGCTTCCTCACGAGGATGAAGGAGAAG\nCACGGTGACATCTTTACTATACTGGTTGGGGGCAGGTATGTCACCGTTCTCCTGGACCCA\nCACTCCTACGACGCGGTGGTGTGGGAGCCTCGCACCAGGCTCGACTTCCATGCCTATGCC\nATCTTCCTCATGGAGAGGATTTTTGATGTGCAGCTTCCACATTACAGCCCCAGTGATGAA\nAAGGCCAGGATGAAACTGACTCTTCTCCACAGAGAGCTCCAGGCACTCACAGAAGCCATG\nTATACCAACCTCCATGCAGTGCTGTTGGGCGATGCTACAGAAGCAGGCAGTGGCTGGCAC\nGAGATGGGTCTCCTCGACTTCTCCTACAGCTTCCTGCTCAGAGCCGGCTACCTGACTCTT\nTACGGAATTGAGGCGCTGCCACGCACCCATGAAAGCCAGGCCCAGGACCGCGTCCACTCA\nGCTGATGTCTTCCACACCTTTCGCCAGCTCGACCGGCTGCTCCCCAAACTGGCCCGTGGC\nTCCCTGTCAGTGGGGGACAAGGACCACATGTGCAGTGTCAAAAGTCGCCTGTGGAAGCTG\nCTATCCCCAGCCAGGCTGGCCAGGCGGGCCCACCGGAGCAAATGGCTGGAGAGTTACCTG\nCTGCACCTGGAGGAGATGGGTGTGTCAGAGGAGATGCAGGCACGGGCCCTGGTGCTGCAG\nCTGTGGGCCACACAGGGGAATATGGGTCCCGCTGCCTTCTGGCTCCTGCTCTTCCTTCTC\nAAGAATCCTGAAGCCCTGGCTGCTGTCCGCGGAGAGCTCGAGAGTATCCTTTGGCAAGCG\nGAGCAGCCTGTCTCGCAGACGACCACTCTCCCACAGAAGGTTCTAGACAGCACACCTGTG\nCTTGATAGCGTGCTGAGTGAGAGCCTCAGGCTTACAGCTGCCCCCTTCATCACCCGCGAG\nGTTGTGGTGGACCTGGCCATGCCCATGGCAGACGGGCGAGAATTCAACCTGCGACGTGGT\nGACCGCCTCCTCCTCTTCCCCTTCCTGAGCCCCCAGAGAGACCCAGAAATCTACACAGAC\nCCAGAGGTATTTAAATACAACCGATTCCTGAACCCTGACGGATCAGAGAAGAAAGACTTT\nTACAAGGATGGGAAACGGCTGAAGAATTACAACATGCCCTGGGGGGCGGGGCACAATCAC\nTGCCTGGGGAGGAGTTATGCGGTCAACAGCATCAAACAATTTGTGTTCCTTGTGCTGGTG\nCACTTGGACTTGGAGCTGATCAACGCAGATGTGGAGATCCCTGAGTTTGACCTCAGCAGG\nTACGGCTTCGGTCTGATGCAGCCGGAACACGACGTGCCCGTCCGCTACCGCATCCGCCCA\nTGA'),('Prostaglandin D2 receptor 2','None','Human','Prostaglandin j receptor activity','Receptor for prostaglandin D2 (PGD2). Coupled to the G(i)-protein. Receptor activation may result in pertussis toxin-sensitive decreases in cAMP levels and Ca(2+) mobilization. PI3K signaling is also implicated in mediating PTGDR2 effects. PGD2 induced receptor internalization. CRTH2 internalization can be regulated by diverse kinases such as, PKC, PKA, ADRBK1/GRK2, GPRK5/GRK5 and GRK6. Receptor activation is responsible, at least in part, in immune regulation and allergic/inflammation responses.','PTGDR2','43267.15','DB00605','>lcl|BSEQ0017141|Prostaglandin D2 receptor 2 (PTGDR2)\nATGTCGGCCAACGCCACACTGAAGCCACTCTGCCCCATCCTGGAGCAGATGAGCCGTCTC\nCAGAGCCACAGCAACACCAGCATCCGCTACATCGACCACGCGGCCGTGCTGCTGCACGGG\nCTGGCCTCGCTGCTGGGCCTGGTGGAGAATGGAGTCATCCTCTTCGTGGTGGGCTGCCGC\nATGCGCCAGACCGTGGTCACCACCTGGGTGCTGCACCTGGCGCTGTCCGACCTGTTGGCC\nTCTGCTTCCCTGCCCTTCTTCACCTACTTCTTGGCCGTGGGCCACTCGTGGGAGCTGGGC\nACCACCTTCTGCAAACTGCACTCCTCCATCTTCTTTCTCAACATGTTCGCCAGCGGCTTC\nCTGCTCAGCGCCATCAGCCTGGACCGCTGCCTGCAGGTGGTGCGGCCGGTGTGGGCGCAG\nAACCACCGCACCGTGGCCGCGGCGCACAAAGTCTGCCTGGTGCTTTGGGCACTAGCGGTG\nCTCAACACGGTGCCCTATTTCGTGTTCCGGGACACCATCTCGCGGCTGGACGGGCGCATT\nATGTGCTACTACAATGTGCTGCTCCTGAACCCGGGGCCTGACCGCGATGCCACGTGCAAC\nTCGCGGCAGGTGGCCCTGGCCGTCAGCAAGTTCCTGCTGGCCTTCCTGGTGCCGCTGGCG\nATCATCGCCTCGAGCCACGCGGCCGTGAGCCTGCGGTTGCAGCACCGCGGCCGCCGGCGG\nCCAGGCCGCTTCGTGCGCCTGGTGGCGGCCGTCGTGGCCGCCTTCGCGCTCTGCTGGGGG\nCCCTACCACGTGTTCAGCCTGCTGGAGGCGCGGGCGCACGCAAACCCGGGGCTGCGGCCG\nCTCGTGTGGCGCGGGCTGCCCTTCGTCACCAGCCTGGCCTTCTTCAACAGCGTGGCCAAC\nCCGGTGCTCTACGTGCTCACCTGCCCCGACATGCTGCGCAAGCTGCGGCGCTCGCTGCGC\nACGGTGCTGGAGAGCGTGCTGGTGGACGACAGCGAGCTGGGTGGCGCGGGAAGCAGCCGC\nCGCCGCCGCACCTCCTCCACCGCCCGCTCGGCCTCCCCTTTAGCTCTCTGCAGCCGCCCG\nGAGGAACCGCGGGGCCCCGCGCGTCTCCTCGGCTGGCTGCTGGGCAGCTGCGCAGCGTCC\nCCGCAGACGGGCCCCCTGAACCGGGCGCTGAGCAGCACCTCGAGTTAG'),('Prostaglandin G/H synthase 1','None','Human','Prostaglandin-endoperoxide synthase activity','Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the generation of thromboxane A2 (TXA2), which promotes platelet activation and aggregation, vasoconstriction and proliferation of vascular smooth muscle cells.','PTGS1','68685.82','DB00784','>lcl|BSEQ0021254|Prostaglandin G/H synthase 1 (PTGS1)\nATGAGCCGGAGTCTCTTGCTCTGGTTCTTGCTGTTCCTGCTCCTGCTCCCGCCGCTCCCC\nGTCCTGCTCGCGGACCCAGGGGCGCCCACGCCAGTGAATCCCTGTTGTTACTATCCATGC\nCAGCACCAGGGCATCTGTGTCCGCTTCGGCCTTGACCGCTACCAGTGTGACTGCACCCGC\nACGGGCTATTCCGGCCCCAACTGCACCATCCCTGGCCTGTGGACCTGGCTCCGGAATTCA\nCTGCGGCCCAGCCCCTCTTTCACCCACTTCCTGCTCACTCACGGGCGCTGGTTCTGGGAG\nTTTGTCAATGCCACCTTCATCCGAGAGATGCTCATGCGCCTGGTACTCACAGTGCGCTCC\nAACCTTATCCCCAGTCCCCCCACCTACAACTCAGCACATGACTACATCAGCTGGGAGTCT\nTTCTCCAACGTGAGCTATTACACTCGTATTCTGCCCTCTGTGCCTAAAGATTGCCCCACA\nCCCATGGGAACCAAAGGGAAGAAGCAGTTGCCAGATGCCCAGCTCCTGGCCCGCCGCTTC\nCTGCTCAGGAGGAAGTTCATACCTGACCCCCAAGGCACCAACCTCATGTTTGCCTTCTTT\nGCACAACACTTCACCCACCAGTTCTTCAAAACTTCTGGCAAGATGGGTCCTGGCTTCACC\nAAGGCCTTGGGCCATGGGGTAGACCTCGGCCACATTTATGGAGACAATCTGGAGCGTCAG\nTATCAACTGCGGCTCTTTAAGGATGGGAAACTCAAGTACCAGGTGCTGGATGGAGAAATG\nTACCCGCCCTCGGTAGAAGAGGCGCCTGTGTTGATGCACTACCCCCGAGGCATCCCGCCC\nCAGAGCCAGATGGCTGTGGGCCAGGAGGTGTTTGGGCTGCTTCCTGGGCTCATGCTGTAT\nGCCACGCTCTGGCTACGTGAGCACAACCGTGTGTGTGACCTGCTGAAGGCTGAGCACCCC\nACCTGGGGCGATGAGCAGCTTTTCCAGACGACCCGCCTCATCCTCATAGGGGAGACCATC\nAAGATTGTCATCGAGGAGTACGTGCAGCAGCTGAGTGGCTATTTCCTGCAGCTGAAATTT\nGACCCAGAGCTGCTGTTCGGTGTCCAGTTCCAATACCGCAACCGCATTGCCATGGAGTTC\nAACCATCTCTACCACTGGCACCCCCTCATGCCTGACTCCTTCAAGGTGGGCTCCCAGGAG\nTACAGCTACGAGCAGTTCTTGTTCAACACCTCCATGTTGGTGGACTATGGGGTTGAGGCC\nCTGGTGGATGCCTTCTCTCGCCAGATTGCTGGCCGGATCGGTGGGGGCAGGAACATGGAC\nCACCACATCCTGCATGTGGCTGTGGATGTCATCAGGGAGTCTCGGGAGATGCGGCTGCAG\nCCCTTCAATGAGTACCGCAAGAGGTTTGGCATGAAACCCTACACCTCCTTCCAGGAGCTC\nGTAGGAGAGAAGGAGATGGCAGCAGAGTTGGAGGAATTGTATGGAGACATTGATGCGTTG\nGAGTTCTACCCTGGACTGCTTCTTGAAAAGTGCCATCCAAACTCTATCTTTGGGGAGAGT\nATGATAGAGATTGGGGCTCCCTTTTCCCTCAAGGGTCTCCTAGGGAATCCCATCTGTTCT\nCCGGAGTACTGGAAGCCGAGCACATTTGGCGGCGAGGTGGGCTTTAACATTGTCAAGACG\nGCCACACTGAAGAAGCTGGTCTGCCTCAACACCAAGACCTGTCCCTACGTTTCCTTCCGT\nGTGCCGGATGCCAGTCAGGATGATGGGCCTGCTGTGGAGCGACCATCCACAGAGCTCTGA'),('Prostaglandin G/H synthase 2','None','Human','Prostaglandin-endoperoxide synthase activity','Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, phenotypic changes, resistance to apoptosis and tumor angiogenesis. In cancer cells, PTGS2 is a key step in the production of prostaglandin E2 (PGE2), which plays important roles in modulating motility, proliferation and resistance to apoptosis.','PTGS2','68995.625','DB00784','>lcl|BSEQ0021833|Prostaglandin G/H synthase 2 (PTGS2)\nATGCTCGCCCGCGCCCTGCTGCTGTGCGCGGTCCTGGCGCTCAGCCATACAGCAAATCCT\nTGCTGTTCCCACCCATGTCAAAACCGAGGTGTATGTATGAGTGTGGGATTTGACCAGTAT\nAAGTGCGATTGTACCCGGACAGGATTCTATGGAGAAAACTGCTCAACACCGGAATTTTTG\nACAAGAATAAAATTATTTCTGAAACCCACTCCAAACACAGTGCACTACATACTTACCCAC\nTTCAAGGGATTTTGGAACGTTGTGAATAACATTCCCTTCCTTCGAAATGCAATTATGAGT\nTATGTGTTGACATCCAGATCACATTTGATTGACAGTCCACCAACTTACAATGCTGACTAT\nGGCTACAAAAGCTGGGAAGCCTTCTCTAACCTCTCCTATTATACTAGAGCCCTTCCTCCT\nGTGCCTGATGATTGCCCGACTCCCTTGGGTGTCAAAGGTAAAAAGCAGCTTCCTGATTCA\nAATGAGATTGTGGAAAAATTGCTTCTAAGAAGAAAGTTCATCCCTGATCCCCAGGGCTCA\nAACATGATGTTTGCATTCTTTGCCCAGCACTTCACGCATCAGTTTTTCAAGACAGATCAT\nAAGCGAGGGCCAGCTTTCACCAACGGGCTGGGCCATGGGGTGGACTTAAATCATATTTAC\nGGTGAAACTCTGGCTAGACAGCGTAAACTGCGCCTTTTCAAGGATGGAAAAATGAAATAT\nCAGATAATTGATGGAGAGATGTATCCTCCCACAGTCAAAGATACTCAGGCAGAGATGATC\nTACCCTCCTCAAGTCCCTGAGCATCTACGGTTTGCTGTGGGGCAGGAGGTCTTTGGTCTG\nGTGCCTGGTCTGATGATGTATGCCACAATCTGGCTGCGGGAACACAACAGAGTATGCGAT\nGTGCTTAAACAGGAGCATCCTGAATGGGGTGATGAGCAGTTGTTCCAGACAAGCAGGCTA\nATACTGATAGGAGAGACTATTAAGATTGTGATTGAAGATTATGTGCAACACTTGAGTGGC\nTATCACTTCAAACTGAAATTTGACCCAGAACTACTTTTCAACAAACAATTCCAGTACCAA\nAATCGTATTGCTGCTGAATTTAACACCCTCTATCACTGGCATCCCCTTCTGCCTGACACC\nTTTCAAATTCATGACCAGAAATACAACTATCAACAGTTTATCTACAACAACTCTATATTG\nCTGGAACATGGAATTACCCAGTTTGTTGAATCATTCACCAGGCAAATTGCTGGCAGGGTT\nGCTGGTGGTAGGAATGTTCCACCCGCAGTACAGAAAGTATCACAGGCTTCCATTGACCAG\nAGCAGGCAGATGAAATACCAGTCTTTTAATGAGTACCGCAAACGCTTTATGCTGAAGCCC\nTATGAATCATTTGAAGAACTTACAGGAGAAAAGGAAATGTCTGCAGAGTTGGAAGCACTC\nTATGGTGACATCGATGCTGTGGAGCTGTATCCTGCCCTTCTGGTAGAAAAGCCTCGGCCA\nGATGCCATCTTTGGTGAAACCATGGTAGAAGTTGGAGCACCATTCTCCTTGAAAGGACTT\nATGGGTAATGTTATATGTTCTCCTGCCTACTGGAAGCCAAGCACTTTTGGTGGAGAAGTG\nGGTTTTCAAATCATCAACACTGCCTCAATTCAGTCTCTCATCTGCAATAACGTGAAGGGC\nTGTCCCTTTACTTCATTCAGTGTTCCAGATCCAGAGCTCATTAAAACAGTCACCATCAAT\nGCAAGTTCTTCCCGCTCCGGACTAGATGATATCAATCCCACAGTACTACTAAAAGAACGT\nTCGACTGAACTGTAG'),('Prostaglandin reductase 2','None','Human','15-oxoprostaglandin 13-oxidase activity','Functions as 15-oxo-prostaglandin 13-reductase and acts on 15-keto-PGE1, 15-keto-PGE2, 15-keto-PGE1-alpha and 15-keto-PGE2-alpha with highest activity towards 15-keto-PGE2. Overexpression represses transcriptional activity of PPARG and inhibits adipocyte differentiation (By similarity).','PTGR2','38498.74','DB00328','>lcl|BSEQ0012477|Prostaglandin reductase 2 (PTGR2)\nATGATTGTTCAAAGAGTGGTATTGAATTCTCGACCTGGAAAAAATGGTAATCCAGTGGCA\nGAGAATTTCCGAATGGAAGAAGTCTATTTACCAGATAATATTAATGAAGGACAAGTACAA\nGTTAGAACTCTTTATCTTTCTGTGGATCCTTACATGCGTTGTAGAATGAATGAAGACACT\nGGCACTGATTATATAACACCTTGGCAGCTATCTCAAGTCGTTGATGGAGGAGGTATTGGA\nATTATAGAAGAAAGCAAACACACAAATTTGACTAAAGGCGATTTTGTGACTTCTTTCTAT\nTGGCCCTGGCAAACCAAGGTTATTCTGGATGGAAATAGCCTTGAAAAGGTAGACCCACAA\nCTTGTGGATGGACACCTTTCATATTTTCTTGGAGCTATAGGTATGCCTGGTTTGACTTCC\nTTGATTGGGATACAGGAAAAAGGTCATATAACTGCTGGATCTAATAAGACAATGGTTGTC\nAGTGGGGCCGCAGGTGCCTGTGGATCTGTGGCTGGGCAGATTGGCCATTTCTTAGGTTGT\nTCCAGAGTGGTGGGAATTTGTGGAACACATGAGAAATGCATCCTCTTGACCTCAGAACTG\nGGCTTTGATGCTGCAATTAATTATAAAAAAGACAATGTGGCAGAACAGCTCCGTGAATCA\nTGCCCAGCTGGAGTGGATGTTTATTTTGACAATGTTGGTGGTAACATCAGTGATACAGTG\nATAAGTCAGATGAATGAGAACAGCCACATCATCCTGTGTGGTCAAATTTCTCAGTACAAC\nAAAGATGTGCCTTATCCTCCCCCGCTATCCCCTGCTATAGAGGCAATCCAGAAAGAAAGA\nAACATCACAAGGGAAAGATTTCTGGTATTAAATTATAAAGACAAATTTGAGCCTGGCATT\nCTACAGCTGAGTCAGTGGTTTAAAGAAGGAAAGCTAAAGATTAAAGAGACGGTAATAAAT\nGGGTTGGAAAACATGGGAGCTGCATTCCAGTCCATGATGACAGGAGGTAACATTGGAAAG\nCAGATAGTTTGCATTTCAGAAGAAATCTCTTTGTAA'),('Protein S100-A1','None','Human','S100 protein binding','Weakly binds calcium but binds zinc very tightly-distinct binding sites with different affinities exist for both ions on each monomer. Physiological concentrations of potassium ion antagonize the binding of both divalent cations, especially affecting high-affinity calcium-binding sites. May mediate calcium-dependent regulation on many physiological processes by interacting with other proteins, such as TPR-containing proteins, and modulating their activity.','S100A1','10545.755','DB00768','>lcl|BSEQ0016312|Protein S100-A1 (S100A1)\nATGGGCTCTGAGCTGGAGACGGCGATGGAGACCCTCATCAACGTGTTCCACGCCCACTCG\nGGCAAAGAGGGGGACAAGTACAAGCTGAGCAAGAAGGAGCTGAAAGAGCTGCTGCAGACG\nGAGCTCTCTGGCTTCCTGGATGCCCAGAAGGATGTGGATGCTGTGGACAAGGTGATGAAG\nGAGCTAGACGAGAATGGAGACGGGGAGGTGGACTTCCAGGAGTATGTGGTGCTTGTGGCT\nGCTCTCACAGTGGCCTGTAACAATTTCTTCTGGGAGAACAGTTGA'),('Protein S100-A12','None','Human','Zinc ion binding','S100A12 is a calcium-, zinc- and copper-binding protein which plays a prominent role in the regulation of inflammatory processes and immune response. Its proinflammatory activity involves recruitment of leukocytes, promotion of cytokine and chemokine production, and regulation of leukocyte adhesion and migration. Acts as an alarmin or a danger associated molecular pattern (DAMP) molecule and stimulates innate immune cells via binding to receptor for advanced glycation endproducts (AGER). Binding to AGER activates the MAP-kinase and NF-kappa-B signaling pathways leading to production of proinflammatory cytokines and up-regulation of cell adhesion molecules ICAM1 and VCAM1. Acts as a monocyte and mast cell chemoattractant. Can stimulate mast cell degranulation and activation which generates chemokines, histamine and cytokines inducing further leukocyte recruitment to the sites of inflammation. Can inhibit the activity of matrix metalloproteinases; MMP2, MMP3 and MMP9 by chelating Zn(2+) from their active sites. Possesses filariacidal and filariastatic activity. Calcitermin possesses antifungal activity against C.albicans and is also active against E.coli and P.aeruginosa but not L.monocytogenes and S.aureus.','S100A12','10574.975','DB00768','>lcl|BSEQ0010841|Protein S100-A12 (S100A12)\nATGACAAAACTTGAAGAGCATCTGGAGGGAATTGTCAATATCTTCCACCAATACTCAGTT\nCGGAAGGGGCATTTTGACACCCTCTCTAAGGGTGAGCTGAAGCAGCTGCTTACAAAGGAG\nCTTGCAAACACCATCAAGAATATCAAAGATAAAGCTGTCATTGATGAAATATTCCAAGGC\nCTGGATGCTAATCAAGATGAACAGGTCGACTTTCAAGAATTCATATCCCTGGTAGCCATT\nGCGCTGAAGGCTGCCCATTACCACACCCACAAAGAGTAG'),('Protein S100-A13','None','Human','Zinc ion binding','Plays a role in the export of proteins that lack a signal peptide and are secreted by an alternative pathway. Binds two calcium ions per subunit. Binds one copper ion. Binding of one copper ion does not interfere with calcium binding. Required for the copper-dependent stress-induced export of IL1A and FGF1. The calcium-free protein binds to lipid vesicles containing phosphatidylserine, but not to vesicles containing phosphatidylcholine (By similarity).','S100A13','11471.095','DB00768','>lcl|BSEQ0016240|Protein S100-A13 (S100A13)\nATGGCAGCAGAACCACTGACAGAGCTAGAGGAGTCCATTGAGACCGTGGTCACCACCTTC\nTTCACCTTTGCAAGGCAGGAGGGCCGGAAGGATAGCCTCAGCGTCAACGAGTTCAAAGAG\nCTGGTTACCCAGCAGTTGCCCCATCTGCTCAAGGATGTGGGCTCTCTTGATGAGAAGATG\nAAGAGCTTGGATGTGAATCAGGACTCGGAGCTCAAGTTCAATGAGTACTGGAGATTGATT\nGGGGAGCTGGCCAAGGAAATCAGGAAGAAGAAAGACCTGAAGATCAGGAAGAAGTAA'),('Protein S100-A2','None','Human','Identical protein binding','May function as calcium sensor and modulator, contributing to cellular calcium signaling. May function by interacting with other proteins, such as TPR-containing proteins, and indirectly play a role in many physiological processes. May also play a role in suppressing tumor cell growth.','S100A2','11116.695','DB00768','>lcl|BSEQ0017155|Protein S100-A2 (S100A2)\nATGTGCAGTTCTCTGGAGCAGGCGCTGGCTGTGCTGGTCACTACCTTCCACAAGTACTCC\nTGCCAAGAGGGCGACAAGTTCAAGCTGAGTAAGGGGGAAATGAAGGAACTTCTGCACAAG\nGAGCTGCCCAGCTTTGTGGGGGAGAAAGTGGATGAGGAGGGGCTGAAGAAGCTGATGGGC\nAGCCTGGATGAGAACAGTGACCAGCAGGTGGACTTCCAGGAGTATGCTGTTTTCCTGGCA\nCTCATCACTGTCATGTGCAATGACTTCTTCCAGGGCTGCCCAGACCGACCCTGA'),('Protein S100-B','None','Human','Zinc ion binding','Weakly binds calcium but binds zinc very tightly-distinct binding sites with different affinities exist for both ions on each monomer. Physiological concentrations of potassium ion antagonize the binding of both divalent cations, especially affecting high-affinity calcium-binding sites. Binds to and initiates the activation of STK38 by releasing autoinhibitory intramolecular interactions within the kinase. Interaction with AGER after myocardial infarction may play a role in myocyte apoptosis by activating ERK1/2 and p53/TP53 signaling. Could assist ATAD3A cytoplasmic processing, preventing aggregation and favoring mitochondrial localization. May mediate calcium-dependent regulation on many physiological processes by interacting with other proteins, such as TPR-containing proteins, and modulating their activity.','S100B','10712.985','DB00768','>lcl|BSEQ0010822|Protein S100-B (S100B)\nATGTCTGAGCTGGAGAAGGCCATGGTGGCCCTCATCGACGTTTTCCACCAATATTCTGGA\nAGGGAGGGAGACAAGCACAAGCTGAAGAAATCCGAACTGAAGGAGCTCATCAACAATGAG\nCTTTCCCATTTCTTAGAGGAAATCAAAGAGCAGGAGGTTGTGGACAAAGTCATGGAAACA\nCTGGACAATGATGGAGACGGCGAATGTGACTTCCAGGAATTCATGGCCTTTGTTGCCATG\nGTTACTACTGCCTGCCACGAGTTCTTTGAACATGAGTGA'),('Prothrombin','None','Human','Thrombospondin receptor activity','Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostasis, inflammation and wound healing.','F2','70036.295','DB12598','>lcl|BSEQ0016005|Prothrombin (F2)\nATGGCGCACGTCCGAGGCTTGCAGCTGCCTGGCTGCCTGGCCCTGGCTGCCCTGTGTAGC\nCTTGTGCACAGCCAGCATGTGTTCCTGGCTCCTCAGCAAGCACGGTCGCTGCTCCAGCGG\nGTCCGGCGAGCCAACACCTTCTTGGAGGAGGTGCGCAAGGGCAACCTGGAGCGAGAGTGC\nGTGGAGGAGACGTGCAGCTACGAGGAGGCCTTCGAGGCTCTGGAGTCCTCCACGGCTACG\nGATGTGTTCTGGGCCAAGTACACAGCTTGTGAGACAGCGAGGACGCCTCGAGATAAGCTT\nGCTGCATGTCTGGAAGGTAACTGTGCTGAGGGTCTGGGTACGAACTACCGAGGGCATGTG\nAACATCACCCGGTCAGGCATTGAGTGCCAGCTATGGAGGAGTCGCTACCCACATAAGCCT\nGAAATCAACTCCACTACCCATCCTGGGGCCGACCTACAGGAGAATTTCTGCCGCAACCCC\nGACAGCAGCACCACGGGACCCTGGTGCTACACTACAGACCCCACCGTGAGGAGGCAGGAA\nTGCAGCATCCCTGTCTGTGGCCAGGATCAAGTCACTGTAGCGATGACTCCACGCTCCGAA\nGGCTCCAGTGTGAATCTGTCACCTCCATTGGAGCAGTGTGTCCCTGATCGGGGGCAGCAG\nTACCAGGGGCGCCTGGCGGTGACCACACATGGGCTCCCCTGCCTGGCCTGGGCCAGCGCA\nCAGGCCAAGGCCCTGAGCAAGCACCAGGACTTCAACTCAGCTGTGCAGCTGGTGGAGAAC\nTTCTGCCGCAACCCAGACGGGGATGAGGAGGGCGTGTGGTGCTATGTGGCCGGGAAGCCT\nGGCGACTTTGGGTACTGCGACCTCAACTATTGTGAGGAGGCCGTGGAGGAGGAGACAGGA\nGATGGGCTGGATGAGGACTCAGACAGGGCCATCGAAGGGCGTACCGCCACCAGTGAGTAC\nCAGACTTTCTTCAATCCGAGGACCTTTGGCTCGGGAGAGGCAGACTGTGGGCTGCGACCT\nCTGTTCGAGAAGAAGTCGCTGGAGGACAAAACCGAAAGAGAGCTCCTGGAATCCTACATC\nGACGGGCGCATTGTGGAGGGCTCGGATGCAGAGATCGGCATGTCACCTTGGCAGGTGATG\nCTTTTCCGGAAGAGTCCCCAGGAGCTGCTGTGTGGGGCCAGCCTCATCAGTGACCGCTGG\nGTCCTCACCGCCGCCCACTGCCTCCTGTACCCGCCCTGGGACAAGAACTTCACCGAGAAT\nGACCTTCTGGTGCGCATTGGCAAGCACTCCCGCACCAGGTACGAGCGAAACATTGAAAAG\nATATCCATGTTGGAAAAGATCTACATCCACCCCAGGTACAACTGGCGGGAGAACCTGGAC\nCGGGACATTGCCCTGATGAAGCTGAAGAAGCCTGTTGCCTTCAGTGACTACATTCACCCT\nGTGTGTCTGCCCGACAGGGAGACGGCAGCCAGCTTGCTCCAGGCTGGATACAAGGGGCGG\nGTGACAGGCTGGGGCAACCTGAAGGAGACGTGGACAGCCAACGTTGGTAAGGGGCAGCCC\nAGTGTCCTGCAGGTGGTGAACCTGCCCATTGTGGAGCGGCCGGTCTGCAAGGACTCCACC\nCGGATCCGCATCACTGACAACATGTTCTGTGCTGGTTACAAGCCTGATGAAGGGAAACGA\nGGGGATGCCTGTGAAGGTGACAGTGGGGGACCCTTTGTCATGAAGAGCCCCTTTAACAAC\nCGCTGGTATCAAATGGGCATCGTCTCATGGGGTGAAGGCTGTGACCGGGATGGGAAATAT\nGGCTTCTACACACATGTGTTCCGCCTGAAGAAGTGGATACAGAAGGTCATTGATCAGTTT\nGGAGAGTAG'),('RAC-alpha serine/threonine-protein kinase','None','Human','Protein serine/threonine/tyrosine kinase activity','AKT1 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates. Over 100 substrate candidates have been reported so far, but for most of them, no isoform specificity has been reported. AKT is responsible of the regulation of glucose uptake by mediating insulin-induced translocation of the SLC2A4/GLUT4 glucose transporter to the cell surface. Phosphorylation of PTPN1 at \'Ser-50\' negatively modulates its phosphatase activity preventing dephosphorylation of the insulin receptor and the attenuation of insulin signaling. Phosphorylation of TBC1D4 triggers the binding of this effector to inhibitory 14-3-3 proteins, which is required for insulin-stimulated glucose transport. AKT regulates also the storage of glucose in the form of glycogen by phosphorylating GSK3A at \'Ser-21\' and GSK3B at \'Ser-9\', resulting in inhibition of its kinase activity. Phosphorylation of GSK3 isoforms by AKT is also thought to be one mechanism by which cell proliferation is driven. AKT regulates also cell survival via the phosphorylation of MAP3K5 (apoptosis signal-related kinase). Phosphorylation of \'Ser-83\' decreases MAP3K5 kinase activity stimulated by oxidative stress and thereby prevents apoptosis. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 at \'Ser-939\' and \'Thr-1462\', thereby activating mTORC1 signaling and leading to both phosphorylation of 4E-BP1 and in activation of RPS6KB1. AKT is involved in the phosphorylation of members of the FOXO factors (Forkhead family of transcription factors), leading to binding of 14-3-3 proteins and cytoplasmic localization. In particular, FOXO1 is phosphorylated at \'Thr-24\', \'Ser-256\' and \'Ser-319\'. FOXO3 and FOXO4 are phosphorylated on equivalent sites. AKT has an important role in the regulation of NF-kappa-B-dependent gene transcription and positively regulates the activity of CREB1 (cyclic AMP (cAMP)-response element binding protein). The phosphorylation of CREB1 induces the binding of accessory proteins that are necessary for the transcription of pro-survival genes such as BCL2 and MCL1. AKT phosphorylates \'Ser-454\' on ATP citrate lyase (ACLY), thereby potentially regulating ACLY activity and fatty acid synthesis. Activates the 3B isoform of cyclic nucleotide phosphodiesterase (PDE3B) via phosphorylation of \'Ser-273\', resulting in reduced cyclic AMP levels and inhibition of lipolysis. Phosphorylates PIKFYVE on \'Ser-318\', which results in increased PI(3)P-5 activity. The Rho GTPase-activating protein DLC1 is another substrate and its phosphorylation is implicated in the regulation cell proliferation and cell growth. AKT plays a role as key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. Signals downstream of phosphatidylinositol 3-kinase (PI(3)K) to mediate the effects of various growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like growth factor I (IGF-I). AKT mediates the antiapoptotic effects of IGF-I. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly. May be involved in the regulation of the placental development. Phosphorylates STK4/MST1 at \'Thr-120\' and \'Thr-387\' leading to inhibition of its: kinase activity, nuclear translocation, autophosphorylation and ability to phosphorylate FOXO3. Phosphorylates STK3/MST2 at \'Thr-117\' and \'Thr-384\' leading to inhibition of its: cleavage, kinase activity, autophosphorylation at Thr-180, binding to RASSF1 and nuclear translocation. Phosphorylates SRPK2 and enhances its kinase activity towards SRSF2 and ACIN1 and promotes its nuclear translocation. Phosphorylates RAF1 at \'Ser-259\' and negatively regulates its activity. Phosphorylation of BAD stimulates its pro-apoptotic activity. Phosphorylates KAT6A at \'Thr-369\' and this phosphorylation inhibits the interaction of KAT6A with PML and negatively regulates its acetylation activity towards p53/TP53.AKT1-specific substrates have been recently identified, including palladin (PALLD), which phosphorylation modulates cytoskeletal organization and cell motility; prohibitin (PHB), playing an important role in cell metabolism and proliferation; and CDKN1A, for which phosphorylation at \'Thr-145\' induces its release from CDK2 and cytoplasmic relocalization. These recent findings indicate that the AKT1 isoform has a more specific role in cell motility and proliferation. Phosphorylates CLK2 thereby controlling cell survival to ionizing radiation.','AKT1','55686.035','DB02709','>lcl|BSEQ0021923|RAC-alpha serine/threonine-protein kinase (AKT1)\nATGAGCGACGTGGCTATTGTGAAGGAGGGTTGGCTGCACAAACGAGGGGAGTACATCAAG\nACCTGGCGGCCACGCTACTTCCTCCTCAAGAATGATGGCACCTTCATTGGCTACAAGGAG\nCGGCCGCAGGATGTGGACCAACGTGAGGCTCCCCTCAACAACTTCTCTGTGGCGCAGTGC\nCAGCTGATGAAGACGGAGCGGCCCCGGCCCAACACCTTCATCATCCGCTGCCTGCAGTGG\nACCACTGTCATCGAACGCACCTTCCATGTGGAGACTCCTGAGGAGCGGGAGGAGTGGACA\nACCGCCATCCAGACTGTGGCTGACGGCCTCAAGAAGCAGGAGGAGGAGGAGATGGACTTC\nCGGTCGGGCTCACCCAGTGACAACTCAGGGGCTGAAGAGATGGAGGTGTCCCTGGCCAAG\nCCCAAGCACCGCGTGACCATGAACGAGTTTGAGTACCTGAAGCTGCTGGGCAAGGGCACT\nTTCGGCAAGGTGATCCTGGTGAAGGAGAAGGCCACAGGCCGCTACTACGCCATGAAGATC\nCTCAAGAAGGAAGTCATCGTGGCCAAGGACGAGGTGGCCCACACACTCACCGAGAACCGC\nGTCCTGCAGAACTCCAGGCACCCCTTCCTCACAGCCCTGAAGTACTCTTTCCAGACCCAC\nGACCGCCTCTGCTTTGTCATGGAGTACGCCAACGGGGGCGAGCTGTTCTTCCACCTGTCC\nCGGGAGCGTGTGTTCTCCGAGGACCGGGCCCGCTTCTATGGCGCTGAGATTGTGTCAGCC\nCTGGACTACCTGCACTCGGAGAAGAACGTGGTGTACCGGGACCTCAAGCTGGAGAACCTC\nATGCTGGACAAGGACGGGCACATTAAGATCACAGACTTCGGGCTGTGCAAGGAGGGGATC\nAAGGACGGTGCCACCATGAAGACCTTTTGCGGCACACCTGAGTACCTGGCCCCCGAGGTG\nCTGGAGGACAATGACTACGGCCGTGCAGTGGACTGGTGGGGGCTGGGCGTGGTCATGTAC\nGAGATGATGTGCGGTCGCCTGCCCTTCTACAACCAGGACCATGAGAAGCTTTTTGAGCTC\nATCCTCATGGAGGAGATCCGCTTCCCGCGCACGCTTGGTCCCGAGGCCAAGTCCTTGCTT\nTCAGGGCTGCTCAAGAAGGACCCCAAGCAGAGGCTTGGCGGGGGCTCCGAGGACGCCAAG\nGAGATCATGCAGCATCGCTTCTTTGCCGGTATCGTGTGGCAGCACGTGTACGAGAAGAAG\nCTCAGCCCACCCTTCAAGCCCCAGGTCACGTCGGAGACTGACACCAGGTATTTTGATGAG\nGAGTTCACGGCCCAGATGATCACCATCACACCACCTGACCAAGATGACAGCATGGAGTGT\nGTGGACAGCGAGCGCAGGCCCCACTTCCCCCAGTTCTCCTACTCGGCCAGCGGCACGGCC\nTGA'),('Retinoic acid receptor alpha','None','Human','Zinc ion binding','Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RXR/RAR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5\'-AGGTCA-3\' sites known as DR1-DR5. In the absence of ligand, the RXR-RAR heterodimers associate with a multiprotein complex containing transcription corepressors that induce histone acetylation, chromatin condensation and transcriptional suppression. On ligand binding, the corepressors dissociate from the receptors and associate with the coactivators leading to transcriptional activation. RARA plays an essential role in the regulation of retinoic acid-induced germ cell development during spermatogenesis. Has a role in the survival of early spermatocytes at the beginning prophase of meiosis. In Sertoli cells, may promote the survival and development of early meiotic prophase spermatocytes. In concert with RARG, required for skeletal growth, matrix homeostasis and growth plate function (By similarity). Regulates expression of target genes in a ligand-dependent manner by recruiting chromatin complexes containing KMT2E/MLL5. Mediates retinoic acid-induced granulopoiesis.','RARA','50770.805','DB00210','>lcl|BSEQ0016168|Retinoic acid receptor alpha (RARA)\nATGGCCAGCAACAGCAGCTCCTGCCCGACACCTGGGGGCGGGCACCTCAATGGGTACCCG\nGTGCCTCCCTACGCCTTCTTCTTCCCCCCTATGCTGGGTGGACTCTCCCCGCCAGGCGCT\nCTGACCACTCTCCAGCACCAGCTTCCAGTTAGTGGATATAGCACACCATCCCCAGCCACC\nATTGAGACCCAGAGCAGCAGTTCTGAAGAGATAGTGCCCAGCCCTCCCTCGCCACCCCCT\nCTACCCCGCATCTACAAGCCTTGCTTTGTCTGTCAGGACAAGTCCTCAGGCTACCACTAT\nGGGGTCAGCGCCTGTGAGGGCTGCAAGGGCTTCTTCCGCCGCAGCATCCAGAAGAACATG\nGTGTACACGTGTCACCGGGACAAGAACTGCATCATCAACAAGGTGACCCGGAACCGCTGC\nCAGTACTGCCGACTGCAGAAGTGCTTTGAAGTGGGCATGTCCAAGGAGTCTGTGAGAAAC\nGACCGAAACAAGAAGAAGAAGGAGGTGCCCAAGCCCGAGTGCTCTGAGAGCTACACGCTG\nACGCCGGAGGTGGGGGAGCTCATTGAGAAGGTGCGCAAAGCGCACCAGGAAACCTTCCCT\nGCCCTCTGCCAGCTGGGCAAATACACTACGAACAACAGCTCAGAACAACGTGTCTCTCTG\nGACATTGACCTCTGGGACAAGTTCAGTGAACTCTCCACCAAGTGCATCATTAAGACTGTG\nGAGTTCGCCAAGCAGCTGCCCGGCTTCACCACCCTCACCATCGCCGACCAGATCACCCTC\nCTCAAGGCTGCCTGCCTGGACATCCTGATCCTGCGGATCTGCACGCGGTACACGCCCGAG\nCAGGACACCATGACCTTCTCGGACGGGCTGACCCTGAACCGGACCCAGATGCACAACGCT\nGGCTTCGGCCCCCTCACCGACCTGGTCTTTGCCTTCGCCAACCAGCTGCTGCCCCTGGAG\nATGGATGATGCGGAGACGGGGCTGCTCAGCGCCATCTGCCTCATCTGCGGAGACCGCCAG\nGACCTGGAGCAGCCGGACCGGGTGGACATGCTGCAGGAGCCGCTGCTGGAGGCGCTAAAG\nGTCTACGTGCGGAAGCGGAGGCCCAGCCGCCCCCACATGTTCCCCAAGATGCTAATGAAG\nATTACTGACCTGCGAAGCATCAGCGCCAAGGGGGCTGAGCGGGTGATCACGCTGAAGATG\nGAGATCCCGGGCTCCATGCCGCCTCTCATCCAGGAAATGTTGGAGAACTCAGAGGGCCTG\nGACACTCTGAGCGGACAGCCGGGGGGTGGGGGGCGGGACGGGGGTGGCCTGGCCCCCCCG\nCCAGGCAGCTGTAGCCCCAGCCTCAGCCCCAGCTCCAACAGAAGCAGCCCGGCCACCCAC\nTCCCCGTGA'),('Retinoic acid receptor beta','None','Human','Zinc ion binding','Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RXR/RAR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5\'-AGGTCA-3\' sites known as DR1-DR5. In the absence or presence of hormone ligand, acts mainly as an activator of gene expression due to weak binding to corepressors. In concert with RARG, required for skeletal growth, matrix homeostasis and growth plate function.','RARB','50488.63','DB00210','>lcl|BSEQ0010005|Retinoic acid receptor beta (RARB)\nATGTTTGACTGTATGGATGTTCTGTCAGTGAGTCCTGGGCAAATCCTGGATTTCTACACT\nGCGAGTCCGTCTTCCTGCATGCTCCAGGAGAAAGCTCTCAAAGCATGCTTCAGTGGATTG\nACCCAAACCGAATGGCAGCATCGGCACACTGCTCAATCAATTGAAACACAGAGCACCAGC\nTCTGAGGAACTCGTCCCAAGCCCCCCATCTCCACTTCCTCCCCCTCGAGTGTACAAACCC\nTGCTTCGTCTGCCAGGACAAATCATCAGGGTACCACTATGGGGTCAGCGCCTGTGAGGGA\nTGTAAGGGCTTTTTCCGCAGAAGTATTCAGAAGAATATGATTTACACTTGTCACCGAGAT\nAAGAACTGTGTTATTAATAAAGTCACCAGGAATCGATGCCAATACTGTCGACTCCAGAAG\nTGCTTTGAAGTGGGAATGTCCAAAGAATCTGTCAGGAATGACAGGAACAAGAAAAAGAAG\nGAGACTTCGAAGCAAGAATGCACAGAGAGCTATGAAATGACAGCTGAGTTGGACGATCTC\nACAGAGAAGATCCGAAAAGCTCACCAGGAAACTTTCCCTTCACTCTGCCAGCTGGGTAAA\nTACACCACGAATTCCAGTGCTGACCATCGAGTCCGACTGGACCTGGGCCTCTGGGACAAA\nTTCAGTGAACTGGCCACCAAGTGCATTATTAAGATCGTGGAGTTTGCTAAACGTCTGCCT\nGGTTTCACTGGCTTGACCATCGCAGACCAAATTACCCTGCTGAAGGCCGCCTGCCTGGAC\nATCCTGATTCTTAGAATTTGCACCAGGTATACCCCAGAACAAGACACCATGACTTTCTCA\nGACGGCCTTACCCTAAATCGAACTCAGATGCACAATGCTGGATTTGGTCCTCTGACTGAC\nCTTGTGTTCACCTTTGCCAACCAGCTCCTGCCTTTGGAAATGGATGACACAGAAACAGGC\nCTTCTCAGTGCCATCTGCTTAATCTGTGGAGACCGCCAGGACCTTGAGGAACCGACAAAA\nGTAGATAAGCTACAAGAACCATTGCTGGAAGCACTAAAAATTTATATCAGAAAAAGACGA\nCCCAGCAAGCCTCACATGTTTCCAAAGATCTTAATGAAAATCACAGATCTCCGTAGCATC\nAGTGCTAAAGGTGCAGAGCGTGTAATTACCTTGAAAATGGAAATTCCTGGATCAATGCCA\nCCTCTCATTCAAGAAATGCTGGAGAATTCTGAAGGACATGAACCCTTGACCCCAAGTTCA\nAGTGGGAACACAGCAGAGCACAGTCCTAGCATCTCACCCAGCTCAGTGGAAAACAGTGGG\nGTCAGTCAGTCACCACTCGTGCAATAA'),('Retinoic acid receptor gamma','None','Human','Zinc ion binding','Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5\'-AGGTCA-3\' sites known as DR1-DR5. In the absence of ligand, acts mainly as an activator of gene expression due to weak binding to corepressors. Required for limb bud development. In concert with RARA or RARB, required for skeletal growth, matrix homeostasis and growth plate function (By similarity).','RARG','50341.405','DB00210','>lcl|BSEQ0020450|Retinoic acid receptor gamma (RARG)\nATGGCCACCAATAAGGAGCGACTCTTTGCGGCTGGTGCCCTGGGGCCTGGATCTGGCTAC\nCCAGGGGCAGGTTTCCCCTTCGCCTTCCCAGGGGCACTCAGGGGGTCTCCGCCTTTCGAG\nATGCTGAGCCCTAGCTTCCGGGGCCTGGGCCAGCCTGACCTCCCCAAGGAGATGGCCTCT\nCTGTCGGTGGAGACACAGAGCACCAGCTCAGAGGAGATGGTGCCCAGCTCGCCCTCGCCC\nCCTCCGCCTCCTCGGGTCTACAAGCCATGCTTCGTGTGCAATGACAAGTCCTCTGGCTAC\nCACTATGGGGTCAGCTCTTGTGAAGGCTGCAAGGGCTTCTTTCGCCGAAGCATCCAGAAG\nAACATGGTGTACACGTGTCACCGCGACAAAAACTGTATCATCAACAAGGTGACCAGGAAT\nCGCTGCCAGTACTGCCGGCTACAGAAGTGCTTCGAAGTGGGCATGTCCAAGGAAGCTGTG\nCGAAATGACCGGAACAAGAAGAAGAAAGAGGTGAAGGAAGAAGGGTCACCTGACAGCTAT\nGAGCTGAGCCCTCAGTTAGAAGAGCTCATCACCAAGGTCAGCAAAGCCCATCAGGAGACT\nTTCCCCTCGCTCTGCCAGCTGGGCAAGTATACCACGAACTCCAGTGCAGACCACCGCGTG\nCAGCTGGATCTGGGGCTGTGGGACAAGTTCAGTGAGCTGGCTACCAAGTGCATCATCAAG\nATCGTGGAGTTTGCCAAGCGGTTGCCTGGCTTTACAGGGCTCAGCATTGCTGACCAGATC\nACTCTGCTCAAAGCTGCCTGCCTAGATATCCTGATGCTGCGTATCTGCACAAGGTACACC\nCCAGAGCAGGACACCATGACCTTCTCCGACGGGCTGACCCTGAACCGGACCCAGATGCAC\nAATGCCGGCTTCGGGCCCCTCACAGACCTTGTCTTTGCCTTTGCTGGGCAGCTCCTGCCC\nCTGGAGATGGATGACACCGAGACAGGGCTGCTCAGCGCCATCTGCCTCATCTGCGGAGAC\nCGCATGGACCTGGAGGAGCCCGAAAAAGTGGACAAGCTGCAGGAGCCACTGCTGGAAGCC\nCTGAGGCTGTACGCCCGGCGCCGGCGGCCCAGCCAGCCCTACATGTTCCCAAGGATGCTA\nATGAAAATCACCGACCTCCGGGGCATCAGCACTAAGGGAGCTGAAAGGGCCATTACTCTG\nAAGATGGAGATTCCAGGCCCGATGCCTCCCTTAATCCGAGAGATGCTGGAGAACCCTGAA\nATGTTTGAGGATGACTCCTCGCAGCCTGGTCCCCACCCCAATGCCTCTAGCGAGGATGAG\nGTTCCTGGGGGCCAGGGCAAAGGGGGCCTGAAGTCCCCAGCCTGA'),('Retinoic acid receptor RXR-alpha','None','Human','Zinc ion binding','Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5\'-AGGTCA-3\' sites known as DR1-DR5. The high affinity ligand for RXRs is 9-cis retinoic acid. RXRA serves as a common heterodimeric partner for a number of nuclear receptors. The RXR/RAR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5\'-AGGTCA-3\' sites known as DR1-DR5. In the absence of ligand, the RXR-RAR heterodimers associate with a multiprotein complex containing transcription corepressors that induce histone acetylation, chromatin condensation and transcriptional suppression. On ligand binding, the corepressors dissociate from the receptors and associate with the coactivators leading to transcriptional activation. The RXRA/PPARA heterodimer is required for PPARA transcriptional activity on fatty acid oxidation genes such as ACOX1 and the P450 system genes.','RXRA','50810.835','DB00749','>lcl|BSEQ0000820|1389 bp\nATGGACACCAAACATTTCCTGCCGCTCGATTTCTCCACCCAGGTGAACTCCTCCCTCACC\nTCCCCGACGGGGCGAGGCTCCATGGCTGCCCCCTCGCTGCACCCGTCCCTGGGGCCTGGC\nATCGGCTCCCCGGGACAGCTGCATTCTCCCATCAGCACCCTGAGCTCCCCCATCAACGGC\nATGGGCCCGCCTTTCTCGGTCATCAGCTCCCCCATGGGCCCCCACTCCATGTCGGTGCCC\nACCACACCCACCCTGGGCTTCAGCACTGGCAGCCCCCAGCTCAGCTCACCTATGAACCCC\nGTCAGCAGCAGCGAGGACATCAAGCCCCCCCTGGGCCTCAATGGCGTCCTCAAGGTCCCC\nGCCCACCCCTCAGGAAACATGGCTTCCTTCACCAAGCACATCTGCGCCATCTGCGGGGAC\nCGCTCCTCAGGCAAGCACTATGGAGTGTACAGCTGCGAGGGGTGCAAGGGCTTCTTCAAG\nCGGACGGTGCGCAAGGACCTGACCTACACCTGCCGCGACAACAAGGACTGCCTGATTGAC\nAAGCGGCAGCGGAACCGGTGCCAGTACTGCCGCTACCAGAAGTGCCTGGCCATGGGCATG\nAAGCGGGAAGCCGTGCAGGAGGAGCGGCAGCGTGGCAAGGACCGGAACGAGAATGAGGTG\nGAGTCGACCAGCAGCGCCAACGAGGACATGCCGGTGGAGAGGATCCTGGAGGCTGAGCTG\nGCCGTGGAGCCCAAGACCGAGACCTACGTGGAGGCAAACATGGGGCTGAACCCCAGCTCG\nCCGAACGACCCTGTCACCAACATTTGCCAAGCAGCCGACAAACAGCTTTTCACCCTGGTG\nGAGTGGGCCAAGCGGATCCCACACTTCTCAGAGCTGCCCCTGGACGACCAGGTCATCCTG\nCTGCGGGCAGGCTGGAATGAGCTGCTCATCGCCTCCTTCTCCCACCGCTCCATCGCCGTG\nAAGGACGGGATCCTCCTGGCCACCGGGCTGCACGTCCACCGGAACAGCGCCCACAGCGCA\nGGGGTGGGCGCCATCTTTGACAGGGTGCTGACGGAGCTTGTGTCCAAGATGCGGGACATG\nCAGATGGACAAGACGGAGCTGGGCTGCCTGCGCGCCATCGTCCTCTTTAACCCTGACTCC\nAAGGGGCTCTCGAACCCGGCCGAGGTGGAGGCGCTGAGGGAGAAGGTCTATGCGTCCTTG\nGAGGCCTACTGCAAGCACAAGTACCCAGAGCAGCCGGGAAGGTTCGCTAAGCTCTTGCTC\nCGCCTGCCGGCTCTGCGCTCCATCGGGCTCAAATGCCTGGAACATCTCTTCTTCTTCAAG\nCTCATCGGGGACACACCCATTGACACCTTCCTTATGGAGATGCTGGAGGCGCCGCACCAA\nATGACTTAG'),('Retinoic acid receptor RXR-beta','None','Human','Zinc ion binding','Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5\'-AGGTCA-3\' sites known as DR1-DR5 (By similarity). Specifically binds 9-cis retinoic acid (9C-RA).','RXRB','56921.38','DB00210','>lcl|BSEQ0016010|Retinoic acid receptor RXR-beta (RXRB)\nATGTCTTGGGCCGCTCGCCCGCCCTTCCTCCCTCAGCGGCATGCCGCAGGGCAGTGTGGG\nCCGGTGGGGGTGCGAAAAGAAATGCATTGTGGGGTCGCGTCCCGGTGGCGGCGGCGACGG\nCCCTGGCTGGATCCCGCAGCGGCGGCGGCGGCGGCGGTGGCAGGCGGAGAACAACAAACC\nCCGGAGCCGGAGCCAGGGGAGGCTGGACGGGACGGGATGGGCGACAGCGGGCGGGACTCC\nCGAAGCCCAGACAGCTCCTCCCCAAATCCCCTTCCCCAGGGAGTCCCTCCCCCTTCTCCT\nCCTGGGCCACCCCTACCCCCTTCAACAGCTCCATCCCTTGGAGGCTCTGGGGCCCCACCC\nCCACCCCCGATGCCACCACCCCCACTGGGCTCTCCCTTTCCAGTCATCAGTTCTTCCATG\nGGGTCCCCTGGTCTGCCCCCTCCAGCTCCCCCAGGATTCTCCGGGCCTGTCAGCAGCCCC\nCAGATTAACTCAACAGTGTCACTCCCTGGGGGTGGGTCTGGCCCCCCTGAAGATGTGAAG\nCCACCAGTCTTAGGGGTCCGGGGCCTGCACTGTCCACCCCCTCCAGGTGGCCCTGGGGCT\nGGCAAACGGCTATGTGCAATCTGCGGGGACAGAAGCTCAGGCAAACACTACGGGGTTTAC\nAGCTGTGAGGGTTGCAAGGGCTTCTTCAAACGCACCATCCGCAAAGACCTTACATACTCT\nTGCCGGGACAACAAAGACTGCACAGTGGACAAGCGCCAGCGGAACCGCTGTCAGTACTGC\nCGCTATCAGAAGTGCCTGGCCACTGGCATGAAGAGGGAGGCGGTACAGGAGGAGCGTCAG\nCGGGGAAAGGACAAGGATGGGGATGGGGAGGGGGCTGGGGGAGCCCCCGAGGAGATGCCT\nGTGGACAGGATCCTGGAGGCAGAGCTTGCTGTGGAACAGAAGAGTGACCAGGGCGTTGAG\nGGTCCTGGGGGAACCGGGGGTAGCGGCAGCAGCCCAAATGACCCTGTGACTAACATCTGT\nCAGGCAGCTGACAAACAGCTATTCACGCTTGTTGAGTGGGCGAAGAGGATCCCACACTTT\nTCCTCCTTGCCTCTGGATGATCAGGTCATATTGCTGCGGGCAGGCTGGAATGAACTCCTC\nATTGCCTCCTTCTCACACCGATCCATTGATGTTCGAGATGGCATCCTCCTTGCCACAGGT\nCTTCACGTGCACCGCAACTCAGCCCATTCAGCAGGAGTAGGAGCCATCTTTGATCGGTCC\nCTCTCCAGGGTGCTGACAGAGCTAGTGTCCAAAATGCGTGACATGAGGATGGACAAGACA\nGAGCTTGGCTGCCTGAGGGCAATCATTCTGTTTAATCCAGATGCCAAGGGCCTCTCCAAC\nCCTAGTGAGGTGGAGGTCCTGCGGGAGAAAGTGTATGCATCACTGGAGACCTACTGCAAA\nCAGAAGTACCCTGAGCAGCAGGGACGGTTTGCCAAGCTGCTGCTACGTCTTCCTGCCCTC\nCGGTCCATTGGCCTTAAGTGTCTAGAGCATCTGTTTTTCTTCAAGCTCATTGGTGACACC\nCCCATCGACACCTTCCTCATGGAGATGCTTGAGGCTCCCCATCAACTGGCCTGA'),('Retinoic acid receptor RXR-gamma','None','Human','Zinc ion binding','Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5\'-AGGTCA-3\' sites known as DR1-DR5. The high affinity ligand for RXRs is 9-cis retinoic acid (By similarity).','RXRG','50870.72','DB00210','>lcl|BSEQ0001409|1392 bp\nATGTATGGAAATTATTCTCACTTCATGAAGTTTCCCGCAGGCTATGGAGGCTCCCCTGGC\nCACACTGGCTCTACATCCATGAGCCCATCAGCAGCCTTGTCCACAGGGAAGCCAATGGAC\nAGCCACCCCAGCTACACAGATACCCCAGTGAGTGCCCCACGGACTCTGAGTGCAGTGGGG\nACCCCCCTCAATGCCCTGGGCTCTCCATATCGAGTCATCACCTCTGCCATGGGCCCACCC\nTCAGGAGCACTTGCAGCGCCTCCAGGAATCAACTTGGTTGCCCCACCCAGCTCTCAGCTA\nAATGTGGTCAACAGTGTCAGCAGTTCAGAGGACATCAAGCCCTTACCAGGGCTTCCCGGG\nATTGGAAACATGAACTACCCATCCACCAGCCCCGGATCTCTGGTTAAACACATCTGTGCT\nATCTGTGGAGACAGATCCTCAGGAAAGCACTACGGGGTATACAGTTGTGAAGGCTGCAAA\nGGGTTCTTCAAGAGGACGATAAGGAAGGACCTCATCTACACGTGTCGGGATAATAAAGAC\nTGCCTCATTGACAAGCGTCAGCGCAACCGCTGCCAGTACTGTCGCTATCAGAAGTGCCTT\nGTCATGGGCATGAAGAGGGAAGCTGTGCAAGAAGAAAGACAGAGGAGCCGAGAGCGAGCT\nGAGAGTGAGGCAGAATGTGCTACCAGTGGTCATGAAGACATGCCTGTGGAGAGGATTCTA\nGAAGCTGAACTTGCTGTTGAACCAAAGACAGAATCCTATGGTGACATGAATATGGAGAAC\nTCGACAAATGACCCTGTTACCAACATATGTCATGCTGCTGACAAGCAGCTTTTCACCCTC\nGTTGAATGGGCCAAGCGTATTCCCCACTTCTCTGACCTCACCTTGGAGGACCAGGTCATT\nTTGCTTCGGGCAGGGTGGAATGAATTGCTGATTGCCTCTTTCTCCCACCGCTCAGTTTCC\nGTGCAGGATGGCATCCTTCTGGCCACGGGTTTACATGTCCACCGGAGCAGTGCCCACAGT\nGCTGGGGTCGGCTCCATCTTTGACAGAGTTCTAACTGAGCTGGTTTCCAAAATGAAAGAC\nATGCAGATGGACAAGTCGGAACTGGGATGCCTGCGAGCCATTGTACTCTTTAACCCAGAT\nGCCAAGGGCCTGTCCAACCCCTCTGAGGTGGAGACTCTGCGAGAGAAGGTTTATGCCACC\nCTTGAGGCCTACACCAAGCAGAAGTATCCGGAACAGCCAGGCAGGTTTGCCAAGCTGCTG\nCTGCGCCTCCCAGCTCTGCGTTCCATTGGCTTGAAATGCCTGGAGCACCTCTTCTTCTTC\nAAGCTCATCGGGGACACCCCCATTGACACCTTCCTCATGGAGATGTTGGAGACCCCGCTG\nCAGATCACCTGA'),('Ribosomal protein S6 kinase alpha-3','None','Human','Ribosomal protein s6 kinase activity','Serine/threonine-protein kinase that acts downstream of ERK (MAPK1/ERK2 and MAPK3/ERK1) signaling and mediates mitogenic and stress-induced activation of the transcription factors CREB1, ETV1/ER81 and NR4A1/NUR77, regulates translation through RPS6 and EIF4B phosphorylation, and mediates cellular proliferation, survival, and differentiation by modulating mTOR signaling and repressing pro-apoptotic function of BAD and DAPK1. In fibroblast, is required for EGF-stimulated phosphorylation of CREB1 and histone H3 at \'Ser-10\', which results in the subsequent transcriptional activation of several immediate-early genes. In response to mitogenic stimulation (EGF and PMA), phosphorylates and activates NR4A1/NUR77 and ETV1/ER81 transcription factors and the cofactor CREBBP. Upon insulin-derived signal, acts indirectly on the transcription regulation of several genes by phosphorylating GSK3B at \'Ser-9\' and inhibiting its activity. Phosphorylates RPS6 in response to serum or EGF via an mTOR-independent mechanism and promotes translation initiation by facilitating assembly of the preinitiation complex. In response to insulin, phosphorylates EIF4B, enhancing EIF4B affinity for the EIF3 complex and stimulating cap-dependent translation. Is involved in the mTOR nutrient-sensing pathway by directly phosphorylating TSC2 at \'Ser-1798\', which potently inhibits TSC2 ability to suppress mTOR signaling, and mediates phosphorylation of RPTOR, which regulates mTORC1 activity and may promote rapamycin-sensitive signaling independently of the PI3K/AKT pathway. Mediates cell survival by phosphorylating the pro-apoptotic proteins BAD and DAPK1 and suppressing their pro-apoptotic function. Promotes the survival of hepatic stellate cells by phosphorylating CEBPB in response to the hepatotoxin carbon tetrachloride (CCl4). Is involved in cell cycle regulation by phosphorylating the CDK inhibitor CDKN1B, which promotes CDKN1B association with 14-3-3 proteins and prevents its translocation to the nucleus and inhibition of G1 progression. In LPS-stimulated dendritic cells, is involved in TLR4-induced macropinocytosis, and in myeloma cells, acts as effector of FGFR3-mediated transformation signaling, after direct phosphorylation at Tyr-529 by FGFR3. Phosphorylates DAPK1.','RPS6KA3','83735.325','DB00945','>lcl|BSEQ0013342|Ribosomal protein S6 kinase alpha-3 (RPS6KA3)\nATGCCGCTGGCGCAGCTGGCGGACCCGTGGCAGAAGATGGCTGTGGAGAGCCCGTCCGAC\nAGCGCTGAGAATGGACAGCAAATTATGGATGAACCTATGGGAGAGGAGGAGATTAACCCA\nCAAACTGAAGAAGTCAGTATCAAAGAAATTGCAATCACACATCATGTAAAGGAAGGACAT\nGAAAAGGCAGATCCTTCCCAGTTTGAACTTTTAAAAGTATTAGGGCAGGGATCATTTGGA\nAAGGTTTTCTTAGTTAAAAAAATCTCAGGCTCTGATGCTAGGCAGCTTTATGCCATGAAG\nGTATTGAAGAAGGCCACACTGAAAGTTCGAGACCGAGTTCGGACAAAAATGGAACGTGAT\nATCTTGGTAGAGGTTAATCATCCTTTTATTGTCAAGTTGCATTATGCTTTTCAAACTGAA\nGGGAAGTTGTATCTTATTTTGGATTTTCTCAGGGGAGGAGATTTGTTTACACGCTTATCC\nAAAGAGGTGATGTTCACAGAAGAAGATGTCAAATTCTACTTGGCTGAACTTGCACTTGCT\nTTAGACCATCTACATAGCCTGGGAATAATTTATAGAGACTTAAAACCAGAAAATATACTT\nCTTGATGAAGAAGGTCACATCAAGTTAACAGATTTCGGCCTAAGTAAAGAGTCTATTGAC\nCATGAAAAGAAGGCATATTCTTTTTGTGGAACTGTGGAGTATATGGCTCCAGAAGTAGTT\nAATCGTCGAGGTCATACTCAGAGTGCTGACTGGTGGTCTTTTGGTGTGTTAATGTTTGAA\nATGCTTACTGGTACACTCCCTTTCCAAGGAAAAGATCGAAAAGAAACAATGACTATGATT\nCTTAAAGCCAAACTTGGAATGCCACAGTTTTTGAGTCCTGAAGCGCAGAGTCTTTTACGA\nATGCTTTTCAAGCGAAATCCTGCAAACAGATTAGGTGCAGGACCAGATGGAGTTGAAGAA\nATTAAAAGACATTCATTTTTCTCAACGATAGACTGGAATAAACTGTATAGAAGAGAAATT\nCATCCGCCATTTAAACCTGCAACGGGCAGGCCTGAAGATACATTCTATTTTGATCCTGAG\nTTTACTGCAAAAACTCCCAAAGATTCACCTGGCATTCCACCTAGTGCTAATGCACATCAG\nCTTTTTCGGGGGTTTAGTTTTGTTGCTATTACCTCAGATGATGAAAGCCAAGCTATGCAG\nACAGTTGGTGTACATTCAATTGTTCAGCAGTTACACAGGAACAGTATTCAGTTTACTGAT\nGGATATGAAGTAAAAGAAGATATTGGAGTTGGCTCCTACTCTGTTTGCAAGAGATGTATA\nCATAAAGCTACAAACATGGAGTTTGCAGTGAAGATTATTGATAAAAGCAAGAGAGACCCA\nACAGAAGAAATTGAAATTCTTCTTCGTTATGGACAGCATCCAAACATTATCACTCTAAAG\nGATGTATATGATGATGGAAAGTATGTGTATGTAGTAACAGAACTTATGAAAGGAGGTGAA\nTTGCTGGATAAAATTCTTAGACAAAAATTTTTCTCTGAACGAGAGGCCAGTGCTGTCCTG\nTTCACTATAACTAAAACCGTTGAATATCTTCACGCACAAGGGGTGGTTCATAGAGACTTG\nAAACCTAGCAACATTCTTTATGTGGATGAATCTGGTAATCCGGAATCTATTCGAATTTGT\nGATTTTGGCTTTGCAAAACAGCTGAGAGCGGAAAATGGTCTTCTCATGACTCCTTGTTAC\nACTGCAAATTTTGTTGCACCAGAGGTTTTAAAAAGACAAGGCTATGATGCTGCTTGTGAT\nATATGGAGTCTTGGTGTCCTACTCTATACAATGCTTACCGGTTACACTCCATTTGCAAAT\nGGTCCTGATGATACACCAGAGGAAATATTGGCACGAATAGGTAGCGGAAAATTCTCACTC\nAGTGGTGGTTACTGGAATTCTGTTTCAGACACAGCAAAGGACCTGGTGTCAAAGATGCTT\nCATGTAGACCCTCATCAGAGACTGACTGCTGCTCTTGTGCTCAGACATCCTTGGATCGTC\nCACTGGGACCAACTGCCACAATACCAACTAAACAGACAGGATGCACCACATCTAGTAAAG\nGGTGCCATGGCAGCTACATATTCTGCTTTGAACCGTAATCAGTCACCAGTTTTGGAACCA\nGTAGGCCGCTCTACTCTTGCTCAGCGGAGAGGTATTAAAAAAATCACCTCAACAGCCCTG\nTGA'),('Ribosyldihydronicotinamide dehydrogenase [quinone]','None','Human','Nadph dehydrogenase (quinone) activity','The enzyme apparently serves as a quinone reductase in connection with conjugation reactions of hydroquinones involved in detoxification pathways as well as in biosynthetic processes such as the vitamin K-dependent gamma-carboxylation of glutamate residues in prothrombin synthesis.','NQO2','25918.4','DB02709','>lcl|BSEQ0010015|Ribosyldihydronicotinamide dehydrogenase [quinone] (NQO2)\nATGGCAGGTAAGAAAGTACTCATTGTCTATGCACACCAGGAACCCAAGTCTTTCAACGGA\nTCCTTGAAGAATGTGGCTGTAGATGAACTGAGCAGGCAGGGCTGCACCGTCACAGTGTCT\nGATTTGTATGCCATGAACCTTGAGCCGAGGGCCACAGACAAAGATATCACTGGTACTCTT\nTCTAATCCTGAGGTTTTCAATTATGGAGTGGAAACCCACGAAGCCTACAAGCAAAGGTCT\nCTGGCTAGCGACATCACTGATGAGCAGAAAAAGGTTCGGGAGGCTGACCTAGTGATATTT\nCAGTTCCCGCTGTACTGGTTCAGCGTGCCAGCCATCCTGAAGGGCTGGATGGATAGGGTG\nCTGTGCCAGGGCTTTGCCTTTGACATCCCAGGATTCTACGATTCCGGTTTGCTCCAGGGT\nAAACTAGCGCTCCTTTCCGTAACCACGGGAGGCACGGCCGAGATGTACACGAAGACAGGA\nGTCAATGGAGATTCTCGATACTTCCTGTGGCCACTCCAGCATGGCACATTACACTTCTGT\nGGATTTAAAGTCCTTGCCCCTCAGATCAGCTTTGCTCCTGAAATTGCATCCGAAGAAGAA\nAGAAAGGGGATGGTGGCTGCGTGGTCCCAGAGGCTGCAGACCATCTGGAAGGAAGAGCCC\nATCCCCTGCACAGCCCACTGGCACTTCGGGCAATAA'),('Serine/threonine-protein kinase mTOR','None','Human','Tfiiic-class transcription factor binding','Serine/threonine protein kinase which is a central regulator of cellular metabolism, growth and survival in response to hormones, growth factors, nutrients, energy and stress signals. MTOR directly or indirectly regulates the phosphorylation of at least 800 proteins. Functions as part of 2 structurally and functionally distinct signaling complexes mTORC1 and mTORC2 (mTOR complex 1 and 2). Activated mTORC1 up-regulates protein synthesis by phosphorylating key regulators of mRNA translation and ribosome synthesis. This includes phosphorylation of EIF4EBP1 and release of its inhibition toward the elongation initiation factor 4E (eiF4E). Moreover, phosphorylates and activates RPS6KB1 and RPS6KB2 that promote protein synthesis by modulating the activity of their downstream targets including ribosomal protein S6, eukaryotic translation initiation factor EIF4B, and the inhibitor of translation initiation PDCD4. Stimulates the pyrimidine biosynthesis pathway, both by acute regulation through RPS6KB1-mediated phosphorylation of the biosynthetic enzyme CAD, and delayed regulation, through transcriptional enhancement of the pentose phosphate pathway which produces 5-phosphoribosyl-1-pyrophosphate (PRPP), an allosteric activator of CAD at a later step in synthesis, this function is dependent on the mTORC1 complex. Regulates ribosome synthesis by activating RNA polymerase III-dependent transcription through phosphorylation and inhibition of MAF1 an RNA polymerase III-repressor. In parallel to protein synthesis, also regulates lipid synthesis through SREBF1/SREBP1 and LPIN1. To maintain energy homeostasis mTORC1 may also regulate mitochondrial biogenesis through regulation of PPARGC1A. mTORC1 also negatively regulates autophagy through phosphorylation of ULK1. Under nutrient sufficiency, phosphorylates ULK1 at \'Ser-758\', disrupting the interaction with AMPK and preventing activation of ULK1. Also prevents autophagy through phosphorylation of the autophagy inhibitor DAP. mTORC1 exerts a feedback control on upstream growth factor signaling that includes phosphorylation and activation of GRB10 a INSR-dependent signaling suppressor. Among other potential targets mTORC1 may phosphorylate CLIP1 and regulate microtubules. As part of the mTORC2 complex MTOR may regulate other cellular processes including survival and organization of the cytoskeleton. Plays a critical role in the phosphorylation at \'Ser-473\' of AKT1, a pro-survival effector of phosphoinositide 3-kinase, facilitating its activation by PDK1. mTORC2 may regulate the actin cytoskeleton, through phosphorylation of PRKCA, PXN and activation of the Rho-type guanine nucleotide exchange factors RHOA and RAC1A or RAC1B. mTORC2 also regulates the phosphorylation of SGK1 at \'Ser-422\'. Regulates osteoclastogensis by adjusting the expression of CEBPB isoforms (By similarity).','MTOR','288889.05','DB00337','>lcl|BSEQ0011711|Serine/threonine-protein kinase mTOR (MTOR)\nATGCTTGGAACCGGACCTGCCGCCGCCACCACCGCTGCCACCACATCTAGCAATGTGAGC\nGTCCTGCAGCAGTTTGCCAGTGGCCTAAAGAGCCGGAATGAGGAAACCAGGGCCAAAGCC\nGCCAAGGAGCTCCAGCACTATGTCACCATGGAACTCCGAGAGATGAGTCAAGAGGAGTCT\nACTCGCTTCTATGACCAACTGAACCATCACATTTTTGAATTGGTTTCCAGCTCAGATGCC\nAATGAGAGGAAAGGTGGCATCTTGGCCATAGCTAGCCTCATAGGAGTGGAAGGTGGGAAT\nGCCACCCGAATTGGCAGATTTGCCAACTATCTTCGGAACCTCCTCCCCTCCAATGACCCA\nGTTGTCATGGAAATGGCATCCAAGGCCATTGGCCGTCTTGCCATGGCAGGGGACACTTTT\nACCGCTGAGTACGTGGAATTTGAGGTGAAGCGAGCCCTGGAATGGCTGGGTGCTGACCGC\nAATGAGGGCCGGAGACATGCAGCTGTCCTGGTTCTCCGTGAGCTGGCCATCAGCGTCCCT\nACCTTCTTCTTCCAGCAAGTGCAACCCTTCTTTGACAACATTTTTGTGGCCGTGTGGGAC\nCCCAAACAGGCCATCCGTGAGGGAGCTGTAGCCGCCCTTCGTGCCTGTCTGATTCTCACA\nACCCAGCGTGAGCCGAAGGAGATGCAGAAGCCTCAGTGGTACAGGCACACATTTGAAGAA\nGCAGAGAAGGGATTTGATGAGACCTTGGCCAAAGAGAAGGGCATGAATCGGGATGATCGG\nATCCATGGAGCCTTGTTGATCCTTAACGAGCTGGTCCGAATCAGCAGCATGGAGGGAGAG\nCGTCTGAGAGAAGAAATGGAAGAAATCACACAGCAGCAGCTGGTACACGACAAGTACTGC\nAAAGATCTCATGGGCTTCGGAACAAAACCTCGTCACATTACCCCCTTCACCAGTTTCCAG\nGCTGTACAGCCCCAGCAGTCAAATGCCTTGGTGGGGCTGCTGGGGTACAGCTCTCACCAA\nGGCCTCATGGGATTTGGGACCTCCCCCAGTCCAGCTAAGTCCACCCTGGTGGAGAGCCGG\nTGTTGCAGAGACTTGATGGAGGAGAAATTTGATCAGGTGTGCCAGTGGGTGCTGAAATGC\nAGGAATAGCAAGAACTCGCTGATCCAAATGACAATCCTTAATTTGTTGCCCCGCTTGGCT\nGCATTCCGACCTTCTGCCTTCACAGATACCCAGTATCTCCAAGATACCATGAACCATGTC\nCTAAGCTGTGTCAAGAAGGAGAAGGAACGTACAGCGGCCTTCCAAGCCCTGGGGCTACTT\nTCTGTGGCTGTGAGGTCTGAGTTTAAGGTCTATTTGCCTCGCGTGCTGGACATCATCCGA\nGCGGCCCTGCCCCCAAAGGACTTCGCCCATAAGAGGCAGAAGGCAATGCAGGTGGATGCC\nACAGTCTTCACTTGCATCAGCATGCTGGCTCGAGCAATGGGGCCAGGCATCCAGCAGGAT\nATCAAGGAGCTGCTGGAGCCCATGCTGGCAGTGGGACTAAGCCCTGCCCTCACTGCAGTG\nCTCTACGACCTGAGCCGTCAGATTCCACAGCTAAAGAAGGACATTCAAGATGGGCTACTG\nAAAATGCTGTCCCTGGTCCTTATGCACAAACCCCTTCGCCACCCAGGCATGCCCAAGGGC\nCTGGCCCATCAGCTGGCCTCTCCTGGCCTCACGACCCTCCCTGAGGCCAGCGATGTGGGC\nAGCATCACTCTTGCCCTCCGAACGCTTGGCAGCTTTGAATTTGAAGGCCACTCTCTGACC\nCAATTTGTTCGCCACTGTGCGGATCATTTCCTGAACAGTGAGCACAAGGAGATCCGCATG\nGAGGCTGCCCGCACCTGCTCCCGCCTGCTCACACCCTCCATCCACCTCATCAGTGGCCAT\nGCTCATGTGGTTAGCCAGACCGCAGTGCAAGTGGTGGCAGATGTGCTTAGCAAACTGCTC\nGTAGTTGGGATAACAGATCCTGACCCTGACATTCGCTACTGTGTCTTGGCGTCCCTGGAC\nGAGCGCTTTGATGCACACCTGGCCCAGGCGGAGAACTTGCAGGCCTTGTTTGTGGCTCTG\nAATGACCAGGTGTTTGAGATCCGGGAGCTGGCCATCTGCACTGTGGGCCGACTCAGTAGC\nATGAACCCTGCCTTTGTCATGCCTTTCCTGCGCAAGATGCTCATCCAGATTTTGACAGAG\nTTGGAGCACAGTGGGATTGGAAGAATCAAAGAGCAGAGTGCCCGCATGCTGGGGCACCTG\nGTCTCCAATGCCCCCCGACTCATCCGCCCCTACATGGAGCCTATTCTGAAGGCATTAATT\nTTGAAACTGAAAGATCCAGACCCTGATCCAAACCCAGGTGTGATCAATAATGTCCTGGCA\nACAATAGGAGAATTGGCACAGGTTAGTGGCCTGGAAATGAGGAAATGGGTTGATGAACTT\nTTTATTATCATCATGGACATGCTCCAGGATTCCTCTTTGTTGGCCAAAAGGCAGGTGGCT\nCTGTGGACCCTGGGACAGTTGGTGGCCAGCACTGGCTATGTAGTAGAGCCCTACAGGAAG\nTACCCTACTTTGCTTGAGGTGCTACTGAATTTTCTGAAGACTGAGCAGAACCAGGGTACA\nCGCAGAGAGGCCATCCGTGTGTTAGGGCTTTTAGGGGCTTTGGATCCTTACAAGCACAAA\nGTGAACATTGGCATGATAGACCAGTCCCGGGATGCCTCTGCTGTCAGCCTGTCAGAATCC\nAAGTCAAGTCAGGATTCCTCTGACTATAGCACTAGTGAAATGCTGGTCAACATGGGAAAC\nTTGCCTCTGGATGAGTTCTACCCAGCTGTGTCCATGGTGGCCCTGATGCGGATCTTCCGA\nGACCAGTCACTCTCTCATCATCACACCATGGTTGTCCAGGCCATCACCTTCATCTTCAAG\nTCCCTGGGACTCAAATGTGTGCAGTTCCTGCCCCAGGTCATGCCCACGTTCCTTAACGTC\nATTCGAGTCTGTGATGGGGCCATCCGGGAATTTTTGTTCCAGCAGCTGGGAATGTTGGTG\nTCCTTTGTGAAGAGCCACATCAGACCTTATATGGATGAAATAGTCACCCTCATGAGAGAA\nTTCTGGGTCATGAACACCTCAATTCAGAGCACGATCATTCTTCTCATTGAGCAAATTGTG\nGTAGCTCTTGGGGGTGAATTTAAGCTCTACCTGCCCCAGCTGATCCCACACATGCTGCGT\nGTCTTCATGCATGACAACAGCCCAGGCCGCATTGTCTCTATCAAGTTACTGGCTGCAATC\nCAGCTGTTTGGCGCCAACCTGGATGACTACCTGCATTTACTGCTGCCTCCTATTGTTAAG\nTTGTTTGATGCCCCTGAAGCTCCACTGCCATCTCGAAAGGCAGCGCTAGAGACTGTGGAC\nCGCCTGACGGAGTCCCTGGATTTCACTGACTATGCCTCCCGGATCATTCACCCTATTGTT\nCGAACACTGGACCAGAGCCCAGAACTGCGCTCCACAGCCATGGACACGCTGTCTTCACTT\nGTTTTTCAGCTGGGGAAGAAGTACCAAATTTTCATTCCAATGGTGAATAAAGTTCTGGTG\nCGACACCGAATCAATCATCAGCGCTATGATGTGCTCATCTGCAGAATTGTCAAGGGATAC\nACACTTGCTGATGAAGAGGAGGATCCTTTGATTTACCAGCATCGGATGCTTAGGAGTGGC\nCAAGGGGATGCATTGGCTAGTGGACCAGTGGAAACAGGACCCATGAAGAAACTGCACGTC\nAGCACCATCAACCTCCAAAAGGCCTGGGGCGCTGCCAGGAGGGTCTCCAAAGATGACTGG\nCTGGAATGGCTGAGACGGCTGAGCCTGGAGCTGCTGAAGGACTCATCATCGCCCTCCCTG\nCGCTCCTGCTGGGCCCTGGCACAGGCCTACAACCCGATGGCCAGGGATCTCTTCAATGCT\nGCATTTGTGTCCTGCTGGTCTGAACTGAATGAAGATCAACAGGATGAGCTCATCAGAAGC\nATCGAGTTGGCCCTCACCTCACAAGACATCGCTGAAGTCACACAGACCCTCTTAAACTTG\nGCTGAATTCATGGAACACAGTGACAAGGGCCCCCTGCCACTGAGAGATGACAATGGCATT\nGTTCTGCTGGGTGAGAGAGCTGCCAAGTGCCGAGCATATGCCAAAGCACTACACTACAAA\nGAACTGGAGTTCCAGAAAGGCCCCACCCCTGCCATTCTAGAATCTCTCATCAGCATTAAT\nAATAAGCTACAGCAGCCGGAGGCAGCGGCCGGAGTGTTAGAATATGCCATGAAACACTTT\nGGAGAGCTGGAGATCCAGGCTACCTGGTATGAGAAACTGCACGAGTGGGAGGATGCCCTT\nGTGGCCTATGACAAGAAAATGGACACCAACAAGGACGACCCAGAGCTGATGCTGGGCCGC\nATGCGCTGCCTCGAGGCCTTGGGGGAATGGGGTCAACTCCACCAGCAGTGCTGTGAAAAG\nTGGACCCTGGTTAATGATGAGACCCAAGCCAAGATGGCCCGGATGGCTGCTGCAGCTGCA\nTGGGGTTTAGGTCAGTGGGACAGCATGGAAGAATACACCTGTATGATCCCTCGGGACACC\nCATGATGGGGCATTTTATAGAGCTGTGCTGGCACTGCATCAGGACCTCTTCTCCTTGGCA\nCAACAGTGCATTGACAAGGCCAGGGACCTGCTGGATGCTGAATTAACTGCGATGGCAGGA\nGAGAGTTACAGTCGGGCATATGGGGCCATGGTTTCTTGCCACATGCTGTCCGAGCTGGAG\nGAGGTTATCCAGTACAAACTTGTCCCCGAGCGACGAGAGATCATCCGCCAGATCTGGTGG\nGAGAGACTGCAGGGCTGCCAGCGTATCGTAGAGGACTGGCAGAAAATCCTTATGGTGCGG\nTCCCTTGTGGTCAGCCCTCATGAAGACATGAGAACCTGGCTCAAGTATGCAAGCCTGTGC\nGGCAAGAGTGGCAGGCTGGCTCTTGCTCATAAAACTTTAGTGTTGCTCCTGGGAGTTGAT\nCCGTCTCGGCAACTTGACCATCCTCTGCCAACAGTTCACCCTCAGGTGACCTATGCCTAC\nATGAAAAACATGTGGAAGAGTGCCCGCAAGATCGATGCCTTCCAGCACATGCAGCATTTT\nGTCCAGACCATGCAGCAACAGGCCCAGCATGCCATCGCTACTGAGGACCAGCAGCATAAG\nCAGGAACTGCACAAGCTCATGGCCCGATGCTTCCTGAAACTTGGAGAGTGGCAGCTGAAT\nCTACAGGGCATCAATGAGAGCACAATCCCCAAAGTGCTGCAGTACTACAGCGCCGCCACA\nGAGCACGACCGCAGCTGGTACAAGGCCTGGCATGCGTGGGCAGTGATGAACTTCGAAGCT\nGTGCTACACTACAAACATCAGAACCAAGCCCGCGATGAGAAGAAGAAACTGCGTCATGCC\nAGCGGGGCCAACATCACCAACGCCACCACTGCCGCCACCACGGCCGCCACTGCCACCACC\nACTGCCAGCACCGAGGGCAGCAACAGTGAGAGCGAGGCCGAGAGCACCGAGAACAGCCCC\nACCCCATCGCCGCTGCAGAAGAAGGTCACTGAGGATCTGTCCAAAACCCTCCTGATGTAC\nACGGTGCCTGCCGTCCAGGGCTTCTTCCGTTCCATCTCCTTGTCACGAGGCAACAACCTC\nCAGGATACACTCAGAGTTCTCACCTTATGGTTTGATTATGGTCACTGGCCAGATGTCAAT\nGAGGCCTTAGTGGAGGGGGTGAAAGCCATCCAGATTGATACCTGGCTACAGGTTATACCT\nCAGCTCATTGCAAGAATTGATACGCCCAGACCCTTGGTGGGACGTCTCATTCACCAGCTT\nCTCACAGACATTGGTCGGTACCACCCCCAGGCCCTCATCTACCCACTGACAGTGGCTTCT\nAAGTCTACCACGACAGCCCGGCACAATGCAGCCAACAAGATTCTGAAGAACATGTGTGAG\nCACAGCAACACCCTGGTCCAGCAGGCCATGATGGTGAGCGAGGAGCTGATCCGAGTGGCC\nATCCTCTGGCATGAGATGTGGCATGAAGGCCTGGAAGAGGCATCTCGTTTGTACTTTGGG\nGAAAGGAACGTGAAAGGCATGTTTGAGGTGCTGGAGCCCTTGCATGCTATGATGGAACGG\nGGCCCCCAGACTCTGAAGGAAACATCCTTTAATCAGGCCTATGGTCGAGATTTAATGGAG\nGCCCAAGAGTGGTGCAGGAAGTACATGAAATCAGGGAATGTCAAGGACCTCACCCAAGCC\nTGGGACCTCTATTATCATGTGTTCCGACGAATCTCAAAGCAGCTGCCTCAGCTCACATCC\nTTAGAGCTGCAATATGTTTCCCCAAAACTTCTGATGTGCCGGGACCTTGAATTGGCTGTG\nCCAGGAACATATGACCCCAACCAGCCAATCATTCGCATTCAGTCCATAGCACCGTCTTTG\nCAAGTCATCACATCCAAGCAGAGGCCCCGGAAATTGACACTTATGGGCAGCAACGGACAT\nGAGTTTGTTTTCCTTCTAAAAGGCCATGAAGATCTGCGCCAGGATGAGCGTGTGATGCAG\nCTCTTCGGCCTGGTTAACACCCTTCTGGCCAATGACCCAACATCTCTTCGGAAAAACCTC\nAGCATCCAGAGATACGCTGTCATCCCTTTATCGACCAACTCGGGCCTCATTGGCTGGGTT\nCCCCACTGTGACACACTGCACGCCCTCATCCGGGACTACAGGGAGAAGAAGAAGATCCTT\nCTCAACATCGAGCATCGCATCATGTTGCGGATGGCTCCGGACTATGACCACTTGACTCTG\nATGCAGAAGGTGGAGGTGTTTGAGCATGCCGTCAATAATACAGCTGGGGACGACCTGGCC\nAAGCTGCTGTGGCTGAAAAGCCCCAGCTCCGAGGTGTGGTTTGACCGAAGAACCAATTAT\nACCCGTTCTTTAGCGGTCATGTCAATGGTTGGGTATATTTTAGGCCTGGGAGATAGACAC\nCCATCCAACCTGATGCTGGACCGTCTGAGTGGGAAGATCCTGCACATTGACTTTGGGGAC\nTGCTTTGAGGTTGCTATGACCCGAGAGAAGTTTCCAGAGAAGATTCCATTTAGACTAACA\nAGAATGTTGACCAATGCTATGGAGGTTACAGGCCTGGATGGCAACTACAGAATCACATGC\nCACACAGTGATGGAGGTGCTGCGAGAGCACAAGGACAGTGTCATGGCCGTGCTGGAAGCC\nTTTGTCTATGACCCCTTGCTGAACTGGAGGCTGATGGACACAAATACCAAAGGCAACAAG\nCGATCCCGAACGAGGACGGATTCCTACTCTGCTGGCCAGTCAGTCGAAATTTTGGACGGT\nGTGGAACTTGGAGAGCCAGCCCATAAGAAAACGGGGACCACAGTGCCAGAATCTATTCAT\nTCTTTCATTGGAGACGGTTTGGTGAAACCAGAGGCCCTAAATAAGAAAGCTATCCAGATT\nATTAACAGGGTTCGAGATAAGCTCACTGGTCGGGACTTCTCTCATGATGACACTTTGGAT\nGTTCCAACGCAAGTTGAGCTGCTCATCAAACAAGCGACATCCCATGAAAACCTCTGCCAG\nTGCTATATTGGCTGGTGCCCTTTCTGGTAA'),('Sex hormone-binding globulin','None','Human','Androgen binding','Functions as an androgen transport protein, but may also be involved in receptor mediated processes. Each dimer binds one molecule of steroid. Specific for 5-alpha-dihydrotestosterone, testosterone, and 17-beta-estradiol. Regulates the plasma metabolic clearance rate of steroid hormones by controlling their plasma concentration.','SHBG','43778.755','DB00179','>lcl|BSEQ0010477|Sex hormone-binding globulin (SHBG)\nATGGAGAGCAGAGGCCCACTGGCTACCTCGCGCCTGCTGCTGTTGCTGCTGTTGCTACTA\nCTGCGTCACACCCGCCAGGGATGGGCCCTGAGACCTGTTCTCCCCACCCAGAGTGCCCAC\nGACCCTCCGGCTGTCCACCTCAGCAATGGCCCAGGACAAGAGCCTATCGCTGTCATGACC\nTTTGACCTCACCAAGATCACAAAAACCTCCTCCTCCTTTGAGGTTCGAACCTGGGACCCA\nGAGGGAGTGATTTTTTATGGGGATACCAACCCTAAGGATGACTGGTTTATGCTGGGACTT\nCGAGACGGCAGGCCTGAGATCCAACTGCACAATCACTGGGCCCAGCTTACGGTGGGTGCT\nGGACCACGGCTGGATGATGGGAGATGGCACCAGGTGGAAGTCAAGATGGAGGGGGACTCT\nGTGCTGCTGGAGGTGGATGGGGAGGAGGTGCTGCGCCTGAGACAGGTCTCTGGGCCCCTG\nACCAGCAAACGCCATCCCATCATGAGGATTGCGCTTGGGGGGCTGCTCTTCCCCGCTTCC\nAACCTTCGGTTGCCGCTGGTTCCTGCCCTGGATGGCTGCCTGCGCCGGGATTCCTGGCTG\nGACAAACAGGCCGAGATCTCAGCATCTGCCCCCACTAGCCTCAGAAGCTGTGATGTAGAA\nTCAAATCCCGGGATATTTCTCCCTCCAGGGACTCAGGCAGAATTCAATCTCCGAGACATT\nCCCCAGCCTCATGCAGAGCCCTGGGCCTTCTCTTTGGACCTGGGACTCAAGCAGGCAGCA\nGGCTCAGGCCACCTCCTTGCTCTTGGGACACCAGAGAACCCATCTTGGCTCAGTCTCCAC\nCTCCAAGATCAAAAGGTGGTGTTGTCTTCTGGGTCGGGGCCAGGGCTGGATCTGCCCCTG\nGTCTTGGGACTCCCTCTTCAGCTGAAGCTGAGTATGTCCAGGGTGGTCTTGAGCCAAGGG\nTCGAAGATGAAGGCCCTTGCCCTGCCTCCCTTAGGCCTGGCTCCCCTCCTTAACCTCTGG\nGCCAAGCCTCAAGGGCGTCTCTTCCTGGGGGCTTTACCAGGAGAAGACTCTTCCACCTCT\nTTTTGCCTGAATGGCCTTTGGGCACAAGGTCAGAGGCTGGATGTGGACCAGGCCCTGAAC\nAGAAGCCATGAGATCTGGACTCACAGCTGCCCCCAGAGCCCAGGCAATGGCACTGACGCT\nTCCCATTAA'),('Sigma non-opioid intracellular receptor 1','None','Human','Opioid receptor activity','Functions in lipid transport from the endoplasmic reticulum and is involved in a wide array of cellular functions probably through regulation of the biogenesis of lipid microdomains at the plasma membrane. Involved in the regulation of different receptors it plays a role in BDNF signaling and EGF signaling. Also regulates ion channels like the potassium channel and could modulate neurotransmitter release. Plays a role in calcium signaling through modulation together with ANK2 of the ITP3R-dependent calcium efflux at the endoplasmic reticulum. Plays a role in several other cell functions including proliferation, survival and death. Originally identified for its ability to bind various psychoactive drugs it is involved in learning processes, memory and mood alteration (PubMed:16472803, PubMed:9341151). Necessary for proper mitochondrial axonal transport in motor neurons, in particular the retrograde movement of mitochondria (By similarity).','SIGMAR1','25127.52','DB00321','>lcl|BSEQ0009974|Sigma non-opioid intracellular receptor 1 (SIGMAR1)\nATGCAGTGGGCCGTGGGCCGGCGGTGGGCGTGGGCCGCGCTGCTCCTGGCTGTCGCAGCG\nGTGCTGACCCAGGTCGTCTGGCTCTGGCTGGGTACGCAGAGCTTCGTCTTCCAGCGCGAA\nGAGATAGCGCAGTTGGCGCGGCAGTACGCTGGGCTGGACCACGAGCTGGCCTTCTCTCGT\nCTGATCGTGGAGCTGCGGCGGCTGCACCCAGGCCACGTGCTGCCCGACGAGGAGCTGCAG\nTGGGTGTTCGTGAATGCGGGTGGCTGGATGGGCGCCATGTGCCTTCTGCACGCCTCGCTG\nTCCGAGTATGTGCTGCTCTTCGGCACCGCCTTGGGCTCCCGCGGCCACTCGGGGCGCTAC\nTGGGCTGAGATCTCGGATACCATCATCTCTGGCACCTTCCACCAGTGGAGAGAGGGCACC\nACCAAAAGTGAGGTCTTCTACCCAGGACCCTTGACCAGCCAGGCCTGA'),('Sodium channel protein type 4 subunit alpha','None','Human','Voltage-gated sodium channel activity','This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. This sodium channel may be present in both denervated and innervated skeletal muscle.','SCN4A','208059.175','DB00586','>lcl|BSEQ0011511|Sodium channel protein type 4 subunit alpha (SCN4A)\nATGGCCAGACCATCTCTGTGCACCCTGGTGCCTCTGGGCCCTGAGTGCTTGCGCCCCTTC\nACCCGGGAGTCACTGGCAGCCATAGAACAGCGGGCGGTGGAGGAGGAGGCCCGGCTGCAG\nCGGAATAAGCAGATGGAGATTGAGGAGCCCGAACGGAAGCCACGAAGTGACTTGGAGGCT\nGGCAAGAACCTACCCATGATCTACGGAGACCCCCCGCCGGAGGTCATCGGCATCCCCCTG\nGAGGACCTGGATCCCTACTACAGCAATAAGAAGACCTTCATCGTACTCAACAAGGGCAAG\nGCCATCTTCCGCTTCTCCGCCACACCTGCTCTCTACCTGCTGAGCCCCTTCAGCGTAGTC\nAGGCGCGGGGCCATCAAGGTGCTCATCCATGCGCTGTTCAGCATGTTCATCATGATCACC\nATCTTGACCAACTGCGTATTCATGACCATGAGTGACCCGCCTCCCTGGTCCAAGAATGTG\nGAGTACACCTTCACAGGGATCTACACCTTTGAGTCCCTCATCAAGATACTGGCCCGAGGC\nTTCTGTGTCGACGACTTCACATTCCTCCGGGACCCCTGGAACTGGCTGGACTTCAGTGTC\nATCATGATGGCGTACCTGACAGAGTTTGTGGACTTGGGCAACATCTCAGCCCTGAGGACC\nTTCCGGGTGCTGCGGGCCCTCAAAACCATCACGGTCATCCCAGGGCTGAAGACGATCGTG\nGGGGCCCTGATCCAGTCGGTGAAAAAGCTGTCGGATGTGATGATCCTCACTGTCTTCTGC\nCTGAGCGTCTTTGCGCTGGTAGGACTGCAGCTCTTCATGGGAAACCTGAGGCAGAAGTGT\nGTGCGCTGGCCCCCGCCGTTCAACGACACCAACACCACGTGGTACAGCAATGACACGTGG\nTACGGCAATGACACATGGTATGGCAATGAGATGTGGTACGGCAATGACTCATGGTATGCC\nAACGACACGTGGAACAGCCATGCAAGCTGGGCCACCAACGATACCTTTGATTGGGACGCC\nTACATCAGTGATGAAGGGAACTTCTACTTCCTGGAGGGCTCCAACGATGCCCTGCTCTGT\nGGGAACAGCAGTGATGCTGGGCACTGCCCTGAGGGTTATGAGTGCATCAAGACCGGGCGG\nAACCCCAACTATGGCTACACCAGCTATGACACCTTCAGCTGGGCCTTCTTGGCTCTCTTC\nCGCCTCATGACACAGGACTATTGGGAGAACCTCTTCCAGCTGACCCTTCGAGCAGCTGGC\nAAGACCTACATGATCTTCTTCGTGGTCATCATCTTCCTGGGCTCTTTCTACCTCATCAAT\nCTGATCCTGGCCGTGGTGGCCATGGCATATGCCGAGCAGAATGAGGCCACCCTGGCCGAG\nGATAAGGAGAAAGAGGAGGAGTTTCAGCAGATGCTTGAGAAGTTCAAAAAGCACCAGGAG\nGAGCTGGAGAAGGCCAAGGCCGCCCAAGCTCTGGAAGGTGGGGAGGCAGATGGGGACCCA\nGCCCATGGCAAAGACTGCAATGGCAGCCTGGACACATCGCAAGGGGAGAAGGGAGCCCCG\nAGGCAGAGCAGCAGCGGAGACAGCGGCATCTCCGACGCCATGGAAGAACTGGAAGAGGCC\nCACCAAAAGTGCCCACCATGGTGGTACAAGTGCGCCCACAAAGTGCTCATATGGAACTGC\nTGCGCCCCGTGGCTGAAGTTCAAGAACATCATCCACCTGATCGTCATGGACCCGTTCGTG\nGACCTGGGCATCACCATCTGCATCGTGCTCAACACCCTCTTCATGGCCATGGAACATTAC\nCCCATGACGGAGCACTTTGACAACGTGCTCACTGTGGGCAACCTGGTCTTCACAGGCATC\nTTCACAGCAGAGATGGTTCTGAAGCTGATTGCCATGGACCCCTACGAGTATTTCCAGCAG\nGGTTGGAATATCTTCGACAGCATCATCGTCACCCTCAGCCTGGTAGAGCTAGGCCTGGCC\nAACGTACAGGGACTGTCTGTGCTACGCTCCTTCCGTCTGCTGCGGGTCTTCAAGCTGGCC\nAAGTCGTGGCCAACGCTGAACATGCTCATCAAGATCATTGGCAATTCAGTGGGGGCGCTG\nGGTAACCTGACGCTGGTGCTGGCTATCATCGTGTTCATCTTCGCCGTGGTGGGCATGCAG\nCTGTTTGGCAAGAGCTACAAGGAGTGCGTGTGCAAGATTGCCTTGGACTGCAACCTGCCG\nCGCTGGCACATGCATGATTTCTTCCACTCCTTCCTCATCGTCTTCCGCATCCTGTGCGGG\nGAGTGGATCGAGACCATGTGGGACTGCATGGAGGTGGCCGGCCAAGCCATGTGCCTCACC\nGTCTTCCTCATGGTCATGGTCATCGGCAATCTTGTGGTCCTGAACCTGTTCCTGGCTCTG\nCTGCTGAGCTCCTTCAGCGCCGACAGTCTGGCAGCCTCGGATGAGGATGGCGAGATGAAC\nAACCTGCAGATTGCCATCGGGCGCATCAAGTTGGGCATCGGCTTTGCCAAGGCCTTCCTC\nCTGGGGCTGCTGCATGGCAAGATCCTGAGCCCCAAGGACATCATGCTCAGCCTCGGGGAG\nGCTGACGGGGCCGGGGAGGCTGGAGAGGCGGGGGAGACTGCCCCCGAGGATGAGAAGAAG\nGAGCCGCCCGAGGAGGACCTGAAGAAGGACAATCACATCCTGAACCACATGGGCCTGGCT\nGACGGCCCCCCATCCAGCCTCGAGCTGGACCACCTTAACTTCATCAACAACCCCTACCTG\nACCATACAGGTGCCCATCGCCTCCGAGGAGTCCGACCTGGAGATGCCCACCGAGGAGGAA\nACCGACACTTTCTCAGAGCCTGAGGATAGCAAGAAGCCGCCGCAGCCTCTCTATGATGGG\nAACTCGTCCGTCTGCAGCACAGCTGACTACAAGCCCCCCGAGGAGGACCCTGAGGAGCAG\nGCAGAGGAGAACCCCGAGGGGGAGCAGCCTGAGGAGTGCTTCACTGAGGCCTGCGTGCAG\nCGCTGGCCCTGCCTCTACGTGGACATCTCCCAGGGCCGTGGGAAGAAGTGGTGGACTCTG\nCGCAGGGCCTGCTTCAAGATTGTCGAGCACAACTGGTTCGAGACCTTCATTGTCTTCATG\nATCCTGCTCAGCAGTGGGGCTCTGGCCTTCGAGGACATCTACATTGAGCAGCGGCGAGTC\nATTCGCACCATCCTAGAATATGCCGACAAGGTCTTCACCTACATCTTCATCATGGAGATG\nCTGCTCAAATGGGTGGCCTACGGCTTTAAGGTGTACTTCACCAACGCCTGGTGCTGGCTC\nGACTTCCTCATCGTGGATGTCTCCATCATCAGCTTGGTGGCCAACTGGCTGGGCTACTCG\nGAGCTGGGACCCATCAAATCCCTGCGGACACTGCGGGCCCTGCGTCCCCTGAGGGCACTG\nTCCCGATTCGAGGGCATGAGGGTGGTGGTGAACGCCCTCCTAGGCGCCATCCCCTCCATC\nATGAATGTGCTGCTTGTCTGCCTCATCTTCTGGCTGATCTTCAGCATCATGGGTGTCAAC\nCTGTTTGCCGGCAAGTTCTACTACTGCATCAACACCACCACCTCTGAGAGGTTCGACATC\nTCCGAGGTCAACAACAAGTCTGAGTGCGAGAGCCTCATGCACACAGGCCAGGTCCGCTGG\nCTCAATGTCAAGGTCAACTACGACAACGTGGGTCTGGGCTACCTCTCCCTCCTGCAGGTG\nGCCACCTTCAAGGGTTGGATGGACATCATGTATGCAGCCGTGGACTCCCGGGAGAAGGAG\nGAGCAGCCGCAGTACGAGGTGAACCTCTACATGTACCTCTACTTTGTCATCTTCATCATC\nTTTGGCTCCTTCTTCACCCTCAACCTCTTCATTGGCGTCATCATTGACAACTTCAACCAG\nCAGAAGAAGAAGTTAGGGGGGAAAGACATCTTTATGACGGAGGAACAGAAGAAATACTAT\nAACGCCATGAAGAAGCTTGGCTCCAAGAAGCCTCAGAAGCCAATTCCCCGGCCCCAGAAC\nAAGATCCAGGGCATGGTGTATGACCTCGTGACGAAGCAGGCCTTCGACATCACCATCATG\nATCCTCATCTGCCTCAACATGGTCACCATGATGGTGGAGACAGACAACCAGAGCCAGCTC\nAAGGTGGACATCCTGTACAACATCAACATGATCTTCATCATCATCTTCACAGGGGAGTGC\nGTGCTCAAGATGCTCGCCCTGCGCCAGTACTACTTCACCGTTGGCTGGAACATCTTTGAC\nTTCGTGGTCGTCATCCTGTCCATTGTGGGCCTTGCCCTCTCTGACCTGATCCAGAAGTAC\nTTCGTGTCACCCACGCTGTTCCGTGTGATCCGCCTGGCGCGGATTGGGCGTGTCCTGCGG\nCTGATCCGCGGGGCCAAGGGCATCCGGACGCTGCTGTTCGCCCTCATGATGTCGCTGCCT\nGCCCTCTTCAACATCGGCCTCCTCCTCTTCCTGGTCATGTTCATCTACTCCATCTTCGGC\nATGTCCAACTTTGCCTACGTCAAGAAGGAGTCGGGCATCGATGATATGTTCAACTTCGAG\nACCTTCGGCAACAGCATCATCTGCCTGTTCGAGATCACCACGTCGGCCGGCTGGGACGGG\nCTCCTCAACCCCATCCTCAACAGCGGGCCCCCAGACTGTGACCCCAACCTGGAGAACCCG\nGGCACCAGTGTCAAGGGTGACTGCGGCAACCCCTCCATCGGCATCTGCTTCTTCTGCAGC\nTATATCATCATCTCCTTCCTCATCGTGGTCAACATGTACATCGCCATCATCCTGGAGAAC\nTTCAATGTGGCCACAGAGGAGAGCAGCGAGCCCCTTGGTGAAGATGACTTTGAGATGTTC\nTACGAGACATGGGAGAAGTTCGACCCCGACGCCACCCAGTTCATCGCCTACAGCCGCCTC\nTCAGACTTCGTGGACACCCTGCAGGAACCGCTGAGGATTGCCAAGCCCAACAAGATCAAG\nCTCATCACACTGGACTTGCCCATGGTGCCAGGGGACAAGATCCACTGCCTGGACATCCTC\nTTTGCCCTGACCAAAGAGGTCCTGGGTGACTCTGGGGAAATGGACGCCCTCAAGCAGACC\nATGGAGGAGAAGTTCATGGCAGCCAACCCCTCCAAGGTGTCCTACGAGCCCATCACCACC\nACCCTCAAGAGGAAGCACGAGGAGGTGTGCGCCATCAAGATCCAGAGGGCCTACCGCCGG\nCACCTGCTACAGCGCTCCATGAAGCAGGCATCCTACATGTACCGCCACAGCCACGACGGC\nAGCGGGGATGACGCCCCTGAGAAGGAGGGGCTGCTTGCCAACACCATGAGCAAGATGTAT\nGGCCACGAGAATGGGAACAGCAGCTCGCCAAGCCCGGAGGAGAAGGGCGAGGCAGGGGAC\nGCCGGACCCACTATGGGGCTGATGCCCATCAGCCCCTCAGACACTGCCTGGCCTCCCGCC\nCCTCCCCCAGGGCAGACTGTGCGCCCAGGTGTCAAGGAGTCTCTTGTCTAG'),('Sodium channel protein type 5 subunit alpha','None','Human','Voltage-gated sodium channel activity involved in sa node cell action potential','This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. It is a tetrodotoxin-resistant Na(+) channel isoform. This channel is responsible for the initial upstroke of the action potential. Channel inactivation is regulated by intracellular calcium levels.','SCN5A','226937.475','DB00564','>lcl|BSEQ0009999|Sodium channel protein type 5 subunit alpha (SCN5A)\nATGGCAAACTTCCTATTACCTCGGGGCACCAGCAGCTTCCGCAGGTTCACACGGGAGTCC\nCTGGCAGCCATCGAGAAGCGCATGGCAGAGAAGCAAGCCCGCGGCTCAACCACCTTGCAG\nGAGAGCCGAGAGGGGCTGCCCGAGGAGGAGGCTCCCCGGCCCCAGCTGGACCTGCAGGCC\nTCCAAAAAGCTGCCAGATCTCTATGGCAATCCACCCCAAGAGCTCATCGGAGAGCCCCTG\nGAGGACCTGGACCCCTTCTATAGCACCCAAAAGACTTTCATCGTACTGAATAAAGGCAAG\nACCATCTTCCGGTTCAGTGCCACCAACGCCTTGTATGTCCTCAGTCCCTTCCACCCCATC\nCGGAGAGCGGCTGTGAAGATTCTGGTTCACTCGCTCTTCAACATGCTCATCATGTGCACC\nATCCTCACCAACTGCGTGTTCATGGCCCAGCACGACCCTCCACCCTGGACCAAGTATGTC\nGAGTACACCTTCACCGCCATTTACACCTTTGAGTCTCTGGTCAAGATTCTGGCTCGAGGC\nTTCTGCCTGCACGCGTTCACTTTCCTTCGGGACCCATGGAACTGGCTGGACTTTAGTGTG\nATTATCATGGCATACACAACTGAATTTGTGGACCTGGGCAATGTCTCAGCCTTACGCACC\nTTCCGAGTCCTCCGGGCCCTGAAAACTATATCAGTCATTTCAGGGCTGAAGACCATCGTG\nGGGGCCCTGATCCAGTCTGTGAAGAAGCTGGCTGATGTGATGGTCCTCACAGTCTTCTGC\nCTCAGCGTCTTTGCCCTCATCGGCCTGCAGCTCTTCATGGGCAACCTAAGGCACAAGTGC\nGTGCGCAACTTCACAGCGCTCAACGGCACCAACGGCTCCGTGGAGGCCGACGGCTTGGTC\nTGGGAATCCCTGGACCTTTACCTCAGTGATCCAGAAAATTACCTGCTCAAGAACGGCACC\nTCTGATGTGTTACTGTGTGGGAACAGCTCTGACGCTGGGACATGTCCGGAGGGCTACCGG\nTGCCTAAAGGCAGGCGAGAACCCCGACCACGGCTACACCAGCTTCGATTCCTTTGCCTGG\nGCCTTTCTTGCACTCTTCCGCCTGATGACGCAGGACTGCTGGGAGCGCCTCTATCAGCAG\nACCCTCAGGTCCGCAGGGAAGATCTACATGATCTTCTTCATGCTTGTCATCTTCCTGGGG\nTCCTTCTACCTGGTGAACCTGATCCTGGCCGTGGTCGCAATGGCCTATGAGGAGCAAAAC\nCAAGCCACCATCGCTGAGACCGAGGAGAAGGAAAAGCGCTTCCAGGAGGCCATGGAAATG\nCTCAAGAAAGAACACGAGGCCCTCACCATCAGGGGTGTGGATACCGTGTCCCGTAGCTCC\nTTGGAGATGTCCCCTTTGGCCCCAGTAAACAGCCATGAGAGAAGAAGCAAGAGGAGAAAA\nCGGATGTCTTCAGGAACTGAGGAGTGTGGGGAGGACAGGCTCCCCAAGTCTGACTCAGAA\nGATGGTCCCAGAGCAATGAATCATCTCAGCCTCACCCGTGGCCTCAGCAGGACTTCTATG\nAAGCCACGTTCCAGCCGCGGGAGCATTTTCACCTTTCGCAGGCGAGACCTGGGTTCTGAA\nGCAGATTTTGCAGATGATGAAAACAGCACAGCGGGGGAGAGCGAGAGCCACCACACATCA\nCTGCTGGTGCCCTGGCCCCTGCGCCGGACCAGTGCCCAGGGACAGCCCAGTCCCGGAACC\nTCGGCTCCTGGCCACGCCCTCCATGGCAAAAAGAACAGCACTGTGGACTGCAATGGGGTG\nGTCTCATTACTGGGGGCAGGCGACCCAGAGGCCACATCCCCAGGAAGCCACCTCCTCCGC\nCCTGTGATGCTAGAGCACCCGCCAGACACGACCACGCCATCGGAGGAGCCAGGCGGGCCC\nCAGATGCTGACCTCCCAGGCTCCGTGTGTAGATGGCTTCGAGGAGCCAGGAGCACGGCAG\nCGGGCCCTCAGCGCAGTCAGCGTCCTCACCAGCGCACTGGAAGAGTTAGAGGAGTCTCGC\nCACAAGTGTCCACCATGCTGGAACCGTCTCGCCCAGCGCTACCTGATCTGGGAGTGCTGC\nCCGCTGTGGATGTCCATCAAGCAGGGAGTGAAGTTGGTGGTCATGGACCCGTTTACTGAC\nCTCACCATCACTATGTGCATCGTACTCAACACACTCTTCATGGCGCTGGAGCACTACAAC\nATGACAAGTGAATTCGAGGAGATGCTGCAGGTCGGAAACCTGGTCTTCACAGGGATTTTC\nACAGCAGAGATGACCTTCAAGATCATTGCCCTCGACCCCTACTACTACTTCCAACAGGGC\nTGGAACATCTTCGACAGCATCATCGTCATCCTTAGCCTCATGGAGCTGGGCCTGTCCCGC\nATGAGCAACTTGTCGGTGCTGCGCTCCTTCCGCCTGCTGCGGGTCTTCAAGCTGGCCAAA\nTCATGGCCCACCCTGAACACACTCATCAAGATCATCGGGAACTCAGTGGGGGCACTGGGG\nAACCTGACACTGGTGCTAGCCATCATCGTGTTCATCTTTGCTGTGGTGGGCATGCAGCTC\nTTTGGCAAGAACTACTCGGAGCTGAGGGACAGCGACTCAGGCCTGCTGCCTCGCTGGCAC\nATGATGGACTTCTTTCATGCCTTCCTCATCATCTTCCGCATCCTCTGTGGAGAGTGGATC\nGAGACCATGTGGGACTGCATGGAGGTGTCGGGGCAGTCATTATGCCTGCTGGTCTTCTTG\nCTTGTTATGGTCATTGGCAACCTTGTGGTCCTGAATCTCTTCCTGGCCTTGCTGCTCAGC\nTCCTTCAGTGCAGACAACCTCACAGCCCCTGATGAGGACAGAGAGATGAACAACCTCCAG\nCTGGCCCTGGCCCGCATCCAGAGGGGCCTGCGCTTTGTCAAGCGGACCACCTGGGATTTC\nTGCTGTGGTCTCCTGCGGCAGCGGCCTCAGAAGCCCGCAGCCCTTGCCGCCCAGGGCCAG\nCTGCCCAGCTGCATTGCCACCCCCTACTCCCCGCCACCCCCAGAGACGGAGAAGGTGCCT\nCCCACCCGCAAGGAAACACGGTTTGAGGAAGGCGAGCAACCAGGCCAGGGCACCCCCGGG\nGATCCAGAGCCCGTGTGTGTGCCCATCGCTGTGGCCGAGTCAGACACAGATGACCAAGAA\nGAAGATGAGGAGAACAGCCTGGGCACGGAGGAGGAGTCCAGCAAGCAGGAATCCCAGCCT\nGTGTCCGGTGGCCCAGAGGCCCCTCCGGATTCCAGGACCTGGAGCCAGGTGTCAGCGACT\nGCCTCCTCTGAGGCCGAGGCCAGTGCATCTCAGGCCGACTGGCGGCAGCAGTGGAAAGCG\nGAACCCCAGGCCCCAGGGTGCGGTGAGACCCCAGAGGACAGTTGCTCCGAGGGCAGCACA\nGCAGACATGACCAACACCGCTGAGCTCCTGGAGCAGATCCCTGACCTCGGCCAGGATGTC\nAAGGACCCAGAGGACTGCTTCACTGAAGGCTGTGTCCGGCGCTGTCCCTGCTGTGCGGTG\nGACACCACACAGGCCCCAGGGAAGGTCTGGTGGCGGTTGCGCAAGACCTGCTACCACATC\nGTGGAGCACAGCTGGTTCGAGACATTCATCATCTTCATGATCCTACTCAGCAGTGGAGCG\nCTGGCCTTCGAGGACATCTACCTAGAGGAGCGGAAGACCATCAAGGTTCTGCTTGAGTAT\nGCCGACAAGATGTTCACATATGTCTTCGTGCTGGAGATGCTGCTCAAGTGGGTGGCCTAC\nGGCTTCAAGAAGTACTTCACCAATGCCTGGTGCTGGCTCGACTTCCTCATCGTAGACGTC\nTCTCTGGTCAGCCTGGTGGCCAACACCCTGGGCTTTGCCGAGATGGGCCCCATCAAGTCA\nCTGCGGACGCTGCGTGCACTCCGTCCTCTGAGAGCTCTGTCACGATTTGAGGGCATGAGG\nGTGGTGGTCAATGCCCTGGTGGGCGCCATCCCGTCCATCATGAACGTCCTCCTCGTCTGC\nCTCATCTTCTGGCTCATCTTCAGCATCATGGGCGTGAACCTCTTTGCGGGGAAGTTTGGG\nAGGTGCATCAACCAGACAGAGGGAGACTTGCCTTTGAACTACACCATCGTGAACAACAAG\nAGCCAGTGTGAGTCCTTGAACTTGACCGGAGAATTGTACTGGACCAAGGTGAAAGTCAAC\nTTTGACAACGTGGGGGCCGGGTACCTGGCCCTTCTGCAGGTGGCAACATTTAAAGGCTGG\nATGGACATTATGTATGCAGCTGTGGACTCCAGGGGGTATGAAGAGCAGCCTCAGTGGGAA\nTACAACCTCTACATGTACATCTATTTTGTCATTTTCATCATCTTTGGGTCTTTCTTCACC\nCTGAACCTCTTTATTGGTGTCATCATTGACAACTTCAACCAACAGAAGAAAAAGTTAGGG\nGGCCAGGACATCTTCATGACAGAGGAGCAGAAGAAGTACTACAATGCCATGAAGAAGCTG\nGGCTCCAAGAAGCCCCAGAAGCCCATCCCACGGCCCCTGAACAAGTACCAGGGCTTCATA\nTTCGACATTGTGACCAAGCAGGCCTTTGACGTCACCATCATGTTTCTGATCTGCTTGAAT\nATGGTGACCATGATGGTGGAGACAGATGACCAAAGTCCTGAGAAAATCAACATCTTGGCC\nAAGATCAACCTGCTCTTTGTGGCCATCTTCACAGGCGAGTGTATTGTCAAGCTGGCTGCC\nCTGCGCCACTACTACTTCACCAACAGCTGGAATATCTTCGACTTCGTGGTTGTCATCCTC\nTCCATCGTGGGCACTGTGCTCTCGGACATCATCCAGAAGTACTTCTTCTCCCCGACGCTC\nTTCCGAGTCATCCGCCTGGCCCGAATAGGCCGCATCCTCAGACTGATCCGAGGGGCCAAG\nGGGATCCGCACGCTGCTCTTTGCCCTCATGATGTCCCTGCCTGCCCTCTTCAACATCGGG\nCTGCTGCTCTTCCTCGTCATGTTCATCTACTCCATCTTTGGCATGGCCAACTTCGCTTAT\nGTCAAGTGGGAGGCTGGCATCGACGACATGTTCAACTTCCAGACCTTCGCCAACAGCATG\nCTGTGCCTCTTCCAGATCACCACGTCGGCCGGCTGGGATGGCCTCCTCAGCCCCATCCTC\nAACACTGGGCCGCCCTACTGCGACCCCACTCTGCCCAACAGCAATGGCTCTCGGGGGGAC\nTGCGGGAGCCCAGCCGTGGGCATCCTCTTCTTCACCACCTACATCATCATCTCCTTCCTC\nATCGTGGTCAACATGTACATTGCCATCATCCTGGAGAACTTCAGCGTGGCCACGGAGGAG\nAGCACCGAGCCCCTGAGTGAGGACGACTTCGATATGTTCTATGAGATCTGGGAGAAATTT\nGACCCAGAGGCCACTCAGTTTATTGAGTATTCGGTCCTGTCTGACTTTGCCGATGCCCTG\nTCTGAGCCACTCCGTATCGCCAAGCCCAACCAGATAAGCCTCATCAACATGGACCTGCCC\nATGGTGAGTGGGGACCGCATCCATTGCATGGACATTCTCTTTGCCTTCACCAAAAGGGTC\nCTGGGGGAGTCTGGGGAGATGGACGCCCTGAAGATCCAGATGGAGGAGAAGTTCATGGCA\nGCCAACCCATCCAAGATCTCCTACGAGCCCATCACCACCACACTCCGGCGCAAGCACGAA\nGAGGTGTCGGCCATGGTTATCCAGAGAGCCTTCCGCAGGCACCTGCTGCAACGCTCTTTG\nAAGCATGCCTCCTTCCTCTTCCGTCAGCAGGCGGGCAGCGGCCTCTCCGAAGAGGATGCC\nCCTGAGCGAGAGGGCCTCATCGCCTACGTGATGAGTGAGAACTTCTCCCGACCCCTTGGC\nCCACCCTCCAGCTCCTCCATCTCCTCCACTTCCTTCCCACCCTCCTATGACAGTGTCACT\nAGAGCCACCAGCGATAACCTCCAGGTGCGGGGGTCTGACTACAGCCACAGTGAAGATCTC\nGCCGACTTCCCCCCTTCTCCGGACAGGGACCGTGAGTCCATCGTGTGA'),('Sodium-dependent dopamine transporter','None','Human','Monoamine transmembrane transporter activity','Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.','SLC6A3','68494.255','DB01149','>lcl|BSEQ0010451|Sodium-dependent dopamine transporter (SLC6A3)\nATGAGTAAGAGCAAATGCTCCGTGGGACTCATGTCTTCCGTGGTGGCCCCGGCTAAGGAG\nCCCAATGCCGTGGGCCCGAAGGAGGTGGAGCTCATCCTTGTCAAGGAGCAGAACGGAGTG\nCAGCTCACCAGCTCCACCCTCACCAACCCGCGGCAGAGCCCCGTGGAGGCCCAGGATCGG\nGAGACCTGGGGCAAGAAGATCGACTTTCTCCTGTCCGTCATTGGCTTTGCTGTGGACCTG\nGCCAACGTCTGGCGGTTCCCCTACCTGTGCTACAAAAATGGTGGCGGTGCCTTCCTGGTC\nCCCTACCTGCTCTTCATGGTCATTGCTGGGATGCCACTTTTCTACATGGAGCTGGCCCTC\nGGCCAGTTCAACAGGGAAGGGGCCGCTGGTGTCTGGAAGATCTGCCCCATACTGAAAGGT\nGTGGGCTTCACGGTCATCCTCATCTCACTGTATGTCGGCTTCTTCTACAACGTCATCATC\nGCCTGGGCGCTGCACTATCTCTTCTCCTCCTTCACCACGGAGCTCCCCTGGATCCACTGC\nAACAACTCCTGGAACAGCCCCAACTGCTCGGATGCCCATCCTGGTGACTCCAGTGGAGAC\nAGCTCGGGCCTCAACGACACTTTTGGGACCACACCTGCTGCCGAGTACTTTGAACGTGGC\nGTGCTGCACCTCCACCAGAGCCATGGCATCGACGACCTGGGGCCTCCGCGGTGGCAGCTC\nACAGCCTGCCTGGTGCTGGTCATCGTGCTGCTCTACTTCAGCCTCTGGAAGGGCGTGAAG\nACCTCAGGGAAGGTGGTATGGATCACAGCCACCATGCCATACGTGGTCCTCACTGCCCTG\nCTCCTGCGTGGGGTCACCCTCCCTGGAGCCATAGACGGCATCAGAGCATACCTGAGCGTT\nGACTTCTACCGGCTCTGCGAGGCGTCTGTTTGGATTGACGCGGCCACCCAGGTGTGCTTC\nTCCCTGGGCGTGGGGTTCGGGGTGCTGATCGCCTTCTCCAGCTACAACAAGTTCACCAAC\nAACTGCTACAGGGACGCGATTGTCACCACCTCCATCAACTCCCTGACGAGCTTCTCCTCC\nGGCTTCGTCGTCTTCTCCTTCCTGGGGTACATGGCACAGAAGCACAGTGTGCCCATCGGG\nGACGTGGCCAAGGACGGGCCAGGGCTGATCTTCATCATCTACCCGGAAGCCATCGCCACG\nCTCCCTCTGTCCTCAGCCTGGGCCGTGGTCTTCTTCATCATGCTGCTCACCCTGGGTATC\nGACAGCGCCATGGGTGGTATGGAGTCAGTGATCACCGGGCTCATCGATGAGTTCCAGCTG\nCTGCACAGACACCGTGAGCTCTTCACGCTCTTCATCGTCCTGGCGACCTTCCTCCTGTCC\nCTGTTCTGCGTCACCAACGGTGGCATCTACGTCTTCACGCTCCTGGACCATTTTGCAGCC\nGGCACGTCCATCCTCTTTGGAGTGCTCATCGAAGCCATCGGAGTGGCCTGGTTCTATGGT\nGTTGGGCAGTTCAGCGACGACATCCAGCAGATGACCGGGCAGCGGCCCAGCCTGTACTGG\nCGGCTGTGCTGGAAGCTGGTCAGCCCCTGCTTTCTCCTGTTCGTGGTCGTGGTCAGCATT\nGTGACCTTCAGACCCCCCCACTACGGAGCCTACATCTTCCCCGACTGGGCCAACGCGCTG\nGGCTGGGTCATCGCCACATCCTCCATGGCCATGGTGCCCATCTATGCGGCCTACAAGTTC\nTGCAGCCTGCCTGGGTCCTTTCGAGAGAAACTGGCCTACGCCATTGCACCCGAGAAGGAC\nCGTGAGCTGGTGGACAGAGGGGAGGTGCGCCAGTTCACGCTCCGCCACTGGCTCAAGGTG\nTAG'),('Sodium-dependent noradrenaline transporter','None','Human','Norepinephrine:sodium symporter activity','Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.','SLC6A2','69331.42','DB01149','>lcl|BSEQ0010343|Sodium-dependent noradrenaline transporter (SLC6A2)\nATGCTTCTGGCGCGGATGAACCCGCAGGTGCAGCCCGAGAACAACGGGGCGGACACGGGT\nCCAGAGCAGCCCCTTCGGGCGCGCAAAACTGCGGAGCTGCTGGTGGTGAAGGAGCGCAAC\nGGCGTCCAGTGCCTGCTGGCGCCCCGCGACGGCGACGCGCAGCCCCGGGAGACCTGGGGC\nAAGAAGATCGACTTCCTGCTGTCCGTAGTCGGCTTCGCAGTGGACCTGGCCAACGTGTGG\nCGCTTCCCCTACCTCTGCTACAAGAACGGCGGCGGTGCCTTCTTGATCCCGTACACACTG\nTTCCTTATCATCGCGGGGATGCCCCTGTTCTACATGGAGCTGGCTCTGGGACAGTACAAC\nCGGGAGGGGGCTGCCACCGTTTGGAAAATCTGCCCATTCTTCAAAGGCGTTGGCTATGCT\nGTCATCCTGATCGCCCTGTACGTTGGCTTCTACTACAACGTCATCATCGCCTGGTCACTC\nTACTACCTCTTCTCCTCCTTCACCCTCAACCTGCCCTGGACCGACTGTGGCCACACCTGG\nAACAGCCCCAACTGTACCGACCCCAAGCTCCTCAATGGCTCCGTGCTTGGCAACCACACC\nAAGTACTCCAAGTACAAGTTCACGCCGGCAGCCGAGTTTTATGAGCGTGGTGTCCTGCAC\nCTTCACGAGAGCAGCGGGATTCATGACATCGGCCTGCCCCAGTGGCAGCTCTTGCTCTGT\nCTGATGGTCGTCGTCATCGTCTTGTATTTTAGCCTCTGGAAAGGGGTGAAGACATCAGGA\nAAGGTGGTGTGGATCACAGCCACGCTGCCTTACTTCGTGCTGTTCGTGCTCCTGGTCCAT\nGGCGTCACGCTGCCCGGAGCCTCCAATGGCATCAATGCCTACCTGCACATCGACTTCTAC\nCGCTTGAAAGAGGCCACGGTATGGATTGATGCCGCAACTCAGATATTTTTTTCCTTGGGG\nGCTGGATTTGGAGTATTGATTGCATTTGCCAGTTACAACAAATTTGACAACAACTGTTAC\nAGGGATGCCCTGCTGACCAGCAGCATCAACTGTATCACCAGCTTCGTCTCTGGGTTCGCC\nATCTTCTCCATCCTTGGTTACATGGCCCATGAACACAAGGTCAACATTGAGGATGTGGCC\nACAGAAGGAGCTGGCCTAGTGTTCATCCTGTATCCAGAGGCCATTTCTACCCTGTCTGGA\nTCTACATTCTGGGCTGTTGTGTTTTTCGTCATGCTCCTGGCGCTGGGCCTTGACAGCTCA\nATGGGAGGCATGGAGGCTGTCATCACGGGCCTGGCAGATGACTTCCAGGTCCTGAAGCGA\nCACCGGAAACTCTTCACATTTGGCGTCACCTTCAGCACTTTCCTTCTCGCCCTGTTCTGC\nATAACCAAGGGTGGAATTTACGTCTTGACCCTCCTGGACACCTTTGCTGCGGGCACCTCC\nATCCTTTTTGCTGTCCTCATGGAAGCCATCGGAGTTTCCTGGTTTTATGGAGTGGACAGG\nTTCAGCAACGACATCCAGCAGATGATGGGGTTCAGGCCGGGTCTATACTGGAGACTGTGC\nTGGAAGTTCGTCAGTCCTGCCTTCCTCCTGTTCGTGGTTGTGGTCAGCATCATCAACTTC\nAAGCCACTCACCTACGACGACTACATCTTCCCGCCCTGGGCCAACTGGGTGGGGTGGGGC\nATCGCCCTGTCCTCCATGGTCCTGGTGCCCATCTACGTCATCTATAAGTTCCTCAGCACG\nCAGGGCTCTCTTTGGGAGAGACTGGCCTATGGCATCACGCCAGAGAACGAGCACCACCTG\nGTGGCTCAGAGGGACATCAGACAGTTCCAGTTGCAACACTGGCTGGCCATCTGA'),('Sodium-dependent serotonin transporter','None','Human','Serotonin:sodium symporter activity','Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin and recycles it in a sodium-dependent manner.','SLC6A4','70324.165','DB01149','>lcl|BSEQ0021275|Sodium-dependent serotonin transporter (SLC6A4)\nATGGAGACGACGCCCTTGAATTCTCAGAAGCAGCTATCAGCGTGTGAAGATGGAGAAGAT\nTGTCAGGAAAACGGAGTTCTACAGAAGGTTGTTCCCACCCCAGGGGACAAAGTGGAGTCC\nGGGCAAATATCCAATGGGTACTCAGCAGTTCCAAGTCCTGGTGCGGGAGATGACACACGG\nCACTCTATCCCAGCGACCACCACCACCCTAGTGGCTGAGCTTCATCAAGGGGAACGGGAG\nACCTGGGGCAAGAAGGTGGATTTCCTTCTCTCAGTGATTGGCTATGCTGTGGACCTGGGC\nAATGTCTGGCGCTTCCCCTACATATGTTACCAGAATGGAGGGGGGGCATTCCTCCTCCCC\nTACACCATCATGGCCATTTTTGGGGGAATCCCGCTCTTTTACATGGAGCTCGCACTGGGA\nCAGTACCACCGAAATGGATGCATTTCAATATGGAGGAAAATCTGCCCGATTTTCAAAGGG\nATTGGTTATGCCATCTGCATCATTGCCTTTTACATTGCTTCCTACTACAACACCATCATG\nGCCTGGGCGCTATACTACCTCATCTCCTCCTTCACGGACCAGCTGCCCTGGACCAGCTGC\nAAGAACTCCTGGAACACTGGCAACTGCACCAATTACTTCTCCGAGGACAACATCACCTGG\nACCCTCCATTCCACGTCCCCTGCTGAAGAATTTTACACGCGCCACGTCCTGCAGATCCAC\nCGGTCTAAGGGGCTCCAGGACCTGGGGGGCATCAGCTGGCAGCTGGCCCTCTGCATCATG\nCTGATCTTCACTGTTATCTACTTCAGCATCTGGAAAGGCGTCAAGACCTCTGGCAAGGTG\nGTGTGGGTGACAGCCACCTTCCCTTATATCATCCTTTCTGTCCTGCTGGTGAGGGGTGCC\nACCCTCCCTGGAGCCTGGAGGGGTGTTCTCTTCTACTTGAAACCCAATTGGCAGAAACTC\nCTGGAGACAGGGGTGTGGATAGATGCAGCCGCTCAGATCTTCTTCTCTCTTGGTCCGGGC\nTTTGGGGTCCTGCTGGCTTTTGCTAGCTACAACAAGTTCAACAACAACTGCTACCAAGAT\nGCCCTGGTGACCAGCGTGGTGAACTGCATGACGAGCTTCGTTTCGGGATTTGTCATCTTC\nACAGTGCTCGGTTACATGGCTGAGATGAGGAATGAAGATGTGTCTGAGGTGGCCAAAGAC\nGCAGGTCCCAGCCTCCTCTTCATCACGTATGCAGAAGCGATAGCCAACATGCCAGCGTCC\nACTTTCTTTGCCATCATCTTCTTTCTGATGTTAATCACGCTGGGCTTGGACAGCACGTTT\nGCAGGCTTGGAGGGGGTGATCACGGCTGTGCTGGATGAGTTCCCACACGTCTGGGCCAAG\nCGCCGGGAGCGGTTCGTGCTCGCCGTGGTCATCACCTGCTTCTTTGGATCCCTGGTCACC\nCTGACTTTTGGAGGGGCCTACGTGGTGAAGCTGCTGGAGGAGTATGCCACGGGGCCCGCA\nGTGCTCACTGTCGCGCTGATCGAAGCAGTCGCTGTGTCTTGGTTCTATGGCATCACTCAG\nTTCTGCAGGGACGTGAAGGAAATGCTCGGCTTCAGCCCGGGGTGGTTCTGGAGGATCTGC\nTGGGTGGCCATCAGCCCTCTGTTTCTCCTGTTCATCATTTGCAGTTTTCTGATGAGCCCG\nCCACAACTACGACTTTTCCAATATAATTATCCTTACTGGAGTATCATCTTGGGTTACTGC\nATAGGAACCTCATCTTTCATTTGCATCCCCACATATATAGCTTATCGGTTGATCATCACT\nCCAGGGACATTTAAAGAGCGTATTATTAAAAGTATTACCCCAGAAACACCAACAGAAATT\nCCTTGTGGGGACATCCGCTTGAATGCTGTGTAA'),('Solute carrier family 15 member 1','None','Human','Proton-dependent oligopeptide secondary active transmembrane transporter activity','Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.','SLC15A1','78805.265','DB01050','>lcl|BSEQ0010714|Solute carrier family 15 member 1 (SLC15A1)\nATGGGAATGTCCAAATCACACAGTTTCTTTGGTTATCCCCTGAGCATCTTCTTCATCGTG\nGTCAATGAGTTTTGCGAAAGATTTTCCTACTATGGAATGCGAGCAATCCTGATTCTGTAC\nTTCACAAATTTCATCAGCTGGGATGATAACCTGTCCACCGCCATCTACCATACGTTTGTG\nGCTCTGTGCTACCTGACGCCAATTCTCGGAGCTCTTATCGCCGACTCGTGGCTGGGAAAG\nTTCAAGACCATTGTGTCGCTCTCCATTGTCTACACAATTGGACAAGCAGTCACCTCAGTA\nAGCTCCATTAATGACCTCACAGACCACAACCATGATGGCACCCCCGACAGCCTTCCTGTG\nCACGTGGTGCTGTCCTTGATCGGCCTGGCCCTGATAGCTCTCGGGACTGGAGGAATCAAA\nCCCTGTGTGTCTGCGTTTGGTGGAGATCAGTTTGAAGAGGGCCAGGAGAAACAAAGAAAC\nAGATTTTTTTCCATCTTTTACTTGGCTATTAATGCTGGAAGTTTGCTTTCCACAATCATC\nACACCCATGCTCAGAGTTCAACAATGTGGAATTCACAGTAAACAAGCTTGTTACCCACTG\nGCCTTTGGGGTTCCTGCTGCTCTCATGGCTGTAGCCCTGATTGTGTTTGTCCTTGGCAGT\nGGGATGTACAAGAAGTTCAAGCCACAGGGCAACATCATGGGTAAAGTGGCCAAGTGCATC\nGGTTTTGCCATCAAAAATAGATTTAGGCATCGGAGTAAGGCATTTCCCAAGAGGGAGCAC\nTGGCTGGACTGGGCTAAAGAGAAATACGATGAGCGGCTCATCTCCCAAATTAAGATGGTT\nACGAGGGTGATGTTCCTGTATATTCCACTCCCAATGTTCTGGGCCTTGTTTGACCAGCAG\nGGCTCCAGGTGGACACTGCAGGCAACAACTATGTCCGGGAAAATCGGAGCTCTTGAAATT\nCAGCCCGATCAGATGCAGACCGTGAACGCCATCCTGATCGTGATCATGGTCCCGATCTTC\nGATGCTGTGCTGTACCCTCTCATTGCAAAATGTGGCTTCAATTTCACCTCCTTGAAGAAG\nATGGCAGTTGGCATGGTCCTGGCCTCCATGGCCTTTGTGGTGGCTGCCATCGTGCAGGTG\nGAAATCGATAAAACTCTTCCAGTCTTCCCCAAAGGAAACGAAGTCCAAATTAAAGTTTTG\nAATATAGGAAACAATACCATGAATATATCTCTTCCTGGAGAGATGGTGACACTTGGCCCA\nATGTCTCAAACAAATGCATTTATGACTTTTGATGTAAACAAACTGACAAGGATAAACATT\nTCTTCTCCTGGATCACCAGTCACTGCTGTAACTGACGACTTCAAGCAGGGCCAACGCCAC\nACGCTTCTAGTGTGGGCCCCCAATCACTACCAGGTGGTAAAGGATGGTCTTAACCAGAAG\nCCAGAAAAAGGGGAAAATGGAATCAGATTTGTAAATACTTTTAACGAGCTCATCACCATC\nACAATGAGTGGGAAAGTTTATGCAAACATCAGCAGCTACAATGCCAGCACATACCAGTTT\nTTTCCTTCTGGCATAAAAGGCTTCACAATAAGCTCAACAGAGATTCCGCCACAATGTCAA\nCCTAATTTCAATACTTTCTACCTTGAATTTGGTAGTGCTTATACCTATATAGTCCAAAGG\nAAGAATGACAGCTGCCCTGAAGTGAAGGTGTTTGAAGATATTTCAGCCAACACAGTTAAC\nATGGCTCTGCAAATCCCGCAGTATTTTCTTCTCACCTGTGGCGAAGTGGTCTTCTCTGTC\nACGGGATTGGAATTCTCATATTCTCAGGCTCCTTCCAACATGAAGTCGGTGCTTCAGGCA\nGGATGGCTGCTGACCGTGGCTGTTGGCAACATCATTGTGCTCATCGTGGCAGGGGCAGGC\nCAGTTCAGCAAACAGTGGGCCGAGTACATTCTATTTGCCGCGTTGCTTCTGGTCGTCTGT\nGTAATTTTTGCCATCATGGCTCGGTTCTATACTTACATCAACCCAGCGGAGATCGAAGCT\nCAATTTGATGAGGATGAAAAGAAAAACAGACTGGAAAAGAGTAACCCATATTTCATGTCA\nGGGGCCAATTCACAGAAACAGATGTGA'),('Solute carrier family 2, facilitated glucose transporter member 1','None','Human','Xenobiotic transporter activity','Facilitative glucose transporter. This isoform may be responsible for constitutive or basal glucose uptake. Has a very broad substrate specificity; can transport a wide range of aldoses including both pentoses and hexoses.','SLC2A1','54083.325','DB02709','>lcl|BSEQ0016299|Solute carrier family 2, facilitated glucose transporter member 1 (SLC2A1)\nATGGAGCCCAGCAGCAAGAAGCTGACGGGTCGCCTCATGCTGGCCGTGGGAGGAGCAGTG\nCTTGGCTCCCTGCAGTTTGGCTACAACACTGGAGTCATCAATGCCCCCCAGAAGGTGATC\nGAGGAGTTCTACAACCAGACATGGGTCCACCGCTATGGGGAGAGCATCCTGCCCACCACG\nCTCACCACGCTCTGGTCCCTCTCAGTGGCCATCTTTTCTGTTGGGGGCATGATTGGCTCC\nTTCTCTGTGGGCCTTTTCGTTAACCGCTTTGGCCGGCGGAATTCAATGCTGATGATGAAC\nCTGCTGGCCTTCGTGTCCGCCGTGCTCATGGGCTTCTCGAAACTGGGCAAGTCCTTTGAG\nATGCTGATCCTGGGCCGCTTCATCATCGGTGTGTACTGCGGCCTGACCACAGGCTTCGTG\nCCCATGTATGTGGGTGAAGTGTCACCCACAGCCCTTCGTGGGGCCCTGGGCACCCTGCAC\nCAGCTGGGCATCGTCGTCGGCATCCTCATCGCCCAGGTGTTCGGCCTGGACTCCATCATG\nGGCAACAAGGACCTGTGGCCCCTGCTGCTGAGCATCATCTTCATCCCGGCCCTGCTGCAG\nTGCATCGTGCTGCCCTTCTGCCCCGAGAGTCCCCGCTTCCTGCTCATCAACCGCAACGAG\nGAGAACCGGGCCAAGAGTGTGCTAAAGAAGCTGCGCGGGACAGCTGACGTGACCCATGAC\nCTGCAGGAGATGAAGGAAGAGAGTCGGCAGATGATGCGGGAGAAGAAGGTCACCATCCTG\nGAGCTGTTCCGCTCCCCCGCCTACCGCCAGCCCATCCTCATCGCTGTGGTGCTGCAGCTG\nTCCCAGCAGCTGTCTGGCATCAACGCTGTCTTCTATTACTCCACGAGCATCTTCGAGAAG\nGCGGGGGTGCAGCAGCCTGTGTATGCCACCATTGGCTCCGGTATCGTCAACACGGCCTTC\nACTGTCGTGTCGCTGTTTGTGGTGGAGCGAGCAGGCCGGCGGACCCTGCACCTCATAGGC\nCTCGCTGGCATGGCGGGTTGTGCCATACTCATGACCATCGCGCTAGCACTGCTGGAGCAG\nCTACCCTGGATGTCCTATCTGAGCATCGTGGCCATCTTTGGCTTTGTGGCCTTCTTTGAA\nGTGGGTCCTGGCCCCATCCCATGGTTCATCGTGGCTGAACTCTTCAGCCAGGGTCCACGT\nCCAGCTGCCATTGCCGTTGCAGGCTTCTCCAACTGGACCTCAAATTTCATTGTGGGCATG\nTGCTTCCAGTATGTGGAGCAACTGTGTGGTCCCTACGTCTTCATCATCTTCACTGTGCTC\nCTGGTTCTGTTCTTCATCTTCACCTACTTCAAAGTTCCTGAGACTAAAGGCCGGACCTTC\nGATGAGATCGCTTCCGGCTTCCGGCAGGGGGGAGCCAGCCAAAGTGACAAGACACCCGAG\nGAGCTGTTCCATCCCCTGGGGGCTGATTCCCAAGTGTGA'),('Somatostatin receptor type 2','None','Human','Somatostatin receptor activity','Receptor for somatostatin-14 and -28. This receptor is coupled via pertussis toxin sensitive G proteins to inhibition of adenylyl cyclase. In addition it stimulates phosphotyrosine phosphatase and PLC via pertussis toxin insensitive as well as sensitive G proteins. Inhibits calcium entry by suppressing voltage-dependent calcium channels. Acts as the functionally dominant somatostatin receptor in pancreatic alpha- and beta-cells where it mediates the inhibitory effect of somatostatin-14 on hormone secretion. Inhibits cell growth through enhancement of MAPK1 and MAPK2 phosphorylation and subsequent up-regulation of CDKN1B. Stimulates neuronal migration and axon outgrowth and may participate in neuron development and maturation during brain development. Mediates negative regulation of insulin receptor signaling through PTPN6. Inactivates SSTR3 receptor function following heterodimerization.','SSTR2','41332.37','DB04894','>lcl|BSEQ0017130|Somatostatin receptor type 2 (SSTR2)\nATGGACATGGCGGATGAGCCACTCAATGGAAGCCACACATGGCTATCCATTCCATTTGAC\nCTCAATGGCTCTGTGGTGTCAACCAACACCTCAAACCAGACAGAGCCGTACTATGACCTG\nACAAGCAATGCAGTCCTCACATTCATCTATTTTGTGGTCTGCATCATTGGGTTGTGTGGC\nAACACACTTGTCATTTATGTCATCCTCCGCTATGCCAAGATGAAGACCATCACCAACATT\nTACATCCTCAACCTGGCCATCGCAGATGAGCTCTTCATGCTGGGTCTGCCTTTCTTGGCT\nATGCAGGTGGCTCTGGTCCACTGGCCCTTTGGCAAGGCCATTTGCCGGGTGGTCATGACT\nGTGGATGGCATCAATCAGTTCACCAGCATCTTCTGCCTGACAGTCATGAGCATCGACCGA\nTACCTGGCTGTGGTCCACCCCATCAAGTCGGCCAAGTGGAGGAGACCCCGGACGGCCAAG\nATGATCACCATGGCTGTGTGGGGAGTCTCTCTGCTGGTCATCTTGCCCATCATGATATAT\nGCTGGGCTCCGGAGCAACCAGTGGGGGAGAAGCAGCTGCACCATCAACTGGCCAGGTGAA\nTCTGGGGCTTGGTACACAGGGTTCATCATCTACACTTTCATTCTGGGGTTCCTGGTACCC\nCTCACCATCATCTGTCTTTGCTACCTGTTCATTATCATCAAGGTGAAGTCCTCTGGAATC\nCGAGTGGGCTCCTCTAAGAGGAAGAAGTCTGAGAAGAAGGTCACCCGAATGGTGTCCATC\nGTGGTGGCTGTCTTCATCTTCTGCTGGCTTCCCTTCTACATATTCAACGTTTCTTCCGTC\nTCCATGGCCATCAGCCCCACCCCAGCCCTTAAAGGCATGTTTGACTTTGTGGTGGTCCTC\nACCTATGCTAACAGCTGTGCCAACCCTATCCTATATGCCTTCTTGTCTGACAACTTCAAG\nAAGAGCTTCCAGAATGTCCTCTGCTTGGTCAAGGTGAGCGGCACAGATGATGGGGAGCGG\nAGTGACAGTAAGCAGGACAAATCCCGGCTGAATGAGACCACGGAGACCCAGAGGACCCTC\nCTCAATGGAGACCTCCAAACCAGTATCTGA'),('Somatostatin receptor type 5','None','Human','Somatostatin receptor activity','Receptor for somatostatin 28 and to a lesser extent for somatostatin-14. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase. Increases cell growth inhibition activity of SSTR2 following heterodimerization.','SSTR5','39201.925','DB04894','>lcl|BSEQ0016699|Somatostatin receptor type 5 (SSTR5)\nATGGAGCCCCTGTTCCCAGCCTCCACGCCCAGCTGGAACGCCTCCTCCCCGGGGGCTGCC\nTCTGGAGGCGGTGACAACAGGACGCTGGTGGGGCCGGCGCCCTCGGCAGGGGCCCGGGCG\nGTGCTGGTGCCCGTGCTGTACCTGCTGGTGTGTGCGGCCGGGCTGGGCGGGAACACGCTG\nGTCATCTACGTGGTGCTGCGCTTCGCCAAGATGAAGACCGTCACCAACATCTACATTCTC\nAACCTGGCAGTGGCCGACGTCCTGTACATGCTGGGGCTGCCTTTCCTGGCCACGCAGAAC\nGCCGCGTCCTTCTGGCCCTTCGGCCCCGTCCTGTGCCGCCTGGTCATGACGCTGGACGGC\nGTCAACCAGTTCACCAGTGTCTTCTGCCTGACAGTCATGAGCGTGGACCGCTACCTGGCA\nGTGGTGCACCCGCTGAGCTCGGCCCGCTGGCGCCGCCCGCGTGTGGCCAAGCTGGCGAGC\nGCCGCGGCCTGGGTCCTGTCTCTGTGCATGTCGCTGCCGCTCCTGGTGTTCGCGGACGTG\nCAGGAGGGCGGTACCTGCAACGCCAGCTGGCCGGAGCCCGTGGGGCTGTGGGGCGCCGTC\nTTCATCATCTACACGGCCGTGCTGGGCTTCTTCGCGCCGCTGCTGGTCATCTGCCTGTGC\nTACCTGCTCATCGTGGTGAAGGTGAGGGCGGCGGGCGTGCGCGTGGGCTGCGTGCGGCGG\nCGCTCGGAGCGGAAGGTGACGCGCATGGTGTTGGTGGTGGTGCTGGTGTTTGCGGGATGT\nTGGCTGCCCTTCTTCACCGTCAACATCGTCAACCTGGCCGTGGCGCTGCCCCAGGAGCCC\nGCCTCCGCCGGCCTCTACTTCTTCGTGGTCATCCTCTCCTACGCCAACAGCTGTGCCAAC\nCCCGTCCTCTACGGCTTCCTCTCTGACAACTTCCGCCAGAGCTTCCAGAAGGTTCTGTGC\nCTCCGCAAGGGCTCTGGTGCCAAGGACGCTGACGCCACGGAGCCGCGTCCAGACAGGATC\nCGGCAGCAGCAGGAGGCCACGCCACCCGCGCACCGCGCCGCAGCCAACGGGCTTATGCAG\nACCAGCAAGCTGTGA'),('Substance-P receptor','None','Human','Tachykinin receptor activity','This is a receptor for the tachykinin neuropeptide substance P. It is probably associated with G proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order of affinity of this receptor to tachykinins is: substance P > substance K > neuromedin-K.','TACR1','46250.5','DB04894','>lcl|BSEQ0010126|Substance-P receptor (TACR1)\nATGGATAACGTCCTCCCGGTGGACTCAGACCTCTCCCCAAACATCTCCACTAACACCTCG\nGAACCCAATCAGTTCGTGCAACCAGCCTGGCAAATTGTCCTTTGGGCAGCTGCCTACACG\nGTCATTGTGGTGACCTCTGTGGTGGGCAACGTGGTAGTGATGTGGATCATCTTAGCCCAC\nAAAAGAATGAGGACAGTGACGAACTATTTTCTGGTGAACCTGGCCTTCGCGGAGGCCTCC\nATGGCTGCATTCAATACAGTGGTGAACTTCACCTATGCTGTCCACAACGAATGGTACTAC\nGGCCTGTTCTACTGCAAGTTCCACAACTTCTTTCCCATCGCCGCTGTCTTCGCCAGTATC\nTACTCCATGACGGCTGTGGCCTTTGATAGGTACATGGCCATCATACATCCCCTCCAGCCC\nCGGCTGTCAGCCACAGCCACCAAAGTGGTCATCTGTGTCATCTGGGTCCTGGCTCTCCTG\nCTGGCCTTCCCCCAGGGCTACTACTCAACCACAGAGACCATGCCCAGCAGAGTCGTGTGC\nATGATCGAATGGCCAGAGCATCCGAACAAGATTTATGAGAAAGTGTACCACATCTGTGTG\nACTGTGCTGATCTACTTCCTCCCCCTGCTGGTGATTGGCTATGCATACACCGTAGTGGGA\nATCACACTATGGGCCAGTGAGATCCCCGGGGACTCCTCTGACCGCTACCACGAGCAAGTC\nTCTGCCAAGCGCAAGGTGGTCAAAATGATGATTGTCGTGGTGTGCACCTTCGCCATCTGC\nTGGCTGCCCTTCCACATCTTCTTCCTCCTGCCCTACATCAACCCAGATCTCTACCTGAAG\nAAGTTTATCCAGCAGGTCTACCTGGCCATCATGTGGCTGGCCATGAGCTCCACCATGTAC\nAACCCCATCATCTACTGCTGCCTCAATGACAGGTTCCGTCTGGGCTTCAAGCATGCCTTC\nCGGTGCTGCCCCTTCATCAGCGCCGGCGACTATGAGGGGCTGGAAATGAAATCCACCCGG\nTATCTCCAGACCCAGGGCAGTGTGTACAAAGTCAGCCGCCTGGAGACCACCATCTCCACA\nGTGGTGGGGGCCCACGAGGAGGAGCCAGAGGACGGCCCCAAGGCCACACCCTCGTCCCTG\nGACCTGACCTCCAACTGCTCTTCACGAAGTGACTCCAAGACCATGACAGAGAGCTTCAGC\nTTCTCCTCCAATGTGCTCTCCTAG'),('Thiopurine S-methyltransferase','None','Human','Thiopurine s-methyltransferase activity','Catalyzes the S-methylation of thiopurine drugs such as 6-mercaptopurine.','TPMT','28180.09','DB01250','>lcl|BSEQ0010692|Thiopurine S-methyltransferase (TPMT)\nATGGATGGTACAAGAACTTCACTTGACATTGAAGAGTACTCGGATACTGAGGTACAGAAA\nAACCAAGTACTAACTCTGGAAGAATGGCAAGACAAGTGGGTGAACGGCAAGACTGCTTTT\nCATCAGGAACAAGGACATCAGCTATTAAAGAAGCATTTAGATACTTTCCTTAAAGGCAAG\nAGTGGACTGAGGGTATTTTTTCCTCTTTGCGGAAAAGCGGTTGAGATGAAATGGTTTGCA\nGACCGGGGACACAGTGTAGTTGGTGTGGAAATCAGTGAACTTGGGATACAAGAATTTTTT\nACAGAGCAGAATCTTTCTTACTCAGAAGAACCAATCACCGAAATTCCTGGAACCAAAGTA\nTTTAAGAGTTCTTCGGGGAACATTTCATTGTACTGTTGCAGTATTTTTGATCTTCCCAGG\nACAAATATTGGCAAATTTGACATGATTTGGGATAGAGGAGCATTAGTTGCCATTAATCCA\nGGTGATCGCAAATGCTATGCAGATACAATGTTTTCCCTCCTGGGAAAGAAGTTTCAGTAT\nCTCCTGTGTGTTCTTTCTTATGATCCAACTAAACATCCAGGTCCACCATTTTATGTTCCA\nCATGCTGAAATTGAAAGGTTGTTTGGTAAAATATGCAATATACGTTGTCTTGAGAAGGTT\nGATGCTTTTGAAGAACGACATAAAAGTTGGGGAATTGACTGTCTTTTTGAAAAGTTATAT\nCTACTTACAGAAAAGTAA'),('Thrombomodulin','None','Human','Transmembrane signaling receptor activity','Thrombomodulin is a specific endothelial cell receptor that forms a 1:1 stoichiometric complex with thrombin. This complex is responsible for the conversion of protein C to the activated protein C (protein Ca). Once evolved, protein Ca scissions the activated cofactors of the coagulation mechanism, factor Va and factor VIIIa, and thereby reduces the amount of thrombin generated.','THBD','60328.72','DB01050','>lcl|BSEQ0016329|Thrombomodulin (THBD)\nATGCTTGGGGTCCTGGTCCTTGGCGCGCTGGCCCTGGCCGGCCTGGGGTTCCCCGCACCC\nGCAGAGCCGCAGCCGGGTGGCAGCCAGTGCGTCGAGCACGACTGCTTCGCGCTCTACCCG\nGGCCCCGCGACCTTCCTCAATGCCAGTCAGATCTGCGACGGACTGCGGGGCCACCTAATG\nACAGTGCGCTCCTCGGTGGCTGCCGATGTCATTTCCTTGCTACTGAACGGCGACGGCGGC\nGTTGGCCGCCGGCGCCTCTGGATCGGCCTGCAGCTGCCACCCGGCTGCGGCGACCCCAAG\nCGCCTCGGGCCCCTGCGCGGCTTCCAGTGGGTTACGGGAGACAACAACACCAGCTATAGC\nAGGTGGGCACGGCTCGACCTCAATGGGGCTCCCCTCTGCGGCCCGTTGTGCGTCGCTGTC\nTCCGCTGCTGAGGCCACTGTGCCCAGCGAGCCGATCTGGGAGGAGCAGCAGTGCGAAGTG\nAAGGCCGATGGCTTCCTCTGCGAGTTCCACTTCCCAGCCACCTGCAGGCCACTGGCTGTG\nGAGCCCGGCGCCGCGGCTGCCGCCGTCTCGATCACCTACGGCACCCCGTTCGCGGCCCGC\nGGAGCGGACTTCCAGGCGCTGCCGGTGGGCAGCTCCGCCGCGGTGGCTCCCCTCGGCTTA\nCAGCTAATGTGCACCGCGCCGCCCGGAGCGGTCCAGGGGCACTGGGCCAGGGAGGCGCCG\nGGCGCTTGGGACTGCAGCGTGGAGAACGGCGGCTGCGAGCACGCGTGCAATGCGATCCCT\nGGGGCTCCCCGCTGCCAGTGCCCAGCCGGCGCCGCCCTGCAGGCAGACGGGCGCTCCTGC\nACCGCATCCGCGACGCAGTCCTGCAACGACCTCTGCGAGCACTTCTGCGTTCCCAACCCC\nGACCAGCCGGGCTCCTACTCGTGCATGTGCGAGACCGGCTACCGGCTGGCGGCCGACCAA\nCACCGGTGCGAGGACGTGGATGACTGCATACTGGAGCCCAGTCCGTGTCCGCAGCGCTGT\nGTCAACACACAGGGTGGCTTCGAGTGCCACTGCTACCCTAACTACGACCTGGTGGACGGC\nGAGTGTGTGGAGCCCGTGGACCCGTGCTTCAGAGCCAACTGCGAGTACCAGTGCCAGCCC\nCTGAACCAAACTAGCTACCTCTGCGTCTGCGCCGAGGGCTTCGCGCCCATTCCCCACGAG\nCCGCACAGGTGCCAGATGTTTTGCAACCAGACTGCCTGTCCAGCCGACTGCGACCCCAAC\nACCCAGGCTAGCTGTGAGTGCCCTGAAGGCTACATCCTGGACGACGGTTTCATCTGCACG\nGACATCGACGAGTGCGAAAACGGCGGCTTCTGCTCCGGGGTGTGCCACAACCTCCCCGGT\nACCTTCGAGTGCATCTGCGGGCCCGACTCGGCCCTTGCCCGCCACATTGGCACCGACTGT\nGACTCCGGCAAGGTGGACGGTGGCGACAGCGGCTCTGGCGAGCCCCCGCCCAGCCCGACG\nCCCGGCTCCACCTTGACTCCTCCGGCCGTGGGGCTCGTGCATTCGGGCTTGCTCATAGGC\nATCTCCATCGCGAGCCTGTGCCTGGTGGTGGCGCTTTTGGCGCTCCTCTGCCACCTGCGC\nAAGAAGCAGGGCGCCGCCAGGGCCAAGATGGAGTACAAGTGCGCGGCCCCTTCCAAGGAG\nGTAGTGCTGCAGCACGTGCGGACCGAGCGGACGCCGCAGAGACTCTGA'),('Thromboxane A2 receptor','None','Human','Thromboxane a2 receptor activity','Receptor for thromboxane A2 (TXA2), a potent stimulator of platelet aggregation. The activity of this receptor is mediated by a G-protein that activates a phosphatidylinositol-calcium second messenger system. In the kidney, the binding of TXA2 to glomerular TP receptors causes intense vasoconstriction. Activates phospholipase C. Isoform 1 activates adenylyl cyclase. Isoform 2 inhibits adenylyl cyclase.','TBXA2R','37430.69','DB06739','>lcl|BSEQ0019006|Thromboxane A2 receptor (TBXA2R)\nATGTGGCCCAACGGCAGTTCCCTGGGGCCCTGTTTCCGGCCCACAAACATTACCCTGGAG\nGAGAGACGGCTGATCGCCTCGCCCTGGTTCGCCGCCTCCTTCTGCGTGGTGGGCCTGGCC\nTCCAACCTGCTGGCCCTGAGCGTGCTGGCGGGCGCGCGGCAGGGGGGTTCGCACACGCGC\nTCCTCCTTCCTCACCTTCCTCTGCGGCCTCGTCCTCACCGACTTCCTGGGGCTGCTGGTG\nACCGGTACCATCGTGGTGTCCCAGCACGCCGCGCTCTTCGAGTGGCACGCCGTGGACCCT\nGGCTGCCGTCTCTGTCGCTTCATGGGCGTCGTCATGATCTTCTTCGGCCTGTCCCCGCTG\nCTGCTGGGGGCCGCCATGGCCTCAGAGCGCTACCTGGGTATCACCCGGCCCTTCTCGCGC\nCCGGCGGTCGCCTCGCAGCGCCGCGCCTGGGCCACCGTGGGGCTGGTGTGGGCGGCCGCG\nCTGGCGCTGGGCCTGCTGCCCCTGCTGGGCGTGGGTCGCTACACCGTGCAATACCCGGGG\nTCCTGGTGCTTCCTGACGCTGGGCGCCGAGTCCGGGGACGTGGCCTTCGGGCTGCTCTTC\nTCCATGCTGGGCGGCCTCTCGGTCGGGCTGTCCTTCCTGCTGAACACGGTCAGCGTGGCC\nACCCTGTGCCACGTCTACCACGGGCAGGAGGCGGCCCAGCAGCGTCCCCGGGACTCCGAG\nGTGGAGATGATGGCTCAGCTCCTGGGGATCATGGTGGTGGCCAGCGTGTGTTGGCTGCCC\nCTTCTGGTCTTCATCGCCCAGACAGTGCTGCGAAACCCGCCTGCCATGAGCCCCGCCGGG\nCAGCTGTCCCGCACCACGGAGAAGGAGCTGCTCATCTACTTGCGCGTGGCCACCTGGAAC\nCAGATCCTGGACCCCTGGGTGTATATCCTGTTCCGCCGCGCCGTGCTCCGGCGTCTCCAG\nCCTCGCCTCAGCACCCGGCCCAGGTCGCTGTCCCTCCAGCCCCAGCTCACGCAGCGCTCC\nGGGCTGCAGTAG'),('Thromboxane-A synthase','None','Human','Thromboxane-a synthase activity','None','TBXAS1','60517.69','DB00795','>lcl|BSEQ0021671|Thromboxane-A synthase (TBXAS1)\nATGATGGAAGCCTTGGGGTTTCTAAAATTGGAAGTGAATGGCCCCATGGTGACGGTGGCC\nCTGTCAGTGGCTCTCTTGGCCCTCCTGAAATGGTACTCCACATCAGCATTCTCAAGACTG\nGAGAAGTTAGGCCTCAGACATCCCAAGCCTTCTCCTTTCATTGGAAACTTGACATTTTTC\nCGCCAGGGTTTTTGGGAAAGCCAAATGGAGCTCAGAAAGCTGTATGGACCTCTGTGTGGG\nTACTATCTTGGTCGTCGGATGTTTATTGTTATTTCTGAGCCAGACATGATCAAGCAGGTG\nTTGGTTGAGAACTTCAGTAACTTTACCAACAGAATGGCGTCGGGTTTGGAGTTCAAGTCG\nGTAGCCGACAGCGTTCTGTTTTTACGTGACAAAAGATGGGAAGAGGTCAGAGGTGCCCTG\nATGTCTGCTTTCAGTCCTGAAAAGCTGAACGAGATGGTTCCCCTCATCAGCCAAGCCTGC\nGACCTTCTCCTGGCTCATTTAAAACGCTATGCGGAATCTGGGGACGCATTTGACATCCAG\nAGGTGCTACTGCAATTACACCACAGATGTGGTTGCCAGCGTCGCCTTTGGCACCCCGGTG\nGACTCCTGGCAGGCCCCTGAGGATCCCTTTGTGAAACACTGCAAGCGTTTCTTCGAATTC\nTGCATCCCCAGACCTATCCTGGTTTTACTCTTATCATTTCCATCCATAATGGTCCCACTG\nGCCCGGATTTTGCCCAATAAGAACCGAGACGAACTGAATGGCTTTTTTAACAAACTCATT\nAGGAATGTGATTGCCTTGCGGGACCAGCAAGCTGCCGAAGAGAGGCGGAGAGACTTCCTC\nCAAATGGTCCTGGATGCCCGACATTCTGCAAGTCCCATGGGCGTGCAAGACTTTGACATC\nGTCAGAGACGTTTTCTCCTCTACTGGGTGCAAGCCGAACCCTTCCCGGCAACACCAGCCC\nAGCCCTATGGCCAGGCCTTTGACTGTGGATGAGATTGTGGGCCAGGCCTTCATCTTCCTC\nATCGCTGGCTATGAAATCATCACCAACACACTTTCTTTTGCCACCTACCTACTGGCCACC\nAACCCTGACTGCCAAGAGAAGCTTCTGAGAGAGGTAGACGTTTTTAAGGAGAAACACATG\nGCCCCTGAGTTCTGCAGCCTCGAGGAAGGCCTGCCCTATCTGGACATGGTGATTGCAGAG\nACGCTGAGGATGTACCCGCCAGCTTTCAGATTCACACGGGAGGCAGCTCAGGACTGCGAG\nGTGCTGGGGCAGCGCATCCCCGCAGGCGCTGTGCTAGAGATGGCCGTGGGTGCCCTGCAC\nCATGACCCTGAGCACTGGCCAAGCCCGGAGACCTTCAACCCTGAAAGGTTCACGGCTGAG\nGCCCGGCAGCAGCACCGGCCCTTCACGTACCTGCCCTTCGGGGCCGGCCCACGGAGCTGC\nCTCGGGGTGCGTCTAGGGCTGCTTGAGGTCAAGTTGACACTGCTCCACGTGCTGCACAAG\nTTCCGGTTCCAAGCCTGCCCTGAGACCCAGGTACCGCTGCAGCTAGAATCCAAATCTGCC\nCTAGGTCCAAAAAATGGTGTCTATATCAAGATCGTATCCCGCTGA'),('Tissue-type plasminogen activator','None','Human','Serine-type endopeptidase activity','Converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond in plasminogen. By controlling plasmin-mediated proteolysis, it plays an important role in tissue remodeling and degradation, in cell migration and many other physiopathological events. Plays a direct role in facilitating neuronal migration.','PLAT','62916.495','DB01050','>lcl|BSEQ0010763|Tissue-type plasminogen activator (PLAT)\nATGGATGCAATGAAGAGAGGGCTCTGCTGTGTGCTGCTGCTGTGTGGAGCAGTCTTCGTT\nTCGCCCAGCCAGGAAATCCATGCCCGATTCAGAAGAGGAGCCAGATCTTACCAAGTGATC\nTGCAGAGATGAAAAAACGCAGATGATATACCAGCAACATCAGTCATGGCTGCGCCCTGTG\nCTCAGAAGCAACCGGGTGGAATATTGCTGGTGCAACAGTGGCAGGGCACAGTGCCACTCA\nGTGCCTGTCAAAAGTTGCAGCGAGCCAAGGTGTTTCAACGGGGGCACCTGCCAGCAGGCC\nCTGTACTTCTCAGATTTCGTGTGCCAGTGCCCCGAAGGATTTGCTGGGAAGTGCTGTGAA\nATAGATACCAGGGCCACGTGCTACGAGGACCAGGGCATCAGCTACAGGGGCACGTGGAGC\nACAGCGGAGAGTGGCGCCGAGTGCACCAACTGGAACAGCAGCGCGTTGGCCCAGAAGCCC\nTACAGCGGGCGGAGGCCAGACGCCATCAGGCTGGGCCTGGGGAACCACAACTACTGCAGA\nAACCCAGATCGAGACTCAAAGCCCTGGTGCTACGTCTTTAAGGCGGGGAAGTACAGCTCA\nGAGTTCTGCAGCACCCCTGCCTGCTCTGAGGGAAACAGTGACTGCTACTTTGGGAATGGG\nTCAGCCTACCGTGGCACGCACAGCCTCACCGAGTCGGGTGCCTCCTGCCTCCCGTGGAAT\nTCCATGATCCTGATAGGCAAGGTTTACACAGCACAGAACCCCAGTGCCCAGGCACTGGGC\nCTGGGCAAACATAATTACTGCCGGAATCCTGATGGGGATGCCAAGCCCTGGTGCCACGTG\nCTGAAGAACCGCAGGCTGACGTGGGAGTACTGTGATGTGCCCTCCTGCTCCACCTGCGGC\nCTGAGACAGTACAGCCAGCCTCAGTTTCGCATCAAAGGAGGGCTCTTCGCCGACATCGCC\nTCCCACCCCTGGCAGGCTGCCATCTTTGCCAAGCACAGGAGGTCGCCCGGAGAGCGGTTC\nCTGTGCGGGGGCATACTCATCAGCTCCTGCTGGATTCTCTCTGCCGCCCACTGCTTCCAG\nGAGAGGTTTCCGCCCCACCACCTGACGGTGATCTTGGGCAGAACATACCGGGTGGTCCCT\nGGCGAGGAGGAGCAGAAATTTGAAGTCGAAAAATACATTGTCCATAAGGAATTCGATGAT\nGACACTTACGACAATGACATTGCGCTGCTGCAGCTGAAATCGGATTCGTCCCGCTGTGCC\nCAGGAGAGCAGCGTGGTCCGCACTGTGTGCCTTCCCCCGGCGGACCTGCAGCTGCCGGAC\nTGGACGGAGTGTGAGCTCTCCGGCTACGGCAAGCATGAGGCCTTGTCTCCTTTCTATTCG\nGAGCGGCTGAAGGAGGCTCATGTCAGACTGTACCCATCCAGCCGCTGCACATCACAACAT\nTTACTTAACAGAACAGTCACCGACAACATGCTGTGTGCTGGAGACACTCGGAGCGGCGGG\nCCCCAGGCAAACTTGCACGACGCCTGCCAGGGCGATTCGGGAGGCCCCCTGGTGTGTCTG\nAACGATGGCCGCATGACTTTGGTGGGCATCATCAGCTGGGGCCTGGGCTGTGGACAGAAG\nGATGTCCCGGGTGTGTACACCAAGGTTACCAACTACCTAGACTGGATTCGTGACAACATG\nCGACCGTGA'),('Toll-like receptor 9','None','Human','Transmembrane signaling receptor activity','Key component of innate and adaptive immunity. TLRs (Toll-like receptors) control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR9 is a nucleotide-sensing TLR which is activated by unmethylated cytidine-phosphate-guanosine (CpG) dinucleotides. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. Controls lymphocyte response to Helicobacter infection.','TLR9','115858.665','DB00608','>lcl|BSEQ0019078|Toll-like receptor 9 (TLR9)\nATGGGTTTCTGCCGCAGCGCCCTGCACCCGCTGTCTCTCCTGGTGCAGGCCATCATGCTG\nGCCATGACCCTGGCCCTGGGTACCTTGCCTGCCTTCCTACCCTGTGAGCTCCAGCCCCAC\nGGCCTGGTGAACTGCAACTGGCTGTTCCTGAAGTCTGTGCCCCACTTCTCCATGGCAGCA\nCCCCGTGGCAATGTCACCAGCCTTTCCTTGTCCTCCAACCGCATCCACCACCTCCATGAT\nTCTGACTTTGCCCACCTGCCCAGCCTGCGGCATCTCAACCTCAAGTGGAACTGCCCGCCG\nGTTGGCCTCAGCCCCATGCACTTCCCCTGCCACATGACCATCGAGCCCAGCACCTTCTTG\nGCTGTGCCCACCCTGGAAGAGCTAAACCTGAGCTACAACAACATCATGACTGTGCCTGCG\nCTGCCCAAATCCCTCATATCCCTGTCCCTCAGCCATACCAACATCCTGATGCTAGACTCT\nGCCAGCCTCGCCGGCCTGCATGCCCTGCGCTTCCTATTCATGGACGGCAACTGTTATTAC\nAAGAACCCCTGCAGGCAGGCACTGGAGGTGGCCCCGGGTGCCCTCCTTGGCCTGGGCAAC\nCTCACCCACCTGTCACTCAAGTACAACAACCTCACTGTGGTGCCCCGCAACCTGCCTTCC\nAGCCTGGAGTATCTGCTGTTGTCCTACAACCGCATCGTCAAACTGGCGCCTGAGGACCTG\nGCCAATCTGACCGCCCTGCGTGTGCTCGATGTGGGCGGAAATTGCCGCCGCTGCGACCAC\nGCTCCCAACCCCTGCATGGAGTGCCCTCGTCACTTCCCCCAGCTACATCCCGATACCTTC\nAGCCACCTGAGCCGTCTTGAAGGCCTGGTGTTGAAGGACAGTTCTCTCTCCTGGCTGAAT\nGCCAGTTGGTTCCGTGGGCTGGGAAACCTCCGAGTGCTGGACCTGAGTGAGAACTTCCTC\nTACAAATGCATCACTAAAACCAAGGCCTTCCAGGGCCTAACACAGCTGCGCAAGCTTAAC\nCTGTCCTTCAATTACCAAAAGAGGGTGTCCTTTGCCCACCTGTCTCTGGCCCCTTCCTTC\nGGGAGCCTGGTCGCCCTGAAGGAGCTGGACATGCACGGCATCTTCTTCCGCTCACTCGAT\nGAGACCACGCTCCGGCCACTGGCCCGCCTGCCCATGCTCCAGACTCTGCGTCTGCAGATG\nAACTTCATCAACCAGGCCCAGCTCGGCATCTTCAGGGCCTTCCCTGGCCTGCGCTACGTG\nGACCTGTCGGACAACCGCATCAGCGGAGCTTCGGAGCTGACAGCCACCATGGGGGAGGCA\nGATGGAGGGGAGAAGGTCTGGCTGCAGCCTGGGGACCTTGCTCCGGCCCCAGTGGACACT\nCCCAGCTCTGAAGACTTCAGGCCCAACTGCAGCACCCTCAACTTCACCTTGGATCTGTCA\nCGGAACAACCTGGTGACCGTGCAGCCGGAGATGTTTGCCCAGCTCTCGCACCTGCAGTGC\nCTGCGCCTGAGCCACAACTGCATCTCGCAGGCAGTCAATGGCTCCCAGTTCCTGCCGCTG\nACCGGTCTGCAGGTGCTAGACCTGTCCCACAATAAGCTGGACCTCTACCACGAGCACTCA\nTTCACGGAGCTACCGCGACTGGAGGCCCTGGACCTCAGCTACAACAGCCAGCCCTTTGGC\nATGCAGGGCGTGGGCCACAACTTCAGCTTCGTGGCTCACCTGCGCACCCTGCGCCACCTC\nAGCCTGGCCCACAACAACATCCACAGCCAAGTGTCCCAGCAGCTCTGCAGTACGTCGCTG\nCGGGCCCTGGACTTCAGCGGCAATGCACTGGGCCATATGTGGGCCGAGGGAGACCTCTAT\nCTGCACTTCTTCCAAGGCCTGAGCGGTTTGATCTGGCTGGACTTGTCCCAGAACCGCCTG\nCACACCCTCCTGCCCCAAACCCTGCGCAACCTCCCCAAGAGCCTACAGGTGCTGCGTCTC\nCGTGACAATTACCTGGCCTTCTTTAAGTGGTGGAGCCTCCACTTCCTGCCCAAACTGGAA\nGTCCTCGACCTGGCAGGAAACCAGCTGAAGGCCCTGACCAATGGCAGCCTGCCTGCTGGC\nACCCGGCTCCGGAGGCTGGATGTCAGCTGCAACAGCATCAGCTTCGTGGCCCCCGGCTTC\nTTTTCCAAGGCCAAGGAGCTGCGAGAGCTCAACCTTAGCGCCAACGCCCTCAAGACAGTG\nGACCACTCCTGGTTTGGGCCCCTGGCGAGTGCCCTGCAAATACTAGATGTAAGCGCCAAC\nCCTCTGCACTGCGCCTGTGGGGCGGCCTTTATGGACTTCCTGCTGGAGGTGCAGGCTGCC\nGTGCCCGGTCTGCCCAGCCGGGTGAAGTGTGGCAGTCCGGGCCAGCTCCAGGGCCTCAGC\nATCTTTGCACAGGACCTGCGCCTCTGCCTGGATGAGGCCCTCTCCTGGGACTGTTTCGCC\nCTCTCGCTGCTGGCTGTGGCTCTGGGCCTGGGTGTGCCCATGCTGCATCACCTCTGTGGC\nTGGGACCTCTGGTACTGCTTCCACCTGTGCCTGGCCTGGCTTCCCTGGCGGGGGCGGCAA\nAGTGGGCGAGATGAGGATGCCCTGCCCTACGATGCCTTCGTGGTCTTCGACAAAACGCAG\nAGCGCAGTGGCAGACTGGGTGTACAACGAGCTTCGGGGGCAGCTGGAGGAGTGCCGTGGG\nCGCTGGGCACTCCGCCTGTGCCTGGAGGAACGCGACTGGCTGCCTGGCAAAACCCTCTTT\nGAGAACCTGTGGGCCTCGGTCTATGGCAGCCGCAAGACGCTGTTTGTGCTGGCCCACACG\nGACCGGGTCAGTGGTCTCTTGCGCGCCAGCTTCCTGCTGGCCCAGCAGCGCCTGCTGGAG\nGACCGCAAGGACGTCGTGGTGCTGGTGATCCTGAGCCCTGACGGCCGCCGCTCCCGCTAC\nGTGCGGCTGCGCCAGCGCCTCTGCCGCCAGAGTGTCCTCCTCTGGCCCCACCAGCCCAGT\nGGTCAGCGCAGCTTCTGGGCCCAGCTGGGCATGGCCCTGACCAGGGACAACCACCACTTC\nTATAACCGGAACTTCTGCCAGGGACCCACGGCCGAATAG'),('Transient receptor potential cation channel subfamily A member 1','None','Human','Temperature-gated cation channel activity','Receptor-activated non-selective cation channel involved in detection of pain and possibly also in cold perception and inner ear function (PubMed:25389312, PubMed:25855297). Has a central role in the pain response to endogenous inflammatory mediators and to a diverse array of volatile irritants, such as mustard oil, cinnamaldehyde, garlic and acrolein, an irritant from tears gas and vehicule exhaust fumes (PubMed:25389312, PubMed:20547126). Is also activated by menthol (in vitro)(PubMed:25389312). Acts also as a ionotropic cannabinoid receptor by being activated by delta(9)-tetrahydrocannabinol (THC), the psychoactive component of marijuana (PubMed:25389312). May be a component for the mechanosensitive transduction channel of hair cells in inner ear, thereby participating in the perception of sounds. Probably operated by a phosphatidylinositol second messenger system (By similarity).','TRPA1','127499.88','DB14011','>lcl|BSEQ0016321|Transient receptor potential cation channel subfamily A member 1 (TRPA1)\nATGAAGCGCAGCCTGAGGAAGATGTGGCGCCCTGGAGAAAAGAAGGAGCCCCAGGGCGTT\nGTCTATGAGGATGTGCCGGACGACACGGAGGATTTCAAGGAATCGCTTAAGGTGGTTTTT\nGAAGGAAGTGCATATGGATTACAAAACTTTAATAAGCAAAAGAAATTAAAAAGATGTGAC\nGATATGGACACCTTCTTCTTGCATTATGCTGCAGCAGAAGGCCAAATTGAGCTAATGGAG\nAAGATCACCAGAGATTCCTCTTTGGAAGTGCTGCATGAAATGGATGATTATGGAAATACC\nCCTCTGCATTGTGCTGTAGAAAAAAACCAAATTGAAAGCGTTAAGTTTCTTCTCAGCAGA\nGGAGCAAACCCAAATCTCCGAAACTTCAACATGATGGCTCCTCTCCACATAGCTGTGCAG\nGGCATGAATAATGAGGTGATGAAGGTCTTGCTTGAGCATAGAACTATTGATGTTAATTTG\nGAAGGAGAAAATGGAAACACAGCTGTGATCATTGCGTGCACCACAAATAATAGCGAAGCA\nTTGCAGATTTTGCTTAAAAAAGGAGCTAAGCCATGTAAATCAAATAAATGGGGATGTTTC\nCCTATTCACCAAGCTGCATTTTCAGGTTCCAAAGAATGCATGGAAATAATACTAAGGTTT\nGGTGAAGAGCATGGGTACAGTAGACAGTTGCACATTAACTTTATGAATAATGGGAAAGCC\nACCCCTCTCCACCTGGCTGTGCAAAATGGTGACTTGGAAATGATCAAAATGTGCCTGGAC\nAATGGTGCACAAATAGACCCAGTGGAGAAGGGAAGGTGCACAGCCATTCATTTTGCTGCC\nACCCAGGGAGCCACTGAGATTGTTAAACTGATGATATCGTCCTATTCTGGTAGCGTGGAT\nATTGTTAACACAACCGATGGATGTCATGAGACCATGCTTCACAGAGCTTCATTGTTTGAT\nCACCATGAGCTAGCAGACTATTTAATTTCAGTGGGAGCAGATATTAATAAGATCGATTCT\nGAAGGACGCTCTCCACTTATATTAGCAACTGCTTCTGCATCTTGGAATATTGTAAATTTG\nCTACTCTCTAAAGGTGCCCAAGTAGACATAAAAGATAATTTTGGACGTAATTTTCTGCAT\nTTAACTGTACAGCAACCTTATGGATTAAAAAATCTGCGACCTGAATTTATGCAGATGCAA\nCAGATCAAAGAGCTGGTAATGGATGAAGACAACGATGGGTGTACTCCTCTACATTATGCA\nTGTAGACAGGGGGGCCCTGGTTCTGTAAATAACCTACTTGGCTTTAATGTGTCCATTCAT\nTCCAAAAGCAAAGATAAGAAATCACCTCTGCATTTTGCAGCCAGTTATGGGCGTATCAAT\nACCTGTCAGAGGCTCCTACAAGACATAAGTGATACGAGGCTTCTGAATGAAGGTGACCTT\nCATGGAATGACTCCTCTCCATCTGGCAGCAAAGAATGGACATGATAAAGTAGTTCAGCTT\nCTTCTGAAAAAAGGTGCATTGTTTCTCAGTGACCACAATGGCTGGACAGCTTTGCATCAT\nGCGTCCATGGGCGGGTACACTCAGACCATGAAGGTCATTCTTGATACTAATTTGAAGTGC\nACAGATCGCCTGGATGAAGACGGGAACACTGCACTTCACTTTGCTGCAAGGGAAGGCCAC\nGCCAAAGCCGTTGCGCTTCTTCTGAGCCACAATGCTGACATAGTCCTGAACAAGCAGCAG\nGCCTCCTTTTTGCACCTTGCACTTCACAATAAGAGGAAGGAGGTTGTTCTTACGATCATC\nAGGAGCAAAAGATGGGATGAATGTCTTAAGATTTTCAGTCATAATTCTCCAGGCAATAAA\nTGTCCAATTACAGAAATGATAGAATACCTCCCTGAATGCATGAAGGTACTTTTAGATTTC\nTGCATGTTGCATTCCACAGAAGACAAGTCCTGCCGAGACTATTATATCGAGTATAATTTC\nAAATATCTTCAATGTCCATTAGAATTCACCAAAAAAACACCTACACAGGATGTTATATAT\nGAACCGCTTACAGCCCTCAACGCAATGGTACAAAATAACCGCATAGAGCTTCTCAATCAT\nCCTGTGTGTAAAGAATATTTACTCATGAAATGGTTGGCTTATGGATTTAGAGCTCATATG\nATGAATTTAGGATCTTACTGTCTTGGTCTCATACCTATGACCATTCTCGTTGTCAATATA\nAAACCAGGAATGGCTTTCAACTCAACTGGCATCATCAATGAAACTAGTGATCATTCAGAA\nATACTAGATACCACGAATTCATATCTAATAAAAACTTGTATGATTTTAGTGTTTTTATCA\nAGTATATTTGGGTATTGCAAAGAAGCGGGGCAAATTTTCCAACAGAAAAGGAATTATTTT\nATGGATATAAGCAATGTTCTTGAATGGATTATCTACACGACGGGCATCATTTTTGTGCTG\nCCCTTGTTTGTTGAAATACCAGCTCATCTGCAGTGGCAATGTGGAGCAATTGCTGTTTAC\nTTCTATTGGATGAATTTCTTATTGTATCTTCAAAGATTTGAAAATTGTGGAATTTTTATT\nGTTATGTTGGAGGTAATTTTGAAAACTTTGTTGAGGTCTACAGTTGTATTTATCTTCCTT\nCTTCTGGCTTTTGGACTCAGCTTTTACATCCTCCTGAATTTACAGGATCCCTTCAGCTCT\nCCATTGCTTTCTATAATCCAGACCTTCAGCATGATGCTAGGAGATATCAATTATCGAGAG\nTCCTTCCTAGAACCATATCTGAGAAATGAATTGGCACATCCAGTTCTGTCCTTTGCACAA\nCTTGTTTCCTTCACAATATTTGTCCCAATTGTCCTCATGAATTTACTTATTGGTTTGGCA\nGTTGGCGACATTGCTGAGGTCCAGAAACATGCATCATTGAAGAGGATAGCTATGCAGGTG\nGAACTTCATACCAGCTTAGAGAAGAAGCTGCCACTTTGGTTTCTACGCAAAGTGGATCAG\nAAATCCACCATCGTGTATCCCAACAAACCCAGATCTGGTGGGATGTTATTCCATATATTC\nTGTTTTTTATTTTGCACTGGGGAAATAAGACAAGAAATACCAAATGCTGATAAATCTTTA\nGAAATGGAAATATTAAAGCAGAAATACCGGCTGAAGGATCTTACTTTTCTCCTGGAAAAA\nCAGCATGAGCTCATTAAACTGATCATTCAGAAGATGGAGATCATCTCTGAGACAGAGGAT\nGATGATAGCCATTGTTCTTTTCAAGACAGGTTTAAGAAAGAGCAGATGGAACAAAGGAAT\nAGCAGATGGAATACTGTGTTGAGAGCAGTCAAGGCAAAAACACACCATCTTGAGCCTTAG'),('Transient receptor potential cation channel subfamily M member 8','None','Human','Calcium channel activity','Receptor-activated non-selective cation channel involved in detection of sensations such as coolness, by being activated by cold temperature below 25 degrees Celsius. Activated by icilin, eucalyptol, menthol, cold and modulation of intracellular pH. Involved in menthol sensation. Permeable for monovalent cations sodium, potassium, and cesium and divalent cation calcium. Temperature sensing is tightly linked to voltage-dependent gating. Activated upon depolarization, changes in temperature resulting in graded shifts of its voltage-dependent activation curves. The chemical agonist menthol functions as a gating modifier, shifting activation curves towards physiological membrane potentials. Temperature sensitivity arises from a tenfold difference in the activation energies associated with voltage-dependent opening and closing. In prostate cancer cells, shows strong inward rectification and high calcium selectivity in contrast to its behavior in normal cells which is characterized by outward rectification and poor cationic selectivity. Plays a role in prostate cancer cell migration (PubMed:25559186). Isoform 2 and isoform 3 negatively regulate menthol- and cold-induced channel activity by stabilizing the closed state of the channel.','TRPM8','127684.035','DB14011','>lcl|BSEQ0019077|Transient receptor potential cation channel subfamily M member 8 (TRPM8)\nATGTCCTTTCGGGCAGCCAGGCTCAGCATGAGGAACAGAAGGAATGACACTCTGGACAGC\nACCCGGACCCTGTACTCCAGCGCGTCTCGGAGCACAGACTTGTCTTACAGTGAAAGCGAC\nTTGGTGAATTTTATTCAAGCAAATTTTAAGAAACGAGAATGTGTCTTCTTTACCAAAGAT\nTCCAAGGCCACGGAGAATGTGTGCAAGTGTGGCTATGCCCAGAGCCAGCACATGGAAGGC\nACCCAGATCAACCAAAGTGAGAAATGGAACTACAAGAAACACACCAAGGAATTTCCTACC\nGACGCCTTTGGGGATATTCAGTTTGAGACACTGGGGAAGAAAGGGAAGTATATACGTCTG\nTCCTGCGACACGGACGCGGAAATCCTTTACGAGCTGCTGACCCAGCACTGGCACCTGAAA\nACACCCAACCTGGTCATTTCTGTGACCGGGGGCGCCAAGAACTTCGCCCTGAAGCCGCGC\nATGCGCAAGATCTTCAGCCGGCTCATCTACATCGCGCAGTCCAAAGGTGCTTGGATTCTC\nACGGGAGGCACCCATTATGGCCTGATGAAGTACATCGGGGAGGTGGTGAGAGATAACACC\nATCAGCAGGAGTTCAGAGGAGAATATTGTGGCCATTGGCATAGCAGCTTGGGGCATGGTC\nTCCAACCGGGACACCCTCATCAGGAATTGCGATGCTGAGGGCTATTTTTTAGCCCAGTAC\nCTTATGGATGACTTCACAAGAGATCCACTGTATATCCTGGACAACAACCACACACATTTG\nCTGCTCGTGGACAATGGCTGTCATGGACATCCCACTGTCGAAGCAAAGCTCCGGAATCAG\nCTAGAGAAGTATATCTCTGAGCGCACTATTCAAGATTCCAACTATGGTGGCAAGATCCCC\nATTGTGTGTTTTGCCCAAGGAGGTGGAAAAGAGACTTTGAAAGCCATCAATACCTCCATC\nAAAAATAAAATTCCTTGTGTGGTGGTGGAAGGCTCGGGCCAGATCGCTGATGTGATCGCT\nAGCCTGGTGGAGGTGGAGGATGCCCTGACATCTTCTGCCGTCAAGGAGAAGCTGGTGCGC\nTTTTTACCCCGCACGGTGTCCCGGCTGCCTGAGGAGGAGACTGAGAGTTGGATCAAATGG\nCTCAAAGAAATTCTCGAATGTTCTCACCTATTAACAGTTATTAAAATGGAAGAAGCTGGG\nGATGAAATTGTGAGCAATGCCATCTCCTACGCTCTATACAAAGCCTTCAGCACCAGTGAG\nCAAGACAAGGATAACTGGAATGGGCAGCTGAAGCTTCTGCTGGAGTGGAACCAGCTGGAC\nTTAGCCAATGATGAGATTTTCACCAATGACCGCCGATGGGAGTCTGCTGACCTTCAAGAA\nGTCATGTTTACGGCTCTCATAAAGGACAGACCCAAGTTTGTCCGCCTCTTTCTGGAGAAT\nGGCTTGAACCTACGGAAGTTTCTCACCCATGATGTCCTCACTGAACTCTTCTCCAACCAC\nTTCAGCACGCTTGTGTACCGGAATCTGCAGATCGCCAAGAATTCCTATAATGATGCCCTC\nCTCACGTTTGTCTGGAAACTGGTTGCGAACTTCCGAAGAGGCTTCCGGAAGGAAGACAGA\nAATGGCCGGGACGAGATGGACATAGAACTCCACGACGTGTCTCCTATTACTCGGCACCCC\nCTGCAAGCTCTCTTCATCTGGGCCATTCTTCAGAATAAGAAGGAACTCTCCAAAGTCATT\nTGGGAGCAGACCAGGGGCTGCACTCTGGCAGCCCTGGGAGCCAGCAAGCTTCTGAAGACT\nCTGGCCAAAGTGAAGAACGACATCAATGCTGCTGGGGAGTCCGAGGAGCTGGCTAATGAG\nTACGAGACCCGGGCTGTTGAGCTGTTCACTGAGTGTTACAGCAGCGATGAAGACTTGGCA\nGAACAGCTGCTGGTCTATTCCTGTGAAGCTTGGGGTGGAAGCAACTGTCTGGAGCTGGCG\nGTGGAGGCCACAGACCAGCATTTCATCGCCCAGCCTGGGGTCCAGAATTTTCTTTCTAAG\nCAATGGTATGGAGAGATTTCCCGAGACACCAAGAACTGGAAGATTATCCTGTGTCTGTTT\nATTATACCCTTGGTGGGCTGTGGCTTTGTATCATTTAGGAAGAAACCTGTCGACAAGCAC\nAAGAAGCTGCTTTGGTACTATGTGGCGTTCTTCACCTCCCCCTTCGTGGTCTTCTCCTGG\nAATGTGGTCTTCTACATCGCCTTCCTCCTGCTGTTTGCCTACGTGCTGCTCATGGATTTC\nCATTCGGTGCCACACCCCCCCGAGCTGGTCCTGTACTCGCTGGTCTTTGTCCTCTTCTGT\nGATGAAGTGAGACAGTGGTACGTAAATGGGGTGAATTATTTTACTGACCTGTGGAATGTG\nATGGACACGCTGGGGCTTTTTTACTTCATAGCAGGAATTGTATTTCGGCTCCACTCTTCT\nAATAAAAGCTCTTTGTATTCTGGACGAGTCATTTTCTGTCTGGACTACATTATTTTCACT\nCTAAGATTGATCCACATTTTTACTGTAAGCAGAAACTTAGGACCCAAGATTATAATGCTG\nCAGAGGATGCTGATCGATGTGTTCTTCTTCCTGTTCCTCTTTGCGGTGTGGATGGTGGCC\nTTTGGCGTGGCCAGGCAAGGGATCCTTAGGCAGAATGAGCAGCGCTGGAGGTGGATATTC\nCGTTCGGTCATCTACGAGCCCTACCTGGCCATGTTCGGCCAGGTGCCCAGTGACGTGGAT\nGGTACCACGTATGACTTTGCCCACTGCACCTTCACTGGGAATGAGTCCAAGCCACTGTGT\nGTGGAGCTGGATGAGCACAACCTGCCCCGGTTCCCCGAGTGGATCACCATCCCCCTGGTG\nTGCATCTACATGTTATCCACCAACATCCTGCTGGTCAACCTGCTGGTCGCCATGTTTGGC\nTACACGGTGGGCACCGTCCAGGAGAACAATGACCAGGTCTGGAAGTTCCAGAGGTACTTC\nCTGGTGCAGGAGTACTGCAGCCGCCTCAATATCCCCTTCCCCTTCATCGTCTTCGCTTAC\nTTCTACATGGTGGTGAAGAAGTGCTTCAAGTGTTGCTGCAAGGAGAAAAACATGGAGTCT\nTCTGTCTGCTGTTTCAAAAATGAAGACAATGAGACTCTGGCATGGGAGGGTGTCATGAAG\nGAAAACTACCTTGTCAAGATCAACACAAAAGCCAACGACACCTCAGAGGAAATGAGGCAT\nCGATTTAGACAACTGGATACAAAGCTTAATGATCTCAAGGGTCTTCTGAAAGAGATTGCT\nAATAAAATCAAATAA'),('Transient receptor potential cation channel subfamily V member 1','None','Human','Transmembrane signaling receptor activity','Ligand-activated non-selective calcium permeant cation channel involved in detection of noxious chemical and thermal stimuli. Seems to mediate proton influx and may be involved in intracellular acidosis in nociceptive neurons. Involved in mediation of inflammatory pain and hyperalgesia. Sensitized by a phosphatidylinositol second messenger system activated by receptor tyrosine kinases, which involves PKC isozymes and PCL. Can be activated by endogenous compounds, including 12-hydroperoxytetraenoic acid and bradykinin. Acts as ionotropic endocannabinoid receptor with central neuromodulatory effects. Triggers a form of long-term depression (TRPV1-LTD) mediated by the endocannabinoid anandamine in the hippocampus and nucleus accumbens by affecting AMPA receptors endocytosis (By similarity). Activation by vanilloids, like capsaicin, and temperatures higher than 42 degrees Celsius, exhibits a time- and Ca(2+)-dependent outward rectification, followed by a long-lasting refractory state. Mild extracellular acidic pH (6.5) potentiates channel activation by noxious heat and vanilloids, whereas acidic conditions (pH <6) directly activate the channel.','TRPV1','94955.33','DB09288','>lcl|BSEQ0020500|Transient receptor potential cation channel subfamily V member 1 (TRPV1)\nATGAAGAAATGGAGCAGCACAGACTTGGGGGCAGCTGCGGACCCACTCCAAAAGGACACC\nTGCCCAGACCCCCTGGATGGAGACCCTAACTCCAGGCCACCTCCAGCCAAGCCCCAGCTC\nTCCACGGCCAAGAGCCGCACCCGGCTCTTTGGGAAGGGTGACTCGGAGGAGGCTTTCCCG\nGTGGATTGCCCTCACGAGGAAGGTGAGCTGGACTCCTGCCCGACCATCACAGTCAGCCCT\nGTTATCACCATCCAGAGGCCAGGAGACGGCCCCACCGGTGCCAGGCTGCTGTCCCAGGAC\nTCTGTCGCCGCCAGCACCGAGAAGACCCTCAGGCTCTATGATCGCAGGAGTATCTTTGAA\nGCCGTTGCTCAGAATAACTGCCAGGATCTGGAGAGCCTGCTGCTCTTCCTGCAGAAGAGC\nAAGAAGCACCTCACAGACAACGAGTTCAAAGACCCTGAGACAGGGAAGACCTGTCTGCTG\nAAAGCCATGCTCAACCTGCACGACGGACAGAACACCACCATCCCCCTGCTCCTGGAGATC\nGCGCGGCAAACGGACAGCCTGAAGGAGCTTGTCAACGCCAGCTACACGGACAGCTACTAC\nAAGGGCCAGACAGCACTGCACATCGCCATCGAGAGACGCAACATGGCCCTGGTGACCCTC\nCTGGTGGAGAACGGAGCAGACGTCCAGGCTGCGGCCCATGGGGACTTCTTTAAGAAAACC\nAAAGGGCGGCCTGGATTCTACTTCGGTGAACTGCCCCTGTCCCTGGCCGCGTGCACCAAC\nCAGCTGGGCATCGTGAAGTTCCTGCTGCAGAACTCCTGGCAGACGGCCGACATCAGCGCC\nAGGGACTCGGTGGGCAACACGGTGCTGCACGCCCTGGTGGAGGTGGCCGACAACACGGCC\nGACAACACGAAGTTTGTGACGAGCATGTACAATGAGATTCTGATGCTGGGGGCCAAACTG\nCACCCGACGCTGAAGCTGGAGGAGCTCACCAACAAGAAGGGAATGACGCCGCTGGCTCTG\nGCAGCTGGGACCGGGAAGATCGGGGTCTTGGCCTATATTCTCCAGCGGGAGATCCAGGAG\nCCCGAGTGCAGGCACCTGTCCAGGAAGTTCACCGAGTGGGCCTACGGGCCCGTGCACTCC\nTCGCTGTACGACCTGTCCTGCATCGACACCTGCGAGAAGAACTCGGTGCTGGAGGTGATC\nGCCTACAGCAGCAGCGAGACCCCTAATCGCCACGACATGCTCTTGGTGGAGCCGCTGAAC\nCGACTCCTGCAGGACAAGTGGGACAGATTCGTCAAGCGCATCTTCTACTTCAACTTCCTG\nGTCTACTGCCTGTACATGATCATCTTCACCATGGCTGCCTACTACAGGCCCGTGGATGGC\nTTGCCTCCCTTTAAGATGGAAAAAACTGGAGACTATTTCCGAGTTACTGGAGAGATCCTG\nTCTGTGTTAGGAGGAGTCTACTTCTTTTTCCGAGGGATTCAGTATTTCCTGCAGAGGCGG\nCCGTCGATGAAGACCCTGTTTGTGGACAGCTACAGTGAGATGCTTTTCTTTCTGCAGTCA\nCTGTTCATGCTGGCCACCGTGGTGCTGTACTTCAGCCACCTCAAGGAGTATGTGGCTTCC\nATGGTATTCTCCCTGGCCTTGGGCTGGACCAACATGCTCTACTACACCCGCGGTTTCCAG\nCAGATGGGCATCTATGCCGTCATGATAGAGAAGATGATCCTGAGAGACCTGTGCCGTTTC\nATGTTTGTCTACATCGTCTTCTTGTTCGGGTTTTCCACAGCGGTGGTGACGCTGATTGAA\nGACGGGAAGAATGACTCCCTGCCGTCTGAGTCCACGTCGCACAGGTGGCGGGGGCCTGCC\nTGCAGGCCCCCCGATAGCTCCTACAACAGCCTGTACTCCACCTGCCTGGAGCTGTTCAAG\nTTCACCATCGGCATGGGCGACCTGGAGTTCACTGAGAACTATGACTTCAAGGCTGTCTTC\nATCATCCTGCTGCTGGCCTATGTAATTCTCACCTACATCCTCCTGCTCAACATGCTCATC\nGCCCTCATGGGTGAGACTGTCAACAAGATCGCACAGGAGAGCAAGAACATCTGGAAGCTG\nCAGAGAGCCATCACCATCCTGGACACGGAGAAGAGCTTCCTTAAGTGCATGAGGAAGGCC\nTTCCGCTCAGGCAAGCTGCTGCAGGTGGGGTACACACCTGATGGCAAGGACGACTACCGG\nTGGTGCTTCAGGGTGGACGAGGTGAACTGGACCACCTGGAACACCAACGTGGGCATCATC\nAACGAAGACCCGGGCAACTGTGAGGGCGTCAAGCGCACCCTGAGCTTCTCCCTGCGGTCA\nAGCAGAGTTTCAGGCAGACACTGGAAGAACTTTGCCCTGGTCCCCCTTTTAAGAGAGGCA\nAGTGCTCGAGATAGGCAGTCTGCTCAGCCCGAGGAAGTTTATCTGCGACAGTTTTCAGGG\nTCTCTGAAGCCAGAGGACGCTGAGGTCTTCAAGAGTCCTGCCGCTTCCGGGGAGAAGTGA'),('Transient receptor potential cation channel subfamily V member 2','None','Human','Calcium-permeable, non-selective cation channel with an outward rectification. Seems to be regulated, at least in part, by IGF-I, PDGF and neuropeptide head activator. May transduce physical stimuli in mast cells. Activated by temperatures higher than 52 degrees Celsius; is not activated by vanilloids and acidic pH.','Calcium channel activity','TRPV2','85980.335','DB14011','>lcl|BSEQ0051340|Transient receptor potential cation channel subfamily V member 2 (TRPV2)\nATGACCTCACCCTCCAGCTCTCCAGTTTTCAGGTTGGAGACATTAGATGGAGGCCAAGAA\nGATGGCTCTGAGGCGGACAGAGGAAAGCTGGATTTTGGGAGCGGGCTGCCTCCCATGGAG\nTCACAGTTCCAGGGCGAGGACCGGAAATTCGCCCCTCAGATAAGAGTCAACCTCAACTAC\nCGAAAGGGAACAGGTGCCAGTCAGCCGGATCCAAACCGATTTGACCGAGATCGGCTCTTC\nAATGCGGTCTCCCGGGGTGTCCCCGAGGATCTGGCTGGACTTCCAGAGTACCTGAGCAAG\nACCAGCAAGTACCTCACCGACTCGGAATACACAGAGGGCTCCACAGGTAAGACGTGCCTG\nATGAAGGCTGTGCTGAACCTTAAGGACGGAGTCAATGCCTGCATTCTGCCACTGCTGCAG\nATCGACAGGGACTCTGGCAATCCTCAGCCCCTGGTAAATGCCCAGTGCACAGATGACTAT\nTACCGAGGCCACAGCGCTCTGCACATCGCCATTGAGAAGAGGAGTCTGCAGTGTGTGAAG\nCTCCTGGTGGAGAATGGGGCCAATGTGCATGCCCGGGCCTGCGGCCGCTTCTTCCAGAAG\nGGCCAAGGGACTTGCTTTTATTTCGGTGAGCTACCCCTCTCTTTGGCCGCTTGCACCAAG\nCAGTGGGATGTGGTAAGCTACCTCCTGGAGAACCCACACCAGCCCGCCAGCCTGCAGGCC\nACTGACTCCCAGGGCAACACAGTCCTGCATGCCCTAGTGATGATCTCGGACAACTCAGCT\nGAGAACATTGCACTGGTGACCAGCATGTATGATGGGCTCCTCCAAGCTGGGGCCCGCCTC\nTGCCCTACCGTGCAGCTTGAGGACATCCGCAACCTGCAGGATCTCACGCCTCTGAAGCTG\nGCCGCCAAGGAGGGCAAGATCGAGATTTTCAGGCACATCCTGCAGCGGGAGTTTTCAGGA\nCTGAGCCACCTTTCCCGAAAGTTCACCGAGTGGTGCTATGGGCCTGTCCGGGTGTCGCTG\nTATGACCTGGCTTCTGTGGACAGCTGTGAGGAGAACTCAGTGCTGGAGATCATTGCCTTT\nCATTGCAAGAGCCCGCACCGACACCGAATGGTCGTTTTGGAGCCCCTGAACAAACTGCTG\nCAGGCGAAATGGGATCTGCTCATCCCCAAGTTCTTCTTAAACTTCCTGTGTAATCTGATC\nTACATGTTCATCTTCACCGCTGTTGCCTACCATCAGCCTACCCTGAAGAAGCAGGCCGCC\nCCTCACCTGAAAGCGGAGGTTGGAAACTCCATGCTGCTGACGGGCCACATCCTTATCCTG\nCTAGGGGGGATCTACCTCCTCGTGGGCCAGCTGTGGTACTTCTGGCGGCGCCACGTGTTC\nATCTGGATCTCGTTCATAGACAGCTACTTTGAAATCCTCTTCCTGTTCCAGGCCCTGCTC\nACAGTGGTGTCCCAGGTGCTGTGTTTCCTGGCCATCGAGTGGTACCTGCCCCTGCTTGTG\nTCTGCGCTGGTGCTGGGCTGGCTGAACCTGCTTTACTATACACGTGGCTTCCAGCACACA\nGGCATCTACAGTGTCATGATCCAGAAGGTCATCCTGCGGGACCTGCTGCGCTTCCTTCTG\nATCTACTTAGTCTTCCTTTTCGGCTTCGCTGTAGCCCTGGTGAGCCTGAGCCAGGAGGCT\nTGGCGCCCCGAAGCTCCTACAGGCCCCAATGCCACAGAGTCAGTGCAGCCCATGGAGGGA\nCAGGAGGACGAGGGCAACGGGGCCCAGTACAGGGGTATCCTGGAAGCCTCCTTGGAGCTC\nTTCAAATTCACCATCGGCATGGGCGAGCTGGCCTTCCAGGAGCAGCTGCACTTCCGCGGC\nATGGTGCTGCTGCTGCTGCTGGCCTACGTGCTGCTCACCTACATCCTGCTGCTCAACATG\nCTCATCGCCCTCATGAGCGAGACCGTCAACAGTGTCGCCACTGACAGCTGGAGCATCTGG\nAAGCTGCAGAAAGCCATCTCTGTCCTGGAGATGGAGAATGGCTATTGGTGGTGCAGGAAG\nAAGCAGCGGGCAGGTGTGATGCTGACCGTTGGCACTAAGCCAGATGGCAGCCCCGATGAG\nCGCTGGTGCTTCAGGGTGGAGGAGGTGAACTGGGCTTCATGGGAGCAGACGCTGCCTACG\nCTGTGTGAGGACCCGTCAGGGGCAGGTGTCCCTCGAACTCTCGAGAACCCTGTCCTGGCT\nTCCCCTCCCAAGGAGGATGAGGATGGTGCCTCTGAGGAAAACTATGTGCCCGTCCAGCTC\nCTCCAGTCCAACTGA'),('Transient receptor potential cation channel subfamily V member 3','None','Human','Calcium channel activity','Putative receptor-activated non-selective calcium permeant cation channel. It is activated by innocuous (warm) temperatures and shows an increased response at noxious temperatures greater than 39 degrees Celsius. Activation exhibits an outward rectification. May associate with TRPV1 and may modulate its activity. Is a negative regulator of hair growth and cycling: TRPV3-coupled signaling suppresses keratinocyte proliferation in hair follicles and induces apoptosis and premature hair follicle regression (catagen).','TRPV3','90635.115','DB14011','>lcl|BSEQ0006665|2373 bp\nATGAAAGCCCACCCCAAGGAGATGGTGCCTCTCATGGGCAAGAGAGTTGCTGCCCCCAGT\nGGGAACCCTGCCGTCCTGCCAGAGAAGAGGCCGGCGGAGATCACCCCCACAAAGAAGAGT\nGCACACTTCTTCCTGGAGATAGAAGGGTTTGAACCCAACCCCACAGTTGCCAAGACCTCT\nCCTCCTGTCTTCTCCAAGCCCATGGATTCCAACATCCGGCAGTGCATCTCTGGTAACTGT\nGATGACATGGACTCCCCCCAGTCTCCTCAGGATGATGTGACAGAGACCCCATCCAATCCC\nAACAGCCCCAGTGCACAGCTGGCCAAGGAAGAGCAGAGGAGGAAAAAGGGGCGGCTGAAG\nAAGCGCATCTTTGCAGCCGTGTCTGAGGGCTGCGTGGAGGAGTTGGTAGAGTTGCTGGTG\nGAGCTGCAGGAGCTTTGCAGGCGGCGCCATGATGAGGATGTGCCTGACTTCCTCATGCAC\nAAGCTGACGGCCTCCGACACGGGGAAGACCTGCCTGATGAAGGCCTTGTTAAACATCAAC\nCCCAACACCAAGGAGATAGTGCGGATCCTGCTTGCCTTTGCTGAAGAGAACGACATCCTG\nGGCAGGTTCATCAACGCCGAGTACACAGAGGAGGCCTATGAAGGGCAGACGGCGCTGAAC\nATCGCCATCGAGCGGCGGCAGGGGGACATCGCAGCCCTGCTCATCGCCGCCGGCGCCGAC\nGTCAACGCGCACGCCAAGGGGGCCTTCTTCAACCCCAAGTACCAACACGAAGGCTTCTAC\nTTCGGTGAGACGCCCCTGGCCCTGGCAGCATGCACCAACCAGCCCGAGATTGTGCAGCTG\nCTGATGGAGCACGAGCAGACGGACATCACCTCGCGGGACTCACGAGGCAACAACATCCTT\nCACGCCCTGGTGACCGTGGCCGAGGACTTCAAGACACAGAATGACTTTGTGAAGCGCATG\nTACGACATGATCCTACTGCGGAGTGGCAACTGGGAGCTGGAGACCACTCGCAACAACGAT\nGGCCTCACGCCGCTGCAGCTGGCCGCCAAGATGGGCAAGGCGGAGATCCTGAAGTACATC\nCTCAGTCGTGAGATCAAGGAGAAGCGGCTCCGGAGCCTGTCCAGGAAGTTCACCGACTGG\nGCGTACGGACCCGTGTCATCCTCCCTCTACGACCTCACCAACGTGGACACCACCACGGAC\nAACTCAGTGCTGGAAATCACTGTCTACAACACCAACATCGACAACCGGCATGAGATGCTG\nACCCTGGAGCCGCTGCACACGCTGCTGCATATGAAGTGGAAGAAGTTTGCCAAGCACATG\nTTCTTTCTGTCCTTCTGCTTTTATTTCTTCTACAACATCACCCTGACCCTCGTCTCGTAC\nTACCGCCCCCGGGAGGAGGAGGCCATCCCGCACCCCTTGGCCCTGACGCACAAGATGGGG\nTGGCTGCAGCTCCTAGGGAGGATGTTTGTGCTCATCTGGGCCATGTGCATCTCTGTGAAA\nGAGGGCATTGCCATCTTCCTGCTGAGACCCTCGGATCTGCAGTCCATCCTCTCGGATGCC\nTGGTTCCACTTTGTCTTTTTTATCCAAGCTGTGCTTGTGATACTGTCTGTCTTCTTGTAC\nTTGTTTGCCTACAAAGAGTACCTCGCCTGCCTCGTGCTGGCCATGGCCCTGGGCTGGGCG\nAACATGCTCTACTATACGCGGGGTTTCCAGTCCATGGGCATGTACAGCGTCATGATCCAG\nAAGGTTATTTTGCATGATGTTCTGAAGTTCTTGTTTGTATATATCGTGTTTTTGCTTGGA\nTTTGGAGTAGCCTTGGCCTCGCTGATCGAGAAGTGTCCCAAAGACAACAAGGACTGCAGC\nTCCTACGGCAGCTTCAGCGACGCAGTGCTGGAACTCTTCAAGCTCACCATAGGCCTGGGT\nGATCTGAACATCCAGCAGAACTCCAAGTATCCCATTCTCTTTCTGTTCCTGCTCATCACC\nTATGTCATCCTCACCTTTGTTCTCCTCCTCAACATGCTCATTGCTCTGATGGGCGAGACT\nGTGGAGAACGTCTCCAAGGAGAGCGAACGCATCTGGCGCCTGCAGAGAGCCAGGACCATC\nTTGGAGTTTGAGAAAATGTTACCAGAATGGCTGAGGAGCAGATTCCGGATGGGAGAGCTG\nTGCAAAGTGGCCGAGGATGATTTCCGACTGTGTTTGCGGATCAATGAGGTGAAGTGGACT\nGAATGGAAGACGCACGTCTCCTTCCTTAACGAAGACCCGGGGCCTGTAAGACGAACAGAT\nTTCAACAAAATCCAAGATTCTTCCAGGAACAACAGCAAAACCACTCTCAATGCATTTGAA\nGAAGTCGAGGAATTCCCGGAAACCTCGGTGTAG'),('Transient receptor potential cation channel subfamily V member 4','None','Human','Non-selective calcium permeant cation channel involved in osmotic sensitivity and mechanosensitivity. Activation by exposure to hypotonicity within the physiological range exhibits an outward rectification (PubMed:18826956, PubMed:18695040). Also activated by heat, low pH, citrate and phorbol esters (PubMed:18826956, PubMed:18695040). Increase of intracellular Ca(2+) potentiates currents. Channel activity seems to be regulated by a calmodulin-dependent mechanism with a negative feedback mechanism (PubMed:12724311, PubMed:18826956). Promotes cell-cell junction formation in skin keratinocytes and plays an important role in the formation and/or maintenance of functional intercellular barriers (By similarity). Acts as a regulator of intracellular Ca(2+) in synoviocytes (PubMed:19759329). Plays an obligatory role as a molecular component in the nonselective cation channel activation induced by 4-alpha-phorbol 12,13-didecanoate and hypotonic stimulation in synoviocytes and also regulates production of IL-8 (PubMed:19759329). Together with PKD2, forms mechano- and thermosensitive channels in cilium (PubMed:18695040). Negatively regulates expression of PPARGC1A, UCP1, oxidative metabolism and respiration in adipocytes (By similarity). Regulates expression of chemokines and cytokines related to proinflammatory pathway in adipocytes (By similarity). Together with AQP5, controls regulatory volume decrease in salivary epithelial cells (By similarity). Required for normal development and maintenance of bone and cartilage (PubMed:26249260).','Actin binding','TRPV4','98280.2','DB14011','>lcl|BSEQ0051342|Transient receptor potential cation channel subfamily V member 4 (TRPV4)\nATGGCGGATTCCAGCGAAGGCCCCCGCGCGGGGCCCGGGGAGGTGGCTGAGCTCCCCGGG\nGATGAGAGTGGCACCCCAGGTGGGGAGGCTTTTCCTCTCTCCTCCCTGGCCAATCTGTTT\nGAGGGGGAGGATGGCTCCCTTTCGCCCTCACCGGCTGATGCCAGTCGCCCTGCTGGCCCA\nGGCGATGGGCGACCAAATCTGCGCATGAAGTTCCAGGGCGCCTTCCGCAAGGGGGTGCCC\nAACCCCATCGATCTGCTGGAGTCCACCCTATATGAGTCCTCGGTGGTGCCTGGGCCCAAG\nAAAGCACCCATGGACTCACTGTTTGACTACGGCACCTATCGTCACCACTCCAGTGACAAC\nAAGAGGTGGAGGAAGAAGATCATAGAGAAGCAGCCGCAGAGCCCCAAAGCCCCTGCCCCT\nCAGCCGCCCCCCATCCTCAAAGTCTTCAACCGGCCTATCCTCTTTGACATCGTGTCCCGG\nGGCTCCACTGCTGACCTGGACGGGCTGCTCCCATTCTTGCTGACCCACAAGAAACGCCTA\nACTGATGAGGAGTTTCGAGAGCCATCTACGGGGAAGACCTGCCTGCCCAAGGCCTTGCTG\nAACCTGAGCAATGGCCGCAACGACACCATCCCTGTGCTGCTGGACATCGCGGAGCGCACC\nGGCAACATGAGGGAGTTCATTAACTCGCCCTTCCGTGACATCTACTATCGAGGTCAGACA\nGCCCTGCACATCGCCATTGAGCGTCGCTGCAAACACTACGTGGAACTTCTCGTGGCCCAG\nGGAGCTGATGTCCACGCCCAGGCCCGTGGGCGCTTCTTCCAGCCCAAGGATGAGGGGGGC\nTACTTCTACTTTGGGGAGCTGCCCCTGTCGCTGGCTGCCTGCACCAACCAGCCCCACATT\nGTCAACTACCTGACGGAGAACCCCCACAAGAAGGCGGACATGCGGCGCCAGGACTCGCGA\nGGCAACACAGTGCTGCATGCGCTGGTGGCCATTGCTGACAACACCCGTGAGAACACCAAG\nTTTGTTACCAAGATGTACGACCTGCTGCTGCTCAAGTGTGCCCGCCTCTTCCCCGACAGC\nAACCTGGAGGCCGTGCTCAACAACGACGGCCTCTCGCCCCTCATGATGGCTGCCAAGACG\nGGCAAGATTGGGATCTTTCAGCACATCATCCGGCGGGAGGTGACGGATGAGGACACACGG\nCACCTGTCCCGCAAGTTCAAGGACTGGGCCTATGGGCCAGTGTATTCCTCGCTTTATGAC\nCTCTCCTCCCTGGACACGTGTGGGGAAGAGGCCTCCGTGCTGGAGATCCTGGTGTACAAC\nAGCAAGATTGAGAACCGCCACGAGATGCTGGCTGTGGAGCCCATCAATGAACTGCTGCGG\nGACAAGTGGCGCAAGTTCGGGGCCGTCTCCTTCTACATCAACGTGGTCTCCTACCTGTGT\nGCCATGGTCATCTTCACTCTCACCGCCTACTACCAGCCGCTGGAGGGCACACCGCCGTAC\nCCTTACCGCACCACGGTGGACTACCTGCGGCTGGCTGGCGAGGTCATTACGCTCTTCACT\nGGGGTCCTGTTCTTCTTCACCAACATCAAAGACTTGTTCATGAAGAAATGCCCTGGAGTG\nAATTCTCTCTTCATTGATGGCTCCTTCCAGCTGCTCTACTTCATCTACTCTGTCCTGGTG\nATCGTCTCAGCAGCCCTCTACCTGGCAGGGATCGAGGCCTACCTGGCCGTGATGGTCTTT\nGCCCTGGTCCTGGGCTGGATGAATGCCCTTTACTTCACCCGTGGGCTGAAGCTGACGGGG\nACCTATAGCATCATGATCCAGAAGATTCTCTTCAAGGACCTTTTCCGATTCCTGCTCGTC\nTACTTGCTCTTCATGATCGGCTACGCTTCAGCCCTGGTCTCCCTCCTGAACCCGTGTGCC\nAACATGAAGGTGTGCAATGAGGACCAGACCAACTGCACAGTGCCCACTTACCCCTCGTGC\nCGTGACAGCGAGACCTTCAGCACCTTCCTCCTGGACCTGTTTAAGCTGACCATCGGCATG\nGGCGACCTGGAGATGCTGAGCAGCACCAAGTACCCCGTGGTCTTCATCATCCTGCTGGTG\nACCTACATCATCCTCACCTTTGTGCTGCTCCTCAACATGCTCATTGCCCTCATGGGCGAG\nACAGTGGGCCAGGTCTCCAAGGAGAGCAAGCACATCTGGAAGCTGCAGTGGGCCACCACC\nATCCTGGACATTGAGCGCTCCTTCCCCGTATTCCTGAGGAAGGCCTTCCGCTCTGGGGAG\nATGGTCACCGTGGGCAAGAGCTCGGACGGCACTCCTGACCGCAGGTGGTGCTTCAGGGTG\nGATGAGGTGAACTGGTCTCACTGGAACCAGAACTTGGGCATCATCAACGAGGACCCGGGC\nAAGAATGAGACCTACCAGTATTATGGCTTCTCGCATACCGTGGGCCGCCTCCGCAGGGAT\nCGCTGGTCCTCGGTGGTACCCCGCGTGGTGGAACTGAACAAGAACTCGAACCCGGACGAG\nGTGGTGGTGCCTCTGGACAGCATGGGGAACCCCCGCTGCGATGGCCACCAGCAGGGTTAC\nCCCCGCAAGTGGAGGACTGATGACGCCCCGCTCTAG'),('Trypsin-1','None','Human','Serine-type endopeptidase activity','Has activity against the synthetic substrates Boc-Phe-Ser-Arg-Mec, Boc-Leu-Thr-Arg-Mec, Boc-Gln-Ala-Arg-Mec and Boc-Val-Pro-Arg-Mec. The single-chain form is more active than the two-chain form against all of these substrates.','PRSS1','26557.88','DB12598','>lcl|BSEQ0016544|Trypsin-1 (PRSS1)\nATGAATCCACTCCTGATCCTTACCTTTGTGGCAGCTGCTCTTGCTGCCCCCTTTGATGAT\nGATGACAAGATCGTTGGGGGCTACAACTGTGAGGAGAATTCTGTCCCCTACCAGGTGTCC\nCTGAATTCTGGCTACCACTTCTGTGGTGGCTCCCTCATCAACGAACAGTGGGTGGTATCA\nGCAGGCCACTGCTACAAGTCCCGCATCCAGGTGAGACTGGGAGAGCACAACATCGAAGTC\nCTGGAGGGGAATGAGCAGTTCATCAATGCAGCCAAGATCATCCGCCACCCCCAATACGAC\nAGGAAGACTCTGAACAATGACATCATGTTAATCAAGCTCTCCTCACGTGCAGTAATCAAC\nGCCCGCGTGTCCACCATCTCTCTGCCCACCGCCCCTCCAGCCACTGGCACGAAGTGCCTC\nATCTCTGGCTGGGGCAACACTGCGAGCTCTGGCGCCGACTACCCAGACGAGCTGCAGTGC\nCTGGATGCTCCTGTGCTGAGCCAGGCTAAGTGTGAAGCCTCCTACCCTGGAAAGATTACC\nAGCAACATGTTCTGTGTGGGCTTCCTTGAGGGAGGCAAGGATTCATGTCAGGGTGATTCT\nGGTGGCCCTGTGGTCTGCAATGGACAGCTCCAAGGAGTTGTCTCCTGGGGTGATGGCTGT\nGCCCAGAAGAACAAGCCTGGAGTCTACACCAAGGTCTACAACTATGTGAAATGGATTAAG\nAACACCATAGCTGCCAATAGCTAA'),('Tumor necrosis factor','None','Human','Tumor necrosis factor receptor binding','Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Impairs regulatory T-cells (Treg) function in individuals with rheumatoid arthritis via FOXP3 dephosphorylation. Upregulates the expression of protein phosphatase 1 (PP1), which dephosphorylates the key \'Ser-418\' residue of FOXP3, thereby inactivating FOXP3 and rendering Treg cells functionally defective (PubMed:23396208). Key mediator of cell death in the anticancer action of BCG-stimulated neutrophils in combination with DIABLO/SMAC mimetic in the RT4v6 bladder cancer cell line (PubMed:22517918).The TNF intracellular domain (ICD) form induces IL12 production in dendritic cells.','TNF','25644.15','DB05676','>lcl|BSEQ0021837|Tumor necrosis factor (TNF)\nATGAGCACTGAAAGCATGATCCGGGACGTGGAGCTGGCCGAGGAGGCGCTCCCCAAGAAG\nACAGGGGGGCCCCAGGGCTCCAGGCGGTGCTTGTTCCTCAGCCTCTTCTCCTTCCTGATC\nGTGGCAGGCGCCACCACGCTCTTCTGCCTGCTGCACTTTGGAGTGATCGGCCCCCAGAGG\nGAAGAGTTCCCCAGGGACCTCTCTCTAATCAGCCCTCTGGCCCAGGCAGTCAGATCATCT\nTCTCGAACCCCGAGTGACAAGCCTGTAGCCCATGTTGTAGCAAACCCTCAAGCTGAGGGG\nCAGCTCCAGTGGCTGAACCGCCGGGCCAATGCCCTCCTGGCCAATGGCGTGGAGCTGAGA\nGATAACCAGCTGGTGGTGCCATCAGAGGGCCTGTACCTCATCTACTCCCAGGTCCTCTTC\nAAGGGCCAAGGCTGCCCCTCCACCCATGTGCTCCTCACCCACACCATCAGCCGCATCGCC\nGTCTCCTACCAGACCAAGGTCAACCTCCTCTCTGCCATCAAGAGCCCCTGCCAGAGGGAG\nACCCCAGAGGGGGCTGAGGCCAAGCCCTGGTATGAGCCCATCTATCTGGGAGGGGTCTTC\nCAGCTGGAGAAGGGTGACCGACTCAGCGCTGAGATCAATCGGCCCGACTATCTCGACTTT\nGCCGAGTCTGGGCAGGTCTACTTTGGGATCATTGCCCTGTGA'),('Tyrosine--tRNA ligase, cytoplasmic','None','Human','Tyrosine-trna ligase activity','Catalyzes the attachment of tyrosine to tRNA(Tyr) in a two-step reaction: tyrosine is first activated by ATP to form Tyr-AMP and then transferred to the acceptor end of tRNA(Tyr).','YARS','59143.025','DB02709','>lcl|BSEQ0010211|Tyrosine--tRNA ligase, cytoplasmic (YARS)\nATGGGGGACGCTCCCAGCCCTGAAGAGAAACTGCACCTTATCACCCGGAACCTGCAGGAG\nGTTCTGGGGGAAGAGAAGCTGAAGGAGATACTGAAGGAGCGGGAACTTAAAATTTACTGG\nGGAACGGCAACCACGGGCAAACCACATGTGGCTTACTTTGTGCCCATGTCAAAGATTGCA\nGACTTCTTAAAGGCAGGGTGTGAGGTAACAATTCTGTTTGCGGACCTCCACGCATACCTG\nGATAACATGAAAGCCCCATGGGAACTTCTAGAACTCCGAGTCAGTTACTATGAGAATGTG\nATCAAAGCAATGCTGGAGAGCATTGGTGTGCCCTTGGAGAAGCTCAAGTTCATCAAAGGC\nACTGATTACCAGCTCAGCAAAGAGTACACACTAGATGTGTACAGACTCTCCTCCGTGGTC\nACACAGCACGATTCCAAGAAGGCTGGAGCTGAGGTGGTAAAGCAGGTGGAGCACCCTTTG\nCTGAGTGGCCTCTTATACCCCGGACTGCAGGCTTTGGATGAAGAGTATTTAAAAGTAGAT\nGCCCAATTTGGAGGCATTGATCAGAGAAAGATTTTCACCTTTGCAGAGAAGTACCTCCCT\nGCACTTGGCTATTCAAAACGGGTCCATCTGATGAATCCTATGGTTCCAGGATTAACAGGC\nAGCAAAATGAGCTCTTCAGAAGAGGAGTCCAAGATTGATCTCCTTGATCGGAAGGAGGAT\nGTGAAGAAAAAACTGAAGAAGGCCTTCTGTGAGCCAGGAAATGTGGAGAACAATGGGGTT\nCTGTCCTTCATCAAGCATGTCCTTTTTCCCCTTAAGTCCGAGTTTGTGATCCTACGAGAT\nGAGAAATGGGGTGGAAACAAAACCTACACAGCTTACGTGGACCTGGAAAAGGACTTTGCT\nGCTGAGGTTGTACATCCTGGAGACCTGAAGAATTCTGTTGAAGTCGCACTGAACAAGTTG\nCTGGATCCAATCCGGGAAAAGTTTAATACCCCTGCCCTGAAAAAACTGGCCAGCGCTGCC\nTACCCAGATCCCTCAAAGCAGAAGCCAATGGCCAAAGGCCCTGCCAAGAATTCAGAACCA\nGAGGAGGTCATCCCATCCCGGCTGGATATCCGTGTGGGGAAAATCATCACTGTGGAGAAG\nCACCCAGATGCAGACAGCCTGTATGTAGAGAAGATTGACGTGGGGGAAGCTGAACCACGG\nACTGTGGTGAGCGGCCTGGTACAGTTCGTGCCCAAGGAGGAACTGCAGGACAGGCTGGTA\nGTGGTGCTGTGCAACCTGAAACCCCAGAAGATGAGAGGAGTCGAGTCCCAAGGCATGCTT\nCTGTGTGCTTCTATAGAAGGGATAAACCGCCAGGTTGAACCTCTGGACCCTCCGGCAGGC\nTCTGCTCCTGGTGAGCACGTGTTTGTGAAGGGCTATGAAAAGGGCCAACCAGATGAGGAG\nCTCAAGCCCAAGAAGAAAGTCTTCGAGAAGTTGCAGGCTGACTTCAAAATTTCTGAGGAG\nTGCATCGCACAGTGGAAGCAAACCAACTTCATGACCAAGCTGGGCTCCATTTCCTGTAAA\nTCGCTGAAAGGGGGGAACATTAGCTAG'),('UDP-glucuronosyltransferase 1-9','None','Human','Retinoic acid binding','UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.','UGT1A9','59940.495','DB04552','>lcl|BSEQ0012464|UDP-glucuronosyltransferase 1-9 (UGT1A9)\nATGGCTTGCACAGGGTGGACCAGCCCCCTTCCTCTATGTGTGTGTCTGCTGCTGACCTGT\nGGCTTTGCCGAGGCAGGGAAGCTACTGGTAGTGCCCATGGATGGGAGCCACTGGTTCACC\nATGAGGTCGGTGGTGGAGAAACTCATTCTCAGGGGGCATGAGGTGGTTGTAGTCATGCCA\nGAGGTGAGTTGGCAACTGGGAAGATCACTGAATTGCACAGTGAAGACTTATTCAACTTCA\nTATACCCTGGAGGATCTGGACCGGGAGTTCAAGGCTTTTGCCCATGCTCAATGGAAAGCA\nCAAGTACGAAGTATATATTCTCTATTAATGGGTTCATACAATGACATTTTTGACTTATTT\nTTTTCAAATTGCAGGAGTTTGTTTAAAGACAAAAAATTAGTAGAATACTTAAAGGAGAGT\nTCTTTTGATGCAGTGTTTCTCGATCCTTTTGATAACTGTGGCTTAATTGTTGCCAAATAT\nTTCTCCCTCCCCTCCGTGGTCTTCGCCAGGGGAATACTTTGCCACTATCTTGAAGAAGGT\nGCACAGTGCCCTGCTCCTCTTTCCTATGTCCCCAGAATTCTCTTAGGGTTCTCAGATGCC\nATGACTTTCAAGGAGAGAGTACGGAACCACATCATGCACTTGGAGGAACATTTATTATGC\nCACCGTTTTTTCAAAAATGCCCTAGAAATAGCCTCTGAAATTCTCCAAACACCTGTTACG\nGAGTATGATCTCTACAGCCACACATCAATTTGGTTGTTGCGAACGGACTTTGTTTTGGAC\nTATCCCAAACCCGTGATGCCCAACATGATCTTCATTGGTGGTATCAACTGCCATCAGGGA\nAAGCCGTTGCCTATGGAATTTGAAGCCTACATTAATGCTTCTGGAGAACATGGAATTGTG\nGTTTTCTCTTTGGGATCAATGGTCTCAGAAATTCCAGAGAAGAAAGCTATGGCAATTGCT\nGATGCTTTGGGCAAAATCCCTCAGACAGTCCTGTGGCGGTACACTGGAACCCGACCATCG\nAATCTTGCGAACAACACGATACTTGTTAAGTGGCTACCCCAAAACGATCTGCTTGGTCAC\nCCGATGACCCGTGCCTTTATCACCCATGCTGGTTCCCATGGTGTTTATGAAAGCATATGC\nAATGGCGTTCCCATGGTGATGATGCCCTTGTTTGGTGATCAGATGGACAATGCAAAGCGC\nATGGAGACTAAGGGAGCTGGAGTGACCCTGAATGTTCTGGAAATGACTTCTGAAGATTTA\nGAAAATGCTCTAAAAGCAGTCATCAATGACAAAAGTTACAAGGAGAACATCATGCGCCTC\nTCCAGCCTTCACAAGGACCGCCCGGTGGAGCCGCTGGACCTGGCCGTGTTCTGGGTGGAG\nTTTGTGATGAGGCACAAGGGCGCGCCACACCTGCGCCCCGCAGCCCACGACCTCACCTGG\nTACCAGTACCATTCCTTGGACGTGATTGGTTTCCTCTTGGCCGTCGTGCTGACAGTGGCC\nTTCATCACCTTTAAATGTTGTGCTTATGGCTACCGGAAATGCTTGGGGAAAAAAGGGCGA\nGTTAAGAAAGCCCACAAATCCAAGACCCATTGA'),('Vitamin D3 receptor','None','Human','Zinc ion binding','Nuclear hormone receptor. Transcription factor that mediates the action of vitamin D3 by controlling the expression of hormone sensitive genes. Recruited to promoters via its interaction with BAZ1B/WSTF which mediates the interaction with acetylated histones, an essential step for VDR-promoter association. Plays a central role in calcium homeostasis.','VDR','48288.64','DB11672','>lcl|BSEQ0010550|Vitamin D3 receptor (VDR)\nATGGAGGCAATGGCGGCCAGCACTTCCCTGCCTGACCCTGGAGACTTTGACCGGAACGTG\nCCCCGGATCTGTGGGGTGTGTGGAGACCGAGCCACTGGCTTTCACTTCAATGCTATGACC\nTGTGAAGGCTGCAAAGGCTTCTTCAGGCGAAGCATGAAGCGGAAGGCACTATTCACCTGC\nCCCTTCAACGGGGACTGCCGCATCACCAAGGACAACCGACGCCACTGCCAGGCCTGCCGG\nCTCAAACGCTGTGTGGACATCGGCATGATGAAGGAGTTCATTCTGACAGATGAGGAAGTG\nCAGAGGAAGCGGGAGATGATCCTGAAGCGGAAGGAGGAGGAGGCCTTGAAGGACAGTCTG\nCGGCCCAAGCTGTCTGAGGAGCAGCAGCGCATCATTGCCATACTGCTGGACGCCCACCAT\nAAGACCTACGACCCCACCTACTCCGACTTCTGCCAGTTCCGGCCTCCAGTTCGTGTGAAT\nGATGGTGGAGGGAGCCATCCTTCCAGGCCCAACTCCAGACACACTCCCAGCTTCTCTGGG\nGACTCCTCCTCCTCCTGCTCAGATCACTGTATCACCTCTTCAGACATGATGGACTCGTCC\nAGCTTCTCCAATCTGGATCTGAGTGAAGAAGATTCAGATGACCCTTCTGTGACCCTAGAG\nCTGTCCCAGCTCTCCATGCTGCCCCACCTGGCTGACCTGGTCAGTTACAGCATCCAAAAG\nGTCATTGGCTTTGCTAAGATGATACCAGGATTCAGAGACCTCACCTCTGAGGACCAGATC\nGTACTGCTGAAGTCAAGTGCCATTGAGGTCATCATGTTGCGCTCCAATGAGTCCTTCACC\nATGGACGACATGTCCTGGACCTGTGGCAACCAAGACTACAAGTACCGCGTCAGTGACGTG\nACCAAAGCCGGACACAGCCTGGAGCTGATTGAGCCCCTCATCAAGTTCCAGGTGGGACTG\nAAGAAGCTGAACTTGCATGAGGAGGAGCATGTCCTGCTCATGGCCATCTGCATCGTCTCC\nCCAGATCGTCCTGGGGTGCAGGACGCCGCGCTGATTGAGGCCATCCAGGACCGCCTGTCC\nAACACACTGCAGACGTACATCCGCTGCCGCCACCCGCCCCCGGGCAGCCACCTGCTCTAT\nGCCAAGATGATCCAGAAGCTAGCCGACCTGCGCAGCCTCAATGAGGAGCACTCCAAGCAG\nTACCGCTGCCTCTCCTTCCAGCCTGAGTGCAGCATGAAGCTAACGCCCCTTGTGCTCGAA\nGTGTTTGGCAATGAGATCTCCTGA'),('Voltage-dependent anion-selective channel protein 1','None','Human','Voltage-gated anion channel activity','Forms a channel through the mitochondrial outer membrane and also the plasma membrane. The channel at the outer mitochondrial membrane allows diffusion of small hydrophilic molecules; in the plasma membrane it is involved in cell volume regulation and apoptosis. It adopts an open conformation at low or zero membrane potential and a closed conformation at potentials above 30-40 mV. The open state has a weak anion selectivity whereas the closed state is cation-selective (PubMed:11845315, PubMed:18755977, PubMed:20230784, PubMed:8420959). May participate in the formation of the permeability transition pore complex (PTPC) responsible for the release of mitochondrial products that triggers apoptosis (PubMed:15033708, PubMed:25296756).','VDAC1','30772.39','DB14011','>lcl|BSEQ0011767|Voltage-dependent anion-selective channel protein 1 (VDAC1)\nATGGCTGTGCCACCCACGTATGCCGATCTTGGCAAATCTGCCAGGGATGTCTTCACCAAG\nGGCTATGGATTTGGCTTAATAAAGCTTGATTTGAAAACAAAATCTGAGAATGGATTGGAA\nTTTACAAGCTCAGGCTCAGCCAACACTGAGACCACCAAAGTGACGGGCAGTCTGGAAACC\nAAGTACAGATGGACTGAGTACGGCCTGACGTTTACAGAGAAATGGAATACCGACAATACA\nCTAGGCACCGAGATTACTGTGGAAGATCAGCTTGCACGTGGACTGAAGCTGACCTTCGAT\nTCATCCTTCTCACCTAACACTGGGAAAAAAAATGCTAAAATCAAGACAGGGTACAAGCGG\nGAGCACATTAACCTGGGCTGCGACATGGATTTCGACATTGCTGGGCCTTCCATCCGGGGT\nGCTCTGGTGCTAGGTTACGAGGGCTGGCTGGCCGGCTACCAGATGAATTTTGAGACTGCA\nAAATCCCGAGTGACCCAGAGCAACTTTGCAGTTGGCTACAAGACTGATGAATTCCAGCTT\nCACACTAATGTGAATGACGGGACAGAGTTTGGCGGCTCCATTTACCAGAAAGTGAACAAG\nAAGTTGGAGACCGCTGTCAATCTTGCCTGGACAGCAGGAAACAGTAACACGCGCTTCGGA\nATAGCAGCCAAGTATCAGATTGACCCTGACGCCTGCTTCTCGGCTAAAGTGAACAACTCC\nAGCCTGATAGGTTTAGGATACACTCAGACTCTAAAGCCAGGTATTAAACTGACACTGTCA\nGCTCTTCTGGATGGCAAGAACGTCAATGCTGGTGGCCACAAGCTTGGTCTAGGACTGGAA\nTTTCAAGCATAA'),('Voltage-dependent calcium channel gamma-1 subunit','None','Human','Voltage-gated calcium channel activity','This protein is a subunit of the dihydropyridine (DHP) sensitive calcium channel. Plays a role in excitation-contraction coupling. The skeletal muscle DHP-sensitive Ca(2+) channel may function only as a multiple subunit complex.','CACNG1','25028.105','DB00653','>lcl|BSEQ0016175|Voltage-dependent calcium channel gamma-1 subunit (CACNG1)\nATGTCCCAGACCAAAATGCTGAAGGTCCGCGTGACCCTCTTCTGCATCCTGGCAGGCATC\nGTGCTGGCCATGACAGCCGTGGTAACCGACCACTGGGCTGTGCTGAGCCCCCACATGGAG\nCACCACAACACTACCTGCGAGGCGGCCCACTTCGGCCTCTGGCGGATTTGTACCAAGCGC\nATCCCCATGGACGACAGCAAGACCTGCGGGCCCATCACCCTGCCCGGGGAGAAGAACTGT\nTCCTACTTCAGGCATTTTAACCCCGGCGAGAGCTCGGAGATCTTCGAATTCACCACTCAG\nAAGGAGTACAGCATCTCGGCAGCCGCCATCGCCATCTTCAGCCTTGGCTTCATCATCCTG\nGGCAGCCTCTGTGTCCTCCTGTCCCTCGGGAAGAAGAGGGACTATCTGCTGCGACCCGCG\nTCCATGTTCTATGCCTTTGCAGGTCTCTGCATCCTCGTCTCGGTGGAGGTCATGCGGCAG\nTCGGTGAAGCGCATGATTGACAGTGAGGACACCGTCTGGATCGAGTACTATTACTCCTGG\nTCCTTTGCCTGCGCCTGTGCCGCCTTCATCCTCCTCTTTCTCGGCGGTCTCGCCCTCCTG\nCTGTTCTCCCTGCCTCGAATGCCCCGGAACCCATGGGAGTCCTGCATGGATGCTGAGCCC\nGAGCACTAA'),('Voltage-dependent calcium channel subunit alpha-2/delta-1','None','Human','Voltage-gated calcium channel activity','The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Plays an important role in excitation-contraction coupling (By similarity).','CACNA2D1','124566.93','DB00996','>lcl|BSEQ0016179|Voltage-dependent calcium channel subunit alpha-2/delta-1 (CACNA2D1)\nATGGCTGCTGGCTGCCTGCTGGCCTTGACTCTGACACTTTTCCAATCTTTGCTCATCGGC\nCCCTCGTCGGAGGAGCCGTTCCCTTCGGCCGTCACTATCAAATCATGGGTGGATAAGATG\nCAAGAAGACCTTGTCACACTGGCAAAAACAGCAAGTGGAGTCAATCAGCTTGTTGATATT\nTATGAGAAATATCAAGATTTGTATACTGTGGAACCAAATAATGCACGCCAGCTGGTAGAA\nATTGCAGCCAGGGATATTGAGAAACTTCTGAGCAACAGATCTAAAGCCCTGGTGCGCCTG\nGCATTGGAAGCGGAGAAAGTTCAAGCAGCTCACCAGTGGAGAGAAGATTTTGCAAGCAAT\nGAAGTTGTCTACTACAATGCAAAGGATGATCTCGATCCTGAGAAAAATGACAGTGAGCCA\nGGCAGCCAGAGGATAAAACCTGTTTTCATTGAAGATGCTAATTTTGGACGACAAATATCT\nTATCAGCACGCAGCAGTCCATATTCCTACTGACATCTATGAGGGCTCAACAATTGTGTTA\nAATGAACTCAACTGGACAAGTGCCTTAGATGAAGTTTTCAAAAAGAATCGCGAGGAAGAC\nCCTTCATTATTGTGGCAGGTTTTTGGCAGTGCCACTGGCCTAGCTCGATATTATCCAGCT\nTCACCATGGGTTGATAATAGTAGAACTCCAAATAAGATTGACCTTTATGATGTACGCAGA\nAGACCATGGTACATCCAAGGAGCTGCATCTCCTAAAGACATGCTTATTCTGGTGGATGTG\nAGTGGAAGTGTTAGTGGATTGACACTTAAACTGATCCGAACATCTGTCTCCGAAATGTTA\nGAAACCCTCTCAGATGATGATTTCGTGAATGTAGCTTCATTTAACAGCAATGCTCAGGAT\nGTAAGCTGTTTTCAGCACCTTGTCCAAGCAAATGTAAGAAATAAAAAAGTGTTGAAAGAC\nGCGGTGAATAATATCACAGCCAAAGGAATTACAGATTATAAGAAGGGCTTTAGTTTTGCT\nTTTGAACAGCTGCTTAATTATAATGTTTCCAGAGCAAACTGCAATAAGATTATTATGCTA\nTTCACGGATGGAGGAGAAGAGAGAGCCCAGGAGATATTTAACAAATACAATAAAGATAAA\nAAAGTACGTGTATTCACGTTTTCAGTTGGTCAACACAATTATGACAGAGGACCTATTCAG\nTGGATGGCCTGTGAAAACAAAGGTTATTATTATGAAATTCCTTCCATTGGTGCAATAAGA\nATCAATACTCAGGAATATTTGGATGTTTTGGGAAGACCAATGGTTTTAGCAGGAGACAAA\nGCTAAGCAAGTCCAATGGACAAATGTGTACCTGGATGCATTGGAACTGGGACTTGTCATT\nACTGGAACTCTTCCGGTCTTCAACATAACCGGCCAATTTGAAAATAAGACAAACTTAAAG\nAACCAGCTGATTCTTGGTGTGATGGGAGTAGATGTGTCTTTGGAAGATATTAAAAGACTG\nACACCACGTTTTACACTGTGCCCCAATGGGTATTACTTTGCAATCGATCCTAATGGTTAT\nGTTTTATTACATCCAAATCTTCAGCCAAAGAACCCCAAATCTCAGGAGCCAGTAACATTG\nGATTTCCTTGATGCAGAGTTAGAGAATGATATTAAAGTGGAGATTCGAAATAAGATGATT\nGATGGGGAAAGTGGAGAAAAAACATTCAGAACTCTGGTTAAATCTCAAGATGAGAGATAT\nATTGACAAAGGAAACAGGACATACACATGGACACCTGTCAATGGCACAGATTACAGTTTG\nGCCTTGGTATTACCAACCTACAGTTTTTACTATATAAAAGCCAAACTAGAAGAGACAATA\nACTCAGGCCAGATCAAAAAAGGGCAAAATGAAGGATTCGGAAACCCTGAAGCCAGATAAT\nTTTGAAGAATCTGGCTATACATTCATAGCACCAAGAGATTACTGCAATGACCTGAAAATA\nTCGGATAATAACACTGAATTTCTTTTAAATTTCAACGAGTTTATTGATAGAAAAACTCCA\nAACAACCCATCATGTAACGCGGATTTGATTAATAGAGTCTTGCTTGATGCAGGCTTTACA\nAATGAACTTGTCCAAAATTACTGGAGTAAGCAGAAAAATATCAAGGGAGTGAAAGCACGA\nTTTGTTGTGACTGATGGTGGGATTACCAGAGTTTATCCCAAAGAGGCTGGAGAAAATTGG\nCAAGAAAACCCAGAGACATATGAGGACAGCTTCTATAAAAGGAGCCTAGATAATGATAAC\nTATGTTTTCACTGCTCCCTACTTTAACAAAAGTGGACCTGGTGCCTATGAATCGGGCATT\nATGGTAAGCAAAGCTGTAGAAATATATATTCAAGGGAAACTTCTTAAACCTGCAGTTGTT\nGGAATTAAAATTGATGTAAATTCCTGGATAGAGAATTTCACCAAAACCTCAATCAGAGAT\nCCGTGTGCTGGTCCAGTTTGTGACTGCAAAAGAAACAGTGACGTAATGGATTGTGTGATT\nCTGGATGATGGTGGGTTTCTTCTGATGGCAAATCATGATGATTATACTAATCAGATTGGA\nAGATTTTTTGGAGAGATTGATCCCAGCTTGATGAGACACCTGGTTAATATATCAGTTTAT\nGCTTTTAACAAATCTTATGATTATCAGTCAGTATGTGAGCCCGGTGCTGCACCAAAACAA\nGGAGCAGGACATCGCTCAGCATATGTGCCATCAGTAGCAGACATATTACAAATTGGCTGG\nTGGGCCACTGCTGCTGCCTGGTCTATTCTACAGCAGTTTCTCTTGAGTTTGACCTTTCCA\nCGACTCCTTGAGGCAGTTGAGATGGAGGATGATGACTTCACGGCCTCCCTGTCCAAGCAG\nAGCTGCATTACTGAACAAACCCAGTATTTCTTCGATAACGACAGTAAATCATTCAGTGGT\nGTATTAGACTGTGGAAACTGTTCCAGAATCTTTCATGGAGAAAAGCTTATGAACACCAAC\nTTAATATTCATAATGGTTGAGAGCAAAGGGACATGTCCATGTGACACACGACTGCTCATA\nCAAGCGGAGCAGACTTCTGACGGTCCAAATCCTTGTGACATGGTTAAGCAACCCAGATAC\nCGAAAAGGGCCTGATGTCTGCTTTGATAACAATGTCTTGGAGGATTATACTGACTGTGGT\nGGTGTTTCTGGATTAAATCCCTCCCTGTGGTATATCATTGGAATCCAGTTTCTACTACTT\nTGGCTGGTATCTGGCAGCACACACCGCCTGTTATGA'),('Voltage-dependent calcium channel subunit alpha-2/delta-2','None','Human','Voltage-gated calcium channel activity','The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-type calcium channel (CACNA1A), N-type (CACNA1B), L-type (CACNA1C OR CACNA1D) and possibly T-type (CACNA1G). Overexpression induces apoptosis.','CACNA2D2','129816.095','DB00996','>lcl|BSEQ0011717|Voltage-dependent calcium channel subunit alpha-2/delta-2 (CACNA2D2)\nATGGCGGTGCCGGCTCGGACCTGCGGCGCCTCTCGGCCCGGCCCAGCGCGGACTGCGCGC\nCCCTGGCCCGGCTGCGGCCCCCACCCTGGCCCCGGCACCCGGCGCCCGACGTCCGGGCCC\nCCGCGCCCGCTGTGGCTGCTGCTGCCGCTTCTACCGCTGCTCGCCGCCCCCGGCGCCTCT\nGCCTACAGCTTCCCCCAGCAGCACACGATGCAGCACTGGGCCCGGCGTCTGGAGCAGGAG\nGTCGACGGCGTGATGCGGATTTTTGGAGGCGTCCAGCAGCTCCGTGAGATTTACAAGGAC\nAACCGGAACCTGTTCGAGGTACAGGAGAATGAGCCTCAGAAGTTGGTGGAGAAGGTGGCA\nGGGGACATTGAGAGCCTTCTGGACAGGAAGGTGCAGGCCCTGAAGAGACTGGCTGATGCT\nGCAGAGAACTTCCAGAAAGCACACCGCTGGCAGGACAACATCAAGGAGGAAGACATCGTG\nTACTATGACGCCAAGGCTGACGCTGAGCTGGACGACCCTGAGAGTGAGGATGTGGAAAGG\nGGGTCTAAGGCCAGCACCCTAAGGCTGGACTTCATCGAGGACCCAAACTTCAAGAACAAG\nGTCAACTATTCATACGCGGCTGTACAGATCCCTACGGACATCTACAAAGGCTCCACTGTC\nATCCTCAATGAGCTCAACTGGACAGAGGCCCTGGAGAATGTGTTCATGGAAAACCGCAGA\nCAAGACCCCACACTGCTGTGGCAGGTCTTCGGCAGCGCCACAGGAGTCACTCGCTACTAC\nCCGGCCACCCCGTGGCGAGCCCCCAAGAAGATCGACCTGTACGATGTCCGAAGGAGACCC\nTGGTATATCCAGGGGGCCTCGTCACCCAAAGACATGGTCATCATCGTGGATGTGAGTGGC\nAGTGTGAGCGGCCTGACCCTGAAGCTGATGAAGACATCTGTCTGCGAGATGCTGGACACG\nCTGTCTGATGATGACTATGTGAATGTGGCCTCGTTCAACGAGAAGGCACAGCCTGTGTCA\nTGCTTCACACACCTGGTGCAGGCCAATGTGCGCAACAAGAAGGTGTTCAAGGAAGCTGTG\nCAGGGCATGGTGGCCAAGGGCACCACAGGCTACAAGGCCGGCTTTGAGTATGCCTTTGAC\nCAGCTGCAGAACTCCAACATCACTCGGGCCAACTGCAACAAGATGATCATGATGTTCACG\nGATGGTGGTGAGGACCGCGTGCAGGACGTCTTTGAGAAGTACAATTGGCCAAACCGGACG\nGTGCGCGTGTTTACTTTCTCCGTGGGGCAGCATAACTATGACGTCACACCGCTGCAGTGG\nATGGCCTGTGCCAACAAAGGCTACTATTTTGAGATCCCTTCCATCGGAGCCATCCGCATC\nAACACACAGGAATATCTAGATGTGTTGGGCAGGCCCATGGTGCTGGCAGGCAAGGAGGCC\nAAGCAGGTGCAGTGGACCAACGTGTATGAGGATGCACTGGGACTGGGGTTGGTGGTAACA\nGGGACCCTCCCTGTTTTCAACCTGACACAGGATGGCCCTGGGGAAAAGAAGAACCAGCTG\nATCCTGGGCGTGATGGGCATTGACGTGGCTCTGAATGACATCAAGAGGCTGACCCCCAAC\nTACACGCTTGGAGCCAACGGCTATGTGTTTGCCATTGACCTGAACGGCTACGTGTTGCTG\nCACCCCAATCTCAAGCCCCAGACCACCAACTTCCGGGAGCCTGTGACTCTGGACTTCCTG\nGATGCGGAGCTAGAGGATGAGAACAAGGAAGAGATCCGTCGGAGCATGATTGATGGCAAC\nAAGGGCCACAAGCAGATCAGAACGTTGGTCAAGTCCCTGGATGAGAGGTACATAGATGAG\nGTGACACGGAACTACACCTGGGTGCCTATAAGGAGCACTAACTACAGCCTGGGGCTGGTG\nCTCCCACCCTACAGCACCTTCTACCTCCAAGCCAATCTCAGTGACCAGATCCTGCAGGTC\nAAGTATTTTGAGTTCCTGCTCCCCAGCAGCTTTGAGTCTGAAGGACACGTTTTCATTGCT\nCCCAGAGAGTACTGCAAGGACCTGAATGCCTCAGACAACAACACCGAGTTCCTGAAAAAC\nTTTATTGAGCTCATGGAGAAAGTGACTCCAGACTCCAAGCAGTGCAACAACTTCCTTCTG\nCACAACCTGATCTTGGACACGGGCATCACGCAGCAGCTGGTAGAGCGTGTGTGGAGGGAC\nCAGGATCTCAACACGTACAGCCTACTGGCCGTGTTCGCTGCCACAGACGGTGGCATCACC\nCGAGTCTTCCCCAACAAGGCAGCTGAGGACTGGACAGAGAACCCTGAGCCCTTCAATGCC\nAGCTTCTACCGCCGCAGCCTGGATAACCACGGTTATGTCTTCAAGCCCCCACACCAGGAT\nGCCCTGTTAAGGCCGCTGGAGCTGGAGAATGACACTGTGGGCATCCTCGTCAGCACAGCT\nGTGGAGCTCAGCCTAGGCAGGCGCACACTGAGGCCAGCAGTGGTGGGCGTCAAGCTGGAC\nCTAGAGGCTTGGGCTGAGAAGTTCAAGGTGCTAGCCAGCAACCGTACCCACCAAGACCAG\nCCTCAGAAGTGCGGCCCCAACAGCCACTGTGAGATGGACTGCGAGGTTAACAATGAGGAC\nTTACTCTGTGTCCTCATTGATGATGGAGGATTCCTGGTGCTGTCAAACCAGAACCATCAG\nTGGGACCAGGTGGGCAGGTTCTTCAGTGAGGTGGATGCCAACCTGATGCTGGCACTCTAC\nAATAACTCCTTCTACACCCGCAAGGAGTCCTATGACTATCAGGCAGCCTGTGCCCCTCAG\nCCCCCTGGCAACCTGGGTGCTGCACCCCGGGGTGTCTTTGTGCCCACCGTTGCAGATTTC\nCTTAACCTGGCCTGGTGGACCTCTGCTGCCGCCTGGTCCCTGTTCCAGCAGCTTCTCTAC\nGGCCTCATCTACCACAGCTGGTTCCAAGCAGACCCCGCGGAGGCCGAGGGGAGCCCCGAG\nACGCGCGAGAGCAGCTGCGTCATGAAACAGACCCAGTACTACTTCGGCTCGGTAAACGCC\nTCCTACAACGCCATCATCGACTGCGGAAACTGCTCCAGGCTGTTCCACGCGCAGAGACTG\nACCAACACCAATCTTCTCTTTGTGGTGGCCGAGAAGCCGCTGTGCAGCCAGTGCGAGGCT\nGGCCGGCTGCTGCAGAAGGAGACGCACTGCCCAGCGGACGGCCCGGAGCAGTGTGAGCTA\nGTGCAGAGACCGCGATACCGGAGAGGCCCGCACATCTGCTTCGACTACAACGCGACAGAA\nGATACCTCAGACTGTGGCCGCGGGGCCTCCTTCCCGCCGTCGCTGGGCGTCCTGGTCTCC\nCTGCAACTGCTGCTCCTCCTGGGCCTGCCGCCCCGGCCGCAGCCTCAAGTCCTCGTCCAC\nGCCTCTCGCCGCCTCTGA'),('Voltage-dependent L-type calcium channel subunit alpha-1C','None','Human','Voltage-gated calcium channel activity','Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1C gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belong to the \'high-voltage activated\' (HVA) group. They are blocked by dihydropyridines (DHP), phenylalkylamines, benzothiazepines, and by omega-agatoxin-IIIA (omega-Aga-IIIA). They are however insensitive to omega-conotoxin-GVIA (omega-CTx-GVIA) and omega-agatoxin-IVA (omega-Aga-IVA). Calcium channels containing the alpha-1C subunit play an important role in excitation-contraction coupling in the heart. The various isoforms display marked differences in the sensitivity to DHP compounds. Binding of calmodulin or CABP1 at the same regulatory sites results in an opposit effects on the channel function.','CACNA1C','248974.1','DB06751','>lcl|BSEQ0016091|Voltage-dependent L-type calcium channel subunit alpha-1C (CACNA1C)\nATGGTCAATGAGAATACGAGGATGTACATTCCAGAGGAAAACCACCAAGGTTCCAACTAT\nGGGAGCCCACGCCCCGCCCATGCCAACATGAATGCCAATGCGGCAGCGGGGCTGGCCCCT\nGAGCACATCCCCACCCCGGGGGCTGCCCTGTCGTGGCAGGCGGCCATCGACGCAGCCCGG\nCAGGCTAAGCTGATGGGCAGCGCTGGCAATGCGACCATCTCCACAGTCAGCTCCACGCAG\nCGGAAGCGGCAGCAATATGGGAAACCCAAGAAGCAGGGCAGCACCACGGCCACACGCCCG\nCCCCGAGCCCTGCTCTGCCTGACCCTGAAGAACCCCATCCGGAGGGCCTGCATCAGCATT\nGTCGAATGGAAACCATTTGAAATAATTATTTTACTGACTATTTTTGCCAATTGTGTGGCC\nTTAGCGATCTATATTCCCTTTCCAGAAGATGATTCCAACGCCACCAATTCCAACCTGGAA\nCGAGTGGAATATCTCTTTCTCATAATTTTTACGGTGGAAGCGTTTTTAAAAGTAATCGCC\nTATGGACTCCTCTTTCACCCCAATGCCTACCTCCGCAACGGCTGGAACCTACTAGATTTT\nATAATTGTGGTTGTGGGGCTTTTTAGTGCAATTTTAGAACAAGCAACCAAAGCAGATGGG\nGCAAACGCTCTCGGAGGGAAAGGGGCCGGATTTGATGTGAAGGCGCTGAGGGCCTTCCGC\nGTGCTGCGCCCCCTGCGGCTGGTGTCCGGAGTCCCAAGTCTCCAGGTGGTCCTGAATTCC\nATCATCAAGGCCATGGTCCCCCTGCTGCACATCGCCCTGCTTGTGCTGTTTGTCATCATC\nATCTACGCCATCATCGGCTTGGAGCTCTTCATGGGGAAGATGCACAAGACCTGCTACAAC\nCAGGAGGGCATAGCAGATGTTCCAGCAGAAGATGACCCTTCCCCTTGTGCGCTGGAAACG\nGGCCACGGGCGGCAGTGCCAGAACGGCACGGTGTGCAAGCCCGGCTGGGATGGTCCCAAG\nCACGGCATCACCAACTTTGACAACTTTGCCTTCGCCATGCTCACGGTGTTCCAGTGCATC\nACCATGGAGGGCTGGACGGACGTGCTGTACTGGGTCAATGATGCCGTAGGAAGGGACTGG\nCCCTGGATCTATTTTGTTACACTAATCATCATAGGGTCATTTTTTGTACTTAACTTGGTT\nCTCGGTGTGCTTAGCGGAGAGTTTTCCAAAGAGAGGGAGAAGGCCAAGGCCCGGGGAGAT\nTTCCAGAAGCTGCGGGAGAAGCAGCAGCTAGAAGAGGATCTCAAAGGCTACCTGGATTGG\nATCACTCAGGCCGAAGACATCGATCCTGAGAATGAGGACGAAGGCATGGATGAGGAGAAG\nCCCCGAAACATGAGCATGCCCACCAGTGAGACCGAGTCCGTCAACACCGAAAACGTGGCT\nGGAGGTGACATCGAGGGAGAAAACTGCGGGGCCAGGCTGGCCCACCGGATCTCCAAGTCA\nAAGTTCAGCCGCTACTGGCGCCGGTGGAATCGGTTCTGCAGAAGGAAGTGCCGCGCCGCA\nGTCAAGTCTAATGTCTTCTACTGGCTGGTGATTTTCCTGGTGTTCCTCAACACGCTCACC\nATTGCCTCTGAGCACTACAACCAGCCCAACTGGCTCACAGAAGTCCAAGACACGGCAAAC\nAAGGCCCTGCTGGCCCTGTTCACGGCAGAGATGCTCCTGAAGATGTACAGCCTGGGCCTG\nCAGGCCTACTTCGTGTCCCTCTTCAACCGCTTTGACTGCTTCGTCGTGTGTGGCGGCATC\nCTGGAGACCATCCTGGTGGAGACCAAGATCATGTCCCCACTGGGCATCTCCGTGCTCAGA\nTGCGTCCGGCTGCTGAGGATTTTCAAGATCACGAGGTACTGGAACTCCTTGAGCAACCTG\nGTGGCATCCTTGCTGAACTCTGTGCGCTCCATCGCCTCCCTGCTCCTTCTCCTCTTCCTC\nTTCATCATCATCTTCTCCCTCCTGGGGATGCAGCTCTTTGGAGGAAAGTTCAACTTTGAT\nGAGATGCAGACCCGGAGGAGCACATTCGATAACTTCCCCCAGTCCCTCCTCACTGTGTTT\nCAGATCCTGACCGGGGAGGACTGGAATTCGGTGATGTATGATGGGATCATGGCTTATGGC\nGGCCCCTCTTTTCCAGGGATGTTAGTCTGTATTTACTTCATCATCCTCTTCATCTGTGGA\nAACTATATCCTACTGAATGTGTTCTTGGCCATTGCTGTGGACAACCTGGCTGATGCTGAG\nAGCCTCACATCTGCCCAAAAGGAGGAGGAAGAGGAGAAGGAGAGAAAGAAGCTGGCCAGG\nACTGCCAGCCCAGAGAAGAAACAAGAGTTGGTGGAGAAGCCGGCAGTGGGGGAATCCAAG\nGAGGAGAAGATTGAGCTGAAATCCATCACGGCTGACGGAGAGTCTCCACCCGCCACCAAG\nATCAACATGGATGACCTCCAGCCCAATGAAAATGAGGATAAGAGCCCCTACCCCAACCCA\nGAAACTACAGGAGAAGAGGATGAGGAGGAGCCAGAGATGCCTGTCGGCCCTCGCCCACGA\nCCACTCTCTGAGCTTCACCTTAAGGAAAAGGCAGTGCCCATGCCAGAAGCCAGCGCGTTT\nTTCATCTTCAGCTCTAACAACAGGTTTCGCCTCCAGTGCCACCGCATTGTCAATGACACG\nATCTTCACCAACCTGATCCTCTTCTTCATTCTGCTCAGCAGCATTTCCCTGGCTGCTGAG\nGACCCGGTCCAGCACACCTCCTTCAGGAACCATATTCTGTTTTATTTTGATATTGTTTTT\nACCACCATTTTCACCATTGAAATTGCTCTGAAGATGACTGCTTATGGGGCTTTCTTGCAC\nAAGGGTTCTTTCTGCCGGAACTACTTCAACATCCTGGACCTGCTGGTGGTCAGCGTGTCC\nCTCATCTCCTTTGGCATCCAGTCCAGTGCAATCAATGTCGTGAAGATCTTGCGAGTCCTG\nCGAGTACTCAGGCCCCTGAGGGCCATCAACAGGGCCAAGGGGCTAAAGCATGTGGTTCAG\nTGTGTGTTTGTCGCCATCCGGACCATCGGGAACATCGTGATTGTCACCACCCTGCTGCAG\nTTCATGTTTGCCTGCATCGGGGTCCAGCTCTTCAAGGGAAAGCTGTACACCTGTTCAGAC\nAGTTCCAAGCAGACAGAGGCGGAATGCAAGGGCAACTACATCACGTACAAAGACGGGGAG\nGTTGACCACCCCATCATCCAACCCCGCAGCTGGGAGAACAGCAAGTTTGACTTTGACAAT\nGTTCTGGCAGCCATGATGGCCCTCTTCACCGTCTCCACCTTCGAAGGGTGGCCAGAGCTG\nCTGTACCGCTCCATCGACTCCCACACGGAAGACAAGGGCCCCATCTACAACTACCGTGTG\nGAGATCTCCATCTTCTTCATCATCTACATCATCATCATCGCCTTCTTCATGATGAACATC\nTTCGTGGGCTTCGTCATCGTCACCTTTCAGGAGCAGGGGGAGCAGGAGTACAAGAACTGT\nGAGCTGGACAAGAACCAGCGACAGTGCGTGGAATACGCCCTCAAGGCCCGGCCCCTGCGG\nAGGTACATCCCCAAGAACCAGCACCAGTACAAAGTGTGGTACGTGGTCAACTCCACCTAC\nTTCGAGTACCTGATGTTCGTCCTCATCCTGCTCAACACCATCTGCCTGGCCATGCAGCAC\nTACGGCCAGAGCTGCCTGTTCAAAATCGCCATGAACATCCTCAACATGCTCTTCACTGGC\nCTCTTCACCGTGGAGATGATCCTGAAGCTCATTGCCTTCAAACCCAAGCACTATTTCTGT\nGATGCATGGAATACATTTGACGCCTTGATTGTTGTGGGTAGCATTGTTGATATAGCAATC\nACCGAGGTAAACCCAGCTGAACATACCCAATGCTCTCCCTCTATGAACGCAGAGGAAAAC\nTCCCGCATCTCCATCACCTTCTTCCGCCTGTTCCGGGTCATGCGTCTGGTGAAGCTGCTG\nAGCCGTGGGGAGGGCATCCGGACGCTGCTGTGGACCTTCATCAAGTCCTTCCAGGCCCTG\nCCCTATGTGGCCCTCCTGATCGTGATGCTGTTCTTCATCTACGCGGTGATCGGGATGCAG\nGTGTTTGGGAAAATTGCCCTGAATGATACCACAGAGATCAACCGGAACAACAACTTTCAG\nACCTTCCCCCAGGCCGTGCTGCTCCTCTTCAGGTGTGCCACCGGGGAGGCCTGGCAGGAC\nATCATGCTGGCCTGCATGCCAGGCAAGAAGTGTGCCCCAGAGTCCGAGCCCAGCAACAGC\nACGGAGGGTGAAACACCCTGTGGTAGCAGCTTTGCTGTCTTCTACTTCATCAGCTTCTAC\nATGCTCTGTGCCTTCCTGATCATCAACCTCTTTGTAGCTGTCATCATGGACAACTTTGAC\nTACCTGACAAGGGACTGGTCCATCCTTGGTCCCCACCACCTGGATGAGTTTAAAAGAATC\nTGGGCAGAGTATGACCCTGAAGCCAAGGGTCGTATCAAACACCTGGATGTGGTGACCCTC\nCTCCGGCGGATTCAGCCGCCACTAGGTTTTGGGAAGCTGTGCCCTCACCGCGTGGCTTGC\nAAACGCCTGGTCTCCATGAACATGCCTCTGAACAGCGACGGGACAGTCATGTTCAATGCC\nACCCTGTTTGCCCTGGTCAGGACGGCCCTGAGGATCAAAACAGAAGGGAACCTAGAACAA\nGCCAATGAGGAGCTGCGGGCGATCATCAAGAAGATCTGGAAGCGGACCAGCATGAAGCTG\nCTGGACCAGGTGGTGCCCCCTGCAGGTGATGATGAGGTCACCGTTGGCAAGTTCTACGCC\nACGTTCCTGATCCAGGAGTACTTCCGGAAGTTCAAGAAGCGCAAAGAGCAGGGCCTTGTG\nGGCAAGCCCTCCCAGAGGAACGCGCTGTCTCTGCAGGCTGGCTTGCGCACACTGCATGAC\nATCGGGCCTGAGATCCGACGGGCCATCTCTGGAGATCTCACCGCTGAGGAGGAGCTGGAC\nAAGGCCATGAAGGAGGCTGTGTCCGCTGCTTCTGAAGATGACATCTTCAGGAGGGCCGGT\nGGCCTGTTCGGCAACCACGTCAGCTACTACCAAAGCGACGGCCGGAGCGCCTTCCCCCAG\nACCTTCACCACTCAGCGCCCGCTGCACATCAACAAGGCGGGCAGCAGCCAGGGCGACACT\nGAGTCGCCATCCCACGAGAAGCTGGTGGACTCCACCTTCACCCCGAGCAGCTACTCGTCC\nACCGGCTCCAACGCCAACATCAACAACGCCAACAACACCGCCCTGGGTCGCCTCCCTCGC\nCCCGCCGGCTACCCCAGCACGGTCAGCACTGTGGAGGGCCACGGGCCCCCCTTGTCCCCT\nGCCATCCGGGTGCAGGAGGTGGCGTGGAAGCTCAGCTCCAACAGGTGCCACTCCCGGGAG\nAGCCAGGCAGCCATGGCGGGTCAGGAGGAGACGTCTCAGGATGAGACCTATGAAGTGAAG\nATGAACCATGACACGGAGGCCTGCAGTGAGCCCAGCCTGCTCTCCACAGAGATGCTCTCC\nTACCAGGATGACGAAAATCGGCAACTGACGCTCCCAGAGGAGGACAAGAGGGACATCCGG\nCAATCTCCGAAGAGGGGTTTCCTCCGCTCTGCCTCACTAGGTCGAAGGGCCTCCTTCCAC\nCTGGAATGTCTGAAGCGACAGAAGGACCGAGGGGGAGACATCTCTCAGAAGACAGTCCTG\nCCCTTGCATCTGGTTCATCATCAGGCATTGGCAGTGGCAGGCCTGAGCCCCCTCCTCCAG\nAGAAGCCATTCCCCTGCCTCATTCCCTAGGCCTTTTGCCACCCCACCAGCCACACCTGGC\nAGCCGAGGCTGGCCCCCACAGCCCGTCCCCACCCTGCGGCTTGAGGGGGTCGAGTCCAGT\nGAGAAACTCAACAGCAGCTTCCCATCCATCCACTGCGGCTCCTGGGCTGAGACCACCCCC\nGGTGGCGGGGGCAGCAGCGCCGCCCGGAGAGTCCGGCCCGTCTCCCTCATGGTGCCCAGC\nCAGGCTGGGGCCCCAGGGAGGCAGTTCCACGGCAGTGCCAGCAGCCTGGTGGAAGCGGTC\nTTGATTTCAGAAGGACTGGGGCAGTTTGCTCAAGATCCCAAGTTCATCGAGGTCACCACC\nCAGGAGCTGGCCGACGCCTGCGACATGACCATAGAGGAGATGGAGAGCGCGGCCGACAAC\nATCCTCAGCGGGGGCGCCCCACAGAGCCCCAATGGCGCCCTCTTACCCTTTGTGAACTGC\nAGGGACGCGGGGCAGGACCGAGCCGGGGGCGAAGAGGACGCGGGCTGTGTGCGCGCGCGG\nGGTCGACCGAGTGAGGAGGAGCTCCAGGACAGCAGGGTCTACGTCAGCAGCCTGTAG'),('Voltage-dependent L-type calcium channel subunit alpha-1S','None','Human','Voltage-gated calcium channel activity','Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1S gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belong to the \'high-voltage activated\' (HVA) group. They are blocked by dihydropyridines (DHP), phenylalkylamines, benzothiazepines, and by omega-agatoxin-IIIA (omega-Aga-IIIA). They are however insensitive to omega-conotoxin-GVIA (omega-CTx-GVIA) and omega-agatoxin-IVA (omega-Aga-IVA). Calcium channels containing the alpha-1S subunit play an important role in excitation-contraction coupling in skeletal muscle.','CACNA1S','212348.1','DB00653','>lcl|BSEQ0016765|Voltage-dependent L-type calcium channel subunit alpha-1S (CACNA1S)\nATGGAGCCATCCTCACCCCAGGATGAAGGCCTGAGGAAGAAACAGCCCAAGAAGCCAGTT\nCCTGAGATTCTGCCAAGGCCACCCCGGGCCTTGTTCTGCCTGACCCTGGAGAACCCCCTG\nAGGAAGGCCTGCATCAGCATTGTAGAATGGAAGCCCTTCGAGACGATCATCTTGCTCACC\nATCTTTGCCAATTGTGTGGCCCTGGCCGTGTACCTGCCCATGCCGGAAGATGACAACAAC\nTCTCTGAACCTCGGCCTGGAGAAGCTGGAGTATTTCTTCCTCATTGTCTTCTCGATTGAA\nGCCGCCATGAAGATCATTGCCTACGGCTTCTTATTCCACCAGGACGCTTACCTGCGCAGT\nGGCTGGAATGTGCTGGACTTCACCATTGTCTTCCTGGGGGTCTTCACCGTGATTCTGGAA\nCAGGTTAACGTCATCCAAAGCCACACAGCCCCAATGAGCAGCAAAGGAGCCGGCTTGGAT\nGTCAAGGCCCTCAGAGCCTTCCGAGTGCTCAGACCCCTCCGGCTGGTGTCGGGGGTGCCT\nAGCCTGCAGGTGGTCCTGAACTCCATCTTCAAGGCCATGCTCCCCCTCTTTCACATCGCC\nCTGCTGGTCCTCTTTATGGTCATCATCTATGCCATCATCGGGCTGGAGCTCTTCAAGGGC\nAAGATGCACAAGACCTGCTACTTCATTGGTACAGATATCGTGGCCACGGTGGAGAATGAA\nGAGCCATCGCCCTGCGCCAGGACGGGCTCAGGGCGCCGGTGCACCATCAATGGCAGTGAG\nTGCCGGGGCGGCTGGCCAGGGCCCAACCATGGCATCACCCACTTCGACAACTTCGGCTTC\nTCCATGCTCACCGTGTACCAGTGCATTACCATGGAGGGATGGACTGACGTCCTTTACTGG\nGTCAATGATGCCATCGGGAATGAGTGGCCCTGGATCTATTTTGTCACCCTCATTTTGCTG\nGGATCCTTCTTCATCCTCAACCTGGTGCTGGGTGTCCTGAGTGGGGAATTCACCAAGGAG\nCGGGAGAAGGCCAAGTCCAGGGGAACCTTCCAGAAGCTCCGGGAGAAGCAGCAACTAGAT\nGAGGACCTTCGGGGCTACATGAGCTGGATCACGCAGGGCGAGGTCATGGATGTTGAGGAC\nTTCAGAGAAGGAAAACTGTCTTTGGATGAAGGTGGCTCTGACACAGAGAGCCTGTATGAA\nATTGCAGGCTTGAACAAAATCATCCAGTTCATCCGACATTGGAGGCAGTGGAACCGCATC\nTTTCGCTGGAAGTGCCATGACATCGTGAAGTCCAAGGTCTTCTATTGGCTGGTGATTCTC\nATCGTTGCCCTCAACACCCTGTCTATCGCCTCAGAGCACCACAACCAGCCTCTCTGGCTG\nACCCGTTTGCAAGACATTGCCAACCGGGTGCTGCTGTCCCTCTTCACCACTGAGATGCTG\nATGAAGATGTACGGGCTGGGCCTGCGCCAGTACTTCATGTCTATCTTCAACCGCTTCGAC\nTGCTTCGTGGTGTGTAGCGGTATCCTGGAGATCCTGCTGGTGGAGTCGGGTGCCATGACA\nCCCCTGGGCATCTCCGTGCTCCGCTGCATCCGCCTCCTGAGGATCTTCAAGATCACCAAA\nTATTGGACGTCGCTGAGCAACCTGGTGGCATCCCTGCTCAACTCCATCCGCTCCATCGCC\nTCCCTGCTGCTGCTGCTCTTCCTCTTCATCGTCATCTTCGCCCTCCTGGGCATGCAGCTC\nTTTGGGGGGAGGTATGACTTTGAAGACACAGAAGTACGGCGCAGCAACTTTGACAACTTT\nCCCCAAGCCCTCATCAGCGTCTTCCAGGTACTGACAGGGGAAGACTGGACCTCAATGATG\nTACAATGGGATCATGGCCTACGGCGGGCCGTCCTACCCTGGCATGCTTGTGTGCATTTAC\nTTCATCATCCTTTTCGTCTGTGGCAACTACATCCTGCTCAATGTCTTCCTGGCCATTGCC\nGTGGACAACCTGGCCGAGGCGGAGAGCCTGACTTCTGCCCAGAAGGCCAAGGCTGAGGAG\nAAAAAACGCAGGAAGATGTCCAAGGGTCTCCCAGACAAGTCAGAAGAGGAGAAGTCAACG\nATGGCCAAGAAGCTGGAGCAGAAACCCAAGGGTGAGGGCATCCCCACCACTGCCAAGCTG\nAAAATCGATGAGTTTGAATCTAATGTCAATGAGGTGAAGGATCCCTACCCCTCAGCCGAC\nTTCCCAGGGGATGACGAGGAAGATGAGCCTGAGATCCCGCTGAGCCCCCGACCACGTCCC\nCTGGCTGAGCTGCAGCTGAAAGAGAAGGCCGTGCCCATTCCAGAAGCCAGCTCCTTCTTC\nATCTTCAGCCCCACCAATAAGATCCGTGTCCTGTGTCACCGCATCGTCAATGCCACCTGG\nTTTACCAACTTCATCCTGCTCTTCATCCTGCTCAGCAGCGCTGCACTGGCTGCGGAAGAC\nCCCATCCGGGCTGATTCCATGAGAAATCAGATCCTTAAACACTTTGACATCGGGTTCACC\nTCTGTCTTCACTGTGGAGATTGTCCTCAAGATGACGACCTACGGAGCCTTCCTGCACAAG\nGGTTCCTTCTGCCGCAATTACTTCAACATGCTGGACCTGCTGGTGGTGGCCGTGTCCCTC\nATCTCCATGGGACTTGAGTCCAGTGCCATCTCCGTGGTGAAGATCCTGAGGGTGCTGAGG\nGTGCTCCGACCACTCAGAGCCATCAACAGAGCCAAGGGGTTGAAGCACGTGGTGCAGTGC\nATGTTCGTGGCCATCAGCACCATCGGGAACATCGTGCTGGTCACTACCCTCCTACAGTTC\nATGTTTGCCTGCATCGGCGTCCAGCTCTTCAAGGGGAAGTTCTTCAGGTGCACCGACTTG\nTCCAAGATGACAGAGGAGGAGTGCAGGGGCTACTACTACGTGTACAAGGACGGGGACCCC\nATGCAGATAGAGCTGCGTCACCGCGAGTGGGTACACAGCGACTTCCACTTCGACAATGTG\nCTCTCAGCCATGATGTCCCTCTTCACGGTCTCCACCTTCGAGGGATGGCCTCAGCTGCTG\nTACAAGGCCATAGACTCCAATGCGGAGGACGTGGGTCCCATCTACAACAACCGTGTGGAG\nATGGCCATCTTCTTCATCATCTACATCATCCTCATTGCCTTCTTCATGATGAACATCTTT\nGTGGGCTTCGTCATTGTCACCTTCCAGGAGCAGGGAGAGACTGAGTACAAGAACTGTGAG\nCTGGACAAGAACCAGCGCCAATGTGTACAGTATGCCCTGAAGGCCCGCCCACTGAGGTGC\nTACATTCCCAAAAACCCATACCAGTACCAGGTGTGGTACATTGTCACCTCCTCCTACTTT\nGAATACCTGATGTTTGCCCTCATCATGCTCAACACCATCTGCCTCGGCATGCAGCACTAC\nAACCAGTCGGAGCAGATGAACCACATCTCAGACATCCTCAATGTGGCCTTCACTATCATC\nTTCACCCTGGAGATGATCCTCAAGCTCATGGCCTTCAAGGCCAGGGGCTACTTTGGAGAC\nCCCTGGAATGTGTTTGACTTCCTGATTGTCATTGGCAGCATCATTGATGTCATCCTCAGT\nGAGATCGACACTTTCCTGGCCTCCAGCGGGGGACTGTATTGCCTGGGTGGAGGCTGCGGG\nAACGTTGACCCAGATGAGAGTGCCCGCATCTCCAGCGCCTTCTTCCGCCTGTTCCGTGTC\nATGAGGCTGATCAAGCTGCTGAGCCGGGCAGAAGGAGTGCGAACCCTCCTGTGGACGTTC\nATCAAGTCCTTCCAGGCCCTACCCTACGTGGCTCTGCTCATCGTCATGCTCTTCTTCATC\nTACGCTGTCATCGGCATGCAGATGTTTGGGAAGATCGCCTTGGTGGATGGGACCCAAATA\nAACCGGAACAACAACTTCCAGACCTTCCCACAAGCTGTGCTACTGCTCTTCAGGTGTGCA\nACAGGTGAGGCCTGGCAGGAGATCCTACTGGCCTGCAGCTATGGGAAGCTGTGTGACCCA\nGAGTCGGACTATGCCCCAGGGGAGGAGTACACATGTGGCACCAACTTTGCATACTACTAC\nTTCATCAGCTTCTACATGCTCTGTGCCTTCCTGGTCATCAACCTCTTTGTGGCTGTCATC\nATGGACAATTTTGACTACCTCACCCGGGACTGGTCCATCCTGGGCCCTCATCACCTGGAT\nGAGTTCAAGGCCATCTGGGCAGAGTATGACCCAGAGGCTAAGGGGAGAATCAAACACCTG\nGACGTGGTGACCCTGCTGAGAAGGATTCAGCCCCCTCTGGGCTTTGGGAAGTTCTGCCCA\nCATCGGGTAGCTTGTAAGCGGCTGGTGGGCATGAACATGCCCCTGAACAGCGACGGCACA\nGTCACCTTCAATGCCACACTCTTTGCCCTGGTCCGCACGGCACTCAAGATCAAGACGGAA\nGGTAACTTTGAGCAGGCCAACGAGGAGCTGAGGGCCATCATCAAGAAGATCTGGAAGAGA\nACCAGCATGAAGCTCTTGGACCAGGTCATCCCTCCAATAGGAGATGATGAGGTGACAGTG\nGGGAAGTTCTACGCCACATTCCTCATCCAGGAGCACTTCCGGAAGTTCATGAAACGCCAA\nGAGGAGTATTATGGCTATCGGCCCAAGAAGGACATTGTACAGATCCAGGCAGGGCTGCGG\nACCATTGAGGAAGAGGCAGCCCCCGAGATCTGTCGCACGGTCTCAGGAGACCTGGCTGCT\nGAGGAGGAGCTGGAGAGAGCCATGGTGGAGGCTGCGATGGAGGAGGGAATATTCCGGAGG\nACTGGAGGCCTGTTTGGCCAGGTGGACAACTTCCTGGAAAGGACCAACTCCCTGCCCCCC\nGTCATGGCCAATCAGAGACCCCTCCAGTTTGCTGAGATAGAGATGGAAGAGATGGAGTCA\nCCTGTCTTCTTGGAGGACTTCCCACAAGATCCACGCACCAACCCCCTGGCTCGTGCCAAT\nACCAACAATGCCAACGCCAATGTCGCCTATGGCAACAGCAACCATAGCAACAGCCATGTG\nTTTTCCAGTGTCCACTATGAAAGGGAGTTCCCAGAAGAGACAGAGACGCCTGCTACCAGA\nGGACGAGCCCTTGGCCAACCCTGCAGGGTCCTGGGACCCCACAGCAAACCCTGTGTGGAG\nATGCTGAAGGGACTGCTGACCCAGAGGGCAATGCCCAGAGGCCAGGCACCTCCTGCCCCC\nTGCCAGTGCCCCAGGGTGGAGTCCTCCATGCCTGAGGACAGAAAGAGCTCCACACCAGGG\nTCTCTTCATGAGGAGACACCCCACAGCAGGAGCACCAGGGAGAATACTTCCAGGTGCTCA\nGCACCAGCTACAGCCCTGCTGATCCAAAAGGCTCTGGTTCGAGGGGGCCTGGGCACCTTG\nGCAGCTGATGCAAACTTCATCATGGCAACAGGCCAGGCCCTGGCAGATGCCTGCCAAATG\nGAACCAGAGGAAGTGGAGATCATGGCAACAGAGCTACTGAAAGGACGAGAGGCCCCAGAG\nGGCATGGCCAGCTCCCTGGGATGCCTGAACCTCGGGTCCTCCCTGGGCAGCCTCGACCAA\nCACCAGGGCTCCCAGGAGACCCTTATTCCTCCAAGGCTGTGA'),('Voltage-dependent L-type calcium channel subunit beta-1','None','Human','Voltage-gated calcium channel activity','The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.','CACNB1','65712.995','DB00653','>lcl|BSEQ0010071|Voltage-dependent L-type calcium channel subunit beta-1 (CACNB1)\nATGGTCCAGAAGACCAGCATGTCCCGGGGCCCTTACCCACCCTCCCAGGAGATCCCCATG\nGAGGTCTTCGACCCCAGCCCGCAGGGCAAATACAGCAAGAGGAAAGGGCGATTCAAACGG\nTCAGATGGGAGCACGTCCTCGGATACCACATCCAACAGCTTTGTCCGCCAGGGCTCAGCG\nGAGTCCTACACCAGCCGTCCATCAGACTCTGATGTATCTCTGGAGGAGGACCGGGAAGCC\nTTAAGGAAGGAAGCAGAGCGCCAGGCATTAGCGCAGCTCGAGAAGGCCAAGACCAAGCCA\nGTGGCATTTGCTGTGCGGACAAATGTTGGCTACAATCCGTCTCCAGGGGATGAGGTGCCT\nGTGCAGGGAGTGGCCATCACCTTCGAGCCCAAAGACTTCCTGCACATCAAGGAGAAATAC\nAATAATGACTGGTGGATCGGGCGGCTGGTGAAGGAGGGCTGTGAGGTTGGCTTCATTCCC\nAGCCCCGTCAAACTGGACAGCCTTCGCCTGCTGCAGGAACAGAAGCTGCGCCAGAACCGC\nCTCGGCTCCAGCAAATCAGGCGATAACTCCAGTTCCAGTCTGGGAGATGTGGTGACTGGC\nACCCGCCGCCCCACACCCCCTGCCAGTGCCAAACAGAAGCAGAAGTCGACAGAGCATGTG\nCCCCCCTATGACGTGGTGCCTTCCATGAGGCCCATCATCCTGGTGGGACCGTCGCTCAAG\nGGCTACGAGGTTACAGACATGATGCAGAAAGCTTTATTTGACTTCTTGAAGCATCGGTTT\nGATGGCAGGATCTCCATCACTCGTGTGACGGCAGATATTTCCCTGGCTAAGCGCTCAGTT\nCTCAACAACCCCAGCAAACACATCATCATTGAGCGCTCCAACACACGCTCCAGCCTGGCT\nGAGGTGCAGAGTGAAATCGAGCGAATCTTCGAGCTGGCCCGGACCCTTCAGTTGGTCGCT\nCTGGATGCTGACACCATCAATCACCCAGCCCAGCTGTCCAAGACCTCGCTGGCCCCCATC\nATTGTTTACATCAAGATCACCTCTCCCAAGGTACTTCAAAGGCTCATCAAGTCCCGAGGA\nAAGTCTCAGTCCAAACACCTCAATGTCCAAATAGCGGCCTCGGAAAAGCTGGCACAGTGC\nCCCCCTGAAATGTTTGACATCATCCTGGATGAGAACCAATTGGAGGATGCCTGCGAGCAT\nCTGGCGGAGTACTTGGAAGCCTATTGGAAGGCCACACACCCGCCCAGCAGCACGCCACCC\nAATCCGCTGCTGAACCGCACCATGGCTACCGCAGCCCTGGCTGCCAGCCCTGCCCCTGTC\nTCCAACCTCCAGGGACCCTACCTTGCTTCCGGGGACCAGCCACTGGAACGGGCCACCGGG\nGAGCACGCCAGCATGCACGAGTACCCAGGGGAGCTGGGCCAGCCCCCAGGCCTTTACCCC\nAGCAGCCACCCACCAGGCCGGGCAGGCACGCTACGGGCACTGTCCCGCCAAGACACTTTT\nGATGCCGACACCCCCGGCAGCCGAAACTCTGCCTACACGGAGCTGGGAGACTCATGTGTG\nGACATGGAGACTGACCCCTCAGAGGGGCCAGGGCTTGGAGACCCTGCAGGGGGCGGCACG\nCCCCCAGCCCGACAGGGATCCTGGGAGGACGAGGAAGAAGACTATGAGGAAGAGCTGACC\nGACAACCGGAACCGGGGCCGGAATAAGGCCCGCTACTGCGCTGAGGGTGGGGGTCCAGTT\nTTGGGGCGCAACAAGAATGAGCTGGAGGGCTGGGGACGAGGCGTCTACATTCGCTGA'),('Voltage-dependent L-type calcium channel subunit beta-2','None','Human','Voltage-gated calcium channel activity','The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.','CACNB2','73579.925','DB00653','>lcl|BSEQ0021669|Voltage-dependent L-type calcium channel subunit beta-2 (CACNB2)\nATGCAGTGCTGCGGGCTGGTGCATCGCCGGCGAGTACGGGTGTCCTATGGTTCGGCAGAC\nTCCTACACTAGCCGTCCATCCGATTCCGATGTATCTCTGGAGGAGGACCGGGAGGCAGTG\nCGCAGAGAAGCGGAGCGGCAGGCCCAGGCACAGTTGGAAAAAGCAAAGACAAAGCCCGTT\nGCATTTGCGGTTCGGACAAATGTCAGCTACAGTGCGGCCCATGAAGATGATGTTCCAGTG\nCCTGGCATGGCCATCTCATTCGAAGCAAAAGATTTTCTGCATGTTAAGGAAAAATTTAAC\nAATGACTGGTGGATAGGGCGATTGGTAAAAGAAGGCTGTGAAATCGGATTCATTCCAAGC\nCCAGTCAAACTAGAAAACATGAGGCTGCAGCATGAACAGAGAGCCAAGCAAGGGAAATTC\nTACTCCAGTAAATCAGGAGGAAATTCATCATCCAGTTTGGGTGACATAGTACCTAGTTCC\nAGAAAATCAACACCTCCATCATCTGCTATAGACATAGATGCTACTGGCTTAGATGCAGAA\nGAAAATGATATTCCAGCAAACCACCGCTCCCCTAAACCCAGTGCAAACAGTGTAACGTCA\nCCCCACTCCAAAGAGAAAAGAATGCCCTTCTTTAAGAAGACAGAGCACACTCCTCCGTAT\nGATGTGGTACCTTCCATGCGACCAGTGGTCCTAGTGGGCCCTTCTCTGAAGGGCTACGAG\nGTCACAGATATGATGCAAAAAGCGCTGTTTGATTTTTTAAAACACAGATTTGAAGGGCGG\nATATCCATCACAAGGGTCACCGCTGACATCTCGCTTGCCAAACGCTCGGTATTAAACAAT\nCCCAGTAAGCACGCAATAATAGAAAGATCCAACACAAGGTCAAGCTTAGCGGAAGTTCAG\nAGTGAAATCGAAAGGATTTTTGAACTTGCAAGAACATTGCAGTTGGTGGTCCTTGACGCG\nGATACAATTAATCATCCAGCTCAACTCAGTAAAACCTCCTTGGCCCCTATTATAGTATAT\nGTAAAGATTTCTTCTCCTAAGGTTTTACAAAGGTTAATAAAATCTCGAGGGAAATCTCAA\nGCTAAACACCTCAACGTCCAGATGGTAGCAGCTGATAAACTGGCTCAGTGTCCTCCAGAG\nCTGTTCGATGTGATCTTGGATGAGAACCAGCTTGAGGATGCCTGTGAGCACCTTGCCGAC\nTATCTGGAGGCCTACTGGAAGGCCACCCATCCTCCCAGCAGTAGCCTCCCCAACCCTCTC\nCTTAGCCGTACATTAGCCACTTCAAGTCTGCCTCTTAGCCCCACCCTAGCCTCTAATTCA\nCAGGGTTCTCAAGGTGATCAGAGGACTGATCGCTCCGCTCCTATCCGTTCTGCTTCCCAA\nGCTGAAGAAGAACCTAGTGTGGAACCAGTCAAGAAATCCCAGCACCGCTCTTCCTCCTCA\nGCCCCACACCACAACCATCGCAGTGGGACAAGTCGCGGCCTCTCCAGGCAAGAGACATTT\nGACTCGGAAACCCAGGAGAGTCGAGACTCTGCCTACGTAGAGCCAAAGGAAGATTATTCC\nCATGACCACGTGGACCACTATGCCTCACACCGTGACCACAACCACAGAGACGAGACCCAC\nGGGAGCAGTGACCACAGACACAGGGAGTCCCGGCACCGTTCCCGGGACGTGGATCGAGAG\nCAGGACCACAACGAGTGCAACAAGCAGCGCAGCCGTCATAAATCCAAGGATCGCTACTGT\nGAAAAGGATGGAGAAGTGATATCAAAAAAACGGAATGAGGCTGGGGAGTGGAACAGGGAT\nGTTTACATCCGCCAATGA'),('Voltage-dependent N-type calcium channel subunit alpha-1B','None','Human','Voltage-gated calcium channel activity','Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1B gives rise to N-type calcium currents. N-type calcium channels belong to the \'high-voltage activated\' (HVA) group and are blocked by omega-conotoxin-GVIA (omega-CTx-GVIA) and by omega-agatoxin-IIIA (omega-Aga-IIIA). They are however insensitive to dihydropyridines (DHP), and omega-agatoxin-IVA (omega-Aga-IVA). Calcium channels containing alpha-1B subunit may play a role in directed migration of immature neurons.','CACNA1B','262493.84','DB00996','>lcl|BSEQ0011606|Voltage-dependent N-type calcium channel subunit alpha-1B (CACNA1B)\nATGGTCCGCTTCGGGGACGAGCTGGGCGGCCGCTATGGGGGCCCCGGCGGCGGAGAGCGG\nGCCCGGGGCGGCGGGGCCGGCGGGGCGGGGGGCCCGGGTCCCGGGGGGCTGCAGCCCGGC\nCAGCGGGTCCTCTACAAGCAATCGATCGCGCAGCGCGCGCGGACCATGGCGCTGTACAAC\nCCCATCCCGGTCAAGCAGAACTGCTTCACCGTCAACCGCTCGCTCTTCGTCTTCAGCGAG\nGACAACGTCGTCCGCAAATACGCGAAGCGCATCACCGAGTGGCCTCCATTCGAGTATATG\nATCCTGGCCACCATCATCGCCAACTGCATCGTGCTGGCCCTGGAGCAGCACCTCCCTGAT\nGGGGACAAAACGCCCATGTCCGAGCGGCTGGACGACACGGAGCCCTATTTCATCGGGATC\nTTTTGCTTCGAGGCAGGGATCAAAATCATCGCTCTGGGCTTTGTCTTCCACAAGGGCTCT\nTACCTGCGGAACGGCTGGAACGTCATGGACTTCGTGGTCGTCCTCACAGGGATCCTTGCC\nACGGCTGGAACTGACTTCGACCTGCGAACACTGAGGGCTGTGCGTGTGCTGAGGCCCCTG\nAAGCTGGTGTCTGGGATTCCAAGTTTGCAGGTGGTGCTCAAGTCCATCATGAAGGCCATG\nGTTCCACTCCTGCAGATTGGGCTGCTTCTCTTCTTTGCCATCCTCATGTTTGCCATCATT\nGGCCTGGAGTTCTACATGGGCAAGTTCCACAAGGCCTGTTTCCCCAACAGCACAGATGCG\nGAGCCCGTGGGTGACTTCCCCTGTGGCAAGGAGGCCCCAGCCCGGCTGTGCGAGGGCGAC\nACTGAGTGCCGGGAGTACTGGCCAGGACCCAACTTTGGCATCACCAACTTTGACAATATC\nCTGTTTGCCATCTTGACGGTGTTCCAGTGCATCACCATGGAGGGCTGGACTGACATCCTC\nTATAATACAAACGATGCGGCCGGCAACACCTGGAACTGGCTCTACTTCATCCCTCTCATC\nATCATCGGCTCCTTCTTCATGCTCAACCTGGTGCTGGGCGTGCTCTCGGGGGAGTTTGCC\nAAGGAGCGAGAGAGGGTGGAGAACCGCCGCGCCTTCCTGAAGCTGCGCCGGCAGCAGCAG\nATCGAGCGAGAGCTCAACGGGTACCTGGAGTGGATCTTCAAGGCGGAGGAAGTCATGCTG\nGCCGAGGAGGACAGGAATGCAGAGGAGAAGTCCCCTTTGGACGTGCTGAAGAGAGCGGCC\nACCAAGAAGAGCAGAAATGACCTGATCCACGCAGAGGAGGGAGAGGACCGGTTTGCAGAT\nCTCTGTGCTGTTGGATCCCCCTTCGCCCGCGCCAGCCTCAAGAGCGGGAAGACAGAGAGC\nTCGTCATACTTCCGGAGGAAGGAGAAGATGTTCCGGTTTTTTATCCGGCGCATGGTGAAG\nGCTCAGAGCTTCTACTGGGTGGTGCTGTGCGTGGTGGCCCTGAACACACTGTGTGTGGCC\nATGGTGCATTACAACCAGCCGCGGCGGCTTACCACGACCCTGTATTTTGCAGAGTTTGTT\nTTCCTGGGTCTCTTCCTCACAGAGATGTCCCTGAAGATGTATGGCCTGGGGCCCAGAAGC\nTACTTCCGGTCCTCCTTCAACTGCTTCGACTTTGGGGTCATCGTGGGGAGCGTCTTTGAA\nGTGGTCTGGGCGGCCATCAAGCCGGGAAGCTCCTTTGGGATCAGTGTGCTGCGGGCCCTC\nCGCCTGCTGAGGATCTTCAAAGTCACGAAGTACTGGAGCTCCCTGCGGAACCTGGTGGTG\nTCCCTGCTGAACTCCATGAAGTCCATCATCAGCCTGCTCTTCTTGCTCTTCCTGTTCATT\nGTGGTCTTCGCCCTGCTGGGGATGCAGCTGTTTGGGGGACAGTTCAACTTCCAGGATGAG\nACTCCCACAACCAACTTCGACACCTTCCCTGCCGCCATCCTCACTGTCTTCCAGATCCTG\nACGGGAGAGGACTGGAATGCAGTGATGTATCACGGGATCGAATCGCAAGGCGGCGTCAGC\nAAAGGCATGTTCTCGTCCTTTTACTTCATTGTCCTGACACTGTTCGGAAACTACACTCTG\nCTGAATGTCTTTCTGGCCATCGCTGTGGACAACCTGGCCAACGCCCAAGAGCTGACCAAG\nGATGAAGAGGAGATGGAAGAAGCAGCCAATCAGAAGCTTGCTCTGCAAAAGGCCAAAGAA\nGTGGCTGAAGTCAGCCCCATGTCTGCCGCGAACATCTCCATCGCCGCCAGGCAGCAGAAC\nTCGGCCAAGGCGCGCTCGGTGTGGGAGCAGCGGGCCAGCCAGCTACGGCTGCAGAACCTG\nCGGGCCAGCTGCGAGGCGCTGTACAGCGAGATGGACCCCGAGGAGCGGCTGCGCTTCGCC\nACTACGCGCCACCTGCGGCCCGACATGAAGACGCACCTGGACCGGCCGCTGGTGGTGGAG\nCTGGGCCGCGACGGCGCGCGGGGGCCCGTGGGAGGCAAAGCCCGACCTGAGGCTGCGGAG\nGCCCCCGAGGGCGTCGACCCTCCGCGCAGGCACCACCGGCACCGCGACAAGGACAAGACC\nCCCGCGGCGGGGGACCAGGACCGAGCAGAGGCCCCGAAGGCGGAGAGCGGGGAGCCCGGT\nGCCCGGGAGGAGCGGCCGCGGCCGCACCGCAGCCACAGCAAGGAGGCCGCGGGGCCCCCG\nGAGGCGCGGAGCGAGCGCGGCCGAGGCCCAGGCCCCGAGGGCGGCCGGCGGCACCACCGG\nCGCGGCTCCCCGGAGGAGGCGGCCGAGCGGGAGCCCCGACGCCACCGCGCGCACCGGCAC\nCAGGATCCGAGCAAGGAGTGCGCCGGCGCCAAGGGCGAGCGGCGCGCGCGGCACCGCGGC\nGGCCCCCGAGCGGGGCCCCGGGAGGCGGAGAGCGGGGAGGAGCCGGCGCGGCGGCACCGG\nGCCCGGCACAAGGCGCAGCCTGCTCACGAGGCTGTGGAGAAGGAGACCACGGAGAAGGAG\nGCCACGGAGAAGGAGGCTGAGATAGTGGAAGCCGACAAGGAAAAGGAGCTCCGGAACCAC\nCAGCCCCGGGAGCCACACTGTGACCTGGAGACCAGTGGGACTGTGACTGTGGGTCCCATG\nCACACACTGCCCAGCACCTGTCTCCAGAAGGTGGAGGAACAGCCAGAGGATGCAGACAAT\nCAGCGGAACGTCACTCGCATGGGCAGTCAGCCCCCAGACCCGAACACTATTGTACATATC\nCCAGTGATGCTGACGGGCCCTCTTGGGGAAGCCACGGTCGTTCCCAGTGGTAACGTGGAC\nCTGGAAAGCCAAGCAGAGGGGAAGAAGGAGGTGGAAGCGGATGACGTGATGAGGAGCGGC\nCCCCGGCCTATCGTCCCATACAGCTCCATGTTCTGTTTAAGCCCCACCAACCTGCTCCGC\nCGCTTCTGCCACTACATCGTGACCATGAGGTACTTCGAGGTGGTCATTCTCGTGGTCATC\nGCCTTGAGCAGCATCGCCCTGGCTGCTGAGGACCCAGTGCGCACAGACTCGCCCAGGAAC\nAACGCTCTGAAATACCTGGATTACATTTTCACTGGTGTCTTTACCTTTGAGATGGTGATA\nAAGATGATCGACTTGGGACTGCTGCTTCACCCTGGAGCCTATTTCCGGGACTTGTGGAAC\nATTCTGGACTTCATTGTGGTCAGTGGCGCCCTGGTGGCGTTTGCTTTCTCAGGATCCAAA\nGGGAAAGACATCAATACCATCAAGTCTCTGAGAGTCCTTCGTGTCCTGCGGCCCCTCAAG\nACCATCAAACGGCTGCCCAAGCTCAAGGCTGTGTTTGACTGTGTGGTGAACTCCCTGAAG\nAATGTCCTCAACATCTTGATTGTCTACATGCTCTTCATGTTCATATTTGCCGTCATTGCG\nGTGCAGCTCTTCAAAGGGAAGTTTTTCTACTGCACAGATGAATCCAAGGAGCTGGAGAGG\nGACTGCAGGGGTCAGTATTTGGATTATGAGAAGGAGGAAGTGGAAGCTCAGCCCAGGCAG\nTGGAAGAAATACGACTTTCACTACGACAATGTGCTCTGGGCTCTGCTGACGCTGTTCACA\nGTGTCCACGGGAGAAGGCTGGCCCATGGTGCTGAAACACTCCGTGGATGCCACCTATGAG\nGAGCAGGGTCCAAGCCCTGGGTACCGCATGGAGCTGTCCATCTTCTACGTGGTCTACTTT\nGTGGTCTTTCCCTTCTTCTTCGTCAACATCTTTGTGGCTTTGATCATCATCACCTTCCAG\nGAGCAGGGGGACAAGGTGATGTCTGAATGCAGCCTGGAGAAGAACGAGAGGGCTTGCATT\nGACTTCGCCATCAGCGCCAAACCCCTGACACGGTACATGCCCCAAAACCGGCAGTCGTTC\nCAGTATAAGACGTGGACATTTGTGGTCTCCCCGCCCTTTGAATACTTCATCATGGCCATG\nATAGCCCTCAACACTGTGGTGCTGATGATGAAGTTCTATGATGCACCCTATGAGTACGAG\nCTGATGCTGAAATGCCTGAACATCGTGTTCACATCCATGTTCTCCATGGAATGCGTGCTG\nAAGATCATCGCCTTTGGGGTGCTGAACTATTTCAGAGATGCCTGGAATGTCTTTGACTTT\nGTCACTGTGTTGGGAAGTATTACTGATATTTTAGTAACAGAGATTGCGGAAACGAACAAT\nTTCATCAACCTCAGCTTCCTCCGCCTCTTTCGAGCTGCGCGGCTGATCAAGCTGCTCCGC\nCAGGGCTACACCATCCGCATCCTGCTGTGGACCTTTGTCCAGTCCTTCAAGGCCCTGCCC\nTACGTGTGTCTGCTCATTGCCATGCTGTTCTTCATCTACGCCATCATCGGCATGCAGGTG\nTTTGGGAATATTGCCCTGGATGATGACACCAGCATCAACCGCCACAACAACTTCCGGACG\nTTTTTGCAAGCCCTGATGCTGCTGTTCAGGAGCGCCACGGGGGAGGCCTGGCACGAGATC\nATGCTGTCCTGCCTGAGCAACCAGGCCTGTGATGAGCAGGCCAATGCCACCGAGTGTGGA\nAGTGACTTTGCCTACTTCTACTTCGTCTCCTTCATCTTCCTGTGCTCCTTTCTGATGTTG\nAACCTCTTTGTGGCTGTGATCATGGACAATTTTGAGTACCTCACGCGGGACTCTTCCATC\nCTAGGTCCTCACCACTTGGATGAGTTCATCCGGGTCTGGGCTGAATACGACCCGGCTGCG\nTGTGGGCGCATCAGTTACAATGACATGTTTGAGATGCTGAAACACATGTCCCCGCCTCTG\nGGGCTGGGGAAGAAATGCCCTGCTCGAGTTGCTTACAAGCGCCTGGTTCGCATGAACATG\nCCCATCTCCAACGAGGACATGACTGTTCACTTCACGTCCACGCTGATGGCCCTCATCCGG\nACGGCACTGGAGATCAAGCTGGCCCCAGCTGGGACAAAGCAGCATCAGTGTGACGCGGAG\nTTGAGGAAGGAGATTTCCGTTGTGTGGGCCAATCTGCCCCAGAAGACTTTGGACTTGCTG\nGTACCACCCCATAAGCCTGATGAGATGACAGTGGGGAAGGTTTATGCAGCTCTGATGATA\nTTCGACTTCTACAAGCAGAACAAAACCACCAGAGACCAGATGCAGCAGGCTCCTGGAGGC\nCTCTCCCAGATGGGTCCTGTGTCCCTGTTCCACCCTCTGAAGGCCACCCTGGAGCAGACA\nCAGCCGGCTGTGCTCCGAGGAGCCCGGGTTTTCCTTCGACAGAAGAGTTCCACCTCCCTC\nAGCAATGGCGGGGCCATACAAAACCAAGAGAGTGGCATCAAAGAGTCTGTCTCCTGGGGC\nACTCAAAGGACCCAGGATGCACCCCATGAGGCCAGGCCACCCCTGGAGCGTGGCCACTCC\nACAGAGATCCCTGTGGGGCGGTCAGGAGCACTGGCTGTGGACGTTCAGATGCAGAGCATA\nACCCGGAGGGGCCCTGATGGGGAGCCCCAGCCTGGGCTGGAGAGCCAGGGTCGAGCGGCC\nTCCATGCCCCGCCTTGCGGCCGAGACTCAGCCCGTCACAGATGCCAGCCCCATGAAGCGC\nTCCATCTCCACGCTGGCCCAGCGGCCCCGTGGGACTCATCTTTGCAGCACCACCCCGGAC\nCGCCCACCCCCTAGCCAGGCGTCGTCGCACCACCACCACCACCGCTGCCACCGCCGCAGG\nGACAGGAAGCAGAGGTCCCTGGAGAAGGGGCCCAGCCTGTCTGCCGATATGGATGGCGCA\nCCAAGCAGTGCTGTGGGGCCGGGGCTGCCCCCGGGAGAGGGGCCTACAGGCTGCCGGCGG\nGAACGAGAGCGCCGGCAGGAGCGGGGCCGGTCCCAGGAGCGGAGGCAGCCCTCATCCTCC\nTCCTCGGAGAAGCAGCGCTTCTACTCCTGCGACCGCTTTGGGGGCCGTGAGCCCCCGAAG\nCCCAAGCCCTCCCTCAGCAGCCACCCAACGTCGCCAACAGCTGGCCAGGAGCCGGGACCC\nCACCCACAGGGCAGTGGTTCCGTGAATGGGAGCCCCTTGCTGTCAACATCTGGTGCTAGC\nACCCCCGGCCGCGGTGGGCGGAGGCAGCTCCCCCAGACGCCCCTGACTCCCCGCCCCAGC\nATCACCTACAAGACGGCCAACTCCTCACCCATCCACTTCGCCGGGGCTCAGACCAGCCTC\nCCTGCCTTCTCCCCAGGCCGGCTCAGCCGTGGGCTTTCCGAACACAACGCCCTGCTGCAG\nAGAGACCCCCTCAGCCAGCCCCTGGCCCCTGGCTCTCGAATTGGCTCTGACCCTTACCTG\nGGGCAGCGTCTGGACAGTGAGGCCTCTGTCCACGCCCTGCCTGAGGACACTCTCACTTTC\nGAGGAGGCTGTGGCCACCAACTCGGGCCGCTCCTCCAGGACTTCCTACGTGTCCTCCCTG\nACCTCCCAGTCTCACCCTCTCCGCCGCGTGCCCAACGGTTACCACTGCACCCTGGGACTC\nAGCTCGGGTGGCCGAGCACGGCACAGCTACCACCACCCTGACCAAGACCACTGGTGCTAG'),('Voltage-dependent P/Q-type calcium channel subunit alpha-1A','None','Human','Voltage-gated calcium channel activity','Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1A gives rise to P and/or Q-type calcium currents. P/Q-type calcium channels belong to the \'high-voltage activated\' (HVA) group and are blocked by the funnel toxin (Ftx) and by the omega-agatoxin-IVA (omega-Aga-IVA). They are however insensitive to dihydropyridines (DHP), and omega-conotoxin-GVIA (omega-CTx-GVIA).','CACNA1A','282362.39','DB00230','>lcl|BSEQ0010260|Voltage-dependent P/Q-type calcium channel subunit alpha-1A (CACNA1A)\nATGGCCCGCTTCGGAGACGAGATGCCGGCCCGCTACGGGGGAGGAGGCTCCGGGGCAGCC\nGCCGGGGTGGTCGTGGGCAGCGGAGGCGGGCGAGGAGCCGGGGGCAGCCGGCAGGGCGGG\nCAGCCCGGGGCGCAAAGGATGTACAAGCAGTCAATGGCGCAGAGAGCGCGGACCATGGCA\nCTCTACAACCCCATCCCCGTCCGACAGAACTGCCTCACGGTTAACCGGTCTCTCTTCCTC\nTTCAGCGAAGACAACGTGGTGAGAAAATACGCCAAAAAGATCACCGAATGGCCTCCCTTT\nGAATATATGATTTTAGCCACCATCATAGCGAATTGCATCGTCCTCGCACTGGAGCAGCAT\nCTGCCTGATGATGACAAGACCCCGATGTCTGAACGGCTGGATGACACAGAACCATACTTC\nATTGGAATTTTTTGTTTCGAGGCTGGAATTAAAATCATTGCCCTTGGGTTTGCCTTCCAC\nAAAGGCTCCTACTTGAGGAATGGCTGGAATGTCATGGACTTTGTGGTGGTGCTAACGGGC\nATCTTGGCGACAGTTGGGACGGAGTTTGACCTACGGACGCTGAGGGCAGTTCGAGTGCTG\nCGGCCGCTCAAGCTGGTGTCTGGAATCCCAAGTTTACAAGTCGTCCTGAAGTCGATCATG\nAAGGCGATGATCCCTTTGCTGCAGATCGGCCTCCTCCTATTTTTTGCAATCCTTATTTTT\nGCAATCATAGGGTTAGAATTTTATATGGGAAAATTTCATACCACCTGCTTTGAAGAGGGG\nACAGATGACATTCAGGGTGAGTCTCCGGCTCCATGTGGGACAGAAGAGCCCGCCCGCACC\nTGCCCCAATGGGACCAAATGTCAGCCCTACTGGGAAGGGCCCAACAACGGGATCACTCAG\nTTCGACAACATCCTGTTTGCAGTGCTGACTGTTTTCCAGTGCATAACCATGGAAGGGTGG\nACTGATCTCCTCTACAATAGCAACGATGCCTCAGGGAACACTTGGAACTGGTTGTACTTC\nATCCCCCTCATCATCATCGGCTCCTTTTTTATGCTGAACCTTGTGCTGGGTGTGCTGTCA\nGGGGAGTTTGCCAAAGAAAGGGAACGGGTGGAGAACCGGCGGGCTTTTCTGAAGCTGAGG\nCGGCAACAACAGATTGAACGTGAGCTCAATGGGTACATGGAGTGGATCTCAAAAGCAGAA\nGAGGTGATCCTCGCCGAGGATGAAACTGACGGGGAGCAGAGGCATCCCTTTGATGGAGCT\nCTGCGGAGAACCACCATAAAGAAAAGCAAGACAGATTTGCTCAACCCCGAAGAGGCTGAG\nGATCAGCTGGCTGATATAGCCTCTGTGGGTTCTCCCTTCGCCCGAGCCAGCATTAAAAGT\nGCCAAGCTGGAGAACTCGACCTTTTTTCACAAAAAGGAGAGGAGGATGCGTTTCTACATC\nCGCCGCATGGTCAAAACTCAGGCCTTCTACTGGACTGTACTCAGTTTGGTAGCTCTCAAC\nACGCTGTGTGTTGCTATTGTTCACTACAACCAGCCCGAGTGGCTCTCCGACTTCCTTTAC\nTATGCAGAATTCATTTTCTTAGGACTCTTTATGTCCGAAATGTTTATAAAAATGTACGGG\nCTTGGGACGCGGCCTTACTTCCACTCTTCCTTCAACTGCTTTGACTGTGGGGTTATCATT\nGGGAGCATCTTCGAGGTCATCTGGGCTGTCATAAAACCTGGCACATCCTTTGGAATCAGC\nGTGTTACGAGCCCTCAGGTTATTGCGTATTTTCAAAGTCACAAAGTACTGGGCATCTCTC\nAGAAACCTGGTCGTCTCTCTCCTCAACTCCATGAAGTCCATCATCAGCCTGTTGTTTCTC\nCTTTTCCTGTTCATTGTCGTCTTCGCCCTTTTGGGAATGCAACTCTTCGGCGGCCAGTTT\nAATTTCGATGAAGGGACTCCTCCCACCAACTTCGATACTTTTCCAGCAGCAATAATGACG\nGTGTTTCAGATCCTGACGGGCGAAGACTGGAACGAGGTCATGTACGACGGGATCAAGTCT\nCAGGGGGGCGTGCAGGGCGGCATGGTGTTCTCCATCTATTTCATTGTACTGACGCTCTTT\nGGGAACTACACCCTCCTGAATGTGTTCTTGGCCATCGCTGTGGACAATCTGGCCAACGCC\nCAGGAGCTCACCAAGGTGGAGGCGGACGAGCAAGAGGAAGAAGAAGCAGCGAACCAGAAA\nCTTGCCCTACAGAAAGCCAAGGAGGTGGCAGAAGTGAGTCCTCTGTCCGCGGCCAACATG\nTCTATAGCTGTGAAAGAGCAACAGAAGAATCAAAAGCCAGCCAAGTCCGTGTGGGAGCAG\nCGGACCAGTGAGATGCGAAAGCAGAACTTGCTGGCCAGCCGGGAGGCCCTGTATAACGAA\nATGGACCCGGACGAGCGCTGGAAGGCTGCCTACACGCGGCACCTGCGGCCAGACATGAAG\nACGCACTTGGACCGGCCGCTGGTGGTGGACCCGCAGGAGAACCGCAACAACAACACCAAC\nAAGAGCCGGGCGGCCGAGCCCACCGTGGACCAGCGCCTCGGCCAGCAGCGCGCCGAGGAC\nTTCCTCAGGAAACAGGCCCGCTACCACGATCGGGCCCGGGACCCCAGCGGCTCGGCGGGC\nCTGGACGCACGGAGGCCCTGGGCGGGAAGCCAGGAGGCCGAGCTGAGCCGGGAGGGACCC\nTACGGCCGCGAGTCGGACCACCACGCCCGGGAGGGCAGCCTGGAGCAACCCGGGTTCTGG\nGAGGGCGAGGCCGAGCGAGGCAAGGCCGGGGACCCCCACCGGAGGCACGTGCACCGGCAG\nGGGGGCAGCAGGGAGAGCCGCAGCGGGTCCCCGCGCACGGGCGCGGACGGGGAGCATCGA\nCGTCATCGCGCGCACCGCAGGCCCGGGGAGGAGGGTCCGGAGGACAAGGCGGAGCGGAGG\nGCGCGGCACCGCGAGGGCAGCCGGCCGGCCCGGGGCGGCGAGGGCGAGGGCGAGGGCCCC\nGACGGGGGCGAGCGCAGGAGAAGGCACCGGCATGGCGCTCCAGCCACGTACGAGGGGGAC\nGCGCGGAGGGAGGACAAGGAGCGGAGGCATCGGAGGAGGAAAGAGAACCAGGGCTCCGGG\nGTCCCTGTGTCGGGCCCCAACCTGTCAACCACCCGGCCAATCCAGCAGGACCTGGGCCGC\nCAAGACCCACCCCTGGCAGAGGATATTGACAACATGAAGAACAACAAGCTGGCCACCGCG\nGAGTCGGCCGCTCCCCACGGCAGCCTTGGCCACGCCGGCCTGCCCCAGAGCCCAGCCAAG\nATGGGAAACAGCACCGACCCCGGCCCCATGCTGGCCATCCCTGCCATGGCCACCAACCCC\nCAGAACGCCGCCAGCCGCCGGACGCCCAACAACCCGGGGAACCCATCCAATCCCGGCCCC\nCCCAAGACCCCCGAGAATAGCCTTATCGTCACCAACCCCAGCGGCACCCAGACCAATTCA\nGCTAAGACTGCCAGGAAACCCGACCACACCACAGTGGACATCCCCCCAGCCTGCCCACCC\nCCCCTCAACCACACCGTCGTACAAGTGAACAAAAACGCCAACCCAGACCCACTGCCAAAA\nAAAGAGGAAGAGAAGAAGGAGGAGGAGGAAGACGACCGTGGGGAAGACGGCCCTAAGCCA\nATGCCTCCCTATAGCTCCATGTTCATCCTGTCCACGACCAACCCCCTTCGCCGCCTGTGC\nCATTACATCCTGAACCTGCGCTACTTTGAGATGTGCATCCTCATGGTCATTGCCATGAGC\nAGCATCGCCCTGGCCGCCGAGGACCCTGTGCAGCCCAACGCACCTCGGAACAACGTGCTG\nCGATACTTTGACTACGTTTTTACAGGCGTCTTTACCTTTGAGATGGTGATCAAGATGATT\nGACCTGGGGCTCGTCCTGCATCAGGGTGCCTACTTCCGTGACCTCTGGAATATTCTCGAC\nTTCATAGTGGTCAGTGGGGCCCTGGTAGCCTTTGCCTTCACTGGCAATAGCAAAGGAAAA\nGACATCAACACGATTAAATCCCTCCGAGTCCTCCGGGTGCTACGACCTCTTAAAACCATC\nAAGCGGCTGCCAAAGCTCAAGGCTGTGTTTGACTGTGTGGTGAACTCACTTAAAAACGTC\nTTCAACATCCTCATCGTCTACATGCTATTCATGTTCATCTTCGCCGTGGTGGCTGTGCAG\nCTCTTCAAGGGGAAATTCTTCCACTGCACTGACGAGTCCAAAGAGTTTGAGAAAGATTGT\nCGAGGCAAATACCTCCTCTACGAGAAGAATGAGGTGAAGGCGCGAGACCGGGAGTGGAAG\nAAGTATGAATTCCATTACGACAATGTGCTGTGGGCTCTGCTGACCCTCTTCACCGTGTCC\nACGGGAGAAGGCTGGCCACAGGTCCTCAAGCATTCGGTGGACGCCACCTTTGAGAACCAG\nGGCCCCAGCCCCGGGTACCGCATGGAGATGTCCATTTTCTACGTCGTCTACTTTGTGGTG\nTTCCCCTTCTTCTTTGTCAATATCTTTGTGGCCTTGATCATCATCACCTTCCAGGAGCAA\nGGGGACAAGATGATGGAGGAATACAGCCTGGAGAAAAATGAGAGGGCCTGCATTGATTTC\nGCCATCAGCGCCAAGCCGCTGACCCGACACATGCCGCAGAACAAGCAGAGCTTCCAGTAC\nCGCATGTGGCAGTTCGTGGTGTCTCCGCCTTTCGAGTACACGATCATGGCCATGATCGCC\nCTCAACACCATCGTGCTTATGATGAAGTTCTATGGGGCTTCTGTTGCTTATGAAAATGCC\nCTGCGGGTGTTCAACATCGTCTTCACCTCCCTCTTCTCTCTGGAATGTGTGCTGAAAGTC\nATGGCTTTTGGGATTCTGAATTATTTCCGCGATGCCTGGAACATCTTCGACTTTGTGACT\nGTTCTGGGCAGCATCACCGATATCCTCGTGACTGAGTTTGGGAATCCGAATAACTTCATC\nAACCTGAGCTTTCTCCGCCTCTTCCGAGCTGCCCGGCTCATCAAACTTCTCCGTCAGGGT\nTACACCATCCGCATTCTTCTCTGGACCTTTGTGCAGTCCTTCAAGGCCCTGCCTTATGTC\nTGTCTGCTGATCGCCATGCTCTTCTTCATCTATGCCATCATTGGGATGCAGGTGTTTGGT\nAACATTGGCATCGACGTGGAGGACGAGGACAGTGATGAAGATGAGTTCCAAATCACTGAG\nCACAATAACTTCCGGACCTTCTTCCAGGCCCTCATGCTTCTCTTCCGGAGTGCCACCGGG\nGAAGCTTGGCACAACATCATGCTTTCCTGCCTCAGCGGGAAACCGTGTGATAAGAACTCT\nGGCATCCTGACTCGAGAGTGTGGCAATGAATTTGCTTATTTTTACTTTGTTTCCTTCATC\nTTCCTCTGCTCGTTTCTGATGCTGAATCTCTTTGTCGCCGTCATCATGGACAACTTTGAG\nTACCTCACCCGAGACTCCTCCATCCTGGGCCCCCACCACCTGGATGAGTACGTGCGTGTC\nTGGGCCGAGTATGACCCCGCAGCTTGGGGCCGCATGCCTTACCTGGACATGTATCAGATG\nCTGAGACACATGTCTCCGCCCCTGGGTCTGGGGAAGAAGTGTCCGGCCAGAGTGGCTTAC\nAAGCGGCTTCTGCGGATGGACCTGCCCGTCGCAGATGACAACACCGTCCACTTCAATTCC\nACCCTCATGGCTCTGATCCGCACAGCCCTGGACATCAAGATTGCCAAGGGAGGAGCCGAC\nAAACAGCAGATGGACGCTGAGCTGCGGAAGGAGATGATGGCGATTTGGCCCAATCTGTCC\nCAGAAGACGCTAGACCTGCTGGTCACACCTCACAAGTCCACGGACCTCACCGTGGGGAAG\nATCTACGCAGCCATGATGATCATGGAGTACTACCGGCAGAGCAAGGCCAAGAAGCTGCAG\nGCCATGCGCGAGGAGCAGGACCGGACACCCCTCATGTTCCAGCGCATGGAGCCCCCGTCC\nCCAACGCAGGAAGGGGGACCTGGCCAGAACGCCCTCCCCTCCACCCAGCTGGACCCAGGA\nGGAGCCCTGATGGCTCACGAAAGCGGCCTCAAGGAGAGCCCGTCCTGGGTGACCCAGCGT\nGCCCAGGAGATGTTCCAGAAGACGGGCACATGGAGTCCGGAACAAGGCCCCCCTACCGAC\nATGCCCAACAGCCAGCCTAACTCTCAGTCCGTGGAGATGCGAGAGATGGGCAGAGATGGC\nTACTCCGACAGCGAGCACTACCTCCCCATGGAAGGCCAGGGCCGGGCTGCCTCCATGCCC\nCGCCTCCCTGCAGAGAACCAGAGGAGAAGGGGCCGGCCACGTGGGAATAACCTCAGTACC\nATCTCAGACACCAGCCCCATGAAGCGTTCAGCCTCCGTGCTGGGCCCCAAGGCCCGACGC\nCTGGACGATTACTCGCTGGAGCGGGTCCCGCCCGAGGAGAACCAGCGGCACCACCAGCGG\nCGCCGCGACCGCAGCCACCGCGCCTCTGAGCGCTCCCTGGGCCGCTACACCGATGTGGAC\nACAGGCTTGGGGACAGACCTGAGCATGACCACCCAATCCGGGGACCTGCCGTCGAAGGAG\nCGGGACCAGGAGCGGGGCCGGCCCAAGGATCGGAAGCATCGACAGCACCACCACCACCAC\nCACCACCACCACCATCCCCCGCCCCCCGACAAGGACCGCTATGCCCAGGAACGGCCGGAC\nCACGGCCGGGCACGGGCTCGGGACCAGCGCTGGTCCCGCTCGCCCAGCGAGGGCCGAGAG\nCACATGGCGCACCGGCAGTAG'),('Voltage-dependent T-type calcium channel subunit alpha-1G','None','Human','Scaffold protein binding','Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1G gives rise to T-type calcium currents. T-type calcium channels belong to the \"low-voltage activated (LVA)\" group and are strongly blocked by mibefradil. A particularity of this type of channel is an opening at quite negative potentials and a voltage-dependent inactivation. T-type channels serve pacemaking functions in both central neurons and cardiac nodal cells and support calcium signaling in secretory cells and vascular smooth muscle. They may also be involved in the modulation of firing patterns of neurons which is important for information processing as well as in cell growth processes.','CACNA1G','262468.62','DB14011','>lcl|BSEQ0021643|Voltage-dependent T-type calcium channel subunit alpha-1G (CACNA1G)\nATGGACGAGGAGGAGGATGGAGCGGGCGCCGAGGAGTCGGGACAGCCCCGGAGCTTCATG\nCGGCTCAACGACCTGTCGGGGGCCGGGGGCCGGCCGGGGCCGGGGTCAGCAGAAAAGGAC\nCCGGGCAGCGCGGACTCCGAGGCGGAGGGGCTGCCGTACCCGGCGCTGGCCCCGGTGGTT\nTTCTTCTACTTGAGCCAGGACAGCCGCCCGCGGAGCTGGTGTCTCCGCACGGTCTGTAAC\nCCCTGGTTTGAGCGCATCAGCATGTTGGTCATCCTTCTCAACTGCGTGACCCTGGGCATG\nTTCCGGCCATGCGAGGACATCGCCTGTGACTCCCAGCGCTGCCGGATCCTGCAGGCCTTT\nGATGACTTCATCTTTGCCTTCTTTGCCGTGGAGATGGTGGTGAAGATGGTGGCCTTGGGC\nATCTTTGGGAAAAAGTGTTACCTGGGAGACACTTGGAACCGGCTTGACTTTTTCATCGTC\nATCGCAGGGATGCTGGAGTACTCGCTGGACCTGCAGAACGTCAGCTTCTCAGCTGTCAGG\nACAGTCCGTGTGCTGCGACCGCTCAGGGCCATTAACCGGGTGCCCAGCATGCGCATCCTT\nGTCACGTTGCTGCTGGATACGCTGCCCATGCTGGGCAACGTCCTGCTGCTCTGCTTCTTC\nGTCTTCTTCATCTTCGGCATCGTCGGCGTCCAGCTGTGGGCAGGGCTGCTTCGGAACCGA\nTGCTTCCTACCTGAGAATTTCAGCCTCCCCCTGAGCGTGGACCTGGAGCGCTATTACCAG\nACAGAGAACGAGGATGAGAGCCCCTTCATCTGCTCCCAGCCACGCGAGAACGGCATGCGG\nTCCTGCAGAAGCGTGCCCACGCTGCGCGGGGACGGGGGCGGTGGCCCACCTTGCGGTCTG\nGACTATGAGGCCTACAACAGCTCCAGCAACACCACCTGTGTCAACTGGAACCAGTACTAC\nACCAACTGCTCAGCGGGGGAGCACAACCCCTTCAAGGGCGCCATCAACTTTGACAACATT\nGGCTATGCCTGGATCGCCATCTTCCAGGTCATCACGCTGGAGGGCTGGGTCGACATCATG\nTACTTTGTGATGGATGCTCATTCCTTCTACAATTTCATCTACTTCATCCTCCTCATCATC\nGTGGGCTCCTTCTTCATGATCAACCTGTGCCTGGTGGTGATTGCCACGCAGTTCTCAGAG\nACCAAGCAGCGGGAAAGCCAGCTGATGCGGGAGCAGCGTGTGCGGTTCCTGTCCAACGCC\nAGCACCCTGGCTAGCTTCTCTGAGCCCGGCAGCTGCTATGAGGAGCTGCTCAAGTACCTG\nGTGTACATCCTTCGTAAGGCAGCCCGCAGGCTGGCTCAGGTCTCTCGGGCAGCAGGTGTG\nCGGGTTGGGCTGCTCAGCAGCCCAGCACCCCTCGGGGGCCAGGAGACCCAGCCCAGCAGC\nAGCTGCTCTCGCTCCCACCGCCGCCTATCCGTCCACCACCTGGTGCACCACCACCACCAC\nCATCACCACCACTACCACCTGGGCAATGGGACGCTCAGGGCCCCCCGGGCCAGCCCGGAG\nATCCAGGACAGGGATGCCAATGGGTCCCGCCGGCTCATGCTGCCACCACCCTCGACGCCT\nGCCCTCTCCGGGGCCCCCCCTGGTGGCGCAGAGTCTGTGCACAGCTTCTACCATGCCGAC\nTGCCACTTAGAGCCAGTCCGCTGCCAGGCGCCCCCTCCCAGGTCCCCATCTGAGGCATCC\nGGCAGGACTGTGGGCAGCGGGAAGGTGTATCCCACCGTGCACACCAGCCCTCCACCGGAG\nACGCTGAAGGAGAAGGCACTAGTAGAGGTGGCTGCCAGCTCTGGGCCCCCAACCCTCACC\nAGCCTCAACATCCCACCCGGGCCCTACAGCTCCATGCACAAGCTGCTGGAGACACAGAGT\nACAGGTGCCTGCCAAAGCTCTTGCAAGATCTCCAGCCCTTGCTTGAAAGCAGACAGTGGA\nGCCTGTGGTCCAGACAGCTGCCCCTACTGTGCCCGGGCCGGGGCAGGGGAGGTGGAGCTC\nGCCGACCGTGAAATGCCTGACTCAGACAGCGAGGCAGTTTATGAGTTCACACAGGATGCC\nCAGCACAGCGACCTCCGGGACCCCCACAGCCGGCGGCAACGGAGCCTGGGCCCAGATGCA\nGAGCCCAGCTCTGTGCTGGCCTTCTGGAGGCTAATCTGTGACACCTTCCGAAAGATTGTG\nGACAGCAAGTACTTTGGCCGGGGAATCATGATCGCCATCCTGGTCAACACACTCAGCATG\nGGCATCGAATACCACGAGCAGCCCGAGGAGCTTACCAACGCCCTAGAAATCAGCAACATC\nGTCTTCACCAGCCTCTTTGCCCTGGAGATGCTGCTGAAGCTGCTTGTGTATGGTCCCTTT\nGGCTACATCAAGAATCCCTACAACATCTTCGATGGTGTCATTGTGGTCATCAGCGTGTGG\nGAGATCGTGGGCCAGCAGGGGGGCGGCCTGTCGGTGCTGCGGACCTTCCGCCTGATGCGT\nGTGCTGAAGCTGGTGCGCTTCCTGCCGGCGCTGCAGCGGCAGCTGGTGGTGCTCATGAAG\nACCATGGACAACGTGGCCACCTTCTGCATGCTGCTTATGCTCTTCATCTTCATCTTCAGC\nATCCTGGGCATGCATCTCTTCGGCTGCAAGTTTGCCTCTGAGCGGGATGGGGACACCCTG\nCCAGACCGGAAGAATTTTGACTCCTTGCTCTGGGCCATCGTCACTGTCTTTCAGATCCTG\nACCCAGGAGGACTGGAACAAAGTCCTCTACAATGGTATGGCCTCCACGTCGTCCTGGGCG\nGCCCTTTATTTCATTGCCCTCATGACCTTCGGCAACTACGTGCTCTTCAATTTGCTGGTC\nGCCATTCTGGTGGAGGGCTTCCAGGCGGAGGAAATCAGCAAACGGGAAGATGCGAGTGGA\nCAGTTAAGCTGTATTCAGCTGCCTGTCGACTCCCAGGGGGGAGATGCCAACAAGTCCGAA\nTCAGAGCCCGATTTCTTCTCACCCAGCCTGGATGGTGATGGGGACAGGAAGAAGTGCTTG\nGCCTTGGTGTCCCTGGGAGAGCACCCGGAGCTGCGGAAGAGCCTGCTGCCGCCTCTCATC\nATCCACACGGCCGCCACACCCATGTCGCTGCCCAAGAGCACCAGCACGGGCCTGGGCGAG\nGCGCTGGGCCCTGCGTCGCGCCGCACCAGCAGCAGCGGGTCGGCAGAGCCTGGGGCGGCC\nCACGAGATGAAGTCACCGCCCAGCGCCCGCAGCTCTCCGCACAGCCCCTGGAGCGCTGCA\nAGCAGCTGGACCAGCAGGCGCTCCAGCCGGAACAGCCTCGGCCGTGCACCCAGCCTGAAG\nCGGAGAAGCCCAAGTGGAGAGCGGCGGTCCCTGTTGTCGGGAGAAGGCCAGGAGAGCCAG\nGATGAAGAGGAGAGCTCAGAAGAGGAGCGGGCCAGCCCTGCGGGCAGTGACCATCGCCAC\nAGGGGGTCCCTGGAGCGGGAGGCCAAGAGTTCCTTTGACCTGCCAGACACACTGCAGGTG\nCCAGGGCTGCATCGCACTGCCAGTGGCCGAGGGTCTGCTTCTGAGCACCAGGACTGCAAT\nGGCAAGTCGGCTTCAGGGCGCCTGGCCCGGGCCCTGCGGCCTGATGACCCCCCACTGGAT\nGGGGATGACGCCGATGACGAGGGCAACCTGAGCAAAGGGGAACGGGTCCGCGCGTGGATC\nCGAGCCCGACTCCCTGCCTGCTGCCTCGAGCGAGACTCCTGGTCAGCCTACATCTTCCCT\nCCTCAGTCCAGGTTCCGCCTCCTGTGTCACCGGATCATCACCCACAAGATGTTCGACCAC\nGTGGTCCTTGTCATCATCTTCCTTAACTGCATCACCATCGCCATGGAGCGCCCCAAAATT\nGACCCCCACAGCGCTGAACGCATCTTCCTGACCCTCTCCAATTACATCTTCACCGCAGTC\nTTTCTGGCTGAAATGACAGTGAAGGTGGTGGCACTGGGCTGGTGCTTCGGGGAGCAGGCG\nTACCTGCGGAGCAGTTGGAACGTGCTGGACGGGCTGTTGGTGCTCATCTCCGTCATCGAC\nATTCTGGTGTCCATGGTCTCTGACAGCGGCACCAAGATCCTGGGCATGCTGAGGGTGCTG\nCGGCTGCTGCGGACCCTGCGCCCGCTCAGGGTGATCAGCCGGGCGCAGGGGCTGAAGCTG\nGTGGTGGAGACGCTGATGTCCTCACTGAAACCCATCGGCAACATTGTAGTCATCTGCTGT\nGCCTTCTTCATCATTTTCGGCATCTTGGGGGTGCAGCTCTTCAAAGGGAAGTTTTTCGTG\nTGCCAGGGCGAGGATACCAGGAACATCACCAATAAATCGGACTGTGCCGAGGCCAGTTAC\nCGGTGGGTCCGGCACAAGTACAACTTTGACAACCTTGGCCAGGCCCTGATGTCCCTGTTC\nGTTTTGGCCTCCAAGGATGGTTGGGTGGACATCATGTACGATGGGCTGGATGCTGTGGGC\nGTGGACCAGCAGCCCATCATGAACCACAACCCCTGGATGCTGCTGTACTTCATCTCGTTC\nCTGCTCATTGTGGCCTTCTTTGTCCTGAACATGTTTGTGGGTGTGGTGGTGGAGAACTTC\nCACAAGTGTCGGCAGCACCAGGAGGAAGAGGAGGCCCGGCGGCGGGAGGAGAAGCGCCTA\nCGAAGACTGGAGAAAAAGAGAAGGAAAGCCCAGTGCAAACCTTACTACTCCGACTACTCC\nCGCTTCCGGCTCCTCGTCCACCACTTGTGCACCAGCCACTACCTGGACCTCTTCATCACA\nGGTGTCATCGGGCTGAACGTGGTCACCATGGCCATGGAGCACTACCAGCAGCCCCAGATT\nCTGGATGAGGCTCTGAAGATCTGCAACTACATCTTCACTGTCATCTTTGTCTTGGAGTCA\nGTTTTCAAACTTGTGGCCTTTGGTTTCCGTCGGTTCTTCCAGGACAGGTGGAACCAGCTG\nGACCTGGCCATTGTGCTGCTGTCCATCATGGGCATCACGCTGGAGGAAATCGAGGTCAAC\nGCCTCGCTGCCCATCAACCCCACCATCATCCGCATCATGAGGGTGCTGCGCATTGCCCGA\nGTGCTGAAGCTGCTGAAGATGGCTGTGGGCATGCGGGCGCTGCTGGACACGGTGATGCAG\nGCCCTGCCCCAGGTGGGGAACCTGGGACTTCTCTTCATGTTGTTGTTTTTCATCTTTGCA\nGCTCTGGGCGTGGAGCTCTTTGGAGACCTGGAGTGTGACGAGACACACCCCTGTGAGGGC\nCTGGGCCGTCATGCCACCTTTCGGAACTTTGGCATGGCCTTCCTAACCCTCTTCCGAGTC\nTCCACAGGTGACAATTGGAATGGCATTATGAAGGACACCCTCCGGGACTGTGACCAGGAG\nTCCACCTGCTACAACACGGTCATCTCGCCTATCTACTTTGTGTCCTTCGTGCTGACGGCC\nCAGTTCGTGCTAGTCAACGTGGTGATCGCCGTGCTGATGAAGCACCTGGAGGAGAGCAAC\nAAGGAGGCCAAGGAGGAGGCCGAGCTAGAGGCTGAGCTGGAGCTGGAGATGAAGACCCTC\nAGCCCCCAGCCCCACTCGCCACTGGGCAGCCCCTTCCTCTGGCCTGGGGTCGAGGGCCCC\nGACAGCCCCGACAGCCCCAAGCCTGGGGCTCTGCACCCAGCGGCCCACGCGAGATCAGCC\nTCCCACTTTTCCCTGGAGCACCCCACGGACAGGCAGCTGTTTGACACCATATCCCTGCTG\nATCCAGGGCTCCCTGGAGTGGGAGCTGAAGCTGATGGACGAGCTGGCAGGCCCAGGGGGC\nCAGCCCTCTGCCTTCCCTTCTGCCCCCAGCCTGGGAGGCTCCGACCCACAGATGCAGCCC\nCACCCCACGGAGCTGCCAGGACCAGACTTACTGACTGTGCGGAAGTCTGGGGTCAGCCGA\nACGCACTCTCTGCCCAATGACAGCTACATGTGTCGGCATGGGAGCACTGCCGAGGGGCCC\nCTGGGACACAGGGGCTGGGGGCTCCCCAAAGCTCAGTCAGGCTCCGTCTTGTCCGTTCAC\nTCCCAGCCAGCAGATACCAGCTACATCCTGCAGCTTCCCAAAGATGCACCTCATCTGCTC\nCAGCCCCACAGCGCCCCAACCTGGGGCACCATCCCCAAACTGCCCCCACCAGGACGCTCC\nCCTTTGGCTCAGAGGCCACTCAGGCGCCAGGCAGCAATAAGGACTGACTCCTTGGACGTT\nCAGGGTCTGGGCAGCCGGGAAGACCTGCTGGCAGAGGTGAGTGGGCCCTCCCCGCCCCTG\nGCCCGGGCCTACTCTTTCTGGGGCCAGTCAAGTACCCAGGCACAGCAGCACTCCCGCAGC\nCACAGCAAGATCTCCAAGCACATGACCCCGCCAGCCCCTTGCCCAGGCCCAGAACCCAAC\nTGGGGCAAGGGCCCTCCAGAGACCAGAAGCAGCTTAGAGTTGGACACGGAGCTGAGCTGG\nATTTCAGGAGACCTCCTGCCCCCTGGCGGCCAGGAGGAGCCCCCATCCCCACGGGACCTG\nAAGAAGTGCTACAGCGTGGAGGCCCAGAGCTGCCAGCGCCGGCCTACGTCCTGGCTGGAT\nGAGCAGAGGAGACACTCTATCGCCGTCAGCTGCCTGGACAGCGGCTCCCAACCCCACCTG\nGGCACAGACCCCTCTAACCTTGGGGGCCAGCCTCTTGGGGGGCCTGGGAGCCGGCCCAAG\nAAAAAACTCAGCCCGCCTAGTATCACCATAGACCCCCCCGAGAGCCAAGGTCCTCGGACC\nCCGCCCAGCCCTGGTATCTGCCTCCGGAGGAGGGCTCCGTCCAGCGACTCCAAGGATCCC\nTTGGCCTCTGGCCCCCCTGACAGCATGGCTGCCTCGCCCTCCCCAAAGAAAGATGTGCTG\nAGTCTCTCCGGTTTATCCTCTGACCCAGCAGACCTGGACCCCTGA'),('Voltage-dependent T-type calcium channel subunit alpha-1H','None','Human','Scaffold protein binding','Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1H gives rise to T-type calcium currents. T-type calcium channels belong to the \"low-voltage activated (LVA)\" group and are strongly blocked by nickel and mibefradil. A particularity of this type of channels is an opening at quite negative potentials, and a voltage-dependent inactivation. T-type channels serve pacemaking functions in both central neurons and cardiac nodal cells and support calcium signaling in secretory cells and vascular smooth muscle. They may also be involved in the modulation of firing patterns of neurons which is important for information processing as well as in cell growth processes.','CACNA1H','259160.2','DB14011','>lcl|BSEQ0010610|Voltage-dependent T-type calcium channel subunit alpha-1H (CACNA1H)\nATGACCGAGGGCGCACGGGCCGCCGACGAGGTCCGGGTGCCCCTGGGCGCGCCGCCCCCT\nGGCCCTGCGGCGTTGGTGGGGGCGTCCCCGGAGAGCCCCGGGGCGCCGGGACGCGAGGCG\nGAGCGGGGGTCCGAGCTCGGCGTGTCACCCTCCGAGAGCCCGGCGGCCGAGCGCGGCGCG\nGAGCTGGGTGCCGACGAGGAGCAGCGCGTCCCGTACCCGGCCTTGGCGGCCACGGTCTTC\nTTCTGCCTCGGTCAGACCACGCGGCCGCGCAGCTGGTGCCTCCGGCTGGTCTGCAACCCA\nTGGTTCGAGCACGTGAGCATGCTGGTAATCATGCTCAACTGCGTGACCCTGGGCATGTTC\nCGGCCCTGTGAGGACGTTGAGTGCGGCTCCGAGCGCTGCAACATCCTGGAGGCCTTTGAC\nGCCTTCATTTTCGCCTTTTTTGCGGTGGAGATGGTCATCAAGATGGTGGCCTTGGGGCTG\nTTCGGGCAGAAGTGTTACCTGGGTGACACGTGGAACAGGCTGGATTTCTTCATCGTCGTG\nGCGGGCATGATGGAGTACTCGTTGGACGGACACAACGTGAGCCTCTCGGCTATCAGGACC\nGTGCGGGTGCTGCGGCCCCTCCGCGCCATCAACCGCGTGCCTAGCATGCGGATCCTGGTC\nACTCTGCTGCTGGATACGCTGCCCATGCTCGGGAACGTCCTTCTGCTGTGCTTCTTCGTC\nTTCTTCATTTTCGGCATCGTTGGCGTCCAGCTCTGGGCTGGCCTCCTGCGGAACCGCTGC\nTTCCTGGACAGTGCCTTTGTCAGGAACAACAACCTGACCTTCCTGCGGCCGTACTACCAG\nACGGAGGAGGGCGAGGAGAACCCGTTCATCTGCTCCTCACGCCGAGACAACGGCATGCAG\nAAGTGCTCGCACATCCCCGGCCGCCGCGAGCTGCGCATGCCCTGCACCCTGGGCTGGGAG\nGCCTACACGCAGCCGCAGGCCGAGGGGGTGGGCGCTGCACGCAACGCCTGCATCAACTGG\nAACCAGTACTACAACGTGTGCCGCTCGGGTGACTCCAACCCCCACAACGGTGCCATCAAC\nTTCGACAACATCGGCTACGCCTGGATTGCCATCTTCCAGGTGATCACGCTGGAAGGCTGG\nGTGGACATCATGTACTACGTCATGGACGCCCACTCATTCTACAACTTCATCTATTTCATC\nCTGCTCATCATCGTGGGCTCCTTCTTCATGATCAACCTGTGCCTGGTGGTGATTGCCACG\nCAGTTCTCGGAGACGAAGCAGCGGGAGAGTCAGCTGATGCGGGAGCAGCGGGCACGCCAC\nCTGTCCAACGACAGCACGCTGGCCAGCTTCTCCGAGCCTGGCAGCTGCTACGAAGAGCTG\nCTGAAGTACGTGGGCCACATATTCCGCAAGGTCAAGCGGCGCAGCTTGCGCCTCTACGCC\nCGCTGGCAGAGCCGCTGGCGCAAGAAGGTGGACCCCAGTGCTGTGCAAGGCCAGGGTCCC\nGGGCACCGCCAGCGCCGGGCAGGCAGGCACACAGCCTCGGTGCACCACCTGGTCTACCAC\nCACCATCACCACCACCACCACCACTACCATTTCAGCCATGGCAGCCCCCGCAGGCCCGGC\nCCCGAGCCAGGCGCCTGCGACACCAGGCTGGTCCGAGCTGGCGCGCCCCCCTCGCCACCT\nTCCCCAGGCCGCGGACCCCCCGACGCAGAGTCTGTGCACAGCATCTACCATGCCGACTGC\nCACATAGAGGGGCCGCAGGAGAGGGCCCGGGTGGCACATGCCGCAGCCACTGCCGCTGCC\nAGCCTCAGACTGGCCACAGGGCTGGGCACCATGAACTACCCCACGATCCTGCCCTCAGGG\nGTGGGCAGCGGCAAAGGCAGCACCAGCCCCGGACCCAAGGGGAAGTGGGCCGGTGGACCG\nCCAGGCACCGGGGGGCACGGCCCGTTGAGCTTGAACAGCCCTGATCCCTACGAGAAGATC\nCCGCATGTGGTCGGGGAGCATGGACTGGGCCAGGCCCCTGGCCATCTGTCGGGCCTCAGT\nGTGCCCTGCCCCCTGCCCAGCCCCCCAGCGGGCACACTGACCTGTGAGCTGAAGAGCTGC\nCCGTACTGCACCCGTGCCCTGGAGGACCCGGAGGGTGAGCTCAGCGGCTCGGAAAGTGGA\nGACTCAGATGGCCGTGGCGTCTATGAATTCACGCAGGACGTCCGGCACGGTGACCGCTGG\nGACCCCACGCGACCACCCCGTGCGACGGACACACCAGGCCCAGGCCCAGGCAGCCCCCAG\nCGGCGGGCACAGCAGAGGGCAGCCCCGGGCGAGCCAGGCTGGATGGGCCGCCTCTGGGTT\nACCTTCAGCGGCAAGCTGCGCCGCATCGTGGACAGCAAGTACTTCAGCCGTGGCATCATG\nATGGCCATCCTTGTCAACACGCTGAGCATGGGCGTGGAGTACCATGAGCAGCCCGAGGAG\nCTGACTAATGCTCTGGAGATCAGCAACATCGTGTTCACCAGCATGTTTGCCCTGGAGATG\nCTGCTGAAGCTGCTGGCCTGCGGCCCTCTGGGCTACATCCGGAACCCGTACAACATCTTC\nGACGGCATCATCGTGGTCATCAGCGTCTGGGAGATCGTGGGGCAGGCGGACGGTGGCTTG\nTCTGTGCTGCGCACCTTCCGGCTGCTGCGTGTGCTGAAGCTGGTGCGCTTTCTGCCAGCC\nCTGCGGCGCCAGCTCGTGGTGCTGGTGAAGACCATGGACAACGTGGCTACCTTCTGCACG\nCTGCTCATGCTCTTCATTTTCATCTTCAGCATCCTGGGCATGCACCTTTTCGGCTGCAAG\nTTCAGCCTGAAGACAGACACCGGAGACACCGTGCCTGACAGGAAGAACTTCGACTCCCTG\nCTGTGGGCCATCGTCACCGTGTTCCAGATCCTGACCCAGGAGGACTGGAACGTGGTCCTG\nTACAACGGCATGGCCTCCACCTCCTCCTGGGCCGCCCTCTACTTCGTGGCCCTCATGACC\nTTCGGCAACTATGTGCTCTTCAACCTGCTGGTGGCCATCCTCGTGGAGGGCTTCCAGGCG\nGAGGGCGATGCCAACAGATCCGACACGGACGAGGACAAGACGTCGGTCCACTTCGAGGAG\nGACTTCCACAAGCTCAGAGAACTCCAGACCACAGAGCTGAAGATGTGTTCCCTGGCCGTG\nACCCCCAACGGGCACCTGGAGGGACGAGGCAGCCTGTCCCCTCCCCTCATCATGTGCACA\nGCTGCCACGCCCATGCCTACCCCCAAGAGCTCACCATTCCTGGATGCAGCCCCCAGCCTC\nCCAGACTCTCGGCGTGGCAGCAGCAGCTCCGGGGACCCGCCACTGGGAGACCAGAAGCCT\nCCGGCCAGCCTCCGAAGTTCTCCCTGTGCCCCCTGGGGCCCCAGTGGCGCCTGGAGCAGC\nCGGCGCTCCAGCTGGAGCAGCCTGGGCCGTGCCCCCAGCCTCAAGCGCCGCGGCCAGTGT\nGGGGAACGTGAGTCCCTGCTGTCTGGCGAGGGCAAGGGCAGCACCGACGACGAAGCTGAG\nGACGGCAGGGCCGCGCCCGGGCCCCGTGCCACCCCACTGCGGCGGGCCGAGTCCCTGGAC\nCCACGGCCCCTGCGGCCGGCCGCCCTCCCGCCTACCAAGTGCCGCGATCGCGACGGGCAG\nGTGGTGGCCCTGCCCAGCGACTTCTTCCTGCGCATCGACAGCCACCGTGAGGATGCAGCC\nGAGCTTGACGACGACTCGGAGGACAGCTGCTGCCTCCGCCTGCATAAAGTGCTGGAGCCC\nTACAAGCCCCAGTGGTGCCGGAGCCGCGAGGCCTGGGCCCTCTACCTCTTCTCCCCACAG\nAACCGGTTCCGCGTCTCCTGCCAGAAGGTCATCACACACAAGATGTTTGATCACGTGGTC\nCTCGTCTTCATCTTCCTCAACTGCGTCACCATCGCCCTGGAGAGGCCTGACATTGATCCC\nGGCAGCACCGAGCGGGTCTTCCTCAGCGTCTCCAATTACATCTTCACGGCCATCTTCGTG\nGCGGAGATGATGGTGAAGGTGGTGGCCCTGGGGCTGCTGTCCGGCGAGCACGCCTACCTG\nCAGAGCAGCTGGAACCTGCTGGATGGGCTGCTGGTGCTGGTGTCCCTGGTGGACATTGTC\nGTGGCCATGGCCTCGGCTGGTGGCGCCAAGATCCTGGGTGTTCTGCGCGTGCTGCGTCTG\nCTGCGGACCCTGCGGCCTCTGAGGGTCATCAGCCGGGCCCCGGGCCTCAAGCTGGTGGTG\nGAGACGCTGATATCATCACTCAGGCCCATTGGGAACATCGTCCTCATCTGCTGCGCCTTC\nTTCATCATTTTTGGCATTTTGGGTGTGCAGCTCTTCAAAGGGAAGTTCTACTACTGCGAG\nGGCCCCGACACCAGGAACATCTCCACCAAGGCACAGTGCCGGGCCGCCCACTACCGCTGG\nGTGCGACGCAAGTACAACTTCGACAACCTGGGCCAGGCCCTGATGTCGCTGTTCGTGCTG\nTCATCCAAGGATGGATGGGTGAACATCATGTACGACGGGCTGGATGCCGTGGGTGTCGAC\nCAGCAGCCTGTGCAGAACCACAACCCCTGGATGCTGCTGTACTTCATCTCCTTCCTGCTC\nATCGTCAGCTTCTTCGTGCTCAACATGTTCGTGGGCGTCGTGGTCGAGAACTTCCACAAG\nTGCCGGCAGCACCAGGAGGCGGAGGAGGCGCGGCGGCGAGAGGAGAAGCGGCTGCGGCGC\nCTAGAGAGGAGGCGCAGGAAGGCCCAGCGCCGGCCCTACTATGCCGACTACTCGCCCACG\nCGCCGCTCCATTCACTCGCTGTGCACCAGCCACTATCTCGACCTCTTCATCACCTTCATC\nATCTGTGTCAACGTCATCACCATGTCCATGGAGCACTATAACCAACCCAAGTCGCTGGAC\nGAGGCCCTCAAGTACTGCAACTACGTCTTCACCATCGTGTTTGTCTTCGAGGCTGCACTG\nAAGCTGGTAGCATTTGGGTTCCGTCGGTTCTTCAAGGACAGGTGGAACCAGCTGGACCTG\nGCCATCGTGCTGCTGTCACTCATGGGCATCACGCTGGAGGAGATAGAGATGAGCGCCGCG\nCTGCCCATCAACCCCACCATCATCCGCATCATGCGCGTGCTTCGCATTGCCCGTGTGCTG\nAAGCTGCTGAAGATGGCTACGGGCATGCGCGCCCTGCTGGACACTGTGGTGCAAGCTCTC\nCCCCAGGTGGGGAACCTGGGCCTTCTTTTCATGCTCCTGTTTTTTATCTATGCTGCGCTG\nGGAGTGGAGCTGTTCGGGAGGCTGGAGTGCAGTGAAGACAACCCCTGCGAGGGCCTGAGC\nAGGCACGCCACCTTCAGCAACTTCGGCATGGCCTTCCTCACGCTGTTCCGCGTGTCCACG\nGGGGACAACTGGAACGGGATCATGAAGGACACGCTGCGCGAGTGCTCCCGTGAGGACAAG\nCACTGCCTGAGCTACCTGCCGGCCCTGTCGCCCGTCTACTTCGTGACCTTCGTGCTGGTG\nGCCCAGTTCGTGCTGGTGAACGTGGTGGTGGCCGTGCTCATGAAGCACCTGGAGGAGAGC\nAACAAGGAGGCACGGGAGGATGCGGAGCTGGACGCCGAGATCGAGCTGGAGATGGCGCAG\nGGCCCCGGGAGTGCACGCCGGGTGGACGCGGACAGGCCTCCCTTGCCCCAGGAGAGTCCG\nGGCGCCAGGGACGCCCCAAACCTGGTTGCACGCAAGGTGTCCGTGTCCAGGATGCTCTCG\nCTGCCCAACGACAGCTACATGTTCAGGCCCGTGGTGCCTGCCTCGGCGCCCCACCCCCGC\nCCGCTGCAGGAGGTGGAGATGGAGACCTATGGGGCCGGCACCCCCTTGGGCTCCGTTGCC\nTCTGTGCACTCTCCGCCCGCAGAGTCCTGTGCCTCCCTCCAGATCCCATTGGCTGTGTCG\nTCCCCAGCCAGGAGCGGCGAGCCCCTCCACGCCCTGTCCCCTCGGGGCACAGCCCGCTCC\nCCCAGTCTCAGCCGGCTGCTCTGCAGACAGGAGGCTGTGCACACCGATTCCTTGGAAGGG\nAAGATTGACAGCCCTAGGGACACCCTGGATCCTGCAGAGCCTGGTGAGAAAACCCCGGTG\nAGGCCGGTGACCCAGGGGGGCTCCCTGCAGTCCCCACCACGCTCCCCACGGCCCGCCAGC\nGTCCGCACTCGTAAGCATACCTTCGGACAGCGCTGCGTCTCCAGCCGGCCGGCGGCCCCA\nGGCGGAGAGGAGGCCGAGGCCTCGGACCCAGCCGACGAGGAGGTCAGCCACATCACCAGC\nTCCGCCTGCCCCTGGCAGCCCACAGCCGAGCCCCATGGCCCCGAAGCCTCTCCGGTGGCC\nGGCGGCGAGCGGGACCTGCGCAGGCTCTACAGCGTGGATGCTCAGGGCTTCCTGGACAAG\nCCGGGCCGGGCAGACGAGCAGTGGCGGCCCTCGGCGGAGCTGGGCAGCGGGGAGCCTGGG\nGAGGCGAAGGCCTGGGGCCCTGAGGCCGAGCCCGCTCTGGGTGCGCGCAGAAAGAAGAAG\nATGAGCCCCCCCTGCATCTCGGTGGAACCCCCTGCGGAGGACGAGGGCTCTGCGCGGCCC\nTCCGCGGCAGAGGGCGGCAGCACCACACTGAGGCGCAGGACCCCGTCCTGTGAGGCCACG\nCCTCACAGGGACTCCCTGGAGCCCACAGAGGGCTCAGGCGCCGGGGGGGACCCTGCAGCC\nAAGGGGGAGCGCTGGGGCCAGGCCTCCTGCCGGGCTGAGCACCTGACCGTCCCCAGCTTT\nGCCTTTGAGCCGCTGGACCTCGGGGTCCCCAGTGGAGACCCTTTCTTGGACGGTAGCCAC\nAGTGTGACCCCAGAATCCAGAGCTTCCTCTTCAGGGGCCATAGTGCCCCTGGAACCCCCA\nGAATCAGAGCCTCCCATGCCCGTCGGTGACCCCCCAGAGAAGAGGCGGGGGCTGTACCTC\nACAGTCCCCCAGTGTCCTCTGGAGAAACCAGGGTCCCCCTCAGCCACCCCTGCCCCAGGG\nGGTGGTGCAGATGACCCCGTGTAG'),('Voltage-dependent T-type calcium channel subunit alpha-1I','None','Human','Voltage-gated calcium channel activity','Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. Isoform alpha-1I gives rise to T-type calcium currents. T-type calcium channels belong to the \"low-voltage activated (LVA)\" group and are strongly blocked by nickel and mibefradil. A particularity of this type of channels is an opening at quite negative potentials, and a voltage-dependent inactivation. T-type channels serve pacemaking functions in both central neurons and cardiac nodal cells and support calcium signaling in secretory cells and vascular smooth muscle. They may also be involved in the modulation of firing patterns of neurons which is important for information processing as well as in cell growth processes. Gates in voltage ranges similar to, but higher than alpha 1G or alpha 1H (By similarity).','CACNA1I','245100.8','DB14011','>lcl|BSEQ0015995|Voltage-dependent T-type calcium channel subunit alpha-1I (CACNA1I)\nATGGCTGAGAGCGCCTCCCCGCCCTCCTCATCTGCAGCAGCCCCAGCCGCTGAGCCAGGA\nGTCACCACGGAGCAGCCCGGACCCCGGAGCCCCCCATCCTCCCCGCCAGGCCTGGAGGAG\nCCTCTGGATGGAGCTGATCCTCATGTCCCACACCCAGACCTGGCGCCTATTGCCTTCTTC\nTGCCTGCGACAGACCACCAGCCCCCGGAACTGGTGCATCAAGATGGTGTGCAACCCGTGG\nTTTGAATGTGTCAGCATGCTGGTGATCCTGCTGAACTGCGTGACACTTGGCATGTACCAG\nCCGTGCGACGACATGGACTGCCTGTCCGACCGCTGCAAGATCCTGCAGGTCTTTGATGAC\nTTCATCTTTATCTTCTTTGCCATGGAGATGGTGCTCAAGATGGTGGCCCTGGGGATTTTT\nGGCAAGAAGTGCTACCTCGGGGACACATGGAACCGCCTGGATTTCTTCATCGTCATGGCA\nGGGATGGTCGAGTACTCCCTGGACCTTCAGAACATCAACCTGTCAGCCATCCGCACCGTG\nCGCGTCCTGAGGCCCCTCAAAGCCATCAACCGCGTGCCCAGTATGCGGATCCTGGTGAAC\nCTGCTCCTGGACACACTGCCCATGCTGGGGAATGTCCTGCTGCTCTGCTTCTTTGTCTTC\nTTCATCTTTGGCATCATAGGTGTGCAGCTCTGGGCGGGCCTGCTGCGTAACCGCTGCTTC\nCTGGAGGAGAACTTCACCATACAAGGGGATGTGGCCTTGCCCCCATACTACCAGCCGGAG\nGAGGATGATGAGATGCCCTTCATCTGCTCCCTGTCGGGCGACAATGGGATAATGGGCTGC\nCATGAGATCCCCCCGCTCAAGGAGCAGGGCCGTGAGTGCTGCCTGTCCAAGGACGACGTC\nTACGACTTTGGGGCGGGGCGCCAGGACCTCAATGCCAGCGGCCTCTGTGTCAACTGGAAC\nCGTTACTACAATGTGTGCCGCACGGGCAGCGCCAACCCCCACAAGGGTGCCATCAACTTT\nGACAACATCGGTTATGCTTGGATTGTCATCTTCCAGGTGATCACTCTGGAAGGCTGGGTG\nGAGATCATGTACTACGTGATGGATGCTCACTCCTTCTACAACTTCATCTACTTCATCCTG\nCTTATCATAGTGGGCTCCTTCTTCATGATCAACCTGTGCCTCGTTGTCATAGCGACCCAG\nTTCTCGGAGACCAAGCAACGGGAGCACCGGCTGATGCTGGAGCAGCGGCAGCGCTACCTG\nTCCTCCAGCACGGTGGCCAGCTACGCCGAGCCTGGCGACTGCTACGAGGAGATCTTCCAG\nTATGTCTGCCACATCCTGCGCAAGGCCAAGCGCCGCGCCCTGGGCCTCTACCAGGCCCTG\nCAGAGCCGGCGCCAGGCCCTGGGCCCGGAGGCCCCGGCCCCCGCCAAACCTGGGCCCCAC\nGCCAAGGAGCCCCGGCACTACCAGCTGTGCCCGCAACATAGCCCCCTGGATGCGACGCCC\nCACACCCTGGTGCAGCCCATCCCCGCCACGCTGGCTTCCGATCCCGCCAGCTGCCCTTGC\nTGCCAGCATGAGGACGGCCGGCGGCCCTCGGGCCTGGGCAGCACCGACTCGGGCCAGGAG\nGGCTCGGGCTCCGGGAGCTCCGCTGGTGGCGAGGACGAGGCGGATGGGGACGGGGCCCGG\nAGCAGCGAGGACGGAGCCTCCTCAGAACTGGGGAAGGAGGAGGAGGAGGAGGAGCAGGCG\nGATGGGGCGGTCTGGCTGTGCGGGGATGTGTGGCGGGAGACGCGAGCCAAGCTGCGCGGC\nATCGTGGACAGCAAGTACTTCAACCGGGGCATCATGATGGCCATCCTGGTCAACACCGTC\nAGCATGGGCATCGAGCACCACGAGCAGCCGGAGGAGCTGACCAACATCCTGGAGATCTGC\nAATGTGGTCTTCACCAGCATGTTTGCCCTGGAGATGATCCTGAAGCTGGCTGCATTTGGG\nCTCTTCGACTACCTGCGTAACCCCTACAACATCTTCGACAGCATCATTGTCATCATCAGC\nATCTGGGAGATTGTGGGGCAGGCGGACGGTGGGCTGTCGGTGCTGCGGACCTTCCGGCTG\nCTGCGCGTGCTGAAACTGGTGCGCTTCATGCCTGCCCTGCGGCGCCAGCTCGTGGTGCTC\nATGAAGACCATGGACAACGTGGCCACCTTCTGCATGCTGCTCATGCTCTTCATCTTCATC\nTTCAGCATCCTTGGGATGCATATTTTTGGCTGCAAGTTCAGCCTCCGCACGGACACTGGA\nGACACGGTGCCCGACAGGAAGAACTTCGACTCCCTGCTGTGGGCCATCGTCACTGTGTTC\nCAGATCCTCACCCAGGAGGACTGGAACGTCGTTCTCTACAATGGCATGGCCTCCACTTCT\nCCCTGGGCCTCCCTCTACTTTGTCGCCCTCATGACCTTCGGCAACTATGTGCTCTTCAAC\nCTGCTGGTGGCCATCCTGGTGGAGGGCTTCCAGGCGGAGGGTGACGCCAATCGCTCCTAC\nTCGGACGAGGACCAGAGCTCATCCAACATAGAAGAGTTTGATAAGCTCCAGGAAGGCCTG\nGACAGCAGCGGAGATCCCAAGCTCTGCCCAATCCCCATGACCCCCAATGGGCACCTGGAC\nCCCAGTCTCCCACTGGGTGGGCACCTAGGTCCTGCTGGGGCTGCGGGACCTGCCCCCCGA\nCTCTCACTGCAGCCGGACCCCATGCTGGTGGCCCTGGGCTCCCGAAAGAGCAGTGTCATG\nTCTCTAGGGAGGATGAGCTATGACCAGCGCTCCCTGTCCAGCTCCCGGAGCTCCTACTAC\nGGGCCATGGGGCCGCAGCGCGGCCTGGGCCAGCCGTCGCTCCAGCTGGAACAGCCTCAAG\nCACAAGCCGCCGTCGGCGGAGCATGAGTCCCTGCTCTCTGCGGAGCGCGGCGGCGGCGCC\nCGGGTCTGCGAGGTTGCCGCGGACGAGGGGCCGCCGCGGGCCGCACCCCTGCACACCCCA\nCACGCCCACCACATTCATCACGGGCCCCATCTGGCGCACCGCCACCGCCACCACCGCCGG\nACGCTGTCCCTCGACAACAGGGACTCGGTGGACCTGGCCGAGCTGGTGCCCGCGGTGGGC\nGCCCACCCCCGGGCCGCCTGGAGGGCGGCAGGCCCGGCCCCCGGGCATGAGGACTGCAAT\nGGCAGGATGCCCAGCATCGCCAAAGACGTCTTCACCAAGATGGGCGACCGCGGGGATCGC\nGGGGAGGATGAGGAGGAAATCGACTACACCCTGTGCTTCCGCGTCCGCAAGATGATCGAC\nGTCTATAAGCCCGACTGGTGCGAGGTCCGCGAAGACTGGTCTGTCTACCTCTTCTCTCCC\nGAGAACAGGTTCCGGGTCCTGTGTCAGACCATTATTGCCCACAAACTCTTCGACTACGTC\nGTCCTGGCCTTCATCTTTCTCAACTGCATCACCATCGCCCTGGAGCGGCCTCAGATCGAG\nGCCGGCAGCACCGAACGCATCTTTCTCACCGTGTCCAACTACATCTTCACGGCCATCTTC\nGTGGGCGAGATGACATTGAAGGTAGTCTCGCTGGGCCTGTACTTCGGCGAGCAGGCGTAC\nCTACGCAGCAGCTGGAACGTGCTGGATGGCTTTCTTGTCTTCGTGTCCATCATCGACATC\nGTGGTGTCCCTGGCCTCAGCCGGGGGAGCCAAGATCTTGGGGGTCCTCCGAGTCTTGCGG\nCTCCTGCGCACCCTACGCCCCCTGCGTGTCATCAGCCGGGCGCCGGGCCTGAAGCTGGTG\nGTGGAGACACTCATCTCCTCCCTCAAGCCCATCGGCAACATCGTGCTCATCTGCTGTGCC\nTTCTTCATCATCTTTGGCATCCTGGGAGTGCAGCTCTTCAAGGGCAAGTTCTACCACTGT\nCTGGGCGTGGACACCCGCAACATCACCAACCGCTCGGACTGCATGGCCGCCAACTACCGC\nTGGGTCCATCACAAATACAACTTCGACAACCTGGGCCAGGCTCTGATGTCCCTCTTTGTC\nCTGGCATCCAAGGATGGTTGGGTGAACATCATGTACAATGGACTGGATGCTGTTGCTGTG\nGACCAGCAGCCTGTGACCAACCACAACCCCTGGATGCTGCTGTACTTCATCTCCTTCCTG\nCTCATCGTCAGCTTCTTTGTGCTCAACATGTTTGTGGGTGTCGTGGTGGAGAACTTCCAC\nAAGTGCCGGCAGCACCAGGAGGCTGAAGAGGCACGGCGGCGTGAGGAGAAGCGGCTGCGG\nCGCCTGGAGAAGAAGCGCCGGAAGGCCCAGCGGCTGCCCTACTATGCCACCTATTGTCAC\nACCCGGCTGCTCATCCACTCCATGTGCACCAGCCACTACCTGGACATCTTCATCACCTTC\nATCATCTGCCTCAACGTGGTCACCATGTCCCTGGAGCACTACAATCAGCCCACGTCCCTG\nGAGACAGCCCTCAAGTACTGCAACTATATGTTCACCACTGTCTTTGTGCTGGAGGCTGTG\nCTGAAGCTGGTGGCATTTGGTCTGAGGCGCTTCTTCAAGGACCGATGGAACCAGCTGGAC\nCTGGCCATTGTGCTACTGTCAGTCATGGGCATCACCCTGGAGGAGATCGAGATCAATGCG\nGCCCTGCCCATCAATCCCACCATCATCCGCATCATGAGGGTTCTGCGCATTGCCCGAGTG\nCTGAAGCTGTTGAAGATGGCCACAGGAATGCGGGCCCTGCTGGACACGGTGGTGCAAGCT\nTTGCCCCAGGTGGGCAACCTGGGCCTCCTCTTCATGCTGCTCTTCTTCATCTATGCTGCT\nCTCGGGGTGGAGCTCTTTGGGAAGCTGGTCTGCAACGACGAGAACCCGTGCGAGGGCATG\nAGCCGGCATGCCACCTTCGAGAACTTCGGCATGGCCTTCCTCACACTCTTCCAGGTCTCC\nACGGGTGACAACTGGAACGGGATCATGAAGGACACGCTGCGGGACTGCACCCACGACGAG\nCGCAGCTGCCTGAGCAGCCTGCAGTTTGTGTCGCCGCTGTACTTCGTGAGCTTCGTGCTC\nACCGCGCAGTTCGTGCTCATCAACGTGGTGGTGGCTGTGCTCATGAAGCACCTGGACGAC\nAGCAACAAGGAGGCGCAGGAGGACGCCGAGATGGATGCCGAGCTCGAGCTGGAGATGGCC\nCATGGCCTGGGCCCTGGCCCGAGGCTGCCTACCGGCTCCCCGGGCGCCCCTGGCCGAGGG\nCCGGGAGGGGCGGGCGGCGGGGGCGACACCGAGGGCGGCTTGTGCCGGCGCTGCTACTCG\nCCTGCCCAGGAGAACCTGTGGCTGGACAGCGTCTCTTTAATCATCAAGGACTCCTTGGAG\nGGGGAGCTGACCATCATCGACAACCTGTCGGGCTCCATCTTCCACCACTACTCCTCGCCT\nGCCGGCTGCAAGAAGTGTCACCACGACAAGCAAGAGGTGCAGCTGGCTGAGACGGAGGCC\nTTCTCCCTGAACTCAGACAGGTCCTCGTCCATCCTGCTGGGTGACGACCTGAGTCTCGAG\nGACCCCACAGCCTGCCCACCTGGCCGCAAAGACAGCAAGGGTGAGCTGGACCCACCTGAG\nCCCATGCGTGTGGGAGACCTGGGCGAATGCTTCTTCCCCTTGTCCTCTACGGCCGTCTCG\nCCGGATCCAGAGAACTTCCTGTGTGAGATGGAGGAGATCCCATTCAACCCTGTCCGGTCC\nTGGCTGAAACATGACAGCAGTCAAGCACCCCCAAGTCCCTTCTCCCCGGATGCCTCCAGC\nCCTCTCCTGCCCATGCCAGCCGAGTTCTTCCACCCTGCAGTGTCTGCCAGCCAGAAAGGC\nCCAGAAAAGGGCACTGGCACTGGAACCCTCCCCAAGATTGCGCTGCAGGGCTCCTGGGCA\nTCTCTGCGGTCACCAAGGGTCAACTGTACCCTCCTCCGGCAGGCCACCGGGAGCGACACG\nTCGCTGGACGCCAGCCCCAGCAGCTCCGCGGGCAGCCTGCAGACCACGCTCGAGGACAGC\nCTGACCCTGAGCGACAGCCCCCGGCGTGCCCTGGGGCCGCCCGCGCCTGCTCCAGGACCC\nCGGGCCGGCCTGTCCCCCGCCGCTCGCCGCCGCCTGAGCCTGCGCGGCCGGGGCCTCTTC\nAGCCTGCGGGGGCTGCGGGCGCATCAGCGCAGCCACAGCAGCGGGGGCTCCACCAGCCCG\nGGCTGCACCCACCACGACTCCATGGACCCCTCGGACGAGGAGGGCCGCGGTGGCGCGGGC\nGGCGGGGGCGCGGGCAGCGAGCACTCGGAGACCCTCAGCAGCCTCTCGCTCACCTCCCTC\nTTCTGCCCGCCGCCCCCGCCGCCAGCCCCCGGCCTCACGCCCGCCAGGAAGTTCAGCAGC\nACCAGCAGCCTGGCCGCCCCCGGCCGCCCCCACGCCGCCGCCCTGGCCCACGGCCTGGCC\nCGGAGCCCCTCGTGGGCCGCGGACCGCAGCAAGGACCCCCCCGGCCGGGCACCGCTGCCC\nATGGGCCTGGGCCCCTTGGCGCCCCCGCCGCAACCGCTCCCCGGAGAGCTGGAGCCGGGA\nGACGCCGCCAGCAAGAGGAAGAGATGA');

/*Table structure for table `kegg_disease` */

DROP TABLE IF EXISTS `kegg_disease`;

CREATE TABLE `kegg_disease` (
  `kegg_disease_link` varchar(200) NOT NULL,
  `kegg_disease_id` varchar(200) DEFAULT NULL,
  `kegg_disease_name` varchar(200) DEFAULT NULL,
  `Description` text,
  `Category` varchar(200) DEFAULT NULL,
  `kegg_disease_pathway_id` varchar(200) DEFAULT NULL,
  `kegg_disease_pathway_link` varchar(200) DEFAULT NULL,
  `img_pathway` varchar(200) DEFAULT NULL,
  `kegg_disease_pathway_name` varchar(200) DEFAULT NULL,
  PRIMARY KEY (`kegg_disease_link`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

/*Data for the table `kegg_disease` */

insert  into `kegg_disease`(`kegg_disease_link`,`kegg_disease_id`,`kegg_disease_name`,`Description`,`Category`,`kegg_disease_pathway_id`,`kegg_disease_pathway_link`,`img_pathway`,`kegg_disease_pathway_name`) values ('https://www.genome.jp/dbget-bin/www_bget?ds:H00017','H00017','Esophageal cancer','Esophageal cancer represents the 9th leading cancer in the world and is associated with a 5-year survival rate under 25%. The two main forms are squamous-cell carcinoma (ECSC) and adenocarcinoma (EAC). ECSC is the most frequent histological subtype in esophageal cancer, although the incidence of EAC is increasing faster than any other malignancy in the western world. Whereas ESCC can be attributed to alcohol and tobacco consumption, the most important risk factor for the development of EAC is duodenal-gastric-esophageal reflux. In the process of tumorigenesis at the cellular level, multiple genetic alterations are involved, including mutation of the p53 gene, amplification of cyclin D1 gene, among others.','Cancer','hsa05206','https://www.genome.jp/kegg-bin/show_pathway?hsa05206','H00017.png','MicroRNAs in cancer'),('https://www.genome.jp/dbget-bin/www_bget?ds:H00025','H00025','Penile cancer','Penile cancer is a disease with a high morbidity and mortality. Its prevalence is relatively rare in developed countries but more common in South America and East Africa. Squamous cell carcinoma (SCC) is the predominant tumor type in penile cancer, accounting for 95% of cases. Penile cancers are thought to arise from the progression of precursor lesions and can be subdivided into human papilloma virus (HPV) positive and HPV negative cases. Most common disrupted pathways, both in HPV-mediated and HPV-independent penile carcinogenesis, involve the p14ARF/MDM2/p53 and/or p16INK4a/cyclin D/Rb pathways. HPVs exert their oncogenic effect by expressing the oncoproteins E6 and E7, which bind to and inactivate the p53 and Rb tumor suppressor gene products, respectively. HPV independent mechanisms of pathway inactivation include silencing of the p16INK4a gene by promoter hypermethylation, somatic mutations of the p53 gene, over-expression of MDM2 and mutation of p14ARF. Several other molecular events include alterations in the activity and/or expression of ras and myc genes, cyclo-oxygenase-2 (COX) pathway and prostaglandin E2 synthase. These alterations have been described in both HPV-positive and -negative penile cancers.','Cancer','hsa05203','https://www.genome.jp/kegg-bin/show_pathway?hsa05203','H00025.png','Viral carcinogenesis'),('https://www.genome.jp/dbget-bin/www_bget?ds:H00046','H00046','Cholangiocarcinoma','Cholangiocarcinoma is a highly malignant neoplasm that carries a poor prognosis and lacks effective therapy. It is the second most common primary hepatic tumor, and it is increasing in incidence and carries a high mortality. The tumor arises from the ductular epithelium of the biliary tree, either within the liver (intrahepatic cholangiocarcinoma: ICC) or more commonly from the extrahepatic bile ducts (extrahepatic cholangiocarcinoma). Several studies have demonstrated mutations resulting in overexpression of K-ras and p53 genes. These genetic alterations are associated with a more aggressive phenotype in this cancer. Many reports have implicated overexpression of the tyrosine kinase proto-oncogenes c-erbB-2 (HER-2/neu) and c-Met, as well as cyclo-oxygenase-2 (COX-2) activity in intrahepatic cholangiocarcinoma.','Cancer','None','None','None','None'),('https://www.genome.jp/dbget-bin/www_bget?ds:H00775','H00775','Familial or sporadic hemiplegic migraine','Sporadic and familial hemiplegic migraines (SHM and FHM) are rare paroxysmal disorders characterized by motor aura and headache. The distinction is based on whether at least one first or second degree relative is also affected, otherwise the diagnostic criteria are similar. The majority of FHM families have a mutation in one of the ion channels CACNA1A, ATP1A2 and SCN1A. SHM is sometimes caused by a de novo mutation in one of the genes. However, at least a quarter of the large families affected and most sporadic cases do not have a mutation in the three genes known to be implicated in this disorder, suggesting that other genes are still to be identified.','Nervous system disease','hsa04010','https://www.genome.jp/kegg-bin/show_pathway?hsa04010+773','H00775.png','MAPK signaling pathway'),('https://www.genome.jp/dbget-bin/www_bget?ds:H00783','H00783','Febrile seizures','Febrile seizures (FS), or febrile convulsions (FEB), are acute symptomatic seizures that occur in response to fever and represent the most common form of childhood seizures. Generalized epilepsy with febrile seizures plus (GEFS+) is a familial epilepsy syndrome with a spectrum of phenotypes including FS. Severe epilepsy phenotypes such as Dravet syndrome (SMEI) have also been described within GEFS+ families. A significant genetic component exists for susceptibility to FS and GEFS+. Extensive genetic studies have shown that at least ten loci are responsible for FS. Furthermore, mutations in the voltage-gated sodium channel subunit genes (SCN1A, SCN2A and SCN1B) and the GABA(A) receptor subunit genes (GABRG2 and GABRD) have been identified in GEFS+.','Nervous system disease','hsa04728','https://www.genome.jp/kegg-bin/show_pathway?hsa04728+6323','H00783.png','Dopaminergic synapse'),('https://www.genome.jp/dbget-bin/www_bget?ds:H01611','H01611','Alcohol dependence','Alcohol dependence (AD) is a chronic but often disease that includes problems in controlling one\'s drinking, being preoccupied with alcohol, continuing to use alcohol even when it causes problems, having to drink more to get the same effect (physical dependence), or having withdrawal symptoms when one rapidly decreases or stops drinking. The contribution of genetic factors to the development of AD is high. The best classical candidate genes for AD are alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH). Both genes are involved in enzymatic degradation of alcohol. Recent genome-wide association studies (GWAS) have reported that the most robust associations for AD have been with such enzyme genes, especially ALDH2 in East Asian populations and ADH1B in European American and African American populations.','Mental and behavioural disorder','hsa05034','https://www.genome.jp/kegg-bin/show_pathway?hsa05034+1813','H01611.png',''),('https://www.genome.jp/dbget-bin/www_bget?ds:H01815','H01815','Malignant migrating partial seizures in infancy','Malignant migrating partial seizures in infancy (MMPSI) are rare, severe early infantile onset epileptic encephalopathy. The common clinical features are seizure onset within the first 6 months of life, occurrence of migrating polymorphic focal seizures, and progressive deterioration of psychomotor development. Seizures in MMPSI are refractory to conventional treatment with anti-epileptic drugs (AEDs). Early and multiple video/EEG recordings are critical to detect the characteristic multifocal and asynchronous long lasting ictal discharges and are essential for MMPSI diagnosis. MMPSI is a genetically heterogeneous disorder with few known etiologies. Recently, mutations of several genes have been reported in sporadic cases of MMPSI.','Nervous system disease','None','None','None','None'),('https://www.genome.jp/dbget-bin/www_bget?ds:H01818','H01818','Dravet syndrome','The Dravet syndrome is a rare form of epileptic encephalopathy, and is accompanied by impaired psychomotor and neurologic development, occurring in the first year of life in apparently normal infants. Patients typically present with febrile hemiclonic or generalised tonic-clonic status epilepticus, followed by the development of other seizure types including myoclonic, focal, absence and atonic seizures between 1-4 years. All seizure types are pharmacoresistent, but a trend toward less severe epilepsy and cognitive impairment is usually observed after the age of 5 years. Development is normal in the first year of life with subsequent developmental slowing and sometimes regression. Approximately 80% of patients have point mutations or small insertions or deletions in the SCN1A gene.','Nervous system disease','hsa04728','https://www.genome.jp/kegg-bin/show_pathway?hsa04728+6323','H01818.png','Dopaminergic synapse');

/*Table structure for table `kegg_disease_gene` */

DROP TABLE IF EXISTS `kegg_disease_gene`;

CREATE TABLE `kegg_disease_gene` (
  `hsa_str` varchar(200) NOT NULL,
  `kegg_disease_link` varchar(200) DEFAULT NULL,
  `kegg_id` varchar(200) DEFAULT NULL,
  PRIMARY KEY (`hsa_str`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

/*Data for the table `kegg_disease_gene` */

insert  into `kegg_disease_gene`(`hsa_str`,`kegg_disease_link`,`kegg_id`) values ('(FEB3A/GEFS+2/SMEI) SCN1A [HSA:6323] [KO:K04833]','https://www.genome.jp/dbget-bin/www_bget?ds:H00783','H00783'),('(FEB3B/GEFS+7) SCN9A [HSA:6335] [KO:K04841]','https://www.genome.jp/dbget-bin/www_bget?ds:H00783','H00783'),('(FEB4) GPR98 [HSA:84059] [KO:K18263]','https://www.genome.jp/dbget-bin/www_bget?ds:H00783','H00783'),('(FEB8/GEFS+3) GABRG2 [HSA:2566] [KO:K05186]','https://www.genome.jp/dbget-bin/www_bget?ds:H00783','H00783'),('(FHM1, SHM1) CACNA1A [HSA:773] [KO:K04344]','https://www.genome.jp/dbget-bin/www_bget?ds:H00775','H00775'),('(FHM2, SHM2) ATP1A2 [HSA:477] [KO:K01539]','https://www.genome.jp/dbget-bin/www_bget?ds:H00775','H00775'),('(FHM3) SCN1A [HSA:6323] [KO:K04833]','https://www.genome.jp/dbget-bin/www_bget?ds:H00775','H00775'),('(GEFS+1) SCN1B [HSA:6324] [KO:K04845]','https://www.genome.jp/dbget-bin/www_bget?ds:H00783','H00783'),('(GEFS+5) GABRD [HSA:2563] [KO:K05184]','https://www.genome.jp/dbget-bin/www_bget?ds:H00783','H00783'),('(GEFS+9) STX1B [HSA:112755] [KO:K08486]','https://www.genome.jp/dbget-bin/www_bget?ds:H00783','H00783'),('ADH1B (polymorphism) [HSA:125] [KO:K13951]','https://www.genome.jp/dbget-bin/www_bget?ds:H01611','H01611'),('ADH1C (polymorphism) [HSA:126] [KO:K13951]','https://www.genome.jp/dbget-bin/www_bget?ds:H01611','H01611'),('ALDH2 (polymorphism) [HSA:217] [KO:K00128]','https://www.genome.jp/dbget-bin/www_bget?ds:H01611','H01611'),('APC (LOH) [HSA:324] [KO:K02085]','https://www.genome.jp/dbget-bin/www_bget?ds:H00017','H00017'),('BMI1 (overexpression) [HSA:648] [KO:K11459]','https://www.genome.jp/dbget-bin/www_bget?ds:H00025','H00025'),('c-Met (overexpression) [HSA:4233] [KO:K05099]','https://www.genome.jp/dbget-bin/www_bget?ds:H00046','H00046'),('c-MYC (mutation) [HSA:4609] [KO:K04377]','https://www.genome.jp/dbget-bin/www_bget?ds:H00025','H00025'),('COX-2 (expression) [HSA:5743] [KO:K11987]','https://www.genome.jp/dbget-bin/www_bget?ds:H00025','H00025'),('COX2 (overexpression) [HSA:5743] [KO:K11987]','https://www.genome.jp/dbget-bin/www_bget?ds:H00046','H00046'),('Cyclin D1 (amplification) [HSA:595] [KO:K04503]','https://www.genome.jp/dbget-bin/www_bget?ds:H00017','H00017'),('DRD2 (polymorphism) [HSA:1813] [KO:K04145]','https://www.genome.jp/dbget-bin/www_bget?ds:H01611','H01611'),('E-Cadherin (expression) [HSA:999] [KO:K05689]','https://www.genome.jp/dbget-bin/www_bget?ds:H00025','H00025'),('EGFR (overexpression) [HSA:1956] [KO:K04361]','https://www.genome.jp/dbget-bin/www_bget?ds:H00017','H00017'),('ERBB2 (overexpression, amplification) [HSA:2064] [KO:K05083]','https://www.genome.jp/dbget-bin/www_bget?ds:H00046','H00046'),('FAS (increased expression) [HSA:355] [KO:K04390]','https://www.genome.jp/dbget-bin/www_bget?ds:H00017','H00017'),('GABRA2 (polymorphism) [HSA:2555] [KO:K05175]','https://www.genome.jp/dbget-bin/www_bget?ds:H01611','H01611'),('H-ras (mutation) [HSA:3265] [KO:K02833]','https://www.genome.jp/dbget-bin/www_bget?ds:H00025','H00025'),('HTR2A (polymorphism) [HSA:3356] [KO:K04157]','https://www.genome.jp/dbget-bin/www_bget?ds:H01611','H01611'),('iNOS (increased expression) [HSA:4843] [KO:K13241]','https://www.genome.jp/dbget-bin/www_bget?ds:H00017','H00017'),('K-ras (mutation) [HSA:3845] [KO:K07827]','https://www.genome.jp/dbget-bin/www_bget?ds:H00046','H00046'),('KCNT1 [HSA:57582] [KO:K04946]','https://www.genome.jp/dbget-bin/www_bget?ds:H01815','H01815'),('MDM2 (overexpression) [HSA:4193] [KO:K06643]','https://www.genome.jp/dbget-bin/www_bget?ds:H00025','H00025'),('MMP-2 (expression) [HSA:4313] [KO:K01398]','https://www.genome.jp/dbget-bin/www_bget?ds:H00025','H00025'),('MMP-9 (expression) [HSA:4318] [KO:K01403]','https://www.genome.jp/dbget-bin/www_bget?ds:H00025','H00025'),('OPRM1 (polymorphism) [HSA:4988] [KO:K04215]','https://www.genome.jp/dbget-bin/www_bget?ds:H01611','H01611'),('p16/INK4A (homozygous deletion, LOH) [HSA:1029] [KO:K06621]','https://www.genome.jp/dbget-bin/www_bget?ds:H00017','H00017'),('p16/INK4A (mutation) [HSA:1029] [KO:K06621]','https://www.genome.jp/dbget-bin/www_bget?ds:H00046','H00046'),('p16/INK4a (promoter hypermethylation) [HSA:1029] [KO:K06621]','https://www.genome.jp/dbget-bin/www_bget?ds:H00025','H00025'),('p53 (mutation) [HSA:7157] [KO:K04451]','https://www.genome.jp/dbget-bin/www_bget?ds:H00025','H00025'),('PLCB1 [HSA:23236] [KO:K05858]','https://www.genome.jp/dbget-bin/www_bget?ds:H01815','H01815'),('RB1 (LOH) [HSA:5925] [KO:K06618]','https://www.genome.jp/dbget-bin/www_bget?ds:H00017','H00017'),('SCN1A [HSA:6323] [KO:K04833]','https://www.genome.jp/dbget-bin/www_bget?ds:H01818','H01818'),('SLC12A5 [HSA:57468] [KO:K14427]','https://www.genome.jp/dbget-bin/www_bget?ds:H01815','H01815'),('TAS2R16 (polymorphism) [HSA:50833] [KO:K08474]','https://www.genome.jp/dbget-bin/www_bget?ds:H01611','H01611'),('TBC1D24 [HSA:57465] [KO:K21841]','https://www.genome.jp/dbget-bin/www_bget?ds:H01815','H01815');

/*Table structure for table `kegg_drug` */

DROP TABLE IF EXISTS `kegg_drug`;

CREATE TABLE `kegg_drug` (
  `kegg_id` varchar(200) NOT NULL,
  `kegg_url` varchar(200) DEFAULT NULL,
  `Formula` varchar(200) DEFAULT NULL,
  `imgPath` varchar(200) DEFAULT NULL,
  `pic_kegg_structure` varchar(200) DEFAULT NULL,
  `Target_href` varchar(200) DEFAULT NULL,
  `Target_id` varchar(200) DEFAULT NULL,
  `Pathway_href` varchar(200) DEFAULT NULL,
  `Pathway_name` varchar(200) DEFAULT NULL,
  `img_pathway_path` varchar(200) DEFAULT NULL,
  `pic_kegg_pathway` varchar(200) DEFAULT NULL,
  `Structure_map_href` varchar(200) DEFAULT NULL,
  `Structure_map_name` varchar(200) DEFAULT NULL,
  `Structure_map_title` varchar(200) DEFAULT NULL,
  `img_Structure_path` varchar(200) DEFAULT NULL,
  `pic_kegg_structure_map` varchar(200) DEFAULT NULL,
  PRIMARY KEY (`kegg_id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

/*Data for the table `kegg_drug` */

insert  into `kegg_drug`(`kegg_id`,`kegg_url`,`Formula`,`imgPath`,`pic_kegg_structure`,`Target_href`,`Target_id`,`Pathway_href`,`Pathway_name`,`img_pathway_path`,`pic_kegg_pathway`,`Structure_map_href`,`Structure_map_name`,`Structure_map_title`,`img_Structure_path`,`pic_kegg_structure_map`) values ('C07042','http://www.genome.jp/dbget-bin/www_bget?cpd:C07042','C17H19NO3','http://www.genome.jp/Fig/compound/C07042.gif','C07042.gif','None','None','None','None','None','None','None','None','None','None','None'),('C07062','http://www.genome.jp/dbget-bin/www_bget?cpd:C07062','C15H13NO3','http://www.genome.jp/Fig/compound/C07062.gif','C07062.gif','None','None','None','None','None','None','None','None','None','None','None'),('C07163','http://www.genome.jp/dbget-bin/www_bget?cpd:C07163','C21H27NO','http://www.genome.jp/Fig/compound/C07163.gif','C07163.gif','None','None','http://www.genome.jp/kegg-bin/show_pathway?map00982+C07163','map00982','http://www.genome.jp/tmp/mark_pathway153382900269888/map00982.png','C07163.png','None','None','None','None','None'),('C07406','http://www.genome.jp/dbget-bin/www_bget?cpd:C07406','C22H29NO2','http://www.genome.jp/Fig/compound/C07406.gif','C07406.gif','None','None','None','None','None','None','None','None','None','None','None'),('C07789','http://www.genome.jp/dbget-bin/www_bget?cpd:C07789','C21H23NO3','http://www.genome.jp/Fig/compound/C07789.gif','C07789.gif','None','None','None','None','None','None','None','None','None','None','None'),('C07995','http://www.genome.jp/dbget-bin/www_bget?cpd:C07995','C14H10MgO6','http://www.genome.jp/Fig/compound/C07995.gif','C07995.gif','None','None','None','None','None','None','None','None','None','None','None'),('C08005','http://www.genome.jp/dbget-bin/www_bget?cpd:C08005','C21H32N6O3','http://www.genome.jp/Fig/compound/C08005.gif','C08005.gif','None','None','None','None','None','None','None','None','None','None','None'),('C08019','http://www.genome.jp/dbget-bin/www_bget?cpd:C08019','C17H19NO4','http://www.genome.jp/Fig/compound/C08019.gif','C08019.gif','None','None','None','None','None','None','None','None','None','None','None'),('C08021','http://www.genome.jp/dbget-bin/www_bget?cpd:C08021','C20H28N2O5','http://www.genome.jp/Fig/compound/C08021.gif','C08021.gif','None','None','None','None','None','None','None','None','None','None','None'),('C11782','http://www.genome.jp/dbget-bin/www_bget?cpd:C11782','C17H21NO3','http://www.genome.jp/Fig/compound/C11782.gif','C11782.gif','None','None','None','None','None','None','None','None','None','None','None'),('C18364','http://www.genome.jp/dbget-bin/www_bget?cpd:C18364','C15H12ClNO2','http://www.genome.jp/Fig/compound/C18364.gif','C18364.gif','None','None','None','None','None','None','None','None','None','None','None'),('D00045','http://www.genome.jp/dbget-bin/www_bget?drug:D00045','C10H13N5O4','http://www.genome.jp/Fig/drug/D00045.gif','D00045.gif','http://www.genome.jp/dbget-bin/www_bget?hsa:134','134','http://www.genome.jp/kegg-bin/show_pathway?hsa04080+134+135+136+140','hsa04080','http://www.genome.jp/tmp/mark_pathway153382633031175/hsa04080.png','D00045.png','None','None','None','None','None'),('D00097','http://www.genome.jp/dbget-bin/www_bget?drug:D00097','C7H6O3','http://www.genome.jp/Fig/drug/D00097.gif','D00097.gif','None','None','None','None','None','None','http://www.genome.jp/kegg-bin/show_pathway?map07110+D00097','map07110','Benzoic acid family','http://www.genome.jp/tmp/mark_pathway153382628421746/map07110.png','D00097.png'),('D00109','http://www.genome.jp/dbget-bin/www_bget?drug:D00109','C9H8O4','http://www.genome.jp/Fig/drug/D00109.gif','D00109.gif','http://www.genome.jp/dbget-bin/www_bget?hsa:5742','5742','http://www.genome.jp/kegg-bin/show_pathway?hsa00590+5742+5743','hsa00590','http://www.genome.jp/tmp/mark_pathway153383108283803/hsa00590.png','D00109.png','http://www.genome.jp/kegg-bin/show_pathway?map07048+D00109','map07048','Antimigraines','http://www.genome.jp/tmp/mark_pathway153383112694450/map07048.png','D00109.png'),('D00118','http://www.genome.jp/dbget-bin/www_bget?drug:D00118','C14H14O3','http://www.genome.jp/Fig/drug/D00118.gif','D00118.gif','http://www.genome.jp/dbget-bin/www_bget?hsa:5742','5742','http://www.genome.jp/kegg-bin/show_pathway?hsa00590+5742+5743','hsa00590','http://www.genome.jp/tmp/mark_pathway153382704541299/hsa00590.png','D00118.png','http://www.genome.jp/kegg-bin/show_pathway?map07048+D00118','map07048','Antimigraines','http://www.genome.jp/tmp/mark_pathway153382707145590/map07048.png','D00118.png'),('D00120','http://www.genome.jp/dbget-bin/www_bget?drug:D00120','C20H17FO3S','http://www.genome.jp/Fig/drug/D00120.gif','D00120.gif','http://www.genome.jp/dbget-bin/www_bget?hsa:5742','5742','http://www.genome.jp/kegg-bin/show_pathway?hsa00590+5742+5743','hsa00590','http://www.genome.jp/tmp/mark_pathway1533830600132347/hsa00590.png','D00120.png','http://www.genome.jp/kegg-bin/show_pathway?map07219+D00120','map07219','Cyclooxygenase inhibitors','http://www.genome.jp/tmp/mark_pathway1533830644142112/map07219.png','D00120.png'),('D00126','http://www.genome.jp/dbget-bin/www_bget?drug:D00126','C13H18O2','http://www.genome.jp/Fig/drug/D00126.gif','D00126.gif','http://www.genome.jp/dbget-bin/www_bget?hsa:5742','5742','http://www.genome.jp/kegg-bin/show_pathway?hsa00590+5742+5743','hsa00590','http://www.genome.jp/tmp/mark_pathway1533828737132047/hsa00590.png','D00126.png','http://www.genome.jp/kegg-bin/show_pathway?map07048+D00126','map07048','Antimigraines','http://www.genome.jp/tmp/mark_pathway15338287835197/map07048.png','D00126.png'),('D00127','http://www.genome.jp/dbget-bin/www_bget?drug:D00127','C15H13N3O4S','http://www.genome.jp/Fig/drug/D00127.gif','D00127.gif','http://www.genome.jp/dbget-bin/www_bget?hsa:5742','5742','http://www.genome.jp/kegg-bin/show_pathway?hsa00590+5742+5743','hsa00590','http://www.genome.jp/tmp/mark_pathway153383020746555/hsa00590.png','D00127.png','http://www.genome.jp/kegg-bin/show_pathway?map07219+D00127','map07219','Cyclooxygenase inhibitors','http://www.genome.jp/tmp/mark_pathway153383025055722/map07219.png','D00127.png'),('D00130','http://www.genome.jp/dbget-bin/www_bget?drug:D00130','C13H8F2O3','http://www.genome.jp/Fig/drug/D00130.gif','D00130.gif','http://www.genome.jp/dbget-bin/www_bget?hsa:5743','5743','http://www.genome.jp/kegg-bin/show_pathway?hsa00590+5743','hsa00590','http://www.genome.jp/tmp/mark_pathway1533829221120023/hsa00590.png','D00130.png','http://www.genome.jp/kegg-bin/show_pathway?map07110+D00130','map07110','Benzoic acid family','http://www.genome.jp/tmp/mark_pathway1533829265129553/map07110.png','D00130.png'),('D00132','http://www.genome.jp/dbget-bin/www_bget?drug:D00132','C16H14O3','http://www.genome.jp/Fig/drug/D00132.gif','D00132.gif','http://www.genome.jp/dbget-bin/www_bget?hsa:5742','5742','http://www.genome.jp/kegg-bin/show_pathway?hsa00590+5742+5743','hsa00590','http://www.genome.jp/tmp/mark_pathway153383007621429/hsa00590.png','D00132.png','http://www.genome.jp/kegg-bin/show_pathway?map07219+D00132','map07219','Cyclooxygenase inhibitors','http://www.genome.jp/tmp/mark_pathway153383012030537/map07219.png','D00132.png'),('D00141','http://www.genome.jp/dbget-bin/www_bget?drug:D00141','C19H16ClNO4','http://www.genome.jp/Fig/drug/D00141.gif','D00141.gif','http://www.genome.jp/dbget-bin/www_bget?hsa:5742','5742','http://www.genome.jp/kegg-bin/show_pathway?hsa00590+5742+5743','hsa00590','http://www.genome.jp/tmp/mark_pathway153382965776654/hsa00590.png','D00141.png','http://www.genome.jp/kegg-bin/show_pathway?map07219+D00141','map07219','Cyclooxygenase inhibitors','http://www.genome.jp/tmp/mark_pathway153382970488020/map07219.png','D00141.png'),('D00217','http://www.genome.jp/dbget-bin/www_bget?drug:D00217','C8H9NO2','http://www.genome.jp/Fig/drug/D00217.gif','D00217.gif','http://www.genome.jp/dbget-bin/www_bget?hsa:5742','5742','http://www.genome.jp/kegg-bin/show_pathway?hsa00590+5742+5743','hsa00590','http://www.genome.jp/tmp/mark_pathway153382908888207/hsa00590.png','D00217.png','http://www.genome.jp/kegg-bin/show_pathway?map07048+D00217','map07048','Antimigraines','http://www.genome.jp/tmp/mark_pathway153382913498705/map07048.png','D00217.png'),('D00252','http://www.genome.jp/dbget-bin/www_bget?drug:D00252','C15H12N2O','http://www.genome.jp/Fig/drug/D00252.gif','D00252.gif','http://www.genome.jp/dbget-bin/www_bget?hsa:6323','6323','http://www.genome.jp/kegg-bin/show_pathway?hsa04728+6323','hsa04728','http://www.genome.jp/tmp/mark_pathway1533826832139488/hsa04728.png','D00252.png','http://www.genome.jp/kegg-bin/show_pathway?map07033+D00252','map07033','Anticonvulsants','http://www.genome.jp/tmp/mark_pathway1533826857144816/map07033.png','D00252.png'),('D00301','http://www.genome.jp/dbget-bin/www_bget?drug:D00301','C30H32N2O2. HCl. H2SO4. C17H23NO3','http://www.genome.jp/Fig/drug/D00301.gif','D00301.gif','None','None','None','None','None','None','None','None','None','None','None'),('D00315','http://www.genome.jp/dbget-bin/www_bget?drug:D00315','C17H21NO3','http://www.genome.jp/Fig/drug/D00315.gif','D00315.gif','http://www.genome.jp/dbget-bin/www_bget?hsa:5743','5743','http://www.genome.jp/kegg-bin/show_pathway?hsa00590+5743','hsa00590','http://www.genome.jp/tmp/mark_pathway153382721277465/hsa00590.png','D00315.png','http://www.genome.jp/kegg-bin/show_pathway?map07219+D00315','map07219','Cyclooxygenase inhibitors','http://www.genome.jp/tmp/mark_pathway153382723984736/map07219.png','D00315.png'),('D00320','http://www.genome.jp/dbget-bin/www_bget?drug:D00320','C22H28N2O','http://www.genome.jp/Fig/drug/D00320.gif','D00320.gif','http://www.genome.jp/dbget-bin/www_bget?hsa:4988','4988','http://www.genome.jp/kegg-bin/show_pathway?hsa04080+4988','hsa04080','http://www.genome.jp/tmp/mark_pathway1533829922138754/hsa04080.png','D00320.png','http://www.genome.jp/kegg-bin/show_pathway?map07039+D00320','map07039','Opioid analgesics','http://www.genome.jp/tmp/mark_pathway1533829967146412/map07039.png','D00320.png'),('D00330','http://www.genome.jp/dbget-bin/www_bget?drug:D00330','C15H13FO2','http://www.genome.jp/Fig/drug/D00330.gif','D00330.gif','http://www.genome.jp/dbget-bin/www_bget?hsa:5742','5742','http://www.genome.jp/kegg-bin/show_pathway?hsa00590+5742+5743','hsa00590','http://www.genome.jp/tmp/mark_pathway153382952743492/hsa00590.png','D00330.png','http://www.genome.jp/kegg-bin/show_pathway?map07219+D00330','map07219','Cyclooxygenase inhibitors','http://www.genome.jp/tmp/mark_pathway153382957155362/map07219.png','D00330.png'),('D00425','http://www.genome.jp/dbget-bin/www_bget?drug:D00425','C15H16O2','http://www.genome.jp/Fig/drug/D00425.gif','D00425.gif','http://www.genome.jp/dbget-bin/www_bget?hsa:5743','5743','http://www.genome.jp/kegg-bin/show_pathway?hsa00590+5742+5743','hsa00590','http://www.genome.jp/tmp/mark_pathway1533830469106435/hsa00590.png','D00425.png','http://www.genome.jp/kegg-bin/show_pathway?map07114+D00425','map07114','Naphthalene family','http://www.genome.jp/tmp/mark_pathway1533830514118390/map07114.png','D00425.png'),('D00463','http://www.genome.jp/dbget-bin/www_bget?drug:D00463','C18H15NO3','http://www.genome.jp/Fig/drug/D00463.gif','D00463.gif','http://www.genome.jp/dbget-bin/www_bget?hsa:5742','5742','http://www.genome.jp/kegg-bin/show_pathway?hsa00590+5742+5743','hsa00590','http://www.genome.jp/tmp/mark_pathway153382651673226/hsa00590.png','D00463.png','http://www.genome.jp/kegg-bin/show_pathway?map07112+D00463','map07112','1,2-Diphenyl substitution family','http://www.genome.jp/tmp/mark_pathway153382654079634/map07112.png','D00463.png'),('D00510','http://www.genome.jp/dbget-bin/www_bget?drug:D00510','C19H20N2O2','http://www.genome.jp/Fig/drug/D00510.gif','D00510.gif','http://www.genome.jp/dbget-bin/www_bget?hsa:5742','5742','http://www.genome.jp/kegg-bin/show_pathway?hsa00590+5742+5743','hsa00590','http://www.genome.jp/tmp/mark_pathway1533826645105345/hsa00590.png','D00510.png','http://www.genome.jp/kegg-bin/show_pathway?map07112+D00510','map07112','1,2-Diphenyl substitution family','http://www.genome.jp/tmp/mark_pathway1533826669108622/map07112.png','D00510.png'),('D00567','http://www.genome.jp/dbget-bin/www_bget?drug:D00567','C17H14F3N3O2S','http://www.genome.jp/Fig/drug/D00567.gif','D00567.gif','http://www.genome.jp/dbget-bin/www_bget?hsa:5743','5743','http://www.genome.jp/kegg-bin/show_pathway?hsa00590+5743','hsa00590','http://www.genome.jp/tmp/mark_pathway15338262156726/hsa00590.png','D00567.png','http://www.genome.jp/kegg-bin/show_pathway?map07112+D00567','map07112','1,2-Diphenyl substitution family','http://www.genome.jp/tmp/mark_pathway153382623812978/map07112.png','D00567.png'),('D00968','http://www.genome.jp/dbget-bin/www_bget?drug:D00968','(C15H13O3)2. Ca. 2H2O','http://www.genome.jp/Fig/drug/D00968.gif','D00968.gif','http://www.genome.jp/dbget-bin/www_bget?hsa:5742','5742','http://www.genome.jp/kegg-bin/show_pathway?hsa00590+5742+5743','hsa00590','http://www.genome.jp/tmp/mark_pathway153382711854223/hsa00590.png','D00968.png','http://www.genome.jp/kegg-bin/show_pathway?map07219+D00968','map07219','Cyclooxygenase inhibitors','http://www.genome.jp/tmp/mark_pathway153382714260735/map07219.png','D00968.png'),('D00969','http://www.genome.jp/dbget-bin/www_bget?drug:D00969','C14H13N3O4S2','http://www.genome.jp/Fig/drug/D00969.gif','D00969.gif','http://www.genome.jp/dbget-bin/www_bget?hsa:5743','5743','http://www.genome.jp/kegg-bin/show_pathway?hsa00590+5743','hsa00590','http://www.genome.jp/tmp/mark_pathway153382639946047/hsa00590.png','D00969.png','http://www.genome.jp/kegg-bin/show_pathway?map07219+D00969','map07219','Cyclooxygenase inhibitors','http://www.genome.jp/tmp/mark_pathway153382642353334/map07219.png','D00969.png'),('D01776','http://www.genome.jp/dbget-bin/www_bget?drug:D01776','C11H12N2O','http://www.genome.jp/Fig/drug/D01776.gif','D01776.gif','None','None','None','None','None','None','None','None','None','None','None'),('D03580','http://www.genome.jp/dbget-bin/www_bget?drug:D03580','(C18H21NO3)2. H2SO4. 3H2O','http://www.genome.jp/Fig/drug/D03580.gif','D03580.gif','http://www.genome.jp/dbget-bin/www_bget?hsa:4988','4988','http://www.genome.jp/kegg-bin/show_pathway?hsa04080+4988','hsa04080','http://www.genome.jp/tmp/mark_pathway153382886942816/hsa04080.png','D03580.png','http://www.genome.jp/kegg-bin/show_pathway?map07039+D03580','map07039','Opioid analgesics','http://www.genome.jp/tmp/mark_pathway153382891553981/map07039.png','D03580.png'),('D03710','http://www.genome.jp/dbget-bin/www_bget?drug:D03710','C18H15ClN2O2S','http://www.genome.jp/Fig/drug/D03710.gif','D03710.gif','http://www.genome.jp/dbget-bin/www_bget?hsa:5743','5743','http://www.genome.jp/kegg-bin/show_pathway?hsa00590+5743','hsa00590','http://www.genome.jp/tmp/mark_pathway1533829790106331/hsa00590.png','D03710.png','http://www.genome.jp/kegg-bin/show_pathway?map07219+D03710','map07219','Cyclooxygenase inhibitors','http://www.genome.jp/tmp/mark_pathway1533829836117897/map07219.png','D03710.png'),('D05312','http://www.genome.jp/dbget-bin/www_bget?drug:D05312','C18H21NO4','http://www.genome.jp/Fig/drug/D05312.gif','D05312.gif','http://www.genome.jp/dbget-bin/www_bget?hsa:4988','4988','http://www.genome.jp/kegg-bin/show_pathway?hsa04080+4985+4986+4988','hsa04080','http://www.genome.jp/tmp/mark_pathway1533828606105095/hsa04080.png','D05312.png','http://www.genome.jp/kegg-bin/show_pathway?map07039+D05312','map07039','Opioid analgesics','http://www.genome.jp/tmp/mark_pathway1533828650113117/map07039.png','D05312.png'),('D05938','http://www.genome.jp/dbget-bin/www_bget?drug:D05938','C22H30N2O2S','http://www.genome.jp/Fig/drug/D05938.gif','D05938.gif','http://www.genome.jp/dbget-bin/www_bget?hsa:4988','4988','http://www.genome.jp/kegg-bin/show_pathway?hsa04080+4988','hsa04080','http://www.genome.jp/tmp/mark_pathway1533826715117223/hsa04080.png','D05938.png','http://www.genome.jp/kegg-bin/show_pathway?map07039+D05938','map07039','Opioid analgesics','http://www.genome.jp/tmp/mark_pathway1533826740121176/map07039.png','D05938.png'),('D07132','http://www.genome.jp/dbget-bin/www_bget?drug:D07132','C29H41NO4','http://www.genome.jp/Fig/drug/D07132.gif','D07132.gif','http://www.genome.jp/dbget-bin/www_bget?hsa:4986','4986','http://www.genome.jp/kegg-bin/show_pathway?hsa04080+4986+4988','hsa04080','http://www.genome.jp/tmp/mark_pathway15338293522531/hsa04080.png','D07132.png','http://www.genome.jp/kegg-bin/show_pathway?map07039+D07132','map07039','Opioid analgesics','http://www.genome.jp/tmp/mark_pathway153382939614472/map07039.png','D07132.png'),('D07690','http://www.genome.jp/dbget-bin/www_bget?drug:D07690','C5H14NO','http://www.genome.jp/Fig/drug/D07690.gif','D07690.gif','None','None','None','None','None','None','None','None','None','None','None'),('D07816','http://www.genome.jp/dbget-bin/www_bget?drug:D07816','C14H11Cl2NO2','http://www.genome.jp/Fig/drug/D07816.gif','D07816.gif','http://www.genome.jp/dbget-bin/www_bget?hsa:5742','5742','http://www.genome.jp/kegg-bin/show_pathway?hsa00590+5742+5743','hsa00590','http://www.genome.jp/tmp/mark_pathway153382658690890/hsa00590.png','D07816.png','None','None','None','None','None'),('D08045','http://www.genome.jp/dbget-bin/www_bget?drug:D08045','C18H21NO3','http://www.genome.jp/Fig/drug/D08045.gif','D08045.gif','http://www.genome.jp/dbget-bin/www_bget?hsa:4988','4988','http://www.genome.jp/kegg-bin/show_pathway?hsa04080+4988','hsa04080','http://www.genome.jp/tmp/mark_pathway1533831213117138/hsa04080.png','D08045.png','http://www.genome.jp/kegg-bin/show_pathway?map07039+D08045','map07039','Opioid analgesics','http://www.genome.jp/tmp/mark_pathway1533831257127395/map07039.png','D08045.png'),('D08123','http://www.genome.jp/dbget-bin/www_bget?drug:D08123','C17H23NO','http://www.genome.jp/Fig/drug/D08123.gif','D08123.gif','http://www.genome.jp/dbget-bin/www_bget?hsa:4988','4988','http://www.genome.jp/kegg-bin/show_pathway?hsa04080+4988','hsa04080','http://www.genome.jp/tmp/mark_pathway153383077327487/hsa04080.png','D08123.png','http://www.genome.jp/kegg-bin/show_pathway?map07039+D08123','map07039','Opioid analgesics','http://www.genome.jp/tmp/mark_pathway153383081833979/map07039.png','D08123.png'),('D08233','http://www.genome.jp/dbget-bin/www_bget?drug:D08233','C17H19NO3','http://www.genome.jp/Fig/drug/D08233.gif','D08233.gif','http://www.genome.jp/dbget-bin/www_bget?hsa:4988','4988','http://www.genome.jp/kegg-bin/show_pathway?hsa04080+4988','hsa04080','http://www.genome.jp/tmp/mark_pathway153382690311221/hsa04080.png','D08233.png','http://www.genome.jp/kegg-bin/show_pathway?map07039+D08233','map07039','Opioid analgesics','http://www.genome.jp/tmp/mark_pathway153382692718157/map07039.png','D08233.png'),('D08246','http://www.genome.jp/dbget-bin/www_bget?drug:D08246','C21H27NO4','http://www.genome.jp/Fig/drug/D08246.gif','D08246.gif','http://www.genome.jp/dbget-bin/www_bget?hsa:4988','4988','http://www.genome.jp/kegg-bin/show_pathway?hsa04080+4985+4986+4988','hsa04080','http://www.genome.jp/tmp/mark_pathway153383033783874/hsa04080.png','D08246.png','http://www.genome.jp/kegg-bin/show_pathway?map07039+D08246','map07039','Opioid analgesics','http://www.genome.jp/tmp/mark_pathway153383038291909/map07039.png','D08246.png'),('D08623','http://www.genome.jp/dbget-bin/www_bget?drug:D08623','C16H25NO2','http://www.genome.jp/Fig/drug/D08623.gif','D08623.gif','http://www.genome.jp/dbget-bin/www_bget?hsa:4988','4988','http://www.genome.jp/kegg-bin/show_pathway?hsa04080+4988','hsa04080','http://www.genome.jp/tmp/mark_pathway153382697326570/hsa04080.png','D08623.png','http://www.genome.jp/kegg-bin/show_pathway?map07224+D08623','map07224','Opioid receptor agonists/antagonists','http://www.genome.jp/tmp/mark_pathway153382699831789/map07224.png','D08623.png'),('None','None','None','None','None','None','None','None','None','None','None','None','None','None','None','None');

/*Table structure for table `kegg_drug_target` */

DROP TABLE IF EXISTS `kegg_drug_target`;

CREATE TABLE `kegg_drug_target` (
  `Target_href` varchar(200) NOT NULL,
  `target_name` varchar(200) DEFAULT NULL,
  `has_disease` varchar(200) DEFAULT NULL,
  `has_pathway` varchar(200) DEFAULT NULL,
  `target_id` varchar(200) DEFAULT NULL,
  `Gene_name` varchar(200) DEFAULT NULL,
  `Definition` text,
  `aa_seq` text,
  `nt_seq` text,
  PRIMARY KEY (`Target_href`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

/*Data for the table `kegg_drug_target` */

insert  into `kegg_drug_target`(`Target_href`,`target_name`,`has_disease`,`has_pathway`,`target_id`,`Gene_name`,`Definition`,`aa_seq`,`nt_seq`) values ('http://www.genome.jp/dbget-bin/www_bget?hsa:134','Homo sapiens (human): 134','None','true','134Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â CDS','ADORA1, RDC7','(RefSeq) adenosine A1 receptor','604 aa \nMLARALLLCAVLALSHTANPCCSHPCQNRGVCMSVGFDQYKCDCTRTGFYGENCSTPEFL\nTRIKLFLKPTPNTVHYILTHFKGFWNVVNNIPFLRNAIMSYVLTSRSHLIDSPPTYNADY\nGYKSWEAFSNLSYYTRALPPVPDDCPTPLGVKGKKQLPDSNEIVEKLLLRRKFIPDPQGS\nNMMFAFFAQHFTHQFFKTDHKRGPAFTNGLGHGVDLNHIYGETLARQRKLRLFKDGKMKY\nQIIDGEMYPPTVKDTQAEMIYPPQVPEHLRFAVGQEVFGLVPGLMMYATIWLREHNRVCD\nVLKQEHPEWGDEQLFQTSRLILIGETIKIVIEDYVQHLSGYHFKLKFDPELLFNKQFQYQ\nNRIAAEFNTLYHWHPLLPDTFQIHDQKYNYQQFIYNNSILLEHGITQFVESFTRQIAGRV\nAGGRNVPPAVQKVSQASIDQSRQMKYQSFNEYRKRFMLKPYESFEELTGEKEMSAELEAL\nYGDIDAVELYPALLVEKPRPDAIFGETMVEVGAPFSLKGLMGNVICSPAYWKPSTFGGEV\nGFQIINTASIQSLICNNVKGCPFTSFSVPDPELIKTVTINASSSRSGLDDINPTVLLKER\nSTEL','1815 nt \natgctcgcccgcgccctgctgctgtgcgcggtcctggcgctcagccatacagcaaatcct\ntgctgttcccacccatgtcaaaaccgaggtgtatgtatgagtgtgggatttgaccagtat\naagtgcgattgtacccggacaggattctatggagaaaactgctcaacaccggaatttttg\nacaagaataaaattatttctgaaacccactccaaacacagtgcactacatacttacccac\nttcaagggattttggaacgttgtgaataacattcccttccttcgaaatgcaattatgagt\ntatgtgttgacatccagatcacatttgattgacagtccaccaacttacaatgctgactat\nggctacaaaagctgggaagccttctctaacctctcctattatactagagcccttcctcct\ngtgcctgatgattgcccgactcccttgggtgtcaaaggtaaaaagcagcttcctgattca\naatgagattgtggaaaaattgcttctaagaagaaagttcatccctgatccccagggctca\naacatgatgtttgcattctttgcccagcacttcacgcatcagtttttcaagacagatcat\naagcgagggccagctttcaccaacgggctgggccatggggtggacttaaatcatatttac\nggtgaaactctggctagacagcgtaaactgcgccttttcaaggatggaaaaatgaaatat\ncagataattgatggagagatgtatcctcccacagtcaaagatactcaggcagagatgatc\ntaccctcctcaagtccctgagcatctacggtttgctgtggggcaggaggtctttggtctg\ngtgcctggtctgatgatgtatgccacaatctggctgcgggaacacaacagagtatgcgat\ngtgcttaaacaggagcatcctgaatggggtgatgagcagttgttccagacaagcaggcta\natactgataggagagactattaagattgtgattgaagattatgtgcaacacttgagtggc\ntatcacttcaaactgaaatttgacccagaactacttttcaacaaacaattccagtaccaa\naatcgtattgctgctgaatttaacaccctctatcactggcatccccttctgcctgacacc\ntttcaaattcatgaccagaaatacaactatcaacagtttatctacaacaactctatattg\nctggaacatggaattacccagtttgttgaatcattcaccaggcaaattgctggcagggtt\ngctggtggtaggaatgttccacccgcagtacagaaagtatcacaggcttccattgaccag\nagcaggcagatgaaataccagtcttttaatgagtaccgcaaacgctttatgctgaagccc\ntatgaatcatttgaagaacttacaggagaaaaggaaatgtctgcagagttggaagcactc\ntatggtgacatcgatgctgtggagctgtatcctgcccttctggtagaaaagcctcggcca\ngatgccatctttggtgaaaccatggtagaagttggagcaccattctccttgaaaggactt\natgggtaatgttatatgttctcctgcctactggaagccaagcacttttggtggagaagtg\nggttttcaaatcatcaacactgcctcaattcagtctctcatctgcaataacgtgaagggc\ntgtccctttacttcattcagtgttccagatccagagctcattaaaacagtcaccatcaat\ngcaagttcttcccgctccggactagatgatatcaatcccacagtactactaaaagaacgt\ntcgactgaactgtag'),('http://www.genome.jp/dbget-bin/www_bget?hsa:4986','Homo sapiens (human): 4986','None','true','4986Â Â Â Â Â Â Â Â Â Â Â Â Â Â CDS','OPRK1, K-OR-1, KOR, KOR-1, OPRK','(RefSeq) opioid receptor kappa 1','604 aa \nMLARALLLCAVLALSHTANPCCSHPCQNRGVCMSVGFDQYKCDCTRTGFYGENCSTPEFL\nTRIKLFLKPTPNTVHYILTHFKGFWNVVNNIPFLRNAIMSYVLTSRSHLIDSPPTYNADY\nGYKSWEAFSNLSYYTRALPPVPDDCPTPLGVKGKKQLPDSNEIVEKLLLRRKFIPDPQGS\nNMMFAFFAQHFTHQFFKTDHKRGPAFTNGLGHGVDLNHIYGETLARQRKLRLFKDGKMKY\nQIIDGEMYPPTVKDTQAEMIYPPQVPEHLRFAVGQEVFGLVPGLMMYATIWLREHNRVCD\nVLKQEHPEWGDEQLFQTSRLILIGETIKIVIEDYVQHLSGYHFKLKFDPELLFNKQFQYQ\nNRIAAEFNTLYHWHPLLPDTFQIHDQKYNYQQFIYNNSILLEHGITQFVESFTRQIAGRV\nAGGRNVPPAVQKVSQASIDQSRQMKYQSFNEYRKRFMLKPYESFEELTGEKEMSAELEAL\nYGDIDAVELYPALLVEKPRPDAIFGETMVEVGAPFSLKGLMGNVICSPAYWKPSTFGGEV\nGFQIINTASIQSLICNNVKGCPFTSFSVPDPELIKTVTINASSSRSGLDDINPTVLLKER\nSTEL','1815 nt \natgctcgcccgcgccctgctgctgtgcgcggtcctggcgctcagccatacagcaaatcct\ntgctgttcccacccatgtcaaaaccgaggtgtatgtatgagtgtgggatttgaccagtat\naagtgcgattgtacccggacaggattctatggagaaaactgctcaacaccggaatttttg\nacaagaataaaattatttctgaaacccactccaaacacagtgcactacatacttacccac\nttcaagggattttggaacgttgtgaataacattcccttccttcgaaatgcaattatgagt\ntatgtgttgacatccagatcacatttgattgacagtccaccaacttacaatgctgactat\nggctacaaaagctgggaagccttctctaacctctcctattatactagagcccttcctcct\ngtgcctgatgattgcccgactcccttgggtgtcaaaggtaaaaagcagcttcctgattca\naatgagattgtggaaaaattgcttctaagaagaaagttcatccctgatccccagggctca\naacatgatgtttgcattctttgcccagcacttcacgcatcagtttttcaagacagatcat\naagcgagggccagctttcaccaacgggctgggccatggggtggacttaaatcatatttac\nggtgaaactctggctagacagcgtaaactgcgccttttcaaggatggaaaaatgaaatat\ncagataattgatggagagatgtatcctcccacagtcaaagatactcaggcagagatgatc\ntaccctcctcaagtccctgagcatctacggtttgctgtggggcaggaggtctttggtctg\ngtgcctggtctgatgatgtatgccacaatctggctgcgggaacacaacagagtatgcgat\ngtgcttaaacaggagcatcctgaatggggtgatgagcagttgttccagacaagcaggcta\natactgataggagagactattaagattgtgattgaagattatgtgcaacacttgagtggc\ntatcacttcaaactgaaatttgacccagaactacttttcaacaaacaattccagtaccaa\naatcgtattgctgctgaatttaacaccctctatcactggcatccccttctgcctgacacc\ntttcaaattcatgaccagaaatacaactatcaacagtttatctacaacaactctatattg\nctggaacatggaattacccagtttgttgaatcattcaccaggcaaattgctggcagggtt\ngctggtggtaggaatgttccacccgcagtacagaaagtatcacaggcttccattgaccag\nagcaggcagatgaaataccagtcttttaatgagtaccgcaaacgctttatgctgaagccc\ntatgaatcatttgaagaacttacaggagaaaaggaaatgtctgcagagttggaagcactc\ntatggtgacatcgatgctgtggagctgtatcctgcccttctggtagaaaagcctcggcca\ngatgccatctttggtgaaaccatggtagaagttggagcaccattctccttgaaaggactt\natgggtaatgttatatgttctcctgcctactggaagccaagcacttttggtggagaagtg\nggttttcaaatcatcaacactgcctcaattcagtctctcatctgcaataacgtgaagggc\ntgtccctttacttcattcagtgttccagatccagagctcattaaaacagtcaccatcaat\ngcaagttcttcccgctccggactagatgatatcaatcccacagtactactaaaagaacgt\ntcgactgaactgtag'),('http://www.genome.jp/dbget-bin/www_bget?hsa:4988','Homo sapiens (human): 4988','true','true','4988Â Â Â Â Â Â Â Â Â Â Â Â Â Â CDS','OPRM1, LMOR, M-OR-1, MOP, MOR, MOR1, OPRM','(RefSeq) opioid receptor mu 1','604 aa \nMLARALLLCAVLALSHTANPCCSHPCQNRGVCMSVGFDQYKCDCTRTGFYGENCSTPEFL\nTRIKLFLKPTPNTVHYILTHFKGFWNVVNNIPFLRNAIMSYVLTSRSHLIDSPPTYNADY\nGYKSWEAFSNLSYYTRALPPVPDDCPTPLGVKGKKQLPDSNEIVEKLLLRRKFIPDPQGS\nNMMFAFFAQHFTHQFFKTDHKRGPAFTNGLGHGVDLNHIYGETLARQRKLRLFKDGKMKY\nQIIDGEMYPPTVKDTQAEMIYPPQVPEHLRFAVGQEVFGLVPGLMMYATIWLREHNRVCD\nVLKQEHPEWGDEQLFQTSRLILIGETIKIVIEDYVQHLSGYHFKLKFDPELLFNKQFQYQ\nNRIAAEFNTLYHWHPLLPDTFQIHDQKYNYQQFIYNNSILLEHGITQFVESFTRQIAGRV\nAGGRNVPPAVQKVSQASIDQSRQMKYQSFNEYRKRFMLKPYESFEELTGEKEMSAELEAL\nYGDIDAVELYPALLVEKPRPDAIFGETMVEVGAPFSLKGLMGNVICSPAYWKPSTFGGEV\nGFQIINTASIQSLICNNVKGCPFTSFSVPDPELIKTVTINASSSRSGLDDINPTVLLKER\nSTEL','1815 nt \natgctcgcccgcgccctgctgctgtgcgcggtcctggcgctcagccatacagcaaatcct\ntgctgttcccacccatgtcaaaaccgaggtgtatgtatgagtgtgggatttgaccagtat\naagtgcgattgtacccggacaggattctatggagaaaactgctcaacaccggaatttttg\nacaagaataaaattatttctgaaacccactccaaacacagtgcactacatacttacccac\nttcaagggattttggaacgttgtgaataacattcccttccttcgaaatgcaattatgagt\ntatgtgttgacatccagatcacatttgattgacagtccaccaacttacaatgctgactat\nggctacaaaagctgggaagccttctctaacctctcctattatactagagcccttcctcct\ngtgcctgatgattgcccgactcccttgggtgtcaaaggtaaaaagcagcttcctgattca\naatgagattgtggaaaaattgcttctaagaagaaagttcatccctgatccccagggctca\naacatgatgtttgcattctttgcccagcacttcacgcatcagtttttcaagacagatcat\naagcgagggccagctttcaccaacgggctgggccatggggtggacttaaatcatatttac\nggtgaaactctggctagacagcgtaaactgcgccttttcaaggatggaaaaatgaaatat\ncagataattgatggagagatgtatcctcccacagtcaaagatactcaggcagagatgatc\ntaccctcctcaagtccctgagcatctacggtttgctgtggggcaggaggtctttggtctg\ngtgcctggtctgatgatgtatgccacaatctggctgcgggaacacaacagagtatgcgat\ngtgcttaaacaggagcatcctgaatggggtgatgagcagttgttccagacaagcaggcta\natactgataggagagactattaagattgtgattgaagattatgtgcaacacttgagtggc\ntatcacttcaaactgaaatttgacccagaactacttttcaacaaacaattccagtaccaa\naatcgtattgctgctgaatttaacaccctctatcactggcatccccttctgcctgacacc\ntttcaaattcatgaccagaaatacaactatcaacagtttatctacaacaactctatattg\nctggaacatggaattacccagtttgttgaatcattcaccaggcaaattgctggcagggtt\ngctggtggtaggaatgttccacccgcagtacagaaagtatcacaggcttccattgaccag\nagcaggcagatgaaataccagtcttttaatgagtaccgcaaacgctttatgctgaagccc\ntatgaatcatttgaagaacttacaggagaaaaggaaatgtctgcagagttggaagcactc\ntatggtgacatcgatgctgtggagctgtatcctgcccttctggtagaaaagcctcggcca\ngatgccatctttggtgaaaccatggtagaagttggagcaccattctccttgaaaggactt\natgggtaatgttatatgttctcctgcctactggaagccaagcacttttggtggagaagtg\nggttttcaaatcatcaacactgcctcaattcagtctctcatctgcaataacgtgaagggc\ntgtccctttacttcattcagtgttccagatccagagctcattaaaacagtcaccatcaat\ngcaagttcttcccgctccggactagatgatatcaatcccacagtactactaaaagaacgt\ntcgactgaactgtag'),('http://www.genome.jp/dbget-bin/www_bget?hsa:5742','Homo sapiens (human): 5742','None','true','5742Â Â Â Â Â Â Â Â Â Â Â Â Â Â CDS','PTGS1, COX1, COX3, PCOX1, PES-1, PGG/HS, PGHS-1, PGHS1, PHS1, PTGHS','(RefSeq) prostaglandin-endoperoxide synthase 1','604 aa \nMLARALLLCAVLALSHTANPCCSHPCQNRGVCMSVGFDQYKCDCTRTGFYGENCSTPEFL\nTRIKLFLKPTPNTVHYILTHFKGFWNVVNNIPFLRNAIMSYVLTSRSHLIDSPPTYNADY\nGYKSWEAFSNLSYYTRALPPVPDDCPTPLGVKGKKQLPDSNEIVEKLLLRRKFIPDPQGS\nNMMFAFFAQHFTHQFFKTDHKRGPAFTNGLGHGVDLNHIYGETLARQRKLRLFKDGKMKY\nQIIDGEMYPPTVKDTQAEMIYPPQVPEHLRFAVGQEVFGLVPGLMMYATIWLREHNRVCD\nVLKQEHPEWGDEQLFQTSRLILIGETIKIVIEDYVQHLSGYHFKLKFDPELLFNKQFQYQ\nNRIAAEFNTLYHWHPLLPDTFQIHDQKYNYQQFIYNNSILLEHGITQFVESFTRQIAGRV\nAGGRNVPPAVQKVSQASIDQSRQMKYQSFNEYRKRFMLKPYESFEELTGEKEMSAELEAL\nYGDIDAVELYPALLVEKPRPDAIFGETMVEVGAPFSLKGLMGNVICSPAYWKPSTFGGEV\nGFQIINTASIQSLICNNVKGCPFTSFSVPDPELIKTVTINASSSRSGLDDINPTVLLKER\nSTEL','1815 nt \natgctcgcccgcgccctgctgctgtgcgcggtcctggcgctcagccatacagcaaatcct\ntgctgttcccacccatgtcaaaaccgaggtgtatgtatgagtgtgggatttgaccagtat\naagtgcgattgtacccggacaggattctatggagaaaactgctcaacaccggaatttttg\nacaagaataaaattatttctgaaacccactccaaacacagtgcactacatacttacccac\nttcaagggattttggaacgttgtgaataacattcccttccttcgaaatgcaattatgagt\ntatgtgttgacatccagatcacatttgattgacagtccaccaacttacaatgctgactat\nggctacaaaagctgggaagccttctctaacctctcctattatactagagcccttcctcct\ngtgcctgatgattgcccgactcccttgggtgtcaaaggtaaaaagcagcttcctgattca\naatgagattgtggaaaaattgcttctaagaagaaagttcatccctgatccccagggctca\naacatgatgtttgcattctttgcccagcacttcacgcatcagtttttcaagacagatcat\naagcgagggccagctttcaccaacgggctgggccatggggtggacttaaatcatatttac\nggtgaaactctggctagacagcgtaaactgcgccttttcaaggatggaaaaatgaaatat\ncagataattgatggagagatgtatcctcccacagtcaaagatactcaggcagagatgatc\ntaccctcctcaagtccctgagcatctacggtttgctgtggggcaggaggtctttggtctg\ngtgcctggtctgatgatgtatgccacaatctggctgcgggaacacaacagagtatgcgat\ngtgcttaaacaggagcatcctgaatggggtgatgagcagttgttccagacaagcaggcta\natactgataggagagactattaagattgtgattgaagattatgtgcaacacttgagtggc\ntatcacttcaaactgaaatttgacccagaactacttttcaacaaacaattccagtaccaa\naatcgtattgctgctgaatttaacaccctctatcactggcatccccttctgcctgacacc\ntttcaaattcatgaccagaaatacaactatcaacagtttatctacaacaactctatattg\nctggaacatggaattacccagtttgttgaatcattcaccaggcaaattgctggcagggtt\ngctggtggtaggaatgttccacccgcagtacagaaagtatcacaggcttccattgaccag\nagcaggcagatgaaataccagtcttttaatgagtaccgcaaacgctttatgctgaagccc\ntatgaatcatttgaagaacttacaggagaaaaggaaatgtctgcagagttggaagcactc\ntatggtgacatcgatgctgtggagctgtatcctgcccttctggtagaaaagcctcggcca\ngatgccatctttggtgaaaccatggtagaagttggagcaccattctccttgaaaggactt\natgggtaatgttatatgttctcctgcctactggaagccaagcacttttggtggagaagtg\nggttttcaaatcatcaacactgcctcaattcagtctctcatctgcaataacgtgaagggc\ntgtccctttacttcattcagtgttccagatccagagctcattaaaacagtcaccatcaat\ngcaagttcttcccgctccggactagatgatatcaatcccacagtactactaaaagaacgt\ntcgactgaactgtag'),('http://www.genome.jp/dbget-bin/www_bget?hsa:5743','Homo sapiens (human): 5743','true','true','5743Â Â Â Â Â Â Â Â Â Â Â Â Â Â CDS','PTGS2, COX-2, COX2, GRIPGHS, PGG/HS, PGHS-2, PHS-2, hCox-2','(RefSeq) prostaglandin-endoperoxide synthase 2','604 aa \nMLARALLLCAVLALSHTANPCCSHPCQNRGVCMSVGFDQYKCDCTRTGFYGENCSTPEFL\nTRIKLFLKPTPNTVHYILTHFKGFWNVVNNIPFLRNAIMSYVLTSRSHLIDSPPTYNADY\nGYKSWEAFSNLSYYTRALPPVPDDCPTPLGVKGKKQLPDSNEIVEKLLLRRKFIPDPQGS\nNMMFAFFAQHFTHQFFKTDHKRGPAFTNGLGHGVDLNHIYGETLARQRKLRLFKDGKMKY\nQIIDGEMYPPTVKDTQAEMIYPPQVPEHLRFAVGQEVFGLVPGLMMYATIWLREHNRVCD\nVLKQEHPEWGDEQLFQTSRLILIGETIKIVIEDYVQHLSGYHFKLKFDPELLFNKQFQYQ\nNRIAAEFNTLYHWHPLLPDTFQIHDQKYNYQQFIYNNSILLEHGITQFVESFTRQIAGRV\nAGGRNVPPAVQKVSQASIDQSRQMKYQSFNEYRKRFMLKPYESFEELTGEKEMSAELEAL\nYGDIDAVELYPALLVEKPRPDAIFGETMVEVGAPFSLKGLMGNVICSPAYWKPSTFGGEV\nGFQIINTASIQSLICNNVKGCPFTSFSVPDPELIKTVTINASSSRSGLDDINPTVLLKER\nSTEL','1815 nt \natgctcgcccgcgccctgctgctgtgcgcggtcctggcgctcagccatacagcaaatcct\ntgctgttcccacccatgtcaaaaccgaggtgtatgtatgagtgtgggatttgaccagtat\naagtgcgattgtacccggacaggattctatggagaaaactgctcaacaccggaatttttg\nacaagaataaaattatttctgaaacccactccaaacacagtgcactacatacttacccac\nttcaagggattttggaacgttgtgaataacattcccttccttcgaaatgcaattatgagt\ntatgtgttgacatccagatcacatttgattgacagtccaccaacttacaatgctgactat\nggctacaaaagctgggaagccttctctaacctctcctattatactagagcccttcctcct\ngtgcctgatgattgcccgactcccttgggtgtcaaaggtaaaaagcagcttcctgattca\naatgagattgtggaaaaattgcttctaagaagaaagttcatccctgatccccagggctca\naacatgatgtttgcattctttgcccagcacttcacgcatcagtttttcaagacagatcat\naagcgagggccagctttcaccaacgggctgggccatggggtggacttaaatcatatttac\nggtgaaactctggctagacagcgtaaactgcgccttttcaaggatggaaaaatgaaatat\ncagataattgatggagagatgtatcctcccacagtcaaagatactcaggcagagatgatc\ntaccctcctcaagtccctgagcatctacggtttgctgtggggcaggaggtctttggtctg\ngtgcctggtctgatgatgtatgccacaatctggctgcgggaacacaacagagtatgcgat\ngtgcttaaacaggagcatcctgaatggggtgatgagcagttgttccagacaagcaggcta\natactgataggagagactattaagattgtgattgaagattatgtgcaacacttgagtggc\ntatcacttcaaactgaaatttgacccagaactacttttcaacaaacaattccagtaccaa\naatcgtattgctgctgaatttaacaccctctatcactggcatccccttctgcctgacacc\ntttcaaattcatgaccagaaatacaactatcaacagtttatctacaacaactctatattg\nctggaacatggaattacccagtttgttgaatcattcaccaggcaaattgctggcagggtt\ngctggtggtaggaatgttccacccgcagtacagaaagtatcacaggcttccattgaccag\nagcaggcagatgaaataccagtcttttaatgagtaccgcaaacgctttatgctgaagccc\ntatgaatcatttgaagaacttacaggagaaaaggaaatgtctgcagagttggaagcactc\ntatggtgacatcgatgctgtggagctgtatcctgcccttctggtagaaaagcctcggcca\ngatgccatctttggtgaaaccatggtagaagttggagcaccattctccttgaaaggactt\natgggtaatgttatatgttctcctgcctactggaagccaagcacttttggtggagaagtg\nggttttcaaatcatcaacactgcctcaattcagtctctcatctgcaataacgtgaagggc\ntgtccctttacttcattcagtgttccagatccagagctcattaaaacagtcaccatcaat\ngcaagttcttcccgctccggactagatgatatcaatcccacagtactactaaaagaacgt\ntcgactgaactgtag'),('http://www.genome.jp/dbget-bin/www_bget?hsa:6323','Homo sapiens (human): 6323','true','true','6323Â Â Â Â Â Â Â Â Â Â Â Â Â Â CDS','SCN1A, EIEE6, FEB3, FEB3A, FHM3, GEFSP2, HBSCI, NAC1, Nav1.1, SCN1, SMEI','(RefSeq) sodium voltage-gated channel alpha subunit 1','604 aa \nMLARALLLCAVLALSHTANPCCSHPCQNRGVCMSVGFDQYKCDCTRTGFYGENCSTPEFL\nTRIKLFLKPTPNTVHYILTHFKGFWNVVNNIPFLRNAIMSYVLTSRSHLIDSPPTYNADY\nGYKSWEAFSNLSYYTRALPPVPDDCPTPLGVKGKKQLPDSNEIVEKLLLRRKFIPDPQGS\nNMMFAFFAQHFTHQFFKTDHKRGPAFTNGLGHGVDLNHIYGETLARQRKLRLFKDGKMKY\nQIIDGEMYPPTVKDTQAEMIYPPQVPEHLRFAVGQEVFGLVPGLMMYATIWLREHNRVCD\nVLKQEHPEWGDEQLFQTSRLILIGETIKIVIEDYVQHLSGYHFKLKFDPELLFNKQFQYQ\nNRIAAEFNTLYHWHPLLPDTFQIHDQKYNYQQFIYNNSILLEHGITQFVESFTRQIAGRV\nAGGRNVPPAVQKVSQASIDQSRQMKYQSFNEYRKRFMLKPYESFEELTGEKEMSAELEAL\nYGDIDAVELYPALLVEKPRPDAIFGETMVEVGAPFSLKGLMGNVICSPAYWKPSTFGGEV\nGFQIINTASIQSLICNNVKGCPFTSFSVPDPELIKTVTINASSSRSGLDDINPTVLLKER\nSTEL','1815 nt \natgctcgcccgcgccctgctgctgtgcgcggtcctggcgctcagccatacagcaaatcct\ntgctgttcccacccatgtcaaaaccgaggtgtatgtatgagtgtgggatttgaccagtat\naagtgcgattgtacccggacaggattctatggagaaaactgctcaacaccggaatttttg\nacaagaataaaattatttctgaaacccactccaaacacagtgcactacatacttacccac\nttcaagggattttggaacgttgtgaataacattcccttccttcgaaatgcaattatgagt\ntatgtgttgacatccagatcacatttgattgacagtccaccaacttacaatgctgactat\nggctacaaaagctgggaagccttctctaacctctcctattatactagagcccttcctcct\ngtgcctgatgattgcccgactcccttgggtgtcaaaggtaaaaagcagcttcctgattca\naatgagattgtggaaaaattgcttctaagaagaaagttcatccctgatccccagggctca\naacatgatgtttgcattctttgcccagcacttcacgcatcagtttttcaagacagatcat\naagcgagggccagctttcaccaacgggctgggccatggggtggacttaaatcatatttac\nggtgaaactctggctagacagcgtaaactgcgccttttcaaggatggaaaaatgaaatat\ncagataattgatggagagatgtatcctcccacagtcaaagatactcaggcagagatgatc\ntaccctcctcaagtccctgagcatctacggtttgctgtggggcaggaggtctttggtctg\ngtgcctggtctgatgatgtatgccacaatctggctgcgggaacacaacagagtatgcgat\ngtgcttaaacaggagcatcctgaatggggtgatgagcagttgttccagacaagcaggcta\natactgataggagagactattaagattgtgattgaagattatgtgcaacacttgagtggc\ntatcacttcaaactgaaatttgacccagaactacttttcaacaaacaattccagtaccaa\naatcgtattgctgctgaatttaacaccctctatcactggcatccccttctgcctgacacc\ntttcaaattcatgaccagaaatacaactatcaacagtttatctacaacaactctatattg\nctggaacatggaattacccagtttgttgaatcattcaccaggcaaattgctggcagggtt\ngctggtggtaggaatgttccacccgcagtacagaaagtatcacaggcttccattgaccag\nagcaggcagatgaaataccagtcttttaatgagtaccgcaaacgctttatgctgaagccc\ntatgaatcatttgaagaacttacaggagaaaaggaaatgtctgcagagttggaagcactc\ntatggtgacatcgatgctgtggagctgtatcctgcccttctggtagaaaagcctcggcca\ngatgccatctttggtgaaaccatggtagaagttggagcaccattctccttgaaaggactt\natgggtaatgttatatgttctcctgcctactggaagccaagcacttttggtggagaagtg\nggttttcaaatcatcaacactgcctcaattcagtctctcatctgcaataacgtgaagggc\ntgtccctttacttcattcagtgttccagatccagagctcattaaaacagtcaccatcaat\ngcaagttcttcccgctccggactagatgatatcaatcccacagtactactaaaagaacgt\ntcgactgaactgtag'),('https://www.genome.jp/dbget-bin/www_bget?hsa:5743','Homo sapiens (human): 5743','true','true','5743Â Â Â Â Â Â Â Â Â Â Â Â Â Â CDS','PTGS2, COX-2, COX2, GRIPGHS, PGG/HS, PGHS-2, PHS-2, hCox-2','(RefSeq) prostaglandin-endoperoxide synthase 2','604 aa \nMLARALLLCAVLALSHTANPCCSHPCQNRGVCMSVGFDQYKCDCTRTGFYGENCSTPEFL\nTRIKLFLKPTPNTVHYILTHFKGFWNVVNNIPFLRNAIMSYVLTSRSHLIDSPPTYNADY\nGYKSWEAFSNLSYYTRALPPVPDDCPTPLGVKGKKQLPDSNEIVEKLLLRRKFIPDPQGS\nNMMFAFFAQHFTHQFFKTDHKRGPAFTNGLGHGVDLNHIYGETLARQRKLRLFKDGKMKY\nQIIDGEMYPPTVKDTQAEMIYPPQVPEHLRFAVGQEVFGLVPGLMMYATIWLREHNRVCD\nVLKQEHPEWGDEQLFQTSRLILIGETIKIVIEDYVQHLSGYHFKLKFDPELLFNKQFQYQ\nNRIAAEFNTLYHWHPLLPDTFQIHDQKYNYQQFIYNNSILLEHGITQFVESFTRQIAGRV\nAGGRNVPPAVQKVSQASIDQSRQMKYQSFNEYRKRFMLKPYESFEELTGEKEMSAELEAL\nYGDIDAVELYPALLVEKPRPDAIFGETMVEVGAPFSLKGLMGNVICSPAYWKPSTFGGEV\nGFQIINTASIQSLICNNVKGCPFTSFSVPDPELIKTVTINASSSRSGLDDINPTVLLKER\nSTEL','1815 nt \natgctcgcccgcgccctgctgctgtgcgcggtcctggcgctcagccatacagcaaatcct\ntgctgttcccacccatgtcaaaaccgaggtgtatgtatgagtgtgggatttgaccagtat\naagtgcgattgtacccggacaggattctatggagaaaactgctcaacaccggaatttttg\nacaagaataaaattatttctgaaacccactccaaacacagtgcactacatacttacccac\nttcaagggattttggaacgttgtgaataacattcccttccttcgaaatgcaattatgagt\ntatgtgttgacatccagatcacatttgattgacagtccaccaacttacaatgctgactat\nggctacaaaagctgggaagccttctctaacctctcctattatactagagcccttcctcct\ngtgcctgatgattgcccgactcccttgggtgtcaaaggtaaaaagcagcttcctgattca\naatgagattgtggaaaaattgcttctaagaagaaagttcatccctgatccccagggctca\naacatgatgtttgcattctttgcccagcacttcacgcatcagtttttcaagacagatcat\naagcgagggccagctttcaccaacgggctgggccatggggtggacttaaatcatatttac\nggtgaaactctggctagacagcgtaaactgcgccttttcaaggatggaaaaatgaaatat\ncagataattgatggagagatgtatcctcccacagtcaaagatactcaggcagagatgatc\ntaccctcctcaagtccctgagcatctacggtttgctgtggggcaggaggtctttggtctg\ngtgcctggtctgatgatgtatgccacaatctggctgcgggaacacaacagagtatgcgat\ngtgcttaaacaggagcatcctgaatggggtgatgagcagttgttccagacaagcaggcta\natactgataggagagactattaagattgtgattgaagattatgtgcaacacttgagtggc\ntatcacttcaaactgaaatttgacccagaactacttttcaacaaacaattccagtaccaa\naatcgtattgctgctgaatttaacaccctctatcactggcatccccttctgcctgacacc\ntttcaaattcatgaccagaaatacaactatcaacagtttatctacaacaactctatattg\nctggaacatggaattacccagtttgttgaatcattcaccaggcaaattgctggcagggtt\ngctggtggtaggaatgttccacccgcagtacagaaagtatcacaggcttccattgaccag\nagcaggcagatgaaataccagtcttttaatgagtaccgcaaacgctttatgctgaagccc\ntatgaatcatttgaagaacttacaggagaaaaggaaatgtctgcagagttggaagcactc\ntatggtgacatcgatgctgtggagctgtatcctgcccttctggtagaaaagcctcggcca\ngatgccatctttggtgaaaccatggtagaagttggagcaccattctccttgaaaggactt\natgggtaatgttatatgttctcctgcctactggaagccaagcacttttggtggagaagtg\nggttttcaaatcatcaacactgcctcaattcagtctctcatctgcaataacgtgaagggc\ntgtccctttacttcattcagtgttccagatccagagctcattaaaacagtcaccatcaat\ngcaagttcttcccgctccggactagatgatatcaatcccacagtactactaaaagaacgt\ntcgactgaactgtag');

/*Table structure for table `pathway_table` */

DROP TABLE IF EXISTS `pathway_table`;

CREATE TABLE `pathway_table` (
  `pathway_name` varchar(200) NOT NULL,
  `pathway_link` varchar(200) DEFAULT NULL,
  `drugbank_id` varchar(200) DEFAULT NULL,
  PRIMARY KEY (`pathway_name`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

/*Data for the table `pathway_table` */

insert  into `pathway_table`(`pathway_name`,`pathway_link`,`drugbank_id`) values ('Acetaminophen Metabolism Pathway','http://smpdb.ca/view/SMP0000640?highlight[compounds][]=DB00316&highlight[proteins][]=DB00316','DB00316'),('Acetylsalicylic Acid Action Pathway','http://smpdb.ca/view/SMP0000083?highlight[compounds][]=DB00945&highlight[proteins][]=DB00945','DB00945'),('Alfentanil Action Pathway','http://smpdb.ca/view/SMP0000413?highlight[compounds][]=DB00802&highlight[proteins][]=DB00802','DB00802'),('Antipyrine Action Pathway','http://smpdb.ca/view/SMP0000692?highlight[compounds][]=DB01435&highlight[proteins][]=DB01435','DB01435'),('Bromfenac Action Pathway','http://smpdb.ca/view/SMP0000102?highlight[compounds][]=DB00963&highlight[proteins][]=DB00963','DB00963'),('Buprenorphine Action Pathway','http://smpdb.ca/view/SMP0000684?highlight[compounds][]=DB00921&highlight[proteins][]=DB00921','DB00921'),('Carbamazepine Metabolism Pathway','http://smpdb.ca/view/SMP0000634?highlight[compounds][]=DB00564&highlight[proteins][]=DB00564','DB00564'),('Carfentanil Action Pathway','http://smpdb.ca/view/SMP00414?highlight[compounds][]=DB01535&highlight[proteins][]=DB01535','DB01535'),('Carprofen Action Pathway','http://smpdb.ca/view/SMP00694?highlight[compounds][]=DB00821&highlight[proteins][]=DB00821','DB00821'),('Celecoxib Metabolism Pathway','http://smpdb.ca/view/SMP0000644?highlight[compounds][]=DB00482&highlight[proteins][]=DB00482','DB00482'),('Codeine Metabolism Pathway','http://smpdb.ca/view/SMP0000621?highlight[compounds][]=DB00318&highlight[proteins][]=DB00318','DB00318'),('Diclofenac Action Pathway','http://smpdb.ca/view/SMP0000093?highlight[compounds][]=DB00586&highlight[proteins][]=DB00586','DB00586'),('Diflunisal Action Pathway','http://smpdb.ca/view/SMP0000289?highlight[compounds][]=DB00861&highlight[proteins][]=DB00861','DB00861'),('Dihydromorphine Action Pathway','http://smpdb.ca/view/SMP00689?highlight[compounds][]=DB01565&highlight[proteins][]=DB01565','DB01565'),('Diphenoxylate Action Pathway','http://smpdb.ca/view/SMP00675?highlight[compounds][]=DB01081&highlight[proteins][]=DB01081','DB01081'),('Etodolac Action Pathway','http://smpdb.ca/view/SMP0000084?highlight[compounds][]=DB00749&highlight[proteins][]=DB00749','DB00749'),('Etoricoxib Action Pathway','http://smpdb.ca/view/SMP00695?highlight[compounds][]=DB01628&highlight[proteins][]=DB01628','DB01628'),('Fenoprofen Action Pathway','http://smpdb.ca/view/SMP0000696?highlight[compounds][]=DB00573&highlight[proteins][]=DB00573','DB00573'),('Fentanyl Action Pathway','http://smpdb.ca/view/SMP0000415?highlight[compounds][]=DB00813&highlight[proteins][]=DB00813','DB00813'),('Flurbiprofen Action Pathway','http://smpdb.ca/view/SMP0000697?highlight[compounds][]=DB00712&highlight[proteins][]=DB00712','DB00712'),('Heroin Metabolism Pathway','http://smpdb.ca/view/SMP0000623?highlight[compounds][]=DB00295&highlight[proteins][]=DB00295','DB00295'),('Hydrocodone Action Pathway','http://smpdb.ca/view/SMP0000411?highlight[compounds][]=DB00956&highlight[proteins][]=DB00956','DB00956'),('Hydromorphone Action Pathway','http://smpdb.ca/view/SMP0000410?highlight[compounds][]=DB00327&highlight[proteins][]=DB00327','DB00327'),('Ibuprofen Metabolism Pathway','http://smpdb.ca/view/SMP0000590?highlight[compounds][]=DB01050&highlight[proteins][]=DB01050','DB01050'),('Indomethacin Action Pathway','http://smpdb.ca/view/SMP0000104?highlight[compounds][]=DB00328&highlight[proteins][]=DB00328','DB00328'),('Ketobemidone Action Pathway','http://smpdb.ca/view/SMP0000690?highlight[compounds][]=DB06738&highlight[proteins][]=DB06738','DB06738'),('Ketoprofen Action Pathway','http://smpdb.ca/view/SMP0000085?highlight[compounds][]=DB01009&highlight[proteins][]=DB01009','DB01009'),('Ketorolac Action Pathway','http://smpdb.ca/view/SMP0000098?highlight[compounds][]=DB00465&highlight[proteins][]=DB00465','DB00465'),('Levorphanol Action Pathway','http://smpdb.ca/view/SMP0000673?highlight[compounds][]=DB00854&highlight[proteins][]=DB00854','DB00854'),('Magnesium salicylate Action Pathway','http://smpdb.ca/view/SMP00698?highlight[compounds][]=DB01397&highlight[proteins][]=DB01397','DB01397'),('Meloxicam Action Pathway','http://smpdb.ca/view/SMP0000106?highlight[compounds][]=DB00814&highlight[proteins][]=DB00814','DB00814'),('Methadone Action Pathway','http://smpdb.ca/view/SMP0000408?highlight[compounds][]=DB00333&highlight[proteins][]=DB00333','DB00333'),('Nabumetone Action Pathway','http://smpdb.ca/view/SMP0000114?highlight[compounds][]=DB00461&highlight[proteins][]=DB00461','DB00461'),('Nalbuphine Action Pathway','http://smpdb.ca/view/SMP0000691?highlight[compounds][]=DB00844&highlight[proteins][]=DB00844','DB00844'),('Naproxen Action Pathway','http://smpdb.ca/view/SMP0000120?highlight[compounds][]=DB00788&highlight[proteins][]=DB00788','DB00788'),('Nepafenac Action Pathway','http://smpdb.ca/view/SMP0000702?highlight[compounds][]=DB06802&highlight[proteins][]=DB06802','DB06802'),('None','None','DB13514'),('Olopatadine H1-Antihistamine Action','http://smpdb.ca/view/SMP0060740?highlight[compounds][]=DB00768&highlight[proteins][]=DB00768','DB00768'),('Oxaprozin Action Pathway','http://smpdb.ca/view/SMP0000113?highlight[compounds][]=DB00991&highlight[proteins][]=DB00991','DB00991'),('Oxycodone Action Pathway','http://smpdb.ca/view/SMP0000409?highlight[compounds][]=DB00497&highlight[proteins][]=DB00497','DB00497'),('Oxymorphone Action Pathway','http://smpdb.ca/view/SMP0000412?highlight[compounds][]=DB01192&highlight[proteins][]=DB01192','DB01192'),('Phenylbutazone Action Pathway','http://smpdb.ca/view/SMP00701?highlight[compounds][]=DB00812&highlight[proteins][]=DB00812','DB00812'),('Phosphatidylcholine Biosynthesis PC(18:0/14:0)','http://smpdb.ca/view/SMP0014361?highlight[compounds][]=DB00122&highlight[proteins][]=DB00122','DB00122'),('Piroxicam Action Pathway','http://smpdb.ca/view/SMP0000077?highlight[compounds][]=DB00554&highlight[proteins][]=DB00554','DB00554'),('Propoxyphene Action Pathway','http://smpdb.ca/view/SMP0000672?highlight[compounds][]=DB00647&highlight[proteins][]=DB00647','DB00647'),('Remifentanil Action Pathway','http://smpdb.ca/view/SMP0000416?highlight[compounds][]=DB00899&highlight[proteins][]=DB00899','DB00899'),('S-Adenosylhomocysteine (SAH) Hydrolase Deficiency','http://smpdb.ca/view/SMP0000214?highlight[compounds][]=DB00640&highlight[proteins][]=DB00640','DB00640'),('Salicylic Acid Action Pathway','http://smpdb.ca/view/SMP0000709?highlight[compounds][]=DB00936&highlight[proteins][]=DB00936','DB00936'),('Sufentanil Action Pathway','http://smpdb.ca/view/SMP0000417?highlight[compounds][]=DB00708&highlight[proteins][]=DB00708','DB00708'),('Sulindac Action Pathway','http://smpdb.ca/view/SMP0000094?highlight[compounds][]=DB00605&highlight[proteins][]=DB00605','DB00605'),('Tolmetin Action Pathway','http://smpdb.ca/view/SMP0000704?highlight[compounds][]=DB00500&highlight[proteins][]=DB00500','DB00500'),('Tramadol Action Action Pathway','http://smpdb.ca/view/SMP0000671?highlight[compounds][]=DB00193&highlight[proteins][]=DB00193','DB00193'),('Valdecoxib Action Pathway','http://smpdb.ca/view/SMP0000116?highlight[compounds][]=DB00580&highlight[proteins][]=DB00580','DB00580');

/*Table structure for table `sideeffect_of_sider_drug` */

DROP TABLE IF EXISTS `sideeffect_of_sider_drug`;

CREATE TABLE `sideeffect_of_sider_drug` (
  `sideeffect_link` varchar(200) NOT NULL,
  `sideeffect_name` varchar(200) DEFAULT NULL,
  `sider_drug_name` varchar(200) DEFAULT NULL,
  `sider_drug_link` varchar(200) DEFAULT NULL,
  PRIMARY KEY (`sideeffect_link`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

/*Data for the table `sideeffect_of_sider_drug` */

insert  into `sideeffect_of_sider_drug`(`sideeffect_link`,`sideeffect_name`,`sider_drug_name`,`sider_drug_link`) values ('http://sideeffects.embl.de/se/C0000727/','Acute abdomen','Vincristine','http://sideeffects.embl.de/drugs/5978/'),('http://sideeffects.embl.de/se/C0000729/','Abdominal cramps','Almotriptan','http://sideeffects.embl.de/drugs/123606/'),('http://sideeffects.embl.de/se/C0000731/','Abdominal distension','Liraglutide','http://sideeffects.embl.de/drugs/16134956/'),('http://sideeffects.embl.de/se/C0000737/','Abdominal pain','K779','http://sideeffects.embl.de/drugs/71306834/'),('http://sideeffects.embl.de/se/C0000768/','Congenital anomaly','Rifabutin','http://sideeffects.embl.de/drugs/5361912/'),('http://sideeffects.embl.de/se/C0000786/','Abortion spontaneous','Sitaxsentan','http://sideeffects.embl.de/drugs/216235/'),('http://sideeffects.embl.de/se/C0000817/','Abortion infected','Copper','http://sideeffects.embl.de/drugs/23978/'),('http://sideeffects.embl.de/se/C0000833/','Abscess','Cabozantinib','http://sideeffects.embl.de/drugs/25102847/'),('http://sideeffects.embl.de/se/C0001122/','Acidosis','Vinflunine','http://sideeffects.embl.de/drugs/157688/'),('http://sideeffects.embl.de/se/C0001125/','Lactic acidosis','Sitaxsentan','http://sideeffects.embl.de/drugs/216235/'),('http://sideeffects.embl.de/se/C0001126/','Renal tubular acidosis','Streptozotocin','http://sideeffects.embl.de/drugs/5300/'),('http://sideeffects.embl.de/se/C0001175/','Acquired immunodeficiency syndrome','D-telaprevir','http://sideeffects.embl.de/drugs/3010818/'),('http://sideeffects.embl.de/se/C0001339/','Pancreatitis acute','Liraglutide','http://sideeffects.embl.de/drugs/16134956/'),('http://sideeffects.embl.de/se/C0001349/','Acute phase reaction','Alendronate','http://sideeffects.embl.de/drugs/2088/'),('http://sideeffects.embl.de/se/C0001364/','Acute yellow liver atrophy','Trovafloxacin','http://sideeffects.embl.de/drugs/62959/'),('http://sideeffects.embl.de/se/C0001416/','Adenitis','Trimipramine','http://sideeffects.embl.de/drugs/5584/'),('http://sideeffects.embl.de/se/C0001430/','Adenoma benign','Celecoxib','http://sideeffects.embl.de/drugs/2662/'),('http://sideeffects.embl.de/se/C0001546/','Adjustment disorder','Doxepin','http://sideeffects.embl.de/drugs/3158/'),('http://sideeffects.embl.de/se/C0001621/','Adrenal disorder','Vincristine','http://sideeffects.embl.de/drugs/5978/'),('http://sideeffects.embl.de/se/C0001622/','Hyperadrenocorticism','Mometasone','http://sideeffects.embl.de/drugs/123620/'),('http://sideeffects.embl.de/se/C0001623/','Adrenal insufficiency','Rifampicin','http://sideeffects.embl.de/drugs/5381226/'),('http://sideeffects.embl.de/se/C0001707/','Aerophagia','Lomitapide','http://sideeffects.embl.de/drugs/9853053/'),('http://sideeffects.embl.de/se/C0001807/','Aggression','Perampanel','http://sideeffects.embl.de/drugs/9924495/'),('http://sideeffects.embl.de/se/C0001824/','Agranulocytosis','Cefdinir','http://sideeffects.embl.de/drugs/6398970/'),('http://sideeffects.embl.de/se/C0001883/','Airway obstruction NOS','Fesoterodine','http://sideeffects.embl.de/drugs/6918558/'),('http://sideeffects.embl.de/se/C0001925/','Albuminuria','Insulin detemir','http://sideeffects.embl.de/drugs/16137271/'),('http://sideeffects.embl.de/se/C0001957/','Delirium tremens','Nitrazepam','http://sideeffects.embl.de/drugs/4506/'),('http://sideeffects.embl.de/se/C0001969/','Alcohol intoxication','Clonazepam','http://sideeffects.embl.de/drugs/2802/'),('http://sideeffects.embl.de/se/C0001973/','Alcoholism','6-thioguanine','http://sideeffects.embl.de/drugs/2723601/'),('http://sideeffects.embl.de/se/C0002063/','Alkalosis','Sodium bicarbonate','http://sideeffects.embl.de/drugs/10340/'),('http://sideeffects.embl.de/se/C0002064/','Respiratory alkalosis','Aspirin','http://sideeffects.embl.de/drugs/2244/'),('http://sideeffects.embl.de/se/C0002170/','Alopecia','K779','http://sideeffects.embl.de/drugs/71306834/'),('http://sideeffects.embl.de/se/C0002390/','Alveolitis allergic','Sitaxsentan','http://sideeffects.embl.de/drugs/216235/'),('http://sideeffects.embl.de/se/C0002418/','Amblyopia','Histrelin','http://sideeffects.embl.de/drugs/25077993/'),('http://sideeffects.embl.de/se/C0002447/','Amelia','Clomiphene citrate','http://sideeffects.embl.de/drugs/2800/'),('http://sideeffects.embl.de/se/C0002453/','Amenorrhoea','Cabozantinib','http://sideeffects.embl.de/drugs/25102847/'),('http://sideeffects.embl.de/se/C0002622/','Amnesia','MDV3100','http://sideeffects.embl.de/drugs/15951529/'),('http://sideeffects.embl.de/se/C0002624/','Retrograde amnesia','Nitrazepam','http://sideeffects.embl.de/drugs/4506/'),('http://sideeffects.embl.de/se/C0002792/','Anaphylactic shock','Pegaptanib','http://sideeffects.embl.de/drugs/56603655/'),('http://sideeffects.embl.de/se/C0002871/','Anaemia','K779','http://sideeffects.embl.de/drugs/71306834/'),('http://sideeffects.embl.de/se/C0002874/','Aplastic anaemia','Cefdinir','http://sideeffects.embl.de/drugs/6398970/'),('http://sideeffects.embl.de/se/C0002878/','Haemolytic anaemia','Cefdinir','http://sideeffects.embl.de/drugs/6398970/'),('http://sideeffects.embl.de/se/C0002880/','Autoimmune haemolytic anaemia','Mefenamic acid','http://sideeffects.embl.de/drugs/4044/'),('http://sideeffects.embl.de/se/C0002884/','Hypochromic anaemia','Insulin detemir','http://sideeffects.embl.de/drugs/16137271/'),('http://sideeffects.embl.de/se/C0002886/','Anaemia macrocytic','Flutamide','http://sideeffects.embl.de/drugs/3397/'),('http://sideeffects.embl.de/se/C0002888/','Anaemia megaloblastic','Voriconazole','http://sideeffects.embl.de/drugs/71616/'),('http://sideeffects.embl.de/se/C0002891/','Anaemia neonatal','Ifosfamide','http://sideeffects.embl.de/drugs/3690/'),('http://sideeffects.embl.de/se/C0002893/','Refractory anemia','Lomustine','http://sideeffects.embl.de/drugs/3950/'),('http://sideeffects.embl.de/se/C0002896/','Sideroblastic anaemia','Pyridoxine','http://sideeffects.embl.de/drugs/1054/'),('http://sideeffects.embl.de/se/C0002902/','Anencephaly','Clomiphene citrate','http://sideeffects.embl.de/drugs/2800/'),('http://sideeffects.embl.de/se/C0002940/','Aneurysm','Insulin detemir','http://sideeffects.embl.de/drugs/16137271/'),('http://sideeffects.embl.de/se/C0002957/','Anger','Lu AA21004','http://sideeffects.embl.de/drugs/9966051/'),('http://sideeffects.embl.de/se/C0002962/','Angina pectoris','Cabozantinib','http://sideeffects.embl.de/drugs/25102847/'),('http://sideeffects.embl.de/se/C0002965/','Angina unstable','Dapagliflozin','http://sideeffects.embl.de/drugs/9887712/'),('http://sideeffects.embl.de/se/C0002994/','Angioedema','Pegaptanib','http://sideeffects.embl.de/drugs/56603655/'),('http://sideeffects.embl.de/se/C0003028/','Anhidrosis','Propantheline','http://sideeffects.embl.de/drugs/4934/'),('http://sideeffects.embl.de/se/C0003044/','Animal bite','Sitaxsentan','http://sideeffects.embl.de/drugs/216235/'),('http://sideeffects.embl.de/se/C0003123/','Anorexia','K779','http://sideeffects.embl.de/drugs/71306834/'),('http://sideeffects.embl.de/se/C0003126/','Anosmia','Telithromycin','http://sideeffects.embl.de/drugs/73658/'),('http://sideeffects.embl.de/se/C0003130/','Anoxia','Dapsone','http://sideeffects.embl.de/drugs/2955/'),('http://sideeffects.embl.de/se/C0003460/','Anuria','Sulfamethoxazole','http://sideeffects.embl.de/drugs/5329/'),('http://sideeffects.embl.de/se/C0003466/','Anal atresia','Clomiphene citrate','http://sideeffects.embl.de/drugs/2800/'),('http://sideeffects.embl.de/se/C0003467/','Anxiety','K779','http://sideeffects.embl.de/drugs/71306834/'),('http://sideeffects.embl.de/se/C0003469/','Anxiety disorder','Hydrochlorothiazide','http://sideeffects.embl.de/drugs/3639/'),('http://sideeffects.embl.de/se/C0003486/','Aortic aneurysm','Pegaptanib','http://sideeffects.embl.de/drugs/56603655/'),('http://sideeffects.embl.de/se/C0003492/','Coarctation of the aorta','Clomiphene citrate','http://sideeffects.embl.de/drugs/2800/'),('http://sideeffects.embl.de/se/C0003507/','Aortic valve stenosis','Valdecoxib','http://sideeffects.embl.de/drugs/119607/'),('http://sideeffects.embl.de/se/C0003537/','Aphasia','Rifabutin','http://sideeffects.embl.de/drugs/5361912/'),('http://sideeffects.embl.de/se/C0003564/','Aphonia','Lidocaine','http://sideeffects.embl.de/drugs/3676/'),('http://sideeffects.embl.de/se/C0003578/','Apnoea','Colimycin M','http://sideeffects.embl.de/drugs/216258/'),('http://sideeffects.embl.de/se/C0003615/','Appendicitis','Vandetanib','http://sideeffects.embl.de/drugs/3081361/'),('http://sideeffects.embl.de/se/C0003621/','Appetite disorder','Sotalol','http://sideeffects.embl.de/drugs/5253/'),('http://sideeffects.embl.de/se/C0003708/','Arachnoiditis','Prilocaine','http://sideeffects.embl.de/drugs/4906/'),('http://sideeffects.embl.de/se/C0003811/','Arrhythmia','Degarelix','http://sideeffects.embl.de/drugs/16136245/'),('http://sideeffects.embl.de/se/C0003813/','Sinus arrhythmia','Paliperidone','http://sideeffects.embl.de/drugs/115237/'),('http://sideeffects.embl.de/se/C0003834/','Arterial insufficiency','Propranolol','http://sideeffects.embl.de/drugs/4946/'),('http://sideeffects.embl.de/se/C0003855/','Arteriovenous fistula','Bivalirudin','http://sideeffects.embl.de/drugs/16129704/'),('http://sideeffects.embl.de/se/C0003862/','Arthralgia','K779','http://sideeffects.embl.de/drugs/71306834/'),('http://sideeffects.embl.de/se/C0003864/','Arthritis','Pegaptanib','http://sideeffects.embl.de/drugs/56603655/'),('http://sideeffects.embl.de/se/C0003868/','Gouty arthritis','Ticagrelor','http://sideeffects.embl.de/drugs/9871419/'),('http://sideeffects.embl.de/se/C0003869/','Arthritis infective','Sitaxsentan','http://sideeffects.embl.de/drugs/216235/'),('http://sideeffects.embl.de/se/C0003873/','Rheumatoid arthritis','Nepafenac','http://sideeffects.embl.de/drugs/151075/'),('http://sideeffects.embl.de/se/C0003962/','Ascites','Nafarelin','http://sideeffects.embl.de/drugs/25077405/'),('http://sideeffects.embl.de/se/C0004044/','Asphyxia','Trifluoperazine','http://sideeffects.embl.de/drugs/5566/'),('http://sideeffects.embl.de/se/C0004063/','Assault','Midazolam','http://sideeffects.embl.de/drugs/4192/'),('http://sideeffects.embl.de/se/C0004093/','Asthenia','K779','http://sideeffects.embl.de/drugs/71306834/'),('http://sideeffects.embl.de/se/C0004095/','Asthenopia','Pegaptanib','http://sideeffects.embl.de/drugs/56603655/'),('http://sideeffects.embl.de/se/C0004096/','Asthma','Insulin','http://sideeffects.embl.de/drugs/16129672/'),('http://sideeffects.embl.de/se/C0004114/','Astrocytoma','Clomiphene citrate','http://sideeffects.embl.de/drugs/2800/'),('http://sideeffects.embl.de/se/C0004134/','Ataxia','Cabozantinib','http://sideeffects.embl.de/drugs/25102847/'),('http://sideeffects.embl.de/se/C0004144/','Atelectasis','Cabozantinib','http://sideeffects.embl.de/drugs/25102847/'),('http://sideeffects.embl.de/se/C0004158/','Athetosis','Midazolam','http://sideeffects.embl.de/drugs/4192/'),('http://sideeffects.embl.de/se/C0004238/','Atrial fibrillation','Cabozantinib','http://sideeffects.embl.de/drugs/25102847/'),('http://sideeffects.embl.de/se/C0004239/','Atrial flutter','Ixabepilone','http://sideeffects.embl.de/drugs/6445540/'),('http://sideeffects.embl.de/se/C0004245/','Atrioventricular block','Fluticasone furoate','http://sideeffects.embl.de/drugs/9854489/'),('http://sideeffects.embl.de/se/C0004331/','Atrioventricular dissociation','Verapamil','http://sideeffects.embl.de/drugs/2520/'),('http://sideeffects.embl.de/se/C0004364/','Autoimmune disorder','Elvitegravir','http://sideeffects.embl.de/drugs/5277135/'),('http://sideeffects.embl.de/se/C0004377/','Automatism','Risperidone','http://sideeffects.embl.de/drugs/5073/'),('http://sideeffects.embl.de/se/C0004509/','Azoospermia','Thiotepa','http://sideeffects.embl.de/drugs/5453/'),('http://sideeffects.embl.de/se/C0004601/','Back injury','Doxepin','http://sideeffects.embl.de/drugs/3158/'),('http://sideeffects.embl.de/se/C0004604/','Back pain','Pegaptanib','http://sideeffects.embl.de/drugs/56603655/'),('http://sideeffects.embl.de/se/C0004610/','Bacteraemia','Rifabutin','http://sideeffects.embl.de/drugs/5361912/'),('http://sideeffects.embl.de/se/C0004623/','Bacterial infection','Carfilzomib','http://sideeffects.embl.de/drugs/11556711/'),('http://sideeffects.embl.de/se/C0004626/','Pneumonia bacterial','Pentamidine','http://sideeffects.embl.de/drugs/4735/'),('http://sideeffects.embl.de/se/C0004659/','Bacteriuria','Itraconazole','http://sideeffects.embl.de/drugs/3793/'),('http://sideeffects.embl.de/se/C0004690/','Balanitis','Empagliflozin','http://sideeffects.embl.de/drugs/11949646/'),('http://sideeffects.embl.de/se/C0004691/','Balanoposthitis','Trovafloxacin','http://sideeffects.embl.de/drugs/62959/'),('http://sideeffects.embl.de/se/C0004930/','Behavior disorder','Lormetazepam','http://sideeffects.embl.de/drugs/13314/'),('http://sideeffects.embl.de/se/C0004936/','Mental disorder','Pegaptanib','http://sideeffects.embl.de/drugs/56603655/'),('http://sideeffects.embl.de/se/C0004998/','Benign neoplasm of skin','Glat copolymer','http://sideeffects.embl.de/drugs/65370/'),('http://sideeffects.embl.de/se/C0005001/','Benign prostatic hypertrophy','Famotidine','http://sideeffects.embl.de/drugs/3325/'),('http://sideeffects.embl.de/se/C0005398/','Cholestasis extrahepatic','Bumetanide','http://sideeffects.embl.de/drugs/2471/'),('http://sideeffects.embl.de/se/C0005586/','Bipolar disorder','Carbamazepine','http://sideeffects.embl.de/drugs/2554/'),('http://sideeffects.embl.de/se/C0005681/','Blackwater fever','Quinidine','http://sideeffects.embl.de/drugs/1065/'),('http://sideeffects.embl.de/se/C0005684/','Bladder cancer','Dapagliflozin','http://sideeffects.embl.de/drugs/9887712/'),('http://sideeffects.embl.de/se/C0005686/','Bladder disorder','Thiotepa','http://sideeffects.embl.de/drugs/5453/'),('http://sideeffects.embl.de/se/C0005694/','Bladder neck obstruction','Acetaminophen','http://sideeffects.embl.de/drugs/1983/'),('http://sideeffects.embl.de/se/C0005697/','Neurogenic bladder','Benzathine penicillin','http://sideeffects.embl.de/drugs/15232/'),('http://sideeffects.embl.de/se/C0005741/','Blepharitis','Pegaptanib','http://sideeffects.embl.de/drugs/56603655/'),('http://sideeffects.embl.de/se/C0005743/','Blepharoconjunctivitis','Cyclopentolate','http://sideeffects.embl.de/drugs/2905/'),('http://sideeffects.embl.de/se/C0005745/','Eyelid ptosis','Pegaptanib','http://sideeffects.embl.de/drugs/56603655/'),('http://sideeffects.embl.de/se/C0005747/','Blepharospasm','Bimatoprost','http://sideeffects.embl.de/drugs/127909/'),('http://sideeffects.embl.de/se/C0005758/','Blister','Cabozantinib','http://sideeffects.embl.de/drugs/25102847/'),('http://sideeffects.embl.de/se/C0005778/','Clotting','Valdecoxib','http://sideeffects.embl.de/drugs/119607/'),('http://sideeffects.embl.de/se/C0005779/','Coagulopathy','Ixabepilone','http://sideeffects.embl.de/drugs/6445540/'),('http://sideeffects.embl.de/se/C0005940/','Bone disorder','Degarelix','http://sideeffects.embl.de/drugs/16136245/'),('http://sideeffects.embl.de/se/C0005944/','Bone metabolism disorder','Eslicarbazepine acetate','http://sideeffects.embl.de/drugs/179344/'),('http://sideeffects.embl.de/se/C0006079/','Bowen\'s disease','Dabrafenib','http://sideeffects.embl.de/drugs/44462760/'),('http://sideeffects.embl.de/se/C0006105/','Brain abscess','BCNU','http://sideeffects.embl.de/drugs/2578/'),('http://sideeffects.embl.de/se/C0006112/','Metabolic encephalopathy','4-PBA','http://sideeffects.embl.de/drugs/4775/'),('http://sideeffects.embl.de/se/C0006114/','Edema cerebral','Sodium bicarbonate','http://sideeffects.embl.de/drugs/10340/'),('http://sideeffects.embl.de/se/C0006118/','Brain neoplasm','NTBC','http://sideeffects.embl.de/drugs/115355/'),('http://sideeffects.embl.de/se/C0006142/','Breast cancer','Mirabegron','http://sideeffects.embl.de/drugs/9865528/'),('http://sideeffects.embl.de/se/C0006145/','Breast disorder','Cabozantinib','http://sideeffects.embl.de/drugs/25102847/'),('http://sideeffects.embl.de/se/C0006147/','Breast feeding','Delavirdine','http://sideeffects.embl.de/drugs/5625/'),('http://sideeffects.embl.de/se/C0006266/','Bronchospasm','Rifapentine','http://sideeffects.embl.de/drugs/6323497/'),('http://sideeffects.embl.de/se/C0006272/','Obliterative bronchiolitis','Cyclophosphamide','http://sideeffects.embl.de/drugs/2907/'),('http://sideeffects.embl.de/se/C0006277/','Bronchitis','Pegaptanib','http://sideeffects.embl.de/drugs/56603655/'),('http://sideeffects.embl.de/se/C0006285/','Bronchopneumonia','Bosutinib','http://sideeffects.embl.de/drugs/5328940/'),('http://sideeffects.embl.de/se/C0006287/','Bronchopulmonary dysplasia','Ibuprofen','http://sideeffects.embl.de/drugs/3672/'),('http://sideeffects.embl.de/se/C0006325/','Bruxism','Lu AA21004','http://sideeffects.embl.de/drugs/9966051/'),('http://sideeffects.embl.de/se/C0006384/','Bundle branch block','Paliperidone','http://sideeffects.embl.de/drugs/115237/'),('http://sideeffects.embl.de/se/C0006413/','Burkitt\'s lymphoma','Rifabutin','http://sideeffects.embl.de/drugs/5361912/'),('http://sideeffects.embl.de/se/C0006444/','Bursitis','Glat copolymer','http://sideeffects.embl.de/drugs/65370/'),('http://sideeffects.embl.de/se/C0006625/','Cachexia','Perhexiline','http://sideeffects.embl.de/drugs/4746/'),('http://sideeffects.embl.de/se/C0006663/','Calcinosis','Doxercalciferol','http://sideeffects.embl.de/drugs/4479094/'),('http://sideeffects.embl.de/se/C0006826/','Neoplasm malignant','Florbetapir','http://sideeffects.embl.de/drugs/24822371/'),('http://sideeffects.embl.de/se/C0006840/','Candida infection','Vinflunine','http://sideeffects.embl.de/drugs/157688/'),('http://sideeffects.embl.de/se/C0006849/','Oral candidiasis','D-telaprevir','http://sideeffects.embl.de/drugs/3010818/'),('http://sideeffects.embl.de/se/C0006852/','Vaginal moniliasis','Empagliflozin','http://sideeffects.embl.de/drugs/11949646/'),('http://sideeffects.embl.de/se/C0007097/','Carcinoma','Rifapentine','http://sideeffects.embl.de/drugs/6323497/'),('http://sideeffects.embl.de/se/C0007114/','Skin cancer','Hydroxyurea','http://sideeffects.embl.de/drugs/3657/'),('http://sideeffects.embl.de/se/C0007117/','Basal cell carcinoma','Dabrafenib','http://sideeffects.embl.de/drugs/44462760/'),('http://sideeffects.embl.de/se/C0007134/','Renal cell carcinoma','Cyclophosphamide','http://sideeffects.embl.de/drugs/2907/'),('http://sideeffects.embl.de/se/C0007137/','Squamous cell carcinoma','Regorafenib','http://sideeffects.embl.de/drugs/11167602/'),('http://sideeffects.embl.de/se/C0007166/','Cardiac output decreased','Disopyramide','http://sideeffects.embl.de/drugs/3114/'),('http://sideeffects.embl.de/se/C0007177/','Cardiac tamponade','Bivalirudin','http://sideeffects.embl.de/drugs/16129704/'),('http://sideeffects.embl.de/se/C0007193/','Congestive cardiomyopathy','Gemifloxacin','http://sideeffects.embl.de/drugs/72938/'),('http://sideeffects.embl.de/se/C0007194/','Hypertrophic cardiomyopathy','Verapamil','http://sideeffects.embl.de/drugs/2520/'),('http://sideeffects.embl.de/se/C0007222/','Cardiovascular disorder','Vinflunine','http://sideeffects.embl.de/drugs/157688/'),('http://sideeffects.embl.de/se/C0007286/','Carpal tunnel syndrome','Exemestane','http://sideeffects.embl.de/drugs/60198/'),('http://sideeffects.embl.de/se/C0007384/','Cataplexy','Hydroxybutyrate','http://sideeffects.embl.de/drugs/10413/'),('http://sideeffects.embl.de/se/C0007398/','Catatonia','Iloperidone','http://sideeffects.embl.de/drugs/71360/'),('http://sideeffects.embl.de/se/C0007642/','Cellulitis','Boceprevir','http://sideeffects.embl.de/drugs/10324367/'),('http://sideeffects.embl.de/se/C0007682/','Central nervous system disorder','Fesoterodine','http://sideeffects.embl.de/drugs/6918558/'),('http://sideeffects.embl.de/se/C0007758/','Cerebellar ataxia','5-FU','http://sideeffects.embl.de/drugs/3385/'),('http://sideeffects.embl.de/se/C0007760/','Cerebellar syndrome','Eslicarbazepine acetate','http://sideeffects.embl.de/drugs/179344/'),('http://sideeffects.embl.de/se/C0007766/','Intracranial aneurysm','Thiotepa','http://sideeffects.embl.de/drugs/5453/'),('http://sideeffects.embl.de/se/C0007773/','Cerebral arteritis','Cisplatin','http://sideeffects.embl.de/drugs/2767/'),('http://sideeffects.embl.de/se/C0007785/','Cerebral infarction','Lasofoxifene','http://sideeffects.embl.de/drugs/216416/'),('http://sideeffects.embl.de/se/C0007787/','Transient ischaemic attack','Pegaptanib','http://sideeffects.embl.de/drugs/56603655/'),('http://sideeffects.embl.de/se/C0007820/','Cerebrovascular disorder','Parecoxib','http://sideeffects.embl.de/drugs/119828/'),('http://sideeffects.embl.de/se/C0007855/','Cervical polyp','Lasofoxifene','http://sideeffects.embl.de/drugs/216416/'),('http://sideeffects.embl.de/se/C0007859/','Neck pain','Histrelin','http://sideeffects.embl.de/drugs/25077993/'),('http://sideeffects.embl.de/se/C0007867/','Cervix disorder','Lasofoxifene','http://sideeffects.embl.de/drugs/216416/'),('http://sideeffects.embl.de/se/C0007868/','Cervical dysplasia','Lasofoxifene','http://sideeffects.embl.de/drugs/216416/'),('http://sideeffects.embl.de/se/C0007869/','Uterine cervical erosion','Lasofoxifene','http://sideeffects.embl.de/drugs/216416/'),('http://sideeffects.embl.de/se/C0007933/','Chalazion','Pegaptanib','http://sideeffects.embl.de/drugs/56603655/'),('http://sideeffects.embl.de/se/C0007971/','Cheilitis','Boceprevir','http://sideeffects.embl.de/drugs/10324367/'),('http://sideeffects.embl.de/se/C0008031/','Chest pain','Pegaptanib','http://sideeffects.embl.de/drugs/56603655/'),('http://sideeffects.embl.de/se/C0008033/','Pleuritic pain','Ivacaftor','http://sideeffects.embl.de/drugs/16220172/'),('http://sideeffects.embl.de/se/C0008035/','Chest wall pain','Carfilzomib','http://sideeffects.embl.de/drugs/11556711/'),('http://sideeffects.embl.de/se/C0008049/','Varicella','Desloratadine','http://sideeffects.embl.de/drugs/124087/'),('http://sideeffects.embl.de/se/C0008301/','Choking','Salmeterol','http://sideeffects.embl.de/drugs/5152/'),('http://sideeffects.embl.de/se/C0008311/','Cholangitis','Rabeprazole','http://sideeffects.embl.de/drugs/5029/'),('http://sideeffects.embl.de/se/C0008325/','Cholecystitis','Teduglutide','http://sideeffects.embl.de/drugs/16139605/'),('http://sideeffects.embl.de/se/C0008350/','Cholelithiasis','SOM230','http://sideeffects.embl.de/drugs/9941444/'),('http://sideeffects.embl.de/se/C0008370/','Cholestasis','Teduglutide','http://sideeffects.embl.de/drugs/16139605/'),('http://sideeffects.embl.de/se/C0008372/','Cholestasis intrahepatic','Pentoxifylline','http://sideeffects.embl.de/drugs/4740/'),('http://sideeffects.embl.de/se/C0008489/','Chorea','Cyclizine','http://sideeffects.embl.de/drugs/6726/'),('http://sideeffects.embl.de/se/C0008497/','Choriocarcinoma','Clomiphene citrate','http://sideeffects.embl.de/drugs/2800/'),('http://sideeffects.embl.de/se/C0008626/','Cytogenetic abnormality','Clomiphene citrate','http://sideeffects.embl.de/drugs/2800/'),('http://sideeffects.embl.de/se/C0008728/','Allergic granulomatous angiitis','Zafirlukast','http://sideeffects.embl.de/drugs/5717/'),('http://sideeffects.embl.de/se/C0008909/','Claustrophobia','Florbetapir','http://sideeffects.embl.de/drugs/24822371/'),('http://sideeffects.embl.de/se/C0008924/','Cleft lip','Clomiphene citrate','http://sideeffects.embl.de/drugs/2800/'),('http://sideeffects.embl.de/se/C0009024/','Clonus','Metaproterenol','http://sideeffects.embl.de/drugs/4086/'),('http://sideeffects.embl.de/se/C0009081/','Congenital clubfoot','Clomiphene citrate','http://sideeffects.embl.de/drugs/2800/'),('http://sideeffects.embl.de/se/C0009241/','Cognitive disorder','MDV3100','http://sideeffects.embl.de/drugs/15951529/'),('http://sideeffects.embl.de/se/C0009319/','Colitis','Vandetanib','http://sideeffects.embl.de/drugs/3081361/'),('http://sideeffects.embl.de/se/C0009324/','Colitis ulcerative','Balsalazide','http://sideeffects.embl.de/drugs/5362070/'),('http://sideeffects.embl.de/se/C0009326/','Collagen disorder','Labetalol','http://sideeffects.embl.de/drugs/3869/'),('http://sideeffects.embl.de/se/C0009377/','Colonic pseudo-obstruction','Vinflunine','http://sideeffects.embl.de/drugs/157688/'),('http://sideeffects.embl.de/se/C0009421/','Coma','Retigabine','http://sideeffects.embl.de/drugs/121892/'),('http://sideeffects.embl.de/se/C0009443/','Common cold','Bimatoprost','http://sideeffects.embl.de/drugs/127909/'),('http://sideeffects.embl.de/se/C0009447/','Immunodeficiency common variable','Gamma-aminobutyric acid','http://sideeffects.embl.de/drugs/119/'),('http://sideeffects.embl.de/se/C0009450/','Infection','Vemurafenib','http://sideeffects.embl.de/drugs/42611257/'),('http://sideeffects.embl.de/se/C0009492/','Compartment syndrome','Bivalirudin','http://sideeffects.embl.de/drugs/16129704/'),('http://sideeffects.embl.de/se/C0009676/','Confusional state','Perampanel','http://sideeffects.embl.de/drugs/9924495/'),('http://sideeffects.embl.de/se/C0009759/','Conjunctival disorder','Betaxolol','http://sideeffects.embl.de/drugs/2369/'),('http://sideeffects.embl.de/se/C0009760/','Conjunctival haemorrhage','Pegaptanib','http://sideeffects.embl.de/drugs/56603655/'),('http://sideeffects.embl.de/se/C0009763/','Conjunctivitis','Pegaptanib','http://sideeffects.embl.de/drugs/56603655/'),('http://sideeffects.embl.de/se/C0009766/','Conjunctivitis allergic','Pegaptanib','http://sideeffects.embl.de/drugs/56603655/'),('http://sideeffects.embl.de/se/C0009782/','Connective tissue disorder','Pegaptanib','http://sideeffects.embl.de/drugs/56603655/'),('http://sideeffects.embl.de/se/C0009806/','Constipation','Vemurafenib','http://sideeffects.embl.de/drugs/42611257/'),('http://sideeffects.embl.de/se/C0009917/','Muscle contracture','Vinflunine','http://sideeffects.embl.de/drugs/157688/'),('http://sideeffects.embl.de/se/C0009938/','Contusion','Pegaptanib','http://sideeffects.embl.de/drugs/56603655/'),('http://sideeffects.embl.de/se/C0009952/','Febrile convulsion','Eslicarbazepine acetate','http://sideeffects.embl.de/drugs/179344/'),('http://sideeffects.embl.de/se/C0010032/','Corneal abrasion','Pegaptanib','http://sideeffects.embl.de/drugs/56603655/'),('http://sideeffects.embl.de/se/C0010034/','Corneal disorder','Pegaptanib','http://sideeffects.embl.de/drugs/56603655/'),('http://sideeffects.embl.de/se/C0010036/','Corneal dystrophy','Pegaptanib','http://sideeffects.embl.de/drugs/56603655/'),('http://sideeffects.embl.de/se/C0010037/','Corneal oedema','Pegaptanib','http://sideeffects.embl.de/drugs/56603655/'),('http://sideeffects.embl.de/se/C0010038/','Corneal opacity','Nepafenac','http://sideeffects.embl.de/drugs/151075/'),('http://sideeffects.embl.de/se/C0010043/','Ulcerative keratitis','Nepafenac','http://sideeffects.embl.de/drugs/151075/'),('http://sideeffects.embl.de/se/C0010068/','Coronary heart disease','Cisplatin','http://sideeffects.embl.de/drugs/2767/'),('http://sideeffects.embl.de/se/C0010072/','Coronary artery thrombosis','Bivalirudin','http://sideeffects.embl.de/drugs/16129704/'),('http://sideeffects.embl.de/se/C0010073/','Arteriospasm coronary','5-FU','http://sideeffects.embl.de/drugs/3385/'),('http://sideeffects.embl.de/se/C0010200/','Cough','K779','http://sideeffects.embl.de/drugs/71306834/'),('http://sideeffects.embl.de/se/C0010346/','Crohn\'s disease','Ketorolac','http://sideeffects.embl.de/drugs/3826/'),('http://sideeffects.embl.de/se/C0010418/','Cryptosporidiosis infection','Paclitaxel','http://sideeffects.embl.de/drugs/4666/'),('http://sideeffects.embl.de/se/C0010481/','Cushing\'s syndrome','Glat copolymer','http://sideeffects.embl.de/drugs/65370/'),('http://sideeffects.embl.de/se/C0010495/','Cutis laxa','Nepafenac','http://sideeffects.embl.de/drugs/151075/'),('http://sideeffects.embl.de/se/C0010520/','Cyanosis','NTBC','http://sideeffects.embl.de/drugs/115355/'),('http://sideeffects.embl.de/se/C0010666/','Acne cystic','Tranylcypromine','http://sideeffects.embl.de/drugs/5530/'),('http://sideeffects.embl.de/se/C0010692/','Cystitis','Nafarelin','http://sideeffects.embl.de/drugs/25077405/'),('http://sideeffects.embl.de/se/C0010695/','Cystocele','Lasofoxifene','http://sideeffects.embl.de/drugs/216416/'),('http://sideeffects.embl.de/se/C0010709/','Cyst','Vemurafenib','http://sideeffects.embl.de/drugs/42611257/'),('http://sideeffects.embl.de/se/C0010823/','Cytomegalovirus infection','Tacrolimus','http://sideeffects.embl.de/drugs/5372/'),('http://sideeffects.embl.de/se/C0010828/','Cytopenia','Deferasirox','http://sideeffects.embl.de/drugs/5493381/'),('http://sideeffects.embl.de/se/C0010930/','Dacryocystitis','Gatifloxacin','http://sideeffects.embl.de/drugs/5379/'),('http://sideeffects.embl.de/se/C0011053/','Deafness','Pegaptanib','http://sideeffects.embl.de/drugs/56603655/'),('http://sideeffects.embl.de/se/C0011057/','Sudden hearing loss','Vardenafil','http://sideeffects.embl.de/drugs/110634/'),('http://sideeffects.embl.de/se/C0011071/','Sudden death','Abiraterone','http://sideeffects.embl.de/drugs/132971/'),('http://sideeffects.embl.de/se/C0011124/','Libido decreased','Histrelin','http://sideeffects.embl.de/drugs/25077993/'),('http://sideeffects.embl.de/se/C0011127/','Decubitus ulcer','FK463','http://sideeffects.embl.de/drugs/477468/'),('http://sideeffects.embl.de/se/C0011168/','Dysphagia','Cabozantinib','http://sideeffects.embl.de/drugs/25102847/'),('http://sideeffects.embl.de/se/C0011175/','Dehydration','Cabozantinib','http://sideeffects.embl.de/drugs/25102847/'),('http://sideeffects.embl.de/se/C0011206/','Delirium','Calcium acetate','http://sideeffects.embl.de/drugs/6116/'),('http://sideeffects.embl.de/se/C0011253/','Delusion','Lormetazepam','http://sideeffects.embl.de/drugs/13314/'),('http://sideeffects.embl.de/se/C0011304/','Demyelination','5-FU','http://sideeffects.embl.de/drugs/3385/'),('http://sideeffects.embl.de/se/C0011334/','Dental caries','Glat copolymer','http://sideeffects.embl.de/drugs/65370/'),('http://sideeffects.embl.de/se/C0011551/','Depersonalisation','Eletriptan','http://sideeffects.embl.de/drugs/77993/'),('http://sideeffects.embl.de/se/C0011570/','Depression','K779','http://sideeffects.embl.de/drugs/71306834/'),('http://sideeffects.embl.de/se/C0011581/','Depressive disorder','Naratriptan','http://sideeffects.embl.de/drugs/4440/'),('http://sideeffects.embl.de/se/C0011603/','Dermatitis','Boceprevir','http://sideeffects.embl.de/drugs/10324367/'),('http://sideeffects.embl.de/se/C0011606/','Dermatitis exfoliative','Cefdinir','http://sideeffects.embl.de/drugs/6398970/'),('http://sideeffects.embl.de/se/C0011609/','Drug eruption','Bosutinib','http://sideeffects.embl.de/drugs/5328940/'),('http://sideeffects.embl.de/se/C0011615/','Dermatitis atopic','Teduglutide','http://sideeffects.embl.de/drugs/16139605/'),('http://sideeffects.embl.de/se/C0011616/','Dermatitis contact','Pegaptanib','http://sideeffects.embl.de/drugs/56603655/'),('http://sideeffects.embl.de/se/C0011630/','Fungal skin infection','Rifapentine','http://sideeffects.embl.de/drugs/6323497/'),('http://sideeffects.embl.de/se/C0011633/','Dermatomyositis','Simvastatin','http://sideeffects.embl.de/drugs/54454/'),('http://sideeffects.embl.de/se/C0011644/','Scleroderma','Cyclophosphamide','http://sideeffects.embl.de/drugs/2907/'),('http://sideeffects.embl.de/se/C0011649/','Dermoid cyst','Metrodin','http://sideeffects.embl.de/drugs/62819/'),('http://sideeffects.embl.de/se/C0011848/','Diabetes insipidus','Lithium','http://sideeffects.embl.de/drugs/28486/'),('http://sideeffects.embl.de/se/C0011849/','Diabetes mellitus','Pegaptanib','http://sideeffects.embl.de/drugs/56603655/'),('http://sideeffects.embl.de/se/C0011860/','Type 2 diabetes mellitus','SOM230','http://sideeffects.embl.de/drugs/9941444/'),('http://sideeffects.embl.de/se/C0011875/','Diabetic vascular disorder','Losartan','http://sideeffects.embl.de/drugs/3961/'),('http://sideeffects.embl.de/se/C0011880/','Diabetic ketoacidosis','Diazoxide','http://sideeffects.embl.de/drugs/3019/'),('http://sideeffects.embl.de/se/C0011881/','Diabetic nephropathy','Empagliflozin','http://sideeffects.embl.de/drugs/11949646/'),('http://sideeffects.embl.de/se/C0011882/','Diabetic neuropathy','Losartan','http://sideeffects.embl.de/drugs/3961/'),('http://sideeffects.embl.de/se/C0011974/','Dermatitis diaper','Ertapenem','http://sideeffects.embl.de/drugs/150610/'),('http://sideeffects.embl.de/se/C0011991/','Diarrhoea','K779','http://sideeffects.embl.de/drugs/71306834/'),('http://sideeffects.embl.de/se/C0012359/','Distention','Metformin','http://sideeffects.embl.de/drugs/4091/'),('http://sideeffects.embl.de/se/C0012569/','Diplopia','Perampanel','http://sideeffects.embl.de/drugs/9924495/'),('http://sideeffects.embl.de/se/C0012739/','Disseminated intravascular coagulation','Cefdinir','http://sideeffects.embl.de/drugs/6398970/'),('http://sideeffects.embl.de/se/C0012797/','Diuresis','Canagliflozin','http://sideeffects.embl.de/drugs/24812758/'),('http://sideeffects.embl.de/se/C0012813/','Diverticulitis','Fesoterodine','http://sideeffects.embl.de/drugs/6918558/'),('http://sideeffects.embl.de/se/C0012833/','Dizziness','K779','http://sideeffects.embl.de/drugs/71306834/'),('http://sideeffects.embl.de/se/C0013080/','Trisomy 21','Clomiphene citrate','http://sideeffects.embl.de/drugs/2800/'),('http://sideeffects.embl.de/se/C0013132/','Drooling','Aripiprazole','http://sideeffects.embl.de/drugs/60795/'),('http://sideeffects.embl.de/se/C0013144/','Drowsiness','Rifampicin','http://sideeffects.embl.de/drugs/5381226/'),('http://sideeffects.embl.de/se/C0013146/','Drug abuse','Rifapentine','http://sideeffects.embl.de/drugs/6323497/'),('http://sideeffects.embl.de/se/C0013182/','Drug hypersensitivity','Bosutinib','http://sideeffects.embl.de/drugs/5328940/'),('http://sideeffects.embl.de/se/C0013220/','Drug tolerance','Propoxyphene','http://sideeffects.embl.de/drugs/10100/'),('http://sideeffects.embl.de/se/C0013221/','Drug toxicity','Eslicarbazepine acetate','http://sideeffects.embl.de/drugs/179344/'),('http://sideeffects.embl.de/se/C0013238/','Dry eye syndrome','Nepafenac','http://sideeffects.embl.de/drugs/151075/'),('http://sideeffects.embl.de/se/C0013240/','Alveolar osteitis','Parecoxib','http://sideeffects.embl.de/drugs/119828/'),('http://sideeffects.embl.de/se/C0013274/','Patent ductus arteriosus','Milrinone','http://sideeffects.embl.de/drugs/4197/'),('http://sideeffects.embl.de/se/C0013295/','Duodenal ulcer','Deferasirox','http://sideeffects.embl.de/drugs/5493381/'),('http://sideeffects.embl.de/se/C0013298/','Duodenitis','Rabeprazole','http://sideeffects.embl.de/drugs/5029/'),('http://sideeffects.embl.de/se/C0013336/','Dwarfism','Vitamin D2','http://sideeffects.embl.de/drugs/3249/'),('http://sideeffects.embl.de/se/C0013362/','Dysarthria','Perampanel','http://sideeffects.embl.de/drugs/9924495/'),('http://sideeffects.embl.de/se/C0013378/','Dysgeusia','Vemurafenib','http://sideeffects.embl.de/drugs/42611257/'),('http://sideeffects.embl.de/se/C0013384/','Dyskinesia','Tolcapone','http://sideeffects.embl.de/drugs/4659569/'),('http://sideeffects.embl.de/se/C0013390/','Dysmenorrhoea','Histrelin','http://sideeffects.embl.de/drugs/25077993/'),('http://sideeffects.embl.de/se/C0013395/','Dyspepsia','Pegaptanib','http://sideeffects.embl.de/drugs/56603655/'),('http://sideeffects.embl.de/se/C0013404/','Dyspnoea','K779','http://sideeffects.embl.de/drugs/71306834/'),('http://sideeffects.embl.de/se/C0013418/','Abnormal labour','Nepafenac','http://sideeffects.embl.de/drugs/151075/'),('http://sideeffects.embl.de/se/C0013428/','Dysuria','Histrelin','http://sideeffects.embl.de/drugs/25077993/'),('http://sideeffects.embl.de/se/C0013447/','Ear disorder','Rifapentine','http://sideeffects.embl.de/drugs/6323497/'),('http://sideeffects.embl.de/se/C0013456/','Ear pain','Ivacaftor','http://sideeffects.embl.de/drugs/16220172/'),('http://sideeffects.embl.de/se/C0013491/','Ecchymosis','ACTH(1-39','http://sideeffects.embl.de/drugs/16132265/'),('http://sideeffects.embl.de/se/C0013589/','Ectromelia','Clomiphene citrate','http://sideeffects.embl.de/drugs/2800/'),('http://sideeffects.embl.de/se/C0013592/','Ectropion','Pegaptanib','http://sideeffects.embl.de/drugs/56603655/'),('http://sideeffects.embl.de/se/C0013595/','Eczema','Pegaptanib','http://sideeffects.embl.de/drugs/56603655/'),('http://sideeffects.embl.de/se/C0013604/','Oedema','Triptorelin','http://sideeffects.embl.de/drugs/25074470/'),('http://sideeffects.embl.de/se/C0013608/','Oedema due to cardiac disease','Alfuzosin','http://sideeffects.embl.de/drugs/2092/'),('http://sideeffects.embl.de/se/C0013609/','Localised oedema','Dasatinib','http://sideeffects.embl.de/drugs/3062316/'),('http://sideeffects.embl.de/se/C0013687/','Effusion','Methylene blue','http://sideeffects.embl.de/drugs/4139/'),('http://sideeffects.embl.de/se/C0013781/','Electric shock','Lidocaine','http://sideeffects.embl.de/drugs/3676/'),('http://sideeffects.embl.de/se/C0013922/','Embolism','Carboplatin','http://sideeffects.embl.de/drugs/38904/'),('http://sideeffects.embl.de/se/C0013985/','Emotional disturbance NOS','Primidone','http://sideeffects.embl.de/drugs/4909/'),('http://sideeffects.embl.de/se/C0014034/','Enanthema','NTBC','http://sideeffects.embl.de/drugs/115355/'),('http://sideeffects.embl.de/se/C0014038/','Encephalitis','Eslicarbazepine acetate','http://sideeffects.embl.de/drugs/179344/'),('http://sideeffects.embl.de/se/C0014130/','Endocrine disorder','OCRH','http://sideeffects.embl.de/drugs/16132344/'),('http://sideeffects.embl.de/se/C0014173/','Endometrial hyperplasia','Lasofoxifene','http://sideeffects.embl.de/drugs/216416/'),('http://sideeffects.embl.de/se/C0014175/','Endometriosis','Clomiphene citrate','http://sideeffects.embl.de/drugs/2800/'),('http://sideeffects.embl.de/se/C0014236/','Endophthalmitis','Pegaptanib','http://sideeffects.embl.de/drugs/56603655/'),('http://sideeffects.embl.de/se/C0014335/','Enteritis','Cyclophosphamide','http://sideeffects.embl.de/drugs/2907/'),('http://sideeffects.embl.de/se/C0014356/','Enterocolitis','Tiaprofenic acid','http://sideeffects.embl.de/drugs/5468/'),('http://sideeffects.embl.de/se/C0014358/','Pseudomembranous enterocolitis','Rifampicin','http://sideeffects.embl.de/drugs/5381226/'),('http://sideeffects.embl.de/se/C0014394/','Enuresis','Rufinamide','http://sideeffects.embl.de/drugs/129228/'),('http://sideeffects.embl.de/se/C0014431/','Enzyme induction','Carbamazepine','http://sideeffects.embl.de/drugs/2554/'),('http://sideeffects.embl.de/se/C0014457/','Eosinophilia','Vemurafenib','http://sideeffects.embl.de/drugs/42611257/'),('http://sideeffects.embl.de/se/C0014518/','Toxic epidermal necrolysis','Vemurafenib','http://sideeffects.embl.de/drugs/42611257/'),('http://sideeffects.embl.de/se/C0014534/','Epididymitis','Testosterone undecanoate','http://sideeffects.embl.de/drugs/65157/'),('http://sideeffects.embl.de/se/C0014544/','Epilepsy','OCRH','http://sideeffects.embl.de/drugs/16132344/'),('http://sideeffects.embl.de/se/C0014549/','Grand mal convulsion','Pimozide','http://sideeffects.embl.de/drugs/16362/'),('http://sideeffects.embl.de/se/C0014553/','Petit mal epilepsy','Trifluoperazine','http://sideeffects.embl.de/drugs/5566/'),('http://sideeffects.embl.de/se/C0014583/','Episcleritis','Alendronate','http://sideeffects.embl.de/drugs/2088/'),('http://sideeffects.embl.de/se/C0014591/','Epistaxis','Histrelin','http://sideeffects.embl.de/drugs/25077993/'),('http://sideeffects.embl.de/se/C0014724/','Eructation','Lomitapide','http://sideeffects.embl.de/drugs/9853053/'),('http://sideeffects.embl.de/se/C0014742/','Erythema multiforme','Regorafenib','http://sideeffects.embl.de/drugs/11167602/'),('http://sideeffects.embl.de/se/C0014743/','Erythema nodosum','Vemurafenib','http://sideeffects.embl.de/drugs/42611257/'),('http://sideeffects.embl.de/se/C0014800/','Hyperplasia erythroid','Pyrazinamide','http://sideeffects.embl.de/drugs/1046/'),('http://sideeffects.embl.de/se/C0014848/','Oesophageal achalasia','Etodolac','http://sideeffects.embl.de/drugs/3308/'),('http://sideeffects.embl.de/se/C0014863/','Oesophageal spasm','Frovatriptan','http://sideeffects.embl.de/drugs/77992/'),('http://sideeffects.embl.de/se/C0014866/','Oesophageal stenosis','Alendronate','http://sideeffects.embl.de/drugs/2088/'),('http://sideeffects.embl.de/se/C0014867/','Varices oesophageal','6-thioguanine','http://sideeffects.embl.de/drugs/2723601/'),('http://sideeffects.embl.de/se/C0014868/','Oesophagitis','Rifapentine','http://sideeffects.embl.de/drugs/6323497/'),('http://sideeffects.embl.de/se/C0014869/','Reflux esophagitis','Lomitapide','http://sideeffects.embl.de/drugs/9853053/'),('http://sideeffects.embl.de/se/C0015230/','Rash','K779','http://sideeffects.embl.de/drugs/71306834/'),('http://sideeffects.embl.de/se/C0015256/','Excoriation','Imiquimod','http://sideeffects.embl.de/drugs/57469/'),('http://sideeffects.embl.de/se/C0015300/','Exophthalmos','ACTH(1-39','http://sideeffects.embl.de/drugs/16132265/'),('http://sideeffects.embl.de/se/C0015371/','Extrapyramidal disorder','Lurasidone','http://sideeffects.embl.de/drugs/213046/'),('http://sideeffects.embl.de/se/C0015376/','Extravasation','Dacarbazine','http://sideeffects.embl.de/drugs/5281007/'),('http://sideeffects.embl.de/se/C0015393/','Congenital eye disorder','Rifapentine','http://sideeffects.embl.de/drugs/6323497/'),('http://sideeffects.embl.de/se/C0015395/','Eye burns','Desflurane','http://sideeffects.embl.de/drugs/42113/'),('http://sideeffects.embl.de/se/C0015397/','Eye disorder','Pegaptanib','http://sideeffects.embl.de/drugs/56603655/'),('http://sideeffects.embl.de/se/C0015402/','Eye haemorrhage','Pegaptanib','http://sideeffects.embl.de/drugs/56603655/'),('http://sideeffects.embl.de/se/C0015408/','Eye injury','Nitrogen mustard','http://sideeffects.embl.de/drugs/4033/'),('http://sideeffects.embl.de/se/C0015423/','Eyelid disorder','Nepafenac','http://sideeffects.embl.de/drugs/151075/'),('http://sideeffects.embl.de/se/C0015468/','Facial pain','Tazarotene','http://sideeffects.embl.de/drugs/5381/'),('http://sideeffects.embl.de/se/C0015469/','Facial paralysis','Eslicarbazepine acetate','http://sideeffects.embl.de/drugs/179344/'),('http://sideeffects.embl.de/se/C0015544/','Failure to thrive','Caffeine','http://sideeffects.embl.de/drugs/2519/'),('http://sideeffects.embl.de/se/C0015624/','Fanconi syndrome','Deferasirox','http://sideeffects.embl.de/drugs/5493381/'),('http://sideeffects.embl.de/se/C0015644/','Fasciculation','Lithium','http://sideeffects.embl.de/drugs/28486/'),('http://sideeffects.embl.de/se/C0015663/','Fasting','Desvenlafaxine','http://sideeffects.embl.de/drugs/125017/'),('http://sideeffects.embl.de/se/C0015668/','Fat necrosis','Methylene blue','http://sideeffects.embl.de/drugs/4139/'),('http://sideeffects.embl.de/se/C0015672/','Fatigue','K779','http://sideeffects.embl.de/drugs/71306834/'),('http://sideeffects.embl.de/se/C0015726/','Fear','Flumazenil','http://sideeffects.embl.de/drugs/3373/'),('http://sideeffects.embl.de/se/C0015732/','Faecal incontinence','Lubiprostone','http://sideeffects.embl.de/drugs/157920/'),('http://sideeffects.embl.de/se/C0015734/','Faecalith','Sevelamer','http://sideeffects.embl.de/drugs/3085017/'),('http://sideeffects.embl.de/se/C0015802/','Femur fracture','Alendronate','http://sideeffects.embl.de/drugs/2088/'),('http://sideeffects.embl.de/se/C0015929/','Foetal disorder','Metrodin','http://sideeffects.embl.de/drugs/62819/'),('http://sideeffects.embl.de/se/C0015930/','Foetal distress syndrome','Bupivacaine','http://sideeffects.embl.de/drugs/2474/'),('http://sideeffects.embl.de/se/C0015967/','Body temperature increased','K779','http://sideeffects.embl.de/drugs/71306834/'),('http://sideeffects.embl.de/se/C0015970/','Fever of unknown origin','Ifosfamide','http://sideeffects.embl.de/drugs/3690/'),('http://sideeffects.embl.de/se/C0016033/','Fibrocystic disease','Clomiphene citrate','http://sideeffects.embl.de/drugs/2800/'),('http://sideeffects.embl.de/se/C0016045/','Fibroma','Lasofoxifene','http://sideeffects.embl.de/drugs/216416/'),('http://sideeffects.embl.de/se/C0016053/','Fibromyalgia','Lubiprostone','http://sideeffects.embl.de/drugs/157920/'),('http://sideeffects.embl.de/se/C0016059/','Fibrosis','6-thioguanine','http://sideeffects.embl.de/drugs/2723601/'),('http://sideeffects.embl.de/se/C0016167/','Anal fissure','D-telaprevir','http://sideeffects.embl.de/drugs/3010818/'),('http://sideeffects.embl.de/se/C0016169/','Fistula','Regorafenib','http://sideeffects.embl.de/drugs/11167602/'),('http://sideeffects.embl.de/se/C0016199/','Flank pain','Vismodegib','http://sideeffects.embl.de/drugs/24776445/'),('http://sideeffects.embl.de/se/C0016204/','Flatulence','Liraglutide','http://sideeffects.embl.de/drugs/16134956/'),('http://sideeffects.embl.de/se/C0016242/','Vitreous floaters','Pegaptanib','http://sideeffects.embl.de/drugs/56603655/'),('http://sideeffects.embl.de/se/C0016382/','Flushing','Histrelin','http://sideeffects.embl.de/drugs/25077993/'),('http://sideeffects.embl.de/se/C0016385/','Cardiac flutter','Regadenoson','http://sideeffects.embl.de/drugs/219024/'),('http://sideeffects.embl.de/se/C0016412/','Folate deficiency','Sulfasalazine','http://sideeffects.embl.de/drugs/5353980/'),('http://sideeffects.embl.de/se/C0016436/','Folliculitis','Vemurafenib','http://sideeffects.embl.de/drugs/42611257/'),('http://sideeffects.embl.de/se/C0016512/','Foot pain','Felodipine','http://sideeffects.embl.de/drugs/3333/'),('http://sideeffects.embl.de/se/C0016579/','Formication','Azathioprine','http://sideeffects.embl.de/drugs/2265/'),('http://sideeffects.embl.de/se/C0016658/','Fracture','Canagliflozin','http://sideeffects.embl.de/drugs/24812758/'),('http://sideeffects.embl.de/se/C0016689/','Ephelides','8-MOP','http://sideeffects.embl.de/drugs/4114/'),('http://sideeffects.embl.de/se/C0016722/','Frigidity','Acamprosate','http://sideeffects.embl.de/drugs/71158/'),('http://sideeffects.embl.de/se/C0016751/','Fructose intolerance','Dextromethorphan','http://sideeffects.embl.de/drugs/3008/'),('http://sideeffects.embl.de/se/C0016807/','Intestinal functional disorder','Lubiprostone','http://sideeffects.embl.de/drugs/157920/'),('http://sideeffects.embl.de/se/C0016867/','Furunculosis','Rifapentine','http://sideeffects.embl.de/drugs/6323497/'),('http://sideeffects.embl.de/se/C0017086/','Gangrene','Benzathine penicillin','http://sideeffects.embl.de/drugs/15232/'),('http://sideeffects.embl.de/se/C0017105/','Gas gangrene','Epinephrine','http://sideeffects.embl.de/drugs/838/'),('http://sideeffects.embl.de/se/C0017152/','Gastritis','Liraglutide','http://sideeffects.embl.de/drugs/16134956/'),('http://sideeffects.embl.de/se/C0017160/','Gastroenteritis','Insulin detemir','http://sideeffects.embl.de/drugs/16137271/'),('http://sideeffects.embl.de/se/C0017168/','Gastrooesophageal reflux disease','Liraglutide','http://sideeffects.embl.de/drugs/16134956/'),('http://sideeffects.embl.de/se/C0017178/','Gastrointestinal disorder','Pegaptanib','http://sideeffects.embl.de/drugs/56603655/'),('http://sideeffects.embl.de/se/C0017181/','Gastrointestinal haemorrhage','Ponatinib','http://sideeffects.embl.de/drugs/24826799/'),('http://sideeffects.embl.de/se/C0017411/','Genital disorder female','Ondansetron','http://sideeffects.embl.de/drugs/4595/'),('http://sideeffects.embl.de/se/C0017565/','Gingival bleeding','Bivalirudin','http://sideeffects.embl.de/drugs/16129704/'),('http://sideeffects.embl.de/se/C0017566/','Gingival hyperplasia','Pimozide','http://sideeffects.embl.de/drugs/16362/'),('http://sideeffects.embl.de/se/C0017567/','Gingival hypertrophy','Ethotoin','http://sideeffects.embl.de/drugs/3292/'),('http://sideeffects.embl.de/se/C0017574/','Gingivitis','Varenicline','http://sideeffects.embl.de/drugs/170361/'),('http://sideeffects.embl.de/se/C0017601/','Glaucoma','Cosyntropin','http://sideeffects.embl.de/drugs/16129617/'),('http://sideeffects.embl.de/se/C0017605/','Angle closure glaucoma','Trihexyphenidyl','http://sideeffects.embl.de/drugs/5572/'),('http://sideeffects.embl.de/se/C0017638/','Glioma','5-aminolevulinic acid','http://sideeffects.embl.de/drugs/137/'),('http://sideeffects.embl.de/se/C0017658/','Glomerulonephritis','Propylthiouracil','http://sideeffects.embl.de/drugs/657298/'),('http://sideeffects.embl.de/se/C0017672/','Glossodynia','Rifampicin','http://sideeffects.embl.de/drugs/5381226/'),('http://sideeffects.embl.de/se/C0017675/','Glossitis','Lercanidipine','http://sideeffects.embl.de/drugs/65866/'),('http://sideeffects.embl.de/se/C0017979/','Glycosuria','Deferasirox','http://sideeffects.embl.de/drugs/5493381/'),('http://sideeffects.embl.de/se/C0018021/','Goitre','Sulfadiazine','http://sideeffects.embl.de/drugs/5215/'),('http://sideeffects.embl.de/se/C0018099/','Gout','Ticagrelor','http://sideeffects.embl.de/drugs/9871419/'),('http://sideeffects.embl.de/se/C0018129/','Transplant rejection','Valganciclovir','http://sideeffects.embl.de/drugs/64147/'),('http://sideeffects.embl.de/se/C0018213/','Basedow\'s disease','Elvitegravir','http://sideeffects.embl.de/drugs/5277135/'),('http://sideeffects.embl.de/se/C0018378/','Guillain-Barre syndrome','Norfloxacin','http://sideeffects.embl.de/drugs/4539/'),('http://sideeffects.embl.de/se/C0018418/','Gynaecomastia','Histrelin','http://sideeffects.embl.de/drugs/25077993/'),('http://sideeffects.embl.de/se/C0018500/','Hair disorder','Midodrine','http://sideeffects.embl.de/drugs/4195/'),('http://sideeffects.embl.de/se/C0018520/','Breath odour','Cysteamine','http://sideeffects.embl.de/drugs/6058/'),('http://sideeffects.embl.de/se/C0018524/','Hallucination','Tolcapone','http://sideeffects.embl.de/drugs/4659569/'),('http://sideeffects.embl.de/se/C0018621/','Seasonal allergy','Avanafil','http://sideeffects.embl.de/drugs/9869929/'),('http://sideeffects.embl.de/se/C0018674/','Head injury','Perampanel','http://sideeffects.embl.de/drugs/9924495/'),('http://sideeffects.embl.de/se/C0018681/','Headache','K779','http://sideeffects.embl.de/drugs/71306834/'),('http://sideeffects.embl.de/se/C0018772/','Partial hearing loss','Ranolazine','http://sideeffects.embl.de/drugs/56959/'),('http://sideeffects.embl.de/se/C0018780/','High frequency deafness','Cisplatin','http://sideeffects.embl.de/drugs/2767/'),('http://sideeffects.embl.de/se/C0018784/','Deafness neurosensory','Deferoxamine','http://sideeffects.embl.de/drugs/2973/'),('http://sideeffects.embl.de/se/C0018790/','Cardiac arrest','OCRH','http://sideeffects.embl.de/drugs/16132344/'),('http://sideeffects.embl.de/se/C0018794/','Block heart','Dofetilide','http://sideeffects.embl.de/drugs/71329/'),('http://sideeffects.embl.de/se/C0018798/','Heart malformation','Cisplatin','http://sideeffects.embl.de/drugs/2767/'),('http://sideeffects.embl.de/se/C0018799/','Cardiac disorder','Pegaptanib','http://sideeffects.embl.de/drugs/56603655/'),('http://sideeffects.embl.de/se/C0018800/','Cardiomegaly','Fludrocortisone','http://sideeffects.embl.de/drugs/31378/'),('http://sideeffects.embl.de/se/C0018801/','Cardiac failure','Ponatinib','http://sideeffects.embl.de/drugs/24826799/'),('http://sideeffects.embl.de/se/C0018802/','Cardiac failure congestive','Teduglutide','http://sideeffects.embl.de/drugs/16139605/'),('http://sideeffects.embl.de/se/C0018808/','Cardiac murmur','Avanafil','http://sideeffects.embl.de/drugs/9869929/'),('http://sideeffects.embl.de/se/C0018816/','Cardiac septal defect','Atenolol','http://sideeffects.embl.de/drugs/2249/'),('http://sideeffects.embl.de/se/C0018824/','Cardiac valve disease','Diethylpropion','http://sideeffects.embl.de/drugs/7029/'),('http://sideeffects.embl.de/se/C0018834/','Heartburn','Rifampicin','http://sideeffects.embl.de/drugs/5381226/'),('http://sideeffects.embl.de/se/C0018843/','Heat stroke','Propantheline','http://sideeffects.embl.de/drugs/4934/'),('http://sideeffects.embl.de/se/C0018924/','Haemarthrosis','Dabigatran etexilate','http://sideeffects.embl.de/drugs/213023/'),('http://sideeffects.embl.de/se/C0018926/','Haematemesis','Apixaban','http://sideeffects.embl.de/drugs/10182969/'),('http://sideeffects.embl.de/se/C0018932/','Haematochezia','Apixaban','http://sideeffects.embl.de/drugs/10182969/'),('http://sideeffects.embl.de/se/C0018939/','Blood disorder','Sulfasalazine','http://sideeffects.embl.de/drugs/5353980/'),('http://sideeffects.embl.de/se/C0018944/','Haematoma','Histrelin','http://sideeffects.embl.de/drugs/25077993/'),('http://sideeffects.embl.de/se/C0018946/','Subdural haematoma','ACTH(1-39','http://sideeffects.embl.de/drugs/16132265/'),('http://sideeffects.embl.de/se/C0018965/','Haematuria','MDV3100','http://sideeffects.embl.de/drugs/15951529/'),('http://sideeffects.embl.de/se/C0018975/','Blindness day','Trimethadione','http://sideeffects.embl.de/drugs/5576/'),('http://sideeffects.embl.de/se/C0018979/','Hemianopia','5-aminolevulinic acid','http://sideeffects.embl.de/drugs/137/'),('http://sideeffects.embl.de/se/C0018989/','Hemiparesis','5-aminolevulinic acid','http://sideeffects.embl.de/drugs/137/'),('http://sideeffects.embl.de/se/C0018991/','Hemiplegia','BCNU','http://sideeffects.embl.de/drugs/2578/'),('http://sideeffects.embl.de/se/C0019048/','Haemoglobinuria','Rifampicin','http://sideeffects.embl.de/drugs/5381226/'),('http://sideeffects.embl.de/se/C0019054/','Haemolysis','Rifampicin','http://sideeffects.embl.de/drugs/5381226/'),('http://sideeffects.embl.de/se/C0019061/','Haemolytic uraemic syndrome','Mitomycin C','http://sideeffects.embl.de/drugs/5746/'),('http://sideeffects.embl.de/se/C0019065/','Peritoneal haemorrhage','Gonadorelin','http://sideeffects.embl.de/drugs/36523/'),('http://sideeffects.embl.de/se/C0019079/','Haemoptysis','Bivalirudin','http://sideeffects.embl.de/drugs/16129704/'),('http://sideeffects.embl.de/se/C0019080/','Haemorrhage','Dabrafenib','http://sideeffects.embl.de/drugs/44462760/'),('http://sideeffects.embl.de/se/C0019087/','Haemorrhagic disorder','Aspirin','http://sideeffects.embl.de/drugs/2244/'),('http://sideeffects.embl.de/se/C0019112/','Haemorrhoids','D-telaprevir','http://sideeffects.embl.de/drugs/3010818/'),('http://sideeffects.embl.de/se/C0019151/','Hepatic encephalopathy','Entecavir','http://sideeffects.embl.de/drugs/153941/'),('http://sideeffects.embl.de/se/C0019154/','Hepatic vein thrombosis','Dacarbazine','http://sideeffects.embl.de/drugs/5281007/'),('http://sideeffects.embl.de/se/C0019156/','Venoocclusive liver disease','6-thioguanine','http://sideeffects.embl.de/drugs/2723601/'),('http://sideeffects.embl.de/se/C0019158/','Hepatitis','Deferasirox','http://sideeffects.embl.de/drugs/5493381/'),('http://sideeffects.embl.de/se/C0019159/','Hepatitis A','Perphenazine','http://sideeffects.embl.de/drugs/4748/'),('http://sideeffects.embl.de/se/C0019163/','Hepatitis B','Entecavir','http://sideeffects.embl.de/drugs/153941/'),('http://sideeffects.embl.de/se/C0019189/','Chronic hepatitis','Methadone','http://sideeffects.embl.de/drugs/4095/'),('http://sideeffects.embl.de/se/C0019193/','Hepatitis toxic','Bosutinib','http://sideeffects.embl.de/drugs/5328940/'),('http://sideeffects.embl.de/se/C0019196/','Hepatitis C','Everolimus','http://sideeffects.embl.de/drugs/6442177/'),('http://sideeffects.embl.de/se/C0019209/','Hepatomegaly','Lomitapide','http://sideeffects.embl.de/drugs/9853053/'),('http://sideeffects.embl.de/se/C0019214/','Hepatosplenomegaly','Trimethadione','http://sideeffects.embl.de/drugs/5576/'),('http://sideeffects.embl.de/se/C0019270/','Hernia','Nefazodone','http://sideeffects.embl.de/drugs/4449/'),('http://sideeffects.embl.de/se/C0019294/','Inguinal hernia','Icodextrin','http://sideeffects.embl.de/drugs/3517/'),('http://sideeffects.embl.de/se/C0019340/','Herpes NOS','Diazoxide','http://sideeffects.embl.de/drugs/3019/'),('http://sideeffects.embl.de/se/C0019345/','Herpes labialis','Adapalene','http://sideeffects.embl.de/drugs/60164/'),('http://sideeffects.embl.de/se/C0019348/','Herpes simplex','Fluticasone furoate','http://sideeffects.embl.de/drugs/9854489/'),('http://sideeffects.embl.de/se/C0019360/','Herpes zoster','Clofarabine','http://sideeffects.embl.de/drugs/119182/'),('http://sideeffects.embl.de/se/C0019521/','Hiccups','Alfentanil','http://sideeffects.embl.de/drugs/51263/'),('http://sideeffects.embl.de/se/C0019557/','Hip fracture','Propoxyphene','http://sideeffects.embl.de/drugs/10100/'),('http://sideeffects.embl.de/se/C0019559/','Coxalgia','Felodipine','http://sideeffects.embl.de/drugs/3333/'),('http://sideeffects.embl.de/se/C0019572/','Hirsutism','ACTH(1-39','http://sideeffects.embl.de/drugs/16132265/'),('http://sideeffects.embl.de/se/C0019825/','Hoarseness','Exemestane','http://sideeffects.embl.de/drugs/60198/'),('http://sideeffects.embl.de/se/C0019829/','Hodgkin\'s disease','Mephenytoin','http://sideeffects.embl.de/drugs/4060/'),('http://sideeffects.embl.de/se/C0019880/','Homocystinuria','Pyridoxine','http://sideeffects.embl.de/drugs/1054/'),('http://sideeffects.embl.de/se/C0020039/','Hostility','Testosterone undecanoate','http://sideeffects.embl.de/drugs/65157/'),('http://sideeffects.embl.de/se/C0020175/','Hunger','Chlorpropamide','http://sideeffects.embl.de/drugs/2727/'),('http://sideeffects.embl.de/se/C0020429/','Hyperpathia','5-aminolevulinic acid','http://sideeffects.embl.de/drugs/137/'),('http://sideeffects.embl.de/se/C0020433/','Hyperbilirubinaemia','Cabozantinib','http://sideeffects.embl.de/drugs/25102847/'),('http://sideeffects.embl.de/se/C0020437/','Hypercalcaemia','Dabrafenib','http://sideeffects.embl.de/drugs/44462760/'),('http://sideeffects.embl.de/se/C0020438/','Hypercalciuria','Vitamin D2','http://sideeffects.embl.de/drugs/3249/'),('http://sideeffects.embl.de/se/C0020440/','Hypercapnia','Alfentanil','http://sideeffects.embl.de/drugs/51263/'),('http://sideeffects.embl.de/se/C0020443/','Hypercholesterolaemia','SOM230','http://sideeffects.embl.de/drugs/9941444/'),('http://sideeffects.embl.de/se/C0020452/','Hyperaemia','Brinzolamide','http://sideeffects.embl.de/drugs/68844/'),('http://sideeffects.embl.de/se/C0020453/','Hyperaesthesia','Frovatriptan','http://sideeffects.embl.de/drugs/77992/'),('http://sideeffects.embl.de/se/C0020455/','Hypergammaglobulinaemia','Procainamide','http://sideeffects.embl.de/drugs/4913/'),('http://sideeffects.embl.de/se/C0020456/','Hyperglycaemia','Dabrafenib','http://sideeffects.embl.de/drugs/44462760/'),('http://sideeffects.embl.de/se/C0020457/','Diabetic hyperosmolar coma','Glucose solution','http://sideeffects.embl.de/drugs/24748/'),('http://sideeffects.embl.de/se/C0020458/','Hyperhidrosis','Degarelix','http://sideeffects.embl.de/drugs/16136245/'),('http://sideeffects.embl.de/se/C0020461/','Hyperkalaemia','Dabrafenib','http://sideeffects.embl.de/drugs/44462760/'),('http://sideeffects.embl.de/se/C0020473/','Hyperlipidaemia','Linagliptin','http://sideeffects.embl.de/drugs/10096344/'),('http://sideeffects.embl.de/se/C0020488/','Hypernatraemia','Cosyntropin','http://sideeffects.embl.de/drugs/16129617/'),('http://sideeffects.embl.de/se/C0020500/','Hyperoxaluria','Pyridoxine','http://sideeffects.embl.de/drugs/1054/'),('http://sideeffects.embl.de/se/C0020502/','Hyperparathyroidism','Lithium','http://sideeffects.embl.de/drugs/28486/'),('http://sideeffects.embl.de/se/C0020503/','Hyperparathyroidism secondary','Clodronate','http://sideeffects.embl.de/drugs/25419/'),('http://sideeffects.embl.de/se/C0020505/','Hyperphagia','Perphenazine','http://sideeffects.embl.de/drugs/4748/'),('http://sideeffects.embl.de/se/C0020507/','Hyperplasia','Felodipine','http://sideeffects.embl.de/drugs/3333/'),('http://sideeffects.embl.de/se/C0020510/','Nodular regenerative hyperplasia','6-thioguanine','http://sideeffects.embl.de/drugs/2723601/'),('http://sideeffects.embl.de/se/C0020514/','Hyperprolactinaemia','Pimozide','http://sideeffects.embl.de/drugs/16362/'),('http://sideeffects.embl.de/se/C0020517/','Hypersensitivity','Canagliflozin','http://sideeffects.embl.de/drugs/24812758/'),('http://sideeffects.embl.de/se/C0020522/','Type IV hypersensitivity reaction','Mometasone','http://sideeffects.embl.de/drugs/123620/'),('http://sideeffects.embl.de/se/C0020523/','Type I hypersensitivity','Clodronate','http://sideeffects.embl.de/drugs/25419/'),('http://sideeffects.embl.de/se/C0020538/','Hypertension','Pegaptanib','http://sideeffects.embl.de/drugs/56603655/'),('http://sideeffects.embl.de/se/C0020540/','Malignant hypertension','Vandetanib','http://sideeffects.embl.de/drugs/3081361/'),('http://sideeffects.embl.de/se/C0020541/','Portal hypertension','6-thioguanine','http://sideeffects.embl.de/drugs/2723601/'),('http://sideeffects.embl.de/se/C0020542/','Pulmonary hypertension','Bosutinib','http://sideeffects.embl.de/drugs/5328940/'),('http://sideeffects.embl.de/se/C0020546/','Hypertensive crisis','Vandetanib','http://sideeffects.embl.de/drugs/3081361/'),('http://sideeffects.embl.de/se/C0020550/','Hyperthyroidism','Lithium','http://sideeffects.embl.de/drugs/28486/'),('http://sideeffects.embl.de/se/C0020555/','Hypertrichosis','Halobetasol','http://sideeffects.embl.de/drugs/5311167/'),('http://sideeffects.embl.de/se/C0020557/','Hypertriglyceridaemia','Linagliptin','http://sideeffects.embl.de/drugs/10096344/'),('http://sideeffects.embl.de/se/C0020569/','Salivary gland enlargement','Glat copolymer','http://sideeffects.embl.de/drugs/65370/'),('http://sideeffects.embl.de/se/C0020578/','Hyperventilation','Pralidoxime','http://sideeffects.embl.de/drugs/5353894/'),('http://sideeffects.embl.de/se/C0020580/','Hypoaesthesia','MDV3100','http://sideeffects.embl.de/drugs/15951529/'),('http://sideeffects.embl.de/se/C0020581/','Hyphaema','Pegaptanib','http://sideeffects.embl.de/drugs/56603655/'),('http://sideeffects.embl.de/se/C0020598/','Hypocalcaemia','Dabrafenib','http://sideeffects.embl.de/drugs/44462760/'),('http://sideeffects.embl.de/se/C0020599/','Hypocalciuria','Bendrofluazide','http://sideeffects.embl.de/drugs/2315/'),('http://sideeffects.embl.de/se/C0020615/','Hypoglycaemia','Canagliflozin','http://sideeffects.embl.de/drugs/24812758/'),('http://sideeffects.embl.de/se/C0020617/','Hypoglycaemic coma','Insulin','http://sideeffects.embl.de/drugs/16129672/'),('http://sideeffects.embl.de/se/C0020619/','Hypogonadism','Testosterone undecanoate','http://sideeffects.embl.de/drugs/65157/'),('http://sideeffects.embl.de/se/C0020621/','Hypokalaemia','Dabrafenib','http://sideeffects.embl.de/drugs/44462760/'),('http://sideeffects.embl.de/se/C0020624/','Hypomenorrhoea','Levonorgestrel','http://sideeffects.embl.de/drugs/4542/'),('http://sideeffects.embl.de/se/C0020625/','Hyponatraemia','Dabrafenib','http://sideeffects.embl.de/drugs/44462760/'),('http://sideeffects.embl.de/se/C0020626/','Hypoparathyroidism','Amifostine','http://sideeffects.embl.de/drugs/2141/'),('http://sideeffects.embl.de/se/C0020635/','Hypopituitarism','Glibenclamide','http://sideeffects.embl.de/drugs/3488/'),('http://sideeffects.embl.de/se/C0020639/','Hypoproteinaemia','Imatinib','http://sideeffects.embl.de/drugs/5291/'),('http://sideeffects.embl.de/se/C0020649/','Hypotension','Cabozantinib','http://sideeffects.embl.de/drugs/25102847/'),('http://sideeffects.embl.de/se/C0020651/','Orthostatic hypotension','Canagliflozin','http://sideeffects.embl.de/drugs/24812758/'),('http://sideeffects.embl.de/se/C0020672/','Body temperature decreased','Pimozide','http://sideeffects.embl.de/drugs/16362/'),('http://sideeffects.embl.de/se/C0020676/','Hypothyroidism','Vandetanib','http://sideeffects.embl.de/drugs/3081361/'),('http://sideeffects.embl.de/se/C0020678/','Hypotrichosis','Glibenclamide','http://sideeffects.embl.de/drugs/3488/'),('http://sideeffects.embl.de/se/C0020701/','Hysteria','Promethazine','http://sideeffects.embl.de/drugs/4927/'),('http://sideeffects.embl.de/se/C0020757/','Ichthyosis','Clofazimine','http://sideeffects.embl.de/drugs/2794/'),('http://sideeffects.embl.de/se/C0020903/','Illusion','Nitrazepam','http://sideeffects.embl.de/drugs/4506/'),('http://sideeffects.embl.de/se/C0021053/','Immune system disorder','Liraglutide','http://sideeffects.embl.de/drugs/16134956/'),('http://sideeffects.embl.de/se/C0021080/','Immunosuppression','Rifampicin','http://sideeffects.embl.de/drugs/5381226/'),('http://sideeffects.embl.de/se/C0021099/','Impetigo','Pimecrolimus','http://sideeffects.embl.de/drugs/3055172/'),('http://sideeffects.embl.de/se/C0021141/','Inappropriate antidiuretic hormone secretion','Vinblastine','http://sideeffects.embl.de/drugs/13342/'),('http://sideeffects.embl.de/se/C0021167/','Incontinence','Rufinamide','http://sideeffects.embl.de/drugs/129228/'),('http://sideeffects.embl.de/se/C0021177/','Libido increased','Molindone','http://sideeffects.embl.de/drugs/23897/'),('http://sideeffects.embl.de/se/C0021308/','Infarction','Sorafenib','http://sideeffects.embl.de/drugs/216239/'),('http://sideeffects.embl.de/se/C0021313/','Kidney infection','Canagliflozin','http://sideeffects.embl.de/drugs/24812758/'),('http://sideeffects.embl.de/se/C0021345/','Infectious mononucleosis','APAs','http://sideeffects.embl.de/drugs/4649/'),('http://sideeffects.embl.de/se/C0021359/','Infertility','Chlorambucil','http://sideeffects.embl.de/drugs/2708/'),('http://sideeffects.embl.de/se/C0021364/','Infertility male','Dapsone','http://sideeffects.embl.de/drugs/2955/'),('http://sideeffects.embl.de/se/C0021368/','Inflammation','Pralidoxime','http://sideeffects.embl.de/drugs/5353894/'),('http://sideeffects.embl.de/se/C0021390/','Inflammatory bowel disease','6-mercaptopurine','http://sideeffects.embl.de/drugs/667490/'),('http://sideeffects.embl.de/se/C0021400/','Influenza','Triptorelin','http://sideeffects.embl.de/drugs/25074470/'),('http://sideeffects.embl.de/se/C0021605/','Insomnia NEC','Clozapine','http://sideeffects.embl.de/drugs/2818/'),('http://sideeffects.embl.de/se/C0021670/','Insulinoma','Streptozotocin','http://sideeffects.embl.de/drugs/5300/'),('http://sideeffects.embl.de/se/C0021775/','Intermittent claudication','Telmisartan','http://sideeffects.embl.de/drugs/65999/'),('http://sideeffects.embl.de/se/C0021831/','Unspecified disorder of intestine','Fenofibrate','http://sideeffects.embl.de/drugs/3339/'),('http://sideeffects.embl.de/se/C0021843/','Intestinal obstruction','Teduglutide','http://sideeffects.embl.de/drugs/16139605/'),('http://sideeffects.embl.de/se/C0021845/','Intestinal perforation','Sevelamer','http://sideeffects.embl.de/drugs/3085017/'),('http://sideeffects.embl.de/se/C0021899/','IUD expelled','Levonorgestrel','http://sideeffects.embl.de/drugs/4542/'),('http://sideeffects.embl.de/se/C0021933/','Intussusception','Acarbose','http://sideeffects.embl.de/drugs/41774/'),('http://sideeffects.embl.de/se/C0022073/','Iridocyclitis','Azelaic acid','http://sideeffects.embl.de/drugs/2266/'),('http://sideeffects.embl.de/se/C0022081/','Iritis','Nepafenac','http://sideeffects.embl.de/drugs/151075/'),('http://sideeffects.embl.de/se/C0022104/','Irritable bowel syndrome','Lasofoxifene','http://sideeffects.embl.de/drugs/216416/'),('http://sideeffects.embl.de/se/C0022107/','Irritability','K779','http://sideeffects.embl.de/drugs/71306834/'),('http://sideeffects.embl.de/se/C0022116/','Ischaemia','Ponatinib','http://sideeffects.embl.de/drugs/24826799/'),('http://sideeffects.embl.de/se/C0022281/','Eye pruritus','Besifloxacin','http://sideeffects.embl.de/drugs/10178705/'),('http://sideeffects.embl.de/se/C0022346/','Jaundice','Cefdinir','http://sideeffects.embl.de/drugs/6398970/'),('http://sideeffects.embl.de/se/C0022354/','Jaundice cholestatic','Balsalazide','http://sideeffects.embl.de/drugs/5362070/'),('http://sideeffects.embl.de/se/C0022408/','Arthropathy','Frovatriptan','http://sideeffects.embl.de/drugs/77992/'),('http://sideeffects.embl.de/se/C0022568/','Keratitis','Nepafenac','http://sideeffects.embl.de/drugs/151075/'),('http://sideeffects.embl.de/se/C0022572/','Keratoacanthoma','Dabrafenib','http://sideeffects.embl.de/drugs/44462760/'),('http://sideeffects.embl.de/se/C0022573/','Keratoconjunctivitis','Adapalene','http://sideeffects.embl.de/drugs/60164/'),('http://sideeffects.embl.de/se/C0022575/','Keratoconjunctivitis sicca','Oxybutynin','http://sideeffects.embl.de/drugs/4634/'),('http://sideeffects.embl.de/se/C0022602/','Actinic keratosis','Dabrafenib','http://sideeffects.embl.de/drugs/44462760/'),('http://sideeffects.embl.de/se/C0022603/','Seborrhoeic keratosis','Dabrafenib','http://sideeffects.embl.de/drugs/44462760/'),('http://sideeffects.embl.de/se/C0022650/','Calculus of kidney','Triamterene','http://sideeffects.embl.de/drugs/5546/'),('http://sideeffects.embl.de/se/C0022656/','Renal cortical necrosis','Tranexamic acid','http://sideeffects.embl.de/drugs/5526/'),('http://sideeffects.embl.de/se/C0022658/','Nephropathy','Cefdinir','http://sideeffects.embl.de/drugs/6398970/'),('http://sideeffects.embl.de/se/C0022660/','Renal failure acute','Canagliflozin','http://sideeffects.embl.de/drugs/24812758/'),('http://sideeffects.embl.de/se/C0022661/','Renal failure chronic','Liraglutide','http://sideeffects.embl.de/drugs/16134956/'),('http://sideeffects.embl.de/se/C0022667/','Renal papillary necrosis','Dapsone','http://sideeffects.embl.de/drugs/2955/'),('http://sideeffects.embl.de/se/C0022672/','Nephrosis lower nephron','Phenylpropanolamine','http://sideeffects.embl.de/drugs/4786/'),('http://sideeffects.embl.de/se/C0022876/','Premature labour','Gonadorelin','http://sideeffects.embl.de/drugs/36523/'),('http://sideeffects.embl.de/se/C0022893/','Labyrinthitis','Diphenhydramine','http://sideeffects.embl.de/drugs/3100/'),('http://sideeffects.embl.de/se/C0022904/','Lacrimal disorder','Sildenafil','http://sideeffects.embl.de/drugs/5212/'),('http://sideeffects.embl.de/se/C0022951/','Lactose intolerance','Entecavir','http://sideeffects.embl.de/drugs/153941/'),('http://sideeffects.embl.de/se/C0023052/','Laryngeal oedema','Cefdinir','http://sideeffects.embl.de/drugs/6398970/'),('http://sideeffects.embl.de/se/C0023066/','Laryngospasm','Almotriptan','http://sideeffects.embl.de/drugs/123606/'),('http://sideeffects.embl.de/se/C0023067/','Laryngitis','Insulin','http://sideeffects.embl.de/drugs/16129672/'),('http://sideeffects.embl.de/se/C0023212/','Left ventricular failure','Eplerenone','http://sideeffects.embl.de/drugs/150310/'),('http://sideeffects.embl.de/se/C0023218/','Cramps of lower extremities','Triptorelin','http://sideeffects.embl.de/drugs/25074470/'),('http://sideeffects.embl.de/se/C0023222/','Leg pain','Triptorelin','http://sideeffects.embl.de/drugs/25074470/'),('http://sideeffects.embl.de/se/C0023223/','Leg ulcer','Hydroxyurea','http://sideeffects.embl.de/drugs/3657/'),('http://sideeffects.embl.de/se/C0023380/','Lethargy','Dacarbazine','http://sideeffects.embl.de/drugs/5281007/'),('http://sideeffects.embl.de/se/C0023418/','Leukaemia','Ticlopidine','http://sideeffects.embl.de/drugs/5472/'),('http://sideeffects.embl.de/se/C0023467/','Acute myeloid leukaemia','Clodronate','http://sideeffects.embl.de/drugs/25419/'),('http://sideeffects.embl.de/se/C0023470/','Myeloid leukaemia','Clodronate','http://sideeffects.embl.de/drugs/25419/'),('http://sideeffects.embl.de/se/C0023518/','Leukocytosis','Cosyntropin','http://sideeffects.embl.de/drugs/16129617/'),('http://sideeffects.embl.de/se/C0023529/','Periventricular leukomalacia','Nitric oxide','http://sideeffects.embl.de/drugs/145068/'),('http://sideeffects.embl.de/se/C0023530/','Leukopenia','K779','http://sideeffects.embl.de/drugs/71306834/'),('http://sideeffects.embl.de/se/C0023533/','Leukorrhea','Copper','http://sideeffects.embl.de/drugs/23978/'),('http://sideeffects.embl.de/se/C0023646/','Lichen planus','Prazosin','http://sideeffects.embl.de/drugs/4893/'),('http://sideeffects.embl.de/se/C0023787/','Lipodystrophy','Insulin','http://sideeffects.embl.de/drugs/16129672/'),('http://sideeffects.embl.de/se/C0023895/','Liver disorder','Febuxostat','http://sideeffects.embl.de/drugs/134018/'),('http://sideeffects.embl.de/se/C0023903/','Hepatic neoplasm','NTBC','http://sideeffects.embl.de/drugs/115355/'),('http://sideeffects.embl.de/se/C0024031/','Low back pain','Carisoprodol','http://sideeffects.embl.de/drugs/2576/'),('http://sideeffects.embl.de/se/C0024050/','Lower gastrointestinal haemorrhage','Lomitapide','http://sideeffects.embl.de/drugs/9853053/'),('http://sideeffects.embl.de/se/C0024103/','Breast mass','Ivacaftor','http://sideeffects.embl.de/drugs/16220172/'),('http://sideeffects.embl.de/se/C0024115/','Lung disorder','Nitazoxanide','http://sideeffects.embl.de/drugs/41684/'),('http://sideeffects.embl.de/se/C0024117/','Chronic obstructive pulmonary disease','Aminophylline','http://sideeffects.embl.de/drugs/9433/'),('http://sideeffects.embl.de/se/C0024141/','Systemic lupus erythematosus','Trifluoperazine','http://sideeffects.embl.de/drugs/5566/'),('http://sideeffects.embl.de/se/C0024236/','Lymphoedema','Letrozole','http://sideeffects.embl.de/drugs/3902/'),('http://sideeffects.embl.de/se/C0024282/','Lymphocytosis','Allopurinol','http://sideeffects.embl.de/drugs/2094/'),('http://sideeffects.embl.de/se/C0024299/','Lymphoma','Trimethadione','http://sideeffects.embl.de/drugs/5576/'),('http://sideeffects.embl.de/se/C0024312/','Lymphopenia','Dabrafenib','http://sideeffects.embl.de/drugs/44462760/'),('http://sideeffects.embl.de/se/C0024437/','Macular degeneration','Hydroxychloroquine','http://sideeffects.embl.de/drugs/3652/'),('http://sideeffects.embl.de/se/C0024523/','Malabsorption','APAs','http://sideeffects.embl.de/drugs/4649/'),('http://sideeffects.embl.de/se/C0024528/','Malaise and fatigue','Isoniazid','http://sideeffects.embl.de/drugs/3767/'),('http://sideeffects.embl.de/se/C0024894/','Mastitis','Ivacaftor','http://sideeffects.embl.de/drugs/16220172/'),('http://sideeffects.embl.de/se/C0024902/','Breast pain','Triptorelin','http://sideeffects.embl.de/drugs/25074470/'),('http://sideeffects.embl.de/se/C0025007/','Measles','Gamma-aminobutyric acid','http://sideeffects.embl.de/drugs/119/'),('http://sideeffects.embl.de/se/C0025061/','Mediastinal disorder','Ivacaftor','http://sideeffects.embl.de/drugs/16220172/'),('http://sideeffects.embl.de/se/C0025063/','Mediastinum neoplasm','Nitrogen mustard','http://sideeffects.embl.de/drugs/4033/'),('http://sideeffects.embl.de/se/C0025202/','Malignant melanoma','Monobenzone','http://sideeffects.embl.de/drugs/7638/'),('http://sideeffects.embl.de/se/C0025222/','Melaena','Bivalirudin','http://sideeffects.embl.de/drugs/16129704/'),('http://sideeffects.embl.de/se/C0025287/','Meningism','Polymyxin B','http://sideeffects.embl.de/drugs/4868/'),('http://sideeffects.embl.de/se/C0025289/','Meningitis','Etodolac','http://sideeffects.embl.de/drugs/3308/'),('http://sideeffects.embl.de/se/C0025290/','Meningitis aseptic','Trimethoprim','http://sideeffects.embl.de/drugs/5578/'),('http://sideeffects.embl.de/se/C0025320/','Menopause','Vismodegib','http://sideeffects.embl.de/drugs/24776445/'),('http://sideeffects.embl.de/se/C0025323/','Menorrhagia','Apixaban','http://sideeffects.embl.de/drugs/10182969/'),('http://sideeffects.embl.de/se/C0025345/','Menstrual disorder','Varenicline','http://sideeffects.embl.de/drugs/170361/'),('http://sideeffects.embl.de/se/C0025362/','Mental retardation','Vitamin D2','http://sideeffects.embl.de/drugs/3249/'),('http://sideeffects.embl.de/se/C0025517/','Metabolic disorder','Letrozole','http://sideeffects.embl.de/drugs/3902/'),('http://sideeffects.embl.de/se/C0025521/','Inborn error of metabolism','Pyridoxine','http://sideeffects.embl.de/drugs/1054/'),('http://sideeffects.embl.de/se/C0025637/','Methaemoglobinaemia','Nitric oxide','http://sideeffects.embl.de/drugs/145068/'),('http://sideeffects.embl.de/se/C0025874/','Metrorrhagia','Lasofoxifene','http://sideeffects.embl.de/drugs/216416/'),('http://sideeffects.embl.de/se/C0026113/','Miliaria','Halobetasol','http://sideeffects.embl.de/drugs/5311167/'),('http://sideeffects.embl.de/se/C0026205/','Miosis','Sufentanil','http://sideeffects.embl.de/drugs/41693/'),('http://sideeffects.embl.de/se/C0026266/','Mitral valve incompetence','Fluphenazine','http://sideeffects.embl.de/drugs/3372/'),('http://sideeffects.embl.de/se/C0026603/','Motion sickness','Methylphenidate','http://sideeffects.embl.de/drugs/4158/'),('http://sideeffects.embl.de/se/C0026636/','Oral disorder','Clodronate','http://sideeffects.embl.de/drugs/25419/'),('http://sideeffects.embl.de/se/C0026650/','Movement disorder','Desloratadine','http://sideeffects.embl.de/drugs/124087/'),('http://sideeffects.embl.de/se/C0026766/','Multi-organ failure','Belinostat','http://sideeffects.embl.de/drugs/6918638/'),('http://sideeffects.embl.de/se/C0026821/','Cramp muscle','Balsalazide','http://sideeffects.embl.de/drugs/5362070/'),('http://sideeffects.embl.de/se/C0026826/','Hypertonia','Doxercalciferol','http://sideeffects.embl.de/drugs/4479094/'),('http://sideeffects.embl.de/se/C0026827/','Hypotonia','Stiripentol','http://sideeffects.embl.de/drugs/39524/'),('http://sideeffects.embl.de/se/C0026837/','Muscle rigidity','Zileuton','http://sideeffects.embl.de/drugs/60490/'),('http://sideeffects.embl.de/se/C0026838/','Muscle spasticity','Triazolam','http://sideeffects.embl.de/drugs/5556/'),('http://sideeffects.embl.de/se/C0026846/','Muscle atrophy','Cosyntropin','http://sideeffects.embl.de/drugs/16129617/'),('http://sideeffects.embl.de/se/C0026848/','Myopathy','Cosyntropin','http://sideeffects.embl.de/drugs/16129617/'),('http://sideeffects.embl.de/se/C0026857/','Musculoskeletal disorder','Vismodegib','http://sideeffects.embl.de/drugs/24776445/'),('http://sideeffects.embl.de/se/C0026858/','Musculoskeletal pain','K779','http://sideeffects.embl.de/drugs/71306834/'),('http://sideeffects.embl.de/se/C0026896/','Myasthenia gravis','Telithromycin','http://sideeffects.embl.de/drugs/73658/'),('http://sideeffects.embl.de/se/C0026946/','Fungal infection','Empagliflozin','http://sideeffects.embl.de/drugs/11949646/'),('http://sideeffects.embl.de/se/C0026961/','Mydriasis','Desvenlafaxine','http://sideeffects.embl.de/drugs/125017/'),('http://sideeffects.embl.de/se/C0026976/','Myelitis transverse','Benzathine penicillin','http://sideeffects.embl.de/drugs/15232/'),('http://sideeffects.embl.de/se/C0026986/','Myelodysplastic syndrome','Chlorambucil','http://sideeffects.embl.de/drugs/2708/'),('http://sideeffects.embl.de/se/C0027051/','Myocardial infarction','Nafarelin','http://sideeffects.embl.de/drugs/25077405/'),('http://sideeffects.embl.de/se/C0027059/','Myocarditis','Balsalazide','http://sideeffects.embl.de/drugs/5362070/'),('http://sideeffects.embl.de/se/C0027066/','Myoclonus','Alfentanil','http://sideeffects.embl.de/drugs/51263/'),('http://sideeffects.embl.de/se/C0027080/','Myoglobinuria','Benzathine penicillin','http://sideeffects.embl.de/drugs/15232/'),('http://sideeffects.embl.de/se/C0027092/','Myopia','Ethosuximide','http://sideeffects.embl.de/drugs/3291/'),('http://sideeffects.embl.de/se/C0027121/','Myositis','Dasatinib','http://sideeffects.embl.de/drugs/3062316/'),('http://sideeffects.embl.de/se/C0027125/','Myotonia','Propranolol','http://sideeffects.embl.de/drugs/4946/'),('http://sideeffects.embl.de/se/C0027145/','Myxoedema','Lithium','http://sideeffects.embl.de/drugs/28486/'),('http://sideeffects.embl.de/se/C0027339/','Nail disorder','Ixabepilone','http://sideeffects.embl.de/drugs/6445540/'),('http://sideeffects.embl.de/se/C0027343/','Ingrowing nail','Ciclopirox','http://sideeffects.embl.de/drugs/2749/'),('http://sideeffects.embl.de/se/C0027404/','Narcolepsy','Prazosin','http://sideeffects.embl.de/drugs/4893/'),('http://sideeffects.embl.de/se/C0027424/','Nasal congestion','Ivacaftor','http://sideeffects.embl.de/drugs/16220172/'),('http://sideeffects.embl.de/se/C0027441/','Nasopharyngitis','Ivacaftor','http://sideeffects.embl.de/drugs/16220172/'),('http://sideeffects.embl.de/se/C0027497/','Nausea','K779','http://sideeffects.embl.de/drugs/71306834/'),('http://sideeffects.embl.de/se/C0027540/','Necrosis','Raltitrexed','http://sideeffects.embl.de/drugs/104758/'),('http://sideeffects.embl.de/se/C0027627/','Metastasis','Flutamide','http://sideeffects.embl.de/drugs/3397/'),('http://sideeffects.embl.de/se/C0027651/','Neoplasm','Dapagliflozin','http://sideeffects.embl.de/drugs/9887712/'),('http://sideeffects.embl.de/se/C0027697/','Nephritis','Methimazole','http://sideeffects.embl.de/drugs/1349907/'),('http://sideeffects.embl.de/se/C0027707/','Nephritis interstitial','Balsalazide','http://sideeffects.embl.de/drugs/5362070/'),('http://sideeffects.embl.de/se/C0027709/','Nephrocalcinosis','Clodronate','http://sideeffects.embl.de/drugs/25419/'),('http://sideeffects.embl.de/se/C0027720/','Nephrosis','EDTA','http://sideeffects.embl.de/drugs/6049/'),('http://sideeffects.embl.de/se/C0027726/','Nephrotic syndrome','Etoricoxib','http://sideeffects.embl.de/drugs/123619/'),('http://sideeffects.embl.de/se/C0027765/','Nervous system disorder','Vemurafenib','http://sideeffects.embl.de/drugs/42611257/'),('http://sideeffects.embl.de/se/C0027769/','Nervousness','Bivalirudin','http://sideeffects.embl.de/drugs/16129704/'),('http://sideeffects.embl.de/se/C0027796/','Neuralgia','Zopiclone','http://sideeffects.embl.de/drugs/5735/'),('http://sideeffects.embl.de/se/C0027813/','Neuritis','Ethionamide','http://sideeffects.embl.de/drugs/2761171/'),('http://sideeffects.embl.de/se/C0027849/','Neuroleptic malignant syndrome','Tetrabenazine','http://sideeffects.embl.de/drugs/6018/'),('http://sideeffects.embl.de/se/C0027868/','Neuromyopathy','Chloroquine','http://sideeffects.embl.de/drugs/2719/'),('http://sideeffects.embl.de/se/C0027947/','Neutropenia','K779','http://sideeffects.embl.de/drugs/71306834/'),('http://sideeffects.embl.de/se/C0027962/','Melanocytic naevus','Monobenzone','http://sideeffects.embl.de/drugs/7638/'),('http://sideeffects.embl.de/se/C0028077/','Night blindness','Deferoxamine','http://sideeffects.embl.de/drugs/2973/'),('http://sideeffects.embl.de/se/C0028081/','Night sweats','Dabrafenib','http://sideeffects.embl.de/drugs/44462760/'),('http://sideeffects.embl.de/se/C0028084/','Nightmare','Agomelatine','http://sideeffects.embl.de/drugs/82148/'),('http://sideeffects.embl.de/se/C0028173/','NPN increased','Carvedilol','http://sideeffects.embl.de/drugs/2585/'),('http://sideeffects.embl.de/se/C0028259/','Nodule','Degarelix','http://sideeffects.embl.de/drugs/16136245/'),('http://sideeffects.embl.de/se/C0028643/','Numbness','Vinblastine','http://sideeffects.embl.de/drugs/13342/'),('http://sideeffects.embl.de/se/C0028734/','Nocturia','Canagliflozin','http://sideeffects.embl.de/drugs/24812758/'),('http://sideeffects.embl.de/se/C0028738/','Nystagmus','Lacosamide','http://sideeffects.embl.de/drugs/219078/'),('http://sideeffects.embl.de/se/C0028778/','Obstruction','Insulin','http://sideeffects.embl.de/drugs/16129672/'),('http://sideeffects.embl.de/se/C0028798/','Occupational exposures','Sevoflurane','http://sideeffects.embl.de/drugs/5206/'),('http://sideeffects.embl.de/se/C0028841/','Hypotony of eye','Cidofovir','http://sideeffects.embl.de/drugs/60613/'),('http://sideeffects.embl.de/se/C0028949/','Oligomenorrhoea','Levonorgestrel','http://sideeffects.embl.de/drugs/4542/'),('http://sideeffects.embl.de/se/C0028960/','Oligospermia','6-mercaptopurine','http://sideeffects.embl.de/drugs/667490/'),('http://sideeffects.embl.de/se/C0028961/','Oliguria','Colimycin M','http://sideeffects.embl.de/drugs/216258/'),('http://sideeffects.embl.de/se/C0029089/','Ophthalmoplegia','Nafarelin','http://sideeffects.embl.de/drugs/25077405/'),('http://sideeffects.embl.de/se/C0029118/','Opportunistic infection','Elvitegravir','http://sideeffects.embl.de/drugs/5277135/'),('http://sideeffects.embl.de/se/C0029124/','Optic atrophy','Lomustine','http://sideeffects.embl.de/drugs/3950/'),('http://sideeffects.embl.de/se/C0029134/','Optic neuritis','Ethionamide','http://sideeffects.embl.de/drugs/2761171/'),('http://sideeffects.embl.de/se/C0029163/','Mouth haemorrhage','Apixaban','http://sideeffects.embl.de/drugs/10182969/'),('http://sideeffects.embl.de/se/C0029221/','Organic brain syndrome','Gentamicin','http://sideeffects.embl.de/drugs/3467/'),('http://sideeffects.embl.de/se/C0029261/','Orgasm abnormal','Citalopram','http://sideeffects.embl.de/drugs/2771/'),('http://sideeffects.embl.de/se/C0029396/','Ectopic ossification','Etidronate','http://sideeffects.embl.de/drugs/3305/'),('http://sideeffects.embl.de/se/C0029408/','Osteoarthritis','Mirabegron','http://sideeffects.embl.de/drugs/9865528/'),('http://sideeffects.embl.de/se/C0029442/','Osteomalacia','Adefovir dipivoxil','http://sideeffects.embl.de/drugs/60871/'),('http://sideeffects.embl.de/se/C0029443/','Osteomyelitis','LY146032','http://sideeffects.embl.de/drugs/16129629/'),('http://sideeffects.embl.de/se/C0029445/','Osteonecrosis','Elvitegravir','http://sideeffects.embl.de/drugs/5277135/'),('http://sideeffects.embl.de/se/C0029453/','Osteopenia','Dapagliflozin','http://sideeffects.embl.de/drugs/9887712/'),('http://sideeffects.embl.de/se/C0029456/','Osteoporosis','Cosyntropin','http://sideeffects.embl.de/drugs/16129617/'),('http://sideeffects.embl.de/se/C0029560/','Other conjunctivitis','Pimecrolimus','http://sideeffects.embl.de/drugs/3055172/'),('http://sideeffects.embl.de/se/C0029574/','Other dermatoses','Orphenadrine','http://sideeffects.embl.de/drugs/4601/'),('http://sideeffects.embl.de/se/C0029877/','Otitis','NTBC','http://sideeffects.embl.de/drugs/115355/'),('http://sideeffects.embl.de/se/C0029882/','Otitis media','Pimecrolimus','http://sideeffects.embl.de/drugs/3055172/'),('http://sideeffects.embl.de/se/C0029927/','Ovarian cyst','Metrodin','http://sideeffects.embl.de/drugs/62819/'),('http://sideeffects.embl.de/se/C0029928/','Ovarian disorder','Metrodin','http://sideeffects.embl.de/drugs/62819/'),('http://sideeffects.embl.de/se/C0030193/','Pain','K779','http://sideeffects.embl.de/drugs/71306834/'),('http://sideeffects.embl.de/se/C0030196/','Pain in extremity','Vemurafenib','http://sideeffects.embl.de/drugs/42611257/'),('http://sideeffects.embl.de/se/C0030201/','Postoperative pain','Valganciclovir','http://sideeffects.embl.de/drugs/64147/'),('http://sideeffects.embl.de/se/C0030232/','Pallor','Sulfasalazine','http://sideeffects.embl.de/drugs/5353980/'),('http://sideeffects.embl.de/se/C0030252/','Palpitations','Liraglutide','http://sideeffects.embl.de/drugs/16134956/'),('http://sideeffects.embl.de/se/C0030305/','Pancreatitis','Ponatinib','http://sideeffects.embl.de/drugs/24826799/'),('http://sideeffects.embl.de/se/C0030312/','Pancytopenia','Cefdinir','http://sideeffects.embl.de/drugs/6398970/'),('http://sideeffects.embl.de/se/C0030318/','Panic reaction','Protriptyline','http://sideeffects.embl.de/drugs/4976/'),('http://sideeffects.embl.de/se/C0030319/','Panic disorder','Flumazenil','http://sideeffects.embl.de/drugs/3373/'),('http://sideeffects.embl.de/se/C0030353/','Papilloedema','ACTH(1-39','http://sideeffects.embl.de/drugs/16132265/'),('http://sideeffects.embl.de/se/C0030446/','Ileus paralytic','Vinblastine','http://sideeffects.embl.de/drugs/13342/'),('http://sideeffects.embl.de/se/C0030469/','Sinus disorder','Rizatriptan','http://sideeffects.embl.de/drugs/5078/'),('http://sideeffects.embl.de/se/C0030552/','Paresis','V 1784','http://sideeffects.embl.de/drugs/2909/'),('http://sideeffects.embl.de/se/C0030554/','Paraesthesia','Teduglutide','http://sideeffects.embl.de/drugs/16139605/'),('http://sideeffects.embl.de/se/C0030578/','Paronychia','Lapatinib','http://sideeffects.embl.de/drugs/208908/'),('http://sideeffects.embl.de/se/C0030583/','Parotitis','Trihexyphenidyl','http://sideeffects.embl.de/drugs/5572/'),('http://sideeffects.embl.de/se/C0030587/','Paroxysmal atrial tachycardia','Procainamide','http://sideeffects.embl.de/drugs/4913/'),('http://sideeffects.embl.de/se/C0030781/','Peliosis hepatis','6-thioguanine','http://sideeffects.embl.de/drugs/2723601/'),('http://sideeffects.embl.de/se/C0030783/','Nicotinic acid deficiency','Isoniazid','http://sideeffects.embl.de/drugs/3767/'),('http://sideeffects.embl.de/se/C0030790/','Pelvic infection','Copper','http://sideeffects.embl.de/drugs/23978/'),('http://sideeffects.embl.de/se/C0030794/','Pelvic pain','Bivalirudin','http://sideeffects.embl.de/drugs/16129704/'),('http://sideeffects.embl.de/se/C0030848/','Peyronie\'s disease','Propranolol','http://sideeffects.embl.de/drugs/4946/'),('http://sideeffects.embl.de/se/C0030920/','Peptic ulcer','Cosyntropin','http://sideeffects.embl.de/drugs/16129617/'),('http://sideeffects.embl.de/se/C0031036/','Polyarteritis nodosa','Sulfadiazine','http://sideeffects.embl.de/drugs/5215/'),('http://sideeffects.embl.de/se/C0031039/','Pericardial effusion','Temsirolimus','http://sideeffects.embl.de/drugs/148191/'),('http://sideeffects.embl.de/se/C0031046/','Pericarditis','Balsalazide','http://sideeffects.embl.de/drugs/5362070/'),('http://sideeffects.embl.de/se/C0031111/','Periostitis','Benzathine penicillin','http://sideeffects.embl.de/drugs/15232/'),('http://sideeffects.embl.de/se/C0031117/','Neuropathy peripheral','Lapatinib','http://sideeffects.embl.de/drugs/208908/'),('http://sideeffects.embl.de/se/C0031133/','Vermiculation','Pyridostigmine','http://sideeffects.embl.de/drugs/4991/'),('http://sideeffects.embl.de/se/C0031154/','Peritonitis','Sevelamer','http://sideeffects.embl.de/drugs/3085017/'),('http://sideeffects.embl.de/se/C0031212/','Personality disorder','Olanzapine','http://sideeffects.embl.de/drugs/4585/'),('http://sideeffects.embl.de/se/C0031256/','Petechiae','ACTH(1-39','http://sideeffects.embl.de/drugs/16132265/'),('http://sideeffects.embl.de/se/C0031345/','Pharyngeal disorder','Capecitabine','http://sideeffects.embl.de/drugs/60953/'),('http://sideeffects.embl.de/se/C0031350/','Pharyngitis','K779','http://sideeffects.embl.de/drugs/71306834/'),('http://sideeffects.embl.de/se/C0031538/','Tight foreskin','Canagliflozin','http://sideeffects.embl.de/drugs/24812758/'),('http://sideeffects.embl.de/se/C0031542/','Phlebitis','Belinostat','http://sideeffects.embl.de/drugs/6918638/'),('http://sideeffects.embl.de/se/C0031736/','Polymorphic light eruption','Canagliflozin','http://sideeffects.embl.de/drugs/24812758/'),('http://sideeffects.embl.de/se/C0031924/','Piloerection','Midodrine','http://sideeffects.embl.de/drugs/4195/'),('http://sideeffects.embl.de/se/C0032000/','Pituitary adenoma','Histrelin','http://sideeffects.embl.de/drugs/25077993/'),('http://sideeffects.embl.de/se/C0032001/','Pituitary apoplexy','Histrelin','http://sideeffects.embl.de/drugs/25077993/'),('http://sideeffects.embl.de/se/C0032227/','Pleural effusion','LY146032','http://sideeffects.embl.de/drugs/16129629/'),('http://sideeffects.embl.de/se/C0032266/','Pneumatosis cystoides intestinalis','Acarbose','http://sideeffects.embl.de/drugs/41774/'),('http://sideeffects.embl.de/se/C0032285/','Pneumonia','Ponatinib','http://sideeffects.embl.de/drugs/24826799/'),('http://sideeffects.embl.de/se/C0032290/','Pneumonia aspiration','Nitrazepam','http://sideeffects.embl.de/drugs/4506/'),('http://sideeffects.embl.de/se/C0032300/','Lobar pneumonia','Vorinostat','http://sideeffects.embl.de/drugs/5311/'),('http://sideeffects.embl.de/se/C0032320/','Pneumoperitoneum','Acarbose','http://sideeffects.embl.de/drugs/41774/'),('http://sideeffects.embl.de/se/C0032519/','Polymenorrhoea','Levonorgestrel','http://sideeffects.embl.de/drugs/4542/'),('http://sideeffects.embl.de/se/C0032541/','Polyneuritis','Disulfiram','http://sideeffects.embl.de/drugs/3117/'),('http://sideeffects.embl.de/se/C0032584/','Polyp','6-mercaptopurine','http://sideeffects.embl.de/drugs/667490/'),('http://sideeffects.embl.de/se/C0032617/','Polyuria','Canagliflozin','http://sideeffects.embl.de/drugs/24812758/'),('http://sideeffects.embl.de/se/C0032708/','Porphyrin metabolism disorder','NTBC','http://sideeffects.embl.de/drugs/115355/'),('http://sideeffects.embl.de/se/C0032787/','Postoperative complications NOS','Valganciclovir','http://sideeffects.embl.de/drugs/64147/'),('http://sideeffects.embl.de/se/C0032788/','Postoperative hemorrhage','Acetaminophen','http://sideeffects.embl.de/drugs/1983/'),('http://sideeffects.embl.de/se/C0032961/','Pregnancy','Nepafenac','http://sideeffects.embl.de/drugs/151075/'),('http://sideeffects.embl.de/se/C0032987/','Ectopic pregnancy','Gonadorelin','http://sideeffects.embl.de/drugs/36523/'),('http://sideeffects.embl.de/se/C0032989/','Multiple pregnancy','Atosiban','http://sideeffects.embl.de/drugs/68613/'),('http://sideeffects.embl.de/se/C0033036/','Supraventricular extrasystoles','Ivabradine','http://sideeffects.embl.de/drugs/132999/'),('http://sideeffects.embl.de/se/C0033038/','Premature ejaculation','Bumetanide','http://sideeffects.embl.de/drugs/2471/'),('http://sideeffects.embl.de/se/C0033117/','Priapism','Molindone','http://sideeffects.embl.de/drugs/23897/'),('http://sideeffects.embl.de/se/C0033246/','Proctitis','D-telaprevir','http://sideeffects.embl.de/drugs/3010818/'),('http://sideeffects.embl.de/se/C0033247/','Proctocolitis','Chlorpropamide','http://sideeffects.embl.de/drugs/2727/'),('http://sideeffects.embl.de/se/C0033575/','Prostatic disorder','Doxazosin','http://sideeffects.embl.de/drugs/3157/'),('http://sideeffects.embl.de/se/C0033578/','Neoplasm prostate','Dapagliflozin','http://sideeffects.embl.de/drugs/9887712/'),('http://sideeffects.embl.de/se/C0033581/','Prostatitis','Venlafaxine','http://sideeffects.embl.de/drugs/5656/'),('http://sideeffects.embl.de/se/C0033687/','Proteinuria','Regorafenib','http://sideeffects.embl.de/drugs/11167602/'),('http://sideeffects.embl.de/se/C0033771/','Prurigo','Canagliflozin','http://sideeffects.embl.de/drugs/24812758/'),('http://sideeffects.embl.de/se/C0033774/','Pruritus','K779','http://sideeffects.embl.de/drugs/71306834/'),('http://sideeffects.embl.de/se/C0033775/','Anal pruritus','D-telaprevir','http://sideeffects.embl.de/drugs/3010818/'),('http://sideeffects.embl.de/se/C0033777/','Pruritus genital','Metronidazole','http://sideeffects.embl.de/drugs/4173/'),('http://sideeffects.embl.de/se/C0033844/','Pseudotumor','Cysteamine','http://sideeffects.embl.de/drugs/6058/'),('http://sideeffects.embl.de/se/C0033845/','Benign intracranial hypertension','ACTH(1-39','http://sideeffects.embl.de/drugs/16132265/'),('http://sideeffects.embl.de/se/C0033860/','Psoriasis','Nebivolol','http://sideeffects.embl.de/drugs/71301/'),('http://sideeffects.embl.de/se/C0033975/','Psychotic disorder','Doxercalciferol','http://sideeffects.embl.de/drugs/4479094/'),('http://sideeffects.embl.de/se/C0034013/','Precocious puberty','Aminoglutethimide','http://sideeffects.embl.de/drugs/2145/'),('http://sideeffects.embl.de/se/C0034063/','Pulmonary oedema','Terlipressin','http://sideeffects.embl.de/drugs/72081/'),('http://sideeffects.embl.de/se/C0034065/','Pulmonary embolism','Nafarelin','http://sideeffects.embl.de/drugs/25077405/'),('http://sideeffects.embl.de/se/C0034068/','Pulmonary eosinophilia','Pyrimethamine','http://sideeffects.embl.de/drugs/4993/'),('http://sideeffects.embl.de/se/C0034069/','Pulmonary fibrosis','Dronedarone','http://sideeffects.embl.de/drugs/208898/'),('http://sideeffects.embl.de/se/C0034150/','Purpura','Mirabegron','http://sideeffects.embl.de/drugs/9865528/'),('http://sideeffects.embl.de/se/C0034152/','Henoch-Schonlein purpura','Ethacrynic acid','http://sideeffects.embl.de/drugs/3278/'),('http://sideeffects.embl.de/se/C0034155/','Thrombotic thrombocytopenic purpura','Prasugrel','http://sideeffects.embl.de/drugs/6918456/'),('http://sideeffects.embl.de/se/C0034530/','Radiation injury','Temozolomide','http://sideeffects.embl.de/drugs/5394/'),('http://sideeffects.embl.de/se/C0034634/','Rage','Lormetazepam','http://sideeffects.embl.de/drugs/13314/'),('http://sideeffects.embl.de/se/C0034642/','Rales','Colimycin M','http://sideeffects.embl.de/drugs/216258/'),('http://sideeffects.embl.de/se/C0034734/','Raynaud\'s disease','Propranolol','http://sideeffects.embl.de/drugs/4946/'),('http://sideeffects.embl.de/se/C0034880/','Hyperacusis','Lormetazepam','http://sideeffects.embl.de/drugs/13314/'),('http://sideeffects.embl.de/se/C0034882/','Rectal disorder','5-ASA','http://sideeffects.embl.de/drugs/4075/'),('http://sideeffects.embl.de/se/C0034886/','Proctalgia','D-telaprevir','http://sideeffects.embl.de/drugs/3010818/'),('http://sideeffects.embl.de/se/C0034931/','Reflex sympathetic dystrophy','Temsirolimus','http://sideeffects.embl.de/drugs/148191/'),('http://sideeffects.embl.de/se/C0035078/','Renal failure','Carfilzomib','http://sideeffects.embl.de/drugs/11556711/'),('http://sideeffects.embl.de/se/C0035222/','Acute respiratory distress syndrome','Voriconazole','http://sideeffects.embl.de/drugs/71616/'),('http://sideeffects.embl.de/se/C0035229/','Respiratory insufficiency','NTBC','http://sideeffects.embl.de/drugs/115355/'),('http://sideeffects.embl.de/se/C0035232/','Respiratory paralysis','Pyridostigmine','http://sideeffects.embl.de/drugs/4991/'),('http://sideeffects.embl.de/se/C0035243/','Respiratory tract infection','Teduglutide','http://sideeffects.embl.de/drugs/16139605/'),('http://sideeffects.embl.de/se/C0035258/','Restless legs syndrome','Agomelatine','http://sideeffects.embl.de/drugs/82148/'),('http://sideeffects.embl.de/se/C0035304/','Retinal degeneration','Deferoxamine','http://sideeffects.embl.de/drugs/2973/'),('http://sideeffects.embl.de/se/C0035305/','Retinal detachment','Valganciclovir','http://sideeffects.embl.de/drugs/64147/'),('http://sideeffects.embl.de/se/C0035309/','Retinal disorder','Insulin detemir','http://sideeffects.embl.de/drugs/16137271/'),('http://sideeffects.embl.de/se/C0035317/','Retinal haemorrhage','Bimatoprost','http://sideeffects.embl.de/drugs/127909/'),('http://sideeffects.embl.de/se/C0035328/','Retinal vein occlusion','Vardenafil','http://sideeffects.embl.de/drugs/110634/'),('http://sideeffects.embl.de/se/C0035333/','Retinitis','Allopurinol','http://sideeffects.embl.de/drugs/2094/'),('http://sideeffects.embl.de/se/C0035344/','Retinopathy of prematurity','Caffeine','http://sideeffects.embl.de/drugs/2519/'),('http://sideeffects.embl.de/se/C0035400/','Reye\'s syndrome','Aspirin','http://sideeffects.embl.de/drugs/2244/'),('http://sideeffects.embl.de/se/C0035410/','Rhabdomyolysis','Cefdinir','http://sideeffects.embl.de/drugs/6398970/'),('http://sideeffects.embl.de/se/C0035435/','Rheumatism','Naratriptan','http://sideeffects.embl.de/drugs/4440/'),('http://sideeffects.embl.de/se/C0035455/','Rhinitis','Nafarelin','http://sideeffects.embl.de/drugs/25077405/'),('http://sideeffects.embl.de/se/C0035508/','Rhonchi','Midazolam','http://sideeffects.embl.de/drugs/4192/'),('http://sideeffects.embl.de/se/C0035854/','Rosacea','DFMO','http://sideeffects.embl.de/drugs/3009/'),('http://sideeffects.embl.de/se/C0035920/','Rubella','Gamma-aminobutyric acid','http://sideeffects.embl.de/drugs/119/'),('http://sideeffects.embl.de/se/C0036104/','Salivation','Molindone','http://sideeffects.embl.de/drugs/23897/'),('http://sideeffects.embl.de/se/C0036341/','Schizophrenia','Oxprenolol','http://sideeffects.embl.de/drugs/4631/'),('http://sideeffects.embl.de/se/C0036396/','Sciatica','Telmisartan','http://sideeffects.embl.de/drugs/65999/'),('http://sideeffects.embl.de/se/C0036416/','Scleritis','Alendronate','http://sideeffects.embl.de/drugs/2088/'),('http://sideeffects.embl.de/se/C0036420/','Circumscribed scleroderma','Tranylcypromine','http://sideeffects.embl.de/drugs/5530/'),('http://sideeffects.embl.de/se/C0036439/','Scoliosis','Cysteamine','http://sideeffects.embl.de/drugs/6058/'),('http://sideeffects.embl.de/se/C0036454/','Scotoma','Vardenafil','http://sideeffects.embl.de/drugs/110634/'),('http://sideeffects.embl.de/se/C0036508/','Seborrhoeic dermatitis','Nafarelin','http://sideeffects.embl.de/drugs/25077405/'),('http://sideeffects.embl.de/se/C0036572/','Convulsion','Histrelin','http://sideeffects.embl.de/drugs/25077993/'),('http://sideeffects.embl.de/se/C0036679/','Separation','Silver nanoparticles','http://sideeffects.embl.de/drugs/23954/'),('http://sideeffects.embl.de/se/C0036690/','Septicemia','NTBC','http://sideeffects.embl.de/drugs/115355/'),('http://sideeffects.embl.de/se/C0036830/','Serum sickness','Cefdinir','http://sideeffects.embl.de/drugs/6398970/'),('http://sideeffects.embl.de/se/C0036973/','Shivering','Sufentanil','http://sideeffects.embl.de/drugs/41693/'),('http://sideeffects.embl.de/se/C0036974/','Shock','Histrelin','http://sideeffects.embl.de/drugs/25077993/'),('http://sideeffects.embl.de/se/C0036980/','Cardiogenic shock','Metoprolol','http://sideeffects.embl.de/drugs/4171/'),('http://sideeffects.embl.de/se/C0036983/','Septic shock','FK463','http://sideeffects.embl.de/drugs/477468/'),('http://sideeffects.embl.de/se/C0037011/','Shoulder pain','Zoledronic acid','http://sideeffects.embl.de/drugs/68740/'),('http://sideeffects.embl.de/se/C0037023/','Sialoadenitis','Methyclothiazide','http://sideeffects.embl.de/drugs/4121/'),('http://sideeffects.embl.de/se/C0037036/','Salivary hypersecretion','Ethionamide','http://sideeffects.embl.de/drugs/2761171/'),('http://sideeffects.embl.de/se/C0037052/','Sick sinus syndrome','Ivabradine','http://sideeffects.embl.de/drugs/132999/'),('http://sideeffects.embl.de/se/C0037195/','Sinus headache','Ivacaftor','http://sideeffects.embl.de/drugs/16220172/'),('http://sideeffects.embl.de/se/C0037199/','Sinusitis','Insulin detemir','http://sideeffects.embl.de/drugs/16137271/'),('http://sideeffects.embl.de/se/C0037274/','Skin disorder','Pazopanib','http://sideeffects.embl.de/drugs/10113978/'),('http://sideeffects.embl.de/se/C0037278/','Skin infection','Pimecrolimus','http://sideeffects.embl.de/drugs/3055172/'),('http://sideeffects.embl.de/se/C0037284/','Skin lesion','Dabrafenib','http://sideeffects.embl.de/drugs/44462760/'),('http://sideeffects.embl.de/se/C0037286/','Neoplasm skin','DFMO','http://sideeffects.embl.de/drugs/3009/'),('http://sideeffects.embl.de/se/C0037290/','Pigmentation skin','Methimazole','http://sideeffects.embl.de/drugs/1349907/'),('http://sideeffects.embl.de/se/C0037293/','Acrochordon','Dabrafenib','http://sideeffects.embl.de/drugs/44462760/'),('http://sideeffects.embl.de/se/C0037299/','Skin ulcer','Propylthiouracil','http://sideeffects.embl.de/drugs/657298/'),('http://sideeffects.embl.de/se/C0037317/','Sleep disturbance','Abarelix','http://sideeffects.embl.de/drugs/16131215/'),('http://sideeffects.embl.de/se/C0037320/','Sleep terror','Ethosuximide','http://sideeffects.embl.de/drugs/3291/'),('http://sideeffects.embl.de/se/C0037383/','Sneezing','Phencyclidine','http://sideeffects.embl.de/drugs/6468/'),('http://sideeffects.embl.de/se/C0037763/','Muscle spasms','Vismodegib','http://sideeffects.embl.de/drugs/24776445/'),('http://sideeffects.embl.de/se/C0037822/','Speech disorder','Tolcapone','http://sideeffects.embl.de/drugs/4659569/'),('http://sideeffects.embl.de/se/C0037926/','Spinal cord compression','MDV3100','http://sideeffects.embl.de/drugs/15951529/'),('http://sideeffects.embl.de/se/C0037929/','Spinal cord injury','Vorinostat','http://sideeffects.embl.de/drugs/5311/'),('http://sideeffects.embl.de/se/C0037998/','Splenic infarction','Clofazimine','http://sideeffects.embl.de/drugs/2794/'),('http://sideeffects.embl.de/se/C0038002/','Splenomegaly','6-thioguanine','http://sideeffects.embl.de/drugs/2723601/'),('http://sideeffects.embl.de/se/C0038325/','Stevens-Johnson syndrome','Cefdinir','http://sideeffects.embl.de/drugs/6398970/'),('http://sideeffects.embl.de/se/C0038340/','Sting','Mepyramine','http://sideeffects.embl.de/drugs/4992/'),('http://sideeffects.embl.de/se/C0038354/','Gastric disorder','Trazodone','http://sideeffects.embl.de/drugs/5533/'),('http://sideeffects.embl.de/se/C0038358/','Gastric ulcer','Deferasirox','http://sideeffects.embl.de/drugs/5493381/'),('http://sideeffects.embl.de/se/C0038362/','Stomatitis','Cabozantinib','http://sideeffects.embl.de/drugs/25102847/'),('http://sideeffects.embl.de/se/C0038363/','Aphthous stomatitis','Lercanidipine','http://sideeffects.embl.de/drugs/65866/'),('http://sideeffects.embl.de/se/C0038367/','Ulcerative stomatitis','Glat copolymer','http://sideeffects.embl.de/drugs/65370/'),('http://sideeffects.embl.de/se/C0038435/','Stress','Disulfiram','http://sideeffects.embl.de/drugs/3117/'),('http://sideeffects.embl.de/se/C0038450/','Stridor','Salmeterol','http://sideeffects.embl.de/drugs/5152/'),('http://sideeffects.embl.de/se/C0038454/','Cerebrovascular accident','Nafarelin','http://sideeffects.embl.de/drugs/25077405/'),('http://sideeffects.embl.de/se/C0038463/','Strongyloidiasis','Cimetidine','http://sideeffects.embl.de/drugs/2756/'),('http://sideeffects.embl.de/se/C0038525/','Subarachnoid haemorrhage','Apixaban','http://sideeffects.embl.de/drugs/10182969/'),('http://sideeffects.embl.de/se/C0038534/','Subconjunctival hemorrhage','Diazoxide','http://sideeffects.embl.de/drugs/3019/'),('http://sideeffects.embl.de/se/C0038538/','Subdural effusion','ACTH(1-39','http://sideeffects.embl.de/drugs/16132265/'),('http://sideeffects.embl.de/se/C0038587/','Withdrawal syndrome','Lormetazepam','http://sideeffects.embl.de/drugs/13314/'),('http://sideeffects.embl.de/se/C0038661/','Suicide','Lu AA21004','http://sideeffects.embl.de/drugs/9966051/'),('http://sideeffects.embl.de/se/C0038663/','Suicide attempt','Elvitegravir','http://sideeffects.embl.de/drugs/5277135/'),('http://sideeffects.embl.de/se/C0038732/','Sulphaemoglobinaemia','Phenylazo','http://sideeffects.embl.de/drugs/4756/'),('http://sideeffects.embl.de/se/C0038814/','Sunburn','Canagliflozin','http://sideeffects.embl.de/drugs/24812758/'),('http://sideeffects.embl.de/se/C0038826/','Superinfection','Ciprofloxacin','http://sideeffects.embl.de/drugs/2764/'),('http://sideeffects.embl.de/se/C0038833/','Superior vena cava syndrome','Nitrogen mustard','http://sideeffects.embl.de/drugs/4033/'),('http://sideeffects.embl.de/se/C0038941/','Postoperative wound infection','Temsirolimus','http://sideeffects.embl.de/drugs/148191/'),('http://sideeffects.embl.de/se/C0038990/','Sweating','Raltitrexed','http://sideeffects.embl.de/drugs/104758/'),('http://sideeffects.embl.de/se/C0038999/','Swelling','Histrelin','http://sideeffects.embl.de/drugs/25077993/'),('http://sideeffects.embl.de/se/C0039070/','Syncope','Canagliflozin','http://sideeffects.embl.de/drugs/24812758/'),('http://sideeffects.embl.de/se/C0039103/','Synovitis','Leflunomide','http://sideeffects.embl.de/drugs/3899/'),('http://sideeffects.embl.de/se/C0039231/','Tachycardia','Liraglutide','http://sideeffects.embl.de/drugs/16134956/'),('http://sideeffects.embl.de/se/C0039235/','Junctional tachycardia','Procainamide','http://sideeffects.embl.de/drugs/4913/'),('http://sideeffects.embl.de/se/C0039239/','Sinus tachycardia','Paliperidone','http://sideeffects.embl.de/drugs/115237/'),('http://sideeffects.embl.de/se/C0039240/','Supraventricular tachycardia','Raltitrexed','http://sideeffects.embl.de/drugs/104758/'),('http://sideeffects.embl.de/se/C0039242/','Tachyphylaxis','Succinylcholine','http://sideeffects.embl.de/drugs/5314/'),('http://sideeffects.embl.de/se/C0039338/','Taste disorders','Vorinostat','http://sideeffects.embl.de/drugs/5311/'),('http://sideeffects.embl.de/se/C0039446/','Telangiectasia','Halobetasol','http://sideeffects.embl.de/drugs/5311167/'),('http://sideeffects.embl.de/se/C0039503/','Tendonitis','Ropinirole','http://sideeffects.embl.de/drugs/5095/'),('http://sideeffects.embl.de/se/C0039520/','Tenosynovitis','Bezafibrate','http://sideeffects.embl.de/drugs/39042/'),('http://sideeffects.embl.de/se/C0039621/','Tetany','Sodium bicarbonate','http://sideeffects.embl.de/drugs/10340/'),('http://sideeffects.embl.de/se/C0039841/','Vitamin B1 deficiency','Thiamine','http://sideeffects.embl.de/drugs/1130/'),('http://sideeffects.embl.de/se/C0039971/','Thirst','Canagliflozin','http://sideeffects.embl.de/drugs/24812758/'),('http://sideeffects.embl.de/se/C0040034/','Thrombocytopenia','Dabrafenib','http://sideeffects.embl.de/drugs/44462760/'),('http://sideeffects.embl.de/se/C0040038/','Thromboembolism','Gonadorelin','http://sideeffects.embl.de/drugs/36523/'),('http://sideeffects.embl.de/se/C0040046/','Thrombophlebitis','Ceftobiprole','http://sideeffects.embl.de/drugs/6918430/'),('http://sideeffects.embl.de/se/C0040053/','Thrombosis','Eltrombopag','http://sideeffects.embl.de/drugs/9846180/'),('http://sideeffects.embl.de/se/C0040100/','Thymoma','Gamma-aminobutyric acid','http://sideeffects.embl.de/drugs/119/'),('http://sideeffects.embl.de/se/C0040156/','Thyrotoxicosis','Celiprolol','http://sideeffects.embl.de/drugs/2663/'),('http://sideeffects.embl.de/se/C0040247/','Tinea infection','Econazole','http://sideeffects.embl.de/drugs/3198/'),('http://sideeffects.embl.de/se/C0040259/','Tinea pedis','Econazole','http://sideeffects.embl.de/drugs/3198/'),('http://sideeffects.embl.de/se/C0040262/','Tinea versicolour','Econazole','http://sideeffects.embl.de/drugs/3198/'),('http://sideeffects.embl.de/se/C0040264/','Tinnitus','Ivacaftor','http://sideeffects.embl.de/drugs/16220172/'),('http://sideeffects.embl.de/se/C0040409/','Tongue disorder','Phenytoin','http://sideeffects.embl.de/drugs/1775/'),('http://sideeffects.embl.de/se/C0040414/','Tongue hairy','Nafcillin','http://sideeffects.embl.de/drugs/8982/'),('http://sideeffects.embl.de/se/C0040425/','Tonsillitis','N-carbamylglutamate','http://sideeffects.embl.de/drugs/121396/'),('http://sideeffects.embl.de/se/C0040435/','Tooth disorder','Tolcapone','http://sideeffects.embl.de/drugs/4659569/'),('http://sideeffects.embl.de/se/C0040460/','Toothache','Insulin detemir','http://sideeffects.embl.de/drugs/16137271/'),('http://sideeffects.embl.de/se/C0040479/','Torsade de pointes','Terlipressin','http://sideeffects.embl.de/drugs/72081/'),('http://sideeffects.embl.de/se/C0040485/','Torticollis','Pimozide','http://sideeffects.embl.de/drugs/16362/'),('http://sideeffects.embl.de/se/C0040584/','Tracheitis','Salmeterol','http://sideeffects.embl.de/drugs/5152/'),('http://sideeffects.embl.de/se/C0040797/','Traumatic haemorrhage','Apixaban','http://sideeffects.embl.de/drugs/10182969/'),('http://sideeffects.embl.de/se/C0040822/','Tremor','Fluticasone furoate','http://sideeffects.embl.de/drugs/9854489/'),('http://sideeffects.embl.de/se/C0040997/','Trigeminal neuralgia','Oxprenolol','http://sideeffects.embl.de/drugs/4631/'),('http://sideeffects.embl.de/se/C0041105/','Trismus','Venlafaxine','http://sideeffects.embl.de/drugs/5656/'),('http://sideeffects.embl.de/se/C0041349/','Tubulointerstitial nephritis','Febuxostat','http://sideeffects.embl.de/drugs/134018/'),('http://sideeffects.embl.de/se/C0041364/','Tumour lysis syndrome','Belinostat','http://sideeffects.embl.de/drugs/6918638/'),('http://sideeffects.embl.de/se/C0041582/','Ulcer','Fluticasone furoate','http://sideeffects.embl.de/drugs/9854489/'),('http://sideeffects.embl.de/se/C0041657/','Loss of consciousness','Canagliflozin','http://sideeffects.embl.de/drugs/24812758/'),('http://sideeffects.embl.de/se/C0041834/','Erythema','Cabozantinib','http://sideeffects.embl.de/drugs/25102847/'),('http://sideeffects.embl.de/se/C0041909/','Upper gastrointestinal haemorrhage','Cefdinir','http://sideeffects.embl.de/drugs/6398970/'),('http://sideeffects.embl.de/se/C0041912/','Upper respiratory tract infection','Ivacaftor','http://sideeffects.embl.de/drugs/16220172/'),('http://sideeffects.embl.de/se/C0041948/','Uremia','Guanidinium','http://sideeffects.embl.de/drugs/3520/'),('http://sideeffects.embl.de/se/C0041956/','Ureteric obstruction','Vorinostat','http://sideeffects.embl.de/drugs/5311/'),('http://sideeffects.embl.de/se/C0041959/','Ureteritis','Cyclophosphamide','http://sideeffects.embl.de/drugs/2907/'),('http://sideeffects.embl.de/se/C0042023/','Pollakiuria','Canagliflozin','http://sideeffects.embl.de/drugs/24812758/'),('http://sideeffects.embl.de/se/C0042024/','Urinary incontinence','Tolcapone','http://sideeffects.embl.de/drugs/4659569/'),('http://sideeffects.embl.de/se/C0042029/','Urinary tract infection','Dabrafenib','http://sideeffects.embl.de/drugs/44462760/'),('http://sideeffects.embl.de/se/C0042035/','Micturition disorder','Imipramine','http://sideeffects.embl.de/drugs/3696/'),('http://sideeffects.embl.de/se/C0042075/','Urinary tract disorder','Histrelin','http://sideeffects.embl.de/drugs/25077993/'),('http://sideeffects.embl.de/se/C0042109/','Urticaria','Florbetapir','http://sideeffects.embl.de/drugs/24822371/'),('http://sideeffects.embl.de/se/C0042130/','Uterine contractions','Phencyclidine','http://sideeffects.embl.de/drugs/6468/'),('http://sideeffects.embl.de/se/C0042131/','Uterine disorder','Raloxifene','http://sideeffects.embl.de/drugs/5035/'),('http://sideeffects.embl.de/se/C0042134/','Uterine haemorrhage','Tadalafil','http://sideeffects.embl.de/drugs/110635/'),('http://sideeffects.embl.de/se/C0042135/','Uterine atony','Atosiban','http://sideeffects.embl.de/drugs/68613/'),('http://sideeffects.embl.de/se/C0042164/','Uveitis','Erlotinib','http://sideeffects.embl.de/drugs/176870/'),('http://sideeffects.embl.de/se/C0042165/','Anterior uveitis','Cyclopentolate','http://sideeffects.embl.de/drugs/2905/'),('http://sideeffects.embl.de/se/C0042167/','Posterior uveitis','Cyclopentolate','http://sideeffects.embl.de/drugs/2905/'),('http://sideeffects.embl.de/se/C0042251/','Vaginal disorder','Lasofoxifene','http://sideeffects.embl.de/drugs/216416/'),('http://sideeffects.embl.de/se/C0042256/','Vaginal itching','Metronidazole','http://sideeffects.embl.de/drugs/4173/'),('http://sideeffects.embl.de/se/C0042267/','Vaginal inflammation','Ertapenem','http://sideeffects.embl.de/drugs/150610/'),('http://sideeffects.embl.de/se/C0042341/','Varicocele','Metrodin','http://sideeffects.embl.de/drugs/62819/'),('http://sideeffects.embl.de/se/C0042345/','Varicose vein','Monoethanolamine','http://sideeffects.embl.de/drugs/700/'),('http://sideeffects.embl.de/se/C0042373/','Angiopathy','Florbetapir','http://sideeffects.embl.de/drugs/24822371/'),('http://sideeffects.embl.de/se/C0042380/','Vascular resistance','Aminoglutethimide','http://sideeffects.embl.de/drugs/2145/'),('http://sideeffects.embl.de/se/C0042384/','Vasculitis','Propylthiouracil','http://sideeffects.embl.de/drugs/657298/'),('http://sideeffects.embl.de/se/C0042401/','Vasodilation','Almotriptan','http://sideeffects.embl.de/drugs/123606/'),('http://sideeffects.embl.de/se/C0042487/','Venous thrombosis','Glucose solution','http://sideeffects.embl.de/drugs/24748/'),('http://sideeffects.embl.de/se/C0042510/','Ventricular fibrillation','Belinostat','http://sideeffects.embl.de/drugs/6918638/'),('http://sideeffects.embl.de/se/C0042514/','Ventricular tachycardia','Bivalirudin','http://sideeffects.embl.de/drugs/16129704/'),('http://sideeffects.embl.de/se/C0042571/','Vertigo','K779','http://sideeffects.embl.de/drugs/71306834/'),('http://sideeffects.embl.de/se/C0042594/','Vestibular disorder','Ivacaftor','http://sideeffects.embl.de/drugs/16220172/'),('http://sideeffects.embl.de/se/C0042721/','Hepatitis viral','Perhexiline','http://sideeffects.embl.de/drugs/4746/'),('http://sideeffects.embl.de/se/C0042755/','Virilism','Oxandrolone','http://sideeffects.embl.de/drugs/5878/'),('http://sideeffects.embl.de/se/C0042769/','Viral infection','K779','http://sideeffects.embl.de/drugs/71306834/'),('http://sideeffects.embl.de/se/C0042790/','Disorder sight','Nedocromil sodium','http://sideeffects.embl.de/drugs/50294/'),('http://sideeffects.embl.de/se/C0042798/','Vision decreased','Thiabendazole','http://sideeffects.embl.de/drugs/5430/'),('http://sideeffects.embl.de/se/C0042900/','Vitiligo','Monobenzone','http://sideeffects.embl.de/drugs/7638/'),('http://sideeffects.embl.de/se/C0042907/','Vitreous detachment','Nepafenac','http://sideeffects.embl.de/drugs/151075/'),('http://sideeffects.embl.de/se/C0042961/','Volvulus','Acarbose','http://sideeffects.embl.de/drugs/41774/'),('http://sideeffects.embl.de/se/C0042963/','Vomiting','K779','http://sideeffects.embl.de/drugs/71306834/'),('http://sideeffects.embl.de/se/C0042996/','Vulvitis','Empagliflozin','http://sideeffects.embl.de/drugs/11949646/'),('http://sideeffects.embl.de/se/C0042998/','Vulvovaginitis','Empagliflozin','http://sideeffects.embl.de/drugs/11949646/'),('http://sideeffects.embl.de/se/C0043049/','Water intoxication','Carbamazepine','http://sideeffects.embl.de/drugs/2554/'),('http://sideeffects.embl.de/se/C0043094/','Weight increased','Degarelix','http://sideeffects.embl.de/drugs/16136245/'),('http://sideeffects.embl.de/se/C0043096/','Weight decreased','K779','http://sideeffects.embl.de/drugs/71306834/'),('http://sideeffects.embl.de/se/C0043117/','Idiopathic thrombocytopenic purpura','Cefdinir','http://sideeffects.embl.de/drugs/6398970/'),('http://sideeffects.embl.de/se/C0043121/','Wernicke\'s encephalopathy','Thiamine','http://sideeffects.embl.de/drugs/1130/'),('http://sideeffects.embl.de/se/C0043144/','Wheezing','Ivacaftor','http://sideeffects.embl.de/drugs/16220172/'),('http://sideeffects.embl.de/se/C0043167/','Pertussis','Azithromycin','http://sideeffects.embl.de/drugs/2269/'),('http://sideeffects.embl.de/se/C0043241/','Wound infection','Ertapenem','http://sideeffects.embl.de/drugs/150610/'),('http://sideeffects.embl.de/se/C0043246/','Laceration','Tetrabenazine','http://sideeffects.embl.de/drugs/6018/'),('http://sideeffects.embl.de/se/C0043250/','Wound','Ondansetron','http://sideeffects.embl.de/drugs/4595/'),('http://sideeffects.embl.de/se/C0043251/','Trauma','Fludrocortisone','http://sideeffects.embl.de/drugs/31378/'),('http://sideeffects.embl.de/se/C0043349/','Xerophthalmia','Azelastine','http://sideeffects.embl.de/drugs/2267/'),('http://sideeffects.embl.de/se/C0043352/','Dry mouth','Trametinib','http://sideeffects.embl.de/drugs/11707110/'),('http://sideeffects.embl.de/se/C0043387/','Yawning','Desvenlafaxine','http://sideeffects.embl.de/drugs/125017/'),('http://sideeffects.embl.de/se/C0079027/','Intraoperative hemorrhage','Apixaban','http://sideeffects.embl.de/drugs/10182969/'),('http://sideeffects.embl.de/se/C0079035/','Bradyarrhythmia','Cilostazol','http://sideeffects.embl.de/drugs/2754/'),('http://sideeffects.embl.de/se/C0079043/','Bronchoconstriction','Clodronate','http://sideeffects.embl.de/drugs/25419/'),('http://sideeffects.embl.de/se/C0079102/','Cerebral thrombosis','Tranexamic acid','http://sideeffects.embl.de/drugs/5526/'),('http://sideeffects.embl.de/se/C0080203/','Tachyarrhythmia','Isoproterenol','http://sideeffects.embl.de/drugs/3779/'),('http://sideeffects.embl.de/se/C0080274/','Urinary retention','Triptorelin','http://sideeffects.embl.de/drugs/25074470/'),('http://sideeffects.embl.de/se/C0080276/','Urogenital disorder','Perhexiline','http://sideeffects.embl.de/drugs/4746/'),('http://sideeffects.embl.de/se/C0085074/','Granuloma annulare','Darifenacin','http://sideeffects.embl.de/drugs/72054/'),('http://sideeffects.embl.de/se/C0085083/','Ovarian hyperstimulation syndrome','Metrodin','http://sideeffects.embl.de/drugs/62819/'),('http://sideeffects.embl.de/se/C0085096/','Peripheral vascular disorder','Amlodipine','http://sideeffects.embl.de/drugs/2162/'),('http://sideeffects.embl.de/se/C0085129/','Bronchial hyperreactivity','Linagliptin','http://sideeffects.embl.de/drugs/10096344/'),('http://sideeffects.embl.de/se/C0085166/','Vaginitis bacterial','Imiquimod','http://sideeffects.embl.de/drugs/57469/'),('http://sideeffects.embl.de/se/C0085383/','Hypocapnia','Enflurane','http://sideeffects.embl.de/drugs/3226/'),('http://sideeffects.embl.de/se/C0085393/','Immunocompromised','Cimetidine','http://sideeffects.embl.de/drugs/2756/'),('http://sideeffects.embl.de/se/C0085570/','Alkalosis hypokalaemic','ACTH(1-39','http://sideeffects.embl.de/drugs/16132265/'),('http://sideeffects.embl.de/se/C0085584/','Encephalopathy','Cysteamine','http://sideeffects.embl.de/drugs/6058/'),('http://sideeffects.embl.de/se/C0085593/','Chills','K779','http://sideeffects.embl.de/drugs/71306834/'),('http://sideeffects.embl.de/se/C0085595/','Body odor','Nafarelin','http://sideeffects.embl.de/drugs/25077405/'),('http://sideeffects.embl.de/se/C0085602/','Polydipsia','Empagliflozin','http://sideeffects.embl.de/drugs/11949646/'),('http://sideeffects.embl.de/se/C0085605/','Hepatic failure','Belinostat','http://sideeffects.embl.de/drugs/6918638/'),('http://sideeffects.embl.de/se/C0085606/','Micturition urgency','Hydroxybutyrate','http://sideeffects.embl.de/drugs/10413/'),('http://sideeffects.embl.de/se/C0085610/','Sinus bradycardia','SOM230','http://sideeffects.embl.de/drugs/9941444/'),('http://sideeffects.embl.de/se/C0085611/','Atrial arrhythmia','Telithromycin','http://sideeffects.embl.de/drugs/73658/'),('http://sideeffects.embl.de/se/C0085612/','Ventricular arrhythmia','Dofetilide','http://sideeffects.embl.de/drugs/71329/'),('http://sideeffects.embl.de/se/C0085614/','Atrioventricular block first degree','Paliperidone','http://sideeffects.embl.de/drugs/115237/'),('http://sideeffects.embl.de/se/C0085616/','Vasospasm','Nimodipine','http://sideeffects.embl.de/drugs/4497/'),('http://sideeffects.embl.de/se/C0085617/','Arterial spasm','Esmolol','http://sideeffects.embl.de/drugs/59768/'),('http://sideeffects.embl.de/se/C0085618/','Venospasm','Tris','http://sideeffects.embl.de/drugs/6503/'),('http://sideeffects.embl.de/se/C0085620/','Paralysis flaccid','Dofetilide','http://sideeffects.embl.de/drugs/71329/'),('http://sideeffects.embl.de/se/C0085623/','Akinesia','Molindone','http://sideeffects.embl.de/drugs/23897/'),('http://sideeffects.embl.de/se/C0085624/','Burning sensation','Retapamulin','http://sideeffects.embl.de/drugs/6918462/'),('http://sideeffects.embl.de/se/C0085628/','Stupor','Glat copolymer','http://sideeffects.embl.de/drugs/65370/'),('http://sideeffects.embl.de/se/C0085631/','Agitation','Ethionamide','http://sideeffects.embl.de/drugs/2761171/'),('http://sideeffects.embl.de/se/C0085632/','Apathy','Oxcarbazepine','http://sideeffects.embl.de/drugs/34312/'),('http://sideeffects.embl.de/se/C0085633/','Mood swings','Nafarelin','http://sideeffects.embl.de/drugs/25077405/'),('http://sideeffects.embl.de/se/C0085636/','Photophobia','Nepafenac','http://sideeffects.embl.de/drugs/151075/'),('http://sideeffects.embl.de/se/C0085637/','Oculogyric crisis','Cyclizine','http://sideeffects.embl.de/drugs/6726/'),('http://sideeffects.embl.de/se/C0085639/','Fall','Oxcarbazepine','http://sideeffects.embl.de/drugs/34312/'),('http://sideeffects.embl.de/se/C0085641/','Rash pustular','Glat copolymer','http://sideeffects.embl.de/drugs/65370/'),('http://sideeffects.embl.de/se/C0085642/','Livedo reticularis','Amantadine','http://sideeffects.embl.de/drugs/2130/'),('http://sideeffects.embl.de/se/C0085649/','Oedema peripheral','Dabrafenib','http://sideeffects.embl.de/drugs/44462760/'),('http://sideeffects.embl.de/se/C0085660/','Aseptic necrosis','ACTH(1-39','http://sideeffects.embl.de/drugs/16132265/'),('http://sideeffects.embl.de/se/C0085661/','Onycholysis','Mitoxantrone','http://sideeffects.embl.de/drugs/4212/'),('http://sideeffects.embl.de/se/C0085669/','Acute leukaemia','Lomustine','http://sideeffects.embl.de/drugs/3950/'),('http://sideeffects.embl.de/se/C0085679/','Hyperchloraemia','Streptozotocin','http://sideeffects.embl.de/drugs/5300/'),('http://sideeffects.embl.de/se/C0085680/','Hypochloraemia','Indapamide','http://sideeffects.embl.de/drugs/3702/'),('http://sideeffects.embl.de/se/C0085681/','Hyperphosphataemia','Clodronate','http://sideeffects.embl.de/drugs/25419/'),('http://sideeffects.embl.de/se/C0085682/','Hypophosphataemia','Dabrafenib','http://sideeffects.embl.de/drugs/44462760/'),('http://sideeffects.embl.de/se/C0085684/','Footdrop','Allopurinol','http://sideeffects.embl.de/drugs/2094/'),('http://sideeffects.embl.de/se/C0085692/','Cystitis haemorrhagic','Vinorelbine','http://sideeffects.embl.de/drugs/5672/'),('http://sideeffects.embl.de/se/C0085693/','Acute appendicitis','Gemfibrozil','http://sideeffects.embl.de/drugs/3463/'),('http://sideeffects.embl.de/se/C0085702/','Monocytosis','Methsuximide','http://sideeffects.embl.de/drugs/6476/'),('http://sideeffects.embl.de/se/C0085932/','Dermatitis bullous','Minoxidil','http://sideeffects.embl.de/drugs/4201/'),('http://sideeffects.embl.de/se/C0086438/','Hypogammaglobulinaemia','Gamma-aminobutyric acid','http://sideeffects.embl.de/drugs/119/'),('http://sideeffects.embl.de/se/C0086439/','Hypokinesia','Mirtazapine','http://sideeffects.embl.de/drugs/4205/'),('http://sideeffects.embl.de/se/C0086525/','Lassitude','Dimenhydrinate','http://sideeffects.embl.de/drugs/10660/'),('http://sideeffects.embl.de/se/C0086543/','Cataract','Fluticasone furoate','http://sideeffects.embl.de/drugs/9854489/'),('http://sideeffects.embl.de/se/C0086565/','Hepatic function abnormal','Cefdinir','http://sideeffects.embl.de/drugs/6398970/'),('http://sideeffects.embl.de/se/C0086769/','Panic attack','Hydroxybutyrate','http://sideeffects.embl.de/drugs/10413/'),('http://sideeffects.embl.de/se/C0086981/','Syndrome sicca','Thiabendazole','http://sideeffects.embl.de/drugs/5430/'),('http://sideeffects.embl.de/se/C0087169/','Withdrawal symptom','Hydroxyzine','http://sideeffects.embl.de/drugs/3658/'),('http://sideeffects.embl.de/se/C0149504/','Toxic encephalopathy','Isoniazid','http://sideeffects.embl.de/drugs/3767/'),('http://sideeffects.embl.de/se/C0149514/','Acute bronchitis','Olmesartan','http://sideeffects.embl.de/drugs/158781/'),('http://sideeffects.embl.de/se/C0149526/','Allergic urticaria','Phentermine','http://sideeffects.embl.de/drugs/4771/'),('http://sideeffects.embl.de/se/C0149725/','Lower respiratory tract infection','Bosentan','http://sideeffects.embl.de/drugs/104865/'),('http://sideeffects.embl.de/se/C0149744/','Oral lesion','6-mercaptopurine','http://sideeffects.embl.de/drugs/667490/'),('http://sideeffects.embl.de/se/C0149745/','Mouth ulceration','Everolimus','http://sideeffects.embl.de/drugs/6442177/'),('http://sideeffects.embl.de/se/C0149871/','Deep vein thrombosis','Nafarelin','http://sideeffects.embl.de/drugs/25077405/'),('http://sideeffects.embl.de/se/C0149904/','Hepatitis cholestatic','Sulfasalazine','http://sideeffects.embl.de/drugs/5353980/'),('http://sideeffects.embl.de/se/C0149911/','Hypercalcaemia of malignancy','Etidronate','http://sideeffects.embl.de/drugs/3305/'),('http://sideeffects.embl.de/se/C0149931/','Migraine','Fluticasone furoate','http://sideeffects.embl.de/drugs/9854489/'),('http://sideeffects.embl.de/se/C0149937/','Acute interstitial nephritis','Triamterene','http://sideeffects.embl.de/drugs/5546/'),('http://sideeffects.embl.de/se/C0150077/','Skin breakdown','Caffeine','http://sideeffects.embl.de/drugs/2519/'),('http://sideeffects.embl.de/se/C0151205/','Periorbital oedema','PEP005','http://sideeffects.embl.de/drugs/6918670/'),('http://sideeffects.embl.de/se/C0151311/','Cranial nerve paralysis','Nalidixic acid','http://sideeffects.embl.de/drugs/4421/'),('http://sideeffects.embl.de/se/C0151313/','Peripheral sensory neuropathy','Ixabepilone','http://sideeffects.embl.de/drugs/6445540/'),('http://sideeffects.embl.de/se/C0151315/','Neck stiffness','Polymyxin B','http://sideeffects.embl.de/drugs/4868/'),('http://sideeffects.embl.de/se/C0151436/','Allergic cutaneous angiitis','Cefdinir','http://sideeffects.embl.de/drugs/6398970/'),('http://sideeffects.embl.de/se/C0151474/','Alcohol intolerance','Nilutamide','http://sideeffects.embl.de/drugs/4493/'),('http://sideeffects.embl.de/se/C0151476/','Alkalosis hypochloraemic','Torasemide','http://sideeffects.embl.de/drugs/41781/'),('http://sideeffects.embl.de/se/C0151479/','Amylase increased','Regorafenib','http://sideeffects.embl.de/drugs/11167602/'),('http://sideeffects.embl.de/se/C0151480/','Antinuclear antibody positive','Amitriptyline','http://sideeffects.embl.de/drugs/2160/'),('http://sideeffects.embl.de/se/C0151505/','Application site reaction','Pimecrolimus','http://sideeffects.embl.de/drugs/3055172/'),('http://sideeffects.embl.de/se/C0151514/','Skin atrophy','Halobetasol','http://sideeffects.embl.de/drugs/5311167/'),('http://sideeffects.embl.de/se/C0151517/','Atrioventricular block complete','Regadenoson','http://sideeffects.embl.de/drugs/219024/'),('http://sideeffects.embl.de/se/C0151529/','Bleeding time prolonged','Nepafenac','http://sideeffects.embl.de/drugs/151075/'),('http://sideeffects.embl.de/se/C0151539/','Blood urea increased','Vismodegib','http://sideeffects.embl.de/drugs/24776445/'),('http://sideeffects.embl.de/se/C0151547/','Cataract specified','Anastrozole','http://sideeffects.embl.de/drugs/2187/'),('http://sideeffects.embl.de/se/C0151559/','CNS depression NOS','Benzonatate','http://sideeffects.embl.de/drugs/7699/'),('http://sideeffects.embl.de/se/C0151565/','Hemorrhagic colitis','Cyclophosphamide','http://sideeffects.embl.de/drugs/2907/'),('http://sideeffects.embl.de/se/C0151576/','Creatine phosphokinase increased','Lurasidone','http://sideeffects.embl.de/drugs/213046/'),('http://sideeffects.embl.de/se/C0151578/','Creatinine increased','Dabrafenib','http://sideeffects.embl.de/drugs/44462760/'),('http://sideeffects.embl.de/se/C0151579/','Crystalluria','Thiabendazole','http://sideeffects.embl.de/drugs/5430/'),('http://sideeffects.embl.de/se/C0151594/','Diarrhoea haemorrhagic','Praziquantel','http://sideeffects.embl.de/drugs/4891/'),('http://sideeffects.embl.de/se/C0151595/','Digitalis intoxication (NOS)','Torasemide','http://sideeffects.embl.de/drugs/41781/'),('http://sideeffects.embl.de/se/C0151596/','Tongue discolouration','Omeprazole','http://sideeffects.embl.de/drugs/4594/'),('http://sideeffects.embl.de/se/C0151599/','Drug level increased','Ropinirole','http://sideeffects.embl.de/drugs/5095/'),('http://sideeffects.embl.de/se/C0151601/','Conjunctival oedema','Nepafenac','http://sideeffects.embl.de/drugs/151075/'),('http://sideeffects.embl.de/se/C0151602/','Swelling face','D-telaprevir','http://sideeffects.embl.de/drugs/3010818/'),('http://sideeffects.embl.de/se/C0151603/','Generalised oedema','Fe(III','http://sideeffects.embl.de/drugs/23925/'),('http://sideeffects.embl.de/se/C0151622/','Endometrial disorder','Lasofoxifene','http://sideeffects.embl.de/drugs/216416/'),('http://sideeffects.embl.de/se/C0151623/','Enterocolitis haemorrhagic','Vinblastine','http://sideeffects.embl.de/drugs/13342/'),('http://sideeffects.embl.de/se/C0151625/','Enzyme abnormality','Famciclovir','http://sideeffects.embl.de/drugs/3324/'),('http://sideeffects.embl.de/se/C0151626/','Necrolysis epidermal','Doripenem','http://sideeffects.embl.de/drugs/73303/'),('http://sideeffects.embl.de/se/C0151636/','Ventricular extrasystoles','Ivabradine','http://sideeffects.embl.de/drugs/132999/'),('http://sideeffects.embl.de/se/C0151638/','Syndrome Fanconi-like','Streptozotocin','http://sideeffects.embl.de/drugs/5300/'),('http://sideeffects.embl.de/se/C0151662/','Gamma-glutamyltransferase increased','Dabrafenib','http://sideeffects.embl.de/drugs/44462760/'),('http://sideeffects.embl.de/se/C0151671/','Glucose tolerance decreased','Fludrocortisone','http://sideeffects.embl.de/drugs/31378/'),('http://sideeffects.embl.de/se/C0151683/','Neutrophil count increased','Gemifloxacin','http://sideeffects.embl.de/drugs/72938/'),('http://sideeffects.embl.de/se/C0151686/','Growth retardation','Deferoxamine','http://sideeffects.embl.de/drugs/2973/'),('http://sideeffects.embl.de/se/C0151689/','Hair discoloration','Ketoconazole','http://sideeffects.embl.de/drugs/3823/'),('http://sideeffects.embl.de/se/C0151691/','High density lipoprotein decreased','Nebivolol','http://sideeffects.embl.de/drugs/71301/'),('http://sideeffects.embl.de/se/C0151692/','Impaired healing','ACTH(1-39','http://sideeffects.embl.de/drugs/16132265/'),('http://sideeffects.embl.de/se/C0151698/','Injection site haemorrhage','Florbetapir','http://sideeffects.embl.de/drugs/24822371/'),('http://sideeffects.embl.de/se/C0151699/','Haemorrhage intracranial','ACTH(1-39','http://sideeffects.embl.de/drugs/16132265/'),('http://sideeffects.embl.de/se/C0151701/','Pulmonary haemorrhage','Riociguat','http://sideeffects.embl.de/drugs/11304743/'),('http://sideeffects.embl.de/se/C0151705/','Retroperitoneal haemorrhage','Bivalirudin','http://sideeffects.embl.de/drugs/16129704/'),('http://sideeffects.embl.de/se/C0151718/','Hypocholesterolaemia','Carvedilol','http://sideeffects.embl.de/drugs/2585/'),('http://sideeffects.embl.de/se/C0151723/','Hypomagnesaemia','Cabozantinib','http://sideeffects.embl.de/drugs/25102847/'),('http://sideeffects.embl.de/se/C0151734/','Injection site inflammation','Metrodin','http://sideeffects.embl.de/drugs/62819/'),('http://sideeffects.embl.de/se/C0151735/','Injection site reaction','K779','http://sideeffects.embl.de/drugs/71306834/'),('http://sideeffects.embl.de/se/C0151736/','Accidental injury','Insulin detemir','http://sideeffects.embl.de/drugs/16137271/'),('http://sideeffects.embl.de/se/C0151740/','Intracranial pressure increased','ACTH(1-39','http://sideeffects.embl.de/drugs/16132265/'),('http://sideeffects.embl.de/se/C0151744/','Myocardial ischaemia','Sorafenib','http://sideeffects.embl.de/drugs/216239/'),('http://sideeffects.embl.de/se/C0151746/','Kidney function abnormal','Adefovir dipivoxil','http://sideeffects.embl.de/drugs/60871/'),('http://sideeffects.embl.de/se/C0151754/','Lactic dehydrogenase activity increased','Bexarotene','http://sideeffects.embl.de/drugs/82146/'),('http://sideeffects.embl.de/se/C0151763/','Hepatocellular injury','Sulfasalazine','http://sideeffects.embl.de/drugs/5353980/'),('http://sideeffects.embl.de/se/C0151766/','Liver function test abnormal','Apixaban','http://sideeffects.embl.de/drugs/10182969/'),('http://sideeffects.embl.de/se/C0151767/','Liver tenderness','Pyrazinamide','http://sideeffects.embl.de/drugs/1046/'),('http://sideeffects.embl.de/se/C0151772/','Manic psychosis','Phenelzine','http://sideeffects.embl.de/drugs/3675/'),('http://sideeffects.embl.de/se/C0151773/','Bone marrow depression','Dacarbazine','http://sideeffects.embl.de/drugs/5281007/'),('http://sideeffects.embl.de/se/C0151786/','Muscular weakness','ACTH(1-39','http://sideeffects.embl.de/drugs/16132265/'),('http://sideeffects.embl.de/se/C0151795/','Injection site necrosis','Terlipressin','http://sideeffects.embl.de/drugs/72081/'),('http://sideeffects.embl.de/se/C0151798/','Hepatic necrosis','Sulfasalazine','http://sideeffects.embl.de/drugs/5353980/'),('http://sideeffects.embl.de/se/C0151799/','Skin necrosis','Terlipressin','http://sideeffects.embl.de/drugs/72081/'),('http://sideeffects.embl.de/se/C0151810/','Lack of drug effect','Adapalene','http://sideeffects.embl.de/drugs/60164/'),('http://sideeffects.embl.de/se/C0151825/','Bone pain','Triptorelin','http://sideeffects.embl.de/drugs/25074470/'),('http://sideeffects.embl.de/se/C0151826/','Retrosternal pain','Venlafaxine','http://sideeffects.embl.de/drugs/5656/'),('http://sideeffects.embl.de/se/C0151827/','Eye pain','Besifloxacin','http://sideeffects.embl.de/drugs/10178705/'),('http://sideeffects.embl.de/se/C0151828/','Injection site pain','Triptorelin','http://sideeffects.embl.de/drugs/25074470/'),('http://sideeffects.embl.de/se/C0151834/','Papanicolaou smear suspicious','Glat copolymer','http://sideeffects.embl.de/drugs/65370/'),('http://sideeffects.embl.de/se/C0151836/','Paranoid reaction','Risperidone','http://sideeffects.embl.de/drugs/5073/'),('http://sideeffects.embl.de/se/C0151838/','Circumoral paresthesia','EDTA','http://sideeffects.embl.de/drugs/6049/'),('http://sideeffects.embl.de/se/C0151849/','Phosphatase alkaline increased','Dabrafenib','http://sideeffects.embl.de/drugs/44462760/'),('http://sideeffects.embl.de/se/C0151859/','Polyserositis','Praziquantel','http://sideeffects.embl.de/drugs/4891/'),('http://sideeffects.embl.de/se/C0151872/','Prothrombin level increased','Sitaxsentan','http://sideeffects.embl.de/drugs/216235/'),('http://sideeffects.embl.de/se/C0151878/','Electrocardiogram QT prolonged','SOM230','http://sideeffects.embl.de/drugs/9941444/'),('http://sideeffects.embl.de/se/C0151883/','Vesiculobullous rash','Emtricitabine','http://sideeffects.embl.de/drugs/60877/'),('http://sideeffects.embl.de/se/C0151888/','Hyporeflexia','Chlorpheniramine','http://sideeffects.embl.de/drugs/2725/'),('http://sideeffects.embl.de/se/C0151889/','Hyperreflexia','Phenelzine','http://sideeffects.embl.de/drugs/3675/'),('http://sideeffects.embl.de/se/C0151900/','Serum iron increased','Pyrazinamide','http://sideeffects.embl.de/drugs/1046/'),('http://sideeffects.embl.de/se/C0151904/','Aspartate aminotransferase increased','K779','http://sideeffects.embl.de/drugs/71306834/'),('http://sideeffects.embl.de/se/C0151905/','Alanine aminotransferase increased','Dabrafenib','http://sideeffects.embl.de/drugs/44462760/'),('http://sideeffects.embl.de/se/C0151907/','Skin discolouration','Capecitabine','http://sideeffects.embl.de/drugs/60953/'),('http://sideeffects.embl.de/se/C0151908/','Dry skin','K779','http://sideeffects.embl.de/drugs/71306834/'),('http://sideeffects.embl.de/se/C0151934/','Hypogeusia','Vismodegib','http://sideeffects.embl.de/drugs/24776445/'),('http://sideeffects.embl.de/se/C0151936/','Tendon disorder','Raloxifene','http://sideeffects.embl.de/drugs/5035/'),('http://sideeffects.embl.de/se/C0151937/','Tendon rupture','Gatifloxacin','http://sideeffects.embl.de/drugs/5379/'),('http://sideeffects.embl.de/se/C0151940/','Hypocalcemic tetany','Phosphate','http://sideeffects.embl.de/drugs/1003/'),('http://sideeffects.embl.de/se/C0151966/','Duodenal ulcer haemorrhage','Omeprazole','http://sideeffects.embl.de/drugs/4594/'),('http://sideeffects.embl.de/se/C0151970/','Oesophageal ulcer','Dabigatran etexilate','http://sideeffects.embl.de/drugs/213023/'),('http://sideeffects.embl.de/se/C0151971/','Intestinal ulcer','6-mercaptopurine','http://sideeffects.embl.de/drugs/667490/'),('http://sideeffects.embl.de/se/C0152025/','Polyneuropathy','Ifosfamide','http://sideeffects.embl.de/drugs/3690/'),('http://sideeffects.embl.de/se/C0152027/','Sensory disturbance','Varenicline','http://sideeffects.embl.de/drugs/170361/'),('http://sideeffects.embl.de/se/C0152029/','Sinus congestion','Ivacaftor','http://sideeffects.embl.de/drugs/16220172/'),('http://sideeffects.embl.de/se/C0152030/','Skin irritation','Adapalene','http://sideeffects.embl.de/drugs/60164/'),('http://sideeffects.embl.de/se/C0152031/','Joint swelling','Abiraterone','http://sideeffects.embl.de/drugs/132971/'),('http://sideeffects.embl.de/se/C0152032/','Urinary hesitation','Desvenlafaxine','http://sideeffects.embl.de/drugs/125017/'),('http://sideeffects.embl.de/se/C0152128/','Drug withdrawal syndrome','Propoxyphene','http://sideeffects.embl.de/drugs/10100/'),('http://sideeffects.embl.de/se/C0152169/','Renal colic','Teduglutide','http://sideeffects.embl.de/drugs/16139605/'),('http://sideeffects.embl.de/se/C0152171/','Primary pulmonary hypertension','Diethylpropion','http://sideeffects.embl.de/drugs/7029/'),('http://sideeffects.embl.de/se/C0152196/','Spasm of accommodation','Edrophonium','http://sideeffects.embl.de/drugs/3202/'),('http://sideeffects.embl.de/se/C0152198/','Accommodation disorder','Venlafaxine','http://sideeffects.embl.de/drugs/5656/'),('http://sideeffects.embl.de/se/C0152227/','Lacrimation increased','Ixabepilone','http://sideeffects.embl.de/drugs/6445540/'),('http://sideeffects.embl.de/se/C0152253/','Posterior synechiae of iris','Cyclopentolate','http://sideeffects.embl.de/drugs/2905/'),('http://sideeffects.embl.de/se/C0152459/','Skin striae','Halobetasol','http://sideeffects.embl.de/drugs/5311167/'),('http://sideeffects.embl.de/se/C0152517/','Viral diarrhoea','Tadalafil','http://sideeffects.embl.de/drugs/110635/'),('http://sideeffects.embl.de/se/C0152965/','Staphylococcal bacteraemia','Vincristine','http://sideeffects.embl.de/drugs/5978/'),('http://sideeffects.embl.de/se/C0154251/','Lipid metabolism disorder','Gliclazide','http://sideeffects.embl.de/drugs/3475/'),('http://sideeffects.embl.de/se/C0154933/','Iris adhesions','Cyclopentolate','http://sideeffects.embl.de/drugs/2905/'),('http://sideeffects.embl.de/se/C0155001/','Subjective visual disturbances','Nalidixic acid','http://sideeffects.embl.de/drugs/4421/'),('http://sideeffects.embl.de/se/C0155169/','Ocular hyperaemia','Nepafenac','http://sideeffects.embl.de/drugs/151075/'),('http://sideeffects.embl.de/se/C0155216/','Eyelid bleeding','Bromfenac','http://sideeffects.embl.de/drugs/60726/'),('http://sideeffects.embl.de/se/C0155320/','Blindness cortical','V 1784','http://sideeffects.embl.de/drugs/2909/'),('http://sideeffects.embl.de/se/C0155626/','Acute myocardial infarction','Metoprolol','http://sideeffects.embl.de/drugs/4171/'),('http://sideeffects.embl.de/se/C0155919/','Acute pulmonary oedema','Nebivolol','http://sideeffects.embl.de/drugs/71301/'),('http://sideeffects.embl.de/se/C0155964/','Atrophic glossitis','Pyrimethamine','http://sideeffects.embl.de/drugs/4993/'),('http://sideeffects.embl.de/se/C0156312/','Testicular atrophy','Triptorelin','http://sideeffects.embl.de/drugs/25074470/'),('http://sideeffects.embl.de/se/C0156369/','Uterine polyp','Lasofoxifene','http://sideeffects.embl.de/drugs/216416/'),('http://sideeffects.embl.de/se/C0156394/','Enlarged clitoris','Oxandrolone','http://sideeffects.embl.de/drugs/5878/'),('http://sideeffects.embl.de/se/C0156404/','Menstruation irregular','ACTH(1-39','http://sideeffects.embl.de/drugs/16132265/'),('http://sideeffects.embl.de/se/C0159060/','Abnormal bowel sounds','Prucalopride','http://sideeffects.embl.de/drugs/3052762/'),('http://sideeffects.embl.de/se/C0160390/','Liver injury','Histrelin','http://sideeffects.embl.de/drugs/25077993/'),('http://sideeffects.embl.de/se/C0161479/','Nerve injury','Prilocaine','http://sideeffects.embl.de/drugs/4906/'),('http://sideeffects.embl.de/se/C0162119/','Haemoglobin decreased','Everolimus','http://sideeffects.embl.de/drugs/6442177/'),('http://sideeffects.embl.de/se/C0162275/','Ketonuria','Streptozotocin','http://sideeffects.embl.de/drugs/5300/'),('http://sideeffects.embl.de/se/C0162281/','Corneal deposits','Nepafenac','http://sideeffects.embl.de/drugs/151075/'),('http://sideeffects.embl.de/se/C0162283/','Nephrogenic diabetes insipidus','Streptozotocin','http://sideeffects.embl.de/drugs/5300/'),('http://sideeffects.embl.de/se/C0162285/','Eyelid oedema','PEP005','http://sideeffects.embl.de/drugs/6918670/'),('http://sideeffects.embl.de/se/C0162287/','Abnormal faeces','Cilostazol','http://sideeffects.embl.de/drugs/2754/'),('http://sideeffects.embl.de/se/C0162296/','Polyarthralgia','Pyrazinamide','http://sideeffects.embl.de/drugs/1046/'),('http://sideeffects.embl.de/se/C0162297/','Respiratory arrest','Propoxyphene','http://sideeffects.embl.de/drugs/10100/'),('http://sideeffects.embl.de/se/C0162298/','Joint stiffness','Zoledronic acid','http://sideeffects.embl.de/drugs/68740/'),('http://sideeffects.embl.de/se/C0162311/','Androgenetic alopecia','Oxandrolone','http://sideeffects.embl.de/drugs/5878/'),('http://sideeffects.embl.de/se/C0162429/','Malnutrition','Vismodegib','http://sideeffects.embl.de/drugs/24776445/'),('http://sideeffects.embl.de/se/C0162529/','Colitis ischaemic','Lubiprostone','http://sideeffects.embl.de/drugs/157920/'),('http://sideeffects.embl.de/se/C0162533/','Porphyria hepatic','Tolbutamide','http://sideeffects.embl.de/drugs/5505/'),('http://sideeffects.embl.de/se/C0162557/','Acute hepatic failure','Dronedarone','http://sideeffects.embl.de/drugs/208898/'),('http://sideeffects.embl.de/se/C0162566/','Porphyria cutanea tarda','Tolbutamide','http://sideeffects.embl.de/drugs/5505/'),('http://sideeffects.embl.de/se/C0162627/','Skin bacterial infection','Nitrogen mustard','http://sideeffects.embl.de/drugs/4033/'),('http://sideeffects.embl.de/se/C0162820/','Allergic contact dermatitis','Halobetasol','http://sideeffects.embl.de/drugs/5311167/'),('http://sideeffects.embl.de/se/C0162823/','Dermatitis irritant contact','Adapalene','http://sideeffects.embl.de/drugs/60164/'),('http://sideeffects.embl.de/se/C0162830/','Photosensitivity reaction','Vemurafenib','http://sideeffects.embl.de/drugs/42611257/'),('http://sideeffects.embl.de/se/C0162834/','Skin hyperpigmentation','6-mercaptopurine','http://sideeffects.embl.de/drugs/667490/'),('http://sideeffects.embl.de/se/C0162835/','Leukoderma','Halobetasol','http://sideeffects.embl.de/drugs/5311167/'),('http://sideeffects.embl.de/se/C0175167/','Acneiform eruption','Halobetasol','http://sideeffects.embl.de/drugs/5311167/'),('http://sideeffects.embl.de/se/C0175683/','Argininosuccinate synthetase deficiency','Haloperidol','http://sideeffects.embl.de/drugs/3559/'),('http://sideeffects.embl.de/se/C0178298/','Unspecified disorder of skin and subcutaneous tissue','Florbetapir','http://sideeffects.embl.de/drugs/24822371/'),('http://sideeffects.embl.de/se/C0178416/','Hypoplastic anaemia','Trimethadione','http://sideeffects.embl.de/drugs/5576/'),('http://sideeffects.embl.de/se/C0205204/','Scab','PEP005','http://sideeffects.embl.de/drugs/6918670/'),('http://sideeffects.embl.de/se/C0205707/','Sprue','6-mercaptopurine','http://sideeffects.embl.de/drugs/667490/'),('http://sideeffects.embl.de/se/C0206061/','Interstitial pneumonia','Propylthiouracil','http://sideeffects.embl.de/drugs/657298/'),('http://sideeffects.embl.de/se/C0206062/','Interstitial lung disease','Lapatinib','http://sideeffects.embl.de/drugs/208908/'),('http://sideeffects.embl.de/se/C0206160/','Reticulocytosis','Acetohydroxamic acid','http://sideeffects.embl.de/drugs/1990/'),('http://sideeffects.embl.de/se/C0206277/','Fatal outcomes','Riociguat','http://sideeffects.embl.de/drugs/11304743/'),('http://sideeffects.embl.de/se/C0220870/','Lightheadedness','Trovafloxacin','http://sideeffects.embl.de/drugs/62959/'),('http://sideeffects.embl.de/se/C0220981/','Metabolic acidosis','4-PBA','http://sideeffects.embl.de/drugs/4775/'),('http://sideeffects.embl.de/se/C0220983/','Metabolic alkalosis','Sodium bicarbonate','http://sideeffects.embl.de/drugs/10340/'),('http://sideeffects.embl.de/se/C0220994/','Hyperammonaemia','Haloperidol','http://sideeffects.embl.de/drugs/3559/'),('http://sideeffects.embl.de/se/C0221021/','Microangiopathic haemolytic anaemia','Mitomycin C','http://sideeffects.embl.de/drugs/5746/'),('http://sideeffects.embl.de/se/C0221100/','Hangover','Hydroxybutyrate','http://sideeffects.embl.de/drugs/10413/'),('http://sideeffects.embl.de/se/C0221158/','Multifocal atrial tachycardia','Aminophylline','http://sideeffects.embl.de/drugs/9433/'),('http://sideeffects.embl.de/se/C0221170/','Muscle stiffness','Midazolam','http://sideeffects.embl.de/drugs/4192/'),('http://sideeffects.embl.de/se/C0221185/','Xanthopsia','Thiabendazole','http://sideeffects.embl.de/drugs/5430/'),('http://sideeffects.embl.de/se/C0221201/','Rash macular','Voriconazole','http://sideeffects.embl.de/drugs/71616/'),('http://sideeffects.embl.de/se/C0221203/','Rash vesicular','Adapalene','http://sideeffects.embl.de/drugs/60164/'),('http://sideeffects.embl.de/se/C0221239/','Glomerulonephritis rapidly progressive','Propylthiouracil','http://sideeffects.embl.de/drugs/657298/'),('http://sideeffects.embl.de/se/C0221242/','Fixed drug eruption','Dacarbazine','http://sideeffects.embl.de/drugs/5281007/'),('http://sideeffects.embl.de/se/C0221264/','Cheilosis','EDTA','http://sideeffects.embl.de/drugs/6049/'),('http://sideeffects.embl.de/se/C0221345/','Nail discolouration','Roxithromycin','http://sideeffects.embl.de/drugs/5106/'),('http://sideeffects.embl.de/se/C0221384/','Follicular conjunctivitis','Dipivefrin','http://sideeffects.embl.de/drugs/3105/'),('http://sideeffects.embl.de/se/C0221406/','Pituitary-dependent Cushing\'s syndrome','SOM230','http://sideeffects.embl.de/drugs/9941444/'),('http://sideeffects.embl.de/se/C0221490/','Epigastric distress','Methimazole','http://sideeffects.embl.de/drugs/1349907/'),('http://sideeffects.embl.de/se/C0221512/','Stomach ache','Eletriptan','http://sideeffects.embl.de/drugs/77993/'),('http://sideeffects.embl.de/se/C0221714/','Injection site infection','Glucose solution','http://sideeffects.embl.de/drugs/24748/'),('http://sideeffects.embl.de/se/C0221776/','Oral pain','Cabozantinib','http://sideeffects.embl.de/drugs/25102847/'),('http://sideeffects.embl.de/se/C0227791/','Vaginal discharge','Nafarelin','http://sideeffects.embl.de/drugs/25077405/'),('http://sideeffects.embl.de/se/C0231218/','Malaise','Dacarbazine','http://sideeffects.embl.de/drugs/5281007/'),('http://sideeffects.embl.de/se/C0231230/','Fatigability','Disulfiram','http://sideeffects.embl.de/drugs/3117/'),('http://sideeffects.embl.de/se/C0231303/','Distress','Carbimazole','http://sideeffects.embl.de/drugs/31072/'),('http://sideeffects.embl.de/se/C0231365/','Urination impaired','Venlafaxine','http://sideeffects.embl.de/drugs/5656/'),('http://sideeffects.embl.de/se/C0231441/','Immobile','Molindone','http://sideeffects.embl.de/drugs/23897/'),('http://sideeffects.embl.de/se/C0231451/','Joint hyperextension','Cysteamine','http://sideeffects.embl.de/drugs/6058/'),('http://sideeffects.embl.de/se/C0231527/','Muscular incoordination','Methocarbamol','http://sideeffects.embl.de/drugs/4107/'),('http://sideeffects.embl.de/se/C0231528/','Myalgia','K779','http://sideeffects.embl.de/drugs/71306834/'),('http://sideeffects.embl.de/se/C0231529/','Tendon pain','APAs','http://sideeffects.embl.de/drugs/4649/'),('http://sideeffects.embl.de/se/C0231530/','Muscle twitching','Pyridostigmine','http://sideeffects.embl.de/drugs/4991/'),('http://sideeffects.embl.de/se/C0231749/','Knee pain','Losartan','http://sideeffects.embl.de/drugs/3961/'),('http://sideeffects.embl.de/se/C0231807/','Dyspnoea exertional','Phentermine','http://sideeffects.embl.de/drugs/4771/'),('http://sideeffects.embl.de/se/C0231835/','Tachypnoea','Omeprazole','http://sideeffects.embl.de/drugs/4594/'),('http://sideeffects.embl.de/se/C0231837/','Respiratory rate decreased','Baclofen','http://sideeffects.embl.de/drugs/2284/'),('http://sideeffects.embl.de/se/C0231856/','Breath sounds abnormal','Busulfan','http://sideeffects.embl.de/drugs/2478/'),('http://sideeffects.embl.de/se/C0231875/','Wheezing expiratory','Retinoic acid','http://sideeffects.embl.de/drugs/5538/'),('http://sideeffects.embl.de/se/C0231919/','Nasal dryness','Fluticasone furoate','http://sideeffects.embl.de/drugs/9854489/'),('http://sideeffects.embl.de/se/C0232097/','Volume plasma increased','Troglitazone','http://sideeffects.embl.de/drugs/5591/'),('http://sideeffects.embl.de/se/C0232124/','Skipped beats','Pirbuterol','http://sideeffects.embl.de/drugs/4845/'),('http://sideeffects.embl.de/se/C0232191/','Reflex bradycardia','Midodrine','http://sideeffects.embl.de/drugs/4195/'),('http://sideeffects.embl.de/se/C0232201/','Sinus rhythm','Isoproterenol','http://sideeffects.embl.de/drugs/3779/'),('http://sideeffects.embl.de/se/C0232208/','Nodal rhythm','Neostigmine','http://sideeffects.embl.de/drugs/4456/'),('http://sideeffects.embl.de/se/C0232286/','Precordial pain','Diethylpropion','http://sideeffects.embl.de/drugs/7029/'),('http://sideeffects.embl.de/se/C0232292/','Chest tightness','Insulin','http://sideeffects.embl.de/drugs/16129672/'),('http://sideeffects.embl.de/se/C0232409/','Hair growth abnormal','Vismodegib','http://sideeffects.embl.de/drugs/24776445/'),('http://sideeffects.embl.de/se/C0232459/','Digestion impaired','Ethionamide','http://sideeffects.embl.de/drugs/2761171/'),('http://sideeffects.embl.de/se/C0232461/','Increased appetite','Lurasidone','http://sideeffects.embl.de/drugs/213046/'),('http://sideeffects.embl.de/se/C0232462/','Decreased appetite','K779','http://sideeffects.embl.de/drugs/71306834/'),('http://sideeffects.embl.de/se/C0232487/','Abdominal discomfort','Regadenoson','http://sideeffects.embl.de/drugs/219024/'),('http://sideeffects.embl.de/se/C0232488/','Abdominal colic','Oxprenolol','http://sideeffects.embl.de/drugs/4631/'),('http://sideeffects.embl.de/se/C0232492/','Abdominal pain upper','K779','http://sideeffects.embl.de/drugs/71306834/'),('http://sideeffects.embl.de/se/C0232493/','Epigastric pain','Tiaprofenic acid','http://sideeffects.embl.de/drugs/5468/'),('http://sideeffects.embl.de/se/C0232495/','Abdominal pain lower','Levonorgestrel','http://sideeffects.embl.de/drugs/4542/'),('http://sideeffects.embl.de/se/C0232570/','Epigastric fullness','Tolbutamide','http://sideeffects.embl.de/drugs/5505/'),('http://sideeffects.embl.de/se/C0232602/','Retching','Baclofen','http://sideeffects.embl.de/drugs/2284/'),('http://sideeffects.embl.de/se/C0232693/','Borborygmi','Bethanechol','http://sideeffects.embl.de/drugs/2370/'),('http://sideeffects.embl.de/se/C0232726/','Rectal tenesmus','Rifaximin','http://sideeffects.embl.de/drugs/72111/'),('http://sideeffects.embl.de/se/C0232807/','Function kidney decreased','Mitomycin C','http://sideeffects.embl.de/drugs/5746/'),('http://sideeffects.embl.de/se/C0232849/','Bladder pain','Darifenacin','http://sideeffects.embl.de/drugs/72054/'),('http://sideeffects.embl.de/se/C0232910/','Teratogenicity','Methacholine','http://sideeffects.embl.de/drugs/1993/'),('http://sideeffects.embl.de/se/C0232943/','Menometrorrhagia','Levonorgestrel','http://sideeffects.embl.de/drugs/4542/'),('http://sideeffects.embl.de/se/C0233407/','Disorientation','Retigabine','http://sideeffects.embl.de/drugs/121892/'),('http://sideeffects.embl.de/se/C0233414/','Disturbance in attention','Varenicline','http://sideeffects.embl.de/drugs/170361/'),('http://sideeffects.embl.de/se/C0233459/','Emotional disorder','Varenicline','http://sideeffects.embl.de/drugs/170361/'),('http://sideeffects.embl.de/se/C0233472/','Affect lability','Oxcarbazepine','http://sideeffects.embl.de/drugs/34312/'),('http://sideeffects.embl.de/se/C0233477/','Dysphoria','Diethylpropion','http://sideeffects.embl.de/drugs/7029/'),('http://sideeffects.embl.de/se/C0233479/','Elevated mood','Amantadine','http://sideeffects.embl.de/drugs/2130/'),('http://sideeffects.embl.de/se/C0233485/','Apprehension','Flurazepam','http://sideeffects.embl.de/drugs/3393/'),('http://sideeffects.embl.de/se/C0233494/','Tension','Lu AA21004','http://sideeffects.embl.de/drugs/9966051/'),('http://sideeffects.embl.de/se/C0233514/','Abnormal behaviour','Clonazepam','http://sideeffects.embl.de/drugs/2802/'),('http://sideeffects.embl.de/se/C0233565/','Bradykinesia','Iloperidone','http://sideeffects.embl.de/drugs/71360/'),('http://sideeffects.embl.de/se/C0233571/','Excitement','Pralidoxime','http://sideeffects.embl.de/drugs/5353894/'),('http://sideeffects.embl.de/se/C0233632/','Thinking abnormal','Ramelteon','http://sideeffects.embl.de/drugs/208902/'),('http://sideeffects.embl.de/se/C0233715/','Speech impairment NOS','Zonisamide','http://sideeffects.embl.de/drugs/5734/'),('http://sideeffects.embl.de/se/C0233762/','Hallucination','auditory','Methsuximide'),('http://sideeffects.embl.de/se/C0233763/','Hallucination','visual','Benzonatate'),('http://sideeffects.embl.de/se/C0233794/','Memory impairment','Perampanel','http://sideeffects.embl.de/drugs/9924495/'),('http://sideeffects.embl.de/se/C0233795/','Anterograde amnesia','Zolpidem','http://sideeffects.embl.de/drugs/5732/'),('http://sideeffects.embl.de/se/C0233796/','Amnesia transient','Oxazepam','http://sideeffects.embl.de/drugs/4616/'),('http://sideeffects.embl.de/se/C0234022/','Anorgasmia','Desvenlafaxine','http://sideeffects.embl.de/drugs/125017/'),('http://sideeffects.embl.de/se/C0234047/','Ejaculation delayed','Desvenlafaxine','http://sideeffects.embl.de/drugs/125017/'),('http://sideeffects.embl.de/se/C0234133/','Extrapyramidal symptoms','Lurasidone','http://sideeffects.embl.de/drugs/213046/'),('http://sideeffects.embl.de/se/C0234146/','Areflexia','Gabapentin','http://sideeffects.embl.de/drugs/3446/'),('http://sideeffects.embl.de/se/C0234192/','Feeling cold','Ondansetron','http://sideeffects.embl.de/drugs/4595/'),('http://sideeffects.embl.de/se/C0234193/','Sensation of heat','Sumatriptan','http://sideeffects.embl.de/drugs/5358/'),('http://sideeffects.embl.de/se/C0234215/','Discomfort','Dapagliflozin','http://sideeffects.embl.de/drugs/9887712/'),('http://sideeffects.embl.de/se/C0234222/','Sensation of pressure','Sumatriptan','http://sideeffects.embl.de/drugs/5358/'),('http://sideeffects.embl.de/se/C0234233/','Tenderness','Histrelin','http://sideeffects.embl.de/drugs/25077993/'),('http://sideeffects.embl.de/se/C0234238/','Ache','Colestipol','http://sideeffects.embl.de/drugs/62816/'),('http://sideeffects.embl.de/se/C0234369/','Trembling','Guanidinium','http://sideeffects.embl.de/drugs/3520/'),('http://sideeffects.embl.de/se/C0234373/','Tremor fine','Metaproterenol','http://sideeffects.embl.de/drugs/4086/'),('http://sideeffects.embl.de/se/C0234376/','Action tremor','Lamotrigine','http://sideeffects.embl.de/drugs/3878/'),('http://sideeffects.embl.de/se/C0234428/','Consciousness abnormal','Sotalol','http://sideeffects.embl.de/drugs/5253/'),('http://sideeffects.embl.de/se/C0234458/','Abnormal dreams','Lu AA21004','http://sideeffects.embl.de/drugs/9966051/'),('http://sideeffects.embl.de/se/C0234518/','Slurred speech','Oxazepam','http://sideeffects.embl.de/drugs/4616/'),('http://sideeffects.embl.de/se/C0234533/','Convulsions generalised','Ifosfamide','http://sideeffects.embl.de/drugs/3690/'),('http://sideeffects.embl.de/se/C0234535/','Clonic convulsion','Benzonatate','http://sideeffects.embl.de/drugs/7699/'),('http://sideeffects.embl.de/se/C0234632/','Visual acuity reduced','Vardenafil','http://sideeffects.embl.de/drugs/110634/'),('http://sideeffects.embl.de/se/C0234655/','Burning sensation in eye','Bimatoprost','http://sideeffects.embl.de/drugs/127909/'),('http://sideeffects.embl.de/se/C0234665/','Eyelid retraction','Bimatoprost','http://sideeffects.embl.de/drugs/127909/'),('http://sideeffects.embl.de/se/C0234708/','Intraocular pressure increased','Trifluorothymidine','http://sideeffects.embl.de/drugs/6256/'),('http://sideeffects.embl.de/se/C0234894/','Dermatitis acneiform','Vandetanib','http://sideeffects.embl.de/drugs/3081361/'),('http://sideeffects.embl.de/se/C0234909/','Nail changes','Erlotinib','http://sideeffects.embl.de/drugs/176870/'),('http://sideeffects.embl.de/se/C0234913/','Rash erythematous','Dronedarone','http://sideeffects.embl.de/drugs/208898/'),('http://sideeffects.embl.de/se/C0234916/','Rash follicular','Etidronate','http://sideeffects.embl.de/drugs/3305/'),('http://sideeffects.embl.de/se/C0234918/','Rash morbilliform','Ketamine','http://sideeffects.embl.de/drugs/3821/'),('http://sideeffects.embl.de/se/C0234930/','Skin odour abnormal','Cysteamine','http://sideeffects.embl.de/drugs/6058/'),('http://sideeffects.embl.de/se/C0234972/','Convulsive disorder','Diethylpropion','http://sideeffects.embl.de/drugs/7029/'),('http://sideeffects.embl.de/se/C0234975/','Convulsions aggravated','Oxcarbazepine','http://sideeffects.embl.de/drugs/34312/'),('http://sideeffects.embl.de/se/C0234987/','Dizziness postural','Canagliflozin','http://sideeffects.embl.de/drugs/24812758/'),('http://sideeffects.embl.de/se/C0235014/','Fontanelle bulging','Ketoconazole','http://sideeffects.embl.de/drugs/3823/'),('http://sideeffects.embl.de/se/C0235025/','Peripheral motor neuropathy','Ixabepilone','http://sideeffects.embl.de/drugs/6445540/'),('http://sideeffects.embl.de/se/C0235030/','Neurologic reaction','Lomustine','http://sideeffects.embl.de/drugs/3950/'),('http://sideeffects.embl.de/se/C0235031/','Neurological symptom','Tolvaptan','http://sideeffects.embl.de/drugs/216237/'),('http://sideeffects.embl.de/se/C0235032/','Neurotoxicity','Ethionamide','http://sideeffects.embl.de/drugs/2761171/'),('http://sideeffects.embl.de/se/C0235046/','Paraesthesia skin','Nevirapine','http://sideeffects.embl.de/drugs/4463/'),('http://sideeffects.embl.de/se/C0235048/','Smarting','Tropicamide','http://sideeffects.embl.de/drugs/5593/'),('http://sideeffects.embl.de/se/C0235050/','Tingling skin','DFMO','http://sideeffects.embl.de/drugs/3009/'),('http://sideeffects.embl.de/se/C0235063/','Respiratory depression','Sufentanil','http://sideeffects.embl.de/drugs/41693/'),('http://sideeffects.embl.de/se/C0235086/','Muscle contractions involuntary','Azelastine','http://sideeffects.embl.de/drugs/2267/'),('http://sideeffects.embl.de/se/C0235146/','Euphoric mood','Perampanel','http://sideeffects.embl.de/drugs/9924495/'),('http://sideeffects.embl.de/se/C0235169/','Excitability','Clonazepam','http://sideeffects.embl.de/drugs/2802/'),('http://sideeffects.embl.de/se/C0235194/','Tranquillisation excessive','Papaverine','http://sideeffects.embl.de/drugs/4680/'),('http://sideeffects.embl.de/se/C0235198/','Cerebration impaired','K779','http://sideeffects.embl.de/drugs/71306834/'),('http://sideeffects.embl.de/se/C0235234/','Dry throat','Fesoterodine','http://sideeffects.embl.de/drugs/6918558/'),('http://sideeffects.embl.de/se/C0235238/','Cycloplegia','Trihexyphenidyl','http://sideeffects.embl.de/drugs/5572/'),('http://sideeffects.embl.de/se/C0235248/','Vasoconstriction peripheral','Terlipressin','http://sideeffects.embl.de/drugs/72081/'),('http://sideeffects.embl.de/se/C0235259/','Cataract subcapsular','Beclomethasone dipropionate','http://sideeffects.embl.de/drugs/2307/'),('http://sideeffects.embl.de/se/C0235266/','Eye irritation','Besifloxacin','http://sideeffects.embl.de/drugs/10178705/'),('http://sideeffects.embl.de/se/C0235267/','Eye redness','Gefitinib','http://sideeffects.embl.de/drugs/123631/'),('http://sideeffects.embl.de/se/C0235270/','Keratopathy','Trifluorothymidine','http://sideeffects.embl.de/drugs/6256/'),('http://sideeffects.embl.de/se/C0235280/','Ototoxicity','Carboplatin','http://sideeffects.embl.de/drugs/38904/'),('http://sideeffects.embl.de/se/C0235290/','Taste bitter','Tinidazole','http://sideeffects.embl.de/drugs/5479/'),('http://sideeffects.embl.de/se/C0235295/','Abdominal distress','Dipyridamole','http://sideeffects.embl.de/drugs/3108/'),('http://sideeffects.embl.de/se/C0235296/','Epigastric pain not food-related','Miglustat','http://sideeffects.embl.de/drugs/51634/'),('http://sideeffects.embl.de/se/C0235299/','Right upper quadrant pain','K779','http://sideeffects.embl.de/drugs/71306834/'),('http://sideeffects.embl.de/se/C0235309/','Upset stomach','Lubiprostone','http://sideeffects.embl.de/drugs/157920/'),('http://sideeffects.embl.de/se/C0235318/','Fullness abdominal','Valdecoxib','http://sideeffects.embl.de/drugs/119607/'),('http://sideeffects.embl.de/se/C0235329/','Small intestinal obstruction','Ertapenem','http://sideeffects.embl.de/drugs/150610/'),('http://sideeffects.embl.de/se/C0235340/','Buccal inflammation','Pantoprazole','http://sideeffects.embl.de/drugs/4679/'),('http://sideeffects.embl.de/se/C0235347/','Black hairy tongue','Isocarboxazid','http://sideeffects.embl.de/drugs/3759/'),('http://sideeffects.embl.de/se/C0235369/','Hepatitis granulomatous','Dacarbazine','http://sideeffects.embl.de/drugs/5281007/'),('http://sideeffects.embl.de/se/C0235378/','Hepatotoxicity','Macitentan','http://sideeffects.embl.de/drugs/16004692/'),('http://sideeffects.embl.de/se/C0235398/','Diabetes mellitus exacerbated','Pioglitazone','http://sideeffects.embl.de/drugs/4829/'),('http://sideeffects.embl.de/se/C0235416/','Blood uric acid increased','Azilsartan medoxomil','http://sideeffects.embl.de/drugs/11238823/'),('http://sideeffects.embl.de/se/C0235431/','Blood creatinine increased','Carfilzomib','http://sideeffects.embl.de/drugs/11556711/'),('http://sideeffects.embl.de/se/C0235437/','Gravitational oedema','Triptorelin','http://sideeffects.embl.de/drugs/25074470/'),('http://sideeffects.embl.de/se/C0235439/','Ankle edema','Budesonide','http://sideeffects.embl.de/drugs/2462/'),('http://sideeffects.embl.de/se/C0235462/','Anginal attack','Bretylium','http://sideeffects.embl.de/drugs/2431/'),('http://sideeffects.embl.de/se/C0235467/','Angina pectoris aggravated','Nitroglycerin','http://sideeffects.embl.de/drugs/4510/'),('http://sideeffects.embl.de/se/C0235490/','Peripheral ischaemia','Terlipressin','http://sideeffects.embl.de/drugs/72081/'),('http://sideeffects.embl.de/se/C0235527/','Cardiac failure right','Macitentan','http://sideeffects.embl.de/drugs/16004692/'),('http://sideeffects.embl.de/se/C0235532/','Cyanosis peripheral','Terlipressin','http://sideeffects.embl.de/drugs/72081/'),('http://sideeffects.embl.de/se/C0235546/','Hypopnoea','Sufentanil','http://sideeffects.embl.de/drugs/41693/'),('http://sideeffects.embl.de/se/C0235567/','Sputum increased','Insulin','http://sideeffects.embl.de/drugs/16129672/'),('http://sideeffects.embl.de/se/C0235634/','Costovertebral angle tenderness','Teduglutide','http://sideeffects.embl.de/drugs/16139605/'),('http://sideeffects.embl.de/se/C0235639/','Urine abnormality','Metronidazole','http://sideeffects.embl.de/drugs/4173/'),('http://sideeffects.embl.de/se/C0235660/','Galactorrhoea','Molindone','http://sideeffects.embl.de/drugs/23897/'),('http://sideeffects.embl.de/se/C0235710/','Chest discomfort','Regadenoson','http://sideeffects.embl.de/drugs/219024/'),('http://sideeffects.embl.de/se/C0235723/','Reaction febrile','EDTA','http://sideeffects.embl.de/drugs/6049/'),('http://sideeffects.embl.de/se/C0235744/','Breath holding','Desflurane','http://sideeffects.embl.de/drugs/42113/'),('http://sideeffects.embl.de/se/C0235761/','Nasal septum perforation','Mometasone','http://sideeffects.embl.de/drugs/123620/'),('http://sideeffects.embl.de/se/C0235807/','Hair texture abnormal','Ketoconazole','http://sideeffects.embl.de/drugs/3823/'),('http://sideeffects.embl.de/se/C0235818/','Bullous eruption','Nevirapine','http://sideeffects.embl.de/drugs/4463/'),('http://sideeffects.embl.de/se/C0235827/','Therapeutic response decreased','Penciclovir','http://sideeffects.embl.de/drugs/4725/'),('http://sideeffects.embl.de/se/C0235855/','Sepsis secondary','Ganciclovir','http://sideeffects.embl.de/drugs/3454/'),('http://sideeffects.embl.de/se/C0235857/','Lacrimation decreased','Imipramine','http://sideeffects.embl.de/drugs/3696/'),('http://sideeffects.embl.de/se/C0235863/','Delayed delivery','Bupivacaine','http://sideeffects.embl.de/drugs/2474/'),('http://sideeffects.embl.de/se/C0235876/','Depression aggravated','Citalopram','http://sideeffects.embl.de/drugs/2771/'),('http://sideeffects.embl.de/se/C0235886/','Leg edema','Exemestane','http://sideeffects.embl.de/drugs/60198/'),('http://sideeffects.embl.de/se/C0235896/','Lung infiltration','Propylthiouracil','http://sideeffects.embl.de/drugs/657298/'),('http://sideeffects.embl.de/se/C0235905/','Myasthenia gravis-like syndrome','Trimethadione','http://sideeffects.embl.de/drugs/5576/'),('http://sideeffects.embl.de/se/C0235919/','Nerve root lesion','Ibandronate','http://sideeffects.embl.de/drugs/60852/'),('http://sideeffects.embl.de/se/C0235950/','Zinc deficiency','EDTA','http://sideeffects.embl.de/drugs/6049/'),('http://sideeffects.embl.de/se/C0235957/','Muscle necrosis','Pralidoxime','http://sideeffects.embl.de/drugs/5353894/'),('http://sideeffects.embl.de/se/C0235966/','Dreaming excessive','Tolcapone','http://sideeffects.embl.de/drugs/4659569/'),('http://sideeffects.embl.de/se/C0235969/','Ejaculation disorder','Citalopram','http://sideeffects.embl.de/drugs/2771/'),('http://sideeffects.embl.de/se/C0235996/','Hepatic enzyme increased','Ivacaftor','http://sideeffects.embl.de/drugs/16220172/'),('http://sideeffects.embl.de/se/C0236000/','Pain in jaw','Regadenoson','http://sideeffects.embl.de/drugs/219024/'),('http://sideeffects.embl.de/se/C0236022/','Neoplasm malignant aggravated','Zoledronic acid','http://sideeffects.embl.de/drugs/68740/'),('http://sideeffects.embl.de/se/C0236024/','Pharyngeal oedema','Penciclovir','http://sideeffects.embl.de/drugs/4725/'),('http://sideeffects.embl.de/se/C0236061/','Haptoglobin increased','Nilutamide','http://sideeffects.embl.de/drugs/4493/'),('http://sideeffects.embl.de/se/C0236065/','Oedema mouth','DFMO','http://sideeffects.embl.de/drugs/3009/'),('http://sideeffects.embl.de/se/C0236071/','Throat tightness','Regadenoson','http://sideeffects.embl.de/drugs/219024/'),('http://sideeffects.embl.de/se/C0236072/','Bronchospasm paradoxical','Salmeterol','http://sideeffects.embl.de/drugs/5152/'),('http://sideeffects.embl.de/se/C0236083/','Burning feeling vagina','Metronidazole','http://sideeffects.embl.de/drugs/4173/'),('http://sideeffects.embl.de/se/C0236141/','Electrocardiogram abnormal specific','Telmisartan','http://sideeffects.embl.de/drugs/65999/'),('http://sideeffects.embl.de/se/C0236171/','Infection susceptibility increased','V 1784','http://sideeffects.embl.de/drugs/2909/'),('http://sideeffects.embl.de/se/C0236178/','Intra-abdominal haemorrhage','Apixaban','http://sideeffects.embl.de/drugs/10182969/'),('http://sideeffects.embl.de/se/C0237849/','Skin exfoliation','Linagliptin','http://sideeffects.embl.de/drugs/10096344/'),('http://sideeffects.embl.de/se/C0237938/','Gastrointestinal ulcer','Dabigatran etexilate','http://sideeffects.embl.de/drugs/213023/'),('http://sideeffects.embl.de/se/C0238106/','Clostridium difficile colitis','Doripenem','http://sideeffects.embl.de/drugs/73303/'),('http://sideeffects.embl.de/se/C0238124/','Necrotising fasciitis','Sulindac','http://sideeffects.embl.de/drugs/5352/'),('http://sideeffects.embl.de/se/C0238304/','Chronic interstitial nephritis','Guanidinium','http://sideeffects.embl.de/drugs/3520/'),('http://sideeffects.embl.de/se/C0238621/','Aminoaciduria','Streptozotocin','http://sideeffects.embl.de/drugs/5300/'),('http://sideeffects.embl.de/se/C0238874/','Antineutrophil cytoplasmic antibody positive','Propylthiouracil','http://sideeffects.embl.de/drugs/657298/'),('http://sideeffects.embl.de/se/C0239093/','Conjunctival irritation','Sulfacetamide','http://sideeffects.embl.de/drugs/5320/'),('http://sideeffects.embl.de/se/C0239134/','Productive cough','Insulin','http://sideeffects.embl.de/drugs/16129672/'),('http://sideeffects.embl.de/se/C0239150/','Creatinine low','Salsalate','http://sideeffects.embl.de/drugs/5161/'),('http://sideeffects.embl.de/se/C0239182/','Watery diarrhoea','Ethacrynic acid','http://sideeffects.embl.de/drugs/3278/'),('http://sideeffects.embl.de/se/C0239293/','Oesophageal haemorrhage','Torasemide','http://sideeffects.embl.de/drugs/41781/'),('http://sideeffects.embl.de/se/C0239296/','Oesophageal obstruction','Colestipol','http://sideeffects.embl.de/drugs/62816/'),('http://sideeffects.embl.de/se/C0239340/','Edema of lower extremities','Valganciclovir','http://sideeffects.embl.de/drugs/64147/'),('http://sideeffects.embl.de/se/C0239376/','Pain of lower extremities','Estazolam','http://sideeffects.embl.de/drugs/3261/'),('http://sideeffects.embl.de/se/C0239385/','Paresthesia of limbs','Potassium','http://sideeffects.embl.de/drugs/813/'),('http://sideeffects.embl.de/se/C0239454/','Erythema of eyelid','Bimatoprost','http://sideeffects.embl.de/drugs/127909/'),('http://sideeffects.embl.de/se/C0239488/','Erythema facial','ACTH(1-39','http://sideeffects.embl.de/drugs/16132265/'),('http://sideeffects.embl.de/se/C0239513/','Pallor facial','Terlipressin','http://sideeffects.embl.de/drugs/72081/'),('http://sideeffects.embl.de/se/C0239517/','Facial paresthesia','Dacarbazine','http://sideeffects.embl.de/drugs/5281007/'),('http://sideeffects.embl.de/se/C0239652/','Paraesthesia foot','Isoniazid','http://sideeffects.embl.de/drugs/3767/'),('http://sideeffects.embl.de/se/C0239739/','Gingival pain','Probenecid','http://sideeffects.embl.de/drugs/4911/'),('http://sideeffects.embl.de/se/C0239783/','Groin pain','Abiraterone','http://sideeffects.embl.de/drugs/132971/'),('http://sideeffects.embl.de/se/C0239935/','Haematocrit increased','Empagliflozin','http://sideeffects.embl.de/drugs/11949646/'),('http://sideeffects.embl.de/se/C0239937/','Microscopic hematuria','Methsuximide','http://sideeffects.embl.de/drugs/6476/'),('http://sideeffects.embl.de/se/C0239940/','Glycosylated haemoglobin increased','SOM230','http://sideeffects.embl.de/drugs/9941444/'),('http://sideeffects.embl.de/se/C0239981/','Hypoalbuminaemia','Dabrafenib','http://sideeffects.embl.de/drugs/44462760/'),('http://sideeffects.embl.de/se/C0240035/','Lung fibrosis interstitial','Chlorambucil','http://sideeffects.embl.de/drugs/2708/'),('http://sideeffects.embl.de/se/C0240059/','Intraventricular haemorrhage','Ibuprofen','http://sideeffects.embl.de/drugs/3672/'),('http://sideeffects.embl.de/se/C0240211/','Lip swelling','Adapalene','http://sideeffects.embl.de/drugs/60164/'),('http://sideeffects.embl.de/se/C0240291/','Mg reduced','Pazopanib','http://sideeffects.embl.de/drugs/10113978/'),('http://sideeffects.embl.de/se/C0240322/','Menstruation delayed','Nitrogen mustard','http://sideeffects.embl.de/drugs/4033/'),('http://sideeffects.embl.de/se/C0240327/','Taste metallic','Ethionamide','http://sideeffects.embl.de/drugs/2761171/'),('http://sideeffects.embl.de/se/C0240417/','Muscle mass','ACTH(1-39','http://sideeffects.embl.de/drugs/16132265/'),('http://sideeffects.embl.de/se/C0240449/','Nasal sinus drainage','Bromfenac','http://sideeffects.embl.de/drugs/60726/'),('http://sideeffects.embl.de/se/C0240515/','Nipple pain','Ivacaftor','http://sideeffects.embl.de/drugs/16220172/'),('http://sideeffects.embl.de/se/C0240521/','Nipple tenderness','Abarelix','http://sideeffects.embl.de/drugs/16131215/'),('http://sideeffects.embl.de/se/C0240557/','Nasal irritation','Fluticasone furoate','http://sideeffects.embl.de/drugs/9854489/'),('http://sideeffects.embl.de/se/C0240735/','Personality change','Trimethadione','http://sideeffects.embl.de/drugs/5576/'),('http://sideeffects.embl.de/se/C0240897/','Retinal exudates','Bromfenac','http://sideeffects.embl.de/drugs/60726/'),('http://sideeffects.embl.de/se/C0240941/','Itchy scalp','Midodrine','http://sideeffects.embl.de/drugs/4195/'),('http://sideeffects.embl.de/se/C0240962/','Scleral icterus','Atazanavir','http://sideeffects.embl.de/drugs/148192/'),('http://sideeffects.embl.de/se/C0241057/','Skin burning sensation','Sertaconazole','http://sideeffects.embl.de/drugs/65863/'),('http://sideeffects.embl.de/se/C0241136/','Pain of skin','Adapalene','http://sideeffects.embl.de/drugs/60164/'),('http://sideeffects.embl.de/se/C0241164/','Skin tenderness','Sertaconazole','http://sideeffects.embl.de/drugs/65863/'),('http://sideeffects.embl.de/se/C0241379/','Increased thirst','Almotriptan','http://sideeffects.embl.de/drugs/123606/'),('http://sideeffects.embl.de/se/C0241426/','Burning tongue','Fenoprofen','http://sideeffects.embl.de/drugs/3342/'),('http://sideeffects.embl.de/se/C0241442/','Protrusion tongue','Molindone','http://sideeffects.embl.de/drugs/23897/'),('http://sideeffects.embl.de/se/C0241558/','Urethral haemorrhage','Apixaban','http://sideeffects.embl.de/drugs/10182969/'),('http://sideeffects.embl.de/se/C0241633/','Vaginal dryness','Nafarelin','http://sideeffects.embl.de/drugs/25077405/'),('http://sideeffects.embl.de/se/C0241669/','Venous occlusion','Tranexamic acid','http://sideeffects.embl.de/drugs/5526/'),('http://sideeffects.embl.de/se/C0241705/','Strangury','Tropicamide','http://sideeffects.embl.de/drugs/5593/'),('http://sideeffects.embl.de/se/C0241742/','Wound haemorrhage','Apixaban','http://sideeffects.embl.de/drugs/10182969/'),('http://sideeffects.embl.de/se/C0241863/','Diabetic','Linagliptin','http://sideeffects.embl.de/drugs/10096344/'),('http://sideeffects.embl.de/se/C0241934/','Hypomania','Lu AA21004','http://sideeffects.embl.de/drugs/9966051/'),('http://sideeffects.embl.de/se/C0242184/','Hypoxia','Ondansetron','http://sideeffects.embl.de/drugs/4595/'),('http://sideeffects.embl.de/se/C0242225/','Colour blindness','Tranexamic acid','http://sideeffects.embl.de/drugs/5526/'),('http://sideeffects.embl.de/se/C0242339/','Dyslipidaemia','Empagliflozin','http://sideeffects.embl.de/drugs/11949646/'),('http://sideeffects.embl.de/se/C0242350/','Erectile dysfunction','Histrelin','http://sideeffects.embl.de/drugs/25077993/'),('http://sideeffects.embl.de/se/C0242422/','Parkinsonism','Lurasidone','http://sideeffects.embl.de/drugs/213046/'),('http://sideeffects.embl.de/se/C0242429/','Throat sore','Insulin','http://sideeffects.embl.de/drugs/16129672/'),('http://sideeffects.embl.de/se/C0242459/','Loeffler\'s syndrome','Nedocromil sodium','http://sideeffects.embl.de/drugs/50294/'),('http://sideeffects.embl.de/se/C0242528/','Azotaemia','Triamterene','http://sideeffects.embl.de/drugs/5546/'),('http://sideeffects.embl.de/se/C0243026/','Sepsis','Ponatinib','http://sideeffects.embl.de/drugs/24826799/'),('http://sideeffects.embl.de/se/C0243065/','Aplasia','Primidone','http://sideeffects.embl.de/drugs/4909/'),('http://sideeffects.embl.de/se/C0259799/','Punctate keratitis','Bimatoprost','http://sideeffects.embl.de/drugs/127909/'),('http://sideeffects.embl.de/se/C0259817/','Xerosis','Naphazoline','http://sideeffects.embl.de/drugs/4436/'),('http://sideeffects.embl.de/se/C0260662/','Auditory disorder NOS','Bupropion','http://sideeffects.embl.de/drugs/444/'),('http://sideeffects.embl.de/se/C0262380/','Asymptomatic bacteriuria','Empagliflozin','http://sideeffects.embl.de/drugs/11949646/'),('http://sideeffects.embl.de/se/C0262385/','Autonomic nervous system imbalance','Droperidol','http://sideeffects.embl.de/drugs/3168/'),('http://sideeffects.embl.de/se/C0262397/','Breast tenderness','Levonorgestrel','http://sideeffects.embl.de/drugs/4542/'),('http://sideeffects.embl.de/se/C0262431/','Spinal compression fracture','ACTH(1-39','http://sideeffects.embl.de/drugs/16132265/'),('http://sideeffects.embl.de/se/C0262662/','Ventricular bigeminy','Midazolam','http://sideeffects.embl.de/drugs/4192/'),('http://sideeffects.embl.de/se/C0262988/','Cutaneous vasculitis','Sitagliptin','http://sideeffects.embl.de/drugs/4369359/'),('http://sideeffects.embl.de/se/C0263338/','Urticaria chronic','Hydroxyzine','http://sideeffects.embl.de/drugs/3658/'),('http://sideeffects.embl.de/se/C0263367/','Koebner phenomenon','Calcipotriol','http://sideeffects.embl.de/drugs/2522/'),('http://sideeffects.embl.de/se/C0263383/','Keratosis pilaris','Vemurafenib','http://sideeffects.embl.de/drugs/42611257/'),('http://sideeffects.embl.de/se/C0263449/','Dermatitis perioral','Halobetasol','http://sideeffects.embl.de/drugs/5311167/'),('http://sideeffects.embl.de/se/C0263492/','Ingrown hair','DFMO','http://sideeffects.embl.de/drugs/3009/'),('http://sideeffects.embl.de/se/C0263591/','Drug-induced lupus erythematosus','Dapsone','http://sideeffects.embl.de/drugs/2955/'),('http://sideeffects.embl.de/se/C0264268/','Nasal septum ulceration','Fluticasone furoate','http://sideeffects.embl.de/drugs/9854489/'),('http://sideeffects.embl.de/se/C0264315/','Glottic edema','Roxithromycin','http://sideeffects.embl.de/drugs/5106/'),('http://sideeffects.embl.de/se/C0264886/','Conduction disorder','Imipramine','http://sideeffects.embl.de/drugs/3696/'),('http://sideeffects.embl.de/se/C0264893/','Nodal arrhythmia','Desflurane','http://sideeffects.embl.de/drugs/42113/'),('http://sideeffects.embl.de/se/C0265031/','Haemorrhoidal haemorrhage','Apixaban','http://sideeffects.embl.de/drugs/10182969/'),('http://sideeffects.embl.de/se/C0265294/','Metaphyseal dysplasia','Deferoxamine','http://sideeffects.embl.de/drugs/2973/'),('http://sideeffects.embl.de/se/C0266813/','Faecal occult blood positive','Nabumetone','http://sideeffects.embl.de/drugs/4409/'),('http://sideeffects.embl.de/se/C0267373/','Intestinal haemorrhage','Acarbose','http://sideeffects.embl.de/drugs/41774/'),('http://sideeffects.embl.de/se/C0267509/','Chronic idiopathic constipation','Lubiprostone','http://sideeffects.embl.de/drugs/157920/'),('http://sideeffects.embl.de/se/C0267596/','Rectal haemorrhage','Apixaban','http://sideeffects.embl.de/drugs/10182969/'),('http://sideeffects.embl.de/se/C0267792/','Hepatobiliary disease','Teduglutide','http://sideeffects.embl.de/drugs/16139605/'),('http://sideeffects.embl.de/se/C0267941/','Pancreatitis necrotising','Sitagliptin','http://sideeffects.embl.de/drugs/4369359/'),('http://sideeffects.embl.de/se/C0268000/','Fluid retention','Macitentan','http://sideeffects.embl.de/drugs/16004692/'),('http://sideeffects.embl.de/se/C0268009/','Plasma osmolality increased','Sodium bicarbonate','http://sideeffects.embl.de/drugs/10340/'),('http://sideeffects.embl.de/se/C0268543/','N-acetylglutamate synthase deficiency','N-carbamylglutamate','http://sideeffects.embl.de/drugs/121396/'),('http://sideeffects.embl.de/se/C0268621/','Hypermethioninaemia','Betaine','http://sideeffects.embl.de/drugs/247/'),('http://sideeffects.embl.de/se/C0269596/','Haemorrhage in pregnancy','Bupivacaine','http://sideeffects.embl.de/drugs/2474/'),('http://sideeffects.embl.de/se/C0269661/','Vomiting in pregnancy','Hydroxyzine','http://sideeffects.embl.de/drugs/3658/'),('http://sideeffects.embl.de/se/C0269842/','Uterine hypertonus','Terlipressin','http://sideeffects.embl.de/drugs/72081/'),('http://sideeffects.embl.de/se/C0270611/','Brain injury','Caffeine','http://sideeffects.embl.de/drugs/2519/'),('http://sideeffects.embl.de/se/C0270996/','Eye swelling','Ciprofloxacin','http://sideeffects.embl.de/drugs/2764/'),('http://sideeffects.embl.de/se/C0271298/','Chemosis','Suprofen','http://sideeffects.embl.de/drugs/5359/'),('http://sideeffects.embl.de/se/C0271412/','Ear haemorrhage','Ofloxacin','http://sideeffects.embl.de/drugs/4583/'),('http://sideeffects.embl.de/se/C0271623/','Secondary hypogonadism','Gonadorelin','http://sideeffects.embl.de/drugs/36523/'),('http://sideeffects.embl.de/se/C0271650/','Glucose tolerance impaired','Furosemide','http://sideeffects.embl.de/drugs/3440/'),('http://sideeffects.embl.de/se/C0271710/','Hypoglycemic reaction','Linagliptin','http://sideeffects.embl.de/drugs/10096344/'),('http://sideeffects.embl.de/se/C0271738/','Secondary adrenocortical insufficiency','Beclomethasone dipropionate','http://sideeffects.embl.de/drugs/2307/'),('http://sideeffects.embl.de/se/C0274312/','Graft complication','Lanthanum carbonate','http://sideeffects.embl.de/drugs/168924/'),('http://sideeffects.embl.de/se/C0277585/','Drug intolerance','Domperidone','http://sideeffects.embl.de/drugs/3151/'),('http://sideeffects.embl.de/se/C0277794/','Prostration','Colchicine','http://sideeffects.embl.de/drugs/2833/'),('http://sideeffects.embl.de/se/C0277884/','Blood pressure systolic increased','Dobutamine','http://sideeffects.embl.de/drugs/36811/'),('http://sideeffects.embl.de/se/C0277885/','Blood pressure systolic decreased','Empagliflozin','http://sideeffects.embl.de/drugs/11949646/'),('http://sideeffects.embl.de/se/C0277890/','Blood pressure diastolic decreased','Metaproterenol','http://sideeffects.embl.de/drugs/4086/'),('http://sideeffects.embl.de/se/C0277925/','Peripheral coldness','Propranolol','http://sideeffects.embl.de/drugs/4946/'),('http://sideeffects.embl.de/se/C0278061/','Mental state abnormal','Histrelin','http://sideeffects.embl.de/drugs/25077993/'),('http://sideeffects.embl.de/se/C0278106/','Ejaculation failure','Desvenlafaxine','http://sideeffects.embl.de/drugs/125017/'),('http://sideeffects.embl.de/se/C0281774/','Acute psychosis','Scopolamine','http://sideeffects.embl.de/drugs/5184/'),('http://sideeffects.embl.de/se/C0282488/','Cystitis interstitial','Pentosan polysulfate','http://sideeffects.embl.de/drugs/37720/'),('http://sideeffects.embl.de/se/C0302295/','Eruption','Benzonatate','http://sideeffects.embl.de/drugs/7699/'),('http://sideeffects.embl.de/se/C0302809/','Hepatitis fulminant','Telithromycin','http://sideeffects.embl.de/drugs/73658/'),('http://sideeffects.embl.de/se/C0302870/','Microcytic','Voriconazole','http://sideeffects.embl.de/drugs/71616/'),('http://sideeffects.embl.de/se/C0311394/','Walking disability','Perhexiline','http://sideeffects.embl.de/drugs/4746/'),('http://sideeffects.embl.de/se/C0311468/','Blood bilirubin increased','Ponatinib','http://sideeffects.embl.de/drugs/24826799/'),('http://sideeffects.embl.de/se/C0312414/','Spotting menstrual','Copper','http://sideeffects.embl.de/drugs/23978/'),('http://sideeffects.embl.de/se/C0314719/','Dry eye','Mirabegron','http://sideeffects.embl.de/drugs/9865528/'),('http://sideeffects.embl.de/se/C0332534/','Induration','Degarelix','http://sideeffects.embl.de/drugs/16136245/'),('http://sideeffects.embl.de/se/C0332563/','Papule','Imiquimod','http://sideeffects.embl.de/drugs/57469/'),('http://sideeffects.embl.de/se/C0332573/','Macule','Oxybutynin','http://sideeffects.embl.de/drugs/4634/'),('http://sideeffects.embl.de/se/C0332575/','Redness','Insulin','http://sideeffects.embl.de/drugs/16129672/'),('http://sideeffects.embl.de/se/C0332601/','Cushingoid','Budesonide','http://sideeffects.embl.de/drugs/2462/'),('http://sideeffects.embl.de/se/C0333139/','Pneumatosis','Acarbose','http://sideeffects.embl.de/drugs/41774/'),('http://sideeffects.embl.de/se/C0333355/','Mucosal inflammation','Ponatinib','http://sideeffects.embl.de/drugs/24826799/'),('http://sideeffects.embl.de/se/C0333641/','Atrophy','Isoniazid','http://sideeffects.embl.de/drugs/3767/'),('http://sideeffects.embl.de/se/C0334044/','Dysplasia','Lomustine','http://sideeffects.embl.de/drugs/3950/'),('http://sideeffects.embl.de/se/C0338591/','Transient global amnesia','Vardenafil','http://sideeffects.embl.de/drugs/110634/'),('http://sideeffects.embl.de/se/C0338614/','Psychotic episode','Phentermine','http://sideeffects.embl.de/drugs/4771/'),('http://sideeffects.embl.de/se/C0338656/','Cognitive impairment','Trihexyphenidyl','http://sideeffects.embl.de/drugs/5572/'),('http://sideeffects.embl.de/se/C0338831/','Mania','Lu AA21004','http://sideeffects.embl.de/drugs/9966051/'),('http://sideeffects.embl.de/se/C0339293/','Corneal perforation','Bromfenac','http://sideeffects.embl.de/drugs/60726/'),('http://sideeffects.embl.de/se/C0339916/','Viral upper respiratory tract infection','Budesonide','http://sideeffects.embl.de/drugs/2462/'),('http://sideeffects.embl.de/se/C0340464/','Extrasystoles','Dyphylline','http://sideeffects.embl.de/drugs/3182/'),('http://sideeffects.embl.de/se/C0340865/','Anaphylactoid reaction','Pegaptanib','http://sideeffects.embl.de/drugs/56603655/'),('http://sideeffects.embl.de/se/C0340909/','Arteriovenous fistula thrombosis','Fe(III','http://sideeffects.embl.de/drugs/23925/'),('http://sideeffects.embl.de/se/C0341439/','Chronic liver disease','Zileuton','http://sideeffects.embl.de/drugs/60490/'),('http://sideeffects.embl.de/se/C0342405/','Pituitary infarction','Histrelin','http://sideeffects.embl.de/drugs/25077993/'),('http://sideeffects.embl.de/se/C0342579/','Electrolyte imbalance','Methyclothiazide','http://sideeffects.embl.de/drugs/4121/'),('http://sideeffects.embl.de/se/C0342649/','Vascular calcification','Vitamin D2','http://sideeffects.embl.de/drugs/3249/'),('http://sideeffects.embl.de/se/C0344232/','Vision blurred','Besifloxacin','http://sideeffects.embl.de/drugs/10178705/'),('http://sideeffects.embl.de/se/C0344315/','Depressed mood','Modafinil','http://sideeffects.embl.de/drugs/4236/'),('http://sideeffects.embl.de/se/C0344320/','Vivid dreams','Trazodone','http://sideeffects.embl.de/drugs/5533/'),('http://sideeffects.embl.de/se/C0344329/','Collapse','Thiamine','http://sideeffects.embl.de/drugs/1130/'),('http://sideeffects.embl.de/se/C0344375/','Stomach cramps','Citric acid','http://sideeffects.embl.de/drugs/311/'),('http://sideeffects.embl.de/se/C0349506/','Photosensitivity','Ethionamide','http://sideeffects.embl.de/drugs/2761171/'),('http://sideeffects.embl.de/se/C0349702/','Corneal scar','Bromfenac','http://sideeffects.embl.de/drugs/60726/'),('http://sideeffects.embl.de/se/C0349790/','Exacerbation of asthma','Metaproterenol','http://sideeffects.embl.de/drugs/4086/'),('http://sideeffects.embl.de/se/C0376297/','Cardiac death','Amphetamine','http://sideeffects.embl.de/drugs/3007/'),('http://sideeffects.embl.de/se/C0376358/','Prostate cancer','Mirabegron','http://sideeffects.embl.de/drugs/9865528/'),('http://sideeffects.embl.de/se/C0391839/','PCO2','Mafenide acetate','http://sideeffects.embl.de/drugs/3998/'),('http://sideeffects.embl.de/se/C0392025/','Enlargement abdomen','Metrodin','http://sideeffects.embl.de/drugs/62819/'),('http://sideeffects.embl.de/se/C0392034/','Gastrooesophagitis','Dabigatran etexilate','http://sideeffects.embl.de/drugs/213023/'),('http://sideeffects.embl.de/se/C0392156/','Akathisia','Lurasidone','http://sideeffects.embl.de/drugs/213046/'),('http://sideeffects.embl.de/se/C0392162/','Sticky skin','Trazodone','http://sideeffects.embl.de/drugs/5533/'),('http://sideeffects.embl.de/se/C0392163/','Corneal erosion','Bimatoprost','http://sideeffects.embl.de/drugs/127909/'),('http://sideeffects.embl.de/se/C0392171/','Influenza-like symptoms','K779','http://sideeffects.embl.de/drugs/71306834/'),('http://sideeffects.embl.de/se/C0392176/','Gastric irritation','Zinc','http://sideeffects.embl.de/drugs/23994/'),('http://sideeffects.embl.de/se/C0392197/','Warmth','Temsirolimus','http://sideeffects.embl.de/drugs/148191/'),('http://sideeffects.embl.de/se/C0392386/','Platelet count decreased','Ponatinib','http://sideeffects.embl.de/drugs/24826799/'),('http://sideeffects.embl.de/se/C0392390/','Hepatitis B e antigen positive','Adefovir dipivoxil','http://sideeffects.embl.de/drugs/60871/'),('http://sideeffects.embl.de/se/C0392525/','Nephrolithiasis','Sulfasalazine','http://sideeffects.embl.de/drugs/5353980/'),('http://sideeffects.embl.de/se/C0392548/','Cauda equina syndrome','MDV3100','http://sideeffects.embl.de/drugs/15951529/'),('http://sideeffects.embl.de/se/C0392618/','Postoperative infection','Ertapenem','http://sideeffects.embl.de/drugs/150610/'),('http://sideeffects.embl.de/se/C0392674/','Exhaustion','Baclofen','http://sideeffects.embl.de/drugs/2284/'),('http://sideeffects.embl.de/se/C0392676/','Hyperpyrexia','Flavoxate','http://sideeffects.embl.de/drugs/3354/'),('http://sideeffects.embl.de/se/C0392699/','Dysaesthesia','Frovatriptan','http://sideeffects.embl.de/drugs/77992/'),('http://sideeffects.embl.de/se/C0392702/','Abnormal involuntary movements','Alprazolam','http://sideeffects.embl.de/drugs/2118/'),('http://sideeffects.embl.de/se/C0392703/','Shakiness','Almotriptan','http://sideeffects.embl.de/drugs/123606/'),('http://sideeffects.embl.de/se/C0393760/','Initial insomnia','Methylphenidate','http://sideeffects.embl.de/drugs/4158/'),('http://sideeffects.embl.de/se/C0399459/','Oral discomfort','Regadenoson','http://sideeffects.embl.de/drugs/219024/'),('http://sideeffects.embl.de/se/C0400877/','Postoperative ileus','Isoflurane','http://sideeffects.embl.de/drugs/3763/'),('http://sideeffects.embl.de/se/C0403639/','Chemical cystitis','Thiotepa','http://sideeffects.embl.de/drugs/5453/'),('http://sideeffects.embl.de/se/C0403673/','Retrograde ejaculation','Iloperidone','http://sideeffects.embl.de/drugs/71360/'),('http://sideeffects.embl.de/se/C0404521/','Vaginal infection','Empagliflozin','http://sideeffects.embl.de/drugs/11949646/'),('http://sideeffects.embl.de/se/C0405479/','Nipple disorder','Ivacaftor','http://sideeffects.embl.de/drugs/16220172/'),('http://sideeffects.embl.de/se/C0409962/','Localized osteoarthritis','Ibandronate','http://sideeffects.embl.de/drugs/60852/'),('http://sideeffects.embl.de/se/C0409974/','Lupus erythematosus','Trimethadione','http://sideeffects.embl.de/drugs/5576/'),('http://sideeffects.embl.de/se/C0423006/','Eye discharge','Bimatoprost','http://sideeffects.embl.de/drugs/127909/'),('http://sideeffects.embl.de/se/C0423124/','Dermatochalasis','Nepafenac','http://sideeffects.embl.de/drugs/151075/'),('http://sideeffects.embl.de/se/C0423153/','Lacrimation','Bimatoprost','http://sideeffects.embl.de/drugs/127909/'),('http://sideeffects.embl.de/se/C0423226/','Corneal pigmentation','Clofazimine','http://sideeffects.embl.de/drugs/2794/'),('http://sideeffects.embl.de/se/C0423232/','Corneal staining','Tropicamide','http://sideeffects.embl.de/drugs/5593/'),('http://sideeffects.embl.de/se/C0423602/','Sensation of foreign body','Bimatoprost','http://sideeffects.embl.de/drugs/127909/'),('http://sideeffects.embl.de/se/C0423636/','Cardiac pain','Sotalol','http://sideeffects.embl.de/drugs/5253/'),('http://sideeffects.embl.de/se/C0423736/','Micturition burning','5-ASA','http://sideeffects.embl.de/drugs/4075/'),('http://sideeffects.embl.de/se/C0423757/','Skin thinness','ACTH(1-39','http://sideeffects.embl.de/drugs/16132265/'),('http://sideeffects.embl.de/se/C0423791/','Rash maculo-papular','Vemurafenib','http://sideeffects.embl.de/drugs/42611257/'),('http://sideeffects.embl.de/se/C0423847/','Growth of eyelashes','Bimatoprost','http://sideeffects.embl.de/drugs/127909/'),('http://sideeffects.embl.de/se/C0424000/','Suicidal ideation','Elvitegravir','http://sideeffects.embl.de/drugs/5277135/'),('http://sideeffects.embl.de/se/C0424109/','Tearfulness','Clonidine','http://sideeffects.embl.de/drugs/2803/'),('http://sideeffects.embl.de/se/C0424230/','Psychomotor retardation','Zolpidem','http://sideeffects.embl.de/drugs/5732/'),('http://sideeffects.embl.de/se/C0424295/','Hyperkinesia','Paliperidone','http://sideeffects.embl.de/drugs/115237/'),('http://sideeffects.embl.de/se/C0424332/','Breath holding attack','Desflurane','http://sideeffects.embl.de/drugs/42113/'),('http://sideeffects.embl.de/se/C0424790/','Rigors','K779','http://sideeffects.embl.de/drugs/71306834/'),('http://sideeffects.embl.de/se/C0424823/','Parotid swelling','Amoxapine','http://sideeffects.embl.de/drugs/2170/'),('http://sideeffects.embl.de/se/C0425945/','Prolonged menses','Mebendazole','http://sideeffects.embl.de/drugs/4030/'),('http://sideeffects.embl.de/se/C0426390/','Bladder spasm','Baclofen','http://sideeffects.embl.de/drugs/2284/'),('http://sideeffects.embl.de/se/C0426576/','Gastrointestinal symptom NOS','Prucalopride','http://sideeffects.embl.de/drugs/3052762/'),('http://sideeffects.embl.de/se/C0426596/','Fluid intake increased','Colestipol','http://sideeffects.embl.de/drugs/62816/'),('http://sideeffects.embl.de/se/C0426636/','Defaecation urgency','Rifaximin','http://sideeffects.embl.de/drugs/72111/'),('http://sideeffects.embl.de/se/C0426747/','Anal haemorrhage','Bupivacaine','http://sideeffects.embl.de/drugs/2474/'),('http://sideeffects.embl.de/se/C0427008/','Stiffness','Zoledronic acid','http://sideeffects.embl.de/drugs/68740/'),('http://sideeffects.embl.de/se/C0427086/','Movements involuntary','Molindone','http://sideeffects.embl.de/drugs/23897/'),('http://sideeffects.embl.de/se/C0427108/','Unsteadiness','Perhexiline','http://sideeffects.embl.de/drugs/4746/'),('http://sideeffects.embl.de/se/C0428167/','Fraction of inspired oxygen','Mitomycin C','http://sideeffects.embl.de/drugs/5746/'),('http://sideeffects.embl.de/se/C0428282/','Serum creatinine decreased','Terlipressin','http://sideeffects.embl.de/drugs/72081/'),('http://sideeffects.embl.de/se/C0428886/','Mean arterial pressure','Cisatracurium','http://sideeffects.embl.de/drugs/47320/'),('http://sideeffects.embl.de/se/C0428974/','Arrhythmia supraventricular','Milrinone','http://sideeffects.embl.de/drugs/4197/'),('http://sideeffects.embl.de/se/C0428977/','Bradycardia','Bivalirudin','http://sideeffects.embl.de/drugs/16129704/'),('http://sideeffects.embl.de/se/C0429029/','Electrocardiogram ST segment','Regadenoson','http://sideeffects.embl.de/drugs/219024/'),('http://sideeffects.embl.de/se/C0429097/','QRS complex','Imipramine','http://sideeffects.embl.de/drugs/3696/'),('http://sideeffects.embl.de/se/C0429774/','Residual urine volume','Oxybutynin','http://sideeffects.embl.de/drugs/4634/'),('http://sideeffects.embl.de/se/C0434437/','Joint sprain','Dapsone','http://sideeffects.embl.de/drugs/2955/'),('http://sideeffects.embl.de/se/C0438215/','Laboratory test abnormal','Troglitazone','http://sideeffects.embl.de/drugs/5591/'),('http://sideeffects.embl.de/se/C0438237/','Hepatic enzyme abnormal','Leflunomide','http://sideeffects.embl.de/drugs/3899/'),('http://sideeffects.embl.de/se/C0438717/','Transaminases increased','Ivacaftor','http://sideeffects.embl.de/drugs/16220172/'),('http://sideeffects.embl.de/se/C0439857/','Dependence','Phentermine','http://sideeffects.embl.de/drugs/4771/'),('http://sideeffects.embl.de/se/C0442874/','Neuropathy','Empagliflozin','http://sideeffects.embl.de/drugs/11949646/'),('http://sideeffects.embl.de/se/C0442886/','Secondary infection','Halobetasol','http://sideeffects.embl.de/drugs/5311167/'),('http://sideeffects.embl.de/se/C0455899/','Pharyngeal erythema','Ivacaftor','http://sideeffects.embl.de/drugs/16220172/'),('http://sideeffects.embl.de/se/C0456511/','Sleep paralysis','Hydroxybutyrate','http://sideeffects.embl.de/drugs/10413/'),('http://sideeffects.embl.de/se/C0456909/','Blindness','Trihexyphenidyl','http://sideeffects.embl.de/drugs/5572/'),('http://sideeffects.embl.de/se/C0457798/','Dermatitis eyelid','Metipranolol','http://sideeffects.embl.de/drugs/31477/'),('http://sideeffects.embl.de/se/C0458219/','Complex regional pain syndrome','Temsirolimus','http://sideeffects.embl.de/drugs/148191/'),('http://sideeffects.embl.de/se/C0459435/','Psychotic state','Guanidinium','http://sideeffects.embl.de/drugs/3520/'),('http://sideeffects.embl.de/se/C0473237/','Frank hematuria','Ifosfamide','http://sideeffects.embl.de/drugs/3690/'),('http://sideeffects.embl.de/se/C0474378/','Hair colour changes','Pazopanib','http://sideeffects.embl.de/drugs/10113978/'),('http://sideeffects.embl.de/se/C0474381/','Chromatopsia','Tranexamic acid','http://sideeffects.embl.de/drugs/5526/'),('http://sideeffects.embl.de/se/C0474444/','Corneal stromal edema','Trifluorothymidine','http://sideeffects.embl.de/drugs/6256/'),('http://sideeffects.embl.de/se/C0475746/','Light anaesthesia','Droperidol','http://sideeffects.embl.de/drugs/3168/'),('http://sideeffects.embl.de/se/C0475858/','Pruritus generalised','Lu AA21004','http://sideeffects.embl.de/drugs/9966051/'),('http://sideeffects.embl.de/se/C0476273/','Respiratory distress','Anidulafungin','http://sideeffects.embl.de/drugs/166548/'),('http://sideeffects.embl.de/se/C0476280/','Musculoskeletal chest pain','Cabozantinib','http://sideeffects.embl.de/drugs/25102847/'),('http://sideeffects.embl.de/se/C0476281/','Non-cardiac chest pain','Ticagrelor','http://sideeffects.embl.de/drugs/9871419/'),('http://sideeffects.embl.de/se/C0476327/','Serum amylase increased','Vandetanib','http://sideeffects.embl.de/drugs/3081361/'),('http://sideeffects.embl.de/se/C0494475/','Tonic-clonic seizures','Trimethadione','http://sideeffects.embl.de/drugs/5576/'),('http://sideeffects.embl.de/se/C0497156/','Lymphadenopathy','Methimazole','http://sideeffects.embl.de/drugs/1349907/'),('http://sideeffects.embl.de/se/C0497201/','Abnormal sensation in eye','Bromfenac','http://sideeffects.embl.de/drugs/60726/'),('http://sideeffects.embl.de/se/C0497247/','Blood pressure increased','Florbetapir','http://sideeffects.embl.de/drugs/24822371/'),('http://sideeffects.embl.de/se/C0497365/','Rash generalised','Tolvaptan','http://sideeffects.embl.de/drugs/216237/'),('http://sideeffects.embl.de/se/C0518988/','Tooth abscess','Pioglitazone','http://sideeffects.embl.de/drugs/4829/'),('http://sideeffects.embl.de/se/C0519030/','Pneumonia klebsiella','Ciprofloxacin','http://sideeffects.embl.de/drugs/2764/'),('http://sideeffects.embl.de/se/C0520459/','Necrotizing enterocolitis','Caffeine','http://sideeffects.embl.de/drugs/2519/'),('http://sideeffects.embl.de/se/C0520589/','Vulvovaginal dryness','Letrozole','http://sideeffects.embl.de/drugs/3902/'),('http://sideeffects.embl.de/se/C0520758/','Neuromuscular block prolonged','Cisatracurium','http://sideeffects.embl.de/drugs/47320/'),('http://sideeffects.embl.de/se/C0520872/','Stroke volume increased','Caffeine','http://sideeffects.embl.de/drugs/2519/'),('http://sideeffects.embl.de/se/C0520887/','Electrocardiogram ST segment depression','Regadenoson','http://sideeffects.embl.de/drugs/219024/'),('http://sideeffects.embl.de/se/C0520893/','Localized exfoliation','Vildagliptin','http://sideeffects.embl.de/drugs/5251896/'),('http://sideeffects.embl.de/se/C0520901/','Increased skin sensitivity','Sulfasalazine','http://sideeffects.embl.de/drugs/5353980/'),('http://sideeffects.embl.de/se/C0520962/','Pain localised','Sotalol','http://sideeffects.embl.de/drugs/5253/'),('http://sideeffects.embl.de/se/C0520966/','Coordination abnormal','Perampanel','http://sideeffects.embl.de/drugs/9924495/'),('http://sideeffects.embl.de/se/C0521169/','Compression fracture','Cysteamine','http://sideeffects.embl.de/drugs/6058/'),('http://sideeffects.embl.de/se/C0521172/','Eschar','Deferoxamine','http://sideeffects.embl.de/drugs/2973/'),('http://sideeffects.embl.de/se/C0521490/','Application site irritation','PEP005','http://sideeffects.embl.de/drugs/6918670/'),('http://sideeffects.embl.de/se/C0521491/','Application site pain','PEP005','http://sideeffects.embl.de/drugs/6918670/'),('http://sideeffects.embl.de/se/C0521492/','Application site ulcer','PEP005','http://sideeffects.embl.de/drugs/6918670/'),('http://sideeffects.embl.de/se/C0521495/','Application site rash','Imiquimod','http://sideeffects.embl.de/drugs/57469/'),('http://sideeffects.embl.de/se/C0521496/','Application site infection','PEP005','http://sideeffects.embl.de/drugs/6918670/'),('http://sideeffects.embl.de/se/C0521498/','Injection site irritation','Florbetapir','http://sideeffects.embl.de/drugs/24822371/'),('http://sideeffects.embl.de/se/C0521508/','Injection site bruising','Metrodin','http://sideeffects.embl.de/drugs/62819/'),('http://sideeffects.embl.de/se/C0521510/','Implant site reaction','Histrelin','http://sideeffects.embl.de/drugs/25077993/'),('http://sideeffects.embl.de/se/C0521591/','Paraesthesia oral','Lacosamide','http://sideeffects.embl.de/drugs/219078/'),('http://sideeffects.embl.de/se/C0521592/','Hypoaesthesia oral','Lacosamide','http://sideeffects.embl.de/drugs/219078/'),('http://sideeffects.embl.de/se/C0521626/','Bladder fibrosis','Mitomycin C','http://sideeffects.embl.de/drugs/5746/'),('http://sideeffects.embl.de/se/C0521839/','Influenza like illness','K779','http://sideeffects.embl.de/drugs/71306834/'),('http://sideeffects.embl.de/se/C0522046/','Cough suppression','Phenylpropanolamine','http://sideeffects.embl.de/drugs/4786/'),('http://sideeffects.embl.de/se/C0522055/','Electrocardiogram abnormal','Avanafil','http://sideeffects.embl.de/drugs/9869929/'),('http://sideeffects.embl.de/se/C0522153/','Urine color abnormal','Rifabutin','http://sideeffects.embl.de/drugs/5361912/'),('http://sideeffects.embl.de/se/C0522172/','Feeling drunk','Hydroxybutyrate','http://sideeffects.embl.de/drugs/10413/'),('http://sideeffects.embl.de/se/C0522224/','Paralysis','Edrophonium','http://sideeffects.embl.de/drugs/3202/'),('http://sideeffects.embl.de/se/C0525045/','Affective disorder','Hexamethylmelamine','http://sideeffects.embl.de/drugs/2123/'),('http://sideeffects.embl.de/se/C0541799/','Bad taste','Nedocromil sodium','http://sideeffects.embl.de/drugs/50294/'),('http://sideeffects.embl.de/se/C0541819/','Burning rectal','Ondansetron','http://sideeffects.embl.de/drugs/4595/'),('http://sideeffects.embl.de/se/C0541820/','Carbohydrate tolerance decreased','ACTH(1-39','http://sideeffects.embl.de/drugs/16132265/'),('http://sideeffects.embl.de/se/C0541832/','Chromaturia','Retigabine','http://sideeffects.embl.de/drugs/121892/'),('http://sideeffects.embl.de/se/C0541900/','Disulfiram like reaction','Tolbutamide','http://sideeffects.embl.de/drugs/5505/'),('http://sideeffects.embl.de/se/C0541919/','Dystonic reaction','Domperidone','http://sideeffects.embl.de/drugs/3151/'),('http://sideeffects.embl.de/se/C0542008/','Injection site haematoma','Teduglutide','http://sideeffects.embl.de/drugs/16139605/'),('http://sideeffects.embl.de/se/C0542035/','Hypoplasia erythroid','Azathioprine','http://sideeffects.embl.de/drugs/2265/'),('http://sideeffects.embl.de/se/C0542044/','Incoherent','Cyclopentolate','http://sideeffects.embl.de/drugs/2905/'),('http://sideeffects.embl.de/se/C0542052/','Coronary artery insufficiency','Isoproterenol','http://sideeffects.embl.de/drugs/3779/'),('http://sideeffects.embl.de/se/C0542101/','Nasal burning','Fluticasone furoate','http://sideeffects.embl.de/drugs/9854489/'),('http://sideeffects.embl.de/se/C0542127/','Oversedation','Midazolam','http://sideeffects.embl.de/drugs/4192/'),('http://sideeffects.embl.de/se/C0542184/','Reaction gastrointestinal','Nafcillin','http://sideeffects.embl.de/drugs/8982/'),('http://sideeffects.embl.de/se/C0542203/','Water retention','Minoxidil','http://sideeffects.embl.de/drugs/4201/'),('http://sideeffects.embl.de/se/C0542247/','Tremulousness','Acetohydroxamic acid','http://sideeffects.embl.de/drugs/1990/'),('http://sideeffects.embl.de/se/C0542476/','Forgetfulness','Trihexyphenidyl','http://sideeffects.embl.de/drugs/5572/'),('http://sideeffects.embl.de/se/C0542571/','Face oedema','Fesoterodine','http://sideeffects.embl.de/drugs/6918558/'),('http://sideeffects.embl.de/se/C0546817/','Fluid overload','Terlipressin','http://sideeffects.embl.de/drugs/72081/'),('http://sideeffects.embl.de/se/C0546884/','Hypovolaemia','Empagliflozin','http://sideeffects.embl.de/drugs/11949646/'),('http://sideeffects.embl.de/se/C0547030/','Visual disturbance','Bimatoprost','http://sideeffects.embl.de/drugs/127909/'),('http://sideeffects.embl.de/se/C0548823/','Distress gastrointestinal','Mexiletine','http://sideeffects.embl.de/drugs/4178/'),('http://sideeffects.embl.de/se/C0549150/','Pseudofolliculitis barbae','DFMO','http://sideeffects.embl.de/drugs/3009/'),('http://sideeffects.embl.de/se/C0549209/','Feeling jittery','Desvenlafaxine','http://sideeffects.embl.de/drugs/125017/'),('http://sideeffects.embl.de/se/C0549249/','Depressed level of consciousness','Thalidomide','http://sideeffects.embl.de/drugs/5426/'),('http://sideeffects.embl.de/se/C0549293/','Nasal soreness','Fluticasone furoate','http://sideeffects.embl.de/drugs/9854489/'),('http://sideeffects.embl.de/se/C0549336/','Asthma aggravated','Pimecrolimus','http://sideeffects.embl.de/drugs/3055172/'),('http://sideeffects.embl.de/se/C0549356/','Inflicted injury','Olmesartan','http://sideeffects.embl.de/drugs/158781/'),('http://sideeffects.embl.de/se/C0549383/','Ovarian hyperstimulation','Metrodin','http://sideeffects.embl.de/drugs/62819/'),('http://sideeffects.embl.de/se/C0549386/','Sensation of warmth','Eletriptan','http://sideeffects.embl.de/drugs/77993/'),('http://sideeffects.embl.de/se/C0549389/','Wound discharge increased','Valganciclovir','http://sideeffects.embl.de/drugs/64147/'),('http://sideeffects.embl.de/se/C0549419/','Skin fragility','Cysteamine','http://sideeffects.embl.de/drugs/6058/'),('http://sideeffects.embl.de/se/C0549433/','Surgical intervention','Prasugrel','http://sideeffects.embl.de/drugs/6918456/'),('http://sideeffects.embl.de/se/C0549448/','Haemoglobin increased','Vandetanib','http://sideeffects.embl.de/drugs/3081361/'),('http://sideeffects.embl.de/se/C0549475/','Lipase increased','Ponatinib','http://sideeffects.embl.de/drugs/24826799/'),('http://sideeffects.embl.de/se/C0549478/','Device expulsion','Levonorgestrel','http://sideeffects.embl.de/drugs/4542/'),('http://sideeffects.embl.de/se/C0549493/','Alveolitis','Temsirolimus','http://sideeffects.embl.de/drugs/148191/'),('http://sideeffects.embl.de/se/C0549567/','Pigmentation disorder','Deferasirox','http://sideeffects.embl.de/drugs/5493381/'),('http://sideeffects.embl.de/se/C0549622/','Sexual dysfunction','Lu AA21004','http://sideeffects.embl.de/drugs/9966051/'),('http://sideeffects.embl.de/se/C0553548/','Angiitis necrotising','ACTH(1-39','http://sideeffects.embl.de/drugs/16132265/'),('http://sideeffects.embl.de/se/C0553576/','Systemic mycosis','V 1784','http://sideeffects.embl.de/drugs/2909/'),('http://sideeffects.embl.de/se/C0553702/','Ca++ increased','Caffeine','http://sideeffects.embl.de/drugs/2519/'),('http://sideeffects.embl.de/se/C0553713/','Breast pain female','Metrodin','http://sideeffects.embl.de/drugs/62819/'),('http://sideeffects.embl.de/se/C0553721/','Sweating decreased','Propantheline','http://sideeffects.embl.de/drugs/4934/'),('http://sideeffects.embl.de/se/C0553723/','Squamous cell carcinoma of skin','Dabrafenib','http://sideeffects.embl.de/drugs/44462760/'),('http://sideeffects.embl.de/se/C0553731/','PRL increased','Olanzapine','http://sideeffects.embl.de/drugs/4585/'),('http://sideeffects.embl.de/se/C0554309/','Azotemia prerenal','D-telaprevir','http://sideeffects.embl.de/drugs/3010818/'),('http://sideeffects.embl.de/se/C0558143/','Skin maceration','Mafenide acetate','http://sideeffects.embl.de/drugs/3998/'),('http://sideeffects.embl.de/se/C0558148/','Yellow skin','Bicalutamide','http://sideeffects.embl.de/drugs/2375/'),('http://sideeffects.embl.de/se/C0558401/','Skin laceration','Perampanel','http://sideeffects.embl.de/drugs/9924495/'),('http://sideeffects.embl.de/se/C0558489/','Renal pain','Fluconazole','http://sideeffects.embl.de/drugs/3365/'),('http://sideeffects.embl.de/se/C0560024/','Swelling of eyelid','Ketotifen','http://sideeffects.embl.de/drugs/3827/'),('http://sideeffects.embl.de/se/C0574002/','Foot edema','Labetalol','http://sideeffects.embl.de/drugs/3869/'),('http://sideeffects.embl.de/se/C0574067/','Cough increased','Insulin','http://sideeffects.embl.de/drugs/16129672/'),('http://sideeffects.embl.de/se/C0575081/','Gait disturbance','Perampanel','http://sideeffects.embl.de/drugs/9924495/'),('http://sideeffects.embl.de/se/C0575090/','Balance disorder','Perampanel','http://sideeffects.embl.de/drugs/9924495/'),('http://sideeffects.embl.de/se/C0576093/','Genu valgum','Cysteamine','http://sideeffects.embl.de/drugs/6058/'),('http://sideeffects.embl.de/se/C0580493/','Serum albumin decreased','Ertapenem','http://sideeffects.embl.de/drugs/150610/'),('http://sideeffects.embl.de/se/C0581164/','Digoxin level increased','Carvedilol','http://sideeffects.embl.de/drugs/2585/'),('http://sideeffects.embl.de/se/C0581912/','Sensation of heaviness','Isocarboxazid','http://sideeffects.embl.de/drugs/3759/'),('http://sideeffects.embl.de/se/C0585186/','Cutaneous hypersensitivity','Stiripentol','http://sideeffects.embl.de/drugs/39524/'),('http://sideeffects.embl.de/se/C0595877/','Blood glucose increased','Ivacaftor','http://sideeffects.embl.de/drugs/16220172/'),('http://sideeffects.embl.de/se/C0595879/','Sodium high','Ponatinib','http://sideeffects.embl.de/drugs/24826799/'),('http://sideeffects.embl.de/se/C0595883/','Blood glucose decreased','Vildagliptin','http://sideeffects.embl.de/drugs/5251896/'),('http://sideeffects.embl.de/se/C0595885/','Serum potassium decreased','Ertapenem','http://sideeffects.embl.de/drugs/150610/'),('http://sideeffects.embl.de/se/C0595916/','Nephropathy toxic','Adefovir dipivoxil','http://sideeffects.embl.de/drugs/60871/'),('http://sideeffects.embl.de/se/C0595930/','Blood cholesterol increased','Furosemide','http://sideeffects.embl.de/drugs/3440/'),('http://sideeffects.embl.de/se/C0596240/','Cancer pain','Fentanyl','http://sideeffects.embl.de/drugs/3345/'),('http://sideeffects.embl.de/se/C0599918/','Nephrotoxicity','Etoricoxib','http://sideeffects.embl.de/drugs/123619/'),('http://sideeffects.embl.de/se/C0600142/','Hot flush','Nafarelin','http://sideeffects.embl.de/drugs/25077405/'),('http://sideeffects.embl.de/se/C0600228/','Cardio-respiratory arrest','Pralatrexate','http://sideeffects.embl.de/drugs/148121/'),('http://sideeffects.embl.de/se/C0677500/','Stinging','Halobetasol','http://sideeffects.embl.de/drugs/5311167/'),('http://sideeffects.embl.de/se/C0684275/','Haemophilia','Tranexamic acid','http://sideeffects.embl.de/drugs/5526/'),('http://sideeffects.embl.de/se/C0686347/','Tardive dyskinesia','Droperidol','http://sideeffects.embl.de/drugs/3168/'),('http://sideeffects.embl.de/se/C0687133/','Drug interaction','OCRH','http://sideeffects.embl.de/drugs/16132344/'),('http://sideeffects.embl.de/se/C0687713/','Gastrointestinal pain','Pazopanib','http://sideeffects.embl.de/drugs/10113978/'),('http://sideeffects.embl.de/se/C0699744/','Ear infection','Pimecrolimus','http://sideeffects.embl.de/drugs/3055172/'),('http://sideeffects.embl.de/se/C0699828/','Serotonin syndrome','Lu AA21004','http://sideeffects.embl.de/drugs/9966051/'),('http://sideeffects.embl.de/se/C0700075/','Motor restlessness','Molindone','http://sideeffects.embl.de/drugs/23897/'),('http://sideeffects.embl.de/se/C0700184/','Throat irritation','Regadenoson','http://sideeffects.embl.de/drugs/219024/'),('http://sideeffects.embl.de/se/C0700198/','Aspiration','Betaine','http://sideeffects.embl.de/drugs/247/'),('http://sideeffects.embl.de/se/C0700200/','Presyncope','Indomethacin','http://sideeffects.embl.de/drugs/3715/'),('http://sideeffects.embl.de/se/C0700225/','Serum creatinine increased','Empagliflozin','http://sideeffects.embl.de/drugs/11949646/'),('http://sideeffects.embl.de/se/C0700292/','Hypoxemia','Cisatracurium','http://sideeffects.embl.de/drugs/47320/'),('http://sideeffects.embl.de/se/C0700345/','Vulvovaginal candidiasis','Empagliflozin','http://sideeffects.embl.de/drugs/11949646/'),('http://sideeffects.embl.de/se/C0700361/','Emotional distress','Oxprenolol','http://sideeffects.embl.de/drugs/4631/'),('http://sideeffects.embl.de/se/C0700363/','Rhythm idioventricular','Isoflurane','http://sideeffects.embl.de/drugs/3763/'),('http://sideeffects.embl.de/se/C0700502/','Primary hypothyroidism','Lenalidomide','http://sideeffects.embl.de/drugs/216326/'),('http://sideeffects.embl.de/se/C0700590/','Sweating increased','ACTH(1-39','http://sideeffects.embl.de/drugs/16132265/'),('http://sideeffects.embl.de/se/C0702166/','Acne','Vandetanib','http://sideeffects.embl.de/drugs/3081361/'),('http://sideeffects.embl.de/se/C0728899/','Intoxication','Magnesium','http://sideeffects.embl.de/drugs/888/'),('http://sideeffects.embl.de/se/C0729552/','Genital infection','Empagliflozin','http://sideeffects.embl.de/drugs/11949646/'),('http://sideeffects.embl.de/se/C0730362/','Maculopathy','Deferasirox','http://sideeffects.embl.de/drugs/5493381/'),('http://sideeffects.embl.de/se/C0740299/','Blood culture positive','Ganciclovir','http://sideeffects.embl.de/drugs/3454/'),('http://sideeffects.embl.de/se/C0740304/','COPD exacerbation','Oxandrolone','http://sideeffects.embl.de/drugs/5878/'),('http://sideeffects.embl.de/se/C0740330/','Genital infection fungal','Canagliflozin','http://sideeffects.embl.de/drugs/24812758/'),('http://sideeffects.embl.de/se/C0740380/','Varicella zoster','Gamma-aminobutyric acid','http://sideeffects.embl.de/drugs/119/'),('http://sideeffects.embl.de/se/C0740394/','Hyperuricaemia','Azilsartan medoxomil','http://sideeffects.embl.de/drugs/11238823/'),('http://sideeffects.embl.de/se/C0740409/','Psychotic behaviour','Febuxostat','http://sideeffects.embl.de/drugs/134018/'),('http://sideeffects.embl.de/se/C0740481/','Hypotension asymptomatic','Esmolol','http://sideeffects.embl.de/drugs/59768/'),('http://sideeffects.embl.de/se/C0741494/','Bilirubin total increased','Ivacaftor','http://sideeffects.embl.de/drugs/16220172/'),('http://sideeffects.embl.de/se/C0741553/','Hemorrhage abnormal','Lu AA21004','http://sideeffects.embl.de/drugs/9966051/'),('http://sideeffects.embl.de/se/C0742006/','Catheter infection','8-MOP','http://sideeffects.embl.de/drugs/4114/'),('http://sideeffects.embl.de/se/C0742906/','C-reactive protein increased','Teduglutide','http://sideeffects.embl.de/drugs/16139605/'),('http://sideeffects.embl.de/se/C0743668/','Limb injury','Perampanel','http://sideeffects.embl.de/drugs/9924495/'),('http://sideeffects.embl.de/se/C0743680/','Eye oedema','Naphazoline','http://sideeffects.embl.de/drugs/4436/'),('http://sideeffects.embl.de/se/C0744727/','Haematocrit decreased','Empagliflozin','http://sideeffects.embl.de/drugs/11949646/'),('http://sideeffects.embl.de/se/C0746883/','Febrile neutropenia','Eltrombopag','http://sideeffects.embl.de/drugs/9846180/'),('http://sideeffects.embl.de/se/C0746961/','Oxygen saturation decreased','Clevidipine','http://sideeffects.embl.de/drugs/153994/'),('http://sideeffects.embl.de/se/C0749249/','Wide complex tachycardia','Propafenone','http://sideeffects.embl.de/drugs/4932/'),('http://sideeffects.embl.de/se/C0749923/','Urinary abnormalities','Clozapine','http://sideeffects.embl.de/drugs/2818/'),('http://sideeffects.embl.de/se/C0750016/','Generalized urticaria','Tropisetron','http://sideeffects.embl.de/drugs/5595/'),('http://sideeffects.embl.de/se/C0750194/','Non-sustained ventricular tachycardia','Milrinone','http://sideeffects.embl.de/drugs/4197/'),('http://sideeffects.embl.de/se/C0750197/','Sustained ventricular tachycardia','Milrinone','http://sideeffects.embl.de/drugs/4197/'),('http://sideeffects.embl.de/se/C0750394/','White blood cell count decreased','Ponatinib','http://sideeffects.embl.de/drugs/24826799/'),('http://sideeffects.embl.de/se/C0750426/','White blood cell count increased','Anidulafungin','http://sideeffects.embl.de/drugs/166548/'),('http://sideeffects.embl.de/se/C0750466/','Yeast infection','Metronidazole','http://sideeffects.embl.de/drugs/4173/'),('http://sideeffects.embl.de/se/C0750876/','Phlebitis superficial','Acetohydroxamic acid','http://sideeffects.embl.de/drugs/1990/'),('http://sideeffects.embl.de/se/C0751249/','Chronic insomnia','Ramelteon','http://sideeffects.embl.de/drugs/208902/'),('http://sideeffects.embl.de/se/C0751295/','Memory loss','Tranylcypromine','http://sideeffects.embl.de/drugs/5530/'),('http://sideeffects.embl.de/se/C0751466/','Phonophobia','Sumatriptan','http://sideeffects.embl.de/drugs/5358/'),('http://sideeffects.embl.de/se/C0751494/','Convulsive seizure','Methocarbamol','http://sideeffects.embl.de/drugs/4107/'),('http://sideeffects.embl.de/se/C0795692/','Hyperlactacidaemia','Belinostat','http://sideeffects.embl.de/drugs/6918638/'),('http://sideeffects.embl.de/se/C0812387/','Coldness','Oxprenolol','http://sideeffects.embl.de/drugs/4631/'),('http://sideeffects.embl.de/se/C0813230/','Serum triglycerides increased','Abarelix','http://sideeffects.embl.de/drugs/16131215/'),('http://sideeffects.embl.de/se/C0836924/','Thrombocytosis','Ertapenem','http://sideeffects.embl.de/drugs/150610/'),('http://sideeffects.embl.de/se/C0849796/','Ear congestion','Ivacaftor','http://sideeffects.embl.de/drugs/16220172/'),('http://sideeffects.embl.de/se/C0849916/','Generalised erythema','Cisatracurium','http://sideeffects.embl.de/drugs/47320/'),('http://sideeffects.embl.de/se/C0849918/','Eyelids pruritus','Bimatoprost','http://sideeffects.embl.de/drugs/127909/'),('http://sideeffects.embl.de/se/C0850569/','Allergic rash','Metyrapone','http://sideeffects.embl.de/drugs/4174/'),('http://sideeffects.embl.de/se/C0850758/','Pelvic pain female','Metrodin','http://sideeffects.embl.de/drugs/62819/'),('http://sideeffects.embl.de/se/C0851341/','Infestation NOS','Ivacaftor','http://sideeffects.embl.de/drugs/16220172/'),('http://sideeffects.embl.de/se/C0851353/','Blood and lymphatic system disorders','LY146032','http://sideeffects.embl.de/drugs/16129629/'),('http://sideeffects.embl.de/se/C0851354/','Ear and labyrinth disorders','Lu AA21004','http://sideeffects.embl.de/drugs/9966051/'),('http://sideeffects.embl.de/se/C0851444/','Allergic conditions','Ketoconazole','http://sideeffects.embl.de/drugs/3823/'),('http://sideeffects.embl.de/se/C0851578/','Sleep disorder','Deferasirox','http://sideeffects.embl.de/drugs/5493381/'),('http://sideeffects.embl.de/se/C0851886/','Pneumocystis carinii infection','Itraconazole','http://sideeffects.embl.de/drugs/3793/'),('http://sideeffects.embl.de/se/C0851976/','Dyspeptic signs and symptoms','Dronedarone','http://sideeffects.embl.de/drugs/208898/'),('http://sideeffects.embl.de/se/C0852192/','Asthenic conditions','MDV3100','http://sideeffects.embl.de/drugs/15951529/'),('http://sideeffects.embl.de/se/C0852361/','Skin haemorrhage','Dabigatran etexilate','http://sideeffects.embl.de/drugs/213023/'),('http://sideeffects.embl.de/se/C0852625/','Injection site erythema','K779','http://sideeffects.embl.de/drugs/71306834/'),('http://sideeffects.embl.de/se/C0852711/','Hand and foot syndrome secondary to sickle cell anaemia','Capecitabine','http://sideeffects.embl.de/drugs/60953/'),('http://sideeffects.embl.de/se/C0852792/','Blood cortisol decreased','Ramelteon','http://sideeffects.embl.de/drugs/208902/'),('http://sideeffects.embl.de/se/C0852909/','Blood bicarbonate decreased','Entecavir','http://sideeffects.embl.de/drugs/153941/'),('http://sideeffects.embl.de/se/C0852911/','Blood alkaline phosphatase increased','FK463','http://sideeffects.embl.de/drugs/477468/'),('http://sideeffects.embl.de/se/C0852913/','Blood amylase increased','Darunavir','http://sideeffects.embl.de/drugs/213039/'),('http://sideeffects.embl.de/se/C0852928/','Insomnia exacerbated','Ramelteon','http://sideeffects.embl.de/drugs/208902/'),('http://sideeffects.embl.de/se/C0853034/','Blood creatine phosphokinase increased','Azilsartan medoxomil','http://sideeffects.embl.de/drugs/11238823/'),('http://sideeffects.embl.de/se/C0853062/','Vascular resistance systemic decreased','Dopamine','http://sideeffects.embl.de/drugs/681/'),('http://sideeffects.embl.de/se/C0853087/','Nail abnormality NOS','Vandetanib','http://sideeffects.embl.de/drugs/3081361/'),('http://sideeffects.embl.de/se/C0853141/','Therapeutic response unexpected','Lasofoxifene','http://sideeffects.embl.de/drugs/216416/'),('http://sideeffects.embl.de/se/C0853225/','International normalised ratio increased','Regorafenib','http://sideeffects.embl.de/drugs/11167602/'),('http://sideeffects.embl.de/se/C0853326/','Dyspnoea exacerbated','Sildenafil','http://sideeffects.embl.de/drugs/5212/'),('http://sideeffects.embl.de/se/C0853336/','Corneal infiltrates','Bromfenac','http://sideeffects.embl.de/drugs/60726/'),('http://sideeffects.embl.de/se/C0853692/','Blood triglycerides increased','Linagliptin','http://sideeffects.embl.de/drugs/10096344/'),('http://sideeffects.embl.de/se/C0853697/','Neutrophil count decreased','Ertapenem','http://sideeffects.embl.de/drugs/150610/'),('http://sideeffects.embl.de/se/C0853700/','Application site erythema','PEP005','http://sideeffects.embl.de/drugs/6918670/'),('http://sideeffects.embl.de/se/C0853714/','Application site pruritus','PEP005','http://sideeffects.embl.de/drugs/6918670/'),('http://sideeffects.embl.de/se/C0853761/','Blood potassium decreased','4-PBA','http://sideeffects.embl.de/drugs/4775/'),('http://sideeffects.embl.de/se/C0853813/','Local reaction','Phencyclidine','http://sideeffects.embl.de/drugs/6468/'),('http://sideeffects.embl.de/se/C0853959/','Device breakage','Levonorgestrel','http://sideeffects.embl.de/drugs/4542/'),('http://sideeffects.embl.de/se/C0853986/','Lymphocyte count decreased','Everolimus','http://sideeffects.embl.de/drugs/6442177/'),('http://sideeffects.embl.de/se/C0854069/','Tumour pain','Pazopanib','http://sideeffects.embl.de/drugs/10113978/'),('http://sideeffects.embl.de/se/C0854113/','Mucosal dryness','Retinoic acid','http://sideeffects.embl.de/drugs/5538/'),('http://sideeffects.embl.de/se/C0854114/','Corneal epithelium defect','Bromfenac','http://sideeffects.embl.de/drugs/60726/'),('http://sideeffects.embl.de/se/C0854165/','Conjunctivitis papillary','Gatifloxacin','http://sideeffects.embl.de/drugs/5379/'),('http://sideeffects.embl.de/se/C0854359/','Insulin autoimmune syndrome','Methimazole','http://sideeffects.embl.de/drugs/1349907/'),('http://sideeffects.embl.de/se/C0854382/','Libido disorder','Imipramine','http://sideeffects.embl.de/drugs/3696/'),('http://sideeffects.embl.de/se/C0854438/','Blepharal pigmentation','Bimatoprost','http://sideeffects.embl.de/drugs/127909/'),('http://sideeffects.embl.de/se/C0854467/','Myelosuppression','6-thioguanine','http://sideeffects.embl.de/drugs/2723601/'),('http://sideeffects.embl.de/se/C0854717/','Corneal epithelium disorder','Bromfenac','http://sideeffects.embl.de/drugs/60726/'),('http://sideeffects.embl.de/se/C0855246/','Abnormal sleep-related event','Clonidine','http://sideeffects.embl.de/drugs/2803/'),('http://sideeffects.embl.de/se/C0855329/','Electrocardiogram change','Fenoprofen','http://sideeffects.embl.de/drugs/3342/'),('http://sideeffects.embl.de/se/C0855333/','Electrocardiogram QT corrected interval prolonged','Belinostat','http://sideeffects.embl.de/drugs/6918638/'),('http://sideeffects.embl.de/se/C0855619/','Alanine aminotransferase abnormal','Apixaban','http://sideeffects.embl.de/drugs/10182969/'),('http://sideeffects.embl.de/se/C0855775/','Pulmonary function test decreased','Insulin','http://sideeffects.embl.de/drugs/16129672/'),('http://sideeffects.embl.de/se/C0855931/','Cardioactive drug level above therapeutic','Propafenone','http://sideeffects.embl.de/drugs/4932/'),('http://sideeffects.embl.de/se/C0856054/','Mental status changes','Vincristine','http://sideeffects.embl.de/drugs/5978/'),('http://sideeffects.embl.de/se/C0856120/','Multiple sclerosis relapse','4-AP','http://sideeffects.embl.de/drugs/1727/'),('http://sideeffects.embl.de/se/C0856882/','Potassium increased','Pazopanib','http://sideeffects.embl.de/drugs/10113978/'),('http://sideeffects.embl.de/se/C0857027/','Feeling sick','Gefitinib','http://sideeffects.embl.de/drugs/123631/'),('http://sideeffects.embl.de/se/C0857073/','Cold hands & feet','Metoprolol','http://sideeffects.embl.de/drugs/4171/'),('http://sideeffects.embl.de/se/C0857093/','Elevated liver enzyme levels','Proguanil','http://sideeffects.embl.de/drugs/4923/'),('http://sideeffects.embl.de/se/C0857121/','Hypertensive','Doxazosin','http://sideeffects.embl.de/drugs/3157/'),('http://sideeffects.embl.de/se/C0857122/','Hyponatraemic','Tolvaptan','http://sideeffects.embl.de/drugs/216237/'),('http://sideeffects.embl.de/se/C0857144/','Metastatic pain','Triptorelin','http://sideeffects.embl.de/drugs/25074470/'),('http://sideeffects.embl.de/se/C0857177/','Arthritic pains','Bumetanide','http://sideeffects.embl.de/drugs/2471/'),('http://sideeffects.embl.de/se/C0857257/','Bloated feeling','Propantheline','http://sideeffects.embl.de/drugs/4934/'),('http://sideeffects.embl.de/se/C0857305/','Thrombocytopenic purpura','Glimepiride','http://sideeffects.embl.de/drugs/3476/'),('http://sideeffects.embl.de/se/C0857332/','Clonic movements','Ketamine','http://sideeffects.embl.de/drugs/3821/'),('http://sideeffects.embl.de/se/C0857353/','Hypotensive','Phentolamine','http://sideeffects.embl.de/drugs/5775/'),('http://sideeffects.embl.de/se/C0857370/','Generalized flushing','Cisatracurium','http://sideeffects.embl.de/drugs/47320/'),('http://sideeffects.embl.de/se/C0857483/','Worsening of diabetes','Chlorthalidone','http://sideeffects.embl.de/drugs/2732/'),('http://sideeffects.embl.de/se/C0857496/','Thromboembolic event','Tranexamic acid','http://sideeffects.embl.de/drugs/5526/'),('http://sideeffects.embl.de/se/C0857807/','Accidental ingestion','Naphazoline','http://sideeffects.embl.de/drugs/4436/'),('http://sideeffects.embl.de/se/C0857980/','Serum prolactin increased','Domperidone','http://sideeffects.embl.de/drugs/3151/'),('http://sideeffects.embl.de/se/C0858259/','Nasal discomfort','Fluticasone furoate','http://sideeffects.embl.de/drugs/9854489/'),('http://sideeffects.embl.de/se/C0858535/','Thrombocytopenia toxic','Doripenem','http://sideeffects.embl.de/drugs/73303/'),('http://sideeffects.embl.de/se/C0858600/','Taste sweet','Azelastine','http://sideeffects.embl.de/drugs/2267/'),('http://sideeffects.embl.de/se/C0858635/','Pharyngolaryngeal pain','LY146032','http://sideeffects.embl.de/drugs/16129629/'),('http://sideeffects.embl.de/se/C0858667/','Urinary protein increased','Norfloxacin','http://sideeffects.embl.de/drugs/4539/'),('http://sideeffects.embl.de/se/C0858678/','Alopecia reversible','Albendazole','http://sideeffects.embl.de/drugs/2082/'),('http://sideeffects.embl.de/se/C0858765/','Vascular pain','Clofazimine','http://sideeffects.embl.de/drugs/2794/'),('http://sideeffects.embl.de/se/C0858794/','Application site warmth','PEP005','http://sideeffects.embl.de/drugs/6918670/'),('http://sideeffects.embl.de/se/C0858814/','Hepatitis symptom','Isoniazid','http://sideeffects.embl.de/drugs/3767/'),('http://sideeffects.embl.de/se/C0858833/','Endometrial hypertrophy','Lasofoxifene','http://sideeffects.embl.de/drugs/216416/'),('http://sideeffects.embl.de/se/C0858854/','Unrest','Dimercaprol','http://sideeffects.embl.de/drugs/3080/'),('http://sideeffects.embl.de/se/C0858867/','Reticulocytopenia','Hydroxyurea','http://sideeffects.embl.de/drugs/3657/'),('http://sideeffects.embl.de/se/C0858924/','General discomfort','Papaverine','http://sideeffects.embl.de/drugs/4680/'),('http://sideeffects.embl.de/se/C0860207/','Drug-induced liver injury','Histrelin','http://sideeffects.embl.de/drugs/25077993/'),('http://sideeffects.embl.de/se/C0860239/','Catheter related infection','Valganciclovir','http://sideeffects.embl.de/drugs/64147/'),('http://sideeffects.embl.de/se/C0860433/','Irreversible renal failure','Triamterene','http://sideeffects.embl.de/drugs/5546/'),('http://sideeffects.embl.de/se/C0860499/','Conjunctival follicles','Brimonidine','http://sideeffects.embl.de/drugs/2435/'),('http://sideeffects.embl.de/se/C0860645/','Bizarre dreams','Betaxolol','http://sideeffects.embl.de/drugs/2369/'),('http://sideeffects.embl.de/se/C0860801/','Glucose low','Ofloxacin','http://sideeffects.embl.de/drugs/4583/'),('http://sideeffects.embl.de/se/C0860803/','Glucose increased','Ponatinib','http://sideeffects.embl.de/drugs/24826799/'),('http://sideeffects.embl.de/se/C0860864/','Albumin low','Ponatinib','http://sideeffects.embl.de/drugs/24826799/'),('http://sideeffects.embl.de/se/C0860866/','Potassium low','Everolimus','http://sideeffects.embl.de/drugs/6442177/'),('http://sideeffects.embl.de/se/C0860871/','Sodium decreased','Pazopanib','http://sideeffects.embl.de/drugs/10113978/'),('http://sideeffects.embl.de/se/C0860901/','Protein total decreased','Gemifloxacin','http://sideeffects.embl.de/drugs/72938/'),('http://sideeffects.embl.de/se/C0860967/','Calcium low','Ponatinib','http://sideeffects.embl.de/drugs/24826799/'),('http://sideeffects.embl.de/se/C0860987/','Phosphate low','Everolimus','http://sideeffects.embl.de/drugs/6442177/'),('http://sideeffects.embl.de/se/C0861148/','Proarrhythmia','Sotalol','http://sideeffects.embl.de/drugs/5253/'),('http://sideeffects.embl.de/se/C0861157/','Decreased night vision','Carteolol','http://sideeffects.embl.de/drugs/2583/'),('http://sideeffects.embl.de/se/C0863083/','Injection site tenderness','Gamma-aminobutyric acid','http://sideeffects.embl.de/drugs/119/'),('http://sideeffects.embl.de/se/C0863084/','Skin discomfort','Adapalene','http://sideeffects.embl.de/drugs/60164/'),('http://sideeffects.embl.de/se/C0863090/','Allergic skin reaction','Copper','http://sideeffects.embl.de/drugs/23978/'),('http://sideeffects.embl.de/se/C0863093/','Cold symptoms','Estazolam','http://sideeffects.embl.de/drugs/3261/'),('http://sideeffects.embl.de/se/C0863113/','Hypotension symptomatic','Esmolol','http://sideeffects.embl.de/drugs/59768/'),('http://sideeffects.embl.de/se/C0863147/','Glucose urine increased','Bumetanide','http://sideeffects.embl.de/drugs/2471/'),('http://sideeffects.embl.de/se/C0870082/','Hyperkeratosis','Vemurafenib','http://sideeffects.embl.de/drugs/42611257/'),('http://sideeffects.embl.de/se/C0876973/','Lung infection','MDV3100','http://sideeffects.embl.de/drugs/15951529/'),('http://sideeffects.embl.de/se/C0876994/','Cardiotoxicity','Ifosfamide','http://sideeffects.embl.de/drugs/3690/'),('http://sideeffects.embl.de/se/C0877055/','Acute generalised exanthematous pustulosis','Ketoconazole','http://sideeffects.embl.de/drugs/3823/'),('http://sideeffects.embl.de/se/C0877056/','Hypoglycaemic seizure','Insulin','http://sideeffects.embl.de/drugs/16129672/'),('http://sideeffects.embl.de/se/C0877094/','Application site haemorrhage','Imiquimod','http://sideeffects.embl.de/drugs/57469/'),('http://sideeffects.embl.de/se/C0877096/','Application site paraesthesia','PEP005','http://sideeffects.embl.de/drugs/6918670/'),('http://sideeffects.embl.de/se/C0877097/','Application site vesicles','PEP005','http://sideeffects.embl.de/drugs/6918670/'),('http://sideeffects.embl.de/se/C0877098/','Application site dryness','Tazarotene','http://sideeffects.embl.de/drugs/5381/'),('http://sideeffects.embl.de/se/C0877127/','Application site papules','Imiquimod','http://sideeffects.embl.de/drugs/57469/'),('http://sideeffects.embl.de/se/C0877128/','Application site pustules','PEP005','http://sideeffects.embl.de/drugs/6918670/'),('http://sideeffects.embl.de/se/C0877303/','Post procedural pain','Phentolamine','http://sideeffects.embl.de/drugs/5775/'),('http://sideeffects.embl.de/se/C0877322/','Muscle tightness','Pimozide','http://sideeffects.embl.de/drugs/16362/'),('http://sideeffects.embl.de/se/C0877338/','Breast discomfort','Clomiphene citrate','http://sideeffects.embl.de/drugs/2800/'),('http://sideeffects.embl.de/se/C0877359/','Raised liver function tests','Sulfasalazine','http://sideeffects.embl.de/drugs/5353980/'),('http://sideeffects.embl.de/se/C0877365/','Infusion site erythema','Conivaptan','http://sideeffects.embl.de/drugs/151171/'),('http://sideeffects.embl.de/se/C0877517/','Blood phosphorus decreased','Nilotinib','http://sideeffects.embl.de/drugs/644241/'),('http://sideeffects.embl.de/se/C0877617/','Intestinal cramps','Neostigmine','http://sideeffects.embl.de/drugs/4456/'),('http://sideeffects.embl.de/se/C0877661/','Application site burn','PEP005','http://sideeffects.embl.de/drugs/6918670/'),('http://sideeffects.embl.de/se/C0877717/','Burning mouth','Benzocaine','http://sideeffects.embl.de/drugs/2337/'),('http://sideeffects.embl.de/se/C0877854/','Cerebral arteriosclerosis','Nalidixic acid','http://sideeffects.embl.de/drugs/4421/'),('http://sideeffects.embl.de/se/C0878544/','Cardiomyopathy','Fluconazole','http://sideeffects.embl.de/drugs/3365/'),('http://sideeffects.embl.de/se/C0917798/','Cerebral ischaemia','Carteolol','http://sideeffects.embl.de/drugs/2583/'),('http://sideeffects.embl.de/se/C0917799/','Hypersomnia','Perampanel','http://sideeffects.embl.de/drugs/9924495/'),('http://sideeffects.embl.de/se/C0917801/','Insomnia','K779','http://sideeffects.embl.de/drugs/71306834/'),('http://sideeffects.embl.de/se/C0919578/','Idiosyncratic drug reaction','Troglitazone','http://sideeffects.embl.de/drugs/5591/'),('http://sideeffects.embl.de/se/C0919591/','Urogenital haemorrhage','Dabigatran etexilate','http://sideeffects.embl.de/drugs/213023/'),('http://sideeffects.embl.de/se/C0919659/','Oropharyngeal candidiasis','Beclomethasone dipropionate','http://sideeffects.embl.de/drugs/2307/'),('http://sideeffects.embl.de/se/C0919671/','Subileus','Sevelamer','http://sideeffects.embl.de/drugs/3085017/'),('http://sideeffects.embl.de/se/C0919715/','Lupus-like syndrome','Methimazole','http://sideeffects.embl.de/drugs/1349907/'),('http://sideeffects.embl.de/se/C0919874/','Post procedural haemorrhage','Apixaban','http://sideeffects.embl.de/drugs/10182969/'),('http://sideeffects.embl.de/se/C0919882/','Incision site haemorrhage','Dabigatran etexilate','http://sideeffects.embl.de/drugs/213023/'),('http://sideeffects.embl.de/se/C0919909/','Tonic clonic movements','Dapsone','http://sideeffects.embl.de/drugs/2955/'),('http://sideeffects.embl.de/se/C0919924/','Pulmonary toxicity','Procarbazine','http://sideeffects.embl.de/drugs/4915/'),('http://sideeffects.embl.de/se/C0919980/','VIIth nerve paralysis','Vemurafenib','http://sideeffects.embl.de/drugs/42611257/'),('http://sideeffects.embl.de/se/C0920102/','Phosphorus low','Ponatinib','http://sideeffects.embl.de/drugs/24826799/'),('http://sideeffects.embl.de/se/C0920166/','Catheter site haemorrhage','Apixaban','http://sideeffects.embl.de/drugs/10182969/'),('http://sideeffects.embl.de/se/C0920171/','Foreign body sensation in eyes','Emedastine','http://sideeffects.embl.de/drugs/3219/'),('http://sideeffects.embl.de/se/C0936215/','Vitamin B6 deficiency','Pyridoxine','http://sideeffects.embl.de/drugs/1054/'),('http://sideeffects.embl.de/se/C0936254/','Polyradiculoneuritis','Perhexiline','http://sideeffects.embl.de/drugs/4746/'),('http://sideeffects.embl.de/se/C0947897/','Potassium imbalance','Bendrofluazide','http://sideeffects.embl.de/drugs/2315/'),('http://sideeffects.embl.de/se/C0947912/','Myasthenia','Tizanidine','http://sideeffects.embl.de/drugs/5487/'),('http://sideeffects.embl.de/se/C0947999/','Blood urine present','Tolvaptan','http://sideeffects.embl.de/drugs/216237/'),('http://sideeffects.embl.de/se/C0948070/','Rhinalgia','Fluticasone furoate','http://sideeffects.embl.de/drugs/9854489/'),('http://sideeffects.embl.de/se/C0948268/','Haemodynamic instability','Aminophylline','http://sideeffects.embl.de/drugs/9433/'),('http://sideeffects.embl.de/se/C0948284/','Corneal decompensation','Acetylcholine','http://sideeffects.embl.de/drugs/187/'),('http://sideeffects.embl.de/se/C0948299/','Application site discharge','PEP005','http://sideeffects.embl.de/drugs/6918670/'),('http://sideeffects.embl.de/se/C0948300/','Application site scab','PEP005','http://sideeffects.embl.de/drugs/6918670/'),('http://sideeffects.embl.de/se/C0948342/','Citrate toxicity','Citric acid','http://sideeffects.embl.de/drugs/311/'),('http://sideeffects.embl.de/se/C0948387/','Secondary adrenal insufficiency','OCRH','http://sideeffects.embl.de/drugs/16132344/'),('http://sideeffects.embl.de/se/C0948441/','Venoocclusive disease','6-thioguanine','http://sideeffects.embl.de/drugs/2723601/'),('http://sideeffects.embl.de/se/C0948525/','Musculoskeletal stiffness','MDV3100','http://sideeffects.embl.de/drugs/15951529/'),('http://sideeffects.embl.de/se/C0948594/','Musculoskeletal discomfort','Regadenoson','http://sideeffects.embl.de/drugs/219024/'),('http://sideeffects.embl.de/se/C0948595/','Ocular discomfort','Bromfenac','http://sideeffects.embl.de/drugs/60726/'),('http://sideeffects.embl.de/se/C0948695/','White blood cell count low','Zileuton','http://sideeffects.embl.de/drugs/60490/'),('http://sideeffects.embl.de/se/C0948715/','Infusion related reaction','FK463','http://sideeffects.embl.de/drugs/477468/'),('http://sideeffects.embl.de/se/C0948807/','Hepatic impairment','Citric acid','http://sideeffects.embl.de/drugs/311/'),('http://sideeffects.embl.de/se/C0948824/','Haemorrhagic anaemia','Apixaban','http://sideeffects.embl.de/drugs/10182969/'),('http://sideeffects.embl.de/se/C0948873/','Flu symptoms','Tizanidine','http://sideeffects.embl.de/drugs/5487/'),('http://sideeffects.embl.de/se/C0973461/','Dysphasia','Retigabine','http://sideeffects.embl.de/drugs/121892/'),('http://sideeffects.embl.de/se/C1096001/','Application site swelling','PEP005','http://sideeffects.embl.de/drugs/6918670/'),('http://sideeffects.embl.de/se/C1096035/','Infusion site pain','Belinostat','http://sideeffects.embl.de/drugs/6918638/'),('http://sideeffects.embl.de/se/C1096049/','Infusion site swelling','Conivaptan','http://sideeffects.embl.de/drugs/151171/'),('http://sideeffects.embl.de/se/C1096106/','Wound complication','Ertapenem','http://sideeffects.embl.de/drugs/150610/'),('http://sideeffects.embl.de/se/C1096213/','Cannula site reaction','Conivaptan','http://sideeffects.embl.de/drugs/151171/'),('http://sideeffects.embl.de/se/C1096250/','Gastrointestinal discomfort','Regadenoson','http://sideeffects.embl.de/drugs/219024/'),('http://sideeffects.embl.de/se/C1096274/','Corneal thinning','Bromfenac','http://sideeffects.embl.de/drugs/60726/'),('http://sideeffects.embl.de/se/C1096278/','Anterior chamber inflammation','Bromfenac','http://sideeffects.embl.de/drugs/60726/'),('http://sideeffects.embl.de/se/C1096343/','Infusion site reaction','LY146032','http://sideeffects.embl.de/drugs/16129629/'),('http://sideeffects.embl.de/se/C1096403/','Left ventricular ejection fraction decreased','Lapatinib','http://sideeffects.embl.de/drugs/208908/'),('http://sideeffects.embl.de/se/C1096458/','Vascular occlusion','Dacarbazine','http://sideeffects.embl.de/drugs/5281007/'),('http://sideeffects.embl.de/se/C1096460/','Infusion site phlebitis','Conivaptan','http://sideeffects.embl.de/drugs/151171/'),('http://sideeffects.embl.de/se/C1096543/','Superficial punctate keratopathy','Trifluorothymidine','http://sideeffects.embl.de/drugs/6256/'),('http://sideeffects.embl.de/se/C1096717/','Pain during injection','Midazolam','http://sideeffects.embl.de/drugs/4192/'),('http://sideeffects.embl.de/se/C1112209/','Abdominal infection','Cefepime','http://sideeffects.embl.de/drugs/2622/'),('http://sideeffects.embl.de/se/C1112214/','Vulvovaginal pruritus','Canagliflozin','http://sideeffects.embl.de/drugs/24812758/'),('http://sideeffects.embl.de/se/C1112256/','Peripheral sensorimotor neuropathy','Disulfiram','http://sideeffects.embl.de/drugs/3117/'),('http://sideeffects.embl.de/se/C1112349/','Spinal cord paralysis','Monoethanolamine','http://sideeffects.embl.de/drugs/700/'),('http://sideeffects.embl.de/se/C1112366/','Eyelid irritation','Scopolamine','http://sideeffects.embl.de/drugs/5184/'),('http://sideeffects.embl.de/se/C1112469/','Cytomegalovirus syndrome','Valganciclovir','http://sideeffects.embl.de/drugs/64147/'),('http://sideeffects.embl.de/se/C1112489/','Corneal irritation','Tropicamide','http://sideeffects.embl.de/drugs/5593/'),('http://sideeffects.embl.de/se/C1112525/','Gastrointestinal ulcer haemorrhage','Potassium','http://sideeffects.embl.de/drugs/813/'),('http://sideeffects.embl.de/se/C1112677/','Protein allergy','Salmeterol','http://sideeffects.embl.de/drugs/5152/'),('http://sideeffects.embl.de/se/C1112722/','Mental impairment disorders','MDV3100','http://sideeffects.embl.de/drugs/15951529/'),('http://sideeffects.embl.de/se/C1140680/','Ovarian cancer','Hexamethylmelamine','http://sideeffects.embl.de/drugs/2123/'),('http://sideeffects.embl.de/se/C1141861/','Procedural complication','Amphotericin B','http://sideeffects.embl.de/drugs/1972/'),('http://sideeffects.embl.de/se/C1141938/','Ocular icterus','Atazanavir','http://sideeffects.embl.de/drugs/148192/'),('http://sideeffects.embl.de/se/C1142111/','Eyelash discolouration','Bimatoprost','http://sideeffects.embl.de/drugs/127909/'),('http://sideeffects.embl.de/se/C1142151/','Scleromalacia','Bromfenac','http://sideeffects.embl.de/drugs/60726/'),('http://sideeffects.embl.de/se/C1142172/','Incision site complication','Tacrolimus','http://sideeffects.embl.de/drugs/5372/'),('http://sideeffects.embl.de/se/C1142248/','Pseudomononucleosis','Sulfasalazine','http://sideeffects.embl.de/drugs/5353980/'),('http://sideeffects.embl.de/se/C1142305/','Melanonychia','Hydroxyurea','http://sideeffects.embl.de/drugs/3657/'),('http://sideeffects.embl.de/se/C1142335/','Bilirubin abnormal','Alosetron','http://sideeffects.embl.de/drugs/2099/'),('http://sideeffects.embl.de/se/C1142397/','Myoglobinaemia','Succinylcholine','http://sideeffects.embl.de/drugs/5314/'),('http://sideeffects.embl.de/se/C1142499/','Gastrointestinal toxicity','Belinostat','http://sideeffects.embl.de/drugs/6918638/'),('http://sideeffects.embl.de/se/C1145628/','Unspecified disorder of autonomic nervous system','Citalopram','http://sideeffects.embl.de/drugs/2771/'),('http://sideeffects.embl.de/se/C1145670/','Respiratory failure','Terlipressin','http://sideeffects.embl.de/drugs/72081/'),('http://sideeffects.embl.de/se/C1167791/','Skin toxicity','Imatinib','http://sideeffects.embl.de/drugs/5291/'),('http://sideeffects.embl.de/se/C1167870/','Graft dysfunction','Tacrolimus','http://sideeffects.embl.de/drugs/5372/'),('http://sideeffects.embl.de/se/C1167945/','Infusion site rash','Florbetapir','http://sideeffects.embl.de/drugs/24822371/'),('http://sideeffects.embl.de/se/C1257843/','Pseudomembranous colitis','Cefprozil','http://sideeffects.embl.de/drugs/2646/'),('http://sideeffects.embl.de/se/C1258215/','Ileus','Sevelamer','http://sideeffects.embl.de/drugs/3085017/'),('http://sideeffects.embl.de/se/C1260880/','Rhinorrhoea','Lu AA21004','http://sideeffects.embl.de/drugs/9966051/'),('http://sideeffects.embl.de/se/C1260922/','Respiration abnormal','Alosetron','http://sideeffects.embl.de/drugs/2099/'),('http://sideeffects.embl.de/se/C1262064/','Oculogyration','Loxapine','http://sideeffects.embl.de/drugs/3964/'),('http://sideeffects.embl.de/se/C1268766/','Change in blood pressure','Methylphenidate','http://sideeffects.embl.de/drugs/4158/'),('http://sideeffects.embl.de/se/C1274926/','Stinging skin','DFMO','http://sideeffects.embl.de/drugs/3009/'),('http://sideeffects.embl.de/se/C1276118/','Urticaria recurrent','Phencyclidine','http://sideeffects.embl.de/drugs/6468/'),('http://sideeffects.embl.de/se/C1287298/','Urine output','Sulindac','http://sideeffects.embl.de/drugs/5352/'),('http://sideeffects.embl.de/se/C1291077/','Abdominal bloating','Miglustat','http://sideeffects.embl.de/drugs/51634/'),('http://sideeffects.embl.de/se/C1291078/','Epigastric discomfort','Tinidazole','http://sideeffects.embl.de/drugs/5479/'),('http://sideeffects.embl.de/se/C1292769/','B-cell type acute leukaemia','Paclitaxel','http://sideeffects.embl.de/drugs/4666/'),('http://sideeffects.embl.de/se/C1302752/','Abrasion NOS','Adapalene','http://sideeffects.embl.de/drugs/60164/'),('http://sideeffects.embl.de/se/C1306341/','Mental disability','Alprazolam','http://sideeffects.embl.de/drugs/2118/'),('http://sideeffects.embl.de/se/C1320835/','Drug fever','Methimazole','http://sideeffects.embl.de/drugs/1349907/'),('http://sideeffects.embl.de/se/C1321587/','Respiratory depth increased','OCRH','http://sideeffects.embl.de/drugs/16132344/'),('http://sideeffects.embl.de/se/C1321898/','Blood in stool','Ketotifen','http://sideeffects.embl.de/drugs/3827/'),('http://sideeffects.embl.de/se/C1325847/','Sensitisation','Monobenzone','http://sideeffects.embl.de/drugs/7638/'),('http://sideeffects.embl.de/se/C1328411/','Post procedural haematoma','Apixaban','http://sideeffects.embl.de/drugs/10182969/'),('http://sideeffects.embl.de/se/C1328539/','Reflex tachycardia','Clevidipine','http://sideeffects.embl.de/drugs/153994/'),('http://sideeffects.embl.de/se/C1333984/','Hepatosplenic T-cell lymphoma','Azathioprine','http://sideeffects.embl.de/drugs/2265/'),('http://sideeffects.embl.de/se/C1383860/','Cardiac hypertrophy','ACTH(1-39','http://sideeffects.embl.de/drugs/16132265/'),('http://sideeffects.embl.de/se/C1384589/','Tinea cruris','Butenafine','http://sideeffects.embl.de/drugs/2484/'),('http://sideeffects.embl.de/se/C1384606/','Dyspareunia','Copper','http://sideeffects.embl.de/drugs/23978/'),('http://sideeffects.embl.de/se/C1384666/','Hearing impaired','Deferasirox','http://sideeffects.embl.de/drugs/5493381/'),('http://sideeffects.embl.de/se/C1442839/','Hypervitaminosis D','Vitamin D2','http://sideeffects.embl.de/drugs/3249/'),('http://sideeffects.embl.de/se/C1455782/','Vagotonia','Methacholine','http://sideeffects.embl.de/drugs/1993/'),('http://sideeffects.embl.de/se/C1456784/','Paranoia','Trihexyphenidyl','http://sideeffects.embl.de/drugs/5572/'),('http://sideeffects.embl.de/se/C1456822/','Claudication','Nebivolol','http://sideeffects.embl.de/drugs/71301/'),('http://sideeffects.embl.de/se/C1457883/','Aggressive reaction','Memantine','http://sideeffects.embl.de/drugs/4054/'),('http://sideeffects.embl.de/se/C1458140/','Bleeding tendency','Suprofen','http://sideeffects.embl.de/drugs/5359/'),('http://sideeffects.embl.de/se/C1504411/','Post procedural oedema','Indomethacin','http://sideeffects.embl.de/drugs/3715/'),('http://sideeffects.embl.de/se/C1504422/','Application site hypersensitivity','Ciclopirox','http://sideeffects.embl.de/drugs/2749/'),('http://sideeffects.embl.de/se/C1504494/','Tingling of extremity','Citric acid','http://sideeffects.embl.de/drugs/311/'),('http://sideeffects.embl.de/se/C1504578/','Implant breakage','Histrelin','http://sideeffects.embl.de/drugs/25077993/'),('http://sideeffects.embl.de/se/C1510410/','Parosmia','Telithromycin','http://sideeffects.embl.de/drugs/73658/'),('http://sideeffects.embl.de/se/C1510497/','Lenticular opacities','Molindone','http://sideeffects.embl.de/drugs/23897/'),('http://sideeffects.embl.de/se/C1519353/','Rash papular','Voriconazole','http://sideeffects.embl.de/drugs/71616/'),('http://sideeffects.embl.de/se/C1527311/','Brain oedema','Lorazepam','http://sideeffects.embl.de/drugs/3958/'),('http://sideeffects.embl.de/se/C1527330/','Pyridoxine deficiency','Isoniazid','http://sideeffects.embl.de/drugs/3767/'),('http://sideeffects.embl.de/se/C1527344/','Dysphonia','Regorafenib','http://sideeffects.embl.de/drugs/11167602/'),('http://sideeffects.embl.de/se/C1527358/','Phototoxicity','Dacarbazine','http://sideeffects.embl.de/drugs/5281007/'),('http://sideeffects.embl.de/se/C1527401/','Shock insulin','Streptozotocin','http://sideeffects.embl.de/drugs/5300/'),('http://sideeffects.embl.de/se/C1533591/','Deposit calcium','Vitamin D2','http://sideeffects.embl.de/drugs/3249/'),('http://sideeffects.embl.de/se/C1535939/','Pneumocystis jirovecii pneumonia','Ganciclovir','http://sideeffects.embl.de/drugs/3454/'),('http://sideeffects.embl.de/se/C1535975/','Pelvic discomfort','Metrodin','http://sideeffects.embl.de/drugs/62819/'),('http://sideeffects.embl.de/se/C1536146/','Eyelash darkening','Bimatoprost','http://sideeffects.embl.de/drugs/127909/'),('http://sideeffects.embl.de/se/C1536459/','Nettle rash','Mepyramine','http://sideeffects.embl.de/drugs/4992/'),('http://sideeffects.embl.de/se/C1565489/','Renal impairment','Tolvaptan','http://sideeffects.embl.de/drugs/216237/'),('http://sideeffects.embl.de/se/C1565662/','Acute renal insufficiency','D-telaprevir','http://sideeffects.embl.de/drugs/3010818/'),('http://sideeffects.embl.de/se/C1579838/','Sore mouth','Gefitinib','http://sideeffects.embl.de/drugs/123631/'),('http://sideeffects.embl.de/se/C1608945/','Exfoliative rash','Pazopanib','http://sideeffects.embl.de/drugs/10113978/'),('http://sideeffects.embl.de/se/C1610049/','Application site exfoliation','PEP005','http://sideeffects.embl.de/drugs/6918670/'),('http://sideeffects.embl.de/se/C1610080/','ANA increased','Celiprolol','http://sideeffects.embl.de/drugs/2663/'),('http://sideeffects.embl.de/se/C1619712/','Procedural pain','Alfentanil','http://sideeffects.embl.de/drugs/51263/'),('http://sideeffects.embl.de/se/C1619727/','Decompensated cirrhosis','Entecavir','http://sideeffects.embl.de/drugs/153941/'),('http://sideeffects.embl.de/se/C1696110/','Vessel puncture site haematoma','Apixaban','http://sideeffects.embl.de/drugs/10182969/'),('http://sideeffects.embl.de/se/C1696574/','Application site erosion','PEP005','http://sideeffects.embl.de/drugs/6918670/'),('http://sideeffects.embl.de/se/C1696708/','Prehypertension','Cabozantinib','http://sideeffects.embl.de/drugs/25102847/'),('http://sideeffects.embl.de/se/C1699324/','Pharyngeal mucositis','Imatinib','http://sideeffects.embl.de/drugs/5291/'),('http://sideeffects.embl.de/se/C1704381/','Glucose decreased','Ponatinib','http://sideeffects.embl.de/drugs/24826799/'),('http://sideeffects.embl.de/se/C1704437/','Respiratory distress syndrome','Voriconazole','http://sideeffects.embl.de/drugs/71616/'),('http://sideeffects.embl.de/se/C1720775/','Renal tubular necrosis','Guanidinium','http://sideeffects.embl.de/drugs/3520/'),('http://sideeffects.embl.de/se/C1735348/','Anal irritation','Sodium bicarbonate','http://sideeffects.embl.de/drugs/10340/'),('http://sideeffects.embl.de/se/C1735368/','Acute dystonia','Amisulpride','http://sideeffects.embl.de/drugs/2159/'),('http://sideeffects.embl.de/se/C1735630/','Acute cholestatic hepatitis','Roxithromycin','http://sideeffects.embl.de/drugs/5106/'),('http://sideeffects.embl.de/se/C1735864/','Administration site infection','Glucose solution','http://sideeffects.embl.de/drugs/24748/'),('http://sideeffects.embl.de/se/C1737224/','Post procedural swelling','Indomethacin','http://sideeffects.embl.de/drugs/3715/'),('http://sideeffects.embl.de/se/C1760428/','Suicidal behaviour','Methsuximide','http://sideeffects.embl.de/drugs/6476/'),('http://sideeffects.embl.de/se/C1761613/','Conjunctival hyperaemia','Besifloxacin','http://sideeffects.embl.de/drugs/10178705/'),('http://sideeffects.embl.de/se/C1852242/','AION','Vardenafil','http://sideeffects.embl.de/drugs/110634/'),('http://sideeffects.embl.de/se/C1861172/','Venous thromboembolism','Fenofibrate','http://sideeffects.embl.de/drugs/3339/'),('http://sideeffects.embl.de/se/C1956346/','Coronary artery disease','Amlodipine','http://sideeffects.embl.de/drugs/2162/'),('http://sideeffects.embl.de/se/C1963921/','Chemical phlebitis','Tris','http://sideeffects.embl.de/drugs/6503/'),('http://sideeffects.embl.de/se/C1963964/','Periungual erythema','Ciclopirox','http://sideeffects.embl.de/drugs/2749/'),('http://sideeffects.embl.de/se/C1971624/','Appetite absent','Gefitinib','http://sideeffects.embl.de/drugs/123631/'),('http://sideeffects.embl.de/se/C1994994/','Excessive thirst','EDTA','http://sideeffects.embl.de/drugs/6049/'),('http://sideeffects.embl.de/se/C2004435/','Intestinal ischaemia','Terlipressin','http://sideeffects.embl.de/drugs/72081/'),('http://sideeffects.embl.de/se/C2004489/','Regurgitation','Simvastatin','http://sideeffects.embl.de/drugs/54454/'),('http://sideeffects.embl.de/se/C2062908/','Gout acute','Ethacrynic acid','http://sideeffects.embl.de/drugs/3278/'),('http://sideeffects.embl.de/se/C2129214/','Loose stools','LY146032','http://sideeffects.embl.de/drugs/16129629/'),('http://sideeffects.embl.de/se/C2225524/','Breast enlargement','Nafarelin','http://sideeffects.embl.de/drugs/25077405/'),('http://sideeffects.embl.de/se/C2242711/','Arteritic anterior ischaemic optic neuropathy','Vardenafil','http://sideeffects.embl.de/drugs/110634/'),('http://sideeffects.embl.de/se/C2242737/','Anorectal discomfort','D-telaprevir','http://sideeffects.embl.de/drugs/3010818/'),('http://sideeffects.embl.de/se/C2242996/','Tingling sensation','EDTA','http://sideeffects.embl.de/drugs/6049/'),('http://sideeffects.embl.de/se/C2243080/','Intestinal necrosis','6-thioguanine','http://sideeffects.embl.de/drugs/2723601/'),('http://sideeffects.embl.de/se/C2363731/','Oropharyngeal pain','Ivacaftor','http://sideeffects.embl.de/drugs/16220172/'),('http://sideeffects.embl.de/se/C2364111/','Ageusia','Vismodegib','http://sideeffects.embl.de/drugs/24776445/'),('http://sideeffects.embl.de/se/C2584688/','Testicular swelling','Amoxapine','http://sideeffects.embl.de/drugs/2170/'),('http://sideeffects.embl.de/se/C2607914/','Rhinitis allergic','Mometasone','http://sideeffects.embl.de/drugs/123620/'),('http://sideeffects.embl.de/se/C2609264/','Color vision change','Voriconazole','http://sideeffects.embl.de/drugs/71616/'),('http://sideeffects.embl.de/se/C2609445/','Infusion site reactions','Ceftobiprole','http://sideeffects.embl.de/drugs/6918430/'),('http://sideeffects.embl.de/se/C2697368/','Gastrointestinal tract irritation','Benzonatate','http://sideeffects.embl.de/drugs/7699/'),('http://sideeffects.embl.de/se/C2712122/','Blood pressure normal','Doxazosin','http://sideeffects.embl.de/drugs/3157/'),('http://sideeffects.embl.de/se/C2712871/','Gout attack','Furosemide','http://sideeffects.embl.de/drugs/3440/'),('http://sideeffects.embl.de/se/C2721559/','Osmotic demyelination syndrome','Tolvaptan','http://sideeffects.embl.de/drugs/216237/'),('http://sideeffects.embl.de/se/C2721563/','Infectious pneumonitis','Abiraterone','http://sideeffects.embl.de/drugs/132971/'),('http://sideeffects.embl.de/se/C2721737/','Application site stinging','Retinoic acid','http://sideeffects.embl.de/drugs/5538/'),('http://sideeffects.embl.de/se/C2747813/','Bacterial colonisation','Silver nanoparticles','http://sideeffects.embl.de/drugs/23954/'),('http://sideeffects.embl.de/se/C2830004/','Somnolence','Perampanel','http://sideeffects.embl.de/drugs/9924495/'),('http://sideeffects.embl.de/se/C2930821/','Keratitis sicca','Trifluorothymidine','http://sideeffects.embl.de/drugs/6256/'),('http://sideeffects.embl.de/se/C2937350/','Abnormal ejaculation','Venlafaxine','http://sideeffects.embl.de/drugs/5656/'),('http://sideeffects.embl.de/se/C2937358/','Cerebral haemorrhage','Sorafenib','http://sideeffects.embl.de/drugs/216239/'),('http://sideeffects.embl.de/se/C2939094/','Skin sensitisation','Mepyramine','http://sideeffects.embl.de/drugs/4992/'),('http://sideeffects.embl.de/se/C2939147/','Feeling hot','Regadenoson','http://sideeffects.embl.de/drugs/219024/'),('http://sideeffects.embl.de/se/C2939186/','Mood alteration NOS','Capecitabine','http://sideeffects.embl.de/drugs/60953/'),('http://sideeffects.embl.de/se/C2939419/','Metastatic neoplasm','Procarbazine','http://sideeffects.embl.de/drugs/4915/'),('http://sideeffects.embl.de/se/C2939465/','Glucose-6-phosphate dehydrogenase deficiency','Phenylazo','http://sideeffects.embl.de/drugs/4756/'),('http://sideeffects.embl.de/se/C2955673/','Urate nephropathy','D-telaprevir','http://sideeffects.embl.de/drugs/3010818/'),('http://sideeffects.embl.de/se/C2973529/','Leukocytoclastic vasculitis','Dronedarone','http://sideeffects.embl.de/drugs/208898/'),('http://sideeffects.embl.de/se/C2979982/','Vaginal haemorrhage','Nafarelin','http://sideeffects.embl.de/drugs/25077405/'),('http://sideeffects.embl.de/se/C2981158/','Loss of libido','Nafarelin','http://sideeffects.embl.de/drugs/25077405/'),('http://sideeffects.embl.de/se/C3160766/','Supine hypotension','Bretylium','http://sideeffects.embl.de/drugs/2431/'),('http://sideeffects.embl.de/se/C3160769/','Major bleed','Bivalirudin','http://sideeffects.embl.de/drugs/16129704/'),('http://sideeffects.embl.de/se/C3160947/','CNS toxicity','Ifosfamide','http://sideeffects.embl.de/drugs/3690/'),('http://sideeffects.embl.de/se/C3203358/','Hypoventilation','Tris','http://sideeffects.embl.de/drugs/6503/'),('http://sideeffects.embl.de/se/C3203646/','Bilirubin total decreased','Olanzapine','http://sideeffects.embl.de/drugs/4585/'),('http://sideeffects.embl.de/se/C3203661/','Bilirubin total low','Olanzapine','http://sideeffects.embl.de/drugs/4585/'),('http://sideeffects.embl.de/se/C3263723/','Injury','Bisoprolol','http://sideeffects.embl.de/drugs/2405/'),('http://sideeffects.embl.de/se/C3544094/','Arterial thromboembolism','Nafarelin','http://sideeffects.embl.de/drugs/25077405/'),('http://sideeffects.embl.de/se/C3665346/','Unspecified visual loss','Vardenafil','http://sideeffects.embl.de/drugs/110634/'),('http://sideeffects.embl.de/se/C3665347/','Visual impairment','Ivabradine','http://sideeffects.embl.de/drugs/132999/'),('http://sideeffects.embl.de/se/C3665386/','Abnormal vision','Frovatriptan','http://sideeffects.embl.de/drugs/77992/'),('http://sideeffects.embl.de/se/C3665596/','Warts','Glat copolymer','http://sideeffects.embl.de/drugs/65370/');

/*Table structure for table `sider_effect` */

DROP TABLE IF EXISTS `sider_effect`;

CREATE TABLE `sider_effect` (
  `sideeffect_link` varchar(200) NOT NULL,
  `sideeffect_name` varchar(200) DEFAULT NULL,
  `Definition` text,
  `Synonyms` text,
  PRIMARY KEY (`sideeffect_link`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

/*Data for the table `sider_effect` */

insert  into `sider_effect`(`sideeffect_link`,`sideeffect_name`,`Definition`,`Synonyms`) values ('http://sideeffects.embl.de/se/C0000729/','Abdominal cramps',': An involuntary muscular contraction involving a muscle of the abdomen or of a hollow organ within the abdomen.','(terms occurring on more labels are shown first): abdominal cramps, abdominal cramping, abdominal cramp, crampy abdominal pain'),('http://sideeffects.embl.de/se/C0000731/','Abdominal distension',': Swelling of the abdomen resulting from excessive food intake, malnutrition, liver disease, primary abdominal tumors, and tumors metastatic to the abdominal cavity.','(terms occurring on more labels are shown first): abdominal distention, abdominal distension, abdomen distention, distended abdomen, swollen abdomen'),('http://sideeffects.embl.de/se/C0000737/','Abdominal pain',': Sensation of discomfort, distress, or agony in the abdominal region; generally associated with functional disorders, tissue injuries, or diseases.','(terms occurring on more labels are shown first): abdominal pain, pain abdominal, abdominal pains, abdomen pain, Pain-abdominal, Abdominalpain, Abdominal - pain, Abdomina l pain, ab- dominal pain, Pain -abdominal, abdomi- nal pain'),('http://sideeffects.embl.de/se/C0000768/','Congenital anomaly',': Any abnormality, anatomical or biochemical, evident at birth or during the neonatal period.','(terms occurring on more labels are shown first): congenital anomalies, ABNORMALITIES, birth defects, congenital anomaly, congenital abnormalities, congenital malformations, birth defect, malformation, dysgenesis, fetal malformation, deformities, abnor-malities, abnor- malities'),('http://sideeffects.embl.de/se/C0000833/','Abscess',': Accumulation of purulent material in tissues, organs, or circumscribed spaces, usually associated with signs of infection.','(terms occurring on more labels are shown first): abscess, abscesses'),('http://sideeffects.embl.de/se/C0001122/','Acidosis',': pathologic condition resulting from accumulation of acid or depletion of the alkaline reserve (bicarbonate) content of the blood and body tissues, and characterized by an increase in hydrogen ion concentration (decrease in pH).','(terms occurring on more labels are shown first): acidosis'),('http://sideeffects.embl.de/se/C0001339/','Pancreatitis acute',': An acute inflammatory process that leads to necrosis of the pancreatic parenchyma. Signs and symptoms include severe abdominal pain, nausea, vomiting, diarrhea, fever, and shock. Causes include alcohol consumption, presence of gallstones, trauma, and drugs.','(terms occurring on more labels are shown first): acute pancreatitis, pancreatitis acute'),('http://sideeffects.embl.de/se/C0001416/','Adenitis','(terms occurring on more labels are shown first): adenitis',':'),('http://sideeffects.embl.de/se/C0001430/','Adenoma benign',': A neoplasm arising from the epithelium. It may be encapsulated or non-encapsulated but non-invasive. The neoplastic epithelial cells may or may not display cellular atypia or dysplasia. In the gastrointestinal tract, when dysplasia becomes severe it is sometimes called carcinoma in situ. Representative examples are pituitary gland adenoma, follicular adenoma of the thyroid gland, and adenomas (or adenomatous polyps) of the gastrointestinal tract.','(terms occurring on more labels are shown first): adenomas, adenoma benign, adenoma'),('http://sideeffects.embl.de/se/C0001623/','Adrenal insufficiency',': An endocrine or hormonal disorder that occurs when the adrenal cortex does not produce enough of the hormone cortisol and in some cases, the hormone aldosterone. It may be due to a disorder of the adrenal cortex (Addison\'s disease or primary adrenal insufficiency) or to inadequate secretion of ACTH by the pituitary gland (secondary adrenal insufficiency).','(terms occurring on more labels are shown first): adrenal insufficiency, hypoadrenalism, Adrenalin sufficiency'),('http://sideeffects.embl.de/se/C0001807/','Aggression',': form of behavior which leads to self-assertion; it may arise from innate drives and/or a response to frustration; may be manifested by destructive and attacking behavior, by covert attitudes of hostility and obstructionism, or by healthy self-expressive drive to mastery.','(terms occurring on more labels are shown first): aggression, aggressive behavior, aggressiveness, aggressive behaviour, aggressive behaviours, aggressive behaviors'),('http://sideeffects.embl.de/se/C0001824/','Agranulocytosis',': A decrease in the number of mature granulocytes (neutrophils, eosinophils, and basophils) in the peripheral blood. -- 2004','(terms occurring on more labels are shown first): agranulocytosis, granulocytopenia, granulopenia, agranulocytoses, agran- ulocytosis, gran- ulocytopenia'),('http://sideeffects.embl.de/se/C0001883/','Airway obstruction NOS',': Any hindrance to the passage of air into and out of the lungs.','(terms occurring on more labels are shown first): airway obstruction, airways obstruction'),('http://sideeffects.embl.de/se/C0001925/','Albuminuria',': The presence of albumin in the urine, an indicator of KIDNEY DISEASES.','(terms occurring on more labels are shown first): albuminuria'),('http://sideeffects.embl.de/se/C0002063/','Alkalosis',': A disorder characterized by abnormally high alkalinity (low hydrogen-ion concentration) of the blood and other body tissues.','(terms occurring on more labels are shown first): alkalosis'),('http://sideeffects.embl.de/se/C0002064/','Respiratory alkalosis',': A pathologic condition resulting from accumulation of base, or from loss of acid without comparable loss of base in the body fluids, and characterized by decrease in hydrogen ion concentration.','(terms occurring on more labels are shown first): respiratory alkalosis'),('http://sideeffects.embl.de/se/C0002170/','Alopecia',': Hair loss usually from the scalp. It may result in bald spots or spread to the entire scalp or the entire epidermis. It may be androgenetic or caused by chemotherapeutic agents, compulsive hair pulling, autoimmune disorders or congenital conditions.','(terms occurring on more labels are shown first): alopecia, hair loss, loss of hair, hair thinning, thinning of hair, baldness, alopecias, falling hair, Thinning Hair, alo- pecia'),('http://sideeffects.embl.de/se/C0002418/','Amblyopia',': A nonspecific term referring to impaired vision. Major subcategories include stimulus deprivation-induced amblyopia and toxic amblyopia. Stimulus deprivation-induced amblyopia is a developmental disorder of the visual cortex. A discrepancy between visual information received by the visual cortex from each eye results in abnormal cortical development. STRABISMUS and REFRACTIVE ERRORS may cause this condition. Toxic amblyopia is a disorder of the OPTIC NERVE which is associated with ALCOHOLISM, tobacco SMOKING, and other toxins and as an adverse effect of the use of some medications.','(terms occurring on more labels are shown first): amblyopia'),('http://sideeffects.embl.de/se/C0002453/','Amenorrhoea',': absence of menses for three months or more.','(terms occurring on more labels are shown first): amenorrhea, amenorrhoea'),('http://sideeffects.embl.de/se/C0002622/','Amnesia',': Pathologic partial or complete loss of the ability to recall past experiences (AMNESIA, RETROGRADE) or to form new memories (AMNESIA, ANTEROGRADE). This condition may be of organic or psychologic origin. Organic forms of amnesia are usually associated with dysfunction of the DIENCEPHALON or HIPPOCAMPUS. (From Adams et al., Principles of Neurology, 6th ed, pp426-7)','(terms occurring on more labels are shown first): amnesia'),('http://sideeffects.embl.de/se/C0002792/','Anaphylactic shock',': A disorder characterized by an acute inflammatory reaction resulting from the release of histamine and histamine-like substances from mast cells, causing a hypersensitivity immune response. Clinically, it presents with breathing difficulty, dizziness, hypotension, cyanosis and loss of consciousness and may lead to death.','(terms occurring on more labels are shown first): anaphylaxis, anaphylactic reactions, anaphylactic reaction, anaphylactic shock, systemic anaphylaxis, anaphy- laxis'),('http://sideeffects.embl.de/se/C0002871/','Anaemia',': A reduction in the number of red blood cells per cu mm, the amount of hemoglobin in 100 ml of blood, and the volume of packed red blood cells per 100 ml of blood. Clinically, anemia represents a reduction in the oxygen-transporting capacity of a designated volume of blood, resulting from an imbalance between blood loss (through hemorrhage or hemolysis) and blood production. Signs and symptoms of anemia may include pallor of the skin and mucous membranes, shortness of breath, palpitations of the heart, soft systolic murmurs, lethargy, and fatigability.','(terms occurring on more labels are shown first): anemia, anaemia, anemias, anaemias'),('http://sideeffects.embl.de/se/C0002874/','Aplastic anaemia',': Anemia resulting from bone marrow failure (aplastic or hypoplastic bone marrow). The production of erythroblasts and red cells is markedly decreased, and it may be associated with decreased production of granulocytes (granulocytopenia) and platelets (thrombocytopenia) as well. Aplastic anemia may be idiopathic or secondary due to bone marrow damage by toxins, radiation, or immunologic factors.','(terms occurring on more labels are shown first): aplastic anemia, aplastic anaemia, bone marrow aplasia, Anemia aplastic, aplasticanemia, Anaemia Aplastic'),('http://sideeffects.embl.de/se/C0002878/','Haemolytic anaemia',': due to premature destruction of erythrocytes in the spleen or peripheral vessels; commonly associated with glucose-6-phosphate dehydrogenase deficiencies, splenomegaly, and malarial or other infections.','(terms occurring on more labels are shown first): hemolytic anemia, haemolytic anaemia, anemiahemolytic, haemolytic anaemias, hemolytic anemias, Anemia-Hemolytic, anemia hemolytic'),('http://sideeffects.embl.de/se/C0002880/','Autoimmune haemolytic anaemia',': A condition in which the body\'s immune system stops red blood cells from forming or causes them to clump together. Autoimmune hemolytic anemia can occur in patients who have chronic lymphocytic leukemia (CLL).','(terms occurring on more labels are shown first): autoimmune hemolytic anemia, autoimmune haemolytic anaemia, auto-immune haemolytic anaemia, auto-immune hemolytic anemia, autoimmune hemolytic anemias'),('http://sideeffects.embl.de/se/C0002940/','Aneurysm',': Pathological outpouching or sac-like dilatation in the wall of any blood vessel (ARTERIES or VEINS) or the heart (HEART ANEURYSM). It indicates a thin and weakened area in the wall which may later rupture. Aneurysms are classified by location, etiology, or other characteristics.','(terms occurring on more labels are shown first): aneurysm, aneurysms'),('http://sideeffects.embl.de/se/C0002962/','Angina pectoris',': The symptom of paroxysmal pain consequent to MYOCARDIAL ISCHEMIA usually of distinctive character, location and radiation. It is thought to be provoked by a transient stressful situation during which the oxygen requirements of the MYOCARDIUM exceed that supplied by the CORONARY CIRCULATION.','(terms occurring on more labels are shown first): angina pectoris, angina, anginal pain, angina syndrome, angina pec toris'),('http://sideeffects.embl.de/se/C0002965/','Angina unstable',': Angina pectoris (or equivalent type of ischemic discomfort) with any 1 of the 3 following features: a) Angina occurring at rest and prolonged, usually greater than 20 minutes; b) New onset angina of at least Canadian Cardiovascular Society Grading Scale (or CCS classification system) classification severity III or greater; c) Recent acceleration in angina accentuated by an increase in severity of at least 1 CCS class to at least CCS class III. The biomarkers of necrosis are below the threshold of myocardial infarction. (NIH Roadmap Cardiovascular Data Standards Working Group)','(terms occurring on more labels are shown first): unstable angina, angina unstable, crescendo angina, angina at rest, unstable angina pectoris, unstable an gina, angina- Unstable, UAP, pre-infarction angina, angina-Unstable, angina -- Unstable, angina - Unstable'),('http://sideeffects.embl.de/se/C0002994/','Angioedema',': Swelling involving the deep DERMIS, subcutaneous, or submucosal tissues, representing localized EDEMA. Angioedema often occurs in the face, lips, tongue, and larynx.','(terms occurring on more labels are shown first): angioedema, angioneurotic edema, angioneurotic oedema, Quincke\'s edema, angio-oedema, giant urticaria, angiooedema, Quincke\'s oedema, Quincke edema, Angio-neurotic oedema, urticaria angioedema, angio-edema, angio- oedema, edema - angioneurotic, angioedema urticaria, Angio- neurotic oedema'),('http://sideeffects.embl.de/se/C0003123/','Anorexia',': The lack or loss of APPETITE accompanied by an aversion to food and the inability to eat. It is the defining characteristic of the disorder ANOREXIA NERVOSA.','(terms occurring on more labels are shown first): anorexia, anorectic, appetite loss, anorexic, ano- rexia'),('http://sideeffects.embl.de/se/C0003460/','Anuria',': Absence of urine formation. It is usually associated with complete bilateral ureteral (URETER) obstruction, complete lower urinary tract obstruction, or unilateral ureteral obstruction when a solitary kidney is present.','(terms occurring on more labels are shown first): anuria'),('http://sideeffects.embl.de/se/C0003467/','Anxiety',': Feelings of fear, dread, and uneasiness that may occur as a reaction to stress. A person with anxiety may sweat, feel restless and tense, and have a rapid heart beat. Extreme anxiety that happens often over time may be a sign of an anxiety disorder.','(terms occurring on more labels are shown first): anxiety, anxious, anxiousness, anxiety reaction, anxi- ety'),('http://sideeffects.embl.de/se/C0003507/','Aortic valve stenosis',': A pathological constriction that can occur above (supravalvular stenosis), below (subvalvular stenosis), or at the AORTIC VALVE. It is characterized by restricted outflow from the LEFT VENTRICLE into the AORTA.','(terms occurring on more labels are shown first): aortic stenosis'),('http://sideeffects.embl.de/se/C0003537/','Aphasia',': A cognitive disorder marked by an impaired ability to comprehend or express language in its written or spoken form. This condition is caused by diseases which affect the language areas of the dominant hemisphere. Clinical features are used to classify the various subtypes of this condition. General categories include receptive, expressive, and mixed forms of aphasia.','(terms occurring on more labels are shown first): aphasia'),('http://sideeffects.embl.de/se/C0003578/','Apnoea',': A disorder characterized by cessation of breathing.','(terms occurring on more labels are shown first): apnea, apnoea, not breathing, apneic'),('http://sideeffects.embl.de/se/C0003615/','Appendicitis',': Acute inflammation of the APPENDIX. Acute appendicitis is classified as simple, gangrenous, or perforated.','(terms occurring on more labels are shown first): appendicitis'),('http://sideeffects.embl.de/se/C0003811/','Arrhythmia',': Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.','(terms occurring on more labels are shown first): arrhythmia, arrhythmias, cardiac arrhythmias, cardiac arrhythmia, dysrhythmias, cardiac dysrhythmias, cardiac rhythm disturbances, cardiac dysrhythmia, dysrhythmia, arrythmia, cardiac rhythm disturbance, cardiacarrhythmias, arrhyth- mias'),('http://sideeffects.embl.de/se/C0003862/','Arthralgia',': A disorder characterized by a sensation of marked discomfort in a joint.','(terms occurring on more labels are shown first): arthralgia, joint pain, arthralgias, joint pains, aching joints, painful joints, painful joint, pain Joint, pain in joint, arthral- gia, art hralgia'),('http://sideeffects.embl.de/se/C0003864/','Arthritis',': An inflammatory process affecting a joint. Causes include infection, autoimmune processes, degenerative processes, and trauma. Signs and symptoms may include swelling around the affected joint and pain.','(terms occurring on more labels are shown first): arthritis, arthritides'),('http://sideeffects.embl.de/se/C0003868/','Gouty arthritis',': Arthritis, especially of the great toe, as a result of gout. Acute gouty arthritis often is precipitated by trauma, infection, surgery, etc. The initial attacks are usually monoarticular but later attacks are often polyarticular.','(terms occurring on more labels are shown first): gouty arthritis'),('http://sideeffects.embl.de/se/C0003873/','Rheumatoid arthritis',': A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.','(terms occurring on more labels are shown first): rheumatoid arthritis, arthritisRheumatoid'),('http://sideeffects.embl.de/se/C0004093/','Asthenia',': The property of lacking physical or mental strength; liability to failure under pressure or stress or strain. (WordNet)','(terms occurring on more labels are shown first): asthenia, weakness, generalized weakness, debility, feelings of weakness, general weakness, asthenic, weakness generalized, weak- ness, Weakness generalised, loss of strength, Asthenias'),('http://sideeffects.embl.de/se/C0004096/','Asthma',': A chronic disease in which the bronchial airways in the lungs become narrowed and swollen, making it difficult to breathe. Symptoms include wheezing, coughing, tightness in the chest, shortness of breath, and rapid breathing. An attack may be brought on by pet hair, dust, smoke, pollen, mold, exercise, cold air, or stress.','(terms occurring on more labels are shown first): asthma, bronchial asthma, asthmatic, asthmatics, Asthma bronchial'),('http://sideeffects.embl.de/se/C0004134/','Ataxia',': Impairment of the ability to perform smoothly coordinated voluntary movements. This condition may affect the limbs, trunk, eyes, pharynx, larynx, and other structures. Ataxia may result from impaired sensory or motor function. Sensory ataxia may result from posterior column injury or PERIPHERAL NERVE DISEASES. Motor ataxia may be associated with CEREBELLAR DISEASES; CEREBRAL CORTEX diseases; THALAMIC DISEASES; BASAL GANGLIA DISEASES; injury to the RED NUCLEUS; and other conditions.','(terms occurring on more labels are shown first): ataxia, ataxias'),('http://sideeffects.embl.de/se/C0004144/','Atelectasis',': Failure of the lung to expand (inflate) completely. This may be caused by a blocked airway, a tumor, general anesthesia, pneumonia or other lung infections, lung disease, or long-term bedrest with shallow breathing. Sometimes called a collapsed lung.','(terms occurring on more labels are shown first): atelectasis, pulmonary collapse'),('http://sideeffects.embl.de/se/C0004238/','Atrial fibrillation',': A supraventricular arrhythmia characterized by uncoordinated atrial myocardium activation due to multiple reentry circuits with consequent deterioration of atrial mechanical function. Instead of intermittently contracting, the atria quiver continuously in a chaotic pattern, causing a totally irregular, often tachycardia ventricular rate. On the ECG it is described by the replacement of consistent P waves by rapid oscillations or fibrillatory waves that vary in size, shape, and timing, associated with an irregular, frequently rapid ventricular response when atrioventricular conduction is intact. (NCI)','(terms occurring on more labels are shown first): atrial fibrillation, AFIB, fibrillation atrial, atrial fibrillations, atrial fibrilla tion, atrialfibrillation'),('http://sideeffects.embl.de/se/C0004239/','Atrial flutter',': Rapid, irregular atrial contractions caused by a block of electrical impulse conduction in the right atrium and a reentrant wave front traveling up the inter-atrial septum and down the right atrial free wall or vice versa. Unlike ATRIAL FIBRILLATION which is caused by abnormal impulse generation, typical atrial flutter is caused by abnormal impulse conduction. As in atrial fibrillation, patients with atrial flutter cannot effectively pump blood into the lower chambers of the heart (HEART VENTRICLES).','(terms occurring on more labels are shown first): atrial flutter'),('http://sideeffects.embl.de/se/C0004245/','Atrioventricular block',': An electrocardiographic finding of delayed or blocked cardiac electrical impulse conduction from the atria to the ventricles at the level of the atrioventricular node.','(terms occurring on more labels are shown first): AV block, atrioventricular block, A-V block, A-V blocks, AV-block, atrioventricular heart block, A-V heart block, AV heart block, atrio-ventricular block, atrio- ventricular block, AV blocks, atrio-ventricular blocks, atrio ventricular block, AV- block, Atrioventricular Blocks'),('http://sideeffects.embl.de/se/C0004604/','Back pain',': acute or chronic pain located in the posterior regions of the thorax, lumbosacral region, or the adjacent regions.','(terms occurring on more labels are shown first): back pain, backache, pain Back, backpain, Back ache, pain in back, back-pain, Back aches, Pain-back, ache Back, Backaches'),('http://sideeffects.embl.de/se/C0004610/','Bacteraemia',': The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.','(terms occurring on more labels are shown first): bacteremia, bacteraemia, bacteremias'),('http://sideeffects.embl.de/se/C0004623/','Bacterial infection',': An acute infectious disorder caused by gram positive or gram negative bacteria. Representative examples include pneumococcal , streptococcal, salmonella and meningeal infections.','(terms occurring on more labels are shown first): bacterial infections, bacterial infection, infection bacterial, Infection--Bacterial, bacterial disease'),('http://sideeffects.embl.de/se/C0004626/','Pneumonia bacterial',': pneumonia caused by various species of bacteria; commonly results from bronchogenic spread of infection following microaspiration of secretions.','(terms occurring on more labels are shown first): bacterial pneumonia, pneumonia bacterial'),('http://sideeffects.embl.de/se/C0004936/','Mental disorder',': A disorder characterized by behavioral and/or psychological abnormalities, often accompanied by physical symptoms. The symptoms may cause clinically significant distress or impairment in social and occupational areas of functioning. Representative examples include anxiety disorders, cognitive disorders, mood disorders and schizophrenia.','(terms occurring on more labels are shown first): psychiatric disorders, psychiatric disorder, mental disorders, mental disorder, psychiatric illness, mental illness, Psychiatricdisorders, psychiatric disease, Psy c hiatric Disorders'),('http://sideeffects.embl.de/se/C0005586/','Bipolar disorder',': A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence. (MeSH)','(terms occurring on more labels are shown first): bipolar disorder, manic depression, manic-depressive reaction, manic-depressive, manic depressive illness, manic depressive reaction, manic-depressive illness, manic-depressive disorders, manic- depressive illness, manic- depressive, bipolar disorders, manic depressive, bipolar affective disorder, manic depressive psychosis, manic depressive disorder'),('http://sideeffects.embl.de/se/C0005681/','Blackwater fever',': A complication of MALARIA, FALCIPARUM characterized by the passage of dark red to black urine.','(terms occurring on more labels are shown first): blackwater fever'),('http://sideeffects.embl.de/se/C0005694/','Bladder neck obstruction',': Blocked urine flow through the bladder neck, the narrow internal urethral opening at the base of the URINARY BLADDER. Narrowing or strictures of the URETHRA can be congenital or acquired. It is often observed in males with enlarged PROSTATE glands.','(terms occurring on more labels are shown first): bladder outlet obstruction'),('http://sideeffects.embl.de/se/C0005741/','Blepharitis',': Inflammation of the eyelids.','(terms occurring on more labels are shown first): blepharitis, eyelid inflammation, eye lid inflammation'),('http://sideeffects.embl.de/se/C0005758/','Blister',': A fluid-filled sac in the outer layer of skin. It can be caused by rubbing, heat, or diseases of the skin.','(terms occurring on more labels are shown first): blisters, blistering, blister, bullae, bullous lesions, blebs, vesication'),('http://sideeffects.embl.de/se/C0005778/','Clotting',': The sequential process in which the multiple coagulation factors of the blood interact, ultimately resulting in the formation of an insoluble fibrin clot; it may be divided into three stages: stage 1, the formation of intrinsic and extrinsic prothrombin converting principle; stage 2, the formation of thrombin; stage 3, the formation of stable fibrin polymers. [http://www.graylab.ac.uk/omd/, ISBN:0198506732]','(terms occurring on more labels are shown first): clotting, blood clotting, blood coagulation, blood-clotting'),('http://sideeffects.embl.de/se/C0005779/','Coagulopathy',': Hemorrhagic and thrombotic disorders that occur as a consequence of abnormalities in blood coagulation due to a variety of factors such as COAGULATION PROTEIN DISORDERS; BLOOD PLATELET DISORDERS; BLOOD PROTEIN DISORDERS or nutritional conditions.','(terms occurring on more labels are shown first): clotting disorders, coagulation disorder, coagulation defect, coagulopathy, coagulopathies, coagulation disorders, clotting disorder, coagulation defects'),('http://sideeffects.embl.de/se/C0005940/','Bone disorder',': condition in which there is a deviation from or interruption of the normal structure or function of the bones.','(terms occurring on more labels are shown first): bone disorders, bone disorder, bone disease, disease of bone'),('http://sideeffects.embl.de/se/C0006142/','Breast cancer',': A primary or metastatic malignant neoplasm involving the breast. The vast majority of cases are carcinomas arising from the breast parenchyma or the nipple. Malignant breast neoplasms occur more frequently in females than in males.','(terms occurring on more labels are shown first): breast cancer, malignant breast neoplasm, breast cancers, mammary cancer, cancer of the breast, breastcancer, breast malignant neoplasm, Breast-cancer'),('http://sideeffects.embl.de/se/C0006145/','Breast disorder',': A non-neoplastic or neoplastic disorder that affects the breast. Representative examples of non-neoplastic disorders include fibrocystic disease, gynecomastia, and mastitis. Representative examples of neoplastic disorders include fibroadenoma, lobular neoplasia, carcinoma, lymphoma, and sarcoma.','(terms occurring on more labels are shown first): breast disorders, breast disorder, breast disease, B reast D isorders'),('http://sideeffects.embl.de/se/C0006147/','Breast feeding',': The nursing of an infant at the mother\'s breast.','(terms occurring on more labels are shown first): breast-feeding, breast feeding, breast-feed, breastfeeding, breastfeed, breast-fed infants, breast- feeding, breast feed, breast-fed infant, breast- feed'),('http://sideeffects.embl.de/se/C0006266/','Bronchospasm',': A disorder characterized by a sudden contraction of the smooth muscles of the bronchial wall.','(terms occurring on more labels are shown first): bronchospasm, bronchospasms, bronchial spasm, bron-chospasm, broncho spasm, broncho- spasms'),('http://sideeffects.embl.de/se/C0006277/','Bronchitis',': Inflammation of the large airways in the lung including any part of the BRONCHI, from the PRIMARY BRONCHI to the TERTIARY BRONCHI.','(terms occurring on more labels are shown first): bronchitis, B ron ch itis'),('http://sideeffects.embl.de/se/C0006287/','Bronchopulmonary dysplasia',': A chronic lung disease developed after OXYGEN INHALATION THERAPY or mechanical ventilation (VENTILATION, MECHANICAL) usually occurring in certain premature infants (INFANT, PREMATURE) or newborn infants with respiratory distress syndrome (RESPIRATORY DISTRESS SYNDROME, NEWBORN). Histologically, it is characterized by the unusual abnormalities of the bronchioles, such as METAPLASIA, decrease in alveolar number, and formation of CYSTS.','(terms occurring on more labels are shown first): bronchopulmonary dysplasia'),('http://sideeffects.embl.de/se/C0006384/','Bundle branch block',': A form of heart block in which the electrical stimulation of HEART VENTRICLES is interrupted at either one of the branches of BUNDLE OF HIS thus preventing the simultaneous depolarization of the two ventricles.','(terms occurring on more labels are shown first): bundle branch block, bundle-branch block, bundle branch heart block, bundle- branch block'),('http://sideeffects.embl.de/se/C0006444/','Bursitis',': Inflammation (swelling, pain, and warmth) of a bursa. A bursa is a flat, fluid-filled sac found between a bone and a tendon or muscle. It forms a cushion to help the tendon or muscle slide smoothly over the bone. Bursitis may be caused by long-term overuse, trauma, rheumatoid arthritis, gout, or infection. It usually affects the shoulder, knee, elbow, hip, or foot.','(terms occurring on more labels are shown first): bursitis'),('http://sideeffects.embl.de/se/C0006826/','Neoplasm malignant',': A term for diseases in which abnormal cells divide without control and can invade nearby tissues. Malignant cells can also spread to other parts of the body through the blood and lymph systems. There are several main types of malignancy. Carcinoma is a malignancy that begins in the skin or in tissues that line or cover internal organs. Sarcoma is a malignancy that begins in bone, cartilage, fat, muscle, blood vessels, or other connective or supportive tissue. Leukemia is a malignancy that starts in blood-forming tissue such as the bone marrow, and causes large numbers of abnormal blood cells to be produced and enter the blood. Lymphoma and multiple myeloma are malignancies that begin in the cells of the immune system. Central nervous system cancers are malignancies that begin in the tissues of the brain and spinal cord.','(terms occurring on more labels are shown first): cancer, malignancies, malignancy, cancers, malignant neoplasms, malignant neoplasm, neoplasm malignant, malignant tumors, malignant tumours, malignant tumour, malignanc y'),('http://sideeffects.embl.de/se/C0006840/','Candida infection',': A condition in which Candida albicans, a type of yeast, grows out of control in moist skin areas of the body. It is usually a result of a weakened immune system, but can be a side effect of chemotherapy or treatment with antibiotics. Thrush usually affects the mouth (oral thrush); however, rarely, it spreads throughout the entire body.','(terms occurring on more labels are shown first): moniliasis, candidiasis, candida infections, candida infection, candidal infections, candidal infection, Candidosis, monilial infection'),('http://sideeffects.embl.de/se/C0007117/','Basal cell carcinoma',': The most frequently seen skin cancer. It arises from basal cells of the epidermis and pilosebaceous units. Clinically it is divided into the following types: nodular, ulcerative, superficial, multicentric, erythematous, and sclerosing or morphea-like.. More than 95% of these carcinomas occur in patients over 40. They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck and the remaining 15% on the trunk and extremities. Basal cell carcinoma usually grows in a slow and indolent fashion. However, if untreated, the tumor may invade the subcutaneous fat, skeletal muscle and bone. Distant metastases are rare. Excision, curettage and irradiation cure most basal cell carcinomas.','(terms occurring on more labels are shown first): basal cell carcinoma, basal cell carcinomas, BCC'),('http://sideeffects.embl.de/se/C0007642/','Cellulitis',': An acute, diffuse, and suppurative inflammation of loose connective tissue, particularly the deep subcutaneous tissues, and sometimes muscle, which is most commonly seen as a result of infection of a wound, ulcer, or other skin lesions.','(terms occurring on more labels are shown first): cellulitis'),('http://sideeffects.embl.de/se/C0007787/','Transient ischaemic attack',': Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)','(terms occurring on more labels are shown first): transient ischemic attack, transient ischemic attacks, transient ischaemic attack, transient ischaemic attacks'),('http://sideeffects.embl.de/se/C0007820/','Cerebrovascular disorder',': A disorder resulting from inadequate blood flow in the arteries that supply the brain. The diagnostic criteria may include current or previous history of the following: Ischemic stroke, TIA, Noninvasive or invasive arterial imaging test demonstrating greater than or equal to 50% stenosis of any of the major extracranial or intracranial vessels to the brain; Previous cervical or cerebral artery revascularization surgery or percutaneous intervention.','(terms occurring on more labels are shown first): cerebrovascular disorder, cerebrovascular disorders, cerebrovascular disease'),('http://sideeffects.embl.de/se/C0007859/','Neck pain',': Discomfort or more intense forms of pain that are localized to the cervical region. This term generally refers to pain in the posterior or lateral regions of the neck.','(terms occurring on more labels are shown first): neck pain, pain neck, pain-neck, Cervical pain'),('http://sideeffects.embl.de/se/C0008031/','Chest pain',': Pressure, burning, or numbness in the chest.','(terms occurring on more labels are shown first): chest pain, pain chest, chest pains, nonspecific chest pain, Chest - pain, pain in chest, non-specific chest pain, Chest-pain, chestpain, Pain -chest'),('http://sideeffects.embl.de/se/C0008049/','Varicella',': A contagious childhood disorder caused by the varicella zoster virus. It is transmitted via respiratory secretions and contact with chickenpox blister contents. It presents with a vesicular skin rush, usually associated with fever, headache, and myalgias. The pruritic fluid-filled vesicles occur 10-21 days after exposure and last for 3-4 days. An additional 3-4 days of malaise follows before the affected individual feels better. An individual is contagious 1-2 days prior to the appearance of the blisters until all blisters are crusted over. Generally, healthy individuals recover without complications.','(terms occurring on more labels are shown first): chickenpox, varicella, chicken pox'),('http://sideeffects.embl.de/se/C0008325/','Cholecystitis',': inflammation of the gallbladder; generally caused by impairment of bile flow, gallstones in the biliary tract, infections, or other diseases.','(terms occurring on more labels are shown first): cholecystitis'),('http://sideeffects.embl.de/se/C0008370/','Cholestasis',': Any condition in which the release of bile from the liver is blocked. The blockage can occur in the liver (intrahepatic cholestasis) or in the bile ducts (extrahepatic cholestasis).','(terms occurring on more labels are shown first): cholestasis, biliary stasis, bile duct obstruction, bile stasis'),('http://sideeffects.embl.de/se/C0009241/','Cognitive disorder',': A category of psychiatric disorders which are characterized by a deficit in cognition or memory.','(terms occurring on more labels are shown first): cognitive disorder, cognitive disorders, cognitive function disorders'),('http://sideeffects.embl.de/se/C0009319/','Colitis',': Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.','(terms occurring on more labels are shown first): colitis'),('http://sideeffects.embl.de/se/C0009324/','Colitis ulcerative',': An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.','(terms occurring on more labels are shown first): ulcerative colitis, colitis ulcerative'),('http://sideeffects.embl.de/se/C0009421/','Coma',': A profound state of unconsciousness associated with depressed cerebral activity from which the individual cannot be aroused. Coma generally occurs when there is dysfunction or injury involving both cerebral hemispheres or the brain stem RETICULAR FORMATION.','(terms occurring on more labels are shown first): coma, comatose'),('http://sideeffects.embl.de/se/C0009450/','Infection',': invasion and growth of microorganisms in body tissues, which may be clinically inapparent or result in local cellular injury; a local infection may persist and spread by extension to become an acute, subacute, or chronic clinical infection or disease state or it may become systemic when the microorganisms gain access to the lymphatic or vascular system; does not always lead to injury of the host even if the pathogen is potentially virulent.','(terms occurring on more labels are shown first): infections, infection, infectious diseases, I NFECTIONS, infectious disease, infec- tions, infection unspecified, infec- tion, infect Dis, Infe cti ons, communicable diseases'),('http://sideeffects.embl.de/se/C0009676/','Confusional state',': A mental state characterized by bewilderment, emotional disturbance, lack of clear thinking, and perceptual disorientation.','(terms occurring on more labels are shown first): confusion, confusional state, mental confusion, confusional states, dazed, confusion state, Disorientation Confusion'),('http://sideeffects.embl.de/se/C0009763/','Conjunctivitis',': inflammation of the mucous membrane that lines the inner surface of the eyelids and the anterior part of the sclera; also called pinkeye and redeye.','(terms occurring on more labels are shown first): conjunctivitis'),('http://sideeffects.embl.de/se/C0009766/','Conjunctivitis allergic',': Conjunctivitis due to hypersensitivity to various allergens.','(terms occurring on more labels are shown first): allergic conjunctivitis, conjunctivitis allergic'),('http://sideeffects.embl.de/se/C0009782/','Connective tissue disorder',': A heterogeneous group of disorders, some hereditary, others acquired, characterized by abnormal structure or function of one or more of the elements of connective tissue, i.e., collagen, elastin, or the mucopolysaccharides.','(terms occurring on more labels are shown first): connective tissue disorders, connective tissue disease, connective tissue disorder, CTD, connective tissue diseases, connectivetissue disorders, connective ti ssue di sorders'),('http://sideeffects.embl.de/se/C0009806/','Constipation',': Infrequent or difficult evacuation of FECES. These symptoms are associated with a variety of causes, including low DIETARY FIBER intake, emotional or nervous disturbances, systemic and structural disorders, drug-induced aggravation, and infections.','(terms occurring on more labels are shown first): constipation, constipated, constipating, consti- pation, Con- stipation, constipa- tion, const ipat ion'),('http://sideeffects.embl.de/se/C0009938/','Contusion',': A finding of injury of the soft tissues or bone characterized by leakage of blood into surrounding tissues.','(terms occurring on more labels are shown first): bruising, contusion, bruises, bruise, contusions'),('http://sideeffects.embl.de/se/C0010034/','Corneal disorder',': pathological process affecting the transparent anterior portion of the fibrous coat of the eye.','(terms occurring on more labels are shown first): corneal disorders, corneal disorder'),('http://sideeffects.embl.de/se/C0010037/','Corneal oedema',': excessive amount of fluid in the transparent anterior portion of the fibrous coat of the eye due to damage of the epithelium or endothelium, causing decreased visual acuity.','(terms occurring on more labels are shown first): corneal edema, corneal oedema'),('http://sideeffects.embl.de/se/C0010038/','Corneal opacity',': clouding that can occur in the transparent part of the coat of the eyeball or cornea, secondary to inflammation, infection or irritant exposure by a foreign body or chemical.','(terms occurring on more labels are shown first): corneal opacity, corneal opacities, corneal clouding'),('http://sideeffects.embl.de/se/C0010043/','Ulcerative keratitis',': A disorder characterized by an area of epithelial tissue loss on the surface of the cornea. It is associated with inflammatory cells in the cornea and anterior chamber.','(terms occurring on more labels are shown first): corneal ulcer, corneal ulceration, corneal ulcers, Corneal ulcerations, ulcerative keratitis'),('http://sideeffects.embl.de/se/C0010200/','Cough',': A sudden, audible expulsion of air from the lungs through a partially closed glottis, preceded by inhalation. It is a protective response that serves to clear the trachea, bronchi, and/or lungs of irritants and secretions, or to prevent aspiration of foreign materials into the lungs.','(terms occurring on more labels are shown first): cough, coughing, coughs, c ough, C ou g h'),('http://sideeffects.embl.de/se/C0010346/','Crohn\'s disease',': A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.','(terms occurring on more labels are shown first): Crohn\'s disease, Crohndisease, Crohn\'s dis- ease, Crohn\' s disease'),('http://sideeffects.embl.de/se/C0010495/','Cutis laxa',': A group of connective tissue diseases in which skin hangs in loose pendulous folds. It is believed to be associated with decreased elastic tissue formation as well as an abnormality in elastin formation. Cutis laxa is usually a genetic disease, but acquired cases have been reported. (From Dorland, 27th ed)','(terms occurring on more labels are shown first): skin laxity, cutis laxa'),('http://sideeffects.embl.de/se/C0010692/','Cystitis',': Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain.','(terms occurring on more labels are shown first): cystitis, bladder inflammation, cystalgia'),('http://sideeffects.embl.de/se/C0011053/','Deafness',': An inherited or acquired condition characterized by a partial or complete loss of hearing in one or both ears. The level of impairment varies from a mild but important loss of sensitivity to a total loss of hearing.','(terms occurring on more labels are shown first): deafness'),('http://sideeffects.embl.de/se/C0011124/','Libido decreased',': A disorder characterized by a decrease in sexual desire.','(terms occurring on more labels are shown first): libido decreased, decreased libido, reduced libido, decreased sexual desire'),('http://sideeffects.embl.de/se/C0011168/','Dysphagia',': Difficulty in SWALLOWING which may result from neuromuscular disorder or mechanical obstruction. Dysphagia is classified into two distinct types: oropharyngeal dysphagia due to malfunction of the PHARYNX and UPPER ESOPHAGEAL SPHINCTER; and esophageal dysphagia due to malfunction of the ESOPHAGUS.','(terms occurring on more labels are shown first): dysphagia, swallowing difficulty, difficulty in swallowing, difficulty swallowing, swallowing disorders, deglutition disorder, swallowing difficult'),('http://sideeffects.embl.de/se/C0011175/','Dehydration',': A condition resulting from the excessive loss of water from the body. It is usually caused by severe diarrhea, vomiting or diaphoresis.','(terms occurring on more labels are shown first): dehydration'),('http://sideeffects.embl.de/se/C0011206/','Delirium',': A disorder characterized by CONFUSION; inattentiveness; disorientation; ILLUSIONS; HALLUCINATIONS; agitation; and in some instances autonomic nervous system overactivity. It may result from toxic/metabolic conditions or structural brain lesions. (From Adams et al., Principles of Neurology, 6th ed, pp411-2)','(terms occurring on more labels are shown first): delirium, acute brain syndrome, acute delirium'),('http://sideeffects.embl.de/se/C0011253/','Delusion',': A false belief regarding the self or persons or objects outside the self that persists despite the facts, and is not considered tenable by one\'s associates.','(terms occurring on more labels are shown first): delusions, delusion'),('http://sideeffects.embl.de/se/C0011551/','Depersonalisation',': State in which an individual perceives or experiences a sensation of unreality concerning the self or the environment; it is seen in disorders such as schizophrenia, affection disorders, organic mental disorders, and personality disorders. (APA, Thesaurus of Psychological Index Terms, 8th ed.)','(terms occurring on more labels are shown first): depersonalization, depersonalisation, de-personalisation'),('http://sideeffects.embl.de/se/C0011570/','Depression',': A mental condition marked by ongoing feelings of sadness, despair, loss of energy, and difficulty dealing with normal daily life. Other symptoms of depression include feelings of worthlessness and hopelessness, loss of pleasure in activities, changes in eating or sleeping habits, and thoughts of death or suicide. Depression can affect anyone, and can be successfully treated. Depression affects 15-25% of cancer patients.','(terms occurring on more labels are shown first): Depression, mental depression, depressions, Depressio n, D EPRESSION'),('http://sideeffects.embl.de/se/C0011581/','Depressive disorder',': An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent.','(terms occurring on more labels are shown first): depressive disorder, depressive illness, depressive disorders, D EPRESSIVE D ISORDER, depressive neurosis'),('http://sideeffects.embl.de/se/C0011603/','Dermatitis',': An inflammatory process affecting the skin. Signs include red rash, itching, and blister formation. Representative examples are contact dermatitis, atopic dermatitis, and seborrheic dermatitis.','(terms occurring on more labels are shown first): dermatitis, skin inflammation, inflammation of the skin, dermatitides'),('http://sideeffects.embl.de/se/C0011606/','Dermatitis exfoliative',': The widespread involvement of the skin by a scaly, erythematous dermatitis occurring either as a secondary or reactive process to an underlying cutaneous disorder (e.g., atopic dermatitis, psoriasis, etc.), or as a primary or idiopathic disease. It is often associated with the loss of hair and nails, hyperkeratosis of the palms and soles, and pruritus. (From Dorland, 27th ed)','(terms occurring on more labels are shown first): exfoliative dermatitis, erythroderma, exfoliative erythroderma, dermatitis exfoliative, generalized exfoliative dermatitis, exfoliativedermatitis, Ex foliative dermatitis, e xfoliative dermatitis'),('http://sideeffects.embl.de/se/C0011609/','Drug eruption',': Adverse cutaneous reactions caused by ingestion, parenteral use, or local application of a drug. These may assume various morphologic patterns and produce various types of lesions.','(terms occurring on more labels are shown first): drug rash, drug eruption, dermatitis medicamentosa, drug eruptions'),('http://sideeffects.embl.de/se/C0011615/','Dermatitis atopic',': A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. In infants it is known as infantile eczema.','(terms occurring on more labels are shown first): atopic dermatitis, allergic dermatitis, dermatitis allergic, dermatitisAtopic, dermatitis atopic, atopic eczema, dermatitisAllergic, allergic eczema'),('http://sideeffects.embl.de/se/C0011616/','Dermatitis contact',': A type of acute or chronic skin reaction in which sensitivity is manifested by reactivity to materials or substances coming in contact with the skin. It may involve allergic or non-allergic mechanisms.','(terms occurring on more labels are shown first): contact dermatitis, dermatitis contact, dermatitisContact, contact sensitivity, Contact eczema'),('http://sideeffects.embl.de/se/C0011849/','Diabetes mellitus',': A disease in which the body does not control the amount of glucose (a type of sugar) in the blood and the kidneys make a large amount of urine. This disease occurs when the body does not make enough insulin or does not use it the way it should.','(terms occurring on more labels are shown first): diabetes mellitus, diabetes'),('http://sideeffects.embl.de/se/C0011991/','Diarrhoea',': An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.','(terms occurring on more labels are shown first): diarrhea, diarrhoea, Stools loose, loose stool, watery stools, loose bowel movement, Diarrh ea, diar- rhea'),('http://sideeffects.embl.de/se/C0012569/','Diplopia',': A visual symptom in which a single object is perceived by the visual cortex as two objects rather than one. Disorders associated with this condition include REFRACTIVE ERRORS; STRABISMUS; OCULOMOTOR NERVE DISEASES; TROCHLEAR NERVE DISEASES; ABDUCENS NERVE DISEASES; and diseases of the BRAIN STEM and OCCIPITAL LOBE.','(terms occurring on more labels are shown first): diplopia, double vision, dou- ble vision'),('http://sideeffects.embl.de/se/C0012739/','Disseminated intravascular coagulation',': disorder characterized by reduction in the elements involved in blood coagulation due to their utilization in widespread blood clotting within the vessels; the activation of the clotting mechanism may arise from any of a number of disorders; in the late stages, it is marked by profuse hemorrhaging.','(terms occurring on more labels are shown first): disseminated intravascular coagulation, consumption coagulopathies'),('http://sideeffects.embl.de/se/C0012797/','Diuresis',': An increase in the excretion of URINE. (McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed)','(terms occurring on more labels are shown first): diuresis, urinary flow'),('http://sideeffects.embl.de/se/C0012833/','Dizziness',': A medically indistinct term used to describe a variety of conditions such as lightheadedness, unsteadiness, giddiness, a sense of turning, spinning or rocking.','(terms occurring on more labels are shown first): dizziness, dizzy, dizzi- ness, dizzi-ness, Diz z in e ss'),('http://sideeffects.embl.de/se/C0013144/','Drowsiness',': The sensation of struggling to remain awake.','(terms occurring on more labels are shown first): drowsiness, sleepiness, sleepy, drowsy'),('http://sideeffects.embl.de/se/C0013182/','Drug hypersensitivity',': immunologically mediated adverse reactions to medicinal substances used legally or illegally.','(terms occurring on more labels are shown first): drug hypersensitivity, drug allergy'),('http://sideeffects.embl.de/se/C0013220/','Drug tolerance',': Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL.','(terms occurring on more labels are shown first): drug tolerance'),('http://sideeffects.embl.de/se/C0013238/','Dry eye syndrome',': Corneal and conjunctival dryness due to deficient tear production, predominantly in menopausal and post-menopausal women. Filamentary keratitis or erosion of the conjunctival and corneal epithelium may be caused by these disorders. Sensation of the presence of a foreign body in the eye and burning of the eyes may occur.','(terms occurring on more labels are shown first): dry eye syndrome, dry eye syndromes'),('http://sideeffects.embl.de/se/C0013240/','Alveolar osteitis',': A condition sometimes occurring after tooth extraction, particularly after traumatic extraction, resulting in a dry appearance of the exposed bone in the socket, due to disintegration or loss of the blood clot. It is basically a focal osteomyelitis without suppuration and is accompanied by severe pain (alveolalgia) and foul odor. (Dorland, 28th ed)','(terms occurring on more labels are shown first): dry socket, alveolar osteitis'),('http://sideeffects.embl.de/se/C0013295/','Duodenal ulcer',': peptic ulcer located in the duodenum, the shortest and widest portion of the small intestine adjacent to the pylorus of the stomach.','(terms occurring on more labels are shown first): duodenal ulcer, duodenal ulcer disease, duodenal ulcers, duodenal ulceration'),('http://sideeffects.embl.de/se/C0013362/','Dysarthria',': Disorders of speech articulation caused by imperfect coordination of pharynx, larynx, tongue, or face muscles. This may result from CRANIAL NERVE DISEASES; NEUROMUSCULAR DISEASES; CEREBELLAR DISEASES; BASAL GANGLIA DISEASES; BRAIN STEM diseases; or diseases of the corticobulbar tracts (see PYRAMIDAL TRACTS). The cortical language centers are intact in this condition. (From Adams et al., Principles of Neurology, 6th ed, p489)','(terms occurring on more labels are shown first): dysarthria'),('http://sideeffects.embl.de/se/C0013378/','Dysgeusia',': A condition characterized by alterations of the sense of taste which may range from mild to severe, including gross distortions of taste quality.','(terms occurring on more labels are shown first): taste perversion, dysgeusia, taste disturbance, taste alteration, alteration of taste, taste impairment, alteration in taste, alterations in taste, disturbances of taste, taste abnormalities, perversion of taste, taste abnormality, disturbances taste, taste per-version'),('http://sideeffects.embl.de/se/C0013384/','Dyskinesia',': Abnormal involuntary movements which primarily affect the extremities, trunk, or jaw that occur as a manifestation of an underlying disease process. Conditions which feature recurrent or persistent episodes of dyskinesia as a primary manifestation of disease may be referred to as dyskinesia syndromes (see MOVEMENT DISORDERS). Dyskinesias are also a relatively common manifestation of BASAL GANGLIA DISEASES.','(terms occurring on more labels are shown first): dyskinesia, dyskinesias, d yskinesia'),('http://sideeffects.embl.de/se/C0013390/','Dysmenorrhoea',': A disorder characterized by abnormally painful abdominal cramps during menses.','(terms occurring on more labels are shown first): dysmenorrhea, dysmenorrhoea, menstrual cramps, menstrual pain, Menstrual Cramp, painful menstruation'),('http://sideeffects.embl.de/se/C0013395/','Dyspepsia',': An uncomfortable, often painful feeling in the stomach, resulting from impaired digestion. Symptoms include burning stomach pain, bloating, heartburn, nausea, and vomiting. Causes include gastritis, gastric ulcer, gastroesophageal reflux disease, pancreatic disease, and gallbladder disease.','(terms occurring on more labels are shown first): dyspepsia, indigestion, d yspepsia, D y spepsia'),('http://sideeffects.embl.de/se/C0013404/','Dyspnoea',': labored or difficult breathing associated with a variety of disorders, indicating inadequate ventilation or low blood oxygen or a subjective experience of breathing discomfort.','(terms occurring on more labels are shown first): dyspnea, shortness of breath, dyspnoea, difficulty breathing, respiratory difficulty, breathing difficulties, difficult breathing, breathing difficulty, breathlessness, respiratory difficulties, breath shortness, Respiratory - difficulty, D y spnea'),('http://sideeffects.embl.de/se/C0013418/','Abnormal labour',': Slow or difficult OBSTETRIC LABOR or CHILDBIRTH.','(terms occurring on more labels are shown first): dystocia, Abnormal labor'),('http://sideeffects.embl.de/se/C0013428/','Dysuria',': Painful URINATION. It is often associated with infections of the lower URINARY TRACT.','(terms occurring on more labels are shown first): dysuria, painful urination, painful micturition'),('http://sideeffects.embl.de/se/C0013447/','Ear disorder',': impairment of health or a condition of abnormal functioning in the sense organ for hearing and equilibrium.','(terms occurring on more labels are shown first): ear disorder, ear disorders, ear disease, DisordersEar'),('http://sideeffects.embl.de/se/C0013456/','Ear pain',': A disorder characterized by a sensation of marked discomfort in the ear.','(terms occurring on more labels are shown first): ear pain, earache, ear ache, otalgia, pain- ear, pain Ear'),('http://sideeffects.embl.de/se/C0013491/','Ecchymosis',': Extravasation of blood into the skin, resulting in a nonelevated, rounded or irregular, blue or purplish patch, larger than a petechia.','(terms occurring on more labels are shown first): ecchymosis, ecchymoses'),('http://sideeffects.embl.de/se/C0013595/','Eczema',': A group of conditions in which the skin becomes inflamed, forms blisters, and becomes crusty, thick, and scaly. Eczema causes burning and itching, and may occur over a long period of time. Atopic dermatitis is the most common type of eczema.','(terms occurring on more labels are shown first): eczema, eczematoid dermatitis, eczematous dermatitis, eczematous rash, eczemas, ecze ma, eczematous skin lesions'),('http://sideeffects.embl.de/se/C0013604/','Oedema',': Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.','(terms occurring on more labels are shown first): edema, oedema, edematous, edemas, oedemas, oedematous, Oedema s'),('http://sideeffects.embl.de/se/C0014356/','Enterocolitis',': Inflammation of the MUCOSA of both the SMALL INTESTINE and the LARGE INTESTINE. Etiology includes ISCHEMIA, infections, allergic, and immune responses.','(terms occurring on more labels are shown first): enterocolitis'),('http://sideeffects.embl.de/se/C0014394/','Enuresis',': Involuntary discharge of URINE after expected age of completed development of urinary control. This can happen during the daytime (DIURNAL ENURESIS) while one is awake or during sleep (NOCTURNAL ENURESIS). Enuresis can be in children or in adults (as persistent primary enuresis and secondary adult-onset enuresis).','(terms occurring on more labels are shown first): enuresis'),('http://sideeffects.embl.de/se/C0014431/','Enzyme induction',': An increase in the rate of synthesis of an enzyme due to the presence of an inducer which acts to derepress the gene responsible for enzyme synthesis.','(terms occurring on more labels are shown first): enzyme induction'),('http://sideeffects.embl.de/se/C0014457/','Eosinophilia',': disordered formation of eosinophils or an abnormal accumulation or deficiency of these cells.','(terms occurring on more labels are shown first): eosinophilia, eosinophils increased, increased eosinophils, increased eosinophil count'),('http://sideeffects.embl.de/se/C0014518/','Toxic epidermal necrolysis',': A systemic, serious, and life-threatening disorder characterized by erythematous and necrotic lesions in the skin and mucous membranes that are associated with bullous detachment of the epidermis. The epidermal and mucous membranes detachment leads to sepsis and may be fatal. The lesions appear throughout the body and occupy more than 30% of the body surfaces. It is a hypersensitivity reaction usually caused by drugs (e.g., sulfonamides, nonsteroidal anti-inflammatory drugs, anticonvulsants, and antiretroviral drugs).','(terms occurring on more labels are shown first): toxic epidermal necrolysis, Lyell\'s syndrome, Lyell syndrome, Lyell\'s disease, Lyell\'s syndromes, toxic-epidermal necrolysis, Lyellsyndrome, Lyell-Syndrome, Lyell s syndrome, toxic epi- dermal necrolysis, Lyell\'ssyndrome'),('http://sideeffects.embl.de/se/C0014544/','Epilepsy',': A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)','(terms occurring on more labels are shown first): epilepsy, epileptic, seizure disorders, epileptic seizures, epileptic seizure, epileptics, seizure disorder, epilepsies, epilepsy types'),('http://sideeffects.embl.de/se/C0014549/','Grand mal convulsion',': A generalized seizure disorder characterized by recurrent major motor seizures. The initial brief tonic phase is marked by trunk flexion followed by diffuse extension of the trunk and extremities. The clonic phase features rhythmic flexor contractions of the trunk and limbs, pupillary dilation, elevations of blood pressure and pulse, urinary incontinence, and tongue biting. This is followed by a profound state of depressed consciousness (post-ictal state) which gradually improves over minutes to hours. The disorder may be cryptogenic, familial, or symptomatic (caused by an identified disease process). (From Adams et al., Principles of Neurology, 6th ed, p329)','(terms occurring on more labels are shown first): primary generalized tonic-clonic seizures, grand mal convulsion, grand mal convulsions, convulsions grand mal, primary generalized tonic- clonic seizures, PrimaryGeneralized Tonic-Clonic Seizures, primary generalized tonicclonic seizures, clonic-tonic convulsions'),('http://sideeffects.embl.de/se/C0014591/','Epistaxis',': A disorder characterized by bleeding from the nose.','(terms occurring on more labels are shown first): epistaxis, nosebleed, nose bleed, nose bleeds, nosebleeds, nose bleeding, nasal bleeding'),('http://sideeffects.embl.de/se/C0014724/','Eructation',': The ejection of gas or air through the mouth from the stomach.','(terms occurring on more labels are shown first): eructation, belching, Eructations, eructa- tion, Burping'),('http://sideeffects.embl.de/se/C0014742/','Erythema multiforme',': A hypersensitivity reaction characterized by the sudden appearance of symmetrical cutaneous and mucocutaneous macular or popular lesions which evolve into lesions with bright red borders (target lesions). The lesions usually appear in the hands, feet, extremities, and face. Symptoms include fever, malaise, sore throat, cough, vomiting, diarrhea, arthalgia, and myalgia. Causes include infections (most commonly herpes simplex virus), drugs (e.g., sulfonamides, anticonvulsants, and antibiotics), malignancies, and collagen vascular disorders.','(terms occurring on more labels are shown first): erythema multiforme, multiforme erythema, multiformeErythema, e rythema multiforme'),('http://sideeffects.embl.de/se/C0014848/','Oesophageal achalasia',': A motility disorder of the ESOPHAGUS in which the LOWER ESOPHAGEAL SPHINCTER (near the CARDIA) fails to relax resulting in functional obstruction of the esophagus, and DYSPHAGIA. Achalasia is characterized by a grossly contorted and dilated esophagus (megaesophagus).','(terms occurring on more labels are shown first): cardiospasm'),('http://sideeffects.embl.de/se/C0014863/','Oesophageal spasm',': A hypermotility disorder of the ESOPHAGUS that is characterized by spastic non-peristaltic responses to SWALLOWING; CHEST PAIN; and DYSPHAGIA.','(terms occurring on more labels are shown first): esophageal spasm, esophagospasm, esophageal spasms, oesophageal spasm'),('http://sideeffects.embl.de/se/C0014868/','Oesophagitis',': INFLAMMATION, acute or chronic, of the ESOPHAGUS caused by BACTERIA, chemicals, or TRAUMA.','(terms occurring on more labels are shown first): esophagitis, oesophagitis'),('http://sideeffects.embl.de/se/C0015230/','Rash',': Diseases in which skin eruptions or rashes are a prominent manifestation. Classically, six such diseases were described with similar rashes; they were numbered in the order in which they were reported. Only the fourth (Duke\'s disease), fifth (ERYTHEMA INFECTIOSUM), and sixth (EXANTHEMA SUBITUM) numeric designations survive as occasional synonyms in current terminology.','(terms occurring on more labels are shown first): rash, skin rash, rashes, skin rashes, exanthema, skin eruption, exanthem, skin-rash, cutaneous eruptions, Exanthemas, Skin - rash, Skinrash, Skin- rash, exanthems, skinrashes, Skin -rash'),('http://sideeffects.embl.de/se/C0015371/','Extrapyramidal disorder',': A movement disorder caused by defects in the basal ganglia. The clinical manifestations include changes in the muscle tone, dyskinesia, and akinesia. Causes include vascular disorders, degenerative disorders, and antipsychotic drugs.','(terms occurring on more labels are shown first): extrapyramidal disorder, extrapyramidal syndrome, extrapyramidal disorders, extrapyramidal syndromes, extra pyramidal disorder, Extrapyramida l disorder, extra pyramidal disorders'),('http://sideeffects.embl.de/se/C0015397/','Eye disorder',': Any deviation from the normal structure or function of the eye that is manifested by a characteristic set of symptoms and signs.','(terms occurring on more labels are shown first): eye disorders, eye disorder, ophthalmic disorders, eye disease, Eyedisorders, eye diseases, E ye Disorders'),('http://sideeffects.embl.de/se/C0015423/','Eyelid disorder',': pathologic condition of either of the two movable folds (upper and lower) that protect the anterior surface of the eyeball or eyelid.','(terms occurring on more labels are shown first): eyelid disorder, eyelid diseases, eyelid disorders'),('http://sideeffects.embl.de/se/C0015672/','Fatigue',': That state, following a period of mental or bodily activity, characterized by a lessened capacity for work and reduced efficiency or accomplishment, usually accompanied by a feeling of weariness, sleepiness, or irritability. (On-line Medical Dictionary)','(terms occurring on more labels are shown first): fatigue, tiredness, fatigued, lack of energy, Fatigue d, loss of energy, weariness, lacking energy, Fat igue, Fat igu e, f atigue, decreased energy'),('http://sideeffects.embl.de/se/C0015929/','Foetal disorder',': Pathophysiological conditions of the FETUS in the UTERUS. Some fetal diseases may be treated with FETAL THERAPIES.','(terms occurring on more labels are shown first): Fetal Disorders, foetal disorders'),('http://sideeffects.embl.de/se/C0015967/','Body temperature increased',': A condition that manifests with abnormally high body temperature. In hyperthermic state, the hypothalamic set-point is normal but body temperature increases and overrides the ability to lose heat, resulting from exogenous heat exposure or endogenous heat production, e.g. in heat stroke, malignant hyperthermia, endocrine hyperthermia, or neuroleptic malignant syndrome. The concept does not refer to hyperpyrexia, the state when the hypothalamic set-point is reset at a higher temperature and is physiologically regulated.','(terms occurring on more labels are shown first): fever, pyrexia, hyperthermia, febrile, fevers, body temperature increased, elevated temperature, increased body temperature, temperature elevation, hyperthermic, feverish, raised temperature, high body temperature, temperature increase'),('http://sideeffects.embl.de/se/C0016059/','Fibrosis',': Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.','(terms occurring on more labels are shown first): fibrosis'),('http://sideeffects.embl.de/se/C0016199/','Flank pain',': A disorder characterized by marked discomfort sensation on the lateral side of the body in the region below the ribs and above the hip.','(terms occurring on more labels are shown first): flank pain, pain flank'),('http://sideeffects.embl.de/se/C0016204/','Flatulence',': Production or presence of gas in the gastrointestinal tract which may be expelled through the anus.','(terms occurring on more labels are shown first): flatulence, flatus, flatu- lence, flat ulence, f latulence'),('http://sideeffects.embl.de/se/C0016382/','Flushing',': A transient reddening of the face that may be due to fever, certain drugs, exertion, stress, or a disease process.','(terms occurring on more labels are shown first): flushing, flushes, facial flushing, flush, facial flush, skin flush, flushing face, flushed skin, Flushed, flushing of face, flushed face'),('http://sideeffects.embl.de/se/C0016412/','Folate deficiency',': A nutritional condition produced by a deficiency of FOLIC ACID in the diet. Many plant and animal tissues contain folic acid, abundant in green leafy vegetables, yeast, liver, and mushrooms but destroyed by long-term cooking. Alcohol interferes with its intermediate metabolism and absorption. Folic acid deficiency may develop in long-term anticonvulsant therapy or with use of oral contraceptives. This deficiency causes anemia, macrocytic anemia, and megaloblastic anemia. It is indistinguishable from vitamin B 12 deficiency in peripheral blood and bone marrow findings, but the neurologic lesions seen in B 12 deficiency do not occur. (Merck Manual, 16th ed)','(terms occurring on more labels are shown first): folate deficiency, deficiency of folic acid, folic acid deficiency'),('http://sideeffects.embl.de/se/C0016436/','Folliculitis',': Inflammation of the hair follicles. Causes include excessive perspiration, skin infections, and skin wounds.','(terms occurring on more labels are shown first): folliculitis, folli- culitis'),('http://sideeffects.embl.de/se/C0016658/','Fracture',': A finding of traumatic injury to the bone in which the continuity of the bone is broken.','(terms occurring on more labels are shown first): fractures, fracture, bone fracture, bone fractures, fracture bone, fractured'),('http://sideeffects.embl.de/se/C0017086/','Gangrene',': Death of tissue, usually in considerable mass and generally associated with loss of vascular (nutritive) supply and followed by bacterial invasion and putrefaction.','(terms occurring on more labels are shown first): gangrene'),('http://sideeffects.embl.de/se/C0017152/','Gastritis',': Inflammation of the GASTRIC MUCOSA, a lesion observed in a number of unrelated disorders.','(terms occurring on more labels are shown first): gastritis, gastric inflammation'),('http://sideeffects.embl.de/se/C0017160/','Gastroenteritis',': Inflammation of the lining of the stomach and the intestines. Symptoms may include nausea, vomiting, diarrhea, and abdominal cramps (dull or sharp pains). Gastroenteritis may be caused by infection with bacteria, parasites, or viruses. It may also be caused by food poisoning, allergic reactions, or reactions to certain medicines or foods.','(terms occurring on more labels are shown first): gastroenteritis'),('http://sideeffects.embl.de/se/C0017168/','Gastrooesophageal reflux disease',': A disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is chronic in nature and usually caused by incompetence of the lower esophageal sphincter, and may result in injury to the esophageal mucosal. Symptoms include heartburn and acid indigestion.','(terms occurring on more labels are shown first): GERD, gastroesophageal reflux, gastroesophageal reflux disease, gastric reflux, gastrooesophageal reflux disease, gastro-oesophageal reflux disease, gastro-esophageal reflux disease, acid reflux, gastro-esophageal reflux, gastro-oesophageal reflux, gastro- oesophageal reflux disease, gastro oesophageal reflux disease, oesophageal reflux, GORD, gastro- oesophageal reflux, Esophageal reflux, Gastrooesophageal reflux, Gastroesophageal refluxdisease, gastro -esophageal reflux disease, Gastrooeso- phageal reflux, GastroesophagealReflux Disease, Gastroesophage al reflux, Gastro-oesophagea l reflux, Gastro-oesophage al reflux disease, Gastro-oesopha geal reflux disease, Gastro- esophageal reflux disease, gastro esophageal reflux disease'),('http://sideeffects.embl.de/se/C0017178/','Gastrointestinal disorder',': determination of disorder(s) in any segment of the gastrointestinal tract from the esophagus to the rectum based on symptoms, medical history, risk factors, and clinical tests.','(terms occurring on more labels are shown first): gastrointestinal disorders, gastrointestinal disorder, gastrointestinal diseases, gastrointestinal disease, gastro-intestinal disorders, gastro-intestinal disorder, Gastrointestinal system disorder, Gastro- intestinal disorders, Gastrointestinal tract disorders, Gastrointestina l disorders, Disorder Gastrointestinal, Gastrointestinaldisorders, Gastrointestinal d isorders, gastro- intestinal disorder, Disorder Gastro-Intestinal, Gastrointestin al disorders, Gastrointestinal Dis, Gastrointesti nal disorders, Gastroi ntestinal di sorders, gas-trointestinal disorder, Disorders Gastrointestinal'),('http://sideeffects.embl.de/se/C0017181/','Gastrointestinal haemorrhage',': Bleeding in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM.','(terms occurring on more labels are shown first): gastrointestinal hemorrhage, gastrointestinal bleeding, GI hemorrhage, gastrointestinal haemorrhage, GI bleeding, gastro-intestinal bleeding, GI haemorrhage, gastro- intestinal bleeding, gastrointestinal haemorrhages, gastrointestinal bleed, Gastro-intestinal haemorrhage, GI bleed, gastro-intestinal hemorrhage, gastro- intestinal hemorrhage, gastro intestinal bleeding, hemorrhage of gastrointestinal tract, gastrointes- tinal bleeding'),('http://sideeffects.embl.de/se/C0017574/','Gingivitis',': A disorder involving inflammation of the gums; may affect surrounding and supporting structures of the teeth.','(terms occurring on more labels are shown first): gingivitis, inflammation of the gums, gum inflammation'),('http://sideeffects.embl.de/se/C0017605/','Angle closure glaucoma',': A form of glaucoma in which the intraocular pressure increases because the angle of the anterior chamber is blocked and the aqueous humor cannot drain from the anterior chamber.','(terms occurring on more labels are shown first): angle-closure glaucoma, angle closure glaucoma, narrow-angle glaucoma, narrow angle glaucoma, closed angle glaucoma, closed-angle glaucoma, angle- closure glaucoma'),('http://sideeffects.embl.de/se/C0017675/','Glossitis',': Inflammation of the tongue.','(terms occurring on more labels are shown first): glossitis, tongue inflammation'),('http://sideeffects.embl.de/se/C0018099/','Gout',': hereditary metabolic disorder characterized by recurrent acute arthritis, hyperuricemia and deposition of sodium urate in and around the joints, sometimes with formation of uric acid calculi.','(terms occurring on more labels are shown first): gout'),('http://sideeffects.embl.de/se/C0018418/','Gynaecomastia',': Enlargement of the BREAST in the males, caused by an excess of ESTROGENS. Physiological gynecomastia is normally observed in NEWBORNS; ADOLESCENT; and AGING males.','(terms occurring on more labels are shown first): gynecomastia, gynaecomastia, Gynaecomas tia, Gynaecom astia, g ynaecomastia'),('http://sideeffects.embl.de/se/C0018520/','Breath odour',': An offensive, foul breath odor resulting from a variety of causes such as poor oral hygiene, dental or oral infections, or the ingestion of certain foods.','(terms occurring on more labels are shown first): halitosis, bad breath, breath odour, breath odor'),('http://sideeffects.embl.de/se/C0018524/','Hallucination',': subjectively experienced sensations in the absence of an appropriate stimulus, but which are regarded by the individual as real; may be of organic origin, drug induced, or associated with a mental disorder.','(terms occurring on more labels are shown first): hallucinations, hallucination, halluci- nations'),('http://sideeffects.embl.de/se/C0018674/','Head injury',': Traumatic injuries involving the cranium and intracranial structures (i.e., BRAIN; CRANIAL NERVES; MENINGES; and other structures). Injuries may be classified by whether or not the skull is penetrated (i.e., penetrating vs. nonpenetrating) or whether there is an associated hemorrhage.','(terms occurring on more labels are shown first): head injury, head trauma, Head Injuries'),('http://sideeffects.embl.de/se/C0018681/','Headache',': A disorder characterized by a sensation of marked discomfort in various parts of the head, not confined to the area of distribution of any nerve.','(terms occurring on more labels are shown first): headache, headaches, head ache, head- aches, cephalalgia, head pain, h eadache, H ea da ch e'),('http://sideeffects.embl.de/se/C0018772/','Partial hearing loss','(terms occurring on more labels are shown first): decreased hearing, impaired hearing, reduced hearing',':'),('http://sideeffects.embl.de/se/C0018790/','Cardiac arrest',': Cardiac arrest is the non-fatal, sudden cessation of cardiac activity so that the victim subject/patient becomes unresponsive, with no normal breathing and no signs of circulation. Cardiac arrest should be used to signify an event as described above that is reversed, usually by CPR, and/or defibrillation or cardioversion, or cardiac pacing.','(terms occurring on more labels are shown first): cardiac arrest, heart arrest, asystole, ventricular asystole, asystolic'),('http://sideeffects.embl.de/se/C0018794/','Block heart',': Impaired conduction of cardiac impulse that can occur anywhere along the conduction pathway, such as between the SINOATRIAL NODE and the right atrium (SA block) or between atria and ventricles (AV block). Heart blocks can be classified by the duration, frequency, or completeness of conduction block. Reversibility depends on the degree of structural or functional defects.','(terms occurring on more labels are shown first): heart block, conduction block, heartblock'),('http://sideeffects.embl.de/se/C0018799/','Cardiac disorder',': Any deviation from the normal structure or function of the cardiac system that is manifested by a characteristic set of symptoms and signs.','(terms occurring on more labels are shown first): cardiac disorders, heart disease, cardiac disease, heart disorder, cardiac disorder, cardiac diseases, Cardiacdisorders, C ardiac disorders'),('http://sideeffects.embl.de/se/C0018801/','Cardiac failure',': A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.','(terms occurring on more labels are shown first): heart failure, cardiac failure, cardiac insufficiency, heart failures, heart insufficiency'),('http://sideeffects.embl.de/se/C0018802/','Cardiac failure congestive',': complication of heart diseases; defective cardiac filling and/or impaired contraction and emptying, resulting in the heart\'s inability to pump a sufficient amount of blood to meet the needs of the body tissues or to be able to do so only with an elevated filling pressure.','(terms occurring on more labels are shown first): congestive heart failure, cardiac failure congestive, congestive cardiac failure, congestive heartfailure, congestive heart disease'),('http://sideeffects.embl.de/se/C0018834/','Heartburn',': Substernal pain or burning sensation, usually associated with regurgitation of gastric juice into the esophagus.','(terms occurring on more labels are shown first): heartburn, pyrosis, b Rash, heart burn, heart-burn'),('http://sideeffects.embl.de/se/C0018926/','Haematemesis',': Vomiting of blood that is either fresh bright red, or older \"coffee-ground\" in character. It generally indicates bleeding of the UPPER GASTROINTESTINAL TRACT.','(terms occurring on more labels are shown first): hematemesis, haematemesis, vomiting blood'),('http://sideeffects.embl.de/se/C0018932/','Haematochezia',': The passage of bright red blood from the rectum. The blood may or may not be mixed with formed stool in the form of blood, blood clots, bloody stool or diarrhea.','(terms occurring on more labels are shown first): bloody stools, hematochezia, haematochezia'),('http://sideeffects.embl.de/se/C0018939/','Blood disorder',': A neoplastic or non-neoplastic disorder that affects the production and proliferation of the hematopoietic cells including lymphoid cells, the synthesis of hemoglobin, and/or the mechanisms of coagulation.','(terms occurring on more labels are shown first): blood dyscrasias, hematologic disorders, blood dyscrasia, Blood and lymphatic disorders, hematological disorders, blood disorders, haematological disorders, Blood and lymphatic systems disorders, Blood and lymphatic system disorder, blood disorder, Disorders of Blood and Lymphatic, Hematologic Disorder, Hematologic Diseases'),('http://sideeffects.embl.de/se/C0018965/','Haematuria',': A disorder characterized by laboratory test results that indicate blood in the urine.','(terms occurring on more labels are shown first): hematuria, haematuria, Urine blood'),('http://sideeffects.embl.de/se/C0019061/','Haemolytic uraemic syndrome',': A syndrome that is associated with microvascular diseases of the KIDNEY, such as RENAL CORTICAL NECROSIS. It is characterized by hemolytic anemia (ANEMIA, HEMOLYTIC); THROMBOCYTOPENIA; and ACUTE RENAL FAILURE.','(terms occurring on more labels are shown first): hemolytic uremic syndrome, hemolytic-uremic syndrome, haemolytic uraemic syndrome, hemolytic- uremic syndrome, hae- molytic uraemic syndrome'),('http://sideeffects.embl.de/se/C0019080/','Haemorrhage',': In medicine, loss of blood from damaged blood vessels. A hemorrhage may be internal or external, and usually involves a lot of bleeding in a short time.','(terms occurring on more labels are shown first): bleeding, hemorrhage, haemorrhage, bleed, hemorrhages, haemorrhages, bleeding problems, haemorrha ge, Bleeds'),('http://sideeffects.embl.de/se/C0019087/','Haemorrhagic disorder',': spontaneous or near spontaneous bleeding caused by a defect in clotting mechanisms (blood coagulation disorders) or another abnormality causing a structural flaw in the blood vessels (vascular hemostatic disorders).','(terms occurring on more labels are shown first): hemorrhagic diathesis, hemorrhagic disorder, Haemorrhagic diathesis, Haemorrhagic disorder'),('http://sideeffects.embl.de/se/C0019112/','Haemorrhoids',': Swollen veins in the lower part of the RECTUM or ANUS. Hemorrhoids can be inside the anus (internal), under the skin around the anus (external), or protruding from inside to outside of the anus. People with hemorrhoids may or may not exhibit symptoms which include bleeding, itching, and pain.','(terms occurring on more labels are shown first): hemorrhoids, haemorrhoids, hemorrhoid, hemo rrhoids'),('http://sideeffects.embl.de/se/C0019158/','Hepatitis',': Disease of the liver causing inflammation. Symptoms include an enlarged liver, fever, nausea, vomiting, abdominal pain, and dark urine.','(terms occurring on more labels are shown first): hepatitis, nonspecific hepatitis'),('http://sideeffects.embl.de/se/C0019189/','Chronic hepatitis',': INFLAMMATION of the LIVER with ongoing hepatocellular injury for 6 months or more, characterized by NECROSIS of HEPATOCYTES and inflammatory cell (LEUKOCYTES) infiltration. Chronic hepatitis can be caused by viruses, medications, autoimmune diseases, and other unknown factors.','(terms occurring on more labels are shown first): chronic hepatitis, recurrent hepatitis'),('http://sideeffects.embl.de/se/C0019209/','Hepatomegaly',': Abnormal enlargement of the liver.','(terms occurring on more labels are shown first): hepatomegaly, enlarged liver, liver enlargement, hepato-megaly'),('http://sideeffects.embl.de/se/C0019270/','Hernia',': Protrusion of tissue, structure, or part of an organ through the bone, muscular tissue, or the membrane by which it is normally contained. Hernia may involve tissues such as the ABDOMINAL WALL or the respiratory DIAPHRAGM. Hernias may be internal, external, congenital, or acquired.','(terms occurring on more labels are shown first): hernia'),('http://sideeffects.embl.de/se/C0019345/','Herpes labialis',': Herpes simplex, caused by type 1 virus, primarily spread by oral secretions and usually occurring as a concomitant of fever. It may also develop in the absence of fever or prior illness. It commonly involves the facial region, especially the lips and the nares. (Dorland, 27th ed.)','(terms occurring on more labels are shown first): cold sores, herpes labialis, cold sore, fever sore, fever blisters'),('http://sideeffects.embl.de/se/C0019348/','Herpes simplex',': A group of acute infections caused by herpes simplex virus type 1 or type 2 that is characterized by the development of one or more small fluid-filled vesicles with a raised erythematous base on the skin or mucous membrane. It occurs as a primary infection or recurs due to a reactivation of a latent infection. (Dorland, 27th ed.)','(terms occurring on more labels are shown first): herpes simplex, herpes simplex infection, herpes simplex infections'),('http://sideeffects.embl.de/se/C0019521/','Hiccups',': A disorder characterized by repeated gulp sounds that result from an involuntary opening and closing of the glottis. This is attributed to a spasm of the diaphragm.','(terms occurring on more labels are shown first): hiccup, hiccups, hiccough, hiccoughs'),('http://sideeffects.embl.de/se/C0019557/','Hip fracture',': Traumatic or pathological injury to the hip in which the continuity of either the femoral head, femoral neck, intertrochanteric or subtrochanteric regions is broken. Symptoms include pain in the hip or groin, bruising and swelling in and around the hip area. The injured hip is turned outward and the leg appears shorter on that side.','(terms occurring on more labels are shown first): hip fracture, hip fractures'),('http://sideeffects.embl.de/se/C0020039/','Hostility',': Tendency to feel anger toward and to seek to inflict harm upon a person or group.','(terms occurring on more labels are shown first): hostility'),('http://sideeffects.embl.de/se/C0020433/','Hyperbilirubinaemia',': A condition characterized by an abnormal increase of BILIRUBIN in the blood, which may result in JAUNDICE. Bilirubin, a breakdown product of HEME, is normally excreted in the BILE or further catabolized before excretion in the urine.','(terms occurring on more labels are shown first): bilirubinemia, hyperbilirubinemia, hyperbilirubinaemia, bilirubinaemia, hyper-bilirubinemia'),('http://sideeffects.embl.de/se/C0020440/','Hypercapnia',': A clinical manifestation of abnormal increase in the amount of carbon dioxide in arterial blood.','(terms occurring on more labels are shown first): hypercapnia, hypercarbia'),('http://sideeffects.embl.de/se/C0020453/','Hyperaesthesia',': Increased sensitivity to cutaneous stimulation due to a diminished threshold or an increased response to stimuli.','(terms occurring on more labels are shown first): hyperesthesia, hyperaesthesia, hyper- aesthesia'),('http://sideeffects.embl.de/se/C0020456/','Hyperglycaemia',': A disorder characterized by laboratory test results that indicate an elevation in the concentration of blood sugar. It is usually an indication of diabetes mellitus or glucose intolerance.','(terms occurring on more labels are shown first): hyperglycemia, hyperglycaemia, increased blood sugar levels, Elevated blood glucose levels, Blood glucose increases, increased blood glucose level, high blood sugar, high blood glucose, increase in blood glucose, hyperglycem ia, Hyperglycaem ia, hyper- glycemia, h yperglycaemia, elevated blood sugar'),('http://sideeffects.embl.de/se/C0020458/','Hyperhidrosis',': Excessive sweating. In the localized type, the most frequent sites are the palms, soles, axillae, inguinal folds, and the perineal area. Its chief cause is thought to be emotional. Generalized hyperhidrosis may be induced by a hot, humid environment, by fever, or by vigorous exercise.','(terms occurring on more labels are shown first): hyperhidrosis, hyperhydrosis, H y perhidrosis, Hyperhidro sis, hyper-hidrosis'),('http://sideeffects.embl.de/se/C0020461/','Hyperkalaemia',': Abnormally high potassium concentration in the blood, most often due to defective renal excretion. It is characterized clinically by electrocardiographic abnormalities (elevated T waves and depressed P waves, and eventually by atrial asystole). In severe cases, weakness and flaccid paralysis may occur. (Dorland, 27th ed)','(terms occurring on more labels are shown first): hyperkalemia, hyperkalaemia, hyper- kalemia'),('http://sideeffects.embl.de/se/C0020488/','Hypernatraemia',': Excessive amount of sodium in the blood. (Dorland, 27th ed)','(terms occurring on more labels are shown first): sodium retention, hypernatremia, hypernatraemia, Sodium overload'),('http://sideeffects.embl.de/se/C0020517/','Hypersensitivity',': Hypersensitivity; a local or general reaction of an organism following contact with a specific allergen to which it has been previously exposed and to which it has become sensitized.','(terms occurring on more labels are shown first): hypersensitivity reactions, hypersensitivity, allergic reaction, allergic reactions, allergy, hypersensitivity reaction, allergies, hypersensitivity symptoms, allergic disorders, allergic response, HypersensitivityReactions, Hyper-sensitivity, hyper- sensitivity, Hy persensitivity reactions, hypersensitivity reac- tions, Hypersensitivit y, Hypersensitivi- ty reactions, Hypersensiti vity, hypersensit ivit y react ions, Hyper- sensitivity reaction, Hype rs e ns itivity, h ypersensitivity, allergic react ion'),('http://sideeffects.embl.de/se/C0020538/','Hypertension',': Pathological increase in blood pressure defined as one of the following: History of hypertension diagnosed and treated with medication, diet, and/or exercise; On at least 2 separate occasions, documented blood pressure greater than 140 mm Hg systolic and/or 90 mm Hg diastolic in patients without diabetes or chronic kidney disease, or blood pressure greater than 130 mm Hg systolic or 80 mm Hg diastolic in patients with diabetes or chronic kidney disease; Currently on pharmacological therapy for the treatment of hypertension.','(terms occurring on more labels are shown first): hypertension, high blood pressure, arterial hypertension, hyperten- sion, Vascular - Hypertension, hyper- tension, Hypertensio n'),('http://sideeffects.embl.de/se/C0020578/','Hyperventilation',': A pulmonary ventilation rate faster than is metabolically necessary for the exchange of gases. It is the result of an increased frequency of breathing, an increased tidal volume, or a combination of both. It causes an excess intake of oxygen and the blowing off of carbon dioxide.','(terms occurring on more labels are shown first): hyperventilation'),('http://sideeffects.embl.de/se/C0020580/','Hypoaesthesia',': Impairment of tactile sensitivity manifesting as partial loss of sensitivity to sensory stimuli.','(terms occurring on more labels are shown first): hypesthesia, hypoesthesia, hypoaesthesia, hypaesthesia, hypo-aesthesia, hypoesthesias, Hypoaesthes ia'),('http://sideeffects.embl.de/se/C0020598/','Hypocalcaemia',': Reduction of the blood calcium below normal. Manifestations include hyperactive deep tendon reflexes, Chvostek\'s sign, muscle and abdominal cramps, and carpopedal spasm. (Dorland, 27th ed)','(terms occurring on more labels are shown first): hypocalcemia, hypocalcaemia, Hypo- calcaemia, hypocalcae- mia'),('http://sideeffects.embl.de/se/C0020615/','Hypoglycaemia',': A syndrome of abnormally low BLOOD GLUCOSE level. Clinical hypoglycemia has diverse etiologies. Severe hypoglycemia eventually lead to glucose deprivation of the CENTRAL NERVOUS SYSTEM resulting in HUNGER; SWEATING; PARESTHESIA; impaired mental function; SEIZURES; COMA; and even DEATH.','(terms occurring on more labels are shown first): hypoglycemia, hypoglycaemia, low blood sugar, hypo-glycaemia, low blood sugar level'),('http://sideeffects.embl.de/se/C0020619/','Hypogonadism',': Condition resulting from deficient gonadal functions, such as GAMETOGENESIS and the production of GONADAL STEROID HORMONES. It is characterized by delay in GROWTH, germ cell maturation, and development of secondary sex characteristics. Hypogonadism can be due to a deficiency of GONADOTROPINS (hypogonadotropic hypogonadism) or due to primary gonadal failure (hypergonadotropic hypogonadism).','(terms occurring on more labels are shown first): hypogonadism'),('http://sideeffects.embl.de/se/C0020621/','Hypokalaemia',': Abnormally low potassium concentration in the blood. It may result from potassium loss by renal secretion or by the gastrointestinal route, as by vomiting or diarrhea. It may be manifested clinically by neuromuscular disorders ranging from weakness to paralysis, by electrocardiographic abnormalities (depression of the T wave and elevation of the U wave), by renal disease, and by gastrointestinal disorders. (Dorland, 27th ed)','(terms occurring on more labels are shown first): hypokalemia, hypokalaemia, hypokalaem- ia'),('http://sideeffects.embl.de/se/C0020625/','Hyponatraemia',': Hyponatremia is an electrolyte disturbance in which the sodium concentration in the serum is lower than normal. Sodium homeostasis is vital to the normal physiologic function of cells. Hyponatremia is defined as a serum level of less than 135 mEq/L and is considered severe when the serum level is below 125 mEq/L.','(terms occurring on more labels are shown first): hyponatremia, hyponatraemia, decreased serum sodium, decrease in serum sodium, Serum sodium decreased, blood sodium decreased, sodium depletion, decreased blood sodium, Hyponatraem ia'),('http://sideeffects.embl.de/se/C0020639/','Hypoproteinaemia',': A condition in which total serum protein level is below the normal range. Hypoproteinemia can be caused by protein malabsorption in the gastrointestinal tract, EDEMA, or PROTEINURIA.','(terms occurring on more labels are shown first): hypoproteinemia, hypoproteinaemia'),('http://sideeffects.embl.de/se/C0020649/','Hypotension',': Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.','(terms occurring on more labels are shown first): hypotension, lower blood pressure, decreased blood pressure, blood pressure decreased, fall in blood pressure, low blood pressure, drop in blood pressure, lowers blood pressure, lowered blood pressure, hypote nsion, arterial hypotension, h ypotension'),('http://sideeffects.embl.de/se/C0020651/','Orthostatic hypotension',': A significant drop in BLOOD PRESSURE after assuming a standing position. Orthostatic hypotension is a finding, and defined as a 20-mm Hg decrease in systolic pressure or a 10-mm Hg decrease in diastolic pressure 3 minutes after the person has risen from supine to standing. Symptoms generally include DIZZINESS, blurred vision, and SYNCOPE.','(terms occurring on more labels are shown first): postural hypotension, orthostatic hypotension, hypotension postural, hypotension orthostatic, posturalhypotension, Orthostatichypotension, hypotension-postural, o rthostatic hypotension, Hypotension - postural'),('http://sideeffects.embl.de/se/C0020672/','Body temperature decreased',': Abnormally low body temperature. Treatment is required when the body temperature is 35C (95F) or below. Symptoms include decreased mental function, lethargy, and disorientation.','(terms occurring on more labels are shown first): hypothermia, body temperature decreased, decreased body temperature, low body temperature, hypothermic'),('http://sideeffects.embl.de/se/C0021053/','Immune system disorder',': Disorders caused by abnormal or absent immunologic mechanisms, whether humoral, cell-mediated, or both.','(terms occurring on more labels are shown first): immune system disorders, immune system disorder, Immune disorders, Immunesystemdisorders, Immune system di sorders, immune disorder, Im mune System Disorders'),('http://sideeffects.embl.de/se/C0021099/','Impetigo',': A common superficial bacterial infection caused by STAPHYLOCOCCUS AUREUS or group A beta-hemolytic streptococci. Characteristics include pustular lesions that rupture and discharge a thin, amber-colored fluid that dries and forms a crust. This condition is commonly located on the face, especially about the mouth and nose.','(terms occurring on more labels are shown first): impetigo'),('http://sideeffects.embl.de/se/C0021177/','Libido increased',': A disorder characterized by an increase in sexual desire.','(terms occurring on more labels are shown first): increased libido, libido increased, increased sexual desire, increase in libido, increasedlibido'),('http://sideeffects.embl.de/se/C0021368/','Inflammation',': A localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.','(terms occurring on more labels are shown first): inflammation, inflammatory reaction, inflammations'),('http://sideeffects.embl.de/se/C0021400/','Influenza',': An acute viral infection of the respiratory tract, occurring in isolated cases, in epidemics, or in pandemics; it is caused by serologically different strains of viruses (influenzaviruses) designated A, B, and C, has a 3-day incubation period, and usually lasts for 3 to 10 days. It is marked by inflammation of the nasal mucosa, pharynx, and conjunctiva; headache; myalgia; often fever, chills, and prostration; and occasionally involvement of the myocardium or central nervous system. (from Dorland)','(terms occurring on more labels are shown first): flu syndrome, influenza, flu-syndrome, grippe, Influenzae'),('http://sideeffects.embl.de/se/C0021843/','Intestinal obstruction',': Any impairment, arrest, or reversal of the normal flow of INTESTINAL CONTENTS toward the ANAL CANAL.','(terms occurring on more labels are shown first): intestinal obstruction, bowel obstruction, i ntestinal obstruction'),('http://sideeffects.embl.de/se/C0022081/','Iritis',': inflammation of the iris characterized by circumcorneal injection, aqueous flare, keratotic precipitates, and constricted and sluggish pupil along with discoloration of the iris.','(terms occurring on more labels are shown first): iritis'),('http://sideeffects.embl.de/se/C0022107/','Irritability',': An abnormal responsiveness or morbid excitability of an organ, its part, or entire organism or its part to stimuli.','(terms occurring on more labels are shown first): irritability, irritable mood, irritable, fussiness, irritabilit y, irritabi lity'),('http://sideeffects.embl.de/se/C0022281/','Eye pruritus','(terms occurring on more labels are shown first): eye itching, eye pruritus, ocular itching, itchy eyes, itching eyes, eye itch, itching eye',':'),('http://sideeffects.embl.de/se/C0022346/','Jaundice',': A condition in which the skin and the whites of the eyes become yellow, urine darkens, and the color of stool becomes lighter than normal. Jaundice occurs when the liver is not working properly or when a bile duct is blocked.','(terms occurring on more labels are shown first): jaundice, icterus, jaun- dice'),('http://sideeffects.embl.de/se/C0022354/','Jaundice cholestatic',': Jaundice, the condition with yellowish staining of the skin and mucous membranes, that is due to impaired BILE flow in the BILIARY TRACT, such as INTRAHEPATIC CHOLESTASIS, or EXTRAHEPATIC CHOLESTASIS.','(terms occurring on more labels are shown first): cholestatic jaundice, obstructive jaundice, jaundice cholestatic, cholestatic icterus'),('http://sideeffects.embl.de/se/C0022408/','Arthropathy',': condition in which there is a deviation from or interruption of the normal structure or function of the joints.','(terms occurring on more labels are shown first): arthrosis, joint disorder, arthropathy, arthropathies, joint disorders, joint disease'),('http://sideeffects.embl.de/se/C0022568/','Keratitis',': A disorder characterized by inflammation to the cornea of the eye.','(terms occurring on more labels are shown first): keratitis'),('http://sideeffects.embl.de/se/C0022573/','Keratoconjunctivitis',': simultaneous inflammation of the cornea and conjunctiva.','(terms occurring on more labels are shown first): keratoconjunctivitis, kerato conjunctivitis'),('http://sideeffects.embl.de/se/C0022650/','Calculus of kidney',': Stones in the KIDNEY, usually formed in the urine-collecting area of the kidney (KIDNEY PELVIS). Their sizes vary and most contains CALCIUM OXALATE.','(terms occurring on more labels are shown first): renal calculus, kidney calculus, renal calculi, renal stone, kidney stones, renal stones, calculus renal, kidney stone, Calculus Kidney, kidneycalculus'),('http://sideeffects.embl.de/se/C0022660/','Renal failure acute',': clinical syndrome characterized by a sudden decrease in glomerular filtration rate, usually associated with oliguria and always associated with biochemical consequences of the reduction in glomerular filtration rate such as a rise in blood urea nitrogen (BUN) and serum creatinine concentrations.','(terms occurring on more labels are shown first): acute renal failure, acute kidney failure, renal failure acute, acut e renal failure'),('http://sideeffects.embl.de/se/C0023066/','Laryngospasm',': Paroxysmal spasmodic muscular contraction of the vocal cords. It is brief, usually lasting for less than one minute, interrupting the speech and breathing and may produce a high-pitched breathing sound. It may occur under anesthesia or may be associated with gastroesophageal reflex disease.','(terms occurring on more labels are shown first): laryngospasm, laryngismus, laryngeal spasm, laryngeal stridor, laryngospasms, laryn-gospasm'),('http://sideeffects.embl.de/se/C0023067/','Laryngitis',': Inflammation of the LARYNGEAL MUCOSA, including the VOCAL CORDS. Laryngitis is characterized by irritation, edema, and reduced pliability of the mucosa leading to VOICE DISORDERS such as APHONIA and HOARSENESS.','(terms occurring on more labels are shown first): laryngitis'),('http://sideeffects.embl.de/se/C0023218/','Cramps of lower extremities','(terms occurring on more labels are shown first): leg cramps, cramps legs, cramps leg, leg cramp, cramps in legs',':'),('http://sideeffects.embl.de/se/C0023380/','Lethargy',': A general state of sluggishness, listless, or uninterested, with being tired, and having difficulty concentrating and doing simple tasks. It may be related to DEPRESSION or DRUG ADDICTION.','(terms occurring on more labels are shown first): lethargy'),('http://sideeffects.embl.de/se/C0023418/','Leukaemia',': A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.','(terms occurring on more labels are shown first): leukemia, leukemias, leukaemia, leukaemias'),('http://sideeffects.embl.de/se/C0023530/','Leukopenia',': reduction in the number of leukocytes in the blood, the count being 5000 per cubic millimeter or less.','(terms occurring on more labels are shown first): leukopenia, leucopenia, leukocytopenia, leu- kopenia, Leucocytopenia'),('http://sideeffects.embl.de/se/C0023533/','Leukorrhea',': A clear or white discharge from the VAGINA, consisting mainly of MUCUS.','(terms occurring on more labels are shown first): leukorrhea, leukorrhoea, leucorrhoea'),('http://sideeffects.embl.de/se/C0023646/','Lichen planus',': An inflammatory, pruritic disease of the skin and mucous membranes, which can be either generalized or localized. It is characterized by distinctive purplish, flat-topped papules having a predilection for the trunk and flexor surfaces. The lesions may be discrete or coalesce to form plaques. Histologically, there is a \"saw-tooth\" pattern of epidermal hyperplasia and vacuolar alteration of the basal layer of the epidermis along with an intense upper dermal inflammatory infiltrate composed predominantly of T-cells. Etiology is unknown.','(terms occurring on more labels are shown first): lichen planus'),('http://sideeffects.embl.de/se/C0023895/','Liver disorder',': A non-neoplastic or neoplastic disorder that affects the liver parenchyma and intrahepatic bile ducts. Representative examples of non-neoplastic disorders include hepatitis, cirrhosis, cholangitis, and polycystic liver disease. Representative examples of neoplastic disorders include hepatocellular adenoma, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, lymphoma, and angiosarcoma.','(terms occurring on more labels are shown first): liver disease, hepatic disease, liver disorders, liver disorder, hepatocellular disease, hepatic disorders, liver diseases, hepatic disorder, liverdisease, liverdisorders, liverdisorder'),('http://sideeffects.embl.de/se/C0024115/','Lung disorder',': A non-neoplastic or neoplastic condition affecting the lung. Representative examples of non-neoplastic conditions include chronic obstructive pulmonary disease and pneumonia. Representative examples of neoplastic conditions include benign processes (e.g., respiratory papilloma) and malignant processes (e.g., lung carcinoma and metastatic cancer to the lung).','(terms occurring on more labels are shown first): lung disorder, pulmonary disease, lung disorders, lung diseases, lung disease, pulmonary disorders, pneumopathy, pulmonary disorder, pulmonary diseases, Disorder Lung'),('http://sideeffects.embl.de/se/C0024437/','Macular degeneration',': deterioration of the macula lutea in the retina; may be inherited, drug induced, or due to aging; leads to a severe loss of central vision while peripheral vision is retained.','(terms occurring on more labels are shown first): macular degeneration, macula lutea degeneration'),('http://sideeffects.embl.de/se/C0024902/','Breast pain',': Pain in the breast generally classified as cyclical (associated with menstrual periods), or noncyclical, i.e. originating from the breast or nearby muscles or joints, ranging from minor discomfort to severely incapacitating.','(terms occurring on more labels are shown first): breast pain, mastalgia, mastodynia, Pain Breast'),('http://sideeffects.embl.de/se/C0025061/','Mediastinal disorder',': Disorders of the mediastinum, general or unspecified.','(terms occurring on more labels are shown first): mediastinal disorders, mediastinal disorder, mediastinal disease, med iastinal disorders, me diastinal di sorders, M ediastinal disorders, m ediastinal d isorders'),('http://sideeffects.embl.de/se/C0025222/','Melaena',': Abnormally dark tarry feces containing blood (usually from gastrointestinal bleeding).','(terms occurring on more labels are shown first): melena, melaena, black tarry stools, tarry stool'),('http://sideeffects.embl.de/se/C0025289/','Meningitis',': Inflammation of the coverings of the brain and/or spinal cord, which consist of the PIA MATER; ARACHNOID; and DURA MATER. Infections (viral, bacterial, and fungal) are the most common causes of this condition, but subarachnoid hemorrhage (HEMORRHAGES, SUBARACHNOID), chemical irritation (chemical MENINGITIS), granulomatous conditions, neoplastic conditions (CARCINOMATOUS MENINGITIS), and other inflammatory conditions may produce this syndrome. (From Joynt, Clinical Neurology, 1994, Ch24, p6)','(terms occurring on more labels are shown first): meningitis, meningitides'),('http://sideeffects.embl.de/se/C0025290/','Meningitis aseptic',': A syndrome characterized by headache, neck stiffness, low grade fever, and CSF lymphocytic pleocytosis in the absence of an acute bacterial pathogen. Viral meningitis is the most frequent cause although MYCOPLASMA INFECTIONS; RICKETTSIA INFECTIONS; diagnostic or therapeutic procedures; NEOPLASTIC PROCESSES; septic perimeningeal foci; and other conditions may result in this syndrome. (From Adams et al., Principles of Neurology, 6th ed, p745)','(terms occurring on more labels are shown first): aseptic meningitis, asepticmeningitis, meningitis aseptic'),('http://sideeffects.embl.de/se/C0025345/','Menstrual disorder',': variations of menstruation or the menstrual cycle which may be indicative of disease.','(terms occurring on more labels are shown first): menstrual disorder, menstrual disorders, abnormal menses, menstruation disorder, menstrual disturbance'),('http://sideeffects.embl.de/se/C0026205/','Miosis',': Pupillary constriction. This may result from congenital absence of the dilatator pupillary muscle, defective sympathetic innervation, or irritation of the CONJUNCTIVA or CORNEA.','(terms occurring on more labels are shown first): miosis, small pupil, constricted pupil'),('http://sideeffects.embl.de/se/C0026650/','Movement disorder',': Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions.','(terms occurring on more labels are shown first): movement disorder, movement disorders'),('http://sideeffects.embl.de/se/C0026821/','Cramp muscle',': A sustained and usually painful contraction of muscle fibers. This may occur as an isolated phenomenon or as a manifestation of an underlying disease process (e.g., UREMIA; HYPOTHYROIDISM; MOTOR NEURON DISEASE; etc.). (From Adams et al., Principles of Neurology, 6th ed, p1398)','(terms occurring on more labels are shown first): muscle cramps, cramps, muscle cramp, cramping, cramp, muscular cramps, muscle cramping, muscular cramp, musclecramps'),('http://sideeffects.embl.de/se/C0026826/','Hypertonia',': abnormal increase in skeletal or smooth muscle tone; skeletal muscle hypertonicity may be associated with pyramidal tract lesions or basal ganglia diseases.','(terms occurring on more labels are shown first): hypertonia, increased muscle tone, increased muscle tonus, hypertonus, muscular tone increased, muscle hypertonia, muscular hypertonus, muscle hypertonicity'),('http://sideeffects.embl.de/se/C0026827/','Hypotonia',': A condition of decreased tone of the skeletal muscles and diminished resistance to passive stretching.','(terms occurring on more labels are shown first): hypotonia, muscular hypotonia'),('http://sideeffects.embl.de/se/C0026837/','Muscle rigidity',': Continuous involuntary sustained muscle contraction which is often a manifestation of BASAL GANGLIA DISEASES. When an affected muscle is passively stretched, the degree of resistance remains constant regardless of the rate at which the muscle is stretched. This feature helps to distinguish rigidity from MUSCLE SPASTICITY. (From Adams et al., Principles of Neurology, 6th ed, p73)','(terms occurring on more labels are shown first): muscle rigidity, rigidity, muscular rigidity'),('http://sideeffects.embl.de/se/C0026848/','Myopathy',': A non-neoplastic disorder that affects the muscles. Representative examples include muscular dystrophy, metabolic myopathies, muscular atrophies, and dermatomyositis.','(terms occurring on more labels are shown first): myopathy, muscle disorders, muscle disorder, muscular disorder, muscular disorders, Myopathies'),('http://sideeffects.embl.de/se/C0026858/','Musculoskeletal pain',': Discomfort referable to either the muscles or the bones themselves.','(terms occurring on more labels are shown first): musculoskeletal pain, musculo-skeletal pain, musculoskeletal pains, Musculo- skeletal pain, musculosk eletal pain, Musculoskelet al pain, Musculo skeletal pain'),('http://sideeffects.embl.de/se/C0026946/','Fungal infection',': An infection caused by a fungus.','(terms occurring on more labels are shown first): fungal infection, fungal infections, infection fungal, infection mycotic, fungal disease, mycoses, mycosis, mycotic infection, fungal diseases'),('http://sideeffects.embl.de/se/C0026961/','Mydriasis',': Dilation of pupils to greater than 6 mm combined with failure of the pupils to constrict when stimulated with light. This condition may occur due to injury of the pupillary fibers in the oculomotor nerve, in acute angle-closure glaucoma, and in ADIE SYNDROME.','(terms occurring on more labels are shown first): mydriasis, dilated pupils, dilation of the pupil, dilatation of pupils, dilatation of the pupil, pupillary dilatation, pupillary dilation, pupil dilation, pupils dilated, dilated pupil'),('http://sideeffects.embl.de/se/C0027051/','Myocardial infarction',': Gross necrosis of the myocardium, as a result of interruption of the blood supply to the area, as in coronary thrombosis.','(terms occurring on more labels are shown first): myocardial infarction, myocardial infarct, heart attack, myocardial infarctions, cardiac infarction, heart attacks'),('http://sideeffects.embl.de/se/C0027059/','Myocarditis',': Inflammatory processes of the muscular walls of the heart (MYOCARDIUM) which result in injury to the cardiac muscle cells (MYOCYTES, CARDIAC). Manifestations range from subclinical to sudden death (DEATH, SUDDEN). Myocarditis in association with cardiac dysfunction is classified as inflammatory CARDIOMYOPATHY usually caused by INFECTION, autoimmune diseases, or responses to toxic substances. Myocarditis is also a common cause of DILATED CARDIOMYOPATHY and other cardiomyopathies.','(terms occurring on more labels are shown first): myocarditis'),('http://sideeffects.embl.de/se/C0027066/','Myoclonus',': Involuntary shock-like contractions, irregular in rhythm and amplitude, followed by relaxation, of a muscle or a group of muscles. This condition may be a feature of some CENTRAL NERVOUS SYSTEM DISEASES; (e.g., EPILEPSY, MYOCLONIC). Nocturnal myoclonus is the principal feature of the NOCTURNAL MYOCLONUS SYNDROME. (From Adams et al., Principles of Neurology, 6th ed, pp102-3).','(terms occurring on more labels are shown first): myoclonus, myoclonic jerks'),('http://sideeffects.embl.de/se/C0027424/','Nasal congestion',': The blockage of the nasal passage due to mucosal edema. It is usually the result of a viral infection or an allergic reaction.','(terms occurring on more labels are shown first): nasal congestion, nasal stuffiness, stuffy nose, nasal con- gestion, n asal congestion, congestion -nasal, blocked nose'),('http://sideeffects.embl.de/se/C0027441/','Nasopharyngitis',': Inflammation of the NASOPHARYNX, usually including its mucosa, related lymphoid structure, and glands.','(terms occurring on more labels are shown first): nasopharyngitis, Nasopharyngiti s, Naso-pharyngitis'),('http://sideeffects.embl.de/se/C0027497/','Nausea',': An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.','(terms occurring on more labels are shown first): nausea, nauseated, nauseous, Naus ea, Nau sea, n ausea, N au sea'),('http://sideeffects.embl.de/se/C0027540/','Necrosis',': The pathological process occurring in cells that are dying from irreparable injuries. It is caused by the progressive, uncontrolled action of degradative ENZYMES, leading to MITOCHONDRIAL SWELLING, nuclear flocculation, and cell lysis. Distinguish it from APOPTOSIS which is a normal, regulated cellular process.','(terms occurring on more labels are shown first): necrosis, necrotic'),('http://sideeffects.embl.de/se/C0027697/','Nephritis',': Inflammation of the kidney. It is a focal or diffuse proliferative or destructive process which may involve the glomerulus, tubule, or interstitial renal tissue. (MeSH)','(terms occurring on more labels are shown first): nephritis'),('http://sideeffects.embl.de/se/C0027707/','Nephritis interstitial',': Inflammation of the interstitial tissue of the kidney. This term is generally used for primary inflammation of KIDNEY TUBULES and/or surrounding interstitium. For primary inflammation of glomerular interstitium, see GLOMERULONEPHRITIS. Infiltration of the inflammatory cells into the interstitial compartment results in EDEMA, increased spaces between the tubules, and tubular renal dysfunction.','(terms occurring on more labels are shown first): interstitial nephritis, nephritis interstitial, tubulo-interstitial nephropathy, i nterstitial nephritis'),('http://sideeffects.embl.de/se/C0027726/','Nephrotic syndrome',': A condition characterized by severe PROTEINURIA, greater than 3.5 g/day in an average adult. The substantial loss of protein in the urine results in complications such as HYPOPROTEINEMIA; generalized EDEMA; HYPERTENSION; and HYPERLIPIDEMIAS. Diseases associated with nephrotic syndrome generally cause chronic kidney dysfunction.','(terms occurring on more labels are shown first): nephrotic syndrome, nephroticsyndrome'),('http://sideeffects.embl.de/se/C0027765/','Nervous system disorder',': Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscle.','(terms occurring on more labels are shown first): nervous system disorders, nervous system disorder, neurological disease, nervous disorders, neurologic disorders, neurological disorders, neurological disorder, neurologic disorder, Nervoussystemdisorders, neurologic diseases, Nervous s ystem d isorders, Nervoussystem disorders, Nervous System Dis'),('http://sideeffects.embl.de/se/C0027769/','Nervousness',': An uneasy psychological state; the anxious feeling you have when you have the jitters.','(terms occurring on more labels are shown first): nervousness, N ervous, nervous tension, N E RVOUS, nervous- ness, nervousne ss, Ner vous, Ne rvous'),('http://sideeffects.embl.de/se/C0027813/','Neuritis',': A general term indicating inflammation of a peripheral or cranial nerve. Clinical manifestation may include PAIN; PARESTHESIAS; PARESIS; or HYPESTHESIA.','(terms occurring on more labels are shown first): neuritis, peripheral neuritis'),('http://sideeffects.embl.de/se/C0027849/','Neuroleptic malignant syndrome',': A potentially fatal syndrome associated primarily with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS) which are in turn associated with dopaminergic receptor blockade (see RECEPTORS, DOPAMINE) in the BASAL GANGLIA and HYPOTHALAMUS, and sympathetic dysregulation. Clinical features include diffuse MUSCLE RIGIDITY; TREMOR; high FEVER; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present. (From Adams et al., Principles of Neurology, 6th ed, p1199; Psychiatr Serv 1998 Sep;49(9):1163-72)','(terms occurring on more labels are shown first): neuroleptic malignant syndrome, neuroleptic malignant, Neuroleptic Malignant Syndrom e, n euroleptic malignant syndrome'),('http://sideeffects.embl.de/se/C0027868/','Neuromyopathy',': A general term encompassing lower MOTOR NEURON DISEASE; PERIPHERAL NERVOUS SYSTEM DISEASES; and certain MUSCULAR DISEASES. Manifestations include MUSCLE WEAKNESS; FASCICULATION; muscle ATROPHY; SPASM; MYOKYMIA; MUSCLE HYPERTONIA, myalgias, and MUSCLE HYPOTONIA.','(terms occurring on more labels are shown first): neuromyopathy, neuromuscular disorders'),('http://sideeffects.embl.de/se/C0027947/','Neutropenia',': decrease in the number of neutrophilic leukocytes in the blood.','(terms occurring on more labels are shown first): neutropenia, neutrophils decreased, neutropenias, N eutr open ia'),('http://sideeffects.embl.de/se/C0028077/','Night blindness',': Failure or imperfection of vision at night or in dim light, with good vision only on bright days. (Dorland, 27th ed)','(terms occurring on more labels are shown first): night blindness, nyctalopia, night-blindness'),('http://sideeffects.embl.de/se/C0028084/','Nightmare',': A sleep disorder characterized by the repeated occurrence of frightening dreams which precipitate awakenings from sleep; on awakening, the individual becomes fully alert and oriented and has detailed recall of the nightmare, which usually involves imminent danger or extreme embarrassment to the individual.','(terms occurring on more labels are shown first): nightmares, paroniria, nightmare'),('http://sideeffects.embl.de/se/C0028259/','Nodule',': A growth or lump that may be malignant (cancer) or benign (not cancer).','(terms occurring on more labels are shown first): nodules, nodule'),('http://sideeffects.embl.de/se/C0028643/','Numbness',': The loss of the sensation of feeling in an area of the body.','(terms occurring on more labels are shown first): numbness'),('http://sideeffects.embl.de/se/C0028738/','Nystagmus',': Involuntary movements of the eye that are divided into two types, jerk and pendular. Jerk nystagmus has a slow phase in one direction followed by a corrective fast phase in the opposite direction, and is usually caused by central or peripheral vestibular dysfunction. Pendular nystagmus features oscillations that are of equal velocity in both directions and this condition is often associated with visual loss early in life. (Adams et al., Principles of Neurology, 6th ed, p272)','(terms occurring on more labels are shown first): nystagmus'),('http://sideeffects.embl.de/se/C0028961/','Oliguria',': Decreased URINE output that is below the normal range. Oliguria can be defined as urine output of less than or equal to 0.5 or 1 ml/kg/hr depending on the age.','(terms occurring on more labels are shown first): oliguria, urine output decreased, decreased urine output, low urine output, urine volume decreased'),('http://sideeffects.embl.de/se/C0029134/','Optic neuritis',': Inflammation of the optic nerve. Commonly associated conditions include autoimmune disorders such as MULTIPLE SCLEROSIS, infections, and granulomatous diseases. Clinical features include retro-orbital pain that is aggravated by eye movement, loss of color vision, and contrast sensitivity that may progress to severe visual loss, an afferent pupillary defect (Marcus-Gunn pupil), and in some instances optic disc hyperemia and swelling. Inflammation may occur in the portion of the nerve within the globe (neuropapillitis or anterior optic neuritis) or the portion behind the globe (retrobulbar neuritis or posterior optic neuritis).','(terms occurring on more labels are shown first): optic neuritis'),('http://sideeffects.embl.de/se/C0029456/','Osteoporosis',': A condition of reduced bone mass, with decreased cortical thickness and a decrease in the number and size of the trabeculae of cancellous bone (but normal chemical composition), resulting in increased fracture incidence. Osteoporosis is classified as primary (Type 1, postmenopausal osteoporosis; Type 2, age-associated osteoporosis; and idiopathic, which can affect juveniles, premenopausal women, and middle-aged men) and secondary osteoporosis (which results from an identifiable cause of bone mass loss).','(terms occurring on more labels are shown first): osteoporosis'),('http://sideeffects.embl.de/se/C0029560/','Other conjunctivitis','(terms occurring on more labels are shown first): Conjunctivitis NEC, Other - Conjunctivitis',':'),('http://sideeffects.embl.de/se/C0029882/','Otitis media',': A disorder characterized by inflammation (physiologic response to irritation), swelling and redness to the middle ear.','(terms occurring on more labels are shown first): otitis media, otitismedia'),('http://sideeffects.embl.de/se/C0030193/','Pain',': An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.','(terms occurring on more labels are shown first): pain, pains, Painful, unspecified pain'),('http://sideeffects.embl.de/se/C0030232/','Pallor',': A clinical manifestation consisting of an unnatural paleness of the skin.','(terms occurring on more labels are shown first): pallor, paleness'),('http://sideeffects.embl.de/se/C0030252/','Palpitations',': A disorder characterized by an unpleasant sensation of irregular and/or forceful beating of the heart.','(terms occurring on more labels are shown first): palpitations, palpitation, heart throbbing'),('http://sideeffects.embl.de/se/C0030305/','Pancreatitis',': INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.','(terms occurring on more labels are shown first): pancreatitis, inflammation of the pancreas, pan- creatitis'),('http://sideeffects.embl.de/se/C0030312/','Pancytopenia',': Deficiency of all three cell elements of the blood, erythrocytes, leukocytes and platelets.','(terms occurring on more labels are shown first): pancytopenia, bone marrow failure, pancy topenia, pancytope- nia'),('http://sideeffects.embl.de/se/C0030353/','Papilloedema',': Swelling of the OPTIC DISK, usually in association with increased intracranial pressure, characterized by hyperemia, blurring of the disk margins, microhemorrhages, blind spot enlargement, and engorgement of retinal veins. Chronic papilledema may cause OPTIC ATROPHY and visual loss. (Miller et al., Clinical Neuro-Ophthalmology, 4th ed, p175)','(terms occurring on more labels are shown first): papilledema, papillitis, papilloedema, optic disc edema'),('http://sideeffects.embl.de/se/C0030469/','Sinus disorder',': Diseases affecting or involving the PARANASAL SINUSES and generally manifesting as inflammation, abscesses, cysts, or tumors.','(terms occurring on more labels are shown first): sinus disorder'),('http://sideeffects.embl.de/se/C0030554/','Paraesthesia',': Abnormal cutaneous sensations of tingling, numbness, pressure, cold, and warmth that an individual experiences without the presence of a stimulus. It results from functional disturbances of sensory neurons. Causes include peripheral vascular disease, peripheral neuropathy, and nerve damage.','(terms occurring on more labels are shown first): paresthesia, paresthesias, paraesthesia, parasthesia, paraesthesias, Paresthesia S, Parasthesias'),('http://sideeffects.embl.de/se/C0030920/','Peptic ulcer',': A break in the lining of the lower part of the esophagus, the stomach, or the upper part of the small intestine. Peptic ulcers form when cells on the surface of the lining become inflamed and die. They are usually caused by Helicobacter pylori bacteria and by certain medicines, such as aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs). Peptic ulcers may be linked to cancer and other diseases.','(terms occurring on more labels are shown first): peptic ulcer, peptic ulcers, peptic ulceration, peptic ulcer disease, gastro-duodenal ulcer, gastroduodenal ulcer, gastroduodenal ulcers, pepticulceration, pepticulcer, pep- tic ulcer, gastro- duodenal ulcer'),('http://sideeffects.embl.de/se/C0031046/','Pericarditis',': Inflammation of the PERICARDIUM from various origins, such as infection, neoplasm, autoimmune process, injuries, or drug-induced. Pericarditis usually leads to PERICARDIAL EFFUSION, or CONSTRICTIVE PERICARDITIS.','(terms occurring on more labels are shown first): pericarditis'),('http://sideeffects.embl.de/se/C0031212/','Personality disorder',': A diverse category of psychiatric disorders characterized by behavior that deviates markedly from the expectations of the individual\'s culture; this pattern of deviation is pervasive and inflexible and is stable over time. The behavioral pattern negatively interferes with relationships and work.','(terms occurring on more labels are shown first): personality disorder, personality disorders'),('http://sideeffects.embl.de/se/C0031350/','Pharyngitis',': Inflammation of the throat most often caused by viral and bacterial infections. Other causes include allergens, chemical substances, and trauma.','(terms occurring on more labels are shown first): pharyngitis, throat inflammation, throat soreness and irritation, pharyngeal inflammation, irritation of the throat, irritation in the throat'),('http://sideeffects.embl.de/se/C0031542/','Phlebitis',': Inflammation (redness, swelling, pain, and heat) of a vein, usually in the legs. Phlebitis may be caused by infection, injury, or irritation.','(terms occurring on more labels are shown first): phlebitis'),('http://sideeffects.embl.de/se/C0031924/','Piloerection',': The reflex process in which the arrectores pilorum (hair follicle) muscles contract and cause the hair to stand erect. [GOC:BHF, http://en.wikipedia.org/wiki/Pilomotor_reflex, PMID:21335239]','(terms occurring on more labels are shown first): piloerection, gooseflesh, goose-flesh, goosebumps, goose bumps, Pilo-erection'),('http://sideeffects.embl.de/se/C0032227/','Pleural effusion',': Increased amounts of fluid within the pleural cavity. Symptoms include shortness of breath, cough, and chest pain. It is usually caused by lung infections, congestive heart failure, pleural and lung tumors, connective tissue disorders, and trauma.','(terms occurring on more labels are shown first): pleural effusion, pleural effusions'),('http://sideeffects.embl.de/se/C0032285/','Pneumonia',': A severe inflammation of the lungs in which the alveoli (tiny air sacs) are filled with fluid. This may cause a decrease in the amount of oxygen that blood can absorb from air breathed into the lung. Pneumonia is usually caused by infection but may also be caused by radiation therapy, allergy, or irritation of lung tissue by inhaled substances. It may involve part or all of the lungs.','(terms occurring on more labels are shown first): pneumonia, pneumonitis, Pulmonary inflammation, Pneumoniae, pneumonias, lung inflammation, pulmonitis, p neumoniae, pneum, pn eumoniae'),('http://sideeffects.embl.de/se/C0032541/','Polyneuritis',': clinical syndrome characterized by widespread involvement of peripheral nerves, weakness, sensory loss, and impairment of reflexes.','(terms occurring on more labels are shown first): polyneuritis'),('http://sideeffects.embl.de/se/C0032617/','Polyuria',': Urination of a large volume of urine with an increase in urinary frequency, commonly seen in diabetes (DIABETES MELLITUS; DIABETES INSIPIDUS).','(terms occurring on more labels are shown first): polyuria, excessive diuresis, increase in urinary output, urine volume increased, high urine output'),('http://sideeffects.embl.de/se/C0032788/','Postoperative hemorrhage',': Bleeding occurring after completion of a surgical procedure. Postoperative bleeding may follow surgery immediately or may be delayed; it may be wound-related or not.','(terms occurring on more labels are shown first): postoperative bleeding, post-operative hemorrhage, post-operative blood loss, postoperative blood loss, post-operative haemorrhage, Post operative hemorrhage, post- operative hemorrhage'),('http://sideeffects.embl.de/se/C0032961/','Pregnancy',': The set of physiological processes that allow an embryo or foetus to develop within the body of a female animal. It covers the time from fertilization of a female ovum by a male spermatozoon until birth. [ISBN:0192800825]','(terms occurring on more labels are shown first): Pregnancy, gestation, Pregnancies'),('http://sideeffects.embl.de/se/C0033687/','Proteinuria',': A disorder characterized by laboratory test results that indicate the presence of excessive protein in the urine. It is predominantly albumin, but also globulin.','(terms occurring on more labels are shown first): proteinuria, urine protein present, proteinuria present, protein- uria'),('http://sideeffects.embl.de/se/C0033771/','Prurigo',': A name applied to several itchy skin eruptions of unknown cause. The characteristic course is the formation of a dome-shaped papule with a small transient vesicle on top, followed by crusting over or lichenification. (From Dorland, 27th ed)','(terms occurring on more labels are shown first): pruritic rash, rash pruritic, prurigo, itchy rash'),('http://sideeffects.embl.de/se/C0033774/','Pruritus',': Itching. Severe itching may be a side effect of some cancer treatments and a symptom of some types of cancers.','(terms occurring on more labels are shown first): pruritus, itching, pruritis, itchy, Skin pruritus, itching skin, itch Skin, Skin itching, pruritic disorder, itchy skin, Skin - pruritus, Prur itu s, p ruritus, itchskin'),('http://sideeffects.embl.de/se/C0033975/','Psychotic disorder',': WHAT: Psychosis.	Psychosis: a loss of contact with reality, a thought disorder, or a change of personality or behavior often associated with delusions, illusions, or hallucinations.	WHY:	Psychosis may occur in systemic lupus erythematosus, mixed connective tissue disease, or with the administration of steroids, cimetadine (Tagemet), or reserpine.	HOW:	A psychosis probably exists if a patient demonstrates one or more of the following major criteria: MAJOR CRITERIA LOSS OF CONTACT WITH REALITY -- evidenced by the misinterpretation of the environment as hostile when friendly or vice versa, generally causing bizarre responses to normal and usual environmental stimuli. THOUGHT DISTURBANCE -- evidenced by incoherence, marked illogical content, marked loose associations, or patient\'s admission of mental confusion and abnormal rate of mental activity. PERSONALITY/BEHAVIOR CHANGES -- characterized by rapid onset and reversals of previous behavior patterns, often observed by reliable family member or friend. The diagnosis is further strengthened by the presence of one or more of the following minor criteria: MINOR CRITERIA DELUSIONS -- firmly held beliefs that cannot be dissuaded by logical discussion; generally of a threatening, powerful, or grandiose nature. ILLUSIONS -- misperceptions of environmental stimuli, e.g. perceiving a person instead of an actual tree shadow. HALLUCINATIONS -- perceptions without environmental stimuli, e.g. hearing voices/noises or seeing a face/vision.	REFS:	1) \"Differential Diagnosis of Psychotic Features\". In Diagnostic and Statistical Manual of Mental Disorders, 3rd ed. (DSM III). Washington, D.C.: American Psychiatric Association, 1980. 2) Rothfield, N: \"Clinical Features of Systemic Lupus Erythematosus\". In Textbook of Rheumatology (Ch. 69). Philadelphia: W.B. Saunders Co., 1981. 3) Bennet, RM and Spargo, BH: Neuropsychiatric problems in mixed connective tissue disease. Am J Med 65(6), December 1978, pp. 955-62. DN19307-1. 4) Steinberg, AD: \"Management of Systemic Lupus Erythematosus\". In Textbook of Rheumatology (Ch. 70). Philadelphia: W.B. Saunders Co., 1981.','(terms occurring on more labels are shown first): psychosis, psychotic, psychotic disorders, psychoses, psychotic disorder, Psychotic disorder s, psy- chotic'),('http://sideeffects.embl.de/se/C0034063/','Pulmonary oedema',': Accumulation of fluid in the lung tissues causing disturbance of the gas exchange that may lead to respiratory failure. It is caused by direct injury to the lung parenchyma or congestive heart failure. The symptoms may appear suddenly or gradually. Suddenly appearing symptoms include difficulty breathing, feeling of suffocation, and coughing associated with frothy sputum. Gradually appearing symptoms include difficulty breathing while lying in bed, shortness of breath during activity, and weight gain (in patients with congestive heart failure).','(terms occurring on more labels are shown first): pulmonary edema, lung edema, pulmonary oedema, lung oedema'),('http://sideeffects.embl.de/se/C0034150/','Purpura',': A disorder characterized by hemorrhagic areas of the skin and mucous membrane. Newer lesions appear reddish in color. Older lesions are usually a darker purple color and eventually become a brownish-yellow color.','(terms occurring on more labels are shown first): purpura, peliosis, purpura Skin'),('http://sideeffects.embl.de/se/C0034882/','Rectal disorder',': Pathological developments in the RECTUM region of the large intestine (INTESTINE, LARGE).','(terms occurring on more labels are shown first): rectal disorder, rectal disorders, Disorder Rectal'),('http://sideeffects.embl.de/se/C0035078/','Renal failure',': A condition in which the kidneys stop working and are not able to remove waste and extra water from the blood or keep body chemicals in balance. Acute or severe renal failure happens suddenly (for example, after an injury) and may be treated and cured. Chronic renal failure develops over many years, may be caused by conditions like high blood pressure or diabetes, and cannot be cured. Chronic renal failure may lead to total and long-lasting renal failure, called end-stage renal disease (ESRD). A person in ESRD needs dialysis (the process of cleaning the blood by passing it through a membrane or filter) or a kidney transplant.','(terms occurring on more labels are shown first): renal failure, kidney failure, renalfailure'),('http://sideeffects.embl.de/se/C0035243/','Respiratory tract infection',': invasion and growth of microorganisms in the respiratory system; may be clinically inapparent or result in local cellular injury.','(terms occurring on more labels are shown first): respiratory tract infections, respiratory tract infection, respiratory infection, respiratory infections, infection Respiratory, Respiratory Inf ec tio n, respirat ory t ract infect'),('http://sideeffects.embl.de/se/C0035309/','Retinal disorder',': pathologic condition of the innermost of the three tunics of the eyeball or retina.','(terms occurring on more labels are shown first): retinopathy, retinal disorder, retinopathies, Disorders - retinal, retinal disorders'),('http://sideeffects.embl.de/se/C0035400/','Reye\'s syndrome',': rare, acute, sometimes fatal disease of childhood, most often occurring as a sequel of varicella or a viral upper respiratory infection of childhood; marked by recurrent vomiting and elevated serum transaminase levels with distinctive changes in the liver and other viscera; an encephalopathic phase with acute brain swelling disturbances of consciousness and seizures may follow.','(terms occurring on more labels are shown first): Reye\'s syndrome, Reye syndrome'),('http://sideeffects.embl.de/se/C0035435/','Rheumatism',': any of a variety of disorders marked by inflammation, degeneration, or metabolic derangement of the connective tissue structures of the body, especially the joints and related structures, including muscles, bursae, tendons, and fibrous tissue.','(terms occurring on more labels are shown first): rheumatism, rheumatic diseases, rheumatics'),('http://sideeffects.embl.de/se/C0035455/','Rhinitis',': An inflammation of the mucous membrane lining the nose, usually associated with nasal discharge.','(terms occurring on more labels are shown first): rhinitis'),('http://sideeffects.embl.de/se/C0036454/','Scotoma',': A localized defect in the visual field bordered by an area of normal vision. This occurs with a variety of EYE DISEASES (e.g., RETINAL DISEASES and GLAUCOMA); OPTIC NERVE DISEASES, and other conditions.','(terms occurring on more labels are shown first): visual field defect, scotoma, scotomata, visual field defects, scotomas, visual field loss, visual field disorders, visual fielddefect, visual field defe ct'),('http://sideeffects.embl.de/se/C0036508/','Seborrhoeic dermatitis',': A chronic inflammatory disease of the skin with unknown etiology. It is characterized by moderate ERYTHEMA, dry, moist, or greasy (SEBACEOUS GLAND) scaling and yellow crusted patches on various areas, especially the scalp, that exfoliate as dandruff. Seborrheic dermatitis is common in children and adolescents with HIV INFECTIONS.','(terms occurring on more labels are shown first): seborrhea, seborrheic dermatitis, seborrhoea, seborrhoeic dermatitis, dermatitis seborrheic, eczema seborrhoeic'),('http://sideeffects.embl.de/se/C0036572/','Convulsion',': WHAT: Seizure.	Seizure: a paroxysmal transient disturbance of brain function that may be manifested as episodic impairment or loss of consciousness, abnormal motor phenomena, psychic or sensory disturbance or perturbation of the autonomic brain electrical activity.	WHY:	Seizures may occur in systemic lupus erythematosus or in necrotizing vasculitides such as polyarteritis, eosinophilic granulomatous vasculitis, aortic arch arteritis, or rheumatoid arteritis.	HOW:	A seizure probably exists when there are generalized convulsions or focal motor/sensory phenomenon. GENERALIZED CONVULSIONS may be preceded by an aura but usually have a sudden loss of consciousness with generalized muscle rigidity then generalized muscle activity. They may have incontinence of urine or feces or laceration of the tongue or buccal mucosa. This usually is followed by flaccidity, drowsiness, or complaints of a headache or sore muscles. FOCAL MOTOR/SENSORY PHENOMENON may precede generalized convulsions but may be tonic or clonic muscle activity that is limited to one extremity, one side of the body, or one side of the face or lateralized/localized sensory sensations. These may only be brief sudden involuntary muscle contractions associated with transitory loss of muscle tone and a brief loss of contact with the environment, repetitive automatic behavior patterns, feelings of familiarity or unfamiliarity associated with compulsive thinking, unpleasant epi- gastric sensations that may radiate to the head, or hallucinations of an auditory, vertiginous, olfactory, gustatory, or visual type.	REFS:	1) Steinberg, AD: \"Management of Systemic Lupus Erythematosus\". In Textbook of Rheumatology (Ch. 70). Philadelphia: W.B. Saunders Co., 1981. 2) Hunder, GG and Conn, DL: \"Necrotizing Vasculitis\". In Textbook of Rheumatology (Ch. 72). Philadelphia: W.B. Saunders Co., 1981. 3) Harris, ED Jr: \"Pathogenesis of Rheumatoid Arthritis\". In Textbook of Rheumatology (Ch. 59). Philadelphia: W.B. Saunders Co., 1981. 4) Bennet, RM and Spargo, BH: Neuropsychiatric problems in mixed connective tissue disease. Am J Med 65(6), December 1978, pp. 955-62. DN19307-1. 5) Duman, S and Ginsburg, S: \"Epilepsy (Seizures)\". In Problem- Oriented Medical Diagnosis (Ch. 10). Boston: Little, Brown and Co., 1975.','(terms occurring on more labels are shown first): seizures, convulsions, seizure, convulsion, fits, Seizure s'),('http://sideeffects.embl.de/se/C0036690/','Septicemia',': The presence of pathogenic microorganisms in the blood stream causing a rapidly progressing systemic reaction that may lead to shock. Symptoms include fever, chills, tachycardia, and increased respiratory rate. It is a medical emergency that requires urgent medical attention.','(terms occurring on more labels are shown first): septicemia, septicaemia, septicemias'),('http://sideeffects.embl.de/se/C0036973/','Shivering',': Involuntary contraction or twitching of the muscles. It is a physiologic method of heat production in man and other mammals.','(terms occurring on more labels are shown first): shivering, Shiver, shivers'),('http://sideeffects.embl.de/se/C0036974/','Shock',': a profound hemodynamic and metabolic disturbance characterized by the failure of the circulatory system to maintain adequate perfusion of vital organs; causes inadequate delivery of nutrients and insufficient removal of cellular waste products to and from the tissues.','(terms occurring on more labels are shown first): shock, circulatory collapse, cardiovascular collapse, circulatory failure, vascular collapse, shock syndrome, circulatory shock, shocks, peripheral circulatory failure, shock Vascular, Shock Circulatory, collapse cardiovascular'),('http://sideeffects.embl.de/se/C0037036/','Salivary hypersecretion',': Increased salivary flow.','(terms occurring on more labels are shown first): increased salivation, salivary hypersecretion, saliva increased, increased saliva, hypersalivation, excessive salivation, sialorrhea, hyper-salivation, Ptyalism, salivation increase, Hypersecretion of saliva, sialorrhoea'),('http://sideeffects.embl.de/se/C0037199/','Sinusitis',': inflammatory process of the mucous membranes of the paranasal sinuses that occurs in three stages: acute, subacute, and chronic; results from any condition causing ostial obstruction or from pathophysiologic changes in the mucociliary transport mechanism.','(terms occurring on more labels are shown first): sinusitis, sinus infection'),('http://sideeffects.embl.de/se/C0037278/','Skin infection',': An inflammatory process affecting the skin, caused by bacteria, viruses, parasites, or fungi. Examples of bacterial infection include carbuncles, furuncles, impetigo, erysipelas, and abscesses. Examples of viral infection include shingles, warts, molluscum contagiosum, and pityriasis rosea. Examples of parasitic infection include scabies and lice. Examples of fungal infection include athlete\'s foot, yeast infection, and ringworm.','(terms occurring on more labels are shown first): skin infections, skin infection'),('http://sideeffects.embl.de/se/C0037284/','Skin lesion','(terms occurring on more labels are shown first): skin lesion',':'),('http://sideeffects.embl.de/se/C0037299/','Skin ulcer',': A circumscribed inflammatory and often suppurating and necrotic lesion on the skin. Causes include trauma, peripheral vascular disorder, diabetes, exposure to heat or cold, exposure to corrosive agents, infections, and prolonged staying in one position (pressure ulcer).','(terms occurring on more labels are shown first): skin ulcer, skin ulceration, cutaneous ulcers, ulcer skin, skin ulcers, skin ulcerations'),('http://sideeffects.embl.de/se/C0037763/','Muscle spasms',': a sudden, violent, involuntary contraction of a muscle or a group of muscles, attended by pain and interference with function, producing involuntary movement and distortion.','(terms occurring on more labels are shown first): spasm, muscle spasm, muscle spasms, spasms, muscular spasm, musclespasm'),('http://sideeffects.embl.de/se/C0037822/','Speech disorder',': A term referring to disorders characterized by the disruption of normal speech. It includes stuttering, lisps, dysarthria and voice disorders.','(terms occurring on more labels are shown first): speech disorder, speech disorders, Disorders Speech'),('http://sideeffects.embl.de/se/C0038325/','Stevens-Johnson syndrome',': A systemic, serious, and life-threatening disorder characterized by lesions in the skin and mucous membranes that may lead to necrosis. The lesions may appear anywhere in the body but they occur more commonly in the palms, soles, dorsum of the hands, and extensor surfaces. The lesions are vesicular or necrotic in the center, surrounded by an erythematous zone and occupy less than 10% of the body surfaces. The appearance of the mucocutaneous lesions is preceded by an upper respiratory tract infection. It is an immune complex hypersensitivity reaction usually caused by drugs (e.g., sulfa, phenytoin, penicillin), viruses (e.g., herpes simplex, influenza, hepatitis), and malignancies (e.g., carcinoma and lymphoma).','(terms occurring on more labels are shown first): Stevens-Johnson syndrome, Stevens Johnson syndrome, SJS, Stevens- Johnson syndrome, Steven-Johnson syndrome, erythema multiforme exudativum, Steven Johnson syndrome, Stevens - Johnson syndrome, Stevens-Johnsons syndrome, Stevens-Johnson-Syndrome, StevensJohnson syndrome, Stevens-Johnson- syndrome, Stevens -Johnson syndrome, Steven-Johnsons syndrome, Steven- Johnson syndrome, Stevens-Johnsonsyndrome, Stevens Johnson-syndrome, Ste-vens-Johnson syndrome, St evens-Johnson syndrome, erythema exudativum multiforme'),('http://sideeffects.embl.de/se/C0038358/','Gastric ulcer',': Ulceration of the GASTRIC MUCOSA due to contact with GASTRIC JUICE. It is often associated with HELICOBACTER PYLORI infection or consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).','(terms occurring on more labels are shown first): gastric ulcer, stomach ulcer, gastric ulcers, gastric ulceration, stomach ulcers, ulcer stomach'),('http://sideeffects.embl.de/se/C0038362/','Stomatitis',': INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP.','(terms occurring on more labels are shown first): stomatitis, stoma- titis, sto- matitis, mucositis oral'),('http://sideeffects.embl.de/se/C0038363/','Aphthous stomatitis',': A recurrent disease of the oral mucosa of unknown etiology. It is characterized by small white ulcerative lesions, single or multiple, round or oval. Two to eight crops of lesions occur per year, lasting for 7 to 14 days and then heal without scarring. (From Jablonski\'s Dictionary of Dentistry, 1992, p742)','(terms occurring on more labels are shown first): aphthous stomatitis, aphthous ulcers, aphthous ulcer, canker sore, aphtha, stomatitis aphthous, aphthous ulcerations, canker sores, canker sores oral'),('http://sideeffects.embl.de/se/C0038454/','Cerebrovascular accident',': A sudden loss of neurological function secondary to hemorrhage or ischemia in the brain parenchyma due to a vascular event. Infarction or hemorrhage may be demonstrated either directly by imaging, laboratory, or pathologic examination in patients with symptom duration less than 24 hours, or inferred by symptoms lasting greater than or equal to 24 hours (or fatal within 24 hours) that cannot be attributed to another cause. Diagnostic tests include CT scan, MRI, angiography, and EEG to locate and evaluate the extent of the hemorrhagic or ischemic damage in the brain parenchyma, coagulation studies, complete blood count, comprehensive metabolic panel, and urinalysis.','(terms occurring on more labels are shown first): cerebrovascular accident, stroke, strokes, cerebral vascular accident, cerebrovascular accidents, apoplexy'),('http://sideeffects.embl.de/se/C0038587/','Withdrawal syndrome',': A substance-specific organic brain syndrome that follows the discontinuation of administration or use, or reduction in intake of an addictive substance, e.g. opioids, barbiturates and alcohol; amphetamines or similarly acting sympathomimetics; cocaine; nicotine; sedatives, hypnotics, or anxiolytics. Syndrome manifests with diverse, often painful physical and psychological symptoms, which include but not limited to intense drug craving, anxiety, depression, insomnia, nausea, perspiration, body aches, tremors, hallucinations, and convulsions.','(terms occurring on more labels are shown first): withdrawal syndrome'),('http://sideeffects.embl.de/se/C0038814/','Sunburn',': An injury to the skin causing erythema, tenderness, and sometimes blistering and resulting from excessive exposure to the sun. The reaction is produced by the ultraviolet radiation in sunlight.','(terms occurring on more labels are shown first): sunburn, sunburns'),('http://sideeffects.embl.de/se/C0038990/','Sweating',': The process of exocrine secretion of the SWEAT GLANDS, including the aqueous sweat from the ECCRINE GLANDS and the complex viscous fluids of the APOCRINE GLANDS.','(terms occurring on more labels are shown first): sweating, sweats, perspiring'),('http://sideeffects.embl.de/se/C0038999/','Swelling',': Enlargement; expansion in size; sign of inflammation','(terms occurring on more labels are shown first): swelling, swollen'),('http://sideeffects.embl.de/se/C0039070/','Syncope',': A transient loss of consciousness and postural tone caused by diminished blood flow to the brain (i.e., BRAIN ISCHEMIA). Presyncope refers to the sensation of lightheadedness and loss of strength that precedes a syncopal event or accompanies an incomplete syncope. (From Adams et al., Principles of Neurology, 6th ed, pp367-9)','(terms occurring on more labels are shown first): syncope, faintness, fainting, Disorders Syncope, syncopes, s yncope, Fainting Syncope, Fainting episodes'),('http://sideeffects.embl.de/se/C0039231/','Tachycardia',': Abnormally rapid heartbeat, usually with a HEART RATE above 100 beats per minute for adults. Tachycardia accompanied by disturbance in the cardiac depolarization (cardiac arrhythmia) is called tachyarrhythmia.','(terms occurring on more labels are shown first): tachycardia, increase in pulse rate, heart rate increased, increase pulse rate, increased heart rate, rapid heartbeat, pulse increased, tachycardias, increased pulse rate, rapid pulse, fast heartbeat, rapid heart rate, fast pulse, tachycar dia, t achycardia, pulse rate increased, increasedHeart rate'),('http://sideeffects.embl.de/se/C0039240/','Supraventricular tachycardia',': A disorder characterized by a dysrhythmia with a heart rate greater than 100 beats per minute that originates above the ventricles.','(terms occurring on more labels are shown first): supraventricular tachycardia, supraventricular tachycardias, tachycardia supraventricular, Tachycardia Supra-ventricular, Supra-ventricular tachycardia, Tachycardia Supra- ventricular, supra ventricular tachycardia'),('http://sideeffects.embl.de/se/C0039971/','Thirst',': sensation associated with a craving to drink, ordinarily interpreted as a desire for water.','(terms occurring on more labels are shown first): thirst'),('http://sideeffects.embl.de/se/C0040034/','Thrombocytopenia',': A condition in which there is a lower-than-normal number of platelets in the blood. It may result in easy bruising and excessive bleeding from wounds or bleeding in mucous membranes and other tissues.','(terms occurring on more labels are shown first): thrombocytopenia, thrombopenia, thrombocytopaenia, thrombocytopenias, thrombocyto- penia, thrombo-cytopenia, thrombo- cytopenia, Thrombocytopen ia, thrombocytope-nia, thrombocytope- nia, Thrombocyto- paenia, Thrombocyt-openia, thromb ocytopenia, Thr om bocyt open ia'),('http://sideeffects.embl.de/se/C0040046/','Thrombophlebitis',': Inflammation of a vein associated with a blood clot (THROMBUS).','(terms occurring on more labels are shown first): thrombophlebitis, thrombo-phlebitis, Thrombo- phlebitis, throm- bophlebitis, throm bophlebitis'),('http://sideeffects.embl.de/se/C0040264/','Tinnitus',': A nonspecific symptom of hearing disorder characterized by the sensation of buzzing, ringing, clicking, pulsations, and other noises in the ear. Objective tinnitus refers to noises generated from within the ear or adjacent structures that can be heard by other individuals. The term subjective tinnitus is used when the sound is audible only to the affected individual. Tinnitus may occur as a manifestation of COCHLEAR DISEASES; VESTIBULOCOCHLEAR NERVE DISEASES; INTRACRANIAL HYPERTENSION; CRANIOCEREBRAL TRAUMA; and other conditions.','(terms occurring on more labels are shown first): tinnitus, buzzing in the ears'),('http://sideeffects.embl.de/se/C0040485/','Torticollis',': A symptom, not a disease, of a twisted neck. In most instances, the head is tipped toward one side and the chin rotated toward the other. The involuntary muscle contractions in the neck region of patients with torticollis can be due to congenital defects, trauma, inflammation, tumors, and neurological or other factors.','(terms occurring on more labels are shown first): torticollis, retrocollis'),('http://sideeffects.embl.de/se/C0040822/','Tremor',': Cyclical movement of a body part that can represent either a physiologic process or a manifestation of disease. Intention or action tremor, a common manifestation of CEREBELLAR DISEASES, is aggravated by movement. In contrast, resting tremor is maximal when there is no attempt at voluntary movement, and occurs as a relatively frequent manifestation of PARKINSON DISEASE.','(terms occurring on more labels are shown first): tremor, tremors, tremo r, Shaking'),('http://sideeffects.embl.de/se/C0040997/','Trigeminal neuralgia',': A syndrome characterized by recurrent episodes of excruciating pain lasting several seconds or longer in the sensory distribution of the TRIGEMINAL NERVE. Pain may be initiated by stimulation of trigger points on the face, lips, or gums or by movement of facial muscles or chewing. Associated conditions include MULTIPLE SCLEROSIS, vascular anomalies, ANEURYSMS, and neoplasms. (Adams et al., Principles of Neurology, 6th ed, p187)','(terms occurring on more labels are shown first): trigeminal neuralgia, tic douloureux'),('http://sideeffects.embl.de/se/C0041582/','Ulcer',': The formation of a break on the skin or on the surface of an organ. An ulcer forms when the surface cells die and are cast off. Ulcers may be associated with cancer and other diseases.','(terms occurring on more labels are shown first): ulceration, ulcer, ulcers, ulcerative, ulcerations, ulcerated'),('http://sideeffects.embl.de/se/C0041834/','Erythema',': Redness of the skin produced by congestion of the capillaries. This condition may result from a variety of causes.','(terms occurring on more labels are shown first): erythema, skin erythema, skin redness, Erythemas, redness of skin, Skin - Erythema, Skin -- erythema, SkinErythema, Er ythema'),('http://sideeffects.embl.de/se/C0041912/','Upper respiratory tract infection',': An infectious process affecting the upper respiratory tract (nose, paranasal sinuses, pharynx, larynx, or trachea). Symptoms include congestion, sneezing, coughing, fever, and sore throat.','(terms occurring on more labels are shown first): upper respiratory tract infection, upper respiratory infection, upper respiratory tract infections, upper respiratory infections, Upper resp tract infection, infection upper respiratory, URTI, upper-respiratory tract infections, upper- respiratory tract infections, upper-respiratory tract infection, Upper RespiratoryTract Infection, u pper respiratory tract infection'),('http://sideeffects.embl.de/se/C0042023/','Pollakiuria',': Urination at short intervals; it may result from increased urine formation, decreased bladder capacity, or lower urinary tract irritation.','(terms occurring on more labels are shown first): urinary frequency, micturition frequency, pollakiuria, frequent urination, urination frequency, increased urinary frequency, micturition frequency increased, increased frequency of urination, Frequency of urination, frequency of micturition, Frequency Urinary, pollakisuria, Increased UrinaryFrequency, increased frequency of micturition, Frequency Urination, micturitionfrequency'),('http://sideeffects.embl.de/se/C0042024/','Urinary incontinence',': Involuntary loss of URINE, such as leaking of urine. It is a symptom of various underlying pathological processes. Major types of incontinence include URINARY URGE INCONTINENCE and URINARY STRESS INCONTINENCE.','(terms occurring on more labels are shown first): urinary incontinence, incontinence of urine, urine incontinence, urinary inconti- nence, urinar y incontinence, Involuntary urination'),('http://sideeffects.embl.de/se/C0042029/','Urinary tract infection',': A bacterial infectious process affecting any part of the urinary tract, most commonly the bladder and the urethra. Symptoms include urinary urgency and frequency, burning sensation during urination, lower abdominal discomfort, and cloudy urine.','(terms occurring on more labels are shown first): urinary tract infection, urinary tract infections, urinary infection, infection urinary tract, UTIs, Urinary tractinfection, Urinary tract infect, Urinarytractinfection, urinarytract infection'),('http://sideeffects.embl.de/se/C0042075/','Urinary tract disorder',': condition in which there is a deviation from or interruption of the normal structure or function of the urinary tract.','(terms occurring on more labels are shown first): renal and urinary disorders, urinary system disorders, urinary tract disorder, urinary tract disorders, Urinary system disorder, Renalandurinarydisorders, Renaland urinary disorders, Renal urinary disorders'),('http://sideeffects.embl.de/se/C0042109/','Urticaria',': A vascular reaction of the skin characterized by erythema and wheal formation due to localized increase of vascular permeability. The causative mechanism may be allergy, infection, or stress.','(terms occurring on more labels are shown first): urticaria, hives, urticarial rash, Urticarial, urticarias, urt icaria'),('http://sideeffects.embl.de/se/C0042130/','Uterine contractions',': A process in which force is generated within smooth muscle tissue, resulting in a change in muscle geometry. This process occurs in the uterus. Force generation involves a chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis. The uterus is a muscular organ of the female mammal for containing and usually for nourishing the young during development prior to birth. [GOC:sl]','(terms occurring on more labels are shown first): uterine contractions'),('http://sideeffects.embl.de/se/C0042267/','Vaginal inflammation',': A disorder characterized by inflammation involving the vagina. Symptoms may include redness, edema, marked discomfort and an increase in vaginal discharge.','(terms occurring on more labels are shown first): vaginitis, Colpitis, inflammation of vagina, vaginal inflammation, v aginitis'),('http://sideeffects.embl.de/se/C0042373/','Angiopathy',': A non-neoplastic or neoplastic disorder affecting the arteries, veins, or lymphatic vessels. Examples include vasculitis, thrombophlebitis, arteriosclerosis, lymphedema, hemangioma, and angiosarcoma.','(terms occurring on more labels are shown first): vascular disorders, vascular disorder, vascular disease, angiopathy, blood vessel disease, vascular diseases, Vasculardisorders, Vascu lar Disorders'),('http://sideeffects.embl.de/se/C0042401/','Vasodilation',': An increase in the internal diameter of blood vessels, especially arterioles or capillaries, usually resulting in a decrease in blood pressure. [ISBN:0192800981]','(terms occurring on more labels are shown first): vasodilation, peripheral vasodilation'),('http://sideeffects.embl.de/se/C0042571/','Vertigo',': An illusion of movement, either of the external world revolving around the individual or of the individual revolving in space. Vertigo may be associated with disorders of the inner ear (EAR, INNER); VESTIBULAR NERVE; BRAINSTEM; or CEREBRAL CORTEX. Lesions in the TEMPORAL LOBE and PARIETAL LOBE may be associated with FOCAL SEIZURES that may feature vertigo as an ictal manifestation. (From Adams et al., Principles of Neurology, 6th ed, pp300-1)','(terms occurring on more labels are shown first): vertigo, spinning sensation, ver- tigo'),('http://sideeffects.embl.de/se/C0042907/','Vitreous detachment',': Detachment of the corpus vitreum (VITREOUS BODY) from its normal attachments, especially the retina, due to shrinkage from degenerative or inflammatory conditions, trauma, myopia, or senility.','(terms occurring on more labels are shown first): vitreous detachment'),('http://sideeffects.embl.de/se/C0042963/','Vomiting',': A disorder characterized by the reflexive act of ejecting the contents of the stomach through the mouth.','(terms occurring on more labels are shown first): vomiting, emesis, vomits, Vomitin g, vomited, vom- iting, throwing up, vomiting symptoms, vomit- ing, vomit ing, v omiting'),('http://sideeffects.embl.de/se/C0043049/','Water intoxication',': A condition resulting from the excessive retention of water with sodium depletion.','(terms occurring on more labels are shown first): water intoxication'),('http://sideeffects.embl.de/se/C0043094/','Weight increased',': A finding characterized by an increase in overall body weight; for pediatrics, greater than the baseline growth curve.','(terms occurring on more labels are shown first): weight gain, weight increase, weight increased, increased weight, increase in body weight, body weight gain, gained weight, weight gains, W eight gain, body-weight gain'),('http://sideeffects.embl.de/se/C0043096/','Weight decreased',': the reduction of overall body mass; may be due to disease, diet, or drugs; can be permanent or temporary, and may involve any tissue.','(terms occurring on more labels are shown first): weight loss, weight decrease, weight decreased, decreased weight, weight reduction, body weight decreasing, loss of weight, decreased body weight, reduced body weight, lower body weight, lose weight, weightdecrease, weight re- duction, reduction Weight, decreasedweight, decrease in body weight'),('http://sideeffects.embl.de/se/C0043251/','Trauma',': damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity; for emotional trauma use PSYCHOLOGICAL SHOCK.','(terms occurring on more labels are shown first): trauma'),('http://sideeffects.embl.de/se/C0043352/','Dry mouth',': A disorder characterized by reduced salivary flow in the oral cavity.','(terms occurring on more labels are shown first): dry mouth, mouth dry, xerostomia, aptyalism, mouth dryness, hyposalivation, oral dryness, drymouth, dry mout h, d ry mouth'),('http://sideeffects.embl.de/se/C0080274/','Urinary retention',': A disorder characterized by accumulation of urine within the bladder because of the inability to urinate.','(terms occurring on more labels are shown first): urinary retention, inability to empty bladder, urine retention, bladder retention, retention of urine, u rinary retention'),('http://sideeffects.embl.de/se/C0085593/','Chills',': A disorder characterized by a sensation of cold that often marks a physiologic response to sweating after a fever.','(terms occurring on more labels are shown first): chills, chilling'),('http://sideeffects.embl.de/se/C0085605/','Hepatic failure',': A disorder characterized by the inability of the liver to metabolize chemicals in the body. Causes include cirrhosis and drug-induced hepatotoxicity. Signs and symptoms include jaundice and encephalopathy. Laboratory test results reveal abnormal plasma levels of ammonia, bilirubin, lactic dehydrogenase, and alkaline phosphatase.','(terms occurring on more labels are shown first): hepatic failure, liver failure, liver decompensation'),('http://sideeffects.embl.de/se/C0085624/','Burning sensation',': A sensation of stinging or heat, not necessarily accompanied by redness or physical signs of irritation.','(terms occurring on more labels are shown first): burning sensation, burning sensations, burningsensation'),('http://sideeffects.embl.de/se/C0085628/','Stupor',': A state of reduced sensibility and response to stimuli which is distinguished from COMA in that the person can be aroused by vigorous and repeated stimulation. The person is still conscious and can make voluntary movements. It can be induced by CENTRAL NERVOUS SYSTEM AGENTS. The word derives from Latin stupere and is related to stunned, stupid, dazed or LETHARGY.','(terms occurring on more labels are shown first): stupor, obtundation, obtunded'),('http://sideeffects.embl.de/se/C0085631/','Agitation',': A condition in which a person is unable to relax and be still. The person may be very tense and irritable, and become easily annoyed by small things. He or she may be eager to have an argument, and be unwilling to work with caregivers to make the situation better.','(terms occurring on more labels are shown first): agitation, restlessness, psychomotor agitation, psychomotor hyperactivity, agitated, agitated behavior, psychomotor restlessness, psychomot or restlessness, restless, Agitate, agita- tion'),('http://sideeffects.embl.de/se/C0085636/','Photophobia',': Abnormal sensitivity to light. This may occur as a manifestation of EYE DISEASES; MIGRAINE; SUBARACHNOID HEMORRHAGE; MENINGITIS; and other disorders. Photophobia may also occur in association with DEPRESSION and other MENTAL DISORDERS.','(terms occurring on more labels are shown first): photophobia, light sensitivity'),('http://sideeffects.embl.de/se/C0085642/','Livedo reticularis',': A recurrent purple discoloration of the skin involving most often the lower extremities. It may be aggravated by exposure to cold and is classified as idiopathic or secondary. Secondary livedo reticularis may be a cutaneous manifestation of immune system disorders (e.g., lupus erythematosus, rheumatoid arthritis, cryoglobulinemia, lymphoma, etc), and hematologic disorders (polycythemia vera).','(terms occurring on more labels are shown first): livedo reticularis'),('http://sideeffects.embl.de/se/C0085649/','Oedema peripheral',': A disorder characterized by swelling due to excessive fluid accumulation in the upper or lower extremities.','(terms occurring on more labels are shown first): peripheral edema, edema peripheral, peripheral oedema, oedema peripheral, oedema of extremities, edema of extremities, Oedema - peripheral, Oedemaperipheral, Edema - Peripheral, peripheraledema'),('http://sideeffects.embl.de/se/C0085661/','Onycholysis',': Separation of nail plate from the underlying nail bed. It can be a sign of skin disease, infection (such as ONYCHOMYCOSIS) or tissue injury.','(terms occurring on more labels are shown first): onycholysis'),('http://sideeffects.embl.de/se/C0086543/','Cataract',': A condition in which the lens of the eye becomes cloudy. Symptoms include blurred, cloudy, or double vision; sensitivity to light; and difficulty seeing at night. Without treatment, cataracts can cause blindness. There are many different types and causes of cataracts. They may occur in people of all ages, but are most common in the elderly.','(terms occurring on more labels are shown first): cataract, cataracts'),('http://sideeffects.embl.de/se/C0086565/','Hepatic function abnormal',': A finding that indicates abnormal liver function.','(terms occurring on more labels are shown first): hepatic dysfunction, abnormal liver function, hepatic function abnormal, liver dysfunction, impaired liver function, impairment of liver function, impaired hepatic function, liver function disorders, hepatic function disorder, impairment of hepatic function, impair-ment of liver function, impair- ment of liver function, Hepaticfunctionabnormal, hepaticdysfunction'),('http://sideeffects.embl.de/se/C0149871/','Deep vein thrombosis',': The formation of a blood clot in a deep vein of the leg or lower pelvis. Symptoms may include pain, swelling, warmth, and redness in the affected area.','(terms occurring on more labels are shown first): deep vein thrombosis, deep venous thrombosis, deep vein thrombophlebitis, deep-vein thrombosis, deep-vein thrombophlebitis, deep vein thromboses'),('http://sideeffects.embl.de/se/C0149904/','Hepatitis cholestatic','(terms occurring on more labels are shown first): cholestatic hepatitis, hepatitis cholestatic, cholestatichepatitis',':'),('http://sideeffects.embl.de/se/C0149931/','Migraine',': neural condition characterized by a severe recurrent vascular headache, usually on one side of the head, often accompanied by nausea, vomiting, and photophobia, sometimes preceded by sensory disturbances; triggers include allergic reactions, excess carbohydrates or iodine in the diet, alcohol, bright lights or loud noises.','(terms occurring on more labels are shown first): migraine, migraine headaches, migraine headache, migraines'),('http://sideeffects.embl.de/se/C0151480/','Antinuclear antibody positive',': Antibodies directed against nuclear antigens; almost invariably found in systemic lupus erythematosus and are frequently found in rheumatoid arthritis, scleroderma, Sjogren\'s Syndrome and mixed connective tissue disease.','(terms occurring on more labels are shown first): positive ANA, positive antinuclear antibody, positive tests for antinuclear antibody, antinuclear factor test positive, positive anti-nuclear antibody, antinuclear antibody present, positive antinuclear antibody test'),('http://sideeffects.embl.de/se/C0151505/','Application site reaction','(terms occurring on more labels are shown first): application site reaction, reactions at the application site, Application-Site Reaction',':'),('http://sideeffects.embl.de/se/C0151529/','Bleeding time prolonged','(terms occurring on more labels are shown first): bleeding time increased, increased bleeding time, bleeding time prolonged, prolonged bleeding time',':'),('http://sideeffects.embl.de/se/C0151539/','Blood urea increased','(terms occurring on more labels are shown first): increases in blood urea nitrogen, Bun increased, increased BUN, blood urea increased, elevated BUN, elevated blood urea nitrogen, increases in blood urea, blood urea nitrogen increased, increased blood urea nitrogen, elevated blood urea levels',':'),('http://sideeffects.embl.de/se/C0151601/','Conjunctival oedema','(terms occurring on more labels are shown first): conjunctival edema, conjunctival oedema',':'),('http://sideeffects.embl.de/se/C0151602/','Swelling face','(terms occurring on more labels are shown first): facial swelling, swelling face, swelling of face, face swelling, swollen face',':'),('http://sideeffects.embl.de/se/C0151662/','Gamma-glutamyltransferase increased',': A finding based on laboratory test results that indicate higher than normal levels of the enzyme gamma-glutamyltransferase in the blood specimen. GGT (gamma-glutamyltransferase ) catalyzes the transfer of a gamma glutamyl group from a gamma glutamyl peptide to another peptide, amino acids or water.','(terms occurring on more labels are shown first): gamma glutamyl transpeptidase increased, GGT increased, gamma-gt increased, gamma-glutamyltransferase increased, increased GGT, gamma GT increased, g-GT increased, gamma-glutamyl transferase increased, increased gamma-GT, gamma- glutamyltransferase increased, elevated GGTP, GGT - Increased, Gamma - GT increased, elevated gamma-GT, GGTP increase, gamma glutamyltransferase increased, GGT-increased, Gamma-glutamyl-transpeptidase increased, gamma glutamyl transferase increased, increased gamma GT, gammaglutamyl transferase increased, gamma-glutamyltransf erase increased, Gamma-glutamyl transpeptidase increased, gamma- glutamyl transferase increased'),('http://sideeffects.embl.de/se/C0151692/','Impaired healing','(terms occurring on more labels are shown first): impaired wound healing, healing abnormal, abnormal healing, delayed healing, impaired healing, delayed wound healing, abnormal wound healing, healing impaired',':'),('http://sideeffects.embl.de/se/C0151698/','Injection site haemorrhage','(terms occurring on more labels are shown first): injection site hemorrhage, injection site haemorrhage, injection site bleeding, injection-site hemorrhage, bleeding at the injection site, hemorrhage Injection site',':'),('http://sideeffects.embl.de/se/C0151701/','Pulmonary haemorrhage',': Bleeding from the lung parenchyma.','(terms occurring on more labels are shown first): pulmonary hemorrhage, pulmonary haemorrhage, lung hemorrhage, Lung haemorrhage'),('http://sideeffects.embl.de/se/C0151735/','Injection site reaction',': A disorder characterized by an intense adverse reaction (usually immunologic) developing at the site of an injection.','(terms occurring on more labels are shown first): injection site reaction, injection site reactions, injection-site reactions, injection-site reaction, ISR, InjectionSite Reactions, Injection S ite R eactions'),('http://sideeffects.embl.de/se/C0151736/','Accidental injury','(terms occurring on more labels are shown first): accidental injury, accidental injuries, AccidentalInjury',':'),('http://sideeffects.embl.de/se/C0151754/','Lactic dehydrogenase activity increased','(terms occurring on more labels are shown first): lactic dehydrogenase increased, elevated LDH, LDH increased, increased LDH, increased lactate dehydrogenase, lactate dehydrogenase increased, increased serum lactate dehydrogenase, lactic dehydrogenaseincreased',':'),('http://sideeffects.embl.de/se/C0151763/','Hepatocellular injury','(terms occurring on more labels are shown first): liver damage, hepatocellular damage, hepatocellular injury, hepatic cytolysis, hepatic damage, damageliver',':'),('http://sideeffects.embl.de/se/C0151766/','Liver function test abnormal','(terms occurring on more labels are shown first): abnormal liver function tests, liver function tests abnormal, abnormal liver function test, liver function test abnormal, abnormal liver-function tests, disturbance of liver function tests, liver function tests NOS abnormal, abnormal LFTs, abnormal liverfunction tests, abnormal LFT',':'),('http://sideeffects.embl.de/se/C0151798/','Hepatic necrosis',': A disorder characterized by a necrotic process occurring in the hepatic parenchyma.','(terms occurring on more labels are shown first): hepatic necrosis, liver necrosis, hepatocellular necrosis'),('http://sideeffects.embl.de/se/C0151810/','Lack of drug effect','(terms occurring on more labels are shown first): lack of drug effect',':'),('http://sideeffects.embl.de/se/C0151825/','Bone pain',': A disorder characterized by marked discomfort sensation in the bones.','(terms occurring on more labels are shown first): bone pain, skeletal pain, Pain-bone'),('http://sideeffects.embl.de/se/C0151827/','Eye pain',': A dull or sharp painful sensation associated with the outer or inner structures of the eyeball, having different causes.','(terms occurring on more labels are shown first): eye pain, ocular pain, pain eye, Pain - Eye, Pain in Eyes'),('http://sideeffects.embl.de/se/C0151828/','Injection site pain','(terms occurring on more labels are shown first): injection site pain, pain at the injection site, pain at injection site, injection-site pain, Pain injection site, pain on injection site, injection- site pain',':'),('http://sideeffects.embl.de/se/C0151849/','Phosphatase alkaline increased','(terms occurring on more labels are shown first): alkaline phosphatase increased, increased alkaline phosphatase, elevated alkaline phosphatase, phosphatase alkaline increased, ALP increased, Alkaline phosphatase -Increased, Alk phos increased, Alkaline phosphatase - Increased, increased ALP, elevated alkalinephosphatase',':'),('http://sideeffects.embl.de/se/C0151883/','Vesiculobullous rash','(terms occurring on more labels are shown first): vesiculobullous rash, vesiculobullous eruptions, vesiculo-bullous rash, vesiculobullous eruption, vesiculobullous dermatitis, vesiculobullousrash, vesicu- lobullous rash, rash Vesiculobullous',':'),('http://sideeffects.embl.de/se/C0151889/','Hyperreflexia','(terms occurring on more labels are shown first): reflexes increased, hyperreflexia, increased reflexes, increased deep tendon reflexes, hyper-reflexia',':'),('http://sideeffects.embl.de/se/C0151904/','Aspartate aminotransferase increased',': A finding based on laboratory test results that indicate an increase in the level of aspartate aminotransferase (AST or SGOT) in a blood specimen.','(terms occurring on more labels are shown first): SGOT increased, AST increased, aspartate aminotransferase increased, increased AST, increased SGOT, elevated SGOT, elevated AST, increases in AST, Aspartate transaminase increased, increased aspartate aminotransferase, increases of SGOT, elevated aspartate aminotransferase, increases in aminotransferase, increases in SGOT, increase in AST, SGOT - Increased, elevated serum aspartate transaminase, AST-increased, aspartate aminotransferase increase, Aspartate amino transferase increased, Aspartate aminotransfer- ase increased'),('http://sideeffects.embl.de/se/C0151905/','Alanine aminotransferase increased',': A finding based on laboratory test results that indicate an increase in the level of alanine aminotransferase (ALT or SGPT) in the blood specimen.','(terms occurring on more labels are shown first): SGPT increased, ALT increased, alanine aminotransferase increased, increased ALT, elevated ALT, increased SGPT, increases in ALT, elevated SGPT, alanine transaminase increase, alanine aminotransferase increase, increases in alanine transaminase, elevated alanine aminotransferase, increases in SGPT, increased alanine aminotransferase, elevated serum alanine aminotransferase, increases in aminotransferase, increases of ALT, raised alanine aminotransferase, SGPT-increased, elevated serum ALT, alanine amino transferase increased, increased alanine amino transferase, increase in SGPT, ALT elevated, Alanine aminotransfer- ase increased, Alanine aminotransfer ase increased'),('http://sideeffects.embl.de/se/C0151907/','Skin discolouration',': A change from the patient\'s baseline skin coloration.','(terms occurring on more labels are shown first): skin discoloration, skin discolouration, discoloration of skin, skin discol- oration'),('http://sideeffects.embl.de/se/C0151908/','Dry skin',': A disorder characterized by flaky and dull skin; the pores are generally fine, the texture is a papery thin texture.','(terms occurring on more labels are shown first): dry skin, skin dry, skin dryness'),('http://sideeffects.embl.de/se/C0152027/','Sensory disturbance',': disorders of the special senses (ie, vision, hearing, taste and smell) or somatosensory system (ie, afferent components of the peripheral nervous system).','(terms occurring on more labels are shown first): sensory disturbance, sensory disorders, Sensory disorder'),('http://sideeffects.embl.de/se/C0152030/','Skin irritation',': A mild inflammatory dermal tissue reaction; it can be caused by physical contact with an irritant or can be a local response to a systemic trigger.','(terms occurring on more labels are shown first): skin irritation, irritation of the skin, Irritation Skin, irritation of skin'),('http://sideeffects.embl.de/se/C0152128/','Drug withdrawal syndrome',': physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation; the concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug.','(terms occurring on more labels are shown first): drug withdrawal syndrome, Drug withdrawal'),('http://sideeffects.embl.de/se/C0152227/','Lacrimation increased','(terms occurring on more labels are shown first): lacrimation increased, excessive tearing, increased lacrimation, epiphora, tearing eyes, excessive lacrimation',':'),('http://sideeffects.embl.de/se/C0155169/','Ocular hyperaemia','(terms occurring on more labels are shown first): ocular hyperemia, ocular hyperaemia, Eye Inflamed, Hyperemia Eye',':'),('http://sideeffects.embl.de/se/C0155216/','Eyelid bleeding','(terms occurring on more labels are shown first): Eyelid bleeding',':'),('http://sideeffects.embl.de/se/C0160390/','Liver injury','(terms occurring on more labels are shown first): liver injury, hepatic injury, liver-injury',':'),('http://sideeffects.embl.de/se/C0162119/','Haemoglobin decreased',': A laboratory test result which indicates decreased levels of hemoglobin in a biological specimen.','(terms occurring on more labels are shown first): decreased hemoglobin, hemoglobin decreased, hemoglobin drop, decreased haemoglobin, haemoglobin decreased, low hemoglobin, drop in hemoglobin, Hemoglobin low, low haemoglobin, DecreasedHaemoglobin'),('http://sideeffects.embl.de/se/C0162281/','Corneal deposits','(terms occurring on more labels are shown first): corneal deposits',':'),('http://sideeffects.embl.de/se/C0162285/','Eyelid oedema','(terms occurring on more labels are shown first): eyelid edema, eyelid oedema, palpebral edema, Eye lid oedema',':'),('http://sideeffects.embl.de/se/C0162297/','Respiratory arrest',': Cessation of breathing function.','(terms occurring on more labels are shown first): respiratory arrest, respiratoryarrest, respir- atory arrest'),('http://sideeffects.embl.de/se/C0162429/','Malnutrition',': A condition caused by not getting enough calories or the right amount of key nutrients, such as vitamins and minerals, that are needed for health. Malnutrition may occur when there is a lack of nutrients in the diet or when the body cannot absorb nutrients from food. Cancer and cancer treatment may cause malnutrition.','(terms occurring on more labels are shown first): nutritional disorders, nutrition disorders, nutritional disorder, malnourished, malnutrition, undernutrition, under nutrition, nutrition disorder, Dietary deficiency, nutritiondisorders, Nutrit io nal Disorders, NUTRITIONALDISORDERS, N utritional D isorders, nutrition di sorders, n utrition disorders, n utrition d isorders'),('http://sideeffects.embl.de/se/C0162823/','Dermatitis irritant contact',': A non-allergic contact dermatitis caused by prolonged exposure to irritants and not explained by delayed hypersensitivity mechanisms.','(terms occurring on more labels are shown first): irritant dermatitis, irritant contact dermatitis'),('http://sideeffects.embl.de/se/C0162830/','Photosensitivity reaction',': A nonimmunologic, chemically induced type of photosensitivity producing a sometimes vesiculating dermatitis. It results in hyperpigmentation and desquamation of the light-exposed areas of the skin.','(terms occurring on more labels are shown first): photosensitivity reaction, photosensitivity reactions, photosensitive reaction, photosensitive dermatitis, photosensitive rash, photosensitivity toxic reaction, photosensitizing, rash Photosensitivity, photosensitivity reac tions, Photo-sensitivity reactions, phototoxic reaction, Photosensiti vity reaction, phototoxic reactions, photosensitivity rash, Photo- sensitivity reactions'),('http://sideeffects.embl.de/se/C0178298/','Unspecified disorder of skin and subcutaneous tissue','(terms occurring on more labels are shown first): skin and subcutaneous tissue disorders, Skin and subcutaneous tissues disorders, Skinandsubcutaneoustissuedisorders, Skin and Subcutaneous TissueDisorders, Skin and SubcutaneousTissue disorders, Skinand subcutaneoustissue disorders',':'),('http://sideeffects.embl.de/se/C0206277/','Fatal outcomes',': Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.','(terms occurring on more labels are shown first): fatal outcome, fatal outcomes, fataloutcome'),('http://sideeffects.embl.de/se/C0220870/','Lightheadedness','(terms occurring on more labels are shown first): lightheadedness, light-headedness, lightheaded, light-headed feeling, light headedness, lightheaded feeling, light-headed, light- headedness, lightheaded-ness, light headed feeling',':'),('http://sideeffects.embl.de/se/C0221201/','Rash macular','(terms occurring on more labels are shown first): rash macular, macular rash, Rash-Macular',':'),('http://sideeffects.embl.de/se/C0221203/','Rash vesicular','(terms occurring on more labels are shown first): vesicular rash, rash vesicular',':'),('http://sideeffects.embl.de/se/C0221242/','Fixed drug eruption','(terms occurring on more labels are shown first): fixed drug eruption, fixed drug eruptions',':'),('http://sideeffects.embl.de/se/C0221490/','Epigastric distress','(terms occurring on more labels are shown first): epigastric distress, epigas- tric distress, epi- gastric distress',':'),('http://sideeffects.embl.de/se/C0221512/','Stomach ache',': A disorder characterized by a sensation of marked discomfort in the stomach.','(terms occurring on more labels are shown first): gastric pain, gastralgia, stomach pain, stomachache, stomach ache, stomach-ache'),('http://sideeffects.embl.de/se/C0231218/','Malaise',': A disorder characterized by a feeling of general discomfort or uneasiness, an out-of-sorts feeling.','(terms occurring on more labels are shown first): malaise, general malaise, feeling unwell, feel unwell, General feeling of illness'),('http://sideeffects.embl.de/se/C0231528/','Myalgia',': A disorder characterized by marked discomfort sensation originating from a muscle or group of muscles.','(terms occurring on more labels are shown first): myalgia, muscle pain, myalgias, muscle aches, muscle ache, muscular pain, pain muscle, muscle pains, myalgic, muscle soreness, painMuscular, muscular pains, Muscle discomfort'),('http://sideeffects.embl.de/se/C0231530/','Muscle twitching',': The occurrence of a single contraction or a series of contractions of a muscle.','(terms occurring on more labels are shown first): twitching, muscle twitching, twitch, twitches, Jerking, muscle twitch, jerks'),('http://sideeffects.embl.de/se/C0232292/','Chest tightness','(terms occurring on more labels are shown first): chest tightness, tightness in chest, tightness of chest, tight chest, Chest - tightness, tightness chest',':'),('http://sideeffects.embl.de/se/C0232461/','Increased appetite','(terms occurring on more labels are shown first): increased appetite, appetite increased, appetite increase, Increasedappetite, increase appetite',':'),('http://sideeffects.embl.de/se/C0232462/','Decreased appetite','(terms occurring on more labels are shown first): decreased appetite, appetite decreased, poor appetite, appetite decrease, reduced appetite, decrease appetite, decrease in appetite',':'),('http://sideeffects.embl.de/se/C0232487/','Abdominal discomfort','(terms occurring on more labels are shown first): abdominal discomfort',':'),('http://sideeffects.embl.de/se/C0232492/','Abdominal pain upper','(terms occurring on more labels are shown first): abdominal pain upper, upper abdominal pain, abdominal pain - upper',':'),('http://sideeffects.embl.de/se/C0232493/','Epigastric pain','(terms occurring on more labels are shown first): epigastric pain, epigastralgia, pain epigastric',':'),('http://sideeffects.embl.de/se/C0232726/','Rectal tenesmus',': Painful spasm of the anal sphincter along with an urgent desire to defecate without the significant production of feces; associated with irritable bowel syndrome.','(terms occurring on more labels are shown first): tenesmus, rectal tenesmus'),('http://sideeffects.embl.de/se/C0233407/','Disorientation','(terms occurring on more labels are shown first): disorientation',':'),('http://sideeffects.embl.de/se/C0233414/','Disturbance in attention','(terms occurring on more labels are shown first): disturbance in attention, attention disturbances',':'),('http://sideeffects.embl.de/se/C0233459/','Emotional disorder','(terms occurring on more labels are shown first): emotional disorder',':'),('http://sideeffects.embl.de/se/C0233477/','Dysphoria','(terms occurring on more labels are shown first): dysphoria, dysphoric mood',':'),('http://sideeffects.embl.de/se/C0233479/','Elevated mood','(terms occurring on more labels are shown first): elevated mood',':'),('http://sideeffects.embl.de/se/C0233571/','Excitement','(terms occurring on more labels are shown first): excitement',':'),('http://sideeffects.embl.de/se/C0234146/','Areflexia','(terms occurring on more labels are shown first): absent reflexes, areflexia',':'),('http://sideeffects.embl.de/se/C0234193/','Sensation of heat','(terms occurring on more labels are shown first): sensations of heat, heat sensation, sensation of heat, heat sensations',':'),('http://sideeffects.embl.de/se/C0234215/','Discomfort',': A feeling of mental or physical uneasiness, pain, or distress.','(terms occurring on more labels are shown first): discomfort, discomforts'),('http://sideeffects.embl.de/se/C0234222/','Sensation of pressure','(terms occurring on more labels are shown first): pressure sensation, sensation of pressure',':'),('http://sideeffects.embl.de/se/C0234233/','Tenderness',': Discomfort elicited through touch or pressure.','(terms occurring on more labels are shown first): tenderness, soreness, sore'),('http://sideeffects.embl.de/se/C0234369/','Trembling','(terms occurring on more labels are shown first): trembling',':'),('http://sideeffects.embl.de/se/C0234632/','Visual acuity reduced','(terms occurring on more labels are shown first): decreased visual acuity, visual acuity reduced, reduced visual acuity, loss of visual acuity, visual acuity decreased, Visual Acuity Decrease',':'),('http://sideeffects.embl.de/se/C0234918/','Rash morbilliform','(terms occurring on more labels are shown first): morbilliform rash, morbilliform eruption, rash morbilliform, measles-like rash',':'),('http://sideeffects.embl.de/se/C0235063/','Respiratory depression','(terms occurring on more labels are shown first): respiratory depression, decreased lung function, lung function decreased, ventilatory depression, depression Respiratory',':'),('http://sideeffects.embl.de/se/C0235146/','Euphoric mood',': exaggerated feeling of physical and emotional well-being and optimism not consonant with apparent stimuli or events; usually of psychologic origin, but also seen in organic brain disease and toxic states.','(terms occurring on more labels are shown first): euphoria, euphoric mood, feeling high, euphoric'),('http://sideeffects.embl.de/se/C0235198/','Cerebration impaired',': A disorder characterized by a deterioration in the ability to concentrate.','(terms occurring on more labels are shown first): impaired concentration, difficulty with concentration, concentration impaired, inability to concentrate, concentration difficulties, disturbed concentration, difficulty in concentration, concentration impairment, impairment of concentration, Concentra- tion impaired, concentrat ion impaired'),('http://sideeffects.embl.de/se/C0235266/','Eye irritation','(terms occurring on more labels are shown first): eye irritation, ocular irritation, ocular irritations, irritation of the eyes, irritation of the eye, irritation eye, irritation of eyes, eye irritations',':'),('http://sideeffects.embl.de/se/C0235267/','Eye redness',': Lay term applied to any condition with dilation of conjunctival or ciliary blood vessels; innumerable causes, especially irritation and infection.','(terms occurring on more labels are shown first): eye redness, red eye, Eyes Red, red eyes'),('http://sideeffects.embl.de/se/C0235309/','Upset stomach','(terms occurring on more labels are shown first): stomach discomfort, upset stomach, stomach upset, gastric upset, stomach upsets, gastric discomfort',':'),('http://sideeffects.embl.de/se/C0235318/','Fullness abdominal','(terms occurring on more labels are shown first): abdominal fullness',':'),('http://sideeffects.embl.de/se/C0235378/','Hepatotoxicity','(terms occurring on more labels are shown first): hepatotoxicity',':'),('http://sideeffects.embl.de/se/C0235431/','Blood creatinine increased','(terms occurring on more labels are shown first): blood creatinine increased, increased blood creatinine, increases in creatinine and blood, increase in blood creatinine, elevated blood creatinine',':'),('http://sideeffects.embl.de/se/C0235546/','Hypopnoea','(terms occurring on more labels are shown first): hypopnea, hypopnoea',':'),('http://sideeffects.embl.de/se/C0235710/','Chest discomfort','(terms occurring on more labels are shown first): chest discomfort, discomfort in chest',':'),('http://sideeffects.embl.de/se/C0236071/','Throat tightness','(terms occurring on more labels are shown first): tightness of the throat, throat tightness, tightness in throat, Tightness Throat, throat constriction, throat-tightness',':'),('http://sideeffects.embl.de/se/C0237849/','Skin exfoliation','(terms occurring on more labels are shown first): desquamation, skin exfoliation, skin desquamation, exfoliation, skin peeling, peeling skin, peeling of skin, exfoliate, flaking skin, skinexfoliation, s kin exfoliation',':'),('http://sideeffects.embl.de/se/C0238124/','Necrotising fasciitis',': Infection of the deep skin and subcutaneous tissues and necrosis of the fascia. It is caused by bacteria including group A streptococcus, Staphylococcus aureus and Clostridium perfringens. It may develop following trauma and invasive procedures.','(terms occurring on more labels are shown first): necrotizing fasciitis, necrotising fasciitis'),('http://sideeffects.embl.de/se/C0239150/','Creatinine low','(terms occurring on more labels are shown first): decreased creatinine, creatinine decreased',':'),('http://sideeffects.embl.de/se/C0239340/','Edema of lower extremities','(terms occurring on more labels are shown first): edema lower limb, lower extremity edema, lower limb oedema, edema lower extremity, oedema lower limb, lower limb edema, edema lower-limb, Edema-lower limb',':'),('http://sideeffects.embl.de/se/C0239454/','Erythema of eyelid','(terms occurring on more labels are shown first): eyelid erythema, erythema of eyelid, erythema eyelid',':'),('http://sideeffects.embl.de/se/C0239981/','Hypoalbuminaemia',': A condition in which albumin level in blood (SERUM ALBUMIN) is below the normal range. Hypoalbuminemia may be due to decreased hepatic albumin synthesis, increased albumin catabolism, altered albumin distribution, or albumin loss through the urine (ALBUMINURIA).','(terms occurring on more labels are shown first): hypoalbuminemia, hypoalbuminaemia, hypo albuminaemia'),('http://sideeffects.embl.de/se/C0240059/','Intraventricular haemorrhage',': Bleeding into the brain\'s ventricles.','(terms occurring on more labels are shown first): Intraventricular Hemorrhage, Intraventricular haemorrhage, intraventricular bleeding'),('http://sideeffects.embl.de/se/C0240211/','Lip swelling','(terms occurring on more labels are shown first): lip swelling, swollen lips, swelling of lips',':'),('http://sideeffects.embl.de/se/C0240327/','Taste metallic','(terms occurring on more labels are shown first): metallic taste',':'),('http://sideeffects.embl.de/se/C0240449/','Nasal sinus drainage','(terms occurring on more labels are shown first): Nasal sinus drainage',':'),('http://sideeffects.embl.de/se/C0240735/','Personality change',': A noticeable change in a person\'s behavior and thinking. Causes include depression, drug or alcohol abuse, brain injuries, brain tumors, and Alzheimer\'s disease.','(terms occurring on more labels are shown first): personality change, personality changes'),('http://sideeffects.embl.de/se/C0240897/','Retinal exudates','(terms occurring on more labels are shown first): retinal exudates',':'),('http://sideeffects.embl.de/se/C0241136/','Pain of skin',': A disorder characterized by marked discomfort sensation in the skin.','(terms occurring on more labels are shown first): pain of skin, skin pain, pain Skin'),('http://sideeffects.embl.de/se/C0241379/','Increased thirst','(terms occurring on more labels are shown first): increased thirst, thirst increased',':'),('http://sideeffects.embl.de/se/C0241426/','Burning tongue','(terms occurring on more labels are shown first): burning of the tongue, burning of tongue, burning tongue, burning sensation of the tongue, burning sensation of tongue',':'),('http://sideeffects.embl.de/se/C0241742/','Wound haemorrhage','(terms occurring on more labels are shown first): wound hemorrhage, wound haemorrhage, bleeding wound, wound bleeding',':'),('http://sideeffects.embl.de/se/C0242350/','Erectile dysfunction',': A disorder characterized by the persistent or recurrent inability to achieve or to maintain an erection during sexual activity.','(terms occurring on more labels are shown first): impotence, erectile dysfunction, male impotence, Erectile disturbance, sexual impotence, Male-impotence, Male- impotence, impo- tence, e rectile dysfunction'),('http://sideeffects.embl.de/se/C0242429/','Throat sore',': Any kind of inflammatory process of the tonsils, pharynx, or/and larynx characterized by pain in swallowing.','(terms occurring on more labels are shown first): sore throat, throat discomfort, throat pain, Pain Throat, Throat sore, sore throats, pharynx discomfort'),('http://sideeffects.embl.de/se/C0243026/','Sepsis',': Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.','(terms occurring on more labels are shown first): sepsis, systemic infection, systemic infections'),('http://sideeffects.embl.de/se/C0266813/','Faecal occult blood positive','(terms occurring on more labels are shown first): stool guaiac, positive fecal occult blood, Fecal occult blood positive',':'),('http://sideeffects.embl.de/se/C0267792/','Hepatobiliary disease',': A non-neoplastic or neoplastic disorder that affects the liver, bile ducts, and gallbladder. Representative examples of non-neoplastic disorders include hepatitis, cirrhosis, cholangitis, and cholecystitis. Representative examples of neoplastic disorders include hepatocellular adenoma, hepatocellular carcinoma, and cholangiocarcinoma.','(terms occurring on more labels are shown first): hepatobiliary disorders, hepato-biliary disorders, Hepatobiliary disorder, Hepato- biliary disorders, Hepatobiliarydisorders, Hepato biliary disorders'),('http://sideeffects.embl.de/se/C0268000/','Fluid retention','(terms occurring on more labels are shown first): fluid retention, retention of fluid',':'),('http://sideeffects.embl.de/se/C0271298/','Chemosis',': Edema of the mucous membrane of the eyeball and eyelid lining.','(terms occurring on more labels are shown first): chemosis'),('http://sideeffects.embl.de/se/C0332575/','Redness',': Coloration of the skin; sign of inflammation','(terms occurring on more labels are shown first): redness'),('http://sideeffects.embl.de/se/C0333355/','Mucosal inflammation',': An INFLAMMATION of the MUCOSA with burning or tingling sensation. It is characterized by atrophy of the squamous EPITHELIUM, vascular damage, inflammatory infiltration, and ulceration. It usually occurs at the mucous lining of the MOUTH, the GASTROINTESTINAL TRACT or the airway due to chemical irritations, CHEMOTHERAPY, or radiation therapy (RADIOTHERAPY).','(terms occurring on more labels are shown first): mucositis, mucosal inflammation, inflammation of the mucous membranes'),('http://sideeffects.embl.de/se/C0339293/','Corneal perforation',': A puncture or hole through the CORNEAL STROMA resulting from various diseases or trauma.','(terms occurring on more labels are shown first): corneal perforation, Corneal perforations'),('http://sideeffects.embl.de/se/C0340865/','Anaphylactoid reaction','(terms occurring on more labels are shown first): anaphylactoid reactions, anaphylactoid reaction, anaphylactoid shock, anaphy- lactoid reactions, anaphylactoid r eactions',':'),('http://sideeffects.embl.de/se/C0341439/','Chronic liver disease','(terms occurring on more labels are shown first): chronic liver disease, chronic hepatic',':'),('http://sideeffects.embl.de/se/C0344232/','Vision blurred',': Blurred vision is the loss of visual acuity (sharpness of vision) resulting in a loss of ability to see small details. (from MedlinePlus Medical Encyclopedia)','(terms occurring on more labels are shown first): blurred vision, vision blurred, blurring of vision, blurry vision, blurring, cloudy vision, blurredvision, v ision blurred, blurred vi- sion'),('http://sideeffects.embl.de/se/C0349506/','Photosensitivity',': A disorder characterized by an increase in sensitivity of the skin to light.','(terms occurring on more labels are shown first): photosensitivity, skin photosensitivity, sun sensitivity, photo-sensitivity'),('http://sideeffects.embl.de/se/C0349702/','Corneal scar','(terms occurring on more labels are shown first): corneal scar',':'),('http://sideeffects.embl.de/se/C0392025/','Enlargement abdomen',': Increasing girth of the mid section of an individual.','(terms occurring on more labels are shown first): abdomen enlarged, enlarged abdomen, abdominal enlargement, abdomen enlargement, abdomenenlarged'),('http://sideeffects.embl.de/se/C0392163/','Corneal erosion','(terms occurring on more labels are shown first): corneal erosion, corneal erosions',':'),('http://sideeffects.embl.de/se/C0392171/','Influenza-like symptoms',': A group of symptoms similar to those observed in patients with the flu. It includes fever, chills, body aches, malaise, loss of appetite, and dry cough. Flu-like symptoms are observed in patients infected with various viruses, including hepatitis virus and HIV (initial phase), and with malignancies.','(terms occurring on more labels are shown first): influenza-like symptoms, flu-like symptoms, influenza- like symptoms, influenza like symptoms, flu like symptoms, Flu - like Symptoms, influenza -like symptoms, flu- like symptoms, Influenza-like-symptoms, Influenza - Like Symptoms'),('http://sideeffects.embl.de/se/C0392525/','Nephrolithiasis',': condition marked by the presence of renal calculi, abnormal concretions within the kidney, usually of mineral salts.','(terms occurring on more labels are shown first): nephrolithiasis'),('http://sideeffects.embl.de/se/C0392699/','Dysaesthesia',': A condition in which a sense, especially touch, is distorted. Dysesthesia can cause an ordinary stimulus to be unpleasant or painful. It can also cause insensitivity to a stimulus.','(terms occurring on more labels are shown first): dysesthesia, dysaesthesia, dysesthesias'),('http://sideeffects.embl.de/se/C0392703/','Shakiness','(terms occurring on more labels are shown first): shakiness',':'),('http://sideeffects.embl.de/se/C0423006/','Eye discharge','(terms occurring on more labels are shown first): eye discharge, sticky eyes',':'),('http://sideeffects.embl.de/se/C0423124/','Dermatochalasis','(terms occurring on more labels are shown first): dermatochalasis',':'),('http://sideeffects.embl.de/se/C0423602/','Sensation of foreign body',': Feeling of grittiness or having something in the eye; frequently caused by a foreign body. Other possible causes include corneal abrasion, corneal ulcer, inturned eye lash or acute conjunctivitis.','(terms occurring on more labels are shown first): foreign body sensation, sensation of foreign body, foreign-body sensation'),('http://sideeffects.embl.de/se/C0423736/','Micturition burning','(terms occurring on more labels are shown first): urinary burning, burning on urination',':'),('http://sideeffects.embl.de/se/C0424109/','Tearfulness','(terms occurring on more labels are shown first): tearfulness, weeping',':'),('http://sideeffects.embl.de/se/C0427008/','Stiffness','(terms occurring on more labels are shown first): stiffness',':'),('http://sideeffects.embl.de/se/C0427108/','Unsteadiness','(terms occurring on more labels are shown first): unsteadiness',':'),('http://sideeffects.embl.de/se/C0428977/','Bradycardia',': Cardiac arrhythmias that are characterized by excessively slow HEART RATE, usually below 50 beats per minute in human adults. They can be classified broadly into SINOATRIAL NODE dysfunction and ATRIOVENTRICULAR BLOCK.','(terms occurring on more labels are shown first): bradycardia, decrease in heart rate, heart rate decreased, decreased heart rate, bradyarrhythmias, slow heartbeat, decreasing heart rate, slow heart rate, bradycardias, decreasein heart rate'),('http://sideeffects.embl.de/se/C0475858/','Pruritus generalised','(terms occurring on more labels are shown first): generalized pruritus, pruritus generalized, generalized pruritis, pruritus generalised, generalized itching, general pruritus, generalised pruritus',':'),('http://sideeffects.embl.de/se/C0497156/','Lymphadenopathy',': A clinical finding indicating that a lymph node is enlarged. Causes include viral and bacterial infections and cancers that affect the lymph nodes.','(terms occurring on more labels are shown first): lymphadenopathy, adenopathy, swollen glands, lymph node enlargement, swollen lymph nodes, lymph-adenopathy, lymphadenopathies, Lymphadenopat hy, lymph-node enlargement, lymph node swelling, enlarged lymph nodes'),('http://sideeffects.embl.de/se/C0497201/','Abnormal sensation in eye','(terms occurring on more labels are shown first): abnormal sensation in eye, abnormal sensation in the eyes',':'),('http://sideeffects.embl.de/se/C0497247/','Blood pressure increased','(terms occurring on more labels are shown first): elevated blood pressure, blood pressure increased, increase in blood pressure, increased blood pressure, blood pressure increase, rise in blood pressure, blood pressure elevation, increase blood pressure, raised blood pressure, elevate blood pressure, blood pressure elevated',':'),('http://sideeffects.embl.de/se/C0520893/','Localized exfoliation',': A peeling off or loss of epidermis, as in sunburn, postscarlatinal peeling, or toxic epidermal necrolysis.','(terms occurring on more labels are shown first): peeling, localised exfoliation, localized exfoliation'),('http://sideeffects.embl.de/se/C0520901/','Increased skin sensitivity','(terms occurring on more labels are shown first):',':'),('http://sideeffects.embl.de/se/C0521490/','Application site irritation','(terms occurring on more labels are shown first): application site irritation, irritation at the application site, Application-site irritation',':'),('http://sideeffects.embl.de/se/C0521491/','Application site pain','(terms occurring on more labels are shown first): pain at the injection site, application site pain, pain on injection site, application-site pain',':'),('http://sideeffects.embl.de/se/C0521508/','Injection site bruising','(terms occurring on more labels are shown first): injection site bruising, injection site ecchymosis',':'),('http://sideeffects.embl.de/se/C0521839/','Influenza like illness','(terms occurring on more labels are shown first): influenza-like illness, influenza like illness, flu-like illness, influenza- like illness, Influenza -like illness',':'),('http://sideeffects.embl.de/se/C0522055/','Electrocardiogram abnormal','(terms occurring on more labels are shown first): abnormal ECG, ECG abnormal, electrocardiogram abnormal, electrocardiographic abnormalities, abnormal electrocardiogram, abnormal EKG, EKG abnormal, electro cardiographic abnormalities, ElectrocardiographicAbnormalities',':'),('http://sideeffects.embl.de/se/C0542571/','Face oedema',': A disorder characterized by swelling due to excessive fluid accumulation in facial tissues.','(terms occurring on more labels are shown first): face edema, facial edema, edema of the face, face oedema, edema face, oedema face'),('http://sideeffects.embl.de/se/C0548823/','Distress gastrointestinal','(terms occurring on more labels are shown first): gastrointestinal distress, GI distress',':'),('http://sideeffects.embl.de/se/C0549336/','Asthma aggravated','(terms occurring on more labels are shown first): asthma aggravated, aggravated asthma',':'),('http://sideeffects.embl.de/se/C0549386/','Sensation of warmth','(terms occurring on more labels are shown first): feeling of warmth, sensation of warmth, sensations of warmth, warmth sensation',':'),('http://sideeffects.embl.de/se/C0549475/','Lipase increased',': A finding based on laboratory test results that indicate an increase in the level of lipase in a biological specimen.','(terms occurring on more labels are shown first): lipase increased, increased lipase, elevated lipase, increase of lipase'),('http://sideeffects.embl.de/se/C0549493/','Alveolitis','(terms occurring on more labels are shown first): alveolitis',':'),('http://sideeffects.embl.de/se/C0596240/','Cancer pain',': somewhat localized sensation of discomfort, distress or agony resulting from the stimulation of specialized nerve endings in the process of cancer growth, or from cancer therapy.','(terms occurring on more labels are shown first): cancer pain'),('http://sideeffects.embl.de/se/C0599918/','Nephrotoxicity','(terms occurring on more labels are shown first): nephrotoxicity',':'),('http://sideeffects.embl.de/se/C0600142/','Hot flush',': A temporary feeling of intense body warmth, flushing, sometimes accompanied by sweating. A common, symptom of menopause; other conditions that can produce hot flushes include antidepressants and drugs blocking the effect of estrogens, carcinoid tumors and a sensitivity to sulfites or other food additives.','(terms occurring on more labels are shown first): hot flushes, hot flashes, hot flush, hot flash, menopausal hot flushes, Flushing Hot'),('http://sideeffects.embl.de/se/C0677500/','Stinging','(terms occurring on more labels are shown first): stinging, stinging sensation, st inging',':'),('http://sideeffects.embl.de/se/C0687713/','Gastrointestinal pain',': A disorder characterized by a sensation of marked discomfort in the gastrointestinal region.','(terms occurring on more labels are shown first): gastrointestinal pain, GI pain, gastro-intestinal pain, gastro- intestinal pain'),('http://sideeffects.embl.de/se/C0699744/','Ear infection',': invasion and growth of microorganisms in the ear; may be clinically inapparent or result in local cellular injury; may result in hearing loss or deafness.','(terms occurring on more labels are shown first): ear infection, ear infections'),('http://sideeffects.embl.de/se/C0699828/','Serotonin syndrome',': An adverse drug interaction characterized by altered mental status, autonomic dysfunction, and neuromuscular abnormalities. It is most frequently caused by use of both serotonin reuptake inhibitors and monoamine oxidase inhibitors, leading to excess serotonin availability in the CNS at the serotonin 1A receptor.','(terms occurring on more labels are shown first): serotonin syndrome, serotonergic syndrome'),('http://sideeffects.embl.de/se/C0700184/','Throat irritation','(terms occurring on more labels are shown first): throat irritation, itchy throat, irritation in the throat',':'),('http://sideeffects.embl.de/se/C0700200/','Presyncope',': A disorder characterized by an episode of lightheadedness and dizziness which may precede an episode of syncope.','(terms occurring on more labels are shown first): presyncope, near syncope, pre-syncope'),('http://sideeffects.embl.de/se/C0700225/','Serum creatinine increased','(terms occurring on more labels are shown first): increases in serum creatinine, increased serum creatinine, raised serum creatinine, serum creatinine increased, increase in serum creatinine, serum creatinine increases, raised serumcreatinine',':'),('http://sideeffects.embl.de/se/C0700590/','Sweating increased','(terms occurring on more labels are shown first): sweating increased, increased sweating, diaphoresis, excessive sweating, excessive perspiration, excess sweating, profuse sweating, sweating increase, s weating increased',':'),('http://sideeffects.embl.de/se/C0750394/','White blood cell count decreased',': A finding based on laboratory test results that indicate an decrease in number of white blood cells in a blood specimen.','(terms occurring on more labels are shown first): white blood cell count decreased, WBC decreased, decreased WBC, low WBC, decreased white blood cell count, WBC count decreased, decreased leukocytes, leukocytes decreased, decreased white blood cells, white blood cells decreased, WBC low, leukocyte count decreased'),('http://sideeffects.embl.de/se/C0751466/','Phonophobia','(terms occurring on more labels are shown first): phonophobia',':'),('http://sideeffects.embl.de/se/C0836924/','Thrombocytosis',': A hematology test result that indicates the presence of higher than normal platelet counts in the peripheral blood.','(terms occurring on more labels are shown first): thrombocythemia, thrombocytosis, thrombocythaemia, platelet count increased, increased platelets, increased platelet count, Platelets increased, Increases in platelet count, increased platelet'),('http://sideeffects.embl.de/se/C0851341/','Infestation NOS','(terms occurring on more labels are shown first): infestations, i nfestations, Infestation s',':'),('http://sideeffects.embl.de/se/C0851578/','Sleep disorder',': Conditions characterized by disturbances of usual sleep patterns or behaviors. Sleep disorders may be divided into three major categories: DYSSOMNIAS (i.e. disorders characterized by insomnia or hypersomnia), PARASOMNIAS (abnormal sleep behaviors), and sleep disorders secondary to medical or psychiatric disorders. (From Thorpy, Sleep Disorders Medicine, 1994, p187)','(terms occurring on more labels are shown first): sleep disorder, sleep disorders, sle ep disorder, Sleep disorders and disturbances, s leep disorder'),('http://sideeffects.embl.de/se/C0853336/','Corneal infiltrates',': Discrete, small lesions present in the cornea as a result of corneal inflammation and, in some cases, after soft contact lens wear especially extended-wear lenses.','(terms occurring on more labels are shown first): corneal infiltrates, corneal infiltrate'),('http://sideeffects.embl.de/se/C0853714/','Application site pruritus','(terms occurring on more labels are shown first): application site pruritus',':'),('http://sideeffects.embl.de/se/C0854114/','Corneal epithelium defect','(terms occurring on more labels are shown first): corneal epithelium defect',':'),('http://sideeffects.embl.de/se/C0854717/','Corneal epithelium disorder','(terms occurring on more labels are shown first): corneal epithelium disorder',':'),('http://sideeffects.embl.de/se/C0855246/','Abnormal sleep-related event','(terms occurring on more labels are shown first): Abnormal Sleep-Related Event',':'),('http://sideeffects.embl.de/se/C0855329/','Electrocardiogram change',': An electrocardiographic finding of a change in cardiac electrical activity.','(terms occurring on more labels are shown first): changes in ECG, electrocardiographic changes, ECG change, electrocardiographic change, changes in the ECG, electrocardiogram change, electro-cardiographic changes, EKG change'),('http://sideeffects.embl.de/se/C0856054/','Mental status changes','(terms occurring on more labels are shown first): mental status changes, changes in mental status, change in mental status',':'),('http://sideeffects.embl.de/se/C0857332/','Clonic movements','(terms occurring on more labels are shown first): clonic movements',':'),('http://sideeffects.embl.de/se/C0858259/','Nasal discomfort','(terms occurring on more labels are shown first): nasal discomfort',':'),('http://sideeffects.embl.de/se/C0858635/','Pharyngolaryngeal pain',': A disorder characterized by marked discomfort sensation in the pharyngolaryngeal region.','(terms occurring on more labels are shown first): pharyngolaryngeal pain, Pharyngo laryngeal pain, Pharyngolaryng eal pain, Pharyngolaryn- geal pain'),('http://sideeffects.embl.de/se/C0863084/','Skin discomfort','(terms occurring on more labels are shown first): skin discomfort',':'),('http://sideeffects.embl.de/se/C0877359/','Raised liver function tests','(terms occurring on more labels are shown first): elevated liver function tests, increases in liver function tests, increased liver function tests, liver function test increased, elevated liver function test, raised liver function tests, liver function tests raised',':'),('http://sideeffects.embl.de/se/C0877661/','Application site burn','(terms occurring on more labels are shown first): application site burning, burning at application site, burning at the application site, application site burn',':'),('http://sideeffects.embl.de/se/C0878544/','Cardiomyopathy',': A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).','(terms occurring on more labels are shown first): cardiomyopathy, cardiomyopathies, myocardial disease'),('http://sideeffects.embl.de/se/C0917798/','Cerebral ischaemia',': A disorder characterized by a decrease or absence of blood supply to the brain caused by obstruction (thrombosis or embolism) of an artery resulting in neurological damage.','(terms occurring on more labels are shown first): cerebral ischemia, cerebral ischaemia, cerebrovascular ischemia, cerebrovascular ischaemia'),('http://sideeffects.embl.de/se/C0917801/','Insomnia',': A sleep disorder characterized by difficulty in falling asleep and/or remaining asleep.','(terms occurring on more labels are shown first): insomnia, sleeplessness'),('http://sideeffects.embl.de/se/C0919715/','Lupus-like syndrome','(terms occurring on more labels are shown first): lupus-like syndrome, lupus like syndrome, lupuslike syndrome, Lupus-likesyndrome, lupus- like syndrome',':'),('http://sideeffects.embl.de/se/C0919874/','Post procedural haemorrhage','(terms occurring on more labels are shown first): post procedural hemorrhage, post procedural haemorrhage, post- procedural hemorrhage, post-procedural haemorrhage, post-procedural hemorrhage, postprocedural hemorrhage, post-procedural bleeding, Postprocedural haemorrhage',':'),('http://sideeffects.embl.de/se/C0947912/','Myasthenia',': abnormal muscular weakness or fatigue','(terms occurring on more labels are shown first): myasthenia'),('http://sideeffects.embl.de/se/C0948070/','Rhinalgia','(terms occurring on more labels are shown first): rhinalgia',':'),('http://sideeffects.embl.de/se/C0948595/','Ocular discomfort','(terms occurring on more labels are shown first): eye discomfort, ocular discomfort',':'),('http://sideeffects.embl.de/se/C0948695/','White blood cell count low','(terms occurring on more labels are shown first): decreased white blood cell counts, low white blood cell count',':'),('http://sideeffects.embl.de/se/C0948873/','Flu symptoms','(terms occurring on more labels are shown first): flu symptoms, Flu symptom, flu-symptoms',':'),('http://sideeffects.embl.de/se/C1096274/','Corneal thinning','(terms occurring on more labels are shown first): corneal thinning, thinning of the cornea',':'),('http://sideeffects.embl.de/se/C1096278/','Anterior chamber inflammation','(terms occurring on more labels are shown first): anterior chamber inflammation',':'),('http://sideeffects.embl.de/se/C1142151/','Scleromalacia','(terms occurring on more labels are shown first): Scleromalacia',':'),('http://sideeffects.embl.de/se/C1142248/','Pseudomononucleosis','(terms occurring on more labels are shown first): pseudomononucleosis',':'),('http://sideeffects.embl.de/se/C1145670/','Respiratory failure',': Impaired gas exchange by the respiratory system resulting in hypoxemia and decreased oxygenation of the tissues that may be associated with increased arterial levels of carbon dioxide. Causes include chronic obstructive pulmonary disease, asthma, emphysema, acute respiratory distress syndrome, pneumonia, pulmonary edema, pneumothorax, and congestive heart failure.','(terms occurring on more labels are shown first): respiratory failure'),('http://sideeffects.embl.de/se/C1287298/','Urine output','(terms occurring on more labels are shown first): urine output',':'),('http://sideeffects.embl.de/se/C1291077/','Abdominal bloating',': A swelling or feeling of fullness in the abdomen. Bloating is usually the result of gas in the intestines and can be caused by many things, including overeating, lactose intolerance, and constipation. Bloating can also be a side effect of cancer or cancer treatment.','(terms occurring on more labels are shown first): bloating, abdominal bloating, meteorism'),('http://sideeffects.embl.de/se/C1291078/','Epigastric discomfort','(terms occurring on more labels are shown first): epigastric discomfort',':'),('http://sideeffects.embl.de/se/C1302752/','Abrasion NOS',': Abraded wound; excoriation or circumscribed removal of the superficial layers of the skin or mucous membrane.','(terms occurring on more labels are shown first): abrasion, abraded'),('http://sideeffects.embl.de/se/C1384666/','Hearing impaired',': Partial or complete loss of the ability to detect or understand sounds resulting from damage to the outer, middle, or inner ear structures. Causes include exposure to loud noise, ear infections, injuries to the ear, genetic, and congenital disorders.','(terms occurring on more labels are shown first): hearing loss, hearing impairment, hypoacusis, hearing impaired, hearing decreased'),('http://sideeffects.embl.de/se/C1458140/','Bleeding tendency','(terms occurring on more labels are shown first): bleeding tendency, bleeding tendencies, bleedingtendency',':'),('http://sideeffects.embl.de/se/C1504411/','Post procedural oedema','(terms occurring on more labels are shown first): Post procedural edema',':'),('http://sideeffects.embl.de/se/C1565489/','Renal impairment',': Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.','(terms occurring on more labels are shown first): renal impairment, renal insufficiency, impaired renal function, impaired renal funct ion'),('http://sideeffects.embl.de/se/C1619712/','Procedural pain','(terms occurring on more labels are shown first): procedural pain',':'),('http://sideeffects.embl.de/se/C1737224/','Post procedural swelling','(terms occurring on more labels are shown first): Post procedural swelling',':'),('http://sideeffects.embl.de/se/C1761613/','Conjunctival hyperaemia','(terms occurring on more labels are shown first): conjunctival hyperemia, conjunctival injection, conjunctival hyperaemia, conjunctival redness',':'),('http://sideeffects.embl.de/se/C2242996/','Tingling sensation',': A sensation as of repetitive pin pricks, caused by cold or by striking a nerve, or as a result of various diseases of the central or peripheral nervous system.','(terms occurring on more labels are shown first): tingling, tingling sensation, sensations Tingling, t ingling, tingl ing'),('http://sideeffects.embl.de/se/C2363731/','Oropharyngeal pain','(terms occurring on more labels are shown first): oropharyngeal pain',':'),('http://sideeffects.embl.de/se/C2364111/','Ageusia',': Complete or severe loss of the subjective sense of taste, frequently accompanied by OLFACTION DISORDERS.','(terms occurring on more labels are shown first): taste loss, ageusia, loss of taste, loss of sense of taste, loss oftaste'),('http://sideeffects.embl.de/se/C2830004/','Somnolence',': A disorder characterized by characterized by excessive sleepiness and drowsiness.','(terms occurring on more labels are shown first): somnolence'),('http://sideeffects.embl.de/se/C3203358/','Hypoventilation',': A state in which there is a reduced amount of air entering the pulmonary alveoli.','(terms occurring on more labels are shown first): hypoventilation'),('http://sideeffects.embl.de/se/C3665386/','Abnormal vision','(terms occurring on more labels are shown first): abnormal vision, vision abnormal',':'),('http://sideeffects.embl.de/se/C3665596/','Warts',': Benign epidermal proliferations or tumors; some are viral in origin.','(terms occurring on more labels are shown first): wart, warts');

/*Table structure for table `sider_to_drug` */

DROP TABLE IF EXISTS `sider_to_drug`;

CREATE TABLE `sider_to_drug` (
  `drug_with_sideeffect_link` varchar(200) NOT NULL,
  `drug_with_sideeffect` varchar(200) DEFAULT NULL,
  `sideeffect_link` varchar(200) DEFAULT NULL,
  PRIMARY KEY (`drug_with_sideeffect_link`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

/*Data for the table `sider_to_drug` */

insert  into `sider_to_drug`(`drug_with_sideeffect_link`,`drug_with_sideeffect`,`sideeffect_link`) values ('http://sideeffects.embl.de/drugs/10028615/','vorapaxar','http://sideeffects.embl.de/se/C0035309/'),('http://sideeffects.embl.de/drugs/1003/','phosphate','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/10096344/','linagliptin','http://sideeffects.embl.de/se/C0237849/'),('http://sideeffects.embl.de/drugs/10100/','propoxyphene','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/10107393/','18F-flutemetamol','http://sideeffects.embl.de/se/C0497247/'),('http://sideeffects.embl.de/drugs/10113978/','pazopanib','http://sideeffects.embl.de/se/C2364111/'),('http://sideeffects.embl.de/drugs/10163178/','afatinib','http://sideeffects.embl.de/se/C1761613/'),('http://sideeffects.embl.de/drugs/10178705/','besifloxacin','http://sideeffects.embl.de/se/C1761613/'),('http://sideeffects.embl.de/drugs/10182969/','apixaban','http://sideeffects.embl.de/se/C0919874/'),('http://sideeffects.embl.de/drugs/102258/','rasburicase','http://sideeffects.embl.de/se/C1145670/'),('http://sideeffects.embl.de/drugs/102399/','dextran','http://sideeffects.embl.de/se/C0340865/'),('http://sideeffects.embl.de/drugs/10324367/','boceprevir','http://sideeffects.embl.de/se/C0700200/'),('http://sideeffects.embl.de/drugs/10340/','sodium bicarbonate','http://sideeffects.embl.de/se/C0020440/'),('http://sideeffects.embl.de/drugs/10413/','hydroxybutyrate','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/1046/','pyrazinamide','http://sideeffects.embl.de/se/C0235378/'),('http://sideeffects.embl.de/drugs/10465263/','lorcaserin','http://sideeffects.embl.de/se/C2363731/'),('http://sideeffects.embl.de/drugs/104741/','ICI 182,780','http://sideeffects.embl.de/se/C0917801/'),('http://sideeffects.embl.de/drugs/104758/','raltitrexed','http://sideeffects.embl.de/se/C0392171/'),('http://sideeffects.embl.de/drugs/104778/','levodopa/carbidopa','http://sideeffects.embl.de/se/C0241426/'),('http://sideeffects.embl.de/drugs/104799/','fotemustine','http://sideeffects.embl.de/se/C2364111/'),('http://sideeffects.embl.de/drugs/10482134/','glycerol phenylbutyrate','http://sideeffects.embl.de/se/C0232492/'),('http://sideeffects.embl.de/drugs/104849/','rimonabant','http://sideeffects.embl.de/se/C0235309/'),('http://sideeffects.embl.de/drugs/104865/','bosentan','http://sideeffects.embl.de/se/C0855329/'),('http://sideeffects.embl.de/drugs/105145/','68Ga','http://sideeffects.embl.de/se/C0002064/'),('http://sideeffects.embl.de/drugs/10547/','echothiophate','http://sideeffects.embl.de/se/C0677500/'),('http://sideeffects.embl.de/drugs/10631/','medroxyprogesterone','http://sideeffects.embl.de/se/C1291077/'),('http://sideeffects.embl.de/drugs/1065/','quinidine','http://sideeffects.embl.de/se/C1384666/'),('http://sideeffects.embl.de/drugs/10660/','dimenhydrinate','http://sideeffects.embl.de/se/C0221490/'),('http://sideeffects.embl.de/drugs/107694/','Diane-35','http://sideeffects.embl.de/se/C0268000/'),('http://sideeffects.embl.de/drugs/107969/','FTY720','http://sideeffects.embl.de/se/C0851341/'),('http://sideeffects.embl.de/drugs/107994/','quinaprilat','http://sideeffects.embl.de/se/C0042401/'),('http://sideeffects.embl.de/drugs/1084/','thiosulfate','http://sideeffects.embl.de/se/C0151529/'),('http://sideeffects.embl.de/drugs/11020241/','ascorbate','http://sideeffects.embl.de/se/C0234233/'),('http://sideeffects.embl.de/drugs/110634/','vardenafil','http://sideeffects.embl.de/se/C0948595/'),('http://sideeffects.embl.de/drugs/110635/','tadalafil','http://sideeffects.embl.de/se/C1761613/'),('http://sideeffects.embl.de/drugs/11125/','lithium carbonate','http://sideeffects.embl.de/se/C0855329/'),('http://sideeffects.embl.de/drugs/11163584/','alogliptin','http://sideeffects.embl.de/se/C0042109/'),('http://sideeffects.embl.de/drugs/11167602/','regorafenib','http://sideeffects.embl.de/se/C0549475/'),('http://sideeffects.embl.de/drugs/11228026/','aclidinium bromide','http://sideeffects.embl.de/se/C0005694/'),('http://sideeffects.embl.de/drugs/11234049/','TR-700','http://sideeffects.embl.de/se/C0917801/'),('http://sideeffects.embl.de/drugs/11235728/','Saxagliptin','http://sideeffects.embl.de/se/C0851341/'),('http://sideeffects.embl.de/drugs/11238823/','azilsartan medoxomil','http://sideeffects.embl.de/se/C0235431/'),('http://sideeffects.embl.de/drugs/1125/','tetrahydrobiopterin','http://sideeffects.embl.de/se/C2363731/'),('http://sideeffects.embl.de/drugs/11254352/','sodium ferric gluconate','http://sideeffects.embl.de/se/C0034882/'),('http://sideeffects.embl.de/drugs/1130/','thiamine','http://sideeffects.embl.de/se/C0549386/'),('http://sideeffects.embl.de/drugs/11304743/','riociguat','http://sideeffects.embl.de/se/C0206277/'),('http://sideeffects.embl.de/drugs/1134/','thymidine','http://sideeffects.embl.de/se/C0858635/'),('http://sideeffects.embl.de/drugs/114709/','eslicarbazepine','http://sideeffects.embl.de/se/C0028738/'),('http://sideeffects.embl.de/drugs/11499245/','AN2690','http://sideeffects.embl.de/se/C0152030/'),('http://sideeffects.embl.de/drugs/11501341/','florbetaben','http://sideeffects.embl.de/se/C0151828/'),('http://sideeffects.embl.de/drugs/11505907/','Zyprexa Relprevv','http://sideeffects.embl.de/se/C2830004/'),('http://sideeffects.embl.de/drugs/11519069/','umeclidinium','http://sideeffects.embl.de/se/C0039240/'),('http://sideeffects.embl.de/drugs/115237/','paliperidone','http://sideeffects.embl.de/se/C0152128/'),('http://sideeffects.embl.de/drugs/11531537/','eliglustat','http://sideeffects.embl.de/se/C2363731/'),('http://sideeffects.embl.de/drugs/115355/','NTBC','http://sideeffects.embl.de/se/C2830004/'),('http://sideeffects.embl.de/drugs/11556711/','Carfilzomib','http://sideeffects.embl.de/se/C0917801/'),('http://sideeffects.embl.de/drugs/11593706/','sevelamer carbonate','http://sideeffects.embl.de/se/C0021843/'),('http://sideeffects.embl.de/drugs/11597571/','crizotinib','http://sideeffects.embl.de/se/C1145670/'),('http://sideeffects.embl.de/drugs/11597697/','lisdexamfetamine dimesylate','http://sideeffects.embl.de/se/C0878544/'),('http://sideeffects.embl.de/drugs/11672461/','gadofosveset','http://sideeffects.embl.de/se/C0497201/'),('http://sideeffects.embl.de/drugs/11707110/','trametinib','http://sideeffects.embl.de/se/C2363731/'),('http://sideeffects.embl.de/drugs/11722286/','spinosad','http://sideeffects.embl.de/se/C0521490/'),('http://sideeffects.embl.de/drugs/119182/','clofarabine','http://sideeffects.embl.de/se/C1384666/'),('http://sideeffects.embl.de/drugs/119212/','benzylpenicilloyl','http://sideeffects.embl.de/se/C0002994/'),('http://sideeffects.embl.de/drugs/11947681/','nitroprusside','http://sideeffects.embl.de/se/C0855329/'),('http://sideeffects.embl.de/drugs/11949646/','empagliflozin','http://sideeffects.embl.de/se/C0700225/'),('http://sideeffects.embl.de/drugs/119607/','valdecoxib','http://sideeffects.embl.de/se/C0007820/'),('http://sideeffects.embl.de/drugs/11973/','Brolene','http://sideeffects.embl.de/se/C0677500/'),('http://sideeffects.embl.de/drugs/11979316/','vasopressin','http://sideeffects.embl.de/se/C0043049/'),('http://sideeffects.embl.de/drugs/119828/','parecoxib','http://sideeffects.embl.de/se/C0013240/'),('http://sideeffects.embl.de/drugs/119830/','tenofovir disoproxil fumarate','http://sideeffects.embl.de/se/C1619712/'),('http://sideeffects.embl.de/drugs/1206/','methamphetamine','http://sideeffects.embl.de/se/C0235146/'),('http://sideeffects.embl.de/drugs/121396/','N-carbamylglutamate','http://sideeffects.embl.de/se/C2830004/'),('http://sideeffects.embl.de/drugs/121749/','ustekinumab','http://sideeffects.embl.de/se/C2363731/'),('http://sideeffects.embl.de/drugs/121892/','retigabine','http://sideeffects.embl.de/se/C0027066/'),('http://sideeffects.embl.de/drugs/122197/','FP-CIT','http://sideeffects.embl.de/se/C0232461/'),('http://sideeffects.embl.de/drugs/122316/','rasagiline','http://sideeffects.embl.de/se/C0027066/'),('http://sideeffects.embl.de/drugs/123015/','SU5416','http://sideeffects.embl.de/se/C0917801/'),('http://sideeffects.embl.de/drugs/123597/','travoprost','http://sideeffects.embl.de/se/C1096278/'),('http://sideeffects.embl.de/drugs/123606/','almotriptan','http://sideeffects.embl.de/se/C2830004/'),('http://sideeffects.embl.de/drugs/123610/','Eptifibatide','http://sideeffects.embl.de/se/C1565489/'),('http://sideeffects.embl.de/drugs/123611/','fondaparinux','http://sideeffects.embl.de/se/C0032788/'),('http://sideeffects.embl.de/drugs/123619/','etoricoxib','http://sideeffects.embl.de/se/C0599918/'),('http://sideeffects.embl.de/drugs/123620/','mometasone','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/123623/','Cancidas','http://sideeffects.embl.de/se/C0599918/'),('http://sideeffects.embl.de/drugs/123631/','gefitinib','http://sideeffects.embl.de/se/C0596240/'),('http://sideeffects.embl.de/drugs/123634/','Trisequens','http://sideeffects.embl.de/se/C1291077/'),('http://sideeffects.embl.de/drugs/123809/','Madopar','http://sideeffects.embl.de/se/C0019521/'),('http://sideeffects.embl.de/drugs/124087/','desloratadine','http://sideeffects.embl.de/se/C0522055/'),('http://sideeffects.embl.de/drugs/12453/','zuclopenthixol','http://sideeffects.embl.de/se/C0026205/'),('http://sideeffects.embl.de/drugs/12460/','phendimetrazine','http://sideeffects.embl.de/se/C0221512/'),('http://sideeffects.embl.de/drugs/125017/','desvenlafaxine','http://sideeffects.embl.de/se/C0007820/'),('http://sideeffects.embl.de/drugs/12536/','desonide','http://sideeffects.embl.de/se/C0877661/'),('http://sideeffects.embl.de/drugs/12555/','benzydamine','http://sideeffects.embl.de/se/C0700184/'),('http://sideeffects.embl.de/drugs/12559/','erythromycin stearate','http://sideeffects.embl.de/se/C1384666/'),('http://sideeffects.embl.de/drugs/125889/','pregabalin','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/12597/','isomannide','http://sideeffects.embl.de/se/C0019521/'),('http://sideeffects.embl.de/drugs/12620/','Tadenan','http://sideeffects.embl.de/se/C0151908/'),('http://sideeffects.embl.de/drugs/127909/','bimatoprost','http://sideeffects.embl.de/se/C2830004/'),('http://sideeffects.embl.de/drugs/128549/','trandolaprilat','http://sideeffects.embl.de/se/C0750394/'),('http://sideeffects.embl.de/drugs/129228/','rufinamide','http://sideeffects.embl.de/se/C0699744/'),('http://sideeffects.embl.de/drugs/129806/','rosuvastatin','http://sideeffects.embl.de/se/C0026848/'),('http://sideeffects.embl.de/drugs/1301/','naproxen','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/130564/','esomeprazole magnesium','http://sideeffects.embl.de/se/C0019521/'),('http://sideeffects.embl.de/drugs/130881/','olmesartan medoxomil','http://sideeffects.embl.de/se/C0392171/'),('http://sideeffects.embl.de/drugs/131535/','fosamprenavir','http://sideeffects.embl.de/se/C0549475/'),('http://sideeffects.embl.de/drugs/132804/','pitavastatin','http://sideeffects.embl.de/se/C0026848/'),('http://sideeffects.embl.de/drugs/132971/','abiraterone','http://sideeffects.embl.de/se/C0917801/'),('http://sideeffects.embl.de/drugs/13314/','lormetazepam','http://sideeffects.embl.de/se/C0233459/'),('http://sideeffects.embl.de/drugs/13342/','vinblastine','http://sideeffects.embl.de/se/C0030920/'),('http://sideeffects.embl.de/drugs/134018/','febuxostat','http://sideeffects.embl.de/se/C0700184/'),('http://sideeffects.embl.de/drugs/134019/','pixantrone','http://sideeffects.embl.de/se/C0025289/'),('http://sideeffects.embl.de/drugs/134780/','pomalidomide','http://sideeffects.embl.de/se/C0750394/'),('http://sideeffects.embl.de/drugs/1349907/','methimazole','http://sideeffects.embl.de/se/C2364111/'),('http://sideeffects.embl.de/drugs/137/','5-aminolevulinic acid','http://sideeffects.embl.de/se/C0851341/'),('http://sideeffects.embl.de/drugs/143/','leucovorin','http://sideeffects.embl.de/se/C0700225/'),('http://sideeffects.embl.de/drugs/145068/','nitric oxide','http://sideeffects.embl.de/se/C0235710/'),('http://sideeffects.embl.de/drugs/147740/','drospirenone (DRSP','http://sideeffects.embl.de/se/C0149931/'),('http://sideeffects.embl.de/drugs/14789/','ferumoxytol','http://sideeffects.embl.de/se/C0162297/'),('http://sideeffects.embl.de/drugs/147912/','posaconazole','http://sideeffects.embl.de/se/C0025289/'),('http://sideeffects.embl.de/drugs/148121/','pralatrexate','http://sideeffects.embl.de/se/C0858635/'),('http://sideeffects.embl.de/drugs/148127/','ospemifene','http://sideeffects.embl.de/se/C0149871/'),('http://sideeffects.embl.de/drugs/148191/','temsirolimus','http://sideeffects.embl.de/se/C0750394/'),('http://sideeffects.embl.de/drugs/148192/','atazanavir','http://sideeffects.embl.de/se/C0019521/'),('http://sideeffects.embl.de/drugs/148211/','palonosetron','http://sideeffects.embl.de/se/C0019521/'),('http://sideeffects.embl.de/drugs/14888/','arsenic trioxide','http://sideeffects.embl.de/se/C2830004/'),('http://sideeffects.embl.de/drugs/14917/','fluoride','http://sideeffects.embl.de/se/C1302752/'),('http://sideeffects.embl.de/drugs/150310/','eplerenone','http://sideeffects.embl.de/se/C0007820/'),('http://sideeffects.embl.de/drugs/150311/','ezetimibe','http://sideeffects.embl.de/se/C0919715/'),('http://sideeffects.embl.de/drugs/150610/','ertapenem','http://sideeffects.embl.de/se/C0027066/'),('http://sideeffects.embl.de/drugs/151075/','nepafenac','http://sideeffects.embl.de/se/C1096274/'),('http://sideeffects.embl.de/drugs/151165/','aprepitant','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/151171/','conivaptan','http://sideeffects.embl.de/se/C0858635/'),('http://sideeffects.embl.de/drugs/15232/','benzathine penicillin','http://sideeffects.embl.de/se/C2830004/'),('http://sideeffects.embl.de/drugs/152945/','dutasteride','http://sideeffects.embl.de/se/C0242350/'),('http://sideeffects.embl.de/drugs/153941/','entecavir','http://sideeffects.embl.de/se/C0700225/'),('http://sideeffects.embl.de/drugs/153994/','clevidipine','http://sideeffects.embl.de/se/C0027051/'),('http://sideeffects.embl.de/drugs/154058/','solifenacin','http://sideeffects.embl.de/se/C0239340/'),('http://sideeffects.embl.de/drugs/154256/','bazedoxifene','http://sideeffects.embl.de/se/C2830004/'),('http://sideeffects.embl.de/drugs/1546/','cladribine','http://sideeffects.embl.de/se/C1287298/'),('http://sideeffects.embl.de/drugs/156326/','asenapine','http://sideeffects.embl.de/se/C2830004/'),('http://sideeffects.embl.de/drugs/156418/','cinacalcet','http://sideeffects.embl.de/se/C0041912/'),('http://sideeffects.embl.de/drugs/157429/','gadopentetate','http://sideeffects.embl.de/se/C0162297/'),('http://sideeffects.embl.de/drugs/157688/','vinflunine','http://sideeffects.embl.de/se/C0596240/'),('http://sideeffects.embl.de/drugs/157920/','lubiprostone','http://sideeffects.embl.de/se/C0858635/'),('http://sideeffects.embl.de/drugs/157921/','methyl aminolevulinate','http://sideeffects.embl.de/se/C0677500/'),('http://sideeffects.embl.de/drugs/158/','PGE2','http://sideeffects.embl.de/se/C0036973/'),('http://sideeffects.embl.de/drugs/158781/','olmesartan','http://sideeffects.embl.de/se/C0858635/'),('http://sideeffects.embl.de/drugs/158786/','pegaptanib sodium','http://sideeffects.embl.de/se/C1096278/'),('http://sideeffects.embl.de/drugs/159/','prostacyclin','http://sideeffects.embl.de/se/C0521491/'),('http://sideeffects.embl.de/drugs/159247/','sevelamer hydrochloride','http://sideeffects.embl.de/se/C0021843/'),('http://sideeffects.embl.de/drugs/15951529/','MDV3100','http://sideeffects.embl.de/se/C0917801/'),('http://sideeffects.embl.de/drugs/160/','prostaglandin','http://sideeffects.embl.de/se/C0032961/'),('http://sideeffects.embl.de/drugs/160036/','MnDPDP','http://sideeffects.embl.de/se/C0600142/'),('http://sideeffects.embl.de/drugs/16004692/','macitentan','http://sideeffects.embl.de/se/C0268000/'),('http://sideeffects.embl.de/drugs/160051/','colesevelam','http://sideeffects.embl.de/se/C0428977/'),('http://sideeffects.embl.de/drugs/160352/','zidovudine/lamivudine','http://sideeffects.embl.de/se/C0878544/'),('http://sideeffects.embl.de/drugs/16065945/','TMC435','http://sideeffects.embl.de/se/C0917801/'),('http://sideeffects.embl.de/drugs/16126651/','PCI-32765','http://sideeffects.embl.de/se/C2363731/'),('http://sideeffects.embl.de/drugs/16129616/','salmon calcitonin acetate','http://sideeffects.embl.de/se/C2364111/'),('http://sideeffects.embl.de/drugs/16129617/','cosyntropin','http://sideeffects.embl.de/se/C0428977/'),('http://sideeffects.embl.de/drugs/16129629/','LY146032','http://sideeffects.embl.de/se/C0010346/'),('http://sideeffects.embl.de/drugs/16129632/','Nuvocid','http://sideeffects.embl.de/se/C0851341/'),('http://sideeffects.embl.de/drugs/16129665/','Vitrum','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/16129672/','Insulin','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/16129682/','Forteo','http://sideeffects.embl.de/se/C0917801/'),('http://sideeffects.embl.de/drugs/16129690/','ziconotide','http://sideeffects.embl.de/se/C0025289/'),('http://sideeffects.embl.de/drugs/16129701/','T-A2-3','http://sideeffects.embl.de/se/C1384666/'),('http://sideeffects.embl.de/drugs/16129703/','Revasc','http://sideeffects.embl.de/se/C0007820/'),('http://sideeffects.embl.de/drugs/16129704/','Bivalirudin','http://sideeffects.embl.de/se/C0032788/'),('http://sideeffects.embl.de/drugs/16130199/','Enfuvirtide','http://sideeffects.embl.de/se/C1565489/'),('http://sideeffects.embl.de/drugs/16130295/','BPTI','http://sideeffects.embl.de/se/C1565489/'),('http://sideeffects.embl.de/drugs/16130957/','Org 37462','http://sideeffects.embl.de/se/C0340865/'),('http://sideeffects.embl.de/drugs/16131215/','Abarelix','http://sideeffects.embl.de/se/C0600142/'),('http://sideeffects.embl.de/drugs/16131310/','hepatitis B vaccines','http://sideeffects.embl.de/se/C0025289/'),('http://sideeffects.embl.de/drugs/16132265/','ACTH(1-39','http://sideeffects.embl.de/se/C0851341/'),('http://sideeffects.embl.de/drugs/16132283/','glucagon','http://sideeffects.embl.de/se/C0497247/'),('http://sideeffects.embl.de/drugs/16132344/','oCRH','http://sideeffects.embl.de/se/C0014544/'),('http://sideeffects.embl.de/drugs/16132418/','NovoLog','http://sideeffects.embl.de/se/C0851341/'),('http://sideeffects.embl.de/drugs/16132438/','Humalog','http://sideeffects.embl.de/se/C0700590/'),('http://sideeffects.embl.de/drugs/16132441/','Refludan','http://sideeffects.embl.de/se/C0917801/'),('http://sideeffects.embl.de/drugs/16132446/','Symlin','http://sideeffects.embl.de/se/C0151735/'),('http://sideeffects.embl.de/drugs/16134956/','liraglutide','http://sideeffects.embl.de/se/C0700225/'),('http://sideeffects.embl.de/drugs/16136245/','degarelix','http://sideeffects.embl.de/se/C0855329/'),('http://sideeffects.embl.de/drugs/16137271/','insulin detemir','http://sideeffects.embl.de/se/C0007820/'),('http://sideeffects.embl.de/drugs/16139342/','Lyxumia','http://sideeffects.embl.de/se/C2830004/'),('http://sideeffects.embl.de/drugs/16139605/','teduglutide','http://sideeffects.embl.de/se/C0035243/'),('http://sideeffects.embl.de/drugs/16156130/','exenatide','http://sideeffects.embl.de/se/C2363731/'),('http://sideeffects.embl.de/drugs/16158207/','linaclotide','http://sideeffects.embl.de/se/C0025222/'),('http://sideeffects.embl.de/drugs/16158473/','o291','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/16213095/','pentastarch','http://sideeffects.embl.de/se/C0241742/'),('http://sideeffects.embl.de/drugs/16220172/','ivacaftor','http://sideeffects.embl.de/se/C2363731/'),('http://sideeffects.embl.de/drugs/16230/','amiloride','http://sideeffects.embl.de/se/C2830004/'),('http://sideeffects.embl.de/drugs/163296/','tipranavir','http://sideeffects.embl.de/se/C0948695/'),('http://sideeffects.embl.de/drugs/16362/','pimozide','http://sideeffects.embl.de/se/C0855329/'),('http://sideeffects.embl.de/drugs/16533/','betamethasone valerate','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/166548/','Anidulafungin','http://sideeffects.embl.de/se/C0917801/'),('http://sideeffects.embl.de/drugs/16850/','fluorescein','http://sideeffects.embl.de/se/C0162297/'),('http://sideeffects.embl.de/drugs/168625/','poly(styrene sulfonate','http://sideeffects.embl.de/se/C0027540/'),('http://sideeffects.embl.de/drugs/16886/','5-aza-2\'-deoxycytidine','http://sideeffects.embl.de/se/C0162297/'),('http://sideeffects.embl.de/drugs/1690/','doxorubicin','http://sideeffects.embl.de/se/C1287298/'),('http://sideeffects.embl.de/drugs/170361/','varenicline','http://sideeffects.embl.de/se/C0700184/'),('http://sideeffects.embl.de/drugs/171558/','Kaluril','http://sideeffects.embl.de/se/C2830004/'),('http://sideeffects.embl.de/drugs/1727/','4-AP','http://sideeffects.embl.de/se/C0917801/'),('http://sideeffects.embl.de/drugs/17358/','SonoVue','http://sideeffects.embl.de/se/C0917801/'),('http://sideeffects.embl.de/drugs/175/','acetate','http://sideeffects.embl.de/se/C0677500/'),('http://sideeffects.embl.de/drugs/176870/','erlotinib','http://sideeffects.embl.de/se/C0339293/'),('http://sideeffects.embl.de/drugs/1775/','phenytoin','http://sideeffects.embl.de/se/C0027066/'),('http://sideeffects.embl.de/drugs/17754772/','ruxolitinib','http://sideeffects.embl.de/se/C0919874/'),('http://sideeffects.embl.de/drugs/179344/','eslicarbazepine acetate','http://sideeffects.embl.de/se/C1384666/'),('http://sideeffects.embl.de/drugs/1798/','methazolamide','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/1805/','5-azacytidine','http://sideeffects.embl.de/se/C0919874/'),('http://sideeffects.embl.de/drugs/18140/','estramustine','http://sideeffects.embl.de/se/C0877359/'),('http://sideeffects.embl.de/drugs/185457/','S-benzoylmercaptoacetyltriglycine','http://sideeffects.embl.de/se/C0085593/'),('http://sideeffects.embl.de/drugs/187/','acetylcholine','http://sideeffects.embl.de/se/C0428977/'),('http://sideeffects.embl.de/drugs/1875/','methylprednisolone sodium succinate','http://sideeffects.embl.de/se/C0025289/'),('http://sideeffects.embl.de/drugs/19090/','megestrol','http://sideeffects.embl.de/se/C0878544/'),('http://sideeffects.embl.de/drugs/191/','adenosine','http://sideeffects.embl.de/se/C0162297/'),('http://sideeffects.embl.de/drugs/192155/','Prednefrin','http://sideeffects.embl.de/se/C1096274/'),('http://sideeffects.embl.de/drugs/19371515/','alcaftadine','http://sideeffects.embl.de/se/C0677500/'),('http://sideeffects.embl.de/drugs/193962/','etravirine','http://sideeffects.embl.de/se/C0851578/'),('http://sideeffects.embl.de/drugs/1971/','abacavir','http://sideeffects.embl.de/se/C1145670/'),('http://sideeffects.embl.de/drugs/1972/','amphotericin B','http://sideeffects.embl.de/se/C0599918/'),('http://sideeffects.embl.de/drugs/197281/','gadobenate dimeglumine','http://sideeffects.embl.de/se/C0855329/'),('http://sideeffects.embl.de/drugs/197712/','ambrisentan','http://sideeffects.embl.de/se/C0917801/'),('http://sideeffects.embl.de/drugs/1978/','acebutolol','http://sideeffects.embl.de/se/C0036973/'),('http://sideeffects.embl.de/drugs/1983/','acetaminophen','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/1986/','acetazolamide','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/1990/','acetohydroxamic acid','http://sideeffects.embl.de/se/C1565489/'),('http://sideeffects.embl.de/drugs/1993/','methacholine','http://sideeffects.embl.de/se/C0700184/'),('http://sideeffects.embl.de/drugs/2019/','actinomycin D','http://sideeffects.embl.de/se/C0877359/'),('http://sideeffects.embl.de/drugs/2021/','spectinomycin','http://sideeffects.embl.de/se/C1287298/'),('http://sideeffects.embl.de/drugs/2022/','acyclovir','http://sideeffects.embl.de/se/C2830004/'),('http://sideeffects.embl.de/drugs/20585/','choline theophyllinate','http://sideeffects.embl.de/se/C0019087/'),('http://sideeffects.embl.de/drugs/206/','glucose','http://sideeffects.embl.de/se/C1145670/'),('http://sideeffects.embl.de/drugs/206527/','L-Dmp','http://sideeffects.embl.de/se/C0036973/'),('http://sideeffects.embl.de/drugs/2082/','albendazole','http://sideeffects.embl.de/se/C0267792/'),('http://sideeffects.embl.de/drugs/2083/','salbutamol','http://sideeffects.embl.de/se/C0855329/'),('http://sideeffects.embl.de/drugs/2085/','Almeta','http://sideeffects.embl.de/se/C0041834/'),('http://sideeffects.embl.de/drugs/2088/','alendronate','http://sideeffects.embl.de/se/C0392525/'),('http://sideeffects.embl.de/drugs/208898/','dronedarone','http://sideeffects.embl.de/se/C2364111/'),('http://sideeffects.embl.de/drugs/208908/','lapatinib','http://sideeffects.embl.de/se/C0333355/'),('http://sideeffects.embl.de/drugs/208920/','NuvaRing','http://sideeffects.embl.de/se/C0851341/'),('http://sideeffects.embl.de/drugs/2092/','alfuzosin','http://sideeffects.embl.de/se/C0026205/'),('http://sideeffects.embl.de/drugs/2094/','allopurinol','http://sideeffects.embl.de/se/C0043049/'),('http://sideeffects.embl.de/drugs/20969/','clocortolone','http://sideeffects.embl.de/se/C0016436/'),('http://sideeffects.embl.de/drugs/2099/','alosetron','http://sideeffects.embl.de/se/C0266813/'),('http://sideeffects.embl.de/drugs/2118/','alprazolam','http://sideeffects.embl.de/se/C2830004/'),('http://sideeffects.embl.de/drugs/2123/','hexamethylmelamine','http://sideeffects.embl.de/se/C0151849/'),('http://sideeffects.embl.de/drugs/2130/','amantadine','http://sideeffects.embl.de/se/C2830004/'),('http://sideeffects.embl.de/drugs/213023/','dabigatran etexilate','http://sideeffects.embl.de/se/C1291078/'),('http://sideeffects.embl.de/drugs/213039/','darunavir','http://sideeffects.embl.de/se/C0019521/'),('http://sideeffects.embl.de/drugs/213046/','lurasidone','http://sideeffects.embl.de/se/C0855329/'),('http://sideeffects.embl.de/drugs/2133/','amcinonide','http://sideeffects.embl.de/se/C0677500/'),('http://sideeffects.embl.de/drugs/214/','PGE1','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/2140/','diatrizoate','http://sideeffects.embl.de/se/C0162297/'),('http://sideeffects.embl.de/drugs/2141/','amifostine','http://sideeffects.embl.de/se/C0162297/'),('http://sideeffects.embl.de/drugs/2142/','amikacin','http://sideeffects.embl.de/se/C0599918/'),('http://sideeffects.embl.de/drugs/214339/','luliconazole','http://sideeffects.embl.de/se/C0011616/'),('http://sideeffects.embl.de/drugs/2145/','aminoglutethimide','http://sideeffects.embl.de/se/C0235378/'),('http://sideeffects.embl.de/drugs/2148/','p-aminohippurate','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/2153/','theophylline','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/2156/','amiodarone','http://sideeffects.embl.de/se/C0948595/'),('http://sideeffects.embl.de/drugs/2159/','amisulpride','http://sideeffects.embl.de/se/C0152128/'),('http://sideeffects.embl.de/drugs/2160/','amitriptyline','http://sideeffects.embl.de/se/C2364111/'),('http://sideeffects.embl.de/drugs/2161/','amlexanox','http://sideeffects.embl.de/se/C0242429/'),('http://sideeffects.embl.de/drugs/2162/','amlodipine','http://sideeffects.embl.de/se/C3665386/'),('http://sideeffects.embl.de/drugs/216209/','aliskiren','http://sideeffects.embl.de/se/C1565489/'),('http://sideeffects.embl.de/drugs/216210/','dabigatran','http://sideeffects.embl.de/se/C1291078/'),('http://sideeffects.embl.de/drugs/216235/','sitaxsentan','http://sideeffects.embl.de/se/C0240449/'),('http://sideeffects.embl.de/drugs/216237/','tolvaptan','http://sideeffects.embl.de/se/C1145670/'),('http://sideeffects.embl.de/drugs/216239/','sorafenib','http://sideeffects.embl.de/se/C0027726/'),('http://sideeffects.embl.de/drugs/216258/','Colimycin M','http://sideeffects.embl.de/se/C0599918/'),('http://sideeffects.embl.de/drugs/2163/','amobarbital','http://sideeffects.embl.de/se/C3203358/'),('http://sideeffects.embl.de/drugs/216326/','lenalidomide','http://sideeffects.embl.de/se/C0019557/'),('http://sideeffects.embl.de/drugs/216416/','lasofoxifene','http://sideeffects.embl.de/se/C0700200/'),('http://sideeffects.embl.de/drugs/2168/','amorolfine','http://sideeffects.embl.de/se/C0085624/'),('http://sideeffects.embl.de/drugs/2170/','amoxapine','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/2171/','amoxicillin','http://sideeffects.embl.de/se/C0025289/'),('http://sideeffects.embl.de/drugs/2173/','ampicillin','http://sideeffects.embl.de/se/C0340865/'),('http://sideeffects.embl.de/drugs/2177/','amprenavir','http://sideeffects.embl.de/se/C0851578/'),('http://sideeffects.embl.de/drugs/2179/','amsacrine','http://sideeffects.embl.de/se/C1287298/'),('http://sideeffects.embl.de/drugs/21800/','betamethasone dipropionate','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/2182/','anagrelide','http://sideeffects.embl.de/se/C3665386/'),('http://sideeffects.embl.de/drugs/2187/','anastrozole','http://sideeffects.embl.de/se/C0019557/'),('http://sideeffects.embl.de/drugs/219024/','regadenoson','http://sideeffects.embl.de/se/C0162297/'),('http://sideeffects.embl.de/drugs/219078/','lacosamide','http://sideeffects.embl.de/se/C0235146/'),('http://sideeffects.embl.de/drugs/219084/','Gd-EOB-DTPA','http://sideeffects.embl.de/se/C0542571/'),('http://sideeffects.embl.de/drugs/219090/','fosaprepitant','http://sideeffects.embl.de/se/C0026205/'),('http://sideeffects.embl.de/drugs/21945/','methenamine hippurate','http://sideeffects.embl.de/se/C0235309/'),('http://sideeffects.embl.de/drugs/2215/','apomorphine','http://sideeffects.embl.de/se/C2830004/'),('http://sideeffects.embl.de/drugs/2216/','apraclonidine','http://sideeffects.embl.de/se/C0948595/'),('http://sideeffects.embl.de/drugs/222/','ammonia','http://sideeffects.embl.de/se/C0031542/'),('http://sideeffects.embl.de/drugs/22258/','hydrocodone','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/222786/','cortisone','http://sideeffects.embl.de/se/C0700590/'),('http://sideeffects.embl.de/drugs/22318/','gold sodium thiomalate','http://sideeffects.embl.de/se/C0027726/'),('http://sideeffects.embl.de/drugs/2232/','argatroban','http://sideeffects.embl.de/se/C0007820/'),('http://sideeffects.embl.de/drugs/2244/','aspirin','http://sideeffects.embl.de/se/C0035400/'),('http://sideeffects.embl.de/drugs/2249/','atenolol','http://sideeffects.embl.de/se/C0600142/'),('http://sideeffects.embl.de/drugs/2250/','atorvastatin','http://sideeffects.embl.de/se/C2830004/'),('http://sideeffects.embl.de/drugs/22502/','procaine penicillin','http://sideeffects.embl.de/se/C0011551/'),('http://sideeffects.embl.de/drugs/2265/','azathioprine','http://sideeffects.embl.de/se/C0025289/'),('http://sideeffects.embl.de/drugs/2266/','azelaic acid','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/2267/','azelastine','http://sideeffects.embl.de/se/C3665386/'),('http://sideeffects.embl.de/drugs/2269/','azithromycin','http://sideeffects.embl.de/se/C0027726/'),('http://sideeffects.embl.de/drugs/2274/','aztreonam','http://sideeffects.embl.de/se/C0858635/'),('http://sideeffects.embl.de/drugs/2284/','baclofen','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/2307/','beclomethasone dipropionate','http://sideeffects.embl.de/se/C2364111/'),('http://sideeffects.embl.de/drugs/2308/','beclomethasone','http://sideeffects.embl.de/se/C2364111/'),('http://sideeffects.embl.de/drugs/2311/','benazepril','http://sideeffects.embl.de/se/C0855329/'),('http://sideeffects.embl.de/drugs/2315/','bendrofluazide','http://sideeffects.embl.de/se/C0242350/'),('http://sideeffects.embl.de/drugs/232/','arginine','http://sideeffects.embl.de/se/C0221201/'),('http://sideeffects.embl.de/drugs/2337/','benzocaine','http://sideeffects.embl.de/se/C0332575/'),('http://sideeffects.embl.de/drugs/2341/','benzphetamine','http://sideeffects.embl.de/se/C0878544/'),('http://sideeffects.embl.de/drugs/2344/','benztropine','http://sideeffects.embl.de/se/C0344232/'),('http://sideeffects.embl.de/drugs/2345/','benzyl benzoate','http://sideeffects.embl.de/se/C0677500/'),('http://sideeffects.embl.de/drugs/2349/','penicillin','http://sideeffects.embl.de/se/C0521491/'),('http://sideeffects.embl.de/drugs/2350/','bepotastine','http://sideeffects.embl.de/se/C0240211/'),('http://sideeffects.embl.de/drugs/2351/','bepridil','http://sideeffects.embl.de/se/C0548823/'),('http://sideeffects.embl.de/drugs/2366/','betahistine','http://sideeffects.embl.de/se/C2830004/'),('http://sideeffects.embl.de/drugs/23668479/','raltegravir','http://sideeffects.embl.de/se/C1291078/'),('http://sideeffects.embl.de/drugs/2367/','dexamethasone sodium phosphate','http://sideeffects.embl.de/se/C0019521/'),('http://sideeffects.embl.de/drugs/2369/','betaxolol','http://sideeffects.embl.de/se/C0948595/'),('http://sideeffects.embl.de/drugs/23690938/','piroxicam','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/2370/','bethanechol','http://sideeffects.embl.de/se/C0026205/'),('http://sideeffects.embl.de/drugs/23703/','ogen','http://sideeffects.embl.de/se/C1291077/'),('http://sideeffects.embl.de/drugs/2375/','bicalutamide','http://sideeffects.embl.de/se/C3665386/'),('http://sideeffects.embl.de/drugs/23897/','molindone','http://sideeffects.embl.de/se/C0236071/'),('http://sideeffects.embl.de/drugs/2391/','bisacodyl','http://sideeffects.embl.de/se/C0232487/'),('http://sideeffects.embl.de/drugs/23925/','Fe(III','http://sideeffects.embl.de/se/C0162297/'),('http://sideeffects.embl.de/drugs/23926/','lanthanum','http://sideeffects.embl.de/se/C0020598/'),('http://sideeffects.embl.de/drugs/23951/','samarium','http://sideeffects.embl.de/se/C0947912/'),('http://sideeffects.embl.de/drugs/23954/','silver nanoparticles','http://sideeffects.embl.de/se/C0085624/'),('http://sideeffects.embl.de/drugs/23976/','chromium','http://sideeffects.embl.de/se/C0151763/'),('http://sideeffects.embl.de/drugs/23978/','copper','http://sideeffects.embl.de/se/C0042267/'),('http://sideeffects.embl.de/drugs/23982/','gadolinium','http://sideeffects.embl.de/se/C0700200/'),('http://sideeffects.embl.de/drugs/2405/','bisoprolol','http://sideeffects.embl.de/se/C0007820/'),('http://sideeffects.embl.de/drugs/24087/','selenium sulfide','http://sideeffects.embl.de/se/C0152030/'),('http://sideeffects.embl.de/drugs/2431/','bretylium','http://sideeffects.embl.de/se/C0019521/'),('http://sideeffects.embl.de/drugs/2435/','brimonidine','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/244/','benzyl alcohol','http://sideeffects.embl.de/se/C0521490/'),('http://sideeffects.embl.de/drugs/2441/','bromazepam','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/24414/','barium sulfate','http://sideeffects.embl.de/se/C0000729/'),('http://sideeffects.embl.de/drugs/2442/','bromhexine','http://sideeffects.embl.de/se/C0232492/'),('http://sideeffects.embl.de/drugs/24424/','zinc sulfate','http://sideeffects.embl.de/se/C1291078/'),('http://sideeffects.embl.de/drugs/2443/','bromocriptine','http://sideeffects.embl.de/se/C0948595/'),('http://sideeffects.embl.de/drugs/24450/','potassium phosphate','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/2462/','budesonide','http://sideeffects.embl.de/se/C3665386/'),('http://sideeffects.embl.de/drugs/24642/','TlCl','http://sideeffects.embl.de/se/C0344232/'),('http://sideeffects.embl.de/drugs/247/','betaine','http://sideeffects.embl.de/se/C0548823/'),('http://sideeffects.embl.de/drugs/24706/','Triphasil','http://sideeffects.embl.de/se/C0268000/'),('http://sideeffects.embl.de/drugs/2471/','bumetanide','http://sideeffects.embl.de/se/C0700225/'),('http://sideeffects.embl.de/drugs/2474/','bupivacaine','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/24748/','glucose solution','http://sideeffects.embl.de/se/C0031542/'),('http://sideeffects.embl.de/drugs/2476/','buprenorphine','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/24762228/','Azarga','http://sideeffects.embl.de/se/C0497201/'),('http://sideeffects.embl.de/drugs/2477/','buspirone','http://sideeffects.embl.de/se/C0855329/'),('http://sideeffects.embl.de/drugs/24776445/','vismodegib','http://sideeffects.embl.de/se/C0016199/'),('http://sideeffects.embl.de/drugs/2478/','busulfan','http://sideeffects.embl.de/se/C1096274/'),('http://sideeffects.embl.de/drugs/2479/','butabarbital','http://sideeffects.embl.de/se/C3203358/'),('http://sideeffects.embl.de/drugs/24812758/','canagliflozin','http://sideeffects.embl.de/se/C0700225/'),('http://sideeffects.embl.de/drugs/24822371/','florbetapir','http://sideeffects.embl.de/se/C0497247/'),('http://sideeffects.embl.de/drugs/24826799/','ponatinib','http://sideeffects.embl.de/se/C0750394/'),('http://sideeffects.embl.de/drugs/24838347/','glucagon hydrochloride','http://sideeffects.embl.de/se/C0497247/'),('http://sideeffects.embl.de/drugs/2484/','butenafine','http://sideeffects.embl.de/se/C0677500/'),('http://sideeffects.embl.de/drugs/24841/','iodide','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/24846132/','hetastarch','http://sideeffects.embl.de/se/C0392171/'),('http://sideeffects.embl.de/drugs/2487/','butorphanol','http://sideeffects.embl.de/se/C3203358/'),('http://sideeffects.embl.de/drugs/24950485/','cobicistat','http://sideeffects.embl.de/se/C1565489/'),('http://sideeffects.embl.de/drugs/25074470/','Triptorelin','http://sideeffects.embl.de/se/C0497201/'),('http://sideeffects.embl.de/drugs/25074886/','cetrorelix','http://sideeffects.embl.de/se/C0600142/'),('http://sideeffects.embl.de/drugs/25077405/','Nafarelin','http://sideeffects.embl.de/se/C0947912/'),('http://sideeffects.embl.de/drugs/25077993/','Histrelin','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/25094462/','sofosbuvir','http://sideeffects.embl.de/se/C0521839/'),('http://sideeffects.embl.de/drugs/25102847/','cabozantinib','http://sideeffects.embl.de/se/C2364111/'),('http://sideeffects.embl.de/drugs/2512/','cabergoline','http://sideeffects.embl.de/se/C3665386/'),('http://sideeffects.embl.de/drugs/2519/','caffeine','http://sideeffects.embl.de/se/C0851341/'),('http://sideeffects.embl.de/drugs/2520/','verapamil','http://sideeffects.embl.de/se/C1145670/'),('http://sideeffects.embl.de/drugs/2522/','calcipotriol','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/2524/','1,25(OH)2D3','http://sideeffects.embl.de/se/C2830004/'),('http://sideeffects.embl.de/drugs/2540/','candesartan cilexetil','http://sideeffects.embl.de/se/C1565489/'),('http://sideeffects.embl.de/drugs/2541/','candesartan','http://sideeffects.embl.de/se/C2830004/'),('http://sideeffects.embl.de/drugs/25419/','clodronate','http://sideeffects.embl.de/se/C1565489/'),('http://sideeffects.embl.de/drugs/2547/','capreomycin','http://sideeffects.embl.de/se/C0599918/'),('http://sideeffects.embl.de/drugs/2548/','capsaicin','http://sideeffects.embl.de/se/C0877661/'),('http://sideeffects.embl.de/drugs/2550/','captopril','http://sideeffects.embl.de/se/C0027726/'),('http://sideeffects.embl.de/drugs/2551/','carbachol','http://sideeffects.embl.de/se/C1761613/'),('http://sideeffects.embl.de/drugs/2554/','carbamazepine','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/2559/','carbenicillin','http://sideeffects.embl.de/se/C0221490/'),('http://sideeffects.embl.de/drugs/2563/','carbidopa','http://sideeffects.embl.de/se/C0241426/'),('http://sideeffects.embl.de/drugs/2564/','carbinoxamine','http://sideeffects.embl.de/se/C0700590/'),('http://sideeffects.embl.de/drugs/2576/','carisoprodol','http://sideeffects.embl.de/se/C0019521/'),('http://sideeffects.embl.de/drugs/2578/','BCNU','http://sideeffects.embl.de/se/C0599918/'),('http://sideeffects.embl.de/drugs/2583/','carteolol','http://sideeffects.embl.de/se/C1761613/'),('http://sideeffects.embl.de/drugs/2585/','carvedilol','http://sideeffects.embl.de/se/C0700200/'),('http://sideeffects.embl.de/drugs/25880656/','doxycycline','http://sideeffects.embl.de/se/C2364111/'),('http://sideeffects.embl.de/drugs/25880664/','tetracycline','http://sideeffects.embl.de/se/C0221490/'),('http://sideeffects.embl.de/drugs/25959/','Prussian blue','http://sideeffects.embl.de/se/C0009806/'),('http://sideeffects.embl.de/drugs/2609/','cefaclor','http://sideeffects.embl.de/se/C0851341/'),('http://sideeffects.embl.de/drugs/2610/','cefadroxil','http://sideeffects.embl.de/se/C0151905/'),('http://sideeffects.embl.de/drugs/2617/','cefazolin','http://sideeffects.embl.de/se/C0836924/'),('http://sideeffects.embl.de/drugs/2622/','cefepime','http://sideeffects.embl.de/se/C0027066/'),('http://sideeffects.embl.de/drugs/26275995/','minocycline','http://sideeffects.embl.de/se/C0599918/'),('http://sideeffects.embl.de/drugs/2631/','cefotaxime','http://sideeffects.embl.de/se/C1565489/'),('http://sideeffects.embl.de/drugs/2637/','cefoxitin','http://sideeffects.embl.de/se/C0234233/'),('http://sideeffects.embl.de/drugs/2646/','cefprozil','http://sideeffects.embl.de/se/C0151754/'),('http://sideeffects.embl.de/drugs/2650/','ceftazidime','http://sideeffects.embl.de/se/C0027066/'),('http://sideeffects.embl.de/drugs/2654/','cephem','http://sideeffects.embl.de/se/C1565489/'),('http://sideeffects.embl.de/drugs/2655/','ceftizoxime','http://sideeffects.embl.de/se/C0836924/'),('http://sideeffects.embl.de/drugs/2656/','ceftriaxone','http://sideeffects.embl.de/se/C0241426/'),('http://sideeffects.embl.de/drugs/2658/','cefuroxime','http://sideeffects.embl.de/se/C1565489/'),('http://sideeffects.embl.de/drugs/2662/','celecoxib','http://sideeffects.embl.de/se/C0027726/'),('http://sideeffects.embl.de/drugs/2663/','celiprolol','http://sideeffects.embl.de/se/C0600142/'),('http://sideeffects.embl.de/drugs/2666/','cephalexin','http://sideeffects.embl.de/se/C0851341/'),('http://sideeffects.embl.de/drugs/2675/','cefixime','http://sideeffects.embl.de/se/C0025289/'),('http://sideeffects.embl.de/drugs/2676/','cerivastatin','http://sideeffects.embl.de/se/C0947912/'),('http://sideeffects.embl.de/drugs/2678/','cetirizine','http://sideeffects.embl.de/se/C0027066/'),('http://sideeffects.embl.de/drugs/2684/','cevimeline','http://sideeffects.embl.de/se/C0032788/'),('http://sideeffects.embl.de/drugs/2708/','chlorambucil','http://sideeffects.embl.de/se/C1287298/'),('http://sideeffects.embl.de/drugs/271/','calcium','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/2712/','chlordiazepoxide','http://sideeffects.embl.de/se/C0086565/'),('http://sideeffects.embl.de/drugs/2713/','chlorhexidine','http://sideeffects.embl.de/se/C0392171/'),('http://sideeffects.embl.de/drugs/2719/','chloroquine','http://sideeffects.embl.de/se/C0855329/'),('http://sideeffects.embl.de/drugs/2720/','thiazide','http://sideeffects.embl.de/se/C0027707/'),('http://sideeffects.embl.de/drugs/2723601/','6-thioguanine','http://sideeffects.embl.de/se/C0268000/'),('http://sideeffects.embl.de/drugs/2725/','chlorpheniramine','http://sideeffects.embl.de/se/C0700590/'),('http://sideeffects.embl.de/drugs/2726/','chlorpromazine','http://sideeffects.embl.de/se/C0026205/'),('http://sideeffects.embl.de/drugs/2727/','chlorpropamide','http://sideeffects.embl.de/se/C0162830/'),('http://sideeffects.embl.de/drugs/27304/','HMDP','http://sideeffects.embl.de/se/C0042963/'),('http://sideeffects.embl.de/drugs/2732/','chlorthalidone','http://sideeffects.embl.de/se/C0548823/'),('http://sideeffects.embl.de/drugs/2733/','chlorzoxazone','http://sideeffects.embl.de/se/C0220870/'),('http://sideeffects.embl.de/drugs/27400/','pizotifen','http://sideeffects.embl.de/se/C0221490/'),('http://sideeffects.embl.de/drugs/2749/','ciclopirox','http://sideeffects.embl.de/se/C0542571/'),('http://sideeffects.embl.de/drugs/2751/','cilazapril','http://sideeffects.embl.de/se/C0007820/'),('http://sideeffects.embl.de/drugs/2754/','cilostazol','http://sideeffects.embl.de/se/C1458140/'),('http://sideeffects.embl.de/drugs/2756/','cimetidine','http://sideeffects.embl.de/se/C1565489/'),('http://sideeffects.embl.de/drugs/2761171/','ethionamide','http://sideeffects.embl.de/se/C0349506/'),('http://sideeffects.embl.de/drugs/2762/','cinoxacin','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/2764/','ciprofloxacin','http://sideeffects.embl.de/se/C0948595/'),('http://sideeffects.embl.de/drugs/27661/','isosorbide-5-mononitrate','http://sideeffects.embl.de/se/C0007820/'),('http://sideeffects.embl.de/drugs/2767/','cisplatin','http://sideeffects.embl.de/se/C1287298/'),('http://sideeffects.embl.de/drugs/2771/','citalopram','http://sideeffects.embl.de/se/C0036973/'),('http://sideeffects.embl.de/drugs/2781/','clemastine','http://sideeffects.embl.de/se/C0700590/'),('http://sideeffects.embl.de/drugs/2786/','clindamycin','http://sideeffects.embl.de/se/C1291077/'),('http://sideeffects.embl.de/drugs/2789/','clobazam','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/2791/','clobetasol propionate','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/2792/','clobetasone butyrate','http://sideeffects.embl.de/se/C0086543/'),('http://sideeffects.embl.de/drugs/2794/','clofazimine','http://sideeffects.embl.de/se/C0497156/'),('http://sideeffects.embl.de/drugs/27991/','desmopressin','http://sideeffects.embl.de/se/C0043049/'),('http://sideeffects.embl.de/drugs/27993/','conjugated estrogens','http://sideeffects.embl.de/se/C1291077/'),('http://sideeffects.embl.de/drugs/2800/','clomiphene citrate','http://sideeffects.embl.de/se/C1291077/'),('http://sideeffects.embl.de/drugs/2801/','clomipramine','http://sideeffects.embl.de/se/C0027066/'),('http://sideeffects.embl.de/drugs/2802/','clonazepam','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/2803/','clonidine','http://sideeffects.embl.de/se/C0025289/'),('http://sideeffects.embl.de/drugs/2806/','clopidogrel','http://sideeffects.embl.de/se/C1565489/'),('http://sideeffects.embl.de/drugs/2809/','clorazepate','http://sideeffects.embl.de/se/C0022107/'),('http://sideeffects.embl.de/drugs/2812/','clotrimazole','http://sideeffects.embl.de/se/C1291077/'),('http://sideeffects.embl.de/drugs/2818/','clozapine','http://sideeffects.embl.de/se/C0855329/'),('http://sideeffects.embl.de/drugs/2826/','cocaine','http://sideeffects.embl.de/se/C1145670/'),('http://sideeffects.embl.de/drugs/2828/','codeine','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/2833/','colchicine','http://sideeffects.embl.de/se/C0858635/'),('http://sideeffects.embl.de/drugs/28332/','propoxyphene napsylate','http://sideeffects.embl.de/se/C0233571/'),('http://sideeffects.embl.de/drugs/28486/','lithium','http://sideeffects.embl.de/se/C0855329/'),('http://sideeffects.embl.de/drugs/2881/','sodium cromoglycate','http://sideeffects.embl.de/se/C1761613/'),('http://sideeffects.embl.de/drugs/2883/','crotamiton','http://sideeffects.embl.de/se/C0011603/'),('http://sideeffects.embl.de/drugs/2891/','cyanocobalamin','http://sideeffects.embl.de/se/C0038999/'),('http://sideeffects.embl.de/drugs/2895/','cyclobenzaprine','http://sideeffects.embl.de/se/C2364111/'),('http://sideeffects.embl.de/drugs/2905/','cyclopentolate','http://sideeffects.embl.de/se/C0235267/'),('http://sideeffects.embl.de/drugs/2907/','cyclophosphamide','http://sideeffects.embl.de/se/C1287298/'),('http://sideeffects.embl.de/drugs/29089/','chlorhexidine gluconate','http://sideeffects.embl.de/se/C0237849/'),('http://sideeffects.embl.de/drugs/2909/','v 1784','http://sideeffects.embl.de/se/C0599918/'),('http://sideeffects.embl.de/drugs/2913/','cyproheptadine','http://sideeffects.embl.de/se/C0700590/'),('http://sideeffects.embl.de/drugs/2914/','cyproterone acetate','http://sideeffects.embl.de/se/C3665386/'),('http://sideeffects.embl.de/drugs/2949/','danazol','http://sideeffects.embl.de/se/C0851578/'),('http://sideeffects.embl.de/drugs/2951/','dantrolene','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/2955/','dapsone','http://sideeffects.embl.de/se/C0027726/'),('http://sideeffects.embl.de/drugs/2958/','anthracycline','http://sideeffects.embl.de/se/C0855329/'),('http://sideeffects.embl.de/drugs/297/','graphene','http://sideeffects.embl.de/se/C0021843/'),('http://sideeffects.embl.de/drugs/2972/','deferiprone','http://sideeffects.embl.de/se/C0836924/'),('http://sideeffects.embl.de/drugs/2973/','deferoxamine','http://sideeffects.embl.de/se/C1565489/'),('http://sideeffects.embl.de/drugs/2978/','delta 9-THC','http://sideeffects.embl.de/se/C0235146/'),('http://sideeffects.embl.de/drugs/298/','chloramphenicol','http://sideeffects.embl.de/se/C1761613/'),('http://sideeffects.embl.de/drugs/2995/','desipramine','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/3000/','desoximetasone','http://sideeffects.embl.de/se/C0853714/'),('http://sideeffects.embl.de/drugs/3003/','dexamethasone','http://sideeffects.embl.de/se/C1096278/'),('http://sideeffects.embl.de/drugs/3006171/','rilpivirine','http://sideeffects.embl.de/se/C0027726/'),('http://sideeffects.embl.de/drugs/3007/','amphetamine','http://sideeffects.embl.de/se/C2830004/'),('http://sideeffects.embl.de/drugs/3008/','dextromethorphan','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/3009/','DFMO','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/3010818/','d-telaprevir','http://sideeffects.embl.de/se/C0267792/'),('http://sideeffects.embl.de/drugs/3015/','cyproterone','http://sideeffects.embl.de/se/C0947912/'),('http://sideeffects.embl.de/drugs/3016/','diazepam','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/3019/','diazoxide','http://sideeffects.embl.de/se/C0027726/'),('http://sideeffects.embl.de/drugs/303/','bile salt','http://sideeffects.embl.de/se/C0267792/'),('http://sideeffects.embl.de/drugs/3032/','diclofenac','http://sideeffects.embl.de/se/C1096274/'),('http://sideeffects.embl.de/drugs/3038/','dichlorphenamide','http://sideeffects.embl.de/se/C0233407/'),('http://sideeffects.embl.de/drugs/3038497/','fospropofol','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/3040/','dicloxacillin','http://sideeffects.embl.de/se/C0027066/'),('http://sideeffects.embl.de/drugs/3042/','dicyclomine','http://sideeffects.embl.de/se/C2364111/'),('http://sideeffects.embl.de/drugs/3043/','didanosine','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/305/','choline','http://sideeffects.embl.de/se/C0151735/'),('http://sideeffects.embl.de/drugs/3053/','diethylenetriaminepentaacetic acid','http://sideeffects.embl.de/se/C0240327/'),('http://sideeffects.embl.de/drugs/3055172/','pimecrolimus','http://sideeffects.embl.de/se/C0877661/'),('http://sideeffects.embl.de/drugs/3056/','diflorasone diacetate','http://sideeffects.embl.de/se/C0016436/'),('http://sideeffects.embl.de/drugs/3059/','diflunisal','http://sideeffects.embl.de/se/C0238124/'),('http://sideeffects.embl.de/drugs/3060/','epitopic','http://sideeffects.embl.de/se/C1096274/'),('http://sideeffects.embl.de/drugs/3062/','digoxin','http://sideeffects.embl.de/se/C0855329/'),('http://sideeffects.embl.de/drugs/30623/','dexrazoxane','http://sideeffects.embl.de/se/C0750394/'),('http://sideeffects.embl.de/drugs/3062316/','dasatinib','http://sideeffects.embl.de/se/C0878544/'),('http://sideeffects.embl.de/drugs/3063/','dihydrocodeine','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/3066/','dihydroergotamine','http://sideeffects.embl.de/se/C0019521/'),('http://sideeffects.embl.de/drugs/3075/','diltiazem','http://sideeffects.embl.de/se/C3665386/'),('http://sideeffects.embl.de/drugs/3080/','dimercaprol','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/3080904/','Estrofem','http://sideeffects.embl.de/se/C3665386/'),('http://sideeffects.embl.de/drugs/3081276/','fluticasone/salmeterol','http://sideeffects.embl.de/se/C0851578/'),('http://sideeffects.embl.de/drugs/3081361/','vandetanib','http://sideeffects.embl.de/se/C0162297/'),('http://sideeffects.embl.de/drugs/3081362/','telavancin','http://sideeffects.embl.de/se/C0599918/'),('http://sideeffects.embl.de/drugs/3081884/','copolymer 1','http://sideeffects.embl.de/se/C0027066/'),('http://sideeffects.embl.de/drugs/3085017/','sevelamer','http://sideeffects.embl.de/se/C0021843/'),('http://sideeffects.embl.de/drugs/3086257/','Photofrin II','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/3086685/','axitinib','http://sideeffects.embl.de/se/C2363731/'),('http://sideeffects.embl.de/drugs/3086686/','sunitinib','http://sideeffects.embl.de/se/C0238124/'),('http://sideeffects.embl.de/drugs/3100/','diphenhydramine','http://sideeffects.embl.de/se/C0349506/'),('http://sideeffects.embl.de/drugs/3105/','dipivefrin','http://sideeffects.embl.de/se/C0677500/'),('http://sideeffects.embl.de/drugs/31072/','carbimazole','http://sideeffects.embl.de/se/C2364111/'),('http://sideeffects.embl.de/drugs/3108/','dipyridamole','http://sideeffects.embl.de/se/C0855329/'),('http://sideeffects.embl.de/drugs/311/','citric acid','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/3114/','disopyramide','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/3117/','disulfiram','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/312/','chloride','http://sideeffects.embl.de/se/C0234233/'),('http://sideeffects.embl.de/drugs/3121/','valproate','http://sideeffects.embl.de/se/C0014431/'),('http://sideeffects.embl.de/drugs/3125/','alpha-methyl-p-tyrosine','http://sideeffects.embl.de/se/C0917801/'),('http://sideeffects.embl.de/drugs/31264/','paraldehyde','http://sideeffects.embl.de/se/C0234369/'),('http://sideeffects.embl.de/drugs/31378/','fludrocortisone','http://sideeffects.embl.de/se/C0340865/'),('http://sideeffects.embl.de/drugs/3143/','docetaxel','http://sideeffects.embl.de/se/C0596240/'),('http://sideeffects.embl.de/drugs/31477/','metipranolol','http://sideeffects.embl.de/se/C3665386/'),('http://sideeffects.embl.de/drugs/3148/','dolasetron','http://sideeffects.embl.de/se/C0036973/'),('http://sideeffects.embl.de/drugs/3151/','domperidone','http://sideeffects.embl.de/se/C0600142/'),('http://sideeffects.embl.de/drugs/3152/','donepezil','http://sideeffects.embl.de/se/C3665386/'),('http://sideeffects.embl.de/drugs/3154/','dorzolamide','http://sideeffects.embl.de/se/C1761613/'),('http://sideeffects.embl.de/drugs/315411/','18F-FDG','http://sideeffects.embl.de/se/C0033774/'),('http://sideeffects.embl.de/drugs/3155/','dothiepin','http://sideeffects.embl.de/se/C0242350/'),('http://sideeffects.embl.de/drugs/3156/','doxapram','http://sideeffects.embl.de/se/C0019521/'),('http://sideeffects.embl.de/drugs/3157/','doxazosin','http://sideeffects.embl.de/se/C0007820/'),('http://sideeffects.embl.de/drugs/3158/','doxepin','http://sideeffects.embl.de/se/C0855329/'),('http://sideeffects.embl.de/drugs/3168/','droperidol','http://sideeffects.embl.de/se/C0036973/'),('http://sideeffects.embl.de/drugs/3171/','L-threo-DOPS','http://sideeffects.embl.de/se/C0497247/'),('http://sideeffects.embl.de/drugs/3182/','dyphylline','http://sideeffects.embl.de/se/C0232493/'),('http://sideeffects.embl.de/drugs/3198/','econazole','http://sideeffects.embl.de/se/C0677500/'),('http://sideeffects.embl.de/drugs/3199/','trabectedin','http://sideeffects.embl.de/se/C0333355/'),('http://sideeffects.embl.de/drugs/3202/','edrophonium','http://sideeffects.embl.de/se/C1761613/'),('http://sideeffects.embl.de/drugs/3203/','efavirenz','http://sideeffects.embl.de/se/C0014431/'),('http://sideeffects.embl.de/drugs/3209/','eicosapentaenoic acid','http://sideeffects.embl.de/se/C2363731/'),('http://sideeffects.embl.de/drugs/32169/','articaine','http://sideeffects.embl.de/se/C2830004/'),('http://sideeffects.embl.de/drugs/3219/','emedastine','http://sideeffects.embl.de/se/C0853336/'),('http://sideeffects.embl.de/drugs/3222/','CAS 76095-16-4','http://sideeffects.embl.de/se/C2830004/'),('http://sideeffects.embl.de/drugs/3226/','enflurane','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/32281/','Protirelin','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/3241/','epinastine','http://sideeffects.embl.de/se/C0152227/'),('http://sideeffects.embl.de/drugs/3249/','vitamin D2','http://sideeffects.embl.de/se/C0427008/'),('http://sideeffects.embl.de/drugs/3250/','ergonovine','http://sideeffects.embl.de/se/C0043049/'),('http://sideeffects.embl.de/drugs/3251/','ergotamine','http://sideeffects.embl.de/se/C0028643/'),('http://sideeffects.embl.de/drugs/3255/','erythromycin','http://sideeffects.embl.de/se/C1384666/'),('http://sideeffects.embl.de/drugs/3256/','monomycin','http://sideeffects.embl.de/se/C1384666/'),('http://sideeffects.embl.de/drugs/32603/','clindamycin phosphate','http://sideeffects.embl.de/se/C1291077/'),('http://sideeffects.embl.de/drugs/3261/','estazolam','http://sideeffects.embl.de/se/C3665386/'),('http://sideeffects.embl.de/drugs/3263/','estradiol cypionate','http://sideeffects.embl.de/se/C1291077/'),('http://sideeffects.embl.de/drugs/3267/','estradiol valerate','http://sideeffects.embl.de/se/C1291077/'),('http://sideeffects.embl.de/drugs/3268/','estramustine phosphate','http://sideeffects.embl.de/se/C0600142/'),('http://sideeffects.embl.de/drugs/3269/','estriol','http://sideeffects.embl.de/se/C0521490/'),('http://sideeffects.embl.de/drugs/3278/','ethacrynic acid','http://sideeffects.embl.de/se/C0232487/'),('http://sideeffects.embl.de/drugs/3279/','ethambutol','http://sideeffects.embl.de/se/C0497156/'),('http://sideeffects.embl.de/drugs/32797/','clobetasol','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/32800/','Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2','http://sideeffects.embl.de/se/C0700590/'),('http://sideeffects.embl.de/drugs/3291/','ethosuximide','http://sideeffects.embl.de/se/C0019521/'),('http://sideeffects.embl.de/drugs/3292/','ethotoin','http://sideeffects.embl.de/se/C0497156/'),('http://sideeffects.embl.de/drugs/3305/','etidronate','http://sideeffects.embl.de/se/C0241426/'),('http://sideeffects.embl.de/drugs/3308/','etodolac','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/3310/','etoposide','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/3324/','famciclovir','http://sideeffects.embl.de/se/C0858635/'),('http://sideeffects.embl.de/drugs/3325/','famotidine','http://sideeffects.embl.de/se/C1761613/'),('http://sideeffects.embl.de/drugs/3325225/','ALX 111','http://sideeffects.embl.de/se/C0851341/'),('http://sideeffects.embl.de/drugs/3331/','felbamate','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/3333/','felodipine','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/3339/','fenofibrate','http://sideeffects.embl.de/se/C3665386/'),('http://sideeffects.embl.de/drugs/3340/','fenoldopam','http://sideeffects.embl.de/se/C0151754/'),('http://sideeffects.embl.de/drugs/3342/','fenoprofen','http://sideeffects.embl.de/se/C0855329/'),('http://sideeffects.embl.de/drugs/3345/','fentanyl','http://sideeffects.embl.de/se/C0596240/'),('http://sideeffects.embl.de/drugs/3348/','fexofenadine','http://sideeffects.embl.de/se/C0851578/'),('http://sideeffects.embl.de/drugs/3350/','finasteride','http://sideeffects.embl.de/se/C0234233/'),('http://sideeffects.embl.de/drugs/3355/','flecainide','http://sideeffects.embl.de/se/C0700200/'),('http://sideeffects.embl.de/drugs/3363/','FdUrd','http://sideeffects.embl.de/se/C0349506/'),('http://sideeffects.embl.de/drugs/3364/','flucloxacillin','http://sideeffects.embl.de/se/C0242429/'),('http://sideeffects.embl.de/drugs/3365/','fluconazole','http://sideeffects.embl.de/se/C3665386/'),('http://sideeffects.embl.de/drugs/3366/','5-fluorocytosine','http://sideeffects.embl.de/se/C0162297/'),('http://sideeffects.embl.de/drugs/3367/','fludarabine','http://sideeffects.embl.de/se/C1384666/'),('http://sideeffects.embl.de/drugs/3368/','FAMP','http://sideeffects.embl.de/se/C1384666/'),('http://sideeffects.embl.de/drugs/3370/','fludrocortisone acetate','http://sideeffects.embl.de/se/C0340865/'),('http://sideeffects.embl.de/drugs/3372/','fluphenazine','http://sideeffects.embl.de/se/C0349506/'),('http://sideeffects.embl.de/drugs/3373/','flumazenil','http://sideeffects.embl.de/se/C0235546/'),('http://sideeffects.embl.de/drugs/3375/','flumethasone','http://sideeffects.embl.de/se/C0016436/'),('http://sideeffects.embl.de/drugs/3379/','flunisolide','http://sideeffects.embl.de/se/C0948595/'),('http://sideeffects.embl.de/drugs/338/','salicylate','http://sideeffects.embl.de/se/C0266813/'),('http://sideeffects.embl.de/drugs/3380/','flunitrazepam','http://sideeffects.embl.de/se/C0019521/'),('http://sideeffects.embl.de/drugs/3381/','fluocinolone acetonide','http://sideeffects.embl.de/se/C1761613/'),('http://sideeffects.embl.de/drugs/3382/','fluocinonide','http://sideeffects.embl.de/se/C0877661/'),('http://sideeffects.embl.de/drugs/3384/','fluorometholone','http://sideeffects.embl.de/se/C0948595/'),('http://sideeffects.embl.de/drugs/3385/','5-FU','http://sideeffects.embl.de/se/C0855329/'),('http://sideeffects.embl.de/drugs/3386/','fluoxetine','http://sideeffects.embl.de/se/C0027066/'),('http://sideeffects.embl.de/drugs/3387/','fluoxymesterone','http://sideeffects.embl.de/se/C0340865/'),('http://sideeffects.embl.de/drugs/3388/','fluphenazine decanoate','http://sideeffects.embl.de/se/C0349506/'),('http://sideeffects.embl.de/drugs/3392/','flurandrenolone','http://sideeffects.embl.de/se/C0151907/'),('http://sideeffects.embl.de/drugs/3393/','flurazepam','http://sideeffects.embl.de/se/C0687713/'),('http://sideeffects.embl.de/drugs/3394/','flurbiprofen','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/3397/','flutamide','http://sideeffects.embl.de/se/C0232461/'),('http://sideeffects.embl.de/drugs/3399/','fluticasone propionate','http://sideeffects.embl.de/se/C2364111/'),('http://sideeffects.embl.de/drugs/3403/','fluvastatin','http://sideeffects.embl.de/se/C3665386/'),('http://sideeffects.embl.de/drugs/3404/','fluvoxamine','http://sideeffects.embl.de/se/C0152128/'),('http://sideeffects.embl.de/drugs/3405/','folate','http://sideeffects.embl.de/se/C0233571/'),('http://sideeffects.embl.de/drugs/3406/','4-methylpyrazole','http://sideeffects.embl.de/se/C0019521/'),('http://sideeffects.embl.de/drugs/3410/','formoterol','http://sideeffects.embl.de/se/C0162297/'),('http://sideeffects.embl.de/drugs/3414/','foscarnet','http://sideeffects.embl.de/se/C0599918/'),('http://sideeffects.embl.de/drugs/3417/','fosfomycin','http://sideeffects.embl.de/se/C1384666/'),('http://sideeffects.embl.de/drugs/3419/','fosinopril','http://sideeffects.embl.de/se/C0162297/'),('http://sideeffects.embl.de/drugs/3425/','Romidepsin','http://sideeffects.embl.de/se/C0243026/'),('http://sideeffects.embl.de/drugs/34312/','oxcarbazepine','http://sideeffects.embl.de/se/C0019521/'),('http://sideeffects.embl.de/drugs/3440/','furosemide','http://sideeffects.embl.de/se/C1384666/'),('http://sideeffects.embl.de/drugs/3443/','fusidic acid','http://sideeffects.embl.de/se/C0677500/'),('http://sideeffects.embl.de/drugs/3446/','gabapentin','http://sideeffects.embl.de/se/C0027066/'),('http://sideeffects.embl.de/drugs/3449/','galantamine','http://sideeffects.embl.de/se/C0019521/'),('http://sideeffects.embl.de/drugs/3454/','ganciclovir','http://sideeffects.embl.de/se/C0599918/'),('http://sideeffects.embl.de/drugs/3461/','gemcitabine','http://sideeffects.embl.de/se/C0036973/'),('http://sideeffects.embl.de/drugs/3462/','gemeprost','http://sideeffects.embl.de/se/C0013390/'),('http://sideeffects.embl.de/drugs/3463/','gemfibrozil','http://sideeffects.embl.de/se/C0947912/'),('http://sideeffects.embl.de/drugs/3467/','gentamicin','http://sideeffects.embl.de/se/C0599918/'),('http://sideeffects.embl.de/drugs/3475/','gliclazide','http://sideeffects.embl.de/se/C0007820/'),('http://sideeffects.embl.de/drugs/3476/','glimepiride','http://sideeffects.embl.de/se/C0687713/'),('http://sideeffects.embl.de/drugs/3478/','glipizide','http://sideeffects.embl.de/se/C3665386/'),('http://sideeffects.embl.de/drugs/3488/','glibenclamide','http://sideeffects.embl.de/se/C0007820/'),('http://sideeffects.embl.de/drugs/3494/','glycopyrrolate','http://sideeffects.embl.de/se/C0162297/'),('http://sideeffects.embl.de/drugs/3510/','granisetron','http://sideeffects.embl.de/se/C0019521/'),('http://sideeffects.embl.de/drugs/3512/','griseofulvin','http://sideeffects.embl.de/se/C0221490/'),('http://sideeffects.embl.de/drugs/3516/','guaifenesin','http://sideeffects.embl.de/se/C0234215/'),('http://sideeffects.embl.de/drugs/3517/','icodextrin','http://sideeffects.embl.de/se/C0019521/'),('http://sideeffects.embl.de/drugs/3519/','guanfacine','http://sideeffects.embl.de/se/C0237849/'),('http://sideeffects.embl.de/drugs/3520/','guanidinium','http://sideeffects.embl.de/se/C0242429/'),('http://sideeffects.embl.de/drugs/3553/','halcinonide','http://sideeffects.embl.de/se/C0085624/'),('http://sideeffects.embl.de/drugs/3559/','haloperidol','http://sideeffects.embl.de/se/C0349506/'),('http://sideeffects.embl.de/drugs/358641/','trimethoprim-sulfamethoxazole','http://sideeffects.embl.de/se/C0221242/'),('http://sideeffects.embl.de/drugs/3598/','hexachlorophene','http://sideeffects.embl.de/se/C0349506/'),('http://sideeffects.embl.de/drugs/3623/','homatropine','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/36339/','etomidate','http://sideeffects.embl.de/se/C0027066/'),('http://sideeffects.embl.de/drugs/3636/','Buscopan','http://sideeffects.embl.de/se/C0340865/'),('http://sideeffects.embl.de/drugs/3637/','hydralazine','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/3639/','hydrochlorothiazide','http://sideeffects.embl.de/se/C0851578/'),('http://sideeffects.embl.de/drugs/3640/','cortisol','http://sideeffects.embl.de/se/C0025289/'),('http://sideeffects.embl.de/drugs/3642/','hydrocortisone butyrate','http://sideeffects.embl.de/se/C0086543/'),('http://sideeffects.embl.de/drugs/3647/','hydroflumethiazide','http://sideeffects.embl.de/se/C0349506/'),('http://sideeffects.embl.de/drugs/3648/','hydromorphone','http://sideeffects.embl.de/se/C0700200/'),('http://sideeffects.embl.de/drugs/3652/','hydroxychloroquine','http://sideeffects.embl.de/se/C1384666/'),('http://sideeffects.embl.de/drugs/36523/','gonadorelin','http://sideeffects.embl.de/se/C0332575/'),('http://sideeffects.embl.de/drugs/3657/','hydroxyurea','http://sideeffects.embl.de/se/C1287298/'),('http://sideeffects.embl.de/drugs/3658/','hydroxyzine','http://sideeffects.embl.de/se/C0221242/'),('http://sideeffects.embl.de/drugs/3661/','atropine','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/3672/','ibuprofen','http://sideeffects.embl.de/se/C1287298/'),('http://sideeffects.embl.de/drugs/3675/','phenelzine','http://sideeffects.embl.de/se/C0919715/'),('http://sideeffects.embl.de/drugs/3676/','lidocaine','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/36811/','dobutamine','http://sideeffects.embl.de/se/C0031542/'),('http://sideeffects.embl.de/drugs/3685/','idarubicin','http://sideeffects.embl.de/se/C0878544/'),('http://sideeffects.embl.de/drugs/3687/','IdUrd','http://sideeffects.embl.de/se/C1761613/'),('http://sideeffects.embl.de/drugs/3690/','ifosfamide','http://sideeffects.embl.de/se/C0599918/'),('http://sideeffects.embl.de/drugs/3696/','imipramine','http://sideeffects.embl.de/se/C0027066/'),('http://sideeffects.embl.de/drugs/3702/','indapamide','http://sideeffects.embl.de/se/C0947912/'),('http://sideeffects.embl.de/drugs/3706/','indinavir','http://sideeffects.embl.de/se/C0007820/'),('http://sideeffects.embl.de/drugs/3715/','indomethacin','http://sideeffects.embl.de/se/C0700200/'),('http://sideeffects.embl.de/drugs/3724/','iodixanol','http://sideeffects.embl.de/se/C0007820/'),('http://sideeffects.embl.de/drugs/3730/','iohexol','http://sideeffects.embl.de/se/C0234215/'),('http://sideeffects.embl.de/drugs/3734/','iopamidol','http://sideeffects.embl.de/se/C0855329/'),('http://sideeffects.embl.de/drugs/3736/','iopromide','http://sideeffects.embl.de/se/C0162297/'),('http://sideeffects.embl.de/drugs/3737/','sodium iothalamate','http://sideeffects.embl.de/se/C0234369/'),('http://sideeffects.embl.de/drugs/3738/','iotrolan','http://sideeffects.embl.de/se/C0036973/'),('http://sideeffects.embl.de/drugs/3739/','iodipamide','http://sideeffects.embl.de/se/C0549386/'),('http://sideeffects.embl.de/drugs/37392/','halofantrine','http://sideeffects.embl.de/se/C3665386/'),('http://sideeffects.embl.de/drugs/3741/','ioversol','http://sideeffects.embl.de/se/C0549386/'),('http://sideeffects.embl.de/drugs/3742/','ioxaglate','http://sideeffects.embl.de/se/C0549386/'),('http://sideeffects.embl.de/drugs/3743/','ioxilan','http://sideeffects.embl.de/se/C0042401/'),('http://sideeffects.embl.de/drugs/3746/','ipratropium bromide','http://sideeffects.embl.de/se/C3665386/'),('http://sideeffects.embl.de/drugs/3749/','irbesartan','http://sideeffects.embl.de/se/C1565489/'),('http://sideeffects.embl.de/drugs/3750/','irinotecan','http://sideeffects.embl.de/se/C0026205/'),('http://sideeffects.embl.de/drugs/3759/','isocarboxazid','http://sideeffects.embl.de/se/C0027066/'),('http://sideeffects.embl.de/drugs/3763/','isoflurane','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/3767/','isoniazid','http://sideeffects.embl.de/se/C0497156/'),('http://sideeffects.embl.de/drugs/37720/','pentosan polysulfate','http://sideeffects.embl.de/se/C0877359/'),('http://sideeffects.embl.de/drugs/3777/','isopropyl unoprostone','http://sideeffects.embl.de/se/C3665386/'),('http://sideeffects.embl.de/drugs/3779/','isoproterenol','http://sideeffects.embl.de/se/C0034063/'),('http://sideeffects.embl.de/drugs/3780/','isosorbide dinitrate','http://sideeffects.embl.de/se/C0220870/'),('http://sideeffects.embl.de/drugs/3783/','isoxsuprine','http://sideeffects.embl.de/se/C0034063/'),('http://sideeffects.embl.de/drugs/3784/','isradipine','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/3793/','itraconazole','http://sideeffects.embl.de/se/C3665386/'),('http://sideeffects.embl.de/drugs/3821/','ketamine','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/3823/','ketoconazole','http://sideeffects.embl.de/se/C0877661/'),('http://sideeffects.embl.de/drugs/3825/','ketoprofen','http://sideeffects.embl.de/se/C0027726/'),('http://sideeffects.embl.de/drugs/3826/','ketorolac','http://sideeffects.embl.de/se/C1096274/'),('http://sideeffects.embl.de/drugs/3827/','ketotifen','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/3830/','cytokinin','http://sideeffects.embl.de/se/C0271298/'),('http://sideeffects.embl.de/drugs/3848/','phenyllactate','http://sideeffects.embl.de/se/C0677500/'),('http://sideeffects.embl.de/drugs/3869/','labetalol','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/3872/','lactulose','http://sideeffects.embl.de/se/C0241379/'),('http://sideeffects.embl.de/drugs/3877/','lamivudine','http://sideeffects.embl.de/se/C0019189/'),('http://sideeffects.embl.de/drugs/3878/','lamotrigine','http://sideeffects.embl.de/se/C0152128/'),('http://sideeffects.embl.de/drugs/3883/','lansoprazole','http://sideeffects.embl.de/se/C0266813/'),('http://sideeffects.embl.de/drugs/3890/','latanoprost','http://sideeffects.embl.de/se/C1761613/'),('http://sideeffects.embl.de/drugs/38904/','carboplatin','http://sideeffects.embl.de/se/C0599918/'),('http://sideeffects.embl.de/drugs/3899/','leflunomide','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/3902/','letrozole','http://sideeffects.embl.de/se/C0596240/'),('http://sideeffects.embl.de/drugs/39042/','bezafibrate','http://sideeffects.embl.de/se/C0700225/'),('http://sideeffects.embl.de/drugs/3911/','Leuprorelin','http://sideeffects.embl.de/se/C2830004/'),('http://sideeffects.embl.de/drugs/3914/','levobunolol','http://sideeffects.embl.de/se/C1145670/'),('http://sideeffects.embl.de/drugs/3915/','levocabastine','http://sideeffects.embl.de/se/C0677500/'),('http://sideeffects.embl.de/drugs/3916/','levomepromazine','http://sideeffects.embl.de/se/C0151763/'),('http://sideeffects.embl.de/drugs/3918/','dextrorphan','http://sideeffects.embl.de/se/C3665386/'),('http://sideeffects.embl.de/drugs/3928/','lincomycin','http://sideeffects.embl.de/se/C0151883/'),('http://sideeffects.embl.de/drugs/3929/','linezolid','http://sideeffects.embl.de/se/C0836924/'),('http://sideeffects.embl.de/drugs/3937/','Lisinopril','http://sideeffects.embl.de/se/C2830004/'),('http://sideeffects.embl.de/drugs/3938/','lisuride','http://sideeffects.embl.de/se/C0027066/'),('http://sideeffects.embl.de/drugs/3939/','LiOH','http://sideeffects.embl.de/se/C2830004/'),('http://sideeffects.embl.de/drugs/3948/','lomefloxacin','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/3950/','lomustine','http://sideeffects.embl.de/se/C0599918/'),('http://sideeffects.embl.de/drugs/39507/','rimexolone','http://sideeffects.embl.de/se/C1096274/'),('http://sideeffects.embl.de/drugs/39524/','stiripentol','http://sideeffects.embl.de/se/C0026827/'),('http://sideeffects.embl.de/drugs/3954/','loperamide','http://sideeffects.embl.de/se/C1291077/'),('http://sideeffects.embl.de/drugs/3957/','loratadine','http://sideeffects.embl.de/se/C0221512/'),('http://sideeffects.embl.de/drugs/3958/','lorazepam','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/3961/','losartan','http://sideeffects.embl.de/se/C0851578/'),('http://sideeffects.embl.de/drugs/3962/','lovastatin','http://sideeffects.embl.de/se/C0919715/'),('http://sideeffects.embl.de/drugs/3964/','loxapine','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/39764/','vecuronium','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/39860/','nabilone','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/3998/','mafenide acetate','http://sideeffects.embl.de/se/C0085624/'),('http://sideeffects.embl.de/drugs/401/','D-cycloserine','http://sideeffects.embl.de/se/C2830004/'),('http://sideeffects.embl.de/drugs/4011/','maprotiline','http://sideeffects.embl.de/se/C0027066/'),('http://sideeffects.embl.de/drugs/40159/','permethrin','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/4031/','mebeverine','http://sideeffects.embl.de/se/C0018834/'),('http://sideeffects.embl.de/drugs/4032/','mecamylamine','http://sideeffects.embl.de/se/C0026961/'),('http://sideeffects.embl.de/drugs/4033/','nitrogen mustard','http://sideeffects.embl.de/se/C0037299/'),('http://sideeffects.embl.de/drugs/4036/','meclofenamate','http://sideeffects.embl.de/se/C0234632/'),('http://sideeffects.embl.de/drugs/4042/','medroxyprogesterone acetate','http://sideeffects.embl.de/se/C0948595/'),('http://sideeffects.embl.de/drugs/4043/','medrysone','http://sideeffects.embl.de/se/C1761613/'),('http://sideeffects.embl.de/drugs/4044/','mefenamic acid','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/4046/','mefloquine','http://sideeffects.embl.de/se/C0013220/'),('http://sideeffects.embl.de/drugs/40468184/','acenocoumarol','http://sideeffects.embl.de/se/C0151763/'),('http://sideeffects.embl.de/drugs/4048/','megestrol acetate','http://sideeffects.embl.de/se/C0268000/'),('http://sideeffects.embl.de/drugs/4051/','meloxicam','http://sideeffects.embl.de/se/C0025289/'),('http://sideeffects.embl.de/drugs/4053/','melphalan','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/4054/','memantine','http://sideeffects.embl.de/se/C0855329/'),('http://sideeffects.embl.de/drugs/4057/','Cantril','http://sideeffects.embl.de/se/C2364111/'),('http://sideeffects.embl.de/drugs/4058/','meperidine','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/4060/','mephenytoin','http://sideeffects.embl.de/se/C0085636/'),('http://sideeffects.embl.de/drugs/4062/','mepivacaine','http://sideeffects.embl.de/se/C0162297/'),('http://sideeffects.embl.de/drugs/40632/','pirfenidone','http://sideeffects.embl.de/se/C0235309/'),('http://sideeffects.embl.de/drugs/4064/','meprobamate','http://sideeffects.embl.de/se/C0235146/'),('http://sideeffects.embl.de/drugs/40703/','pinaverium bromide','http://sideeffects.embl.de/se/C0232493/'),('http://sideeffects.embl.de/drugs/4075/','5-ASA','http://sideeffects.embl.de/se/C0599918/'),('http://sideeffects.embl.de/drugs/4086/','metaproterenol','http://sideeffects.embl.de/se/C0948873/'),('http://sideeffects.embl.de/drugs/4091/','metformin','http://sideeffects.embl.de/se/C1291078/'),('http://sideeffects.embl.de/drugs/4095/','methadone','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/40973/','desogestrel','http://sideeffects.embl.de/se/C0268000/'),('http://sideeffects.embl.de/drugs/40976/','Implanon','http://sideeffects.embl.de/se/C3665386/'),('http://sideeffects.embl.de/drugs/4101/','methenamine silver','http://sideeffects.embl.de/se/C0235309/'),('http://sideeffects.embl.de/drugs/4107/','methocarbamol','http://sideeffects.embl.de/se/C0240327/'),('http://sideeffects.embl.de/drugs/4112/','methotrexate','http://sideeffects.embl.de/se/C1287298/'),('http://sideeffects.embl.de/drugs/4114/','8-MOP','http://sideeffects.embl.de/se/C0917801/'),('http://sideeffects.embl.de/drugs/4120/','N-methylscopolamine','http://sideeffects.embl.de/se/C2364111/'),('http://sideeffects.embl.de/drugs/41317/','acitretin','http://sideeffects.embl.de/se/C2830004/'),('http://sideeffects.embl.de/drugs/4138/','methyldopa','http://sideeffects.embl.de/se/C0919715/'),('http://sideeffects.embl.de/drugs/4139/','methylene blue','http://sideeffects.embl.de/se/C0699828/'),('http://sideeffects.embl.de/drugs/4140/','methylergometrine','http://sideeffects.embl.de/se/C0043049/'),('http://sideeffects.embl.de/drugs/4158/','methylphenidate','http://sideeffects.embl.de/se/C0019521/'),('http://sideeffects.embl.de/drugs/4159/','methylprednisolone','http://sideeffects.embl.de/se/C0025289/'),('http://sideeffects.embl.de/drugs/4160/','methyltestosterone','http://sideeffects.embl.de/se/C0022354/'),('http://sideeffects.embl.de/drugs/4163/','methysergide','http://sideeffects.embl.de/se/C0235146/'),('http://sideeffects.embl.de/drugs/4168/','metoclopramide','http://sideeffects.embl.de/se/C1145670/'),('http://sideeffects.embl.de/drugs/41684/','nitazoxanide','http://sideeffects.embl.de/se/C0024115/'),('http://sideeffects.embl.de/drugs/41693/','sufentanil','http://sideeffects.embl.de/se/C0235546/'),('http://sideeffects.embl.de/drugs/4170/','metolazone','http://sideeffects.embl.de/se/C1291077/'),('http://sideeffects.embl.de/drugs/4171/','metoprolol','http://sideeffects.embl.de/se/C0007820/'),('http://sideeffects.embl.de/drugs/4173/','metronidazole','http://sideeffects.embl.de/se/C0019521/'),('http://sideeffects.embl.de/drugs/4174/','metyrapone','http://sideeffects.embl.de/se/C0750394/'),('http://sideeffects.embl.de/drugs/41744/','valrubicin','http://sideeffects.embl.de/se/C0232726/'),('http://sideeffects.embl.de/drugs/41774/','acarbose','http://sideeffects.embl.de/se/C0267792/'),('http://sideeffects.embl.de/drugs/4178/','mexiletine','http://sideeffects.embl.de/se/C0019521/'),('http://sideeffects.embl.de/drugs/41781/','torasemide','http://sideeffects.embl.de/se/C0242429/'),('http://sideeffects.embl.de/drugs/4184/','mianserin','http://sideeffects.embl.de/se/C0027849/'),('http://sideeffects.embl.de/drugs/4189/','miconazole','http://sideeffects.embl.de/se/C2364111/'),('http://sideeffects.embl.de/drugs/4192/','midazolam','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/4195/','midodrine','http://sideeffects.embl.de/se/C0851578/'),('http://sideeffects.embl.de/drugs/4196/','mifepristone','http://sideeffects.embl.de/se/C0042130/'),('http://sideeffects.embl.de/drugs/4201/','minoxidil','http://sideeffects.embl.de/se/C0700225/'),('http://sideeffects.embl.de/drugs/4205/','mirtazapine','http://sideeffects.embl.de/se/C0027066/'),('http://sideeffects.embl.de/drugs/4211/','mitotane','http://sideeffects.embl.de/se/C1291078/'),('http://sideeffects.embl.de/drugs/42113/','desflurane','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/4212/','mitoxantrone','http://sideeffects.embl.de/se/C1287298/'),('http://sideeffects.embl.de/drugs/4235/','moclobemide','http://sideeffects.embl.de/se/C1291078/'),('http://sideeffects.embl.de/drugs/4236/','modafinil','http://sideeffects.embl.de/se/C0947912/'),('http://sideeffects.embl.de/drugs/42395/','Westcort','http://sideeffects.embl.de/se/C0677500/'),('http://sideeffects.embl.de/drugs/4240/','mometasone furoate','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/4248/','montelukast','http://sideeffects.embl.de/se/C1458140/'),('http://sideeffects.embl.de/drugs/4253/','morphine','http://sideeffects.embl.de/se/C0700200/'),('http://sideeffects.embl.de/drugs/4259/','moxifloxacin','http://sideeffects.embl.de/se/C0948595/'),('http://sideeffects.embl.de/drugs/42611257/','vemurafenib','http://sideeffects.embl.de/se/C0038814/'),('http://sideeffects.embl.de/drugs/42615/','Supremon','http://sideeffects.embl.de/se/C2830004/'),('http://sideeffects.embl.de/drugs/4264/','mupirocin','http://sideeffects.embl.de/se/C0877661/'),('http://sideeffects.embl.de/drugs/4271/','mycophenolate mofetil','http://sideeffects.embl.de/se/C0025289/'),('http://sideeffects.embl.de/drugs/4272/','mycophenolic acid','http://sideeffects.embl.de/se/C0025289/'),('http://sideeffects.embl.de/drugs/4274/','tetrofosmin','http://sideeffects.embl.de/se/C0162297/'),('http://sideeffects.embl.de/drugs/42955/','misoprostol','http://sideeffects.embl.de/se/C0427008/'),('http://sideeffects.embl.de/drugs/4369359/','sitagliptin','http://sideeffects.embl.de/se/C0858635/'),('http://sideeffects.embl.de/drugs/4409/','nabumetone','http://sideeffects.embl.de/se/C0266813/'),('http://sideeffects.embl.de/drugs/4411/','nadolol','http://sideeffects.embl.de/se/C1291077/'),('http://sideeffects.embl.de/drugs/441332/','carboprost','http://sideeffects.embl.de/se/C0036973/'),('http://sideeffects.embl.de/drugs/44134877/','oxytetracycline','http://sideeffects.embl.de/se/C0031046/'),('http://sideeffects.embl.de/drugs/441382/','natamycin','http://sideeffects.embl.de/se/C0948595/'),('http://sideeffects.embl.de/drugs/44146714/','Lantus','http://sideeffects.embl.de/se/C0521491/'),('http://sideeffects.embl.de/drugs/4419/','nalbuphine','http://sideeffects.embl.de/se/C0162297/'),('http://sideeffects.embl.de/drugs/44201342/','tesamorelin','http://sideeffects.embl.de/se/C0151698/'),('http://sideeffects.embl.de/drugs/44201343/','ecallantide','http://sideeffects.embl.de/se/C0232492/'),('http://sideeffects.embl.de/drugs/4421/','nalidixic acid','http://sideeffects.embl.de/se/C0162830/'),('http://sideeffects.embl.de/drugs/4422/','nalmefene','http://sideeffects.embl.de/se/C0027066/'),('http://sideeffects.embl.de/drugs/4425/','naloxone','http://sideeffects.embl.de/se/C0036973/'),('http://sideeffects.embl.de/drugs/4428/','naltrexone','http://sideeffects.embl.de/se/C0858635/'),('http://sideeffects.embl.de/drugs/4432/','nandrolone decanoate','http://sideeffects.embl.de/se/C0002453/'),('http://sideeffects.embl.de/drugs/443379/','CAS 76420-72-9','http://sideeffects.embl.de/se/C2830004/'),('http://sideeffects.embl.de/drugs/4436/','naphazoline','http://sideeffects.embl.de/se/C0948595/'),('http://sideeffects.embl.de/drugs/444/','bupropion','http://sideeffects.embl.de/se/C0027066/'),('http://sideeffects.embl.de/drugs/4440/','naratriptan','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/444006/','cefditoren','http://sideeffects.embl.de/se/C0836924/'),('http://sideeffects.embl.de/drugs/444013/','gadoversetamide','http://sideeffects.embl.de/se/C0025289/'),('http://sideeffects.embl.de/drugs/444033/','ciclesonide','http://sideeffects.embl.de/se/C2363731/'),('http://sideeffects.embl.de/drugs/4443/','nateglinide','http://sideeffects.embl.de/se/C0948873/'),('http://sideeffects.embl.de/drugs/44462760/','dabrafenib','http://sideeffects.embl.de/se/C2363731/'),('http://sideeffects.embl.de/drugs/4449/','nefazodone','http://sideeffects.embl.de/se/C0027066/'),('http://sideeffects.embl.de/drugs/4451/','nelfinavir','http://sideeffects.embl.de/se/C0947912/'),('http://sideeffects.embl.de/drugs/4454/','neomycin','http://sideeffects.embl.de/se/C0599918/'),('http://sideeffects.embl.de/drugs/4456/','neostigmine','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/44563/','lodoxamide tromethamine','http://sideeffects.embl.de/se/C0677500/'),('http://sideeffects.embl.de/drugs/44564/','lodoxamide','http://sideeffects.embl.de/se/C0677500/'),('http://sideeffects.embl.de/drugs/44564107/','mipomersen','http://sideeffects.embl.de/se/C0521839/'),('http://sideeffects.embl.de/drugs/44564722/','Promacta','http://sideeffects.embl.de/se/C0917801/'),('http://sideeffects.embl.de/drugs/44567678/','dalbavancin','http://sideeffects.embl.de/se/C0836924/'),('http://sideeffects.embl.de/drugs/4463/','nevirapine','http://sideeffects.embl.de/se/C0237849/'),('http://sideeffects.embl.de/drugs/4473/','nicardipine','http://sideeffects.embl.de/se/C0917798/'),('http://sideeffects.embl.de/drugs/4474778/','2-hydroxysuccinaldehyde','http://sideeffects.embl.de/se/C0917801/'),('http://sideeffects.embl.de/drugs/4479094/','doxercalciferol','http://sideeffects.embl.de/se/C0851578/'),('http://sideeffects.embl.de/drugs/4479097/','hydroxocobalamin','http://sideeffects.embl.de/se/C0497247/'),('http://sideeffects.embl.de/drugs/4485/','nifedipine','http://sideeffects.embl.de/se/C1287298/'),('http://sideeffects.embl.de/drugs/449193/','roflumilast','http://sideeffects.embl.de/se/C0035243/'),('http://sideeffects.embl.de/drugs/4493/','nilutamide','http://sideeffects.embl.de/se/C0151825/'),('http://sideeffects.embl.de/drugs/4497/','nimodipine','http://sideeffects.embl.de/se/C0268000/'),('http://sideeffects.embl.de/drugs/4499/','nisoldipine','http://sideeffects.embl.de/se/C0947912/'),('http://sideeffects.embl.de/drugs/450/','estradiol','http://sideeffects.embl.de/se/C0027066/'),('http://sideeffects.embl.de/drugs/4506/','nitrazepam','http://sideeffects.embl.de/se/C0427108/'),('http://sideeffects.embl.de/drugs/4509/','nitrofurantoin','http://sideeffects.embl.de/se/C0855329/'),('http://sideeffects.embl.de/drugs/4510/','nitroglycerin','http://sideeffects.embl.de/se/C0917798/'),('http://sideeffects.embl.de/drugs/4513/','nizatidine','http://sideeffects.embl.de/se/C0392525/'),('http://sideeffects.embl.de/drugs/453/','mannitol','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/4536/','norethisterone','http://sideeffects.embl.de/se/C0001430/'),('http://sideeffects.embl.de/drugs/4539/','norfloxacin','http://sideeffects.embl.de/se/C0027066/'),('http://sideeffects.embl.de/drugs/4542/','levonorgestrel','http://sideeffects.embl.de/se/C3665386/'),('http://sideeffects.embl.de/drugs/4543/','nortriptyline','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/45469/','sodium nitroprusside','http://sideeffects.embl.de/se/C0855329/'),('http://sideeffects.embl.de/drugs/4547/','repaglinide','http://sideeffects.embl.de/se/C0522055/'),('http://sideeffects.embl.de/drugs/455658/','hemin','http://sideeffects.embl.de/se/C0031542/'),('http://sideeffects.embl.de/drugs/4568/','nystatin','http://sideeffects.embl.de/se/C0548823/'),('http://sideeffects.embl.de/drugs/4583/','ofloxacin','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/4585/','olanzapine','http://sideeffects.embl.de/se/C0855329/'),('http://sideeffects.embl.de/drugs/4594/','omeprazole','http://sideeffects.embl.de/se/C0019521/'),('http://sideeffects.embl.de/drugs/4595/','ondansetron','http://sideeffects.embl.de/se/C0036973/'),('http://sideeffects.embl.de/drugs/4599/','orlistat','http://sideeffects.embl.de/se/C0851578/'),('http://sideeffects.embl.de/drugs/4601/','orphenadrine','http://sideeffects.embl.de/se/C0026961/'),('http://sideeffects.embl.de/drugs/4603/','oseltamivir','http://sideeffects.embl.de/se/C0549336/'),('http://sideeffects.embl.de/drugs/4607/','oxacillin','http://sideeffects.embl.de/se/C0235378/'),('http://sideeffects.embl.de/drugs/4609/','oxaliplatin','http://sideeffects.embl.de/se/C0027066/'),('http://sideeffects.embl.de/drugs/4614/','oxaprozin','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/4616/','oxazepam','http://sideeffects.embl.de/se/C0233571/'),('http://sideeffects.embl.de/drugs/46181941/','Signifor','http://sideeffects.embl.de/se/C0917801/'),('http://sideeffects.embl.de/drugs/46216142/','dolutegravir','http://sideeffects.embl.de/se/C1565489/'),('http://sideeffects.embl.de/drugs/4623/','oxiconazole','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/4630253/','alclometasone','http://sideeffects.embl.de/se/C0041834/'),('http://sideeffects.embl.de/drugs/4631/','oxprenolol','http://sideeffects.embl.de/se/C0040997/'),('http://sideeffects.embl.de/drugs/4634/','oxybutynin','http://sideeffects.embl.de/se/C0019521/'),('http://sideeffects.embl.de/drugs/4635/','oxycodone','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/4638/','oxymetholone','http://sideeffects.embl.de/se/C0151798/'),('http://sideeffects.embl.de/drugs/4639/','oxymorphone','http://sideeffects.embl.de/se/C0596240/'),('http://sideeffects.embl.de/drugs/4649/','APAs','http://sideeffects.embl.de/se/C1291077/'),('http://sideeffects.embl.de/drugs/4659568/','entacapone','http://sideeffects.embl.de/se/C2364111/'),('http://sideeffects.embl.de/drugs/4659569/','tolcapone','http://sideeffects.embl.de/se/C0027066/'),('http://sideeffects.embl.de/drugs/4666/','paclitaxel','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/4673/','pamidronate','http://sideeffects.embl.de/se/C0027726/'),('http://sideeffects.embl.de/drugs/4675/','pancuronium','http://sideeffects.embl.de/se/C0332575/'),('http://sideeffects.embl.de/drugs/4678/','dexpanthenol','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/4679/','pantoprazole','http://sideeffects.embl.de/se/C0019521/'),('http://sideeffects.embl.de/drugs/4689/','paromomycin','http://sideeffects.embl.de/se/C0000729/'),('http://sideeffects.embl.de/drugs/4691/','paroxetine','http://sideeffects.embl.de/se/C0152128/'),('http://sideeffects.embl.de/drugs/4724/','penbutolol','http://sideeffects.embl.de/se/C0242429/'),('http://sideeffects.embl.de/drugs/4725/','penciclovir','http://sideeffects.embl.de/se/C0151907/'),('http://sideeffects.embl.de/drugs/4727/','D-penicillamine','http://sideeffects.embl.de/se/C0027726/'),('http://sideeffects.embl.de/drugs/4730/','penicillin V','http://sideeffects.embl.de/se/C0221490/'),('http://sideeffects.embl.de/drugs/47319/','atracurium','http://sideeffects.embl.de/se/C0428977/'),('http://sideeffects.embl.de/drugs/47320/','cisatracurium','http://sideeffects.embl.de/se/C0428977/'),('http://sideeffects.embl.de/drugs/4735/','pentamidine','http://sideeffects.embl.de/se/C2364111/'),('http://sideeffects.embl.de/drugs/4736/','pentazocine','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/4737/','pentobarbital','http://sideeffects.embl.de/se/C3203358/'),('http://sideeffects.embl.de/drugs/4739/','pentostatin','http://sideeffects.embl.de/se/C0877359/'),('http://sideeffects.embl.de/drugs/4740/','pentoxifylline','http://sideeffects.embl.de/se/C1291077/'),('http://sideeffects.embl.de/drugs/47419/','cefuroxime axetil','http://sideeffects.embl.de/se/C0151849/'),('http://sideeffects.embl.de/drugs/4745/','pergolide','http://sideeffects.embl.de/se/C0027066/'),('http://sideeffects.embl.de/drugs/4746/','perhexiline','http://sideeffects.embl.de/se/C0427108/'),('http://sideeffects.embl.de/drugs/4747/','propericiazine','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/47471/','butoconazole','http://sideeffects.embl.de/se/C0234233/'),('http://sideeffects.embl.de/drugs/4748/','perphenazine','http://sideeffects.embl.de/se/C0242429/'),('http://sideeffects.embl.de/drugs/47528/','nicorandil','http://sideeffects.embl.de/se/C0851578/'),('http://sideeffects.embl.de/drugs/4756/','phenylazo','http://sideeffects.embl.de/se/C0025290/'),('http://sideeffects.embl.de/drugs/4763/','phenobarbital','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/47640/','naftifine','http://sideeffects.embl.de/se/C0677500/'),('http://sideeffects.embl.de/drugs/4768/','phenoxybenzamine','http://sideeffects.embl.de/se/C0026205/'),('http://sideeffects.embl.de/drugs/4771/','phentermine','http://sideeffects.embl.de/se/C0233477/'),('http://sideeffects.embl.de/drugs/47725/','Goserelin','http://sideeffects.embl.de/se/C2830004/'),('http://sideeffects.embl.de/drugs/477468/','FK463','http://sideeffects.embl.de/se/C0019521/'),('http://sideeffects.embl.de/drugs/4775/','4-PBA','http://sideeffects.embl.de/se/C0836924/'),('http://sideeffects.embl.de/drugs/4782/','phenylephrine','http://sideeffects.embl.de/se/C0026205/'),('http://sideeffects.embl.de/drugs/4786/','phenylpropanolamine','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/4812/','vitamin K','http://sideeffects.embl.de/se/C0027540/'),('http://sideeffects.embl.de/drugs/4819/','pilocarpine','http://sideeffects.embl.de/se/C2364111/'),('http://sideeffects.embl.de/drugs/4828/','pindolol','http://sideeffects.embl.de/se/C0948595/'),('http://sideeffects.embl.de/drugs/4829/','pioglitazone','http://sideeffects.embl.de/se/C0522055/'),('http://sideeffects.embl.de/drugs/4834/','piperacillin','http://sideeffects.embl.de/se/C0836924/'),('http://sideeffects.embl.de/drugs/483407/','maraviroc','http://sideeffects.embl.de/se/C0025289/'),('http://sideeffects.embl.de/drugs/4845/','pirbuterol','http://sideeffects.embl.de/se/C0242429/'),('http://sideeffects.embl.de/drugs/4865/','podophyllotoxin','http://sideeffects.embl.de/se/C3665596/'),('http://sideeffects.embl.de/drugs/4868/','polymyxin B','http://sideeffects.embl.de/se/C0003578/'),('http://sideeffects.embl.de/drugs/4885/','pramipexole','http://sideeffects.embl.de/se/C0497201/'),('http://sideeffects.embl.de/drugs/4889/','pravastatin','http://sideeffects.embl.de/se/C1384666/'),('http://sideeffects.embl.de/drugs/4891/','praziquantel','http://sideeffects.embl.de/se/C0005940/'),('http://sideeffects.embl.de/drugs/489129/','efinaconazole','http://sideeffects.embl.de/se/C0521491/'),('http://sideeffects.embl.de/drugs/4893/','prazosin','http://sideeffects.embl.de/se/C0026205/'),('http://sideeffects.embl.de/drugs/4894/','prednisolone','http://sideeffects.embl.de/se/C0025289/'),('http://sideeffects.embl.de/drugs/4895/','prednisolone acetate','http://sideeffects.embl.de/se/C0339293/'),('http://sideeffects.embl.de/drugs/4896/','prednisolone phosphate','http://sideeffects.embl.de/se/C0858635/'),('http://sideeffects.embl.de/drugs/4900/','prednisone','http://sideeffects.embl.de/se/C0025289/'),('http://sideeffects.embl.de/drugs/4906/','prilocaine','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/4908/','primaquine','http://sideeffects.embl.de/se/C0221490/'),('http://sideeffects.embl.de/drugs/4909/','primidone','http://sideeffects.embl.de/se/C0240735/'),('http://sideeffects.embl.de/drugs/4911/','probenecid','http://sideeffects.embl.de/se/C0027726/'),('http://sideeffects.embl.de/drugs/4913/','procainamide','http://sideeffects.embl.de/se/C0855329/'),('http://sideeffects.embl.de/drugs/4914/','procaine','http://sideeffects.embl.de/se/C0162297/'),('http://sideeffects.embl.de/drugs/4915/','procarbazine','http://sideeffects.embl.de/se/C1458140/'),('http://sideeffects.embl.de/drugs/4917/','prochlorperazine','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/4920/','progesterone','http://sideeffects.embl.de/se/C1291077/'),('http://sideeffects.embl.de/drugs/4927/','promethazine','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/4932/','propafenone','http://sideeffects.embl.de/se/C0700200/'),('http://sideeffects.embl.de/drugs/4934/','propantheline','http://sideeffects.embl.de/se/C0026961/'),('http://sideeffects.embl.de/drugs/4935/','proparacaine','http://sideeffects.embl.de/se/C1761613/'),('http://sideeffects.embl.de/drugs/4943/','propofol','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/4946/','propranolol','http://sideeffects.embl.de/se/C0242429/'),('http://sideeffects.embl.de/drugs/4976/','protriptyline','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/4991/','pyridostigmine','http://sideeffects.embl.de/se/C0026205/'),('http://sideeffects.embl.de/drugs/4999/','quazepam','http://sideeffects.embl.de/se/C0038587/'),('http://sideeffects.embl.de/drugs/5001396/','warfarin','http://sideeffects.embl.de/se/C1291077/'),('http://sideeffects.embl.de/drugs/5002/','quetiapine','http://sideeffects.embl.de/se/C0855329/'),('http://sideeffects.embl.de/drugs/5005/','quinapril','http://sideeffects.embl.de/se/C0042401/'),('http://sideeffects.embl.de/drugs/5029/','rabeprazole','http://sideeffects.embl.de/se/C3203358/'),('http://sideeffects.embl.de/drugs/50294/','nedocromil sodium','http://sideeffects.embl.de/se/C0677500/'),('http://sideeffects.embl.de/drugs/5032/','ephedrine','http://sideeffects.embl.de/se/C0497247/'),('http://sideeffects.embl.de/drugs/5035/','raloxifene','http://sideeffects.embl.de/se/C0149871/'),('http://sideeffects.embl.de/drugs/5038/','ramipril','http://sideeffects.embl.de/se/C0007820/'),('http://sideeffects.embl.de/drugs/5039/','ranitidine','http://sideeffects.embl.de/se/C0599918/'),('http://sideeffects.embl.de/drugs/5040/','rapamycin','http://sideeffects.embl.de/se/C0027726/'),('http://sideeffects.embl.de/drugs/5051/','rescinnamine','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/5052/','reserpine','http://sideeffects.embl.de/se/C1761613/'),('http://sideeffects.embl.de/drugs/50614/','cefotetan','http://sideeffects.embl.de/se/C0836924/'),('http://sideeffects.embl.de/drugs/5064/','ribavirin','http://sideeffects.embl.de/se/C0240897/'),('http://sideeffects.embl.de/drugs/5070/','riluzole','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/5071/','rimantadine','http://sideeffects.embl.de/se/C0007820/'),('http://sideeffects.embl.de/drugs/5073/','risperidone','http://sideeffects.embl.de/se/C0855329/'),('http://sideeffects.embl.de/drugs/5076/','ritonavir','http://sideeffects.embl.de/se/C3203358/'),('http://sideeffects.embl.de/drugs/5077/','rivastigmine','http://sideeffects.embl.de/se/C0027066/'),('http://sideeffects.embl.de/drugs/5078/','rizatriptan','http://sideeffects.embl.de/se/C0700200/'),('http://sideeffects.embl.de/drugs/5090/','rofecoxib','http://sideeffects.embl.de/se/C0013240/'),('http://sideeffects.embl.de/drugs/5095/','ropinirole','http://sideeffects.embl.de/se/C0007820/'),('http://sideeffects.embl.de/drugs/5106/','roxithromycin','http://sideeffects.embl.de/se/C1384666/'),('http://sideeffects.embl.de/drugs/51263/','alfentanil','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/51508717/','tenoxicam','http://sideeffects.embl.de/se/C0010346/'),('http://sideeffects.embl.de/drugs/5152/','salmeterol','http://sideeffects.embl.de/se/C0700184/'),('http://sideeffects.embl.de/drugs/5155/','stavudine','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/51577/','miglitol','http://sideeffects.embl.de/se/C0687713/'),('http://sideeffects.embl.de/drugs/51601240/','demeclocycline','http://sideeffects.embl.de/se/C0919715/'),('http://sideeffects.embl.de/drugs/5161/','salsalate','http://sideeffects.embl.de/se/C0239150/'),('http://sideeffects.embl.de/drugs/51634/','miglustat','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/517045/','sodium acetate','http://sideeffects.embl.de/se/C1145670/'),('http://sideeffects.embl.de/drugs/5184/','scopolamine','http://sideeffects.embl.de/se/C0152128/'),('http://sideeffects.embl.de/drugs/5193/','secobarbital','http://sideeffects.embl.de/se/C3203358/'),('http://sideeffects.embl.de/drugs/5195/','deprenyl','http://sideeffects.embl.de/se/C0855329/'),('http://sideeffects.embl.de/drugs/5203/','sertraline','http://sideeffects.embl.de/se/C0027066/'),('http://sideeffects.embl.de/drugs/5206/','sevoflurane','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/5210/','sibutramine','http://sideeffects.embl.de/se/C0027066/'),('http://sideeffects.embl.de/drugs/5212/','sildenafil','http://sideeffects.embl.de/se/C0497201/'),('http://sideeffects.embl.de/drugs/5214/','silver sulfadiazine','http://sideeffects.embl.de/se/C0151798/'),('http://sideeffects.embl.de/drugs/5215/','sulfadiazine','http://sideeffects.embl.de/se/C0151798/'),('http://sideeffects.embl.de/drugs/52421/','prednicarbate','http://sideeffects.embl.de/se/C0162823/'),('http://sideeffects.embl.de/drugs/5245/','risedronate','http://sideeffects.embl.de/se/C1291077/'),('http://sideeffects.embl.de/drugs/5248/','sodium tetradecyl sulphate','http://sideeffects.embl.de/se/C0027540/'),('http://sideeffects.embl.de/drugs/5251896/','vildagliptin','http://sideeffects.embl.de/se/C0520893/'),('http://sideeffects.embl.de/drugs/5253/','sotalol','http://sideeffects.embl.de/se/C0700200/'),('http://sideeffects.embl.de/drugs/5257/','sparfloxacin','http://sideeffects.embl.de/se/C0522055/'),('http://sideeffects.embl.de/drugs/5267/','spironolactone','http://sideeffects.embl.de/se/C0011609/'),('http://sideeffects.embl.de/drugs/5273759/','abacavir-lamivudine','http://sideeffects.embl.de/se/C1145670/'),('http://sideeffects.embl.de/drugs/5277135/','elvitegravir','http://sideeffects.embl.de/se/C0021368/'),('http://sideeffects.embl.de/drugs/5281007/','dacarbazine','http://sideeffects.embl.de/se/C0235378/'),('http://sideeffects.embl.de/drugs/5291/','imatinib','http://sideeffects.embl.de/se/C1384666/'),('http://sideeffects.embl.de/drugs/5297/','streptomycin','http://sideeffects.embl.de/se/C0599918/'),('http://sideeffects.embl.de/drugs/5300/','streptozotocin','http://sideeffects.embl.de/se/C0599918/'),('http://sideeffects.embl.de/drugs/5310993/','acipimox','http://sideeffects.embl.de/se/C0340865/'),('http://sideeffects.embl.de/drugs/5311/','vorinostat','http://sideeffects.embl.de/se/C0700225/'),('http://sideeffects.embl.de/drugs/5311167/','halobetasol','http://sideeffects.embl.de/se/C0677500/'),('http://sideeffects.embl.de/drugs/5314/','succinylcholine','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/5318/','sulconazole','http://sideeffects.embl.de/se/C0332575/'),('http://sideeffects.embl.de/drugs/5320/','sulfacetamide','http://sideeffects.embl.de/se/C1761613/'),('http://sideeffects.embl.de/drugs/5327147/','polyoxyethylene','http://sideeffects.embl.de/se/C1291077/'),('http://sideeffects.embl.de/drugs/5328940/','bosutinib','http://sideeffects.embl.de/se/C1565489/'),('http://sideeffects.embl.de/drugs/5329/','sulfamethoxazole','http://sideeffects.embl.de/se/C0599918/'),('http://sideeffects.embl.de/drugs/5333/','sulfonamide','http://sideeffects.embl.de/se/C0085624/'),('http://sideeffects.embl.de/drugs/53477714/','heparin','http://sideeffects.embl.de/se/C0041582/'),('http://sideeffects.embl.de/drugs/5352/','sulindac','http://sideeffects.embl.de/se/C1287298/'),('http://sideeffects.embl.de/drugs/5353894/','pralidoxime','http://sideeffects.embl.de/se/C0233571/'),('http://sideeffects.embl.de/drugs/5353980/','sulfasalazine','http://sideeffects.embl.de/se/C0027726/'),('http://sideeffects.embl.de/drugs/5358/','sumatriptan','http://sideeffects.embl.de/se/C0855329/'),('http://sideeffects.embl.de/drugs/5359/','suprofen','http://sideeffects.embl.de/se/C1458140/'),('http://sideeffects.embl.de/drugs/5359596/','arsenic','http://sideeffects.embl.de/se/C2830004/'),('http://sideeffects.embl.de/drugs/5360237/','Paroven','http://sideeffects.embl.de/se/C0221512/'),('http://sideeffects.embl.de/drugs/5361912/','rifabutin','http://sideeffects.embl.de/se/C0750394/'),('http://sideeffects.embl.de/drugs/5361917/','methylnaltrexone','http://sideeffects.embl.de/se/C0677500/'),('http://sideeffects.embl.de/drugs/5362070/','balsalazide','http://sideeffects.embl.de/se/C0877359/'),('http://sideeffects.embl.de/drugs/5362420/','verteporfin','http://sideeffects.embl.de/se/C1761613/'),('http://sideeffects.embl.de/drugs/53627505/','hydroxypropyl','http://sideeffects.embl.de/se/C0948595/'),('http://sideeffects.embl.de/drugs/5372/','tacrolimus','http://sideeffects.embl.de/se/C0599918/'),('http://sideeffects.embl.de/drugs/5376/','tamoxifen','http://sideeffects.embl.de/se/C0019557/'),('http://sideeffects.embl.de/drugs/5379/','gatifloxacin','http://sideeffects.embl.de/se/C1096274/'),('http://sideeffects.embl.de/drugs/5381/','tazarotene','http://sideeffects.embl.de/se/C0853714/'),('http://sideeffects.embl.de/drugs/5381226/','rifampicin','http://sideeffects.embl.de/se/C0235198/'),('http://sideeffects.embl.de/drugs/5391/','temazepam','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/5394/','temozolomide','http://sideeffects.embl.de/se/C1145670/'),('http://sideeffects.embl.de/drugs/5396/','teniposide','http://sideeffects.embl.de/se/C0855329/'),('http://sideeffects.embl.de/drugs/5401/','terazosin','http://sideeffects.embl.de/se/C0026205/'),('http://sideeffects.embl.de/drugs/5402/','terbinafine','http://sideeffects.embl.de/se/C0858635/'),('http://sideeffects.embl.de/drugs/5403/','terbutaline','http://sideeffects.embl.de/se/C0235710/'),('http://sideeffects.embl.de/drugs/5404/','terconazole','http://sideeffects.embl.de/se/C0521839/'),('http://sideeffects.embl.de/drugs/5408/','testosterone','http://sideeffects.embl.de/se/C1619712/'),('http://sideeffects.embl.de/drugs/5409/','testosterone enanthate','http://sideeffects.embl.de/se/C0877661/'),('http://sideeffects.embl.de/drugs/5410/','testosterone propionate','http://sideeffects.embl.de/se/C0877661/'),('http://sideeffects.embl.de/drugs/5411/','tetracaine','http://sideeffects.embl.de/se/C1761613/'),('http://sideeffects.embl.de/drugs/5419/','tetrahydrozoline','http://sideeffects.embl.de/se/C0332575/'),('http://sideeffects.embl.de/drugs/5426/','thalidomide','http://sideeffects.embl.de/se/C0025289/'),('http://sideeffects.embl.de/drugs/5430/','thiabendazole','http://sideeffects.embl.de/se/C1761613/'),('http://sideeffects.embl.de/drugs/54313/','iloprost','http://sideeffects.embl.de/se/C0858635/'),('http://sideeffects.embl.de/drugs/54331/','fosfomycin trometamol','http://sideeffects.embl.de/se/C1384666/'),('http://sideeffects.embl.de/drugs/54373/','Octreotide','http://sideeffects.embl.de/se/C2830004/'),('http://sideeffects.embl.de/drugs/54454/','simvastatin','http://sideeffects.embl.de/se/C0919715/'),('http://sideeffects.embl.de/drugs/5452/','thioridazine','http://sideeffects.embl.de/se/C0026205/'),('http://sideeffects.embl.de/drugs/5453/','thiotepa','http://sideeffects.embl.de/se/C0162297/'),('http://sideeffects.embl.de/drugs/5454/','thiothixene','http://sideeffects.embl.de/se/C0026205/'),('http://sideeffects.embl.de/drugs/54547/','cefpodoxime','http://sideeffects.embl.de/se/C2364111/'),('http://sideeffects.embl.de/drugs/5462337/','olsalazine','http://sideeffects.embl.de/se/C0027726/'),('http://sideeffects.embl.de/drugs/5464096/','ramiprilat','http://sideeffects.embl.de/se/C1384666/'),('http://sideeffects.embl.de/drugs/5466/','tiagabine','http://sideeffects.embl.de/se/C0027066/'),('http://sideeffects.embl.de/drugs/54677977/','A77 1726','http://sideeffects.embl.de/se/C0851341/'),('http://sideeffects.embl.de/drugs/5468/','tiaprofenic acid','http://sideeffects.embl.de/se/C0235267/'),('http://sideeffects.embl.de/drugs/54681041/','tigecycline','http://sideeffects.embl.de/se/C0836924/'),('http://sideeffects.embl.de/drugs/54682541/','doxycycline hyclate','http://sideeffects.embl.de/se/C0948873/'),('http://sideeffects.embl.de/drugs/54687131/','lymecycline','http://sideeffects.embl.de/se/C0232493/'),('http://sideeffects.embl.de/drugs/54688/','clarithromycin','http://sideeffects.embl.de/se/C2364111/'),('http://sideeffects.embl.de/drugs/5472/','ticlopidine','http://sideeffects.embl.de/se/C0027726/'),('http://sideeffects.embl.de/drugs/5478/','timolol','http://sideeffects.embl.de/se/C0007820/'),('http://sideeffects.embl.de/drugs/54786/','treprostinil','http://sideeffects.embl.de/se/C0858635/'),('http://sideeffects.embl.de/drugs/5479/','tinidazole','http://sideeffects.embl.de/se/C1291078/'),('http://sideeffects.embl.de/drugs/5479141/','CGP 19835A','http://sideeffects.embl.de/se/C0596240/'),('http://sideeffects.embl.de/drugs/54808/','loteprednol etabonate','http://sideeffects.embl.de/se/C1096278/'),('http://sideeffects.embl.de/drugs/5483/','tiopronin','http://sideeffects.embl.de/se/C0027726/'),('http://sideeffects.embl.de/drugs/54840/','atomoxetine','http://sideeffects.embl.de/se/C0027066/'),('http://sideeffects.embl.de/drugs/5486/','tirofiban','http://sideeffects.embl.de/se/C0018926/'),('http://sideeffects.embl.de/drugs/5487/','tizanidine','http://sideeffects.embl.de/se/C0948873/'),('http://sideeffects.embl.de/drugs/5487068/','Mersyndol','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/5487301/','tegaserod','http://sideeffects.embl.de/se/C0858635/'),('http://sideeffects.embl.de/drugs/5488383/','ofatumumab','http://sideeffects.embl.de/se/C0858635/'),('http://sideeffects.embl.de/drugs/5488547/','alvimopan','http://sideeffects.embl.de/se/C0162429/'),('http://sideeffects.embl.de/drugs/5493381/','deferasirox','http://sideeffects.embl.de/se/C1384666/'),('http://sideeffects.embl.de/drugs/54949/','NSC 352122','http://sideeffects.embl.de/se/C0700225/'),('http://sideeffects.embl.de/drugs/5496/','tobramycin','http://sideeffects.embl.de/se/C0948595/'),('http://sideeffects.embl.de/drugs/5503/','tolazamide','http://sideeffects.embl.de/se/C0018834/'),('http://sideeffects.embl.de/drugs/5505/','tolbutamide','http://sideeffects.embl.de/se/C0018834/'),('http://sideeffects.embl.de/drugs/5508/','tolmetin','http://sideeffects.embl.de/se/C0548823/'),('http://sideeffects.embl.de/drugs/5512/','tolterodine','http://sideeffects.embl.de/se/C0392171/'),('http://sideeffects.embl.de/drugs/5514/','topiramate','http://sideeffects.embl.de/se/C0700200/'),('http://sideeffects.embl.de/drugs/5515/','topotecan','http://sideeffects.embl.de/se/C1145670/'),('http://sideeffects.embl.de/drugs/5516/','toremifene','http://sideeffects.embl.de/se/C0427008/'),('http://sideeffects.embl.de/drugs/5523/','tramadol','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/5524/','tramazoline','http://sideeffects.embl.de/se/C0858259/'),('http://sideeffects.embl.de/drugs/5525/','trandolapril','http://sideeffects.embl.de/se/C0700200/'),('http://sideeffects.embl.de/drugs/5526/','tranexamic acid','http://sideeffects.embl.de/se/C1145670/'),('http://sideeffects.embl.de/drugs/5530/','tranylcypromine','http://sideeffects.embl.de/se/C0027066/'),('http://sideeffects.embl.de/drugs/5533/','trazodone','http://sideeffects.embl.de/se/C0026205/'),('http://sideeffects.embl.de/drugs/55331/','moexiprilat','http://sideeffects.embl.de/se/C0700225/'),('http://sideeffects.embl.de/drugs/5538/','retinoic acid','http://sideeffects.embl.de/se/C0036973/'),('http://sideeffects.embl.de/drugs/5544/','triamcinolone','http://sideeffects.embl.de/se/C0025289/'),('http://sideeffects.embl.de/drugs/5546/','triamterene','http://sideeffects.embl.de/se/C0022650/'),('http://sideeffects.embl.de/drugs/55466/','Gd-DTPA','http://sideeffects.embl.de/se/C0162297/'),('http://sideeffects.embl.de/drugs/55480/','milnacipran','http://sideeffects.embl.de/se/C0699828/'),('http://sideeffects.embl.de/drugs/5556/','triazolam','http://sideeffects.embl.de/se/C0241426/'),('http://sideeffects.embl.de/drugs/5565/','trien','http://sideeffects.embl.de/se/C0232493/'),('http://sideeffects.embl.de/drugs/5566/','trifluoperazine','http://sideeffects.embl.de/se/C0026205/'),('http://sideeffects.embl.de/drugs/5572/','trihexyphenidyl','http://sideeffects.embl.de/se/C0027849/'),('http://sideeffects.embl.de/drugs/5576/','trimethadione','http://sideeffects.embl.de/se/C0240735/'),('http://sideeffects.embl.de/drugs/5578/','trimethoprim','http://sideeffects.embl.de/se/C0221490/'),('http://sideeffects.embl.de/drugs/5582/','trimetrexate','http://sideeffects.embl.de/se/C0700225/'),('http://sideeffects.embl.de/drugs/5584/','trimipramine','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/5593/','tropicamide','http://sideeffects.embl.de/se/C0235198/'),('http://sideeffects.embl.de/drugs/5595/','tropisetron','http://sideeffects.embl.de/se/C0036973/'),('http://sideeffects.embl.de/drugs/5596/','trospium chloride','http://sideeffects.embl.de/se/C0522055/'),('http://sideeffects.embl.de/drugs/5625/','delavirdine','http://sideeffects.embl.de/se/C0019521/'),('http://sideeffects.embl.de/drugs/56338/','fosphenytoin','http://sideeffects.embl.de/se/C0027066/'),('http://sideeffects.embl.de/drugs/5636/','unoprostone','http://sideeffects.embl.de/se/C0423602/'),('http://sideeffects.embl.de/drugs/564/','EACA','http://sideeffects.embl.de/se/C0428977/'),('http://sideeffects.embl.de/drugs/5645/','UDCA','http://sideeffects.embl.de/se/C0019557/'),('http://sideeffects.embl.de/drugs/5647/','VACV','http://sideeffects.embl.de/se/C2830004/'),('http://sideeffects.embl.de/drugs/5650/','valsartan','http://sideeffects.embl.de/se/C0700225/'),('http://sideeffects.embl.de/drugs/5651/','Vancocine','http://sideeffects.embl.de/se/C0599918/'),('http://sideeffects.embl.de/drugs/5656/','venlafaxine','http://sideeffects.embl.de/se/C0027066/'),('http://sideeffects.embl.de/drugs/56603655/','pegaptanib','http://sideeffects.embl.de/se/C1096278/'),('http://sideeffects.embl.de/drugs/5665/','vigabatrin','http://sideeffects.embl.de/se/C0027066/'),('http://sideeffects.embl.de/drugs/5672/','vinorelbine','http://sideeffects.embl.de/se/C1145670/'),('http://sideeffects.embl.de/drugs/56842239/','n-3 PUFA','http://sideeffects.embl.de/se/C0019087/'),('http://sideeffects.embl.de/drugs/56959/','ranolazine','http://sideeffects.embl.de/se/C0836924/'),('http://sideeffects.embl.de/drugs/57166/','Photofrin','http://sideeffects.embl.de/se/C0019521/'),('http://sideeffects.embl.de/drugs/5717/','zafirlukast','http://sideeffects.embl.de/se/C0877359/'),('http://sideeffects.embl.de/drugs/5718/','zalcitabine','http://sideeffects.embl.de/se/C1291077/'),('http://sideeffects.embl.de/drugs/5719/','zaleplon','http://sideeffects.embl.de/se/C0027066/'),('http://sideeffects.embl.de/drugs/5721/','zanamivir','http://sideeffects.embl.de/se/C0521839/'),('http://sideeffects.embl.de/drugs/5726/','zidovudine','http://sideeffects.embl.de/se/C0878544/'),('http://sideeffects.embl.de/drugs/5727/','ZnCl2','http://sideeffects.embl.de/se/C0002871/'),('http://sideeffects.embl.de/drugs/5731/','zolmitriptan','http://sideeffects.embl.de/se/C0947912/'),('http://sideeffects.embl.de/drugs/5732/','zolpidem','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/5734/','zonisamide','http://sideeffects.embl.de/se/C0027066/'),('http://sideeffects.embl.de/drugs/5735/','zopiclone','http://sideeffects.embl.de/se/C0947912/'),('http://sideeffects.embl.de/drugs/5746/','mitomycin C','http://sideeffects.embl.de/se/C0677500/'),('http://sideeffects.embl.de/drugs/57469/','imiquimod','http://sideeffects.embl.de/se/C3665596/'),('http://sideeffects.embl.de/drugs/57537/','rotigotine','http://sideeffects.embl.de/se/C0858635/'),('http://sideeffects.embl.de/drugs/57697/','pemirolast','http://sideeffects.embl.de/se/C0948595/'),('http://sideeffects.embl.de/drugs/5771/','oxytocin injection','http://sideeffects.embl.de/se/C0043049/'),('http://sideeffects.embl.de/drugs/5775/','phentolamine','http://sideeffects.embl.de/se/C0234233/'),('http://sideeffects.embl.de/drugs/581/','N-acetylcysteine','http://sideeffects.embl.de/se/C0542571/'),('http://sideeffects.embl.de/drugs/5877/','demethyl','http://sideeffects.embl.de/se/C0025289/'),('http://sideeffects.embl.de/drugs/5878/','oxandrolone','http://sideeffects.embl.de/se/C0268000/'),('http://sideeffects.embl.de/drugs/5939/','biguanide','http://sideeffects.embl.de/se/C0002994/'),('http://sideeffects.embl.de/drugs/596/','cytarabine','http://sideeffects.embl.de/se/C1287298/'),('http://sideeffects.embl.de/drugs/59708/','levetiracetam','http://sideeffects.embl.de/se/C1145670/'),('http://sideeffects.embl.de/drugs/59768/','esmolol','http://sideeffects.embl.de/se/C3665386/'),('http://sideeffects.embl.de/drugs/5978/','vincristine','http://sideeffects.embl.de/se/C0027066/'),('http://sideeffects.embl.de/drugs/598/','mesna','http://sideeffects.embl.de/se/C0392171/'),('http://sideeffects.embl.de/drugs/60146/','tamsulosin','http://sideeffects.embl.de/se/C0026205/'),('http://sideeffects.embl.de/drugs/60164/','adapalene','http://sideeffects.embl.de/se/C1302752/'),('http://sideeffects.embl.de/drugs/60172/','adefovir','http://sideeffects.embl.de/se/C0599918/'),('http://sideeffects.embl.de/drugs/6018/','tetrabenazine','http://sideeffects.embl.de/se/C0234369/'),('http://sideeffects.embl.de/drugs/60183/','perindopril erbumine','http://sideeffects.embl.de/se/C0947912/'),('http://sideeffects.embl.de/drugs/60184/','perindopril','http://sideeffects.embl.de/se/C0700225/'),('http://sideeffects.embl.de/drugs/60198/','exemestane','http://sideeffects.embl.de/se/C0600142/'),('http://sideeffects.embl.de/drugs/6049/','EDTA','http://sideeffects.embl.de/se/C0599918/'),('http://sideeffects.embl.de/drugs/60490/','zileuton','http://sideeffects.embl.de/se/C0948695/'),('http://sideeffects.embl.de/drugs/60496/','amlodipine besylate','http://sideeffects.embl.de/se/C3665386/'),('http://sideeffects.embl.de/drugs/6058/','cysteamine','http://sideeffects.embl.de/se/C0027726/'),('http://sideeffects.embl.de/drugs/60612/','dexmedetomidine','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/60613/','cidofovir','http://sideeffects.embl.de/se/C0599918/'),('http://sideeffects.embl.de/drugs/60668/','etoposide phosphate','http://sideeffects.embl.de/se/C0333355/'),('http://sideeffects.embl.de/drugs/60695/','rocuronium','http://sideeffects.embl.de/se/C0522055/'),('http://sideeffects.embl.de/drugs/60706/','meropenem','http://sideeffects.embl.de/se/C1145670/'),('http://sideeffects.embl.de/drugs/60714/','gadoteridol','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/60726/','bromfenac','http://sideeffects.embl.de/se/C1142151/'),('http://sideeffects.embl.de/drugs/60751/','mTHPC','http://sideeffects.embl.de/se/C0162830/'),('http://sideeffects.embl.de/drugs/60752/','ibutilide','http://sideeffects.embl.de/se/C0039240/'),('http://sideeffects.embl.de/drugs/60754/','gadodiamide','http://sideeffects.embl.de/se/C3665386/'),('http://sideeffects.embl.de/drugs/60787/','saquinavir','http://sideeffects.embl.de/se/C0036973/'),('http://sideeffects.embl.de/drugs/60795/','aripiprazole','http://sideeffects.embl.de/se/C0162297/'),('http://sideeffects.embl.de/drugs/60814/','remifentanil','http://sideeffects.embl.de/se/C0855329/'),('http://sideeffects.embl.de/drugs/60830/','tiotropium','http://sideeffects.embl.de/se/C0005694/'),('http://sideeffects.embl.de/drugs/60834/','duloxetine','http://sideeffects.embl.de/se/C0027066/'),('http://sideeffects.embl.de/drugs/60843/','pemetrexed','http://sideeffects.embl.de/se/C0750394/'),('http://sideeffects.embl.de/drugs/60852/','ibandronate','http://sideeffects.embl.de/se/C0007820/'),('http://sideeffects.embl.de/drugs/60853/','ziprasidone','http://sideeffects.embl.de/se/C0027066/'),('http://sideeffects.embl.de/drugs/60860/','metaiodobenzylguanidine','http://sideeffects.embl.de/se/C0151698/'),('http://sideeffects.embl.de/drugs/60864/','olopatadine','http://sideeffects.embl.de/se/C0948595/'),('http://sideeffects.embl.de/drugs/60867/','levosimendan','http://sideeffects.embl.de/se/C0162119/'),('http://sideeffects.embl.de/drugs/60871/','adefovir dipivoxil','http://sideeffects.embl.de/se/C0599918/'),('http://sideeffects.embl.de/drugs/60877/','emtricitabine','http://sideeffects.embl.de/se/C1565489/'),('http://sideeffects.embl.de/drugs/60878/','eprosartan','http://sideeffects.embl.de/se/C3665386/'),('http://sideeffects.embl.de/drugs/60936/','tiludronate','http://sideeffects.embl.de/se/C0392171/'),('http://sideeffects.embl.de/drugs/60953/','capecitabine','http://sideeffects.embl.de/se/C0036973/'),('http://sideeffects.embl.de/drugs/6102852/','gadobutrol','http://sideeffects.embl.de/se/C3665386/'),('http://sideeffects.embl.de/drugs/6116/','calcium acetate','http://sideeffects.embl.de/se/C0085628/'),('http://sideeffects.embl.de/drugs/612/','lactate','http://sideeffects.embl.de/se/C0677500/'),('http://sideeffects.embl.de/drugs/61475/','sodium thiosulfate','http://sideeffects.embl.de/se/C0151889/'),('http://sideeffects.embl.de/drugs/62305/','doxycycline calcium','http://sideeffects.embl.de/se/C0349506/'),('http://sideeffects.embl.de/drugs/62358/','ammonium lactate','http://sideeffects.embl.de/se/C0677500/'),('http://sideeffects.embl.de/drugs/6238/','17-hydroxyprogesterone','http://sideeffects.embl.de/se/C0600142/'),('http://sideeffects.embl.de/drugs/6256/','trifluorothymidine','http://sideeffects.embl.de/se/C0162285/'),('http://sideeffects.embl.de/drugs/62816/','colestipol','http://sideeffects.embl.de/se/C1291077/'),('http://sideeffects.embl.de/drugs/62819/','Metrodin','http://sideeffects.embl.de/se/C2830004/'),('http://sideeffects.embl.de/drugs/62924/','fluticasone','http://sideeffects.embl.de/se/C2364111/'),('http://sideeffects.embl.de/drugs/62956/','fosinoprilat','http://sideeffects.embl.de/se/C1565489/'),('http://sideeffects.embl.de/drugs/62959/','trovafloxacin','http://sideeffects.embl.de/se/C0836924/'),('http://sideeffects.embl.de/drugs/62965/','beclomethasone monopropionate','http://sideeffects.embl.de/se/C0041912/'),('http://sideeffects.embl.de/drugs/63001/','benazeprilat','http://sideeffects.embl.de/se/C0855329/'),('http://sideeffects.embl.de/drugs/6323497/','rifapentine','http://sideeffects.embl.de/se/C0025289/'),('http://sideeffects.embl.de/drugs/6326970/','selenium','http://sideeffects.embl.de/se/C0152030/'),('http://sideeffects.embl.de/drugs/6328144/','radium','http://sideeffects.embl.de/se/C0023418/'),('http://sideeffects.embl.de/drugs/6328526/','AC1O3HA7','http://sideeffects.embl.de/se/C0025289/'),('http://sideeffects.embl.de/drugs/6331630/','eribulin','http://sideeffects.embl.de/se/C2363731/'),('http://sideeffects.embl.de/drugs/6333887/','auranofin','http://sideeffects.embl.de/se/C0027726/'),('http://sideeffects.embl.de/drugs/6398970/','cefdinir','http://sideeffects.embl.de/se/C1565489/'),('http://sideeffects.embl.de/drugs/64147/','valganciclovir','http://sideeffects.embl.de/se/C0027066/'),('http://sideeffects.embl.de/drugs/6432/','Optison','http://sideeffects.embl.de/se/C0162297/'),('http://sideeffects.embl.de/drugs/6433082/','hexaminolevulinate','http://sideeffects.embl.de/se/C0010692/'),('http://sideeffects.embl.de/drugs/6433091/','tapentadol','http://sideeffects.embl.de/se/C0700200/'),('http://sideeffects.embl.de/drugs/6433101/','tafluprost','http://sideeffects.embl.de/se/C1761613/'),('http://sideeffects.embl.de/drugs/6433117/','indacaterol','http://sideeffects.embl.de/se/C2363731/'),('http://sideeffects.embl.de/drugs/6433119/','rivaroxaban','http://sideeffects.embl.de/se/C2363731/'),('http://sideeffects.embl.de/drugs/6435110/','ivermectin','http://sideeffects.embl.de/se/C0497201/'),('http://sideeffects.embl.de/drugs/6436/','triamcinolone acetonide','http://sideeffects.embl.de/se/C0497201/'),('http://sideeffects.embl.de/drugs/6437075/','Timentin','http://sideeffects.embl.de/se/C0042109/'),('http://sideeffects.embl.de/drugs/6440191/','fidaxomicin','http://sideeffects.embl.de/se/C0232462/'),('http://sideeffects.embl.de/drugs/6442177/','everolimus','http://sideeffects.embl.de/se/C0599918/'),('http://sideeffects.embl.de/drugs/644241/','nilotinib','http://sideeffects.embl.de/se/C2363731/'),('http://sideeffects.embl.de/drugs/6445540/','ixabepilone','http://sideeffects.embl.de/se/C1145670/'),('http://sideeffects.embl.de/drugs/6451/','bromcresol green','http://sideeffects.embl.de/se/C0700590/'),('http://sideeffects.embl.de/drugs/6452749/','Locorten Vioform','http://sideeffects.embl.de/se/C0085624/'),('http://sideeffects.embl.de/drugs/6453361/','Sativex','http://sideeffects.embl.de/se/C2830004/'),('http://sideeffects.embl.de/drugs/6468/','phencyclidine','http://sideeffects.embl.de/se/C0234233/'),('http://sideeffects.embl.de/drugs/6476/','methsuximide','http://sideeffects.embl.de/se/C0019521/'),('http://sideeffects.embl.de/drugs/6477186/','delamanid','http://sideeffects.embl.de/se/C2363731/'),('http://sideeffects.embl.de/drugs/64778/','Meropenem anhydrous','http://sideeffects.embl.de/se/C2830004/'),('http://sideeffects.embl.de/drugs/64929/','fenofibric acid','http://sideeffects.embl.de/se/C0877359/'),('http://sideeffects.embl.de/drugs/64987/','tenofovir','http://sideeffects.embl.de/se/C0700225/'),('http://sideeffects.embl.de/drugs/65014/','AMD3100','http://sideeffects.embl.de/se/C0917801/'),('http://sideeffects.embl.de/drugs/6503/','tris','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/65157/','testosterone undecanoate','http://sideeffects.embl.de/se/C0877661/'),('http://sideeffects.embl.de/drugs/65281/','CAS 1405-87-4','http://sideeffects.embl.de/se/C0042963/'),('http://sideeffects.embl.de/drugs/65370/','Glat copolymer','http://sideeffects.embl.de/se/C0027066/'),('http://sideeffects.embl.de/drugs/65628/','bendamustine','http://sideeffects.embl.de/se/C2830004/'),('http://sideeffects.embl.de/drugs/656628/','silodosin','http://sideeffects.embl.de/se/C0151602/'),('http://sideeffects.embl.de/drugs/656892/','TMC207','http://sideeffects.embl.de/se/C0267792/'),('http://sideeffects.embl.de/drugs/657298/','propylthiouracil','http://sideeffects.embl.de/se/C2364111/'),('http://sideeffects.embl.de/drugs/65840/','colestimide','http://sideeffects.embl.de/se/C0267792/'),('http://sideeffects.embl.de/drugs/65856/','reboxetine','http://sideeffects.embl.de/se/C0855329/'),('http://sideeffects.embl.de/drugs/65863/','sertaconazole','http://sideeffects.embl.de/se/C0237849/'),('http://sideeffects.embl.de/drugs/65866/','lercanidipine','http://sideeffects.embl.de/se/C0858635/'),('http://sideeffects.embl.de/drugs/65999/','telmisartan','http://sideeffects.embl.de/se/C0007820/'),('http://sideeffects.embl.de/drugs/667490/','6-mercaptopurine','http://sideeffects.embl.de/se/C0267792/'),('http://sideeffects.embl.de/drugs/6726/','cyclizine','http://sideeffects.embl.de/se/C0267792/'),('http://sideeffects.embl.de/drugs/679/','DMSO','http://sideeffects.embl.de/se/C0234215/'),('http://sideeffects.embl.de/drugs/681/','dopamine','http://sideeffects.embl.de/se/C0031924/'),('http://sideeffects.embl.de/drugs/6850789/','iron sucrose','http://sideeffects.embl.de/se/C0266813/'),('http://sideeffects.embl.de/drugs/6850791/','leuprorelin acetate','http://sideeffects.embl.de/se/C0019521/'),('http://sideeffects.embl.de/drugs/68613/','atosiban','http://sideeffects.embl.de/se/C0600142/'),('http://sideeffects.embl.de/drugs/68740/','zoledronic acid','http://sideeffects.embl.de/se/C0521839/'),('http://sideeffects.embl.de/drugs/68844/','brinzolamide','http://sideeffects.embl.de/se/C0948595/'),('http://sideeffects.embl.de/drugs/6918182/','strontium ranelate','http://sideeffects.embl.de/se/C0011609/'),('http://sideeffects.embl.de/drugs/6918313/','vilazodone','http://sideeffects.embl.de/se/C0699828/'),('http://sideeffects.embl.de/drugs/6918366/','fosaprepitant dimeglumine','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/6918430/','ceftobiprole','http://sideeffects.embl.de/se/C0851341/'),('http://sideeffects.embl.de/drugs/6918456/','prasugrel','http://sideeffects.embl.de/se/C0919874/'),('http://sideeffects.embl.de/drugs/6918462/','retapamulin','http://sideeffects.embl.de/se/C0877661/'),('http://sideeffects.embl.de/drugs/6918558/','fesoterodine','http://sideeffects.embl.de/se/C0858635/'),('http://sideeffects.embl.de/drugs/6918584/','sugammadex','http://sideeffects.embl.de/se/C1619712/'),('http://sideeffects.embl.de/drugs/6918638/','belinostat','http://sideeffects.embl.de/se/C0235378/'),('http://sideeffects.embl.de/drugs/6918670/','PEP005','http://sideeffects.embl.de/se/C0877661/'),('http://sideeffects.embl.de/drugs/69512/','malvidin','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/698/','estrone','http://sideeffects.embl.de/se/C1291077/'),('http://sideeffects.embl.de/drugs/699/','Oestrogen','http://sideeffects.embl.de/se/C2830004/'),('http://sideeffects.embl.de/drugs/700/','monoethanolamine','http://sideeffects.embl.de/se/C0041582/'),('http://sideeffects.embl.de/drugs/7012/','phenylbutyric acid','http://sideeffects.embl.de/se/C1384666/'),('http://sideeffects.embl.de/drugs/7029/','diethylpropion','http://sideeffects.embl.de/se/C0855329/'),('http://sideeffects.embl.de/drugs/70683024/','x M22','http://sideeffects.embl.de/se/C1145670/'),('http://sideeffects.embl.de/drugs/70695640/','colestyramine','http://sideeffects.embl.de/se/C0019521/'),('http://sideeffects.embl.de/drugs/71158/','acamprosate','http://sideeffects.embl.de/se/C3665386/'),('http://sideeffects.embl.de/drugs/71273/','ropivacaine','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/71301/','nebivolol','http://sideeffects.embl.de/se/C0004245/'),('http://sideeffects.embl.de/drugs/71306834/','K779','http://sideeffects.embl.de/se/C0027726/'),('http://sideeffects.embl.de/drugs/71329/','dofetilide','http://sideeffects.embl.de/se/C0917798/'),('http://sideeffects.embl.de/drugs/71348/','lanreotide','http://sideeffects.embl.de/se/C0522055/'),('http://sideeffects.embl.de/drugs/71360/','iloperidone','http://sideeffects.embl.de/se/C0392525/'),('http://sideeffects.embl.de/drugs/71362/','Hoe 140','http://sideeffects.embl.de/se/C0151735/'),('http://sideeffects.embl.de/drugs/71406/','TPGS','http://sideeffects.embl.de/se/C0178298/'),('http://sideeffects.embl.de/drugs/71436/','Lutalyse','http://sideeffects.embl.de/se/C0019521/'),('http://sideeffects.embl.de/drugs/71469/','erythromycin lactobionate','http://sideeffects.embl.de/se/C0043251/'),('http://sideeffects.embl.de/drugs/71616/','voriconazole','http://sideeffects.embl.de/se/C0947912/'),('http://sideeffects.embl.de/drugs/7187/','benzoyl','http://sideeffects.embl.de/se/C0520893/'),('http://sideeffects.embl.de/drugs/72022/','perindoprilat','http://sideeffects.embl.de/se/C0151480/'),('http://sideeffects.embl.de/drugs/72054/','darifenacin','http://sideeffects.embl.de/se/C3665386/'),('http://sideeffects.embl.de/drugs/72081/','Terlipressin','http://sideeffects.embl.de/se/C1145670/'),('http://sideeffects.embl.de/drugs/72111/','rifaximin','http://sideeffects.embl.de/se/C2364111/'),('http://sideeffects.embl.de/drugs/72466/','bleomycin hydrochloride','http://sideeffects.embl.de/se/C0520893/'),('http://sideeffects.embl.de/drugs/727/','lindane','http://sideeffects.embl.de/se/C0162823/'),('http://sideeffects.embl.de/drugs/72938/','gemifloxacin','http://sideeffects.embl.de/se/C0162297/'),('http://sideeffects.embl.de/drugs/73303/','doripenem','http://sideeffects.embl.de/se/C0031542/'),('http://sideeffects.embl.de/drugs/73658/','telithromycin','http://sideeffects.embl.de/se/C0858635/'),('http://sideeffects.embl.de/drugs/738/','glutamine','http://sideeffects.embl.de/se/C0392025/'),('http://sideeffects.embl.de/drugs/74989/','atovaquone','http://sideeffects.embl.de/se/C1565489/'),('http://sideeffects.embl.de/drugs/750/','glycine','http://sideeffects.embl.de/se/C0220870/'),('http://sideeffects.embl.de/drugs/753/','glycerol','http://sideeffects.embl.de/se/C0030232/'),('http://sideeffects.embl.de/drugs/7638/','monobenzone','http://sideeffects.embl.de/se/C0152030/'),('http://sideeffects.embl.de/drugs/767/','bicarbonate','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/7699/','benzonatate','http://sideeffects.embl.de/se/C0085631/'),('http://sideeffects.embl.de/drugs/772/','LMWH','http://sideeffects.embl.de/se/C0836924/'),('http://sideeffects.embl.de/drugs/774/','histamine','http://sideeffects.embl.de/se/C0521839/'),('http://sideeffects.embl.de/drugs/77992/','frovatriptan','http://sideeffects.embl.de/se/C0019521/'),('http://sideeffects.embl.de/drugs/77993/','eletriptan','http://sideeffects.embl.de/se/C0019521/'),('http://sideeffects.embl.de/drugs/77996/','paricalcitol','http://sideeffects.embl.de/se/C0027066/'),('http://sideeffects.embl.de/drugs/77997/','MK-462','http://sideeffects.embl.de/se/C2830004/'),('http://sideeffects.embl.de/drugs/77998/','rosiglitazone','http://sideeffects.embl.de/se/C0268000/'),('http://sideeffects.embl.de/drugs/78032/','Vallergan','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/785/','quinol','http://sideeffects.embl.de/se/C0677500/'),('http://sideeffects.embl.de/drugs/813/','potassium','http://sideeffects.embl.de/se/C0522055/'),('http://sideeffects.embl.de/drugs/815/','kanamycin','http://sideeffects.embl.de/se/C0599918/'),('http://sideeffects.embl.de/drugs/8197/','tetraen','http://sideeffects.embl.de/se/C0030920/'),('http://sideeffects.embl.de/drugs/82146/','bexarotene','http://sideeffects.embl.de/se/C2830004/'),('http://sideeffects.embl.de/drugs/82148/','agomelatine','http://sideeffects.embl.de/se/C2830004/'),('http://sideeffects.embl.de/drugs/8230/','argenine vasopressin','http://sideeffects.embl.de/se/C0042571/'),('http://sideeffects.embl.de/drugs/83030/','Ge-132','http://sideeffects.embl.de/se/C0162297/'),('http://sideeffects.embl.de/drugs/83513/','barium','http://sideeffects.embl.de/se/C0003615/'),('http://sideeffects.embl.de/drugs/83606/','strontium','http://sideeffects.embl.de/se/C0036690/'),('http://sideeffects.embl.de/drugs/838/','epinephrine','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/84003/','ketorolac tromethamine','http://sideeffects.embl.de/se/C1096274/'),('http://sideeffects.embl.de/drugs/85/','carnitine','http://sideeffects.embl.de/se/C0947912/'),('http://sideeffects.embl.de/drugs/853/','thyroxine','http://sideeffects.embl.de/se/C0000729/'),('http://sideeffects.embl.de/drugs/8612/','chloroprocaine','http://sideeffects.embl.de/se/C0162297/'),('http://sideeffects.embl.de/drugs/888/','magnesium','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/896/','melatonin','http://sideeffects.embl.de/se/C0475858/'),('http://sideeffects.embl.de/drugs/8982/','nafcillin','http://sideeffects.embl.de/se/C0235378/'),('http://sideeffects.embl.de/drugs/9034/','methohexital','http://sideeffects.embl.de/se/C0235063/'),('http://sideeffects.embl.de/drugs/91488/','fluocinolone','http://sideeffects.embl.de/se/C0016436/'),('http://sideeffects.embl.de/drugs/923/','sodium','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/9354/','dimercaptosuccinic acid','http://sideeffects.embl.de/se/C0836924/'),('http://sideeffects.embl.de/drugs/937/','niacin','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/93860/','bortezomib','http://sideeffects.embl.de/se/C1287298/'),('http://sideeffects.embl.de/drugs/942/','nicotine','http://sideeffects.embl.de/se/C0019521/'),('http://sideeffects.embl.de/drugs/9433/','aminophylline','http://sideeffects.embl.de/se/C0917801/'),('http://sideeffects.embl.de/drugs/946/','nitrite','http://sideeffects.embl.de/se/C2242996/'),('http://sideeffects.embl.de/drugs/948/','nitrous oxide','http://sideeffects.embl.de/se/C0032961/'),('http://sideeffects.embl.de/drugs/951/','norepinephrine','http://sideeffects.embl.de/se/C0085636/'),('http://sideeffects.embl.de/drugs/961/','hydroxyl radicals','http://sideeffects.embl.de/se/C0031542/'),('http://sideeffects.embl.de/drugs/96312/','nelarabine','http://sideeffects.embl.de/se/C0162297/'),('http://sideeffects.embl.de/drugs/9810131/','ceftaroline','http://sideeffects.embl.de/se/C0851341/'),('http://sideeffects.embl.de/drugs/9811221/','cabazitaxel','http://sideeffects.embl.de/se/C2363731/'),('http://sideeffects.embl.de/drugs/9812414/','dalteparin','http://sideeffects.embl.de/se/C0836924/'),('http://sideeffects.embl.de/drugs/9815559/','trans 4-cyclohexyl-L-proline','http://sideeffects.embl.de/se/C0162297/'),('http://sideeffects.embl.de/drugs/9818231/','tofacitinib','http://sideeffects.embl.de/se/C0700225/'),('http://sideeffects.embl.de/drugs/9825285/','azilsartan','http://sideeffects.embl.de/se/C1565489/'),('http://sideeffects.embl.de/drugs/9831414/','Lovaza','http://sideeffects.embl.de/se/C0019087/'),('http://sideeffects.embl.de/drugs/9831761/','irbesartan-hydrochlorothiazide','http://sideeffects.embl.de/se/C1565489/'),('http://sideeffects.embl.de/drugs/9831783/','Stalevo 50','http://sideeffects.embl.de/se/C0241426/'),('http://sideeffects.embl.de/drugs/9846180/','eltrombopag','http://sideeffects.embl.de/se/C2363731/'),('http://sideeffects.embl.de/drugs/9853053/','lomitapide','http://sideeffects.embl.de/se/C1291078/'),('http://sideeffects.embl.de/drugs/9854489/','fluticasone furoate','http://sideeffects.embl.de/se/C0948070/'),('http://sideeffects.embl.de/drugs/9865528/','mirabegron','http://sideeffects.embl.de/se/C0497247/'),('http://sideeffects.embl.de/drugs/9869929/','avanafil','http://sideeffects.embl.de/se/C2830004/'),('http://sideeffects.embl.de/drugs/9871419/','ticagrelor','http://sideeffects.embl.de/se/C0700200/'),('http://sideeffects.embl.de/drugs/9887712/','dapagliflozin','http://sideeffects.embl.de/se/C0700225/'),('http://sideeffects.embl.de/drugs/9898619/','Depreotide','http://sideeffects.embl.de/se/C0042963/'),('http://sideeffects.embl.de/drugs/9912092/','apremilast','http://sideeffects.embl.de/se/C0232492/'),('http://sideeffects.embl.de/drugs/9924495/','perampanel','http://sideeffects.embl.de/se/C2363731/'),('http://sideeffects.embl.de/drugs/9930048/','vernakalant','http://sideeffects.embl.de/se/C0858259/'),('http://sideeffects.embl.de/drugs/9940864/','Benicar-HCT','http://sideeffects.embl.de/se/C0542571/'),('http://sideeffects.embl.de/drugs/9941444/','SOM230','http://sideeffects.embl.de/se/C0917801/'),('http://sideeffects.embl.de/drugs/9966051/','Lu AA21004','http://sideeffects.embl.de/se/C0699828/');

/*Table structure for table `siderdrug_drugbank` */

DROP TABLE IF EXISTS `siderdrug_drugbank`;

CREATE TABLE `siderdrug_drugbank` (
  `drugbank_id` varchar(200) NOT NULL,
  `sider_drug_link` varchar(200) DEFAULT NULL,
  PRIMARY KEY (`drugbank_id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

/*Data for the table `siderdrug_drugbank` */

insert  into `siderdrug_drugbank`(`drugbank_id`,`sider_drug_link`) values ('DB00006','http://sideeffects.embl.de/drugs/16129704/'),('DB00066','http://sideeffects.embl.de/drugs/62819/'),('DB00080','http://sideeffects.embl.de/drugs/16129629/'),('DB00082','http://sideeffects.embl.de/drugs/16129672/'),('DB00091','http://sideeffects.embl.de/drugs/2909/'),('DB00105','http://sideeffects.embl.de/drugs/71306834/'),('DB00106','http://sideeffects.embl.de/drugs/16131215/'),('DB00152','http://sideeffects.embl.de/drugs/1130/'),('DB00153','http://sideeffects.embl.de/drugs/3249/'),('DB00165','http://sideeffects.embl.de/drugs/1054/'),('DB00176','http://sideeffects.embl.de/drugs/3404/'),('DB00181','http://sideeffects.embl.de/drugs/2284/'),('DB00182','http://sideeffects.embl.de/drugs/3007/'),('DB00186','http://sideeffects.embl.de/drugs/3958/'),('DB00187','http://sideeffects.embl.de/drugs/59768/'),('DB00191','http://sideeffects.embl.de/drugs/4771/'),('DB00195','http://sideeffects.embl.de/drugs/2369/'),('DB00196','http://sideeffects.embl.de/drugs/3365/'),('DB00197','http://sideeffects.embl.de/drugs/5591/'),('DB00201','http://sideeffects.embl.de/drugs/2519/'),('DB00202','http://sideeffects.embl.de/drugs/5314/'),('DB00203','http://sideeffects.embl.de/drugs/5212/'),('DB00204','http://sideeffects.embl.de/drugs/71329/'),('DB00205','http://sideeffects.embl.de/drugs/4993/'),('DB00207','http://sideeffects.embl.de/drugs/2269/'),('DB00208','http://sideeffects.embl.de/drugs/5472/'),('DB00210','http://sideeffects.embl.de/drugs/60164/'),('DB00211','http://sideeffects.embl.de/drugs/4195/'),('DB00213','http://sideeffects.embl.de/drugs/4679/'),('DB00214','http://sideeffects.embl.de/drugs/41781/'),('DB00215','http://sideeffects.embl.de/drugs/2771/'),('DB00216','http://sideeffects.embl.de/drugs/77993/'),('DB00222','http://sideeffects.embl.de/drugs/3476/'),('DB00228','http://sideeffects.embl.de/drugs/3226/'),('DB00231','http://sideeffects.embl.de/drugs/5391/'),('DB00232','http://sideeffects.embl.de/drugs/4121/'),('DB00233','http://sideeffects.embl.de/drugs/4649/'),('DB00235','http://sideeffects.embl.de/drugs/4197/'),('DB00237','http://sideeffects.embl.de/drugs/2479/'),('DB00238','http://sideeffects.embl.de/drugs/4463/'),('DB00243','http://sideeffects.embl.de/drugs/56959/'),('DB00244','http://sideeffects.embl.de/drugs/4075/'),('DB00250','http://sideeffects.embl.de/drugs/2955/'),('DB00252','http://sideeffects.embl.de/drugs/1775/'),('DB00255','http://sideeffects.embl.de/drugs/3054/'),('DB00257','http://sideeffects.embl.de/drugs/2812/'),('DB00258','http://sideeffects.embl.de/drugs/6116/'),('DB00259','http://sideeffects.embl.de/drugs/5333/'),('DB00261','http://sideeffects.embl.de/drugs/2182/'),('DB00262','http://sideeffects.embl.de/drugs/2578/'),('DB00264','http://sideeffects.embl.de/drugs/4171/'),('DB00268','http://sideeffects.embl.de/drugs/5095/'),('DB00270','http://sideeffects.embl.de/drugs/3784/'),('DB00275','http://sideeffects.embl.de/drugs/158781/'),('DB00276','http://sideeffects.embl.de/drugs/2179/'),('DB00277','http://sideeffects.embl.de/drugs/2153/'),('DB00280','http://sideeffects.embl.de/drugs/3114/'),('DB00281','http://sideeffects.embl.de/drugs/3676/'),('DB00284','http://sideeffects.embl.de/drugs/41774/'),('DB00285','http://sideeffects.embl.de/drugs/5656/'),('DB00291','http://sideeffects.embl.de/drugs/2708/'),('DB00293','http://sideeffects.embl.de/drugs/104758/'),('DB00297','http://sideeffects.embl.de/drugs/2474/'),('DB00299','http://sideeffects.embl.de/drugs/4725/'),('DB00302','http://sideeffects.embl.de/drugs/5526/'),('DB00303','http://sideeffects.embl.de/drugs/150610/'),('DB00305','http://sideeffects.embl.de/drugs/5746/'),('DB00307','http://sideeffects.embl.de/drugs/82146/'),('DB00310','http://sideeffects.embl.de/drugs/2732/'),('DB00312','http://sideeffects.embl.de/drugs/4737/'),('DB00313','http://sideeffects.embl.de/drugs/3121/'),('DB00316','http://sideeffects.embl.de/drugs/1983/'),('DB00317','http://sideeffects.embl.de/drugs/123631/'),('DB00321','http://sideeffects.embl.de/drugs/2160/'),('DB00323','http://sideeffects.embl.de/drugs/4659569/'),('DB00328','http://sideeffects.embl.de/drugs/3715/'),('DB00331','http://sideeffects.embl.de/drugs/4091/'),('DB00333','http://sideeffects.embl.de/drugs/4095/'),('DB00334','http://sideeffects.embl.de/drugs/4585/'),('DB00335','http://sideeffects.embl.de/drugs/2249/'),('DB00337','http://sideeffects.embl.de/drugs/3055172/'),('DB00338','http://sideeffects.embl.de/drugs/4594/'),('DB00339','http://sideeffects.embl.de/drugs/1046/'),('DB00341','http://sideeffects.embl.de/drugs/2678/'),('DB00344','http://sideeffects.embl.de/drugs/4976/'),('DB00346','http://sideeffects.embl.de/drugs/2092/'),('DB00347','http://sideeffects.embl.de/drugs/5576/'),('DB00348','http://sideeffects.embl.de/drugs/115355/'),('DB00349','http://sideeffects.embl.de/drugs/2789/'),('DB00350','http://sideeffects.embl.de/drugs/4201/'),('DB00352','http://sideeffects.embl.de/drugs/2723601/'),('DB00355','http://sideeffects.embl.de/drugs/2274/'),('DB00356','http://sideeffects.embl.de/drugs/2733/'),('DB00357','http://sideeffects.embl.de/drugs/2145/'),('DB00358','http://sideeffects.embl.de/drugs/4046/'),('DB00359','http://sideeffects.embl.de/drugs/5215/'),('DB00361','http://sideeffects.embl.de/drugs/5672/'),('DB00362','http://sideeffects.embl.de/drugs/166548/'),('DB00363','http://sideeffects.embl.de/drugs/2818/'),('DB00369','http://sideeffects.embl.de/drugs/60613/'),('DB00370','http://sideeffects.embl.de/drugs/4205/'),('DB00371','http://sideeffects.embl.de/drugs/4064/'),('DB00375','http://sideeffects.embl.de/drugs/62816/'),('DB00376','http://sideeffects.embl.de/drugs/5572/'),('DB00379','http://sideeffects.embl.de/drugs/4178/'),('DB00381','http://sideeffects.embl.de/drugs/2162/'),('DB00384','http://sideeffects.embl.de/drugs/5546/'),('DB00389','http://sideeffects.embl.de/drugs/31072/'),('DB00393','http://sideeffects.embl.de/drugs/4497/'),('DB00394','http://sideeffects.embl.de/drugs/2307/'),('DB00395','http://sideeffects.embl.de/drugs/2576/'),('DB00397','http://sideeffects.embl.de/drugs/4786/'),('DB00398','http://sideeffects.embl.de/drugs/216239/'),('DB00399','http://sideeffects.embl.de/drugs/68740/'),('DB00401','http://sideeffects.embl.de/drugs/4499/'),('DB00404','http://sideeffects.embl.de/drugs/2118/'),('DB00408','http://sideeffects.embl.de/drugs/3964/'),('DB00418','http://sideeffects.embl.de/drugs/5193/'),('DB00419','http://sideeffects.embl.de/drugs/51634/'),('DB00422','http://sideeffects.embl.de/drugs/4158/'),('DB00423','http://sideeffects.embl.de/drugs/4107/'),('DB00425','http://sideeffects.embl.de/drugs/5732/'),('DB00426','http://sideeffects.embl.de/drugs/3324/'),('DB00428','http://sideeffects.embl.de/drugs/5300/'),('DB00429','http://sideeffects.embl.de/drugs/5281074/'),('DB00431','http://sideeffects.embl.de/drugs/727/'),('DB00432','http://sideeffects.embl.de/drugs/6256/'),('DB00433','http://sideeffects.embl.de/drugs/4917/'),('DB00434','http://sideeffects.embl.de/drugs/2913/'),('DB00435','http://sideeffects.embl.de/drugs/145068/'),('DB00436','http://sideeffects.embl.de/drugs/2315/'),('DB00437','http://sideeffects.embl.de/drugs/2094/'),('DB00438','http://sideeffects.embl.de/drugs/2650/'),('DB00440','http://sideeffects.embl.de/drugs/5578/'),('DB00442','http://sideeffects.embl.de/drugs/153941/'),('DB00448','http://sideeffects.embl.de/drugs/3883/'),('DB00449','http://sideeffects.embl.de/drugs/3105/'),('DB00450','http://sideeffects.embl.de/drugs/3168/'),('DB00454','http://sideeffects.embl.de/drugs/4058/'),('DB00455','http://sideeffects.embl.de/drugs/3957/'),('DB00457','http://sideeffects.embl.de/drugs/4893/'),('DB00458','http://sideeffects.embl.de/drugs/3696/'),('DB00461','http://sideeffects.embl.de/drugs/4409/'),('DB00465','http://sideeffects.embl.de/drugs/3826/'),('DB00468','http://sideeffects.embl.de/drugs/1065/'),('DB00472','http://sideeffects.embl.de/drugs/3386/'),('DB00475','http://sideeffects.embl.de/drugs/2712/'),('DB00477','http://sideeffects.embl.de/drugs/2726/'),('DB00478','http://sideeffects.embl.de/drugs/5071/'),('DB00480','http://sideeffects.embl.de/drugs/216326/'),('DB00481','http://sideeffects.embl.de/drugs/5035/'),('DB00482','http://sideeffects.embl.de/drugs/2662/'),('DB00484','http://sideeffects.embl.de/drugs/2435/'),('DB00488','http://sideeffects.embl.de/drugs/2123/'),('DB00489','http://sideeffects.embl.de/drugs/5253/'),('DB00490','http://sideeffects.embl.de/drugs/2477/'),('DB00496','http://sideeffects.embl.de/drugs/72054/'),('DB00499','http://sideeffects.embl.de/drugs/3397/'),('DB00501','http://sideeffects.embl.de/drugs/2756/'),('DB00502','http://sideeffects.embl.de/drugs/3559/'),('DB00507','http://sideeffects.embl.de/drugs/41684/'),('DB00513','http://sideeffects.embl.de/drugs/564/'),('DB00514','http://sideeffects.embl.de/drugs/3008/'),('DB00515','http://sideeffects.embl.de/drugs/2767/'),('DB00518','http://sideeffects.embl.de/drugs/2082/'),('DB00521','http://sideeffects.embl.de/drugs/2583/'),('DB00524','http://sideeffects.embl.de/drugs/4170/'),('DB00528','http://sideeffects.embl.de/drugs/65866/'),('DB00530','http://sideeffects.embl.de/drugs/176870/'),('DB00531','http://sideeffects.embl.de/drugs/2907/'),('DB00532','http://sideeffects.embl.de/drugs/4060/'),('DB00533','http://sideeffects.embl.de/drugs/5090/'),('DB00535','http://sideeffects.embl.de/drugs/6398970/'),('DB00536','http://sideeffects.embl.de/drugs/3520/'),('DB00537','http://sideeffects.embl.de/drugs/2764/'),('DB00540','http://sideeffects.embl.de/drugs/4543/'),('DB00541','http://sideeffects.embl.de/drugs/5978/'),('DB00543','http://sideeffects.embl.de/drugs/2170/'),('DB00544','http://sideeffects.embl.de/drugs/3385/'),('DB00545','http://sideeffects.embl.de/drugs/4991/'),('DB00548','http://sideeffects.embl.de/drugs/2266/'),('DB00549','http://sideeffects.embl.de/drugs/5717/'),('DB00550','http://sideeffects.embl.de/drugs/657298/'),('DB00551','http://sideeffects.embl.de/drugs/1990/'),('DB00553','http://sideeffects.embl.de/drugs/4114/'),('DB00555','http://sideeffects.embl.de/drugs/3878/'),('DB00557','http://sideeffects.embl.de/drugs/3658/'),('DB00559','http://sideeffects.embl.de/drugs/104865/'),('DB00561','http://sideeffects.embl.de/drugs/3156/'),('DB00564','http://sideeffects.embl.de/drugs/2554/'),('DB00570','http://sideeffects.embl.de/drugs/13342/'),('DB00571','http://sideeffects.embl.de/drugs/4946/'),('DB00573','http://sideeffects.embl.de/drugs/3342/'),('DB00575','http://sideeffects.embl.de/drugs/2803/'),('DB00580','http://sideeffects.embl.de/drugs/119828/'),('DB00582','http://sideeffects.embl.de/drugs/71616/'),('DB00590','http://sideeffects.embl.de/drugs/3157/'),('DB00593','http://sideeffects.embl.de/drugs/3291/'),('DB00596','http://sideeffects.embl.de/drugs/5311167/'),('DB00598','http://sideeffects.embl.de/drugs/3869/'),('DB00600','http://sideeffects.embl.de/drugs/7638/'),('DB00605','http://sideeffects.embl.de/drugs/5352/'),('DB00607','http://sideeffects.embl.de/drugs/8982/'),('DB00608','http://sideeffects.embl.de/drugs/2719/'),('DB00609','http://sideeffects.embl.de/drugs/2761171/'),('DB00612','http://sideeffects.embl.de/drugs/2405/'),('DB00615','http://sideeffects.embl.de/drugs/5361912/'),('DB00619','http://sideeffects.embl.de/drugs/5291/'),('DB00621','http://sideeffects.embl.de/drugs/5878/'),('DB00623','http://sideeffects.embl.de/drugs/3372/'),('DB00628','http://sideeffects.embl.de/drugs/2809/'),('DB00629','http://sideeffects.embl.de/drugs/3517/'),('DB00630','http://sideeffects.embl.de/drugs/2088/'),('DB00631','http://sideeffects.embl.de/drugs/119182/'),('DB00632','http://sideeffects.embl.de/drugs/12620/'),('DB00634','http://sideeffects.embl.de/drugs/5320/'),('DB00641','http://sideeffects.embl.de/drugs/54454/'),('DB00643','http://sideeffects.embl.de/drugs/4030/'),('DB00644','http://sideeffects.embl.de/drugs/36523/'),('DB00647','http://sideeffects.embl.de/drugs/10100/'),('DB00648','http://sideeffects.embl.de/drugs/4211/'),('DB00651','http://sideeffects.embl.de/drugs/3182/'),('DB00652','http://sideeffects.embl.de/drugs/4736/'),('DB00653','http://sideeffects.embl.de/drugs/24083/'),('DB00656','http://sideeffects.embl.de/drugs/5533/'),('DB00657','http://sideeffects.embl.de/drugs/4032/'),('DB00658','http://sideeffects.embl.de/drugs/3085017/'),('DB00659','http://sideeffects.embl.de/drugs/71158/'),('DB00661','http://sideeffects.embl.de/drugs/2520/'),('DB00665','http://sideeffects.embl.de/drugs/4493/'),('DB00666','http://sideeffects.embl.de/drugs/25077405/'),('DB00669','http://sideeffects.embl.de/drugs/5358/'),('DB00672','http://sideeffects.embl.de/drugs/2727/'),('DB00678','http://sideeffects.embl.de/drugs/3961/'),('DB00681','http://sideeffects.embl.de/drugs/1972/'),('DB00683','http://sideeffects.embl.de/drugs/4192/'),('DB00685','http://sideeffects.embl.de/drugs/62959/'),('DB00686','http://sideeffects.embl.de/drugs/37720/'),('DB00687','http://sideeffects.embl.de/drugs/31378/'),('DB00690','http://sideeffects.embl.de/drugs/3393/'),('DB00692','http://sideeffects.embl.de/drugs/5775/'),('DB00693','http://sideeffects.embl.de/drugs/16850/'),('DB00695','http://sideeffects.embl.de/drugs/3440/'),('DB00697','http://sideeffects.embl.de/drugs/5487/'),('DB00700','http://sideeffects.embl.de/drugs/150310/'),('DB00705','http://sideeffects.embl.de/drugs/5625/'),('DB00708','http://sideeffects.embl.de/drugs/41693/'),('DB00710','http://sideeffects.embl.de/drugs/60852/'),('DB00712','http://sideeffects.embl.de/drugs/3394/'),('DB00716','http://sideeffects.embl.de/drugs/50294/'),('DB00718','http://sideeffects.embl.de/drugs/60871/'),('DB00720','http://sideeffects.embl.de/drugs/25419/'),('DB00724','http://sideeffects.embl.de/drugs/57469/'),('DB00726','http://sideeffects.embl.de/drugs/5584/'),('DB00727','http://sideeffects.embl.de/drugs/4510/'),('DB00730','http://sideeffects.embl.de/drugs/5430/'),('DB00732','http://sideeffects.embl.de/drugs/47320/'),('DB00733','http://sideeffects.embl.de/drugs/5353894/'),('DB00734','http://sideeffects.embl.de/drugs/5073/'),('DB00737','http://sideeffects.embl.de/drugs/4034/'),('DB00738','http://sideeffects.embl.de/drugs/4735/'),('DB00740','http://sideeffects.embl.de/drugs/5070/'),('DB00744','http://sideeffects.embl.de/drugs/60490/'),('DB00745','http://sideeffects.embl.de/drugs/4236/'),('DB00746','http://sideeffects.embl.de/drugs/2973/'),('DB00747','http://sideeffects.embl.de/drugs/5184/'),('DB00748','http://sideeffects.embl.de/drugs/2564/'),('DB00749','http://sideeffects.embl.de/drugs/3308/'),('DB00750','http://sideeffects.embl.de/drugs/4906/'),('DB00751','http://sideeffects.embl.de/drugs/3241/'),('DB00752','http://sideeffects.embl.de/drugs/5530/'),('DB00753','http://sideeffects.embl.de/drugs/3763/'),('DB00754','http://sideeffects.embl.de/drugs/3292/'),('DB00755','http://sideeffects.embl.de/drugs/5538/'),('DB00756','http://sideeffects.embl.de/drugs/3598/'),('DB00757','http://sideeffects.embl.de/drugs/3148/'),('DB00763','http://sideeffects.embl.de/drugs/1349907/'),('DB00764','http://sideeffects.embl.de/drugs/123620/'),('DB00774','http://sideeffects.embl.de/drugs/3647/'),('DB00776','http://sideeffects.embl.de/drugs/34312/'),('DB00778','http://sideeffects.embl.de/drugs/5106/'),('DB00779','http://sideeffects.embl.de/drugs/4421/'),('DB00780','http://sideeffects.embl.de/drugs/3675/'),('DB00781','http://sideeffects.embl.de/drugs/4868/'),('DB00782','http://sideeffects.embl.de/drugs/4934/'),('DB00784','http://sideeffects.embl.de/drugs/4044/'),('DB00787','http://sideeffects.embl.de/drugs/2022/'),('DB00789','http://sideeffects.embl.de/drugs/55466/'),('DB00794','http://sideeffects.embl.de/drugs/4909/'),('DB00795','http://sideeffects.embl.de/drugs/5353980/'),('DB00796','http://sideeffects.embl.de/drugs/2540/'),('DB00798','http://sideeffects.embl.de/drugs/3467/'),('DB00799','http://sideeffects.embl.de/drugs/5381/'),('DB00802','http://sideeffects.embl.de/drugs/51263/'),('DB00804','http://sideeffects.embl.de/drugs/3042/'),('DB00806','http://sideeffects.embl.de/drugs/4740/'),('DB00808','http://sideeffects.embl.de/drugs/3702/'),('DB00809','http://sideeffects.embl.de/drugs/5593/'),('DB00813','http://sideeffects.embl.de/drugs/3345/'),('DB00816','http://sideeffects.embl.de/drugs/4086/'),('DB00819','http://sideeffects.embl.de/drugs/1986/'),('DB00820','http://sideeffects.embl.de/drugs/110635/'),('DB00822','http://sideeffects.embl.de/drugs/3117/'),('DB00827','http://sideeffects.embl.de/drugs/2762/'),('DB00829','http://sideeffects.embl.de/drugs/3016/'),('DB00831','http://sideeffects.embl.de/drugs/5566/'),('DB00839','http://sideeffects.embl.de/drugs/5503/'),('DB00841','http://sideeffects.embl.de/drugs/36811/'),('DB00842','http://sideeffects.embl.de/drugs/4616/'),('DB00843','http://sideeffects.embl.de/drugs/3152/'),('DB00845','http://sideeffects.embl.de/drugs/2794/'),('DB00847','http://sideeffects.embl.de/drugs/6058/'),('DB00850','http://sideeffects.embl.de/drugs/4748/'),('DB00851','http://sideeffects.embl.de/drugs/5281007/'),('DB00853','http://sideeffects.embl.de/drugs/5394/'),('DB00855','http://sideeffects.embl.de/drugs/137/'),('DB00861','http://sideeffects.embl.de/drugs/3059/'),('DB00862','http://sideeffects.embl.de/drugs/110634/'),('DB00864','http://sideeffects.embl.de/drugs/5372/'),('DB00868','http://sideeffects.embl.de/drugs/7699/'),('DB00870','http://sideeffects.embl.de/drugs/5359/'),('DB00871','http://sideeffects.embl.de/drugs/5403/'),('DB00872','http://sideeffects.embl.de/drugs/151171/'),('DB00879','http://sideeffects.embl.de/drugs/60877/'),('DB00880','http://sideeffects.embl.de/drugs/2720/'),('DB00882','http://sideeffects.embl.de/drugs/2800/'),('DB00884','http://sideeffects.embl.de/drugs/5245/'),('DB00887','http://sideeffects.embl.de/drugs/2471/'),('DB00888','http://sideeffects.embl.de/drugs/4033/'),('DB00889','http://sideeffects.embl.de/drugs/3510/'),('DB00897','http://sideeffects.embl.de/drugs/5556/'),('DB00903','http://sideeffects.embl.de/drugs/3278/'),('DB00904','http://sideeffects.embl.de/drugs/4595/'),('DB00905','http://sideeffects.embl.de/drugs/127909/'),('DB00909','http://sideeffects.embl.de/drugs/5734/'),('DB00911','http://sideeffects.embl.de/drugs/5479/'),('DB00915','http://sideeffects.embl.de/drugs/2130/'),('DB00916','http://sideeffects.embl.de/drugs/4173/'),('DB00918','http://sideeffects.embl.de/drugs/123606/'),('DB00920','http://sideeffects.embl.de/drugs/3827/'),('DB00924','http://sideeffects.embl.de/drugs/2895/'),('DB00927','http://sideeffects.embl.de/drugs/3325/'),('DB00934','http://sideeffects.embl.de/drugs/4011/'),('DB00936','http://sideeffects.embl.de/drugs/338/'),('DB00937','http://sideeffects.embl.de/drugs/7029/'),('DB00938','http://sideeffects.embl.de/drugs/5152/'),('DB00945','http://sideeffects.embl.de/drugs/2244/'),('DB00947','http://sideeffects.embl.de/drugs/104741/'),('DB00949','http://sideeffects.embl.de/drugs/3331/'),('DB00950','http://sideeffects.embl.de/drugs/3348/'),('DB00951','http://sideeffects.embl.de/drugs/3767/'),('DB00952','http://sideeffects.embl.de/drugs/4440/'),('DB00953','http://sideeffects.embl.de/drugs/5078/'),('DB00958','http://sideeffects.embl.de/drugs/38904/'),('DB00960','http://sideeffects.embl.de/drugs/4828/'),('DB00962','http://sideeffects.embl.de/drugs/5719/'),('DB00963','http://sideeffects.embl.de/drugs/60726/'),('DB00964','http://sideeffects.embl.de/drugs/2216/'),('DB00966','http://sideeffects.embl.de/drugs/65999/'),('DB00967','http://sideeffects.embl.de/drugs/124087/'),('DB00969','http://sideeffects.embl.de/drugs/2099/'),('DB00970','http://sideeffects.embl.de/drugs/2019/'),('DB00972','http://sideeffects.embl.de/drugs/2267/'),('DB00973','http://sideeffects.embl.de/drugs/150311/'),('DB00974','http://sideeffects.embl.de/drugs/6049/'),('DB00975','http://sideeffects.embl.de/drugs/3108/'),('DB00976','http://sideeffects.embl.de/drugs/73658/'),('DB00978','http://sideeffects.embl.de/drugs/3948/'),('DB00979','http://sideeffects.embl.de/drugs/2905/'),('DB00980','http://sideeffects.embl.de/drugs/208902/'),('DB00983','http://sideeffects.embl.de/drugs/3410/'),('DB00985','http://sideeffects.embl.de/drugs/10660/'),('DB00986','http://sideeffects.embl.de/drugs/3494/'),('DB00988','http://sideeffects.embl.de/drugs/681/'),('DB00990','http://sideeffects.embl.de/drugs/60198/'),('DB00991','http://sideeffects.embl.de/drugs/4614/'),('DB00993','http://sideeffects.embl.de/drugs/2265/'),('DB00996','http://sideeffects.embl.de/drugs/3446/'),('DB00998','http://sideeffects.embl.de/drugs/77992/'),('DB00999','http://sideeffects.embl.de/drugs/3639/'),('DB01001','http://sideeffects.embl.de/drugs/2083/'),('DB01004','http://sideeffects.embl.de/drugs/3454/'),('DB01005','http://sideeffects.embl.de/drugs/3657/'),('DB01006','http://sideeffects.embl.de/drugs/3902/'),('DB01008','http://sideeffects.embl.de/drugs/2478/'),('DB01009','http://sideeffects.embl.de/drugs/3825/'),('DB01010','http://sideeffects.embl.de/drugs/3202/'),('DB01011','http://sideeffects.embl.de/drugs/4174/'),('DB01014','http://sideeffects.embl.de/drugs/5362070/'),('DB01015','http://sideeffects.embl.de/drugs/5329/'),('DB01016','http://sideeffects.embl.de/drugs/3488/'),('DB01018','http://sideeffects.embl.de/drugs/3519/'),('DB01019','http://sideeffects.embl.de/drugs/2370/'),('DB01020','http://sideeffects.embl.de/drugs/27661/'),('DB01023','http://sideeffects.embl.de/drugs/3333/'),('DB01025','http://sideeffects.embl.de/drugs/2161/'),('DB01026','http://sideeffects.embl.de/drugs/3823/'),('DB01029','http://sideeffects.embl.de/drugs/3749/'),('DB01032','http://sideeffects.embl.de/drugs/4911/'),('DB01033','http://sideeffects.embl.de/drugs/667490/'),('DB01035','http://sideeffects.embl.de/drugs/4913/'),('DB01039','http://sideeffects.embl.de/drugs/3339/'),('DB01041','http://sideeffects.embl.de/drugs/5426/'),('DB01043','http://sideeffects.embl.de/drugs/4054/'),('DB01044','http://sideeffects.embl.de/drugs/5379/'),('DB01045','http://sideeffects.embl.de/drugs/5381226/'),('DB01046','http://sideeffects.embl.de/drugs/157920/'),('DB01050','http://sideeffects.embl.de/drugs/3672/'),('DB01058','http://sideeffects.embl.de/drugs/4891/'),('DB01059','http://sideeffects.embl.de/drugs/4539/'),('DB01062','http://sideeffects.embl.de/drugs/4634/'),('DB01064','http://sideeffects.embl.de/drugs/3779/'),('DB01065','http://sideeffects.embl.de/drugs/896/'),('DB01067','http://sideeffects.embl.de/drugs/3478/'),('DB01068','http://sideeffects.embl.de/drugs/2802/'),('DB01069','http://sideeffects.embl.de/drugs/4927/'),('DB01072','http://sideeffects.embl.de/drugs/148192/'),('DB01074','http://sideeffects.embl.de/drugs/4746/'),('DB01075','http://sideeffects.embl.de/drugs/3100/'),('DB01077','http://sideeffects.embl.de/drugs/3305/'),('DB01080','http://sideeffects.embl.de/drugs/5665/'),('DB01084','http://sideeffects.embl.de/drugs/3219/'),('DB01086','http://sideeffects.embl.de/drugs/2337/'),('DB01087','http://sideeffects.embl.de/drugs/4908/'),('DB01091','http://sideeffects.embl.de/drugs/2484/'),('DB01097','http://sideeffects.embl.de/drugs/3899/'),('DB01099','http://sideeffects.embl.de/drugs/3366/'),('DB01100','http://sideeffects.embl.de/drugs/16362/'),('DB01101','http://sideeffects.embl.de/drugs/60953/'),('DB01105','http://sideeffects.embl.de/drugs/5210/'),('DB01106','http://sideeffects.embl.de/drugs/3915/'),('DB01110','http://sideeffects.embl.de/drugs/4189/'),('DB01111','http://sideeffects.embl.de/drugs/216258/'),('DB01113','http://sideeffects.embl.de/drugs/4680/'),('DB01114','http://sideeffects.embl.de/drugs/2725/'),('DB01115','http://sideeffects.embl.de/drugs/4485/'),('DB01117','http://sideeffects.embl.de/drugs/74989/'),('DB01119','http://sideeffects.embl.de/drugs/3019/'),('DB01120','http://sideeffects.embl.de/drugs/3475/'),('DB01124','http://sideeffects.embl.de/drugs/5505/'),('DB01127','http://sideeffects.embl.de/drugs/3198/'),('DB01128','http://sideeffects.embl.de/drugs/2375/'),('DB01129','http://sideeffects.embl.de/drugs/5029/'),('DB01131','http://sideeffects.embl.de/drugs/4923/'),('DB01132','http://sideeffects.embl.de/drugs/4829/'),('DB01136','http://sideeffects.embl.de/drugs/2585/'),('DB01141','http://sideeffects.embl.de/drugs/477468/'),('DB01142','http://sideeffects.embl.de/drugs/3158/'),('DB01143','http://sideeffects.embl.de/drugs/2141/'),('DB01148','http://sideeffects.embl.de/drugs/3354/'),('DB01149','http://sideeffects.embl.de/drugs/4449/'),('DB01150','http://sideeffects.embl.de/drugs/2646/'),('DB01151','http://sideeffects.embl.de/drugs/2995/'),('DB01153','http://sideeffects.embl.de/drugs/65863/'),('DB01155','http://sideeffects.embl.de/drugs/72938/'),('DB01156','http://sideeffects.embl.de/drugs/444/'),('DB01158','http://sideeffects.embl.de/drugs/2431/'),('DB01162','http://sideeffects.embl.de/drugs/5401/'),('DB01165','http://sideeffects.embl.de/drugs/4583/'),('DB01166','http://sideeffects.embl.de/drugs/2754/'),('DB01167','http://sideeffects.embl.de/drugs/3793/'),('DB01168','http://sideeffects.embl.de/drugs/4915/'),('DB01171','http://sideeffects.embl.de/drugs/4235/'),('DB01173','http://sideeffects.embl.de/drugs/4601/'),('DB01174','http://sideeffects.embl.de/drugs/4763/'),('DB01176','http://sideeffects.embl.de/drugs/6726/'),('DB01181','http://sideeffects.embl.de/drugs/3690/'),('DB01182','http://sideeffects.embl.de/drugs/4932/'),('DB01184','http://sideeffects.embl.de/drugs/3151/'),('DB01188','http://sideeffects.embl.de/drugs/2749/'),('DB01189','http://sideeffects.embl.de/drugs/42113/'),('DB01193','http://sideeffects.embl.de/drugs/1978/'),('DB01194','http://sideeffects.embl.de/drugs/68844/'),('DB01198','http://sideeffects.embl.de/drugs/5735/'),('DB01201','http://sideeffects.embl.de/drugs/6323497/'),('DB01204','http://sideeffects.embl.de/drugs/4212/'),('DB01205','http://sideeffects.embl.de/drugs/3373/'),('DB01206','http://sideeffects.embl.de/drugs/3950/'),('DB01214','http://sideeffects.embl.de/drugs/31477/'),('DB01215','http://sideeffects.embl.de/drugs/3261/'),('DB01217','http://sideeffects.embl.de/drugs/2187/'),('DB01220','http://sideeffects.embl.de/drugs/72111/'),('DB01221','http://sideeffects.embl.de/drugs/3821/'),('DB01222','http://sideeffects.embl.de/drugs/2462/'),('DB01223','http://sideeffects.embl.de/drugs/9433/'),('DB01224','http://sideeffects.embl.de/drugs/5002/'),('DB01229','http://sideeffects.embl.de/drugs/4666/'),('DB01233','http://sideeffects.embl.de/drugs/4168/'),('DB01236','http://sideeffects.embl.de/drugs/5206/'),('DB01238','http://sideeffects.embl.de/drugs/60795/'),('DB01241','http://sideeffects.embl.de/drugs/3463/'),('DB01242','http://sideeffects.embl.de/drugs/2801/'),('DB01244','http://sideeffects.embl.de/drugs/2351/'),('DB01247','http://sideeffects.embl.de/drugs/3759/'),('DB01254','http://sideeffects.embl.de/drugs/3062316/'),('DB01256','http://sideeffects.embl.de/drugs/6918462/'),('DB01259','http://sideeffects.embl.de/drugs/208908/'),('DB01261','http://sideeffects.embl.de/drugs/4369359/'),('DB01264','http://sideeffects.embl.de/drugs/213039/'),('DB01265','http://sideeffects.embl.de/drugs/1134/'),('DB01267','http://sideeffects.embl.de/drugs/115237/'),('DB01273','http://sideeffects.embl.de/drugs/170361/'),('DB01275','http://sideeffects.embl.de/drugs/3637/'),('DB01284','http://sideeffects.embl.de/drugs/16129617/'),('DB01285','http://sideeffects.embl.de/drugs/16132265/'),('DB01291','http://sideeffects.embl.de/drugs/4845/'),('DB01307','http://sideeffects.embl.de/drugs/16137271/'),('DB01324','http://sideeffects.embl.de/drugs/4870/'),('DB01345','http://sideeffects.embl.de/drugs/813/'),('DB01356','http://sideeffects.embl.de/drugs/28486/'),('DB01378','http://sideeffects.embl.de/drugs/888/'),('DB01393','http://sideeffects.embl.de/drugs/39042/'),('DB01394','http://sideeffects.embl.de/drugs/2833/'),('DB01399','http://sideeffects.embl.de/drugs/5161/'),('DB01400','http://sideeffects.embl.de/drugs/4456/'),('DB01413','http://sideeffects.embl.de/drugs/2622/'),('DB01438','http://sideeffects.embl.de/drugs/4756/'),('DB01440','http://sideeffects.embl.de/drugs/10413/'),('DB01544','http://sideeffects.embl.de/drugs/3380/'),('DB01558','http://sideeffects.embl.de/drugs/2441/'),('DB01580','http://sideeffects.embl.de/drugs/4631/'),('DB01589','http://sideeffects.embl.de/drugs/4999/'),('DB01590','http://sideeffects.embl.de/drugs/6442177/'),('DB01592','http://sideeffects.embl.de/drugs/23925/'),('DB01593','http://sideeffects.embl.de/drugs/23994/'),('DB01595','http://sideeffects.embl.de/drugs/4506/'),('DB01600','http://sideeffects.embl.de/drugs/5468/'),('DB01608','http://sideeffects.embl.de/drugs/4747/'),('DB01609','http://sideeffects.embl.de/drugs/5493381/'),('DB01610','http://sideeffects.embl.de/drugs/64147/'),('DB01611','http://sideeffects.embl.de/drugs/3652/'),('DB01618','http://sideeffects.embl.de/drugs/23897/'),('DB01628','http://sideeffects.embl.de/drugs/123619/'),('DB01656','http://sideeffects.embl.de/drugs/449193/'),('DB02300','http://sideeffects.embl.de/drugs/2522/'),('DB02530','http://sideeffects.embl.de/drugs/119/'),('DB02546','http://sideeffects.embl.de/drugs/5311/'),('DB02638','http://sideeffects.embl.de/drugs/72081/'),('DB02831','http://sideeffects.embl.de/drugs/1003/'),('DB03128','http://sideeffects.embl.de/drugs/187/'),('DB03193','http://sideeffects.embl.de/drugs/5281/'),('DB03575','http://sideeffects.embl.de/drugs/6468/'),('DB03754','http://sideeffects.embl.de/drugs/6503/'),('DB03856','http://sideeffects.embl.de/drugs/3009/'),('DB03904','http://sideeffects.embl.de/drugs/1176/'),('DB03994','http://sideeffects.embl.de/drugs/700/'),('DB04160','http://sideeffects.embl.de/drugs/1023/'),('DB04272','http://sideeffects.embl.de/drugs/311/'),('DB04398','http://sideeffects.embl.de/drugs/612/'),('DB04572','http://sideeffects.embl.de/drugs/5453/'),('DB04729','http://sideeffects.embl.de/drugs/72396/'),('DB04843','http://sideeffects.embl.de/drugs/4057/'),('DB04844','http://sideeffects.embl.de/drugs/6018/'),('DB04845','http://sideeffects.embl.de/drugs/6445540/'),('DB04846','http://sideeffects.embl.de/drugs/2663/'),('DB04854','http://sideeffects.embl.de/drugs/134018/'),('DB04855','http://sideeffects.embl.de/drugs/208898/'),('DB04861','http://sideeffects.embl.de/drugs/71301/'),('DB04868','http://sideeffects.embl.de/drugs/644241/'),('DB04876','http://sideeffects.embl.de/drugs/5251896/'),('DB04890','http://sideeffects.embl.de/drugs/2350/'),('DB04895','http://sideeffects.embl.de/drugs/56603655/'),('DB04918','http://sideeffects.embl.de/drugs/6918430/'),('DB04920','http://sideeffects.embl.de/drugs/153994/'),('DB04946','http://sideeffects.embl.de/drugs/71360/'),('DB04951','http://sideeffects.embl.de/drugs/40632/'),('DB04953','http://sideeffects.embl.de/drugs/121892/'),('DB05013','http://sideeffects.embl.de/drugs/6918670/'),('DB05015','http://sideeffects.embl.de/drugs/6918638/'),('DB05246','http://sideeffects.embl.de/drugs/6476/'),('DB05259','http://sideeffects.embl.de/drugs/65370/'),('DB05260','http://sideeffects.embl.de/drugs/61635/'),('DB05294','http://sideeffects.embl.de/drugs/3081361/'),('DB05381','http://sideeffects.embl.de/drugs/774/'),('DB05521','http://sideeffects.embl.de/drugs/3010818/'),('DB05812','http://sideeffects.embl.de/drugs/132971/'),('DB06005','http://sideeffects.embl.de/drugs/772/'),('DB06148','http://sideeffects.embl.de/drugs/4184/'),('DB06153','http://sideeffects.embl.de/drugs/27400/'),('DB06176','http://sideeffects.embl.de/drugs/3425/'),('DB06201','http://sideeffects.embl.de/drugs/129228/'),('DB06202','http://sideeffects.embl.de/drugs/216416/'),('DB06209','http://sideeffects.embl.de/drugs/6918456/'),('DB06210','http://sideeffects.embl.de/drugs/9846180/'),('DB06211','http://sideeffects.embl.de/drugs/73303/'),('DB06212','http://sideeffects.embl.de/drugs/216237/'),('DB06213','http://sideeffects.embl.de/drugs/219024/'),('DB06218','http://sideeffects.embl.de/drugs/219078/'),('DB06237','http://sideeffects.embl.de/drugs/9869929/'),('DB06268','http://sideeffects.embl.de/drugs/216235/'),('DB06287','http://sideeffects.embl.de/drugs/148191/'),('DB06288','http://sideeffects.embl.de/drugs/2159/'),('DB06292','http://sideeffects.embl.de/drugs/9887712/'),('DB06410','http://sideeffects.embl.de/drugs/4479094/'),('DB06414','http://sideeffects.embl.de/drugs/193962/'),('DB06480','http://sideeffects.embl.de/drugs/3052762/'),('DB06558','http://sideeffects.embl.de/drugs/151174/'),('DB06589','http://sideeffects.embl.de/drugs/10113978/'),('DB06594','http://sideeffects.embl.de/drugs/82148/'),('DB06605','http://sideeffects.embl.de/drugs/10182969/'),('DB06616','http://sideeffects.embl.de/drugs/5328940/'),('DB06637','http://sideeffects.embl.de/drugs/1727/'),('DB06655','http://sideeffects.embl.de/drugs/16134956/'),('DB06663','http://sideeffects.embl.de/drugs/9941444/'),('DB06691','http://sideeffects.embl.de/drugs/4992/'),('DB06695','http://sideeffects.embl.de/drugs/213023/'),('DB06698','http://sideeffects.embl.de/drugs/2366/'),('DB06699','http://sideeffects.embl.de/drugs/16136245/'),('DB06700','http://sideeffects.embl.de/drugs/125017/'),('DB06702','http://sideeffects.embl.de/drugs/6918558/'),('DB06709','http://sideeffects.embl.de/drugs/1993/'),('DB06711','http://sideeffects.embl.de/drugs/4436/'),('DB06756','http://sideeffects.embl.de/drugs/247/'),('DB06771','http://sideeffects.embl.de/drugs/10178705/'),('DB06775','http://sideeffects.embl.de/drugs/121396/'),('DB06782','http://sideeffects.embl.de/drugs/3080/'),('DB06788','http://sideeffects.embl.de/drugs/25077993/'),('DB06792','http://sideeffects.embl.de/drugs/168924/'),('DB06795','http://sideeffects.embl.de/drugs/3998/'),('DB06802','http://sideeffects.embl.de/drugs/151075/'),('DB06813','http://sideeffects.embl.de/drugs/148121/'),('DB06819','http://sideeffects.embl.de/drugs/4775/'),('DB06825','http://sideeffects.embl.de/drugs/25074470/'),('DB08167','http://sideeffects.embl.de/drugs/4139/'),('DB08604','http://sideeffects.embl.de/drugs/5564/'),('DB08815','http://sideeffects.embl.de/drugs/213046/'),('DB08816','http://sideeffects.embl.de/drugs/9871419/'),('DB08820','http://sideeffects.embl.de/drugs/16220172/'),('DB08822','http://sideeffects.embl.de/drugs/11238823/'),('DB08827','http://sideeffects.embl.de/drugs/9853053/'),('DB08828','http://sideeffects.embl.de/drugs/24776445/'),('DB08839','http://sideeffects.embl.de/drugs/5202/'),('DB08872','http://sideeffects.embl.de/drugs/9883933/'),('DB08873','http://sideeffects.embl.de/drugs/10324367/'),('DB08875','http://sideeffects.embl.de/drugs/25102847/'),('DB08881','http://sideeffects.embl.de/drugs/42611257/'),('DB08882','http://sideeffects.embl.de/drugs/10096344/'),('DB08883','http://sideeffects.embl.de/drugs/9924495/'),('DB08889','http://sideeffects.embl.de/drugs/11556711/'),('DB08893','http://sideeffects.embl.de/drugs/9865528/'),('DB08896','http://sideeffects.embl.de/drugs/11167602/'),('DB08899','http://sideeffects.embl.de/drugs/15951529/'),('DB08900','http://sideeffects.embl.de/drugs/16139605/'),('DB08901','http://sideeffects.embl.de/drugs/24826799/'),('DB08906','http://sideeffects.embl.de/drugs/9854489/'),('DB08907','http://sideeffects.embl.de/drugs/24812758/'),('DB08910','http://sideeffects.embl.de/drugs/134780/'),('DB08911','http://sideeffects.embl.de/drugs/11707110/'),('DB08912','http://sideeffects.embl.de/drugs/44462760/'),('DB08931','http://sideeffects.embl.de/drugs/11304743/'),('DB08932','http://sideeffects.embl.de/drugs/16004692/'),('DB09038','http://sideeffects.embl.de/drugs/11949646/'),('DB09059','http://sideeffects.embl.de/drugs/68613/'),('DB09067','http://sideeffects.embl.de/drugs/16132344/'),('DB09068','http://sideeffects.embl.de/drugs/9966051/'),('DB09083','http://sideeffects.embl.de/drugs/132999/'),('DB09101','http://sideeffects.embl.de/drugs/5277135/'),('DB09118','http://sideeffects.embl.de/drugs/39524/'),('DB09119','http://sideeffects.embl.de/drugs/179344/'),('DB09130','http://sideeffects.embl.de/drugs/23978/'),('DB09149','http://sideeffects.embl.de/drugs/24822371/'),('DB09167','http://sideeffects.embl.de/drugs/3155/'),('DB09220','http://sideeffects.embl.de/drugs/47528/'),('DB09242','http://sideeffects.embl.de/drugs/4810/'),('DB09323','http://sideeffects.embl.de/drugs/15232/'),('DB09389','http://sideeffects.embl.de/drugs/4542/'),('DB09401','http://sideeffects.embl.de/drugs/12597/'),('DB09460','http://sideeffects.embl.de/drugs/10340/'),('DB09462','http://sideeffects.embl.de/drugs/753/'),('DB09526','http://sideeffects.embl.de/drugs/785/'),('DB11059','http://sideeffects.embl.de/drugs/24748/'),('DB11124','http://sideeffects.embl.de/drugs/838/'),('DB11136','http://sideeffects.embl.de/drugs/23976/'),('DB11641','http://sideeffects.embl.de/drugs/157688/'),('DB11644','http://sideeffects.embl.de/drugs/11001318/'),('DB11699','http://sideeffects.embl.de/drugs/5595/'),('DB12965','http://sideeffects.embl.de/drugs/23954/'),('DB13257','http://sideeffects.embl.de/drugs/24393/'),('DB13868','http://sideeffects.embl.de/drugs/60172/'),('DB13872','http://sideeffects.embl.de/drugs/13314/'),('DB13873','http://sideeffects.embl.de/drugs/64929/'),('DB13919','http://sideeffects.embl.de/drugs/2541/'),('DB13946','http://sideeffects.embl.de/drugs/65157/'),('DB14007','http://sideeffects.embl.de/drugs/3053/');

/*Table structure for table `target_disease` */

DROP TABLE IF EXISTS `target_disease`;

CREATE TABLE `target_disease` (
  `target_disease_link` varchar(200) NOT NULL,
  `target_disease_id` varchar(200) DEFAULT NULL,
  `target_disease_name` varchar(200) DEFAULT NULL,
  `Target_href` varchar(200) DEFAULT NULL,
  PRIMARY KEY (`target_disease_link`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

/*Data for the table `target_disease` */

insert  into `target_disease`(`target_disease_link`,`target_disease_id`,`target_disease_name`,`Target_href`) values ('https://www.genome.jp/dbget-bin/www_bget?ds:H00017','H00017','https://www.genome.jpEsophageal cancer','http://www.genome.jp/dbget-bin/www_bget?hsa:5743'),('https://www.genome.jp/dbget-bin/www_bget?ds:H00025','H00025','https://www.genome.jpPenile cancer','http://www.genome.jp/dbget-bin/www_bget?hsa:5743'),('https://www.genome.jp/dbget-bin/www_bget?ds:H00046','H00046','https://www.genome.jpCholangiocarcinoma','http://www.genome.jp/dbget-bin/www_bget?hsa:5743'),('https://www.genome.jp/dbget-bin/www_bget?ds:H00775','H00775','https://www.genome.jpFamilial or sporadic hemiplegic migraine','http://www.genome.jp/dbget-bin/www_bget?hsa:6323'),('https://www.genome.jp/dbget-bin/www_bget?ds:H00783','H00783','https://www.genome.jpFebrile seizures','http://www.genome.jp/dbget-bin/www_bget?hsa:6323'),('https://www.genome.jp/dbget-bin/www_bget?ds:H01611','H01611','https://www.genome.jpAlcohol dependence','http://www.genome.jp/dbget-bin/www_bget?hsa:4988'),('https://www.genome.jp/dbget-bin/www_bget?ds:H01815','H01815','https://www.genome.jpMalignant migrating partial seizures in infancy','http://www.genome.jp/dbget-bin/www_bget?hsa:6323'),('https://www.genome.jp/dbget-bin/www_bget?ds:H01818','H01818','https://www.genome.jpDravet syndrome','http://www.genome.jp/dbget-bin/www_bget?hsa:6323');

/*Table structure for table `target_pathway` */

DROP TABLE IF EXISTS `target_pathway`;

CREATE TABLE `target_pathway` (
  `kegg_target_hsa` varchar(200) NOT NULL,
  `kegg_target_hsa_link` varchar(200) DEFAULT NULL,
  `kegg_target_pathway_name` varchar(200) DEFAULT NULL,
  `pic_kegg_targets_pathway` varchar(200) DEFAULT NULL,
  `Target_href` varchar(200) DEFAULT NULL,
  PRIMARY KEY (`kegg_target_hsa`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

/*Data for the table `target_pathway` */

insert  into `target_pathway`(`kegg_target_hsa`,`kegg_target_hsa_link`,`kegg_target_pathway_name`,`pic_kegg_targets_pathway`,`Target_href`) values ('hsa00590','https://www.genome.jp/kegg-bin/show_pathway?hsa00590+5742','Arachidonic acid metabolism','None','http://www.genome.jp/dbget-bin/www_bget?hsa:5742'),('hsa04022','https://www.genome.jp/kegg-bin/show_pathway?hsa04022+134','cGMP-PKG signaling pathway','None','http://www.genome.jp/dbget-bin/www_bget?hsa:134'),('hsa04024','https://www.genome.jp/kegg-bin/show_pathway?hsa04024+134','cAMP signaling pathway','None','http://www.genome.jp/dbget-bin/www_bget?hsa:134'),('hsa04064','https://www.genome.jp/kegg-bin/show_pathway?hsa04064+5743','NF-kappa B signaling pathway','None','http://www.genome.jp/dbget-bin/www_bget?hsa:5743'),('hsa04071','https://www.genome.jp/kegg-bin/show_pathway?hsa04071+134','Sphingolipid signaling pathway','None','http://www.genome.jp/dbget-bin/www_bget?hsa:134'),('hsa04080','https://www.genome.jp/kegg-bin/show_pathway?hsa04080+4988','Neuroactive ligand-receptor interaction','None','http://www.genome.jp/dbget-bin/www_bget?hsa:4988'),('hsa04370','https://www.genome.jp/kegg-bin/show_pathway?hsa04370+5743','VEGF signaling pathway','None','http://www.genome.jp/dbget-bin/www_bget?hsa:5743'),('hsa04611','https://www.genome.jp/kegg-bin/show_pathway?hsa04611+5742','Platelet activation','None','http://www.genome.jp/dbget-bin/www_bget?hsa:5742'),('hsa04625','https://www.genome.jp/kegg-bin/show_pathway?hsa04625+5743','C-type lectin receptor signaling pathway','None','http://www.genome.jp/dbget-bin/www_bget?hsa:5743'),('hsa04657','https://www.genome.jp/kegg-bin/show_pathway?hsa04657+5743','IL-17 signaling pathway','None','http://www.genome.jp/dbget-bin/www_bget?hsa:5743'),('hsa04668','https://www.genome.jp/kegg-bin/show_pathway?hsa04668+5743','TNF signaling pathway','None','http://www.genome.jp/dbget-bin/www_bget?hsa:5743'),('hsa04723','https://www.genome.jp/kegg-bin/show_pathway?hsa04723+5743','Retrograde endocannabinoid signaling','None','http://www.genome.jp/dbget-bin/www_bget?hsa:5743'),('hsa04726','https://www.genome.jp/kegg-bin/show_pathway?hsa04726+5742','Serotonergic synapse','None','http://www.genome.jp/dbget-bin/www_bget?hsa:5742'),('hsa04728','https://www.genome.jp/kegg-bin/show_pathway?hsa04728+6323','Dopaminergic synapse','None','http://www.genome.jp/dbget-bin/www_bget?hsa:6323'),('hsa04913','https://www.genome.jp/kegg-bin/show_pathway?hsa04913+5743','Ovarian steroidogenesis','None','http://www.genome.jp/dbget-bin/www_bget?hsa:5743'),('hsa04915','https://www.genome.jp/kegg-bin/show_pathway?hsa04915+4988','Estrogen signaling pathway','None','http://www.genome.jp/dbget-bin/www_bget?hsa:4988'),('hsa04921','https://www.genome.jp/kegg-bin/show_pathway?hsa04921+5743','Oxytocin signaling pathway','None','http://www.genome.jp/dbget-bin/www_bget?hsa:5743'),('hsa04923','https://www.genome.jp/kegg-bin/show_pathway?hsa04923+5742','Regulation of lipolysis in adipocytes','None','http://www.genome.jp/dbget-bin/www_bget?hsa:5742'),('hsa04924','https://www.genome.jp/kegg-bin/show_pathway?hsa04924+134','Renin secretion','None','http://www.genome.jp/dbget-bin/www_bget?hsa:134'),('hsa05032','https://www.genome.jp/kegg-bin/show_pathway?hsa05032+4988','Morphine addiction','None','http://www.genome.jp/dbget-bin/www_bget?hsa:4988'),('hsa05140','https://www.genome.jp/kegg-bin/show_pathway?hsa05140+5743','Leishmaniasis','None','http://www.genome.jp/dbget-bin/www_bget?hsa:5743'),('hsa05163','https://www.genome.jp/kegg-bin/show_pathway?hsa05163+5743','Human cytomegalovirus infection','None','http://www.genome.jp/dbget-bin/www_bget?hsa:5743'),('hsa05165','https://www.genome.jp/kegg-bin/show_pathway?hsa05165+5743','Human papillomavirus infection','None','http://www.genome.jp/dbget-bin/www_bget?hsa:5743'),('hsa05167','https://www.genome.jp/kegg-bin/show_pathway?hsa05167+5743','Kaposi sarcoma-associated herpesvirus infection','None','http://www.genome.jp/dbget-bin/www_bget?hsa:5743'),('hsa05200','https://www.genome.jp/kegg-bin/show_pathway?hsa05200+5743','Pathways in cancer','None','http://www.genome.jp/dbget-bin/www_bget?hsa:5743'),('hsa05204','https://www.genome.jp/kegg-bin/show_pathway?hsa05204+5743','Chemical carcinogenesis','None','http://www.genome.jp/dbget-bin/www_bget?hsa:5743'),('hsa05206','https://www.genome.jp/kegg-bin/show_pathway?hsa05206+5743','MicroRNAs in cancer','None','http://www.genome.jp/dbget-bin/www_bget?hsa:5743');

/*!40101 SET SQL_MODE=@OLD_SQL_MODE */;
/*!40014 SET FOREIGN_KEY_CHECKS=@OLD_FOREIGN_KEY_CHECKS */;
/*!40014 SET UNIQUE_CHECKS=@OLD_UNIQUE_CHECKS */;
/*!40111 SET SQL_NOTES=@OLD_SQL_NOTES */;
